Independent Evaluation of Phase 1 of the Affordable Medicines Facility - malaria (AMFm), Multi-Country Independent Evaluation Final Report by Amfm Independent Evaluation Team: Hanson, K et al.
Amfm Independent Evaluation Team: Hanson, K; Goodman, C; Tougher,
S; Mann, A; Willey, B; Arnold, F; Ye, Y; Ren, R; Yoder, S (2012)
Independent Evaluation of Phase 1 of the Affordable Medicines Facil-
ity - malaria (AMFm), Multi-Country Independent Evaluation Final
Report. Technical Report. ICF International and London School of
Hygiene and Tropical Medicine, Calverton, Maryland and London.
Downloaded from: http://researchonline.lshtm.ac.uk/2869474/
DOI:
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
  
 
Multi-Country Independent Evaluation Report 
Independent Evaluation of the 
Affordable Medicines 
Facility - malaria (AMFm) Phase 1 
Final Report 
September 28, 2012 
1 
 
Independent Evaluation of Phase 1 of the Affordable Medicines 
Facility - malaria (AMFm) 
 
 
Multi-Country Independent Evaluation Report: 
Final Report 
 
September 28, 2012 
 
 
 
 
AMFm Independent Evaluation Team 
 
ICF International:  
 
London School of Hygiene and 
Tropical Medicine: 
Fred Arnold 
Yazoume Ye 
Ruilin Ren 
Stan Yoder 
Kara Hanson 
Catherine Goodman 
Sarah Tougher 
Andrea Mann 
Barbara Willey 
 
Submitted to: 
The Global Fund to Fight AIDS, Tuberculosis and Malaria 
 
Submitted by:  
ICF International  
11785 Beltsville Drive, Suite 300, Calverton, MD 20705, USA 
 
and 
 
The London School of Hygiene and Tropical Medicine 
 
Recommend citation: 
AMFm Independent Evaluation Team (2012). Independent Evaluation of Phase 1 of the 
Affordable Medicines Facility - malaria (AMFm), Multi-Country Independent Evaluation Report: 
Final Report. Calverton, Maryland and London: ICF International and London School of Hygiene 
and Tropical Medicine. 
 
This version of the report includes the following information not previously included in the Preliminary 
Report of July 18, 2012: (i) results from the remote areas study; (ii) results from the logo study (exit 
interviews and focus group discussions); (iii) an annex describing the Consultative Forum held in June 
2012 in Nairobi; and (iv) some new content to Section 1.2 Overview of the AMFm, including orders 
requested, approved and delivered as of end September 2012. None of this new information has affected the 
assessment of the achievements of the Phase 1 benchmarks that were included in the preliminary report of 
July 18, 2012. 
 
This version of the report does not include findings from the endline household surveys. Those findings will 
be included in a supplemental report when endline data become available. 
 
i 
 
Data Contributors (Institutions in alphabetical order): 
Data Contributors for Outlet Surveys 
 
African Population and Health Research Centre, Kenya 
 Marilyn Wamukoya 
 Yohannes Kinfu 
 Blessing Mberu 
Centre de Recherche pour le Développement Humain (CRDH) / International d'Etudes et de 
Recherches sur les Populations Africaines (CIERPA), Niger 
 Salif Ndiaye 
 Idrissa Alichina Kourgueni 
 Moctar Seydou 
 Oumarou Malam 
Drugs for Neglected Diseases initiative (DNDi)/Research and Development Unit, Komfo Anokye 
Teaching Hospital (KATH), Ghana 
 Graciela Diap 
 John Amuasi 
 Samuel Blay Nguah 
 Ohene Buabeng 
Ifakara Health Institute (IHI) - IMPACT 2 Project, Tanzania 
 Rebecca Thomson 
 Johanes Boniface 
 Admirabilis Kalolella 
 Charles Festo 
 Mark Taylor 
 Katia Bruxvoort 
Population Service International (PSI) - ACTwatch Project, Kenya, Madagascar, Nigeria, Uganda, 
Zanzibar  
 Tanya Shewchuk 
 Kate O’Connell 
 Hellen Gatakaa  
 Stephen Poyer 
 Julius Njogu 
 Mitsuru Toda 
 Illah Evance 
 James Kajuna 
 Baraka Kaaya 
 Jacky Raharinijatovo 
 Ekundayo Arogundade 
 Peter Buyungo 
 Edna Adhiambo Ogada 
 
ii 
 
 
Data Contributors for Remote Area Surveys 
 
African Population and Health Reseach Centre (APHRC)  
 Catherine Kyobutungi 
 Blessing Nberu 
 Marylin Wamukoya 
 Fredrick Wekesa 
Komfo Anokye Teaching Hospital (KATH)  
 John Amuasi 
 Samual Blay 
 Daniel Ansong 
Independent consultant – Defining the remote areas 
 Abdisalan Noor 
  
Data Contributors for Logo Study (Exit Interviews and Focus Group Discussions) 
 
Ghana: TNS RMS Ghana  
 Adewake Obaseki 
 Agyakwa Ayisi Addo 
 Marilyn Oduro-Ntiamoah 
  
Kenya: African Institute for Health and Development (AIHD) 
 Mary Amuyunzu-Nyamongo 
 Monica Wabuke 
  
Madagascar: Institut National des Statistiques de Madagascar (INSTAT) 
 Victor Rabeza Rafaralahy 
 Heretiana Randriandrasana 
  
Nigeria: TNS RMS Nigeria Limited 
 Mariam Fagbemi 
 Olugbenga Afolabi Ogunmefun 
 
Data Contributors for Country Case Studies 
 
Ghana Elizabeth Juma 
Kenya Abdinasir Amin 
Madagascar Sergio Torres Rueda 
Niger Diadier Diallo 
Nigeria Catherine Adegoke 
Tanzania – mainland Catherine Goodman 
Uganda Sarah Tougher 
Zanzibar Yazoume Ye 
iii 
 
Table of contents 
TABLE OF CONTENTS .................................................................................................................................. III 
LIST OF TABLES ............................................................................................................................................ VII 
LIST OF FIGURES .......................................................................................................................................... XII 
LIST OF ABBREVIATIONS ......................................................................................................................... XIV 
DEFINITION OF KEY TERMS ................................................................................................................. XVIII 
OVERVIEW OF THE INDEPENDENT EVALUATION OF AMFM ....................................................... XIX 
EXECUTIVE SUMMARY .......................................................................................................................... XXIV 
1 BACKGROUND AND METHODS .......................................................................................................... 1 
1.1 EVALUATION BACKGROUND ..................................................................................................................... 1 
1.2 OVERVIEW OF AMFM ............................................................................................................................... 2 
1.2.1 Origins of the AMFm ...................................................................................................................... 2 
1.2.2 Technical Design of the AMFm ...................................................................................................... 3 
1.2.3 Global Fund’s Hosting and Management of the AMFm ................................................................. 3 
1.2.4 Funding sources .............................................................................................................................. 5 
1.2.5 Negotiations with eligible manufacturers ....................................................................................... 5 
1.2.6 AMFm copayments processed and volume of copaid ACTs delivered ............................................ 7 
1.2.7 Typical ordering behavior: Differences between public and private sector buyers ..................... 12 
1.2.8 Implementation and country-level effects of demand-shaping levers ........................................... 14 
1.2.9 Evolution of adult versus child pack orders over time .................................................................. 15 
1.2.10 Disbursement delays for supporting interventions ................................................................... 17 
1.2.11 Overview of timing of AMFm implementation ......................................................................... 17 
1.2.12 Summary of AMFm implementation ......................................................................................... 20 
1.3 OVERVIEW OF AMFM PHASE 1 COUNTRIES ............................................................................................ 22 
1.3.1 Ghana ........................................................................................................................................... 22 
1.3.2 Kenya ............................................................................................................................................ 23 
1.3.3 Madagascar .................................................................................................................................. 24 
1.3.4 Niger ............................................................................................................................................. 25 
1.3.5 Nigeria .......................................................................................................................................... 27 
1.3.6 Tanzania – mainland .................................................................................................................... 28 
1.3.7 Uganda ......................................................................................................................................... 29 
1.3.8 Zanzibar ........................................................................................................................................ 30 
1.4 EVALUATION FRAMEWORK ..................................................................................................................... 32 
1.4.1 Impact model ................................................................................................................................ 33 
1.4.2 Evaluation design ......................................................................................................................... 36 
1.4.3 Additional studies ......................................................................................................................... 37 
1.5 KEY EVALUATION QUESTIONS AND INDICATORS ..................................................................................... 38 
1.6 EVALUATION APPROACH ......................................................................................................................... 41 
1.6.1 Overview of methods and tools ..................................................................................................... 41 
1.6.2 Outlet surveys ............................................................................................................................... 42 
1.6.3 Household survey data - Secondary analysis................................................................................ 51 
1.6.4 Implementation process and contextual information .................................................................... 53 
1.6.5 Remote area study ......................................................................................................................... 55 
1.6.6 Public awareness - AMFm logo study .......................................................................................... 60 
1.6.7 Interpretation and operationalization of success metrics ............................................................. 63 
1.6.8 Ethical approval ........................................................................................................................... 67 
1.6.9 Discussion of strengths and limitations of the Independent Evaluation ....................................... 67 
1.7 CONSULTATIVE FORUM .......................................................................................................................... 73 
2 RESULTS FROM OUTLET SURVEYS ................................................................................................ 74 
2.1 DESCRIPTION OF SAMPLE AND CHARACTERISTICS OF OUTLETS ............................................................... 74 
2.1.1 Description of sample at baseline and at endline ......................................................................... 74 
2.1.2 Characteristics of the outlets ........................................................................................................ 82 
2.2 EVALUATION QUESTION ON ACT AVAILABILITY .................................................................................... 94 
2.2.1 Antimalarials in stock ................................................................................................................... 94 
iv 
 
2.2.2 Antimalarials in stock by type ....................................................................................................... 97 
2.2.1 Stockouts of quality-assured ACTs ............................................................................................. 112 
2.2.2 Population coverage of outlets with quality-assured ACTs ........................................................ 115 
2.3 EVALUATION QUESTION ON ACT AFFORDABILITY ................................................................................ 118 
2.3.1 Cost to patients of antimalarials ................................................................................................. 118 
2.3.2 Gross markup between purchase price and retail selling price .................................................. 141 
2.3.3 Total gross markup from first line buyer purchase price to retail selling price ......................... 152 
2.3.4 Availability and cost to patients of diagnostic tests (RDT/microscopy) ..................................... 155 
2.4 MARKET SHARE OF QUALITY-ASSURED ACTS ...................................................................................... 170 
2.5 PROVIDER KNOWLEDGE OF FIRST LINE ANTIMALARIAL TREATMENT AND QUALITY-ASSURED ACT 
DOSING REGIMEN ............................................................................................................................................ 182 
2.5.1 Provider Knowledge of first line antimalarial treatment ............................................................ 182 
2.5.2 Provider knowledge of quality-assured ACT dosing regimen for an adult and a child .............. 185 
2.5.3 Reasons for not stocking quality-assured ACTs.......................................................................... 190 
2.6 AMFM LOGO, RECOMMENDED RETAIL PRICE AND PROVIDER TRAINING ................................................ 193 
3 RESULTS FROM HOUSEHOLD SURVEYS ..................................................................................... 211 
3.1 FEVER PREVALENCE .............................................................................................................................. 211 
3.2 ANTIMALARIAL TREATMENT AMONG CHILDREN WITH FEVER ............................................................... 213 
3.3 DIAGNOSTIC TESTING ............................................................................................................................ 220 
3.4 ANTIMALARIAL TREATMENT AMONG CHILDREN WITH FEVER FROM THE POOREST HOUSEHOLDS.......... 222 
4 IMPLEMENTATION PROCESS AND CONTEXT - FINDINGS FROM THE COUNTRY CASE 
STUDIES ........................................................................................................................................................... 224 
4.1 GHANA .................................................................................................................................................. 224 
4.1.1 AMFm implementation process .................................................................................................. 224 
4.1.2 Implementation of AMFm supporting interventions ................................................................... 226 
4.1.3 Implementation of non-AMFm interventions .............................................................................. 227 
4.1.4 Key events and context ................................................................................................................ 228 
4.1.5 Conclusion .................................................................................................................................. 228 
4.2 KENYA .................................................................................................................................................. 231 
4.2.1 AMFm implementation process .................................................................................................. 231 
4.2.2 Implementation of AMFm supporting interventions ................................................................... 234 
4.2.3 Implementation of non-AMFm interventions .............................................................................. 238 
4.2.4 Key events and context ................................................................................................................ 239 
4.2.5 Conclusion .................................................................................................................................. 239 
4.3 MADAGASCAR ...................................................................................................................................... 242 
4.3.1 Description of the AMFm implementation process ..................................................................... 242 
4.3.2 Implementation of AMFm supporting interventions ................................................................... 243 
4.3.3 Key events and context ................................................................................................................ 247 
4.3.4 Conclusion .................................................................................................................................. 247 
4.4 NIGER ................................................................................................................................................... 250 
4.4.1 AMFm implementation process .................................................................................................. 250 
4.4.2 Implementation of AMFm supporting interventions ................................................................... 253 
4.4.3 Key events and context ................................................................................................................ 257 
4.4.4 Conclusion .................................................................................................................................. 257 
4.5 NIGERIA ................................................................................................................................................ 260 
4.5.1 AMFm intervention process ........................................................................................................ 260 
4.5.2 Implementation of AMFm supporting intervention ..................................................................... 262 
4.5.3 Key events and context ................................................................................................................ 265 
4.5.4 Conclusion .................................................................................................................................. 266 
4.6 TANZANIA - MAINLAND ........................................................................................................................ 270 
4.6.1 AMFm implementation process .................................................................................................. 270 
4.6.2 Implementation of AMFm supporting interventions ................................................................... 272 
4.6.3 Key event and context ................................................................................................................. 277 
4.6.4 Conclusion .................................................................................................................................. 277 
4.7 UGANDA ............................................................................................................................................... 280 
4.7.1 AMFm implementation process .................................................................................................. 280 
4.7.2 Implementation of AMFm Supporting Interventions ................................................................... 285 
4.7.3 Key events and context ................................................................................................................ 289 
v 
 
4.7.4 Conclusion .................................................................................................................................. 290 
4.8 ZANZIBAR ............................................................................................................................................. 292 
4.8.1 AMFm implementation process .................................................................................................. 292 
4.8.2 Implementation of AMFm supporting interventions ................................................................... 295 
4.8.3 Key events and context ................................................................................................................ 299 
4.8.4 Conclusion .................................................................................................................................. 299 
5 RESULTS FROM THE REMOTE AREA STUDY............................................................................. 302 
5.1 DESCRIPTION OF THE SAMPLE ............................................................................................................... 302 
5.2 AVAILABILITY OF QUALITY-ASSURED ACTS IN REMOTE AREAS ........................................................... 305 
5.2.1 Stockouts of quality-assured ACTs in remote areas ................................................................... 308 
5.2.2 Population coverage of outlets with quality-assured ACTs in remote areas .............................. 308 
5.3 PRICING OF QUALITY-ASSURED ACTS IN REMOTE AREAS ..................................................................... 310 
5.4 GROSS MARKUP BETWEEN PURCHASE PRICE AND RETAIL SELLING PRICE OF QUALITY-ASSURED ACTS IN 
REMOTE AREAS ............................................................................................................................................... 314 
5.5 AVAILABILITY AND COST TO PATIENTS OF MALARIA DIAGNOSTIC TESTS IN REMOTE AREAS ................. 316 
5.6 MARKET SHARE FOR QUALITY-ASSURED ACTS IN REMOTE AREAS ....................................................... 319 
5.7 AMFM LOGO IN REMOTE AREAS ........................................................................................................... 321 
5.8 SUMMARY OF RESULTS ......................................................................................................................... 323 
6 RESULTS FROM THE LOGO STUDY (EXIT INTERVIEWS AND FOCUS GROUP 
DISCUSSIONS) ................................................................................................................................................ 324 
6.1 EXIT INTERVIEWS .................................................................................................................................. 324 
6.1.1 Description of the sample ........................................................................................................... 324 
6.1.2 Reasons for choosing a malaria treatment ................................................................................. 325 
6.1.3 Source of information about ACTs ............................................................................................. 326 
6.1.4 Knowledge of AMFm logo .......................................................................................................... 327 
6.1.5 Meaning of the AMFm logo ........................................................................................................ 330 
6.1.6 Summary of results from exit interviews ..................................................................................... 331 
6.2 FOCUS GROUP DISCUSSIONS .................................................................................................................. 332 
6.2.1 Description of the sample ........................................................................................................... 332 
6.2.2 Knowledge of treatment of malaria ............................................................................................ 332 
6.2.3 Knowledge and perceived availability of ACTs .......................................................................... 333 
6.2.4 Knowledge and perception of the AMFm logo ........................................................................... 334 
6.2.5 Summary of the results of the focus group discussions ............................................................... 335 
7 SUMMARY OF KEY FINDINGS FROM RELEVANT OPERATIONAL RESEARCH ............... 337 
8 SUCCESS METRICS AND INTERPRETATION .............................................................................. 343 
8.1 GHANA .................................................................................................................................................. 343 
8.1.1 Achievement of AMFm objectives ............................................................................................... 343 
8.1.2 Supply of AMFm copaid drugs ................................................................................................... 346 
8.1.3 Implementation of supporting interventions ............................................................................... 347 
8.1.4 Context ........................................................................................................................................ 348 
8.1.5 Summary ..................................................................................................................................... 348 
8.2 KENYA .................................................................................................................................................. 350 
8.2.1 Achievement of AMFm objectives ............................................................................................... 350 
8.2.2 Supply of AMFm copaid drugs ................................................................................................... 353 
8.2.3 Implementation of supporting interventions ............................................................................... 354 
8.2.4 Context ........................................................................................................................................ 355 
8.2.5 Summary ..................................................................................................................................... 355 
8.3 MADAGASCAR ...................................................................................................................................... 356 
8.3.1 Achievement of the objectives ..................................................................................................... 356 
8.3.2 Supply of AMFm copaid drugs ................................................................................................... 360 
8.3.3 Implementation of supporting interventions ............................................................................... 360 
8.3.4 Context ........................................................................................................................................ 361 
8.3.5 Summary ..................................................................................................................................... 362 
8.4 NIGER ................................................................................................................................................... 363 
8.4.1 Achievement of the objectives ..................................................................................................... 363 
8.4.2 Supply of AMFm copaid drugs ................................................................................................... 365 
8.4.3 Implementation of supporting interventions ............................................................................... 366 
vi 
 
8.4.4 Context ........................................................................................................................................ 367 
8.4.5 Summary ..................................................................................................................................... 367 
8.5 NIGERIA ................................................................................................................................................ 368 
8.5.1 Achievement of the objectives ..................................................................................................... 368 
8.5.2 Supply of AMFm copaid drugs ................................................................................................... 370 
8.5.3 Implementation of supporting interventions ............................................................................... 371 
8.5.4 Context ........................................................................................................................................ 373 
8.5.5 Summary ..................................................................................................................................... 373 
8.6 TANZANIA MAINLAND ........................................................................................................................... 374 
8.6.1 Achievement of AMFm objectives ............................................................................................... 374 
8.6.2 Supply of AMFm copaid drugs ................................................................................................... 376 
8.6.3 Implementation of supporting interventions ............................................................................... 377 
8.6.4 Context ........................................................................................................................................ 378 
8.6.5 Summary ..................................................................................................................................... 379 
8.7 UGANDA ............................................................................................................................................... 380 
8.7.1 Achievement of AMFm objectives ............................................................................................... 380 
8.7.2 Supply of AMFm copaid drugs ................................................................................................... 383 
8.7.3 Implementation of supporting interventions ............................................................................... 384 
8.7.4 Context ........................................................................................................................................ 385 
8.7.5 Summary ..................................................................................................................................... 385 
8.8 ZANZIBAR ............................................................................................................................................. 386 
8.8.1 Achievement of AMFm objectives ............................................................................................... 386 
8.8.2 Supply of AMFm copaid drugs ................................................................................................... 389 
8.8.3 Implementation of supporting interventions ............................................................................... 389 
8.8.4 Context ........................................................................................................................................ 390 
8.8.5 Summary ..................................................................................................................................... 391 
9 CONCLUSION........................................................................................................................................ 392 
9.1 CONCLUSION ......................................................................................................................................... 392 
10 REFERENCES ........................................................................................................................................ 396 
11 ACKNOWLEDGEMENTS .................................................................................................................... 403 
12 APPENDICES ......................................................................................................................................... 404 
vii 
 
 
List of tables 
Table 1: Quantity of copaid quality-assured ACTs delivered, July 2010 – December 2011 ........................... xxviii 
Table 2: Quantity of copaid quality-assured ACTs delivered, January 2012 – September 2012 .................... xxviii 
Table 1.2.1: Quantity of copaid quality-assured ACTs requested, approved, and delivered, July 2010 – 
December 2011 ............................................................................................................................................. 8 
Table 1.2.2: Quantity of copaid quality-assured ACTs requested, approved, and delivered, January 2012 – 
September 2012........................................................................................................................................... 10 
Table 1.2.3: Differences between public and private sector buyers ..................................................................... 12 
Table 1.2.4: Number of first-line buyers which received deliveries* of quality-assured ACT treatments through 
AMFm ......................................................................................................................................................... 13 
Table 1.2.5: Quality-assured ACT treatments requested by private not-for-profit and private for-profit first-line 
buyers and approved by the Global Fund, 3
rd
 quarter and 4
th
 quarter of 2011 ............................................ 15 
Table 1.2.6: Quality-assured ACT treatments requested by private not-for-profit and private for-profit first-line 
buyers and approved by the Global Fund, 1
st
 quarter, 2
nd
 quarter and 3
rd
 quarter of 2012 .......................... 15 
Table 1.2.7: Summary of AMFm implementation ................................................................................................ 21 
Table 1.5.1: List of key indicators for the independent evaluation ....................................................................... 40 
Table 1.6.1: Link between outlet and household surveys and the evaluation questions ....................................... 41 
Table 1.6.2: Timing of data collection for outlet surveys and arrival of copaid ACTs by country ...................... 43 
Table 1.6.3: Number of clusters by domain for each country ............................................................................... 44 
Table 1.6.4: Local currencies and their USD equivalents using the average interbank rate, 2010 ....................... 50 
Table 1.6.5: Summary of existing household surveys that include information on ACT use ............................... 52 
Table 1.6.6: Timing of data collection for baseline and endline household surveys in relation to arrival of the 
first copaid ACTs by country ...................................................................................................................... 53 
Table 1.6.7: Number and dates of key informant interviews conducted ............................................................... 54 
Table 1.6.8: Remote area clusters selected for the AMFm Independent Evaluation remote area survey ............. 58 
Table 1.6.9: E2Pi metrics and benchmarks for success and their operationalization by the IE ............................ 64 
Table 2.1.1: Survey sample breakdown: Number of outlets enumerated and number stocking antimalarials by 
urban-rural location, according to country at baseline (2010) and endline (2011) ...................................... 75 
Table 2.1.2: Number of outlets by final interview status and urban-rural location, according to country at 
baseline (2010) and endline (2011) ............................................................................................................. 76 
Table 2.1.3: Number of outlets enumerated by type of outlet and urban-rural location, according to country at 
baseline (2010) and endline (2011) ............................................................................................................. 78 
Table 2.1.4: Number of outlets with antimalarials in stock by type of outlet and urban-rural location, according 
to country at baseline (2010) and endline (2011) ........................................................................................ 80 
Table 2.2.1: Outlets with antimalarials in stock at baseline (2010) and endline (2011) ....................................... 95 
Table 2.2.2: Outlets with non-artemisinin therapy in stock at baseline (2010) and endline (2011)...................... 99 
Table 2.2.3: Outlets with artemisinin monotherapy in stock at baseline (2010) and endline (2011) .................. 101 
Table 2.2.4: Outlets with oral artemisinin monotherapy in stock at baseline (2010) and endline (2011) ........... 103 
Table 2.2.5: Outlets with non-quality-assured ACTs in stock at baseline (2010) and endline (2011)................ 105 
Table 2.2.6: Outlets with quality-assured ACTs in stock at baseline (2010) and endline (2011) ....................... 107 
Table 2.2.7: Outlets with quality-assured ACTs with and without the AMFm logo in stock at endline, 2011 .. 109 
Table 2.2.8: Public health facilities with quality-assured ACTs in stock among ALL public health facilities at 
baseline (2010) and endline (2011) ........................................................................................................... 111 
Table 2.2.9: Outlets with stock-outs of quality-assured ACTs at baseline (2010) and endline (2011) ............... 113 
Table 2.2.10: Percentage of the population living in “subdistricts” with outlets with quality-assured ACTs in 
stock at baseline (2010) and endline (2011) .............................................................................................. 116 
Table 2.3.1: Cost to patients of non-artemisinin therapy, in 2010 US dollars, at baseline (2010) and 
endline(2011) ............................................................................................................................................ 121 
Table 2.3.2: Cost to patients of artemisinin monotherapy, in 2010 US dollars, at baseline (2010) and endline 
(2011) ........................................................................................................................................................ 123 
viii 
 
Table 2.3.3: Cost to patients of oral artemisinin monotherapy, in 2010 US dollars, at endline, 2011 ................ 125 
Table 2.3.4: Cost to patients of non-quality-assured ACTs, in 2010 US dollars, at baseline (2010) and endline 
(2011) ........................................................................................................................................................ 127 
Table 2.3.5: Cost to patients of quality-assured ACTs (including formulations for adults and children), in 2010 
US dollars, at baseline (2010) and endline (2011) .................................................................................... 129 
Table 2.3.6: Cost to patients of quality-assured ACTs (including formulations for adults and children) by 
presence of the AMFm logo, in 2010 US dollars, at endline, 2011 .......................................................... 131 
Table 2.3.7: Cost to patients of quality-assured ACTs (pediatric formulations only), in 2010 US dollars, at 
baseline (2010) and endline (2011) ........................................................................................................... 133 
Table 2.3.8: Cost to patients of quality-assured ACTs (pediatric formulations only) by presence of the AMFm 
logo, in 2010 US dollars, at endline, 2011 ................................................................................................ 135 
Table 2.3.9: Cost to patients in private for-profit outlets, of the most popular antimalarial which is not a QAACT 
in terms of private for-profit outlet sales volumes for TABLETS and ALL DOSAGE FORMS in 2010 US 
dollars at endline 2011 .............................................................................................................................. 138 
Table 2.3.10: Ratio of the cost to patients of quality-assured ACTs with the AMFm logo to the cost to patients 
of the most popular antimalarial which is not a QAACT for TABLETS in private for-profit outlets in 2010 
US dollars, at endline, 2011 ...................................................................................................................... 138 
Table 2.3.11: Ratio of the cost to patients of quality-assured ACTs with the AMFm logo to the cost to patients 
of the most popular antimalarial which is not a QAACT for ALL DOSAGE FORMS in private for-profit 
outlets in 2010 US dollars, at endline, 2011.............................................................................................. 139 
Table 2.3.12: Ratio of the cost to patients of quality-assured ACTs with the AMFm logo to the cost to patients 
of artemisinin monotherapy TABLETS in private for-profit outlets in 2010 US dollars, at endline, 2011
 .................................................................................................................................................................. 139 
Table 2.3.13: Ratio of the cost to patients of quality-assured ACTs with the AMFm logo to the cost to patients 
of artemisinin monotherapy for ALL ORAL DOSAGE FORMS in private for-profit outlets in 2010 US 
dollars, at endline, 2011 ............................................................................................................................ 140 
Table 2.3.14: Gross markup between purchase price and retail selling price of non-artemisinin therapy at 
baseline (2010) and endline (2011) ........................................................................................................... 142 
Table 2.3.15: Gross markup between purchase price and retail selling price of artemisinin monotherapy at 
baseline (2010) and endline (2011) ........................................................................................................... 144 
Table 2.3.16: Gross markup between purchase price and retail selling price of non-quality-assured ACTs at 
baseline (2010) and endline (2011) ........................................................................................................... 146 
Table 2.3.17: Gross markup between purchase price and retail selling price of quality-assured ACTs, at baseline 
(2010) and endline (2011) ......................................................................................................................... 148 
Table 2.3.18: Gross markup between purchase price and retail selling price of quality-assured ACTs, by 
presence of the AMFm logo, at endline, 2011 .......................................................................................... 150 
Table 2.3.19: Median total gross markup from first line buyer price to retail selling price for quality-assured 
ACTs bearing the AMFm logo, in 2010 US dollars, at endline, 2011 ...................................................... 153 
Table 2.3.20: Availability of any diagnostic test for malaria at baseline (2010) and endline (2011) ................. 156 
Table 2.3.21: Availability of malaria microscopy at baseline (2010) and endline (2011) .................................. 158 
Table 2.3.22: Availability of RDTs at baseline (2010) and endline (2011) ........................................................ 160 
Table 2.3.23: Cost to adult patients of malaria microscopy, in 2010 US dollars, at baseline (2010) and endline 
(2011) ........................................................................................................................................................ 162 
Table 2.3.24: Cost to child patients of malaria microscopy, in 2010 US dollars, at baseline (2010) and endline 
(2011) ........................................................................................................................................................ 164 
Table 2.3.25: Cost to adult patients of rapid diagnostic tests for malaria (RDTs), in 2010 US dollars, at baseline 
(2010) and endline (2011) ......................................................................................................................... 166 
Table 2.3.26: Cost to child patients of rapid diagnostic tests for malaria (RDTs), in 2010 US dollars, at baseline 
(2010) and endline (2011) ......................................................................................................................... 168 
Table 2.4.1: Percent distribution of antimalarial sales volumes for public health facilities, at baseline (2010) and 
endline (2011) ........................................................................................................................................... 173 
ix 
 
Table 2.4.2: Percent distribution of antimalarial sales volumes for private not-for-profit facilities, at baseline 
(2010) and endline (2011) ......................................................................................................................... 174 
Table 2.4.3: Percent distribution of antimalarial sales volumes for private for-profit facilities, at baseline (2010) 
and endline (2011) .................................................................................................................................... 175 
Table 2.4.4: Percent distribution of antimalarial sales volumes for all outlets (all sectors combined), at baseline 
(2010) and endline (2011) ......................................................................................................................... 176 
Table 2.4.5: Market share of quality-assured ACTs, by presence of the AMFm logo at endline, 2011 ............. 177 
Table 2.4.6: Percent distribution of antimalarial sales volumes of ALL antimalarials by outlet type at baseline 
(2010) and endline (2011) ......................................................................................................................... 178 
Table 2.4.7: Percent distribution of antimalarial sales volumes by private for-profit outlets by outlet type at 
baseline (2010) and endline (2011) ........................................................................................................... 179 
Table 2.4.8: Percent distribution of sales volumes of quality-assured ACTs by outlet type at baseline (2010) and 
endline (2011) ........................................................................................................................................... 180 
Table 2.5.1: Provider knowledge of first line antimalarial treatment at baseline (2010) and endline (2011) ..... 183 
Table 2.5.2: Provider knowledge of dosing regimen for quality-assured ACTs (QAACTs) for an adult, at 
baseline (2010) and endline (2011) ........................................................................................................... 186 
Table 2.5.3: Provider knowledge of dosing regimen for quality-assured ACTs (QAACTs) for a child, at baseline 
(2010) and endline (2011) ......................................................................................................................... 188 
Table 2.5.4: Reasons for not stocking quality-assured ACTs (QAACTs) for private providers, at baseline (2010) 
and endline (2011) .................................................................................................................................... 191 
Table 2.6.1: Provider recognition of AMFm logo, at baseline (2010) and endline (2011) ................................. 195 
Table 2.6.2: Provider knowledge of the meaning of the AMFm logo at endline, 2011 ...................................... 197 
Table 2.6.3: Sources from which providers have seen or heard of the AMFm logo at endline, 2011 ................ 199 
Table 2.6.4: Percentage of quality-assured ACTs bearing the AMFm logo, at baseline (2010) and endline (2011)
 .................................................................................................................................................................. 201 
Table 2.6.5: Percentage of all antimalarials other than quality-assured ACTs bearing the AMFm logo, at 
baseline (2010) and endline (2011) ........................................................................................................... 203 
Table 2.6.6: Provider knowledge of the AMFm program at endline, 2011 ........................................................ 205 
Table 2.6.7: Sources from which providers heard of the AMFm program at endline, 2011 .............................. 206 
Table 2.6.8: Providers stating that there is a maximum/recommended retail price (RRP) for antimalarials with 
the AMFm logo at endline, 2011 .............................................................................................................. 208 
Table 2.6.9: Providers stating the correct maximum/recommended retail price (RRP) for antimalarials with the 
AMFm logo at endline, 2011 .................................................................................................................... 209 
Table 2.6.10: Providers who have received training on antimalarials with the AMFm logo at endline, 2011 ... 210 
Table 3.1.1: Prevalence of fever among children under five years by selected background characteristics ....... 212 
Table 3.2.1: Any antimalarial treatment of fever among children under five years by selected background 
characteristics ............................................................................................................................................ 214 
Table 3.2.2: ACT treatment among children under five years with fever by selected background characteristics
 .................................................................................................................................................................. 216 
Table 3.2.3: Prompt ACT treatment of fever among under five children by selected background characteristics
 .................................................................................................................................................................. 219 
Table 3.3.1: Diagnostic testing among children under five years with fever by selected background 
characteristics ............................................................................................................................................ 221 
Table 3.4.1: Treatment of fever among children under five years from the poorest households (lowest two 
wealth quintiles), by urban-rural residence ............................................................................................... 223 
Table 4.1.1: Summary of key factors likely to have supported or hindered achievement of AMFm goals in 
Ghana ........................................................................................................................................................ 229 
Table 4.2.1: Summary of key factors likely to have supported or hindered achievement of AMFm goals in 
Kenya ........................................................................................................................................................ 240 
Table 4.3.1. Summary of key factors likely to have supported or hindered achievement of AMFm goals in 
Madagascar ............................................................................................................................................... 248 
x 
 
Table 4.4.1: Summary of key factors likely to have supported or hindered achievement of AMFm goals in Niger
 .................................................................................................................................................................. 258 
Table 4.5.1: Summary of key factors likely to have supported or hindered achievement of AMFm goals in 
Nigeria....................................................................................................................................................... 267 
Table 4.6.1: Summary of key factors likely to have supported or hindered achievement of AMFm goals in 
Tanzania mainland .................................................................................................................................... 278 
Table 4.7.1 Recommended retail prices for AMFm copaid ACTs in 2010 US dollars ...................................... 287 
Table 4.7.2: Summary of key factors likely to have supported or hindered achievement of AMFm goals in 
Uganda) ..................................................................................................................................................... 290 
Table 4.8.1: Summary of key factors likely to have supported or hindered achievement of AMFm goals in 
Zanzibar .................................................................................................................................................... 300 
Table 5.1.1: Number of remote area outlets enumerated and number stocking antimalarials at the time of the 
survey, according to country, 2011-2012 .................................................................................................. 303 
Table 5.1.2 Number of outlets in remote areas at endline by final interview status, according to country, 2011-
2012 .......................................................................................................................................................... 303 
Table 5.1.3: Number of outlets enumerated by type of outlet in remote areas at endline, according to country, 
2011-2012 ................................................................................................................................................. 304 
Table 5.1.4: Number of outlets with antimalarials in stock by type of outlet in the remote areas at endline, 
according to country, 2011-2012 .............................................................................................................. 304 
Table 5.2.1: Outlets in remote areas and non-remote areas with antimalarials in stock at endline, 2011-2012 . 306 
Table 5.2.2:Outlets in remote areas and non-remote areas with quality-assured ACTs in stock at endline, 2011-
2012 .......................................................................................................................................................... 306 
Table 5.2.3: Outlets in remote areas and non-remote areas with quality-assured ACTs with the AMFm logo in 
stock at endline, 2011-2012 ...................................................................................................................... 307 
Table 5.2.4: Outlets in remote areas and non-remote areas with stockouts of quality-assured ACTs at endline, 
2011-2012 ................................................................................................................................................. 308 
Table 5.2.5: Percentage of the population living in “subdistricts” in remote areas and non-remote areas with 
outlets with quality-assured ACTs in stock at endline, 2011-2012 ........................................................... 309 
Table 5.3.1: Cost to patients of quality-assured ACTs (including formulations for adults and children) in remote 
areas and non-remote areas at endline, in US dollars, 2011-2012 ............................................................ 311 
Table 5.3.2: Cost to patients of quality-assured ACTs (pediatric formulations only) in remote areas and non-
remote areas at endline, in US dollars, 2011-2012 .................................................................................... 312 
Table 5.3.3: Cost to patients of non-quality-assured ACTs (including formulations for adults and children) in 
remote areas and non-remote areas at endline, in US dollars, 2011-2012 ................................................ 313 
Table 5.4.1: Gross markup between purchase price and retail selling price of quality-assured ACTs in remote 
areas and non-remote areas at endline, in US dollars, 2011-2012 ............................................................ 315 
Table 5.5.1: Availability of malaria diagnostic tests in remote areas and non-remote areas at endline, 2011-2012
 .................................................................................................................................................................. 317 
Table 5.5.2: Cost to patients of malaria diagnostic tests in remote areas and non-remote areas at endline, in US 
dollars, Kenya, 2011-2012 ........................................................................................................................ 318 
Table 5.6.1: Percent distribution of antimalarial sales volumes in remote areas and non-remote areas at endline, 
2011-2012 ................................................................................................................................................. 320 
Table 5.7.1: Provider recognition of the AMFm logo in remote areas and non-remote areas at endline, 2011-
2012 .......................................................................................................................................................... 322 
Table 5.7.2: Percentage of quality-assured ACTs bearing the AMFm logo in remote areas and non-remote areas 
at endline, 2011-2012 ................................................................................................................................ 322 
Table 6.1.1: Number of individuals contacted by the interviewer and the number who were interviewed by 
urban/rural clusters, according to country, 2012 ....................................................................................... 324 
Table 6.1.2: Number of respondents by sex, age and urban/rural cluster, according to country, 2012 .............. 325 
Table 6.1.3: Reasons for choosing a malaria treatment ...................................................................................... 326 
Table 6.1.4: Source from which respondents had most recently heard of ACTs ................................................ 327 
Table 6.1.5: Respondents who saw the AMFm logo in the outlet they visited ................................................... 328 
xi 
 
Table 6.1.6: Respondents who saw the AMFm logo in the outlet they visited (among those who visited the outlet 
to obtain an antimalarial) .......................................................................................................................... 329 
Table 6.1.7: Source from which respondents have ever seen the AMFm logo ................................................... 330 
Table 6.1.8: Meaning of the AMFm logo: Respondents who have seen the AMFm logo before ....................... 331 
 
xii 
 
 
List of figures 
Figure 1: Overview of the achievement of the AMFm Success Benchmarks by county, indicating benchmarks 
achieved (in green), nearly or possibly achieved (in amber) and not achieved (in red), (point estimate, and 
p-value for statistical test of whether the level stated in the benchmark was achieved)  ......................... xxiii 
Figure 2: Timeline of AMFm Phase 1 Independent Evaluation data collection; grant amendments and 
disbursements; arrival in-country of copaid QAACTs; launch events; IEC/ BCC implementation; and 
application of demand levers by the Global Fund ................................................................................... xxvii 
Figure 3: Breakdown of outlets stocking antimalarials by outlet type at endline Figure .................................... xxx 
Figure 4: Breakdown of private for-profit outlets stocking antimalarials market structure by outlet type at 
endline, 2011 ............................................................................................................................................ xxxi 
Figure 5: Percentage of outlets with QAACTs in stock at baseline and endline, and the Success Benchmark 1 
threshold (20 percentage point increase in availability of QAACTs) ..................................................... xxxii 
Figure 6: Percentage of public health facilities and private for-profit outlets with QAACTs in stock at baseline 
and endlin ............................................................................................................................................... xxxiii 
Figure 7: Percentage of outlets with QAACTs in stock in urban and rural areas at baseline and endline ....... xxxiii 
Figure 8: Percentage of outlets with QAACTs in stock by presence of the AMFm logo at endline ............... xxxiv 
Figure 9: Percentage of outlets with oral AMT and non-artemisinin therapies in stock at baseline and endline
 ................................................................................................................................................................ xxxv 
Figure 10. Median cost to patients of one adult equivalent treatment dose (AETD) of QAACTs in public and 
private for-profit outlets (2010 US dollar equivalent), at baseline and endline ..................................... xxxvi 
Figure 11. Median cost to patients of one AETD of QAACTs in private for-profit outlets in rural and urban 
areas (2010 US dollar equivalent), at baseline and endline ................................................................... xxxvii 
Figure 12. Median cost to patients of one AETD of QAACTs in private for-profit outlets by presence of the 
AMFm logo (2010 US dollar equivalent), at baseline and endline ...................................................... xxxviii 
Figure 13: Median cost to patients of one AETD of QAACTs with the AMFm logo and the recommended retail 
price in private for-profit outlets (2010 US dollar equivalent) at endline ............................................ xxxviii 
Figure 14: Median cost to patients in private for-profit outlets of one AETD of QAACTs bearing the AMFm 
logo compared with the cost per AETD of the most popular antimalarial that is not a quality-assured ACT 
(2010 US dollar equivalent) at endline, and the Success Benchmark 2 threshold (median price ratio <3) 
 ............................................................................................................................................................... xxxix 
Figure 15: Median cost to patients in private for-profit outlets of one AETD of QAACTs bearing the AMFm 
logo and oral artemisinin monotherapy (AMT) in tablet form (2010 US dollar equivalent) at endline ....... xl 
Figure 16: Median gross percentage markup between purchase price and retail selling price of QAACTs bearing 
the AMFm logo and non-artemisinin therapy in private for-profit outlets at endline ................................. xli 
Figure 17: Median total absolute markup from first line buyer purchase price per AETD to retail selling price 
per AETD for QAACTs bearing the AMFm logo in private for-profit outlets (2010 US dollar equivalent) 
at endline .................................................................................................................................................... xlii 
Figure 18: Market share of antimalarials by antimalarial type at baseline and endline, all sectors combined, and 
Success Benchmark 5 threshold (10 precentage points increase in QAACT market share) ..................... xliii 
Figure 19: Market share of antimalarials sold in private for-profit outlets by antimalarial type at baseline and 
endline ....................................................................................................................................................... xliv 
Figure 20: Market share of all antimalarials by sector at baseline and endline ................................................... xlv 
Figure 21: Percentage of outlets where the AMFm logo was recognised and respondents had knowledge of the 
AMFm program, endline only, all outlets combined ................................................................................ xlvi 
Figure 22: Percentage of outlets where the provider knew that there was a recommended retail price (RRP), and 
of those that knew there was an RRP, percentage where the provider knew the correct RRP, endline only, 
all outlets combined1 ............................................................................................................................... xlvii 
Figure 23: Availability in public health facilities and private for-profit outlets of any diagnostic test for malaria 
at baseline and endline ............................................................................................................................ xlviii 
xiii 
 
Figure 24: Overview of the achievement of the AMFm Success Benchmarks by county, indicating benchmarks 
achieved (in green), nearly or possibly achieved (in amber) and not achieved (in red), (point estimate, and 
p-value for statistical test of whether the level stated in the benchmark was achieved) Figure .............. lxviii 
Figure 1.2.1: Artemether-lumefantrine: Relative percentage of pack sizes, pre- and post-revision of co-payment 
structure and introduction of levers ............................................................................................................. 16 
Figure 1.2.2: Artesunate-Amodiaquine: Relative percentage of pack sizes, pre- and post-revision of co-payment 
structure and introduction of levers ............................................................................................................. 17 
Figure 1.2.3: Timeline of AMFm Phase 1 Independent Evaluation data collection; grant amendments and 
disbursements; arrival in-country of copaid QAACTs; launch events; IEC/ BCC implementation; and 
application of demand levers by the Global Fund ....................................................................................... 19 
Figure 1.3.1: Location of the AMFm Phase 1 countries ....................................................................................... 22 
Figure 1.4.1: AMFm Phase 1 Results Framework ................................................................................................ 33 
Figure 1.4.2: AMFm Theory of Change ............................................................................................................... 35 
Figure 1.4.3: The Independent Evaluation Design ............................................................................................... 37 
Figure 1.4.4: AMFm logo ..................................................................................................................................... 38 
Figure 1.6.1: Remoteness classification (quintiles) based on the remoteness index, Kenya and Ghana .............. 57 
Figure 1.6.2: Remoteness classification map showing the location of clusters sampled in the remote areas for the 
AMFm Independent Evaluation remote area survey ................................................................................... 59 
Figure 4.1.1:Timeline of key events related to AMFm implementation process and context in Ghana ............. 230 
Figure 4.2.1: Timeline of key events related to AMFm implementation process and context in Kenya ............ 241 
Figure 4.3.1: Timeline of key events related to AMFm implementation process and context in Madagascar ... 249 
Figure 4.4.1: Timeline of key events related to AMFm implementation process and context in Niger ............. 259 
Figure 4.5.1: Timeline of key events related to the AMFm implementation process and context in Nigeria ..... 268 
Figure 4.6.1: Timeline of key events related to AMFm implementation process and context in Tanzania 
mainland .................................................................................................................................................... 279 
Figure 4.7.1: Timeline of key events related to AMFm implementation process and context Uganda .............. 291 
Figure 4.8.1: Timeline of key events related to AMFm implementation process and context in Zanzibar ........ 301 
Figure 8.1.1: AMFm success metrics scorecard – Ghana ................................................................................... 344 
Figure 8.2.1: AMFm success metrics scorecard – Kenya ................................................................................... 352 
Figure 8.3.1: AMFm success metrics scorecard – Madagascar .......................................................................... 358 
Figure 8.4.1: AMFm success metrics scorecard – Niger .................................................................................... 364 
Figure 8.5.1: AMFm success metrics scorecard – Nigeria ................................................................................. 369 
Figure 8.6.1: AMFm success metrics scorecard – Tanzania mainland ............................................................... 375 
Figure 8.7.1: AMFm success metrics scorecard – Uganda ................................................................................. 381 
Figure 8.8.1:AMFm success metrics scorecard – Zanzibar ................................................................................ 387 
Figure 9.1.1: Overview of the achievement of the AMFm Success Benchmarks by county, indicating 
benchmarks achieved (in green), nearly or possibly achieved (in amber) and not achieved (in red), (point 
estimate, and p-value for statistical test of whether the level stated in the benchmark was achieved) ..... 395 
xiv 
 
 
List of abbreviations 
ACT Artemisinin-Based Combination Therapy 
ADDO Accredited Drug Dispensing Outlets 
AETD Adult Equivalent Treatment Dose 
AGOA Africa Growth Opportunity Act 
AHC Ad Hoc Committee 
AL Artemether-Lumefantrine 
ALMA 
AM 
African Leaders Malaria Alliance 
Antimalarial 
AMT Artemisinin monotherapy 
AMFm Affordable Medicines Facility – malaria 
AMFmCC AMFm Coordinating Committee 
API Active Pharmaceutical Ingredient 
ARI Acute Respiratory Infection 
ASAQ Amodiaquine and Artesunate 
BCC 
CAPSS 
Behavior change communication 
Consortium for ACT Private Sector Subsidy 
CCA Community Change Agent 
CCM County Coordinating Mechanism 
CEM Cohort Event Monitoring 
CERMES Centre de Recherches Médicales et Sanitaires 
CHAG Christian Health Association of Ghana 
CHAI Clinton Health Access Initiative 
CHW Community Health Worker 
CI Confidence Interval 
CIERPA Centre International d'Etudes et de Recherches sur les Populations Africaines 
CIF Cost-Insurance-Freight 
CMS Central Medical Stores 
CP Condition Precedent 
CPC Consumer Protection Council 
CPD Continuing Professional Development 
CRDH Centre de Recherche pour le Développement Humain 
CRS Catholic Relief Services 
CSI Centre de Santé Intégré 
DAMM Direction d’Agence de Medicament de Madagascar 
DCs Data Contributors 
DFID Department for International Development 
DHAP Dihydroartemisinin-Piperaquine 
DHS Demographic and Health Survey 
DLDB Duka la Dawa Baridi 
DNDi Drugs for Neglected Diseases initiative 
DOMC Division of Malaria Control 
ERP Expert Review Panel 
E2Pi Evidence to Policy Initiative 
FBO Faith-Based Organization 
xv 
 
FCO Focal Coordinating Office 
FGD Focus group discussion 
FLB First Line Buyer 
FMOH Federal Ministry of Health 
FOB Free on Board 
GDP Gross Domestic Product 
Gh₡ Ghana Cedis 
GHS Ghana Health Service 
Global Fund The Global Fund to Fight AIDS, Tuberculosis and Malaria 
GoU Government of Uganda 
HAI Health Action International 
HBC Home Based Care 
HMM Home Management of Malaria 
HPLC High-performance Liquid Chromatography 
ICCM Integrated Community Care and Management 
ICH The International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use 
IE Independent Evaluation/Evaluator 
IEC Information, Education and Communication 
IPT Intermittent Preventive Treatment 
IMCI Integrated Management of Childhood Illnesses 
IOM Institute of Medicine 
IQR Interquartile Range 
IRB Institutional Review Board 
IRS Indoor Residual Spraying 
IOM Institute of Medicine 
ITN Insecticide-Treated Net  
JHU Johns Hopkins University 
JMS Joint Medical Stores 
KAP Knowledge, Attitude, and Perception 
KCM Kenya Country Mechanism 
KEMSA Kenya Medical Supplies Agency 
KII Key Informant Interview 
LANSPEX Laboratoire National de Santé Publique et d’Expertise 
LCS Licensed Chemical Sellers 
LFA Local Fund Agent 
LGA Local Government Area 
LLIN Long-lasting Insecticidal Net 
LTR Local Technical Representative 
LSHTM London School of Hygiene and Tropical Medicine 
MEEDS Malaria Early Epidemic Detection System 
MICC Malaria Interagency Coordinating Committee 
MICS Multiple Indicator Cluster Survey 
MIS Malaria Indicator Survey 
MMV Medicines for Malaria Venture 
MOF Ministry of Finance 
MOFEA Ministry of Finance and Economic Affairs 
xvi 
 
MOH Ministry of Health 
MoHSW Ministry of Health and Social Welfare 
MOMS Ministry of Medical Services 
MOPHS Ministry of Public Health and Sanitation 
MSA Master Supply Agreement 
MVU Mobile Video Unit 
NAFDAC National Agency for Food and Drug Administration and Control 
nAT Non-Artemisinin Therapy 
NDA National Drug Authority 
NGO Nongovernmental Organization 
NHIS National Health Insurance Scheme 
NHS National Health System 
NMCP National Malaria Control Program 
NMS National Medical Stores  
NOC National Oversight Committee 
nQAACT Non-Quality-Assured Artemisinin-Based Combination Therapy 
NSA National Strategy Application 
OJT On-the-Job Training 
ONEN Organisation National des Educateurs Novateurs 
OS Outlet survey 
ONPPC Office National des Produits Pharmaceutiques et Chimiques  
OTC Over-the-Counter 
PCN Pharmacists Council of Nigeria 
PDA Personal Digital Assistant 
PHCC Primary Health Care Center  
PHCU Primary Health Care Unit 
PMI President’s Malaria Initiative 
PNLP Programme National de Lutte contre le Paludisme 
POM Prescription-Only Medicines 
POP Part One Pharmacy 
PPB Pharmacy & Poisons Board 
PPS Probability Proportional to Size 
PR Principal Recipient 
PSI Population Services International 
PSM Procurement Supply Management 
PV Pharmacovigilance 
PwC PricewaterhouseCoopers 
QAACT Quality-Assured Artemisinin-Based Combination Therapy 
QCIL Quality Chemicals Industries Limited 
RBM Roll Back Malaria 
RDT Rapid Diagnostic Test 
RFP Request for Proposal 
RMCG Role Model Care Givers 
RMS Regional Medical Stores 
RRP Recommended Retail Price 
RSE Relative standard error 
SADC Southern Africa Development Community  
xvii 
 
SC Steering Committee 
SI Supporting Intervention 
SMOH State Ministry of Health  
SOP Standard Operating Procedures 
SP Sulfadoxine-Pyrimethamine 
SR Sub-Recipient 
SSA sub-Saharan Africa 
SSF Single Stream Funding 
SuNMaP Support to National Malaria Control Program 
SURE Securing Ugandans’ Rights to Essential Medicines 
TANAM Tanzania National Malaria Movement 
TERG Technical Evaluation Reference Group 
TFDA Tanzania Food and Drug Authority 
TLC Technologie de l’Information et de Communication 
TWG Technical Working Group 
TZ-RDIP Tanzania Remote Distribution Incentive Program 
UGP Unité de Gestion de Projet 
UN United Nations 
UNDP United Nations Development Program 
UNICEF United Nations Children's Fund 
USD United States Dollar 
VHT Village Health Team 
VPP Voluntary Pooled Procurement 
WHO World Health Organization 
WHO/AFRO World Health Organization/Africa region 
YGC Yakubu Gowon Centre 
ZFDB Zanzibar Food and Drug Board 
ZILS Zanzibar Integrated Logistics System 
ZMCP Zanzibar Malaria Control Program 
 
xviii 
 
Definition of key terms 
Key terms Definition 
Adult Equivalent Treatment 
Dose (AETD) 
An AETD is the number of milligrams (mg) of an antimalarial drug needed to treat a 60 kg 
adult. 
Antimalarial Any medicine recognized by WHO for the treatment of malaria. Medicines used solely for 
the prevention of malaria are excluded from analysis in this report. 
Artemisinin-Based 
Combination Therapy (ACT) 
An antimalarial that combines artemisinin or one of its derivatives with an antimalarial or 
antimalarials of a different class. 
Artemisinin monotherapy An antimalarial medicine that has a single active compound, where this active compound is 
artemisinin or one of its derivatives. 
Booster Sample A booster sample is an extra sample of units (or in this case outlets) of a type not adequately 
represented in the main survey, but which are of special interest. 
 
In this survey, we have included a booster sample of public health facilities and Part One 
pharmacies in the entire district that includes the selected subdistrict, consisting of all of the 
public health facilities and Part One pharmacies in the district that are not in the selected 
subdistrict. 
Censused subdistrict A subdistrict where field teams conducted a full census of all outlets with the potential to sell 
antimalarials. 
Combination therapy The use of two or more classes of antimalarial drugs/molecules in the treatment of malaria 
that have independent modes of action. 
Dosing/treatment regimen The posology or timing and number of doses of an antimalarial used to treat malaria. This 
schedule often varies by patient weight. 
Enumerated Outlets Outlets that were visited by a member of one of the field teams and from which at a 
minimum basic descriptive information was collected (Sections C1-C9 of the outlet survey 
questionnaire).  
First-line treatment  The government-recommended treatment for uncomplicated malaria. 
Monotherapy An antimalarial medicine that has a single mode of action. This may be a medicine with a 
single active compound or a synergistic combination of two compounds with related 
mechanisms of action. 
Non-artemisinin therapy An antimalarial medicine that does not contain artemisinin or any of its derivatives. 
Outlet Any point of sale or provision of a commodity to an individual. Outlets are not restricted to 
stationary points of sale and may include mobile units or individuals. 
Pediatric formulation Antimalarial drug packaged specifically for children. 
Quality-Assured 
Artemisinin-Based 
Combination Therapies 
(QAACTs) 
QAACTs are ACTs that comply with the Global Fund to Fight AIDS, Tuberculosis and 
Malaria’s Quality Assurance Policy. 
 
For the purpose of the Independent Evaluation, a QAACT is any ACT that appeared on the 
Global Fund's indicative list of antimalarials meeting the Global Fund's quality assurance 
policy prior to baseline or endline data collection (see 
http://www.theglobalfund.org/en/procurement/quality/pharmaceutical/#General), or which 
previously had C-status in an earlier Global Fund quality assurance policy and was used in a 
program supplying subsidized ACTs. 
 
At baseline, QAACTs were defined as any ACT that appeared on the Global Fund’s 
indicative list of antimalarials meeting its quality assurance policy as at June 2010, or which 
previously had C-status in an earlier Global Fund quality assurance policy and was used in a 
program supplying subsidized ACTs. 
 
At endline, QAACTs were defined as any ACT that appeared on the Global Fund’s 
indicative list of antimalarials meeting its quality assurance policy as of September 2011, or 
which previously had C-status in an earlier Global Fund quality assurance policy and was 
used in a program supplying subsidized ACTs. 
Rapid-Diagnostic Test 
(RDT) for malaria  
A test used to confirm the presence of malaria parasites in a patient‘s bloodstream. 
Screened An outlet that was administered the screening questions (S1 to S4) of the outlet survey 
questionnaire (see screening criteria). 
Screening criteria The set of requirements that must be satisfied before the full questionnaire is administered. 
 
In this survey, an outlet met the screening criteria if (1) it had antimalarials in stock at the 
time of the survey visit, or (2) it reported having stocked them in the past three months. 
Subdistrict (SD) 
 
The primary sampling unit, or cluster, for the outlet survey. It is an administrative unit that 
has a population size of approximately 10,000 to 15,000 inhabitants. These units frequently 
are defined by geographical, health or political boundaries. 
Treatment/dosing regimen The posology or timing and number of doses of an antimalarial used to treat malaria. This 
schedule often varies by patient weight. 
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Overview of the Independent Evaluation of AMFm 
 
The success of malaria control efforts depends on a high level of coverage in the use of 
effective antimalarials such as artemisinin-based combination therapies (ACTs). Although 
these antimalarials have been procured in large amounts by countries, evidence suggests that 
ACT use still remains far below target levels. In response to this issue, the Affordable 
Medicines Facility – malaria (AMFm) hosted by the Global Fund to Fight AIDS, 
Tuberculosis and Malaria (Global Fund) was set up. AMFm comprises three key elements: (i) 
price reductions through negotiations with ACT manufacturers; (ii) a buyer subsidy through a 
‘co-payment’ for ACTs at the top of the global supply chain; and (iii) supporting 
interventions to promote appropriate use of ACTs. Examples of these supporting 
interventions include training providers and outreach to communities to promote ACT use. 
All ACTs subsidized through AMFm bear a green leaf logo on their packaging. The four 
main objectives of AMFm are to: (i) increase ACT affordability; (ii) increase ACT 
availability; (iii) increase ACT use, including among vulnerable groups; and (iv) “crowd out” 
oral artemisinin monotherapies, chloroquine and sulfadoxine-pyrimethamine (SP) by 
increasing the market share for ACTs. 
 
The Independent Evaluation of AMFm was designed to assess whether, and to what extent, 
AMFm Phase 1 achieves its objectives. The evaluation was carried out in all of the currently 
operational Phase 1 pilots (Ghana, Kenya, Madagascar, Niger, Nigeria, Tanzania mainland, 
Uganda, and Zanzibar). The evaluation is based on a non-experimental design with a pre- and 
post-test intervention assessment in which each participating country is treated independently 
as a case study. The evaluation includes two major components: (1) a pre-intervention 
(baseline) and post-intervention (endline) study of key outcomes through nationally 
representative outlet surveys and use of secondary household survey data; and (2) 
documentation of key features of the context at baseline and endline and the AMFm 
implementation process in each country. The results of the outlet and household surveys are 
compared to the AMFm success benchmarks (see Figure 1), and interpreted using the process 
and context data to facilitate interpretation of the changes in outcomes over the 
implementation period and to judge whether any observed changes are likely to be due to 
AMFm. Availability, price and market share benchmarks focus on quality assured ACTs 
(QAACTs) defined as products meeting the Global Fund’s quality assurance criteria. (At the 
time this report was written, no endline household survey data were available to measure use 
of ACTs to treat fever in young children, but it is expected that household data will be 
available for some countries before November 2012.) In addition, two complementary studies 
were carried out in selected countries at endline. The remote area study examined the 
availability, price and market share of ACTs at the end of the main endline outlet survey in 
areas considered remote and those considered non-remote. The AMFm logo study assessed 
whether or not the AMFm logo achieved its intended effect with respect to public awareness 
and marketing. 
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A number of key findings can be distilled: 
 
1. Achievement of success benchmarks – Figure 1 provides an overview of the 
performance of each pilot against the AMFm success benchmarks. Of the 8 pilots, 
success benchmarks were clearly met in 5 pilots for availability, 5 pilots for QAACT 
price relative to the most popular antimalarial that is not a QAACT, and 4 pilots for 
QAACT market share (all shaded green). It is also possible that benchmarks were met in 
one additional pilot for availability and price, and in 3 additional pilots for market share, 
although the evidence is not as strong (shaded amber). The success benchmarks related to 
artemisinin monotherapy (AMT) price and market share were met in all pilots with 
sufficient AMTs in the market to make these benchmarks relevant. 
 
2. AMFm and the private for-profit sector – AMFm has been a “game changer” in the 
private for-profit sector for all pilots except Niger and Madagascar, with a dramatic 
impact on the antimalarial market, through large increases in QAACT availability, 
decreases in QAACT prices, and increases in QAACT market share. These changes were 
substantial and achieved in only a few months, demonstrating the power of tapping into 
the distributional capacity of the private sector. The changes are very likely to be largely 
attributable to AMFm. The private for-profit sector response was similar in rural and 
urban areas, in some cases reducing or closing a rural-urban gap in availability and 
market share. There was considerable penetration of copaid QAACTs even in remote 
areas in Ghana and Kenya, where this was evaluated. 
 
3. AMFm and the public sector – AMFm led to fewer fundamental changes to public 
sector antimalarial supply, where QAACT supply continued to be hindered by problems 
with procurement and grant requirements, leading to substantial delays in ordering. 
Increases in QAACT market share were seen in the public sector in four pilots (Ghana, 
Nigeria, Uganda and Zanzibar), although in Nigeria most QAACTs distributed through 
the public sector were not copaid. QAACTs were available in less than 80% of all public 
facilities at endline in five pilots, and there was generally no change in public sector 
QAACT prices as most countries already provided QAACTs for free at baseline (except 
Ghana where public sector QAACT prices fell). 
 
4. Limited impact in Madagascar and Niger – The impact of AMFm on the private for-
profit sector was limited in Madagascar and Niger, where orders of copaid ACTs were 
very low. Explanations may include (i) the lack of full-scale mass media campaigns; (ii) 
the structure of the private for-profit antimalarial sector, which had a much higher 
proportion of general stores, and in Niger itinerant vendors, who are not allowed to stock 
QAACTs; and (iii) an unfavourable context of political and/or economic instability and 
severe weather conditions. 
 
5. Effect of duration of implementation – Longer duration of implementation appears to 
be positively correlated with performance, if the combined presence of copaid ACTs and 
the operation of a large-scale sustained IEC/BCC campaign is considered a proxy for full 
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AMFm implementation. With the exception of Zanzibar, pilots with earlier start dates 
achieved more success benchmarks. No large-scale sustained IEC/BCC campaign was in 
place by the end of 2011 in Madagascar, Niger or Uganda, and these pilots achieved 
fewer benchmarks. However, it is possible that delayed start dates reflect weaker 
implementation capacity in general, and therefore one should be cautious in attributing 
performance to duration of implementation alone. 
 
6. Prices and markups in the private for-profit sector – The price of copaid QAACTs in 
the private for-profit sector at endline was very variable across pilots, ranging from USD 
0.51 in Madagascar to USD 1.96 in Uganda. Reasons for this variability are unclear but 
may include (i) variations in the recommended retail price and its promotion through 
national IEC/BCC campaigns; (ii) guidelines on markups (in Madagascar); (iii) 
differences in cost structure including tax components; and (iv) time since copaid ACTs 
first arrived in each country. The median retail gross markup on copaid QAACTs was 
less than 70% in all pilots (which can be considered reasonable for the retail sector), 
except Uganda (133%) and Zanzibar (100%). 
 
7. Crowding out oral artemisinin monotherapy – Even at baseline, market share for oral 
AMT was less than 4% in Ghana and less than 1% in Kenya, Madagascar, Niger, 
Tanzania Mainland and Uganda. In Nigeria and Zanzibar where oral AMT market share 
was somewhat higher at baseline, large and significant falls were observed, likely 
reflecting a combination of the AMFm subsidy and complementary regulatory measures 
with particularly strong enforcement of the latter in Zanzibar. 
 
8. Availability of non-artemisinin therapies – Availability of non-artemisinin therapies 
such as chloroquine and sulphadoxine-pyrimethamine fell in some countries, but 
remained very high in most countries. However, most of the increase in QAACT market 
share was at the expense of the market share of non-artemisinin therapies. 
 
9. Market structure – The private sector was a major player in the antimalarial market in 
all pilots, accounting for between 40% and 97% of antimalarial sales volumes at baseline, 
and between 49% and 92% at endline. There was no clear pattern across pilots in the 
change in private for-profit market share between baseline and endline. 
 
10. Availability of malaria diagnosis – Diagnostic availability (rapid diagnostic tests or 
microscopy) varied substantially in the public sector, from 29% in Nigeria to 98% in 
Zanzibar at endline. However, in private for-profit outlets, only three pilots had 
substantial availability at endline (Kenya - 14%, Uganda – 21%, Zanzibar - 32%). In this 
sector, health facilities/pharmacies have higher availability of diagnostics than drug and 
general stores. 
 
11. Results of operational research – Results from studies of interventions to enhance the 
implementation of antimalarial subsidies by improving targeting and/or drug use show 
that implementation of such interventions is feasible on a small scale, but more evidence 
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on effectiveness and cost-effectiveness of large-scale programs is needed to inform 
policy. 
 
12. Issues not covered by the Independent Evaluation – A number of important issues 
related to AMFm policy decisions were beyond the scope of the Independent Evaluation, 
including the impact on targeting copaid ACTs to persons with parasitemia; advice 
provided to patients; adherence to dosing regimens; global artemisinin supply; and 
prevalence of counterfeit products. 
 
13. Possible hindering factors for AMFm in some countries include: 
 Delays in the public sector procurement process for copaid ACTs  
 Issues with Global Fund grants and delays in procurement of supporting interventions, 
meaning that implementation of most interventions lagged behind the arrival of 
copaid ACTs by several months 
 Suspension of Global Fund disbursements or grants interrupting implementation of 
supporting interventions 
 Application of Global Fund demand levers to ration orders 
 Political and/or economic instability 
 An antimalarial provider market dominated by highly informal outlets operating 
outside of regulated distribution channels (in Madagascar and Niger) 
 
14. Possible facilitating factors for AMFm in some countries include: 
 Strong AMFm governance structures (including steering committees), involvement of 
the private sector and technical assistance from the Clinton Health Access Initiative  
 Generally smooth operation of the registration process for first-line buyers and 
ordering through the copayment mechanism  
 Strong, large-scale mass media campaigns, including promotion of the AMFm logo 
 Longer duration of implementation 
 Establishment and promotion of a recommended retail price set at an appropriate level 
 Complementary regulatory changes, such as giving ACTs over-the-counter status, and 
implementation of the AMT ban 
 AMFm training in some countries (although only Ghana and Zanzibar had over 20% 
training coverage)  
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Figure 1: Overview of the achievement of the AMFm Success Benchmarks by county, indicating benchmarks achieved (in green), nearly or possibly achieved (in 
amber) and not achieved (in red), (point estimate, and p-value for statistical test of whether the level stated in the benchmark was achieved) 1.1.1 
Benchmark  Ghana Kenya Madagascar Niger Nigeria 
Tanzania 
mainland Uganda Zanzibar* 
1. 20 percentage point increase in 
QAACT availability  
52 
(p<0.01) 
35 
(p<0.01) 
4.6  
(p=0.99) 
10 
(p=0.99) 
26 
(p=0.14) 
44  
(p<0.01) 
46 
(p<0.01) 
39 
2.  Median price of QAACTs with AMFm 
logo is <3 times the median price of the 
most popular antimalarial in tablet form 
that is not a QAACT (ratio)  
3.0 
(p=0.81) 
1.0 
(p<0.01) 
1.6 
(p<0.01) 
2.5 
(p<0.01) 
3.1 
(p=0.99) 
1.0 
(p<0.01) 
3.3 
(p=0.99) 
1.5 
3. Median price of QAACTs with AMFm 
logo is less than the median price of 
AMT tablets (difference, QAACT – 
AMT)  
-0.94 
(p<0.01)    
-1.17 
(p<0.01)   
-6.3 
4. 5 percentage point increase in 
percentage of children with fever who 
received ACT treatment  
 na  na  na  na  na  na  na  na 
5. 10 percentage point increase in market 
share of QAACTs  
40 
(p<0.01) 
31 
(p=0.01) 
8.6 
(p=0.61) 
-8.8 
(p=0.99) 
18 
(p<0.01) 
16 
(p=0.23) 
17 
(p=0.08) 
48 
6. Decrease in market share of oral AMTs 
(percentage point change)      
-3.9 
(p=0.03)   
-12 
Notes: Green shading = the benchmark was achieved, with strong statistical evidence (generally p<0.01); Amber shading = either the benchmark was nearly, but not fully, met, or the evidence that the change seen was 
unlikely to be due to chance is weak (p≥0.05). However, the power to detect a 10 percentage point increase in market share was only 35% in Tanzania, 66% in Uganda and 70% in Madagascar, compared with the usual 
minimum standard of 80%; therefore, p-values should be interpreted with caution. Red shading = the benchmark was not met; Grey shading for Benchmarks 3 and 6 = not relevant because the number of AMT products 
was very low at baseline. * p-values not shown for Zanzibar because a complete census of antimalarial stocking outlets was undertaken; na = not available; ACT= artemisinin-based combination therapy; AMT= 
artemisinin montherapy; QAACT= quality-assured artemisinin-based combination therapy 
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Executive Summary 
Overview of the independent evaluation 
The success of malaria control efforts depends on a high level of coverage in the use of 
effective antimalarials such as artemisinin-based combination therapies (ACTs). Although 
these antimalarials have been procured in large amounts by countries, evidence suggests that 
ACT use still remains far below target levels.  
 
In response to this issue, the Affordable Medicines Facility – malaria (AMFm) hosted by the 
Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) was set up. AMFm 
comprises three key elements: (i) price reductions through negotiations with ACT 
manufacturers; (ii) a buyer subsidy through a ‘co-payment’ for ACTs at the top of the global 
supply chain; and (iii) supporting interventions to promote appropriate use of ACTs. 
Examples of these supporting interventions include training providers and outreach to 
communities to promote ACT use. All ACTs subsidized through AMFm bear a green leaf 
logo on their packaging. 
 
The four main objectives of AMFm are to: (i) to increase ACT affordability; (ii) to increase 
ACT availability; (iii) to increase ACT use, including among vulnerable groups; and (iv) to 
“crowd out” oral artemisinin monotherapies, chloroquine and sulfadoxine-pyrimethamine 
(SP) by gaining market share. AMFm is being tested in a first phase that includes nine pilots 
in eight countries: Cambodia, Ghana, Kenya, Madagascar, Niger, Nigeria, Republic of 
Tanzania (mainland and Zanzibar) and Uganda.  
 
The Independent Evaluation (IE) of AMFm was designed to assess whether, and to what 
extent, AMFm Phase 1 achieves its objectives. The IE is part of a multi-faceted monitoring 
and evaluation framework developed for AMFm Phase 1. Through a competitive bid, the 
Global Fund contracted ICF International and the London School of Hygiene and Tropical 
Medicine (LSHTM) to conduct the IE. The IE was carried out in all of the currently 
operational Phase 1 pilots (Ghana, Kenya, Madagascar, Niger, Nigeria, Tanzania mainland, 
Uganda, and Zanzibar). In addition, the Global Fund contracted with Data Contributors 
(DCs) that were responsible for in-country fieldwork and data analysis for the outlet surveys. 
These institutions are Population Services International (PSI), Drugs for Neglected Diseases 
initiative (DNDi), and Centre de Recherche pour le Développement Humain (CRDH). PSI 
was responsible for the work in Kenya, Madagascar, Nigeria, Uganda, Tanzania mainland 
(which was subcontracted to the Ifakara Health Institute) and Zanzibar. For the surveys in 
Madagascar, Nigeria and Uganda the IE has drawn on outlet surveys commissioned prior to 
AMFm and carried out by PSI's ACTwatch Project (www.actwatch.info) through a grant 
from the Bill and Melinda Gates Foundation, which either partially or fully funded outlet 
survey rounds in these Phase 1 pilots. DNDi subcontracted with the Komfo Anokye Teaching 
Hospital, Kumasi, to undertake the work in Ghana. CRDH subcontracted with the Centre 
International d'Etudes et de Recherches sur les Populations Africaines (CIERPA) to 
undertake the work in Niger. 
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The IE is based on a non-experimental design with a pre- and post-test intervention 
assessment in which each participating country is treated independently as a case study. The 
evaluation includes two major components: (1) a pre-intervention (baseline) and post-
intervention (endline) study of key outcomes through nationally representative outlet surveys 
and use of secondary household survey data; and (2) documentation of key features of the 
context at baseline and endline and the AMFm implementation process in each country 
through key informant interviews and document review, to facilitate interpretation of the 
changes in outcomes over the implementation period and to judge whether any observed 
changes are likely to be due to AMFm. These data sources are supplemented by additional 
primary data on outlets in remote areas in Ghana and Kenya; and primary data on user views 
of the AMFm logo in four pilots (Ghana, Kenya, Madagascar and Nigeria). Operational 
research conducted by other groups was also reviewed. The results of the baseline and 
endline outlet and household surveys are compared to the AMFm success metrics (see 
below). The findings on achievement of success metrics are synthesized with the process and 
context data collected for each country and the other studies outlined above to assess the 
performance of AMFm in each operational pilot, and to help learn how and why this new 
model unfolds in a variety of contexts, while drawing lessons that can help future operations. 
 
Methods for the IE outlet surveys were built on those developed for the ACTwatch project, 
and cover outlets across the public, private for-profit and private not-for-profit sectors in rural 
and urban areas. Baseline outlet surveys were conducted between April and December 2010 
(except Nigeria which was conducted from September to November 2009), and endline outlet 
surveys were conducted between October 2011 and January 2012. The midpoint of endline 
survey fieldwork was between 6.5 and 15.5 months after the arrival in the country of the first 
AMFm copaid drugs. 
 
For the purpose of analysis, antimalarials were split into three categories: non-artemisinin 
therapy (nAT) (e.g., SP, amodaquine, and quinine), artemisinin monotherapy (AMT) and 
artemisinin-based combination therapy (ACT). AMTs were further classified into oral and 
non-oral AMTs, as while non-oral AMT are recommended for treatment of severe malaria, 
the removal of oral AMTs from the market is a key policy goal. ACTs were further 
subdivided into those that met the Global Fund’s standards as “quality-assured ACTs” 
(QAACTs) and those that did not. At endline, QAACTs are further classified based on 
whether the AMFm green-leaf logo was present on the packaging, as a proxy for whether the 
product was subsidized by AMFm. Antimalarial volume and price data are reported in terms 
of adult equivalent treatment doses (AETDs). An AETD is defined as the number of 
milligrams (mg) of an antimalarial drug needed to treat a 60 kg adult. Price data were 
adjusted to 2010 USD.  
 
Existing nationally representative household survey reports and data were used to extract 
information for the ACT use indicators from four types of national surveys (DHS, MICS, 
MIS and ACTwatch). At the time this report was written, no endline household survey data 
were available for any countries. A supplemental report, including revised tables and a 
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discussion of the household survey results in the interpretation of the success metrics in 
Chapter 8, will be prepared if a sufficient quantity of endline data becomes available in the 
coming months.  
 
Interpretation and operationalization of success metrics  
The Global Fund’s AMFm Ad Hoc Committee commissioned the Evidence to Policy 
Initiative (E2Pi) to propose benchmarks for outcomes which could realistically be expected in 
the first and second years of the pilots. To inform the setting of the benchmarks, the E2Pi 
team conducted a literature review and key informant interviews to review the experience of 
relevant programs and developed metrics and benchmarks for QAACT availability, price, 
market share and ACT use. 
 
The IE has refined and operationalized these metrics for use in this report as follows:  
 Benchmark 1: At least a 20 percentage point increase from baseline to endline in the 
percentage of outlets stocking ALL QAACTs (both with and without the AMFm logo) 
 Benchmark 2: In private for-profit outlets, a ratio of the median price of QAACTs with 
the AMFm logo to the median price of the most popular antimalarial that is not a QAACT 
in tablet form of less than 3. 
 Benchmark 3: In private for-profit outlets, a median price of QAACTs with the AMFm 
logo of less than the median price of AMT tablets  
 Benchmark 4: At least a 5 percentage point increase from baseline to endline in the 
percentage of children under age 5 years with fever in the last 2 weeks who received ACT 
treatment 
 Benchmark 5: At least a 10 percentage point increase from baseline to endline in the 
market share of ALL QAACTs (both with and without the AMFm logo) 
 Benchmark 6: A decrease from baseline to endline in the market share of AMTs (all oral 
dosage forms) 
Price metrics are calculated for the private for-profit sector only because in most settings 
QAACTs are free in public and private not-for-profit health facilities. Price metrics are 
calculated for QAACTs with the logo only in order to focus on the extent to which the 
subsidy provided through AMFm has been passed through to final retail prices.  
 
These benchmarks are based on the thresholds proposed by E2Pi for one year after “the 
effective start date of AMFm at the country level.” It should be noted that while half of the 
pilots had at least some copaid drugs in the country for more than 12 months before the 
endline outlet survey (16.5 months in Ghana, 15 months in Kenya, 14 months in Madagascar 
and 13.5 months in Tanzania), the time between the arrival of drugs and the endline outlet 
survey in the remaining countries ranged from 6.5-9.5 months. Implementation of supporting 
interventions often trailed the arrival of copaid drugs in country, in some cases by six months, 
and in 3 pilots (Madagascar, Niger, Uganda) no large scale sustained communications 
campaign for AMFm had been established by the time of endline data collection. Figure 2 
provides an overview of the timeline of AMFm implementation in each pilot, from the 
signing of the grant amendment to grant disbursements, arrival of copaid drugs, and 
implementation of the IEC/BCC campaign (this supporting intervention has been highlighted 
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as it is a key intervention included in all pilot AMFm proposals). The figure also shows the 
timing of the implementation of demand levers, and the dates of the Independent Evaluation 
baseline and endline outlet survey data collection. This duration of effective implementation 
needs to be taken into account when interpreting country performance against the 
benchmarks, together with other elements of implementation process and country context.  
 
Figure 2: Timeline of AMFm Phase 1 Independent Evaluation data collection; grant amendments and 
disbursements; arrival in-country of copaid QAACTs; launch events; IEC/ BCC implementation; and 
application of demand levers by the Global Fund 1.1.1 
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Notes:   = Baseline and endline data collection for Independent Evaluation outlet surveys.     = Signing of grant amendment 
and Global Fund grant disbursements for implementation of Supporting Interventions.     = Copaid QAACTs in-country 
(although not necessarily in continuous supply); + = copaid QAACTs delivered,    = Implementation of AMFm public 
awareness (IEC/BCC) campaign at scale.     =Interim AMFm public awareness (IEC/BCC) campaign i.e. Ghana: talk shows 
only; Niger: activities not at scale; Nigeria: stop-gap soft launch; Uganda: stop-gap radio.     = Application of Global Fund 
demand levers.  GA= grant amendment; $= disbursement for implementation of SIs; L= launch; L *= “Soft” Launch; in 
Tanzania- mainland a “soft” launch was held with a press conference on January 25, 2011; in Uganda a “soft” launch was 
held on April 29, 2011- linked to World Malaria Day celebrations, however no IEC/BCC or trainings began until after 
endline data collection. **Nigeria: Baseline data collection completed Sept-Nov 2009 
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Key findings  
The key findings begin with a presentation of the aggregate orders for copaid drugs and their 
breakdown by country. The results of the baseline and endline outlet surveys and the changes 
over time in availability, price and market share indicators across all countries are 
subsequently presented. This is followed by presentation of results from household surveys, 
the remote areas study, the public awareness/logo study and findings from operational 
research. An assessment of the achievement of the AMFm Success Benchmarks is given for 
each country individually, which draws on the country case studies of implementation 
process and context in order to understand the extent to which observed changes in key 
outcomes can plausibly be attributed to AMFm.  
 
Key findings on aggregate orders and demand levers 
The total number of QAACT doses delivered to 81 first line buyers (FLB) by the end of 2011 
was 155.8 million (Table 1). Just over one-third of these doses were delivered to Nigeria. 
Ghana, Kenya, Uganda and Tanzania mainland were the next largest recipients with much 
smaller amounts delivered to Niger, Madagascar and Zanzibar. The majority were delivered 
to private for-profit FLBs in Ghana, Madagascar, Nigeria, Tanzania mainland and Zanzibar. 
In Kenya, the public sector received similar quantities as the private for-profit sector, and in 
Niger and Uganda the public sector was the main recipient.Table 2 shows the quantity of 
copaid QAACTs delivered between January and September 2012. 
 
Table 1: Quantity of copaid quality-assured ACTs delivered, July 2010 – December 2011 1.1.1 
Quantity of copaid quality-assured ACT treatments delivered* to countries, by sector, according to country 
Country Public Private not-for-profit Private for-profit Total 
Ghana  1,404,325 0 23,269,401 24,673,726 
Kenya  14,347,410 0 14,109,228 28,456,638 
Madagascar  489,050 0 1,199,128 1,688,178 
Niger  1,783,480 0 441,640 2,225,120 
Nigeria 7,827,690 5,389,830 44,043,781 57,261,301 
Tanzania – mainland 4,917,600 0 8,122,020 13,039,620 
Uganda 20,705,490 599,900 6,921,310 28,226,700 
Zanzibar 91,075 0 150,000 241,075 
* Manufacturers must provide proof of delivery to The Global Fund with all invoices for co-payment. Due to the delay between delivery 
and submission of an invoice by manufacturers, the actual treatment quantities delivered may be higher than what is officially reported in 
this table. 
Source: Global Fund data base 
 
Table 2: Quantity of copaid quality-assured ACTs delivered, January 2012 – September 2012  
Quantity of copaid quality-assured ACT treatments delivered* to countries, by sector, according to country 
Country Public Private not-for-profit Private for-profit Total 
Ghana  1,801,710 0 11,896,780 13,698,490 
Kenya  2,233,980 0 9,736,660 11,970,640 
Madagascar  218,100 0 563,664 781,764 
Niger  381,390 0 1,250,360 1,631,750 
Nigeria 827,425 3,036,140 29,407,679 33,271,244 
Tanzania – mainland 4,917,780 0 10,625,308 15,543,088 
Uganda 2,166,360 500,000 7,555,960 10,222,320 
Zanzibar 0 0 0 0 
* Manufacturers must provide proof of delivery to The Global Fund with all invoices for co-payment. Due to the delay between delivery 
and submission of an invoice by manufacturers, the actual treatment quantities delivered may be higher than what is officially reported in 
this table. 
Source: Global Fund data base 
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There are some systematic differences in the purchasing behavior of public and private sector 
first-line buyers.  For the public sector, typically there is a single first-line buyer that places a 
single order (with staggered deliveries) to cover the entire public sector need for a full year, 
following a competitive tender process. In contrast, to cover the private sector needs, several 
private sector first-line buyers place multiple, relatively smaller orders periodically 
throughout the year, after directly contacting a manufacturer and reaching an agreement. 
 
Up until July 2011 all orders made by FLB were approved by the Global Fund in the same 
quarter. However, it became apparent that the demand for AMFm copaid ACTs was greater 
than the resources available for co-payment during Phase 1. In order to ensure the availability 
of co-payment funding until additional resources might be secured, the AMFm Secretariat 
developed a framework for rationing co-payment. Since August 2011, each request for co-
payment received is evaluated on the basis of several criteria (for example, the ratio of 
cumulative approved orders to estimated demand, relative proportion of pediatric 
formulations/pack sizes, and sector) and approved within the constraint of USD 8-10 million 
per month.  
 
The immediate result of the application of these levers was a drastic reduction in the 
proportion of orders approved for co-payment, particularly for the private sector as all public 
sector requests for co-payment received in 2011 were approved for co-payment. In Q3 and 
Q4 of 2011, the AMFm approved only 32% of the private not-for-profit and private for-profit 
sector requests for co-payment received; Nigeria, Ghana, Kenya, and Uganda were the most 
affected, with only 24%, 27%, 56% and 57%, respectively, of private sector orders approved 
during this period. By contrast, all requests had been approved for Madagascar and Niger, 
and relatively few orders were pending or cancelled in Tanzania mainland and Zanzibar. 
Although orders take several months to arrive in country and be distributed, it is likely that 
non-approval of orders due to demand levers, particularly in Q3 of 2011, may have 
influenced QAACT availability by the time of the endline outlet surveys in at least four of the 
pilots. 
 
The relative percentage of child versus adult packs of AL, which represents 85% of all co-
paid ACTs approved, has evolved over time. In March 2011, the co-payment structure was 
revised to favor pediatric packs, which began to have an effect, with child packs of AL 
increasing from 32% to 49% of approved orders in the period March to July 2011. Following 
implementation of the demand-shaping levers, this resulted in further increases in the relative 
proportion of child packs, to 65% for the period August to December 2011 and to 69% for the 
period January to August 2012. 
 
Key findings from the outlet surveys 
Figures 3 and 4 show the breakdown of the structure of the antimalarial market (that is, all 
antimalarials, including quality-assured ACTs as well as other products) in the eight pilots for 
all outlet types (Figure 3) and for private for-profit outlets (Figure 4). Over 75% of outlets 
stocking antimalarials at endline were private for-profit outlets, except in Zanzibar where this 
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was 63%. Differences across pilots were seen, however, in the composition of the private for-
profit sector (Figure 4). In Ghana, Nigeria, Tanzania mainland, Uganda, and Zanzibar, drug 
stores were the most common type of private for-profit sector outlet stocking antimalarials, 
while in Kenya, Madagascar, and Niger, general stores were the most common such outlet at 
endline. Of note, itinerant vendors were only frequently found in Niger where they made up 
28% of the total private for-profit outlets stocking antimalarials at endline. 
 
Figure 3: Breakdown of outlets stocking antimalarials by outlet type at endline Figure 1.1.2 
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Figure 4: Breakdown of private for-profit outlets stocking antimalarials market structure by outlet type at 
endline, 2011 1.1.3 
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Availability of quality-assured ACTs 
At endline, QAACT availability across all sectors ranged from 19% to 85% (Figure 5). 
QAACT availability was lowest in Niger (19%) and Madagascar (28%), ranged from 54% to 
70% in Kenya, Nigeria, Tanzania mainland and Uganda, and exceeded 80% in Ghana and 
Zanzibar. In Ghana and Zanzibar, QAACT availability was over 80% in both public facilities 
and private for-profit outlets (results for private non-profit outlets and community health 
workers are not generally presented separately due to the small samples for these outlet types) 
(Figure 6). In Kenya, Tanzania mainland and Uganda availability in private for-profit outlets 
was over 60%, but this was lower than availability in the public sector (over 80%). There 
were much bigger differences in availability between the public and private for-profit sectors 
in Madagascar (94% vs. 9%) and Niger (73% vs. 14%). Nigeria stands out as having similar 
levels of availability in the public and private for-profit sectors, with public sector availability 
lower than in other countries (57% in public facilities vs. 53% in private for-profit outlets).  
 
The change in QAACT availability between baseline and endline is used to assess Success 
Benchmark 1 (Figure 5). Between baseline and endline there were large and significant 
increases in QAACT availability among all outlets in Ghana, Kenya, Nigeria, Tanzania 
mainland, Uganda and Zanzibar, with increases of 24-52 percentage points, with the majority 
of the increase observed in the private for-profit sector in all cases (Figure 6). Niger had a 
more modest increase of 10 percentage points. In public health facilities, there were increases 
in QAACT availability in Kenya, Madagascar, Niger and Zanzibar. In the remaining pilots, 
xxxii 
 
there was no evidence of change in public health facilities. Increases in QAACT availability 
were seen in both urban and rural areas in all countries (Figure 7). No change was observed 
in Madagascar. 
 
Figure 5: Percentage of outlets with QAACTs in stock at baseline and endline, and the Success Benchmark 1 
threshold (20 percentage point increase in availability of QAACTs) 1.1.4 
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Figure 6: Percentage of public health facilities and private for-profit outlets with QAACTs in stock at baseline 
and endline1.1.5 
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Figure 7: Percentage of outlets with QAACTs in stock in urban and rural areas at baseline and endline1.1.6 
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At endline, availability of QAACTs with the AMFm logo was substantially higher than those 
without the logo everywhere except Madagascar and Niger. The availability of QAACTs 
without the logo varied from 6% to 21% (Figure 8). 
 
At endline, the availability of oral artemisinin monotherapy (AMT) was high in Ghana (41%) 
and Nigeria (34%) [Figure 9]. Everywhere else oral AMT was stocked by less than 1% of 
outlets. There was little change between baseline and endline in all countries other than 
Zanzibar, where oral AMT availability fell from 17% at baseline to a negligible level at 
endline. In Ghana, oral AMT was primarily available in the private for-profit sector (47% of 
outlets at endline). In Nigeria, oral AMT availability at endline was 15% in public facilities 
and 35% in private for-profit outlets. At endline, nATs remained common in all countries, 
with availability among all outlets over 75% except in Zanzibar, where it was 47% (Figure 
9). 
 
Figure 8: Percentage of outlets with QAACTs in stock by presence of the AMFm logo at endline1.1.7 
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Figure 9: Percentage of outlets with oral AMT and non-artemisinin therapies in stock at baseline and 
endline1.1.8 
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Affordability of quality-assured ACTs 
In the public sector the median price per AETD of QAACTs was zero in all countries except 
Ghana at baseline and endline, reflecting widespread free provision of QAACTs (Figure 10). 
In Ghana, the median QAACT price fell from USD 2.74 at baseline to USD 0.94 at endline. 
It is recognised that patients face a variety of other costs when using the public sector, 
including consultation fees, transport costs, etc, and these may pose a considerable barrier to 
care even when drugs are supplied free of charge. Given the predominance of free QAACTs 
in the public sector, this section focuses on prices in the private for-profit sector.  
 
In the private for-profit sector, the lowest median prices were in Kenya (USD 0.58) and 
Madagascar (USD 0.60), followed by Tanzania mainland (USD 0.94). In other countries, 
prices were USD 1.13 in Ghana, USD 1.17 in Zanzibar, USD 1.19 in Niger, USD 1.48 in 
Nigeria and USD 1.96 in Uganda (Figure 10). Prices for pediatric QAACT doses in the 
private for-profit sector ranged from USD 0.19 in Madagascar to USD 0.89 in Nigeria.  
 
Large and significant falls in median QAACT price per AETD were seen in the private for-
profit sectors of six of the eight pilots, with the decline ranging from USD 1.28 to USD 4.82. 
No significant price change was observed overall in Uganda, but there was a significant fall 
of USD 2.68 in urban areas. In Madagascar, there was a significant increase in the median 
price of USD 0.46, but the median price at baseline was only USD 0.14, reflecting the 
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presence of an ACT subsidy program at baseline (brand name ACTipal), which included a 
very low recommended retail price (USD 0.10-0.20 for an adult equivalent treatment dose). 
QAACTs were slightly more expensive in urban than rural areas, except in Uganda where the 
median prices were the same, and in Nigeria where the price was higher in rural areas (Figure 
11). 
 
Figure 10. Median cost to patients of one adult equivalent treatment dose (AETD) of QAACTs in public and 
private for-profit outlets (2010 US dollar equivalent), at baseline and endline1.1.9 
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Figure 11. Median cost to patients of one AETD of QAACTs in private for-profit outlets in rural and urban 
areas (2010 US dollar equivalent), at baseline and endline1.1.10 
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In the private for-profit sector at endline, quality-assured ACTs with the AMFm logo were 
generally much less expensive than those without the logo. In Ghana and Zanzibar, the price 
of QAACTs without the logo in the private for-profit sector was around seven times higher 
than those with the logo. In Kenya, Niger and Nigeria, QAACTs without the logo were 
somewhat more expensive. In Uganda, the median price was the same for the two types of 
products, while in Tanzania mainland, QAACTs without the logo were less expensive in rural 
areas, but considerably more expensive in urban areas (Figure 12). In Madagascar, QAACTs 
without the logo were much more expensive in urban areas than those with the logo, but in 
rural areas they were less expensive, possibly reflecting the presence of the subsidized ACT 
product ACTipal.  
 
Figure 13 shows the cost to patients of QAACTs with the AMFm logo in comparison to the 
recommended retail price (RRP) for QAACTs with the logo, showing that, on the whole, 
median prices charged were higher than the RRP. 
 
Figure 14 shows the median cost of QAACTs with the logo and the cost of the most popular 
antimalarial which is not a QAACT in tablet form at endline in private for-profit outlets. 
These data are used to assess Success Benchmark 2. The most popular antimalarial which is 
not a QAACT in tablet form was SP in Ghana, Kenya, Nigeria, Tanzania mainland and 
Uganda; amodiaquine in Zanzibar; and chloroquine in Madagascar and Niger. QAACTs with 
the logo were the same price as the most popular antimalarial which is not a QAACT in 
Kenya and Tanzania mainland. In Zanzibar and Madagascar, they were 1.5 and 1.6 times 
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more expensive, respectively, and in Niger they were 2.5 times more expensive. In Ghana, 
Nigeria and Uganda, QAACTs with the logo were three or more times as costly as the most 
popular antimalarial which is not a QAACT.  
 
Figure 12. Median cost to patients of one AETD of QAACTs in private for-profit outlets by presence of the 
AMFm logo (2010 US dollar equivalent), at baseline and endline1.1.11 
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Figure 13: Median cost to patients of one AETD of QAACTs with the AMFm logo and the recommended 
retail price in private for-profit outlets (2010 US dollar equivalent) at endline1.1.12 
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Figure 14: Median cost to patients in private for-profit outlets of one AETD of QAACTs bearing the AMFm 
logo compared with the cost per AETD of the most popular antimalarial that is not a quality-assured ACT 
(2010 US dollar equivalent) at endline, and the Success Benchmark 2 threshold (median price ratio <3) 1.1.13 
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Note: The most popoular antimalarial which is not a QAACT (tablet form) was calculated in terms of total sales volumes of 
tablets in private for-profit outlets 
 
Figure 15 shows the cost to patients of QAACTs with the AMFm logo and the cost of 
artemisinin monotherapy tablets at endline in private for-profit outlets in Ghana and Nigeria 
(data are not shown for other countries due to the low number of observations for artemisinin 
monotherapy tablets). These data are used to assess Success Benchmark 3. QAACTs with the 
logo were much less costly than oral AMT tablets in both countries. 
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Figure 15: Median cost to patients in private for-profit outlets of one AETD of QAACTs bearing the AMFm 
logo and oral artemisinin monotherapy (AMT) in tablet form (2010 US dollar equivalent) at endline1.1.14 
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Note: Results are only presented for Ghana and Nigeria as in the other countries the number of AMT tablets 
products was very small. 
 
The gross percentage markup at the outlet level for QAACTs bearing the AMFm logo at 
endline in private for-profit outlets ranged from 36% in Niger to 133% in Uganda (Figure 
16). Note that these are gross markups that include both profit margin and the cost of doing 
business. Between baseline and endline, percentage markups increased somewhat (except in 
Niger), bringing them up to a level similar to those of nATs, which ranged from 41% in 
Nigeria to 85% in Niger. With the dramatic fall in the median QAACT price in most 
countries, an increase in percentage markups may not imply any increase in absolute 
markups.  
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Figure 16: Median gross percentage markup between purchase price and retail selling price of QAACTs 
bearing the AMFm logo and non-artemisinin therapy in private for-profit outlets at endline1.1.15 
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Figure 17 shows the total gross markup in USD for QAACTs with the AMFm logo in private 
for-profit outlets from the point of purchase by first line buyers to the point of sale to patients, 
capturing both the additional costs and profit margins that are added by first line buyers, any 
intermediate wholesalers and retailers. Total gross markup varied from USD 0.40 in Kenya to 
USD 1.83 in Uganda.  
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Figure 17: Median total absolute markup from first line buyer purchase price per AETD to retail selling price 
per AETD for QAACTs bearing the AMFm logo in private for-profit outlets (2010 US dollar equivalent) at 
endline1.1.16 
 
0.87
0.40
0.45
1.31 1.33
0.84
1.83
1.11
0.00
0.50
1.00
1.50
2.00
2.50
3.00
Ghana Kenya Madagascar Niger Nigeria Tanzania
mainland
Uganda Zanzibar
M
ed
ia
n
 t
o
ta
l 
a
b
so
lu
te
 m
a
rk
u
p
 f
ro
m
 f
ir
st
 l
in
e 
b
u
y
er
 p
u
rc
h
a
se
 p
ri
ce
 p
er
 
A
E
T
D
 t
o
 r
et
a
il
 s
el
li
n
g
 p
ri
ce
 p
er
 A
E
T
D
 f
o
r 
Q
A
A
C
T
s 
b
ea
ri
n
g
 t
h
e 
A
M
F
m
 l
o
g
o
 
in
 p
ri
v
a
te
 f
o
r-
p
ro
fi
t 
o
u
tl
et
s 
(U
S
 d
o
ll
a
r 
eq
u
iv
a
le
n
t)
 
 
Market share of quality-assured ACTs 
Across all outlet types, the QAACT market share at endline ranged from 10% in Niger to 
58% in Ghana and Zanzibar (Figure 18). The change in QAACT market share between 
baseline and endline is used to assess Success Benchmark 5. Large and significant increases 
in QAACT market share were seen between baseline and endline in Ghana, Kenya, Nigeria, 
Tanzania mainland, Uganda and Zanzibar, ranging from 16 percentage points in Tanzania 
mainland to 48 percentage points in Zanzibar. Madagascar saw a significant increase in 
QAACT share in urban areas of 23 percentage points. There was a large decrease in the 
market share of nAT in all countries, except Madagascar, where the decrease was small, and 
Niger which saw an increase in the share of nAT and a corresponding fall in QAACT share. 
It should be noted that there are legitimate uses of nATs, such as use of SP for intermittent 
preventive treatment for pregnant women and infants, and quinine for management of severe 
malaria. It is therefore not a policy objective to reduce availability or market share of these 
products to zero. Ghana also saw a decrease in the share of non-quality-assured ACTs. 
Zanzibar saw a substantial decrease in the market share of oral AMT, from 12% to less than 
1%, while the market share of oral AMTs fell by 4 percentage points to 4% at endline in 
Nigeria. These data are used to assess Success Benchmark 6, but this Benchmark is of limited 
relevance to other countries as the market share of oral AMT was already minimal at 
baseline. In Ghana, Kenya, Nigeria and Uganda, increases in QAACT market share were 
similar in rural and urban areas, while all of the increase in QAACT market share in Tanzania 
mainland occurred in rural areas, and in Zanzibar, urban areas saw the greater increase. In 
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Niger, there was a significant decrease in the QAACT share, with an equivalent increase in 
the share of nAT.  
 
Figure 18: Market share of antimalarials by antimalarial type at baseline and endline, all sectors combined, and 
Success Benchmark 5 threshold (10 precentage points increase in QAACT market share) 1.1.17 
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Considering the private for-profit sector alone, the results for QAACT market share were 
very similar to those for all outlet types combined. The exceptions were Tanzania mainland 
and Uganda, where the QAACT market share overall was higher than in the private for-profit 
sector (42% vs. 32% in Tanzania mainland and 57% vs. 39% in Uganda) (Figure 19). 
 
The vast majority of QAACTs sold in the private for-profit sector bore the AMFm logo in all 
countries except Niger, where both product types had a very low market share (each less than 
5%). In the public sector, the picture was more mixed. In this sector, the majority of 
QAACTs carried the logo in Ghana, Kenya, Madagascar, Uganda and Zanzibar, but similar 
levels of QAACTs with and without the logo were seen in Niger, and those without the logo 
predominated in Tanzania mainland and Nigeria. 
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Figure 19: Market share of antimalarials sold in private for-profit outlets by antimalarial type at baseline and 
endline1.1.18 
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A key feature of the antimalarial markets was the predominance of the private for-profit 
sector, which had the largest market share in all countries at endline, ranging from 49% in 
Niger to 92% in Nigeria (Figure 20). No change in the private for-profit share was seen in 
Ghana, Kenya, Niger or Nigeria between baseline and endline. However, increases in the 
private for-profit sector share were seen in Uganda (from 40% to 53%), Tanzania mainland 
(from 45% to 59%) and in Zanzibar (from 62% to 87%). In Uganda this shift mainly took 
place in rural areas, while it took place in both rural and urban areas in Zanzibar. Madagascar 
saw a fall in the private sector share, from 82% to 70%. 
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Figure 20: Market share of all antimalarials by sector at baseline and endline1.1.19 
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AMFm logo, recommended retail prices and provider knowledge 
Provider recognition of the AMFm logo at endline was lowest in Niger (30%) and 
Madagascar (31%) and highest in Tanzania mainland (87%), Ghana and Zanzibar (both 93%) 
(Figure 21). Recognition of the logo was higher in urban areas than in rural areas in Ghana, 
Madagascar, Niger and Zanzibar. The most common responses on the meaning of the logo 
were that it meant an effective/quality antimalarial, an affordable antimalarial, an antimalarial 
or an ACT. Provider knowledge of the AMFm program was lower than recognition of the 
logo everywhere, but followed a similar pattern, with knowledge being lowest in Niger and 
Madagascar and highest in Tanzania mainland, Ghana and Zanzibar.  
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Figure 21: Percentage of outlets where the AMFm logo was recognised and respondents had knowledge of 
the AMFm program, endline only, all outlets combined 1.1.20 
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Recommended retail prices for copaid QAACTs were set in all countries except Madagascar. 
The percentage of respondents stating that there was an RRP for QAACTs bearing the green 
leaf logo varied from 13% in Niger to 84% in Ghana (Figure 22). Knowledge of the RRP was 
higher in urban areas than in rural areas in Ghana, Niger and Zanzibar. Of those that knew 
there was an RRP, the percentage of respondents stating the correct RRP for an adult dose 
was over 90% in Ghana, Kenya and Zanzibar, but as low as 5% in Uganda. 
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Figure 22: Percentage of outlets where the provider knew that there was a recommended retail price 
(RRP), and of those that knew there was an RRP, percentage where the provider knew the correct RRP, 
endline only, all outlets combined1.1.21 
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Note: No data are shown for Madagascar as an RRP was not set for copaid ACTs in this country 
 
Malaria Diagnosis 
Availability of any diagnostic test for malaria (microscopy or rapid diagnostic test (RDTs)) 
overall at endline varied from 6% in Nigeria to 56% in Zanzibar (Figure 23). Availability of 
diagnostics was significantly higher in the public sector than in private for-profit outlets in all 
countries. Kenya, Uganda and Zanzibar stand out as the only countries with substantial 
availability in the private for-profit sector, with diagnostics available in 14%, 21% and 32% 
of outlets, respectively.  
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Figure 23: Availability in public health facilities and private for-profit outlets of any diagnostic test for 
malaria at baseline and endline 1.1.22 
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Key findings from the household surveys 
[To be included when endline household survey results become available] 
 
Key findings from the remote areas surveys 
The remote area studies were conducted only at the endline so no baseline data were 
available to assess changes over time in availability, price and market share of QAACTs in 
these areas. However, using the baseline data from rural areas, we attempted to estimate 
changes in availability, assuming that the baseline estimates for remote areas were likely to 
have been the same or lower than estimates from rural areas. This is a conservative approach, 
but does not imply that baseline estimates from rural areas are statistically comparable with 
those from remote areas at endline. 
 
The results show that QAACTs were widely available in remote areas in both Ghana and 
Kenya at endline. The availability of QAACTs was particularly high in public health facilities 
(96% in each country), but still substantial in private for-profit outlets (66% in Ghana and 
45% in Kenya). Although the availability of QAACTs was lower in remote areas than in non-
remote areas, there was a substantial increase in availability if we use the level of availability 
in rural areas at baseline as a reference (26% in Ghana and 27% in Kenya). In remote areas in 
both countries, QAACTs had a substantial market share (59% in Ghana and 48% in Kenya), 
and this was dominated by QAACTs with the AMFm logo. Overall, the findings suggest that 
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the AMFm program has been instrumental in making QAACTs more available in remote 
areas in these two countries. 
 
The median price of QAACTs with the AMFm logo at endline was similar in remote and 
non-remote areas (about USD 1.00 in both areas in Ghana and USD 0.46 in both areas in 
Kenya). These median prices are very much in line with the recommended retail prices of 
USD 0.94 in Ghana and USD 0.46 in Kenya. The median prices of all QAACTs in private 
for-profit facilities in remote areas at endline (USD 1.25 in Ghana and USD 0.81 in Kenya) 
were much lower than the median prices of all QAACTs in rural areas at baseline (USD 2.74 
in Ghana and USD 2.36 in Kenya). 
 
The availability of diagnostic tests for malaria was very low in both remote and non-remote 
areas in both countries, especially in the private for-profit sector. When the tests were 
available, they were fairly inexpensive; however, due to the small number of cases, the price 
data should be interpreted with caution. 
 
In both countries the majority of providers in the remote areas were able to recognize the 
AMFm logo, suggesting that IEC/BCC efforts were able to reach these areas. The majority of 
QAACTs in remote areas had the AMFm logo. 
 
Despite the challenges in geographical access posed by remote areas, the results suggest that 
the AMFm intervention has been able to reach these areas in Ghana and Kenya. This 
contributed to making QAACTs more available and more affordable in these disadvantaged 
areas. 
 
Key findings from the public awareness/logo studies 
Exit interviews 
These findings indicate that the promotion of ACTs as the main treatment for malaria is well 
underway in Kenya, and to a lesser degree in Ghana, but that the situation is much different 
in Nigeria and Madagascar. In Madagascar in particular, few people had heard of ACTs or 
seen the logo. More than half of those who had seen the logo in Madagascar did not know 
what it means, which is not surprising since the supporting interventions on the logo had not 
started in Madagascar by the time of the logo study survey. The reliance on the 
recommendations of health care personnel and pharmacists (respondents may have been 
referring to drug store staff) suggests that the promotion of ACTs through those channels will 
be crucial in encouraging the use of ACTs in the future. It should be noted that while this 
study provides interesting insights about the population-level awareness of the AMFm 
program, the results should be interpreted with caution because of the small number and the 
non-random selection process of participants. The results cannot be generalized to groups 
other than the participants. However, some of the keys issues raised can be the subject of 
further assessment to better understand the implications for the implementation of the AMFm 
program in these countries. 
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Focus group discussions 
It should be noted that the findings of the focus group discussions (FGD) do not necessarily 
address the coverage or effectiveness of the awareness campaigns, but highlight some of the 
social perceptions about malaria medicine and the AMFm logo. The FGD revealed the 
following: 
 
 FGD participants in Madagascar spoke more about the importance of consulting a 
health care professional for malaria treatment than did those from other countries. 
 In all countries, individuals with experience of using ACTs find they are very 
effective in treating malaria. 
 FGDs revealed a great deal of variation in whether or not participants knew about 
ACTs or had used them themselves. 
 Most participants in these FGDs associate the AMFm logo with leaves or herbal 
medicine, although many of the participants had not seen the logo before or had not 
been exposed to accompanying communications. In part, this could be the result of 
the late introduction and limited reach of the supporting interventions on the AMFm 
logo, especially in Madagascar and Nigeria. 
 
Summary of relevant operational research  
During the Phase 1 timeframe, a number of operational research studies were conducted by 
other research groups alongside AMFm implementation in the pilot countries. These studies 
offer potential insights into the effects of additional or complementary interventions aimed at 
improving malaria case management. Results of projects for which results were available at 
the time of writing of this report are summarized here. These were all commissioned and 
managed by the Clinton Health Access Initiative (CHAI) through a grant from the Bill and 
Melinda Gates Foundation.  
 
These studies cover a range of different types of interventions that have the potential to 
improve malaria case management and targeting of antimalarials, particularly in private for-
profit outlets. They also provide important background information on the context in which 
the ACT subsidy is being introduced, such as the low level of adherence to ACT treatment 
and the generally high use of ACTs for treatment of non-malarial fevers, both of which are 
consistent with the evidence from the broader literature, and reflect the complex set of factors 
affecting both of these behaviors.  
 
The interventions include studies which modify the core AMFm intervention by varying the 
subsidy level to examine the impact on both ACT use and targeting; and measures which 
could complement the AMFm subsidy on ACTs, such as providing subsidized RDTs to 
improve targeting of ACTs to those with malaria and increasing treatment adherence through 
text messaging. All of the studies show that such interventions are feasible to implement at a 
small scale (with the exception of the Cambodia study which took place against the backdrop 
of a national-level program). However, the evidence on their effectiveness is mixed, and 
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more evidence of the effectiveness and cost-effectiveness of such measures in large-scale 
programs is needed.  
 
Evidence on such interventions should also be seen in the context of the broader literature on 
improving malaria case management. A number of review papers have found that medicine 
sellers are willing to participate in such interventions and that a range of interventions can be 
effective in improving provider knowledge and treatment practices. These include various 
forms of training; quality assurance programs such as accreditation, franchising and 
supervision; demand generation and consumer information; and adapting medicine 
packaging.  
 
Interpretation of key findings based on success metrics in light of the AMFm 
implementation 
 
In this section, we present the performance of each AMFm pilot against the Success 
Benchmarks (see Section 8). Results for all benchmarks, estimated from outlet and household 
survey data, are presented in a scorecard which allows for the achievements to be seen 
together. These results are then interpreted using the Theory of Change presented in Section 
1.4, which provides a framework for integrating the description of progress in supply of 
AMFm copaid drugs, the implementation of supporting interventions (SI), and the effects of 
important contextual factors. This draws on the country case studies of implementation and 
context undertaken at the time of endline outlet survey implementation (Section 4) and the 
description of country context provided in the baseline IE report. Together with the results of 
the benchmarks, this integrated narrative is aimed at helping to assess progress of AMFm 
after periods of implementation which varied considerably across the different pilots, and to 
understand the extent to which observed changes in key outcomes can plausibly be attributed 
to AMFm.  
 
Ghana 
AMFm implementation: A total of 32 private for-profit FLBs were registered with the 
Global Fund as of January 31, 2012, of which 14 had placed orders by the end of 2011. The 
first orders for copaid QAACTs were placed in July 2010 by a private for-profit FLB and 
were delivered in August 2010. A total of 15.5 months elapsed between the date the first 
drugs arrived in Ghana (August 2010) and the midpoint of endline outlet survey fieldwork. 
Supporting interventions started in February 2011, giving nine months of effective SI 
implementation, and included public awareness and mass media campaigns; training of 
public sector workers, pharmacists, private practitioners and licensed chemical sellers; private 
sector monitoring; operational research; and the setting of the recommended retail price at 
USD 0.94. A total of 24.7 million copaid QAACT treatments were delivered between July 
2010 and December 2011, amounting to 1.01 treatments per capita (the whole population of 
Ghana is considered at risk of malaria), of which 95% were delivered to private for-profit 
FLBs. The application of the Global Fund’s demand levers in Ghana resulted in only 27% of 
treatments requested by FLBs in the second half of 2011 being approved. 
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Availability: QAACT availability across all outlets increased by 52 percentage points, from 
31% at baseline to 83% at endline (Benchmark 1). Ghana has therefore easily met the 
benchmark of a 20 percentage point increase in QAACT availability. The largest rise was in 
private for-profit outlets, which saw an increase in QAACT availability of 58 percentage 
points. The urban-rural gap in QAACT availability that was observed at baseline overall and 
for private for-profit outlets was eliminated at endline. Even in remote areas, 78% of all 
outlets had QAACTs in stock at the time of the remote areas study (96% of public health 
facilities and 68% of private for-profit facilities).  
 
Price: A dramatic decrease in median QAACT price was observed between baseline and 
endline. Across all outlets, the median price per AETD fell from USD 3.42 to USD 0.94. In 
public health facilities, the QAACT price fell from USD 2.74 to USD 0.94, while in the 
private for-profit sector, the median price of QAACTs fell from USD 3.42 to USD 1.13, 
which is slightly higher than the RRP of USD 0.94. At endline, QAACTs were slightly more 
expensive in urban than rural areas (USD 1.25 vs. USD 0.94), and no difference in price was 
observed between private for-profit outlets in remote and non-remote areas. The median price 
in private for-profit outlets for a QAACT carrying the AMFm logo was USD 0.94 per AETD. 
This is 3.0 times the median price of the most popular antimalarial which is not a QAACT in 
tablet form (SP) whether this is measured in tablet form or among all dosage types, and 
therefore Ghana appears to have just missed Benchmark 2, which states that the ratio should 
be less than 3. The price of copaid QAACTs in the private for-profit sector was lower than 
that of AMT tablets only (USD 1.88), strongly suggesting that Benchmark 3 was met.  
 
Market share: The market share of QAACTs has more than tripled overall, from 17% to 
58% of all antimalarials sold/distributed in the week preceding the survey. There was no 
difference in the market share between urban and rural areas, and QAACT market share 
reached the same level in remote areas. Benchmark 5 of a 10 percentage point increase in 
market share from baseline to endline has easily been achieved overall, with a 40 percentage 
point increase. The benchmark has also been met in each sector individually (with percentage 
point increases ranging from 23 to 61). The market share of oral AMTs was very low at 
baseline (4% in all types of outlets combined) and remained very low at endline (3%). The 
decrease between baseline and endline (Benchmark 6) is of borderline statistical significance 
but the relevance of this benchmark to Ghana is questionable given the low share for oral 
AMTs at baseline. 
 
Context: Relevant contextual factors include the distribution of long-lasting insecticidal nets 
(LLINs) concurrent with AMFm implementation (5 million nets distributed by the end of 
2011). ACTs had over-the-counter status. 
 
Summary: The evidence about impressive changes in the availability and price of QAACTs, 
together with strong evidence of increased knowledge and awareness, the flow of copaid drug 
orders and the evidence on SI implementation, provide plausible evidence that AMFm is 
responsible for the substantial increase observed in QAACT market share. These changes are 
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unlikely to be due to other contextual factors. The high levels of availability and market share 
in remote areas underline the success of AMFm in reaching more vulnerable populations. The 
decrease in the market share of nAT in private for-profit outlets is consistent with AMFm 
crowding out nATs and not simply shifting demand from other ACTs. Although there was a 
large decrease in the price of QAACTs, the price benchmark appears to have just been 
missed. This may be because the relatively high RRP is acting as a floor for the QAACT 
price and stopping it from falling below this level. This could also be due to the very low 
price of the most popular antimalarial which is not a QAACT in tablet form (USD 0.31), 
making this quite a difficult benchmark to reach.  
 
Kenya 
AMFm implementation: Seven private sector FLBs registered and established relationships 
with manufacturers, of which six had placed orders by the end of 2011. The FLB for the 
public sector was the Kenya Medical Supplies Agency (KEMSA). The first orders for copaid 
QAACTs were placed in July 2010 by a private for-profit FLB and delivered in August 2010. 
A total of 15 months elapsed between the date the first drugs arrived in Kenya and the 
midpoint of endline outlet survey fieldwork. Supporting interventions mainly started in 
February 2011, giving nine months of effective SI implementation. The supporting 
interventions included a communication campaign, training of private sector health workers, 
pharmacovigilance activities and a recommended retail price set at USD 0.46 for all pack 
sizes. A total of 28.4 million copaid QAACT treatments were delivered between July 2010 
and December 2011 (0.9 treatments per person at risk of malaria), half of which were 
delivered to the private for-profit sector. The application of the Global Fund’s demand levers 
in Kenya resulted in only 56% of treatments requested by FLBs in the second half of 2011 
being approved. 
 
Availability: QAACT availability across all outlets increased by 34 percentage points, from 
32% at baseline to 66% at endline (Benchmark 1). Kenya has therefore easily met the 
benchmark of a 20 percentage point increase in QAACT availability. The largest increase 
was in private for-profit outlets, which saw an increase in QAACT availability of 39 
percentage points. Even in remote areas, QAACTs were available in 56% of outlets at the 
time of the remote areas study. QAACTs with the logo had also substantially penetrated 
remote areas, with 45% of private for-profit outlets stocking them. 
 
Price: The median price of QAACTs in the private for-profit sector fell dramatically between 
baseline and endline, from USD 2.63 per AETD to USD 0.58, although the endline median 
price was still somewhat higher than the RRP of USD 0.46. The median price at endline for a 
QAACT with the AMFm logo was USD 0.52 in the private for-profit sector, exactly equal to 
the median price of the most popular antimalarial which is not a QAACT in tablet form (SP) 
in private for-profit outlets, strongly suggesting that Kenya comfortably met pricing 
Benchmark 2. It was not possible to compute Benchmark 3 for Kenya, as the number of AMT 
products audited at endline was fewer than 50. Copaid QAACT prices were slightly higher in 
remote than non-remote areas (USD 0.69 vs. USD 0.46), although the remote areas study 
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took place four months after the endline survey when the Global Fund’s demand levers may 
have placed upwards pressure on QAACT prices.  
 
Market share: The market share of QAACTs has increased overall, from 26% to 57% of all 
antimalarials sold/distributed in the week preceding the survey, with similar increases in 
urban and rural areas. Benchmark 5 of a 10 percentage point increase in QAACT market 
share from baseline to endline was achieved overall and within the private for-profit and 
private not-for-profit sectors. Even in remote areas, QAACT market share was 48% among 
all outlets (77% in public health facilities and 40% in private for-profit outlets). Overall 
market share of oral AMTs was negligible at baseline (0.9%) and almost zero at endline 
(0.05%). 
 
Context: A predicted malaria epidemic led to an emergency response, although the epidemic 
did not arise. Mass distribution of LLINs took place. There was depreciation of the Kenya 
shilling. Political support for AMFm was high. ACTs did not have over-the-counter status. 
 
Summary: Kenya has comfortably met Success Benchmarks 1 on QAACT availability, 2 on 
price, and 5 on market share. Data are not available to assess Benchmark 4 on use, and 
Benchmarks 3 and 6 on AMTs are not relevant given the negligible amounts of AMT in the 
market at baseline and endline. Substantial levels of QAACT availability and market share 
were also observed in remote areas. QAACT prices in private for-profit outlets were slightly 
higher in remote areas, although the demand levers may have placed upward pressure on 
prices by the time the remote areas survey was undertaken. The evidence about changes in 
the availability and price of QAACTs, together with strong evidence of increased knowledge 
and awareness, the flow of copaid drug orders and evidence on implementation of the 
IEC/BCC campaign, provide plausible evidence that AMFm is responsible for the substantial 
increase in QAACT market share observed. Contextual factors that could also have 
contributed to increased QAACT availability (PMI procurement and epidemic preparedness) 
operated mainly in the public sector where QAACT market share actually fell, and not in the 
private for-profit and private not-for-profit sectors, which saw substantial and significant 
increases. The decrease in the market share of nAT in private for-profit outlets is consistent 
with a view that AMFm is crowding out less effective antimalarials. 
 
Madagascar 
AMFm implementation: Eight private sector FLBs registered, all of whom placed orders 
with manufacturers, and the FLB for the public sector was the public sector procurement 
agency, the Unité de Gestion de Projet (UGP). The first orders for copaid QAACTs were 
placed in September 2010 by a private for-profit FLB, with small quantities being delivered 
in October and December 2010 and larger quantities in February 2011. A total of 14 months 
elapsed between the date the first drugs arrived in Madagascar and the midpoint of endline 
outlet survey fieldwork. Supporting interventions (SIs) started in January 2011. A radio and 
TV campaign was begun in April 2011, but terminated in May 2011 because it was deemed 
to contravene the law prohibiting advertising of prescription drugs to the general population. 
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Training activities focused on doctors, paramedics, lab technicians and CHWs, and there was 
an intervention involving medical representatives. There was no recommended retail price. 
By the end of December 2011, a total of 1.2 million treatment doses had been received by 
private sector FLBs, and 489,000 by the public sector, amounting to only 0.08 treatments per 
capita (the whole population of Madagascar is considered at risk of malaria), one treatment 
for every 12 people. 
 
Availability: There was no significant difference in overall QAACT availability between 
baseline (23%) and endline (28%), meaning that Madagascar did not meet Benchmark 1. 
There was no change in QAACT availability in the private for-profit sector, which remained 
low (8% at baseline and 9% at endline). However, there was considerable variation within the 
private for-profit sector. QAACT availability at baseline and endline was much higher in 
private for-profit health facilities/pharmacies (47% at baseline and 63% at endline) and drug 
stores (56% at baseline and endline), than in general retailers (3% at baseline and 2% at 
endline) - although the latter were not licensed to stock or sell ACTs. A very high number of 
general stores were screened for the outlet surveys, of which antimalarials were stocked by 
32% baseline and 21% at endline (principally cholorquine), meaning that general stores 
represented a high proportion of private for-profit antimalarial outlets, thereby pulling down 
average QAACT availability in the private for-profit sector as a whole. In public facilities, 
QAACT availability was already high at baseline (83%) and increased further to 94% at 
endline. This represents a significant increase from baseline. QAACT availability was high 
among community health workers (CHWs) at both baseline (99.8%) and endline (92%). 
 
Price: In the public and private not-for-profit sectors, the median QAACT price remained 
USD 0.00 at baseline and endline, reflecting the policy of free ACT provision. However, the 
median price of QAACTs in the private for-profit sector increased significantly between 
baseline and endline, from USD 0.14 to USD 0.60 per AETD. This mainly reflected 
significant increases in prices in drug stores and general retailers, especially in rural areas. 
Low QAACT prices at baseline are due to the pediatric ACT subsidy program for Actipal 
(artesunate-amodiaquine) that PSI had been operating in Madagascar since 2008 with 
distribution through CHWs and authorized retailers (pharmacies and depots). The median 
price at endline for a QAACT with the logo in private for-profit outlets (USD 0.51) was 1.6 
times the median price of the most popular antimalarial which is not a QAACT in tablet form 
(chloroquine) in private for-profit outlets. This suggests that Madagascar comfortably met 
price Benchmark 2. Benchmark 3 was not relevant in Madagascar as there were no price 
observations for oral AMT, reflecting its absence from the market. 
 
Market share: Overall market share of QAACTs was 12% at baseline and 21% at endline, 
but this change did not meet Benchmark 5 of a 10 percentage point increase. However, the 
power to detect a 10 percentage point increase was below the usual minimum standard of 
80%, so the p-value should be interpreted with caution. In the private for-profit sector, market 
share increased from 7% to 22%. This 15 percentage point change is significantly different 
from zero, but there is only weak evidence that the 10 percentage point threshold was met in 
this sector.  
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Context: ACTs did not have over-the-counter status, and their sale was not permitted in 
general stores. PSI had been distributing subsidized pediatric ACTs to CHWs and private 
retailers since 2008. IRS and mass distribution of LLINs were taking place. There were 
continued effects from the 2009 coup d’état, leading to political and economic deterioration. 
 
Summary: Madagascar has not met success Benchmarks 1 on QAACT availability or 5 on 
QAACT market share. However, Benchmark 2 on the relative price of copaid QAACTs 
compared with the most popular antimalarial which is not a QAACT has been met, despite 
the lack of an RRP. Benchmarks 3 and 6 were not relevant because there was an almost 
complete absence of oral AMT in the market at baseline and endline. Data are not available 
to assess Benchmark 4 on use.  
 
Although a significant increase in QAACT market share was observed from baseline to 
endline in the private for-profit sector, the increase was not sufficient to meet the market 
share benchmark, especially given the lack of improvement in the public sector. This limited 
improvement in market share was associated with the low level of copaid drugs delivered to 
Madagascar, at only one treatment for every 12 people, or 0.08 treatments per capita. This 
partly reflects long delivery times, but more importantly low copaid drug orders, which 
amounted to only one treatment for every 11 people, or 0.09 treatments per capita. Reasons 
for these low orders are likely to reflect low confidence by FLBs in ordering due to a lack of 
data on the unmet need for ACTs within the private sector and a fear of overstocking. The 
low level of provider and exit survey respondent awareness and understanding of the logo are 
no doubt due to the curtailment of the mass media campaign, which is likely to have had a 
substantial impact on consumer demand for QAACTs. However, the Madagascar experience 
should be seen in the light of the recent political instability and economic challenges, which 
provided a highly problematic context for both the public and private sectors during the 
period of AMFm Phase 1.  
 
Niger 
AMFm implementation: Seven first line buyers had registered with the Global Fund as of 
January 31, 2012, including five private for-profit firms, one UN agency and one public 
sector agency. Three of the private first line buyers had placed orders by the end of 2011. The 
first order to be placed by a private for-profit first line buyer (FLB) was in August 2010, and 
the medicines arrived in Niger in January 2011, giving 9.5 months of implementation 
between the arrival of the first drugs and the midpoint of endline outlet survey fieldwork. 
Supporting interventions began at the same time as the arrival of the first drugs, but only 
about 30% of planned communication activities took place due to delays in receiving funds, 
delays in the selection of communications firms to undertake the activities and the suspension 
of the Global Fund AMFm supporting intervention grant in the second half of 2011. An RRP 
was set at USD 0.40 for a child dose and USD 0.70 for an adult dose. Training activities 
started in December 2010, but not all planned training took place.  
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Availability: QAACT availability among all outlets increased by 10 percentage points 
between baseline and endline, from 9% to 19% (Benchmark 1). This was a statistically 
significant increase, but did not meet the AMFm benchmark of a 20 percentage point 
increase. There was a significant increase in public sector outlets (from 45% to 73%) and a 
smaller, but also significant, increase in private for-profit outlets from 6% at baseline to 14% 
at endline. A very high number of general stores and itinerant vendors were screened for the 
outlet surveys, and it was common for them to have antimalarials in stock (42% of general 
stores and 63% of itinerant vendors enumerated at baseline stocked antimalarials), meaning 
that they represented a high proportion of private for-profit antimalarial outlets. They had 
lower stocking rates of QAACTs at endline (13% compared with 62% in private health 
facilities/pharmacies and 65% in drug stores), which therefore pulled down average QAACT 
availability in the private for-profit sector as a whole. 
 
Price: The median price per adult equivalent treatment dose (AETD) of QAACTs fell 
considerably between baseline and endline, from USD 2.06 to USD 0.79 among all outlets. 
The median price remained zero in public health facilities, and in private for-profit outlets the 
median price fell from USD 2.47 to USD 1.19, somewhat higher than the RRP of USD 0.69 
for an adult treatment. The median price in private for-profit outlets for a QAACT carrying 
the AMFm logo was USD 1.19 per AETD. This is 2.5 times higher than the median price of 
the most popular antimalarial which is not a QAACT in tablet form (chloroquine), indicating 
that Niger achieved AMFm Benchmark 2 which states that the ratio should be less than 3. It 
was not possible to compute Benchmark 3for Niger, as the number of AMT products audited 
at endline was fewer than 50. 
 
Market share: QAACT market share measured across all outlets fell from 18% at baseline to 
10% at endline, although the change is not significantly different from zero; and there was a 
significant increase in the share of nAT, from 73% at baseline to 87% at endline. This means 
that Benchmark 5 of a 10 percentage point increase in QAACT market share from baseline to 
endline has not been achieved in Niger. In the private for-profit sector, the QAACT share 
doubled, but from a very low starting level of 4% at baseline to 8% at endline. 
 
Context: The security situation in Niger continued to be challenging. Rainfall in 2011 was 
erratic and uneven. Fewer LLINs were distributed in 2011 than in previous years. 
Disbursement of the AMFm supporting intervention grant was suspended. ACTs did not have 
over-the-counter status. 
 
Summary: Niger met Benchmark 2 relating to the price of copaid QAACTs, which specifies 
that the median price should be less than three times the price of the most popular 
antimalarial which is not a QAACT in tablet form. It has not, however, achieved Benchmark 
1 on availability or Benchmark 5 on market share of QAACTs. The market share of oral 
AMT (Benchmark 6) was already so low that it is not relevant to assessing the impact of 
AMFm in Niger. The amount of time elapsed between the arrival of copaid drugs and the 
endline outlet survey was only around 9.5 months, so the short time for implementation could 
be responsible for the slow progress of the program. However, it also seems that the quantity 
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of copaid QAACTs ordered, particularly by private for-profit FLBs, was too low to have 
made much of an impact on availability and market share. The implementation of supporting 
interventions, which might have helped to increase demand for copaid QAACTs, and thereby 
might have stimulated private for-profit orders, was also derailed by delays and the 
suspension of disbursement of the Global Fund SI grant. Finally, the implementation context 
in Niger is challenging, with problems of adverse weather interrupting supply chains, difficult 
transport outside the main cities and problems of insecurity.  
 
Nigeria 
AMFm implementation: A total of 54 FLBs were registered with the Global Fund as of 
January 31, 2012 (51 private for-profit, 2 private non-profit and 1 public sector). Orders had 
been placed by 28 private first line buyers by the end of 2011. The first orders were placed by 
private for-profit sector FLBs in October 2010, and arrived in Nigeria in January 2011. 
Approximately 9.5 months elapsed between the arrival of the first copaid drugs and the 
midpoint of endline outlet survey fieldwork. Implementation of supporting interventions 
trailed the arrival of the first copaid drugs by approximately 3 months, giving about 6 months 
from the start of implementation of SIs before the midpoint of the endline outlet survey. 
Some delays in initiating communications activities were caused by problems of coordination 
among the Principal Recipients (PRs). In the interim, a number of activities were undertaken 
(albeit not at scale) by other stakeholders such as professional associations and 
pharmaceutical firms. Private sector BCC activities only started in August 2011, and some 
mass media activities did not start until September 2011. The range of activities implemented 
from April 2011 onwards included advocacy, mass media communications, community 
dramas and road shows, training, regulatory changes and an RRP. By the end of 2011, a total 
of 67,219,660 copaid ACT doses had been delivered to Nigeria (0.42 doses per capita, the 
whole population of Nigeria is considered at risk of malaria), of which 80% were to private 
for-profit FLBs, 12% to the public sector and 8% to private not-for-profit FLBs. Only 24% of 
treatments requested by Nigeria FLBs in the second half of 2011 were approved due to the 
application of the Global Fund’s demand levers. 
 
Availability: QAACT availability in all outlets increased from 28% to 54%, an increase of 
26 percentage points (p=0.14) from baseline to endline (Benchmark 1). There is therefore 
some evidence that Nigeria has met the benchmark of a 20 percentage point increase in 
QAACT availability, although the large p-value means we do not have strong evidence for 
this. In public health facilities, availability was 46% at baseline and 57% at endline, but this 
increase was not statistically significant. The major contributor to the overall increase in 
availability was the private for-profit sector, in which availability increased significantly from 
27% to 53%.  
 
Price: There was a substantial fall in the price of QAACTs between baseline and endline. 
Among all outlets, the median price per AETD fell from USD 3.72 to USD 1.48 at endline. In 
private for-profit outlets the decline in median price of QAACTs is even larger, from USD 
4.47 to USD 1.48. Despite this large decline in the price of QAACTs in private for-profit 
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outlets, the ratio of the median price of QAACTs with the AMFm logo to that of the most 
popular antimalarial which is not a QAACT in tablet form was 3.1, and therefore Nigeria 
appears to have just missed Benchmarks 2 which states that the ratio should be less than 3. 
The price of QAACTs with the AMFm logo was less than that of AMT tablets (USD 2.66), 
so Nigeria did meet Benchmark 3.  
 
Market share: QAACT market share measured across all outlets increased from 2% at 
baseline to 20% at endline, with very similar results in urban and rural areas. Benchmark 5 of 
a 10 percentage point increase in market share from baseline to endline was therefore met, 
with an 18 percentage point increase. The QAACT share of all antimalarials sold increased 
even more dramatically in the public sector, from 6% at baseline to 48% at endline, while it 
increased in private for-profit outlets from 2% to 18%. The market share of AMTs decreased 
from 8% at baseline to 4% at endline, meaning that Nigeria also met Benchmark 6. The 
increase in QAACT share in both the public sector and the private for-profit sector was 
accompanied by a reduction in the share of nATs which fell in the public sector from 85% to 
38% and in the private for-profit sector from 84% to 69%. The private sector accounted for 
97% of all antimalarials distributed at baseline and 92% at endline.  
 
Context: Important contextual factors include the distribution of LLINs and indoor residual 
spraying (IRS) in some states, introducing RDTs into public and private health facilities in 12 
states, a large domestic pharmaceutical manufacturing sector that initially resisted AMFm, 
and elections in 2011. ACTs had over-the-counter status. 
 
Summary: Nigeria fully met Success Benchmarks 3 (QAACT price relative to AMT), 5 
(QAACT market share) and 6 (AMT market share). There is some evidence that Nigeria also 
met Benchmark 1 (availability). Nigeria just missed the threshold for Benchmark 2 (QAACT 
prices relative to the most popular antimalarial which is not a QAACT in tablet form). The 
price of SP tablets was quite low (USD 0.47), making this target difficult to meet, but there 
was also poor adherence to the RRP. This could reflect the relatively low awareness of the 
RRP or perhaps market pressures linked to the exercise of the Global Fund demand levers. 
Benchmark 4 could not be calculated. These results were achieved despite the context of 
instability caused by the post-election crisis and terrorist attacks, which may have affected 
supply in some areas. There have been impressive increases in knowledge of the first-line 
drug, particularly in public health facilities, but achievements in recognition of the AMFm 
logo and knowledge of the AMFm program are more modest, consistent with the relatively 
short period of implementation of SIs before the endline outlet survey was conducted.  
 
Tanzania - mainland 
AMFm implementation: A total of 10 private for-profit FLBs were registered with the 
Global Fund, and the Medical Stores Department (MSD) was registered as an FLB for the 
public sector. Five of the private first line buyers had placed orders by the end of 2011. The 
first orders for copaid QAACTs were placed in August 2010 by a private for-profit FLB and 
were delivered in October 2010. A number of delays affected the ordering process in the 
public sector, resulting in public sector stockouts during 2011. A total of 13.5 months elapsed 
lx 
 
between the date the first drugs arrived in Tanzania (October 2010) and the midpoint of 
endline outlet survey fieldwork. Supporting interventions started in January 2011, giving only 
10 months of effective SI implementation. These included a communications campaign; 
upgrading of drug stores to accredited drug dispensing outlets (ADDOs); pharmacovigilance 
activities; monitoring and evaluation; and the setting of the recommended retail price at USD 
0.62. The start of the communications campaign was delayed, and took place only seven 
months before endline data collection. A total of 13,039,620 copaid QAACT treatments were 
delivered between October 2010 and December 2011, amounting to 0.31 treatments per 
capita, of which 62% were delivered to private for-profit FLBs. The application of the Global 
Fund’s demand levers in Tanzania reduced the orders approved by a modest amount (90% of 
treatments requested by FLBs were approved in the second half of 2011).  
 
Availability: QAACT availability across all outlets increased by 44 percentage points, from 
26% at baseline to 70% at endline (Benchmark 1). Tanzania has therefore easily met the 
benchmark of a 20 percentage point increase in QAACT availability (p<0.0001). There has 
been no increase in availability in the public sector, which was already 80% at baseline. 
Rather, the increase was concentrated in private for-profit outlets, which saw an increase in 
QAACT availability of 56 percentage points, with QAACTs available at endline in 79% of 
private for-profit health facilities/pharmacies and 69% of drug stores. 
 
Price: In public and private not-for-profit health facilities, the median QAACT price 
remained at USD 0.00 at baseline and endline, reflecting the policy of free provision of 
QAACTs. Dramatic decreases in median QAACT prices were observed in the private for-
profit sector between baseline and endline, from USD 5.28 to USD 0.94 per AETD, although 
this was still somewhat higher than the RRP of USD 0.62. The median price in private for-
profit outlets for a QAACT carrying the AMFm logo was USD 0.94 per AETD. This is the 
same as the median price of the dominant antimalarial which is not a QAACT in tablet form 
(SP), and therefore Tanzania met Benchmark 2, which states that the ratio should be less than 
3. As the number of oral AMT products in the market was negligible, Benchmark 3 was not 
relevant to Tanzania.  
 
Market share: The market share of QAACTs overall increased by 16 percentage points, 
from 26% at baseline to 42% at endline. The increase took place mainly in the private for-
profit sector, which saw a 30 percentage point increase from 2% to 32%. By contrast the 
market share was unchanged in public health facilities, where a fall in QAACT market share 
in urban areas was not sufficiently offset by an increase in rural areas. The implications for 
Benchmark 5 (a 10 percentage point increase in market share from baseline to endline) are 
that, while the point estimate for all sectors combined was greater than 10, the evidence that 
the benchmark has been reached is not strong (p=0.23). However, the power to detect a 10 
percentage point increase was below the usual minimum standard of 80%; so the p-values 
should be interpreted with caution. In the private for-profit sector alone, the increase was 
significantly greater than 10 percentage points (p<0.0001). Benchmark 6 was not relevant to 
Tanzania given the negligible market share of oral AMTs at both baseline and endline. 
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Context: AMFm was implemented against the background of a large-scale malaria control 
communications campaign funded by PMI and the Global Fund. RDTs were being distributed 
to public facilities. IRS and mass distribution of LLINs were taking place. The Tanzanian 
shilling depreciated over this period. ACTs did not have over-the-counter status. 
 
Summary: There is strong evidence that Tanzania has met Success Benchmarks 1 (QAACT 
availability) and 2 (QAACT price relative to the most popular antimalarial which is not a 
QAACT). It is possible that Benchmark 5 (QAACT market share) was also met across all 
sectors, but the evidence is not strong. However, we can be confident that a 10 percentage 
point increase in market share was easily achieved in the private for-profit sector. 
Benchmarks 3 and 6 are not relevant to Tanzania given the negligible presence of oral AMT 
in the market at baseline and endline. Data were not available to assess Benchmark 4 on use. 
The evidence about impressive changes in the availability and price of QAACTs, together 
with strong evidence of awareness of AMFm, the flow of copaid drug orders and SI 
implementation, provide plausible evidence that AMFm is responsible for the increases 
observed in QAACT market share. These changes may have also been supported by the 
complementary malaria communications campaign funded by other sources. The decrease in 
the market share of nAT in private for-profit outlets suggests that AMFm may be crowding 
out nATs and not simply shifting demand from other ACTs. 
 
Uganda 
AMFm implementation: Fourteen FLBs were registered with the Global Fund as of January 
31, 2012 (nine private for-profit FLBs, three private not-for-profit FLBs and two FLBs for 
the public sector). Four of the private for-profit FLBs had placed orders by the end of 2011. 
FLBs from both the private for-profit and private not-for-profit sector placed their first orders 
in March 2011. The first deliveries for the private sector arrived in April 2011. Delays 
receiving orders were reported in both the private for-profit and private not-for-profit sectors. 
In the public sector, a number of factors contributed to delays in the placement of the first 
order. The first shipment of copaid ACTs for the public sector arrived in July 2011, and no 
stockouts of the adult package size of AL at the National Medical Stores resulting from the 
delays were reported. However, stock levels of the adolescent and pediatric package sizes of 
AL were low by December 2010, and by March 2011 the NMS was out of stock of these 
pack sizes. A total of 28,226,700 copaid QAACT treatments were delivered between April 
2011 and December 2011, amounting to 0.84 treatments per capita (all of the population of 
Uganda is considered at risk of malaria), of which 73% were delivered to the public sector, 
25% to the private for-profit sector, and 2% to the private non-for-profit FLB. The 
application of the Global Fund’s demand levers in Uganda resulted in only 57% of treatments 
requested by FLBs in the second half of 2011 being approved. Only seven months had 
elapsed between the date the first drugs arrived in Uganda and the midpoint of the endline 
outlet survey fieldwork. Approximately USD 28.6 million was available from the Global 
Fund for supporting interventions. The first disbursement of these funds was delayed until 
November 2011, and none of this money was spent by the end of 2011.The only supporting 
interventions that occurred prior to the end of data collection were the National Launch, a 
small-scale AMFm pre-disbursement marketing campaign, and the establishment of 
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recommended retail prices. These activities likely had limited influence on AMFm outcomes, 
due to their scale.  
 
Availability: QAACT availability across all outlets increased by 46 percentage points, from 
21% at baseline to 67% at endline. Uganda therefore comfortably met the benchmark of a 20 
percentage point increase of QAACT availability. The increase in availability in the public 
sector was not significant, meaning that most of the overall increase arose in the private for-
profit sector. The increase was higher in urban areas than in rural areas (57 vs. 43 percentage 
points). Availability of QAACTs with the AMFm logo was much higher than that of 
QAACTs without the logo (58% vs. 16%). Availability of non-quality-assured ACTs 
decreased significantly, from 48% at baseline to 28% at endline. Availability of oral AMT 
was negligible at both baseline and endline.  
 
Price: In the public and private not-for-profit sectors and for CHWs, the median price 
remained USD 0.00 at baseline and endline, reflecting the policy of free ACT provision. In 
the private for-profit sector, the median QAACT price at endline was USD 1.96 in urban and 
rural areas. In urban areas, this represented a fall of over 50% from the baseline median of 
USD 4.41, but in rural areas the decrease from USD 2.21 at baseline was not significant. The 
median price for QAACTs at endline was much higher than the RRP, which was USD 0.47. 
The median price in private for-profit outlets for a QAACT carrying the AMFm logo was 
USD 1.96 per AETD. This is 3.3 times the median price of the dominant antimalarial which 
is not a QAACT in tablet form (SP), and therefore Uganda did not meet Benchmark 2. The 
benchmark relating to the price of oral AMTs is not relevant for Uganda, due to negligible 
quantities of AMTs found in outlets in Uganda. There was no difference in the private for-
profit sector between the median price of QAACTs with and without the AMFm logo. 
 
Market share: The market share of QAACTs overall increased significantly from 40% to 
57%, an increase of 17 percentage points (95% CI 7.1-26.5). This represents a significant 
increase from baseline, and provides some evidence that the benchmark of a 10 percentage 
point increase in QAACT market share had been met, although this evidence is not strong 
(p=0.08). However, the power to detect a 10 percentage point increase was below the usual 
minimum standard of 80%, so the p-values should be interpreted with caution. The 
benchmark of the market share of AMTs was not relevant for Uganda, as the overall market 
share of oral AMTs was close to zero at both baseline and endline. 
 
Context: ACTs were recently granted over-the-counter status. There was no significant 
increase in the availability of microscopy between baseline and endline, but availability of 
RDTs increased significantly in public health facilities (4% to 53%) and in private not for-
profit outlets (9% to 51%). There was also a substantial depreciation of the Ugandan shilling 
against the US dollar between the baseline and endline outlet surveys. 
 
Summary: There is strong evidence that Uganda met the availability benchmark (Benchmark 
1), and some evidence that the indicator related to QAACT market share (Benchmark 5) was 
met. Benchmark 2 comparing the median price of QAACTs to the median price of the most 
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popular antimalarial which is not a QAACT in tablet form was not met. The price and market 
share indicators related to AMTs are not relevant for Uganda, as these products are rare. The 
improvements in QAACT availability and market share were achieved despite the relatively 
short time between first arrival of copaid drugs and the endline outlet survey (seven months) 
and the lack of AMFm supporting interventions. 
 
Zanzibar 
AMFm implementation: One private for-profit FLB was registered, together with two 
international FLBs. The first order of copaid QAACTs was placed by the private for-profit 
FLB in February 2011 and these drugs were delivered in April 2011. A public sector order 
was placed in July 2011 and delivered in September 2011. By the end of 2011, a total of 
241,075 treatments had been delivered, amounting to 0.19 treatments per capita (the entire 
population of Zanzibar is considered at risk of malaria). Only 6.5 months elapsed between the 
arrival of the first copaid drugs in Zanzibar (April 2011) and the midpoint of endline outlet 
survey fieldwork (October 2011). Supporting interventions started one month later, in May 
2011, with a media campaign, so that only 5.5 months of SI implementation had occurred 
before the midpoint of the endline outlet survey. SIs included public awareness and mass 
media; limited training of public and private health workers; increased enforcement of the 
AMT ban; and the setting of the recommended retail price of USD 0.58 for an adult dose and 
USD 0.47 for a child dose. 
 
Availability: QAACT availability across all outlets increased by 39 percentage points, from 
46% at baseline to 85% at endline (Benchmark 1), easily meeting the benchmark of a 20 
percentage point increase in QAACT availability. Availability was slightly higher in rural 
than in urban areas at endline (90% vs. 82%). Virtually all of the increase in QAACT 
availability occurred in private for-profit outlets, as availability in public sector health 
facilities was already 92% at baseline and increased only marginally to 94% at endline. 
Within the private for-profit sector, QAACT availability increased by 71 percentage points 
from 9% at baseline to 80% at endline. 
 
Price: Because nearly all the QAACTs at baseline were in public health facilities (and 
therefore free), the increased availability in the private for-profit sector led to an increase in 
the overall median price from USD 0.00 at baseline to USD 0.58. However, there was a very 
substantial decrease in the median price of QAACTs in private for-profit outlets, from USD 
5.99 at baseline to USD 1.17 at endline. The endline median price is 83% higher than the 
recommended retail price (RRP) of USD 0.58 for an adult dose. The median price of 
QAACTs with the AMFm logo in private for-profit outlets at endline was USD 1.17 per 
AETD. This is 1.5 times higher than the price of the most popular antimalarial which is not a 
QAACT in tablet form which in Zanzibar was amodiaquine (with a price of USD 0.79 per 
AETD). Zanzibar has therefore clearly met Benchmark 2, which states that the ratio of 
median prices should be less than 3. The median price of QAACTs with the logo was also 
much lower than the price of AMT tablets (USD 7.46), so Benchmark 3 was also met. 
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Market share: Zanzibar has seen a nearly six-fold increase in the market share of QAACTs 
from baseline to endline, from 10% of all antimalarial AETDs sold/dispensed at baseline to 
58% at endline. Benchmark 5 of a 10% increase in QAACT market share has therefore been 
easily achieved. In public sector outlets, the QAACT share has increased by 15 percentage 
points, from 23% to 38%, with the main shift being away from non-quality-assured ACTs, 
from 21% at baseline to only 3% at endline. In private for-profit sector outlets, the increase in 
QAACT market share is even more dramatic, with a 59 percentage point increase, from 2% at 
baseline to 61% at endline. Benchmark 6 has also been achieved, with the market share of 
AMTs measured in all outlets falling by 12 percentage points, from 12% to nearly 0 at 
endline. 
 
Context: Contextual factors included early adoption of ACTs as the first-line drug (in 2003); 
enforcement of AMT ban; allowing ACTs to be sold in drug stores with over-the-counter 
status; scale up of diagnostics; IRS and distribution of LLINs; and a dramatic reduction in the 
number of malaria cases. 
 
Summary: Zanzibar has met all of the Success Benchmarks that could be assessed. These 
very substantial improvements in QAACT availability and market share; reductions in 
QAACT prices; and reductions in availability and market share of nATs, AMTs and non-
quality-assured ACTs have occurred despite less than seven months of effective 
implementation of AMFm, and with a relatively limited flow of copaid antimalarials into the 
country (0.19 treatments per capita delivered as of the end of 2011). It seems appropriate to 
conclude, therefore, that in Zanzibar AMFm has met with a highly supportive and conducive 
environment. Key regulatory steps to support OTC sales of QAACTs and to intensify 
enforcement of the ban on AMT are likely to have played an important role in the 
achievement of the benchmarks, in addition to core AMFm interventions of the supply of 
copaid QAACTs and the strong communication campaign. Although information on 
appropriate use of ACTs was not collected as part of the IE, the relatively high availability of 
diagnostic testing in the public sector should contribute to rational use of QAACTs, providing 
another supporting contextual factor. In this light, the shift in market share toward the private 
for-profit sector, where diagnostic testing is not universally available, should be seen with 
some concern, and efforts to improve availability of RDTs especially in drug stores are 
needed.  
 
Conclusions 
A number of key findings can be distilled on the process and impact of AMFm: 
 
1. Achievement of success benchmarks – Figure 24 provides an overview of the 
performance of each pilot against the AMFm success benchmarks. Of the 8 pilots, 
success benchmarks were clearly met in 5 pilots for availability, 5 pilots for QAACT 
price relative to the most popular antimalarial that is not a QAACT, and 4 pilots for 
QAACT market share (all shaded green). It is also possible that benchmarks were met in 
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a one additional pilot for availability and price, and in 3 additional pilots for market 
share, although the evidence is not as strong (shaded amber). The success benchmarks 
related to AMT price and market share were met in all pilots with sufficient AMTs in the 
market to make these benchmarks relevant. 
 
2. AMFm and the private for-profit sector – AMFm has been a “game changer” in the 
private for-profit sector for all pilots except Niger and Madagascar, with a dramatic 
impact on the antimalarial market, through large increases in QAACT availability, 
decreases in QAACT prices, and increases in QAACT market share. These changes were 
substantial and achieved in only a few months, demonstrating the power of tapping into 
the distributional capacity of the private sector. The changes are very likely to be largely 
attributable to AMFm. The private for-profit sector response was similar in rural and 
urban areas, in some cases reducing or closing a rural-urban gap in availability and 
market share. There was considerable penetration of copaid QAACTs even in remote 
areas in Ghana and Kenya, where this was evaluated. 
 
3. AMFm and the public sector – AMFm led to fewer fundamental changes to public 
sector antimalarial supply, where QAACT supply continued to be hindered by problems 
with procurement and grant requirements, leading to substantial delays in ordering. 
Increases in QAACT market share were seen in the public sector in four pilots (Ghana, 
Nigeria, Uganda and Zanzibar), although in Nigeria most QAACTs distributed through 
the public sector were not copaid. QAACTs were available in less than 80% of all public 
facilities at endline in five pilots, and there was generally no change in public sector 
QAACT prices as most countries already provided QAACTs for free at baseline (except 
Ghana where public sector QAACT prices fell). 
 
4. Limited impact in Madagascar and Niger – The impact of AMFm on the private for-
profit sector was limited in Madagascar and Niger, where orders of copaid ACTs were 
very low. Explanations may include (i) the lack of full-scale mass media campaigns; (ii) 
the structure of the private for-profit antimalarial sector, which had a much higher 
proportion of general stores, and in Niger itinerant vendors, who are not allowed to stock 
QAACTs; and (iii) an unfavourable context of political and/or economic instability and 
severe weather conditions.  
5. Effect of duration of implementation – Longer duration of implementation appears to 
be positively correlated with performance, if the combined presence of copaid ACTs and 
the operation of a large-scale sustained IEC/BCC campaign is considered a proxy for full 
AMFm implementation. With the exception of Zanzibar, pilots with earlier start dates 
achieved more success benchmarks. No large-scale sustained IEC/BCC campaign was in 
place by the end of 2011 in Madagascar, Niger or Uganda, and these pilots achieved 
fewer benchmarks. However, it is possible that delayed start dates reflect weaker 
implementation capacity in general, and therefore one should be cautious in attributing 
performance to duration of implementation alone. 
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6. Prices and markups in the private for-profit sector – The price of copaid QAACTs in 
the private for-profit sector at endline was very variable across pilots, ranging from USD 
0.51 in Madagascar to USD 1.96 in Uganda. Reasons for this variability are unclear but 
may include (i) variations in the RRP and its promotion through national IEC/BCC 
campaigns; (ii) guidelines on markups (in Madagascar); (iii) differences in cost structure 
including tax components; and (iv) time since copaid ACTs first arrived in each country. 
The median retail gross markup on copaid QAACTs was less than 70% in all pilots 
(which can be considered reasonable for the retail sector), except Uganda (133%) and 
Zanzibar (100%). 
 
7. Crowding out oral artemisinin monotherapy – Even at baseline, market share for oral 
AMT was less than 4% in Ghana and less than 1% in Kenya, Madagascar, Niger, 
Tanzania Mainland and Uganda. In Nigeria and Zanzibar where oral AMT market share 
was somewhat higher at baseline, large and significant falls were observed, likely 
reflecting a combination of the AMFm subsidy and complementary regulatory measures 
with particularly strong enforcement of the latter in Zanzibar. 
 
8. Availability and market share of non-artemisinin therapies – nAT availability fell in 
some countries, but remained very high in most countries. However, the increases in 
QAACT market share were accompanied by decreases in nAT market share. 
 
9. Market structure – The private sector was a major player in the antimalarial market in 
all pilots, accounting for between 40% and 97% of antimalarial sales volumes at baseline, 
and between 49% and 92% at endline. There was no clear pattern across pilots in the 
change in private for-profit market share between baseline and endline. 
 
10. Availability of malaria diagnosis – Diagnostic availability (RDT or microscopy) varied 
substantially in the public sector, from 29% in Nigeria to 98% in Zanzibar at endline. 
However, in private for-profit outlets, only three pilots had substantial availability at 
endline (Kenya - 14%, Uganda – 21%, Zanzibar - 32%). In this sector, health facilities/ 
pharmacies have higher availability of diagnostics than drug and general stores. 
 
11. Results of operational research – Results from studies of interventions to enhance the 
implementation of antimalarial subsidies by improving targeting and/or drug use show 
that implementation of such interventions is feasible on a small scale, but more evidence 
on effectiveness and cost-effectiveness of large-scale programs is needed to inform 
policy. 
 
12. Issues not covered by the Independent Evaluation – A number of important issues 
related to AMFm policy decisions were beyond the scope of the Independent Evaluation, 
including the impact on targeting copaid ACTs to persons with parasitemia; advice 
provided to patients; adherence to dosing regimens; global artemisinin supply and 
prevalence of counterfeit products. 
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13. Possible hindering factors for AMFm in some countries include: 
 Delays in the public sector procurement process for copaid ACTs  
 Issues with Global Fund grants and delays in procurement of supporting interventions, 
meaning that implementation of most SIs lagged behind the arrival of copaid ACTs 
by several months 
 Suspension of Global Fund disbursements or grants interrupting implementation of 
supporting interventions 
 Application of Global Fund demand levers to ration orders 
 Political and/or economic instability 
 An antimalarial provider market dominated by highly informal outlets operating 
outside of regulated distribution channels (in Madagascar and Niger) 
14. Possible facilitating factors for AMFm in some countries include: 
 Strong AMFm governance structures (including steering committees), involvement of 
the private sector and technical assistance from the Clinton Health Access Initiative  
 Generally smooth operation of the registration process for first-line buyers and 
ordering through the copayment mechanism  
 Strong, large-scale mass media campaigns, including promotion of the AMFm logo 
 Longer duration of implementation 
 Establishment and promotion of an RRP set at an appropriate level 
 Complementary regulatory changes, such as giving ACTs over-the-counter status, and 
implementation of the AMT ban 
 AMFm training in some countries (although only Ghana and Zanzibar had over 20% 
training coverage)  
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Figure 24: Overview of the achievement of the AMFm Success Benchmarks by county, indicating benchmarks achieved (in green), nearly or possibly achieved (in 
amber) and not achieved (in red), (point estimate, and p-value for statistical test of whether the level stated in the benchmark was achieved) Figure 1.1.23 
Benchmark Ghana Kenya Madagascar Niger Nigeria 
Tanzania 
mainland Uganda Zanzibar* 
1. 20 percentage point increase in 
QAACT availability  
52 
(p<0.01) 
35 
(p<0.01) 
4.6  
(p=0.99) 
10 
(p=0.99) 
26 
(p=0.14) 
44  
(p<0.01) 
46 
(p<0.01) 
39 
2.  Median price of QAACTs with 
AMFm logo is <3 times the median 
price of the most popular 
antimalarial in tablet form that is 
not a QAACT (ratio)  
3.0 
(p=0.81) 
1.0 
(p<0.01) 
1.6 
(p<0.01) 
2.5 
(p<0.01) 
3.1 
(p=0.99) 
1.0 
(p<0.01) 
3.3 
(p=0.99) 
1.5 
3. Median price of QAACTs with 
AMFm logo is less than the median 
price of AMT tablets (difference, 
QAACT – AMT)  
-0.94 
(p<0.01)    
-1.17 
(p<0.01)   
-6.3 
4. 5 percentage point increase in 
percentage of children with fever 
who received ACT treatment  
 na  na  na  na  na  na  na na 
5. 10 percentage point increase in 
market share of QAACTs  
40 
(p<0.01) 
31 
(p=0.01) 
8.6 
(p=0.61) 
-8.8 
(p=0.99) 
18 
(p<0.01) 
16 
(p=0.23) 
17 
(p=0.08) 
48 
6. Decrease in market share of oral 
AMTs (percentage point change)      
-3.9 
(p=0.03)   
-12 
Notes: Green shading = the benchmark was achieved, with strong statistical evidence (generally p<0.01); Amber shading = either the benchmark was nearly, but not fully, met, or the evidence that the 
change seen was unlikely to be due to chance is weak (p≥0.05). However, the power to detect a 10 percentage point increase in market share was only 35% in Tanzania, 66% in Uganda and 70% in 
Madagascar, compared with the usual minimum standard of 80%; therefore, p-values should be interpreted with caution. Red shading = the benchmark was not met; Grey shading for Benchmarks 3 and 
6 = not relevant because the number of AMT products was very low at baseline. * p-values not shown for Zanzibar because a complete census of antimalarial stocking outlets was undertaken; na = not 
available; ACT= artemisinin-based combination therapy; AMT= artemisinin montherapy; QAACT= quality-assured artemisinin-based combination therapy 
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1 Background and Methods 
1.1 Evaluation background 
The success of malaria control efforts depends on a high level of coverage in the use of effective 
antimalarials such as artemisinin-based combination therapies (ACTs). Although these 
antimalarials have been procured in large amounts by countries, evidence suggests that ACT use 
still remains far below target levels. Reasons suggested for the low uptake of ACTs include 
interruptions in public sector supply; limited availability outside major urban centers; the high 
prices of the drugs, particularly in the private sector; lack of provider adherence to new 
recommendations; and patient self-treatment with other more common and cheaper antimalarials 
(Sabot et al. 2009). Lowering the cost of ACTs to the end user through a subsidy mechanism 
could be an effective way to increase their uptake (Arrow et al. 2004). 
 
In response to this issue, the Affordable Medicines Facility – malaria (AMFm) hosted by the 
Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) was set up. As described 
by Adeyi and Atun (2010), AMFm is a financing mechanism designed to incorporate three 
elements: (1) price reductions through negotiations with manufacturers of ACTs; (2) a buyer 
subsidy, via a co-payment at the top of the global supply chain by AMFm on behalf of eligible 
buyers from the public, private for-profit and private not-for-profit sectors; and (3) support of 
interventions to promote appropriate use of ACTs. Examples of these “supporting interventions” 
include training providers and outreach to communities to promote ACT use. AMFm is being 
tested in a first phase that includes nine pilots in eight countries: Cambodia, Ghana, Kenya, 
Madagascar, Niger, Nigeria, Republic of Tanzania (mainland and Zanzibar) and Uganda. 
 
The Independent Evaluation (IE) is part of a multi-faceted monitoring and evaluation framework 
developed for Phase 1 of AMFm. It was commissioned by the Global Fund and is intended to 
assess whether, and to what extent, AMFm Phase 1 achieves its four main objectives: (i) to 
increase ACT affordability, (ii) to increase ACT availability, (iii) to increase ACT use, including 
among vulnerable groups, and (iv) to “crowd out” oral artemisinin monotherapies, chloroquine 
and sulfadoxine-pyrimethamine by gaining market share. It is expected that in the last quarter of 
2012, the Global Fund Board will make a decision regarding the future of AMFm on the basis of 
evidence gathered during Phase 1. This report presents the findings of the IE.  
 
Through a competitive bid, the Global Fund contracted ICF International and the London School 
of Hygiene and Tropical Medicine (LSHTM) to conduct the IE. The IE was carried out in all of 
the currently operational Phase 1 pilots (Ghana, Kenya, Madagascar, Niger, Nigeria, Tanzania 
mainland, Uganda, and Zanzibar)
1
. In addition, the Global Fund contracted with Data 
Contributors (DCs) that were responsible for in-country fieldwork, data analysis and country 
                                                 
1
 In March 2011 the AMFm Ad Hoc Committee decided to drop Cambodia from the evaluation due to the lack of an 
eligible ACT for subsidy. 
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reports. These institutions are Population Services International (PSI), Drugs for Neglected 
Diseases initiative (DNDi) and Centre de Recherche pour le Développement Humain (CRDH). 
DNDi subcontracted with the Komfo Anokye Teaching Hospital, Kumasi, to undertake the work 
in Ghana. CRDH subcontracted with the Centre International d'Etudes et de Recherches sur les 
Populations Africaines (CIERPA) to undertake the work in Niger. PSI was responsible for the 
work in Kenya, Madagascar, Nigeria, Uganda, Tanzania mainland (which was subcontracted to 
the Ifakara Health Institute) and Zanzibar. For the surveys in Madagascar, Nigeria and Uganda, 
the IE has drawn on outlet surveys commissioned prior to AMFm and carried out by PSI's 
ACTwatch Project (www.actwatch.info) through a grant from the Bill and Melinda Gates 
Foundation, which either partially or fully funded outlet survey rounds in these Phase 1 pilots. 
ACTwatch adapted its methodologies to help meet the needs of the IE.  
 
1.2 Overview of AMFm2 
1.2.1 Origins of the AMFm 
The Affordable Medicines Facility – malaria has its origins in the 2004 report of the Institute of 
Medicine (IOM) committee chaired by Professor Kenneth Arrow, Nobel Laureate in economics, 
published in Saving Lives, Buying Time: Economics of Malaria Drugs in an Age of Resistance 
(Arrow et al. 2004). The committee called for a “sustained global subsidy of artemisinins 
coformulated with other antimalarial drugs” to address the challenge that older and cheaper 
medicines, such as chloroquine and sulfadoxine-pyrimethamine, were increasingly less effective 
against Plasmodium falciparum, and ACTs, recommended by WHO for uncomplicated 
Plasmodium falciparum malaria, were too expensive for many seeking treatment in the private 
sector. The committee recognized that low coverage with ACTs and persistent use of oral 
artemisinin monotherapies (AMTs) were increasing the risk of widespread parasite resistance to 
artemisinin, the only widely effective first-line treatment. The committee recommended a global 
subsidy approach as the most economically and biomedically sound means to meet the dual 
challenge of increasing access to artemisinins while preserving their effectiveness as long as 
possible, and a key feature of the recommendation included that both public sector and private 
sector channels that already exist to deliver antimalarials to consumers be utilized to achieve 
maximum reach.  
 
While the IOM report recognized that efforts to improve drug delivery must continue, for 
example, by utilizing better information, technology (including rapid diagnostic tests) and 
supporting health systems more generally, it also recognized that those improvements will 
realistically be implemented over a longer time frame and there was an urgent need to move 
treatment-seekers away from artemisinin monotherapies and ineffective treatments to ACTs. 
Subsequent analyses supported this recommendation with studies concluding that a subsidy for 
                                                 
2
 The majority of the content of this section was drafted by the Global Fund and reviewed by the IE team. 
3 
 
ACTs was likely to slow the rate of the emergence of resistance to artemisinin and partner drugs, 
even if such a subsidy were to increase the use of ACTs significantly (Laxminarayan et al. 2006). 
The conclusion was robust to alternative assumptions regarding the responsiveness of demand to 
the lower price of ACTs and a wide range of epidemiological and economic parameters. 
1.2.2  Technical Design of the AMFm  
In 2006, the Finance and Resources Working Group of the Roll Back Malaria (RBM) 
Partnership, chaired by the World Bank, initiated a work program to translate the IOM 
recommendation into a reality. With financing from the Bill and Melinda Gates Foundation, the 
RBM Partnership convened and fostered a multi-institutional process which resulted in a 
technical design approved by the RBM Board in November 2007 (Laxminarayan and Gelband 
2009; Roll Back Malaria Partnership 2007).  
1.2.3  Global Fund’s Hosting and Management of the AMFm  
In late 2007, RBM and the Institutional Founders of the AMFm invited the Global Fund Board to 
consider hosting and managing the AMFm, and over the next two Board meetings, a business 
plan was developed as well as a policy framework and implementation plan for integrating the 
proposed new AMFm business line into existing Global Fund systems and policies.
3
 As 
described in the Board meeting documents, due to concerns that the AMFm was an unproven 
intervention, the Policy and Strategy Committee of the Global Fund Board recommended, 
instead of a global rollout, that the AMFm be launched in a small first phase in order to prove the 
concept and learn lessons; this constituted a key difference from the original IOM 
recommendation, introducing the risk of cross-border price arbitrage. In November 2008, the 
Global Fund Board requested the Secretariat to begin operations of AMFm Phase 1. 
 
As approved by the Global Fund Board, the AMFm has the following three elements: 
 
(i) Price reductions through negotiations with ACT manufacturers. The immediate objective 
of these negotiations was to reduce the ex-manufacturer prices of ACTs for private-
sector importers (i.e., first-line buyers) to the same level as the prices for public-
sector buyers.  
(ii) A buyer subsidy through a ‘co-payment’ at the top of the global supply chain. This is the 
mechanism through which the AMFm further reduces the ex-manufacturer price that 
is paid by first line buyers,
4
whether in the public or the private sector. 
                                                 
3 For example, see Global Fund Board decision point GF/B17/DP16 available at: 
http://www.theglobalfund.org/documents/board/17/BM17_BoardMeeting_Decisions_en/ and GF/B18/DP7 available at: 
http://www.theglobalfund.org/documents/board/18/BM18_BoardMeeting_Decisions_en/. 
 
4 First line buyers for AMFm include international, regional and national buyers from the public, private not-for-profit and 
private for-profit sectors who purchase ACTs directly from the manufacturer, or procurement agents buying on their behalf. To 
be eligible, a first line buyer must sign an undertaking with the Global Fund that sets out several conditions of participation. The 
undertaking is available at: http://www.theglobalfund.org/documents/amfm/AMFm_FirstLineBuyerUndertakingExecution_Form_en/ 
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(iii) Supporting interventions to promote appropriate use of ACTs. In their applications, 
countries were encouraged to propose the following activities: 
 Public education and awareness campaigns; 
 Training, monitoring and supervision for ACT providers; 
 Planning for national policy and regulatory preparedness; 
 Planning for monitoring of drug quality; and 
 Interventions to reach poor people and other vulnerable groups. 
 
The key innovation in the AMFm is the combined approach to significantly reduce prices 
through negotiations with ACT manufacturers and a global-level subsidy to further reduce 
prices. This involves financing by AMFm to pay a large part of the post-negotiation price (the 
‘co-payment’) on behalf of eligible first line buyers from the public, NGO and private sectors 
who purchase ACTs directly from the manufacturer. The first two elements had never been 
combined at the supra-national level in the financing of access to antimalarials. Examples of 
other approaches to subsidies do exist, including social marketing and franchises that operate at 
the country or sub-country levels; however, none was designed explicitly to achieve country-
wide scale in all eligible countries, and none was explicitly open to all service delivery channels. 
The Global Fund’s Technical Evaluation Reference Group (TERG) considered this ‘co-payment’ 
at the top of the global supply chain to be the innovative aspect of the mechanism.
5 
 
Following the November 2008 Board decision, the Secretariat began operations of AMFm Phase 
1. Negotiations with qualified manufacturers were initiated, and select countries with existing 
Global Fund malaria grants were invited to submit applications, in which AMFm pilots proposed 
how savings from the lower purchase price of ACTs would be reprogrammed for the 
implementation of key supporting interventions. Following invited applications by 12 countries, 
the evaluation of those applications, the approval of 10 of them by the Global Fund Board and 
the withdrawal of one of the countries, AMFm Phase 1 includes nine pilots in eight countries 
(Cambodia, Ghana, Kenya, Madagascar, Niger, Nigeria, Tanzania mainland, Uganda and 
Zanzibar). Of these, all but Cambodia were fully operational as of May 2012. 
 
Following the Global Fund Board decision of November 2009, Principal Recipients and the 
Secretariat advanced negotiations to revise the existing grant agreements, and when 
implementation letters were signed for the grant amendments, eligible first line buyers, including 
Principal Recipients, could place requests for copaid ACTs. 
 
It should be noted that the AMFm is a financing mechanism that works with the existing supply 
chain in the public, private not-for-profit and private for-profit sectors, inheriting both the 
                                                                                                                                                             
 
5 The Global Fund’s Technical Evaluation Reference Group’s Position Paper on the Independent Evaluation of the AMFm is 
available as Attachment 2 at: 
http://www.theglobalfund.org/documents/board/21/BM21_07AMFmAdHocCommitteeAttachments1And2_Report_en/.  
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strengths and weaknesses of each. Per its design, as AMFm is a demand-driven financing 
mechanism involving a multitude of private sector actors, a definitive prediction of requests for 
copaid ACTs under AMFm could not be known in advance. Per the implementation plan, with 
respect to ACT orders, eligible first line buyers place an order with an eligible manufacturer, 
after confirmation that they hold all necessary licenses, waivers or documentation to allow them 
to export, import, sell and/or distribute copaid ACTs in the AMFm pilot countries. The 
manufacturer then forwards the order (including the request for co-payment), and estimated 
carriage and insurance costs to the Global Fund Secretariat for approval. The manufacturer 
proceeds with filling the order once the Global Fund Secretariat gives its approval. An invoice 
for co-payment from the manufacturer is then sent to the Secretariat after drugs are delivered to 
the country’s first point of entry. In parallel, the first line buyer proceeds with payment of their 
portion to the manufacturer for the purchased ACTs. 
1.2.4  Funding sources 
AMFm Phase 1 is funded by two streams of funding. There were initial contributions to the 
AMFm Phase 1 Co-payment Trust Fund of USD 216 million by the Bill and Melinda Gates 
Foundation, the Government of the United Kingdom and UNITAID, which covered the period 
July 2010 to February 2012. The AMFm Co-payment Trust Fund was replenished in 2012 with 
an additional USD 120 million from the Government of Canada, the Government of the United 
Kingdom and UNITAID, to cover the period March 2012 to December 2012. The Co-payment 
Trust Fund, which is managed in a sub-account separate from regular Global Fund grants, covers 
the costs of high-level subsidies for ACTs to be financed by the AMFm. The second funding 
source is through regular Global Fund grants and consists of up to USD 127 million to finance 
supporting interventions at the country level. The interventions include, for example, expanded 
use of diagnostics, training and supervision of health workers, pharmacovigilance, monitoring, 
operational research and additional activities intended to deliver services to vulnerable 
populations such as the poorest and those living in remote locations.  
1.2.5 Negotiations with eligible manufacturers 
In order to be eligible to supply ACTs under AMFm, a manufacturer must meet the criteria set 
out in the Global Fund’s Quality Assurance Policy (see text box below).6 In keeping with the 
AMFm objective of countering resistance to artemisinin, manufacturers must also commit to not 
market oral artemisinin monotherapies for the treatment of patients. Participating manufacturers 
sign a contract, the Master Supply Agreement (MSA), with the Global Fund which sets out the 
conditions of supplying ACTs under AMFm and includes the agreed maximum selling prices. As 
stipulated in the MSA, the Global Fund may review prices at least once per year. 
                                                 
6
 For more information, see:  http://www.theglobalfund.org/en/procurement/quality/pharmaceutical/  
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Global Fund Quality Assurance Policy for Pharmaceutical Products 
For any pharmaceutical products to be eligible for purchase with the Global Fund resources, its 
compliance with quality standards must be assured. All pharmaceutical products should meet at 
least one of the following criteria: 
 products are prequalified by the WHO Prequalification Programme 
 products are approved or authorized for use by a stringent regulatory authority (a 
member, observer or associate of the International Conference on Harmonisation of 
Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) 
 products are permitted for time limited-use by the Expert Review Panel (ERP)  
 
The AMFm negotiation of maximum prices with the eligible manufacturers of ACTs was 
intended to reduce the ex-works
7
 manufacturer ACT prices paid by the private sector to the same 
level as the public sector. It is important to note that the maximum prices are ceiling prices and 
manufacturers can sell below those prices. The maximum prices established by AMFm were 
intended to preserve competition among eligible manufacturers and provide incentives for 
continuous cost/price reduction.  
 
Negotiations were informed by data on markets for artemisinin and active pharmaceutical 
ingredient (API), cost structures for each ACT formulation, ACT prices in the public and private 
sector, exchange rate variations, and other market intelligence. Maximum prices were first 
agreed in 2009, and incorporated into MSAs in 2010, reducing the ex-works manufacturer prices 
paid by private for-profit first-line buyers to approximately the same levels paid by the public 
sector. For private for-profit first-line buyers, this resulted in a reduction of up to 80% from 
prices they had paid in 2008/2009 before the AMFm.
8
  
 
Maximum prices were increased in March 2011,
9
 with co-payment levels also increased to even 
further reduce the prices paid by first-line buyers and to favor pediatric packs. In 2012 no further 
adjustments were made, despite higher artemisinin prices in 2011. This reflected financial 
constraints within the co-payment fund, which meant that the co-payment levels could not be 
further increased, and the importance attached to avoiding increases in the first line buyer 
purchase prices during AMFm Phase 1.  
 
                                                 
7
 The ex-works price is the price at the manufacturer warehouse excluding all transportation and export/import costs. 
8
 See 
http://www.theglobalfund.org/en/mediacenter/newsreleases/Agreements_reduce_prices_of_malaria_medicines_by_
up_to_80__/  
9
 See: http://www.theglobalfund.org/documents/partners/rbm/RBM_ACTPricing_FactSheet_en/  
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1.2.6  AMFm copayments processed and volume of copaid ACTs delivered 
Table 1.2.1 shows the quantity of copaid QAACTs requested, approved and delivered between 
the start of AMFm and December 2011. The total number of doses delivered by the end of 2011 
was 155.8 million. Just over one-third of these doses (57.3 million) were delivered to Nigeria. 
Ghana, Kenya and Uganda were the next largest recipients, with 28.5 million doses in Kenya, 
28.2 million doses in Uganda and 24.7 million doses in Ghana. Tanzania mainland received 13.0 
million doses and mMuch smaller amounts were delivered to Niger (2.2 million doses), 
Madagascar (1.7 million doses) and Zanzibar (0.2 million doses). The majority were delivered to 
private for-profit FLBs in Ghana, Madagascar, Nigeria, Tanzania mainland and Zanzibar. In 
Kenya, the public sector received similar quantities as the private for-profit sector, and in Niger 
and Uganda the public sector was the main recipient. Table 1.2.2 shows the quantity of copaid 
QAACTs requested, approved and delivered between January and September 2012. 
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Table 1.2.1: Quantity of copaid quality-assured ACTs requested, approved, and delivered, July 2010 – December 2011 
Indicator 4.2: Quantity of quality-assured ACT treatments requested by first line buyers, approved by the Global Fund, and delivered to countries, by sector, according to country 
Country/Sector 
3rd quarter 
2010 
4th quarter 
2010 
1st quarter 
2011 
2nd quarter 
2011 
3rd quarter 
2011 
4th quarter 
2011 Total 
Ghana         
New requests for co-payments received (Number of treatments) – Total 4,265,620 2,297,000 5,614,080 10,096,060 27,680,147 5,014,321 54,967,228 
   Public  0 0 0 0 4,610,347 1 4,610,348 
   Private not-for-profit 0 0 0 0 0 0 0 
   Private for-profit 4,265,620 2,297,000 5,614,080 10,096,060 23,069,800 5,014,320 50,356,880 
Orders approved (Number of treatments) – Total 4,265,620 2,297,000 5,614,080 10,096,060 4,003,025 8,307,243 34,583,028 
   Public  0 0 0 0 3,206,035 1,404,313 4,610,348 
   Private not-for-profit 0 0 0 0 0 0 0 
   Private for-profit 4,265,620 2,297,000 5,614,080 10,096,060 796,990 6,902,930 29,972,680 
Orders delivered* (Number of treatments) – Total 395,000 1,515,620 3,753,242 3,888,620 7,178,780 7,942,464 24,673,726 
   Public  0 0 0 0 0 1,404,325 1,404,325 
   Private not-for-profit 0 0 0 0 0 0 0 
   Private for-profit 395,000 1,515,620 3,753,242 3,888,620 7,178,780 6,538,139 23,269,401 
Kenya         
New requests for co-payments received (# treatments) – Total 3,427,300 2,047,500 3,115,100 15,581,330 9,642,370 2,041,000 35,854,600 
   Public  0 0 0 12,161,340 4,420,050 0 16,581,390 
   Private not-for-profit 0 0 0 0 0 0 0 
   Private for-profit 3,427,300 2,047,500 3,115,100 3,419,990 5,222,320 2,041,000 19,273,210 
Orders approved (Number of treatments) – Total 3,427,300 2,047,500 3,115,100 15,581,330 5,709,820 2,781,230 32,662,280 
   Public  0 0 0 12,161,340 4,420,050 0 16,581,390 
   Private not-for-profit 0 0 0 0 0 0 0 
   Private for-profit 3,427,300 2,047,500 3,115,100 3,419,990 1,289,770 2,781,230 16,080,890 
Orders delivered* (Number of treatments) – Total 734,990 1,662,780 2,561,968 4,326,080 7,840,970 11,329,850 28,456,638 
   Public  0 0 0 1,407,120 3,754,110 9,186,180 14,347,410 
   Private not-for-profit 0 0 0 0 0 0 0 
   Private for-profit 734,990 1,662,780 2,561,968 2,918,960 4,086,860 2,143,670 14,109,228 
Madagascar         
New requests for co-payments received (Number of treatments) – Total 231,600 316,275 130,248 895,695 265,824 51,230 1,890,872 
   Public  0 211,275 0 277,775 0 0 489,050 
   Private not-for-profit 0 0 0 0 0 0 0 
   Private for-profit 231,600 105,000 130,248 617,920 265,824 51,230 1,401,822 
Orders approved (Number of treatments) – Total 231,600 316,275 130,248 895,695 265,824 51,230 1,890,872 
   Public  0 211,275 0 277,775 0 0 489,050 
   Private not-for-profit 0 0 0 0 0 0 0 
   Private for-profit 231,600 105,000 130,248 617,920 265,824 51,230 1,401,822 
Orders delivered* (Number of treatments) – Total 0 21,600 451,275 357,324 157,090 700,889 1,688,178 
   Public  0 0 211,275 0 0 277,775 489,050 
   Private not-for-profit 0 0 0 0 0 0 0 
   Private for-profit 0 21,600 240,000 357,324 157,090 423,114 1,199,128 
Niger         
New requests for co-payments received (Number of treatments) – Total 425,000 0 1,245,050 96,480 508,640 434,960 2,710,130 
   Public  0 0 1,015,050 0 368,460 0 1,383,510 
   Private not-for-profit 0 0 0 0 0 0 0 
   Private for-profit 425,000 0 230,000 96,480 140,180 434,960 1,326,620 
Orders approved (Number of treatments) – Total 425,000 0 1,245,050 96,480 508,640 434,960 2,710,130 
   Public  0 0 1,015,050 0 368,460 0 1,383,510 
   Private not-for-profit 0 0 0 0 0 0 0 
   Private for-profit 425,000 0 230,000 96,480 140,180 434,960 1,326,620 
Orders delivered* (Number of treatments) – Total 0 0 1,002,470 632,870 90,160 499,620 2,225,120 
   Public  0 0 977,470 437,550 0 368,460 1,783,480 
   Private not-for-profit 0 0 0 0 0 0 0 
   Private for-profit 0 0 25,000 195,320 90,160 131,160 441,640 
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Table 1.2.1: Cont. 
Country/Sector 
3rd quarter 
2010 
4th quarter 
2010 
1st quarter 
2011 
2nd quarter 
2011 
3rd quarter 
2011 
4th quarter 
2011 Total 
Nigeria         
New requests for co-payments received (Number of treatments) – Total 0 14,507,840 16,971,410 27,494,810 45,738,870 21,796,888 126,509,818 
   Public  0 0 3,914,400 0 5,869,990 0 9,784,390 
   Private not-for-profit 0 4,953,120 502,000 0 0 670,000 6,125,120 
   Private for-profit 0 9,554,720 12,555,010 27,494,810 39,868,880 21,126,888 110,600,308 
Orders approved (Number of treatments) – Total 0 14,507,840 16,971,410 27,494,810 8,344,990 12,849,600 80,168,650 
   Public  0 0 3,914,400 0 5,869,990 0 9,784,390 
   Private not-for-profit 0 4,953,120 502,000 0 0 670,000 6,125,120 
   Private for-profit 0 9,554,720 12,555,010 27,494,810 2,475,000 12,179,600 64,259,140 
Orders delivered* (Number of treatments) – Total 0 0 8,209,875 14,138,928 13,932,799 22,620,474 58,902,076 
   Public  0 0 0 3,914,400 0 5,042,565 8,956,965 
   Private not-for-profit 0 0 2,563,950 1,164,940 1,660,940 0 5,389,830 
   Private for-profit 0 0 5,645,925 9,059,588 12,271,859 17,577,909 44,555,281 
Tanzania - mainland         
New requests for co-payments received (Number of treatments) – Total 210,000 1,655,050 2,200,150 8,192,770 1,613,200 3,159,000 17,030,170 
   Public  0 0 0 4,917,780 0 0 4,917,780 
   Private not-for-profit 0 0 0 0 0 0 0 
   Private for-profit 210,000 1,655,050 2,200,150 3,274,990 1,613,200 3,159,000 12,112,390 
Orders approved (Number of treatments) – Total 210,000 1,655,050 2,200,150 8,192,770 635,210 3,636,990 16,530,170 
   Public  0 0 0 4,917,780 0 0 4,917,780 
   Private not-for-profit 0 0 0 0 0 0 0 
   Private for-profit 210,000 1,655,050 2,200,150 3,274,990 635,210 3,636,990 11,612,390 
Orders delivered* (Number of treatments) – Total 0 210,000 1,345,150 1,863,150 8,408,370 1,212,950 13,039,620 
   Public  0 0 0 0 4,917,600 0 4,917,600 
   Private not-for-profit 0 0 0 0 0 0 0 
   Private for-profit 0 210,000 1,345,150 1,863,150 3,490,770 1,212,950 8,122,020 
Uganda         
New requests for co-payments received (Number of treatments) – Total 0 0 3,550,050 17,102,327 7,884,215 5,084,167 33,620,759 
   Public  0 0 0 14,662,475 4,683,225 3,101,277 22,446,977 
   Private not-for-profit 0 0 300,000 0 500,000 250,000 1,050,000 
   Private for-profit 0 0 3,250,050 2,439,852 2,700,990 1,732,890 10,123,782 
Orders approved (Number of treatments) – Total 0 0 3,550,050 17,102,327 6,737,105 2,259,990 29,649,472 
   Public  0 0 0 14,662,475 4,683,225 1,359,990 20,705,690 
   Private not-for-profit 0 0 300,000 0 500,000 250,000 1,050,000 
   Private for-profit 0 0 3,250,050 2,439,852 1,553,880 650,000 7,893,782 
Orders delivered* (Number of treatments) – Total 0 0 0 3,566,240 18,319,670 6,340,790 28,226,700 
   Public  0 0 0 0 16,840,740 3,864,750 20,705,490 
   Private not-for-profit 0 0 0 299,950 0 299,950 599,900 
   Private for-profit 0 0 0 3,266,290 1,478,930 2,176,090 6,921,310 
Zanzibar         
New requests for co-payments received (Number of treatments) – Total 0 0 150,000 0 136,105 -45,030 ** 241,075 
   Public  0 0 0 0 91,075 0 91,075 
   Private not-for-profit 0 0 0 0 0 0 0 
   Private for-profit 0 0 150,000 0 45,030 -45,030 ** 150,000 
Orders approved (Number of treatments) – Total 0 0 150,000 0 91,075 0 241,075 
   Public  0 0 0 0 91,075 0 91,075 
   Private not-for-profit 0 0 0 0 0 0 0 
   Private for-profit 0 0 150,000 0 0 0 150,000 
Orders delivered* (Number of treatments) – Total 0 0 0 150,000 91,075 0 241,075 
   Public  0 0 0 0 91,075 0 91,075 
   Private not-for-profit 0 0 0 0 0 0 0 
   Private for-profit 0 0 0 150,000 0 0 150,000 
* Manufacturers must provide proof of delivery to the Global Fund with all invoices for co-payment. Due to the delay between delivery and submission of an invoice by manufacturers, the actual 
treatment quantities delivered may be higher than what is officially reported in this table.** Negative figures for Zanzibar reflect withdrawal of a request after approval was not granted by AMFm.  
Source: Global Fund data base 
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Table 1.2.2: Quantity of copaid quality-assured ACTs requested, approved, and delivered, January 2012 – September 2012 
Indicator 4.2: Quantity of quality-assured ACT treatments requested by first line buyers, approved by the Global Fund, and delivered to countries, by sector, according to country 
Country/Sector 1st quarter 2012 2nd quarter 2012 3rd quarter 2012 Total 
Ghana      
New requests for co-payments received (Number of treatments) – Total 13,689,480 13,861,720 942,000 28,493,200 
   Public  0 0 0 0 
   Private not-for-profit 0 0 0 0 
   Private for-profit 13,689,480 13,861,720 942,000 28,493,200 
Orders approved (Number of treatments) – Total 3,123,300 6,125,660 4,623,260 13,872,220 
   Public  0 0 0 0 
   Private not-for-profit 0 0 0 0 
   Private for-profit 3,123,300 6,125,660 4,623,260 13,872,220 
Orders delivered* (Number of treatments) – Total 5,673,480 4,906,930 3,118,080 13,698,490 
   Public  1,801,710 0 0 1,801,710 
   Private not-for-profit 0 0 0 0 
   Private for-profit 3,871,770 4,906,930 3,118,080 11,896,780 
Kenya      
New requests for co-payments received (# treatments) – Total 18,087,240 14,254,000 18,468,580 50,809,820 
   Public  0 0 11,957,580 11,957,580 
   Private not-for-profit 0 0 0 0 
   Private for-profit 18,087,240 14,254,000 6,511,000 38,852,240 
Orders approved (Number of treatments) – Total 2,824,400 6,579,500 7,940,440 17,344,340 
   Public  0 0 4,185,540 4,185,540 
   Private not-for-profit 0 0 0 0 
   Private for-profit 2,824,400 6,579,500 3,754,900 13,158,800 
Orders delivered* (Number of treatments) – Total 4,719,040 2,202,920 5,048,680 11,970,640 
   Public  2,233,980 0 0 2,233,980 
   Private not-for-profit 0 0 0 0 
   Private for-profit 2,485,060 2,202,920 5,048,680 9,736,660 
Madagascar      
New requests for co-payments received (Number of treatments) – Total 463,100 631,380 139,770 1,234,250 
   Public  218,100 0 0 218,100 
   Private not-for-profit 0 0 0 0 
   Private for-profit 245,000 631,380 139,770 1,016,150 
Orders approved (Number of treatments) – Total 463,100 631,380 45,360 1,139,840 
   Public  218,100 0 0 218,100 
   Private not-for-profit 0 0 0 0 
   Private for-profit 245,000 631,380 45,360 921,740 
Orders delivered* (Number of treatments) – Total 187,632 464,132 130,000 781,764 
   Public  0 218,100 0 218,100 
   Private not-for-profit 0 0 0 0 
   Private for-profit 187,632 246,032 130,000 563,664 
Niger      
New requests for co-payments received (Number of treatments) – Total 1,220,000 381,390 1,761,915 3,363,305 
   Public  0 381,390 1,661,915 2,043,305 
   Private not-for-profit 0 0 0 0 
   Private for-profit 1,220,000 0 100,000 1,320,000 
Orders approved (Number of treatments) – Total 670,000 931,390 395,325 1,996,715 
   Public  0 381,390 295,325 676,715 
   Private not-for-profit 0 0 0 0 
   Private for-profit 670,000 550,000 100,000 1,320,000 
Orders delivered* (Number of treatments) – Total 284,960 619,900 726,890 1,631,750 
   Public  0 0 381,390 381,390 
   Private not-for-profit 0 0 0 0 
   Private for-profit 284,960 619,900 345,500 1,250,360 
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Table 1.2.2: Cont. 
Country/Sector 1st quarter 2012 2nd quarter 2012 3rd quarter 2012 Total 
Nigeria      
New requests for co-payments received (Number of treatments) – Total 89,834,000 14,618,912 28,834,000 133,286,912 
   Public  1,956,690 0 0 1,956,690 
   Private not-for-profit 25,539,520 0 0 25,539,520 
   Private for-profit 62,337,790 14,618,912 28,834,000 105,790,702 
Orders approved (Number of treatments) – Total 13,133,681 12,078,720 13,785,850 38,998,251 
   Public  1,048,110 908,580 0 1,956,690 
   Private not-for-profit 2,368,421 0 0 2,368,421 
   Private for-profit 9,717,150 11,170,140 13,785,850 34,673,140 
Orders delivered* (Number of treatments) – Total 12,866,054 8,584,440 11,820,750 33,271,244 
   Public  0 827,425 0 827,425 
   Private not-for-profit 0 2,368,420 667,720 3,036,140 
   Private for-profit 12,866,054 5,388,595 11,153,030 29,407,679 
Tanzania - mainland      
New requests for co-payments received (Number of treatments) – Total 15,471,780 10,614,800 9,207,600 35,294,180 
   Public  4,917,780 0 0 4,917,780 
   Private not-for-profit 0 0 0 0 
   Private for-profit 10,554,000 10,614,800 9,207,600 30,376,400 
Orders approved (Number of treatments) – Total 5,520,620 8,146,510 4,804,450 18,471,580 
   Public  2,739,420 2,178,360 0 4,917,780 
   Private not-for-profit 0 0 0 0 
   Private for-profit 2,781,200 5,968,150 4,804,450 13,553,800 
Orders delivered* (Number of treatments) – Total 962,760 10,541,160 4,039,168 15,543,088 
   Public  0 4,848,660 69,120 4,917,780 
   Private not-for-profit 0 0 0 0 
   Private for-profit 962,760 5,692,500 3,970,048 10,625,308 
Uganda      
New requests for co-payments received (Number of treatments) – Total 14,655,433 5,275,000 10,559,400 30,489,833 
   Public  5,850,033 0 0 5,850,033 
   Private not-for-profit 500,000 620,000 0 1,120,000 
   Private for-profit 8,305,400 4,655,000 10,559,400 23,519,800 
Orders approved (Number of treatments) – Total 6,519,120 4,691,600 5,078,100 16,288,820 
   Public  2,241,320 1,500,000 0 3,741,320 
   Private not-for-profit 500,000 220,000 0 720,000 
   Private for-profit 3,777,800 2,971,600 5,078,100 11,827,500 
Orders delivered* (Number of treatments) – Total 2,945,940 4,764,580 2,511,800 10,222,320 
   Public  1,640,130 0 526,230 2,166,360 
   Private not-for-profit 0 500,000 0 500,000 
   Private for-profit 1,305,810 4,264,580 1,985,570 7,555,960 
Zanzibar      
New requests for co-payments received (Number of treatments) – Total 134,000 0 0 134,000 
   Public  0 0 0 0 
   Private not-for-profit 0 0 0 0 
   Private for-profit 134,000 0 0 134,000 
Orders approved (Number of treatments) – Total 0 0 0 0 
   Public  0 0 0 0 
   Private not-for-profit 0 0 0 0 
   Private for-profit 0 0 0 0 
Orders delivered* (Number of treatments) – Total 0 0 0 0 
   Public  0 0 0 0 
   Private not-for-profit 0 0 0 0 
   Private for-profit 0 0 0 0 
* Manufacturers must provide proof of delivery to the Global Fund with all invoices for co-payment. Due to the delay between delivery and submission of an invoice by manufacturers, the actual 
treatment quantities delivered may be higher than what is officially reported in this table..  
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1.2.7  Typical ordering behavior: Differences between public and private sector 
buyers 
During AMFm Phase 1, some systematic differences between the purchasing behavior of public 
and private sector first-line buyers became evident. Table 1.2.3 summarizes some of these key 
differences. For the public sector, typically there is a single first-line buyer that places a single 
order (with staggered deliveries) to cover the public sector need for a full year, following a 
competitive tender process. In contrast, to cover the private sector needs, several private sector 
first-line buyers place multiple, relatively smaller orders periodically throughout the year, after 
directly contacting a manufacturer and reaching an agreement. 
 
For example, in Kenya, between June 2010 and December 2011, one public sector first-line 
buyer placed 2 orders for a total of 16.5 million co-paid ACTs, and six private sector first-line 
buyers placed 34 orders for a total of 16 million ACTs (see Table 1.2.4). 
 
Table 1.2.3: Differences between public and private sector buyers 
Item Public sector buyers Private sector buyers 
Number of buyers Often only one public sector first-line 
buyer places an order for the entire 
public sector needs 
Several private sector first-line buyers 
typically cover the private sector needs 
Frequency of orders Single order placed for entire year (with 
staggered deliveries) 
Several orders placed throughout the 
year 
Order size Public sector need is addressed in one 
single order 
Part of private sector need addressed 
through multiple smaller orders 
Competition Competitive tender required Can (and may be obliged to) engage 
directly with preferred suppliers 
Source: Global Fund 
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Table 1.2.4: Number of first-line buyers which received deliveries* of quality-assured ACT treatments through AMFm 
Country 
June 2010 - December 2011  January 2012 - September 2012  June 2010 - September 2012 
Public 
Private 
for-profit 
Private 
not-for-profit 
 
Public 
Private 
for-profit 
Private 
not-for-profit 
 
Public 
Private 
for-profit 
Private 
not-for-profit 
Cambodia 0 0 0  0 0 1  0 0 1 
Ghana 1 14 0  1 12 0  1 15 0 
Kenya 1 6 0  1 7 0  1 7 0 
Madagascar 1 8 0  1 3 0  1 8 0 
Niger 2 3 0  1 3 0  2 3 0 
Nigeria 1 25 2  1 23 2  1 26 2 
Tanzania mainland 1 6 0  1 8 0  1 9 0 
Uganda 2 4 2  2 3 1  3 4 2 
Zanzibar 1 1 0  0 0 0  1 1 0 
Total 10 67 4  8 59 4  11 73 5 
* Manufacturers must provide proof of delivery to The Global Fund with all invoices for co-payment. Due to the delay between delivery and submission of an 
invoice by manufacturers, the actual number of first-line buyers which received deliveries may be higher than what is officially reported in this table. 
Source: Global Fund 
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1.2.8 Implementation and country-level effects of demand-shaping levers 
Up until July 2011, all orders made by FLBs were approved by the Global Fund in the same 
quarter. However, for several reasons, including that co-payment costs for covering actual orders 
placed were initially higher than anticipated, it became apparent that the demand for AMFm 
copaid ACTs was greater than the resources available for co-payment during Phase 1. In order to 
ensure the availability of co-payment funding until additional resources might be secured, the 
AMFm Secretariat developed a framework for rationing co-payment. Since August 2011, each 
request for co-payment received is evaluated on the basis of several criteria (for example, the 
ratio of cumulative approved orders to estimated demand, relative proportion of pediatric 
formulations/pack sizes, and sector) and approved within the constraint of USD 8-10 million per 
month. Further details on the framework for rationing and demand-shaping levers applied are 
available in Appendix A. 
 
The immediate result of the application of these levers was a drastic reduction in the proportion 
of orders approved for co-payment, particularly for the private sector as all public sector requests 
for co-payment received in 2011 were approved for co-payment. Table 1.2.5 shows the quantity 
of copaid quality-assured ACTs requested by private not-for-profit and private for-profit first-
line buyers and approved by the Global Fund in the last two quarters of 2011. In the 3
rd
 and 4
th
 
quarters of 2011, AMFm approved only 32% of the private not-for-profit and private for-profit 
sector requests for co-payment received; Nigeria, Ghana, Kenya and Uganda were the most 
affected, with only 24%, 27%, 56% and 57% of private sector orders, respectively, approved 
during this period. By contrast, all requests were approved for Madagascar and Niger and 
relatively few orders were pending or cancelled in Tanzania mainland or Zanzibar. 
 
Given that the quantities of ACTs approved by the AMFm were significantly smaller than the 
demand from first-line buyers, it is reasonable to expect the imbalance to lead to pockets of low 
stocks at the level of the first-line buyer and potentially decreased availability and increased 
prices at the retail level in affected countries following application of the levers. Although orders 
take several months to arrive in country and be distributed, it is likely that application of demand 
levers, particularly in the 3
rd
 quarter of 2011, may have influenced QAACT availability by the 
time of the endline outlet surveys. Key informants in some countries reported problems of 
delayed and reduced order approvals, and the AMFm Secretariat frequently received feedback 
from first-line buyers and manufacturers expressing frustration with the partial fulfillment of 
ACT orders. 
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Table 1.2.5: Quality-assured ACT treatments requested by private not-for-profit and private for-profit first-
line buyers and approved by the Global Fund, 3
rd
 quarter and 4
th
 quarter of 2011 
Country 
Quantity of quality-assured 
ACT treatments requested 
by first-line buyers 
Quantity of quality-
assured ACT treatments 
approved by the Global 
Fund 
Percentage of quality-
assured ACT treatments 
approved by the Global 
Fund 
Ghana 28,084,120 7,699,920 27 
Kenya 7,263,320 4,071,000 56 
Madagascar 317,054 317,054 100 
Niger 575,140 575,140 100 
Nigeria 62,665,768 15,324,600 24 
Tanzania mainland 4,772,200 4,272,200 90 
Uganda 5,183,880 2,953,880 57 
Zanzibar 0 0 Na 
Total 108,861,482 35,213,794 32 
na = Not applicable  
   Source: Global Fund 
 
Table 1.2.6: Quality-assured ACT treatments requested by private not-for-profit and private for-profit first-
line buyers and approved by the Global Fund, 1
st
 quarter, 2
nd
 quarter and 3
rd
 quarter of 2012 
Country 
Quantity of quality-assured 
ACT treatments requested 
by first-line buyers 
Quantity of quality-
assured ACT treatments 
approved by the Global 
Fund 
Percentage of quality-
assured ACT treatments 
approved by the Global 
Fund 
Ghana 28,493,200 13,872,220 49 
Kenya 50,809,820 17,344,340 34 
Madagascar 1,234,250 1,139,840 92 
Niger 3,363,305 1,996,715 59 
Nigeria 133,286,912 38,998,251 29 
Tanzania mainland 35,294,180 18,471,580 52 
Uganda 30,489,833 16,288,820 53 
Zanzibar 134,000 0 0 
Total 283,105,500 108,111,766 38 
Source: Global Fund 
1.2.9 Evolution of adult versus child pack orders over time 
The relative percentage of child
10
 versus adult packs of AL, which represents 85% of all copaid 
ACTs approved, has evolved over time (Figure 1.2.1). In March 2011, the co-payment structure 
was revised to favor child packs, which began to have an effect, with child packs of AL 
increasing from 32% to 49% of approved orders in the period March to July 2011. Following 
implementation of the demand-shaping levers, this resulted in further increases in the relative 
proportion of child packs, to 65% for the period August to December 2011 and to 69% for the 
period January to August 2012. 
                                                 
10
 Child packs include all sizes other than the highest weight band 
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In contrast, the relative shares of child versus adult packs of ASAQ and AS+AQ (co-blister 
packs) were more in favor of child packs from the beginning and have remained stable over time 
(see Figure 1.2.2), likely related to the fact that ASAQ tablets come in different formulations for 
child and adult packs. 
 
For all copaid ACTs together, the percentage of all packs approved that were child packs was 
51% between June 2010 and December 2011, and 69% between January and September 2012. 
For the same periods, the child pack share of copaid ACTs delivered to Phase 1 countries was 
slightly lower (48% and 66%, respectively). Overall, for the June 2010 to September 2012 
period, 57% of ACTs approved for copayment were for child packs, and 55% of copaid ACTs 
delivered to Phase 1 countries were child packs. 
 
Figure 1.2.1: Artemether-lumefantrine: Relative percentage of pack sizes, pre- and post-revision of co-
payment structure and introduction of levers 
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AL: Artemether-Lumefantrine, fixed-dose combination tablets (traditional and dispersible) 
Adult (35 kg or more): 6x4 20/120 mg 
Child (25 kg up to 35 kg): 6x3 20/120 mg; Child (15 kg up to 25 kg): 6x2 20/120 mg 
Infant/Toddler (5 kg up to 15 kg): 6x1 20/120 mg 
Source: Global Fund 
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Figure 1.2.2: Artesunate-Amodiaquine: Relative percentage of pack sizes, pre- and post-revision of co-
payment structure and introduction of levers 
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ASAQ: Artesunate-Amodiaquine, fixed-dose combination tablets 
Adult: 3x2 100/270 mg 
Child: 3x1 100/270 mg 
Toddler: 3x1 50/135 mg 
Infant: 3x1 25/67.5 mg 
Source: Global Fund 
1.2.10 Disbursement delays for supporting interventions 
Due to a wide variety of factors at both the global and country levels, the timely disbursement of 
Global Fund grant funds to AMFm pilot countries remained a major challenge throughout Phase 
1. This resulted in delayed implementation of supporting interventions with critical elements, 
particularly public awareness and provider training, lagging behind distribution of copaid ACTs 
in the private sector. Late disbursement also hindered procurement of copaid ACTs by the public 
sector. These disbursement delays are discussed in greater detail in the country case studies. To 
be noted is that in some instances stop-gap activities were undertaken by partners to address the 
delays. 
1.2.11 Overview of timing of AMFm implementation 
Figure 1.2.1 provides an overview of the timeline of AMFm implementation in each pilot, from 
the signing of the grant amendment to grant disbursements, arrival of copaid drugs, and 
implementation of the IEC/BCC campaign (this supporting intervention has been highlighted as 
18 
 
it is a key intervention included in all pilot AMFm proposals). The figure also shows the timing 
of the implementation of demand levers and the dates of the Independent Evaluation baseline and 
endline outlet survey data collection. Further details on timing in specific pilots and reasons for 
any delays can be found in Section 4.  
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Figure 1.2.3: Timeline of AMFm Phase 1 Independent Evaluation data collection; grant amendments and 
disbursements; arrival in-country of copaid QAACTs; launch events; IEC/ BCC implementation; and application of 
demand levers by the Global Fund 
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Notes:   = Baseline and endline data collection for Independent Evaluation outlet surveys.     = Signing of grant amendment and Global Fund 
grant disbursements for implementation of Supporting Interventions.     = Copaid QAACTs in-country (although not necessarily in continuous 
supply); + = copaid QAACTs delivered,    = Implementation of AMFm public awareness (IEC/BCC) campaign at scale.     =Interim AMFm 
public awareness (IEC/BCC) campaign i.e. Ghana: talk shows only; Niger: activities not at scale; Nigeria: stop-gap soft launch; Uganda: stop-
gap radio.     = Application of Global Fund demand levers.  GA= grant amendment; $= disbursement for implementation of SIs; L= launch; L 
*= “Soft” Launch; in Tanzania- mainland a “soft” launch was held with a press conference on January 25, 2011; in Uganda a “soft” launch 
was held on April 29, 2011- linked to World Malaria Day celebrations, however no IEC/BCC or trainings began until after endline data 
collection. **Nigeria: Baseline data collection completed Sept-Nov 2009 
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1.2.12 Summary of AMFm implementation 
Table 1.2.3 summarizes key elements of AMFm implementation across the eight 
pilots, including the number of doses of copaid ACTs delivered in relation to the 
population at risk of malaria; the percentage of copaid ACTs delivered that were 
purchased by private for-profit first line buyers; the timing of the midpoint of the 
endline outlet surveys from the arrival of copaid ACTs in the country and from 
implementation at scale of IEC/BCC activities; and whether or not demand levers on 
orders were applied by the Global Fund, with corresponding percentages of requested 
private not-for-profit and private for-profit sector orders that were approved during the 
second half of 2011. 
 
In three pilots (Ghana, Kenya and Uganda), between 0.84 and 1.01 doses of copaid 
ACTs were delivered per person at risk of malaria. In Zanzibar, Tanzania mainland 
and Nigeria, the range was between 0.19 and 0.42 doses per person at risk, while in 
Madagascar and Niger, only 0.08 and 0.14 doses of copaid ACTs per person at risk of 
malaria were delivered. 
 
In most pilots, the majority of copaid ACTs delivered were purchased by private for-
profit FLBs, with five pilots having over 62% purchased by FLBs. In Niger and 
Uganda, on the other hand, less than 25% of copaid ACTs were purchased by FLBs in 
this sector. 
 
The time elapsed between arrival of copaid ACTs in the country and the midpoint of 
endline outlet surveys was over 12 months in 4 pilots (Ghana, Kenya, Madagascar and 
Tanzania mainland). The elapsed time was 9-1/2 months in Nigeria and Niger, and 7 
and 6-1/2 months in Uganda and Zanzibar, respectively. 
 
In Madagascar, Niger and Uganda, no sustained IEC/BCC campaign had been 
implemented at scale at the time of endline outlet survey fieldwork. In the other pilots 
between three and nine months elapsed between implementation of IEC/BCC 
activities at-scale and the midpoint of endline outlet surveys, illustrating that these 
activities lagged behind the arrival of copaid ACTs by between one and a half and 
seven months.  
 
Five of the eight pilots experienced application of Global Fund demand levers during 
the second half of 2011, with between 24% and 90% of orders requested by private 
not-for-profit and private for-profit FLBs approved. The demand levers had the 
greatest effect in Ghana and Nigeria. 
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Table 1.2.7: Summary of AMFm implementation 
Country 
Doses of copaid ACTs 
delivered per person 
at risk of malaria 
(2010-2011)* 
Percentage of 
copaid ACTs 
delivered to 
private for-profit 
sector first line 
buyers* 
Months from 
arrival of  copaid 
ACTs to 
midpoint of 
endline outlet 
survey* 
Months from 
IEC/BCC 
implementation 
at scale to 
midpoint of 
endline outlet 
survey** 
Application of Global 
Fund demand levers 
(percentage of 
private not-for-profit 
and private-for-
profit sector orders 
approved in 2
nd
 half 
of 2011)*** 
Ghana 1.01 94.3% 15-1/2 9 Yes (27%) 
Kenya 0.90 49.6% 15 9 Yes (56%) 
Madagascar 0.08 71.0% 14 † No 
Niger 0.14 19.8% 9-1/2 †* No 
Nigeria 0.42 76.9% 9-1/2 3 Yes (24%) 
Tanzania 
mainland 
0.31 62.3% 13-1/2 7 Yes (90%) 
Uganda 0.84 24.5% 7 0 Yes (57%) 
Zanzibar 0.19 62.2% 6-1/2 5 No 
Note: Population at risk of malaria obtained from World Malaria Report (2011), which states that 100% of the population was considered at 
risk in all countries except Kenya (where it was 76%). 
† Some implementation of IEC/BCC activities, but these activities were suspended prior to endline data collection. 
Source: 
* Information collated from Global Fund orders database (additional detail available in Table 1.2.1). Population at risk of malaria obtained 
from World Malaria Report (2011), which states that 100% of the population was considered at risk in all countries except Kenya (76%). 
** Information from country case studies (see Chapter 4) 
***Global Fund (see Section 1.2.6) 
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1.3 Overview of AMFm Phase 1 Countries 
The seven AMFm Phase 1 countries in which the IE has taken place are located in sub-Saharan 
Africa. Of these countries, three are in West Africa (Ghana, Niger and Nigeria), three are in East 
Africa (Kenya, Uganda and the United Republic of Tanzania) and one is in southern Africa 
(Madagascar) (Figure 1.2.1). An overview of each country (with separate summaries for 
Tanzania mainland and Zanzibar) is given below. 
 
Figure 1.3.1: Location of the AMFm Phase 1 countries 
 
1.3.1  Ghana 
Ghana has a population of approximately 24 million, of which 46% are 15 years or younger. The 
population of Ghana is growing and expected to double in 26 years. Due to the recent discovery 
of oil, Ghana is also a growing economy, with one of the highest Gross Domestic Products 
(GDPs) per capita in Africa (USD 1,325 in 2010). 
 
Malaria is a public health concern in Ghana with 100% of the population at risk of malaria. 
Transmission occurs year round and is higher in rural and peri-urban areas than in urban areas. 
The Ghana Health Service (GHS) estimates that 3 million cases of clinical malaria are reported 
from government health facilities annually, of which about 900,000 are in children less than 5 
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years of age. The majority of cases are caused by Plasmodium falciparum, but Plasmodium 
malariae and Plasmodium ovale cases are also found. 
 
Facilities considered part of the private health sector in Ghana include private for-profit 
institutions (such as privately owned hospitals/clinics, maternity homes, pharmacies and licensed 
chemical shops) and private not-for-profit facilities (such as those run by faith-based 
organizations and nongovernmental organizations). As part of the private sector, the Christian 
Health Association of Ghana (CHAG) operates under the umbrella of the Private Medical and 
Dental Practitioners Association of Ghana.  
 
The Ministry of Health (MOH) oversees the entire health system in Ghana. Under the MOH, the 
Ghana Health Service (GHS) ensures health service delivery in the public sector and implements 
health programs and policies. The National Health Insurance Scheme was introduced in 2004, 
and presently covers about 60% of the population. Beneficiaries of the scheme typically pay a 
card processing fee, an annual premium and a renewal fee, and the service covers about 95% of 
all illnesses including diagnostics and treatment costs, including the cost of diagnosis and 
treatment of malaria.  
 
The National Malarial Control Programme (NMCP) is responsible for providing technical 
leadership and coordination of all malaria control activities in Ghana. In 2002, the MOH revised 
Ghana’s malaria treatment policy and recommended that ACTs be used as the first line of 
treatment for uncomplicated malaria instead of chloroquine. Artesunate-amodiaquine (ASAQ) is 
the recommended first-line drug, and for those who cannot tolerate ASAQ, artemether-
lumefantrine (AL) and dihydroartemisinin-piperaquine (DHAP) are alternative first-line 
therapies. In addition to this recommended change, all ACTs have been declassified from 
prescription only to over-the-counter medicines, so that all health providers are able to stock, 
prescribe and supply ACTs. 
 
1.3.2  Kenya 
Kenya is an East African country located across the equator and bordered by five countries 
(Ethiopia, Sudan, Uganda, Tanzania and Somalia). The population of Kenya is 38.6 million, of 
which almost 43% is below 15 years of age. Approximately two-thirds of the population lives in 
rural areas, where 49% live below the poverty line, compared with 39% in urban areas. As of 
2010, the per capita GDP in Kenya was USD 795. 
 
Seventy-six percent of the population lives at risk of malaria infection. Kenya has four distinct 
malaria transmission zones: 1) endemic areas with intense transmission throughout the year, 2) 
seasonal transmission areas which have intense transmission during the rainy season, 3) 
epidemic-prone areas with seasonal and unstable transmission and 4) low risk areas where the 
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temperature is too low for the parasite to complete its life cycle in the vector. Plasmodium 
falciparum is the most prevalent parasite species at 96%, of which 16% comprises mixed 
infections with Plasmodium ovale, Plasmodium malariae or both.  
 
The health care system in Kenya is made up of more than 6,700 facilities from the public and 
private sectors. Approximately half of these facilities are public sector facilities, which employ 
60% of the health care personnel in Kenya. The Ministry of Medical Services (MOMS) and the 
Ministry of Public Health and Sanitation (MOPHS) are jointly responsible for health care 
services and delivery in Kenya. The public sector health system operates on a multi-tiered 
system, starting with community-level health units to district level facilities to regional facilities 
and finally to national referral hospitals. Most of the private not-for-profit facilities are operated 
by faith-based organizations. In both the public sector and the private not-for-profit sector, 
children under five years should receive free medical care, and there is a system of exemptions 
for all others who cannot afford care. In addition, medicines for malaria, HIV/AIDS and TB 
should be provided for free to everyone. The private for-profit health sector accounts for 
approximately 33.4% of the health facilities in Kenya and provides services and medicines on a 
full cost basis. Retail sector drug provision is through registered and unregistered pharmacies, 
with the latter believed to make up at least 50% of retail pharmacy outlets.  
 
In 2004, the National Malaria Control Program (NMCP) adopted artemether-lumefantrine (AL) 
as the first-line treatment and dihydroartemisinin-piperaquine as the second-line treatment for 
uncomplicated malaria. In addition, the NMCP updated its policy guidelines in 2010 to 
recommend that all suspected cases of malaria have parasitological diagnosis using microcopy or 
rapid diagnostic tests. ACTs in Kenya are considered prescription only medicines, with 
distribution supposed to be limited to government facilities, private clinics and registered 
pharmacies. The sale of oral artemisinin was banned in 2006.  
 
The funding for malaria control activities primarily comes from the government and international 
donors, including the Global Fund, PMI, DfID and UN agencies. The Global Fund provides the 
most substantial amount of funding to Kenya for malaria control activities.  
 
1.3.3  Madagascar 
Madagascar is the fourth largest island in the world with a population of approximately 21 
million. GDP per capita was USD 421 in 2010. Approximately 68% of Madagascar’s population 
lives below the poverty line. Since February 2009, Madagascar has been experiencing a political 
crisis which has affected the economic growth of the country. Madagascar’s GDP decreased by 
4.6% in 2009 after increasing by 7.1% in 2008, according to the World Bank. Due to this 
political crisis, a considerable proportion of official aid, which makes up 40% of Madagascar’s 
budget, has been on hold. 
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While 100% of the population of Madagascar is at risk of malaria, malaria transmission occurs at 
varying levels throughout the island. In the north, malaria transmission occurs year round. On the 
east and west coasts, transmission is stable and perennial. In contrast, malaria transmission in the 
south and central highlands is seasonal and unstable and sometimes prone to epidemics. 
Approximately 75% of the population lives in low and unstable transmission regions, and 25% 
lives in areas of high and intense transmission. In all, 299,094 clinical malaria cases were 
reported in 2009. 
 
The public sector health system is the main source of health care, particularly in rural areas, 
accounting for 70% of primary contacts in rural areas and 40% of primary contacts in urban 
areas. The public health care system operates at four functional levels: central, regional, district 
and community. The system comprises a total of 138 hospitals, 1,335 secondary health centers, 
1,059 primary health centers, and 14,989 community health workers (CHW). CHWs have 
historically been a key distribution channel for malaria medicines. The central medical store is 
the sole importer and distributor of drugs to the public sector health facilities, except for ACTs 
which are purchased by UGP, a principal recipient of the Global Fund, and distributed by the 
National Malaria Program. The private sector health system includes 44 hospitals, 724 private 
health centers and 1,500 doctors. In addition, there is a network of 22 pharmaceutical 
wholesalers, 200 pharmacies and more than 1,000 rural pharmacies. 
 
In 2006, the NMCP adopted ASAQ as the first-line treatment and AL as the second-line 
treatment for uncomplicated malaria. ASAQ is provided for free at public health facilities. 
Malaria treatment requires a prescription and can be stocked at legally registered pharmacies and 
drugstores. Children with uncomplicated malaria are treated free of charge. As part of case 
management training by the NMCP, training on the use of microscopic diagnosis and the use of 
rapid diagnostics was initiated in 2005, and PMI has supported a program to train CHWs to use 
RDTs. From 2008, ACTs have also been distributed through a social marketing project (funded 
by the Global Fund and implemented by PSI) that at the time of the endline outlet survey 
provided subsidized artesunate-amodiaquine in the form of a branded product (ACTipal®) to 
CHWs, pharmacies and drug stores. 
 
Funding for malaria control activities has steadily increased over the last several years from 
about $25 million in 2009 to $89 million in 2011. This funding primarily comes from the Global 
Fund, UN agencies and the President’s Malaria Initiative (PMI). 
 
1.3.4  Niger 
Located in West Africa, Niger is bordered by Algeria, Burkina Faso, Benin, Chad, Libya, Mali 
and Nigeria. The estimated population of 15.2 million persons in 2010 lives in an area of 
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1,267,000 km². Niger remains one of the poorest countries in the world, with a GDP per capita in 
2010 of USD 358. About 63% of the population lives below the poverty line. 
 
Malaria is a major public health problem in Niger. The burden of malaria was estimated at 7.59 
million episodes (suspected cases) in 2010 (WHO 2012). These numbers place malaria in first 
place, ahead of acute respiratory infections (ARI) and diarrheal diseases. Malaria accounts for an 
average of 20% of the causes of consultations during the dry season and 80% during the rainy 
season. The disease affects all age groups, but particularly children under five years and pregnant 
women. 
 
In Niger, the public sector is the main health care provider and is structured in three levels. The 
first level, referred to as the central level, comprises national referral hospitals (3) and national 
specialized hospitals. The second level, called the regional level, includes six regional hospitals 
and three referral maternities. The peripheral level of the health care system is the district health 
system, which includes district hospitals and a network of 578 primary health care facilities 
called integrated health care centers (Centres de Santé Intégrés or CSI) and 1,201 operational 
health posts (Cases de Santé). The private sector includes 201 clinics and health care centers 
providing different level of health care; two-thirds of them (68%) are located in the capital of 
Niamey. 
 
The National Malaria Control Program is responsible for implementing the malaria control 
strategies, which are organized around the following areas: malaria case management, prevention 
of malaria during pregnancy, integrated vector control, forecasting, prevention and management 
of epidemics, communication and social mobilization on the dangers of malaria, and advocacy 
and action at the individual and community levels. The Global Fund is the major source of 
funding for malaria control activities in Niger. 
 
With high levels of resistance to chloroquine observed in 2003, the country adopted an ACT as a 
first-line treatment for uncomplicated malaria cases in adults and children. Since January 2005, 
artemether-lumefantrine (AL) has been the recommended first-line drug for uncomplicated 
malaria (replacing chloroquine), and artesunate-amodiaquine (ASAQ) has been the second-
choice treatment. Artemisinin monotherapy is banned for the treatment of uncomplicated 
malaria, and through 2011 quinine was the recommended antimalarial for the treatment of severe 
and complicated malaria. From 2008, Niger introduced a pediatric form for ACT. For prevention 
of malaria in pregnant women, sulfadoxine-pyrimethamine (SP) is recommended for intermittent 
preventive treatment (IPTp), in addition to insecticide-treated bednets (ITNs). Quinine and ACTs 
are the recommended drugs for treatment of malaria in pregnancy (in the 2
nd
 and 3
rd
 trimesters). 
ACTs are registered as prescription only medicines, and the national policy is that all presumed 
malaria cases should be parasitologically confirmed before treatment with ACTs. In practice, 
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however, due to a lack of RDTs, only 24% of fever cases are tested (23% using RDTs and 1.5% 
using microscopy). 
 
The coverage of insecticide-treated nets (ITNs), including long-lasting insecticide-treated nets 
(LLINs), has increased substantially in Niger in recent years, with an estimated 2,530,809 
million ITNs distributed or sold in 2010 (WHO 2012). A similar number of ITNs was sold or 
distributed in 2009. In 2010, it was estimated that 50-60% of the population at risk of malaria 
was protected by ITNs or IRS and that ITN coverage in the general population was 33% (WHO 
2012). 
1.3.5  Nigeria 
Nigeria is the most populous country in Africa with a population of 158 million. The country is 
made up of 36 states (plus the Federal Capital Territory) and 774 Local Government Areas 
(LGAs). Nigeria’s gross domestic product per capita was USD 1,278 in 2010. Despite a rapid 
increase in GDP per capita in the last 10 years, primarily due to oil revenues, 55% of the 
population is below the poverty line. 
 
Malaria is a major public health issue in Nigeria, with 100% of the population at risk of malaria. 
Nigeria has five ecological strata from north to south, resulting in varying malaria transmission 
intensities and seasonality. The north has intense transmission during the 3-month wet season, 
whereas the south experiences intense and stable transmission throughout the year. Malaria 
accounts for about 50% of the total disease burden and total health expenditures in Nigeria. The 
National Malaria Control Program (NMCP) estimates that malaria causes 300,000 deaths in 
children under the age of five years each year. 
 
The public health care system in Nigeria operates on a three-tiered system with the Federal 
Ministry of Health (FMOH) at the top, followed by the State Ministries of Health (SMOH) and 
Local Government Areas (LGAs). The FMOH is responsible for providing policy and technical 
guidance, and manages tertiary level care, research and academic centers of excellence. The 
SMOHs manage state hospitals and training of health care staff for primary and secondary health 
care facilities. The LGAs are responsible for managing and implementing primary health care 
(PHC) services. The private sector provides 65% of health care in Nigeria, and many Nigerians, 
particularly the poor, use the proprietary patent medicine vendors (PPMVs) as the first choice for 
health care. 
 
In 2005, the NMCP adopted AL as the first-line treatment for uncomplicated malaria and ASAQ 
as the alternative first-line treatment. Both AL and ASAQ were declassified from prescription 
medicines to over-the-counter medicines in 2006. Oral artemisinin monotherapies were banned 
in 2006, and their importation and local manufacturing are prohibited by law. The National 
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Agency for Food and Drug Administration and Control (NAFDAC) regulates both the public and 
private sector drug supply chains. 
 
1.3.6 Tanzania – mainland 
The population of Tanzania - mainland is estimated to be 41.9 million, with an annual growth 
rate of 2.9%. The majority of the population (75%) lives in rural areas. Tanzania mainland has 
maintained a GDP growth of 7% for the last 10 years. The per capita income in 2010 was USD 
524. Despite the growth in per capita income, 38% of households in rural areas and 24% of 
households in urban areas continue to fall below the poverty line. 
 
One hundred percent of Tanzania’s population is at risk of malaria infection, although 
transmission varies across the country, with the highest prevalence in Northern Tanzania. Many 
malaria deaths go unreported, yet of all deaths recorded at health facilities, 44% and 26% are 
attributed to malaria in children under five and those aged five years and above, respectively.  
 
Health services are provided by both the government and the private sector, and they are 
overseen by the Ministry of Health and Social Welfare (MoHSW). Public health care is provided 
through a network of hospitals, health centers and dispensaries, with many similar facilities 
owned by faith-based organizations. Private retail sector providers include Part II drug stores 
(known as Duka la Dawa Baridi - DLDB), Accredited Drug Dispensing outlets (ADDOs) and 
Part One pharmacies (POPs), which should all be licensed by the Tanzania Food and Drug 
Authority (TFDA). DLDBs are allowed to stock a limited range of over-the-counter medicines. 
ADDOs are upgraded DLDBs after undergoing TFDA training, and they are allowed to sell a 
limited range of prescription only medicines. POPs should be staffed by a pharmacist, and are 
allowed to sell a wider range of medical supplies than ADDOs and DLDBs.  
 
The ACT artemether-lumefantrine (AL) was introduced as first-line antimalarial in 2006, with 
quinine as a second–line antimalarial. Amodiaquine and SP are over-the-counter medicines, 
whereas quinine and artemisinin based drugs, including ACTs, are prescription only. Artemisinin 
monotherapies were banned in 2008, but some are still present in the market. Until 2010, most 
malaria cases were treated based on clinical symptoms alone, with very partial coverage with 
microscopy, but the MoHSW is now in the process of rolling out rapid diagnostic tests (RDTs) in 
public health facilities. 
 
Prior to AMFm, subsidized ACTs had been made available in the private sector through two 
projects in 2007-9 (through ADDOs in the Morogoro and Ruvuma regions and through DLDB in 
Maswa District in the Shinyanga region and Kongwa District in the Dodoma region). However, 
it was expected that only minimal quantities of these subsidized ACTs remained in the market by 
the start of the AMFm rollout. 
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1.3.7  Uganda 
Uganda is bordered by Sudan to the north, Kenya to the east, Tanzania and Rwanda to the south 
and the Democratic Republic of Congo to the west. The country has a population of 
approximately 33.4 million, 18.6% of whom are children under five years of age. From 2009-
2010, the GDP increased by 5.8% and reached USD 509 in 2010; however, 35% of the 
population continues to live below the poverty line. 
 
Most parts of Uganda experience perennial malaria transmission, and 99% of malaria cases are 
caused by Plasmodium falciparum. Malaria is the most frequently reported disease in both public 
and private health facilities, making it a major public health problem in Uganda. Indeed, clinical 
malaria is the leading cause of morbidity and mortality, accounting for 9-14% of all hospital 
deaths. In addition, about half of all deaths in children less than five years of age are attributed to 
malaria. Currently, it is estimated that malaria accounts for 70,000-110,000 deaths annually in 
Uganda. 
 
Uganda’s National Health System (NHS) is comprised of both public and private sector health 
care systems. The public sector health system is decentralized, and it is made up of five levels of 
service: hospitals, including National Referral Hospitals, Regional Referral Hospitals and 
district-level hospitals; sub-district-level health centers (health center IV), subcounty-level health 
centers (health center III), parish-level health centers (health center II) and Village Health 
Teams.  
 
Procurement of medicines in the public sector health system occurs through the National 
Medical Stores (NMS). In 2010, NMS and the Ministry of Health (MOH) changed the policy 
under which lower level health facilities receive supplies; now each health center II and health 
center III receives a standard kit of drugs and commodities, including ACTs. Facilities are 
supposed to receive the kits bimonthly, the composition of which is determined by the facility 
type, irrespective of catchment population or case mix. Health center IVs and hospitals continue 
to order essential medicines from a budget line at the NMS.  
 
The private health system consists of private not-for-profit providers, private for-profit providers, 
and traditional and complementary practitioners. Private not-for-profit facilities are 
predominantly faith-based organizations that are coordinated by national bureaus and diocesan 
boards. Across Uganda, private not-for-profit facilities were reported to provide 1.5 million 
outpatient services, 360,000 hospital admissions and 70,000 deliveries in 2008. The Joint 
Medical Stores procures and warehouses drugs and other medical supplies for the private not-for 
profit sector. 
 
30 
 
Private for-profit providers are an important source of care for treatment for malaria, and they are 
commonly the first avenue for seeking treatment during an episode of fever in children. Private 
for-profit providers include health facilities, which mainly provide primary and secondary care, 
retail pharmacies, licensed drug shops, and an unknown number of unregistered drug shops that 
operate illegally. Pharmacies should be supervised by a registered pharmacist, and they are 
permitted to dispense prescription only medicines. Drug shops, which outnumber pharmacies by 
a ratio of 10:1, should be located at least 1.5 km away from the nearest licensed retail pharmacy, 
and they should be supervised by a professional with an approved medical or pharmaceutical 
qualification. Drug shops are only permitted to sell over-the-counter medicines. 
 
Private for-profit providers purchase medicines through the private commercial sector 
distribution chain. The distribution chain has a pyramidal structure, and includes approximately 
250 wholesale pharmacies, 70 drug importers and distributors and 15 local manufacturers. In 
December of 2010, the Quality Chemicals Industries Limited (QCIL) manufacturing site in 
Kampala became pre-qualified to produce AL under license from Cipla Limited. QCIL is the 
first African manufacturer to receive WHO pre-qualification to manufacture ACTs. 
 
In 2004, Uganda’s NMCP adopted AL as the first-line treatment and ASAQ as the alternative 
first-line treatment for uncomplicated malaria. Treatment of uncomplicated malaria is provided 
free of charge to all age groups in public health facilities. Oral artemisinin monotherapies were 
banned in 2007. 
 
Funding for malaria control activities in Uganda has come from multiple sources including the 
Global Fund, PMI, UNICEF, DFID and the Bill and Melinda Gates Foundation. 
 
Prior to AMFm, the Consortium for ACT Private Sector Subsidy (CAPSS), led by the Ministry 
of Health Uganda and Medicines for Malaria Venture (MMV), piloted the distribution of 
subsidized ACTs through the private sector in four districts (Budaka, Pallisa, Kaliro and 
Kamuli). The pilot took place in 2008-2010. The ACT distributed through CAPSS was Coartem 
repackaged with a green leaf logo that was the prototype for the AMFm logo. It is likely that 
stock of the CAPSS-subsidized ACTs remained in the market at the time of the baseline outlet 
survey in Uganda. 
1.3.8  Zanzibar 
Zanzibar is a series of islands, which are part of the United Republic of Tanzania, located 36 km 
off the coast in the Indian Ocean. There are two main islands, Pemba and Unguja (with areas of 
900 km
2 
and 1,500 km
2
,
 
respectively), and several sparsely populated islets. Based on the 2002 
census, the total population of Zanzibar is 981,754 with an annual growth rate of 3.1%. The 
enumerated population was 620,957 in Unguja and 360,797 in Pemba. Tourism accounts for one-
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fifth of the total GDP in Zanzibar. Despite the growth in tourism, 50% of the population still 
lives below the poverty line. 
 
One hundred percent of Zanzibar’s population is at risk of malaria, which is primarily caused by 
Plasmodium falciparum infection. Each of the main islands has different transmission patterns. 
Unguja has two-peak transmission seasons, one during the long rainy season from March to June 
and one during the shorter rainy season from October to December. Pemba has only a one-peak 
transmission season during the long rainy season. Historically, malaria has been a leading cause 
of morbidity in Zanzibar. However, in recent years the incidence of malaria has been 
substantially reduced due to consolidated and scaled-up effective malaria control interventions. 
In 2005, malaria prevalence was reported to be 20% in many parts of Zanzibar; however, after 
six years of scale up, the prevalence is now below 1%. 
 
The public health system in Zanzibar is administered through the directorates of the Ministry of 
Health and Social Welfare (MOHSW) and is focused on using district health services as the 
foundation. The public health system is comprised of primary, secondary and tertiary levels of 
care and specialized hospitals. The primary level of care consists of 113 first-line and 26 second-
line Primary Health Care Units (PHCUs). The secondary level of care consists of Primary Health 
Care Centers (PHCC) and District Hospitals which provide some surgical services, emergency 
obstetric care and emergency referrals. There are two PHCCs on each island and three district 
hospitals, all on Pemba. The tertiary level of care is a national-level hospital with 400 beds. 
There are two specialized hospitals, the Mwembeladu Maternity Hospital and the 
Kidongechekundu Mental Hospital. These two hospitals, in addition to their specific services, 
offer case management of malaria, and the Mwembeladu Maternity Hospital also provides IPTp. 
 
The private sector health system is well established in Zanzibar with three hospitals (all in 
Zanzibar Town), 100 outpatient clinics, 60 registered pharmacies and 200 over-the-counter 
(OTC) outlets. The majority of private facilities are located in and around Zanzibar Town. 
 
In 2003, the Government of Zanzibar implemented a new policy to use artemisinin-based 
combination therapy (ACTs) for malaria treatment, being one of the first in the region to adopt 
this policy. Artesunate-amodiaquine (ASAQ) is the first-line treatment for uncomplicated 
malaria and artemether-lumefantrine (AL) is the alternative first-line treatment. ACT treatment is 
provided free of charge in public health facilities. In 2008, Zanzibar banned artemisinin 
monotherapy for treatment of malaria, and the ban was further enforced in 2011 within the 
framework of the AMFm program. Since January 2011, OTC outlets have been able to sell first-
line antimalarial medicines, including copaid ACTs. 
 
The Zanzibar Malaria Control Program (ZMCP) coordinates and implements malaria control 
strategies. Zanzibar aims to reduce malaria incidence by 70% by 2012 by focusing on effective 
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case management, preventing and controlling malaria in pregnancy, integrated vector control, 
and epidemic preparedness and response. Effective case management is based on providing 
prompt diagnosis by microscopy or a rapid diagnostic test (RDT) and treatment with ACTs. To 
prevent malaria in pregnancy, all pregnant women are provided intermittent preventive treatment 
(IPTp) with two doses of SP for free in public health facilities. Integrated vector control involves 
the distribution of long-lasting insecticide-treated nets (LLINs) and regular indoor residual 
spraying (IRS). In 2008, the ZMCP, in collaboration with the President’s Malaria Initiative 
(PMI), established a malaria early epidemic detection system (MEEDS) in which weekly data are 
reported to ZMCP, allowing for early identification of epidemics for appropriate intervention. 
 
Zanzibar receives funds for malaria control activities primarily from the Global Fund and PMI. 
With the goal of further expanding coverage of effective treatment for malaria, in November 
2010, the Government of Zanzibar signed a two-year grant with the Global Fund to implement 
the Affordable Medicines Facility – malaria (AMFm) pilot. 
 
1.4 Evaluation framework 
The purpose of the Independent Evaluation is to assess how AMFm has evolved in each pilot and 
estimate changes between the baseline and endline surveys in the values of key measures 
(availability, price, market share and use of quality-assured ACTs
11
) to inform decisions 
regarding the future of AMFm beyond Phase 1. The IE is based on the AMFm (Phase 1) 
Monitoring and Evaluation (M&E) Results Framework, but with a focus on Outputs and 
Outcomes (Figure 1.4.1). The IE is therefore designed to answer four questions related to the 
availability, affordability, market share and use of ACTs. These questions are formulated as 
follows: 
1. Question 1: Has the AMFm mechanism helped increase the availability of quality-
assured ACTs to patients across the public, private for-profit and not-for-profit sectors, in 
rural/urban areas? 
2. Question 2: Has the AMFm mechanism helped to reduce the cost of quality-assured 
ACTs to patients at public, private for-profit and not-for-profit outlets in rural/urban areas 
to a price comparable to the price of the most popular antimalarial? 
3. Question 3: Has the AMFm mechanism helped increase use of quality-assured ACTs, 
including among vulnerable groups, such as poor people, rural residents and children? 
4. Question 4: Has the AMFm mechanism helped increase the market share of quality-
assured ACTs relative to all antimalarial treatments in the public, private for-profit and 
not-for-profit sectors in rural/urban areas? 
                                                 
11
 Quality-assured ACTs are defined as those ACTs that meet the requirements of the Global Fund’s quality 
assurance policy. 
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Figure 1.4.1: AMFm Phase 1 Results Framework 
 
ACTs: Artemisinin-based combination therapies; IEC: Information Education and Communication; GF: Global 
Fund; AMTs: artemisinin monotherapies; SP: Sulfadoxine-pyrimethamine, CQ: Chloroquine; TA: Technical 
assistance, SIVs: Supporting interventions 
Source: Global Fund, AMFm Phase 1 Monitoring and Evaluation Framework, 2009 
 
1.4.1  Impact model 
The IE theory of change depicts our conceptualization of how AMFm is intended to work. It 
proposes a causal pathway which runs from the inputs of the AMFm intervention, including the 
supporting interventions, through the intermediate outputs measured by the IE, outcomes and the 
final impacts which are the ultimate objective of AMFm. The theory of change makes explicit 
how far down the causal pathway the IE is able to measure directly, and those outcomes and 
impacts which are not measured in the IE. It locates the potential influence of key elements of 
the implementation process on program outputs, including the volume and tempo of QAACTs 
ordered, approved and delivered. It identifies the different types of supporting interventions that 
have been implemented across the eight pilots, and where on the causal pathway they are 
expected to operate. Finally, it considers the main contextual factors with potential to influence 
AMFm outputs and outcomes. It is intended to serve as an aid to interpretation of the AMFm 
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indicators in each of the eight pilots and to the challenge of attributing observed changes to the 
AMFm program.  
 
The theory of change is shown in Figure 1.4.2, which shows how two of the main inputs of the 
AMFm program (manufacturer price negotiations and application of the global subsidy) flow 
through to the volume of copaid QAACTs that are ordered, approved, delivered and made 
available in country. In distinguishing these different steps in the delivery process, the theory of 
change allows for blockages in any of these individual processes to influence impact. It also 
explicitly identifies the application by the AMFm Secretariat of “demand levers” to mediate the 
quantities of copaid QAACTs approved for each country. 
 
The IE indicators are shown in blue boxes: these are QAACT availability, relative prices, market 
share and use. In the language of program evaluation, these are most appropriately described as 
outputs rather than outcomes. There is a direct relationship between the volume of drugs that 
arrive in a country and availability. Relative prices will also influence availability (which will in 
turn influence price), and we also identify demand side factors, not directly investigated in the 
IE, as an important influence on availability. QAACT use and its proxy, QAACT market share, 
are shown as following from availability. We also indicate overall antimalarial market size as a 
separate outcome, not directly measured by the IE. Even further downstream from QAACT use 
and market share is appropriate treatment of malaria (which might reflect the extent to which 
ACTs are targeted to those with malaria parasites, to those in the most vulnerable age groups and 
to the most economically vulnerable). Finally, AMFm would be expected to influence the 
outcomes of reduction in malaria burden and slowed growth of resistance to artemisinins. 
Neither appropriate treatment nor malaria burden/resistance are within the scope of the IE. 
 
Supporting interventions, which are a core AMFm input, are shown in green. They include the 
presence of a recommended retail price (RRP) (which would influence both relative prices of 
QAACTS and their availability); AMFm communications, including the application of the 
ACTm logo and any communication around an RRP (which would influence relative prices, 
availability and demand for QAACTS); regulatory interventions, including changes to 
prescription only status, the range of outlets that are allowed to sell QAACTS, a ban on AMT, 
and the enforcement of all of these measures; and training of providers (which, through provision 
of new knowledge about ACTs, will impact prices and availability of QAACTS, but also the 
more downstream output of appropriate treatment). 
 
The impact of AMFm will also be influenced by contextual factors, which are identified in red. 
These include the influences of the broader macroeconomic and political climate, including 
exchange rates, on prices, availability and demand; overall health system financing, which will 
affect prices; and the role of taxes and market structure on prices and markups. These would 
affect relative prices, availability and demand, and through these channels influence market share 
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and use. The presence of large public sector purchases of QAACTs through other donor-funded 
programs would directly influence availability of QAACTs; as would other donor investments in 
IEC/BCC on case management. Communication can also have a negative effect, such as media 
scare stories about ACTs negatively influencing demand for QAACTS and thereby availability 
and market share. The availability and widespread use of diagnostics such as RDTs could reduce 
demand for QAACTS, the overall size of the market for antimalarials, and effective targeting of 
QAACTs to those with malaria. 
 
Figure 1.4.2: AMFm Theory of Change 
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1.4.2 Evaluation design 
While an evaluation based on a quasi-experimental design would have provided stronger 
evidence to attribute any change in primary outcomes to the intervention, it is challenging to 
execute such a study design for an evaluation of a complex public health program such as 
AMFm that is implemented on a national scale with multiple players. Comparison groups could 
not be created within the pilots because AMFm was implemented on a national scale; 
furthermore, it would have been infeasible with an intervention using private sector distribution 
channels to restrict implementation to certain parts of the country. 
 
The possibility of including other countries as comparators for AMFm pilots was also considered 
at an early stage of the evaluation. However, for a number of reasons this approach was not 
adopted. Due to the wide variety of country contexts represented among the AMFm pilots, it 
would have been necessary to include a set of comparator countries, reflecting a similar mix of 
antimalarial market conditions, malaria transmission levels, and other key features of country 
context. Because of the challenges of reproducing this mix, it is likely that only weak inferences 
could have been made on the basis of comparison of AMFm countries with such a set of 
comparators. Moreover, as resources were not available to undertake a new set of nationally 
representative outlet surveys in an additional group of countries, in practice the only potential 
comparators were the ACTwatch countries with appropriately timed outlet surveys that were not 
part of AMFm Phase 1: Benin, Cambodia and Zambia. In each case, there would have been 
important challenges in making such comparisons. Benin is a small country bordering a number 
of AMFm countries and therefore potentially affected by cross-border leakage of AMFm copaid 
antimalarials. Zambia has a very different market structure, with a much smaller role played by 
the private for-profit sector. Cambodia is different in a number of important ways, including the 
structure of antimalarial supply and regulation, the history of interventions in the ACT market 
and differences in malaria species mix. For these reasons, the IE did not include an explicit 
comparison of outcomes in the AMFm countries with non-AMFm countries. 
 
Considering these challenges, the IE team therefore adopted a non-experimental design with a 
pre-test and post-test intervention assessment (Figure 1.4.3) in which each participating country 
is treated independently as a case study. As the literature suggests (Craig et al. 2008, deSavigny 
and Adam 2009, Habicht et al. 1999), evaluation of such a complex intervention should 
supplement measurement of changes in key indicators pre-intervention and post-intervention 
with an assessment of the implementation process (to provide a check that the intervention has 
been implemented as planned, and to help determine whether any lack of impact reflects 
implementation failure or genuine ineffectiveness) and a comprehensive documentation of the 
context both to inform assessments about causality and to aid in generalizability to other 
contexts. 
 
37 
 
The evaluation, therefore, includes two major components: (1) a pre-intervention and post-
intervention study of key outcomes through outlet surveys and use of secondary household 
survey data, and (2) documentation of key features of the context at baseline and endline and the 
implementation process in each country to facilitate interpretation of the changes in outcomes 
over the implementation period and to judge whether any observed changes are likely to be due 
to AMFm. These data sources are supplemented by additional primary data on outlets in remote 
areas in Ghana and Kenya; on user views of the AMFm logo in four pilots (Ghana, Kenya, 
Madagascar and Nigeria); and by operational research conducted by other groups. 
 
Figure 1.4.3: The Independent Evaluation Design 
 
 
For each country, relevant indicators have been computed for the baseline and endline from the 
outlet surveys. For secondary data from existing national household surveys, appropriate 
indicators have been extracted from existing reports. To assess change, the IE has calculated the 
percentage point change or the percent change (whichever is relevant for each indicator) between 
the baseline and the endline. The results have been compared to the AMFm “success metrics” for 
availability, cost, market share and use (Schäferhoff et al. 2010). 
 
These findings on changes in key indicators have then been synthesized with the process and 
context data collected for each country and the other studies outlined above to assess the 
performance of AMFm in each operational pilot, and to help learn how and why this new model 
unfolds in a variety of contexts, while drawing lessons that can help future operations. 
 
1.4.3  Additional studies 
In addition to the main study, on the request of the Global Fund, two additional studies were conduted 
to 1) to assess uptake of AMFm Phase 1 in remote locations (Remote area study) and 2) to 
understand how well AMFm Phase 1 achieved the intended effects of the AMFm logo (Logo study). 
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1.4.3.1 Remote area study 
In most cases, remote areas have the worst indicators of access to health care. AMFm aims to ensure 
that this disadvantage is leveled out, at least as a far as access to effective malaria treatment is 
concerned, by making copaid ACTs available in outlets in remote areas. The remote area study, 
therefore, was designed to examine the availability, price and market share of ACTs in areas 
considered remote and non-remote areas at the end of the main endline outlet survey. The study was 
not designed to assess changes because of a lack of baseline data. The remote area study was carried 
out in only two of the phase 1 countries considered fast moving in the implementation process of the 
AMFm intervention. Such countries were expected to have received the copaid drugs, started the 
intervention and implemented the supporting intervention about 12 months before the endline survey. 
At the time of the decision on countries, from all indications, Kenya and Ghana were seen as 
fulfilling these criteria. 
1.4.3.2 AMFm logo study (exit interviews and focus group discussions) 
For easy identification and marketing purposes of AMFm Phase 1 copaid ACTs, a logo (Figure 
1.4.4) was created. This logo includes a green leaf and the word ACTm. The logo has been printed 
on all copaid ACT packages and blisters and is supposed to help in marketing and public awareness 
campaigns through displays in newspapers, posters, television and billboards. In addition to its 
marketing purpose, the logo may facilitate the identification of leakage to neighboring countries 
where the program is not being implemented. The AMFm logo study assessed whether or not the 
logo achieved the intended effect with respect to public awareness and marketing. The leakage 
component was not addressed in this study as all data collection took place only in Phase 1 countries. 
The study was carried out at endline in four fast-moving countries (Ghana, Kenya, Madagascar and 
Nigeria) using qualitative (focus group discussion) and quantitative (exit interview) methods. 
 
Figure 1.4.4: AMFm logo 
 
1.5 Key evaluation questions and indicators 
The indicators for the IE were initially defined by the AMFm monitoring and evaluation 
framework, which was included as an appendix in the request for proposals for the Independent 
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Evaluation. After a review of the initial indicators, the IE team proposed some revisions to 
clarify or operationalize the indicators in the Inception Report (ICF Macro and London School of 
Hygiene and Tropical Medicine 2010), which was approved by the Global Fund. In this section, 
we list the core indicators approved by the Global Fund. For further details about the changes 
compared to the initial formulation of the indicators, please refer to the IE Inception Report. The 
21 indicators are grouped according to the four evaluation questions, which address availability, 
affordability, use and market share of ACTs (Table 1.5.1). 
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Table 1.5.1: List of key indicators for the independent evaluation 
Question 1: ACT availability indicators 
1.1 Proportion of enumerated outlets in rural/urban areas that have any antimalarials in stock at the time of the 
survey visit 
1.2 Proportion of outlets in rural/urban areas that have non-artemisinin monotherapy or non-artemisinin 
combination therapy in stock among outlets with any antimalarials in stock at the time of survey visit 
1.3 Proportion of outlets in rural/urban areas that have artemisinin monotherapy in stock among outlets with any 
antimalarials in stock at the time of survey visit 
1.4 Proportion of outlets in rural/urban areas that have non-quality-assured ACTs in stock among outlets with 
any antimalarials in stock at the time of the survey visit 
1.5 Proportion of outlets in rural/urban areas that have quality-assured ACTs in stock among outlets with any 
antimalarials in stock at the time of the survey visit 
1.6 Proportion of outlets in rural/urban areas with any quality-assured ACTs in stock at the time of the survey 
visit or in the 4 weeks preceding the survey visit that have been out of stock of all quality-assured ACTs for 
at least 1 day in the last 7 days 
1.7 Proportion of the population living in a rural/urban “subdistrict” where there is at least one outlet that had a 
quality-assured ACT in stock at the time of survey visit 
Question 2:ACT affordability indicators 
2.1 Median cost to patients of one adult equivalent treatment dose (AETD)/pediatric dose of quality-assured 
ACTs for a two-year old child in rural/urban outlets 
2.2 Median cost to patients of one adult equivalent treatment dose (AETD) of non-quality-assured ACTs in 
rural/urban outlets 
2.3 Median cost to patients of one adult equivalent treatment dose (AETD) of artemisinin monotherapy in 
rural/urban outlets 
2.4 Median cost to patients of one adult equivalent treatment dose (AETD) of non-artemisinin monotherapy or 
non-artemisinin combination therapy in rural/urban outlets 
2.5 Median percentage markup between purchase price and retail selling price of quality-assured ACTs 
2.6 Median total markup from first-line buyer purchase price to retail selling price for quality-assured ACTs* 
Question 3: ACT use indicators  
3.1 Proportion of children under five years with fever in the two weeks preceding the survey who received ACT 
treatment 
3.2 Proportion of children under five years with fever in the two weeks preceding the survey who received ACT 
treatment the same day/next day after the onset of the fever 
3.3 Proportion of children under five years with fever in the two weeks preceding the survey who received any 
antimalarial treatment 
3.4 Proportion of children under five with fever in the two weeks preceding the survey in the two lowest wealth 
quintile(s) who received ACT treatment 
3.5 Proportion of children under five with fever in the two weeks preceding the survey in the two lowest wealth 
quintile(s) who received ACT treatment the same day/next day after the onset of the fever 
3.6 Proportion of children under five years with fever in the two weeks preceding the survey in the two lowest 
wealth quintile(s) who received any antimalarial treatment 
Question 4: ACT market share indicators  
4.1 Total volume of quality-assured ACTs sold or distributed in the last week, as a proportion of the total volume 
of all antimalarials sold or distributed in the last week via outlets included in the outlet survey, in rural/urban 
areas 
4.2 Quantity of quality-assured ACTs procured by first-line buyers (‘unit’ = boxes of ACTs by type and 
dosage)* 
*Since the baseline surveys in most countries took place before the arrival of copaid drugs, Indicators 2.6 and 4.2 
were not calculated at baseline. 
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1.6 Evaluation approach 
This section begins with an overview of the IE methods and tools, and is followed by details of 
the methods for each data source, a discussion of the operationalization of the success metrics, 
and a description of ethical approval obtained.  
1.6.1 Overview of methods and tools 
The evaluation is based on six data sources: 
 Primary data collected from outlet surveys conducted at baseline and endline (for 
questions related to availability, affordability and market share of quality-assured ACTs)  
 Secondary data from national household surveys (for question related to use of ACTs), 
such as Demographic and Health Surveys (DHS), Malaria Indicators Surveys (MIS), 
Multiple Indicator Cluster Surveys (MICS) and ACTwatch household surveys  
 Process and context data from in-depth interviews with key country-level stakeholders 
involved in AMFm implementation and malaria control more generally, and a review of 
country documents 
 Additional primary data from a sample of outlets in remote areas in Kenya and Ghana, to 
assess differences in availability, price and market share of quality-assured ACTs in 
remote and non-remote areas 
 Primary data from exit interviews with persons visiting outlets and focus group 
discussions to assess understanding of the AMFm logo in four pilots (Ghana, Kenya, 
Madagascar and Nigeria) 
 Review of operational research on interventions to enhance AMFm implementation in 
Phase 1 pilots. 
 
The link between the outlet and household survey data and the key evaluation questions are 
mapped in Table 1.6.1. The other sources of data are used to provide additional information on 
AMFm rollout, facilitate the interpretation of outlet and household data, and contribute to the 
identification of potential strategies for enhancing AMFm implementation.  
 
Table 1.6.1: Link between outlet and household surveys and the evaluation questions 
Evaluation measures 
Outlet survey 
(primary data) 
Nationally representative household 
surveys (secondary data/reports) 
ACT availability X  
ACT affordability X  
ACT use  X 
ACT market share X X 
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1.6.2 Outlet surveys 
Baseline and endline outlet surveys were carried out in each participating country with the 
objectives of assessing availability, cost and market share of quality-assured ACTs in outlets 
across the public, private for-profit and private not-for-profit sectors in rural and urban areas, 
before and after implementation of AMFm. The methods for the IE outlet surveys were built on 
the outlet survey study design developed for the ACTwatch project (O’Connell et al. 2011). For 
the baseline surveys in Madagascar, Nigeria and Uganda the IE has drawn on outlet surveys 
commissioned prior to AMFm and carried out by PSI's ACTwatch Project (www.actwatch.info) 
through a grant from the Bill and Melinda Gates Foundation (Shewchuk et al. 2011). ACTwatch 
adapted its methodologies to help meet the needs of the IE. 
 
Table 1.6.2 presents the timing of the baseline and endline outlet surveys in each country, as well 
as the time between the midpoint of fieldwork and the first arrival of copaid drugs in each 
country. For example, in Uganda the midpoints of baseline and endline fieldwork were, 
respectively, 4-1/2 months before and 7 months after the first arrival of copaid drugs in country. 
In most pilots, the baseline data collection was well-timed in relation to the first arrival of copaid 
drugs. Baseline data collection took place between August and December 2010 in most pilots. 
However, for Nigeria and Madagascar fairly recent ACTwatch outlet surveys were already 
available at the time of planning for the baseline surveys (www.actwatch.info), so those surveys 
were used as the IE baseline. The survey methodologies for ACTwatch and the IE are very 
similar, but there are some differences in the questionnaires, so a few of the Independent 
Evaluation indicators cannot be calculated for Nigeria and Madagascar at baseline (see the 
analysis section and country-specific baseline reports available on the Global Fund website). 
Endline outlet survey data collection was conducted under the IE in all operational pilots 
between October 2011 and January 2012. In four of the pilots, the time between the first arrival 
of copaid drugs and the midpoint of the endline outlet survey was 13-1/2 to 15-1/2 months. In 
Niger and Nigeria, the interval was 9-1/2 months and it was 7 months in Uganda. The shortest 
interval was 6-1/2 months in Zanzibar.  
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Table 1.6.2: Timing of data collection for outlet surveys and arrival of copaid ACTs by country 
 
Start date End date 
Date of first 
arrival of copaid 
drugs in country 
Time between 
midpoint of 
fieldwork and first 
arrival of copaid 
drugs 
Baseline     
Ghana Aug 1, 2010 Aug 19, 2010 Aug 2, 2010 0 months 
Kenya Sep 13, 2010 Nov 19, 2010 Aug 10, 2010 (2 months)* 
Madagascar** Apr 27, 2010 Jun 21, 2010 Oct 14, 2010 5 months 
Niger Aug 17, 2010 Oct 10, 2010 Feb 3, 2011 5 months 
Nigeria** Sep 14, 2009 Nov 2, 2009 Jan 25, 2011 15 months 
Tanzania - mainland Sep 16, 2010 Nov 11, 2010 Oct 10, 2010 0 months 
Uganda Nov 15, 2010 Dec 31, 2010 Apr 23, 2011 4-1/2 months 
Zanzibar Sep 4, 2010 Oct 5, 2010 Apr 21, 2011 7 months 
Endline     
Ghana Nov 7, 2011 Nov 28, 2011 Aug 2, 2010 15-1/2 months 
Kenya Oct 7, 2011 Dec 10, 2011 Aug 10, 2010 15 months 
Madagascar Nov 7, 2011 Jan 7, 2012 Oct 14, 2010 14 months 
Niger Nov 9, 2011 Dec 14, 2011 Feb 3, 2011 9-1/2 months 
Nigeria Oct 14, 2011 Nov 30, 2011 Jan 25, 2011 9-1/2 months 
Tanzania - mainland Oct 11, 2011 Jan 14, 2012 Oct 10, 2010 13-1/2 months 
Uganda Nov 8, 2011 Dec 12, 2011 Apr 23, 2011 7 months 
Zanzibar Oct 1, 2011 Dec 7, 2011 Apr 21, 2011 6-1/2 months 
* In Kenya the first arrival of copaid drugs in country was two months before the midpoint of baseline fieldwork. 
** Surveys conducted by ACTwatch were used as the IE baseline in Madagascar and Nigeria. 
 
1.6.2.1 Sampling 
For all outlet surveys under the IE, the sample size was estimated for each country to be able to 
detect a 20 percentage point change between the baseline survey and the endline survey in 
Indicator 1.5 (proportion of outlets with antimalarials in stock that have quality-assured ACTs in 
stock at the time of the survey visit), separately for rural and urban domains, pooling across 
outlet types and sectors.
12
 The required sample size was calculated based on the following 
parameters: 
 The value of Indicator 1.5 at baseline was set to 40%, which was used to achieve the 
required sample size and ensure that a 20 percentage point difference between the 
baseline and the endline could be detected, as the true value of the indicator was 
unknown  
 95% significance and 80% power were chosen 
 A design effect of 4 was assumed, to account for the clustered survey design  
Based on these parameters, at least 305 outlets stocking antimalarials per domain (rural/urban) 
were required in each country. To translate this into the required number of urban and rural 
                                                 
12
 The sampling approach used for Madagascar and Nigeria is described elsewhere (O’Connell et al. 2011). 
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clusters, we estimated the proportion of enumerated outlets that stock antimalarials and the 
number of outlets enumerated per cluster using ACTwatch data (averaged across three 
countries). To illustrate the approach: assuming that 35% of enumerated outlets have 
antimalarials in stock in urban clusters and 23% in rural clusters, a total of 872 (305/0.35) outlets 
must be enumerated in the urban domain and 1,327 (305/0.23) outlets in the rural domain. To 
convert this into the number of clusters required, given an average of 41.6 outlets enumerated per 
urban cluster and 52.6 outlets enumerated per rural cluster, the minimum number of clusters 
would be 21 (872/41.6) in the urban domain (rounded up) and 26 (1,327/52.6) in the rural 
domain for total of 47 clusters in this country. At endline, the number of clusters was adjusted 
drawing on the baseline findings on the level of Indicator 1.5, the number of outlets per cluster 
and the degree of clustering in each country. Table 1.6.3 provides details of the number of 
clusters required in each country at baseline and endline. In Zanzibar, a full census of all outlets 
was conducted, given the small number of outlets overall. It was not possible to power the 
surveys to detect a similar change in Indicator 2.1 (median cost to patients of quality-assured 
ACTs) because the small number of quality-assured ACTs at baseline would have resulted in the 
need for a very large sample size.  
 
Table 1.6.3: Number of clusters by domain for each country 
Country Baseline Endline 
Urban Rural Total  Urban Rural Total 
Ghana 25 30 55 24 30 54 
Kenya 23 34 57 26 34 57 
Madagascar 19 19 38 18 28 46 
Niger 30 45 75 30 34 64 
Nigeria 43 71 114 39 85 124 
Tanzania – mainland 9 39 48 20 29 49 
Uganda 5 34 39 18 26 44 
Note: Zanzibar is not shown as, given the small number of outlets nationwide; a full national census was 
conducted. In Uganda, the baseline sample was stratified by malaria endemicity, with 19 high endemicity and 
20 low endemicity clusters.  
 
The sampling approach was based on that used in the ACTwatch outlet surveys (O’Connell et al. 
2011). The surveys include outlets in the public, private for-profit and not-for-profit sectors. 
Given that there were no reliable lists of all outlets stocking antimalarials in any country, the IE 
team adopted a cluster sampling approach, with all outlets found in selected clusters included in 
the sample. Clusters are generally administrative units such as subdistricts, with an average of 
10,000-15,000 inhabitants. In each country, a predetermined number of clusters was selected 
with probability proportional to size (PPS), a sampling technique in which the probability that a 
particular subdistrict was selected is proportional to its population. The clusters were selected 
randomly for each country using the most up-to-date available national sampling frame. 
Independent samples of subdistricts were drawn at baseline and endline. Additional details about 
the sampling methodology can be found in Appendix B. 
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Two outlet types, public health facilities (PHFs) and Part One pharmacies (POPs), are especially 
important because these facilities typically serve a large number of patients and they may be the 
main providers of quality-assured ACTs. However, few of these outlet types were expected to be 
found in any given cluster. PHFs and POPs were therefore oversampled. The oversampling was 
carried out according to the following general approach: for each sampled subdistrict, PHFs and 
POPs found within the district within which the subdistrict was located were censused. There 
were differences among countries in how oversampling was implemented (e.g., in Tanzania, only 
POPs were oversampled). We refer to the PHFs and POPs oversampled in this way as the 
“booster sample”. The details of country-specific variations can be found in the country baseline 
and endline outlet survey reports.  
1.6.2.2 Data collection 
All outlets in the selected subdistricts that could potentially stock manufactured medicines were 
considered as “eligible” for the outlet survey and were visited by the survey team. The final 
classification of outlets in each country is shown in Appendix C, which also indicates which 
outlet types are permitted to stock ACTs. Eligible outlets were identified by using official lists, 
by consulting with local officials and leaders, and by asking staff at outlets surveyed to identify 
other neighboring outlets stocking antimalarials. Outlets included in the booster sample (public 
health facilities and Part One pharmacies) were identified through official lists updated with 
local health care managers. 
 
At the start of the interview, fieldworkers recorded the outlet’s basic details and then asked the 
following screening question about the availability of antimalarials: “Do you have any 
antimalarial medicines in stock today?” If the outlet did not currently have any antimalarials in 
stock, the interviewer asked “Have you stocked any antimalarials in the last three months?” If the 
interviewee answered no to both questions, the interview was terminated at that point. If the 
interviewee answered yes to either screening question, the fieldworker requested permission to 
conduct the full interview. 
 
The field teams used a structured questionnaire (Appendices D, E, F, G and H) directed to a 
senior person at the outlet to collect data on outlet identification, outlet characteristics, provider 
knowledge, antimalarials and rapid diagnostic tests (RDTs) stocked, stockouts of quality-assured 
ACTs, and at endline, experience of AMFm supporting interventions. They recorded information 
on all antimalarials and RDT products stocked in terms of their price and volume sold in the past 
week on “audit sheets.” 
 
The IE team developed the generic questionnaire in consultation with the DCs, the Global Fund 
and other key stakeholders. The questionnaire is based on the ACTwatch outlet survey 
questionnaire, and wherever possible the questions have been kept the same to permit 
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comparability with data collected in ACTwatch surveys in Nigeria and Madagascar (ACTwatch 
2010a). The IE team made several adaptations to the ACTwatch tool to ensure that the IE 
indicators were included and other requests from key stakeholders were met (e.g., the addition of 
questions on stockouts of quality-assured ACTs, training courses attended, knowledge on proper 
dosing of quality-assured ACTs, and knowledge of the AMFm logo). It was possible to measure 
all key IE outlet indicators in a comparable way across countries at baseline and endline, with the 
exception of Indicator 1.6 (the proportion of outlets that have been out of stock of all quality-
assured ACTs for at least one day in the last seven days), which is not available from the 
Madagascar and Nigeria baseline surveys, as stockout data were collected in a different way by 
ACTwatch. In addition, these surveys did not include questions on providers’ recognition and 
understanding of the AMFm logo, and whether the logo was present on any antimalarial products 
stocked. The IE team provided the generic questionnaire in English and French, and the DCs 
produced versions in local languages where necessary (Kiswahili in Tanzania mainland and 
Zanzibar, Malagasy in Madgascar, five local languages in Uganda and three local languages in 
Nigeria). The DCs made minor adaptations to the coding of certain questions to provide relevant 
country-specific categories (e.g., titles of health worker cadres and first-line antimalarial 
treatment). The DCs pretested the questionnaire in each country and then received final approval 
of the questionnaires from the IE team. The pretest covered at least four outlets of each of the 
main outlet types in rural and urban domains. Tanzania mainland and Madagascar used personal 
digital assistants (PDAs) for baseline and endline data collection, and Zanzibar used PDAs at 
endline. All other surveys were conducted using paper-based questionnaires. 
 
1.6.2.3 Data quality assurance 
To ensure high quality data across countries, the Independent Evaluation team drew on Standard 
Operating Procedures (SOPs) developed for the ACTwatch project 
(http://www.actwatch.info/research/data_quality.php) (ACTwatch 2010b). In addition, the DCs 
ensured that only the best interviewers and other members of the field team were recruited and 
trained for the fieldwork. During the fieldwork, daily supervision of data collection was 
performed. This included a full review of completed questionnaires, ensuring that all potential 
eligible outlets were visited, and random spot-checks in 5-15% of all outlets surveyed. 
 
The training materials were adapted with permission from ACTwatch (www.actwatch.info) 
(copyright © 2010 Population Service International) and were modified at the country level as 
required. The training courses were led by the DCs with support from the IE team. Trainees 
included all members of the field team, including team leaders, quality control officers and 
interviewers. In some cases, the data entry team attended the training as well to familiarize 
themselves with the content of the survey. The training lasted for seven days and included 
theory, practical information and field practice. The aim of the training was to provide the field 
teams with an understanding of the purpose of the study and the technical skills to conduct the 
survey, particularly in identifying antimalarial medicines, including the differences between 
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ACTs and non-ACTs, trade names and generics, packaged and loose tablets, and the various 
formulations of antimalarial medicines. 
1.6.2.4 Data processing and analysis 
Data entry and cleaning 
Data were managed at the country level by the DCs. For the paper-based surveys, data entry 
programs were developed in CSPro or Microsoft Access. The programs included range checks 
and consistency checks and allowed double data entry. Following the double entry, a data entry 
supervisor ran the verification program to check for mismatches between the two entries. Any 
mismatches were corrected by referring to the questionnaires until the two entries matched 
perfectly.  
 
Detailed data cleaning guidelines giving step-by-step instructions on how to clean each section 
of the data using range and consistency checks were utilized during the cleaning process. 
Commands executed for data cleaning were documented using a syntax file, and the results of 
running these commands were documented using a “log file,” with spot-checks on cleaning 
syntax conducted by the IE. 
 
Data analysis 
A standardized tabulation plan was used for all outlet survey baseline and endline tables, which 
were produced using standard analysis do-files in STATA, with results recorded in log files. The 
following aspects were considered during analysis: 
 Classification - Urban-rural 
The outlets were categorized as rural or urban depending on the classification of their subdistrict 
in the sampling frame. 
 Accounting for the survey design in data analysis 
The analysis accounted for three aspects of the sampling design: 
o Sampling weights 
Sample weights were calculated for the outlet survey data to allow for 1) differences in sampling 
probabilities due to variation in the size of strata, 2) the oversampling for the booster sample and 
3) the sampling strategy, which involved selection of clusters using probability proportional to 
size (PPS) sampling, followed by a census of all outlets within selected clusters. The weights 
were based on sampling probabilities and were calculated by the IE after data cleaning was 
complete. 
o Clustering 
As the sample was clustered at the level of the district for the booster sample and the subdistrict 
for other outlets, the calculation of the standard errors takes the clustering into account. This was 
48 
 
done because outlets in a given cluster are likely to be more similar to each other than to outlets 
in other clusters, and not allowing for this would result in under-estimation of the uncertainty in 
the estimates of indicators.  
Stratification 
As clusters were sampled separately in each stratum, this was allowed for in the calculation of 
standard errors. 
 
To account for these design features in the tabulations, the STATA commands for analyzing 
complex survey data (“svy” commands) were used to weight the data and calculate confidence 
intervals taking clustering and stratification into account. The IE team declared the primary 
sampling unit (district), the weight variable (wt), the strata and the finite population correction 
(fpc) factor equaling the sampling fraction for each stratum (the number of sampled subdistricts 
in a stratum divided by the total number of subdistricts in the stratum, or 0.5 if the sampling 
fraction was greater than 50 percent).
13
 Data were survey set as follows: 
svyset district [pweight=wt ], strata(strata) fpc(fpc) 
The team calculated a proportion and its 95 percent confidence interval (CI) as follows: 
svy: proportion VariableName 
Note that for Zanzibar a full census of all outlets in the country was undertaken. Therefore, we 
did not need to account for weighting, clustering or stratification in the analysis, and confidence 
intervals are not presented. 
 Classification of antimalarials 
For the purpose of analysis, antimalarials were split into three categories, in line with the IE 
indicators, which require information to be shown separately for non-artemisinin therapy, 
artemisinin monotherapy (AMT) and artemisinin-based combination therapy (ACT). AMTs were 
further classified into oral and non-oral AMTs, as while non-oral AMT are recommended for 
treatment of severe malaria, the removal of oral AMTs from the market is a key policy goal. 
ACTs were further subdivided into quality-assured ACTs (QAACTs) and non-quality-assured 
ACTs. According to this classification, a quality-assured product must be WHO pre-qualified 
and/or authorized for marketing by a Stringent Drug Regulatory Authority. Products that have 
not yet been WHO pre-qualified or approved by a Stringent Drug Regulatory Authority must be 
evaluated and recommended for use by an independent panel of technical experts hosted by 
World Health Organization’s Department for Essential Medicines and Pharmaceutical Policies 
(The Global Fund 2010). A list of all ACTs qualifying as QAACTs at the time of the baseline 
and endline surveys is included in Appendix I. 
 
At endline, QAACTs were further classified based on whether the AMFm green-leaf logo was 
present on the packaging. QAACTs that were not subsidized by AMFm are likely to continue to 
                                                 
13
 Note: In Niger at baseline no fpc was declared as the sampling fraction was not constant across outlet types. 
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be found in the markets of the participating countries. Consequently, the presence of the logo on 
a product’s packaging, as recorded by the interviewer during the audit, is used as a proxy for 
whether or not the product was subsidized by AMFm.  
 Calculation of antimalarial volumes, prices and markups 
Antimalarial volume and price data are reported in terms of adult equivalent treatment doses 
(AETDs) using the AETD calculator developed by ACTwatch (Shewchuk et al. 2011) with some 
modifications. An AETD is defined as the number of milligrams (mg) of an antimalarial drug 
needed to treat a 60 kg adult (refer to Appendix J for details). The number of mg/kg used to 
calculate one AETD was defined according to what was recommended for a particular drug in 
the treatment guidelines for uncomplicated malaria in areas of low drug resistance issued by 
WHO (as of April 5, 2011). Where WHO treatment guidelines did not exist, AETDs were based 
on the product manufacturer’s treatment guidelines. In the case of ACTs, which have two or 
more active antimalarial ingredients packaged together (either co-formulated or co-blistered), the 
strength of the artemisinin-based component was used as the basis for the AETD calculations. 
Information collected on the medicine strength and unit size, as listed on the product packaging, 
was then used to calculate the number of AETDs contained in each unit. 
 
Market share was calculated by dividing the number of AETDs of a particular antimalarial 
category sold by the total number of AETDs of all antimalarials sold. In cases where outlets 
stocked antimalarials, but some or all sales volumes were missing, there was no imputation for 
missing values. The total volume presented in the market share tables is the volume sold in the 
outlets in the censused subdistricts (booster sample outlet sales are not included in these tables as 
only certain outlet types were included in the booster sample). Since the sampling fraction 
(number of clusters sampled/number of clusters in the country) is very different across the pilots, 
these Ns cannot be used to compare total volumes sold across countries. 
 
Price data were collected in local currencies and endline data were adjusted to 2010 prices to 
facilitate comparison with baseline estimates. Prices, including recommended retail prices for 
copaid quality-assured ACTs, were adjusted using the ratio of the average national consumer 
price index for 2011 to the national average consumer price index for 2010 (source: International 
Monetary Fund [IMF] International Financial Statistics). Since the Nigeria baseline was 
conducted in 2009, these prices were also adjusted to 2010. The 2010 prices were then converted 
to their USD equivalent using the average interbank rate for 2010 (Table 1.6.4).  
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Table 1.6.4: Local currencies and their USD equivalents using the average interbank rate, 2010 
Country Local currency unit Exchange rate (USD 1) Source 
Ghana Cedis (GHS) 1.46 www.bog.gov.gh  
Kenya Kenyan shilling 76.18 www.oanda.com 
Madagascar Malagasy ariary (MGA) 2138.56 www.oanda.com 
Niger FCFA 486.418 www.oanda.com 
Nigeria Naira 152.803 www.oanda.com 
Tanzania - mainland Tanzanian shilling 1419.97 www.oanda.com 
Uganda Ugandan shilling 2153.61 www.oanda.com  
Zanzibar Tanzanian shilling 1419.97 www.oanda.com 
 
Price data are reported using the median and inter-quartile range, which are appropriate for 
describing distributions likely to be skewed. Retail percentage markups were calculated for each 
product as the difference between the selling price and the purchase price, divided by the 
purchase price. In cases where an outlet received an antimalarial for free from its supplier and 
distributed the product for free, the retail markup was set to 0%. In cases where an outlet 
received an antimalarial for free from its supplier, but did not distribute the product for free, the 
retail markup was set to missing. It should be noted that these indicators are for gross markups, 
including both provider overhead costs and profit margins. Markups are presented in percentage 
terms rather than absolute terms to facilitate comparison across products where there is 
considerable variation in wholesale purchase price. An exception is Indicator 2.6 (Median total 
markup from first-line buyer purchase price to retail selling price for quality-assured ACTs), 
which is presented in absolute terms. To calculate this markup, we compared retail prices per 
AETD for each QAACT bearing the AMFm logo audited with the average first line buyer 
purchase price for that product in that country. The product was defined on the basis of its 
manufacturer, generic name, dosage strength and number of tablets in a treatment unit. The 
average first line buyer price was calculated as the mean first line buyer price per AETD per 
product, weighted by volumes purchased (as there were generally several orders for a given 
product and purchase price varied across orders). Only orders delivered before the start of 
endline outlet survey data collection were included in the price figures, which were calculated 
from data provided by the Global Fund.  
 Analysis of changes between baseline and endline  
The analysis of changes in indicators between baseline and endline outlet surveys was conducted 
by the IE team for each country. Baseline and endline analysis was run independently by the IE 
team for each country and any discrepancies with the DCs’ results were resolved. Analysis was 
conducted within the survey commands frameworks in Stata version 11 and R version 2.14.2, 
and thus takes account of the clustered, stratified nature of the data, as well as the survey 
weights. We calculated the difference in indicators between baseline and endline. For indicators 
expressed as percentages, the difference is expressed in terms of the percentage point change, 
with a 95% confidence interval to indicate the range within which we are 95% confident that the 
true value for the percentage point change lies. Where the 95% confidence interval includes 0 
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(no difference), we cannot exclude the possibility that there may have been no changes in the 
value of the indicator between baseline and endline. For indicators expressed as medians, we 
show the p value from the Wilcoxon rank sum test of the hypothesis of no difference in median 
between baseline and endline. Significance testing in relation to the success metrics is discussed 
below in Section 1.6.7.  
 
1.6.3 Household survey data - Secondary analysis 
1.6.3.1 Survey inclusion criteria 
Existing nationally representative household survey reports and data were used to extract 
information for the ACT use indicators. The IE team identified four types of national surveys 
(DHS, MICS, MIS and ACTwatch) that could provide relevant data. It should be noted that 
primary household data collected within the framework of the evaluation would have been 
preferred to answer the evaluation question on use; however, this component of the Independent 
Evaluation was dropped from the Independent Evaluation design by the AMFm secretariat due 
largely to cost considerations and on the technical advice of the TERG, as described in the AMFm Ad 
Hoc Committee’s report to the Global Fund’s Twenty-First Meeting14. Relying on secondary data 
means that the IE was constrained in the extent to which the indicators were measured in all 
countries and at the appropriate time. 
 
For the baseline, surveys were included if they were conducted within two years before the 
beginning of AMFm in 2010. However, since there was no survey that fell within the defined 
period in Niger, the IE team used the 2006 MICS/DHS survey report as the baseline. Table 1.5.5 
provides the list of baseline surveys for each country. For all the countries, there was at least one 
survey that could be used to extract baseline information. 
 
For the endline, one country (Kenya) does not have any completed, ongoing or planned surveys 
during the endline period. The remaining countries have surveys that can be used to calculate the 
endline indicators, but at the time this report was written, none of those surveys had published 
reports on the survey results and none of the data sets were available. It is currently planned that 
a supplemental report, based on endline household survey data that become available at a later 
date, will be prepared if a sufficient amount of endline data is available in the coming months.  
                                                 
14
 The report to the Board is available at: http://www.theglobalfund.org/documents/board/21/BM21_07AMFmAdHocCommittee_Report_en / 
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Table 1.6.5: Summary of existing household surveys that include information on ACT use 
Country Baseline surveys Endline surveys 
Ghana Sep – Nov 2008 (DHS) Sep – Dec 2011 (MICS)  
Kenya Jul – Sep 2010 (MIS) None 
Madagascar Nov 2008 – Jul 2009 (DHS); Dec 2008 – Jan 2009 
(ACTwatch) 
Apr – May 2012 (ACTwatch) 
Niger Jan – May 2006 (MICS/DHS) Mar – Jun 2012 (DHS) 
Nigeria Jun – Oct 2008 (DHS); Aug – Sep 2009 (ACTwatch) May – Jun 2012 (ACTwatch) 
Tanzania - mainland Dec 2009 – Apr 2010 (DHS) Dec 2011 – Apr 2012 (MIS) 
Uganda Nov – Dec 2009 (MIS); Mar – Apr 2009 (ACTwatch)  Apr – May 2012 (ACTwatch) 
Zanzibar Dec 2009 – Apr 2010 (DHS) Dec 2011 – Apr 2012 (MIS) 
Source: www.measuredhs.com, www.actwatch.info. 
 
1.6.3.2 Data analysis 
For the baseline household surveys, the IE team extracted each indicator of use directly from the 
reports. However, we computed the values of Indicators 3.4, 3.5 and 3.6 (on treatment among the 
lowest wealth quintiles) from the data sets because this information was not presented in the 
reports. These indicators were calculated from data readily available to the IE team. Indicators 
3.4, 3.5, and 3.6 could not be calculated for urban and rural areas separately because the wealth 
index is not computed separately for urban and rural areas. In calculating Indicators 3.4, 3.5 and 
3.6, we restricted the analysis to children in households in the two lowest wealth quintiles. 
 
Since existing household surveys were used for information on ACT use, the timing of those 
surveys may not be ideal to measure changes in ACT use in the first year of AMFm. It would be 
best if the baseline surveys were conducted shortly before the rollout of AMFm in a country, and 
the endline surveys were conducted at least 12 months after the rollout. Table 1.6.2 shows the 
amount of time between the midpoint of the fieldwork for each of the baseline household surveys 
and the arrival of the first copaid ACTs in the country, as well as the amount of time between the 
arrival of the first copaid ACTs and the midpoint of the fieldwork for each of the endline 
surveys.  
 
The timing of the baseline survey in Kenya was optimal, but there is no endline survey in that 
country. The remaining baseline surveys were conducted between 7 and 25 months before the 
arrival of the first copaid ACTs, except for Niger which had an interval of nearly five years. 
Therefore, in all countries the baseline estimates refer to a period several months before the 
arrival of the first copaid ACTs. If there were substantial changes between the baseline survey 
and the timing of arrival of the first copaid ACTs in a country, those changes could not have 
resulted from the AMFm program. On the other hand, every endline survey except the Zanzibar 
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survey occurred at least 12 months after the arrival of the first copaid ACTs, which is the 
minimum desired period to assess changes in use. In Zanzibar, the period was only 10 months.  
 
Table 1.6.6: Timing of data collection for baseline and endline household surveys in relation to arrival of the first copaid 
ACTs by country 
  
Date of arrival of first 
copaid ACTS 
Number of months between 
midpoint of baseline 
household survey fieldwork 
and arrival of first copaid 
ACTs 
Number of months between 
arrival of first copaid ACTS 
and midpoint of endline 
household survey fieldwork 
Ghana  August 2, 2010  21-1/2 months 15 months 
Kenya  August 10, 2010  0 months na 
Madagascar DHS  October 14, 2010  19 months na 
Madagascar ACTwatch  October 14, 2010  7 months 18-1/2 months 
Niger  February 3, 2011  58-1/2 months 15 months 
Nigeria  January 25, 2011  17 months 16 months 
Tanzania – mainland  October 10, 2010  8 months 16 months 
Uganda MIS  April 23, 2011  17 months na 
Uganda ACTwatch  April 23, 2011  25 months 12 months 
Zanzibar  April 21, 2011  14 months 10 months 
na = Not available      
 
1.6.4 Implementation process and contextual information 
Country case studies aimed to document the implementation process of AMFm (supply of copaid 
ACTs and supporting interventions) and contextual factors that may influence the effectiveness 
of AMFm. The Theory of Change was used to guide the topics investigated during the case 
studies and to explore their likely impact on IE indicators. Together, these data allow an 
assessment of (1) whether any improvement observed in the indicators is likely to be due to 
AMFm and (2) whether a lack of improvement in indicators can be reasonably attributed to a 
failure of AMFm. 
 
Case studies were conducted by IE team members or consultants in each operational pilot 
between November 2011 and January 2012. They involved three main types of data collection: a 
structured tool for quantifying supporting interventions, key informant interviews (KII) and 
document review. 
1.6.4.1 Key informant interviews 
A form for quantifying supporting interventions was sent to the National Malaria Control 
Program in each country, who was asked to complete the form prior to the arrival of the case 
study researcher. The form is included at the end of Appendices K and L. This form included 
details on the type of activities conducted, their dates and scale and the organizations involved, 
which provided a basis for follow up of these issues during the KII.  
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KIIs were conducted with three main types of respondents:  
 Those centrally involved in AMFm implementation, such as the principal recipients, sub-
recipients and those providing technical assistance  
 Antimalarial importers from all sectors, including first line buyers (FLB) who have made 
orders, FLB who have not made orders, and importers not registered as FLBs 
 Other stakeholders who were knowledgeable about the AMFm process or other key 
contextual factors that may have affected AMFm indicators, such as those responsible for 
other communications activities, public sector drug distribution, other malaria control 
interventions, and civil society groups.  
 
Key informants were identified through discussions with key personnel, review of documents, 
the Global Fund database of FLBs and snowball sampling where, at the end of each interview, 
the interviewee was asked whether there were other people who it would be useful to include. 
The total number of interviews conducted in each country and dates of data collection are shown 
in Table 1.6.7. Most interviews were conducted in the capital city or administrative capital.  
 
Table 1.6.7: Number and dates of key informant interviews conducted  
 
Country 
Number of key informant 
interviews conducted 
Dates of key informant interview 
data collection 
Ghana 20 Nov – Dec 2011 
Kenya 28 Nov – Dec 2011 
Madagascar 26 Nov – Dec 2011 
Niger 31 Dec 2011 – Jan 2012 
Nigeria 40 Nov 2011 – Jan 2012 
Tanzania - mainland 26 Dec 2011 
Uganda 23 Nov – Dec 2011 
Zanzibar 10 Nov 2011 
 
Interviewers used a semi-structured KII guide (Appendices K and L) that covered AMFm 
governance, registration of FLBs, ordering and distribution of copaid drugs, supporting 
interventions (e.g., communications, training, regulation and recommended retail prices), 
diagnostics, and key contextual events (e.g., weather anomalies, economic and political factors, 
changes in other malaria control activities and changes in the health system more broadly).  
 
Interviewees were generally informed of the purpose of the interview in advance by email and/or 
phone. At the beginning of the interview, the interviewer read out or asked the interviewee to 
read the information sheet for the study, which assured them of confidentiality. The interviewee 
was asked if he or she had any questions before the start of the interview, and after oral consent 
was given, the interviewer signed the consent form as a witness to this. Most interviews were 
conducted in English or French, generally in person, although a few were conducted by 
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telephone. Participants were given the option of whether they wanted their interviews to be 
recorded, and notes were also taken. We aimed to conduct interviews in places where the 
interviewees could not be overheard. Most interviews were conducted with just one participant, 
but in some cases more than one participant was included where the respondents felt this would 
be the most efficient way to share the relevant information. 
 
1.6.4.2 Review of documents 
Documents for inclusion in the document review were primarily identified through discussions 
with key informants and through internet searches for information on specific topics. The types 
of documents reviewed include government policy and regulatory documents; government 
reports; briefing documents and reports prepared by the Clinton Health Access Initiative (CHAI), 
which provides technical support for AMFm implementation; Global Fund grant and copaid drug 
order documents; and reports from research groups and NGOs. This was complemented by 
background and contextual data collected for each country at the time of the outlet survey 
baseline data collection by the DCs.  
1.6.4.3 Processing of the information 
To analyze the data, the information from the KIIs and document review was broken into the 
appropriate reporting categories using a standard template, and findings across interviews were 
synthesized and presented in a confidential report to the IE. A summary, which was produced 
from the reports for each country, is presented in Chapter 4. 
1.6.5 Remote area study 
1.6.5.1 Defining remoteness and selecting remote area clusters 
As indicated in Section 1.4.3.1, the remote area study was designed to examine the availability, 
price and market share of ACTs in areas considered remote and non-remote at the end of the 
main endline outlet survey. The methodology for defining remote areas is summarized below. 
 
Defining remoteness 
Measures of remoteness are useful for health service planning and equitable distribution of 
resources. Remoteness indices are also used in understanding disparities in health indicators of 
the population. Various definitions have been proposed to conceptualize remoteness. It can be 
understood in terms of distance from infrastructure, services, or centers of economic activity or 
from political or social decision making. In conceptualizing remoteness, two distinct approaches 
stand out: the sociological approach which is based on how perceptions, behavior and the 
socioeconomic characteristics of individuals of an area impact service accessibility; and the 
geographical approach which defines remoteness in terms of the environmental factors which 
impact access to needed services. In its practical applications, remoteness has largely been 
associated with lack of geographical accessibility to services because it can be quantified more 
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objectively. Geographic accessibility has in turn been shown to be related to socioeconomic 
status. There are several examples of remoteness indices based on geographic accessibility in 
developed countries using distance alone (AIHW 2004, Lapointe and Andrew 2011), or distance, 
population density and travel time (Power 2004). These indices have been used to study the 
geographical disparity in risk of health outcomes (Baade et al. 2011, Turrell et al. 2004, Pong et 
al. 2009) and the reconfiguration of health service provision (Swan et al. 2008). 
 
In sub-Saharan African, the dominant concept of remoteness is based on a broader breakdown of 
populated areas into urban and rural and is used for census area classifications, survey sampling 
and evaluation of geographic and socioeconomic equity. This binary approach ignores the fact 
that on a continuous scale, some urban areas are more remote than other urban areas, while some 
rural areas are more remote than other rural areas. In some countries there are also some rural 
areas that are better connected than isolated urban areas. For these reasons, the rural-urban 
classification may be too simplistic to properly describe the significant variations in a 
population’s potential access to services. 
 
For the purpose of the AMFm Independent Evaluation remote area study, to define remoteness 
for both Kenya and Ghana, we adapted the approach used to compute the Accessibility-
Remoteness Index of Australia (AIHW 2004) by using weighted spatial access to different types 
of services centers. A surface of travel time to service centers was generated for Kenya and 
Ghana to define access to these centers and determine the degree of remoteness on a continuous 
surface of 1 × 1 km spatial resolution. Access to three layers of service centers was determined 
by assuming that people travel to a destination (a) by walking or using non-motorized transport 
(cycling), (b) by walking from the origin (e.g., place of residence) through the landscape to the 
nearest road before finishing the remainder of the journey by motorized transport, or (c) walking 
from the origin along the road. 
 
Population settlements were classified by distance to three service centers: Service Centers 1 
(market and trading centers for Kenya; all grid squares with population of 5,000-10,000 for 
Ghana); Service Centers 2 (divisional headquarters and towns for Kenya; all grid squares with 
population of 10,000-50,000 for Ghana); and Service Centers 3 (cities, municipalities, major 
towns and district headquarters for Kenya; all grid squares with population equal to or more than 
50,000 for Ghana). Note that for Kenya we used pre-defined settlement classifications by the 
Ministry of Roads and Public Works that mapped settlements in cities, municipalities, major 
towns, district headquarters, divisional headquarters, towns, market centers and trading centers. 
For Ghana, similar data were not readily available; therefore, we used the gridded population 
surface for 2010 at a resolution of 1×1 km (www.afripop.org) to define the service centers. 
 
The average travel times to any category of service center were calculated from the 1×1 km grid 
surfaces for the two countries. From each grid pixel, the travel time to any category of service 
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center was divided by the average travel time to that category. The result was a surface of ratio-
to-mean travel time. For example, if a grid pixel had a ratio-to-mean travel time of 2 to Service 
Center 1, this implied that it took twice as long to reach the nearest Service Center 1 as the 
average grid pixel. This ratio for each pixel was capped at a value of 0.5 for Kenya and 0.6 for 
Ghana to be equivalent to approximately half an hour to a Service Center 1; 1.5 hours to a 
Service Center 2 and 2 hours to a Service Center 3. All pixels where the ratio-to-mean to any 
service center was ≥0.5 were then assigned a ratio-to-mean of 0.5. This was done to reduce the 
influence of the longer travel times to larger but fewer service centers on the overall index. The 
capped ratio-to-mean surfaces to each type of Service Center were summed, resulting in a 
continuous index of remoteness ranging from 0 to 1.5. The continuous surface was then 
classified into five categories as follows: Highly accessible (≤0.3), accessible (>0.3 - ≤0.6), 
moderately accessible (>0.6 - ≤0.9), remote (>0.9 - ≤1.2) and very remote (>1.2 – 1.5) (see 
Figure 1.6.1). For further details about the methodology used for defining remote areas, refer to 
Appendix M or Noor et al. (2012). 
 
Figure 1.6.1: Remoteness classification (quintiles) based on the remoteness index, Kenya and Ghana 
Kenya Ghana 
  
 
Source: Noor et al. (2012).  
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Selecting remote area clusters 
For the purpose of the IE, these five categories of remoteness were collapsed into two categories: 
accessible areas that are not remote (≤0.90) or remote areas (>0.90). Using this binary 
classification, we identified the number of clusters from the endline OS sample which are located 
in the remote areas, then estimated the number of additional clusters needed in the remote areas 
to have sufficient statistical power to compare estimates from remote areas with the estimates 
from non-remote areas. The sample size estimation was based on the ACT availability indicator 
and follows the same procedure as described in the main outlet survey methods section. The final 
numbers of clusters required in remote areas are presented in Table 1.6.8 and the spatial 
distribution of the clusters is depicted in Figure 1.6.2. It is important to note that for Kenya, non-
malaria zones were excluded from the sampling frame used for the selection of additional remote 
area clusters. 
 
Table 1.6.8: Remote area clusters selected for the AMFm Independent Evaluation remote area 
survey 
Country 
New clusters selected in 
remote areas 
Existing remote area clusters 
in the endline outlet survey 
Total clusters in 
remote areas 
Kenya 10 9 19 
Ghana 10 5 15 
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Figure 1.6.2: Remoteness classification map showing the location of clusters sampled in the remote 
areas for the AMFm Independent Evaluation remote area survey 
Kenya Ghana 
  
 
Source: Noor et al. (2012).  
 
1.6.5.2 Data collection 
Data collection was done using paper-based questionnaires in Kenya and Ghana. The tools and 
procedures used in the remote area survey in both countries were similar to the ones used in the 
main endline outlet survey. The remote area surveys were carried out in Kenya from February 27 
to March 16, 2012, and in Ghana from March 4–13, 2012, by the Africa Population and Health 
Research Centre (APHRC) and the Komfo Anokye Teaching Hospital (KATH), respectively. 
These two organization were responsible for the endline OS in their respective countries. Given 
the difference in timing between the remote areas data collection and the endline OS, a new 
question (P23a. Have you stocked any of these antimalarials (show prompt card of QAACTs) in 
the last four months? (November 2011 - February 2012) was added to the questionnaire to cover 
a longer recall period of four months in order to overlap with the endline survey period (see 
Table 1.6.2 for endline OS data collection dates). Other minor changes included changing the 
default year to 2012 and changing the tools title from endline to remote area survey.  
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1.6.5.3 Data processing and analysis 
Similar data entry and processing procedures as in the endline OS were used in both countries. 
Cleaning was done using the endline OS data cleaning procedures. For analysis, we did not 
calculate change indicators since we did not have baseline data with sufficient statistical power 
for the remote areas. We computed indicators of availability, price and market share of quality-
assured ACTs at endline separately for remote and non-remote areas in each country. It should 
be noted that the booster sample was not included in the remote area analysis as it was the case 
for the main endline survey. Also Ghana estimates are unweighted because there was no way to 
calculate the weight due to a lack of estimates for the total population of the remote areas. 
 
1.6.6 Public awareness - AMFm logo study 
Exit interviews with clients of outlets were conducted in four countries with a structured 
questionnaire to obtain data on the knowledge and availability of ACTs and on the effect of the 
use of the AMFm logo in branding ACTs on the sales of copaid ACTs. Data from exit interviews 
were used to determine to what extent the logo assists patients in their recognition of the ACTs 
available. Information on public awareness and knowledge of quality-assured ACTs and the 
AMFm logo were obtained through focus group discussions with men and women. Focus group 
discussions focused on three themes: the treatment of malaria, the knowledge of participants of 
ACTs available to them, and their awareness of the AMFm logo. 
 
1.6.6.1 Exit interviews 
Identification and selection of participants 
The exit interviews were conducted in eight clusters─four urban and four rural─that were 
randomly chosen from the list of clusters used in the endline outlet survey in each country. In 
each cluster, six outlets were selected randomly from a list of outlets within the cluster obtained 
through an outlet census. The census included all public, private, for-profit and not-for-profit 
locations where anti-malarial drugs were sold.  
 
In each outlet, clients who had just left the outlet were asked to participate in a survey related to 
malaria. Individuals 18 years old and older were interviewed. No quota was given for the 
male/female ratio of respondents. Clients leaving the selected outlets were contacted until 12 
valid interviews had been completed, with at least six interviews with clients who came to obtain 
an antimalarial. Research teams in all countries succeeded in meeting that target in nearly all 
clusters. The target number of interviews per country was 576: 12 interviews per outlet in six 
outlets per cluster and eight clusters per country.  
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Data collection procedures 
After completion of training and the pre-testing of the questionnaire (Appendices N and O), 
research teams of three or four persons, accompanied by a supervisor, traveled to the clusters and 
contacted local authorities to explain the purpose of their visit, show their credentials and enlist 
their support. The team then conducted a census of the outlets in the cluster. Once the sample of 
six outlets had been identified, a team member or supervisor contacted the person in charge of 
the outlet to explain the purpose of the survey and request permission to interview clients after 
they leave the outlet. A team member then stationed himself/herself a short distance from the 
outlet to approach clients as they walked by. The data collection in Ghana, Kenya and Nigeria 
began the second week of February 2012 and lasted for 3-4 weeks. In Madagascar, fieldwork 
began on March 18, 2012 and was completed in four weeks. 
 
The questionnaire included questions about the reason for their visit to the outlet, their 
purchasing of antimalarials, their knowledge of ACTs and their awareness of the AMFm logo. 
The questions were prepared initially in English for Ghana, Kenya and Nigeria, and were then 
translated into French for Madagascar. The paper questionnaires were translated and printed in 
three local languages in Ghana and Nigeria, and in Kiswahili in Kenya. The questionnaire was 
translated and printed in Malagasy in Madagascar. Once informed consent was granted by a 
client, the interviewer asked the client about 25 questions with pre-coded answers. A small 
number of potential respondents declined to be interviewed. A record was kept of the number of 
clients who declined in each cluster.  
 
Data processing and analysis 
A data entry specialist developed the data entry screens for each country with the Microsoft SQL 
Server that was set up for double entry of the data. The specialist worked with the data 
processing team in each country to assist them in downloading the software and following the 
manuals for installation and initialization. Each research agency used its own pool of data entry 
specialists to enter the data. Once cleaned, the data sets were sent to the office of ICF 
International for analysis. ICF prepared a tabulation plan for presenting data to respond to the 
main research questions of the studies.  
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1.6.6.2 Focus group discussions 
Identification and selection of participants 
Two focus group discussions were conducted in each of the eight clusters: one with men and one 
with women. Women aged 25-40 years old and men aged 35-50 years old were recruited since 
they were likely to be responsible for young children. Participants were recruited in some 
clusters through their membership in a local organization such as an association of teachers, male 
farmers, fishmongers or market women. In others, the local political or administrative head 
recruited individuals directly to participate. In most cases, the local chief or political authority 
advised and assisted in the process of recruitment. The number of participants in each focus 
group varied from 6 to 12. Potential participants were invited to meet in a venue where they 
could hold discussions in private. 
 
Conducting the focus group discussions 
The focus group discussions (FGDs) were directed by a moderator assisted by a note taker who 
also organized the recording. Most FGDs took place in a room rented for that purpose. The 
moderator and note taker welcomed the participants as they arrived and began learning names. 
The discussion began after the introduction of all individuals present and a welcome by the 
moderator who also explained the purpose of the meeting.  
 
The moderators followed a two-page guide in English or in French (Appendices P and Q) that 
described the three themes central to the discussions and the elements that form part of each 
theme. However, most FGDs were held in a language other than English or French. The main 
themes were symptoms and treatment of malaria, knowledge and experience with ACTs, and 
awareness and knowledge of the AMFm logo. The participants were free to address these topics 
in any order.  
 
Information processing 
The focus group discussions were recorded with permission of the participants. In only a few 
cases was permission not granted. In those cases, the moderator and note taker reconstructed the 
discussion as completely as possible after the completion of the discussion. The recordings were 
transcribed in the language of the discussion, translated into English or French, typed in 
Microsoft Word and sent to ICF International for analysis. Reports were written by the 
implementing agency about each focus group discussion to provide context for the analysis. 
These reports provided summaries of main points of the discussions, brief descriptions of the 
discussion process and comments on any elements that influenced the discussions. 
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1.6.7 Interpretation and operationalization of success metrics  
It was recognized early in the Independent Evaluation process that it would be useful to define in 
advance how “success” would be assessed in relation to the achievement of the AMFm outcomes 
(availability, price, use and market share), in order for a judgement of the effectiveness of the 
program in different country settings to be made. To assist in this process, the AMFm Ad Hoc 
Committee commissioned the Evidence to Policy Initiative (E2Pi) to propose benchmarks for 
outcomes which could realistically be expected in the first and second years of the pilots, 
together with an approach to balancing and judging performance across multiple indicators. To 
inform the setting of the benchmarks, the E2Pi team conducted a literature review and key 
informant interviews to review the experience of sub-national pilots of subsidized ACTs, 
national programs of subsidized ACTs, other national ACT scale-up initiatives (e.g., those 
supported by the Global Fund), commodity social marketing programs, national scale-up 
programs for oral rehydration therapy and drug company efforts to launch a new product into an 
emerging market or a developing country. 
 
The E2Pi team produced a draft paper for discussion at the June 2010 meeting of the AMFm Ad 
Hoc Committee. Committee members provided feedback on the draft paper and suggested 
additional literature to review and key informants to interview. The revised report was reviewed 
by nine external reviewers, revised again and presented at the October 2010 meeting of the 
AMFm Ad Hoc Committee, where additional modifications were requested. The final version of 
the E2Pi report (Schäferhoff and Yamey 2010) was presented in a pre-Board briefing session in 
advance of the December 2010 Board meeting and was released in the public domain. This work 
formed the basis for the “Success Metrics” presented in Chapter 8 of this report. Table 1.6.8 
shows the original E2Pi formulation of the metrics, the success benchmarks proposed by E2Pi 
for 1 year after the effective start date of AMFm, and the way these have been refined and 
operationalized by the IE. Further clarification on decisions that were taken to operationalize the 
metrics follows. 
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Table 1.6.9: E2Pi metrics and benchmarks for success and their operationalization by the IE 
E2Pi metric E2Pi benchmark for 1 Year IE operationalization 
Availability 
The proportion of all 
facilities, private and 
public [including 
informal outlets], 
stocking QAACTs, 
among outlets with any 
antimalarials in stock 
at the time of the 
survey 
Increase of 20 percentage 
points from baseline 
 
Benchmark 1: Percentage point change from baseline to endline in the percentage of outlets stocking 
ALL QAACTs (both with and without the AMFm logo). 
 
We report the p-value from a one-sided unadjusted Wald test, which is the probability that QAACT 
availability is at least 20 percentage points higher at endline than baseline. 
 
This metric is shown for all outlets combined, and separately for public health facilities and private for-
profit outlets. 
Price  
QAACT price per 
adult equivalent 
treatment dose 
(AETD) relative to the 
price of the most 
popular non-QAACT  
 
Copaid QAACT price 
per adult equivalent 
treatment dose relative 
to the price of 
artemisinin 
monotherapy 
QAACT price <300% of the 
price of the most popular 
non-QAACT (in most 
countries this is chloroquine 
or SP) 
and 
Price of AMFm copaid 
QAACT < price of AMT; this 
is useful but not sufficient to 
determine success 
 
Benchmark 2: Ratio of the median price of QAACTs with the AMFm logo to the median price of the 
most popular antimalarial which is not a QAACT.  
 This metric is presented for private for-profit outlets only.  
 The most popular antimalarial in tablet form which is not a QAACT is defined as the antimalarial, 
excluding QAACTs, with the highest sales volume measured in terms of AETDs sold in private 
for-profit outlets. 
 
Benchmark 3: Difference between the median price of QAACTs with the AMFm logo and the median 
price of AMT tablets. 
 This metric is presented for private for-profit outlets only. 
 
Bootstrapping was used to test the statistical significance of Benchmarks 2 and 3.  
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Table 1.6.9: Cont. 
E2Pi metric E2Pi benchmark for 1 Year IE operationalization 
Use 
Proportion of children 
under 5 years with 
fever who received a 
QAACT on the day 
that the fever started or 
on the following day 
Increase of 5-10 percentage 
points from baseline 
 
Benchmark 4: Percentage point increase from baseline in percentage of children under age 5 years with 
fever in the last 2 weeks who received ACT treatment. 
 
The IE does not restrict the denominator to children who received the medicine on the day the fever 
started or on the following day (see below). 
 
A statistical t-test is undertaken for the lower bound of the range given in the benchmark (i.e., 5 
percentage points). 
Market share 
Total volume of 
QAACTs sold or 
distributed as a 
proportion of the total 
volume of all 
antimalarials sold or 
distributed in the last 
week via outlets that 
will be included in the 
Independent 
Evaluation outlet 
surveys 
Increase in ACT market share 
of 10-15 percentage points 
from baseline 
and 
Decrease in market share of 
artemisinin monotherapy 
(AMT) from baseline (note 
that the E2Pi document 
specified a metric for AMT, 
but not a benchmark) 
Benchmark 5: Percentage point change from baseline to endline in the market share of ALL QAACTS. 
 
Benchmark 6: Percentage point change from baseline to endline in the market share of AMTs (all oral 
dosage forms). 
 
Sales volumes are calculated in terms of AETDs sold/distributed in the last 7 days. 
 
Statistical testing was undertaken for the lower bound of the range given in Benchmark 5 (i.e., 10 
percentage points). We report p-values from one-sided unadjusted Wald tests, which are the probability 
that QAACT market share is at least 10 percentage points higher at endline (Benchmark 5) and that 
AMT market share is lower at endline (Benchmark 6). 
 
This metric is shown for all outlets combined, and separately for public health facilities and private for-
profit outlets. 
Source: Adapted from Schäferhoff and Yamey (2010) 
 
66 
 
The availability metric measures the availability of all QAACTs (both with and without the 
AMFm logo). This is in order to capture the overall change in QAACT availability, net of any 
potential substitution between copaid and non-copaid QAACTs. The market share metric is also 
based on all QAACTs.  
 
For the use metric, the IE has operationalised the metric using IE Indicator 3.1 (any ACT 
treatment) rather than Indicator 3.2 (prompt treatment). This is because of the difficulty in 
measuring the timing of treatment in relation to the onset of fever and of interpreting its 
appropriateness. It is also consistent with the revised Roll Back Malaria indicator for case 
management of malaria, which considers whether or not ACTs were used, but not the timing of 
ACT use.  
 
Price metrics are computed for QAACTs with the AMFm logo only, in order to focus on the 
extent to which the subsidy provided through AMFm has been passed through to final retail 
prices. It would also be expected that a low price for QAACTs with the AMFm logo would 
affect the price for QAACTs without the logo, however this is not a key metric and this 
information is presented in the main tables. The following points are relevant to the calculation 
of the price of the comparators (the most popular antimalarial which is not a QAACT and 
artemisinin monotherapy): 
 The price of QAACTs in the private for-profit sector was selected as the focus of these 
metrics because in many settings drugs are free in public and not-for-profit health 
facilities. 
 To compare like with like, for Benchmark 2 the comparator is the most popular 
antimalarial which is not a QAACT in the for-profit sector, in tablet form (as all 
QAACTs are tablets). 
 The most popular antimalarial which is not a QAACT in private for-profit outlets is 
determined in terms of total AETDs sold. It is defined in terms of the generic drug type, 
e.g., SP. 
 For Benchmark 3 the comparator price of AMT is calculated as the median price of 
AMTs sold in private for-profit outlets, in tablet form. The rationale for restricting the 
comparison to AMT tablets is that all QAACTs are tablets and non-oral forms of AMT 
(injectables, suppositories) are used in the management of severe malaria and are 
therefore not the target of “crowding out” efforts by AMFm. 
 
The E2Pi document states that the price benchmark after 1 year of implementation has the 
weakest empirical basis, and that interpretation will need to take careful account of the country 
context.  
 
The E2Pi report provides benchmarks for one year and two years after “the effective start date of 
AMFm at the Country level” (E2Pi). Table 1.6.2 shows the time gap between the date the first 
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copaid drugs arrived in a country and the midpoint of data collection for the endline outlet 
survey. The first arrival of drugs may not be a very strong indication of the start of “effective 
implementation,” particularly if supporting interventions were implemented after a considerable 
delay. This limitation notwithstanding, it should be noted that half of the pilots had at least some 
copaid drugs in country for more than 12 months before the endline outlet survey (16-1/2 months 
in Ghana, 15 months in Kenya, 14 months in Madagascar and 13-1/2 months in Tanzania). 
However, the time between the arrival of drugs and the endline outlet survey in the remaining 
countries ranged from 6-1/2 to 9-1/2 months. This duration of effective implementation needs to 
be taken into account when interpreting country performance against the benchmarks.  
 
Finally, as recommended by the E2Pi report, a Balanced Scorecard approach has been used for 
presenting success metrics outcomes for the different program objectives (Section 8). The 
scorecard has four quadrants, one each for availability, price, use and market share, and also 
highlights other key results, and process and contextual factors.  
 
1.6.8 Ethical approval 
ICF International and LSHTM received ethical clearance for the IE as a whole from their 
respective Institutional Review Boards (IRBs). The DCs received ethical approval for the 
baseline and endline outlet surveys, the remote area surveys and the collection of process and 
context data from the relevant national ethical review boards. Organizations contracted to carry 
out the logo study and the exit interviews received ethical clearance from the relevant national 
ethical review separately from the main outlet survey. 
 
For all data collected, interviewers obtained informed consent before interviews were conducted. 
The results were not linked to individual providers, outlets or participants to ensure that 
confidentiality was protected. 
 
1.6.9 Discussion of strengths and limitations of the Independent Evaluation  
This section highlights key methodological and practical strengths of the evaluation, and 
discusses the potential limitations and their likely impact. 
1.6.9.1 Strengths 
The evaluation benefits from a number of key strengths. Data were collected from all eight 
operational pilots, which included both East and West African countries, and both Anglophone 
and Francophone countries, thus encompassing a wide range of institutional and cultural settings. 
The pilots also exhibited considerable variation in intensity and seasonality of malaria 
transmission, and in levels of economic development, allowing for assessment of AMFm phase 1 
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in a wide variety of contexts. This variety of settings helps to increase the external validity of the 
evaluation, and can also be used to inform thinking about other countries where AMFm might be 
expected to be effective. 
 
Given that AMFm represents a complex intervention implemented in real life settings at large 
scale, the plausibility study design used in the IE was appropriate and well suited to 
understanding impact (Habicht et al. 1999). In particular, the combination of the quantitative 
surveys with detailed case studies on process of implementation and country context, guided by 
an explicit theory of change (Section 1.4), allows for assessment of the likelihood that impacts 
observed can be attributed to AMFm. For example, the case studies were able to highlight the 
variation in order rates for copaid drugs and in SI implementation across countries, and other 
interventions or events that may have affected AMFm indicators. 
  
Findings were based on nationally representative outlet surveys and (where possible) household 
surveys, which were powered to look at key metrics separately in rural and urban areas (although 
not within all outlet categories). The methods for the outlet surveys, which form the core of the 
evaluation data, drew heavily on materials developed by the ACTwatch group, which had been 
tested and refined during several years in a wide range of countries (www.actwatch.info). In 
addition, outlet survey data collection in each country was conducted by experienced local 
research organizations, whose staff had a strong understanding of the local context. 
 
Outlet survey data collection and analysis was carefully coordinated across countries, using 
standardized approaches and tools. A comprehensive set of quality assurance strategies were put 
in place, guided by three principles: 
 
 ensuring high quality standards at every stage of the data collection and analysis process 
 ensuring comparability among pilots by use of consistent methods 
 allowing country-specific adaptation, for example, in the sampling strategy and 
questionnaire responses, where this would enhance quality and be appropriate to the 
country setting, without compromising cross-country comparability. 
To ensure data quality, the DCs were provided with a set of key documents and materials, as 
described in Sections 1.6.2.3 on Data Quality Assurance and 1.6.2.4 on Data Processing and 
Analysis. These included a generic study design, generic questionnaires, a field manual, field 
monitoring forms, training materials, cleaning guidelines, analysis guidelines, analysis “do” files 
and the tabulation plan. The IE team provided assistance during fieldwork and throughout the 
research process. The IE team also undertook certain key steps in the process on behalf of 
countries, specifically selection of the sample of clusters and calculation of the sampling weights 
for analysis. In addition, the DCs themselves had a set of quality control procedures in place, for 
example, to ensure recruitment of high-quality field staff, quality of data collection in the field 
and the accuracy of double data entry. 
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The DCs were required to obtain approval from the IE team at a number of key milestones in the 
data collection, data entry and data analysis process. This oversight by the IE team involved 
submission of documents or data sets to the IE team, and frequently involved a number of drafts 
and extensive discussions by email and phone until approval was obtained. All DCs received 
approval for the following milestones at baseline and endline: 
 
1. Adapted country-specific questionnaire approved  
2. Sampling frame of clusters approved by the IE sampling statistician 
3. Quality of fieldworker training verified by an attending IE team member where feasible 
4. Confirmation that quality control visits were conducted during all surveys  
5. Accuracy and completeness of data cleaning syntax and log files checked 
6. Spot checking of country adaptations to analysis syntax files  
7. Report tables carefully reviewed to highlight any inconsistencies  
Baseline and endline analysis was also run independently by the IE team and the relevant DC for 
each country and any discrepancies were resolved. 
  
The IE also conducted a set of quality assurance steps for the collection of process and context 
data through the country case studies. These included training of consultants, provision of 
generic data collection tools and a detailed report template, support to interviewers in the field, 
and careful review of all draft reports.  
 
Finally, the study was conducted by a team that were independent from those implementing and 
funding AMFm, and all scientific decisions remained the sole responsibility of the IE team. 
1.6.9.2 Limitations 
A number of limitations should be noted in relation to the overall IE study design. The use of 
control or comparison areas can play an important role in the identification of intervention 
impact, but this approach was not adopted within the IE. It was not possible to create comparison 
areas within pilot countries, given the nature of the intervention, which involved the use of 
existing private sector distribution channels, meaning that the intervention could not be restricted 
to certain areas of the country. An alternative would have been to compare the experience in 
AMFm pilots with that in non-AMFm countries. However, given the substantial variations in 
political, economic and health system contexts among countries, and varied implementation of 
other malaria control strategies, it would have been challenging to identify a sufficient number of 
countries that were appropriate “matches” for the pilots. Moreover, some export of AMFm drugs 
is likely to have taken place from the pilots, which would have led to “contamination” in 
neighboring comparator countries. 
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Similarly, care should be taken in extrapolating the findings from the pilots to other countries 
within and especially beyond sub-Saharan Africa, especially to settings with very different 
antimalarial market structures. Only 11 countries were invited to apply for AMFm Phase 1. 
These countries were selected based on a set of criteria comprising malaria burden, experience 
with large-scale ACT deployment, the importance of the private sector in antimalarial 
distribution, presence of strong monitoring and evaluation systems, community deployment or 
‘over-the-counter’ sale of ACTs and existing or planned ACT subsidy schemes. This implies that 
the AMFm countries may be systematically different from non-AMFm countries, and several of 
the criteria imply that selected countries may be relatively likely to benefit from AMFm. 
However, the presence of pre-existing ACT subsidy programs in several pilots (at national scale 
in Madagascar, in 18 states in Nigeria and in 4 districts in Uganda) may imply that less impact 
would be seen in these settings than in those without any pre-AMFm ACT subsidies in the 
private sector. In sum, differences in context should be carefully considered in assessing the 
generalizability of IE results to other settings. 
 
Another limitation is the relatively short time of AMFm implementation before endline data 
collection in several countries. In four pilots there was over one year between the arrival of the 
first copaid drugs in the pilot countries and the midpoint of the endline outlet survey data 
collection (Table 1.6.2). However, in most settings drug orders were low at first and full SI 
implementation lagged several months behind drug arrival. In four pilots there was less than one 
year between arrival of the first copaid ACTs and the midpoint of OS data collection (9.5 months 
in Nigeria and Niger, 7 months in Uganda, and 6.5 months in Zanzibar). These periods are less 
than ideal for evaluating an intervention that operates on a national scale and requires behavior 
change by multiple groups. One might therefore expect that under sustained AMFm 
implementation, greater impact would have been achieved if a longer study period had been 
possible. Furthermore, at end May 2012, no national endline household survey data were 
available for any of the pilot countries. However, the timeline was constrained by the need to 
report to the Global Fund before the end of 2012. 
 
In some cases there were also quite long lags between baseline data collection and the start of the 
AMFm rollout. This was particularly a problem for the secondary household survey data used as 
the baseline in most countries, where the lags between the midpoint of data collection and arrival 
of first copaid drugs were over one year in five pilots and almost five years in Niger. In two 
pilots, there were also quite long lags between baseline OS data collection and arrival of the first 
copaid drugs (7 months in Zanzibar and 15 months in Nigeria where the ACTwatch survey was 
used as the baseline. It is therefore possible that the AMFm indicators measured at baseline had 
changed to some degree before the AMFm rollout. This is a particular challenge for Nigeria 
given the long time lag and challenges experienced in documenting contextual factors prior to 
the start of AMFm and the IE. By contrast in Kenya, a small quantity of copaid drugs had arrived 
in the country before baseline data collection, and a national launch had taken place, implying 
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that the baseline indicators may capture some AMFm implementation, leading to an 
underestimate of impact. 
 
The influence of seasonality should also be considered in the timing of the surveys. In four 
pilots, outlet survey data collection was conducted during the same months at baseline and 
endline (Kenya, Nigeria, Tanzania – mainland, and Uganda), and at similar times in two pilots 
(Niger and Zanzibar). However, the differences were larger in Ghana (where the baseline survey 
was in August and the endline survey was in November) and Madagascar (where the baseline 
survey was in April-June and the endline survey was in November-January). The impact of this 
is unclear as transmission occurs year round in Ghana, and although transmission is seasonal in 
the south and central highlands in Madagascar, both surveys were conducted in high 
transmission seasons. Additional outlet survey data collected for the remote areas studies had to 
be collected after the end of the main endline outlet surveys for logistical reasons. In both 
countries the surveys took place in March 2012, which does not correspond to the peak malaria 
transmission season. To assess the implications of this an additional question was added on 
whether the outlet had stocked QAACTs at any point in the 4 months preceding the interview, 
which would include the period in which the main outlet survey took place. Even where baseline 
and endline surveys were conducted at the same time of the year, there may be year-to-year 
fluctuations in transmission, although factors affecting this should be captured in the country 
case studies. 
 
It is important to bear in mind the scope of the Independent Evaluation and specifically what is 
not covered. The evaluation was designed to look at impact on QAACT availability, price, 
market share and use (in terms of coverage of ACTs among children with fever). There are a 
number of other important questions and concerns about AMFm implementation which are 
beyond the scope of the IE. These include whether copaid drugs are targeted at those with 
parasitemia; advice provided to patients by providers; patient adherence to dosing regimens; 
impact on global artemisinin supplies; impact on prevalence of counterfeit products; and re-
export of copaid drugs to countries not included in AMFm. 
 
All surveys relying on self-reported behavior are subject to recall bias, with respondents less 
likely to remember events that occurred further in the past. This may be the case in household 
surveys where respondents were asked to recall treatment-seeking behavior over the previous 
two weeks, but recall bias is not likely to be substantial over a two-week period. In the OS, we 
aimed to minimize recall bias by asking for reported sales volumes and stockouts for the 
previous week only, although recall may still have been imperfect. Interviewers were also trained 
to probe respondents about all antimalarials stocked to maximize the number reported, although 
it is likely that some were still missed out, particularly non-tablet formulations that respondents 
tend to forget. Although we aimed to interview a senior person in the outlet, interviewees were 
not always well informed about all aspects of the antimalarial business (e.g., wholesale purchase 
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prices). There may also have been incentives for social desirability bias, where interviewees 
responded inaccurately to survey questions in order to present themselves in a good light. For 
example, they may have concealed antimalarials which they believed they were not allowed to 
stock, underestimated sales volumes if they were concerned about the possible tax implications 
of reporting a high income or reported lower prices and mark-ups than they actually charged, 
especially if they were aware that they should be charging a specific RRP. We tried to minimize 
such behavior by reassuring interviewees during the consent process about confidentiality and 
emphasizing that we were not undertaking an inspection. It was encouraging to note that the 
outlet surveys obtained high response rates, even in private-for-profit outlets, despite the 
potentially sensitive nature of the questions in legal and commercial terms. Recall and social 
desirability bias may also have arisen in the key informant interviews for the case studies. In 
some cases, it was not possible to interview certain key informants, and those that did respond 
were not always fully knowledgeable, especially of events taking place outside the capital city. 
 
Rigorous outlet survey methods were used to identify QAACTs and to measure their price, 
markups and sales volumes based on AETDs. However, there were some limitations to this 
approach. Drugs were classified as QAACTs on the basis of a set of characteristics (generic 
name, brand name, strength, pack size, manufacturer, country of manufacture and whether the 
product was a fixed dose combination). QAACT status is also linked to specific manufacturing 
sites, but data were not collected on this in the outlet survey. In addition, there have been minor 
changes in the set of products classified by the Global Fund as QAACTs at baseline and endline 
(see Appendix I). Specifically there were two products that were QAACTs at baseline but not at 
endline, and five products that were QAACTs at endline but not at baseline. With the exception 
of the artemeter + lumefantrine product produced by Quality Chemicals Industries Limited, the 
products that were QAACTs at endline but not baseline were not likely to be present in the 
market during baseline data collection. This implies that some changes in QAACT indicators 
between baseline and endline may reflect changes in regulatory status rather than changes in the 
quality of available products.  
 
Two ACTwatch outlet surveys from Nigeria and Madagascar were used as IE baseline surveys 
because their timing was reasonably suitable, and it was not therefore deemed appropriate to 
fund additional surveys. In general, this met the needs of the Independent Evaluation well, as the 
methods and questionnaire were very similar. However, a number of differences in cleaning 
procedures could mean that there were slight differences in the products classified as QAACTs 
during the ACTwatch surveys. 
 
Other challenges experienced with the outlet survey data included use of relatively old 
population sampling frames in some countries for the weighting of observations and calculation 
of Indicator 1.7 on QAACT population coverage, and difficulties in identifying itinerant vendors 
where these were common. 
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1.7 Consultative Forum 
 
The Independent Evaluation team organized a Consultative Forum to present and discuss the 
preliminary results of the Independent Evaluation to ensure that the final report is informed by 
the body of knowledge from key institutions, thought leaders and practitioners. The forum took 
place on June 27-28, 2012, at the Tribe Hotel in Nairobi, Kenya, and involved participants from 
the Independent Evaluation team (ICF and LSHTM), PSI - ACTWatch, DNDi/KATH, 
CRDH/CIERPA, and IHI, senior NMCP officials and persons with a solid understanding of the 
AMFm progam from the study countries, co-chairs of the Roll Back Malaria Harmonization 
Working Group’s AMFm Workstream, designated experts, and the Global Fund. 
 
The Consultative Forum was advisory in nature. The IE team had the responsibility to document 
the major issues discussed and decide how to handle each of these major points in the final 
AMFm Phase 1 Independent Evaluation Report. The Consultative Forum provided an 
opportunity to all key knowledgeable stakeholders in the public and private sectors and 
independent experts to review and discuss the IE report extensively and to further fact-
check/validate implementation and contextual information. See Appendix R for the narrative 
report of the Consultative Forum, including a list of key issues raised and how the IE team has 
addressed them. 
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2 Results from Outlet surveys 
2.1 Description of sample and characteristics of outlets  
2.1.1 Description of sample at baseline and at endline 
Table 2.1.1 describes the samples at baseline and endline. Some of the differences in the number 
of outlets enumerated reflect differences in the number of clusters sampled (see Table 1.6.3). In 
Kenya, although the number of outlets stocking antimalarials was very similar at baseline and 
endline, the number of outlets enumerated was much higher at baseline. This most likely reflects 
data collectors being less likely to enumerate permanently closed outlets at endline, although this 
practice was still more common in Kenya than in other countries.  
 
Table 2.1.2 shows the final interview status and location of outlets at baseline and endline. 
Response rates were high, and the proportion of outlets enumerated that were screened was 90% 
or above at baseline and endline in all countries other than Kenya. In Kenya, the percentage of 
outlets enumerated that were screened was lower, reflecting the number of permanently closed 
outlets, but the percentage meeting the screening criteria that were interviewed was very high 
(98%). 
 
In Ghana, of all the private for-profit outlets enumerated, 44% were in rural areas at baseline, but 
only 30% at endline. The Data Contributor reported that this reflected the fact that the rural 
districts in the sample were less densely populated in the endline sample.  
 
Table 2.1.4 shows the number of outlets with antimalarials in stock on the day of the survey. 
Following a similar pattern to that seen for outlets enumerated in Ghana, the percentage of 
private for-profit outlets with antimalarials in stock located in rural areas was 43% at baseline 
but only 26% at endline. The Data Contributor reported that this reflected the fact that rural 
districts in the sample were less densely populated in the endline. This has some consequences 
for interpretation of changes over time in the private for-profit sector in Ghana. 
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Table 2.1.1: Survey sample breakdown: Number of outlets enumerated and number stocking antimalarials by urban-rural location, according to 
country at baseline (2010) and endline (2011) 
Country 
BASELINE ENDLINE 
# of outlets 
enumerated* 
# of 
outlets 
screened 
# of 
outlets 
which 
met 
screening 
criteria 
# of outlets 
interviewed** 
# of outlets 
stocking 
antimalarials 
at the time of 
the survey 
visit 
# of outlets 
without 
antimalarials 
in stock at 
the time of 
the survey 
visit but had 
antimalarials 
in stock at 
some time in 
the 3 months 
preceding 
the survey 
# of outlets 
enumerated* 
# of 
outlets 
screened 
# of outlets 
which met 
screening 
criteria 
# of outlets 
interviewed** 
# of outlets 
stocking 
antimalarials 
at the time of 
the survey 
visit 
# of outlets 
without 
antimalarials 
in stock at 
the time of 
the survey 
visit but had 
antimalarials 
in stock at 
some time in 
the 3 months 
precedings 
to the survey 
A B C D E F A B C D E F 
Ghana –Total 1,241 1,187 1,167 1,154 1,144 10 1,093 1,002 974 968 957 11 
Urban 648 616 611 604 601 3 629 591 583 577 575 2 
Rural 593 571 556 550 543 7 464 411 391 391 382 9 
Kenya –Total 18,250 13,913 2,625 2,582 1,916 666 13,376 11,386 2,112 2,088 1,856 232 
Urban 9,564 7,745 1,409 1,375 1,039 336 7,648 6,868 1,183 1,162 1,053 109 
Rural 8,686 6,168 1,216 1,207 877 330 5,728 4,518 929 926 803 123 
Madagascar – Total 7,221  6,769  2,642  2,616  2,414  202 10,723 10,041 2,854 2,806 2,371 435 
Urban 5,274 4,980 1,604 1,581 1,444 137 6,894 6,519 1,282 1,251 982 269 
Rural 1,947 1,789 1,038 1,035 970 65 3,829 3,522 1,572 1,555 1,389 166 
Niger – Total 3,745 3,738 2,444 2,380 2,031 349 3,541 3,292 2,070 2,034 1,662 372 
Urban 1,335 1,333 920 910 833 77 1,791 1,778 1,112 1,094 924 170 
Rural 2,410 2,405 1,524 1,470 1,198 272 1,750 1,514 958 940 738 202 
Nigeria – Total 6,089 5,456 2,210 2,206 2,113 97 8,507 7,939 1,567 1,562 1,504 58 
Urban 4,654 4,162 1,816 1,813 1,746 69 6,063 5,706 1,071 1,068 1,032 36 
Rural 1,435 1,294 394 393 367 28 2,444 2,233 496 494 472 22 
Tanzania – mainland – Total 3,151 3,120 710 660 631 29 3,786 3,709 799 798 787 11 
Urban 1,146 1,126 353 327 325 2 2,533 2,481 598 597 596 1 
Rural 2,005 1,994 357 333 306 27 1,253 1,228 201 201 191 10 
Uganda – Total 11,369 11,153 2,590 2,511 2,420 91 16,521 16,207 3,285 3,227 3,138 89 
Urban 1,752 1,723 571 548 544 4 8,031 7,914 1,459 1,423 1,416 7 
Rural 9,617 9,430 2,019 1,963 1,876 87 8,490 8,293 1,826 1,804 1,722 82 
Zanzibar – Total 2,256 2,231 322 321 313 8 4,303 4,221 374 374 342 32 
Urban 1,137 1,117 196 195 189 6 2,295 2,250 242 242 222 20 
Rural 1,119 1,114 126 126 124 2 2,008 1,971 132 132 120 12 
*Outlets that were visited and where at a minimum basic descriptive information (Sections C1-C9 of questionnaire) was collected  
**Outlets that had a final interview status of ‘completed’ or ‘partially completed’ 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
Note: Nigeria baseline data collection was conducted in 2009. 
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Table 2.1.2: Number of outlets by final interview status and urban-rural location, according to country at 
baseline (2010) and endline (2011) 
Country/Final interview status 
BASELINE ENDLINE 
Urban Rural Total Urban Rural Total 
Ghana       
Number of outlets       
Outlet not screened 32 22 54 38 53 91 
Outlet did not meet screening criteria 5 15 20 8 20 28 
Outlet met screening criteria, but not interviewed 7 6 13 6 0 6 
Completed interview 604 550 1154 573 391 964 
Partially completed interview 0 0 0 4 0 4 
Response rate (%)       
Proportion of outlets enumerated that were screened 95.1 96.3 95.6 94.0 88.6 91.7 
Proportion of outlets meeting screening criteria that were interviewed* 98.9 98.9 98.9 99.0 100.0 99.4 
Kenya       
Number of outlets       
Outlet not screened 1,819 2,518 4,337 780 1210 1990 
Outlet did not meet screening criteria 6,336 4,952 11,288 5,685 3589 9274 
Outlet met screening criteria, but not interviewed 34 9 43 21 3 24 
Completed interview 1,360 1200 2,560 1149 922 2071 
Partially completed interview 15 7 22 13 4 17 
Response rate (%)       
Proportion of outlets enumerated that were screened** 81.0 71.0 76.2 89.8 78.9 85.1 
Proportion of outlets meeting screening criteria that were interviewed* 97.6 99.3 98.4 98.2 99.7 98.9 
Madagascar       
Number of outlets       
Outlet not screened 294 158 452 375 307 682 
Outlet did not meet screening criteria 3,376 751 4,127 5,237 1,950 7,187 
Outlet met screening criteria, but not interviewed 23 3 26 31 17 48 
Completed interview 1,554 1025 2,579 1,238 1,510 2,748 
Partially completed interview 27 10 37 13 45 58 
Response rate (%)       
Proportion of outlets enumerated that were screened 94.5 91.9 93.7 94.6 92.0 93.6 
Proportion of outlets meeting screening criteria that were interviewed* 98.6 99.7 99.0 97.6 98.9 98.3 
Niger       
Number of outlets       
Outlet not screened 2 5 7 13 236 249 
Outlet did not meet screening criteria 413 881 1,294 666 556 1,222 
Outlet met screening criteria, but not interviewed 10 54 64 18 18 36 
Completed interview 910 1470 2,380 1,093 940 2,033 
Partially completed interview 0 0 0 1 0 1 
Response rate (%)       
Proportion of outlets enumerated that were screened 99.9 99.8 99.8 99.3 86.5 93.0 
Proportion of outlets meeting screening criteria that were interviewed* 98.9 96.5 97.4 98.4 98.1 98.3 
Nigeria       
Number of outlets       
Outlet not screened 492 141 633 357 211 568 
Outlet did not meet screening criteria 2,348 898 3,246 4635 1737 6372 
Outlet met screening criteria, but not interviewed 3 1 4 3 2 5 
Completed interview 1,740 380 2,120 1048 490 1538 
Partially completed interview 73 13 86 20 4 24 
Response rate (%)       
Proportion of outlets enumerated that were screened 89.4 90.2 89.6 94.1 91.4 93.3 
Proportion of outlets meeting screening criteria that were interviewed* 99.8 99.7 99.8 99.7 99.6 99.7 
Tanzania – mainland       
Number of outlets       
Outlet not screened 20 11 31 52 25 77 
Outlet did not meet screening criteria 773 1637 2,410 1,883 1,027 2,910 
Outlet met screening criteria, but not interviewed 26 24 50 1 0 1 
Completed interview 320 311 631 584 201 785 
Partially completed interview 7 22 29 13 0 13 
Response rate (%)       
Proportion of outlets enumerated that were screened 98.3 99.5 99.0 97.9 98.0 98.0 
Proportion of outlets meeting screening criteria that were interviewed* 92.6 93.3 93.0 99.8 100.0 99.9 
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Table 2.1.2: Cont. 
Country/Final interview status BASELINE ENDLINE 
 Urban Rural Total Urban Rural Total 
Uganda       
Number of outlets       
Outlet not screened 29 187 216 117 197 314 
Outlet did not meet screening criteria 1,152 7,411 8,563 6,455 6,467 12,922 
Outlet met screening criteria, but not interviewed 23 56 79 36 22 58 
Completed interview 531 1,948 2,479 1,403 1,794 3,197 
Partially completed interview 17 15 32 20 10 30 
Response rate (%)       
Proportion of outlets enumerated that were screened 98.3 98.1 98.1 98.5 97.7 98.1 
Proportion of outlets meeting screening criteria that were interviewed* 96.0 97.2 96.9 97.5 98.8 98.2 
Zanzibar       
Number of outlets       
Outlet not screened 20 5 25 45 37 82 
Outlet did not meet screening criteria 921 988 1,909 2,008 1,839 3,847 
Outlet met screening criteria, but not interviewed 1 0 1 0 0 0 
Completed interview 195 125 320 237 131 368 
Partially completed interview 0 1 1 5 1 6 
Response rate (%)       
Proportion of outlets enumerated that were screened 98.2 99.6 98.9 98.0 98.2 98.1 
Proportion of outlets meeting screening criteria that were interviewed* 99.5 100.0 99.7 100.0 100.0 100.0 
Note: The number of outlets meeting the screening criteria is defined as the sum of the number of outlets stocking antimalarials at the time of the 
survey and the number of outlets without antimalarials in stock at the time of the survey, but which had antimalarials in stock at some time in the 
3 months preceding the survey. Note: Nigeria baseline data collection was conducted in 2009. 
* The response rate was calculated as the percentage of outlets where the final interview status was “Completed interview” or “Partially 
completed interview” among of all outlets meeting the screening criteria (Table 2.1.1 Column D divided by Column C). 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.1.3: Number of outlets enumerated by type of outlet and urban-rural location, according to country at baseline (2010) and endline (2011) 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban Rural Total 
CSD BS Total CSD BS Total CSD BS Total CSD BS Total CSD BS Total CSD BS Total 
Ghana – Total 396 252 648 470 123 593 866 375 1,241 350 279 629 269 195 464 619 474 1,093 
Public health facility 30 42 72 48 93 141 78 135 213 21 81 102 46 179 225 67 260 327 
Private not-for-profit health facility 6 0 6 9 0 9 15 0 15 4 0 4 9 0 9 13 0 13 
Private for-profit outlet                   
Health facility/pharmacy 139 210 349 37 30 67 176 240 416 103 198 301 11 16 27 114 214 328 
Drug store 218 0 218 367 0 367 585 0 585 217 0 217 195 0 195 412 0 412 
General retailer/itinerant 2 0 2 6 0 6 8 0 8 5 0 5 7 0 7 12 0 12 
Total 359 210 569 410 30 440 769 240 1,009 325 198 523 213 16 229 538 214 752 
Community health worker 1 0 1 3 0 3 4 0 4 0 0 0 1 0 1 1 0 1 
Kenya – Total 9,314 245 9,559 8,434 239 8673 17,748 484 18,232 7,360 286 7,646 5,470 257 5,727 12,830 543 13,373 
Public health facility 59 106 165 83 205 288 142 311 453 ,54 97 151 84 224 308 138 321 459 
Private not-for-profit health facility 34 0 34 18 0 18 52 0 52 23 0 23 30 0 30 53 0 53 
Private for-profit outlet                   
Health facility/pharmacy 451 139 590 141 34 175 592 173 765 314 189 503 117 33 150 431 222 653 
Drug store 363 0 363 205 0 205 568 0 568 384 0 384 181 0 181 565 0 565 
General retailer/itinerant 8,070 0 8,070 6,953 0 6,953 15,023 0 15,023 6,483 0 6,483 4,811 0 4,811 11,294 0 11,294 
Total 8,884 139 9,023 7,299 34 7,333 16,183 173 16,356 7,181 189 7,370 5,109 33 5,142 12,290 222 12,512 
Community health worker 337 0 337 1,034 0 1,034 1,371 0 1,371 102 0 102 247 0 247 349 0 349 
Madagascar – Total 5,212 65 5,277 1,226 718 1,944 6,438 783 7,221 6,828 66 6,894 2,861 968 3,829 9,689 1034 10,723 
Public health facility 46 33 79 45 475 520 91 508 599 41 31 72 61 605 666 102 636 738 
Private not-for-profit health facility 8 0 8 0 0 0 8 0 8 34 0 34 6 0 6 40 0 40 
Private for-profit outlet                   
Health facility/pharmacy 159 18 177 9 2 11 168 20 188 146 33 179 19 0 19 165 33 198 
Drug store 22 14 36 26 241 267 48 255 303 30 2 32 39 363 402 69 365 434 
General retailer/itinerant 4,918 0 4,918 971 0 971 5,889 0 5,889 6,342 0 6,342 2,142 0 2,142 8,484 0 8,484 
Total 5,099 32 5,131 1,006 243 1,249 6,105 275 6,380 6,518 35 6,553 2,200 363 2,563 8,718 398 9,116 
Community health worker 59 0 59 175 0 175 234 0 234 235 0 235 594 0 594 829 0 8,29 
Niger – Total 1,209 126 1,335 2,028 382 2,410 3,237 508 3,745 1,671 120 1,791 1,542 208 1,750 3,213 328 3541 
Public health facility 44 53 97 163 371 534 207 424 631 39 69 108 118 208 326 157 277 434 
Private not-for-profit health facility 5 0 5 0 0 0 5 0 5 2 0 2 1 0 1 3 0 3 
Private for-profit outlet                   
Health facility/pharmacy 43 73 116 3 11 14 46 84 130 51 51 102 4 0 4 55 51 106 
Drug store 15 0 15 8 0 8 23 0 23 17 0 17 3 0 3 20 0 20 
General retailer/itinerant 1,101 0 1,101 1850 0 1,850 2,951 0 2,951 1,562 0 1,562 1,414 0 1,414 2,976 0 2,976 
Total 1,159 73 1,232 1861 11 1,872 3,020 84 3,104 1,630 51 1,681 1,421 0 1,421 3,051 51 3,102 
Community health worker 1 0 1 4 0 4 5 0 5 0 0 0 2 0 2 2 0 2 
Nigeria – Total 4,615 39 4,654 1,435 0 1435 6,050 39 6,089 6,062 0 6,062 2,444 0 2,444 8,506 0 8,506 
Public health facility 239 15 254 83 0 83 322 15 337 54 0 54 78 0 78 132 0 132 
Private not-for-profit health facility 11 0 11 3 0 3 14 0 14 9 0 9 4 0 4 13 0 13 
Private for-profit outlet 4,356 24 4,380 1,333 0 1,333 5,689 24 5,713          
Health facility/pharmacy - - - - - - - - - 129 0 129 44 0 44 173 0 173 
Drug store - - - - - - - - - 959 0 959 442 0 442 1,401 0 1,401 
General retailer/itinerant - - - - - - - - - 4,907 0 4,907 1,864 0 1,864 6,771 0 6,771 
Total - - - - - - - - - 5,995 0 5,995 2,350 0 2,350 8,345 0 8,345 
Community health worker 9 0 9 16 0 16 25 0 25 4 0 4 12 0 12 16 0 16 
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Table 2.1.3: Cont.  
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban Rural Total 
CSD BS Total CSD BS Total CSD BS Total CSD BS Total CSD BS Total CSD BS Total 
Tanzania – mainland – Total 897 248 1,145 1,998 7 2,005 2,895 255 3,150 2,252 274 2526 1245 8 1253 3497 282 3779 
Public health facility 9 0 9 67 0 67 76 0 76 7 0 7 55 0 55 62 0 62 
Private not-for-profit health facility 7 0 7 20 0 20 27 0 27 6 0 6 2 0 2 8 0 8 
Private for-profit outlet                   
Health facility/pharmacy 22 248 270 10 7 17 32 255 287 73 274 347 8 8 16 81 282 363 
Drug store 99 0 99 172 0 172 271 0 271 281 0 281 128 0 128 409 0 409 
General retailer/itinerant 759 0 759 1,725 0 1,725 2,484 0 2,484 1,884 0 1884 1,052 0 1,052 2,936 0 2,936 
Total 880 248 1,128 1,907 7 1,914 2,787 255 3,042 2,238 274 2512 1,188 8 1,196 3,426 282 3708 
Community health worker 1 0 1 4 0 4 5 0 5 1 0 1 0 0 0 1 0 1 
Uganda – Total 1,360 392 1,752 8,934 683 9,617 10,294 1,075 11,369 7,612 419 8,031 7,975 515 8,490 15,587 934 16,521 
Public health facility 4 80 84 136 629 765 140 709 849 36 115 151 96 462 558 132 577 709 
Private not-for-profit health facility 5 0 5 31 0 31 36 0 36 14 0 14 30 0 30 44 0 44 
Private for-profit outlet                   
Health facility/pharmacy 115 312 427 373 54 427 488 366 854 602 304 906 388 53 441 990 357 1,347 
Drug store 79 0 79 929 0 929 1,008 0 1,008 477 0 477 838 0 838 1,315 0 1,315 
General retailer/itinerant 1,120 0 1,120 6,710 0 6,710 7,830 0 7,830 6,290 0 6,290 5,782 0 5,782 1,2072 0 12,072 
Total 1,314 312 1,626 8,012 54 8,066 9,326 366 9,692 7,369 304 7,673 7,008 53 7,061 1,4377 357 14,734 
Community health worker 37 0 37 755 0 755 792 0 792 193 0 193 841 0 841 1,034 0 1,034 
Zanzibar – Total 1,137 0 1,137 1,119 0 1,119 2,256 0 2256 2,295 0 2,295 2,008 0 2,008 4303 0 4,303 
Public health facility 65 0 65 87 0 87 152 0 152 71 0 71 93 0 93 164 0 164 
Private not-for-profit health facility 3 0 3 1 0 1 4 0 4 4 0 4 1 0 1 5 0 5 
Private for-profit outlet                   
Health facility/pharmacy 98 0 98 16 0 16 114 0 114 94 0 94 25 0 25 119 0 119 
Drug store 96 0 96 43 0 43 139 0 139 137 0 137 59 0 59 196 0 196 
General retailer/itinerant 875 0 875 972 0 972 1,847 0 1,847 1,989 0 1,989 1,830 0 1,830 3,819 0 3,819 
Total 1,069 0 1,069 1,031 0 1,031 2,100 0 2,100 2,220 0 2,220 1,914 0 1,914 4,134 0 4,134 
Community health worker 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Note: The number of outlets enumerated is taken from Table 2.1.1, Column A. Any differences from Table 2.1.1 are due to outlets for which the outlet type is unknown; Nigeria baseline data collection was 
conducted in 2009 
CSD: Censused Subdistrict, BS: Booster Sample 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys. 
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Table 2.1.4: Number of outlets with antimalarials in stock by type of outlet and urban-rural location, according to country at baseline (2010) and 
endline (2011) 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban Rural Total 
CSD BS Total CSD BS Total CSD BS Total CSD BS Total CSD BS Total CSD BS Total 
Ghana – Total 371 230 601 423 120 543 794 350 1,144 315 260 575 204 178 382 519 438 957 
Public health facility 27 41 68 45 90 135 72 131 203 19 75 94 41 163 204 60 238 298 
Private not-for-profit health facility 5 0 5 9 0 9 14 0 14 4 0 4 9 0 9 13 0 13 
Private for-profit outlet                   
Health facility/pharmacy 126 189 315 32 30 62 158 219 377 87 185 272 11 15 26 98 200 298 
Drug store 211 0 211 331 0 331 542 0 542 202 0 202 140 0 140 342 0 342 
General retailer/itinerant 2 0 2 3 0 3 5 0 5 3 0 3 3 0 3 6 0 6 
Total 339 189 528 366 30 396 705 219 924 292 185 477 154 15 169 446 200 646 
Community health worker 0 0 0 3 0 3 3 0 3 0 0 0 0 0 0 0 0 0 
Kenya – Total 843 196 1,039 655 222 877 1,498 418 1,916 791 261 1,052 558 245 803 1,349 506 1,855 
Public health facility 41 96 137 67 192 259 108 288 396 44 93 137 78 216 294 122 309 431 
Private not-for-profit health facility 23 0 23 15 0 15 38 0 38 19 0 19 27 0 27 46 0 46 
Private for-profit outlet                   
Health facility/pharmacy 264 100 364 73 30 103 337 130 467 243 168 411 84 29 113 327 197 524 
Drug store 272 0 272 156 0 156 428 0 428 329 0 329 145 0 145 474 0 474 
General retailer/itinerant 239 0 239 323 0 323 562 0 562 156 0 156 224 0 224 380 0 380 
Total 775 100 875 552 30 582 1,327 130 1,457 728 168 896 453 29 482 1,181 197 1,378 
Community health worker 4 0 4 21 0 21 25 0 25 0 0 0 0 0 0 0 0 0 
Madagascar – Total 1,387 60 1,447 346 621 967 1,733 681 2,414 925 57 982 572 817 1,389 1,497 874 2,371 
Public health facility 38 30 68 31 415 446 69 445 514 39 26 65 49 504 553 88 530 618 
Private not-for-profit health facility 6 0 6 0 0 0 6 0 6 26 0 26 5 0 5 31 0 31 
Private for-profit outlet                   
Health facility/pharmacy 110 16 126 7 2 9 117 18 135 76 29 105 12 0 12 88 29 117 
Drug store 14 14 28 24 204 228 38 218 256 26 2 28 34 313 347 60 315 375 
General retailer/itinerant 1,217 0 1,217 246 0 246 1,463 0 1,463 743 0 743 406 0 406 1,149 0 1,149 
Total 1,341 30 1,371 277 206 483 1,618 236 1,854 845 31 876 452 313 765 1,297 344 1,641 
Community health worker 2 0 2 38 0 38 40 0 40 15 0 15 66 0 66 81 0 81 
Niger – Total 712 121 833 910 288 1,198 1,622 409 2,031 809 115 924 593 145 738 1,402 260 1,662 
Public health facility 39 52 91 107 278 385 146 330 476 35 67 102 75 145 220 110 212 322 
Private not-for-profit health facility 4 0 4 0 0 0 4 0 4 2 0 2 1 0 1 3 0 3 
Private for-profit outlet                   
Health facility/pharmacy 37 69 106 2 10 12 39 79 118 47 48 95 4 0 4 51 48 99 
Drug store 14 0 14 7 0 7 21 0 21 15 0 15 3 0 3 18 0 18 
General retailer/itinerant 617 0 617 792 0 792 1,409 0 1,409 710 0 710 510 0 510 1,220 0 1,220 
Total 668 69 737 801 10 811 1,469 79 1,548 772 48 820 517 0 517 1,289 48 1,337 
Community health worker 1 0 1 2 0 2 3 0 3 0 0 0 0 0 0 0 0 0 
Nigeria – Total 1,726 23 1,749 364 0 364 2,090 23 2,113 1,032 0 1,032 472 0 472 1,504 0 1,504 
Public health facility 174 9 183 45 0 45 219 9 228 43 0 43 52 0 52 95 0 95 
Private not-for-profit health facility 7 0 7 2 0 2 9 0 9 6 0 6 3 0 3 9 0 9 
Private for-profit outlet                   
Health facility/pharmacy 723 14 737 24 0 24 747 14 761 99 0 99 32 0 32 131 0 131 
Drug store 722 0 722 268 0 268 990 0 990 807 0 807 362 0 362 1,169 0 1,169 
General retailer/itinerant 94 0 94 19 0 19 113 0 113 74 0 74 19 0 19 93 0 93 
Total 1,539 14 1,553 311 0 311 1,850 14 1,864 980 0 980 413 0 413 1,393 0 1,393 
Community health worker 6 0 6 6 0 6 12 0 12 3 0 3 4 0 4 7 0 7 
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Table 2.1.4: Cont. 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban Rural Total 
CSD BS Total CSD BS Total CSD BS Total CSD BS Total CSD BS Total CSD BS Total 
Tanzania – mainland – Total 118 206 324 300 6 306 418 212 630 341 255 596 183 8 191 524 263 787 
Public health facility 5 0 5 56 0 56 61 0 61 7 0 7 48 0 48 55 0 55 
Private not-for-profit health facility 6 0 6 17 0 17 23 0 23 4 0 4 2 0 2 6 0 6 
Private for-profit outlet                   
Health facility/pharmacy 18 206 224 6 6 12 24 212 236 66 255 321 8 8 16 74 263 337 
Drug store 88 0 88 149 0 149 237 0 237 259 0 259 113 0 113 372 0 372 
General retailer/itinerant 1 0 1 71 0 71 72 0 72 5 0 5 12 0 12 17 0 17 
Total 107 206 313 226 6 232 333 212 545 330 255 585 133 8 141 463 263 726 
Community health worker 0 0 0 1 0 1 1 0 1 0 0 0 0 0 0 0 0 0 
Uganda – Total 187 357 544 1,253 623 1,876 1,440 980 2,420 1,028 388 1,416 1,225 497 1,722 2,253 885 3,138 
Public health facility 4 72 76 119 574 693 123 646 769 32 112 144 89 445 534 121 557 678 
Private not-for-profit health facility 4 0 4 27 0 27 31 0 31 13 0 13 28 0 28 41 0 41 
Private for-profit outlet                   
Health facility/pharmacy 104 285 389 307 49 356 411 334 745 541 276 817 336 52 388 877 328 1,205 
Drug store 72 0 72 752 0 752 824 0 824 436 0 436 676 0 676 1,112 0 1,112 
General retailer/itinerant 2 0 2 19 0 19 21 0 21 4 0 4 14 0 14 18 0 18 
Total 178 285 463 1,078 49 1,127 1,256 334 1,590 981 276 1,257 1,026 52 1078 2007 328 2,335 
Community health worker 1 0 1 29 0 29 30 0 30 2 0 2 82 0 82 84 0 84 
Zanzibar – Total 189 0 189 124 0 124 313 0 313 222 0 222 120 0 120 342 0 342 
Public health facility 56 0 56 83 0 83 139 0 139 48 0 48 76 0 76 124 0 124 
Private not-for-profit health facility 2 0 2 1 0 1 3 0 3 1 0 1 1 0 1 2 0 2 
Private for-profit outlet                   
Health facility/pharmacy 73 0 73 11 0 11 84 0 84 82 0 82 16 0 16 98 0 98 
Drug store 57 0 57 25 0 25 82 0 82 88 0 88 24 0 24 112 0 112 
General retailer/itinerant 1 0 1 4 0 4 5 0 5 3 0 3 3 0 3 6 0 6 
Total 131 0 131 40 0 40 171 0 171 173 0 173 43 0 43 216 0 216 
Community health worker 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Note: Number of outlets with antimalarials in stock is taken from Table 2.1.1, Column E. Any differences from Table 2.1.1 are due to outlets for which the outlet type is unknown. An interview was conducted if the 
final interview status for an outlet was “Completed interview” or “Partially completed interview.” ‘Outlets with antimalarials in stock’ form the denominator for all subsequent tables, unless specified otherwise. Any 
variation in the stated denominator in subsequent tables is due to missing data on specific variables; Nigeria baseline data collection was conducted in 2009. 
CSD: Censused Subdistrict, BS: Booster Sample 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys  
82 
 
2.1.2  Characteristics of the outlets 
Table 2.1.5 shows the breakdown of outlets stocking antimalarials by outlet type. At endline 
across all pilots, private for-profit outlets made up over 75% of outlets stocking antimalarials, 
except for Zanzibar (63%). The public sector share of outlets stocking antimalarials was under 
20% in all countries other than Zanzibar (36%). Community health workers did not make up a 
substantial percentage of outlets stocking antimalarials except in Madagascar and Uganda (13% 
and 9%, respectively). The structure of the market in terms of the breakdown of outlets stocking 
antimalarials did not change substantially between baseline and endline surveys, except in 
Zanzibar where a 10 percentage point increase for private for-profit outlets was seen. 
 
Table 2.1.6 shows the breakdown of private for-profit outlets stocking antimalarials by outlet 
type, which varied considerably across the pilots. In Ghana, Nigeria, Tanzania mainland, Uganda 
and Zanzibar, drug stores were the most numerous type of private for-profit outlet, making up 
between 52% and 87% of outlets at endline. In Kenya, the market structure of private for-profit 
outlets was relatively evenly split with private pharmacies/health facilities accounting for 21%, 
drug stores 37% and general retailers 38%. In Niger and Madagascar, general stores were the 
most common type of private for-profit outlet (70% and 89%, respectively). Almost all the 
remainder of Niger’s private for-profit outlets were itinerant vendors, which accounted for 28% 
of private for-profit outlets stocking antimalarials at endline. For private for-profit outlets, the 
structure of the antimalarial market in most pilots did not change substantially between baseline 
and endline. However, in mainland Tanzania, an increase of over 17 percentage points in the 
percentage of drug stores and a corresponding 22 percentage point decline in that of general 
retailers with antimalarials in stock was seen, principally driven by changes in urban areas. In 
Ghana, there was a 12 percentage point decline in the number of drug stores with antimalarials 
and an 11 percentage point increase in private pharmacies and health facilities with antimalarials 
were seen between baseline and endline, although the overall patterns are different from those 
seen within urban and rural areas. The Ghanaian Data Contributor reported that this reflected the 
fact that rural districts in the endline sample were less densely populated.  
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Table 2.1.5: Breakdown of outlets stocking antimalarials by outlet type at baseline (2010) and endline (2011) 
Breakdown of outlets with any antimalarials in stock at the time of the survey visit by outlet type, by urban-rural location, according to country 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N 
Ghana - Total 100.0 321 100 412 100.0 733 100.0 303 100.0 191 100.0 494 
Public health facility  7.2 (5.0-10.2)  11.0 (9.0-13.4)  10.4 (8.6-12.4)  4.8 (2.7-8.3)  19.5 (14.5-25.7)  10.1 (7.5-13.6)  
Private not-for-profit health facility 1.4 (0.6-3.1)  1.7 (0.9-3.2)  1.6 (0.9-2.9)  1.7 (0.8-3.7)  3.7 (1.9-7.2)  2.5 (1.5-4.1)  
Private for-profit outlet 91.5 (88.0-94.0)  86.8 (84.1-89.1)  87.6 (85.3-89.5)  93.5 (89.6-96)  76.7 (71.4-81.3)  87.4 (83.9-90.3)  
Community health worker -  0.5 (0.1-2.6)  0.4 (0.1-2.2)  -  -  -  
Kenya - Total 100.0 771 100.0 594 100.0 1,365 100.0 752 100.0 543 100.0 1,295 
Public health facility  5.6 (3.9-7.9)  13.6 (9.3-19.3)  11.8 (8.6-15.9)  4.4 (2.9-6.6)  17.5 (13.5-22.4)  13.9 (11.0-17.5)  
Private not-for-profit health facility 3.2 (2.1-4.9)  2.5 (1.5-4.2)  2.7 (1.8-3.9)  2.2 (1.2-4.1)  4.2 (2.5-6.9)  3.6 (2.4-5.6)  
Private for-profit outlet 90.8 (87.8-93.1)  79.5 (68.9-87.2)  82.1 (74.1-88.0)  93.4 (90.6-95.4)  78.3 (72.9-82.9)  82.5 (78.5-85.8)  
Community health worker 0.4 (0.1-1.4)  4.4 (1.2-14.7)  3.5 (1.0-11.4)  -  -  -  
Madagascar - Total 100.0 1,235 100.0 324 100.0 1,559 100.0 836 100.0 530 100.0 1,366 
Public health facility  4.0 (2.3-6.7)  8.5 (6.5-11.1)  7.8 (6.1-9.9)  5.1 (3.9-6.6)  10.0 (7.8-12.7)  9.4 (7.5-11.7)  
Private not-for-profit health facility 0.3 (0.2-0.6)  -  0.1 (0.0-0.1)  3.4 (2.4-4.8)  0.8 (0.3-2.0)  1.1 (0.6-2.0)  
Private for-profit outlet 95.6 (92.7-97.3)  79.6 (68.8-87.3)  82.1 (72.7-88.8)  89.0 (85.4-91.8)  75.2 (65.1-83.2)  76.9 (68.0-83.9)  
Community health worker 0.1 (0.0-0.4)  11.9 (4.8-26.5)  10.0 (4.0-22.9)  2.5 (1.1-5.6)  14.0 (7.6-24.4)  12.6 (7.0-21.7)  
Niger - Total 100.0 558 100.0 755 100.0 1,313 100.0 686 100.0 499 100.0 1,180 
Public health facility  6.3 (4.3-9.2)  12.7 (9.6-16.6)  11.5 (8.9-14.6)  4.6 (2.9-7.2)  12.6 (10.3-15.3)  10.4 (8.7-12.4)  
Private not-for-profit health facility 0.5 (0.2-1.6)  -  0.1 (0.0-0.3)  0.1 (0.0-0.6)  0.2 (0.0-1.1)  0.2 (0.1-0.8)  
Private for-profit outlet 93.2 (90.2-95.3)  87.2 (83.2-90.3)  88.3 (85.2-90.9)  95.2 (92.7-96.9)  87.2 (84.5-89.5)  89.4 (87.4-91.1)  
Community health worker -  0.1 (0.0-1.0)  0.1 (0.0-0.8)  -  -  -  
Nigeria - Total 100.0 1,630 100.0 353 100.0 1,983 100.0 982 100.0 456 100.0 1,438 
Public health facility  0.3 (0.2-0.5)  16.5 (10.7-24.6)  3.5 (1.9-6.2)  3.3 (2.4-4.7)  10.4 (6.8-15.6)  6.2 (4.5-8.4)  
Private not-for-profit health facility -  0.4 (0.1-1.8)  0.1 (0.0-0.4)  1.0 (0.4-2.5)  0.9 (0.2-3.2)  1.0 (0.5-2.1)  
Private for-profit outlet 99.1 (97.8-99.7)  80.2 (70.5-87.3)  95.4 (92.2-97.3)  95.7 (93.6-97.1)  88.0 (83.2-91.6)  92.6 (90.2-94.4)  
Community health worker 0.6 (0.1-2.2)  2.9 (1.0-8.6)  1.0 (0.4-2.5)  0.0 (0.0-0.1)  0.6 (0.2-2.5)  0.3 (0.1-1.1)  
Tanzania – mainland - Total 100.0 117 100 280 100.0 397 100.0 329 100.0 180 100.0 509 
Public health facility  4.4 (2.3-8.3)  22.1 (16.8-28.5)  17.5 (13.5-22.4)  2 (0.9-4.2)  28.1 (21.3-36.1)  18.3 (13.6-24.1)  
Private not-for-profit health facility 4.4 (1.4-12.8)  5.6 (3.4-9.1)  5.3 (3.3-8.3)  1.5 (0.7-3.5)  0.8 (0.2-3.4)  1.1 (0.5-2.4)  
Private for-profit outlet 91.1 (83.7-95.4)  72.0 (66.2-77.1)  77.0 (72.2-81.2)  96.5 (93.7-98.0)  71.1 (63.2-77.9)  80.6 (74.9-85.3)  
Community health worker -  0.3 (0.0-2.2)  0.2 (0.0-1.6)  -  -  -  
Uganda – Total 100.0 174 100.0 1,205 100.0 1,379 100.0 1,011 100.0 1,202 100.0 2,213 
Public health facility  2.2 (0.5-8.6)  12.1 (9.2-15.8)  10.2 (7.4-14)  3.3 (1.3-8.4)  9.4 (6.8-12.7)  8.2 (6.0-11.1)  
Private not-for-profit health facility 2.2 (1.6-3.1)  2.9 (1.4-5.7)  2.7 (1.5-4.9)  1.0 (0.5-2.0)  2.5 (1.6-3.9)  2.2 (1.5-3.4)  
Private for-profit outlet 95.1 (90.5-97.6)  80.5 (71.9-86.9)  83.3 (75.4-89.0)  95.4 (90.0-98.0)  76.7 (63.9-86.0)  80.5 (69.3-88.3)  
Community health worker 0.5 (0.1-1.5)  4.5 (0.9-19.6)  3.7 (0.8-16.3)  0.2 (0.0-0.8)  11.4 (3.9-28.9)  9.1 (3.1-24.1)  
Zanzibar – Total 100.0 141 100.0 110 100.0 251 100.0 220 100.0 116 100.0 336 
Public health facility  28.4  66.4  45.0  21.8  63.8  36.3  
Private not-for-profit health facility 1.4  0.9  1.2  -  0.9  0.3  
Private for-profit outlet 70.2  32.7  53.8  78.2  35.3  63.4  
Community health worker -  -  -  -  -  -  
Note: Nigeria baseline data collection was conducted in 2009. CI = Confidence interval 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.1.6: Breakdown of private for-profit outlets stocking antimalarials by outlet type at baseline (2010) and endline (2011) 
Breakdown of private for-profit outlets with any antimalarials in stock at the time of the survey visit by private for-profit outlet type, by urban-rural location, according to country 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N 
Ghana – Total private for-profit 100.0 294 100.0 359 100.0 653 100.0 281 100.0 148 100.0 429 
Health facility 11.8 (6.4-20.8)  3.9 (2.7-5.5)  5.2 (3.7-7.3)  5.0 (3.1-8.0)  5.8 (3.2-10.3)  5.3 (3.6-7.6)  
Pharmacy 26.2 (19.4-34.3)  4.6 (2.4-8.8)  8.3 (5.8-11.7)  27.3 (18.7-38.1)  1.2 (0.2-6.5)  19.0 (12.3-28.3)  
Drug store 61.4 (47.5-73.7)  90.6 (86.6-93.5)  85.6 (81.3-89.1)  66.7 (56.8-75.3)  90.8 (85.7-94.2)  74.3 (66.1-81.1)  
General retailer 0.3 (0.1-1.5)  -  0.1 (0.0-0.2)  0.7 (0.2-2.3)  2.1 (0.6-7.2)  1.2 (0.5-2.9)  
Itinerant 0.3 (0.1-1.1)  0.9 (0.3-3.0)  0.8 (0.3-2.5)  0.3 (0.1-1.2)  -  0.2 (0.0-0.8)  
Kenya – Total private for-profit 100.0 708 100.0 496 100.0 1,204 100.0 693 100.0 438 100.0 1,131 
Health facility 22.3 (18.2-27.0)  12.7 (7.1-21.8)  15.1 (10.1-22.0)  24.4 (19.4-30.2)  20.1 (13.4-28.9)  21.4 (16.5-27.3)  
Pharmacy 10.7 (7.0-16.0)  0.4 (0.1-1.9)  3.0 (1.7-5.2)  6.4 (4.0-10.3)  2.8 (1.0-7.9)  4.0 (2.3-6.8)  
Drug store 34.3 (26.0-43.7)  40.4 (21.8-62.3)  38.9 (24.1-56.1)  47.1 (39.9-54.3)  31.9 (24.7-40.1)  36.6 (30.5-43.2)  
General retailer 32.7 (25.2-41.2)  46.2 (29.8-63.5)  42.8 (30.8-55.8)  22.1 (14.6-31.9)  45.2 (32.8-58.2)  38.0 (29.2-47.6)  
Itinerant -  0.2 (0.0-1.3)  0.1 (0.0-1.0)  -  -  -  
Madagascar – Total private for-profit 100.0 1,190 100.0 261 100.0 1,451 100.0 760 100.0 411 100.0 1,171 
Health facility 5.4 (3.9-7.5)  2.6 (1.2-5.6)  3.1 (1.8-5.5)  3.8 (2.7-5.4)  2.4 (1.2-4.9)  2.6 (1.5-4.6)  
Pharmacy 3.4 (2.6-4.3)  -  0.6 (0.4-1.0)  6.0 (3.5-10.0)  0.1 (0.0-0.7)  0.9 (0.5-1.6)  
Drug store 1.8 (0.7-4.9)  7.1 (3.9-12.7)  6.1 (3.5-10.6)  5.8 (2.5-13.3)  7.8 (5.2-11.6)  7.5 (5.2-10.8)  
General retailer 89.4 (85.6-92.2)  90.3 (83.3-94.5)  90.1 (84.6-93.8)  84.4 (78-89.2)  89.7 (85.5-92.7)  88.9 (85.3-91.7)  
Itinerant -  -  -  -  -  -  
Niger – Total private for-profit 100.0 518 100.0 660 100.0 1,178 100.0 656 100.0 432 100.0 1,086 
Health facility 1.9 (0.9-4.1)  -  0.4 (0.2-0.8)  3.1 (2.3-4.2)  0.1 (0.0-0.6)  1.0 (0.7-1.4)  
Pharmacy 3.9 (2.4-6.3)  -  0.8 (0.5-1.2)  2.7 (1.8-4.0)  -  0.8 (0.5-1.2)  
Drug store 2.2 (0.9-5.2)  0.7 (0.2-2.2)  1.0 (0.5-2.2)  1.4 (0.8-2.4)  0.7 (0.3-1.8)  0.9 (0.5-1.6)  
General retailer 48.2 (38.3-58.2)  72.0 (66.7-76.7)  67.2 (62.1-71.9)  60.3 (52.7-67.4)  73.7 (67.3-79.3)  69.8 (64.8-74.3)  
Itinerant 43.7 (33.2-54.9)  27.3 (22.6-32.5)  30.6 (26.0-35.6)  32.6 (26.1-39.7)  25.4 (19.8-32.0)  27.5 (23.0-32.5)  
Nigeria – Total private for-profit 100.0 1,452 100.0 304 100.0 1,756 100.0 932 100.0 402 100.0 1,334 
Health facility 0.5 (0.3-0.8)  7.0 (3.2-14.8)  1.6 (0.7-3.4)  5.1 (2.7-9.5)  8.5 (5.7-12.5)  6.4 (4.2-9.6)  
Pharmacy 0.5 (0.3-0.9)  0.1 (0.0-0.8)  0.5 (0.3-0.8)  3.2 (1.4-7.1)  0.2 (0.0-1.4)  2.0 (0.9-4.5)  
Drug store 88.0 (81.5-92.4)  79.9 (68.9-87.7)  86.7 (81.1-90.8)  85.9 (79.4-90.6)  87.7 (83.1-91.2)  86.6 (82.4-89.9)  
General retailer 9.7 (5.5-16.6)  11.3 (6.4-19.2)  10.0 (6.3-15.6)  3.6 (1.9-6.5)  2.9 (1.3-6.5)  3.3 (2.0-5.4)  
Itinerant 1.3 (0.3-5.2)  1.7 (0.4-6.1)  1.3 (0.4-4.2)  2.3 (0.4-11.0)  0.7 (0.2-2.6)  1.7 (0.4-6.7)  
Tanzania – mainland – Total private for-profit 100.0 107 100.0 211 100.0 318 100.0 319 100.0 131 100.0 450 
Health facility 4.3 (1.1-15.6)  1.4 (0.4-4.4)  2.3 (0.9-5.6)  7.5 (5.2-10.5)  3.5 (1.1-10.4)  5.3 (3.3-8.5)  
Pharmacy 18.4 (5.4-47.1)  0.4 (0.1-2.6)  5.9 (1.5-20.8)  13.5 (5.9-28)  2.2 (0.8-5.8)  7.3 (3.4-15.0)  
Drug store 76.6 (53.1-90.4)  58.2 (41.5-73.2)  63.9 (50.4-75.5)  78.0 (64.7-87.3)  84.4 (64.9-94.0)  81.5 (70.3-89.1)  
General retailer 0.7 (0.1-4.8)  40.0 (24.9-57.3)  27.9 (16.5-43.1)  1.0 (0.4-2.5)  9.9 (2.0-36.7)  5.9 (1.4-22.0)  
Itinerant -  -  -  -  -  -  
Uganda – Total private for-profit 100.0 166 100.0 1,032 100.0 1,198 100.0 966 100.0 1,007 100.0 1,973 
Health facility 55.3 (31.5-76.9)  17.7 (10.2-29.1)  25.9 (15.4-40.2)  50.5 (30.2-70.6)  21.5 (12.8-33.8)  28.4 (18.5-40.9)  
Pharmacy 1.9 (1.0-3.5)  0.9 (0.3-2.8)  1.1 (0.5-2.4)  6.2 (3.6-10.4)  0.7 (0.3-1.6)  2.0 (1.2-3.3)  
Drug store 41.3 (21.1-65.1)  79.6 (67.7-87.9)  71.3 (57.0-82.3)  42.8 (24.4-63.4)  75.3 (63.9-84)  67.6 (55.4-77.8)  
General retailer 1.4 (0.4-5.1)  1.3 (0.6-2.7)  1.3 (0.7-2.5)  0.5 (0.2-1.2)  2.6 (0.8-7.9)  2.1 (0.7-6.0)  
Itinerant -  0.4 (0.1-3.2)  0.4 (0.0-2.6)  -  -  -  
Zanzibar – Total private for-profit 100.0 99 100.0 36 100.0 135 100.0 172 100.0 41 100.0 213 
Health facility 41.4  30.6  38.5  32.0  31.7  31.9  
Pharmacy 16.2  -  11.9  15.7  4.9  13.6  
Drug store 41.4  58.3  45.9  50.6  56.1  51.6  
General retailer 1.0  11.1  3.7  1.7  7.3  2.8  
Itinerant -  -  -  -  -  -  
Note: Nigeria baseline data collection was conducted in 2009. CI = Confidence interval 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.1.7 shows the mean number of outlets stocking antimalarials per 100,000 population for 
each pilot, a measure of the density of different outlet types, which can be interpreted as a proxy 
for their accessibility. At endline, the mean number of outlets of all types stocking antimalarials 
varied from 54 per 100,000 people in Tanzania mainland to 513 per 100,000 people in Nigeria. 
For public health facilities, the mean number with antimalarials in stock varied from 7 per 
100,000 in Ghana to 29 per 100,000 in Nigeria. In all pilots, private for-profit outlets stocking 
antimalarials were much more numerous than public outlets, ranging from 42 per 100,000 in 
mainland Tanzania to over 10 times as many, 478 per 100,000, in Nigeria. Countries also differ 
in terms of the relative density of different outlet types within the private for-profit sector, with a 
greater density of drug stores in Ghana, Nigeria, Tanzania and Uganda, and greater density of 
general retailers and itinerant vendors in Madagascar and Niger. In Kenya, the number of drug 
stores and general retailers stocking antimalarials was very similar. In no countries were 
pharmacies/health facilities the most common type of private for-profit outlet stocking 
antimalarials. Overall, there were no substantial changes in the density of outlets between 
baseline and endline, although in Niger there was a 26% decline in the mean number of itinerant 
vendors stocking antimalarials, to about 120 per 100,000.  
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Table 2.1.7: Mean number of outlets with antimalarials in stock per 100,000 population at baseline (2010) and endline 
(2011) 
Mean number of outlets with any antimalarials in stock at the time of the survey visit per 100,000 population, by urban-rural 
location and type of outlet, according to country 
Country/Type of outlet 
Baseline Endline 
Urban Rural Total Urban Rural Total 
Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) 
Ghana – Total 49.9 (42.6-57.1) 71.8 (64.6-78.9) 66.5 (60.8-72.3) 86.9 (64.1-109.7) 46.3 (38.7-53.9) 65.4 (53.9-77.0) 
Public health facility  3.7 (2.4-5.0) 8.0 (6.4-9.6) 7.0 (5.7-8.2) 4.3 (2.4-6.3) 9.9 (7.7-12.2) 7.3 (5.7-8.8) 
Private not-for-profit health 
facility 
0.9 (0.2-1.5) 1.4 (0.6-2.2) 1.3 (0.6-1.9) 1.4 (0.4-2.5) 2.0 (0.7-3.4) 1.8 (0.9-2.6) 
Private for-profit outlet 
      
Health facility/pharmacy 23.8 (16.0-31.5) 4.9 (2.9-6.9) 9.4 (6.8-12.1) 26.5 (12.7-40.3) 2.2 (1.0-3.4) 13.7 (6.9-20.4) 
Drug store 21.3 (14.2-28.4) 56.4 (50.4-62.3) 48.0 (42.9-53.1) 53.8 (40.7-67.0) 31.4 (24.7-38.1) 42.0 (34.9-49.1) 
General retailer/itinerant 0.2 (0.0-0.5) 0.6 (-0.1-1.3) 0.5 (0.0-1.1) 0.8 (0.1-1.4) 0.7 (-0.2-1.7) 0.8 (0.2-1.4) 
Total 45.3 (38.1-52.5) 61.9 (55.3-68.5) 57.9 (52.6-63.2) 81.2 (57.9-104.4) 34.3 (26.9-41.7) 56.4 (44.6-68.2) 
Community health worker - 0.5 (-0.1-1.1) 0.4 (-0.1-0.9) - - - 
Kenya – Total 142.9 (113.4-172.5) 153.3 (82.9-223.8) 152.0 (90.5-213.4) 159.2 (112.9-205.5) 106.8 (68.2-145.4) 114.4 (80.7-148.1) 
Public health facility  8.5 (4.6-12.4) 22.8 (13.9-31.7) 20.9 (13.0-28.8) 7.7 (4.7-10.8) 20.9 (16.1-25.6) 19.0 (14.7-23.3) 
Private not-for-profit health 
facility 
5.5 (2.6-8.3) 3.5 (0.0-7.0) 3.8 (0.7-6.8) 5.0 (1.4-8.6) 3.2 (1.3-5.2) 3.5 (1.8-5.2) 
Private for-profit outlet 
      
Health facility/pharmacy 42.3 (27.0-57.5) 15.2 (3.4-27.1) 18.8 (8.3-29.2) 44.5 (30.5-58.5) 23.7 (1.5-46.0) 26.8 (7.7-45.8) 
Drug store 39.0 (25.7-52.3) 55.4 (-4.6-115.4) 53.2 (0.9-105.5) 64.6 (34.6-94.6) 26.5 (12.3-40.8) 32.0 (18.9-45.1) 
General retailer/itinerant 47.1 (28.2-66.1) 45.6 (31.0-60.3) 45.8 (32.8-58.8) 37.4 (18.5-56.3) 32.4 (19.5-45.3) 33.1 (21.7-44.5) 
Total 128.4 (101.6-155.2) 116.2 (50.5-182.0) 117.8 (60.5-175.1) 146.5 (101.4-191.6) 82.7 (45.7-119.7) 91.9 (59.5-124.3) 
Community health worker 0.5 (-0.2-1.3) 10.8 (-3.2-24.7) 9.5 (-2.7-21.7) - - - 
Madagascar – Total 281.9 (195.7-368.1) 171.9 (113.4-230.3) 177.0 (122.1-231.8) 155.6 (124.8-186.3) 121.9 (95.4-148.5) 123.7 (98.7-148.8) 
Public health facility  13.3 (6.6-20) 15.4 (10.7-20.2) 15.3 (10.8-19.9) 9.0 (7.1-10.9) 12.6 (8.8-16.4) 12.4 (8.8-16.1) 
Private not-for-profit health 
facility 
0.5 (0.1-0.9) - 0.02 (0.006-0.04) 6.0 (3.8-8.2) 0.7 (-0.2-1.7) 1.0 (0.1-1.9) 
Private for-profit outlet 
      
Health facility/pharmacy 24.3 (18.7-30.0) 2.3 (0.4-4.3) 3.4 (1.3-5.4) 13.6 (7.4-19.9) 1.8 (0.2-3.4) 2.4 (0.8-4.0) 
Drug store 11.9 (-0.6-24.3) 5.8 (1.5-10.2) 6.1 (1.9-10.3) 10.6 (1.1-20.0) 5.5 (2.6-8.4) 5.8 (3.0-8.6) 
General retailer/itinerant 231.7 (139.7-323.7) 130.6 (72.4-188.9) 135.3 (80.6-190.0) 112.3 (81.9-142.6) 76.3 (50.1-102.6) 78.2 (53.2-103.3) 
Total 267.9 (178.6-357.2) 138.8 (83.8-193.8) 144.8 (93.5-196.1) 136.5 (107.5-165.4) 83.6 (55.6-111.7) 86.5 (59.6-113.3) 
Community health worker 0.2 (-0.1-0.5) 17.6 (-3.0-38.3) 16.8 (-2.9-36.5) 4.1 (1.0-7.2) 24.9 (-0.3-50.1) 23.8 (-0.2-47.9) 
Niger – Total 197.7 (160.3-235.1) 162.9 (137.0-188.8) 168.8 (146.4-191.3) 195.0 (173.5-216.5) 124.9 (109.5-140.3) 138.6 (125.5-151.8) 
Public health facility  10.5 (7.1-13.9) 19.7 (15.9-23.4) 18.1 (14.9-21.3) 9.3 (5.5-13.2) 15.2 (12.5-17.8) 14.0 (11.8-16.3) 
Private not-for-profit health 
facility 
0.8 (0.0-1.6) - 0.1 (0.0-0.3) 0.5 (0.0-1.0) 0.2 (-0.2-0.6) 0.3 (0.0-0.6) 
Private for-profit outlet 
      
Health facility/pharmacy 10.0 (6.8-13.1) 0.4 (-0.1-0.8) 2.0 (1.3-2.7) 11.6 (8.6-14.7) 0.7 (-0.3-1.8) 2.9 (1.8-4.0) 
Drug store 3.3 (0.5-6.1) 1.2 (0.1-2.3) 1.6 (0.6-2.6) 2.2 (1.0-3.3) 0.7 (0.1-1.3) 1.0 (0.4-1.5) 
General retailer/itinerant 172.9 (135.6-210.2) 141.3 (115.1-167.5) 146.7 (124.0-169.4) 171.3 (151.6-191.1) 108.0 (93.3-122.8) 120.5 (107.9-133.0) 
Total 186.2 (149.2-223.2) 142.9 (116.9-168.9) 150.3 (127.8-172.8) 185.1 (163.4-206.9) 109.5 (94.5-124.4) 124.3 (111.5-137.1) 
Community health worker 0.2 (-0.2-0.7) 0.3 (-0.1-0.8) 0.3 (-0.1-0.7) - - - 
Nigeria – Total - - - 1,701.5 (959.9-2,443.2) 183.7 (106.0-261.5) 513.0 (302.9-723.2) 
Public health facility  - - - 54.1 (23.4-84.8) 21.7 (11.9-31.6) 28.7 (18.3-39.2) 
Private not-for-profit health 
facility 
- - - 17.2 (-0.6-35.0) 2.0 (-0.9-4.8) 5.3 (0.6-9.9) 
Private for-profit outlet 
      
Health facility/pharmacy - - - 158.0 (82.2-233.9) 17.1 (4.0-30.2) 47.7 (25.6-69.8) 
Drug store - - - 1,363.2 (707.8-2,018.5) 136.0 (72.9-199.0) 402.2 (222.0-582.4) 
General retailer/itinerant - - - 109.0 (33.7-184.3) 5.7 (0.4-11.1) 28.1 (9.7-46.5) 
Total - - - 1,630.2 (919.2-2,341.3) 158.8 (86.0-231.6) 478.0 (276.1-679.9) 
Community health worker - - - 0.01 (-0.01-0.04) 1.3 (-1.1-3.7) 1.0 (-0.9-2.9) 
Tanzania - mainland – Total 103.3 (37.9-168.7) 56.9 (43.0-70.7) 63.6 (47.2-79.9) 109.7 (71.9-147.4) 42.8 (29.3-56.4) 54.2 (39.8-68.5) 
Public health facility  6.3 (0.2-12.4) 14.4 (10.8-18.0) 13.2 (10.0-16.5) 2.5 (0.8-4.3) 13.4 (9.0-17.7) 11.5 (7.9-15.1) 
Private not-for-profit health 
facility 
3.0 (-0.9-7.0) 3.5 (1.3-5.7) 3.4 (1.4-5.4) 1.9 (0.3-3.6) 0.2 (-0.1-0.5) 0.5 (0.1-0.9) 
Private for-profit outlet 
      
Health facility/pharmacy 30.1 (-9.8-70.1) 0.6 (0.0-1.1) 4.8 (-2.2-11.9) 21.9 (8.9-34.9) 1.7 (-0.2-3.5) 5.1 (1.9-8.2) 
Drug store 63.5 (40.8-86.2) 18.3 (11.6-24.9) 24.8 (16.8-32.8) 82.2 (48.5-115.9) 24.4 (14.2-34.6) 34.2 (23.0-45.4) 
General retailer/itinerant 0.3 (-0.4-1.0) 20.0 (8.3-31.8) 17.2 (7.0-27.4) 1.1 (0.1-2.1) 3.2 (-1.8-8.2) 2.8 (-1.3-7.0) 
Total 94.0 (33.2-154.7) 38.8 (26.2-51.5) 46.8 (31.3-62.4) 105.2 (67.7-142.6) 29.2 (17.3-41.2) 42.1 (28.6-55.5) 
Community health worker - 0.1 (-0.1-0.3) 0.1 (-0.1-0.3) - - - 
Uganda – Total 198.2 (173.1-223.4) 94.7 (76.1-113.4) 110.5 (85.1-136.0) 204.1 (168.3-239.8) 116.4 (84.8-148.1) 128.7 (99.6-157.8) 
Public health facility  4.7 (-2.9-12.2) 12.0 (9.9-14.1) 10.9 (8.2-13.5) 7.0 (0.7-13.2) 11.5 (8.3-14.7) 10.9 (7.9-13.9) 
Private not-for-profit health 
facility 3.5 (2.4-4.6) 3.2 (0.6-5.9) 3.3 (1.0-5.5) 2.5 (0.9-4.2) 2.9 (1.3-4.6) 2.9 (1.4-4.3) 
Private for-profit outlet 
      Health facility/pharmacy 115.4 (44.2-186.6) 10.7 (5.2-16.3) 26.7 (1.7-51.8) 113.9 (50.5-177.2) 15.0 (7.3-22.8) 28.9 (10.7-47.1) 
Drug store 71.8 (34.2-109.4) 58.6 (49.4-67.9) 60.7 (51.4-69.9) 79.0 (49.5-108.5) 65.7 (54.2-77.2) 67.6 (57.2-77.9) 
General retailer/itinerant 2.0 (-0.8-4.7) 2.0 (0.4-3.6) 2.0 (0.6-3.4) 1.4 (0.2-2.7) 3.8 (-1.1-8.7) 3.5 (-0.8-7.7) 
Total 189.2 (157.8-220.6) 71.4 (59.0-83.7) 89.4 (63.6-115.1) 194.3 (153.3-235.3) 84.5 (67.7-101.3) 99.9 (79.9-119.8) 
Community health worker 0.9 (-0.1-1.8) 8.2 (-6.0-22.4) 7.1 (-5.0-19.2) 0.3 (-0.2-0.7) 17.5 (-4.1-39.0) 15.0 (-3.6-33.7) 
Note: This indicator could not be calculated for Zanzibar because subdistrict population numbers were unavailable. It could not be 
calculated for Nigeria at baseline because of the nature of the sample design. CI = Confidence interval 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys  
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Tables 2.1.8 and 2.1.9 show the percentage of antimalarial-stocking outlets with a staff member 
who had completed at least primary and at least secondary education. In most countries, the vast 
majority of outlets had a staff member with complete primary education–over 94% in Ghana, 
Kenya, Nigeria, Tanzania mainland, Uganda and Zanzibar for both rural and urban areas. This 
figure was somewhat lower overall in Madagascar and much lower in Niger (33% at baseline 
and 41% at endline). This is mainly due to lower education standards in private for-profit outlets, 
which reflects the much higher proportion of antimalarial stockists that are general 
retailers/itinerant vendors in Madagascar and Nigeria. Similar patterns were observed for 
secondary education. At endline, over 87% of outlets had a staff member with complete 
secondary education everywhere apart from Madagascar (37%) and Niger (13%). There were 
significant increases in educational attainment in Kenya and Tanzania mainland between 
baseline and endline. Education levels were lower in private for-profit outlets than in public or 
not-for-profit health facilities, particularly in Madagascar and Niger. In all countries except 
Nigeria and Zanzibar, secondary education levels were much lower in rural than in urban areas.  
 
Table 2.1.10 shows the percentage of outlets with a staff member with a relevant health-related 
qualification (pharmacy, nurse or medical doctor-related training). At endline, this figure was 7% 
in Niger and 15% in Madagascar; 27%-66% in Nigeria, Ghana and Kenya; and 90%-98% in 
Uganda, Tanzania mainland and Zanzibar. There was a significant increase between baseline and 
endline in Tanzania mainland. The low figures in Niger and Madagascar reflect the very low 
prevalence of health qualifications among private for-profit outlets (2% and 6%, respectively, at 
endline), reflecting the heavy predominance of general stores/itinerant vendors in the private for-
profit sectors of these countries. In other countries, health-related qualifications were also 
generally less common in private for-profit outlets than in other outlet types although there was 
no difference in Uganda at endline. In Ghana, Kenya and Madagascar, health-related 
qualifications were much less common in rural than in urban areas, but in other countries the 
difference was less marked or not evident. 
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Table 2.1.8: Outlets with at least one staff member who completed primary school at baseline (2010) and endline (2011) 
Percentage of outlets with at least one staff member who completed primary school (n) among all outlets with any antimalarials in stock at the time of the survey visit (N), by urban-
rural location and type of outlet, according to country 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N 
Ghana – Total 99.6 (98.3-99.9) 599 99.2 (97.5-99.8) 543 99.3 (98-99.8) 1,142 100.0 567 98.1 (94.7-99.3) 376 99.3 (97.9-99.7) 943 
Public health facility  100.0 67 100.0 135 100.0 202 100.0 90 100.0 200 100.0 290 
Private not-for-profit health facility 100.0 5 100.0 9 100.0 14 100.0 4 100.0 9 100.0 13 
Private for-profit outlet             
Health facility/pharmacy 100.0 314 100.0 62 100.0 376 100.0 270 100.0 26 100.0 296 
Drug store 99.1 (96.8-99.8) 211 99.4 (97-99.9) 331 99.4 (97.5-99.8) 542 100.0 200 97.2 (92.3-99) 139 98.9 (97-99.6) 339 
General retailer/itinerant 100.0 2 64.2 (13.8-95.2) 3 68.6 (19.3-95.2) 5 100.0 3 100.0 2 100.0 5 
Total 99.5 (98.2-99.9) 527 99.1 (97.2-99.7) 396 99.2 (97.7-99.7) 923 100.0 473 97.4 (93-99.1) 167 99.1 (97.6-99.7) 640 
Community health worker - 0 100.0 3 100.0 3 - 0 - 0 - 0 
Kenya – Total 98.6 (97.4-99.2) 1,038 94.1 (90.3-96.5) 874 95.2 (92.2-97) 1,912 99.3 (97.9-99.8) 1,051 96.9 (94.5-98.3) 801 97.6 (95.9-98.6) 1,852 
Public health facility  100.0 137 100.0 259 100.0 396 100.0 137 100.0 294 100.0 431 
Private not-for-profit health facility 100.0 23 100.0 15 100.0 38 100.0 19 100.0 27 100.0 46 
Private for-profit outlet             
Health facility/pharmacy 100.0 364 100.0 103 100.0 467 100.0 411 100.0 113 100.0 524 
Drug store 100.0 272 97.3 (93.2-99) 156 97.9 (93.8-99.3) 428 100.0 329 100.0 145 100.0 474 
General retailer/itinerant 95 (90.9-97.3) 238 87.9 (77.9-93.7) 320 89.2 (81.3-94) 558 96.8 (90.6-98.9) 155 91.7 (85.8-95.3) 222 92.6 (87.9-95.6) 377 
Total 98.3 (97-99.1) 874 93.1 (88.6-95.9) 579 94.4 (90.9-96.6) 1453 99.3 (97.8-99.8) 895 96.2 (93.1-98) 480 97.2 (95.1-98.4) 1375 
Community health worker 100.0 4 94.9 (66.9-99.4) 21 95.1 (67.7-99.4) 25 - 0 - 0 - 0 
Madagascar – Total 93.3 (91.3-94.9) 1,434 80.6 (72.9-86.5) 961 83.2 (76.8-88.1) 2,395 96.6 (94.9-97.8) 982 88.6 (83.1-92.4) 1,386 89.7 (84.9-93.1) 2,368 
Public health facility  98.3 (92.3-99.7) 67 100.0 444 99.5 (98-99.9) 511 100.0 65 99.9 (99.4-100) 553 99.9 (99.4-100) 618 
Private not-for-profit health facility 100.0 6 - 0 100.0 6 100.0 26 100.0 5 100.0 31 
Private for-profit outlet             
Health facility/pharmacy 98.1 (91.6-99.6) 122 100.0 9 99 (95.3-99.8) 131 100.0 105 100.0 12 100.0 117 
Drug store 85.4 (77.3-91) 28 98.6 (93.9-99.7) 227 93.6 (84.6-97.5) 255 100.0 28 98.9 (96.3-99.7) 347 99 (96.7-99.7) 375 
General retailer/itinerant 92.9 (90.9-94.5) 1,209 76.3 (66.7-83.8) 243 79.5 (71.2-85.9) 1,452 95.1 (92.7-96.7) 743 85 (78.3-89.8) 403 86.4 (80.6-90.6) 1,146 
Total 92.6 (90.1-94.6) 1,359 78 (68.8-85.1) 479 81.3 (73.6-87.1) 1,838 96.1 (94.1-97.4) 876 86.5 (80.3-90.9) 762 87.9 (82.6-91.8) 1,638 
Community health worker 100.0 2 85.1 (69-93.6) 38 85.1 (69-93.6) 40 100.0 15 90.5 (73.2-97.1) 66 90.8 (73.9-97.2) 81 
Niger – Total 39.5 (33-46.3) 831 31.5 (28-35.1) 1,198 33.1 (29.9-36.4) 2,029 44.5 (39.4-49.6) 920 39 (35-43.1) 736 40.5 (37.2-43.8) 1,656 
Public health facility  100.0 91 98.8 (96.5-99.6) 385 98.9 (96.9-99.6) 476 100.0 102 100.0 220 100.0 322 
Private not-for-profit health facility 68 (15.2-96.2) 4 - 0 68 (15.2-96.2) 4 100.0 2 100.0 1 100.0 3 
Private for-profit outlet             
Health facility/pharmacy 100.0 106 96.4 (70.1-99.7) 12 99.5 (96.1-99.9) 118 100.0 94 100.0 4 100.0 98 
Drug store 100.0 14 100.0 7 100.0 21 100.0 15 100.0 3 100.0 18 
General retailer/itinerant 32.2 (25.4-39.8) 615 24 (20.9-27.5) 792 25.6 (22.7-28.8) 1,407 37.4 (31.7-43.5) 707 30.9 (26.8-35.3) 508 32.7 (29.3-36.2) 1,215 
Total 36.7 (30.3-43.6) 735 24.8 (21.6-28.3) 811 27.3 (24.3-30.5) 1,546 41.5 (36.2-47) 816 31.4 (27.2-35.9) 515 34.3 (30.9-37.8) 1,331 
Community health worker 100.0 1 0.0 2 12.5 (1.2-61.9) 3 - 0 - 0 - 0 
Nigeria – Total 99.5 (98.1-99.9) 1,690 99.1 (95.1-99.8) 350 99.4 (98.3-99.8) 2,040 99.6 (97.8-99.9) 1,032 99.7 (97.9-100) 471 99.7 (98.7-99.9) 1,503 
Public health facility  100.0 181 100.0 43 100.0 224 100.0 43 100.0 52 100.0 95 
Private not-for-profit health facility 100.0 6 100.0 2 100.0 8 100.0 6 100.0 3 100.0 9 
Private for-profit outlet             
Health facility/pharmacy 100.0 715 100.0 24 100.0 739 100.0 99 100.0 32 100.0 131 
Drug store 99.8 (98.9-100) 699 99.9 (99.3-100) 259 99.8 (99.1-100) 958 99.8 (98.6-100) 807 100.0 361 99.9 (99.1-100) 1,168 
General retailer/itinerant 96.4 (79.8-99.5) 83 90.6 (57.5-98.5) 16 95.2 (83-98.8) 99 97.1 (87.5-99.4) 74 91.6 (57-98.9) 19 95.7 (86.7-98.7) 93 
Total 99.5 (98.1-99.9) 1,497 98.9 (93.8-99.8) 299 99.4 (98.2-99.8) 1,796 99.6 (97.7-99.9) 980 99.7 (97.6-100) 412 99.6 (98.5-99.9) 1,392 
Community health worker 100.0 6 100.0 6 100.0 12 100.0 3 100.0 4 100.0 7 
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Table 2.1.8: Cont. 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N 
Tanzania - mainland – Total 100.0 321 97.0 (94.8-98.2) 306 97.6 (95.9-98.7) 627 100.0 596 100.0 191 100.0 787 
Public health facility  100.0 5 100.0 56 100.0 61 100.0 7 100.0 48 100.0 55 
Private not-for-profit health facility 100.0 6 100.0 17 100.0 23 100.0 4 100.0 2 100.0 6 
Private for-profit outlet             
Health facility/pharmacy 100.0 221 100.0 12 100.0 233 100.0 321 100.0 16 100.0 337 
Drug store 100.0 88 98.6 (96.1-99.5) 149 99.1 (97.3-99.7) 237 100.0 259 100.0 259 100.0 372 
General retailer/itinerant 100.0 1 91.7 (85.6-95.4) 71 91.8 (85.7-95.4) 72 100.0 5 100.0 12 100.0 17 
Total 100.0 310 95.8 (93-97.5) 232 96.9 (94.6-98.2) 542 100.0 585 100.0 141 100.0 726 
Community health worker - 0 100.0 1 100.0 1 - 0 - 0 - 0 
Uganda – Total 100.0 544 99.2 (97.6-99.7) 1,869 99.4 (98.1-99.8) 2,413 100.0 1,406 98.7 (97.3-99.4) 1,720 99 (97.8-99.5) 3,126 
Public health facility  100.0 76 99.9 (99-100) 693 99.9 (99.1-100) 769 100.0 142 100.0 532 100.0 674 
Private not-for-profit health facility 100.0 4 100.0 27 100.0 31 100.0 13 100.0 28 100.0 41 
Private for-profit outlet             
Health facility/pharmacy 100.0 389 100.0 355 100.0 744 100.0 811 99.3 (94.2-99.9) 388 99.6 (96.9-100) 1,199 
Drug store 100.0 72 99.6 (98.5-99.9) 746 99.7 (98.7-99.9) 818 100.0 434 100.0 676 100.0 1,110 
General retailer/itinerant 100.0 2 82.4 (48.6-95.9) 19 84.8 (53.6-96.4) 21 100.0 4 80.3 (61.6-91.1) 14 81.4 (63-91.8) 18 
Total 100.0 463 99.3 (97.1-99.8) 1,120 99.4 (97.7-99.9) 1,583 100.0 1249 99.3 (97.6-99.8) 1,078 99.5 (98.2-99.8) 2,327 
Community health worker 100.0 1 95.9 (93.2-97.6) 29 96 (93.2-97.7) 30 100.0 2 93.2 (87.2-96.5) 82 93.2 (87.2-96.5) 84 
Zanzibar – Total 100.0 189 99. 124 99.7 313 100.0 222 100.0 120 100.0 342 
Public health facility  100.0 56 100.0 83 100.0 139 100.0 48 100.0 76 100.0 124 
Private not-for-profit health facility 100.0 2 100.0 1 100.0 3 100.0 1 100.0 1 100.0 2 
Private for-profit outlet             
Health facility/pharmacy 100.0 73 100.0 11 100.0 84 100.0 82 100.0 16 100.0 98 
Drug store 100.0 57 100.0 25 100.0 82 100.0 88 100.0 24 100.0 112 
General retailer/itinerant 100.0 1 75 4 80 5 100.0 3 100.0 3 100.0 6 
Total 100.0 131 97.5 40 99.4 171 100.0 173 100.0 43 100.0 216 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Note: Providers noted as having completed primary school include those who have completed secondary school and those who have not completed secondary school but who have completed primary school.  
Nigeria baseline data collection was conducted in 2009. 
CI = Confidence interval  
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.1.9: Outlets with at least one staff member who completed secondary school at baseline (2010) and endline (2011) 
Percentage of outlets with at least one staff member who completed secondary school (n) among all outlets with any antimalarials in stock at the time of the survey visit (N), by 
urban-rural location and type of outlet, according to country 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N 
Ghana – Total 97.7 (95.7-98.8) 598 88.8 (85.2-91.5) 543 90.5 (87.5-92.8) 1,141 95.5 (92.2-97.5) 565 86.9 (80.5-91.4) 377 92.1 (89.0-94.4) 942 
Public health facility  100.0 66 98.6 (95.4-99.6) 135 98.8 (96.0-99.6) 201 100.0 89 100.0 199 100.0 288 
Private not-for-profit health facility 100.0 5 100.0 9 100.0 14 100.0 4 100.0 9 100.0 13 
Private for-profit outlet             
Health facility/pharmacy 100.0 314 100.0 62 100.0 376 99.7 (98.8-99.9) 271 100.0 26 99.8 (98.9-99.9) 297 
Drug store 95.8 (92.4-97.8) 211 87.1 (83.1-90.2) 331 88.1 (84.7-90.9) 542 94.3 (89.7-96.9) 199 82.0 (73.2-88.4) 140 89.4 (85.1-92.6) 339 
General retailer/itinerant 55.7 (14.0-90.7) 2 32.1 (11.7-62.8) 3 35.0 (15.4-61.4) 5 0.0 2 32.7 (3.8-85.7) 3 20.2 (3.1-66.7) 5 
Total 97.6 (95.3-98.7) 527 87.5 (83.7-90.5) 396 89.5 (86.3-92.0) 923 95.2 (91.5-97.3) 472 82.4 (74.1-88.5) 169 90.8 (87.0-93.5) 641 
Community health worker - 0 100.0 3 100.0 3 - 0 - 0 - 0 
Kenya – Total 91.4 (85.7-95) 1,038 75.1 (69.9-79.6) 876 79.0 (74.9-82.6) 1,914 93.7 (88.2-96.7) 1,051 84.8 (79.0-89.2) 802 87.3 (82.8-90.8) 1,853 
Public health facility  100.0 137 100.0 259 100.0 396 100.0 137 100.0 294 100.0 431 
Private not-for-profit health facility 100.0 23 100.0 15 100.0 38 100.0 19 100.0 27 100.0 46 
Private for-profit outlet             
Health facility/pharmacy 100.0 364 100.0 103 100.0 467 100.0 411 100.0 113 100.0 524 
Drug store 100.0 272 88.4 (81.6-92.9) 156 91.0 (83.6-95.2) 428 100.0 329 99.4 (95.7-99.9) 145 99.6 (97.4-99.9) 474 
General retailer/itinerant 70.0 (57.0-80.4) 238 52.5 (43.9-61) 322 55.7 (48.6-62.6) 560 69.6 (57.8-79.2) 155 59.4 (49.9-68.3) 223 61.3 (53.2-68.8) 378 
Total 90.1 (83.3-94.4) 874 72.5 (67-77.4) 581 76.9 (72.7-80.6) 1,455 93.3 (87.4-96.6) 895 81.3 (74.0-86.9) 481 85.0 (79.7-89.2) 1,376 
Community health worker 83.9 (41.9-97.4) 4 52.1 (28.2-75.1) 21 52.9 (28.9-75.6) 25 - 0  0 - 0 
Madagascar – Total 55.0 (46.8-63.0) 1,433 18.8 (13.2-26) 958 26.3 (19.9-33.8) 2,391 57.1 (46.9-66.7) 975 34.2 (27.0-42.3) 1,386 37.3 (30.5-44.6) 2,361 
Public health facility  93.2 (84.0-97.2) 67 91.7 (87.3-94.7) 442 92.1 (88.3-94.7) 509 98.5 (96.3-99.4) 65 84.9 (74.6-91.5) 551 86.4 (77.0-92.3) 616 
Private not-for-profit health facility 100.0 6 - 0 100.0 6 100.0 26 100.0 5 100.0 31 
Private for-profit outlet             
Health facility/pharmacy 95.6 (89.3-98.3) 122 99.4 (94.9-99.9) 9 97.3 (93.7-98.8) 131 97.6 (92.8-99.2) 105 90.2 (50.0-98.8) 12 94.2 (75.9-98.8) 117 
Drug store 74.7 (65.2-82.3) 28 51.3 (42.5-60) 227 60.3 (50.1-69.6) 255 74.5 (54.2-87.8) 28 56.0 (48.4-63.3) 347 58.0 (50.8-64.8) 375 
General retailer/itinerant 39.5 (33.7-45.6) 1,208 9.1 (4.5-17.7) 242 15.0 (9.5-22.9) 1,450 42.1 (31.3-53.6) 736 26.4 (18.4-36.4) 405 28.6 (21.2-37.3) 1,141 
Total 49.9 (43.3-56.5) 1,358 13.6 (8.2-21.9) 478 21.7 (15.3-29.9) 1,836 52.2 (40.9-63.2) 869 30.3 (22.7-39.3) 764 33.7 (26.5-41.7) 1,633 
Community health worker 70.1 (21.7-95.2) 2 7.3 (2.2-21.8) 38 7.4 (2.3-21.6) 40 26.3 (12.4-47.4) 15 10.1 (3.5-25.5) 66 10.5 (3.9-25.4) 81 
Niger – Total 16.3 (12.4-21.1) 830 11.0 (8.4-14.3) 1,197 12.1 (9.8-14.8) 2,027 16.9 (14.4-19.7) 921 11.0 (8.3-14.5) 738 12.6 (10.5-15.1) 1,659 
Public health facility  91.9 (78.3-97.3) 90 71.7 (64.2-78.1) 384 73.7 (66.7-79.6) 474 90.8 (81.9-95.6) 102 69.2 (61.0-76.3) 220 72.2 (65.3-78.2) 322 
Private not-for-profit health facility 68.0 (15.2-96.2) 4 - 0 68.0 (15.2-96.2) 4 100.0 2 100.0 1 100.0 3 
Private for-profit outlet             
Health facility/pharmacy 98.2 (94.1-99.4) 106 89.2 (56.7-98.1) 12 96.8 (92.6-98.7) 118 94.8 (84.0-98.4) 94 100.0 4 95.1 (84.9-98.5) 98 
Drug store 84.9 (60.2-95.4) 14 42.2 (11.2-80.8) 7 57.9 (26.6-84.0) 21 39.4 (25-55.8) 15 32.3 (5.9-78.3) 3 35.4 (15.1-62.9) 18 
General retailer/itinerant 7.1 (4.8-10.6) 615 4.5 (2.6-7.7) 792 5.0 (3.3-7.5) 1,407 7.9 (5.7-10.7) 708 3.5 (2.0-5.9) 510 4.7 (3.4-6.4) 1,218 
Total 13.0 (9.6-17.3) 735 5.0 (3.1-8.1) 811 6.7 (4.9-9.0) 1,546 12.9 (10.6-15.7) 817 3.8 (2.2-6.4) 517 6.4 (4.9-8.2) 1,334 
Community health worker 0.0 1 0.0 2 0.0 3 - 0 - 0 - 0 
Nigeria – Total 95.5 (92.3-97.5) 1,690 94.6 (89.2-97.3) 350 95.3 (92.7-97.0) 2,040 94.6 (91-96.9) 1,031 95.9 (92.5-97.8) 472 95.1 (92.6-96.8) 1,503 
Public health facility  99.1 (94.4-99.9) 181 100.0 43 99.9 (99.6-100.0) 224 100.0 43 100.0 52 100.0 95 
Private not-for-profit health facility 100.0 6 100.0 2 100.0 8 100.0 6 100.0 3 100.0 9 
Private for-profit outlet             
Health facility/pharmacy 99.9 (99.3-100.0) 715 100.0 24 
100.0 (99.8-
100.0) 739 100.0 99 100.0 32 100.0 131 
Drug store 97.5 (94.9-98.8) 699 94.3 (80.6-98.5) 259 97 (94.3-98.4) 958 95.1 (93.2-96.5) 806 96.9 (93.5-98.5) 362 95.8 (94.2-97.0) 1,168 
General retailer/itinerant 76.4 (60.5-87.3) 83 76.6 (47.1-92.3) 16 76.4 (63.0-86.1) 99 77.8 (46.5-93.4) 74 49.1 (20.2-78.6) 19 70.6 (48.6-86.0) 93 
Total 95.5 (92.3-97.4) 1,497 93.2 (87.3-96.5) 299 95.1 (92.4-96.9) 1,796 94.4 (90.5-96.8) 979 95.3 (91.4-97.5) 413 94.7 (92.0-96.6) 1,392 
Community health worker 100.0 6 100.0 6 100.0 12 66.7 (66.7-66.7) 3 100.0 4 98.7 (87.3-99.9) 7 
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Table 2.1.9: Cont. 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N 
Tanzania - mainland - Total 95.3 (89.2-98.0) 321 58.0 (48.5-66.9) 304 66.3 (57.1-74.4) 625 95.4 (93.5-96.8) 596 82.8 (72.7-89.7) 191 87.4 (80.5-92.1) 787 
Public health facility  100.0 5 78.3 (63.0-88.4) 55 79.8 (65.3-89.2) 60 100.0 7 89.1 (75.4-95.6) 48 89.6 (76.4-95.8) 55 
Private not-for-profit health facility 100.0 6 93.1 (61.8-99.1) 17 94.3 (67.2-99.3) 23 100.0 4 47.8 (4.9-94.2) 2 75.6 (25.6-96.5) 6 
Private for-profit outlet             
Health facility/pharmacy 99.1 (96.1-99.8) 221 100.0 12 99.3 (96.8-99.8) 233 100.0 (99.7-100.0) 321 100.0 16 100.0 337 
Drug store 93.8 (85.3-97.5) 88 73.7 (65.4-80.7) 149 80.4 (73.6-85.8) 237 94.8 (91.9-96.6) 259 86.8 (77.9-92.4) 113 90.3 (85-93.8) 372 
General retailer/itinerant 100.0 1 12.6 (5.2-27.7) 70 13.2 (5.5-28.2) 71 74.3 (22.0-96.7) 5 24.9 (14.0-40.2) 12 29.3 (16.9-45.7) 17 
Total 94.7 (87.7-97.9) 310 49.2 (36.8-61.6) 231 61.1 (49.1-71.9) 541 95.2 (93.2-96.7) 585 80.7 (67.1-89.5) 141 87.1 (78.8-92.5) 726 
Community health worker - 0 100.0 1 100.0 1 - 0 - 0 - 0 
Uganda – Total 98.9 (97.0-99.6) 539 89.1 (79.1-94.7) 1,824 91.2 (82.5-95.7) 2,363 98.7 (97.7-99.2) 1,387 87.0 (74.1-94.0) 1,686 89.4 (78.5-95.1) 3,073 
Public health facility  100.0 73 98.2 (94.4-99.4) 662 98.3 (94.9-99.5) 735 100.0 137 99.5 (97.3-99.9) 514 99.5 (97.7-99.9) 651 
Private not-for-profit health facility 100.0 4 100.0 27 100.0 31 100.0 13 100.0 28 100.0 41 
Private for-profit outlet             
Health facility/pharmacy 100.0 388 98.5 (92.7-99.7) 351 99.2 (95.7-99.9) 739 99.3 (98.3-99.7) 807 96.1 (91.0-98.4) 387 97.5 (94.5-98.9) 1,194 
Drug store 98.1 (92.5-99.6) 71 92.7 (87.9-95.7) 736 93.4 (89.2-96.1) 807 97.7 (96.1-98.7) 424 97.4 (95.1-98.7) 664 97.5 (95.5-98.6) 1,088 
General retailer/itinerant 100.0 2 33.6 (17.4-54.9) 19 42.6 (23.9-63.6) 21 89.7 (47.4-98.8) 4 38.8 (21.3-59.8) 14 41.7 (25.1-60.5) 18 
Total 99.2 (95.1-99.9) 461 92.3 (87.5-95.3) 1,106 93.9 (89.7-96.4) 1,567 98.6 (97.5-99.2) 1,235 95.5 (92.8-97.2) 1,065 96.2 (94.2-97.6) 2,300 
Community health worker 0.0 1 2.0 (0.1-26.4) 29 2.0 (0.1-25.4) 30 100.0 2 14.0 (8.9-21.4) 79 14.4 (9.2-21.8) 81 
Zanzibar – Total 100.0 189 99.2 124 99.7 313 99.5 222 100.0 120 99.7 342 
Public health facility  100.0 56 100.0 83 100.0 139 100.0 48 100.0 76 100.0 124 
Private not-for-profit health facility 100.0 2 100.0 1 100.0 3 100.0 1 100.0 1 100.0 2 
Private for-profit outlet             
Health facility/pharmacy 100.0 73 100.0 11 100.0 84 100.0 82 100.0 16 100.0 98 
Drug store 100.0 57 100.0 25 100.0 82 100.0 88 100.0 24 100.0 112 
General retailer/itinerant 100.0 1 75 4 8 5 66.7 3 100.0 3 83.3 6 
Total 100.0 131 97.5 40 99.4 171 99.4 173 100.0 43 99.5 216 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Note: Nigeria baseline data collection was conducted in 2009. CI = Confidence interval 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.1.10: Outlets with at least one staff member with a health-related qualification at baseline (2010) and endline (2011) 
Percentage of outlets with at least one staff member with a health-related qualification (n) among all outlets with any antimalarials in stock at the time of the survey visit (N), by 
urban-rural location and type of outlet, according to country 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N 
Ghana – Total 64.8 (58.7-70.5) 588 34.2 (28.5-40.4) 527 40.1 (35.2-45.3) 1,115 48 (41.8-54.2) 548 40.0 (33.5-46.9) 365 44.8 (40.2-49.5) 913 
Public health facility  98.9 (95.2-99.7) 67 91.5 (84.4-95.5) 
13 
5 92.5 (86.4-96.0) 202 86.2 (77.6-91.8) 85 91.8 (84.4-95.9) 195 90.2 (84.7-93.8) 280 
Private not-for-profit health facility 100.0 5 100.0 9 100.0 14 80.0 (38.0-96.3) 4 100.0 9 92.1 (69.0-98.4) 13 
Private for-profit outlet             
Health facility/pharmacy 92.3 (84.8-96.3) 314 92.9 (80.5-97.7) 61 92.6 (86.7-96.0) 375 89.7 (83.6-93.7) 266 71.9 (41.3-90.3) 26 87.3 (80.2-92.1) 292 
Drug store 35.1 (29.3-41.4) 200 21.2 (15.6-28.2) 316 22.9 (17.8-29.0) 516 27.5 (23.3-32.2) 190 17.3 (10.7-26.7) 132 23.5 (19.6-27.9) 322 
General retailer/itinerant 0.0 2 0.0 3 0.0 5 38.0 (8.0-81.2) 3 0.0 3 18.9 (3.7-59.0) 6 
Total 62.0 (55.6-68) 516 26.3 (20.6-33.0) 380 33.5 (28.4-39.0) 896 45.0 (38.1-52.0) 459 21.4 (14.0-31.3) 161 36.9 (31.3-42.9) 620 
Community health worker - 0 100.0 3 100.0 3 - 0 - 0 - 0 
Kenya – Total 71.1 (64.1-77.2) 1,035 46.6 (38.7-54.7) 873 52.5 (45.8-59.1) 1,908 77.4 (69.2-84.0) 1,049 60.8 (50.5-70.2) 798 65.5 (57.6-72.6) 1,847 
Public health facility  99.1 (96.0-99.8) 137 100.0 259 99.8 (99.2-99.9) 396 99.5 (96.7-99.9) 137 98.1 (88.8-99.7) 294 98.3 (89.7-99.7) 431 
Private not-for-profit health facility 100.0 23 96.7 (79.2-99.6) 15 97.7 (84.9-99.7) 38 97.7 (85.3-99.7) 19 96.1 (79.6-99.4) 27 96.4 (83.9-99.3) 46 
Private for-profit outlet             
Health facility/pharmacy 98.7 (95.6-99.6) 364 96.6 (82.1-99.4) 103 97.6 (90.8-99.4) 467 96.4 (91.6-98.5) 411 98.4 (88.1-99.8) 113 97.6 (93.4-99.2) 524 
Drug store 98.7 (97.1-99.4) 271 69.7 (44.3-86.9) 155 76.2 (49.9-91.1) 426 97.1 (93.2-98.8) 329 90.3 (82.1-94.9) 145 93.0 (88.3-95.9) 474 
General retailer/itinerant 2.5 (1.0-6.2) 236 2.2 (0.8-5.5) 320 2.2 (1.0-4.8) 556 1.6 (0.4-5.5) 153 2.9 (1.1-7.7) 219 2.7 (1.1-6.5) 372 
Total 67.1 (58.6-74.6) 871 40.4 (32.3-49.2) 578 47.1 (40.1-54.2) 1,449 76.1 (67.4-83.1) 893 52.2 (39.3-64.8) 477 59.7 (50.3-68.5) 1,370 
Community health worker 0.0 4 9.7 (2.2-34.4) 21 9.5 (2.2-33.4) 25 - 0 - 0 - 0 
Madagascar – Total 22.5 (13.5-35.1) 1,433 10.7 (7.2-15.6) 960 13.1 (9.3-18.2)  2,393 26.4 (21.6-31.9) 978 13.6 (10.9-16.8) 1,374 15.3 (12.6-18.5) 2,352 
Public health facility  90.4 (80.5-95.6) 67 95.1 (91.9-97.1) 444 93.8 (90.9-95.8) 511 94.1 (87.2-97.4) 65 87.3 (77.0-93.4) 553 88.1 (78.8-93.6) 618 
Private not-for-profit health facility 76.2 (35.9-94.8) 6 - 0 76.2 (35.9-94.8) 6 100.0 26 100.0 5 100.0 31 
Private for-profit outlet             
Health facility/pharmacy - - - - - - 96.4 (90.3-98.7) 104 100.0 12 98.0 (95.0-99.2) 116 
Drug store - - - - - - 30.1 (18.4-45.2) 28 15.3 (8.5-26.2) 335 16.9 (10.4-26.4) 363 
General retailer/itinerant - - - - - - 2.2 (1.4-3.6) 740 0.8 (0.3-2.2) 403 1.0 (0.5-2.1) 1,143 
Total 13.0 (7.8-20.8) 1,358 3.8 (2.0-7.2) 478 5.9 (3.8-9.2) 1,836 17.7 (13.4-23.1) 872 4.2 (2.6-6.8) 750 6.3 (4.5-8.8) 1,622 
Community health worker 70.1 (20.6-95.5) 2 0.0 38 3.4 (0.4-23.1) 40 0.0 15 0.0 66 0.0 81 
Niger – Total 8.4 (5.9-11.8) 832 5.7 (4.3-7.5) 1,198 6.2 (5.0-7.8) 2,030 9.9 (8.6-11.3) 910 6.2 (5.1-7.5) 734 7.2 (6.3-8.2) 1,644 
Public health facility  83.2 (68.8-91.7) 91 59.6 (53.0-65.9) 385 61.9 (55.9-67.6) 476 81.9 (74.8-87.3) 102 54.1 (48.2-59.8) 220 58.0 (52.5-63.3) 322 
Private not-for-profit health facility 68.0 (15.2-96.2) 4 - 0 68.0 (15.2-96.2) 4 100.0 2 100.0 1 100.0 3 
Private for-profit outlet             
Health facility/pharmacy 92.6 (84.9-96.5) 105 78.3 (34.9-96) 12 90.5 (82.8-94.9) 117 92.6 (86.9-95.9) 95 91.6 (61.9-98.6) 4 92.6 (87.1-95.8) 99 
Drug store 19.5 (7.5-42.2) 14 14.6 (1.8-61.8) 7 16.4 (4.6-44.2) 21 19.1 (6.7-43.5) 14 - 3 8.3 (2.7-22.9) 17 
General retailer/itinerant 0.3 (0.1-1.1) 617 0.0 792 0.1 (0.0-0.2) 1,409 0.7 (0.3-1.7) 697 0.0 506 0.2 (0.1-0.5) 1,203 
Total 5.0 (3.1-8) 736 0.3 (0.1-1.0) 811 1.3 (0.8-1.9) 1,547 6.0 (4.9-7.3) 806 0.1 (0-0.5) 513 1.8 (1.4-2.3) 1,319 
Community health worker 0.0 1 0.0 2 0.0 3 - 0 - 0 - 0 
Nigeria – Total 37.0 (29.4-45.3) 1,624 35.7 (22.4-51.7) 336 36.7 (29.9-44.1) 1,960 31.7 (25.1-39.2) 1,020 31.1 (25.0-37.9) 470 31.5 (26.7-36.7) 1,490 
Public health facility  83.0 (73.7-89.5) 175 45.8 (21.7-72.0) 42 48.1 (24.7-72.4) 217 66.0 (50.0-79.0) 43 50.8 (32.2-69.2) 52 55.7 (41.4-69) 95 
Private not-for-profit health facility 100.0 6 85.5 (29.0-98.8) 2 86.7 (34.0-98.8) 8 79.7 (39.3-96.0) 6 93.1 (54.1-99.4) 3 84.8 (52.2-96.6) 9 
Private for-profit outlet             
Health facility/pharmacy 94.0 (88.7-96.9) 696 95.3 (75.7-99.2) 23 95.0 (82.2-98.7) 719 94.3 (86.5-97.7) 99 74.7 (52.8-88.6) 32 87.2 (76.9-93.3) 131 
Drug store 36.7 (28.9-45.4) 661 20.1 (13.7-28.5) 247 34.2 (27.4-41.7) 908 23.8 (19.0-29.4) 796 24.0 (17.1-32.7) 360 23.9 (19.8-28.6) 1,156 
General retailer/itinerant 30.7 (18.5-46.4) 80 36.7 (10.1-75.1) 16 32.0 (19.6-47.6) 96 12.1 (4.0-31.2) 73 4.9 (0.9-22.5) 19 10.3 (3.9-24.5) 92 
Total 36.8 (29.1-45.2) 1,437 34.4 (19.6-52.9) 286 36.4 (29.3-44.1) 1,723 30.0 (23.6-37.3) 968 28.2 (21.1-36.4) 411 29.3 (24.5-34.6) 1,379 
Community health worker 41.7 (11.0-80.6) 6 4.5 (0.8-21.2) 6 20.9 (4.6-58.8) 12 0.0 3 7.3 (0.6-50.4) 4 7.0 (0.6-48.3) 7 
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Table 2.1.10: Cont. 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N 
Tanzania - mainland - Total 96.5 (91.4-98.7) 324 66.0 (55.8-75.0) 304 72.9 (63.4-80.7) 628 98.4 (96.2-99.3) 596 91.0 (74.0-97.3) 190 93.7 (82.6-97.9) 786 
Public health facility  100.0 5 98.2 (93.0-99.5) 56 98.3 (93.5-99.6) 61 100.0 7 100.0 48 100.0 55 
Private not-for-profit health facility 100.0 6 100.0 17 100.0 23 100.0 4 100.0 2 100.0 6 
Private for-profit outlet             
Health facility/pharmacy 98.1 (93.4-99.5) 224 100.0 12 98.5 (94.6-99.6) 236 99.7 (98.5-99.9) 321 100.0 16 99.8 (98.9-100.0) 337 
Drug store 96.6 (89.4-98.9) 88 85.5 (77.0-91.2) 148 89.2 (83.1-93.3) 236 98.4 (96.5-99.3) 259 95.9 (89.5-98.5) 113 97.0 (93.5-98.6) 372 
General retailer/itinerant 0.0 1 7.8 (3.5-16.5) 70 7.7 (3.4-16.4) 71 74.3 (22.0-96.7) 5 7.4 (0.5-53.4) 11 13.8 (2.1-54.6) 16 
Total 96.2 (90.8-98.5) 313 53.8 (40.8-66.2) 230 65.0 (53.0-75.3) 543 98.3 (96.0-99.3) 585 87.2 (64.9-96.2) 140 92.1 (78.5-97.4) 725 
Community health worker - 0 100.0 1 100.0 1 - 0 - 0 - 0 
Uganda – Total 97.5 (94.1-99.0) 544 89.0 (78.8-94.6) 1,865 90.8 (82.2-95.4) 2,409 98.8 (98.3-99.2) 1,415 87.5 (72.3-94.9) 1,713 89.8 (77.2-95.8) 3,128 
Public health facility  96.8 (86.7-99.3) 76 98.0 (95.4-99.2) 693 97.9 (95.5-99.0) 769 99.8 (98.8-100.0) 144 99.7 (97.9-100.0) 534 99.7 (98.3-100.0) 678 
Private not-for-profit health facility 100.0 4 100.0 27 100.0 31 100.0 13 100.0 28 100.0 41 
Private for-profit outlet             
Health facility/pharmacy 99.1 (98.3-99.5) 389 96.9 (91.4-99) 356 98.0 (95.4-99.1) 745 100.0 816 100.0 387 100.0 1,203 
Drug store 96.3 (85.4-99.2) 72 93.2 (89.0-95.9) 741 93.6 (89.9-96) 813 98.5 (96.4-99.4) 436 98.6 (97.1-99.3) 676 98.6 (97.4-99.2) 1,112 
General retailer/itinerant 100.0 2 23.0 (8.4-49.2) 19 33.3 (15.1-58.4) 21 0.0 4 16.3 (4.8-42.8) 11 15.1 (4.2-41.7) 15 
Total 98.0 (93.1-99.4) 463 92.1 (87.8-95.0) 1,116 93.5 (89.8-95.9) 1,579 98.8 (98.2-99.2) 1,256 97.2 (94.7-98.5) 1,074 97.6 (95.8-98.6) 2,330 
Community health worker 0.0 1 0.0 29 0.0 30 46.3 (5.2-93.1) 2 2.6 (0.6-10.0) 77 2.7 (0.7-9.7) 79 
Zanzibar – Total 96.3 188 94.4 124 95.5 312 97.7 221 97.5 120 97.7 341 
Public health facility  100.0 56 98.8 83 99.3 139 100.0 48 100.0 76 100.0 124 
Private not-for-profit health facility 100.0 2 100.0 1 100.0 3 100.0 1 100.0 1 100.0 2 
Private for-profit outlet             
Health facility/pharmacy 100.0 73 90.9 11 98.8 84 100.0 81 100.0 16 100.0 97 
Drug store 89.3 56 92.0 25 90.1 81 95.5 88 91.7 24 94.6 112 
General retailer/itinerant 0.0 1 25.0 4 20.0 5 66.7 3 66.7 3 66.7 6 
Total 94.6 130 85.0 40 92.4 170 97.1 172 93 43 96.3 215 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Note: A health-related qualification is defined as pharmacy, nurse or medical doctor related training. Pharmacy related training includes studying to a certificate or diploma level. Nurse related training includes 
studying nursing to a certificate level (nurse aid) and diploma level. Medical doctor training includes clinical officers who studied medicine to a diploma level and fully qualified physicians. Nigeria baseline data 
collection was conducted in 2009. 
CI = Confidence interval 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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2.2 Evaluation question on ACT availability 
Question 1: Has the AMFm mechanism helped increase the availability of quality-assured ACTs 
to patients across public, private for-profit and not-for-profit sectors, in rural /urban areas? 
2.2.1 Antimalarials in stock 
Table 2.2.1 shows the percentage of outlets screened that had any antimalarials in stock. For 
public health facilities at endline, this was 88% or higher in all countries except Tanzania and 
Zanzibar where it was 77% and 78%, respectively. This represents an increase since baseline in 
Niger and a decrease in Zanzibar. This figure was highly variable for private for-profit outlets, 
ranging at endline from less than 20% in Zanzibar, Kenya, Tanzania mainland, Uganda and 
Nigeria to 20-45% in Madagascar and Niger and 94% in Ghana, reflecting variation in outlet 
types enumerated. In Kenya, Tanzania mainland, Uganda and Zanzibar, all general stores were 
enumerated as they occasionally stock antimalarials, but in Ghana such outlets were enumerated 
only in exceptional circumstances as they were believed to stock such drugs only very rarely. 
Decreases over time in the proportion of private for-profit outlets stocking antimalarials were 
observed in urban areas in Madagascar (32% to 15%) and in Nigeria (27% to 17%). 
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Table 2.2.1: Outlets with antimalarials in stock at baseline (2010) and endline (2011) 
Indicator 1.1 Percentage of outlets that had any antimalarials in stock at the time of the survey visit (n) among all outlets where screening questions were completed (N), by urban-
rural location and type of outlet, according to country 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N 
Ghana – Total 98.4 (96.7-99.2) 616 95.5 (93.5-96.8) 571 96.0 (94.4-97.2) 1,187 97.7 (95.5-98.9) 591 90.2 (80.3-95.5) 411 94.7 (90.3-97.1) 1,002 
Public health facility  95.9 (86.7-98.8) 70 98.1 (95.1-99.2) 139 97.8 (95.2-99.0) 209 98.8 (94.2-99.8) 95 96.4 (92.9-98.2) 212 97.1 (94.5-98.5) 307 
Private not-for-profit health facility 100. 0 5 100.0 9 100.0 14 100.0 4 100.0 9 100.0 13 
Private for-profit outlet             
Health facility/pharmacy 98.1 (95.0-99.3) 323 89.3 (71.9-96.5) 66 94.5 (86.5-97.9) 389 97.7 (91.0-99.4) 281 100.0 26 98.0 (92.0-99.5) 307 
Drug store 99.4 (98.3-99.8) 215 95.8 (93.6-97.3) 350 96.2 (94.3-97.5) 565 98.5 (96.4-99.4) 206 88.9 (77.6-94.9) 157 94.5 (89.3-97.3) 363 
General retailer/itinerant 100.0 2 74.2 (25.7-96.0) 4 76.7 (30.1-96.2) 6 58.9 (32.3-81.1) 5 49.6 (29.9-69.4) 6 53.8 (37.2-69.6) 11 
Total 98.8 (97.3-99.4) 540 95.1 (92.8-96.7) 420 95.8 (94.0-97.1) 960 97.6 (95.2-98.8) 492 88.2 (75.5-94.8) 189 94.2 (89.1-97.0) 681 
Community health worker 0.0 1 100.0 3 93.6 (68.6-99.0) 4 - 0 0.0 1 0.0 1 
Kenya – Total 12.5 (10.8-14.4) 7,741 9.8 (8.0-11.9) 6,156 10.3 (8.8-12.1) 13,897 11.6 (10.2-13.0) 6,866 11.9 (10.1-13.9) 4,517 11.8 (10.4-13.3) 11,383 
Public health facility  81.9 (65.0-91.6) 157 95.4 (90-97.9) 269 91.9 (84.8-95.8) 426 95.0 (90.9-97.4) 145 97.0 (91.3-99.0) 300 96.9 (92.0-98.8) 445 
Private not-for-profit health facility 75.1 (55.7-87.9) 30 92.1 (68.7-98.4) 17 86.5 (70.5-94.5) 47 80.4 (59.5-91.9) 22 97.5 (82.9-99.7) 28 93.6 (83.5-97.7) 50 
Private for-profit outlet             
Health facility/pharmacy 79.8 (70.8-86.5) 457 64.0 (40.7-82.2) 144 70.4 (54.9-82.3) 601 91.4 (88.1-93.9) 439 91.1 (80.1-96.3) 125 91.3 (85.3-95.0) 564 
Drug store 94.6 (90.0-97.1) 296 89.2 (83.1-93.3) 181 90.3 (86.0-93.4) 477 95.4 (91.1-97.7) 349 95.7 (91.2-97.9) 154 95.6 (92.7-97.4) 503 
General retailer/itinerant 4.2 (3.4-5.2) 6,476 5.2 (3.3-8.1) 4,537 5.0 (3.4-7.1) 11,013 2.7 (1.7-4.2) 5,809 5.1 (3.4-7.7) 3,663 4.4 (3.1-6.1) 9,472 
Total 11.6 (10.1-13.2) 7,229 9.9 (8.1-12.1) 4,862 10.3 (8.8-12.0) 12,091 11.2 (9.9-12.7) 6,597 10.5 (8.7-12.6) 3,942 10.7 (9.3-12.2) 10,539 
Community health worker 1.7 (0.6-4.5) 325 2.8 (1.0-7.8) 1,008 2.8 (1.0-7.3) 1,333 0.0 102 0.0 247 0.0 349 
Madagascar – Total 34.0 (28.5-39.9) 4,983 36.0 (28.4-44.4) 1,786 35.6 (29.4-42.2) 6,769 16.4 (13.7-19.4) 6,519 23.6 (19.9-27.6) 3,522 22.2 (19.3-25.5) 10,041 
Public health facility  99.1 (96.9-99.7) 71 96.9 (93.9-98.4) 460 97.5 (95.3-98.7) 531 100.0 66 96.5 (92.1-98.5) 576 96.8 (93.0-98.6) 642 
Private not-for-profit health facility 80.6 (43.0-95.8) 7 - 0 80.6 (43.0-95.8) 7 80.9 (66.1-90.2) 32 82.5 (43.2-96.7) 6 81.9 (59.8-93.2) 38 
Private for-profit outlet             
Health facility/pharmacy 91.1 (82.2-95.8) 146 96.2 (74.2-99.6) 10 93.2 (86.0-96.8) 156 77.1 (64.1-86.5) 145 81.1 (55.9-93.6) 16 78.9 (66.8-87.4) 161 
Drug store 100.0 30 98.0 (95.1-99.2) 233 98.8 (96.8-99.5) 263 94.7 (81.1-98.7) 30 96.3 (93.1-98.0) 363 96.1 (93.2-97.8) 393 
General retailer/itinerant 26.6 (22.1-31.6) 4,671 33.7 (24.9-43.7) 915 32.0 (25.2-39.6) 5,586 12.5 (10.2-15.3) 6,013 23.0 (19.3-27.1) 1,992 20.6 (17.6-23.9) 8,005 
Total 31.7 (27.1-36.8) 4,847 35.4 (26.9-45) 1,158 34.5 (27.9-41.7) 6,005 15.1 (12.6-18.1) 6,188 24.9 (21.2-29.1) 2,371 22.7 (19.7-26.0) 8,559 
Community health worker 2.5 (0.6-10.6) 58 28.3 (10.3-57.5) 168 27.8 (10.2-56.6) 226 7.2 (2.9-16.8) 233 11.7 (6.1-21.4) 569 11.5 (6.1-20.8) 802 
Niger – Total 59.6 (50.9-67.7) 1,333 46.5 (40.0-53.1) 2,405 48.6 (42.8-54.4) 3,738 49.5 (44.3-54.6) 1,778 44.4 (39.8-49.1) 1,514 45.7 (42-49.4) 3,292 
Public health facility  92.1 (77.9-97.5) 97 75.1 (70.5-79.2) 533 76.4 (72.2-80.2) 630 100.0 106 91.5 (85.2-95.3) 260 92.6 (87.0-95.9) 366 
Private not-for-profit health facility 74.9 (21.9-96.9) 5 - 0 74.9 (21.9-96.9) 5 100.0 2 100.0 1 100.0 3 
Private for-profit outlet             
Health facility/pharmacy 94.3 (81.5-98.4) 116 96.6 (73.8-99.7) 14 94.6 (83.8-98.4) 130 95.3 (89.1-98.1) 101 100.0 4 95.6 (89.6-98.2) 105 
Drug store 91.8 (59.0-98.9) 15 86.8 (42.0-98.4) 8 88.6 (58.6-97.7) 23 81.6 (64.5-91.5) 17 100.0 3 90.9 (77.8-96.6) 20 
General retailer/itinerant 57.1 (47.9-65.9) 1,099 44.6 (37.8-51.6) 1,846 46.6 (40.5-52.7) 2,945 46.6 (41.5-51.8) 1,552 41.4 (36.8-46.2) 1,245 42.7 (39.0-46.6) 2,797 
Total 58.7 (49.7-67.1) 1,230 44.8 (38.1-51.8) 1,868 47.1 (41.1-53.1) 3,098 48.2 (43.0-53.4) 1,670 41.6 (37.0-46.4) 1,252 43.3 (39.6-47.1) 2,922 
Community health worker 100.0 1 49.5 (19.5-79.8) 4 52.8 (21.1-82.4) 5 - 0 0.0 1 0.0 1 
Nigeria – Total 27.6 (23.7-31.8) 4,167 27.8 (21.9-34.7) 1,289 27.6 (24.3-31.2) 5,456 17.9 (14.9-21.4) 5,705 21.7 (19.7-24.0) 2,233 19.2 (17.1-21.6) 7,938 
Public health facility  90.8 (83.5-95.0) 203 92.2 (79.4-97.3) 52 92.1 (80.4-97.1) 255 98.6 (95.4-99.6) 48 76.9 (58.7-88.6) 61 82.8 (68.1-91.5) 109 
Private not-for-profit health facility 97.8 (84.8-99.7) 9 100.0 2 99.7 (97.2-100.0) 11 60.7 (22.9-88.9) 8 100.0 3 71.2 (29.8-93.5) 11 
Private for-profit outlet             
Health facility/pharmacy 95.4 (92.3-97.3) 784 93.3 (69.8-98.8) 30 93.8 (79.0-98.4) 814 94.9 (88.6-97.8) 107 83.6 (66.4-92.9) 38 90.6 (82.9-95.0) 145 
Drug store 97.7 (96.0-98.7) 748 94.9 (88.6-97.8) 283 97.3 (95.7-98.3) 1,031 98.1 (96.0-99.1) 823 97.3 (91.0-99.3) 370 97.8 (95.5-98.9) 1,193 
General retailer/itinerant 4.6 (3.1-6.9) 2,417 4.4 (2.6-7.4) 909 4.6 (3.3-6.3) 3,326 1.4 (1.0-2.0) 4,716 1.0 (0.5-1.9) 1,750 1.3 (0.9-1.8) 6,466 
Total 27.4 (23.6-31.6) 3,949 23.9 (17.5-31.7) 1,222 26.7 (23.4-30.3) 5,171 17.3 (14.3-20.8) 5,646 19.8 (17.8-21.8) 2,158 18.1 (16.0-20.5) 7,804 
Community health worker 100.0 6 69.1 (36.6-89.6) 13 80.0 (54.6-93.0) 19 100.0 3 32.9 (6.5-77.6) 11 33.8 (7.0-77.6) 14 
96 
 
 
 
Table 2.2.1: Cont. 
Country/Type of outlet 
BASELINE ENDLINE 
Urban  Rural Total Urban  Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N 
Tanzania – mainland - Total 12.6 (8.9-17.6) 1,125 17.0 (14.2-20.3) 1,994 15.8 (13.3-18.7) 3,119 13.9 (11.2- 17.2) 2,481 14.0 (11.7- 16.8) 1,228 14.0 (12.2- 16.0) 3,709 
Public health facility  89.6 (52.0-98.6) 7 93.2 (82.0-97.6) 65 92.9 (82.8-97.3) 72 100.0 7 93.1 (82.2- 97.5) 52 93.4 (83.0- 97.6) 59 
Private not-for-profit health facility 84.4 (65.2-93.9) 7 90.6 (68.2-97.8) 20 89.5 (72.3-96.5) 27 75.0 (40.4- 93.0) 6 100.0 2 84.9 (55.6- 96.2) 8 
Private for-profit outlet             
Health facility/pharmacy 79.8 (55.0-92.7) 260 99.1 (92.0-99.9) 14 82.6 (60.1-93.8) 274 
99.9 (99.2- 
100.0) 
323 100.0 16 99.9 (99.3- 
100.0) 
339 
Drug store 95.1 (86.5-98.3) 94 91.5 (81.4-96.4) 169 92.6 (85.5-96.4) 263 100.0 259 98.6 (94.2- 99.7) 115 99.2 (96.7- 99.8) 374 
General retailer/itinerant 0.3 (0.1-1.1) 756 5.9 (3.6-9.5) 1,722 4.3 (2.6-7.2) 2,478 0.2 (0.1- 0.5) 1,879 1.2 (0.3- 5.0) 1,043 0.9 (0.2- 3.1) 2,922 
Total 11.5 (8.2-15.9) 1,110 13.1 (10.6-16.0) 1,905 12.6 (10.5-15.1) 3,015 13.5 (10.8- 16.8) 2,461 10.4 (8.3- 12.8) 1,174 11.5 (9.8- 13.6) 3,635 
Community health worker 0.0 1 25.2 (6.1-63.4) 4 21.3 (4.7-59.6) 5 0.0 1 - 0 0.0 1 
Uganda – Total 14.6 (12.3-17.3) 1,723 14.0 (11.9-16.4) 9,430 14.1 (12.4-16.1) 11,153 14.1 (12.5-15.8) 7,914 15.0 (12.5-18.0) 8,293 14.8 (12.8-17.1) 16,207 
Public health facility  96.8 (85.5-99.4) 80 96.4 (93.6-98.0) 725 96.5 (93.9-98.0) 805 98.3 (92.2-99.6) 148 98.8 (95.8-99.7) 544 98.7 (96.4-99.6) 692 
Private not-for-profit health facility 84.7 (55.7-96.1) 5 96.6 (82.4-99.4) 30 94.7 (82.0-98.6) 35 100.0 13 93.4 (74.8-98.6) 30 94.1 (76.7-98.7) 43 
Private for-profit outlet             
Health facility/pharmacy 100.0 409 92.6 (86.9-95.9) 393 96.0 (90.8-98.3) 802 96.3 (94.9-97.3) 860 94.0 (86.6-97.5) 403 95.0 (91.6-97.1) 1,263 
Drug store 93.3 (89.4-95.8) 79 87.6 (81.6-91.8) 867 88.3 (83.0-92.1) 946 98.2 (97.1-98.9) 456 91.2 (86.8-94.3) 757 92.2 (88.4-94.9) 1,213 
General retailer/itinerant 0.3 (0.1-0.9) 1,113 0.4 (0.2-0.8) 6,664 0.4 (0.2-0.7) 7,777 0.1 (0.0-0.2) 6,244 0.4 (0.2-1.2) 5,731 0.3 (0.1-0.9) 11,975 
Total 14.2 (11.7-17.2) 1,601 13.3 (11.2-15.8) 7,924 13.5 (11.7-15.5) 9,525 13.5 (11.8-15.5) 7,560 14.0 (12.1-16.1) 6,891 13.9 (12.4-15.5) 14,451 
Community health worker 1.6 (0.1-19.1) 37 5.2 (1.0-22.7) 751 5.0 (1.0-21.0) 788 0.8 (0.1-5.0) 193 11.1 (3.1-32.8) 828 10.6 (3.0-31.2) 1,021 
Zanzibar – Total 17 1,117 11.1 1,114 14.1 2,231 9.9 2,250 6.1 1,971 8.1 4,221 
Public health facility  86.2 65 95.4 87 91.4 152 68.6 70 85.4 89 78 159 
Private not-for-profit health facility 100.0 2 100.0 1 100.0 3 25 4 100.0 1 40.0 5 
Private for-profit outlet             
Health facility/pharmacy 83.1 89 73.3 15 81.7 104 92.1 89 76.2 21 89.1 110 
Drug store 65.5 87 62.5 40 64.6 127 77.9 113 50.0 48 69.6 161 
General retailer/itinerant 0.1 874 0.4 971 0.3 1,845 0.2 1,974 0.2 1,812 0.2 3,786 
Total 12.6 1,050 3.9 1,026 8.3 2,076 8.0 2,176 2.3 1,881 5.3 4,057 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Note: Information on outlets with antimalarials in stock comes from Table 2.1.1, Column E. Information on outlets where screening questions were completed comes from Table 2.1.1, Column B. 
Screening questions asked whether outlets had any medicines or any antimalarials in stock that day, and if not whether they had had any medicines or any antimalarials, in stock in the previous 3 month. 
Nigeria baseline data collection was conducted in 2009. CI = Confidence interval 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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2.2.2  Antimalarials in stock by type 
Table 2.2.2 shows the percentage of outlets stocking non-artemisinin therapies, typically 
sulfadoxine-pyrimethamine (SP), amodiaquine, chloroquine and quinine. At endline, the level of 
nAT availability among all outlets was over 75% in all countries other than Zanzibar, where it 
was 47%. Overall, there was a large fall in availability of nAT in Zanzibar (41 percentage 
points). There were also smaller declines in Ghana (13 percentage points), Kenya (10 percentage 
points) and Niger (5 percentage points). In Ghana, Niger and Zanzibar, nAT availability fell in 
both the public and private for-profit sectors, while in Kenya it fell only in the private for-profit 
sector. It should be noted that there are legitimate uses of nATs, such as use of SP for 
intermittent preventive treatment for pregnant women and infants, and quinine for management 
of severe malaria. It is therefore not a policy objective to reduce availability or market share of 
these products to zero. 
 
Tables 2.2.3 and 2.2.4 show the percentage of outlets stocking artemisinin monotherapies for all 
dosage types and oral formulations only. Interpretation focuses on oral AMT, because crowding 
out oral AMT is the object of policy intervention. At endline, the availability of oral AMT was 
high in Ghana (41%) and Nigeria (33%). Everywhere else, it was stocked by less than 1% of 
outlets. There was little change between baseline and endline in all countries other than Zanzibar, 
where it fell from 17% at baseline to a negligible percentage at endline. In Ghana, oral AMT was 
primarily available in the private for-profit sector (47% of outlets at endline). In Nigeria, oral 
AMT availability at endline was 10% in public facilities and 34% in private for-profit facilities.  
 
Table 2.2.5 shows the percentage of outlets stocking non-quality-assured ACTs. At endline, 
these drugs were rare in Madagascar and Niger; available in 19-28% of outlets in Kenya, 
Nigeria, Tanzania mainland, Uganda and Zanzibar; and widely available in Ghana (67%). 
Generally, non-quality-assured ACTs were more available in urban than rural areas. Overall, 
availability of these products fell in Uganda and Zanzibar. In Uganda, the change was focused in 
private for-profit outlets, while in Zanzibar availability decreased in both the public sector and 
private for-profit outlets.  
 
Table 2.2.6 shows the percentage of outlets stocking quality-assured ACTs. At endline, QAACT 
availability was 19% in Niger and 28% in Madagascar. It ranged from 52 to 70% in Kenya, 
Nigeria, Tanzania mainland and Uganda. QAACT availability exceeded 80% in Ghana and 
Zanzibar. In Ghana and Zanzibar, QAACT availability was over 80% in both public facilities 
and private for-profit outlets. In Kenya, Tanzania mainland and Uganda, availability in private 
for-profit outlets was over 60%, but this was lower than availability in the public sector (over 
80%). There were much bigger differences in availability between the public and private for-
profit sectors in Madagascar (94% vs. 9%) and Niger (73% vs. 14%). Nigeria stands out as 
having similar levels of availability in the public and for-profit sectors, with low public sector 
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availability (58% in public facilities vs. 51% in private for-profit outlets). At endline, availability 
in all outlets was higher in rural areas in Zanzibar and urban areas in Niger and Uganda. 
 
There were large and significant increases in QAACT availability in Ghana, Kenya, Nigeria, 
Tanzania mainland, Uganda and Zanzibar, with changes of 24-52 percentage points, with the 
majority of the increase observed in the private for-profit sector in all cases. Niger had a more 
modest increase of 10 percentage points, with a greater increase in public than private for-profit 
facilities. These increases in the availability of QAACTs were seen in both urban and rural areas 
in all countries. No change in QAACT availability was observed in Madagascar 
 
Table 2.2.7 shows availability of QAACTs with and without the AMFm logo. Availability of 
QAACTs with the AMFm logo was substantially higher than QAACTs without the logo 
everywhere except Madagascar and Niger. The availability of QAACTs without the logo varied 
from 6% and 21%  
 
Table 2.2.8 shows availability of QAACTs among all public health facilities. This differs from 
Table 2.2.6 in that it includes in the denominator public health facilities with and without any 
antimalarials in stock. This is important because some countries have had severe problems in 
availability of all antimalarials in the public sector (see Table 2.2.1). Public sector QAACT 
availability was over 90% in Kenya, Uganda and Madagascar; between 67 and 78% in Ghana, 
Niger, Tanzania mainland and Zanzibar; and only 45% in Nigeria. Public sector availability 
improved in Niger between baseline and endline, from 34% to 67%.  
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Table 2.2.2: Outlets with non-artemisinin therapy in stock at baseline (2010) and endline (2011) 
Indicator 1.2 Percentage of outlets that had non-artemisinin monotherapy or non-artemisinin combination therapy in stock (n) among outlets with any antimalarials in stock at the time of the survey 
visit (N), by urban-rural location and type of outlet, according to country 
Country/Type of outlet 
BASELINE ENDLINE PERCENTAGE POINT CHANGE 
Urban Rural Total Urban Rural Total Urban Rural  Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95%CI) N % (95% CI) % (95% CI) % (95% CI) 
Ghana - Total 90.0 (86.3-92.7) 601 92.4 (89.7-94.5) 543 92.0 (89.7-93.7) 1,144 80.5 (76.8-83.8) 574 77.0 (72.0-81.3) 382 79.1 (76.2-81.7) 956 -9.5 (-14.1- -4.8) -15.5 (-20.6- -10.3) -12.8 (-16.2- -9.5) 
Public health facility  71.7 (60.4-80.8) 68 75.2 (69.2-80.4) 135 74.7 (69.4-79.4) 203 65.2 (47.5-79.4) 94 56.9 (49.4-64.1) 204 59.4 (52.2-66.2) 298 -6.5 (-25.7-12.7) -18.3 (-27.4- -9.1) -15.3 (-23.9- -6.8) 
Private not-for-profit health facility 46.1 (15.3-80.2) 5 100.0 9 90.6 (75.3-96.8) 14 100.0 4 75.6 (46.7-91.6) 9 85.2 (62.2-95.3) 13 53.9 (15.7-92.0) -24.4 (-47.5- -1.4) -5.4 (-23.8-12.9) 
Private for-profit outlet                
Health facility/pharmacy 86.7 (79.5-91.7) 315 85.1 (67.6-94) 62 86.1 (78.8-91.2) 377 77.2 (69.9-83.1) 271 68.3 (50.3-82.2) 26 76.0 (69.5-81.5) 297 -9.6 (-18.4- -0.7) -16.8 (-37.3-3.7) -10.1 (-18.6- -1.6) 
Drug store 96.5 (93.6-98.1) 211 95.4 (92.0-97.4) 331 95.5 (92.6-97.3) 542 83.2 (79.6-86.3) 202 84.4 (77.0-89.8) 140 83.7 (80.2-86.7) 342 -13.3 (-17.2- -9.4) -10.9 (-17.7- -4.1) -11.8 (-15.7- -7.9) 
General retailer/itinerant 100.0 2 100.0 3 100.0 5 38.0 (8.0-81.2) 3 66.3 (36.4-87.2) 3 52.2 (27.1-76.3) 6 
-62.0 (-107.4- -
16.6) -33.7 (-61.0- -6.4) -47.8 (-74.4- -21.2) 
Total 92.0 (87.7-94.8) 528 94.7 (91.5-96.7) 396 94.1 (91.6-95.9) 924 81.1 (77.5-84.2) 476 82.8 (76.2-87.9) 169 81.7 (78.5-84.5) 645 -10.9 (-15.6- -6.1) -11.9 (-18.1- -5.6) -12.4 (-16.1- -8.8) 
Community health worker - 0 - 3 - 3 - 0 - 0 - 0 - - - 
Kenya - Total 84.6 (80.7-87.9) 1,025 92.9 (85.7-96.7) 870 91.0 (86.0-94.3) 1,895 71.9 (65.5-77.5) 1,047 84.3 (79.9-88.0) 802 80.9 (77.3-84) 1,849 -12.7 (-19.6- -5.8) -8.6 (-15.1- -2.1) -10.1 (-15.3- -4.9) 
Public health facility  94.5 (86.0-98.0) 137 95.2 (91.4-97.3) 259 95.0 (91.8-97.0) 396 85.8 (75.9-92.1) 137 95.0 (88.4-98.0) 294 94.3 (88.6-97.3) 431 -8.7 (-18.2-0.8) -0.1 (-5.3-5.0) -0.7 (-5.4-4.0) 
Private not-for-profit health facility 84.0 (66.3-93.3) 23 85.0 (47.9-97.2) 15 84.7 (59.9-95.4) 38 67.3 (28.8-91.3) 19 97.8 (84.6-99.7) 27 91.8 (76.0-97.6) 46 -16.6 (-54.3-21.1) 12.8 (-10.5-36.2) 7.1 (-12.1-26.4) 
Private for-profit outlet                
Health facility/pharmacy 70.8 (64.3-76.6) 358 91.3 (81.3-96.2) 103 82.1 (75.2-87.3) 461 63.2 (57.4-68.6) 408 77.5 (66.0-85.9) 113 72.0 (65.4-77.8) 521 -7.6 (-15.8-0.6) -13.8 (-25.9- -1.7) -10.1 (-18.6- -1.5) 
Drug store 80.3 (73.5-85.8) 267 93.5 (87.8-96.6) 155 90.6 (87.4-93.0) 422 70.0 (60.0-78.5) 328 84.9 (77.1-90.4) 145 79.0 (72.6-84.1) 473 -10.3 (-21.4-0.7) -8.6 (-16.3- -0.9) -11.6 (-18- -5.3) 
General retailer/itinerant 100.0 236 100.0 318 100.0 554 86.5 (72.6-93.9) 155 81.6 (70.3-89.2) 223 82.4 (73.0-89.0) 378 -13.5 (-23.7- -3.4) -18.4 (-27.8- -9.1) -17.6 (-25.4- -9.7) 
Total 83.6 (79.4-87.1) 861 96.3 (92.8-98.2) 576 93.2 (90.9-94.9) 1,437 71.6 (64.6-77.6) 891 81.7 (76.8-85.8) 481 78.6 (74.7-82.0) 1,372 -12.0 (-19.5- -4.6) -14.6 (-19.7- -9.5) -14.6 (-18.7- -10.5) 
Community health worker 52.7 (9.1-92.5) 4 33.5 (7.8-74.9) 20 34.0 (8.3-74.5) 24 - 0 - 0 - 0 - - - 
Madagascar - Total 97.1 (94.2-98.6) 1,445 85.5 (71.6-93.3) 967 87.9 (76.5-94.2) 2,412 95.7 (93.3-97.3) 973 86.2 (76.6-92.2) 1,369 87.5 (79.3-92.7) 2,342 -1.4 (-4.2-1.3) 0.7 (-12.2-13.5) -0.5 (-11.1-10.2) 
Public health facility  78.9 (53.9-92.3) 67 75.4 (68-81.5) 446 76.4 (68.1-83.0) 513 92.5 (83.7-96.7) 63 86.3 (80.4-90.7) 536 87.0 (81.8-90.9) 599 13.6 (-6.4-33.6) 11.0 (2.6-19.3) 10.7 (2.0-19.3) 
Private not-for-profit health facility 100.0 6 - 0 100.0 6 62.5 (54.9-69.5) 25 60.3 (13.7-93.5) 5 61.1 (27.8-86.6) 30 -37.5 (-44.8- -30.3) - -38.9 (-72.1- -5.6) 
Private for-profit outlet                
Health facility/pharmacy 96.9 (89.8-99.1) 125 100.0 9 98.3 (94.3-99.5) 134 97.6 (92.5-99.2) 103 100.0 12 98.7 (96.0-99.6) 115 0.6 (-4.0-5.3) - 0.4 (-2.1-3) 
Drug store 99.5 (96.8-99.9) 28 98.8 (96.3-99.6) 228 99.0 (97.3-99.7) 256 100.0 28 98.3 (96.3-99.2) 347 98.5 (96.7-99.3) 375 0.5 (-0.4-1.5) -0.4 (-2.3-1.4) -0.5 (-2.1-1) 
General retailer/itinerant 99.8 (99.5-99.9) 1,217 99.3 (97.8-99.8) 246 99.4 (98.2-99.8) 1,463 99.6 (98.8-99.9) 739 99.4 (98.3-99.8) 404 99.5 (98.5-99.8) 1,143 -0.2 (-0.7-0.2) 0.1 (-0.9-1.1) 0.1 (-0.8-0.9) 
Total 99.5 (98.7-99.8) 1,370 99.3 (98.0-99.8) 483 99.3 (98.4-99.7) 1,853 99.3 (98.6-99.7) 870 99.4 (98.4-99.7) 763 99.4 (98.6-99.7) 1,633 -0.1 (-0.8-0.5) 0.1 (-0.9-1.0) 0.0 (-0.7-0.8) 
Community health worker 100.0 2 1.2 (0.1-11.1) 38 1.4 (0.2-10.3) 40 0.0 15 9.5 (3.6-23.1) 65 9.3 (3.5-22.4) 80 -100.0 (0.0-0.0) 8.3 (-1.1-17.7) 7.9 (-1.2-17) 
Niger - Total 98.1 (96.0-99.1) 833 98.8 (98.1-99.2) 1,198 98.7 (98.0-99.1) 2,031 92.7 (90.4-94.5) 924 94.3 (92.6-95.7) 738 93.9 (92.5-95.0) 1,662 -5.5 (-7.9- -3.0) -4.5 (-6.1- -2.9) -4.8 (-6.1- -3.4) 
Public health facility  94.3 (85.0-98) 91 94.3 (90.4-96.7) 385 94.3 (90.8-96.5) 476 93.3 (87.5-96.5) 102 86.1 (80.5-90.3) 220 87.1 (82.2-90.9) 322 -1.0 (-8.1-6.1) -8.2 (-13.8- -2.5) -7.1 (-12.2- -2.1) 
Private not-for-profit health facility 100.0 4 - 0 100.0 4 50.8 (11.9-88.7) 2 100.0 1 83.8 (42.4-97.3) 3 -49.2 (-99.7-1.3) - -16.2 (-42.5-10.1) 
Private for-profit outlet                
Health facility/pharmacy 98.2 (94.6-99.4) 106 100.0 12 98.4 (95.3-99.5) 118 98.5 (96.5-99.3) 95 16.9 (2.4-62.2) 4 93.8 (82.5-98.0) 99 0.3 (-2.0-2.7) -83.1 (-112.2- -54.1) -4.6 (-11.5-2.3) 
Drug store 81.8 (54.4-94.4) 14 100.0 7 93.3 (76.7-98.3) 21 100.0 15 100.0 3 100.0 18 18.2 (-1.4-37.8) 0.0 6.7 (-2.3-15.6) 
General retailer/itinerant 98.6 (96.7-99.4) 617 99.2 (98.4-99.6) 792 99.1 (98.4-99.5) 1,409 92.3 (89.9-94.3) 710 95.4 (93.6-96.7) 510 94.6 (93.2-95.7) 1,220 -6.3 (-8.7- -3.8) -3.8 (-5.4- -2.3) -4.6 (-5.9- -3.2) 
Total 98.3 (96.3-99.2) 737 99.2 (98.5-99.6) 811 99.0 (98.4-99.4) 1,548 92.8 (90.4-94.6) 820 95.3 (93.6-96.6) 517 94.6 (93.2-95.7) 1,337 -5.5 (-7.9- -3.1) -3.9 (-5.5- -2.3) -4.5 (-5.8- -3.1) 
Community health worker 100.0 1 100.0 2 100.0 3 - 0 - 0 - 0 - - - 
Nigeria - Total 98.0 (96.2-98.9) 1,745 95.0 (89.8-97.6) 364 97.3 (95.6-98.4) 2,109 97.1 (94.5-98.5) 1,020 95.7 (93.2-97.3) 470 96.6 (94.8-97.8) 1,490 -0.9 (-3.1-1.4) 0.7 (-3.5-4.8) -0.8 (-2.8-1.2) 
Public health facility  97.7 (92.7-99.3) 182 87.2 (67.3-95.7) 45 87.8 (69.2-95.9) 227 78.2 (47.9-93.4) 42 74.0 (55.4-86.7) 52 75.4 (60.1-86.2) 94 -19.5 (-42.8-3.8) -13.1 (-33.9-7.6) -12.4 (-30.5-5.6) 
Private not-for-profit health facility 89.5 (52.0-98.5) 7 100.0 2 98.9 (89.0-99.9) 9 100.0 6 53.2 (7.4-94.1) 3 82.4 (34.3-97.7) 9 10.5 (-8.8-29.8) -46.8 (-112.5-18.8) -16.5 (-48.3-15.3) 
Private for-profit outlet                
Health facility/pharmacy 94.5 (90.0-97.1) 734 79.2 (70.7-85.7) 24 83.0 (71.2-90.6) 758 90.0 (77.7-95.9) 95 88.2 (67.7-96.4) 30 89.3 (79.6-94.7) 125 -4.5 (-13.7-4.6) 9.0 (-6.1-24.1) 6.4 (-5.6-18.4) 
Drug store 98.8 (96.8-99.5) 722 
99.7 (98.1-
100.0) 268 98.9 (97.3-99.6) 990 99.2 (97.7-99.7) 801 
99.9 (99.1-
100.0) 362 99.5 (98.6-99.8) 1,163 0.4 (-1.0-1.8) 0.2 (-0.4-0.7) 0.5 (-0.6-1.7) 
General retailer/itinerant 96.7 (90.3-99) 94 100.0 19 97.4 (91.9-99.2) 113 91.2 (81.7-96.0) 73 100.0 19 93.5 (85.7-97.2) 92 -5.5 (-13.2-2.1) 0.0 -3.9 (-10.0-2.2) 
Total 98.5 (97-99.3) 1,550 96.5 (87.9-99.1) 311 98.2 (96.5-99.1) 1,861 97.8 (95.6-98.9) 969 98.8 (97.1-99.5) 411 98.2 (96.8-98.9) 1,380 -0.7 (-2.6-1.1) 2.3 (-2.3-6.9) 0.0 (-1.6-1.6) 
Community health worker 1.0 (0.1-9.6) 6 100.0 6 56.4 (18.6-88.0) 12 0.0 3 100.0 4 96.1 (67.6-99.7) 7 -1.0 (-3.4-1.3) 0.0 39.6 (-3.7-83.0) 
Tanzania – mainland - Total 98.5 (94.3-99.6) 320 98.4 (96.1-99.3) 302 98.4 (96.6-99.3) 622 99.0 (96.7-99.7) 596 92.4 (85.4-96.2) 191 94.8 (90.4-97.3) 787 0.5 (-1.8-2.9) -5.9 (-11.2- -0.7) -3.6 (-7- -0.1) 
Public health facility  84.0 (32.9-98.3) 5 97.8 (85.9-99.7) 55 96.9 (87.5-99.3) 60 100.0 7 73.5 (56.5-85.5) 48 74.7 (58.2-86.2) 55 16.0 (-15.5-47.5) -24.4 (-39.5- -9.2) -22.2 (-36.9- -7.5) 
Private not-for-profit health facility 100.0 6 100.0 16 100.0 22 100.0 4 100.0 2 100.0 6 0.0 0.0 0.0 
Private for-profit outlet                
Health facility/pharmacy 95.8 (79.2-99.3) 220 100.0 12 96.6 (81.9-99.4) 232 99.8 (99.1-99.9) 321 100.0 16 
99.8 (99.3-
100.0) 337 3.9 (-3.2-11.0) 0.0 3.2 (-2.7-9.2) 
Drug store 100.0 88 99.4 (95.3-99.9) 148 99.6 (96.9-99.9) 236 99.2 (95.4-99.9) 259 100.0 113 99.6 (97.7-99.9) 372 -0.8 (-2.2-0.6) 0.6 (-0.6-1.9) 0.1 (-1-1.1) 
General retailer/itinerant 100.0 1 97.0 (90.8-99.1) 70 97.0 (90.8-99.1) 71 74.3 (22.0-96.7) 5 100.0 12 97.7 (79.7-99.8) 17 -25.7 (-69.5-18.2) 3.0 (-0.4-6.4) 0.7 (-5.6-7) 
Total 99.3 (95-99.9) 309 98.4 (95.6-99.4) 230 98.6 (96.6-99.5) 539 98.9 (96.6-99.7) 585 100.0 141 99.5 (98.3-99.9) 726 -0.3 (-2.2-1.6) 1.6 (0-3.2) 0.9 (-0.5-2.3) 
Community health worker - 0 100.0 1 100.0 1 - 0 - 0 - 0 - - - 
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Table 2.2.2: Cont. 
Indicator 1.2 Percentage of outlets that had non-artemisinin monotherapy or non-artemisinin combination therapy in stock (n) among outlets with any antimalarials in stock at the time of the survey 
visit (N), by urban-rural location and type of outlet, according to country 
Country/Type of outlet 
BASELINE ENDLINE PERCENTAGE POINT CHANGE 
Urban Rural Total Urban Rural Total Urban Rural  Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95%CI) N % (95% CI) % (95% CI) % (95% CI) 
Uganda - Total 98.8 (97.7-99.4) 536 93.8 (82.4-98.0) 1,869 94.8 (85.4-98.3) 2,405 95.1 (94.3-95.8) 1,412 84.1 (69.3-92.5) 1,720 86.4 (74.3-93.3) 3,132 -3.7 (-4.8- -2.6) -9.7 (-22.7-3.4) -8.4 (-19.1-2.2) 
Public health facility  97.1 (85.8-99.5) 76 96.8 (95.0-98.0) 690 96.8 (95.3-97.9) 766 94.8 (87.9-97.9) 144 96.0 (93.6-97.4) 534 95.8 (93.7-97.2) 678 -2.3 (-8.8-4.2) -0.9 (-3.2-1.4) -1.0 (-3.2-1.1) 
Private not-for-profit health facility 100.0 4 100.0 27 100.0 31 100.0 12 100.0 27 100.0 39 0.0 0.0 0.0 
Private for-profit outlet                
Health facility/pharmacy 99.8 (99.6-99.9) 383 
99.9 (99.5-
100.0) 356 99.8 (99.7-99.9) 739 95.5 (94.2-96.6) 814 97.6 (95.3-98.8) 387 96.7 (95.4-97.6) 1,201 -4.2 (-5.4- -3.1) -2.2 (-3.9- -0.6) -3.1 (-4.2- -2.0) 
Drug store 97.7 (93.2-99.2) 70 98.1 (96.2-99.0) 748 98.0 (96.4-98.9) 818 96.0 (94.3-97.1) 436 95.2 (92.5-97) 676 95.3 (93.1-96.9) 1,112 -1.7 (-4.5-1.1) -2.8 (-5.3- -0.3) -2.7 (-4.8- -0.5) 
General retailer/itinerant 100.0 2 85.5 (65.9-94.7) 19 87.4 (69.8-95.5) 21 10.3 (1.2-52.6) 4 44.1 (21.3-69.7) 14 42.2 (21.6-66.0) 18 
-89.7 (-110.5- -
69.0) -41.3 (-70.8- -11.9) -45.2 (-71.6- -18.8) 
Total 98.9 (97.7-99.5) 455 98.1 (96.5-98.9) 1,123 98.3 (97.1-99.0) 1,578 95.3 (94.5-95.9) 1,254 94.4 (91.1-96.5) 1,077 94.6 (92.2-96.3) 2,331 -3.6 (-4.7- -2.6) -3.7 (-6.5- -0.9) -3.7 (-5.9- -1.5) 
Community health worker 100.0 1 2.0 (0.1-26.4) 29 4.3 (0.4-33.5) 30 0.0 2 0.2 (0-2) 82 0.2 (0.0-2.0) 84 -100.0 -1.8 (-7-3.4) -4.1 (-13.2-5.1) 
Zanzibar - Total 89.9 189 85.4 123 88.1  312 50.9 222 40.3 119 47.2 341 -39.0 -45.0 -40.9 
Public health facility  73.2 56 78.3 83 76.3 139 35.4 48 28.0 75 30.9 123 -37.8 -50.3 -45.4 
Private not-for-profit health facility 100.0 2 100.0 1 100.0 3 0.0 1 0.0 1 0.0 2 -100 -100.0 -100.0 
Private for-profit outlet                
Health facility/pharmacy 95.9 73 100.0 11 96.4 84 51.2 82 75.0 16 55.1  98 -44.7 -25.0 -41.3  
Drug store 98.2 57 100.0 24 98.8  81 58.0 88 58.3  24 58.0 112 -40.3  -41.7  -40.7  
General retailer/itinerant 100.0 1 100.0 4 100.0 5 100.0 3 33.3 3 66.7  6 0.0 -66.7 -33.3  
Total 96.9 131 100.0 39 97.6 170 55.5 173 62.8 43 56.9 216 -41.5 -37.2 -40.7 
Community health worker - 0 -  0 - 0 - 0 -  0 - 0 - - - 
Note: Nigeria baseline data collection was conducted in 2009. 
CI = Confidence interval  
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys  
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Table 2.2.3: Outlets with artemisinin monotherapy in stock at baseline (2010) and endline (2011) 
Indicator 1.3 Percentage of outlets that had artemisinin monotherapy in stock (n) among outlets with any antimalarials in stock at the time of the survey visit (N), by urban-rural location and type of 
outlet, according to country 
Country/Type of outlet 
BASELINE ENDLINE PERCENTAGE POINT CHANGE 
Urban Rural Total Urban Rural Total Urban Rural  Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95%CI) N % (95% CI) % (95% CI) % (95% CI) 
Ghana - Total 73.0 (66.4-78.8) 601 53.6 (45.7-61.3) 543 57.3(50.8-63.7) 1,144 56.1(47.4-64.4) 574 41.8 (33.4-50.8) 382 50.5 (44.1-56.9) 956 -17.0 (-27.5- -6.5) -11.8 (-23.5- -0.1) -6.8 (-15.9-2.2) 
Public health facility  38.4 (25.6-53.1) 68 38.1 (25.6-52.3) 135 38.1 (27.1-50.5) 203 29.4 (17.6-44.7) 94 28.2 (19.7-38.6) 204 28.6 (21.4-37.0) 298 -9.0 (-28.5-10.5) -9.8 (-26.3-6.7) -9.5 (-23.7-4.6) 
Private not-for-profit health facility 48.9 (16.9-81.8) 5 76.5 (34.2-95.3) 9 71.7 (39.4-90.8) 14 80.0 (38.0-96.3) 4 54.0 (28.0-78.0) 9 64.2 (41.2-82.2) 13 31.1 (-17.3-79.5) -22.5 (-64.9-19.9) -7.5 (-42.2-27.2) 
Private for-profit outlet                
Health facility/pharmacy 89.2 (83.4-93.1) 315 73.1 (55.1-85.7) 62 83.0 (75.4-88.6) 377 83.8 (76.1-89.3) 271 59.3 (33.1-81.1) 26 80.6 (72.5-86.7) 297 -5.4 (-13.4-2.6) -13.8 (-43.8-16.2) -2.4 (-12-7.1) 
Drug store 64.5 (56.3-72.0) 211 54.2 (45.3-62.7) 331 55.5 (47.6-63.0) 542 48.3 (39.5-57.2) 202 44.8 (33.8-56.3) 140 46.9 (40.0-54.0) 342 -16.3 (-28- -4.5) -9.4 (-23.6-4.9) -8.5 (-18.9-1.8) 
General retailer/itinerant 0.0 2 0.0 3 0.0 5 0.0 3 0.0 3 0.0 6    
Total 75.7 (68.9-81.4) 528 55.0 (46.4-63.4) 396 59.1 (52-65.9) 924 57.3 (48.5-65.6) 476 45.0 (34.3-56.2) 169 53.1 (46.1-60.0) 645 -18.4 (-29.0- -7.8) -10.0 (-23.9-3.9) -6.0 (-15.8-3.8) 
Community health worker - 0 0.0- 3 0.0 3 - 0 - 0 - 0 - - - 
Kenya - Total 22.1 (14.0-33.1) 1,025 9.2 (3.1-24.2) 870 12.3 (6.7-21.5) 1,895 15.0 (10.5-21.2) 1,045 6.2 (4.4-8.8) 801 8.7 (6.9-10.9) 1,846 -7.1 (-17.9-3.7) -3.0 (-12.7-6.7) -3.6 (-11.0-3.8) 
Public health facility  10.0 (3.4-25.9) 137 2.1 (0.8-5.2) 259 3.9 (1.7-8.7) 396 13.3 (7.3-23.0) 137 1.7 (0.6-5.0) 294 2.6 (1.3-5.3) 431 3.4 (-9.4-16.1) -0.4 (-3.0-2.3) -1.3 (-4.9-2.4) 
Private not-for-profit health facility 30.5 (14.5-53.3) 23 3.3 (0.4-20.8) 15 11.1 (4.9-23.2) 38 43.5 (24.3-64.8) 19 13.9 (5.3-31.7) 27 19.7 (10.2-34.6) 46 12.9 (-16.2-42.0) 10.6 (-3.4-24.6) 8.6 (-6.2-23.4) 
Private for-profit outlet                
Health facility/pharmacy 51.9 (34.1-69.3) 358 19.1 (8.3-38.2) 103 33.9 (22.6-47.3) 461 29.1 (21.7-37.8) 406 19.4 (12.9-28) 113 23.1 (17.7-29.5) 519 -22.8 (-42.7- -2.9) 0.3 (-16.2-16.7) -10.8 (-24.5-2.9) 
Drug store 17.3 (10.9-26.5) 267 21.8 (7.3-49.6) 155 20.8 (8.3-43.1) 422 11.4 (6.2-20.0) 328 7.3 (3.3-15.3) 145 9.0 (5.5-14.2) 473 -5.9 (-16.1-4.2) -14.4 (-36.4-7.6) -11.8 (-29.6-5.9) 
General retailer/itinerant 0.0 236 0.0 318 0.0 554 0.0 155 0.0 222 0.0 377 0.0 0.0 0.0 
Total 23.4 (14.6-35.2) 861 10.8 (3.6-28.3) 576 13.9 (7.4-24.7) 1,437 14.3 (9.8-20.4) 889 6.7 (4.5-9.7) 480 9.0 (7.0-11.5) 1,369 -9.1 (-20.6-2.4) -4.2 (-15.7-7.3) -4.9 (-13.5-3.7) 
Community health worker 0.0 4 0.0 20 0.0 24 0.0 0 0.0 0 0.0 0 - - - 
Madagascar - Total 1.6.0 (0.5-5.1) 1,438 0 (0-0.2) 962 0.4 (0.1-1.1) 2,400 0.8 (0.2-3.2) 971 0.0 (0.0-0.2) 1,347 0.1 (0.0-0.5) 2,318 -0.8 (-3.0-1.3) 0.0 (-0.1-0.1) -0.2 (-0.7-0.2) 
Public health facility  0.0 67 0.0 444 0.0 511 0.0 62 0.3 (0.0-2.2) 514 0.3 (0-1.9) 576 0.0 0.3 (-0.3-0.9) 0.3 (-0.3-0.8) 
Private not-for-profit health facility 0.0 6 - 0 0.0 6 0.0 25 0.0 5 0.0 30 0.0 - 0.0 
Private for-profit outlet                
Health facility/pharmacy 15.3 (7.3-29.6) 122 0.0 9 8.7 (3.2-21.4) 131 6.0 (1.9-17.9) 102 0.0 12 3.3 (0.8-12.8) 114 -9.3 (-22.1-3.4) 0.0 -5.4 (-14.8-4.0) 
Drug store 0.5 (0.1-3.2) 28 0.6 (0.1-4.8) 227 0.6 (0.1-2.6) 255 0.0 28 0.0 347 0.0 375 -0.5 (-1.5-0.4) -0.6 (-1.9-0.7) -0.6 (-1.5-0.3) 
General retailer/itinerant 0.0 1,213 0.0 244 0.0 1,457 0.0 739 0.0 404 0.0 1,143 0.0 0.0 0.0 
Total 1.8 (0.5-5.9) 1,363 0.0 (0.0-0.3) 480 0.4 (0.1-1.3) 1,843 0.9 (0.2-3.6) 869 0.0 763 0.1 (0.0-0.7) 1,632 -0.9 (-3.4-1.5) 0.0 (-0.1-0.0) -0.3 (-0.8-0.2) 
Community health worker 0.0 2 0.0 38 0.0 40 0.0 15 0.0 65 0.0 80 0.0 0.0 0.0 
Niger - Total 3.0 (1.8-4.9) 833 0.2 (0.1-0.5) 1,198 0.8 (0.5-1.2) 2,031 2.3 (1.8-3.1) 924 0.4 (0.0-2.1) 738 0.9 (0.7-1.3) 1,662 -0.7 (-2.3-0.9) 0.2 (-0.2-0.6) 0.2 (-0.3-0.6) 
Public health facility  0.6 (0.1-4.4) 91 2.4 (1.0-5.7) 385 2.3 (1.0-5.2) 476 5.0 (2.6-9.3) 102 2.1.0 (0.9-5.0) 220 2.5 (1.3-4.8) 322 4.4 (1.0-7.7) -0.3 (-3.1-2.4) 0.3 (-2.2-2.8) 
Private not-for-profit health facility 0.0 4 - 0 0.0 4 0.0 2 100.0 1 67.1 (23.4-93.1) 3 0.0 - 67.1 (25.4-108.7) 
Private for-profit outlet                
Health facility/pharmacy 40.3 (25.5-57.0) 106 0.0 12 34.4 (21.1-50.7) 118 29.3 (19.4-41.6) 95 0.0 4 27.6 (18.2-39.6) 99 -11.0 (-30.6-8.6) 0.0 -6.8 (-25.3-11.7) 
Drug store 12.1 (2.3-45.2) 14 0.0 7 4.5 (0.6-25.0) 21 18.8 (6.4-43.8) 15 0.0 3 8.3 (2.6-23.6) 18 6.7 (-19.6-33.0) 0.0 3.9 (-8.6-16.3) 
General retailer/itinerant 1.0 (0.4-2.8) 617 0.0 792 0.2 (0.1-0.6) 1,409 0.4 (0.2-1.2) 710 0.0 510 0.1 (0.0-0.3) 1,220 -0.6 (-1.7-0.5) 0.0 -0.1 (-0.3-0.2) 
Total 3.1 (1.9-5.1) 737 0.0 811 0.6 (0.4-1.0) 1,548 2.2 (1.6-3.0) 820 0.0 517 0.6 (0.4-0.9) 1,337 -0.9 (-2.6-0.7) 0.0 0.0 (-0.4-0.4) 
Community health worker 0.0 1 0.0 2 0.0 3 - 0 - 0 - 0 - - - 
Nigeria - Total 47.5 (35.1-60.1) 1,726 38.2 (29.1-48.2) 361 45.5 (35.5-55.8) 2,087 39.4 (27.2-53.0) 1,020 34.6 (28.6-41.2) 469 37.5 (29.8-45.9) 1,489 -8.1 (-26.4-10.2) -3.6 (-15.0-7.9) -8.0 (-21.0-5.0) 
Public health facility  32.5 (22.7-44.1) 181 28.3 (9.0-61.2) 45 28.5 (9.9-59.2) 226 33.0 (16.9-54.3) 42 27.7 (14.7-45.8) 52 29.4 (18.5-43.3) 94 0.5 (-21.7-22.6) -0.6 (-32.7-31.5) 0.8 (-28.2-29.9) 
Private not-for-profit health facility 
30.9 (7.3-71.7) 6 85.5 (29.0-98.8) 2 80.8 (30.3-97.6) 8 46.7 (14.7-81.6) 6 46.3 (5.7-92.4) 3 46.5 (17.4-78.3) 9 15.8 (-38.7-70.3) -39.2 (-112.6-34.2) 
-34.3 (-83.9-
15.3) 
Private for-profit outlet                
Health facility/pharmacy 71.7 (65.3-77.4) 733 65.2 (47.4-79.6) 24 66.8 (54.7-77.1) 757 69.1 (56.7-79.2) 95 21.9 (9.2-43.6) 30 51.9 (37.7-65.8) 125 -2.7 (-15.5-10.2) -43.3 (-67.2- -19.4) -14.9 (-33.2-3.3) 
Drug store 48.5 (35.8-61.4) 715 42.1 (31.3-53.7) 268 47.5 (36.5-58.7) 983 38.1 (24.8-53.5) 801 38.2 (31.7-45.2) 361 38.2 (29.3-48.0) 1,162 -10.3 (-29.9-9.3) -3.8 (-17.0-9.3) -9.3 (-23.9-5.3) 
General retailer/itinerant 39.0 (21.4-60.0) 85 3.1 (0.4-19.3) 16 32.0 (17.5-51.1) 101 14.7 (5.0-36.0) 73 10.2 (2.5-34.1) 19 13.6 (5.6-29.5) 92 -24.3 (-49.3-0.7) 7.2 (-7.9-22.2) -18.4 (-39.2-2.3) 
Total 47.8 (35.3-60.5) 1,533 41.4 (31.3-52.3) 308 46.6 (36.2-57.4) 1,841 39.5 (26.8-53.8) 969 35.6 (29.6-42.2) 410 38.1 (29.8-47.1) 1,379 -8.3 (-27.1-10.5) -5.7 (-18.0-6.6) -8.6 (-22.3-5.2) 
Community health worker 1.0 (0.1-9.6) 6 2.2 (0.3-16.6) 6 1.7 (0.3-8.5) 12 0.0 3 0.0 4 0.0 7 -1.0 (-3.4-1.3) -2.2 (-6.8-2.5) -1.7 (-4.5-1.1) 
Tanzania – mainland - Total 8.6 (3.9-18.0) 317 0.9 (0.2-3.4) 284 2.8 (1.3-5.7) 601 5.9 (3.9-8.8) 596 1.6 (0.4-6.3) 191 3.2 (1.8-5.5) 787 -2.8 (-9.8-4.2) 0.7 (-1.9-3.2) 0.4 (-2.2-3.000) 
Public health facility  16.0 (1.7-67.2) 5 0.0 51 1.2 (0.2-8.2) 56 17.2 (2.3-65.0) 7 0.0 48 0.8 (0.1-5.3) 55 1.2 (-42.9-45.3) 0.0 -0.4 (-3.2-2.3) 
Private not-for-profit health facility 48.7 (20-78.3) 6 13.2 (3.4-39.4) 16 19.8 (7.9-41.5) 22 45.4 (10.0-86.2) 4 47.8 (4.9-94.2) 2 46.5 (13.5-82.9) 6 -3.3 (-62.5-55.9) 34.6 (-38-107.2) 26.8 (-18.6-72.1) 
Private for-profit outlet                
Health facility/pharmacy 33.7 (19.3-51.9) 220 7.3 (1.2-34.3) 12 28.9 (16.5-45.4) 232 26.3 (17.5-37.5) 321 23.0 (3.3-72.3) 16 25.4 (14.9-39.9) 337 -7.5 (-26.8-11.9) 15.7 (-24.2-55.7) -3.4 (-22.6-15.7) 
Drug store 0.0 85 0.0 144 0.0 229 1.4 (0.7-2.7) 259 0.9 (0.1-5.9) 113 1.1 (0.4-2.9) 372 1.4 (0.4-2.3) 0.9 (-0.8-2.6) 1.1 (0.1-2.2) 
General retailer/itinerant 0.0 1 0.0 60 0.0 61 0.0 5 0.0 12 0.0 17 0.0 0.0 0.0 
Total 6.1 (3.4-10.7) 306 0.1 (0.0-0.5) 216 1.8 (0.9-3.3) 522 4.9 (3.2-7.6) 585 1.7 (0.3-9.1) 141 3.1 (1.7-5.7) 726 -1.1 (-5.2-3.0) 1.6 (-1.3-4.5) 1.3 (-0.8-3.5) 
Community health worker - 0 0.0 1 0.0 1 - 0 - 0 - 0 - - - 
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Table 2.2.3: Cont. 
Country/Type of outlet 
BASELINE ENDLINE    
Urban Rural Total Urban Rural Total Urban Rural  Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) % (95% CI) % (95% CI) 
Uganda - Total 25.4 (18.4-34) 533 6.5 (3.6-11.4) 1,863 10.4 (6.4-16.4) 2,396 25.6 (20.8-31.2) 1,411 16.1 (10.0-24.7) 1,717 18 (12.8-24.7) 3,128 -2.8 (-9.8-4.2) 0.7 (-1.9-3.2) 0.4 (-2.0.2.3) 
Public health facility  8.8 (3.7-19.5) 76 0.4 (0.1-1.6) 686 1.2 (0.4-3.6) 762 13.4 (7.6-22.6) 144 2.7 (1.6-4.7) 534 4.3 (2.9-6.3) 678 4.7 (-5.6-14.9) 2.3 (0.8-3.9) 3 (0.9-5.2) 
Private not-for-profit health facility 31.1 (3.4-85.3) 3 17.3 (5.0-45.5) 27 19.0 (6.2-45.2) 30 53.9 (42.9-64.6) 12 33.0 (14.8-58.3) 27 35.2 (17.8-57.6) 39 22.9 (-31.7-77.4) 15.6 (-14.3-45.6) 16.2 (-11.8-44.2) 
Private for-profit outlet                
Health facility/pharmacy 37.1 (29.5-45.5) 381 
24.0 (15.9-
34.6) 354 30.4 (24.6-36.8) 735 41.0 (34.3-48.2) 813 26.8 (20.6-34.1) 385 33.1 (29.0-37.5) 1,198 3.9 (-6.5-14.4) 2.8 (-8.6-14.2) 2.7 (-4.6-10.1) 
Drug store 12.3 (3.3-36.5) 70 3.6 (1.9-7.0) 748 4.8 (2.4-9.4) 818 6.7 (4.5-9.7) 436 4.3 (2.5-7.3) 675 4.7 (3.0-7.1) 1,111 -5.6 (-20.6-9.5) 0.7 (-2.6-4) -0.1 (-3.9-3.7) 
General retailer/itinerant 0.0 2 0.0 19 0.0 21 0.0 4 0.0 14 0.0 18 0.0 0.0 0.0 
Total 26.3 (18.4-36.2) 453 7.2 (4.1-12.4) 1,121 11.5 (7.2-18.1) 1,574 26.0 (21.1-31.7) 1,253 9.1 (5.7-14.2) 1,074 13.1 (9.5-17.8) 2,327 -0.3 (-10.5-9.9) 1.9 (-3.8-7.6) 1.6 (-5.1-8.2) 
Community health worker 0.0 1 2.0 (0.1-22.8) 29 2.0 (0.1-21.9) 30 53.7 (6.9-94.8) 2 71.0 (53.5-84) 82 71.0 (53.5-83.9) 84 53.7 (-14.5-121.9) 69.0 (52.7-85.3) 69 (52.8-85.2) 
Zanzibar - Total 38.6  189 5.7  123 25.6 312 17.6 222 6.7 119 13.8 341 -21.1 1.0 -11.9 
Public health facility  8.9  56 2.4  83 5.0  139 12.5 48 2.7 75 6.5 123 3.6 0.3 1.5 
Private not-for-profit health facility 0.0 2 0.0 1 0.0 3 100.0 1 100.0 1 100.0 2 100.0 100.0 100.0 
Private for-profit outlet                
Health facility/pharmacy 76.7 73 36.4  11 71.4  84 36.6  82 25.0  16 34.7  98 -40.1  -11.4  -36.7 
Drug store 21.1  57 4.2  24 16.0 81 1.1 88 4.2 24 1.8 112 -19.9 0.0 -14.3 
General retailer/itinerant 0.0 1 0.0  4 0.0 5 33.3 3 0 .0 3 16.7  6 33.3  0.0 16.7 
Total 51.9  131 12.8  39 42.9  170 18.5  173 11.6  43 17.1  216 -33.4  -1.2  -25.8  
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 - - - 
Note: Nigeria baseline data collection was conducted in 2009. 
CI = Confidence interval 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.2.4: Outlets with oral artemisinin monotherapy in stock at baseline (2010) and endline (2011) 
Percentage of outlets that had oral artemisinin monotherapy in stock (n) among outlets with any antimalarials in stock at the time of the survey visit (N), by urban-rural location and type of outlet, 
according to country 
Country/Type of outlet 
BASELINE ENDLINE PERCENTAGE POINT CHANGE 
Urban Rural Total Urban Rural Total Urban Rural  Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) % (95% CI) % (95% CI) 
Ghana - Total 
61.1 (56.1-65.9) 601 46.4 (39-53.9) 543 49.2 (43.2-55.3) 1,144 
46.8 (38.8-
54.9) 574 
30.8 (22.7-
40.3) 382 40.5 (34.5-46.9) 956 
-14.3 (-23.7- -
4.9) -15.6 (-27.1- -4.1) -8.7 (-17.3-0) 
Public health facility  6.2 (3.1-12.2) 68 6.3 (3.1-12.5) 135 6.3 (3.4-11.4) 203 0.9 (0.2-4.6) 94 1.8 (0.6-5.1) 204 1.5 (0.6-3.8) 298 -5.3 (-9.8- -0.8) -4.5 (-9.3-0.2) -4.8 (-8.8- -0.7) 
Private not-for-profit health facility 0.0 5 13.8 (2.5-50.3) 9 11.4 (2.1-43.8) 14 0.0 4 21.8 (8.7-45.1) 9 13.3 (4.5-33) 13 0.0 8.1 (-20.3-36.4) 1.9 (-20.4-24.2) 
Private for-profit outlet                
Health facility/pharmacy 69.5 (61.8-76.2) 315 41.8 (31.9-52.3) 62 58.8 (52.5-64.9) 377 
61.5 (54.2-
68.3) 271 13.6 (6.2-27.3) 26 55.2 (47.3-62.9) 297 -8.0 (-18.0-2.1) -28.2 (-42.5- -13.8) -3.6 (-13.5-6.3) 
Drug store 63.1 (55.4-70.1) 211 52.6 (44-61.1) 331 53.9 (46.3-61.4) 542 
47.3 (38.5-
56.3) 202 
42.8 (31.9-
54.5) 140 45.5 (38.6-52.7) 342 
-15.8 (-27.3- -
4.2) -9.8 (-24.0-4.4) -8.4 (-18.6-1.9) 
General retailer/itinerant 0.0 2 0.0 3 0.0 5 0.0 3 0.0 3 0.0 6 0.0 0.0 0.0 
Total 65.7 (60.5-70.6) 528 51.3 (43.1-59.5) 396 54.2 (47.4-60.8) 924 
50.6 (42.7-
58.5) 476 
39.6 (29.4-
50.9) 169 46.9 (40.4-53.4) 645 
-15.1 (-24.4- -
5.8) -11.7 (-25.3-1.8) -7.3 (-16.6-2.0) 
Community health worker - 0 0.0 3 0.0 3 - 0 - 0 - 0 - - - 
Kenya - Total 1.2 (0.3-4.4) 1,024 5.3 (0.9-26) 870 4.3 (0.8-20.6) 1,894 0.3 (0.0-2.0) 1,044 0 (0.0-0.3) 800 0.1 (0.0-0.5) 1,844 -0.9 (-2.5-0.8) -5.3 (-14.4-3.8) -4.2 (-11.4-2.9) 
Public health facility  0.0 137 0.0 259 0.0 396 0.0 137 0.0 294 0.0 431 0.0 0.0 0.0 
Private not-for-profit health facility 0.0 23 0.0 15 0.0 38 0.0 19 0.0 27 0.0 46 0.0 0.0 0.0 
Private for-profit outlet                
Health facility/pharmacy 3.5 (0.8-14.6) 357 0.0 103 1.6 (0.4-6.7) 460 1.0 (0.1-6.7) 405 0.2 (0.0-1.8) 112 0.5 (0.1-2.4) 517 -2.6 (-8.1-3.0) 0.2 (-0.2-0.7) -1.1 (-3.5-1.4) 
Drug store 0.4 (0.1-2.4) 267 17.2 (4.6-47.1) 155 13.5 (3.1-42.9) 422 0.0 328 0.0 145 0.0 473 -0.4 (-1.2-0.3) -17.2 (-37.6-3.3) -13.5 (-31.6-4.6) 
General retailer/itinerant 0.0 236 0.0 318 0.0 554 0.0 155 0.0 222 0.0 377 0.0 0.0 0.0 
Total 1.4 (0.3-5.1) 860 6.5 (1.1-30) 576 5.2 (1.0-23.8) 1436 0.3 (0.0-2.2) 888 0.1 (0.0-0.4) 479 0.1 (0.0-0.6) 1,367 -1.1 (-2.9-0.8) -6.4 (-17.3-4.5) -5.1 (-13.6-3.4) 
Community health worker 0.0 4 0.0 20 0.0 24 - 0 - 0 - 0 - - - 
Madagascar - Total 0.2 (0.1-0.6) 1,438 0 (0-0.2) 962 0.1 (0.0-0.2) 2,400 0.1 (0.0-0.3) 971 0.0 1,347 0.0 2,318 -0.1 (-0.4-0.1) 0.0 (-0.1-0.0) -0.1 (-0.1-0.0) 
Public health facility  0.0 67 0.0 444 0.0 511 0.0 62 0.0 514 0.0 576 0.0 0.0 0.0 
Private not-for-profit health facility 0.0 6 - 0 0.0 6 0.0 25 0.0 5 0.0 30 0.0 - 0/0 
Private for-profit outlet                
Health facility/pharmacy 1.5 (0.5-4.8) 122 0.0 9 0.9 (0.3-2.6) 131 0.6 (0.2-1.7) 102 0.0 12 0.3 (0.1-1.2) 114 -1.0 (-2.8-0.9) 0.0 -0.6 (-1.6-0.5) 
Drug store 0.5 (0.1-3.2) 28 0.6 (0.1-4.8) 227 0.6 (0.1-2.6) 255 0.0 28 0.0 347 0.0 375 -0.5 (-1.5-0.4) -0.6 (-1.9-0.7) -0.6 (-1.5-0.3) 
General retailer/itinerant 0.0 1,213 0.0 244 0.0 1,457 0.0 739 0.0 404 0.0 1,143 0.0 0.0 0.0 
Total 0.2 (0.1-0.6) 1,363 0 (0-0.3) 480 0.1 (0.0-0.2) 1,843 0.1 (0.0-0.3) 869 0.0 763 0.0 (0.0-0.1) 1,632 -0.2 (-0.4-0.1) 0.0 (-0.1-0.0) -0.1 (-0.1-0.0) 
Community health worker 0.0 2 0.0 38 0.0 40 0.0 15 0.0 65 0.0 80 0.0 0.0 0.0 
Niger - Total 1.6 (0.8-3.0) 833 0 (0-0.2) 1,198 0.3 (0.2-0.7) 2,031 1.1 (0.7-1.6) 924 0.0 738 0.3 (0.2-0.5) 1,662 -0.5 (-1.6-0.6) 0.0 (-0.1-0.0) -0.1 (-0.3-0.2) 
Public health facility  0.0 91 0.5 (0.1-1.9) 385 0.4 (0.1-1.7) 476 0.8 (0.2-3.2) 102 0.0 220 0.1 (0.0-0.4) 322 0.8 (-0.3-1.8) -0.5 (-1.1-0.2) -0.3 (-0.9-0.3) 
Private not-for-profit health facility 0.0 4 - 0 0.0 4 0.0 2 0.0 1 0.0 3 0.0 - 0.0 
Private for-profit outlet                
Health facility/pharmacy 14.8 (8.5-24.4) 106 0.0 12 12.6 (7.1-21.5) 118 9.8 (5.5-17) 95 0.0 4 9.3 (5.2-16.1) 99 -4.9 (-14.5-4.6) 0.0 -3.4 (-12.1-5.4) 
Drug store 12.1 (2.3-45.2) 14 0.0 7 4.5 (0.6-25) 21 13.1 (3.1-41.7) 15 0.0 3 5.8 (1.3-22.5) 18 1.0 (-24.7-26.8) 0.0 1.4 (-10.4-13.2) 
General retailer/itinerant 0.8 (0.2-2.5) 617 0.0 792 0.2 (0.0-0.5) 1,409 0.4 (0.2-1.2) 710 0.0 510 0.1 (0.0-0.3) 1,220 -0.3 (-1.3-0.7) 0.0 0.0 (-0.3-0.2) 
Total 1.6 (0.8-3.2) 737 0.0 811 0.3 (0.2-0.7) 1,548 1.1 (0.7-1.6) 820 0.0 517 0.3 (0.2-0.5) 1,337 -0.6 (-1.7-0.6) 0.0 0.0 (-0.3-0.2) 
Community health worker 0.0 1 0.0 2 0.0 3 - 0 - 0 - 0 - - - 
Nigeria - Total 
46.6 (34.6-59.1) 1,726 33.3 (23.3-45.1) 361 43.8 (34.0-54.1) 2,087 
35.9 (24.7-
48.8) 1,020 
30.2 (25.0-
35.9) 469 33.6 (26.7-41.4) 1,489 -10.8 (-28.2-6.7) -3.1 (-15.4-9.1) -10.1 (-22.6-2.3) 
Public health facility  
17.3 (10.7-26.7) 181 3.9 (1.3-11.6) 45 4.7 (1.9-11.4) 226 
24.6 (10.6-
47.3) 42 10.4 (4.4-22.3) 52 14.9 (7.8-26.6) 94 7.3 (-13.0-27.6) 6.5 (-3.0-15.9) 10.2 (0.1-20.3) 
Private not-for-profit health facility 30.9 (7.3-71.7) 6 0.0 2 2.6 (0.3-17.1) 8 26.4 (3.3-79.3) 6 46.3 (5.7-92.4) 3 33.9 (8.0-75.1) 9 -4.5 (-63.2-54.3) 46.3 (-19.4-111.9) 31.3 (-8.5-71.1) 
Private for-profit outlet                
Health facility/pharmacy 66.5 (60.3-72.1) 733 63.9 (44.5-79.6) 24 64.5 (50.4-76.5) 757 
55.8 (37.8-
72.4) 95 5.6 (1.6-17.5) 30 37.5 (22.4-55.5) 125 -10.7 (-29.6-8.2) -58.3 (-77.6- -39.0) 
-27.0 (-48.6- -
5.4) 
Drug store 47.7 (35.3-60.3) 715 41.7 (31.0-53.3) 268 46.7 (36.1-57.7) 983 
35.9 (23.4-
50.7) 801 
36.6 (30.4-
43.3) 361 36.2 (27.7-45.6) 1,162 -11.8 (-30.6-7.1) -5.1 (-18.0-7.9) -10.6 (-24.7-3.6) 
General retailer/itinerant 39.0 (21.4-60.0) 85 3.1 (0.4-19.3) 16 32.0 (17.5-51.1) 101 14.7 (5.0-36.0) 73 10.2 (2.5-34.1) 19 13.6 (5.6-29.5) 92 -24.3 (-49.3-0.7) 7.2 (-7.9-22.2) -18.4 (-39.2-2.3) 
Total 47.0 (34.8-59.5) 1,533 40.9 (30.8-51.9) 308 45.9 (35.7-56.4) 1,841 
36.3 (24.6-
50.0) 969 
32.8 (27.2-
38.8) 410 35.0 (27.3-43.5) 1,379 -10.6 (-28.6-7.3) -8.1 (-20.2-4) -10.9 (-24.1-2.4) 
Community health worker 1.0 (0.1-9.6) 6 2.2 (0.3-16.6) 6 1.7 (0.3-8.5) 12 0.0 3 0.0 4 0.0 7 -1.0 (-3.4-1.3) -2.2 (-6.8-2.5) -1.7 (-4.5-1.1) 
Tanzania – mainland - Total 0.2 (0.1-0.6) 317 0.1 (0.0-0.4) 284 0.1 (0.0-0.3) 601 0.0 (0.0-0.1) 596 0.0 191 0 (0.0-0.1) 787 -0.1 (-0.4-0.1) -0.1 (-0.2-0.1) -0.1 (-0.2-0.0) 
Public health facility  0.0 5 0.0 51 0.0 56 0.0 7 0.0 48 0.0 55 0.0 0.0 0.0 
Private not-for-profit health facility 0.0 6 0.0 16 0.0 22 0.0 4 0.0 2 0.0 6 0.0 0.0 0.0 
Private for-profit outlet                
Health facility/pharmacy 1.1 (0.4-3.3) 220 5.2 (0.6-34.7) 12 1.8 (0.6-5.8) 232 0.2 (0-1) 321 0.0 16 0.2 (0.0-0.7) 337 -0.9 (-2.1-0.4) -5.2 (-16.2-5.9) -1.7 (-3.8-0.5) 
Drug store 0.0 85 0.0 144 0.0 229 0.0 259 0.0 113 0.0 372 0.0 0.0 0.0 
General retailer/itinerant 0.0 1 0.0 60 0.0 61 0.0 5 0.0 12 0.0 17 0.0 0.0 0.0 
Total 0.2 (0.1-0.7) 306 0.1 (0.0-0.6) 216 0.1 (0.0-0.4) 522 0.0 585 0.0 141 0.0 726 -0.2 (-0.4-0.1) -0.1 (-0.2-0.1) -0.1 (-0.2-0.0) 
Community health worker - 0 - 1 - 1 - 0 - 0 - 0 - - - 
104 
 
 
 
Table 2.2.4: Cont. 
 BASELINE ENDLINE PERCENTAGE POINT CHANGE 
 Urban Rural Total Urban Rural Total Urban Rural  Total 
Country/Type of outlet % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) % (95% CI) % (95% CI) 
Uganda – Total 0.3 (0.1-0.7) 527 0.2 (0.1-0.7) 1,862 0.3 (0.1-0.6) 2,389 0.1 (0.0-1.0) 1,408 0.0 1,715 0.0 3,123 -0.2 (-0.5-0.2) -0.2 (-0.5-0.0) -0.2 (-0.4- 0.0) 
Public health facility  0.0 76 0.0 686 0.0 762 0.0 144 0.0 534 0.0 678 0.0 0.0 0.0 
Private not-for-profit health facility 0.0 3 3.8 (0.4-26.6) 27 3.3 (0.4-23.5) 30 0.0 12 0.0 27 0.0 39 0.0 -3.8 (-11.7-4.1) -3.3 (-10.2-3.5) 
Private for-profit outlet                
Health facility/pharmacy 0.5 (0.3-0.9) 375 0.4 (0.1-1.3) 354 0.5 (0.3-0.8) 729 0.3 (0-2.3) 810 0.0 383 0.1 (0.0-0.8) 1,193 -0.3 (-0.9-0.3) -0.4 (-0.8-0.1) -0.3 (-0.7- 0.0) 
Drug store 0.0 70 0.1 (0-0.8) 747 0.1 (0.0-0.7) 817 0.0 436 0.0 675 0.0 1,111 0.0 -0.1 (-0.4-0.1) -0.1 (-0.3-0.1) 
General retailer/itinerant 0.0 2 0.0 19 0.0 21 0.0 4 0.0 14 0.0 18 0.0 0.0 0.0 
Total 0.3 (0.1-0.7) 447 0.2 (0.1-0.5) 1,120 0.2 (0.1-0.4) 1,567 0.1 (0.0-1.1) 1,250 0.0 1,072 0.0 2,322 -0.2 (-0.6-0.2) -0.2 (-0.4-0) -0.2 (-0.3- 0.0) 
Community health worker 0.0 1 0.0 29 0.0 30 0.0 2 0.0 82 0.0 84 0.0 0.0 0.0 
Zanzibar – Total 26.5  189 3.3  123 17.3  312 0.9 222 0.8 119 0.9 341 -25.6 -2.4 -16.4  
Public health facility  5.4 56 0.0 83 2.2 139 0.0 48 0.0 75 0.0 123 -5.4 0.0 -2.2 
Private not-for-profit health facility - 2 0.0 1 0.0 3 0.0 1 0.0 1 0.0 2 0.0 0.0 0.0 
Private for-profit outlet                
Health facility/pharmacy 47.9 73 27.3 11 45.2 84 1.2 82 6.3 16 2.0 98 -46.7 -21.0 -43.2  
Drug store 21.1 57 4.2 24 16 81 0.0 88 0.0 24 0.0  112 -21.1 -4.2 -16.0  
General retailer/itinerant 0.0 1 0.0 4 0.0 5 33.3 3 0.0 3 16.7 6 33.3 0.0 16.7  
Total 35.9 131 10.3 39 30  170 1.2 173 2.3 43 1.4 216 -34.7 -7.9 -28.6 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 - - - 
Note: Nigeria baseline data collection was conducted in 2009. 
CI = Confidence interval 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys  
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Table 2.2.5: Outlets with non-quality-assured ACTs in stock at baseline (2010) and endline (2011) 
Indicator 1.4 Percentage of outlets that had non-quality-assured ACTs in stock (n) among outlets with any antimalarials in stock at the time of the survey visit (N), by urban-rural location and type of 
outlet, according to country 
Country/Type of outlet 
BASELINE ENDLINE PERCENTAGE POINT CHANGE 
Urban Rural Total Urban Rural Total Urban Rural  Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) % (95% CI) % (95% CI) 
Ghana - Total 85.3 (80.6-89.0) 601 66.7 (61.0-71.9) 543 70.2 (65.5-74.6) 1,144 73.7 (67.2-79.3) 574 56.5 (48.8-63.9) 382 67.0 (61.8-71.8) 956 -11.6 (-18.9- -4.3) -10.1 (-19.4- -0.9) -3.2 (-9.9-3.4) 
Public health facility  69.9 (54.4-81.9) 68 67.8 (57.2-76.9) 135 68.1 (58.7-76.2) 203 65.1 (54.7-74.2) 94 61.5 (51.6-70.5) 204 62.6 (55-69.5) 298 -4.8 (-21.8-12.1) -6.3 (-20.0-7.3) -5.5 (-16.8-5.7) 
Private not-for-profit health facility 100.0 5 100.0 9 100.0 14 61.6 (23.6-89.3) 4 88.3 (52.2-98.1) 9 77.8 (52.9-91.7) 13 -38.4 (-76.9-0.2) -11.7 (-31.4-8.1) -22.2 (-41.6- -2.7) 
Private for-profit outlet                
Health facility/pharmacy 98.7 (96.6-99.5) 315 96.8 (86.3-99.3) 62 98.0 (94.4-99.3) 377 91.6 (82.8-96.2) 271 73.7 (48.1-89.5) 26 89.3 (80.8-94.3) 297 -7.0 (-13.4- -0.7) -23.1 (-44.9- -1.3) -8.7 (-15.4- -1.9) 
Drug store 75.7 (70.3-80.3) 211 64.6 (58.3-70.4) 331 66.0 (60.4-71.2) 542 69.2 (62.6-75.1) 202 52.7 (42.7-62.4) 140 62.7 (57.1-68.1) 342 -6.5 (-14.4-1.5) -11.9 (-23.5- -0.4) -3.3 (-10.9-4.4) 
General retailer/itinerant 0.0 2 0.0 3 0.0 5 0.0 3 0.0 3 0.0 6 0.0 0.0 0.0 
Total 86.0 (81.5-89.5) 528 66.3 (60.2-71.9) 396 70.2 (65.1-74.9) 924 74.5 (67.9-80.1) 476 53.2 (43.5-62.7) 169 67.3 (61.5-72.6) 645 -11.5 (-18.7- -4.3) -13.1 (-24.3 -1.9) -3.0 (-10.3-4.3) 
Community health worker - 0 0.0 3 0.0 3 - 0 - 0 - 0    
Kenya - Total 43.6 (36.5-51.0) 1,025 11.2 (8.5-14.6) 870 18.9 (15.8-22.4) 1,895 40.8 (33.7-48.4) 1,046 15.6 (11.3-21.2) 801 22.7 (18.7-27.3) 1,847 -2.8 (-13.1-7.5) 4.4 (-1.3-10.1) 3.8 (-1.6-9.2) 
Public health facility  8.0 (4.4-14.0) 137 2.4 (1.0-5.5) 259 3.7 (2.0-6.5) 396 11.5 (5.7-21.8) 137 5.8 (2.8-11.8) 294 6.2 (3.3-11.5) 431 3.5 (-5.4-12.5) 3.4 (-1.2-8.1) 2.6 (-1.8-7.0) 
Private not-for-profit health facility 59.7 (41.8-75.2) 23 17.7 (3.8-53.8) 15 29.7 (13.6-53) 38 24.2 (9.9-48.3) 19 5.4 (1.3-19.4) 27 9.1 (3.9-19.9) 46 -35.4 (-61.4- -9.5) -12.3 (-37.6-13.1) -20.6 (-42.2-1.0) 
Private for-profit outlet                
Health facility/pharmacy 73.8 (61.4-83.2) 358 39.9 (27.8-53.4) 103 55.1 (44.6-65.2) 461 54.8 (43.9-65.2) 407 33.6 (21.6-48.2) 113 41.7 (33.3-50.7) 520 -19.0 (-34.3- -3.7) -6.3 (-25-12.4) -13.4 (-26.9-0.1) 
Drug store 68.5 (58.0-77.4) 267 18.1 (13.7-23.5) 155 29.2 (20.5-39.8) 422 54.0 (44.2-63.5) 328 30 (20.7-41.4) 145 39.6 (31.5-48.4) 473 -14.5 (-28.2- -0.9) 11.9 (0.5-23.4) 10.4 (-2.4-23.2) 
General retailer/itinerant 0.0 236 0.0 318 0.0 554 0.0 155 1.8 (0.6-5.2) 222 1.5 (0.5-4.3) 377  1.8 (-0.1-3.7) 1.5 (-0.1-3.1) 
Total 47.5 (39.5-55.6) 861 12.3 (9.2-16.3) 576 21.0 (17.3-25.3) 1,437 42.3 (34.7-50.2) 890 17.9 (12.9-24.3) 480 25.5 (21.0-30.6) 1,370 -5.2 (-16.4-5.9) 5.6 (-1.1-12.2) 4.5 (-1.7-10.7) 
Community health worker 0.0 4 9.0 (1.2-45.1) 20 8.8 (1.2-43.9) 24 - 0 - 0 - 0 - - - 
Madagascar - Total 5.9 (2.9-11.8) 1,440 2.7 (1.4-5.2) 962 3.4 (2.0-5.6) 2,402 4.8 (2.4-9.3) 971 0.7 (0.4-1.2) 1,348 1.3 (0.8-2.1) 2,319 -1.1 (-6.4-4.1) -2.0 (-3.8- -0.2) -2.1 (-3.9- -0.3) 
Public health facility  19.3 (11.7-30.2) 67 30.5 (20.3-43.1) 444 27.4 (19.7-36.7) 511 0.4 (0.1-2.2) 62 4.1 (2.4-6.8) 515 3.7 (2.2-6.1) 577 -18.9 (-28.0-9.8) -26.4 (-38- -14.9) -23.7 (-32.3- -15.1) 
Private not-for-profit health facility 21.0 (5.6-54.5) 6 - 0 21.0 (5.6-54.5) 6 6.3 (2.0-18.4) 25 0.0 5 2.4 (0.7-8.5) 30 -14.7 (-39.6-10.2) - -18.6 (-42.7-5.5) 
Private for-profit outlet                
Health facility/pharmacy 36.3 (20.6-55.7) 124 0.0 9 20.6 (8.9-40.8) 133 31.9 (17.4-51.2) 102 0.0 12 17.3 (7.0-36.8) 114 -4.4 (-29.4-20.6) 0.0 -3.3 (-24.6-18.1) 
Drug store 0.0 28 0.3 (0-1.8) 227 0.2 (0.0-1.2) 255 10.6 (4.5-23.2) 28 0.8 (0.3-2.4) 347 1.8 (0.8-4.0) 375 10.6 (1.9-19.4) 0.5 (-0.5-1.5) 1.7 (0.2-3.1) 
General retailer/itinerant 0.0 1,213 0.0 244 0.0 1,457 0.0 739 0.0 404 0.0 1,143    
Total 4.2 (1.4-11.7) 1,365 0.0 (0.0-0.1) 480 0.9 (0.3-2.7) 1,845 5.3 (2.7-10.3) 869 0.1 (0.0-0.2) 763 0.9 (0.4-2.0) 1,632 1.1 (-4.5-6.8) 0.1 (0.0-0.1) -0.1 (-1.3-1.1) 
Community health worker 0.0 2 2.9 (0.3-23.4) 38 2.9 (0.3-23.3) 40 0.0 15 1.8 (0.4-7.7) 65 1.8 (0.4-7.5) 80 0.0 -1.1 (-8.1-5.9) -1.1 (-8.1-5.8) 
Niger - Total 9.5 (7.0-12.7) 833 2.5 (1.8-3.5) 1,198 3.9 (3.1-5.0) 2,031 13.0 (10.9-15.4) 924 6.6 (4.9-8.7) 738 8.3 (6.9-10.0) 1,662 3.5 (0.0-7.0) 4.0 (2.0-6.1) 4.4 (2.6-6.2) 
Public health facility  55.8 (38.8-71.4) 91 23.3 (16.8-31.4) 385 26.5 (20.1-34.0) 476 60.2 (45.2-73.5) 102 29.2 (19.7-40.8) 220 33.5 (24.8-43.6) 322 4.5 (-17.6-26.5) 5.8 (-6.9-18.6) 7.0 (-4.6-18.7) 
Private not-for-profit health facility 6.6 (0.6-43.7) 4 - 0 6.6 (0.6-43.7) 4 49.2 (11.3-88.1) 2 100.0 1 83.3 (41.4-97.2) 3 42.6 (-9.9-95.1) - 76.7 (46.1-107.3) 
Private for-profit outlet                
Health facility/pharmacy 62.5 (43.2-78.5) 106 32.5 (7.9-73.2) 12 58.1 (39.6-74.6) 118 57.4 (45.8-68.3) 95 91.6 (61.9-98.6) 4 59.4 (47.8-70.0) 99 -5.0 (-26.5-16.5) 59.0 (18.6-99.5) 1.3 (-20.0-22.6) 
Drug store 62.6 (36.1-83.1) 14 0.0 7 23 (8.9-47.7) 21 87.6 (68.1-95.9) 15 0.0 3 38.8 (19.1-63) 18 25.0 (-3.2-53.3) 0.0 15.8 (-14.5-46.2) 
General retailer/itinerant 3.7 (1.9-6.9) 617 0.4 (0.1-1.1) 792 1.0 (0.6-1.9) 1,409 6.8 (5.2-8.9) 710 3.5 (2.3-5.4) 510 4.4 (3.3-5.8) 1,220 3.2 (0.2-6.1) 3.1 (1.6-4.7) 3.4 (2.0-4.7) 
Total 7.6 (5.4-10.5) 737 0.4 (0.2-1.1) 811 1.9 (1.4-2.7) 1,548 10.5 (8.8-12.5) 820 3.6 (2.4-5.5) 517 5.6 (4.4-7.0) 1,337 3.0 (-0.1-6.0) 3.2 (1.6-4.7) 3.7 (2.2-5.1) 
Community health worker 0.0 1 0.0 2 0.0 3 - 0 - 0 - 0 - - - 
Nigeria - Total 24.8 (14.6-38.9) 1,726 15.5 (10.6-22.1) 359 22.8 (14.5-34.0) 2,085 30.0 (19.6-43.1) 1,020 21.4 (15.9-28.2) 469 26.6 (20.1-34.4) 1,489 5.2 (-11.8-22.3) 5.9 (-2.4-14.3) 3.8 (-8.3-15.9) 
Public health facility  44.0 (33.3-55.3) 180 16.0 (6.0-36.5) 45 17.7 (7.7-35.8) 225 44.3 (19.8-72.0) 42 16.1 (6.9-33.2) 52 25.2 (13.8-41.4) 94 0.3 (-30.6-31.2) 0.1 (-19.4-19.6) 7.5 (-12.1-27.1) 
Private not-for-profit health facility 
70.2 (33.9-91.5) 7 85.5 (29.0-98.8) 2 83.9 (34.0-98.1) 9 1.2 (0.1-10.8) 6 0.0 3 0.7 (0.1-6.2) 9 -69.0 (-100.8-37.2) 
-85.5 (-118.4- -
52.5) 
-83.1 (-114.2- -
52.0) 
Private for-profit outlet                
Health facility/pharmacy 63.3 (53.2-72.4) 734 42.4 (30.9-54.7) 24 47.5 (41.2-53.9) 758 55.2 (42.8-66.9) 95 20.6 (8.4-42.6) 30 42.6 (31.2-54.8) 125 -8.2 (-23.8-7.5) -21.7 (-42.7- -0.8) -4.9 (-18.5-8.7) 
Drug store 24.7 (14.1-39.7) 714 12.1 (7.0-20.0) 266 22.8 (13.6-35.7) 980 27.6 (16.9-41.5) 801 23.3 (17.4-30.4) 361 25.9 (18.9-34.5) 1,162 2.9 (-15.0-20.7) 11.2 (2.2-20.3) 3.1 (-10.4-16.6) 
General retailer/itinerant 22.1 (10.7-40.3) 85 0.0 16 17.8 (8.0-35.0) 101 21.8 (8.9-44.3) 73 7.7 (1.3-34.6) 19 18.2 (8.1-35.8) 92 -0.3 (-23.5-22.9) 7.7 (-5.4-20.8) 0.4 (-18.6-19.4) 
Total 24.9 (14.6-39.1) 1,533 15.5 (9.8-23.7) 306 23.2 (14.5-35.0) 1,839 29.8 (19.1-43.2) 969 22.4 (16.6-29.5) 410 27.1 (20.1-35.4) 1,379 4.9 (-12.4-22.3) 6.9 (-2.5-16.3) 3.8 (-8.9-16.6) 
Community health worker 0.0 6 2.3 (0.3-17.3) 6 1.3 (0.2-9.4) 12 0.0 3 0.0 4 0.0 7 0.0 -2.3 (-7.1-2.6) -1.3 (-3.9-1.3) 
Tanzania – mainland - Total 36.6 (27.2-47.0) 317 7.3 (3.4-14.9) 284 14.2 (10-19.9) 601 48.9 (35.1-62.9) 596 11.7 (5.2-24.2) 191 25.3 (16.7-36.5) 787 12.3 (-4.9-29.6) 4.5 (-6-14.9) 11.1 (0.2-22.1) 
Public health facility  16.0 (1.7-67.2) 5 4.2 (1.4-12.0) 51 5.1 (1.9-12.6) 56 14.5 (1.9-60.2) 7 5.1 (1.6-14.8) 48 5.5 (2.0-14.5) 55 -1.5 (-42.9-39.9) 0.9 (-6.3-8.1) 0.4 (-6.8-7.7) 
Private not-for-profit health facility 48.7 (20.0-78.3) 6 25.9 (8.8-56) 16 30.1 (13.1-55.3) 22 75.2 (22.9-96.9) 4 0.0 2 40.0 (11.7-77.1) 6 26.4 (-27.5-80.4) -25.9 (-50.4- -1.4) 9.9 (-34.2-54) 
Private for-profit outlet                
Health facility/pharmacy 89.4 (64.2-97.5) 220 33.0 (12.5-63.0) 12 
79.0 (60.0.1-
90.4) 232 74.3 (54.8-87.4) 321 43.5 (11.7-81.7) 16 66.3 (45.8-82.1) 337 -15.1 (-37.0-6.8) 10.5 (-40.1-61.0) -12.7 (-36.7-11.3) 
Drug store 25.9 (16.0-39.1) 85 9.4 (3.0-25.9) 144 15.0 (9.0-23.9) 229 45.3 (28.8-62.8) 259 15.0 (6.3-31.7) 113 28.2 (17.7-41.9) 372 19.3 (-1.6-40.3) 5.7 (-10.2-21.5) 13.2 (-0.9-27.4) 
General retailer/itinerant 0.0 1 0.9 (0.1-6.4) 60 0.9 (0.1-6.4) 61 31.3 (4.3-82.3) 5 0.0 12 2.8 (0.3-23.9) 17 31.3 (-17.9-80.5) -0.9 (-2.6-0.9) 1.9 (-4.7-8.5) 
Total 37.2 (26.5-49.3) 306 6.6 (2.3-17.5) 216 15.1 (10.1-22.0) 522 49.3 (35.3-63.3) 585 14.6 (6.0-31.1) 141 29.8 (19.9-42.1) 726 12.1 (-6.2-30.4) 8.0 (-5.7-21.7) 14.7 (2.2-27.3) 
Community health worker - 0 0.0 1 0.0 1 - 0 - 0 - 0 - - - 
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Table 2.2.5: Cont.  
Country/Type of outlet 
BASELINE ENDLINE PERCENTAGE POINT CHANGE 
Urban Rural Total Urban Rural Total Urban Rural  Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) % (95% CI) % (95% CI) 
Uganda - Total 75.7 (61.6-85.8) 540 40.2 (28.9-52.6) 1,866 47.5 (36.0-59.2) 2,406 51.9 (37.5-66.1) 1,412 22.0 (12.9-35.0) 1,717 28.1 (19.2-39.2) 3,129 -23.7 (-42.6- -4.9) -18.1 (-34.3- -2.0) -19.4 (-34.7- -4) 
Public health facility  22.1 (14.3-32.5) 76 6.4 (3.5-11.3) 687 8.0 (5.0-12.6) 763 28.7 (20.1-39) 144 2.3 (1.2-4.1) 534 6.0 (4.1-8.8) 678 6.5 (-6.4-19.5) -4.1 (-8- -0.3) -1.9 (-6.2-2.3) 
Private not-for-profit health facility 100.0 4 25.8 (12.8-45.2) 27 36.7 (19.6-58.1) 31 72.3 (30-94.1) 12 14.8 (4.4-39.2) 27 20.8 (8.9-41.2) 39 -27.7 (-63.6-8.2) -11.1 (-34-11.9) -16.0 (-41.4-9.5) 
Private for-profit outlet                
Health facility/pharmacy 83.9 (72.4-91.2) 387 63.5 (45.6-78.3) 355 73.4 (60.5-83.3) 742 64.7 (56.9-71.8) 814 47.7 (32.4-63.4) 385 55.2 (45.7-64.4) 1,199 -19.2 (-30.9- -7.5) -15.8 (-38.7-7.1) -18.2 (-32.8- -3.6) 
Drug store 72.0 (57.6-82.9) 70 40.7 (28.8-53.8) 749 44.8 (33.3-57.0) 819 38.6 (27.0-51.8) 436 23.0 (15.6-32.6) 675 25.4 (18.7-33.5) 1,111 -33.4 (-51.1- -15.6) -17.6 (-32.6- -2.6) -19.4 (-33.3- -5.6) 
General retailer/itinerant 0.0 2 14.5 (5.3-34.1) 19 12.6 (4.5-30.2) 21 33.7 (4.7-83.9) 4 0.0 14 1.9 (0.2-14.3) 18 33.7 (-17.8-85.3) -14.5 (-28- -1.0) -10.6 (-23.1-1.9) 
Total 77.9 (65.0-87.0) 459 44.1 (30.9-58.2) 1,123 51.8 (39.1-64.3) 1,582 53.3 (39.3-66.8) 1,254 27.8 (17.4-41.3) 1,074 33.8 (24.3-44.8) 2,328 -24.6 (-42.2- -6.9) -16.3 (-34.4-1.9) -18.0 (-34.2- -1.8) 
Community health worker 
100.0 1 65.1 (29.7-89.2) 29 65.9 (31.7-89.0) 30 0.0 2 0.2 (0.0-2.0) 82 0.2 (0.0-2.0) 84 -100.0 
-64.9 (-95.9- -
33.9) 
-65.7 (-95.2- -
36.3) 
Zanzibar - Total 43.4 189 21.1 123 34.6 312 23.9 222 9.2 119 18.8 341 -19.5 -11.9 -15.8 
Public health facility  46.4 56 22.9 83 32.4 139 8.3 48 8.0 75 8.1 123 -38.1 -14.9 -24.2 
Private not-for-profit health facility 100.0 2 100.0 1 100.0 3 100.0 1 0.0 1 50.0 2 0.0 -100.0 -50.0 
Private for-profit outlet                
Health facility/pharmacy 61.6 73 36.4 11 58.3 84 43.9 82 31.3 16 41.8 98 -17.7 -5.1 -16.5 
Drug store 15.8 57 8.3 24 13.6 81 13.6 88 0.0 24 10.7 112 -2.2 -8.3 -2.9 
General retailer/itinerant 0.0 1 0.0 4 0.0 5 0.0 3 0.0 3 0.0 6 0.0 0.0 0.0 
Total 41.2 131 15.4 39 35.3 170 27.7 173 11.6 43 24.5 216 -13.5 -3.8  -10.8 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 - - - 
Note: Nigeria baseline data collection was conducted in 2009. 
CI = Confidence interval 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys  
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Table 2.2.6: Outlets with quality-assured ACTs in stock at baseline (2010) and endline (2011) 
Indicator 1.5 Percentage of censused outlets that had quality-assured ACTs in stock (n) among outlets with any antimalarials in stock at the time of the survey visit (N), by urban-rural location and 
type of outlet, according to country 
Country/Type of outlet 
BASELINE ENDLINE PERCENTAGE POINT CHANGE 
Urban Rural Total Urban Rural Total Urban Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) % (95% CI) % (95% CI) 
Ghana – Total 49.7 (43.0-56.3) 601 26.2 (21.5-31.5) 543 30.7 (26.6-35.2) 1,144 85.2 (80.3-89.0) 574 78.7 (71.3-84.6) 382 82.7 (78.5-86.2) 956 35.5 (27.7-43.4) 52.5 (44.2-60.8) 51.9 (46.2-57.7) 
Public health facility  84.0 (74.5-90.4) 68 86.6 (79.0-91.7) 135 86.2 (79.7-90.8) 203 73.2 (58.5-84.1) 94 83.9 (73.3-90.8) 204 80.7 (72.5-86.9) 298 -10.7 (-25.7-4.3) -2.7 (-13.2-7.9) -5.5 (-14.5-3.5) 
Private not-for-profit health facility 49.2 (17.0-82.0) 5 52.1 (22.5-80.2) 9 51.6 (25.8-76.5) 14 100.0 4 87.5 (57.3-97.3) 9 92.4 (69-98.5) 13 50.8 (12.5-89.1) 35.4 (-1.7-72.5) 40.8 (10.8-70.9) 
Private for-profit outlet                
Health facility/pharmacy 69.6 (64.6-74.2) 315 41.4 (28.5-55.7) 62 58.8 (52.3-65.0) 377 93.5 (89.2-96.1) 271 96.9 (89.4-99.1) 26 93.9 (90.2-96.3) 297 23.9 (18.1-29.7) 55.5 (41.2-69.8) 35.1 (28.2-42.1) 
Drug store 28.6 (22.4-35.8) 211 17.7 (13.2-23.2) 331 19.0 (15.0-23.9) 542 82.6 (75.0-88.2) 202 75.2 (65.6-82.8) 140 79.7 (73.9-84.5) 342 54.0 (44.7-63.2) 57.5 (47.6-67.4) 60.6 (53.8-67.5) 
General retailer/itinerant 0.0 2 0.0 3 0.0 5 100.0 3 66.3 (36.4-87.2) 3 83.1 (51.4-95.8) 6 100.0 66.3 (39-93.6) 83.1 (61.8-104.4) 
Total 47.5 (40.4-54.8) 528 19.2 (14.8-24.6) 396 24.8 (20.8-29.4) 924 85.7 (80.0-89.9) 476 76.7 (67.6-83.9) 169 82.6 (77.8-86.6) 645 38.1 (29.5-46.8) 57.5 (48.1-66.9) 57.8 (51.7-63.8) 
Community health worker - 0 100.0 3 100.0 3 - 0 - 0 - 0 - - - 
Kenya – Total 43.7 (37.8-49.8) 1,025 27.3 (20.4-35.5) 870 31.2 (25.6-37.5) 1,895 71.9 (64.2-78.5) 1,049 63.4 (54.5-71.5) 801 65.8 (59.0-72.0) 1,850 28.2 (18.9-37.4) 36.1 (24.8-47.4) 34.6 (25.8-43.4) 
Public health facility  72.8 (42.2-90.7) 137 91.8 (83.4-96.2) 259 87.5 (76.1-93.9) 396 92.0 (81.5-96.8) 137 97.4 (93.7-98.9) 294 97 (93.7-98.6) 431 19.2 (-7.2-45.6) 5.5 (-0.9-11.9) 9.5 (0.7-18.3) 
Private not-for-profit health facility 69.0 (36.8-89.5) 23 85.0 (49.1-97.1) 15 80.4 (57.6-92.5) 38 93.9 (74.3-98.8) 19 100.0 27 98.8 (94.5-99.7) 46 24.9 (-5.0-54.8) 15.0 (-7.3-37.4) 18.4 (1.1-35.7) 
Private for-profit outlet                
Health facility/pharmacy 63.3 (51-74.1) 358 37.4 (28.5-47.2) 103 49.0 (40.7-57.5) 461 78.2 (69.5-85.0) 408 74.5 (67.2-80.6) 113 75.9 (70.3-80.8) 521 14.9 (1.0-28.9) 37.1 (25.7-48.6) 26.9 (17.0-36.8) 
Drug store 54 (42.2-65.4) 267 26.9 (20.8-34) 155 32.9 (27.5-38.8) 422 91.9 (87.3-94.9) 329 84.1 (76.2-89.7) 145 87.2 (82.3-90.9) 474 37.9 (25.6-50.1) 57.2 (47.8-66.5) 54.3 (47.3-61.4) 
General retailer/itinerant 0.0 236 0.0 318 0.0 554 14.6 (6.9-28.5) 156 26.1 (14.9-41.5) 222 24.0 (14.6-36.9) 378 14.6 (4.2-25.0) 26.1 (12.7-39.4) 24.0 (12.9-35.1) 
Total 39.2 (31.6-47.4) 861 15.3 (9.7-23.3) 576 21.2 (16.5-26.8) 1,437 70.6 (62.7-77.5) 893 55.4 (44.5-65.8) 480 60.2 (52.1-67.7) 1,373 31.4 (20.6-42.2) 40.1 (27.5-52.7) 38.9 (29.7-48.2) 
Community health worker 79.5 (26.1-97.7) 4 59.2 (15.2-92.1) 20 59.7 (16.3-91.9) 24 - 0 - 0 - 0 - - - 
Madagascar – Total 19.9 (11.6-32.0) 1,442 24.3 (14.4-38.0) 963 23.4 (15.2-34.3) 2,405 28.4 (23.3-34.1) 973 28 (20.6-36.9) 1,369 28.1 (21.5-35.7) 2,342 8.4 (-2.9-19.8) 3.7 (-10.6-17.9) 4.6 (-7.2-16.5) 
Public health facility  66.1 (55.1-75.6) 68 89.8 (85.2-93) 445 83.2 (77.1-87.9) 513 91.1 (84.5-95.1) 64 94 (90.8-96.2) 536 93.7 (90.8-95.7) 600 25 (13.6-36.4) 4.2 (-0.4-8.9) 10.5 (4.7-16.4) 
Private not-for-profit health facility 47.8 (18.5-78.8) 6 - 0 47.8 (18.5-78.8) 6 89.6 (76.7-95.7) 25 60.8 (18.9-91.2) 5 71.9 (41.4-90.3) 30 41.8 (7.1-76.4) - 24.1 (-18.2-66.4) 
Private for-profit outlet                
Health facility/pharmacy 54.9 (40.4-68.6) 125 37.6 (9.8-77) 9 47.4 (30.0-65.4) 134 90.0 (84.8-93.5) 102 30.2 (9.1-65) 12 62.6 (42.7-79.1) 114 35.1 (20.2-49.9) -7.4 (-57.3-42.6) 15.2 (-10.9-41.4) 
Drug store 64.2 (56.9-70.9) 28 51 (42.5-59.4) 227 56.1 (50.1-61.9) 255 87.9 (67.9-96.2) 28 52.5 (42-62.8) 347 56.2 (46.1-65.9) 375 23.7 (9.0-38.5) 1.5 (-12-14.9) 0.2 (-11.3-11.7) 
General retailer/itinerant 0.5 (0.2-1.3) 1,213 3.1 (1.2-8.0) 244 2.6 (1.1-6.4) 1,457 0.4 (0.2-1.2) 739 2.7 (1.4-4.9) 404 2.4 (1.3-4.3) 1143 -0.1 (-0.7-0.5) -0.4 (-3.8-2.9) -0.3 (-3-2.5) 
Total 13.9 (7.8-23.5) 1,366 6.5 (3.6-11.5) 480 8.1 (5.1-12.6) 1846 18.5 (14.2-23.8) 869 7.5 (5.3-10.5) 763 9.2 (6.9-12) 1632 4.6 (-4.3-13.6) 1 (-3.5-5.5) 1 (-3.3-5.4) 
Community health worker 0.0 2 100.0 38 99.8 (99.2-100) 40 100.0 15 91.8 (78.4-97.2) 65 92.0 (79.0-97.2) 80 100.0 -8.2 (-16.6-0.2) -7.8 (-16.0-0.3) 
Niger – Total 14.8 (10.4-20.8) 833 8.0 (6.1-10.4) 1,198 9.4 (7.4-11.7) 2,031 27.3 (24.0-30.8) 924 16.4 (14-19.3) 738 19.4 (17.3-21.7) 1662 12.4 (6.2-18.6) 8.5 (5.1-11.9) 10 (7-13.1) 
Public health facility  75.1 (55.4-88) 91 41.4 (32.6-50.9) 385 44.8 (36.3-53.5) 476 86.2 (70.7-94.1) 102 70.7 (61.6-78.3) 220 72.9 (65.0-79.5) 322 11.1 (-8.8-30.9) 29.2 (16.8-41.6) 28.1 (16.9-39.3) 
Private not-for-profit health facility 6.6 (0.6-43.7) 4 - 0 6.6 (0.6-43.7) 4 49.2 (11.3-88.1) 2 100.0 1 83.3 (41.4-97.2) 3 42.6 (-9.9-95.1) - 76.7 (46.1-107.3) 
Private for-profit outlet                
Health facility/pharmacy 58.4 (40.9-74.0) 106 71.1 (33.3-92.4) 12 60.2 (43.5-74.9) 118 59.8 (49.6-69.3) 95 100.0 4 62.1 (51.8-71.4) 99 1.4 (-18.3-21.1) 28.9 (-3.6-61.5) 1.9 (-17.0-20.7) 
Drug store 54.7 (37.2-71.2) 14 14.6 (1.8-61.8) 7 29.3 (12.4-54.9) 21 68.4 (48.1-83.5) 15 63 (18.5-92.8) 3 65.4 (35.8-86.5) 18 13.7 (-11.6-39) 48.4 (-5.8-102.6) 36.1 (0.9-71.2) 
General retailer/itinerant 9.2 (4.7-17.3) 617 4.4 (2.8-7.0) 792 5.4 (3.6-7.9) 1,409 21.6 (17.7-26.1) 710 9.2 (7-12.1) 510 12.6 (10.5-15.0) 1,220 12.4 (5.1-19.8) 4.8 (1.6-8.0) 7.3 (4.2-10.3) 
Total 12.4 (7.9-18.9) 737 4.6 (3.0-7.2) 811 6.3 (4.5-8.7) 1,548 24.3 (20.7-28.2) 820 9.7 (7.4-12.6) 517 13.8 (11.8-16.2) 1,337 11.9 (5.3-18.4) 5.0 (1.7-8.3) 7.6 (4.6-10.6) 
Community health worker 0.0 1 0.0 2 0.0 3 - 0 - 0 - 0 - - - 
Nigeria – Total 28.8 (22.6-36) 1,718 23.7 (16.3-33.1) 359 27.7 (22.4-33.9) 2,077 53.7 (39.4-67.5) 1,020 53.2 (46.6-59.8) 469 53.5 (44.4-62.4) 1,489 24.9 (9.1-40.7) 29.5 (18.8-40.2) 25.8 (15.1-36.5) 
Public health facility  18.3 (11.1-28.7) 181 48.1 (27.4-69.5) 45 46.3 (26.6-67.3) 226 57.4 (42.3-71.2) 42 56.4 (39.3-72.0) 52 56.7 (44.1-68.5) 94 39.1 (21.9-56.3) 8.3 (-19.7-36.3) 10.4 (-14.4-35.2) 
Private not-for-profit health facility 77.1 (36.2-95.2) 6 100.0 2 98.1 (85.8-99.8) 8 79.7 (39.3-96.0) 6 100.0 3 87.3 (51.3-97.8) 9 2.6 (-40.0-45.3) 0.0 -10.7 (-31.8-10.4) 
Private for-profit outlet                
Health facility/pharmacy 42.2 (28.9-56.8) 725 24.9 (19.6-31.1) 24 29.1 (22.7-36.5) 749 81.7 (67.7-90.4) 95 30.3 (14.5-52.8) 30 63.0 (46.1-77.2) 125 39.4 (21.3-57.6) 5.4 (-15.3-26.0) 33.8 (16.4-51.2) 
Drug store 29.4 (22.7-37.2) 715 19.3 (12.4-28.7) 266 27.9 (21.9-34.8) 981 52.8 (37.7-67.4) 801 56.5 (49.4-63.3) 361 54.2 (44.1-64.0) 1,162 23.4 (6.5-40.3) 37.2 (26.6-47.8) 26.3 (14.4-38.3) 
General retailer/itinerant 18.5 (8.5-35.6) 85 0.6 (0.1-4.3) 16 15.0 (6.4-31.1) 101 19.4 (7.3-42.3) 73 7.5 (2.0-24.1) 19 16.3 (7.2-33.0) 92 1.0 (-20.9-22.8) 6.9 (-2.6-16.4) 1.4 (-15.9-18.7) 
Total 28.5 (22.2-35.8) 1,525 18.1 (12.6-25.2) 306 26.6 (21.0-33.0) 1,831 53.3 (38.9-67.3) 969 52.2 (44.8-59.4) 410 52.9 (43.4-62.2) 1,379 24.9 (8.8-40.9) 34.1 (24.5-43.7) 26.3 (15.1-37.5) 
Community health worker 99.5 (95.0-99.9) 6 23.5 (3.4-72.6) 6 56.9 (19.8-87.6) 12 100.0 3 80.9 (29.6-97.7) 4 81.6 (32.1-97.7) 7 0.5 (-0.7-1.7) 57.4 (5.0-109.7) 24.7 (-28.0-77.4) 
Tanzania – mainland – Total 24.8 (18.5-32.5) 317 25.7 (20.7-31.5) 284 25.5 (21.3-30.2) 601 71.6 (62.4-79.4) 596 68.3 (57.9-77) 191 69.5 (62.2-75.9) 787 46.8 (35.8-57.8) 42.5 (31.6-53.4) 44.0 (35.8-52.1) 
Public health facility  86.5 (37.6-98.6) 5 79.6 (63.8-89.6) 51 80.1 (65.3-89.6) 56 100.0 7 80.6 (64.3-90.5) 48 81.4 (65.9-90.9) 55 13.5 (-13.8-40.8) 0.9 (-17.2-19) 1.3 (-15.8-18.4) 
Private not-for-profit health facility 55.6 (10.4-93.1) 6 53.6 (25.3-79.8) 16 54.0 (28.2-77.9) 22 75.2 (22.9-96.9) 4 100.0 2 86.8 (42.3-98.3) 6 19.5 (-52.6-91.7) 46.4 (16.2-76.5) 32.8 (-3.9-69.4) 
Private for-profit outlet                
Health facility/pharmacy 56.7 (40.4-71.7) 220 26.7 (8.5-58.8) 12 51.2 (37.1-65.1) 232 82.9 (70.9-90.6) 321 68.4 (17.1-95.8) 16 79.2 (60.0-90.6) 337 26.2 (7.5-44.9) 41.8 (-14.9-98.5) 28.0 (7.2-48.7) 
Drug store 11.4 (5.9-20.7) 85 8.9 (4.9-15.6) 144 9.8 (6.3-14.8) 229 68.9 (57.8-78.1) 259 68.6 (56.5-78.5) 113 68.7 (60.5-75.8) 372 57.5 (45.2-69.8) 59.6 (47.5-71.7) 58.9 (50.3-67.6) 
General retailer/itinerant 0.0 1 4.3 (1.8-10.1) 60 4.3 (1.7-10.1) 61 69.4 (28.8-92.7) 5 15.8 (6.3-34.4) 12 20.6 (8.5-42.1) 17 69.4 (33.3-105.6) 11.5 (-2.4-25.5) 16.4 (-0.7-33.4) 
Total 19.4 (12.9-28.2) 306 7.5 (4.7-11.8) 216 10.8 (7.9-14.7) 522 70.9 (61.2-79.0) 585 62.9 (48.6-75.3) 141 66.4 (57.3-74.5) 726 51.5 (39.9-63.0) 55.5 (41.5-69.4) 55.6 (46.4-64.8) 
Community health worker - 0 - 1 - 1 - 0 - 0 - 0 - - - 
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Table 2.2.6: Cont. 
Country/Type of outlet 
BASELINE ENDLINE PERCENTAGE POINT CHANGE 
Urban Rural Total Urban Rural Total Urban Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) % (95% CI) % (95% CI) 
Uganda - Total 19.7 (17.0-22.7) 534 21.3 (17.2-26.0) 1,866 21.0 (17.7-24.6) 2,400 77.0 (72.9-80.7) 1,412 64.6 (57.3-71.3) 1,720 67.1 (61.1-72.7) 3,132 57.3 (52.6-62.0) 43.3 (35.2-51.5) 46.2 (39.5-52.9) 
Public health facility  83.9 (63.5-94.0) 76 87.7 (81.9-91.9) 690 87.3 (82-91.3) 766 90.2 (83-94.5) 144 91.9 (87.5-94.9) 534 91.7 (87.9-94.4) 678 6.3 (-9.1-21.8) 4.2 (-1.8-10.2) 4.3 (-1.2-9.8) 
Private not-for-profit health facility 77.2 (23.1-97.5) 3 41.0 (25.7-58.2) 26 45.5 (29.1-62.9) 29 91.1 (51.9-99) 12 79.1 (59.7-90.7) 27 80.4 (62.5-91.0) 39 13.8 (-31.5-59.2) 38.2 (15.6-60.7) 34.9 (12.7-57.1) 
Private for-profit outlet                
Health facility/pharmacy 21.2 (18.2-24.6) 382 12.0 (7.5-18.6) 355 16.5 (13.0-20.7) 737 80.9 (78.4-83.1) 814 75.5 (69.6-80.5) 387 77.9 (74.3-81.0) 1,201 59.6 (55.7-63.5) 63.5 (55.9-71.1) 61.4 (56.4-66.4) 
Drug store 7.8 (5.4-11.2) 70 9.9 (6.1-15.6) 747 9.6 (6.3-14.5) 817 69.8 (62.9-75.9) 436 58.0 (49.6-65.9) 676 59.7 (52.6-66.5) 1,112 61.9 (54.9-68.9) 48.1 (38.8-57.4) 50.1 (42.1-58.1) 
General retailer/itinerant 0.0 2 4.4 (0.9-19.4) 19 3.8 (0.7-17.6) 21 56.0 (13.0-91.6) 4 74.7 (35.8-94) 14 73.7 (36.6-93.1) 18 56.0 (3.8-108.3) 70.3 (38.4-102.3) 69.9 (38.9-100.8) 
Total 15.4 (12.8-18.4) 454 10.1 (6.8-14.9) 1,121 11.3 (8.3-15.2) 1,575 76.0 (71.3-80.1) 1,254 62.3 (54.3-69.6) 1,077 65.5 (59.2-71.3) 2,331 60.5 (55.4-65.7) 52.1 (43.6-60.7) 54.2 (47.3-61) 
Community health worker 0.0 1 41.0 (18.4-68.2) 29 40.1 (18.6-66.1) 30 100.0 2 55.0 (27.6-79.7) 82 55.2 (27.8-79.8) 84 100.0 14 (-24.1-52.1) 15.1 (-22.0-52.2) 
Zanzibar – Total 32.8 189 65.9 123 45.8 312 82.4 222 90 120 85.1 342 49.6 24.1  39.3 
Public health facility  
85.7 56 96.4 83 92.1 139 91.7 48 94.7 76 93.5 124 6.0 -1.6 1.5 
Private not-for-profit health facility 0.0 2 0.0 1 0.0 3 100.0 1 100.0 1 100.0 2 100.0 100.0 100.0 
Private for-profit outlet                
Health facility/pharmacy 16.4 73 9.1 11 15.5 84 87.8 82 93.8 16 88.8 98 71.4 84.7  73.3 
Drug store 3.5 57 0 24 2.5 81 73.9 88 75.0 24 74.1 112 70.4 75.0 71.6 
General retailer/itinerant 0.0 1 0.0 4 0.0 5 33.3 3 66.7 3 50.0 6 33.3  66.7 50.0 
Total 10.7 131 2.6 39 8.8 170 79.8 173 81.4 43 80.1 216 69.1 78.8  71.3 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 - - - 
Note: Nigeria baseline data collection was conducted in 2009. 
CI = Confidence interval 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys  
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Table 2.2.7: Outlets with quality-assured ACTs with and without the AMFm logo in stock at endline, 2011 
Percentage of censused outlets that had quality-assured ACTs with and without the AMFm logo in stock (n) among outlets with any antimalarials in stock at the time of the survey visit (N), by 
urban-rural location and type of outlet, according to country 
Country/Type of outlet 
WITH LOGO WITHOUT LOGO 
Urban Rural Total Urban  Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N 
Ghana – Total 83.7 (78.0.8-87.6) 574 74.8 (67.1-81.2) 382 80.2 (76.0-83.8) 956 16.5 (12.3-21.7) 574 7.2 (4.6-11.2) 382 12.9 (9.9-16.6) 956 
Public health facility  71.5 (56.6-82.8) 94 77.5 (62.4-87.7) 204 75.7 (64.7-84) 298 12.0 (6.4-21.4) 94 13.2 (7.5-22.2) 204 12.8 (8.3-19.4) 298 
Private not-for-profit health facility 100.0 4 76.3 (47.7-91.9) 9 85.6 (63.0-95.4) 13 0.0 4 11.2 (1.8-46.7) 9 6.8 (1.1-31.8) 13 
Private for-profit outlet             
Health facility/pharmacy 89.1 (85.0-92.2) 271 96.9 (89.4-99.1) 26 90.1 (86.4-92.9) 297 46.7 (42.1-51.4) 271 17.7 (6.6-39.5) 26 42.9 (37.7-48.3) 297 
Drug store 82.1 (74.7-87.7) 202 72.8 (63.1-80.8) 140 78.4 (72.7-83.3) 342 6.4 (4-10.1) 202 3.6 (1.4-9.2) 140 5.3 (3.4-8.2) 342 
General retailer/itinerant 100.0 3 33.7 (12.8-63.6) 3 66.7 (38.7-86.4) 6 0.0 3 32.7 (3.8-85.7) 3 16.4 (2.6-58.6) 6 
Total 84.1 (78.6-88.5) 476 73.9 (64.7-81.4) 169 80.7 (75.9-84.7) 645 17.1 (12.8-22.4) 476 5.3 (2.7-10.3) 169 13.1 (9.8-17.2) 645 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Kenya – Total 68.1 (60.6-74.8) 1,049 56.5 (47.2-65.4) 801 59.8 (52.7-66.5) 1,850 9.9 (8.6-11.3) 1,044 15.4 (12.1-19.5) 800 13.9 (11.5-16.7) 1,844 
Public health facility  69.6 (57.7-79.4) 137 68.3 (55.2-78.9) 294 68.4 (56.3-78.4) 431 55.6 (43.7-67) 137 65.2 (50.2-77.6) 294 64.4 (50.6-76.2) 431 
Private not-for-profit health facility 55.8 (23.9-83.5) 19 59.6 (37.2-78.6) 27 58.8 (39.6-75.7) 46 46 (17.3-77.5) 19 62.4 (40.4-80.2) 27 59.2 (40.2-75.7) 46 
Private for-profit outlet             
Health facility/pharmacy 75.7 (67.9-82) 408 73.3 (65.8-79.6) 113 74.2 (68.8-78.9) 521 8.4 (5.6-12.6) 405 10.2 (6.1-16.6) 112 9.5 (6.5-13.6) 517 
Drug store 88.9 (83.9-92.5) 329 81.9 (73.7-87.9) 145 84.7 (79.7-88.7) 474 10.2 (7.5-13.8) 328 4.9 (2.1-11) 145 7.0 (4.5-10.8) 473 
General retailer/itinerant 14.6 (6.9-28.5) 156 25.6 (14.7-40.8) 222 23.6 (14.4-36.3) 378 0.0 155 0.5 (0.1-1.8) 222 0.4 (0.1-1.5) 377 
Total 68.4 (60.7-75.2) 893 54.2 (43.4-64.6) 480 58.7 (50.8-66.1) 1,373 7.4 (5.8-9.5) 888 4 (2.5-6.3) 479 5.1 (3.8-6.8) 1,367 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Madagascar – Total 24.0 (18.9-29.9) 971 13.1 (9.7-17.5) 1,361 14.6 (11.3-18.6) 2,332 19.5 (15.6-24.2) 973 20.8 (14-29.7) 1,364 20.6 (14.6-28.2) 2,337 
Public health facility  70.7 (54.0-83.2) 62 72.6 (63.9-79.8) 528 72.4 (64.5-79.1) 590 63.6 (45.0-78.8) 64 72.3 (65.2-78.4) 531 71.3 (64.8-77.1) 595 
Private not-for-profit health facility 61.9 (46.2-75.5) 25 21.1 (2.6-73.1) 5 36.9 (15.4-65.2) 30 69.9 (48.7-85.1) 25 60.8 (18.9-91.2) 5 64.3 (34.8-85.9) 30 
Private for-profit outlet             
Health facility/pharmacy 83.7 (75.4-89.5) 102 10.9 (2.6-35.5) 12 50.4 (33.3-67.3) 114 69.6 (59.3-78.3) 102 20.4 (3.0-68) 12 47.1 (27.3-67.9) 114 
Drug store 87.9 (67.9-96.2) 28 46.8 (36.3-57.6) 347 51.2 (41-61.2) 375 30.7 (15.2-52.3) 28 9.7 (6.3-14.6) 347 11.9 (8.4-16.7) 375 
General retailer/itinerant 0.2 (0.1-0.7) 739 1.2 (0.4-3.3) 404 1.1 (0.4-2.8) 1,143 0.2 (0.0-1.2) 739 1.5 (0.6-3.6) 404 1.3 (0.5-3.1) 1,143 
Total 17.4 (13.2-22.6) 869 5.3 (3.7-7.5) 763 7.1 (5.3-9.5) 1,632 12.2 (8.4-17.3) 869 2.6 (1.6-4.3) 763 4.0 (2.8-5.8) 1,632 
Community health worker 62.3 (37.7-81.9) 15 9.5 (2-35.5) 65 10.8 (2.7-34.5) 80 79.2 (53.1-92.8) 15 82.9 (59.7-94.1) 65 82.8 (60.3-93.9) 80 
Niger – Total 20.4 (17.8-23.3) 924 9.9 (7.9-12.5) 738 12.8 (11-14.9) 1,662 11.2 (9.5-13.3) 924 8.4 (6.8-10.3) 738 9.2 (7.9-10.6) 1,662 
Public health facility  46.9 (39.2-54.7) 102 26.8 (17.8-38.2) 220 29.6 (21.6-39.2) 322 56.9 (45.2-67.9) 102 57.9 (49.2-66.1) 220 57.7 (50.1-65) 322 
Private not-for-profit health facility 0.0 2 100.0 1 67.1 (23.4-93.1) 3 49.2 (11.3-88.1) 2 0.0 1 16.2 (2.7-57.6) 3 
Private for-profit outlet             
Health facility/pharmacy 47.1 (38.8-55.5) 95 100.0 4 50.1 (41.3-58.8) 99 41.1 (30.1-53.1) 95 8.4 (1.4-38.1) 4 39.2 (28.6-51) 99 
Drug store 56.0 (34.4-75.6) 15 63.0 (18.5-92.8) 3 59.9 (32.0-82.6) 18 21.4 (8.8-43.6) 15 32.3 (5.9-78.3) 3 27.5 (9.3-58.3) 18 
General retailer/itinerant 17.1 (14.0-20.7) 710 7.2 (5.4-9.6) 510 9.9 (8.2-11.9) 1,220 6.8 (4.9-9.5) 710 2.2 (1.4-3.5) 510 3.5 (2.6-4.6) 1,220 
Total 19.2 (16.3-22.4) 820 7.7 (5.8-10.2) 517 11 (9.2-13) 1,337 8.9 (7.1-11.1) 820 2.4 (1.6-3.7) 517 4.3 (3.4-5.3) 1,337 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Nigeria – Total 49.3 (36.2-62.6) 1,020 44.5 (37.0-52.2) 469 47.4 (39.1-55.9) 1,489 15.2 (9.9-22.5) 1,020 16.5 (12.9-20.7) 469 15.7 (12.0-20.3) 1,489 
Public health facility  45.0 (31.0-59.9) 42 18.6 (9.3-33.7) 52 27.1 (18.0-38.6) 94 30.4 (14.9-52.1) 42 41.8 (24.8-60.9) 52 38.1 (25.1-53.0) 94 
Private not-for-profit health facility 79.7 (39.3-96.0) 6 93.1 (54.1-99.4) 3 84.8 (52.2-96.6) 9 52.6 (18.0-84.9) 6 53.2 (7.4-94.1) 3 52.8 (21.3-82.3) 9 
Private for-profit outlet             
Health facility/pharmacy 70.5 (50.4-84.9) 95 24.6 (11.2-45.8) 30 53.8 (36.4-70.4) 125 26.5 (17.0-38.8) 95 11.2 (3.1-32.9) 30 20.9 (13.7-30.5) 125 
Drug store 49.7 (35.0-64.5) 801 51.7 (44.0-59.2) 361 50.5 (40.6-60.3) 1,162 13.3 (7.9-21.7) 801 13.2 (9.6-18.0) 361 13.3 (9.4-18.5) 1,162 
General retailer/itinerant 12.2 (4.1-31.3) 73 7.5 (2.0-24.1) 19 11.0 (4.4-24.9) 92 8.3 (1.9-30.1) 73 0.0 19 6.2 (1.5-21.8) 92 
Total 49.2 (35.8-62.7) 969 47.5 (39.5-55.6) 410 48.5 (39.7-57.5) 1,379 14.3 (9.0-21.9) 969 12.5 (9.2-16.9) 410 13.6 (9.9-18.4) 1,379 
Community health worker 100.0 3 7.3 (0.6-50.4) 4 11.0 (1.4-51.8) 7 0.0 3 73.6 (21.7-96.5) 4 70.7 (20.3-95.8) 7 
Tanzania - mainland - Total 68.6 (58.6-77.1) 596 57.4 (45.4-68.6) 191 61.5 (52.8-69.5) 787 14.9 (10.8-20.4) 596 23.9 (17.7-31.5) 191 20.6 (16.4-25.6) 787 
Public health facility  82.8 (35-97.7) 7 53.3 (36.2-69.6) 48 54.6 (38.1-70.1) 55 64.4 (26.5-90.1) 7 64.2 (47.6-78) 48 64.2 (48.3-77.5) 55 
Private not-for-profit health facility 50.7 (12-88.6) 4 47.8 (4.9-94.2) 2 49.3 (14.8-84.5) 6 45.4 (10-86.2) 4 52.2 (5.8-95.1) 2 48.6 (14.5-84.1) 6 
Private for-profit outlet             
Health facility/pharmacy 82.0 (70.2-89.8) 321 27.6 (4.4-75.9) 16 67.9 (45.9-84.1) 337 25.5 (19.4-32.8) 321 43.4 (7.3-88.3) 16 30.1 (16.5-48.6) 337 
Drug store 66.3 (54.4-76.4) 259 68.0 (55.9-78.1) 113 67.3 (58.8-74.7) 372 11.4 (7.4-17.1) 259 4.6 (1.7-11.6) 113 7.5 (4.7-11.9) 372 
General retailer/itinerant 69.4 (28.8-92.7) 5 0.0 12 6.2 (1.1-28.9) 17 0.0 5 15.8 (6.3-34.4) 12 14.4 (6.0-30.7) 17 
Total 68.6 (58.2-77.4) 585 59.2 (43.7-73) 141 63.3 (53.3-72.3) 726 13.3 (9.5-18.2) 585 7.3 (4.0-13.1) 141 9.9 (7.1-13.7) 726 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
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Table 2.2.7: Cont. 
Country/Type of outlet 
WITH LOGO WITHOUT LOGO 
Urban Rural Total Urban  Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N 
Uganda – Total 69.6 (63.9-74.8) 1,412 54.7 (46-63.1) 1,718 57.7 (50.4-64.7) 3,130 14.8 (10.5-20.6) 1,409 15.8 (10.8-22.4) 1,717 15.6 (11.4-20.9) 3,126 
Public health facility  69.2 (53.9-81.2) 144 85.6 (80.4-89.6) 534 83.3 (78.2-87.3) 678 49.3 (30.4-68.5) 144 41 (27.4-56.2) 534 42.2 (30.0-55.5) 678 
Private not-for-profit health facility 38.2 (14.7-69) 12 39.4 (23-58.6) 27 39.3 (24.1-56.8) 39 70.2 (52.4-83.5) 12 52.2 (33.8-70.1) 27 54.1 (36.9-70.4) 39 
Private for-profit outlet             
Health facility/pharmacy 75.3 (72.3-78) 814 71.2 (63.6-77.8) 385 73.0 (68.6-76.9) 1,199 13.1 (8.3-20) 811 11.8 (8.9-15.6) 385 12.4 (9.7-15.7) 1,196 
Drug store 63.7 (55.3-71.2) 436 53.3 (43.9-62.5) 676 54.9 (46.8-62.7) 1,112 10.1 (6.9-14.6) 436 6.2 (4.5-8.5) 675 6.8 (5.2-8.8) 1,111 
General retailer/itinerant 38.2 (5.8-86.2) 4 74.7 (35.8-94) 14 72.6 (35.4-92.8) 18 17.8 (2.1-68.5) 4 3.5 (0.4-25.4) 14 4.3 (0.7-22.6) 18 
Total 70.1 (63.8-75.7) 1,254 57.8 (48.6-66.5) 1,075 60.7 (53.4-67.5) 2,329 11.8 (8.5-16.3) 1,251 7.4 (5.8-9.3) 1,074 8.4 (7.0-10.1) 2,325 
Community health worker 46.3 (5.2-93.1) 2 11.0 (4.9-23.2) 82 11.2 (5-23.2) 84 53.7 (6.9-94.8) 2 44.6 (14.8-78.9) 82 44.7 (14.8-78.9) 84 
Zanzibar – Total 79.3 222 89.1 119 82.7 341 6.8 222 4.2 120 5.8 342 
Public health facility  81.3 48 93.3 75 88.6 123 10.4 48 3.9 76 6.5 124 
Private not-for-profit health facility 100.0 1 100.0 1 100.0 2 0.0 1 0.0 1 0.0 2 
Private for-profit outlet             
Health facility/pharmacy 85.4 82 93.8 16 86.7 98 11 82 6.3 16 10.2 98 
Drug store 73.9 88 75.0 24 74.1 112 1.1 88 4.2 24 1.8 112 
General retailer/itinerant 33.3 3 66.7 3 50.0 6 0.0 3 0.0 3 0.0 6 
Total 78.6 173 81.4 43 79.2 216 5.8 173 4.7 43 5.6 216 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
CI = Confidence interval 
Source: AMFm Phase 1 Independent Evaluation Outlet Survey  
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Table 2.2.8: Public health facilities with quality-assured ACTs in stock among ALL public health facilities at baseline (2010) and endline (2011) 
Public health facilities that had quality-assured ACTs in stock (n) as a percentage of ALL PUBLIC HEALTH FACILITIES screened (N), by urban-rural location and type of 
outlet, according to country 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N 
Ghana 80.5 (68.5-88.7) 70 84.9 (77.0-90.4) 138 84.3 (77.4-89.3) 208 72.3 (58.1-83.1) 95 80.9 (71.4-87.8) 212 78.4 (70.8-84.4) 307 
Kenya 59.6 (29.5-83.8) 157 87.6 (78.7-93.1) 269 80.4 (66.0-89.6) 426 87.4 (78.0-93.2) 145 94.5 (89.5-97.2) 300 93.9 (89.5-96.6) 445 
Madagascar - - - - - - 91.1 (84.5-95.1) 64 90.6 (86.5-93.6) 558 90.7 (87.0-93.4) 622 
Niger 69.2 (52.6-81.9) 97 30.9 (24.2-38.5) 526 34.0 (27.6-41.1) 623 86.2 (70.7-94.1) 102 64.3 (54.5-73.0) 244 67.2 (58.5-74.8) 346 
Nigeria - - - - - - 56.6 (41.8-70.3) 47 43.4 (28.8-59.1) 61 46.9 (35.2-59.0) 108 
Tanzania – mainland 76.2 (23.2-97.1) 6 75.0 (57.7-86.8) 55 75.1 (58.7-86.4) 61 100.0 7 75.0 (58.7-86.4) 52 76.1 (60.3-86.9) 59 
Uganda 81.2 (59.0-92.8) 79 84.6 (77.8-89.5) 716 84.2 (77.8-89.1) 795 88.7 (81.4-93.3) 147 90.8 (84.9-94.5) 543 90.5 (85.5-93.9) 690 
Zanzibar 73.8 65 92.0 87 84.2 152 62.9 70 80.9 89 73.0 159 
Note: These data were not available at baseline for Nigeria and Madagascar. 
CI = Confidence interval 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys  
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2.2.1  Stockouts of quality-assured ACTs 
Table 2.2.9 shows stockouts of QAACTs among outlets that regularly stock them (defined as 
those with QAACTs in stock on the day of interview or that reported stocking them in the past 
four weeks). A stockout is defined as being out of stock of all QAACTs for at least one day in 
the last seven days, as reported by the respondent. It should be noted that this differs from the 
standard indicator for stockouts which relies on written records for each product to calculate the 
number of days that a product was out of stock in the preceding 12 months, for products for 
which data were available for at least six months. It was not feasible to use the standard indicator 
during the outlet surveys because of the lack of written records in most outlets (WHO 2006). 
Stockout levels ranged from 1.4% in Niger to 10% in Tanzania mainland at endline. The 
proportion of outlets experiencing stockouts fell significantly in Niger between baseline and 
endline in both the public and private for-profit sectors. 
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Table 2.2.9: Outlets with stock-outs of quality-assured ACTs at baseline (2010) and endline (2011) 
Indicator 1.6 Percentage of outlets that were out of stock of all quality-assured ACTs for at least 1 day in the last 7 days (n) among outlets with any quality-assured ACTs in stock at the time of the 
survey visit or in the 4 weeks preceding the survey visit (N), by urban-rural location and type of outlet, according to country, 2010-2011 
Country/Type of outlet 
BASELINE ENDLINE PERCENTAGE POINT CHANGE 
Urban Rural Total Urban Rural Total Urban Rural  Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) % (95% CI) % (95% CI) 
Ghana - Total 3.7 (2.0-6.7) 398 3.8 (1.8-8.2) 216 3.8 (2.1-6.6) 614 1.9 (1-3.7) 499 1.5 (0.5-4.4) 314 1.8 (1-3.1) 813 -1.7 (-4.3-0.8) -2.3 (-5.7-1) -2.0 (-4.4-0.3) 
Public health facility  2.9 (1.0-8.0) 58 2.8 (0.9-8.4) 106 2.8 (1.1-7.2) 164 1.1 (0.2-5.1) 75 1.5 (0.6-4.1) 172 1.4 (0.6-3.3) 247 -1.8 (-5.2-1.6) -1.2 (-4.7-2.2) -1.4 (-4.3-1.6) 
Private not-for-profit health facility 0.0 4 0.0 5 0.0 9 0.0 4 0.0 9 0.0 13 0.0 0/0 0/0 
Private for-profit outlet                
Health facility/pharmacy 3.6 (2.3-5.8) 259 4.8 (1.0-19.8) 34 3.9 (2.2-7.0) 293 0.7 (0.3-1.6) 241 0.0 26 0.6 (0.3-1.4) 267 -2.9 (-4.7- -1.1) -4.8 (-11.9-2.4) -3.3 (-5.6- -1.0) 
Drug store 4.3 (1.2-14.7) 77 4.5 (1.8-10.9) 68 4.5 (2.1-9.6) 145 2.5 (1.2-5.3) 176 1.8 (0.5-6.4) 105 2.3 (1.2-4.3) 281 -1.8 (-7.6-4) -2.7 (-7.4-1.9) -2.2 (-6-1.5) 
General retailer/itinerant - 0 - 0 - 0 0.0 3 0.0 2 0.0 5 - - - 
Total 3.9 (2-7.4) 336 4.6 (1.8-11.1) 102 4.3 (2.2-8.2) 438 2 (1-3.9) 420 1.6 (0.4-5.7) 133 1.9 (1-3.4) 553 -1.9 (-4.7-1.0) -3 (-7.6-1.7) -2.4 (-5.4-0.6) 
Community health worker - 0 0.0 3 0.0 3 - 0 - 0 - 0 - - - 
Kenya - Total 4.2 (2.8-6.4) 674 5.3 (2.7-10.1) 431 5.0 (2.9-8.2) 1,105 5.4 (3.1-9.3) 877 5.4 (3.7-7.8) 633 5.4 (4-7.3) 1510 1.2 (-2.3-4.6) 0.2 (-3.9-4.2) 0.5 (-2.5-3.5) 
Public health facility  11.8 (6.2-21.3) 121 5.4 (2.1-12.8) 223 6.8 (3.6-12.4) 344 2.2 (0.9-5.2) 125 3.8 (1.4-9.6) 287 3.7 (1.4-9) 412 -9.6 (-17.1- -2.1) -1.6 (-7.5-4.4) -3.1 (-8.4-2.2) 
Private not-for-profit health facility 15.6 (4.2-43.4) 21 14.4 (1.9-59.2) 14 14.8 (3.6-44.3) 35 2.4 (0.3-16.6) 17 5.1 (0.7-30.7) 25 4.6 (0.7-24) 42 -13.2 (-32.3-6) -9.3 (-37.4-18.8) -10.2 (-30.8-10.5) 
Private for-profit outlet                
Health facility/pharmacy 1.4 (0.5-3.7) 296 1.6 (0.4-7.1) 79 1.5 (0.6-3.9) 375 6.4 (2.5-15.2) 366 3.9 (1.2-12.5) 103 4.9 (2.2-10.4) 469 5.0 (-0.9-10.8) 2.3 (-3.0-7.6) 3.3 (-0.7-7.4) 
Drug store 3.6 (1.5-8.1) 204 9.6 (5.5-16.3) 75 7.7 (4.4-13.3) 279 5.7 (3.0-10.7) 316 8.8 (4.6-16) 131 7.5 (4.6-12.1) 447 2.2 (-2.5-6.8) -0.8 (-8.3-6.7) -0.2 (-5.8-5.4) 
General retailer/itinerant 0.0 21 0.0 14 0.0 35 1.5 (0.3-6.3) 53 3.0 (1.0-8.8) 86 2.8 (1.0-7.7) 139 1.5 (-0.7-3.7) 3.0 (-0.3-6.3) 2.8 (-0.1-5.7) 
Total 2.3 (1.3-4.0) 521 6 (2.9-11.9) 168 4.6 (2.5-8.6) 689 5.6 (3.1-9.9) 735 5.9 (3.8-9.2) 320 5.8 (4.1-8.3) 1,055 3.3 (-0.1-6.8) -0.1 (-5.0-4.9) 1.2 (-2.4-4.7) 
Community health worker 0.0 11 0.0 26 0.0 37 - 0 0.0 1 0.0 1 - 0.0 0.0 
Madagascar - Total       2 (0.6-6.2) 205 1.6 (0.7-3.8) 786 1.7 (0.8-3.5) 991    
Public health facility  - - - - - - 1.3 (0.2-6.5) 54 1.1 (0.4-3.2) 515 1.1 (0.4-2.9) 569 - - - 
Private not-for-profit health facility - - - - - - 0.0 22 0.0 2 0.0 24 - - - 
Private for-profit outlet - - - - - -       - - - 
Health facility/pharmacy - - - - - - 4.1 (1.2-12.5) 86 0.0 2 3.7 (1.1-12) 88 - - - 
Drug store - - - - - - 0.0 24 4.2 (1.7-10) 198 3.5 (1.4-8.6) 222 - - - 
General retailer/itinerant - - - - - - 0.0 3 0.0 5 0.0 8 - - - 
Total - - - - - - 2.9 (0.8-10.6) 113 3.3 (1.2-8.3) 205 3.1 (1.4-6.7) 318 - - - 
Community health worker - - - - - - 0.0 16 1.5 (0.2-9.9) 64 1.4 (0.2-9.6) 80 - - - 
Niger - Total 5.3 (2.5-10.7) 205 6.7 (3.4-12.9) 282 6.3 (3.7-10.8) 487 2.4 (1.4-4.3) 415 0.9 (0.3-2.5) 331 1.4 (0.8-2.4) 746 -2.9 (-6.9-1.2) -5.8 (-10.4- -1.2) -4.9 (-8.4- -1.5) 
Public health facility  2.9 (0.6-12.1) 61 6.4 (3.8-10.7) 234 6.0 (3.6-9.8) 295 0.7 (0.2-2.8) 89 1.7 (0.5-5.1) 180 1.5 (0.5-4.4) 269 -2.2 (-6.6-2.1) -4.8 (-8.6- -0.9) -4.5 (-7.9- -1.1) 
Private not-for-profit health facility 0.0 1 - 0 0.0 1 0.0 1 0.0 1 0.0 2 0.0 - 0.0 
Private for-profit outlet                
Health facility/pharmacy 1.0 (0.1-7.8) 78 0.0 4 0.9 (0.1-6.5) 82 0.7 (0.2-3.2) 72 0.0 3 0.7 (0.2-2.9) 75 -0.3 (-2.7-2.1) 0.0 -0.2 (-2.2-1.9) 
Drug store 0.0 12 0.0 3 0.0 15 0.0 10 0.0 1 0.0 11 0.0 0.0 0.0 
General retailer/itinerant 8.4 (4.5-15.1) 53 7.7 (2.6-20.7) 41 7.9 (3.8-15.9) 94 2.9 (1.6-5.2) 243 0.7 (0.1-3.3) 146 1.4 (0.7-2.7) 389 -5.5 (-10.9- -0.1) -7.0 (-15.2-1.1) -6.5 (-12.3- -0.7) 
Total 5.8 (2.7-12.2) 143 7 (2.4-19.1) 48 6.6 (3.1-13.4) 191 2.6 (1.5-4.6) 325 0.7 (0.1-3.3) 150 1.4 (0.7-2.6) 475 -3.2 (-7.9-1.4) -6.4 (-13.8-1.1) -5.2 (-10.1- -0.3) 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 - - - 
Nigeria - Total - - - - - - 5.1 (2.8-9.3) 739 6.6 (3.7-11.5) 334 5.7 (3.8-8.6) 1,073 - - - 
Public health facility  - - - - - - 1.1 (0.2-5.4) 36 2.4 (0.3-15.6) 39 2.0 (0.4-10.0) 75 - - - 
Private not-for-profit health facility - - - - - - 0.0 6 0.0 3 0.0 9 - - - 
Private for-profit outlet - - - - - -       - - - 
Health facility/pharmacy - - - - - - 0.7 (0.2-3.3) 78 0.0 25 0.5 (0.1-2.1) 103 - - - 
Drug store - - - - - - 5.6 (3.0-10.2) 583 8.3 (4.5-15.1) 251 6.7 (4.3-10.2) 834 - - - 
General retailer/itinerant - - - - - - 13.6 (4.8-33.0) 33 0.0 12 10.6 (3.6-27.8) 45 - - - 
Total - - - - - - 5.4 (2.9-9.9) 694 7.3 (3.9-13.2) 288 6.1 (4.0-9.4) 982 - - - 
Community health worker - - - - - - 0.0 3 0.0 4 0.0 7 - - - 
Tanzania – mainland - Total 1.4 (0.8-2.5) 177 3.3 (0.9-11.3) 72 2.9 (0.9-8.7) 249 8 (5.6-11.2) 485 11.4 (7.4-17.3) 151 10.2 (7.3-14.1) 636 6.6 (3.8-9.4) 8.1 (1.8-14.5) 7.3 (2.7-11.9) 
Public health facility  0.0 3 2.9 (0.4-19.4) 39 2.7 (0.4-18.1) 42 9.2 (1.1-49.1) 5 7.4 (2.5-19.9) 47 7.5 (2.6-19.3) 52 9.2 (-9.4-27.8) 4.4 (-5.2-14.1) 4.7 (-4.5-13.9) 
Private not-for-profit health facility 0.0 4 0.0 7 0.0 11 0.0 3 0.0 2 0.0 5 0.0 0.0 0.0 
Private for-profit outlet                
Health facility/pharmacy 3.6 (2-6.3) 161 0.0 4 3.3 (1.8-5.9) 165 2.3 (1.1-4.7) 291 1.8 (0.2-16.4) 13 2.2 (1-4.6) 304 -1.3 (-3.9-1.3) 1.8 (-2.3-5.9) -1.1 (-3.6-1.4) 
Drug store 0.0 9 8.1 (1.7-30.7) 16 5.5 (1.3-21.3) 25 9.3 (6.5-13.2) 183 14.7 (8.7-23.8) 87 12.5 (8.6-17.7) 270 9.3 (6-12.6) 6.5 (-7.5-20.6) 6.9 (-2.1-16) 
General retailer/itinerant - 0 0.0 6 0.0 6 0.0 3 0.0 2 0.0 5 - 0.0 0.0 
Total 2 (1.1-3.6) 170 5.2 (1.1-21.1) 26 3.9 (1.2-12.2) 196 8.1 (5.7-11.3) 477 13.8 (8.3-22.1) 102 11.3 (7.9-15.8) 579 6.1 (3.2-9.1) 8.6 (-1.6-18.9) 7.4 (1.4-13.3) 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 - - - 
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Table 2.2.9: Cont. 
Country/Type of outlet 
BASELINE ENDLINE PERCENTAGE POINT CHANGE 
Urban Rural Total Urban Rural Total Urban Rural  Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) % (95% CI) % (95% CI) 
Uganda - Total 6.6 (1.8-21.5) 325 7.8 (4.9-12.3) 901 7.6 (4.8-11.8) 1,226 4.7 (3.2-6.9) 1208 6.5 (4.5-9.2) 1,449 6.1 (4.5-8.3) 2,657 -1.9 (-10.3-6.4) -1.3 (-5.5-2.8) -1.5 (-5.3-2.4) 
Public health facility  20.2 (9.0-39.2) 68 8.3 (4.8-14.2) 616 9.6 (5.6-15.8) 684 2.2 (0.4-9.9) 133 2.9 (0.8-9.7) 497 2.8 (0.9-8.3) 630 -18.0 (-33.1- -3.0) -5.5 (-11.2-0.2) -6.8 (-12.5- -1.0) 
Private not-for-profit health facility 44.7 (6.2-90.8) 3 0.0 12 10.6 (1.3-52.1) 15 0.0 11 0.0 24 0.0 35 -44.7 (-105-15.7) 0.0 -10.6 (-31.1-9.9) 
Private for-profit outlet                
Health facility/pharmacy 2.5 (0.3-18.7) 244 4.9 (1.3-16.8) 119 3.5 (1.0-11.5) 363 3.4 (1.6-6.8) 730 9.4 (5.8-15) 325 6.6 (4.1-10.6) 1,055 0.9 (-4.8-6.6) 4.5 (-3.1-12.1) 3.1 (-2.1-8.4) 
Drug store 0.0 10 6.8 (3.7-12.3) 131 6.2 (3.3-11.3) 141 7.5 (4.8-11.6) 329 7.4 (5.1-10.8) 514 7.5 (5.4-10.3) 843 7.5 (4.2-10.8) 0.6 (-4.3-5.5) 1.3 (-3.2-5.8) 
General retailer/itinerant - 0 0.0 2 0.0 2 0.0 3 11.7 (1.5-52.9) 12 11.1 (1.5-49.7) 15 - 
11.7 (-10.2-33.5) 
 11.1 (-9.1-31.3) 
Total 2.0 (0.3-13.6) 254 6.3 (3.6-10.7) 252 5.1 (2.7-9.2) 506 5.0 (3.3-7.5) 1062 8.0 (6.1-10.6) 851 7.3 (5.5-9.6) 1,913 3.0 (-1.4-7.4) 1.7 (-2.3-5.7) 2.2 (-1.4-5.8) 
Community health worker - 0 17.9 (4.7-49.5) 21 17.9 (4.7-49.5) 21 0.0 2 1.8 (0.3-9.0) 77 1.8 (0.3-8.9) 79 - -16.2 (-37.9- 55.5) -16.2 (-37.9-5.5) 
Zanzibar - Total 1.4 69 2.3 86 1.9 155 5.2 192 5.5 109 5.3 301 3.8 3.2  3.4  
Public health facility  2 49 2.4 82 2.3 131 4.1 49 5.6 71 5 120 2  3.2  2.7 
Private not-for-profit health facility 0.0 1 - 0 0 1 0.0 1 0.0 1 0.0 2 0.0 - 0 
Private for-profit outlet                
Health facility/pharmacy 0.0 16 0.0 2 0.0 18 5.4 74 6.3 16 5.6 90 5.4 6.3 5.6 
Drug store 0.0 3 0.0 2 0.0 5 6.0 67 5.3 19 5.8 86 6 5.3 5.8 
General retailer/itinerant - 0 - 0 - 0 0.0 1 0.0 2 0.0 3 - - - 
Total 0.0 19 0.0 4 0.0 23 5.6 142 5.4 37 5.6 179 5.6 5.4 5.6 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 - - - 
Note: This indicator measures stock-outs of quality-assured ACTs among outlets that have recently stocked these products. The denominator includes outlets which had no antimalarials in stock on the day of the survey but 
which had stocked them in the previous 3 months. A stock-out is defined as being out of stock of all quality-assured ACTs for at least 1 day in the last seven days. Outlets that have recently stocked QAACTs are defined as 
outlets with any QAACTs in stock at the time of the survey visit or in the 4 weeks preceding the survey visit. Nigeria baseline data collection was conducted in 2009. 
*These data are not available for Madagascar and Nigeria at baseline as they were not collected in the ACTwatch questionnaire. CI = Confidence interval 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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2.2.2 Population coverage of outlets with quality-assured ACTs 
Table 2.2.10 shows the percentage of the population living in “subdistricts” with at least one 
outlet that stocks QAACTs. At endline, Kenya and Madagascar reached 100% coverage (Ghana 
and Uganda had already reached this level at baseline); coverage in Niger was 88% and Tanzania 
mainland 92% (100% in urban areas and 90% in rural areas). In interpreting this indicator, it 
should be noted that the size of a subdistrict varied across countries to some degree in terms of 
both the number of residents and geographical size, so the percentage of the population covered 
is likely to be higher in countries with larger subdistricts, other things being equal. The study 
design aimed to choose for the sample administrative units with a population size of about 
10,000-15,000 but in practice, the population size was often larger, meaning that having at least 
one QAACT outlet available in the subdistrict does not necessarily ensure good access to the 
whole population. It also captures only supply side availability and does not reflect other 
dimensions of access such as information, provider behavior and affordability. 
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Table 2.2.10: Percentage of the population living in “subdistricts” with outlets with quality-assured ACTs in stock at baseline (2010) and endline (2011)  
Indicator 1.7 Population living in a censused “subdistrict” where there was at least one of a given type of outlet with a quality-assured ACT in stock at the time of the survey visit (n) as a 
percentage of the total population living in all the censused “subdistricts” (N), by urban-rural location, according to country 
 
Country/Type of outlet 
BASELINE ENDLINE PERCENTAGE POINT CHANGE 
Urban Rural Total Urban Rural Total Urban Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) % (95% CI) % (95% CI) 
Ghana                
At least one public health facility 
stocking quality-assured ACTs 48.4 (33.7-63.3) 815,507 86.7 (72.2-94.2) 666,331 76.5 (66.5-84.3) 1,481,838 28.6 (16.4-44.9) 363,574 76.7 (60.4-87.6) 437,796 53.5 (43.1-63.6) 801,370 -19.8 (-40.7-1.1) -10.0 (-27.1-7.1) -23.0 (-36.6- -9.5) 
At least one private not-for-profit 
health facility stocking quality-assured 
ACTs 8.1 (2.7-22) 815,507 13.3 (5.8-27.8) 666,331 11.9 (5.9-22.7) 1,481,838 21.4 (9.6-41.3) 363,574 23.3 (12.4-39.6) 437,796 22.4 (13.7-34.5) 801,370 13.3 (-4.6-31.3) 10.0 (-7.1-27.1) 10.5 (-2.6-23.5) 
At least one private for-profit outlet 
stocking quality-assured ACTs 100.0 815,507 83.3 (68.4-92.0) 666,331 87.7 (76.4-94.1) 1,481,838 100.0 363,574 90.0 (75.3-96.4) 437,796 94.8 (86.7-98.1) 801,370 0.0 6.7 (-8.3-21.6) 7.1 (-2.7-16.9) 
At least one community health worker 
stocking quality-assured ACTs 0.0 815,507 6.7 (2-19.9) 666,331 4.9 (1.5-14.9) 1,481,838 0.0 363,574 0.0 437,796 0.0 801,370 0.0 -6.7 (-14.4-1.0) -4.9 (-10.6-0.7) 
At least one outlet of any type 
stocking quality-assured ACTs 100.0 815,507 100.0 666,331 100.0 148,1838 100.0 363,574 100.0 437,796 100.0 801,370 0.0 0.0 0.0 
Kenya                
At least one public health facility 
stocking quality-assured ACTs 73.9 (52.9-87.7) 590,950 88.2 (71.9-95.6) 534,059 85.2 (72.9-92.5) 1,125,009 63.4 (39.4-82.2) 582,959 96.4 (77.5-99.5) 579,885 89.4 (79-95) 1,162,844 -10.6 (-39.1-18.0) 8.2 (-4.9-21.2) 4.2 (-7.9-16.3) 
At least one private not-for-profit 
health facility stocking quality-assured 
ACTs 52.2 (32.6-71.1) 590,950 29.4 (16.3-47.1) 534,059 34.2 (22.5-48.3) 1,125,009 44.3 (24.0-66.7) 582,959 47.7 (31.0-64.9) 579,885 47.0 (32.9-61.5) 1,162,844 -7.8 (-38.0-22.3) 18.3 (-5.1-41.7) 12.7 (-6.8-32.2) 
At least one private for-profit outlet 
stocking quality-assured ACTs 95.7 (75.0-99.4) 590,950 58.8 (41.4-74.3) 534,059 66.6 (52.1-78.6) 1,125,009 97.9 (86.2-99.7) 582,959 87.5 (70.3-95.4) 579,885 89.7 (75.9-96) 1,162,844 2.2 (-6.9-11.4) 28.7 (8.1-49.2) 23.1 (6.7-39.4) 
At least one community health worker 
stocking quality-assured ACTs 8.7 (2.2-28.7) 590,950 11.8 (4.4-28.1) 534,059 11.1 (4.7-23.9) 1,125,009 0.0 582,959 0.0 579,885 0.0 1,162,844 -8.7 (-20.0-2.6) -11.8 (-22.8- -0.7) -11.1 (-20.1- -2.1) 
At least one outlet of any type 
stocking quality-assured ACTs 95.7 (75.0-99.4) 590,950 94.1 (78.6-98.6) 534,059 94.4 (82.7-98.4) 1,125,009 100.0 582,959 100.0 579,885 100.0 1,162,844 4.3 (-3.8-12.5) 5.9 (-2.2-13.9) 5.6 (-1.0-12.1) 
Madagascar          ,      
At least one public health facility 
stocking quality-assured ACTs 68.4 (51.5-81.5) 838,897 89.5 (65.1-97.5) 339,277 87.3 (68.1-95.7) 1,178,174 94.4 (78.4-98.8) 638,229 89.3 (71.1-96.6) 509,449 89.8 (73.5-96.5) 1,147,678 26.0 (8.9-43.2) -0.2 (-18.4-18.0) 2.5 (-14.1-19.0) 
At least one private not-for-profit 
health facility stocking quality-assured 
ACTs 15.8 (7.8-29.4) 838,897 0.0 339,277 1.6 (0.7-3.6) 1,178,174 77.8 (60.8-88.8) 638,229 7.1 (1.7-25.0) 509,449 14.1 (7.2-25.9) 1,147,678 62.0 (44.6-79.4) 7.1 (-2.5-16.8) 12.5 (3.3-21.6) 
At least one private for-profit outlet 
stocking quality-assured ACTs 94.7 (78.9-98.9) 838,897 57.9 (34.9-77.9) 339,277 61.7 (40.1-79.4) 1,178,174 94.4 (74.6-99.0) 638,229 64.3 (45.0-79.8) 509,449 67.3 (49.4-81.2) 1,147,678 -0.3 (-12.2-11.6) 6.4 (-22.5-35.3) 5.6 (-20.5-31.7) 
At least one community health worker 
stocking quality-assured ACTs 0.0 838,897 52.6 (30.4-73.9) 339,277 47.3 (27.9-67.5) 1,178,174 27.8 (12.7-50.4) 638,229 57.1 (38.3-74.1) 509,449 54.3 (37.4-70.2) 1,147,678 27.8 (8.5-47.1) 4.5 (-25.0-34.0) 7.0 (-19.7-33.7) 
At least one outlet of any type 
stocking quality-assured ACTs 94.7 (78.9-98.9) 838,897 89.5 (65.1-97.5) 339,277 90.0 (68.3-97.4) 1,178,174 100.0 638,229 100.0 509,449 100.0 1,147,678 5.3 (-2.4-13.0) 10.5 (-3.6-24.6) 10.0 (-2.7-22.7) 
Niger          ,      
At least one public health facility 
stocking quality-assured ACTs 58.9 (40.0-75.5) 366,272 57.1 (42.0-71.0) 552,717 57.4 (44.4-69.5) 918,989 48.9 (35.2-62.7) 414,798 77.9 (63.5-87.7) 481,099 72.4 (61.1-81.4) 895,897 -10.0 (-33.1-13.1) 20.8 (1.8-39.9) 15.0 (-1.3-31.2) 
At least one private not-for-profit 
health facility stocking quality-assured 
ACTs 0.5 (0.1-4.1) 366,272 0.0 552,717 0.1 (0.0-0.7) 918,989 3.3 (0.8-12.8) 414,798 3.5 (0.7-16.0) 481,099 3.4 (0.9-12.5) 895,897 2.7 (-2.0-7.5) 3.5 (-2.1-9.0) 3.3 (-1.2-7.9) 
At least one private for-profit outlet 
stocking quality-assured ACTs 85.0 (67.6-93.9) 366,272 40.1 (26.6-55.3) 552,717 47.7 (35.6-60.1) 918,989 93.2 (82.6-97.5) 414,798 57.9 (43.2-71.3) 481,099 64.7 (52.3-75.4) 895,897 8.2 (-6.1-22.5) 17.8 (-2.6-38.3) 17.0 (0.0-34.0) 
At least one community health worker 
stocking quality-assured ACTs 0.0 366,272 0.0 552,717 0.0 918,989 0.0 414,798 0.0 481,099 0.0 895,897 0.0 0.0 0.0 
At least one outlet of any type 
stocking quality-assured ACTs 94.3 (78.7-98.7) 366,272 81.7 (67-90.7) 552,717 83.8 (71.4-91.5) 918,989 93.2 (82.6-97.5) 414,798 87.3 (73.9-94.3) 481,099 88.4 (77.7-94.3) 895,897 -1.1 (-11.5-9.3) 5.6 (-9.6-20.8) 4.6 (-8.0-17.2) 
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Table 2.2.10: Cont.  
Country/Type of outlet 
BASELINE ENDLINE PERCENTAGE POINT CHANGE 
Urban Rural Total Urban Rural Total Urban Rural Total 
% (95% CI) N % (95% CI) N % 
 (95% CI) 
N % 
 (95% CI) 
N %  
(95% CI) 
N % 
 (95% CI) 
N % (95% CI) % (95% CI) % (95% CI) 
Nigeria                
At least one public health facility 
stocking quality-assured ACTs  
- - - - - - - - - - - - - - - 
At least one private not-for-profit 
health facility stocking quality-
assured ACTs 
- - - - - - - - - - - - - - - 
At least one private for-profit 
outlet stocking quality-assured 
ACTs 
- - - - - - - - - - - - - - - 
At least one community health 
worker stocking quality-assured 
ACTs 
- - - - - - - - - - - - - - - 
At least one outlet of any type 
stocking quality-assured ACTs 
- - - - - - - - - - - - - - - 
Tanzania – mainland                
At least one public health facility 
stocking quality-assured ACTs 44.5 (16.8-76.0) 154,580 59.0 (42.7-73.5) 519,954 56.3 (41.8-69.8) 674,534 35.0 (20.1-53.5) 288,563 69.2 (49.8-83.5) 392,886 62.4 (47.3-75.5) 681,449 -9.5 (-47.2-28.2) 10.2 (-13.0-33.4) 6..1 (14.0-26.5) 
At least one private not-for-profit 
health facility stocking quality-
assured ACTs 11.1 (1.4-52.4) 154,580 20.5 (10.4-36.4) 519,954 18.8 (9.9-32.8) 674,534 15.0 (5.7-34.1) 288,563 6.9 (1.6-24.6) 392,886 8.5 (3.1-20.9) 681,449 3.9 (-21.3-29.1) -13.7 (-29.6-2.3) -10.3 (-24.2-3.5) 
At least one private for-profit 
outlet stocking quality-assured 
ACTs 66.7 (31.9-89.5) 154,580 35.9 (22.2-52.3) 519,954 41.5 (28.4-55.9) 674,534 100.0 288,563 75.4 (55.9-88.1) 392,886 80.2 (63.8-90.3) 681,449 33.3 (1.4-65.2) 39.5 (17.2-61.7) 38.7 (19.6-57.8) 
At least one community health 
worker stocking quality-assured 
ACTs 0.0 154,580 0.0 519,954 0.0 674,534 0.0 288,563 0.0 392,886 0.0 681,449 0.0 0.0 0.0 
At least one outlet of any type 
stocking quality-assured ACTs 88.9 (47.6-98.6) 154,580 79.5 (63.6-89.6) 519,954 81.2 (67.2-90.1) 674,534 100.0 288563 89.7 (71.7-96.8) 392,886 91.7 (76.8-97.4) 681,449 11.1 (-10.2-32.4) 10.2 (-6.9-27.3) 10.6 (-3.9-57.8) 
Uganda                
At least one public health facility 
stocking quality-assured ACTs 57.6 (10.9-93.8) 96,159 100.0 1,069,824 95.3 (72.7-99.4) 1,165,983 66.7 (23.7-92.8) 487,554 96.2 (76.1-99.5) 902,154 92.5 (74.9-98.1) 1,389,708 9.1 (-61.5-79.6) -3.8 (-11.4-3.7) -2.7 (-15.9-10.4) 
At least one private not-for-profit 
health facility stocking quality-
assured ACTs 57.6 (10.9-93.8) 96,159 26.0 (13.2-44.7) 1,069,824 29.5 (16.5-46.9) 1,165,983 27.8 (14.8-46.1) 487,554 46.2 (27.2-66.3) 902,154 43.9 (27.1-62.2) 1,389,708 -29.8 (-89.3-29.7) 20.2 (-5.6-45.9) 14.4 (-9.3-38.0) 
At least one private for-profit 
outlet stocking quality-assured 
ACTs 100.0 96,159 70.2 (52.1-83.6) 1,069,824 73.5 (56.4-85.6) 1,165,983 100.0 487,554 100.0 902,154 100.0 1,389,708 0.0 29.8 (14.0-45.5) 26.5 (12.0-41.0) 
At least one community health 
worker stocking quality-assured 
ACTs 0.0 96,159 6.6 (2.3-17.2) 1,069,824 5.9 (2.1-15.6) 1,165,983 11.1 (2.3-39.7) 487,554 19.2 (7.0-43.1) 902,154 18.2 (7.1-39.4) 1,389,708 11.1 (-5.1-27.4) 12.6 (-6.3-31.6) 12.4 (-4.5-29.2) 
At least one outlet of any type 
stocking quality-assured ACTs 100.0 96,159 100.0 1,069,824 100.0 1,165,983 100.0 487,554 100.0 902,154 100.0 1,389,708 0.0 0.0 0.0 
Zanzibar                
At least one public health facility 
stocking quality-assured ACTs  
- - - - - - - - - - - - - - - 
At least one private not-for-profit 
health facility stocking quality-
assured ACTs 
- - - - - - - - - - - - - - - 
At least one private for-profit 
outlet stocking quality-assured 
ACTs 
- - - - - - - - - - - - - - - 
At least one community health 
worker stocking quality-assured 
ACTs 
- - - - - - - - - - - - - - - 
At least one outlet of any type 
stocking quality-assured ACTs 
- - - - - - - - - - - - - - - 
Note: This indicator could not be calculated for Zanzibar because subdistrict population numbers were unavailable. It could not be calculated for Nigeria because of the nature of the sample design.   
CI = confidence interval 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys   
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2.3 Evaluation question on ACT affordability 
Question 2: Has the cost of quality-assured ACTs to patients been reduced at public, private for-
profit and not-for-profit outlets in rural/urban areas to a price comparable to the price of the most 
popular antimalarials? 
2.3.1 Cost to patients of antimalarials 
Table 2.3.1 shows the cost to patients of non-artemisinin therapies such as SP, amodiaquine, 
chloroquine and quinine. It should be noted that some of the variation across countries is likely 
to reflect differences in the shares of different generic drug types and formulations (for example, 
quinine tends to be more costly than other generic types, and injections and syrups tend to be 
more costly than tablets). In Kenya, Niger, Tanzania mainland, Uganda and Zanzibar, the median 
price per AETD was zero in public health facilities, reflecting generally free drug provision in 
these outlets. At endline, in the private for-profit sector, the median price was less than USD 1.00 
in Madagascar, Niger and Nigeria. It was between USD 1.00 and 2.00 in Tanzania mainland, 
Ghana and Kenya; and it was most expensive in Zanzibar (USD 2.62) and Uganda (USD 4.93). 
There was no change in median price from baseline to endline in most countries in the private 
for-profit sector. There was a small increase in median price in Niger (USD 0.11). In Ghana, 
there were small but significant price decreases in both rural and urban areas, but an overall 
increase in median price of USD 0.40. This reflects the higher proportion of urban outlets 
enumerated at endline than at baseline, and the lower proportion of rural outlets that stocked 
antimalarials at endline (see Tables 2.1.4 and 2.2.1), combined with the higher median price in 
urban than rural outlets. 
 
Table 2.3.2 shows the cost to patients of artemisinin monotherapies. These products were rare at 
endline in Madagascar, Niger and Zanzibar. Where they were more common, the median price 
per AETD in private for-profit outlets was more than USD 15.00 in Uganda, Tanzania mainland 
and Kenya. In Ghana the median price at endline was USD 5.63 and in Nigeria it was USD 2.95. 
In Nigeria this represented a significant fall from a baseline price of USD 4.09 at baseline. 
 
Table 2.3.3 shows the cost to patients of oral artemisinin monotherapies at endline, 
distinguishing all oral dosage forms and tablets only. The median prices in private for-profit 
outlets are used in Success Benchmarks 3a and 3b. These products are very rare in most 
countries. In Ghana and Nigeria, where they were more common, the median price in private for-
profit outlets for all oral dosage forms was USD 5.63 in Ghana and USD 2.83 in Nigeria. For 
tablets only, the median price was USD 1.88 in Ghana and USD 2.66 in Nigeria.  
 
Table 2.3.4 shows the cost to patients of non-quality-assured ACTs. The median price in public 
health facilities was USD 0.00 in Kenya, Madagascar, Niger, Tanzania mainland, Uganda and 
Zanzibar, although these drugs were very rare in this sector in many countries. In private for-
profit outlets at endline, prices ranged from USD 3.50 in Ghana to USD 9.36 in Tanzania 
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mainland. In all countries, prices were higher in urban than in rural areas. Among private for-
profit outlets, there was a significant decrease in median price in Ghana, Zanzibar and Tanzania 
mainland (though of a small size in the latter) and an increase in median price in Madagascar and 
Niger.  
 
Table 2.3.5 shows the cost to patients of QAACTs. In the public sector, the median price at 
endline was zero in all countries, reflecting widespread free provision, except for Ghana where it 
was $0.94. It is recognised that users of public health facilities may face a variety of other direct 
(e.g., consultation or registration fees, transport costs) or indirect (opportunity cost of waiting 
time) costs associated with seeking care in the public sector, which may pose substantial barriers 
to careseeking even when drugs are provided free of charge. In the private for-profit sector, the 
lowest median prices were in Kenya (USD 0.58) and Madagascar (USD 0.60), followed by 
Tanzania mainland USD 0.94. In other countries, prices were USD 1.13 in Ghana, USD 1.17 in 
ZZB, USD 1.19 in Niger, USD 1.48 in Nigeria and USD 1.96 in Uganda. Large and significant 
falls in prices were seen in 6 of the 8 pilots, with the decline ranging from USD 1.28 to USD 
4.82. In Uganda, no significant price change was observed overall, but there was a significant 
fall in urban areas of USD 2.68. In Madagascar, there was a significant increase in the median 
price of USD 0.46, but the median price at baseline was only USD 0.14, reflecting the presence 
of an ACT subsidy program at baseline (brand name ACTipal), which included a very low 
recommended retail price (USD 0.10-0.20 for an adult equivalent treatment dose). QAACTs 
were slightly more expensive in urban than rural areas, except in Uganda where the median 
prices were the same, and in Nigeria where the price was higher in rural areas.  
 
Table 2.3.6 shows the cost to patients of QAACTs disaggregated by the presence of the AMFm 
logo. In Ghana and Zanzibar, the price of QAACTs without the logo in the private for-profit 
sector was around 7 times higher than those with the logo. In Kenya, Niger and Nigeria, 
QAACTs without the logo were somewhat more expensive. In Uganda, the median price was the 
same for the two types of product; while in Tanzania mainland, QAACTs without the logo were 
less expensive in rural areas, but considerably higher in urban areas. In Madagascar, QAACTs 
without the logo were much more expensive in urban areas than those with the logo, but in rural 
areas they were less expensive, possibly reflecting the presence of the subsidized ACT product 
ACTipal.  
 
Table 2.3.7 presents the cost of pediatric formulations of QAACTs for which the age range 
included a two-year old child. As noted for all QAACTs, in the public sector the median price at 
endline was zero in all countries reflecting widespread free provision, except for Ghana where it 
was USD 0.31. In the private for-profit sector, prices ranged from USD 0.19 in Madagascar 
(reflecting the presence of ACTipal) to USD 0.89 in Nigeria. In most countries, pediatric 
QAACTs had the same or very similar median cost in urban and rural areas at endline; 
exceptions were Tanzania mainland and Zanzibar, where costs were higher in urban areas. 
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Significant declines in price between baseline and endline were observed in Ghana, Kenya, 
Niger, Zanzibar and urban areas of Tanzania mainland. There was no change in Nigeria, Uganda 
and rural areas in Tanzania mainland. In Uganda and rural Tanzania, this reflected the low 
median price in rural areas at baseline in both countries, possibly due to the low price of the 
CAPSS subsidized ACT product in Uganda. The median price increased in Madagascar, possibly 
reflecting the presence of the subsidized ACT product ACTipal at baseline. 
 
Table 2.3.8 shows the cost to patients of pediatric formulations of QAACTs at endline 
disaggregated by the presence of the AMFm logo. Pediatric QAACTs without the logo were rare 
except in Kenya, Madagascar, Nigeria and Uganda, where the difference in price of QAACTs 
with and without the logo was not that large. In Madagascar, QAACTs without the logo were 
much more expensive in urban areas than those with the logo, but in rural areas they were less 
expensive, possible reflecting the presence of the subsidized ACT product ACTipal. 
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Table 2.3.1: Cost to patients of non-artemisinin therapy, in 2010 US dollars, at baseline (2010) and endline(2011) 
Indicator 2.4 Median cost to patients of one adult equivalent treatment dose (AETD) of non-artemisinin monotherapy or non-artemisinin combination therapy for ALL DOSAGE FORMS, by urban-rural 
location and type of outlet, according to country 
Country/Type of outlet 
BASELINE ENDLINE CHANGE IN MEDIAN 
Urban Rural Total Urban Rural Total Urban Rural Total 
Median ost 
[IQR] 
No. of 
Products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Change in 
 median 
[p-value]  
Change in 
 median 
 [p-value*] 
Change in 
 median 
 [p-value*] 
Ghana – Total 1.64 [0.34-4.03] 1,961 0.68 [0.34-3.08] 1,298 1.03 [0.34-3.08] 3,259 1.75 [0.31-3.38] 1,122 0.70 [0.31-3.19] 457 1.50 [0.31-3.19] 1,579 0.11 [0.022] 0.02 [0.0062] 0.47 [0.0234] 
Public health facility  4.75 [0.21-10.55] 88 2.05 [0.00-6.27] 174 2.74 [0.00-6.65] 262 5.26 [0.00-13.02] 103 5.26 [0.00-10.85] 169 5.26 [0.00-10.85] 272 0.50 [0.8246] 3.20 [0.4828] 2.52 [0.3773] 
Private not-for-profit health facility 0.21 [0.21-0.27] 3 5.75 [2.38-9.49] 25 5.75 [1.19-9.49] 28 13.14 [5.26-13.23] 9 0.06 [0.00-5.26] 17 5.26 [0.00-13.23] 26 12.93 [0.0089] -5.69 [0.0399] -0.50 [0.8671] 
Private for-profit outlet                
   Health facility/pharmacy 2.38 [0.82-7.98] 1,244 2.47 [0.55-8.17] 220 2.40 [0.68-7.98] 1,464 1.88 [0.38-5.26] 650 2.25 [0.31-3.94] 35 1.88 [0.38-5.26] 685 -0.50 [0.0004] -0.21 [0.5861] -0.52 [0.0011] 
   Drug store 0.51 [0.34-2.67] 620 0.68 [0.34-3.08] 873 0.64 [0.34-3.08] 1,493 0.94 [0.31-2.82] 359 0.63 [0.31-2.82] 232 0.63 [0.31-2.82] 591 0.42 [0.7542] -0.06 [0.0041] -0.01 [0.0042] 
   General retailer/itinerant 0.34 [0.34-0.34] 6 0.34 [0.34-2.47] 6 0.34 [0.34-2.47] 12 0.31 [0.31-0.31] 1 0.38 [0.31-0.38] 4 0.38 [0.31-0.38] 5 -0.03 0.03 [0.6796] 0.03[0.8171] 
   Total 1.64 [0.34-3.70] 1,870 0.68 [0.34-3.08] 1,099 0.91 [0.34-3.08] 2,969 1.56 [0.31-2.82] 1,010 0.63 [0.31-2.82] 271 1.31 [0.31-2.82] 1,281 -0.08 [0.006] -0.06 [0.0024] 0.40 [0.0081] 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 - - - 
Kenya – Total 1.31 [0.39-6.94] 1,801 0.79 [0.39-1.97] 1,694 0.98 [0.39-2.36] 3,495 1.55 [0.58-9.21] 1,622 0.58 [0.23-2.42] 1,563 0.73 [0.35-3.45] 3,185 0.24 [0.2708] -0.21 [0.3080] -0.26 [0.4781] 
Public health facility  0.00 [0.00-0.00] 284 0.00 [0.00-0.00] 627 0.00 [0.00-0.00] 911 0.00 [0.00-0.00] 272 0.00 [0.00-0.00] 764 0.00 [0.00-0.00] 1,036 0.00 [0.9007] 0.00 [0.3705] 0.00 [0.2320] 
Private not-for-profit health facility 3.54 [1.05-11.11] 43 0.00 [0.00-0.66] 29 0.00 [0.00-5.55] 72 2.07 [0.12-9.74] 37 0.35 [0.00-7.31] 67 0.69 [0.00-7.31] 104 -1.47 [0.4058] 0.35 [0.2056] 0.69 [0.5302] 
Private for-profit outlet                
   Health facility/pharmacy 5.55 [1.31-13.91] 627 2.36 [0.92-17.31] 197 3.15 [1.05-16.16] 824 3.38 [1.15-14.61] 661 2.76 [0.69-14.61] 221 2.76 [0.81-14.61] 882 -2.17 [0.5593] 0.40 [0.8105] -0.39 [0.6118] 
   Drug store 1.97 [0.79-8.33] 593 1.64 [0.74-5.51] 474 1.77 [0.79-5.91] 1,067 1.73 [0.86-9.74] 510 1.73 [0.52-9.74] 314 1.73 [0.58-9.74] 824 -0.24 [0.2520] 0.09 [0.5940] -0.05 [0.6946] 
   General retailer/itinerant 0.53 [0.39-0.79] 251 0.53 [0.39-0.83] 352 0.53 [0.39-0.83] 603 0.52 [0.35-0.86] 142 0.52 [0.35-1.04] 197 0.52 [0.35-1.04] 339 -0.01 [0.5681] -0.01 [0.9999] -0.01 [0.7975] 
   Total 1.97 [0.59-8.33] 1,471 1.05 [0.53-2.36] 1,023 1.18 [0.53-3.28] 2,494 1.73 [0.69-9.79] 1,313 1.04 [0.46-7.31] 732 1.15 [0.52-7.31] 2,045 -0.20 [0.9507] -0.01 [0.8292] -0.03 [0.9749] 
Community health worker 1.97 [0.66-1.97] 3 0.46 [0.00-3.15] 15 0.46 [0.00-3.15] 18 - 0 - 0 - 0 - - - 
Madagascar – Total 0.35 [0.35-6.87] 2,038 0.35 [0.35-0.42] 1,509 0.35 [0.35-0.56] 3,547 0.34 [0.32-6.33] 1,498 0.32 [0.32-0.43] 2,223 0.32 [0.32-0.64] 3,721 -0.01 [0.1092] -0.03[<0.0001] -0.03[<0.0001] 
Public health facility  2.45 [0.0-10.13] 88 0.12 [0.00-5.08] 554 1.75 [0.00-5.08] 642 2.78 [0.00-3.98] 94 1.44 [0.00-3.98] 759 1.85 [0.00-3.98] 853 0.33 [<0.0001] 1.31 [0.1687] 0.10 [0.0040] 
Private not-for-profit health facility 2.40 [0.00-7.36] 17 - 0 2.40 [0.00-7.36] 17 5.42 [0.38-7.23] 32 2.69 [0.96-3.62] 6 2.69 [0.73-6.33] 38 3.03 [0.5868] 2.69 0.30 [0.7130] 
Private for-profit outlet                
   Health facility/pharmacy 5.75 [0.33-8.56] 512 5.89 [0.35-8.84] 20 5.89 [0.35-8.84] 532 5.98 [0.91-10.09] 480 9.04 [0.38-13.56] 25 6.24 [0.77-10.85] 505 0.23 [0.1392] 3.15 [0.1813] 0.35 [0.0294] 
   Drug store 2.10 [0.33-11.78] 143 0.37 [0.28-6.87] 677 1.12 [0.30-8.84] 820 4.52 [0.30-7.69] 138 0.43 [0.32-7.23] 1,004 0.51 [0.32-7.23] 1,142 2.42 [0.07044] 0.05 [0.6082] -0.61 [0.0748] 
   General retailer/itinerant 0.35 [0.35-0.35] 1,276 0.35 [0.35-0.35] 257 0.35 [0.35-0.35] 1,533 0.32 [0.32-0.32] 754 0.32 [0.32-0.32] 422 0.32 [0.32-0.32] 1,176 -0.03 [<0.0001] -0.03 [<0.0001] -0.03 [<0.0001] 
   Total 0.35 [0.35-6.87] 1,931 0.35 [0.35-0.35] 954 0.35 [0.35-0.47] 2,885 0.32 [0.32-6.67] 1,372 0.32 [0.32-0.34] 1,451 0.32 [0.32-0.43] 2,823 -0.03 [0.1056] -0.03 [<0.0001] -0.03 [<0.0001] 
Community health worker 0.00 [0.00-0.21] 2 0.70 [0.70-0.70] 1 0.70 [0.70-0.70] 3 - 0 0.38 [0.32-0.38] 7 0.38 [0.32-0.38] 7 - -0.32  [0.02081] -0.32 [0.134] 
Niger – Total 0.31 [0.26-0.99] 1,944 0.31 [0.26-0.46] 1,879 0.31 [0.26-0.51] 3,823 0.48 [0.36-1.19] 1,748 0.48 [0.28-0.62] 1,026 0.48 [0.30-0.69] 2,774 0.17 [0.004198] 0.17  [<0.0001] 0.17  [<0.0001] 
Public health facility  
0.00 [0.00-7.13] 246 0.00 [0.00-0.20] 854 0.00 [0.00-0.31] 1,100 0.00 [0.00-3.33] 257 0.00 [0.00-0.00] 451 0.00 [0.00-0.00] 708 0.00 [0.732] 0.00 [<0.0001] 0.00 [0.0000] 
Private not-for-profit health facility 10.70 [10.70-14.26] 7 - 0 10.70 [10.70-14.26] 7 15.72 [4.13-25.15] 3 0.00 [0.00-0.00] 6 0.00 [0.00-0.00] 9 5.02 [0.202] - -10.7 [0.01923] 
Private for-profit outlet                
   Health facility/pharmacy 9.12 [2.05-16.07] 718 9.36 [4.64-13.37] 38 9.36 [2.36-16.05] 756 7.61 [1.03-15.47] 574 2.50 [0.50-3.57] 3 7.61 [1.03-15.47] 577 -1.51 [0.1516] -6.86 [0.0001] -1.75 [0.1393] 
   Drug store 3.57 [1.03-10.7] 36 4.28 [0.51-8.02] 22 3.57 [0.51-10.7] 58 3.96 [0.50-9.91] 66 7.73 [2.91-10.31] 8 4.76 [1.54-10.31] 74 0.40 [0.9125] 3.46 [0.1112] 1.19 [0.2946] 
   General retailer/itinerant 0.31 [0.26-0.48] 936 0.39 [0.31-0.46] 963 0.31 [0.31-0.46] 1,899 0.48 [0.36-0.60] 848 0.60 [0.40-0.72] 558 0.50 [0.37-0.62] 1,406 0.17  [<0.0001] 0.21  [<0.0001] 0.19 [<0.0001] 
   Total 0.36 [0.31-0.96] 1,690 0.39 [0.31-0.48] 1,023 0.39 [0.31-0.51] 2,713 0.50 [0.36-1.15] 1,488 0.60 [0.40-0.72] 569 0.50 [0.37-0.80] 2,057 0.14 [0.0014] 0.21  [<0.0001] 0.11 [<0.0001] 
Community health worker 0.31 [0.31-0.31] 1 0.39 [0.23-0.39] 2 0.31 [0.23-0.39] 3 - 0 - 0 - 0 - - - 
Nigeria – Total 0.93 [0.52-1.49] 9,424 0.93 [0.45-1.4] 1,820 0.93 [0.52-1.49] 11,244 1.01 [0.41-1.54] 5,827 0.89 [0.47-1.77] 2,371 1.00 [0.44-1.54] 8,198 0.08 [0.4519] -0.04 [0.2525] 0.07 [0.7108] 
Public health facility  
0.00 [0.00-0.78] 463 0.60 [0.07-1.12] 85 0.60 [0.02-1.12] 548 0.92 [0.30-2.21] 78 0.53 [0.00-1.18] 79 0.71 [0.12-1.48] 157 0.92 [0.001] -0.06 [0.6928] 0.11 [0.7195] 
Private not-for-profit health facility 0.93 [0.67-2.01] 20 1.86 [0.43-4.69] 7 1.86 [0.67-4.69] 27 1.48 [0.59-1.77] 20 3.69 [1.14-6.25] 2 1.48 [0.89-1.77] 22 0.55 [0.7463] 1.83  -0.38 [0.3721] 
Private for-profit outlet                
   Health facility/pharmacy 1.19 [0.62-2.23] 4,268 1.49 [0.60-1.67] 63 1.30 [0.60-1.86] 4,331 1.18 [0.57-2.51] 576 1.33 [0.59-2.21] 61 1.18 [0.59-2.31] 637 -0.01 [0.1194] -0.16 [0.8456] -0.12 [0.2630] 
   Drug store 0.93 [0.52-1.49] 4,281 0.93 [0.52-1.49] 1,589 0.93 [0.52-1.49] 5,870 0.94 [0.41-1.54] 4,947 1.00 [0.47-1.77] 2,162 0.96 [0.46-1.54] 7,109 0.01 [0.2592] 0.07 [0.4208] 0.03 [0.4927] 
   General retailer/itinerant 0.93 [0.52-1.40] 384 0.70 [0.37-1.30] 62 0.93 [0.52-1.3] 446 0.89 [0.41-1.54] 206 0.59 [0.30-0.89] 58 0.71 [0.41-1.54] 264 -0.04 [0.4989] -0.11 [0.2114] -0.22 [0.2317] 
   Total 0.93 [0.52-1.49] 8,933 0.93 [0.52-1.4] 1,714 0.93 [0.52-1.49] 10,647 1.01 [0.41-1.54] 5,729 0.96 [0.47-1.77] 2,281 1.00 [0.47-1.54] 8,010 0.08 [0.4293] 0.03 [0.3396] 0.07 [0.7072] 
Community health worker 1.21 [0.41-1.56] 8 0.74 [0.00-4.69] 14 0.74 [0.00-4.69] 22 - 0 0.59 [0.41-2.31] 9 0.59 [0.41-2.31] 9 -  -0.15 [0.7681] -0.15 [0.7369] 
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Table 2.3.1: Cont. 
Country/Type of outlet 
BASELINE ENDLINE CHANGE IN MEDIAN 
Urban Rural Total Urban Rural Total Urban Rural Total 
Median ost 
[IQR] 
No. of 
Products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Change in 
 median 
[p-value]  
Change in 
 median 
 [p-value*] 
Change in 
 median 
 [p-value*] 
Tanzania – mainland – Total 1.48 [0.85-3.17] 2,504 1.06 [0.49-2.54] 1,022 1.06 [0.63-2.54] 3,526 1.41 [0.94-2.81] 4,265 1.41 [0.62-3.75] 770 1.41 [0.81-2.81] 5,035 -0.07 [0.8915] 0.35 [0.0962] 0.35 [0.0554] 
Public health facility  0.00 [0.00-0.00] 6 0.00 [0.00-0.00] 106 0.00 [0.00-0.00] 112 2.62 [0.35-3.97] 13 0.00 [0.00-2.64] 64 0.00 [0.00-2.64] 77 2.62 [<0.0001] 0.00 [0.01199] 0.00 [0.0024] 
Private not-for-profit health facility 2.54 [1.06-5.5] 32 1.36 [0.56-7.45] 59 1.58 [0.63-7.45] 91 2.81 [1.31-13.22] 10 0.66 [0.00-3.94] 5 1.87 [0.66-13.22] 15 0.28 [0.6942] -0.70 [0.3978] 0.29 [0.9795] 
Private for-profit outlet                
   Health facility/pharmacy 2.11 [1.06-4.47] 1,934 1.69 [0.63-14.79] 80 2.11 [0.85-5.92] 2,014 1.87 [0.94-4.88] 2,646 1.41 [0.62-5.25] 130 1.87 [0.94-5.25] 2,776 -0.24 [0.7722] -0.28 [0.9351] -0.24 [0.8867] 
   Drug store 1.37 [0.85-2.54] 5,31 1.48 [0.70-2.96] 691 1.41 [0.85-2.82] 1,222 1.41 [0.94-2.81] 1,584 1.41 [0.75-3.75] 559 1.41 [0.94-2.81] 2,143 0.03 [0.8617] -0.07 [0.7496] 0.00 [0.7700] 
   General retailer/itinerant 0.42 [0.42-0.42] 1 0.7 [0.63-2.11] 83 0.63 [0.63-2.11] 84 1.87 [0.94-1.87] 12 0.37 [0.37-0.56] 12 0.42 [0.37-0.56] 24 1.45 -0.33 [0.0002] -0.21 [0.0319] 
   Total 1.48 [0.85-2.96] 2,466 1.27 [0.63-2.82] 854 1.41 [0.70-2.82] 3,320 1.41 [0.94-2.81] 4,242 1.41 [0.70-3.75] 701 1.41 [0.94-2.81] 4,943 -0.07 [0.9743] 0.14 [0.4312] 0.00 [0.4522] 
Community health worker - 0 2.64 [0.21-14.9] 3 2.64 [0.21-14.9] 3 - 0 - 0 - 0 - - - 
Uganda – Total 3.93 [0.93-7.25] 2,021 3.90 [0.70-6.04] 4,819 3.90 [0.70-7.25] 6,840 4.93 [0.78-8.14] 4,487 4.59 [0.78-7.13] 4,363 4.93 [0.78-7.13] 8,850 1.00 [0.8506] 0.69 [0.3077] 1.03 [0.3787] 
Public health facility  0.00 [0.00-0.00] 168 0.00 [0.00-0.00] 1,372 0.00 [0.00-0.00] 1,540 0.00 [0.00-0.00] 284 0.00 [0.00-0.00] 1,109 0.00 [0.00-0.00] 1,393 0.00 [0.04336] 0.00 [0.2317] 0.00 [0.0481] 
Private not-for-profit health facility 3.90 [0.56-6.04] 16 1.39 [0.00-4.83] 65 2.93 [0.14-5.07] 81 4.11 [0.35-6.11] 34 2.46 [0.00-6.11] 85 2.46 [0.00-6.11] 119 0.21 [0.7733] 1.07 [0.5992] -0.47 [0.8893] 
Private for-profit outlet                
   Health facility/pharmacy 5.32 [1.16-8.46] 1,601 5.85 [1.21-7.86] 1,320 5.85 [1.16-8.46] 2,921 5.09 [1.17-8.28] 3,041 5.09 [1.17-8.28] 1,419 5.09 [1.17-8.28] 4,460 -0.23 [0.5805] -0.76 [0.3044] -0.76 [0.2461] 
   Drug store 3.90 [0.84-7.25] 228 4.83 [1.25-6.04] 2,042 4.18 [1.16-6.77] 2,270 4.11 [0.78-6.57] 1,127 4.93 [1.14-7.13] 1,742 4.93 [1.06-7.13] 2,869 0.21 [0.8975] 0.10 [0.1933] 0.75 [0.2388] 
   General retailer/itinerant 2.93 [0.42-7.25] 7 3.90 [1.95-6.04] 19 3.90 [0.70-6.04] 26 3.29 [3.29-3.29] 1 3.29 [0.59-3.29] 8 3.29 [0.59-3.29] 9 0.36 -0.61 [0.0381] -0.61 [0.1189] 
   Total 4.83 [0.93-7.25] 1,836 4.83 [1.25-7.25] 3,381 4.83 [1.16-7.25] 5,217 4.93 [1.14-8.14] 4,169 4.93 [1.14-7.13] 3,169 4.93 [1.14-7.13] 7,338 0.10 [0.7339] 0.10 [0.1924] 0.10 [0.2240] 
Community health worker 0.28  1 19.65  1 0.28 [0.28-19.65] 2 - 0 - 0 - 0 - - - 
Zanzibar – Total 2.32 [0.63-3.17] 336 0.00 [0.00-2.39] 173 1.69[0.00-3.17] 509 2.45 [0.87-3.50] 175 1.05 [0.00-2.62] 69 2.10 [0.52-2.80] 244 0.12 1.05 0.41 
Public health facility  0.00 [0.00-0.00] 56 0.00 [0.00-0.00] 92 0.00 [0.00-0.00] 148 0.00 [0.00-2.45] 23 0.00 [0.00-0.00] 23 0.00 [0.00-0.00] 46 0.00 0.00 0.00  
Private not-for-profit health facility 2.96 [0.63-3.17] 5 16.96 [2.96-30.95] 2 2.96 [0.63-9.77] 7 - 0 - 0 - 0 - - - 
Private for-profit outlet                
   Health facility/pharmacy 3.17 [1.27-7.33] 163 3.17 [1.06-6.11] 28 3.17 [1.27-7.33] 191 4.55 [2.45-12.33] 71 2.45 [1.75-3.50] 22 2.62 [2.10-12.33] 93 1.38 -0.72 -0.55 
   Drug store 2.11 [0.63-3.17] 111 2.11 [1.27-3.17] 47 2.11 [0.95-3.17] 158 1.75 [0.87-2.62] 78 1.75 [0.58-2.62] 22 1.75 [0.87-2.62] 100 -0.36 -0.36 -0.36 
   General retailer/itinerant 0.42 [0.42-0.42] 1 0.58 [0.42-0.63] 4 0.53 [0.42-0.63] 5 0.87 [0.52-3.50] 3 3.50 [3.50-3.50] 2 3.50 [0.87-3.50] 5 0.45 2.92 2.97 
   Total 2.82 [1.06-4.23] 275 2.11 [1.06-3.17] 79 2.54 [1.06-3.66] 354 2.62 [1.24-3.50] 152 2.45 [1.05-2.62] 46 2.62 [1.05-3.50] 198 -0.19 0.34 0.09 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 - - - 
Note: An AETD is the number of milligrams (mg) of a given drug that is required to treat a 60 kg adult. AETDs were calculated for every audited antimalarial. 
*This is the p-value for the result of a Wilcoxon ranksum test of no difference in median between baseline and endline. Nigeria baseline data collection was conducted in 2009. 
na = Not applicable, IQR = Interquartile range 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.3.2: Cost to patients of artemisinin monotherapy, in 2010 US dollars, at baseline (2010) and endline (2011) 
Indicator 2.3 Median cost to patients of one adult equivalent treatment dose (AETD) of artemisinin monotherapy for ALL DOSAGE FORMS, by urban-rural location and type of outlet, according to 
country 
Country/Type of outlet 
BASELINE ENDLINE CHANGE IN MEDIAN 
Urban Rural Total Urban Rural Total Urban Rural Total 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. 
of products 
Median Cost 
[IQR] 
No.of 
products 
Median Cost 
[IQR] 
No. of 
products 
Change in  
median  
[p-value*] 
Change in 
median  
[p-value*] 
Change in 
median 
 [p-value*] 
Ghana – Total 
6.16 [2.74-9.86] 1,471 5.14 [2.40-7.19] 602 5.48 [2.40-7.67] 2,073 5.63 [2.19-7.61] 892 4.69 [1.88-7.51] 195 5.63 [2.19-7.51] 1,087 -0.53 [0.0324] -0.44 [0.0732] 0.15 [0.33] 
Public health facility  8.77 [4.11-13.15] 47 11.84 [6.99-15.62] 75 11.51 [6.16-15.62] 122 9.01 [7.51-11.41] 41 3.60 [1.50-10.01] 66 9.01 [1.88-11.26] 107 0.24 [0.8380] -8.23 [<0.0001] -2.50 [0<0.0001] 
Private not-for-profit health facility 16.44 [11.51-16.44] 6 3.29 [0.82-9.21] 12 3.29 [0.99-9.86] 18 9.01 [7.51-15.01] 6 0.00 [0.00-9.01] 6 7.51 [0.90-15.01] 12 -7.43 [0.183] -3.29 [0.0236] 4.22[0.911] 
Private for-profit outlet                
   Health facility/pharmacy 6.58 [3.84-10.96] 1,121 6.16 [2.40-12.05] 153 6.16 [3.29-10.96] 1,274 6.01 [2.40-10.01] 655 6.01 [2.00-9.76] 35 6.01 [2.40-10.01] 690 -0.57 [0.0814] -0.16 [0.1445] -0.16[0.0701] 
   Drug store 5.14 [2.40-7.19] 297 5.14 [2.40-6.58] 362 5.14 [2.40-6.58] 659 5.63 [2.19-6.61] 190 4.69 [2.00-6.57] 88 5.63 [2.19-6.57] 278 0.49 [0.1871] -0.44 [0.3512] 0.49[0.2624] 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 - - - 
   Total 5.96 [2.74-9.25] 1,418 5.14 [2.40-6.58] 515 5.14 [2.40-7.19] 1,933 5.63 [2.19-7.51] 845 5.00 [2.00-6.57] 123 5.63 [2.19-7.51] 968 -0.33 [0.0095] -0.13 [0.2238] 0.49 [0.3279] 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 - - - 
Kenya – Total 
17.33 [12.60-28.49] 351 9.85 [3.28-15.12] 75 12.60 [7.88-22.05] 426 15.47 [11.05-27.63] 360 15.20 [11.60-16.58] 71 15.20 [11.05-22.1] 431 -1.86 [0.348] 5.35 [0.087] 2.59 [0.437] 
Public health facility  12.60 [0.00-18.90] 8 7.88 [0.00-12.6] 6 12.60 [0.00-12.60] 14 8.29 [0.00-13.81] 26 0.00 [0.00-0.00] 6 0.00 [0.00-6.91] 32 -4.31 [0.761] -7.88 [0.073] -12.6 [0.148] 
Private not-for-profit health facility 15.75 [10.87-18.90] 7 22.05 [18.90-25.2] 2 18.90 [12.60-18.90] 9 16.58 [9.21-27.63] 11 13.81 [11.05-16.58] 6 13.81 [11.05-22.1] 17 0.83 [0.679] -8.24 [0.042] -5.09 [0.539] 
Private for-profit outlet                
   Health facility/pharmacy 18.9 [11.81-31.51] 268 18.90 [15.12-25.2] 38 18.90 [12.60-28.35] 306 18.65 [12.66-33.16] 196 16.58 [12.09-17.96] 51 16.58 [12.66-23.21] 247 -0.25 [0.801] -2.33 [0.082] -2.33 [0.261] 
   Drug store 16.38 [12.60-28.49] 68 6.56 [2.63-11.55] 29 9.19 [3.28-12.60] 97 13.81 [11.05-22.10] 127 15.20 [13.81-15.47] 8 14.37 [11.05-20.15] 135 -2.57 [0.064] 8.63 [0.002] 5.18 [0.006] 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 - - - 
   Total 17.64 [12.60-30.63] 336 9.85 [3.28-15.12] 67 12.60 [7.88-22.68] 403 15.47 [11.05-27.63] 323 15.20 [13.26-16.58] 59 15.47 [11.6-22.1] 382 -2.17 [0.304] 5.35 [0.045] 2.87 [0.37] 
Community health worker 
- 0 - 0 - 0 - 0 - 0 - 0 - - - 
Madagascar – Total 22.45 [22.45-22.45] 8 25.81 1 22.45 [22.45-22.45] 9 36.83 [31.62-42.04] 2 0.00 [0.00-0.00] 2 31.62 [0.00-42.04] 4 14.39 [<0.0001] -25.81 9.17 [0.4395] 
Public health facility  - 0 - 0 - 0 - 0 0.00 [0.00.0.00] 2 0.00 [0.00-0.00] 2 - - - 
Private not-for-profit health facility - 0 - 0 - 0 - 0 - 0 - 0 - - - 
Private for-profit outlet                
   Health facility/pharmacy 22.45 [22.45-22.45] 8 - 0 22.45 [22.45-22.45] 8 36.83 [31.62-42.04] 2 
- 
0 36.83 [31.62-42.04] 2 14.39 [<0.0001] - 14.39 
   Drug store - 0 25.81 1 25.81 1 
- 
0 
- 
0 
- 
0 - - - 
   General retailer/itinerant - 0 - 0 - 0 
- 
0 
- 
0 
- 
0 - - - 
   Total 22.45 [22.45-22.45] 8 25.81 1 22.45 [22.45-22.45] 9 36.83 [31.62-42.04] 2 
- 
0 36.83 [31.62-42.04] 2 14.39 [<0.0001] -- 14.39 [0.0001] 
Community health worker 
- 0 - 0 - 0 - 0 - 0 - 0 - - - 
Niger – Total 13.32 [6.43-22.52] 150 - 11 6.58 [3.29-18.5] 161 17.12 [6.21-28.35] 158 0.00 [0.00-0.00] 10 6.25 [0.00-22.59] 168 3.80 [0.37] 0.00 [0.2] -0.33 [0.59] 
Public health facility  
0.00 [0.00-0.00] 1 0.00 [0.00-0.00] 11 0.0 [0.00-0.00] 12 0.00 [0.00-1.11] 5 0.0 [0.00-0.00] 7 0.0 [0.00-0.00] 12 0.00 [0.14] 0.00 [0.2] 0.00 [0.43] 
Private not-for-profit health facility - 0 - 0 - 0 - 0 0.0 [0.00-0.00] 3 0.0 [0.00-0.00] 3 - - - 
Private for-profit outlet                
   Health facility/pharmacy 15.87 [6.50-24.56] 140 - 0 15.87 [6.50-24.56] 140 21.7 [11.89-33.13] 144 - 0 21.7 [11.89-33.13] 144 5.84 [0.06] - 5.84 [0.06] 
   Drug store 6.58 [6.58-6.58] 2 
- 
0 6.58 [6.58-6.58] 2 6.34 [4.76-16.65] 5 - 0 6.34 [4.76-16.65] 5 -0.24  - -0.24  
   General retailer/itinerant 3.29 [0.00-4.93] 7 
- 
0 3.29 [0.00-4.93] 7 1.27 [0.63-6.34] 4 - 0 1.27 [0.63-6.34] 4 -2.02 [0.98] -  -2.02 [0.98] 
   Total 13.35 [6.43-22.52] 149 
- 
0 13.35 [6.43-22.52] 149 17.28 [6.26-30.76] 153 - 0 17.28 [6.26-30.76] 153 3.93 [0.24] -  3.93 [0.24] 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 - - - 
Nigeria – Total 3.81 [2.98-10.05] 2,378 4.52 [2.98-17.86] 230 4.17 [2.98-11.16] 2,608 3.25 [2.36-9.74] 958 3.31 [2.83-9.74] 271 3.31 [2.36-9.74] 1,229 -0.56 [0.0001] -1.22 [0.0083] -0.86 [<0.0001] 
Public health facility  
9.82 [2.98-15.00] 108 40.19 [2.62-44.65] 15 40.19 [2.62-44.65] 123 5.67 [2.08-10.63] 23 5.67 [4.25-9.74] 24 5.67 [2.08-10.63] 47 -4.16 [0.0756] -34.52 [0.1771] -34.52 [0.1827] 
Private not-for-profit health facility 22.1 [11.91-35.72] 10 17.86 1 17.86 [17.86-17.86] 11 21.26 [0.94-24.80] 6 5.67 1 21.26 [5.67-24.80] 7 -0.85 [0.4971] -12.19  3.39 [0.9459] 
Private for-profit outlet                
   Health facility/pharmacy 4.52 [3.57-14.29] 1,544 11.16 [2.98-17.86] 23 11.16 [3.35-17.86] 1,567 7.09 [2.83-15.94] 186 16.53 [7.97-28.93] 19 7.97 [2.83-15.94] 205 2.56 [0.05474] 5.37 [0.1513] -3.19 [0.02191] 
   Drug store 3.81 [2.98-10.05] 663 4.17 [2.98-10.72] 188 3.81 [2.98-10.05] 851 2.83 [2.36-7.97] 722 3.31 [2.66-9.45] 224 2.95 [2.36-7.97] 946 -0.98 [<0.0001] -0.86 [0.0258] -0.86 [<0.0001] 
   General retailer/itinerant 3.57 [3.57-7.74] 51 11.83 [3.57-20.09] 2 3.57 [3.57-8.93] 53 8.86 [2.83-10.63] 21 2.83 [2.83-2.83] 3 8.86 [2.83-10.63] 24 5.28 [0.9078] -90.00 [0.0213] 5.28 [0.5550] 
   Total 3.81 [2.98-10.05] 2,258 4.17 [2.98-12.28] 213 4.09 [2.98-10.72] 2,471 3.25 [2.36-9.74] 929 3.31 [2.83-9.74] 246 3.31 [2.36-9.74] 1,175 -0.56 [<0.0001] -0.86 [0.0046] -0.79 [<0.0001] 
Community health worker 1.79 [0.00-3.57] 2 29.02 1 29.02 3 - 0 - 0 - 0 -  - - 
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Table 2.3.2: Cont. 
Country/Type of outlet 
BASELINE ENDLINE CHANGE IN MEDIAN 
Urban Rural Total Urban Rural Total Urban Rural Total 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. 
of products 
Median Cost 
[IQR] 
No.of 
products 
Median Cost 
[IQR] 
No. of 
products 
Change in 
median 
[p-value*] 
Change in 
median 
[p-value*] 
Change in 
median 
[p-value*] 
Tanzania – mainland – Total 
18.31 [6.52-29.58] 122 0.94 [0.94-1.41] 7 16.90 [1.41-25.35] 129 21.00 [15.00-31.25] 227 22.50 [5.25-22.5] 10 22.50 [15.00-30.00] 237 2.69 [0.0448] 21.56 [0.2501] 5.60 [0.0401] 
Public health facility  0.00 [0.00-0.00] 2 - 0 0.00 [0.00-0.00] 2 5.62 [3.75-7.50] 2 - 0 5.62 [3.75-7.50] 2 5.62 - 5.62 
Private not-for-profit health facility 29.58 [16.90-40.56] 4 0.94 [0.94-1.41] 2 16.90 [0.94-29.58] 6 21.00 [15.00-974.91] 3 0.00 1 15.00 [0.00-21.00] 4 -8.58 [0.8747] -0.94 -1.90 [0.8135] 
Private for-profit outlet                
   Health facility/pharmacy 18.59 [6.52-25.35] 116 8.11 [3.72-21.13] 5 18.31 [6.52-25.35] 121 22.5 [18.75-37.5] 217 22.50 [22.5-22.5] 8 22.50 [21.00-37.50] 225 3.91 [0.0002] 14.39 [0.0031] 4.19 [0.0002] 
   Drug store - 0 - 0 - 0 18.00 [11.25-18.75] 5 22.5 1 22.50 [12.50-22.50] 6 - - - 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 - - - 
   Total 18.59 [6.52-25.35] 116 8.11 [3.72-21.13] 5 18.31 [6.52-25.35] 121 22.5 [18.75-37.50] 222 22.50 [22.5-22.5] 9 22.5 [18.75-30.00] 231 3.91 [0.0067] 14.39 [0.0004] 4.19 [0.0015] 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 - - - 
Uganda – Total 16.72 [11.14-27.86] 383 16.72 [11.14-22.29] 197 16.72 [11.14-27.86] 580 14.08 [10.52-21.91] 635 0.17 [0.00-14.08] 281 11.27 [0.00-18.78] 916 -2.64 [0.362] -16.55 [0.0249] -5.45 [0.0313] 
Public health facility  0.00 [0.00-0.00] 10 13.93 [0.00-13.93] 2 0.00 [0.00-0.00] 12 0.00 [0.00-0.00] 27 0.00 [0.00-0.00] 15 0.00 [0.00-0.00] 42 0.00 [0.314] -13.93 [0.1236] 0.00 [0.5548] 
Private not-for-profit health facility 11.14  1 2.97 [2.97-13.37] 5 11.14 [2.97-13.37] 6 14.08 [9.39-35.21] 7 12.78 [11.27-14.08] 11 12.78 [11.27-14.08] 18 2.94 [0.1263] 9.81 [0.3247] 1.64 [0.1156] 
Private for-profit outlet                
   Health facility/pharmacy 16.72 [11.14-27.86] 366 16.72 [13.37-22.29] 157 16.72 [11.14-27.86] 523 15.02 [11.27-23.47] 572 15.02 [11.27-23.47] 169 15.02 [11.27-23.47] 741 -1.70 [0.6188] -1.70 [0.8378] -1.70 [0.5898] 
   Drug store 19.5 [16.72-27.86] 6 16.72 [11.14-27.86] 32 18.57 [13.37-27.86] 38 11.74 [9.39-15.65] 28 15.02 [14.08-18.78] 30 14.08 [11.74-18.78] 58 -7.76 [<0.0001] -1.70 [0.9404] -4.49 [0.3646] 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 - - - 
   Total 16.72 [11.14-27.86] 372 16.72 [13.37-25.07] 189 16.72 [11.14-27.86] 561 15.02 [11.27-22.82] 600 15.02 [11.74-23.47] 199 15.02 [11.74-23.47] 799 -1.70 [0.2922] -1.70 [0.9325] -1.70 [0.4319] 
Community health worker - 0 0.00 1 0.00 1 0.00 1 0.00 [0.00-0.00] 56 0.00 [0.00-0.00] 57 - 0 [0.007987] 0.00 [<0.0001] 
Zanzibar - Total 19.01 [6.76-25.35] 102 5.63 [4.79-18.17] 8 12.96 [5.63-25.35] 110 20.99 [13.99-24.49] 46 20.99 [4.08-24.49] 11 20.99 [13.99-24.49] 57 1.97 15.35 8.03 
Public health facility  5.63 [0.00-21.13] 9 14.79 [0.00-29.58] 2 5.63 [0.00-29.58] 11 5.25 [0.00-83.95] 6 0.00 [0.00-0.00] 2 0.00 [0.00-47.22] 8 -0.39 -14.79 -5.63 
Private not-for-profit health facility - 0 - 0 - 0 20.99 [13.99-27.98] 2 24.49 [20.99-27.98] 2 24.49 [17.49-27.98] 4 - - - 
Private for-profit outlet                
   Health facility/pharmacy 21.13 [6.76-25.35] 80 5.63 [5.07-6.76] 5 21.13 [6.76-25.35] 85 20.99 [17.49-24.49] 35 18.89 [4.66-20.99] 5 20.99 [17.49-24.49] 40 -0.14 13.25 -0.14 
   Drug store 6.76 [4.51-6.76] 13 5.63 1 6.2 [4.51-6.76] 14 17.49 1 24.49 [24.49-24.49] 2 24.49 [17.49-24.49] 3 10.73 18.85 18.29 
   General retailer/itinerant - 0 - 0 - 0 12.48 [7.46-17.49] 2 - 0 12.48 [7.46-17.49] 2 - - - 
   Total 21.13 [6.76-25.35] 93 5.63 [5.07-6.76] 6 16.9 [6.76-25.35] 99 20.99 [17.49-24.49] 38 20.99 [4.66-24.49] 7 20.99 [17.49-24.49] 45 -0.14 15.35 4.09 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 - - - 
Note: An AETD is the number of milligrams (mg) of a given drug that is required to treat a 60 kg adult. AETDs were calculated for every audited antimalarial. Nigeria baseline data collection was conducted in 2009. 
*This is the p-value for the result of a Wilcoxon ranksum test of no difference in median between baseline and endline. 
na = Not applicable, IQR = Interquartile range 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.3.3: Cost to patients of oral artemisinin monotherapy, in 2010 US dollars, at endline, 2011 
Median cost to patients of one adult equivalent treatment dose (AETD) of oral artemisinin monotherapy by ALL ORAL DOSAGE FORMS and TABLETS, by urban-rural location and type of outlet, 
according to country 
Country/Type of outlet 
ALL ORAL DOSAGE FORMS  TABLETS 
Urban Rural Total  Urban Rural Total 
Median Cost  
[IQR] 
No. of  
Products 
Median  
Cost [IQR] 
No. of  
Products 
Median Cost  
[IQR] 
No. of  
product 
 
 
Median  
Cost [IQR] 
No. of  
products 
Median Cost 
[IQR] 
No. of  
products 
Median Cost  
[IQR] 
No. of  
products 
Ghana – Total 5.63 [2.19-6.57] 582 4.69 [1.88-6.57] 101 5.63 [2.19-6.57] 683  1.88 [1.88-2.19] 224 1.88 [1.56-2.19] 42 1.88 [1.88-2.19] 266 
Public health facility  1.88 1 6.01 [1.90-11.41] 4 6.01 [1.90-7.01] 5  1.88 1 7.01 [1.90-11.41] 3 1.90 [1.90-11.41] 4 
Private not-for-profit health facility - 0 0.00 1 0.00 1  - 0 - 0 - 0 
Private for-profit outlet              
   Health facility/pharmacy 5.63 [2.19-6.61] 403 2.19 [1.75-6.01] 12 5.63 [2.19-6.57] 415  1.94 [1.88-2.19] 152 1.88 [1.56-2.19] 7 1.88 [1.88-2.19] 159 
   Drug store 5.63 [2.19-6.57] 178 4.69 [2.00-6.57] 84 5.63 [2.19-6.57] 262  1.88 [1.88-2.19] 71 1.88 [1.56-2.19] 32 1.88 [1.88-2.19] 103 
   General retailer/itinerant - 0 - 0 - 0  - 0 - 0 - 0 
   Total 5.63 [2.19-6.57] 581 4.69 [1.88-6.57] 96 5.63 [2.19-6.57] 677  1.88 [1.88-2.19] 223 1.88 [1.56-2.19] 39 1.88 [1.88-2.19] 262 
Community health worker - 0 - 0 - 0  - 0 - 0 - 0 
Kenya – Total 3.45 [3.45-10.36] 3 3.45  1 3.45 [3.45-10.36] 4  3.45 [3.45-3.45] 2 3.45 1 3.45 [3.45-3.45] 3 
Public health facility  - 0 - 0 - 0  - 0 - 0 - 0 
Private not-for-profit health facility - 0 - 0 - 0  - 0 - 0 - 0 
Private for-profit outlet              
   Health facility/pharmacy 3.45 [3.45-10.36] 3 3.45 1 3.45 [3.45-10.36] 4  3.45 [3.45-3.45] 2 3.45 1 3.45 [3.45-3.45] 3 
   Drug store - 0 - 0 - 0  - 0 - 0 - 0 
   General retailer/itinerant - 0 - 0 - 0  - 0 - 0 - 0 
   Total 3.45 [3.45-10.36] 3 3.45 1 3.45 [3.45-10.36] 4  3.45 [3.45-3.45] 2 3.45 1 3.45 [3.45-3.45] 3 
Community health worker - 0 - 0 - 0  - 0 - 0 - 0 
Madagascar – Total - 0 - 0 - 0  - 0 - 0 - 0 
Public health facility  - 0 - 0 - 0  - 0 - 0 - 0 
Private not-for-profit health facility - 0 - 0 - 0  - 0 - 0 - 0 
Private for-profit outlet              
   Health facility/pharmacy - 0 - 0 - 0  - 0 - 0 - 0 
   Drug store - 0 - 0 - 0  - 0 - 0 - 0 
   General retailer/itinerant - 0 - 0 - 0  - 0 - 0 - 0 
   Total - 0 - 0 - 0  - 0 - 0 - 0 
Community health worker - 0 - 0 - 0  - 0 - 0 - 0 
Niger – Total 2.22 [1.11-6.26] 22 - 0 2.22 [1.11-6.26] 22  2.22 [1.11-6.26] 20 - 0 2.22 [1.11-6.26] 20 
Public health facility  1.11 1 - 0 1.11 1  1.11 1 - 0 1.11 1 
Private not-for-profit health facility - 0 - 0 - 0  - 0 - 0 - 0 
Private for-profit outlet              
   Health facility/pharmacy 6.25 [2.22-6.34] 15 - 0 6.25 [2.22-6.34] 15  6.25 [2.22-6.26] 14 - 0 6.25 [2.22-6.26] 14 
   Drug store 5.55 [4.28-11.49] 4 - 0 5.55 [4.28-11.49] 4  4.76 [3.80-6.34] 3 - 0 4.76 [3.80-6.34] 3 
   General retailer/itinerant 0.63 [0.63-1.27] 2 - 0 0.63 [0.63-1.27] 2  0.63 [0.63-1.27] 2 - 0 0.63 [0.63-1.27] 2 
   Total 3.8 [1.27-6.26] 21 - 0 3.80 [1.27-6.26] 21  2.22 [1.27-6.26] 19 - 0 2.22 [1.27-6.26] 19 
Community health worker - 0 - 0 - 0  - 0 - 0 - 0 
Nigeria – Total 2.83 [2.36-8.86] 745 3.31 [2.66-9.45] 230 2.83 [2.36-8.86] 975  2.65 [2.17-2.83] 515 2.83 [2.36-3.31] 163 2.66 [2.36-2.83] 678 
Public health facility  1.98 [0.47-2.08] 7 9.74 [2.83-10.63] 11 2.08 [1.98-9.74] 18  1.98 [0.47-2.08] 5 2.83 [2.83-4.72] 7 2.08 [0.47-2.83] 12 
Private not-for-profit health facility 24.80 [24.80-24.80] 2 5.67 1 5.67 [5.67-24.80] 3  2.27 1 5.67 1 5.67 [5.67-5.67] 2 
Private for-profit outlet              
   Health facility/pharmacy 3.25 [2.66-9.74] 121 4.13 [3.78-9.39] 10 3.31 [2.66-9.74] 131  2.66 [2.36-2.83] 75 3.78 [3.25-3.78] 6 2.66 [2.36-2.83] 81 
   Drug store 2.83 [2.36-7.97] 594 3.31 [2.36-8.86] 205 2.83 [2.36-7.97] 799  2.36 [2.17-2.83] 419 2.83 [2.36-3.31] 146 2.65 [2.36-2.83] 565 
   General retailer/itinerant 8.86 [2.83-10.63] 21 2.83 [2.83-2.83] 3 8.86 [2.83-10.63] 24  2.83 [2.83-2.83] 15 2.83 [2.83-2.83] 3 2.83 [2.83-2.83] 18 
   Total 2.83 [2.36-8.86] 736 3.31 [2.65-8.86] 218 2.83 [2.36-8.86] 954  2.65 [2.36-2.83] 509 2.83 [2.36-3.31] 155 2.66 [2.36-2.83] 664 
Community health worker - 0 - 0 - 0  - 0 - 0 - 0 
Tanzania – mainland – Total 27.00 [27.00-27.00] 2 - 0 27.00 [27.00-27.00] 2  27.00 [27.00-27.00] 2 - 0 27.00 [27.00-27.00] 2 
Public health facility  - 0 - 0 - 0  - 0 - 0 - 0 
Private not-for-profit health facility - 0 - 0 - 0  - 0 - 0 - 0 
Private for-profit outlet              
   Health facility/pharmacy 27.00 [27.00-27.00] 2 - 0 27.00 [27.00-27.00] 2  27.00 [27.00-27.00] 2 - 0 27.00 [27.00-27.00] 2 
   Drug store - 0 - 0 - 0  - 0 - 0 - 0 
   General retailer/itinerant - 0 - 0 - 0  - 0 - 0 - 0 
   Total 27.00 [27.00-27.00] 2 - 0 27.00 [27.00-27.00] 2  27.00 [27.00-27.00] 2 - 0 27.00 [27.00-27.00] 2 
Community health worker - 0 - 0 - 0  - 0 - 0 - 0 
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Table 2.3.3: Cont. 
Median cost to patients of one adult equivalent treatment dose (AETD) of oral artemisinin monotherapy by ALL ORAL DOSAGE FORMS and TABLETS, by urban-rural location and type of outlet, 
according to country 
Country/Type of outlet 
ALL ORAL DOSAGE FORMS  TABLETS 
Urban Rural Total  Urban Rural Total 
Median Cost  
[IQR] 
No. of  
Products 
Median  
Cost [IQR] 
No. of  
Products 
Median Cost  
[IQR] 
No. of  
product 
 
 
Median  
Cost [IQR] 
No. of  
products 
Median Cost 
[IQR] 
No. of  
products 
Median Cost  
[IQR] 
No. of  
products 
Uganda – Total 19.56  1 - 0 19.56  1  19.56  1 - 0 19.56  1 
Public health facility  - 0 - 0 - 0  - 0 - 0 - 0 
Private not-for-profit health facility - 0 - 0 - 0  - 0 - 0 - 0 
Private for-profit outlet              
   Health facility/pharmacy 19.56  1 - 0 19.56  1  19.56  1 - 0 19.56  1 
   Drug store - 0 - 0 - 0  - 0 - 0 - 0 
   General retailer/itinerant - 0 - 0 - 0  - 0 - 0 - 0 
   Total 19.56 1 - 0 19.56  1  19.56  1 - 0 19.56  1 
Community health worker - 0 - 0 - 0  - 0 - 0 - 0 
Zanzibar – Total 7.46 2 4.66  1 7.46 3  7.46  2 4.66  1 7.46  3 
Public health facility  - 0 - 0 - 0  - 0 - 0 - 0 
Private not-for-profit health facility - 0 - 0 - 0  - 0 - 0 - 0 
Private for-profit outlet              
   Health facility/pharmacy 7.46 1 4.66  1 6.06 [4.66-7.46] 2  7.46  1 4.66  1 6.06 [4.66-7.46] 2 
   Drug store - 0 - 0 - 0  - 0 - 0 - 0 
   General retailer/itinerant 7.46 1 - 0 7.46  1  7.46  1 - 0 7.46  1 
   Total 7.46 2 4.66 1 7.46 [4.66-7.46] 3  7.46  2 4.66 1 7.46 3 
Community health worker - 0 - 0 - 0  - 0 - 0 - 0 
Note: An AETD is the number of milligrams (mg) of a given drug that is required to treat a 60 kg adult. AETDs were calculated for every audited antimalarial. 
*This is the p-value for the result of a Wilcoxon ranksum test of no difference in median between baseline and endline. 
na = Not applicable, IQR = Interquartile range 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.3.4: Cost to patients of non-quality-assured ACTs, in 2010 US dollars, at baseline (2010) and endline (2011) 
Indicator 2.2 Median cost to patients of one adult equivalent treatment dose (AETD) of non-quality-assured ACTs for ALL DOSAGE FORMS, by urban-rural location and type of outlet, according to 
country 
Country/Type of outlet 
BASELINE ENDLINE CHANGE IN MEDIAN 
Urban Rural Total Urban Rural Total Urban Rural Total 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Change in 
median 
[p-value*] 
Change in 
median 
[p-value*] 
Change in 
median 
[p-value*] 
Ghana - Total 4.11 [3.22-6.65] 3,636 3.42 [3.08-5.48] 1,385 3.70 [3.08-6.03] 5,021 3.52 [2.82-6.26] 1,978 3.13 [1.88-5.00] 450 3.44 [2.82-5.63] 2,428 -0.59 [0.0010] -0.3  [<0.0001] -0.26 [0.0038] 
Public health facility  4.11 [3.29-6.65] 127 3.42 [2.95-5.92] 195 3.42 [3.07-5.97] 322 1.88 [0.94-3.75] 118 2.28 [0.94-5.00] 202 1.88 [0.94-4.55] 320 -2.23 [<0.0001] -1.15  [<0.0001]] -1.55  [<0.0001] 
Private not-for-profit health facility 4.11 [2.74-5.92] 22 3.42 [3.08-5.48] 27 3.42 [2.96-5.48] 49 4.5 [1.88-4.5.00] 3 1.88 [0.94-5.00] 13 1.88 [0.94-5.00] 16 0.39 [0.297]  -1.55 [0.02057] -1.55 [0.0112] 
Private for-profit outlet                
   Health facility/pharmacy 4.11 [3.42-6.85] 2,753 4.11 [3.29-6.14] 423 4.11 [3.42-6.65] 3,176 4.17 [3.13-8.34] 1,420 2.82 [1.88-4.75] 59 3.75 [3.13-7.51] 1,479 0.06 [0.0439] -1.29 [0.0029] -0.36 [0.0990] 
   Drug store 3.42 [3.08-6.16] 734 3.42 [3.08-5.48] 740 3.42 [3.08-5.48] 1,474 3.13 [2.82-5.63] 437 3.13 [2.5-5.00] 176 3.13 [2.50-5.00] 613 -0.30 [0.0108] -0.30[0.0013] -0.30[0.0054] 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 - - - 
   Total 4.11 [3.29-6.76] 3,487 3.42 [3.08-5.48] 1,163 3.77 [3.08-6.16] 4,650 3.75 [2.82-6.26] 1,857 3.13 [2.5-5.00] 235 3.50 [2.82-5.84] 2,092 -0.36 [0.002543] -0.30 [0.000142] -0.26 [0.03394] 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 - - - 
Kenya - Total 
7.88 [4.59-12.60] 1,919 5.91 [3.94-9.80] 283 6.96 [4.56-12.25] 2,202 7.37 [4.03-11.94] 1,842 5.76 [3.63-11.05] 247 6.45 [4.03-11.67] 2,089 -0.51 [0.016] -0.15 [0.948] -0.51 [0.154] 
Public health facility  1.97 [0.00-2.36] 15 0.00 [0.00-0.00] 13 0.00 [0.00-1.97] 28 2.30 [0.46-6.14] 23 0.00 [0.00-0.00] 8 0.00 [0.00-0.00] 31 0.33 [0.302] 0.00 [0.25] 0.00 [0.184] 
Private not-for-profit health facility 5.25 [3.15-8.86] 24 3.15 [0.00-8.12] 6 5.25 [1.90-8.86] 30 6.14 [5.76-10.36] 12 0.00 [0.00-0.00] 2 5.76 [0.00-7.67] 14 0.89 [0.306] -3.15 [0.331] 0.51 [0.716] 
Private for-profit outlet                
   Health facility/pharmacy 7.88 [4.59-13.3] 1,296 5.91 [3.94-9.45] 181 7.35 [4.46-12.25] 1,477 6.91 [4.03-11.94] 1,134 8.06 [4.03-13.26] 160 7.67 [4.03-12.28] 1,294 -0.97 [0.077] 2.15 [0.199] 0.32 [0.704] 
   Drug store 7.88 [5.17-12.25] 584 6.13 [4.43-12.25] 81 6.65 [4.59-12.25] 665 7.67 [4.03-11.94] 673 4.72 [4.03-10.74] 74 6.16 [4.03-11.05] 747 -0.20 [0.019] -1.41 [0.244] -0.49 [0.082] 
   General retailer/itinerant - 0 - 0 - 0 - 0 0.46 [0.46-0.46] 3 0.46 [0.46-0.46] 3 - - - 
   Total 7.88 [4.73-13.13] 1,880 5.91 [4.14-9.98] 262 7.00 [4.59-12.25] 2,142 7.52 [4.03-11.94] 1,807 5.76 [4.03-11.67] 237 6.91 [4.03-11.67] 2,044 -0.35 [0.005] -0.15 [0.931] -0.09 [0.108] 
Community health worker 
- 0 0.00 [0.00-0.00] 2 0.00 [0.00-0.00] 2 - 0 - 0 - 0 - - - 
Madagascar - Total 4.77 [0.00-7.23] 51 0.00 [0.00-0.00] 132 0.00 [0.00-2.81] 183 9.14 [7.48-10.25] 57 0.00 [0.00-0.00] 26 7.90 [0.00-9.74] 83 4.37 [0.007] 0.00 [0.8] 7.90 [0.004] 
Public health facility  0.00 [0.00-0.00] 16 0.00 [0.00-0.00] 130 0.00 [0.00-0.00] 146 4.70 1 0.00 [0.00-0.00] 21 0.00 [0.00-0.00] 22 4.70  [<0.0001] 0.00 [0.681] 0.00 [0.248] 
Private not-for-profit health facility 0.00 [0.00-0.00] 2 - 0 0.00 [0.00-0.00] 2 0.00 [0.00-0.00] 2 - 0 0.00 [0.00-0.00] 2 0.00 [0.583] - 0.00 [0.583] 
Private for-profit outlet 
               
   Health facility/pharmacy 5.82 [4.77-11.22] 33 - 0 5.82 [4.77-11.22] 33 9.14 [7.90-10.25] 50 - 0 9.14 [7.90-10.25] 50 3.33 [0.015] - 3.33 [0.015] 
   Drug store - 0 4.49  1 4.49  1 1.71 [1.37-12.82] 4 0.85 [0.34-10.25] 3 1.71 [0.85-10.25] 7 - -3.63 [0.447] -2.78 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 - - - 
   Total 5.82 [4.77-11.22] 33 4.49  1 5.61 [4.77-11.22] 34 9.14 [7.48-10.25] 54 0.85 [0.34-10.25] 3 9.14 [7.48-10.25] 57 3.33 [0.025] -3.63 [0.447] 3.53 [0.04] 
Community health worker 
- 0 2.81 1 2.81  1 - 0 0.00 [0.00-0.34] 2 0.00 [0.00-0.34] 2 - -2.81 -2.81 
Niger - Total 9.38 [7.78-16.08] 1,525 0.00 [0.00-2.26] 173 8.80 [2.31-12.25] 1,698 8.19 [2.38-11.89] 1,411 0.00 [0.00-1.19] 128 3.75 [0.15-10.18] 1,539 3.80 [0.0016] 0.00 [0.1869] -0.33 [0.0047] 
Public health facility  
0.00 [0.00-3.29] 110 0.00 [0.00-1.85] 139 0.00 [0.00-1.85] 249 0.00 [0.00-0.92] 122 0.00 [0.00-0.00] 103 0.00 [0.00-0.00] 225 0.00 [0.4589] 0.00 [0.0001] 0.00 [0.0009] 
Private not-for-profit health facility 1.85 [1.23-2.47] 2 - 0 1.85 [1.23-2.47] 2 0.00 [0.00-0.00] 1 0.00 [0.00-0.00] 3 0.00 [0.00-0.00] 4 0.00 - 0.0 0 
Private for-profit outlet 
               
   Health facility/pharmacy 11.27 [8.79-18.66] 1,363 10.09 [6.31-17.7] 31 11.27 [8.79-18.66] 1,394 9.87 [7.24-14.47] 1,207 0.92 [0.92-1.39] 4 9.87 [7.24-14.00] 1,211 5.84  [<0.0001] 0.00[0.00701] 5.84  [<0.0001] 
   Drug store 10.29 [6.94-14.31] 22 - 0 10.29 [6.94-14.31] 22 7.93 [2.18-12.29] 35 - 0 7.93 [2.18-12.29] 35 -0.24 [0.1522] - -0.24 [0.1522] 
   General retailer/itinerant 2.31 [2.06-4.11] 28 2.88 [2.26-9.25] 3 2.47 [2.06-4.11] 31 1.19 [0.89-2.38] 46 1.19 [1.07-1.78] 18 1.19 [0.89-1.78] 64 -2.02  [<0.0001] 0.00 [<0.0001] -2.02  [<0.0001] 
   Total 10.26 [8.31-17.17] 1,413 6.31 [2.87-9.25] 34 10.24 [8.05-16.61] 1,447 8.51 [4.95-12.92] 1,288 1.19 [0.92-1.78] 22 7.58 [1.78-11.79] 1,310 3.93 [0.0002] 0.00  [<0.0001] 3.93 [<0.0001] 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 - - - 
Nigeria - Total 4.60 [3.35-5.95] 4,072 4.47 [3.35-5.21] 117 4.47 [3.35-5.95] 4,189 4.13 [2.95-6.30] 1,253 4.13 [2.36-7.87] 285 4.13 [2.95-6.49] 1,538 -0.47 [0.3942] -0.33 [0.9277] -0.33 [0.372] 
Public health facility  
0.00 [0.00-4.09] 180 4.54 10 2.98 [0.00-4.54] 190 6.30 [5.90-11.81] 30 0.00 [0.00-3.84] 32 4.72 [0.00-9.45] 62 6.30 [0.0001] -4.54 [0.5167] 1.75 [0.3133] 
Private not-for-profit health facility 5.21 [2.23-10.42] 5 5.21 1 5.21 [5.21-5.21] 6 3.19 [2.83-5.31] 4 - 0 3.19 [2.83-5.31] 4 -2.02  -5.21  -2.02  
Private for-profit outlet                
   Health facility/pharmacy 5.86 [4.35-8.93] 3,405 4.47 [3.72-8.93] 33 5.21 [3.72-8.93] 3,438 4.13 [3.25-6.49] 372 4.72 [3.54-6.61] 43 4.13 [3.32-6.49] 415 -1.73 [<0.0001] 0.26 [0.3429] -1.08 [0.0632] 
   Drug store 4.47 [3.35-5.95] 443 4.09 [3.72-5.21] 71 4.47 [3.35-5.95] 514 4.13 [2.95-5.90] 822 4.43 [2.95-7.87] 207 4.13 [2.95-6.49] 1,029 -0.33 [0.4082] 0.33 [0.7946] -0.33 [0.4823] 
   General retailer/itinerant 5.58 [4.19-6.7] 39 - 0 5.58 [4.19-6.7] 39 2.95 [2.07-6.64] 25 1.77 [1.77-2.95] 3 2.95 [2.07-5.90] 28 -2.63 [0.2809] -  -2.63 [0.1724] 
   Total 4.60 [3.35-5.95] 3,887 4.47 [3.72-5.95] 104 4.47 [3.35-5.95] 3,991 4.13 [2.95-6.20] 1,219 4.43 [2.95-7.87] 253 4.13 [2.95-6.49] 1,472 -0.47 [0.3186] -0.04 [0.974] -0.33 [0.3440] 
Community health worker 0.00 [0.00-0.00] 0 0.00 [0.00-0.00] 2 - 2 - 0 - 0 - 0 - - - 
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Table 2.3.4: Cont. 
Country/Type of outlet 
BASELINE ENDLINE CHANGE IN MEDIAN 
Urban Rural Total Urban Rural Total Urban Rural Total 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Change in 
median 
[p-value*] 
Change in 
median 
[p-value*] 
Change in 
median 
[p-value*] 
Tanzania – mainland - Total 10.30 [7.04-14.6] 1,317 6.34 [3.17-11.36] 90 8.56 [5.28-14.08] 1,407 9.37 [5.00-14.4] 2,131 6.25 [2.50-14.4] 118 8.44 [3.75-14.40] 2,249 -0.93 [0.064] -0.09 [0.55] -0.12 [0.273] 
Public health facility  0.00 1 0.00 [0.00-0.00] 3 0.00 [0.00-0.00] 4 0.75 1 0.00 [0.00-0.00] 4 0.00 [0.00-0.00] 5 0.75  0.00 [0.702] 0.00 [0.404] 
Private not-for-profit health facility 6.34 [3.52-11.27] 12 3.96 [3.17-7.92] 8 6.34 [3.17-11.27] 20 9.37 10 - 0 9.37 [6.25-15.00] 10 3.04 [0.436] -  3.04 [0.153] 
Private for-profit outlet                
   Health facility/pharmacy 11.09 [7.04-15.02] 1,241 7.92 [3.38-13.38] 44 11.09 [7.04-15.02] 1,285 11.25 [5.62-14.4] 1,783 6.56 [3.56-14.4] 62 10.8 [5.31-14.40] 1,845 0.16 [0.015] -1.36 [0.832] -0.29 [0.009] 
   Drug store 9.51 [7.04-14.08] 63 7.13 [3.52-13.52] 35 8.45 [6.18-14.08] 98 8.75 [4.06-14.4] 336 6.25 [3.12-15.00] 52 8.33 [3.75-14.40] 388 -0.76 [0.327] -0.88 [0.979] -0.12 [0.509] 
   General retailer/itinerant - 0 - 0 - 0 1.25 1 - 0 1.25 1 - - -  
   Total 10.56 [7.04-14.6] 1,304 7.13 [3.52-13.52] 79 9.51 [6.73-14.6] 1,383 9.37 [5.00-14.4] 2,120 6.25 [3.12-15.00] 114 9.36 [3.75-14.40] 2,234 -1.19 [0.016] -0.88 [0.977] -0.15 [0.047] 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 - - - 
Uganda - Total 5.57 [3.34-11.14] 2,229 3.48 [2.79-5.57] 1,474 4.18 [2.79-7.43] 3,703 5.09 [3.13-10.43] 3,322 3.91 [2.74-7.82] 1,265 4.69 [2.74-8.80] 4,587 -0.48 [0.5122] 0.43 [0.5271] 0.51 [0.7435] 
Public health facility  0.00 [0.00-0.00] 28 0.00 [0.00-0.00] 53 0.00 [0.00-0.00] 81 0.00 [0.00-0.00] 75 0.00 [0.00-0.00] 17 0.00 [0.00-0.00] 92 0.00 [0.0779] 0.00 [0.5857] 0.00 [0.6018] 
Private not-for-profit health facility 3.25 [2.48-3.25] 4 0.31 [0.00-1.86] 8 2.32 [0.31-3.25] 12 7.04 [2.20-7.82] 15 2.35 [1.56-9.39] 16 5.48 [1.56-9.39] 31 3.79 [0.2217] 2.04 [0.102] 3.16 [0.1136] 
Private for-profit outlet                   
   Health facility/pharmacy 6.04 [3.71-11.14] 2,108 4.64 [3.25-7.84] 855 5.57 [3.71-9.91] 2,963 5.87 [3.91-10.43] 2,893 4.69 [3.08-10.43] 889 5.22 [3.13-10.43] 3,782 -0.17 [0.2505] 0.05 [0.8871] -0.35 [0.4094] 
   Drug store 5.22 [3.25-7.84] 88 3.34 [2.79-4.64] 539 3.71 [2.79-5.57] 627 3.91 [2.74-8.35] 338 3.52 [2.35-6.57] 342 3.91 [2.54-7.04] 680 -1.31 [0.6001] 0.18 [0.9615] 0.20 [0.9289] 
   General retailer/itinerant - 0 2.79 [1.86-3.71] 3 2.79 [1.86-3.71] 3 0.78 1 - 0 0.78  1 - - -2.01 
   Total 5.57 [3.71-11.14] 2,196 3.71 [2.79-5.57] 1,397 4.64 [3.25-7.84] 3,593 5.09 [3.13-10.43] 3,232 3.91 [2.74-7.82] 1,231 4.69 [2.82-8.87] 4,463 -0.48 [0.4827] 0.20 [0.7713] 0.05 [0.9913] 
Community health worker 2.32 1 0.00 [0.00-0.00] 16 0.00 [0.00-0.00] 17 - 0 1.96 [1.96-1.96] 1 1.96 [1.96-1.96] 1 - 1.96 1.96 
Zanzibar - Total 7.13 [3.52-11.88] 172 0.00 [0.00-3.17] 30 5.59 [2.11-10.56] 202 6.41 [2.91-11.66] 143 2.48 [0.00-5.83] 16 5.83 [2.91-11.66] 159 -0.72  2.48  0.24  
Public health facility  0.00 [0.00-0.00] 33 0.00 [0.00-0.00] 21 0.00 [0.00-0.00] 54 4.08 [2.91-6.41] 5 0.00 [0.00-0.00] 7 0.00 [0.00-3.50] 12 4.08  0.00  0 .00 
Private not-for-profit health facility 7.44 [3.52-11.36] 2 3.52 1 3.52 [3.52-11.36] 3 4.08 [0.79-5.83] 3 - 0 4.08 [0.79-5.83] 3 -3.36 - 0.56 
Private for-profit outlet                
   Health facility/pharmacy 7.92 [5.24-13.66] 124 4.29 [3.17-10.30] 6 7.92 [4.36-13.52] 130 7 [3.21-11.66] 113 5.83 [3.50-6.22] 9 6.85 [3.21-11.66] 122 
-0.93 [0.025] 
 
1.54 [0.677] 
 
-1.07 [0.015] 
 
   Drug store 4.23 [3.52-11.36] 13 3.17 [2.82-3.52] 2 4.23 15 4.81 [2.33-11.81] 22 - 0 4.81 [2.33-11.81] 22 0.58  -3.17 0.58  
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 - - - 
   Total 7.92 [4.23-13.52] 137 3.87 [2.99-7.33] 8 7.92 [4.23-12.98] 145 7 [2.91-11.81] 135 5.83 [3.50-6.22] 9 6.46 [2.91-11.73] 144 -0.93  1.96  -1.46  
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 - - - 
Note: An AETD is the number of milligrams (mg) of a given drug that is required to treat a 60 kg adult. AETDs were calculated for every audited antimalarial. Nigeria baseline data collection was conducted in 2009. 
*This is the p-value for the result of a Wilcoxon ranksum test of no difference in median between baseline and endline. 
na = Not applicable, IQR = Interquartile range 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.3.5: Cost to patients of quality-assured ACTs (including formulations for adults and children), in 2010 US dollars, at baseline (2010) and endline (2011) 
Indicator 2.1 Median cost to patients of one ADULT equivalent treatment dose (AETD) of quality-assured ACTs, by urban-rural location and type of outlet, according to country 
Country/Type of outlet 
BASELINE ENDLINE CHANGE IN MEDIAN 
Urban Rural Total Urban Rural Total Urban Rural Total 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Change in 
median 
[p-value
*
] 
Change in 
median 
[p-value
*
] 
Change in 
median 
[p-value
*
] 
Ghana - Total 7.40 [2.74-8.22] 735 2.74 [2.05-5.48] 357 3.42 [2.40-7.53] 1,092 1.25 [0.94-1.88] 1,527 0.94 [0.94-1.25] 540 0.94 [0.94-1.88] 2,067 -6.15 [<0.0001] -1.80 [<0.0001] -2.49 [<0.0001] 
Public health facility  2.74 [2.33-6.58] 126 2.74 [2.74-5.48] 214 2.74 [2.74-5.48] 340 0.94 [0.94-1.25] 121 0.94 [0.94-0.94] 285 0.94 [0.94-0.95] 406 -1.80 [<0.0001] -1.80 [<0.0001] -1.80 [<0.0001] 
Private not-for-profit health facility 4.79 [3.42-5.48] 7 6.85 [2.95-9.97] 5 5.48 [2.95-9.97] 12 0.94 [0.94-1.50] 12 0.94 [0.00-0.94] 12 0.94 [0.00-0.95] 24 -3.86 [0.0118] -5.91 [0.0002] -4.54 [<0.0001] 
Private for-profit outlet                
   Health facility/pharmacy 8.22 [6.85-8.90] 528 6.85 [2.60-7.88] 54 7.53 [4.11-8.77] 582 1.25 [0.94-2.5] 1,008 0.94 [0.94-1.25] 64 1.25 [0.94-2.50] 1,072 -6.97 [<0.0001] -5.91 [<0.0001] -6.28 [<0.0001] 
   Drug store 2.74 [1.37-4.11] 74 2.6 [1.71-3.42] 76 2.60 [1.64-3.42] 150 0.94 [0.94-1.88] 384 0.94 [0.94-1.88] 177 0.94 [0.94-1.88] 561 -1.80 [<0.0001] -1.66 [<0.0001] -1.66 [<0.0001] 
   General retailer/itinerant - 0 - 0 - 0 1.25 [0.94-1.25] 2 10.01 [0.94-10.01] 2 1.25 [0.94-10.01] 4 - - - 
   Total 7.53 [3.08-8.22] 602 2.74 [1.71-4.11] 130 3.42 [2.05-8.22] 732 1.25 [0.94-2.00] 1,394 0.94 [0.94-1.88] 243 1.13 [0.94-1.88] 1,637 -6.28 [<0.0001] -1.80 [<0.0001] -2.30 [<0.0001] 
Community health worker - 0 3.42 [2.23-5.48] 8 3.42 [2.23-5.48] 8 - 0 - 0 - 0 - - - 
Kenya - Total 
1.58 [0.00-6.04] 1,008 0.00 [0.00-0.79] 1,014 0.00 [0.00-1.97] 2,022 0.58 [0.46-1.15] 1,999 0.46 [0.00-0.46] 1,605 0.46 [0.00-0.69] 3,604 -1.00 [0.0115] 0.46 [0.2514] 0.46 [0.6381] 
Public health facility  0.00 [0.00-0.00] 340 - 832 0.00 [0.00-0.00] 1,172 0.00 [0.00-0.00] 396 0.00 [0.00-0.00] 1,102 0.00 [0.00-0.00] 1,498 0.00 [0.6754] 0.00 [0.5216] 0.00 [0.5336] 
Private not-for-profit health facility 0.00 [0.00-1.31] 49 0.00 [0.00-0.53] 41 0.00 [0.00-0.66] 90 0.46 [0.00-0.92] 41 0.00 [0.00-0.77] 81 0.00 [0.00-0.77] 122 0.46 [0.6525] 0.00 [0.5760] 0.00 [0.5339] 
Private for-profit outlet                
   Health facility/pharmacy 3.94 [1.31-6.71] 390 1.31 [0.00-3.15] 79 2.63 [0.92-6.30] 469 0.69 [0.46-1.38] 824 0.58 [0.46-1.15] 167 0.58 [0.46-1.15] 991 -3.25 [<0.0001] -0.74 [0.6343] -2.05 [0.0002] 
   Drug store 3.94 [1.31-7.22] 226 2.63 [1.84-4.59] 47 2.63 [1.58-6.30] 273 0.61 [0.46-1.15] 697 0.46 [0.46-0.69] 185 0.58 [0.46-0.92] 882 -3.32 [<0.0001] -2.16 [<0.0001] -2.05 [<0.0001] 
   General retailer/itinerant - 0 - 0 - 0 0.46 [0.46-0.69] 41 0.46 [0.46-0.46] 70 0.46 [0.46-0.46] 111 - - - 
   Total 3.94 [1.31-6.96] 616 2.36 [1.31-3.94] 126 2.63 [1.31-6.30] 742 0.61 [0.46-1.15] 1,562 0.46 [0.46-0.92] 422 0.58 [0.46-0.92] 1,984 -3.32 [<0.0001] -1.90 [<0.0001] -2.05 [<0.0001] 
Community health worker 
1.97 [1.97-1.97] 3 0.00 [0.00-0.00] 15 0.00 [0.00-0.00] 18 - 0 - 0 - 0 - - - 
Madagascar - Total 0.00 [0.00-0.56] 398 0.00 [0.00-0.09] 1,379 0.00 [0.00-0.09] 1,777 0.43 [0.00-1.03] 861 0.00 [0.00-0.34] 2,385 0.00 [0.00-0.34] 3,246 0.43 [0.004642] 0.00 [0.1007] 0.00 [0.00495] 
Public health facility  0.00 [0.00-0.00] 150 0.00 [0.00-0.00] 1,203 0.00 [0.00-0.00] 1,353 0.00 [0.00-0.00] 201 0.00 [0.00-0.00] 1,780 0.00 [0.00-0.00] 1,981 0.00 [0.08834] 0.00 [0.2448] 0.00 [0.7278] 
Private not-for-profit health facility 0.00 [0.00-0.00] 5 - 0 0.00 [0.00-0.00] 5 0.00 [0.00-0.00] 75 0.00 [0.00-0.00] 7 0.00 [0.00-0.00] 82 0.00 [0.01841] - 0.00 [0.0758] 
Private for-profit outlet 
               
   Health facility/pharmacy 6.55 [0.09-11.22] 212 0.09 [0.09-0.09] 3 1.54 [0.09-11.22] 215 0.68 [0.38-7.35] 471 0.43 [0.34-0.85] 9 0.68 [0.34-4.61] 480 -5.86 [0.543] 0.33 [0.01307] -0.86 [0.6443] 
   Drug store 0.56 [0.09-0.56] 25 0.09 [0.09-0.19] 125 0.14 [0.09-0.56] 150 0.68 [0.38-1.71] 86 0.60 [0.43-1.03] 478 0.64 [0.40-1.37] 564 0.12 [0.0006] 0.50 [<0.0001] 0.50 [<0.0001] 
   General retailer/itinerant 0.19 [0.09-0.28] 6 0.14 [0.09-0.28] 9 0.14 [0.09-0.28] 15 0.51 [0.51-1.03] 3 0.51 [0.34-0.85] 10 0.51 [0.34-0.85] 13 0.33 [0.0009] 0.37 [0.0292] 0.37 [0.0205] 
   Total 0.56 [0.09-9.65] 243 0.09 [0.09-0.28] 137 0.14 [0.09-1.54] 380 0.68 [0.38-5.98] 560 0.51 [0.34-1.03] 497 0.60 [0.34-1.37] 1,057 0.12 [0.5423] 0.42 [<0.0001] 0.46 [0.0001] 
Community health worker 
- 0 0.09 [0.09-0.09] 39 0.09 [0.09-0.09] 39 0.34 [0.17-0.68] 25 0.17 [0.17-0.34] 101 0.17 [0.17-0.34] 126 - 0.08 [<0.0001] 0.08 [<0.0001] 
Niger - Total 2.67 [1.64-8.89] 419 1.23 [0.00-2.47] 280 2.06 [0.00-3.08] 699 1.19 [0.69-1.98] 743 0.00 [0.00-1.19] 294 0.79 [0.00-1.49] 1,037 -1.48 [<0.0001] -1.23 [0.0054] -1.26 [<0.0001] 
Public health facility  
0.00 [0.00-1.64] 116 0.00 [0.00-0.00] 228 0.00 [0.00-0.00] 344 0.00 [0.00-0.69] 216 0.00 [0.00-0.00] 226 0.00 [0.00-0.00] 442 0.00 [0.9854] 0.00 [0.04638] 0.00 [0.4272] 
Private not-for-profit health facility 1.03 [1.03-1.03] 1 - 0 1.03 [1.03-1.03] 1 0.00 1 0.00 [0.00-0.00] 5 0.00 [0.00-0.00] 6 -1.03 [<0.0001] - -1.03 [<0.0001] 
Private for-profit outlet 
               
   Health facility/pharmacy 9.38 [8.93-12.77] 222 8.79 [8.79-8.79] 5 9.38 [8.93-12.77] 227 3.17 [0.99-9.04] 327 0.69 [0.69-0.69] 8 1.98 [0.79-9.02] 335 -6.21 [<0.0001] -8.10 [0.0042] -7.40 [<0.0001] 
   Drug store 4.11 [4.11-7.2] 13 2.67 [2.47-2.88] 2 4.11 [2.88-6.17] 15 0.99 [0.79-2.77] 19 1.39 [1.19-2.97] 4 1.39 [1.09-2.77] 23 -3.12 [0.0024] -1.29 [<0.0001] -2.72 [0.0019] 
   General retailer/itinerant 2.06 [1.92-3.08] 67 2.47 [2.06-2.88] 45 2.47 [2.06-2.88] 112 1.19 [0.99-1.78] 180 1.19 [0.79-1.59] 51 1.19 [0.99-1.59] 231 -0.87 [<0.0001] -1.28 [<0.0001] -1.28 [<0.0001] 
   Total 3.29 [2.06-8.93] 302 2.47 [2.06-2.96] 52 2.47 [2.06-4.11] 354 1.39 [0.99-2.38] 526 1.19 [0.79-1.59] 63 1.19 [0.99-1.98] 589 -1.90  [<0.0001] -1.28  [<0.0001] -1.28 [<0.0001] 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 - - - 
Nigeria - Total 
4.47 [2.23-6.7] 963 2.38 [0.00-3.57] 131 3.72 [2.08-5.95] 1,094 1.48 [0.89-2.66] 1,464 1.48 [0.89-2.36] 586 1.48 [0.89-2.36] 2,050 -2.99 [<0.0001] -0.91 [0.4602] -2.25 [<0.0001] 
Public health facility  
0.00 [0.00-0.00] 55 0.00 [0.00-2.60] 24 0.00 [0.00-2.60] 79 0.00 [0.00-0.00] 70 0.00 [0.00-0.00] 65 0.00 [0.00-0.00] 135 0.00 [0.9454] 0.00 [0.1703] 0.00 [0.1658] 
Private not-for-profit health facility 2.98 [1.49-2.98] 3 0.89 [0.00-0.89] 3 0.89 [0.00-0.89] 6 0.71 [0.71-2.95] 10 1.48 [1.48-4.72] 3 1.48 [0.71-3.54] 13 -2.27 [0.7836] 0.58 [0.1697] 0.58 [0.5065] 
Private for-profit outlet                
   Health facility/pharmacy 7.07 [4.47-7.81] 588 1.49 [1.49-8.19] 5 6.70 [2.98-7.81] 593 1.77 [0.89-3.25] 168 2.36 [1.18-7.09] 15 1.77 [0.89-3.25] 183 -5.30 [<0.0001] 0.87 [0.9187] -4.93 [<0.0001] 
   Drug store 4.47 [2.23-6.55] 293 2.98 [2.38-4.47] 95 4.47 [2.23-5.95] 388 1.48 [0.89-2.36] 1,166 1.57 [1-2.36] 497 1.48 [0.89-2.36] 1,663 -2.99 [<0.0001] -1.40 [<0.0001] -2.99 [<0.0001] 
   General retailer/itinerant 5.95 [2.98-7.44] 19 4.47 [4.47-4.47] 1 5.95 [2.98-7.44] 20 1.77 [1.48-2.07] 44 1.89 [1.77-5.2] 4 1.77 [1.48-2.36] 48 -4.18 [<0.0001] -2.58 [0.1094] -4.18 [<0.0001] 
   Total 4.47 [2.38-6.7] 900 2.98 [2.23-5.21] 101 4.47 [2.38-6.33] 1,001 1.48 [0.89-2.66] 1,378 1.57 [1.06-2.36] 516 1.48 [0.89-2.36] 1,894 -2.99 [<0.0001] -1.40 [<0.0001] -2.99 [<0.0001] 
Community health worker 1.49 [0.89-1.49] 5 0.00 [0.00-0.00] 3 0.89 [0.00-1.49] 8 0.00 [0.00-0.00] 6 3.54 [3.54-3.54] 2 3.54 [3.54-3.54] 8 -1.49 [<0.0001] 3.54 [<0.0001] 2.65 [0.0505] 
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Table 2.3.5: Cont. 
Country/Type of outlet 
BASELINE ENDLINE CHANGE IN MEDIAN 
Urban Rural Total Urban Rural Total Urban Rural Total 
Median ost 
[IQR] 
No. of 
products 
Median ost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Median ost 
[IQR] 
No. of 
products 
Median ost 
[IQR] 
No. of 
products 
Change in 
median 
[p-value
*
] 
Change in 
median 
[p-value
*
] 
Change in 
median 
[p-value
*
] 
Tanzania – mainland - Total 
5.63 [0.70-8.45] 275 0.00 [0.00-0.42] 141 0.00 [0.00-0.85] 416 1.25 [0.62-2.50] 1,661 0.62 [0.00-0.94] 354 0.83 [0.62-1.25] 2,015 -4.38 [0.0235] 0.62 [0.0004] 0.83 [0.0015] 
Public health facility  0.00 [0.00-0.35] 9 0.00 [0.00-0.00] 101 0.00 [0.00-0.00] 110 0.31 [0.00-0.62] 22 0.00 [0.00-0.62] 129 0.00 [0.00-0.62] 151 0.31 [0.2237] 0.00[0.07051] 0.00 [0.0513] 
Private not-for-profit health facility 0.85 [0.35-4.93] 7 0.00 [0.00-0.00] 13 0.00 [0.00-0.47] 20 1.25 [0.94-1.87] 6 0.00 [0.00-0.00] 7 0.00 [0.00-0.94] 13 0.40 [0.1305] 0.00[0.1321] 0.00 [0.8682] 
Private for-profit outlet                
   Health facility/pharmacy 8.45 [6.34-9.86] 245 0.00 [0.00-8.45] 5 8.45 [5.99-9.51] 250 1.25 [0.62-2.50] 1,205 0.62 [0.31-0.75] 48 1.25 [0.62-2.5] 1,253 -7.20 [<0.0001] 0.62 [0.5872] -7.20 [<0.0001] 
   Drug store 5.99 [5.63-9.86] 14 1.41 [0.85-3.52] 17 4.23 [1.41-7.04] 31 1.25 [0.83-2.50] 422 0.94 [0.62-1.25] 165 0.94 [0.62-1.25] 587 -4.74  [<0.0001] -0.47 [0.0058] -3.29 [0.0001] 
   General retailer/itinerant - 0 0.85 [0.56-1.13] 5 0.85 [0.56-1.13] 5 0.62 [0.62-0.62] 6 0.00 [0.00-0.00] 5 0.00 [0.00-0.62] 11 0.62 [<0.0001] -0.85 [0.1065] -0.85 [0.1512] 
   Total 7.04 [5.63-9.86] 259 1.41 [0.85-2.11] 27 5.28 [1.41-8.45] 286 1.25 [0.75-2.5] 1,633 0.87 [0.62-1.25] 218 0.94 [0.62-1.25] 1,851 -5.79 [<0.0001]] -0.53 [0.0778] -4.34 [<0.0001] 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 - - - 
Uganda - Total 2.79 [0.00-4.64] 543 0.00 [0.00-0.00] 2,331 0.00 [0.00-0.93] 2,874 1.96 [0.98-3.13] 2,477 1.17 [0.00-1.96] 2,944 1.37 [0.00-2.35] 5,421 -0.83 [0.9521] 1.17 [0.0002] 1.37 [0.0005] 
Public health facility  0.00 [0.00-0.00] 169 0.00[0.00-0.00] 2,063 0.00 [0.00-0.00] 2,232 0.00 [0.00-0.00] 350 0.00 [0.00-0.00] 1,614 0.00 [0.00-0.00] 1,964 0.00 [0.09156] 0.00 [0.0186] 0.00 [0.0049] 
Private not-for-profit health facility 2.79 [0.00-2.79] 7 0.00 [0.00-0.46] 27 0.00 [0.00-0.93] 34 0.00 [0.00-1.17] 23 0.00 [0.00-1.17] 62 0.00 [0.00-1.17] 85 -2.79 [0.7546] 0.00 [0.3746] 0.00 [0.8554] 
Private for-profit outlet                
   Health facility/pharmacy 4.64 [3.25-9.29] 359 3.71 [2.32-4.64] 125 3.71 [3.02-8.36] 484 2.09 [1.56-3.91] 1,644 1.96 [1.56-3.13] 635 1.96 [1.56-3.13] 2,279 -2.55 [0.0059] -1.75 [0.2554] -1.75 [0.0042] 
   Drug store 3.71 [3.25-6.97] 8 2.23 [1.16-2.79] 90 2.32 [1.39-3.25] 98 1.96 [1.17-2.74] 455 1.88 [1.17-2.35] 544 1.88 [1.17-2.54] 999 -1.75 [<0.0001] -0.35 [0.8932] -0.44 [0.6574] 
   General retailer/itinerant - 0 2.79 1 2.79 1 1.96 [1.96-28.17] 2 1.17 [0.94-2.35] 11 1.17 [0.94-2.35] 13 - -1.62 [0.0042] -1.62 [0.0017] 
   Total 4.64 [3.25-8.36] 367 2.32 [1.39-3.25] 216 2.79 [1.39-3.71] 583 1.96 [1.37-3.13] 2,101 1.96 [1.17-2.74] 1,190 1.96 [1.17-2.82] 3,291 -2.68 [0.0011] -0.36 [0.8261] -0.83 [0.2647] 
Community health worker - 0 0.00 [0.00-0.00] 25 0.00 [0.00-0.00] 25 0.00 [0.00-1.96] 3 0.00 [0.00-0.00] 78 0.00 [0.00-0.00] 81 - 0.00 [0.0222] 0.00 [0.0112] 
Zanzibar - Total 0.00 [0.00-0.00] 139 0.00 [0.00-0.00] 221 0.00 [0.00-0.00] 360 0.58 [0.47-1.87] 523 0.00 [0.00-0.58] 335 0.58 [0.00-1.17] 858 0.58  0.00 0.58  
Public health facility  0.00 [0.00-0.00] 124 0.00 [0.00-0.00] 220 0.00 [0.00-0.00] 344 0.00 [0.00-0.00] 135 0.00 [0.00-0.00] 232 0.00 [0.00-0.00] 367 0.00 0.00 0.00 
Private not-for-profit health facility - 0 - 0 - 0 0.58 [0.58-0.58] 1 0.35 [0.29-1.40] 3 0.47 [0.32-0.99] 4 - - - 
Private for-profit outlet                
   Health facility/pharmacy 7.04 [5.63-8.45] 13 5.63 [5.63-5.63] 1 6.69 [5.63-8.45] 14 1.17 [0.58-2.33] 212 0.93 [0.58-1.87] 50 1.17 [0.58-2.33] 262 -5.88  -4.70 -5.52  
   Drug store 1.76 [0.00-3.52] 2 - 0 1.76 [0.00-3.52] 2 1.17 [0.58-2.33] 173 0.93 [0.58-2.33] 47 1.17 [0.58-2.33] 220 -0.59  0.93 -0.59  
   General retailer/itinerant - 0 - 0 - 0 1.46 [0.58-2.33] 2 0.58 [0.58-0.58] 3 0.58 [0.58-0.58] 5 - - - 
   Total 6.34 [4.23-8.45] 15 5.63 [5.63-5.63] 1 5.99 [4.23-8.45] 16 1.17 [0.58-2.33] 387 0.93 [0.58-1.87] 100 1.17 [0.58-2.33] 487 -5.17  -4.70  -4.82  
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 - - - 
Note: An AETD is the number of milligrams (mg) of a given drug that is required to treat a 60 kg adult. AETDs were calculated for every audited antimalarial. Nigeria baseline data collection was conducted in 2009. 
*This is the p-value for the result of a Wilcoxon ranksum test of no difference in median between baseline and endline. 
na = Not applicable, IQR = Interquartile range  
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.3.6: Cost to patients of quality-assured ACTs (including formulations for adults and children) by presence of the AMFm logo, in 2010 US dollars, at endline, 
2011 
Median cost to patients of one ADULT equivalent treatment dose (AETD) of quality-assured ACTs, by presence of the AMFm logo, urban-rural location and type of outlet, according to country 
Country/Type of outlet 
WITH LOGO WITHOUT LOGO 
Urban Rural Total Urban  Rural Total 
Median Cost  
[IQR] 
No. of  
products 
Median Cost 
 [IQR] 
No. of  
products 
Median Cost  
[IQR] 
No. of  
products 
Median Cost  
[IQR] 
No. of  
products 
Median Cost  
[IQR] 
No. of  
products 
Median Cost 
 [IQR] 
No. of 
products 
Ghana - Total 0.95 [0.94-1.88] 1,304 0.94 [0.94-1.25] 502 0.94 [0.94-1.88] 1,806 7.51 [2.50-8.76] 223 0.95 [0.94-2.50] 36 6.88 [1.25-8.76] 259 
Public health facility  0.94 [0.94-1.25] 107 0.94 [0.94-0.94] 259 0.94 [0.94-0.94] 366 0.94 [0.94-6.88] 14 0.95 [0.94-2.50] 25 0.94 [0.94-2.50] 39 
Private not-for-profit health facility 0.94 [0.94-1.50] 12 0.00 [0.00-0.94] 11 0.94 [0.00-0.95] 23 - 0 0.94 [0.94-0.94] 1 0.94 [0.94-0.94] 1 
Private for-profit outlet             
   Health facility/pharmacy 1.25 [0.94-1.88] 811 0.94 [0.94-1.25] 61 1.25 [0.94-1.88] 872 8.13 [3.44-8.76] 197 2.50 [1.25-12.51] 3 8.13 [3.25-8.76] 200 
   Drug store 0.94 [0.94-1.88] 372 0.94 [0.94-1.88] 170 0.94 [0.94-1.88] 542 3.13 [0.94-8.13] 12 1.00 [0.94-7.51] 6 2.50 [0.94-7.82] 18 
   General retailer/itinerant 1.25 [0.94-1.25] 2 10.01 [10.01-10.01] 1 1.25 [0.94-10.01] 3 - 0 0.94 1 0.94 [0.94-0.94] 1 
   Total 1.00 [0.94-1.88] 1,185 0.94 [0.94-1.88] 232 0.94 [0.94-1.88] 1,417 7.82 [2.50-8.76] 209 1.00 [0.94-7.51] 10 7.51 [1.88-8.76] 219 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Kenya - Total 0.58 [0.46-1.15] 1,696 0.46 [0.00-0.58] 943 0.46 [0.46-0.81] 2,639 0.46 [0.00-0.92] 301 0.00 [0.00-0.00] 662 0.00 [0.00-0.00] 963 
Public health facility  0.00 [0.00-0.00] 180 0.00 [0.00-0.00] 524 0.00 [0.00-0.00] 704 0.00 [0.00-0.00] 214 0.00 [0.00-0.00] 578 0.00 [0.00-0.00] 792 
Private not-for-profit health facility 0.46 [0-1.15] 21 0.00 [0.00-0.69] 27 0.46 [0.00-0.69] 48 0.00 [0.00-0.69] 20 0.00 [0.00-1.15] 54 0.00 [0.00-0.92] 74 
Private for-profit outlet             
   Health facility/pharmacy 0.69 [0.46-1.15] 786 0.58 [0.46-1.15] 153 0.58 [0.46-1.15] 939 1.84 [0.58-6.91] 38 1.53 [0.35-3.45] 14 1.53 [0.46-3.45] 52 
   Drug store 0.61 [0.46-1.15] 668 0.46 [0.46-0.69] 172 0.54 [0.46-0.92] 840 0.92 [0.58-1.84] 29 0.69 [0.46-2.30] 13 0.81 [0.58-1.84] 42 
   General retailer/itinerant 0.46 [0.46-0.69] 41 0.46 [0.46-0.46] 67 0.46 [0.46-0.46] 108 - 0 0.46 [0.46-0.69] 3 0.46 [0.46-0.69] 3 
   Total 0.61 [0.46-1.15] 1,495 0.46 [0.46-0.81] 392 0.52 [0.46-0.92] 1,887 0.92 [0.58-2.30] 67 0.92 [0.46-3.45] 30 0.92 [0.46-2.30] 97 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Madagascar - Total 0.40 [0.21-0.68] 554 0.00 [0.00-0.43] 1,350 0.00 [0.00-0.51] 1,904 3.59 [0.00-9.36] 307 0.09 [0.00-0.17] 1,035 0.17 [0.00-0.34] 1,342 
Public health facility  0.00 [0.00-0.00] 100 0.00 [0.00-0.00] 873 0.00 [0.00-0.00] 973 0.00 [0.00-0.00] 101 0.00 [0.00-0.00] 907 0.00 [0.00-0.00] 1,008 
Private not-for-profit health facility 0.00 [0.00-0.00] 46 0.00 [0.00-0.00] 4 0.00 [0.00-0.00] 50 0.00 [0.00-0.00] 29 0.00 [0.00-0.00] 3 0.00 [0.00-0.00] 32 
Private for-profit outlet             
   Health facility/pharmacy 0.51 [0.34-0.85] 325 0.85 [0.43-1.71] 7 0.51 [0.34-0.85] 332 9.02 [7.90-11.79] 146 0.34 [0.34-0.34] 2 8.63 [5.98-11.28] 148 
   Drug store 0.43 [0.34-0.85] 72 0.60 [0.43-1.03] 444 0.60 [0.40-1.03] 516 9.36 [7.78-15.21] 14 0.51 [0.30-8.42] 34 7.78 [0.43-10.25] 48 
   General retailer/itinerant 1.03 [1.03-2.56] 2 0.60 [0.34-1.03] 4 0.60 [0.34-1.03] 6 0.51 [0.51-0.51] 1 0.51 [0.34-0.51] 6 0.51 [0.51-0.51] 7 
   Total 0.51 [0.34-0.85] 399 0.60 [0.43-1.03] 455 0.51 [0.34-1.03] 854 9.10 [7.69-14.36] 161 0.51 [0.34-0.68] 42 7.9 [0.51-10.25] 203 
Community health worker 0.34 [0.10-0.68] 9 0.00 [0.00-0.17] 18 0.17 [0.00-0.34] 27 0.26 [0.17-0.68] 16 0.17 [0.17-0.34] 83 0.17 [0.17-0.34] 99 
Niger - Total 0.99 [0.69-1.59] 422 0.69 [0-1.19] 124 0.99 [0.59-1.39] 546 1.59 [0.79-5.95] 320 0.00 [0.00-0.00] 170 0.00 [0.00-1.59] 490 
Public health facility  0.69 [0.00-0.92] 120 0.00 [0.00-0.00] 73 0.00 [0.00-0.69] 193 0.00 [0.00-0.00] 95 0.00 [0.00-0.00] 153 0.00 [0.00-0.00] 248 
Private not-for-profit health facility - 0 0.00 [0.00-0.00] 5 0.00 [0.00-0.00] 5 0.00 1 - 0 0.00 1 
Private for-profit outlet             
   Health facility/pharmacy 1.39 [0.79-1.98] 157 0.69 [0.69-0.69] 5 1.39 [0.69-1.98] 162 9.04 [8.13-12.29] 170 1.19 [0.69-6.18] 3 9.04 [6.18-12.29] 173 
   Drug store 0.95 [0.79-1.59] 15 1.39 [1.19-1.39] 3 1.19 [0.95-1.39] 18 2.77 [1.39-10.05] 4 2.97 [2.97-2.97] 1 2.97 [2.97-2.97] 5 
   General retailer/itinerant 1.19 [0.99-1.59] 130 0.99 [0.79-1.49] 38 1.19 [0.79-1.49] 168 1.59 [1.19-1.98] 50 1.59 [1.19-2.38] 13 1.59 [1.19-2.38] 63 
   Total 1.19 [0.79-1.59] 302 1.19 [0.79-1.49] 46 1.19 [0.79-1.59] 348 1.98 [1.19-8.61] 224 1.59 [1.19-2.38] 17 1.98 [1.19-5.95] 241 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Nigeria - Total 1.42 [0.89-2.36] 1,252 1.48 [0.89-2.36] 468 1.48 [0.89-2.36] 1,720 2.83 [0.94-5.02] 212 1.18 [0.00-3.84] 118 2.36 [0.71-4.72] 330 
Public health facility  0.00 [0.00-0.00] 45 0.00 [0.00-0.00] 23 0.00 [0.00-0.00] 68 0.00 [0.00-0.00] 25 0.00 [0.00-0.00] 42 0.00 [0.00-0.00] 67 
Private not-for-profit health facility 2.36 [0.71-2.95] 7 1.48  1 1.48 [0.71-2.95] 8 0.71 [0.71-0.71] 3 4.72 [4.72-4.72] 2 0.71 [0.71-4.72] 5 
Private for-profit outlet             
   Health facility/pharmacy 0.89 [0.89-2.76] 138 2.36 [1.18-3.54] 8 1.18 [0.89-2.95] 146 4.72 [2.07-5.43] 30 3.54 [0.59-7.09] 7 3.54 [2.07-5.43] 37 
   Drug store 1.48 [0.89-2.36] 1,017 1.48 [0.89-2.36] 431 1.48 [0.89-2.36] 1,448 2.95 [1.42-5.02] 149 2.36 [1.18-5.90] 66 2.95 [1.42-5.02] 215 
   General retailer/itinerant 1.77 [1.48-2.36] 39 1.89 [1.77-5.20] 4 1.77 [1.48-2.36] 43 0.35 [0.35-0.79] 5 - 0 0.35 [0.35-0.79] 5 
   Total 1.48 [0.89-2.36] 1,194 1.48 [0.89-2.36] 443 1.48 [0.89-2.36] 1,637 2.95 [1.48-5.02] 184 2.76 [1.18-5.90] 73 2.95 [1.42-5.31] 257 
Community health worker 0.00 [0.00-0.00] 6 7.09 1 0.00 [0.00-7.09] 7 - 0 3.54  1 3.54  1 
Tanzania mainland - Total 1.25 [0.62-1.87] 1,431 0.75 [0.62-1.25] 262 0.94 [0.62-1.25] 1,693 2.5 [1.25-8.75] 230 0.00 [0.00-0.62] 92 0.31 [0.00-0.83] 322 
Public health facility  0.31 [0.00-0.62] 16 0.00 [0.00-0.62] 60 0.00 [0.00-0.62] 76 0.62 [0.31-0.62] 6 0.00 [0.00-0.62] 69 0.00 [0.00-0.62] 75 
Private not-for-profit health facility 1.25 [0.94-1.87] 4 0.00 [0.00-0.00] 4 0.00 [0.00-0.94] 8 1.25 [1.25-9.37] 2 0.00 [0.00-0.00] 3 0.00 [0.00-0.00] 5 
Private for-profit outlet             
   Health facility/pharmacy 1.25 [0.62-1.75] 1,015 0.75 [0.62-1.25] 40 1.25 [0.62-1.56] 1,055 7.50 [3.75-10.00] 190 0.31 [0.00-0.31] 8 0.62 [0.31-7.81] 198 
   Drug store 1.25 [0.83-1.87] 390 0.94 [0.62-1.25] 158 0.94 [0.62-1.25] 548 2.50 [1.25-8.75] 32 0.75 [0.62-1.00] 7 1.25 [0.75-3.75] 39 
   General retailer/itinerant 0.62 [0.62-0.62] 6 - 0 0.62 [0.62-0.62] 6 - 0 0.00 [0.00-0.00] 5 0.00 [0.00-0.00] 5 
   Total 1.25 [0.62-1.87] 1,411 0.94 [0.62-1.25] 198 0.94 [0.62-1.25] 1,609 3.75 [1.25-9.37] 222 0.31 [0.00-0.75] 20 1.00 [0.31-3.75] 242 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
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Table: 2.3.6: Cont. 
Country/Type of outlet 
WITH LOGO WITHOUT LOGO 
Urban Rural Total Urban  Rural Total 
Median Cost  
[IQR] 
No. of 
products 
Median Cost 
 [IQR] 
No. of 
products 
Median Cost  
[IQR] 
No. of 
products 
Median Cost  
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
 [IQR] 
No. of 
products 
Uganda - Total 1.96 [1.17-3.13] 1,986 1.56 [0.00-2.35] 2,350 1.56 [0.47-2.35] 4,336 1.56 [0.00-3.13] 490 0.00 [0.00-1.17] 594 0.00 [0.00-1.56] 1,084 
Public health facility  0.00 [0.00-0.00] 212 0.00 [0.00-0.00] 1,265 0.00 [0.00-0.00] 1,477 0.00 [0.00-0.00] 138 0.00 [0.00-0.00] 349 0.00 [0.00-0.00] 487 
Private not-for-profit health facility 2.93 [1.17-4.69] 5 0.98 [0.00-1.56] 13 0.98 [0.00-1.56] 18 0.00 [0.00-0.00] 18 0.00 [0.00-0.78] 49 0.00 [0.00-0.78] 67 
Private for-profit outlet             
   Health facility/pharmacy 1.96 [1.56-3.91] 1,361 1.96 [1.56-3.13] 553 1.96 [1.56-3.13] 1,914 2.82 [1.56-4.69] 282 2.35 [1.37-3.13] 82 2.35 [1.56-3.91] 364 
   Drug store 1.96 [1.17-2.74] 406 1.88 [1.17-2.35] 501 1.88 [1.17-2.35] 907 1.96 [1.96-3.13] 49 1.88 [1.17-2.74] 43 1.96 [1.17-2.74] 92 
   General retailer/itinerant 1.96 [1.96-1.96] 1 1.17 [0.94-2.35] 10 1.17 [0.94-2.35] 11 28.17 1 0.00 1 0.00 [0.00-0.00] 2 
   Total 1.96 [1.17-3.13] 1,768 1.96 [1.17-2.74] 1,064 1.96 [1.17-2.82] 2,832 2.74 [1.88-3.91] 332 1.96 [1.17-2.74] 126 1.96 [1.37-3.13] 458 
Community health worker 1.96 [1.96-1.96] 1 0.00 [0.00-0.00] 8 0.00 [0.00-0.00] 9 0.00 [0.00-0.00] 2 0.00 [0.00-0.00] 70 0.00 [0.00-0.00] 72 
Zanzibar - Total 0.58 [0.58-1.75] 499 0.00 [0.00-0.58] 326 0.58 [0.00-1.17] 825 0.41 [0.00-7.29] 24 0.00 [0.00-0.00] 9 0.00 [0.00-7.00] 33 
Public health facility  0.00 [0.00-0.00] 124 0.00 [0.00-0.00] 225 0.00 [0.00-0.00] 349 0.00 [0.00-0.00] 11 0.00 [0.00-0.00] 7 0.00 [0.00-0.00] 18 
Private not-for-profit health facility 0.58 [0.58-0.58] 1 0.35 [0.29-1.40] 3 0.47 [0.32-0.99] 4 - 0 - 0 - 0 
Private for-profit outlet             
   Health facility/pharmacy 1.17 [0.58-2.33] 200 0.93 [0.58-1.87] 49 1.17 [0.58-2.33] 249 7.00 [1.75-8.74] 12 9.33 1 7.00 [2.33-8.74] 13 
   Drug store 1.17 [0.58-2.33] 172 0.87 [0.58-1.87] 46 1.05 [0.58-2.33] 218 8.74 1 4.66 1 6.70 [4.66-8.74] 2 
   General retailer/itinerant 1.46 [0.58-2.33] 2 0.58 [0.58-0.58] 3 0.58 [0.58-0.58] 5 - 0 - 0 - 0 
   Total 1.17 [0.58-2.33] 374 0.87 [0.58-1.87] 98 1.17 [0.58-2.33] 472 7.00 [2.33-8.74] 13 7.00 [4.66-9.33] 2 7.00 [2.33-8.74] 15 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Note: An AETD is the number of milligrams (mg) of a given drug that is required to treat a 60 kg adult. AETDs were calculated for every audited antimalarial. na = Not applicable, IQR = Interquartile range 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.3.7: Cost to patients of quality-assured ACTs (pediatric formulations only), in 2010 US dollars, at baseline (2010) and endline (2011) 
Indicator 2.1 Median cost to patients of one PEDIATRIC FORMULATION of quality-assured ACTs for a two-year old child (10kg), by urban-rural location and type of outlet, according to country 
Country/Type of outlet 
BASELINE ENDLINE CHANGE IN MEDIAN 
Urban Rural Total Urban Rural Total Urban Rural Total 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Change in 
 median 
 [p-value*] 
Change in  
median  
[p-value*] 
Change in 
 median  
[p-value*] 
Ghana - Total 
2.05 [0.68-2.40] 177 1.37 [0.68-2.40] 79 1.58 [0.68-2.40] 256 0.63 [0.63-0.94] 291 0.63 [0.50-0.75] 76 0.63 [0.63-0.94] 367 -1.43 [<0.0001] -0.74 <0.0001] -0.95 [<0.0001] 
Public health facility  2.05 [1.03-2.40] 43 1.64 [1.03-2.40] 52 1.64 [1.03-2.40] 95 0.47 [0.24-0.63] 22 0.24 [0.24-0.47] 34 0.31 [0.24-0.63] 56 -1.59 [<0.0001] -1.41 <0.0001] -1.33 [<0.0001] 
Private not-for-profit health facility 1.37 [1.20-2.40] 3 2.49 [1.71-2.74] 3 2.49 [1.71-2.74] 6 0.94 [0.24-0.94] 2 - 0 0.94 [0.24-0.94] 2 -0.43 -2.49 -1.55 [0.1079] 
Private for-profit outlet                
   Health facility/pharmacy 2.33 [2.05-2.88] 107 0.68 [0.00-2.40] 9 2.26 [2.05-2.47] 116 0.63 [0.63-0.94] 203 0.63 [0.00-0.63] 9 0.63 [0.63-0.94] 212 -1.70 [<0.0001] -0.06 [0.116] -1.63 [<0.0001] 
   Drug store 0.34 [0.34-0.68] 24 1.03 [0.68-2.05] 12 0.68 [0.68-2.05] 36 0.63 [0.63-0.94] 64 0.63 [0.63-0.94] 33 0.63 [0.63-0.94] 97 0.28 [0.0019] -0.40 [0.0059] -0.06 [0.1506] 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 - - - 
   Total 2.05 [0.68-2.42] 131 1.03 [0.68-2.05] 21 1.37 [0.68-2.40] 152 0.63 [0.63-0.94] 267 0.63 [0.63-0.81] 42 0.63 [0.63-0.94] 309 -1.43 [0.0006] -0.40 [0.01385] -0.74 [<0.0001] 
Community health worker - 0 1.37 [1.03-1.37] 3 1.37 [1.03-1.37] 3 - 0 - 0 - 0 - - - 
Kenya - Total 0.00 [0.00-1.31] 152 0.00 [0.00-0.00] 269 0.00 [0.00-0.00] 421 0.46 [0.35-0.46] 325 0.00 [0.00-0.35] 192 0.35 [0.00-0.46] 517 0.46 [0.3201] 0.00 [0.0085] 0.35 [<0.0001] 
Public health facility  0.00 [0.00-0.00] 93 0.00 [0.00-0.00] 239 0.00 [0.00-0.00] 332 0.00 [0.00-0.00] 42 0.00 [0.00-0.00] 143 0.00 [0.00-0.00] 185 0.00[0.6591] 0.00[0.418] 0.00[0.3239] 
Private not-for-profit health facility 0.00 [0.00-0.00] 17 0.00 [0.00-0.26] 12 0.00 [0.00-0.26] 29 0.00 [0.00-0.46] 7 0.00 [0.00-0.00] 8 0.00 [0.00-0.46] 15 0.00[0.8735] 0.00[0.8179] 0.00[0.8810] 
Private for-profit outlet                
   Health facility/pharmacy 1.58 [0.66-2.63] 31 0.00 [0.00-0.00] 7 0.66 [0.00-1.97] 38 0.46 [0.46-0.58] 154 0.46 [0.46-0.46] 20 0.46 [0.46-0.58] 174 -1.11 [0.0003] 0.46 [<0.0001] -0.20 [0.4846] 
   Drug store 2.36 [0.66-3.94] 11 0.66 [0.53-0.79] 5 0.66 [0.53-0.92] 16 0.46 [0.35-0.46] 116 0.35 [0.29-0.46] 19 0.46 [0.35-0.46] 135 -1.90 [<0.0001] -0.31 [0.0001] -0.20 [<0.0001] 
   General retailer/itinerant - 0 - 0 - 0 0.46 [0.35-0.52] 6 0.46 [0.17-0.46] 2 0.46 [0.35-0.46] 8 - - - 
   Total 1.58 [0.66-2.63] 42 0.53 [0.00-0.66] 12 0.66 [0.53-1.71] 54 0.46 [0.35-0.52] 276 0.46 [0.32-0.46] 41 0.46 [0.35-0.46] 317 
-1.11 [<0.0001] 
 
-0.06 [0.4223] 
 
-0.20 [0.0151] 
 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 - - - 
Madagascar - Total 0.05 [0.00-0.19] 137 0.05 [0.00-0.05] 535 0.05 [0.00-0.05] 672 0.13 [0.00-0.21] 210 0.04 [0.00-0.04] 635 0.04 [0.00-0.09] 845 0.08 [0.165] 0.00 [0.009773] 0.00 [0.0480] 
Public health facility  0.00 [0.00-0.00] 39 0.00 [0.00-0.00] 366 0.00 [0.00-0.00] 405 0.00 [0.00-0.00] 50 0.00 [0.00-0.00] 453 0.00 [0.00-0.00] 503 0.00 [0.1647] 0.00 [0.05802] 0.00 [0.1335] 
Private not-for-profit health facility 0.00 [0.00-0.00] 2 - 0 0.00 [0.00-0.00] 2 - 20 0.00 1 0.00 [0.00-0.00] 21 0.00 [0.04697] - 0.00 [0.0994] 
Private for-profit outlet                
   Health facility/pharmacy 0.05 [0.05-2.81] 73 0.05 [0.05-0.05] 3 0.05 [0.05-2.81] 76 0.19 [0.13-0.51] 109 0.09 [0.09-0.21] 3 0.17 [0.13-0.34] 112 0.15 [0.01482] 0.04 [0.0082] 0.12 [0.0040] 
   Drug store 0.05 [0.05-0.28] 18 0.05 [0.05-0.09] 122 0.05 [0.05-0.09] 140 0.21 [0.17-0.26] 16 0.21 [0.17-0.26] 113 0.21 [0.17-0.26] 129 0.17 [0.02586] 0.17 [<0.0001] 0.17 [<0.0001] 
   General retailer/itinerant 0.09 [0.05-0.09] 5 0.07 [0.05-0.14] 9 0.07 [0.05-0.14] 14 0.13 [0.13-0.13] 2 0.13 [0.09-0.13] 6 0.13 [0.13-0.13] 8 0.03 [0.04395] 0.06 [0.5196] 0.06 [0.5349] 
   Total 0.05 [0.05-2.81] 96 0.05 [0.05-0.09] 134 0.05 [0.05-0.14] 230 0.21 [0.13-0.51] 127 0.17 [0.13-0.21] 122 0.19 [0.13-0.26] 249 0.17 [0.001037] 0.12 [0.00024] 0.15 [<0.0001] 
Community health worker - 0 0.05 [0.05-0.05] 35 0.05 [0.05-0.05] 35 0.04 [0.02-0.09] 13 0.04 [0.04-0.04] 59 0.04 [0.04-0.04] 72 - 0.00 [<0.0001] 0.00 [<0.0001] 
Niger - Total 0.62 [0.31-1.03] 96 0.51 [0.00-0.62] 88 0.62 [0.00-0.82] 184 0.40 [0.40-0.59] 150 0.00 [0.00-0.30] 55 0.40 [0.00-0.59] 205 -0.22 [<0.0001] -0.51 [0.0129] -0.22 [0.0028] 
Public health facility  0.00 [0.00-0.00] 29 0.00 [0.00-0.00] 69 0.00 [0.00-0.00] 98 0.00 [0.00-0.00] 67 0.00 [0.00-0.00] 46 0.00 [0.00-0.00] 113 0.00 [0.6041] 0.00 [0.9618] 0.00 [0.3239] 
Private not-for-profit health facility - 0 - 0 - 0 - 0 - 1 0.00 1 - - - 
Private for-profit outlet                
   Health facility/pharmacy 2.71 [2.67-5.60] 39 - 0 2.71 [2.67-5.60] 39 0.40 [0.40-3.17] 47 0.97 [0.40-1.55] 2 0.40 [0.40-3.17] 49 -2.32 [0.06393] - -2.32 [0.0591] 
   Drug store 1.03 [1.03-1.03] 5 0.62 [0.62-0.62] 1 0.62 [0.62-1.03] 6 0.35 [0.24-2.58] 4 - 0 0.35 [0.24-2.58] 4 -0.68 [0.1857] -  -0.27 [0.2674] 
   General retailer/itinerant 0.62 [0.51-0.82] 23 0.62 [0.62-0.82] 18 0.62 [0.62-0.82] 41 0.50 [0.40-0.59] 32 0.59 [0.59-0.59] 6 0.50 [0.40-0.59] 38 -0.12 [0.0008] -0.02 [0.1885] -0.12 [0.0038] 
   Total 0.82 [0.51-1.03] 67 0.62 [0.62-0.82] 19 0.62 [0.62-0.93] 86 0.50 [0.40-0.59] 83 0.59 [0.59-0.59] 8 0.50 [0.40-0.59] 91 -0.33 [0.0001] -0.02 [0.1729] -0.12 [0.0008] 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 - - - 
Nigeria - Total 
1.12 [0.52-1.49] 531 0.74 [0.22-0.89] 95 0.89 [0.52-1.49] 626 0.71 [0.59-1.18] 371 0.71 [0.59-1.18] 165 0.71 [0.59-1.18] 536 -0.41 [0.196] -0.04 [0.492] -0.18 [0.269] 
Public health facility  0.00 [0.00-0.00] 28 0.00 [0.00-0.82] 13 0.00 [0.00-0.82] 41 0.00 [0.00-0.00] 21 0.00 [0.00-0.00] 15 0.00 [0.00-0.00] 36 0.00 [0.076] 0.00 [0.122] 0.00 [0.109] 
Private not-for-profit health facility 0.74 [0.37-0.74] 3 0.22 [0.22-0.22] 2 0.22 [0.22-0.22] 5 0.89 [0.18-2.36] 4 1.18 1 0.89 [0.18-1.18] 5 0.14 [0.438] 0.96  0.66 [0.272] 
Private for-profit outlet                
   Health facility/pharmacy 1.86 [0.74-2.08] 270 0.37 [0.37-0.37] 2 1.49 [0.37-2.08] 272 1.18 [0.59-1.48] 31 0.59 [0.59-1.77] 2 1.18 [0.59-1.48] 33 -0.68 [0.004] 0.22  -0.31 [0.302] 
   Drug store 1.12 [0.52-1.49] 212 0.74 [0.60-1.12] 76 1.04 [0.52-1.49] 288 0.71 [0.59-1.18] 305 0.89 [0.59-1.18] 143 0.89 [0.59-1.18] 448 -0.41 [0.176] 0.14 [0.816] -0.16 [0.218] 
   General retailer/itinerant 1.12 [0.74-1.86] 13 1.12 [1.12-1.12] 1 1.12 [0.74-1.86] 14 0.89 [0.71-1.18] 7 1.30 [0.47-1.30] 2 0.89 [0.59-1.30] 9 -0.23 [0.765] 0.18  -0.23 [0.513] 
   Total 1.12 [0.52-1.49] 495 0.74 [0.60-1.12] 79 1.04 [0.52-1.49] 574 0.71 [0.59-1.18] 343 0.89 [0.59-1.18] 147 0.89 [0.59-1.18] 490 -0.41 [0.176] 0.14 [0.886] -0.16 [0.209] 
Community health worker 0.37 [0.22-0.37] 5 0.00 1 0.22 [0.22-0.37] 6 0.00 [0.00-0.00] 3 0.89 [0.89-0.89] 2 0.89 [0.89-0.89] 5 -0.37  0.89  0.66 [0.054] 
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Table 2.3.7: Cont. 
Country/Type of outlet 
BASELINE ENDLINE CHANGE IN MEDIAN 
Urban Rural Total Urban Rural Total Urban Rural Total 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Median Cost 
[IQR] 
No. of 
products 
Change in 
 median 
 [p-value*] 
Change in  
median  
[p-value*] 
Change in  
median  
[p-value*] 
Tanzania - mainland - Total 1.76 [0.21-2.46] 42 0.00 [0.00-0.00] 41 0.00 [0.00-0.28] 83 0.62 [0.31-0.62] 400 0.31 [0.00-0.37] 86 0.31 [0.00-0.62] 486 -1.14 [0.1563] 0.31 [0.0172] 0.31 [0.0006] 
Public health facility  0.00 [0.00-0.00] 2 0.00 [0.00-0.00] 31 0.00 [0.00-0.00] 33 0.00 [0.00-0.31] 6 0.00 [0.00-0.00] 33 0.00 [0.00-0.00] 39 0.00 [0.1267] 0.00 [0.58] 0.00 [0.4624] 
Private not-for-profit health facility 0.99 [0.21-1.76] 2 0.00 [0.00-0.35] 5 0.00 [0.00-0.35] 7 0.31 [0.31-0.31] 1 0.00 [0.00-0.00] 2 0.00 [0.00-0.00] 3 -0.67  0.00 [0.2072] 0.00 [0.3448] 
Private for-profit outlet                
   Health facility/pharmacy 2.11 [1.76-2.15] 36 - 0 2.11 [1.76-2.15] 36 0.62 [0.31-0.62] 285 0.00 [0.00-0.31] 13 0.50 [0.31-0.62] 298 -1.49 [<0.0001] -  -1.61 [<0.0001] 
   Drug store 2.46 [2.46-2.46] 2 0.35 [0.35-0.35] 4 0.35 [0.35-2.46] 6 0.62 [0.62-0.62] 108 0.44 [0.31-0.62] 37 0.62 [0.31-0.62] 145 -1.84 [<0.0001] 0.09 [0.6698] 0.27 [0.5384] 
   General retailer/itinerant - 0 0.28 [0.28-0.28] 1 0.28 [0.28-0.28] 1 0.00 [0.00-0.00] 0 0.00 [0.00-0.00] 1 0.00 [0.00-0.00] 1 - -0.28  -0.28  
   Total 2.29 [1.76-2.46] 38 0.35 [0.28-0.35] 5 0.70 [0.35-2.15] 43 0.62 [0.44-0.62] 393 0.37 [0.31-0.62] 51 0.62 [0.31-0.62] 444 -1.66 [<0.0001] 0.02 [0.5129] -0.08 [0.2298] 
Community health worker 
- 0 - 0 - 0 - 0 - 0 - 0 - - - 
Uganda - Total 0.00 [0.00-0.70] 69 0.00 [0.00-0.00] 586 0.00 [0.00-0.00] 655 0.59 [0.00-1.17] 309 0.00 [0.00-0.00] 560 0.00 [0.00-0.23] 869 0.59 [0.2882] 0.00 [0.2243] 0.00 [0.0605] 
Public health facility  0.00 [0.00-0.00] 45 0.00 [0.00-0.00] 561 0.00 [0.00-0.00] 606 0.00 [0.00-0.00] 74 0.00 [0.00-0.00] 415 0.00 [0.00-0.00] 489 0.00 [0.432] 0.00 [0.1499] 0.00 [0.1489] 
Private not-for-profit health facility 0.70 [0.00-0.70] 2 0.00 [0.00-0.23] 8 0.00 [0.00-0.23] 10 0.00 [0.00-0.00] 4 0.00 [0.00-0.00] 15 0.00 [0.00-0.00] 19 -0.70 [0.233] 0.00 [0.8925] 0.00 [0.4788] 
Private for-profit outlet                   
   Health facility/pharmacy 2.32 [2.09-2.79] 22 0.00 [0.00-0.00] 3 2.32 [0.00-2.79] 25 0.98 [0.39-1.96] 199 0.78 [0.59-1.56] 59 0.98 [0.59-1.96] 258 -1.34 [0.1058] 0.78 [0.0039] -1.34 [0.5949] 
   Drug store - 0 0.46 [0.23-0.70] 6 0.46 [0.23-0.70] 6 0.59 [0.59-0.98] 31 0.78 [0.23-1.17] 23 0.78 [0.27-1.17] 54  - 0.32 [0.3563] 0.32 [0.1787] 
   General retailer/itinerant - 0 - 0 0.00 [0.00-0.00] 0 - 0 - 0 - 0   - -   - 
   Total 2.32 [2.09-2.79] 22 0.46 [0.09-0.70] 9 0.56 [0.09-0.93] 31 0.78 [0.39-1.56] 230 0.78 [0.27-1.17] 83 0.78 [0.39-1.17] 313 -1.54 [0.1184] 0.32 [0.0485] 0.22 [0.3213] 
Community health worker - 0 0.00 [0.00-0.00] 8 0.00 [0.00-0.00] 8 0.00 1 0.00 [0.00-0.00] 47 0.00 [0.00-0.00] 48   0.00 [0.7596] 0.00 [0.611] 
Zanzibar - Total 0.00 [0.00-0.00] 43 0.00 [0.00-0.00] 75 0.00 [0.00-0.00] 118 0.38 [0.00-0.58] 132 0.00 [0.00-0.00] 85 0.23 [0.00-0.58] 217 0.38  0  0.23  
Public health facility  0.00 [0.00-0.00] 42 0.00 [0.00-0.00] 75 0.00 [0.00-0.00] 117 0.00 [0.00-0.00] 41 0.00 [0.00-0.00] 64 0.00 [0.00-0.00] 105 0.00  0  0  
Private not-for-profit health facility - 0 - 0 - 0 - 0 - 0 - 0 - - - 
Private for-profit outlet                
   Health facility/pharmacy 2.11 1 - 0 2.11 1 0.55 [0.35-0.58] 50 0.44 [0.29-0.58] 10 0.47 [0.29-0.58] 60 
-1.56 [0.05087] 
 - 
-1.65 [0.0006] 
 
   Drug store - 0 - 0 - 0 0.52 [0.32-0.58] 40 0.58 [0.47-0.58] 11 0.58 [0.35-0.58] 51 - - - 
   General retailer/itinerant - 0 - 0 - 0 0.58 1 - 0 0.58 [0.58-0.58] 1 - - - 
   Total 2.11 1 - 0 2.11 1 0.58 [0.35-0.58] 91 0.47 [0.29-0.58] 21 0.55 [0.32-0.58] 112 -1.53  - -1.56  
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 - - - 
Note: Pediatric formulations (PFs) are packages intended for children. In the calculation of median cost, we include only packages whose age (weight) range includes a 2 year old (10 kg) child. 
*This is the p-value for the result of a Wilcoxon ranksum test of no difference in median between baseline and endline. Nigeria baseline data collection was conducted in 2009. 
na = Not applicable, IQR = Interquartile range 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.3.8: Cost to patients of quality-assured ACTs (pediatric formulations only) by presence of the AMFm logo, in 2010 US dollars, at endline, 2011 
Median cost to patients of one PEDIATRIC FORMULATION of quality-assured ACTs for a two-year old child (10kg), by presence of the AMFm logo, urban-rural location and type of outlet, 
according to country 
Country/Type of outlet 
WITH LOGO WITHOUT LOGO 
Urban Rural Total Urban Rural Total 
Median Cost [IQR] No. of products Median Cost [IQR] 
No. of 
products Median Cost [IQR] 
No. of 
products Median Cost [IQR] 
No. of 
products Median Cost [IQR] No. of products Median Cost [IQR] 
No. of 
products 
Ghana - Total 0.63 [0.63-0.94] 269 0.63 [0.63-0.81] 69 0.63 [0.63-0.94] 338 0.94 [0.63-4.07] 22 0.38 [0.38-0.63] 6 0.94 [0.38-1.56] 28 
Public health facility  0.47 [0.24-0.47] 19 0.24 [0.24-0.44] 29 0.31 [0.24-0.47] 48 0.94 [0.24-4.44] 3 0.47 [0.24-0.94] 4 0.63 [0.24-0.94] 7 
Private not-for-profit health facility 0.94 [0.24-0.94] 2 - 0 0.94 [0.24-0.94] 2  0  0  0 
Private for-profit outlet             
   Health facility/pharmacy 0.63 [0.56-0.94] 186 0.63 [0.00-0.63] 8 0.63 [0.56-0.94] 194 1.25 [0.94-4.88] 17 0.63 [0.63-0.63] 1 1.25 [0.75-4.88] 18 
   Drug store 0.63 [0.63-0.94] 62 0.63 [0.63-0.94] 32 0.63 [0.63-0.94] 94 0.19 [0.19-0.94] 2 0.38 [0.38-0.38] 1 0.38 [0.19-0.94] 3 
   General retailer/itinerant - 0 - 0 - 0  0  0  0 
   Total 0.63 [0.63-0.94] 248 0.63 [0.63-0.81] 40 0.63 [0.63-0.94] 288 0.94 [0.63-3.13] 19 0.38 [0.38-0.38] 2 0.94 [0.38-1.56] 21 
Community health worker - 0 - 0  0  0  0 0.00 [0.00-0.00] 0 
Kenya - Total 0.46 [0.35-0.46] 293 0.23 [0.00-0.46] 114 0.35 [0.00-0.46] 407 0.46 [0.00-0.58] 32 0.00 [0.00-0.00] 78 0.00 [0.00-0.00] 110 
Public health facility  0.00 [0.00-0.00] 23 0.00 [0.00-0.00] 74 0.00 [0.00-0.00] 97 0.00 [0.00-0.00] 19 0.00 [0.00-0.00] 69 0.00 [0.00-0.00] 88 
Private not-for-profit health facility 0.46 [0.46-0.46] 3 0.00 [0.00-0.58] 3 0.00 [0.00-0.58] 6 0.00 [0.00-0.00] 4 0.00 [0.00-0.00] 5 0.00 [0.00-0.00] 9 
Private for-profit outlet             
   Health facility/pharmacy 0.46 [0.35-0.58] 149 0.46 [0.46-0.46] 19 0.46 [0.46-0.46] 168 1.73 [0.58-1.73] 5 0.35 [0.35-0.35] 1 0.58 [0.35-1.73] 6 
   Drug store 0.46 [0.35-0.46] 112 0.35 [0.29-0.46] 17 0.46 [0.35-0.46] 129 0.58 [0.46-0.58] 4 0.46 [0.46-0.58] 2 0.58 [0.46-0.58] 6 
   General retailer/itinerant 0.46 [0.35-0.52] 6 0.46 [0.46-0.46] 1 0.46 [0.46-0.52] 7 ] 0 0.17 [0.17-0.17] 1 0.17 [0.17-0.17] 1 
   Total 0.46 [0.35-0.46] 267 0.46 [0.32-0.46] 37 0.46 [0.35-0.46] 304 0.58 [0.46-0.58] 9 0.46 [0.35-0.46] 4 0.46 [0.46-0.58] 13 
Community health worker  0  0  0  0  0  0 
Madagascar - Total 0.13 [0.00-0.21] 132 0.00 [0.00-0.13] 332 0.00 [0.00-0.17] 464 0.09 [0.00-3.43] 78 0.04 [0.00-0.04] 303 0.04 [0.00-0.04] 381 
Public health facility  0.00 [0.00-0.00] 26 0.00 [0.00-0.00] 222 0.00 [0.00-0.00] 248 0.00 [0.00-0.00] 24 0.00 [0.00-0.00] 231 0.00 [0.00-0.00] 255 
Private not-for-profit health facility 0.00 [0.00-0.00] 10 0.00 [0.00-0.00] 1 0.00 [0.00-0.00] 11 0.00 [0.00-0.00] 10  0 0.00 [0.00-0.00] 10 
Private for-profit outlet             
   Health facility/pharmacy 0.17 [0.13-0.21] 80 0.21 [0.21-0.21] 2 0.17 [0.13-0.21] 82 2.82 [0.90-4.57] 29 0.09 [0.09-0.09] 1 0.90 [0.09-4.14] 30 
   Drug store 0.21 [0.17-0.21] 14 0.21 [0.17-0.30] 97 0.21 [0.17-0.26] 111 3.80 [3.80-3.80] 2 0.09 [0.04-0.13] 16 0.09 [0.04-2.56] 18 
   General retailer/itinerant 0.64 [0.64-0.64] 1  0 0.64 [0.64-0.64] 1 0.13 [0.13-0.13] 1 0.13 [0.09-0.13] 6 0.13 [0.13-0.13] 7 
   Total 0.17 [0.13-0.21] 95 0.21 [0.21-0.26] 99 0.21 [0.17-0.26] 194 3.43 [0.90-4.46] 32 0.13 [0.09-0.13] 23 0.13 [0.09-0.90] 55 
Community health worker 0.00 [0.00-0.00] 1 0.04 [0.00-0.04] 10 0.00 [0.00-0.04] 11 0.04 [0.04-0.09] 12 0.04 [0.04-0.04] 49 0.04 [0.04-0.04] 61 
Niger - Total 0.40 [0.40-0.59] 90 0.00 [0.00-0.59] 28 0.40 [0.00-0.59] 118 0.45 [0.00-0.5] 60 0.00 [0.00-0.30] 27 0.00 [0.00-0.50] 87 
Public health facility  0.00 [0.00-0.40] 37 0.00 [0.00-0.00] 23 0.00 [0.00-0.00] 60 0.00 [0.00-0.00] 30 0.00 [0.00-0.00] 23 0.00 [0.00-0.00] 53 
Private not-for-profit health facility  0 0.00 [0.00-0.00] 1 0.00 [0.00-0.00] 1  0 - 0  0 
Private for-profit outlet             
   Health facility/pharmacy 0.40 [0.40-0.40] 29 0.40 [0.40-0.40] 1 0.40 [0.40-0.40] 30 5.40 [2.58-5.40] 18 1.55 [1.55-1.55] 1 5.40 [1.98-5.40] 19 
   Drug store 0.35 [0.24-2.58] 4  0 0.35 [0.24-2.58] 4  0  0  0 
   General retailer/itinerant 0.50 [0.40-0.59] 20 0.59 [0.59-0.59] 3 0.59 [0.40-0.59] 23 0.50 [0.40-0.50] 12 0.59 [0.30-1.19] 3 0.50 [0.40-0.59] 15 
   Total 0.50 [0.40-0.59] 53 0.59 [0.59-0.59] 4 0.59 [0.40-0.59] 57 0.50 [0.40-0.59] 30 1.19 [0.30-1.19] 4 0.50 [0.40-1.19] 34 
Community health worker  0  0  0  0  0  0 
Nigeria - Total 0.71 [0.59-0.89] 299 0.71 [0.59-1.18] 125 0.71 [0.59-1.18] 424 0.89 [0.59-1.48] 72 0.59 [0.00-1.06] 40 0.89 [0.35-1.18] 112 
Public health facility  0.00 [0.00-0.00] 11 0.00 [0.00-0.00] 4 0.00 [0.00-0.00] 15 0.00 [0.00-0.00] 10 0.00 [0.00-0.00] 11 0.00 [0.00-0.00] 21 
Private not-for-profit health facility 0.18 [0.18-0.89] 3 - 0 0.18 [0.18-0.89] 3 2.36 1 1.18 1 1.18 [1.18-2.36] 2 
Private for-profit outlet             
   Health facility/pharmacy 1.18 [0.59-1.48] 23 0.59 1 0.59 [0.59-1.48] 24 1.18 [0.59-1.18] 8 1.77 1 1.18 [0.59-1.77] 9 
   Drug store 0.71 [0.59-0.89] 253 0.89 [0.59-1.18] 117 0.71 [0.59-1.18] 370 0.89 [0.59-1.48] 52 0.89 [0.59-1.18] 26 0.89 [0.59-1.48] 78 
   General retailer/itinerant 0.89 [0.71-0.89] 6 1.30 [0.47-1.30] 2 0.89 [0.59-1.30] 8 1.48 1 - 0 1.48 1 
   Total 0.71 [0.59-1.18] 282 0.89 [0.59-1.18] 120 0.71 [0.59-1.18] 402 0.89 [0.59-1.48] 61 0.89 [0.59-1.18] 27 0.89 [0.59-1.48] 88 
Community health worker 0.00 [0.00-0.00] 3 1.77 1 1.77 [0.00-1.77] 4 - 0 0.89 1 0.89 1 
Tanzania - mainland - Total 0.62 [0.34-0.62] 371 0.31 [0.00-0.62] 64 0.62 [0.31-0.62] 435 0.62 [0.31-0.94] 29 0.00 [0.00-0.19] 22 0.00 [0.00-0.31] 51 
Public health facility  0.00 [0.00-0.31] 4 0.00 [0.00-0.00] 17 0.00 [0.00-0.00] 21 0.31 [0.00-0.31] 2 0.00 [0.00-0.00] 16 0.00 [0.00-0.00] 18 
Private not-for-profit health facility  0 0.00 [0.00-0.00] 1 0.00 [0.00-0.00] 1 0.31 [0.31-0.31] 1 0.00 [0.00-0.00] 1 0.00 [0.00-0.31] 2 
Private for-profit outlet             
   Health facility/pharmacy 0.62 [0.31-0.62] 264 0.31 [0.31-0.31] 12 0.62 [0.31-0.62] 276 5.00 [0.62-5.00] 21 0.00 [0.00-0.00] 1 0.00 [0.00-0.31] 22 
   Drug store 0.62 [0.62-0.62] 103 0.62 [0.31-0.62] 34 0.62 [0.31-0.62] 137 0.62 [0.62-0.94] 5 0.19 [0.19-0.31] 3 0.31 [0.19-0.62] 8 
   General retailer/itinerant  0  0  0  0 0.00 [0.00-0.00] 1 0.00 [0.00-0.00] 1 
   Total 0.62 [0.44-0.62] 367 0.62 [0.31-0.62] 46 0.62 [0.31-0.62] 413 0.94 [0.62-0.94] 26 0.19 [0.00-0.31] 5 0.19 [0.00-0.31] 31 
Community health worker  0  0  0  0  0  0 
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Table 2.3.8: Cont. 
Country/Type of outlet 
WITH LOGO WITHOUT LOGO 
Urban Rural Total Urban Rural Total 
Median Cost [IQR] No. of products Median Cost [IQR] 
No. of 
products Median Cost [IQR] 
No. of 
products Median Cost [IQR] 
No. of 
products Median Cost [IQR] No. of products Median Cost [IQR] 
No. of 
products 
Uganda - Total 0.78 [0.20-1.17] 266 0.00 [0.00-0.20] 425 0.00 [0.00-0.59] 691 0.00 [0.00-0.00] 43 0.00 [0.00-0.00] 135 0.00 [0.00-0.00] 178 
Public health facility  0.00 [0.00-0.00] 51 0.00 [0.00-0.00] 343 0.00 [0.00-0.00] 394 0.00 [0.00-0.00] 23 0.00 [0.00-0.00] 72 0.00 [0.00-0.00] 95 
Private not-for-profit health facility 0.39 [0.39-0.39] 1 0.00 [0.00-0.00] 2 0.00 [0.00-0.00] 3 0.00 [0.00-0.00] 3 0.00 [0.00-0.27] 13 0.00 [0.00-0.00] 16 
Private for-profit outlet             
   Health facility/pharmacy 0.98 [0.59-1.96] 186 1.17 [0.59-1.96] 54 1.17 [0.59-1.96] 240 0.00 [0.00-0.98] 13 0.59 [0.59-0.59] 5 0.59 [0.59-0.59] 18 
   Drug store 0.78 [0.59-0.78] 28 0.59 [0.23-1.17] 22 0.59 [0.27-1.17] 50 0.59 [0.59-3.13] 3 0.98 [0.98-0.98] 1 0.98 [0.59-0.98] 4 
   General retailer/itinerant - 0 - 0 - 0 - 0 0.00 [0.00-0.00] 1 0.00 [0.00-0.00] 1 
   Total 0.78 [0.59-1.56] 214 0.78 [0.27-1.17] 76 0.78 [0.39-1.17] 290 0.59 [0.00-1.17] 16 0.59 [0.59-0.98] 7 0.59 [0.59-0.98] 23 
Community health worker  0 0.00 [0.00-0.00] 4 0.00 [0.00-0.00] 4 0.00 [0.00-0.00] 1 0.00 [0.00-0.00] 43 0.00 [0.00-0.00] 44 
Zanzibar – Total 0.41 [0.00-0.58] 125 0.00 [0.00-0.00] 81 0.29 [0.00-0.58] 206 0.00 [0.00-0.58] 7 0.00 [0.00-0.58] 4 0.00 [0.00-0.58] 11 
Public health facility  0.00 [0.00-0.00] 36 0.00 [0.00-0.00] 61 0.00 [0.00-0.00] 97 0.00 [0.00-0.00] 5 0.00 [0.00-0.00] 3 0.00 [0.00-0.00] 8 
Private not-for-profit health facility - 0 - 0 - 0 - 0 - 0 - 0 
Private for-profit outlet             
   Health facility/pharmacy 0.50 [0.32-0.58] 48 0.44 [0.29-0.58] 10 0.47 [0.29-0.58] 58 1.17 [0.58-1.75] 2  0 1.17 [0.58-1.75] 2 
   Drug store 0.52 [0.32-0.58] 40 0.58 [0.47-0.58] 10 0.58 [0.35-0.58] 50 - 0 1.17 [1.17-1.17] 1 1.17 [1.17-1.17] 1 
   General retailer/itinerant 0.58 [0.58-0.58] 1 0.00 [0.00-0.00] 0 0.58 [0.58-0.58] 1 - 0  0 - 0 
   Total 0.52 [0.35-0.58] 89 0.47 [0.29-0.58] 20 0.47 [0.29-0.58] 109 1.17 [0.58-1.75] 2 1.17 [1.17-1.17] 1 1.17 [0.58-1.75] 3 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Note: Pediatric formulations (PFs) are packages intended for children. In the calculation of median cost, we include only packages whose age (weight) range includes a 2 year old (10 kg) child. 
na = Not applicable, IQR = Interquartile range 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.3.9 shows the median price in private for-profit outlets of the most popular antimalarial 
which is not a QAACT in terms of sales volumes, for tablets and all dosage forms separately. 
This variable is used in the calculation of Success Benchmark 2. The most popular antimalarial 
which is not a QAACT in both tablet and all dosage forms was SP in Ghana, Kenya, Nigeria, 
Tanzania mainland and Uganda; amodiaquine in Zanzibar; and chloroquine in Madagascar and 
Niger. Due to the predominance of tablets as a dosage form, the same or very similar prices for 
tablets and all dosage forms were observed in all countries other than Zanzibar, where the price 
of all dosage forms was much higher. For tablets, median prices varied from USD 0.31 in Ghana 
to USD 0.94 in Tanzania mainland. Prices were similar in urban and rural areas except in Kenya 
and Zanzibar (where they were higher in urban areas) and Niger (where the rural price was 
slightly higher).  
 
Tables 2.3.10 and 2.3.11 show the ratio of the cost to patients of QAACTs with the AMFm logo 
to the cost to patients of the most popular antimalarial which is not a QAACT for tablets and all 
dosage forms for private for-profit outlets at endline. These provide the data for Success 
Benchmark 2. Interpretation is focused on Table 2.3.10, as the comparison with QAACTs is 
most appropriate for tablet forms. The ratio was lowest in Kenya and Tanzania mainland (1.0); 
1.5 in Zanzibar, 1.6 in Madagascar and 2.5 in Niger; 3 or above in Ghana, Nigeria and Uganda. 
The low ratio in Tanzania mainland reflects the relatively high price of the most popular 
antimalarial which is not a QAACT, while in Kenya it reflects the relatively low price of 
QAACTs.  
 
Tables 2.3.12 and 2.3.13 present the ratio of the cost to patients of QAACTs with the AMFm 
logo to the cost to patients of artemisinin monotherapies for tablets and for all oral dosage forms. 
Interpretation focuses on the former. These data are used to assess Success Benchmark 3. The 
number of observations for artemisinin monotherapy is too low to make valid comparisons, 
except in Ghana and Nigeria where QAACTs with the logo were clearly less costly than oral 
AMT for tablets and all dosage forms.  
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Table 2.3.9: Cost to patients in private for-profit outlets, of the most popular antimalarial which is not a QAACT in terms of private for-profit outlet 
sales volumes for TABLETS and ALL DOSAGE FORMS in 2010 US dollars at endline 2011 
Median cost to patients in private for-profit outlets, of one adult equivalent treatment dose (AETD) of the most popular antimalarial that is not a quality-assured ACT in terms of 
private for-profit sales volumes, for TABLETS and ALL DOSAGE FORMS, by location, according to country  
Country 
TABLETS ALL DOSAGE FORMS 
Urban Rural Total Urban Rural Total 
Median Cost  
[IQR] 
No. of  
Products 
Median Cost  
[IQR] 
No. of  
products 
Median Cost  
[IQR] 
No. of 
products 
Median Cost  
[IQR] 
No. of  
products 
Median Cost  
[IQR] 
No. of  
products 
Median Cost  
[IQR] 
No. of  
products 
Ghana 0.31 [0.31-0.63] 532 0.31 [0.31-0.38] 134 0.31 [0.31-0.50] 666 0.31 [0.31-0.63] 532 0.31 [0.31-0.38] 134 0.31 [0.31-0.50] 666 
Kenya  0.69 [0.46-1.38] 609 0.46 [0.35-0.69] 364 0.52 [0.35-0.86] 973 0.69 [0.46-1.38] 612 0.46 [0.35-0.69] 369 0.52 [0.35-0.92] 981 
Madagascar 0.32 [0.32-0.32] 829 0.32 [0.32-0.32] 718 0.32 [0.32-0.32] 1,547 0.32 [0.32-0.32] 864 0.32 [0.32-0.32] 740 0.32 [0.32-0.32] 1,604 
Niger 0.41 [0.36-0.50] 631 0.50 [0.40-0.60] 420 0.48 [0.37-0.60] 1,051 0.48 [0.36-0.60] 731 0.60 [0.41-0.69] 519 0.50 [0.37-0.62] 1,250 
Nigeria 0.47 [0.35-0.89] 2,296 0.47 [0.41-0.89] 1,004 0.47 [0.35-0.89] 3,300 0.47 [0.35-0.71] 2,098 0.47 [0.41-0.71] 947 0.47 [0.35-0.71] 3,045 
Tanzania – mainland 0.94 [0.75-1.41] 1,735 0.94 [0.62-0.94] 284 0.94 [0.62-1.12] 2,019 0.94 [0.94-1.41] 2,230 0.94 [0.62-0.94] 322 0.94 [0.75-1.41] 2,552 
Uganda 0.59 [0.59-0.78] 871 0.59 [0.59-0.78] 646 0.59 [0.59-0.78] 1,517 0.59 [0.59-0.78] 871 0.59 [0.59-0.78] 646 0.59 [0.59-0.78] 1,517 
Zanzibar 0.83 [0.52-1.40] 36 0.52 [0.52-1.05] 9 0.79 [0.52-1.40] 45 2.10 [0.87-2.62] 96 2.36 [1.75-2.62] 32 2.10 [1.05-2.62] 128 
Note: An AETD is the number of milligrams (mg) of a given drug that is required to treat a 60 kg adult. AETDs were calculated for every audited antimalarial. The most popular antimalarial which is 
not a QAACT in terms of private-for-profit outlet sales volumes for TABLETS is as follows: Ghana - SP, Kenya - SP, Madagascar - CQ, Niger - CQ, Nigeria - SP, Tanzania mainland - SP, Uganda - 
SP, Zanzibar - AQ. The most popular antimalarial which is not a QAACT in terms of private for-profit outlet sales volumes for ALL DOSAGE FORMS is as follows: Ghana - SP, Kenya - SP, 
Madagascar - CQ, Niger - CQ, Nigeria - SP, Tanzania mainland - SP, Uganda - SP, Zanzibar - AQ.  
 na = Not applicable, IQR = Interquartile range 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
 
Table 2.3.10: Ratio of the cost to patients of quality-assured ACTs with the AMFm logo to the cost to patients of the most popular antimalarial which is 
not a QAACT for TABLETS in private for-profit outlets in 2010 US dollars, at endline, 2011 
Ratio of the median cost to patients of one adult equivalent treatment dose (AETD) of quality-assured ACTs with the AMFm logo in private for-profit outlets to the median cost to 
patients of one AETD for TABLETS of the most popular antimalarial that is not a quality-assured ACT in private for-profit outlets, according to country 
 
Urban Rural Total 
Ratio 
No. of 
observations of 
copaid QAACTs 
No. of 
observations of 
most popular non-
QAACT 
antimalarial Ratio 
No. of 
observations of 
copaid QAACTs 
No. of 
observations of 
most popular non-
QAACT 
antimalarial Ratio 
No. of 
observations of 
copaid QAACTs 
No. of 
observations of 
most popular non-
QAACT 
antimalarial 
Ghana 3.2 1,185 532 3 232 134 3 1,417 666 
Kenya  0.9 1,495 609 1 392 364 1 1,887 973 
Madagascar 1.6 399 829 1.9 455 718 1.6 854 1,547 
Niger 2.9 302 631 2.4 46 420 2.5 348 1,051 
Nigeria 3.1 1,194 2,098 3.1 443 947 3.1 1,637 3,045 
Tanzania – mainland 1.3 1,411 1,735 1 198 284 1 1,609 2,019 
Uganda 3.3 1,768 871 3.3 1,064 646 3.3 2,832 1,517 
Zanzibar 1.4 374 36 1.7 98 9 1.5 472 45 
Note: The most popular antimalarial which is not a QAACT in terms of private-for-profit outlet sales volumes for TABLETS is as follows: Ghana - SP, Kenya - SP, Madagascar - CQ, Niger - CQ, 
Nigeria - SP, Tanzania mainland - SP, Uganda - SP, Zanzibar - AQ.  
Source: AMFm Phase 1 Independent Evaluation Outlet Survey 
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Table 2.3.11: Ratio of the cost to patients of quality-assured ACTs with the AMFm logo to the cost to patients of the most popular antimalarial which is 
not a QAACT for ALL DOSAGE FORMS in private for-profit outlets in 2010 US dollars, at endline, 2011 
Ratio of the median cost to patients of one adult equivalent treatment dose (AETD) of quality-assured ACTs with the AMFm logo in private for-profit outlets to the median cost to 
patients of one AETD for ALL DOSAGE FORMS of the most popular antimalarial that is not a quality-assured ACT in private for-profit outlets, according to country 
 
Urban Rural Total 
Ratio 
No. of 
observations of 
copaid QAACTs 
No. of 
observations of 
most popular non-
QAACT 
antimalarial Ratio 
No. of 
observations of 
copaid QAACTs 
No. of 
observations of 
most popular non-
QAACT 
antimalarial Ratio 
No. of 
observations of 
copaid QAACTs 
No. of 
observations of 
most popular non-
QAACT 
antimalarial 
Ghana 3.2 1,185 532 3 232 134 3.0 1,417 666 
Kenya  0.9 1,495 612 1.0 392 369 1.0 1,887 981 
Madagascar 1.6 399 864 1.9 455 740 1.6 854 1,604 
Niger 2.5 302 731 2.0 46 519 2.4 348 1,250 
Nigeria 3.1 1,194 2,296 3.1 443 1,004 3.1 1,637 3,300 
Tanzania – mainland 1.3 1,411 2,230 1.0 198 322 1.0 1,609 2,552 
Uganda 3.3 1,768 871 3.3 1,064 646 3.3 2,832 1,517 
Zanzibar 0.6 374 96 0.4 98 32 0.6 472 128 
Note: The most popular antimalarial which is not a QAACT in terms of private for-profit outlet sales volumes for ALL DOSAGE FORMS is as follows: Ghana - SP, Kenya - SP, Madagascar - CQ, 
Niger - CQ, Nigeria - SP, Tanzania mainland - SP, Uganda - SP, Zanzibar - AQ.  
Source: AMFm Phase 1 Independent Evaluation Outlet Survey 
 
Table 2.3.12: Ratio of the cost to patients of quality-assured ACTs with the AMFm logo to the cost to patients of artemisinin monotherapy TABLETS in 
private for-profit outlets in 2010 US dollars, at endline, 2011  
Ratio of the median cost to patients of one ADULT equivalent treatment dose (AETD) of quality-assured ACTs with the AMFm logo in private for-profit outlets (n) to the median 
cost to patients of one AETD for TABLETS of artemisinin monotherapies in private-for-profit outlets, according to country 
 
Urban Rural Total 
Ratio 
No. of 
observations of 
copaid QAACTs 
No. of 
observations of 
artemisinin 
monotherapy 
tablets Ratio 
No. of 
observations of 
copaid QAACTs 
No. of 
observations of 
artemisinin 
monotherapy 
tablets Ratio 
No. of 
observations of 
copaid QAACTs 
No. of 
observations of 
artemisinin 
monotherapy 
tablets 
Ghana 0.5 1,185 223 0.5 232 39 0.5 1,417 262 
Kenya  0.2 1,495 2 0.1 392 1 0.2 1,887 3 
Madagascar - 399 0 - 455 0 - 854 0 
Niger 0.5 302 19 - 46 0 0.5 348 19 
Nigeria 0.6 1,194 509 0.5 443 155 0.6 1,637 664 
Tanzania – mainland 0.0 1,411 2 - 198 0 - 1,609 2 
Uganda 0.1 1,768 1 - 1,064 0 0.1 2,832 1 
Zanzibar 0.2 374 2 0.2 98 1 0.2 472 3 
Source: AMFm Phase 1 Independent Evaluation Outlet Survey 
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Table 2.3.13: Ratio of the cost to patients of quality-assured ACTs with the AMFm logo to the cost to patients of artemisinin monotherapy for ALL 
ORAL DOSAGE FORMS in private for-profit outlets in 2010 US dollars, at endline, 2011  
Ratio of the median cost to patients of one ADULT equivalent treatment dose (AETD) of quality-assured ACTs with the AMFm logo in private for-profit outlets (n) to the median 
cost to patients of one AETD for ALL ORAL DOSAGE FORMS of artemisinin monotherapies in private-for-profit outlets, according to country 
 
Urban Rural Total 
Ratio 
No. of 
observations of 
copaid QAACTs 
No. of artemisinin 
monotherapy 
observations (all oral 
dosage forms) Ratio 
No. of observations of 
copaid QAACTs 
No. of artemisinin 
monotherapy 
observations (all oral 
dosage forms) Ratio 
No. of 
observations of 
copaid QAACTs 
No. of artemisinin 
monotherapy 
observations (all 
oral dosage forms) 
Ghana 0.2 1,185 581 0.2 232 96 0.2 1,417 677 
Kenya  0.2 1,495 3 0.1 392 1 0.2 1,887 4 
Madagascar - 399 0 - 455 0 - 854 0 
Niger 0.3 302 21 - 46 0 0.3 348 21 
Nigeria 0.5 1,194 736 0.4 443 218 0.5 1,637 954 
Tanzania – mainland - 1,411 2 - 198 0 0.0 1,609 2 
Uganda 0.1 1,768 1 - 1,064 0 0.1 2,832 1 
Zanzibar 0.2 374 2 0.2 98 1 0.2 472 3 
Source: AMFm Phase 1 Independent Evaluation Outlet Survey 
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2.3.2 Gross markup between purchase price and retail selling price 
Table 2.3.14 shows the percent markup between the outlet purchase price and the retail selling 
price for non-artemisinin therapies. Note that these are gross markups that do not take into 
account the cost of doing business. Some of the variation in percentage markups may reflect 
variations in the composition of nATs by dosage form, which has an important influence on their 
price. Interpretation focuses on the private for-profit sector because the key policy questions 
relate to transmission of the subsidy to customers in these outlets. At endline, the percent markup 
ranged from 41% in Nigeria to 85% in Niger. In most countries, private for-profit markups were 
similar between rural and urban areas, with the exception of Niger and Zanzibar where they were 
higher in rural areas than in urban areas (92% vs. 67% in Niger and 63% vs. 50% in Zanzibar) 
and Tanzania mainland where they were higher in urban areas (82% vs. 67%). There was no 
change between baseline and endline other than in Niger and Tanzania mainland, which saw 
modest increases.  
 
Table 2.3.15 shows the percent markup between outlet purchase price and retail selling price for 
artemisinin monotherapies. At endline in the private for-profit sector, the markup ranged from 
25% in Nigeria to 67% in Uganda. Although the percent markups for AMTs were generally 
lower than for nAT, this does not necessarily translate into a lower absolute markup because 
AMT prices tend to be higher. There were no observations of AMT in Madagascar. There were 
few or no observations in rural areas in Niger, Tanzania mainland and Zanzibar. Elsewhere, 
median prices were similar between urban and rural areas. Levels of markup were little changed 
between baseline and endline.  
 
Table 2.3.16 shows the percent markup between outlet purchase price and retail selling price for 
non-quality-assured ACTs. At endline in private for-profit outlets, the markup ranged from 20% 
in Nigeria to 50% in Uganda. These levels are very similar to the markups on AMTs. No 
differences were observed between urban and rural areas. Between baseline and endline, 
markups increased slightly in Tanzania mainland (from 39% to 47%) and in Zanzibar (from 25% 
to 41%), and decreased in Uganda from 67% to 50%.  
 
Table 2.3.17 shows the percent markup between outlet purchase price and retail selling price for 
QAACTs. At endline, percentage markups on QAACTs in private for-profit outlets varied from 
35% in Niger to 127% in Uganda. They were very similar in all countries between urban and 
rural areas. Between baseline and endline, markups increased somewhat (except in Niger), 
bringing them up to a level similar to those of nATs. With the dramatic fall in the median 
QAACT price in most countries, this may not imply any increase in absolute markups.  
 
Table 2.3.18 disaggregates markups between QAACTs with and without the logo at endline. In 
private for-profit outlets, QAACTs without the AMFm logo carried a lower percentage markup 
in all countries except Madagascar and Niger, where the markups are the same on both types of 
product. The lower percent markups on QAACTs without the logo are to be expected given their 
generally higher absolute price.  
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Table 2.3.14: Gross markup between purchase price and retail selling price of non-artemisinin therapy at baseline (2010) and endline (2011) 
Median percentage markup between purchase price and retail selling price of non-artemisinin monotherapy or non-artemisinin combination therapy, by urban-rural location and type of outlet, 
according to country 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
Median markup 
[IQR] 
No. of 
 products 
Median markup  
[IQR] 
No. of 
 products Median markup [IQR] 
No. of 
products 
Median markup 
[IQR] 
No. of 
products 
Median markup 
[IQR] 
No. of 
 products 
Median markup 
[IQR] 
No. of 
products 
Ghana - Total 50.0 [33.3-66.7] 783 42.9 [29.0-66.7] 828 46.7 [30.0-66.7] 1,611 47.1 [25.0-66.7] 467 50.0 [25.0-66.7] 256 47.1 [25.0-66.7] 723 
Public health facility  0.0 [0.0-33.3] 26 4.7 [0.0-38.9] 92 0.0 [0.0-33.3] 118 0.0 [0.0-25.0] 46 0.0 [0.0-13.6] 71 0.0 [0.0-17.6] 117 
Private not-for-profit health facility - 0 33.3 [0.0-92.3] 17 33.3 [0.0-92.3] 17 25.0 [16.3-58.7] 9 0.0 [0.0-41.7] 8 25.0 [0.0-50.0] 17 
Private for-profit outlet             
   Health facility/pharmacy 41.2 [30.1-56.3] 378 50.0 [33.3-66.7] 114 42.9 [31.7-66.7] 492 38.9 [25.0-57.9] 211 25.0 [17.6-66.7] 23 38.9 [25.0-57.9] 234 
   Drug store 56.3 [33.3-71.4] 373 50.0 [33.3-66.7] 599 50.0 [33.3-66.7] 972 50.0 [31.6-66.7] 201 50.0 [33.3-66.7] 150 50.0 [31.6-66.7] 351 
   General retailer/itinerant 42.9 [33.3-42.9] 6 108.3 [25.0-284.6] 6 42.9 [25.0-284.6] 12 - 0 50.0 [25.0-50.0] 4 50.0 [25.0-50.0] 4 
   Total 50.0 [33.3-66.7] 757 50.0 [33.3-66.7] 719 50.0 [33.3-66.7] 1,476 49.3 [25.0-66.7] 412 50.0 [28.6-66.7] 177 50.0 [26.3-66.7] 589 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Kenya - Total 38.5 [20.0-66.7] 1,405 38.9 [11.1-71.4] 1,432 38.9 [11.1-68.8] 2,837 50.0 [25.0-100.0] 1,272 33.3 [0.0-66.7] 1,377 33.3 [0.0-75.0] 2,649 
Public health facility  0.0 [0.0-0.0] 271 0.0 [0.0-0.0] 590 0.0 [0.0-0.0] 861 0.0 [0.0-0.0] 234 0.0 [0.0-0.0] 735 0.0 [0.0-0.0] 969 
Private not-for-profit health facility 42.9 [0.0-149.1] 32 0.0 [-100.0-0.0] 21 0.0 [-100.0-33.3] 53 40.0 [0.0-71.4] 28 0.0 [0.0-76.5] 56 0.0 [0.0-75.8] 84 
Private for-profit outlet             
   Health facility/pharmacy 42.9 [25.0-76.5] 456 63.6 [27.3-100.0] 177 50.0 [25.0-100.0] 633 56.3 [31.6-140.0] 501 66.7 [33.3-100.0] 175 60.0 [33.3-100.0] 676 
   Drug store 50.0 [33.3-66.7] 508 50.0 [25-85.2] 405 50.0 [27.3-76.5] 913 57.9 [31.6-100.0] 415 50.0 [30.0-75.0] 282 50.0 [31.6-76.5] 697 
   General retailer/itinerant 38.9 [25.0-87.5] 134 34.6 [20-81.8] 224 35.1 [20.0-83.8] 358 33.3 [20.0-78.6] 94 33.3 [20.0-66.7] 129 33.3 [20.0-66.7] 223 
   Total 44.0 [28.6-71.4] 1,098 50.0 [25-97.4] 806 48.1 [25.0-85.2] 1,904 53.8 [30.2-100.0] 1,010 50.0 [25.0-81.8] 586 50.0 [28.6-87.5] 1,596 
Community health worker 66.7 [66.7-111.1] 4 50.0 [0.0-150.0] 15 50.0 [0.0-150.0] 19 - 0 - 0 - 0 
Madagascar - Total 66.7 [37.9-100.0] 1,757 66.7 [35.1-81.8] 1,351 66.7 [35.6-100.0] 3,108 66.7 [35.0-66.7] 1,047 66.7 [25.0-100.0] 1,819 66.7 [25.6-100.0] 2,866 
Public health facility  33.2 [0.0-35.0] 82 0.0 [0.0-35.3] 491 7.7 [0.0-35.1] 573 15.1 [0.0-30.9] 77 0.0 [0.0-15.2] 675 0.0 [0.0-15.2] 752 
Private not-for-profit health facility 34.1 [20.0-35.0] 8 - 0 34.1 [20.0-35.0] 8 20.0 [9.1-60.0] 14 15.4 [14.3-448.6] 5 20.0 [9.1-448.6] 19 
Private for-profit outlet             
   Health facility/pharmacy 38.0 [16.7-66.7] 362 66.7 [50.0-100.0] 17 50.0 [25.0-81.8] 379 38.9 [34.9-55.6] 206 66.7 [38.9-100.0] 23 40.0 [35.0-71.4] 229 
   Drug store 81.8 [53.8-150.0] 110 50.0 [33.3-77.8] 595 66.7 [42.9-114.3] 705 42.9 [30.0-60.0] 105 50.0 [33.3-78.6] 733 50.0 [33.3-75.0] 838 
   General retailer/itinerant 66.7 [66.7-100.0] 1,194 66.7 [42.9-100.0] 247 66.7 [50.0-100.0] 1,441 66.7 [66.7-100.0] 645 66.7 [60.0-100.0] 376 66.7 [60.0-100.0] 1,021 
   Total 66.7 [51.5-100.0] 1,666 66.7 [42.9-100.0] 859 66.7 [42.9-100.0] 2,525 66.7 [38.8-66.7] 956 66.7 [42.9-100.0] 1,132 66.7 [42.9-100.0] 2,088 
Community health worker 0.0 [0.0-0.0] 1 66.7 [66.7-66.7] 1 66.7 [66.7-66.7] 2 - 0 100.0 [25.0-100.0] 7 100.0 [25.0-100.0] 7 
Niger – Total 50.0 [33.3-100.0] 1,789 66.7 [33.3-142.7] 1,576 66.7 [33.3-122.2] 3,365 51.5 [33.3-122.2] 1,585 66.7 [25.0-150.0] 941 66.7 [25.0-150.0] 2,526 
Public health facility  0.0 [0.0-0.0] 179 0.0 [0.0-0.0] 633 0.0 [0.0-0.0] 812 0.0 [0.0-0.1] 220 0.0 [0.0-0.0] 411 0.0 [0.0-0.0] 631 
Private not-for-profit health facility 35.1 [35.1-40.0] 3 - 0 35.1 [35.1-40.0] 3 - 0 -100.0 [-100.0- -100.0] 3 -100.0 [-100.0- -100.0] 3 
Private for-profit outlet             
   Health facility/pharmacy 35.1 [35.0-35.1] 687 50.0 [33.3-62.5] 28 35.1 [35.0-35.2] 715 35.0 [35.0-35.1] 528 66.7 [35.1-100.0] 3 35.0 [35.0-35.1] 531 
   Drug store 50.0 [33.3-66.7] 29 33.3 [18.4-66.7] 19 33.3 [20.0-66.7] 48 38.3 [33.3-50.0] 52 38.9 [38.3-38.9] 3 38.9 [35.1-41.2] 55 
   General retailer/itinerant 66.7 [33.3-100.0] 890 87.5 [50.0-150.0] 894 81.8 [50.0-150.0] 1,784 87.5 [42.9-150.0] 785 100.0 [50.0-166.7] 521 92.3 [42.9-150.0] 1,306 
   Total 50.0 [35-100.0] 1,606 87.5 [50.0-150.0] 941 66.7 [40.0-127.3] 2,547 66.7 [35.0-138.1] 1,365 92.3 [42.9-150.0] 527 85.2 [35.1-150.0] 1,892 
Community health worker 100.0 [100.0-100.0] 1 25.0 [25.0-50.0] 2 50.0 [25.0-50.0] 3 - 0 - 0 - 0 
Nigeria - Total 40.0 [25.0-60.0] 6,982 33.3 [25.0-60.0] 1,623 40.0 [25.0-60.0] 8,605 40.0 [25.0-66.7] 5,344 42.9 [25.0-66.7] 2,245 41.2 [25.0-66.7] 7,589 
Public health facility  0.0 [0.0-20.0] 342 19.0 [0.0-50.0] 70 19.0 [0.0-42.9] 412 0.0 [0.0-31.6] 65 33.3 [0.0-100.0] 71 25.0 [0.0-80.0] 136 
Private not-for-profit health facility 40.0 [15.4-66.7] 13 25.0 [8.7-50.0] 6 25.0 [8.7-50.0] 19 66.7 [33.3-100.0] 15 225.0 [150.0-300.0] 2 66.7 [33.3-100.0] 17 
Private for-profit outlet             
   Health facility/pharmacy 36.4 [25.0-57.9] 2,466 47.1 [38.9-66.7] 59 42.9 [27.3-60.0] 2,525 37.5 [25.0-53.8] 401 66.7 [42.9-114.3] 48 40.0 [27.7-62.5] 449 
   Drug store 40.0 [25.0-60.0] 3,847 40.0 [25.0-60.0] 1,423 40.0 [25.0-60.0] 5,270 41.2 [25.0-66.7] 4,673 42.9 [25.0-60.0] 2,062 41.2 [25.0-66.7] 6,735 
   General retailer/itinerant 33.3 [20.0-50.0] 306 27.3 [20.0-42.9] 51 27.3 [20.0-50.0] 357 50.0 [25.9-66.7] 190 42.9 [33.3-66.7] 56 45.5 [27.3-66.7] 246 
   Total 40.0 [25.0-60.0] 6,619 38.9 [25.0-60.0] 1,533 40.0 [25.0-60.0] 8,152 40.0 [25.0-66.7] 5,264 42.9 [25.0-62.8] 2,166 41.2 [25.0-66.7] 7,430 
Community health worker 20.8 [10.7-50.0] 8 42.9 [0.0-50.0] 14 42.9 [0.0-50.0] 22 - 0 40.0 [25.0-40.0] 6 40.0 [25.0-40.0] 6 
Tanzania - mainland - Total 66.7 [42.9-100.0] 1,534 50.0 [17.6-100] 717 53.8 [25.0-100.0] 2,251 81.8 [50.0-100.0] 2,131 66.7 [25.0-100.0] 382 70.5 [41.2-100.0] 2,513 
Public health facility  0.0 [0.0-0.0] 4 0.0 [0.0-0.0] 92 0.0 [0.0-0.0] 96 19.0 [0.0-66.7] 5 0.0 [0.0-0.0] 26 0.0 [0.0-0.0] 31 
Private not-for-profit health facility 122.2 [25.0-185.7] 26 33.3 [0.0-61.3] 43 42.9 [11.1-100.0] 69 - 0 16.7 [0.0-33.3] 2 16.7 [0.0-33.3] 2 
Private for-profit outlet             
   Health facility/pharmacy 53.8 [33.3-100.0] 1,155 66.7 [33.3-100.0] 58 53.8 [33.3-100.0] 1,213 77.8 [50.0-122.2] 1,353 108.3 [100.0-122.2] 78 87.5 [50.0-122.2] 1,431 
   Drug store 66.7 [50.0-100.0] 349 60.0 [42.9-100.0] 467 66.7 [42.9-100.0] 816 81.8 [50.0-100.0] 768 66.7 [33.3-100.0] 265 76.5 [42.9-100.0] 1,033 
   General retailer/itinerant - 0 38.9 [11.1-100.0] 55 38.9 [11.1-100.0] 55 87.5 [66.7-150.0] 5 0.0 [-6.3-50.0] 11 0.0 [-6.3-50.0] 16 
   Total 66.7 [48.1-100.0] 1,504 60.0 [33.3-100.0] 580 66.7 [42.9-100.0] 2,084 81.8 [50.0-100.0] 2,126 66.7 [33.3-100.0] 354 76.5 [42.9-100.0] 2,480 
Community health worker - 0 366.7 [233.3-500.0] 2 366.7 [233.3-500.0] 2 - 0 - 0 - 0 
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Table 2.3.14: Cont. 
Median percentage markup between purchase price and retail selling price of non-artemisinin monotherapy or non-artemisinin combination therapy, by urban-rural location and type of outlet, 
according to country 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban Rural Total 
Median markup 
[IQR] 
No. of  
Products 
Median markup  
[IQR] 
No. of  
products Median markup [IQR] 
No. of  
products 
Median markup 
[IQR] 
No. of  
products 
Median markup 
[IQR] 
No. of 
 products 
Median markup 
[IQR] 
No. of 
products 
Uganda - Total 66.7 [38.9-122.2] 1,436 50.0 [25.0-100.0] 4,221 51.5 [25.0-100.0] 5,657 66.7 [33.3-127.3] 3,351 50.0 [25.0-100.0] 3,588 52.2 [25.0-100.0] 6,939 
Public health facility  0.0 [0.0-0.0] 167 0.0 [0.0-0.0] 1,399 0.0 [0.0-0.0] 1,566 0.0 [0.0-0.0] 259 0.0 [0.0-0.0] 1,104 0.0 [0.0-0.0] 1,363 
Private not-for-profit health facility -2.8 [-5.6-644.4] 4 42.9 [-13.1-57.7] 37 0.0 [-5.6-57.7] 41 40.0 [0.0-166.0] 19 36.4 [0.0-78.6] 56 36.4 [0.0-86.7] 75 
Private for-profit outlet             
   Health facility/pharmacy 87.5 [50.0-150.0] 1,117 66.7 [42.9-122.2] 966 75.0 [50.0-150.0] 2,083 81.8 [42.9-150.0] 2,227 76.5 [40.0-150.0] 931 78.6 [40.0-150.0] 3,158 
   Drug store 66.7 [42.9-108.3] 147 50.0 [33.3-100.0] 1,798 53.8 [33.3-100.0] 1,945 53.8 [33.3-100.0] 845 53.8 [33.3-100.0] 1,489 53.8 [33.3-100.0] 2,334 
   General retailer/itinerant - 0 42.9 [25.0-100.0] 20 42.9 [25.0-100.0] 20 33.3 [33.3-33.3] 1 20.0 [7.1-100.0] 7 20.0 [7.1-100.0] 8 
   Total 76.5 [50.0-127.3] 1,264 57.9 [33.3-100.0] 2,784 66.7 [33.3-105.9] 4,048 66.7 [36.4-150.0] 3,073 60.0 [33.3-106.4] 2,427 66.7 [33.3-109.4] 5,500 
Community health worker 185.7 1 -80.0  1 185.7 [-80.0-185.7] 2 - 0 47.1 [47.1-47.1] 1 47.1 [47.1-47.1] 1 
Zanzibar - Total 50.0 [0.0-66.7] 182 0.0 [0.0-50.0] 130 33.3 [0.0-66.7] 312 50.0 [25.0-66.7] 113 42.9 [0.0-80.0] 57 50.0 [25.0-70.0] 170 
Public health facility  0.0 [0.0-0.0] 53 0.0 [0.0-0.0] 86 0.0 [0.0-0.0] 139 0.0 [0.0-0.0] 20 0.0 [0.0-0.0] 19 0.0 [0.0-0.0] 39 
Private not-for-profit health facility 0.0 [0.0-0.0] 1 25.0 [25.0-25.0] 1 12.5 [0.0-25.0] 2 - 0 - 0 - 0 
Private for-profit outlet             
   Health facility/pharmacy 66.7 [42.9-100.0] 67 100.0 [53.8-122.2] 21 66.7 [50.0-107.1] 88 50.0 [42.9-70.0] 41 66.7 [42.9-100.0] 21 53.8 [42.9-87.5] 62 
   Drug store 50.0 [33.3-66.7] 60 50.0 [42.9-66.7] 21 50.0 [38.9-66.7] 81 50.0 [42.9-87.5] 51 53.8 [40.0-114.3] 17 50.0 [42.9-93.8] 68 
   General retailer/itinerant 25.0 [25.0-25.0] 1 -3.8 [-3.8- -3.8] 1 10.6 [-3.8-25.0] 2 100.0 [100.0-100.0] 1 - 0 100.0 [100.0-100.0] 1 
   Total 54.7 [38.2-76.5] 128 53.8 [50.0-100.0] 43 53.8 [42.9-87.5] 171 50.0 [42.9-76.5] 93 63.3 [42.9-100.0] 38 50.0 [42.9-100.0] 131 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Note: Nigeria baseline data collection was conducted in 2009. 
IQR = Interquartile range 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.3.15: Gross markup between purchase price and retail selling price of artemisinin monotherapy at baseline (2010) and endline (2011) 
Median percentage markup between purchase price and retail selling price of artemisinin monotherapy, by urban-rural location and type of outlet, according to country 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
Median markup  
[IQR] 
No. of  
Products 
Median markup  
[IQR] 
No. of  
products 
Median markup  
[IQR] 
No. of  
products 
Median markup  
[IQR] 
No. of  
products 
Median markup 
 [IQR] 
No. of  
products 
Median markup 
[IQR] 
No. of  
products 
Ghana - Total 35.7 [25.0-50.0] 541 27.3 [20.0-40.0] 355 29.6 [20.0-40.0] 896 29.6 [20.0-40.0] 346 25.0 [16.7-33.3] 110 27.3 [18.7-39.5] 456 
Public health facility  23.3 [19.0-25.0] 13 20.0 [0.0-36.4] 35 20.0 [3.7-36.4] 48 25.0 [20.0-33.3] 12 25.0 [16.3-34.8] 31 25.0 [18.8-34.8] 43 
Private not-for-profit health facility 26.3 [12.5-40.0] 2 20.0 [-36.6-50.0] 7 20.0 [-36.6-50.0] 9 25.0 [25.0-26.3] 6 0.0 [-5.5-0.0] 2 25.0 [11.1-26.3] 8 
Private for-profit outlet             
   Health facility/pharmacy 41.6 [30.3-66.7] 357 33.3 [20.0-50.0] 79 38.9 [25.0-60.7] 436 36.4 [25.0-50.0] 231 25.0 [18.4-30.0] 21 35.1 [20.0-50.0] 252 
   Drug store 33.3 [20.0-40.0] 169 26.7 [20.0-38.9] 234 28.2 [20.0-39.1] 403 28 [20.0-36.4] 97 25.0 [16.7-33.3] 56 25.0 [16.7-36.4] 153 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 
   Total 35.7 [25.0-50.0] 526 28.0 [20.0-40.0] 313 30.4 [20.0-40.0] 839 30.4 [20.0-42.9] 328 25.0 [16.7-33.3] 77 28.0 [20.0-40.0] 405 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Kenya - Total 33.3 [20.0-45.5] 295 38.9 [25.0-50.0] 63 33.3 [23.1-50.0] 358 33.3 [25.0-50.0] 314 33.3 [12.0-50.0] 45 33.3 [18.8-50.0] 359 
Public health facility  45.5 [0.0-71.4] 7 0.0 [0.0-78.6] 5 45.5 [0.0-71.4] 12 9.1 [0.0-28.6] 16 0.0 [0.0-0.0] 6 0.0 [0.0-0.0] 22 
Private not-for-profit health facility 77.8 [50.0-100.0] 7 - 0 77.8 [50.0-100.0] 7 42.9 [31.9-50.9] 9 42.9 [33.3-207.7] 5 42.9 [31.9-207.7] 14 
Private for-profit outlet             
   Health facility/pharmacy 31.8 [20.0-41.2] 217 45.5 [28.4-50.0] 34 33.3 [22.7-50.0] 251 36.4 [25.0-57.1] 171 36.4 [25.0-50.0] 30 36.4 [25.0-50.0] 201 
   Drug store 33.3 [25.0-45.5] 64 38.9 [23.1-50.0] 24 36.8 [25.0-50.0] 88 33.3 [25.0-40.0] 118 10.0 [10.0-12.0] 4 26.4 [12.0-35.0] 122 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 
   Total 33.1 [20.0-42.9] 281 38.9 [25.0-50.0] 58 33.3 [23.1-50.0] 339 33.3 [25.0-50.0] 289 30.8 [12.0-50.0] 34 33.3 [20.0-50.0] 323 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Madagascar - Total 38.9 [38.9-38.9] 6 31.4 [31.4-31.4] 1 38.9 [38.9-38.9] 7 - 0 0.0 [0.0-0.0] 2 0.0 [0.0-0.0] 2 
Public health facility  - 0 - 0 - 0 - 0 0.0 [0.0-0.0] 2 0.0 [0.0-0.0] 2 
Private not-for-profit health facility - 0 - 0 - 0 - 0 - 0 - 0 
Private for-profit outlet   -          
   Health facility/pharmacy 38.9 [38.9-38.9] 6 - 0 38.9 [38.9-38.9] 6 - 0 - 0 - 0 
   Drug store - 0 31.4 [31.4-31.4] 1 31.4 [31.4-31.4] 1 - 0 - 0 - 0 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 
   Total 38.9 [38.9-38.9] 6 31.4 [31.4-31.4] 1 38.9 [38.9-38.9] 7 - 0 - 0 - 0 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Niger – Total 35.0 [35.0-35.0] 143 0.0 [0.0-0.0] 9 35.0 [24.5-35.0] 152 35 [33.3-35.0] 153 0.0 [0.0-0.0] 7 35.0 [0.0-35.0] 160 
Public health facility  - 0 0.0 [0.0-0.0] 9 0.0 [0.0-0.0] 9 0.0 [0.0-16.7] 5 0.0 [0.0-0.0] 7 0.0 [0.0-0.0] 12 
Private not-for-profit health facility - 0 - 0 - 0 - 0 - 0 - 0 
Private for-profit outlet             
   Health facility/pharmacy 35.0 [35.0-35.1] 136 - 0 35.0 [35.0-35.1] 136 35.0 [35.0-35.0] 139 - 0 35.0 [35.0-35.0] 139 
   Drug store 17.6 [17.6-17.6] 1 - 0 17.6 [17.6-17.6] 1 27.3 [20.0-36.4] 5 - 0 27.3 [20.0-36.4] 5 
   General retailer/itinerant 33.3 [0.0-33.3] 6 - 0 33.3 [0.0-33.3] 6 0.0 [0.0-33.3] 4 - 0 0.0 [0.0-33.3] 4 
   Total 35.0 [35.0-35.0] 143 - 0 35.0 [35.0-35.0] 143 35.0 [35.0-35.0] 148 - 0 35.0 [35.0-35.0] 148 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Nigeria - Total 21.6 [14.3-33.3] 1,632 29.6 [14.3-50.0] 198 22.4 [14.3-36.4] 1,830 25.0 [19.0-38.9] 840 25.0 [16.7-40.0] 247 25.0 [18.4-40.0] 1,087 
Public health facility  11.1 [5.3-21.1] 74 0.0 [0.0-22.2] 10 4.2 [0.0-22.2] 84 15.4 [0.0-20.0] 18 20.0 [10.0-42.9] 20 20.0 [2.1-33.3] 38 
Private not-for-profit health facility 28.0 [20.3-75.0] 10 - 0 28.0 [20.3-75] 10 71.4 [71.4-71.4] 4 50.0 1 50.0 [50.0-71.4] 5 
Private for-profit outlet             
   Health facility/pharmacy 28.6 [18.4-40.0] 915 29.9 [11.1-56.3] 24 29.9 [16.7-47.1] 939 28.2 [18.4-50.0] 126 42.9 [20.0-56.3] 10 28.2 [19.4-50.0] 136 
   Drug store 21.6 [14.3-33.3] 597 25.0 [14.3-50.0] 163 22.2 [14.3-36.4] 760 25.0 [20.0-38.9] 675 25.0 [16.7-36.4] 213 25.0 [18.6-38.9] 888 
   General retailer/itinerant 21.7 [13.6-25.0] 34 - 0 21.7 [13.6-25.0] 34 21.6 [20.0-44.4] 17 20.0 [20.0-36.4] 3 20.0 [20.0-40.0] 20 
   Total 21.6 [14.3-33.3] 1,546 29.9 [14.3-50.0] 187 22.4 [14.3-36.4] 1,733 25.6 [19.4-38.9] 818 25.0 [16.7-40.0] 226 25.0 [18.6-38.9] 1,044 
Community health worker 10.0 [0.0-20.0] 2 30.0 [30.0-30.0] 1 30.0 [20.0-30.0] 3 - 0 - 0 - 0 
Tanzania - mainland - Total 33.3 [10.0-50.0] 65 25.0 [25.0-25.0] 1 33.3 [10.0-50.0] 66 50.0 [25.0-61.3] 77 50.0 [0.0-63.6] 8 50.0 [20.0-61.3] 85 
Public health facility  0.0 [0.0-0.0] 2 - 0 0.0 [0.0-0.0] 2 - 0 - 0 - 0 
Private not-for-profit health facility 75.0 [36.4-75.0] 2 - 0 75.0 [36.4-75.0] 2 - 0 0.0 [0.0-0.0] 1 0.0 [0.0-0.0] 1 
Private for-profit outlet             
   Health facility/pharmacy 38.9 [25.0-50.0] 61 25.0 [25.0-25.0] 1 33.3 [25.0-50.0] 62 35.1 [20.0-58.3] 73 63.6 [63.6-63.6] 6 50.0 [20.0-63.6] 79 
   Drug store - 0 - 0 - 0 57.9 [50.0-61.3] 4 50.0 [50.0-50.0] 1 50.0 [50.0-57.9] 5 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 
   Total 38.9 [25-50] 61 25.0 [25.0-25.0] 1 33.3 [25.0-50.0] 62 50.0 [25.0-61.3] 77 50.0 [50.0-63.6] 7 50.0 [35.1-63.6] 84 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
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Table: 2.3.15: Cont. 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
Median markup  
[IQR] 
No. of  
Products 
Median markup  
[IQR] 
No. of  
products 
Median markup  
[IQR] 
No. of  
products 
Median markup  
[IQR] 
No. of  
products 
Median markup 
 [IQR] 
No. of  
products 
Median markup 
[IQR] 
No. of  
products 
Uganda - Total 78.6 [44.0-100.0] 256 60.0 [28.6-125.0] 122 75.0 [33.3-114.3] 378 60.0 [25.0-104.2] 444 0.0 [0.0-50.0] 204 16.7 [0.0-66.7] 648 
Public health facility  0.0 [0.0-0.0] 9 0.0 1 0.0 [0.0-0.0] 10 0.0 [0.0-0.0] 19 0.0 [0.0-0.0] 14 0.0 [0.0-0.0] 33 
Private not-for-profit health facility - 0 14.3 [14.3-16.7] 4 14.3 [14.3-16.7] 4 14.3 [-100.0-14.3] 3 33.3 [16.7-200.0] 6 33.3 [16.7-200.0] 9 
Private for-profit outlet             
   Health facility/pharmacy 94.4 [50.0-164.7] 243 80.0 [33.3-150.0] 91 87.5 [40.0-150.0] 334 66.7 [27.3-108.3] 405 66.7 [38.5-133.3] 106 66.7 [33.3-113.3] 511 
   Drug store 70.8 [53.3-76.8] 4 60.0 [33.3-100.0] 25 66.7 [33.3-80.0] 29 40.0 [20.0-87.5] 16 66.7 [50.0-100.0] 22 66.7 [50.0-100.0] 38 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 
   Total 78.6 [50.0-114.3] 247 75.0 [33.3-125.0] 116 76.5 [40.0-122.2] 363 60.0 [25-108.3] 421 66.7 [42.9-113.3] 128 66.7 [33.3-108.3] 549 
Community health worker - 0 0.0 1 0.0 1 0.0 1 0.0 [0.0-0.0] 56 0.0 [0.0-0.0] 57 
Zanzibar - Total 43.4 [25.0-50.0] 48 22.5 [7.1-44.3] 8 41.4 [22.5-50.0] 56 50.0 [25.0-66.7] 21 22.5 [16.7-50.0] 10 50.0 [20.0-66.7] 31 
Public health facility  0.0 [-100.0-11.1] 5 33.3 [0.0-66.7] 2 0.0 [-100.0-25.0] 7 0.0 [0.0-50.0] 3 0.0 [0.0-0.0] 2 0.0 [0.0-0.0] 5 
Private not-for-profit health facility - 0 - 0 - 0 - 0 41.7 [33.3-50.0] 2 41.7 [33.3-50.0] 2 
Private for-profit outlet             
   Health facility/pharmacy 45.8 [25.0-66.7] 39 20.0 [14.3-25.0] 5 43.4 [25.0-50.0] 44 50.0 [33.3-66.7] 17 50.0 [22.5-122.5] 4 50.0 [25.0-68.0] 21 
   Drug store 40.2 [22.4-50.0] 4 56.3 [56.3-56.3] 1 50.0 [30.4-50.0] 5 - 0 16.7 [16.7-16.7] 2 16.7 [16.7-16.7] 2 
   General retailer/itinerant - 0 - 0 - 0 100.0 1 - 0 100.0 1 
   Total 45.8 [25.0-50.0] 43 22.5 [14.3-32.4] 6 44.0 [25.0-50.0] 49 50.0 [33.3-68.0] 18 22.5 [16.7-75.0] 6 50.0 [25.0-71.5] 24 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Note: Nigeria baseline data collection was conducted in 2009. 
IQR = Interquartile range 
Source: AMFm Phase 1 Independent Evaluation Outlet Survey 
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Table 2.3.16: Gross markup between purchase price and retail selling price of non-quality-assured ACTs at baseline (2010) and endline (2011) 
Median percentage markup between purchase price and retail selling price of non-quality-assured ACTs, by urban-rural location and type of outlet, according to country 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
Median markup  
[IQR] 
No. of  
products 
Median markup  
[IQR] 
No. of  
products 
Median markup  
[IQR] 
No. of  
products 
Median markup 
[IQR] 
No. of  
products 
Median markup  
[IQR] 
No. of  
products 
Median markup  
[IQR] 
No. of  
products 
Ghana – Total 33.3 [20.0-42.9] 1,356 28.6 [17.6-42.9] 845 28.6 [18.4-42.9] 2,201 28.6 [17.6-42.9] 747 25.0 [16.7-42.9] 232 28.6 [17.6-42.9] 979 
Public health facility  25.0 [12.5-42.9] 33 17.5 [12.5-36.4] 91 17.6 [12.5-37.0] 124 19.0 [1.4-33.3] 39 11.1 [0.0-27.4] 81 13.2 [0.0-29.0] 120 
Private not-for-profit health facility - 0 25.0 [19.4-43.7] 14 25.0 [19.4-43.7] 14 12.5 [12.5-50.0] 3 80.0 [25.0-80.0] 2 25.0 [12.5-50.0] 5 
Private for-profit outlet             
   Health facility/pharmacy 36.7 [26.1-42.9] 848 33.3 [22.9-42.9] 239 34.6 [25.0-42.9] 1,087 33.3 [22.7-42.9] 481 29.6 [7.1-52.0] 31 33.3 [20.0-42.9] 512 
   Drug store 28.6 [16.7-42.9] 475 27.3 [17.6-42.9] 501 27.3 [16.9-42.9] 976 25.0 [16.7-36.4] 224 28.2 [19.0-42.9] 118 25.0 [17.6-41.1] 342 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 
   Total 33.3 [20.2-42.9] 1,323 28.6 [18.4-42.9] 740 28.6 [18.4-42.9] 2,063 28.6 [18.4-42.9] 705 28.2 [18.4-42.9] 149 28.6 [18.4-42.9] 854 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Kenya – Total 31.6 [20.7-40.0] 1,497 26.8 [17.6-34.3] 230 28.8 [20.0-38.9] 1,727 30.6 [20.0-37.6] 1,514 32.1 [19.0-48.9] 188 31.0 [20.0-41.5] 1,702 
Public health facility  80.0 [0.0-114.3] 13 0.0 [0.0-0.0] 12 0.0 [0.0-80.0] 25 9.1 [0.0-25.0] 14 0.0 [0.0-0.0] 8 0.0 [0.0-0.0] 22 
Private not-for-profit health facility 33.8 [12.5-34.7] 18 89.7 [89.7-89.7] 1 33.8 [12.5-50.0] 19 12.5 [11.1-25.0] 12 0.0 [0.0-0.0] 2 11.1 [0.0-17.6] 14 
Private for-profit outlet             
   Health facility/pharmacy 28.0 [18.5-36.4] 955 33.1 [20.0-38.5] 147 28.6 [19.0-38.5] 1,102 31.0 [21.4-37.5] 894 36.2 [21.6-50.0] 114 33.3 [21.6-42.9] 1,008 
   Drug store 33.3 [25.0-42.9] 511 25.7 [17.6-31.6] 69 30.0 [22.8-39.7] 580 31.0 [20.0-38.9] 594 25.0 [19.0-48.9] 61 29.7 [20.0-40.0] 655 
   General retailer/itinerant - 0 - 0 - 0 - 0 14.3 [14.3-42.9] 3 14.3 [14.3-42.9] 3 
   Total 30.9 [21.2-40.0] 1,466 27.3 [20.0-34.6] 216 29.2 [20.0-38.5] 1,682 31.0 [20.0-38.5] 1,488 33.3 [20.7-48.9] 178 32.0 [20.5-42.9] 1,666 
Community health worker - 0 0.0 1 0.0 1 - 0 - 0 - 0 
Madagascar – Total 0.0 [0.0-38.8] 42 0.0 [0.0-0.0] 132 0.0 [0.0-0.0] 174 38.0 [37.3-38.1] 23 0.0 [0.0-0.0] 24 11.1 [0.0-38] 47 
Public health facility  0.0 [0.0-0.0] 16 0.0 [0.0-0.0] 130 0.0 [0.0-0.0] 146 11.1 [11.1-11.1] 1 0.0 [0.0-0.0] 21 0.0 [0.0-0.0] 22 
Private not-for-profit health facility 0.0 [0.0-0.0] 2 - 0 0.0 [0.0-0.0] 2 0.0 [0.0-0.0] 2 - 0 0.0 [0.0-0.0] 2 
Private for-profit outlet             
   Health facility/pharmacy 38.8 [38.1-38.8] 24 - 0 38.8 [38.1-38.8] 24 38.0 [38.0-38.0] 16 - 0 38.0 [38.0-38.0] 16 
   Drug store - 0 60.0 [60.0-60.0] 1 60.0 [60.0-60.0] 1 66.7 [23.0-135.3] 4 100.0 [100.0-100.0] 1 66.7 [23.0-100.0] 5 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 
   Total 38.8 [38.1-38.8] 24 60.0 [60.0-60.0] 1 38.8 [38.1-38.8] 25 38.0 [38.0-38.2] 20 100.0 [100.0-100.0] 1 38.0 [38.0-41] 21 
Community health worker - 0 0.0 1 0.0 1 - 0 0.0 [0.0-100.0] 2 0.0 [0.0-100.0] 2 
Niger – Total 35.0 [35.0-35.0] 1,457 0.0 [0.0-4.8] 119 35.0 [31.9-35.0] 1,576 35.0 [35.0-35.0] 1,333 0.0 [0.0-14.3] 117 35.0 [0.0-35.0] 1,450 
Public health facility  0.0 [0.0-0.0] 77 0.0 [0.0-0.0] 89 0.0 [0.0-0.0] 166 0.0 [0.0-0.0] 110 0.0 [0.0-0.0] 94 0.0 [0.0-0.0] 204 
Private not-for-profit health facility -76.9 [-76.9- -76.9] 1 - 0 -76.9 [-76.9- -76.9] 1 -100.0 [-100.0- -100.0] 1 -100.0 [-100.0- -100.0] 2 
-100.0 [-100.0- -
100.0] 3 
Private for-profit outlet             
   Health facility/pharmacy 35.0 [35.0-35.0] 1,333 35.0 [35.0-35.0] 27 35.0 [35.0-35.0] 1,360 35.0 [35.0-35.0] 1,156 -30.0 [-30.0-35.0] 4 35.0 [35.0-35.0] 1,160 
   Drug store 52.0 [35.0-52.1] 20 - 0 52.0 [35.0-52.1] 20 35.0 [25.0-35.0] 23 - 0 35.0 [25.0-35.0] 23 
   General retailer/itinerant 25.0 [20.0-33.3] 26 11.1 [4.8-16.7] 3 20.0 [11.1-33.3] 29 33.3 [20.0-50.0] 43 33.3 [0.0-71.4] 17 33.3 [16.7-59.1] 60 
   Total 35.0 [35.0-35.0] 1,379 16.7 [11.1-35.0] 30 35.0 [35.0-35.0] 1,409 35.0 [35.0-35.0] 1,222 33.3 [0.0-71.4] 21 35.0 [35.0-35.0] 1,243 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Nigeria – Total 19.0 [11.1-31] 2,542 22.2 [12.4-25.0] 98 19.0 [11.1-29.6] 2,640 22.9 [14.6-31.6] 1,043 20.0 [11.1-30.8] 235 22.2 [14.3-31.6] 1,278 
Public health facility  0.0 [0.0-7.8] 139 0.0 [0.0-0.0] 6 0.0 [0.0-0.0] 145 14.3 [0.0-25.0] 24 0.0 [0.0-1.2] 30 0.0 [0.0-14.3] 54 
Private not-for-profit health facility 12.9 [11.1-40] 3 7.7 [7.7-7.7] 1 7.7 [7.7-7.7] 4 63.3 [55.0-83.3] 4 - 0 63.3 [55.0-83.3] 4 
Private for-profit outlet             
   Health facility/pharmacy 25.0 [15.4-36.4] 1,983 25.0 [16.9-25.0] 30 25.0 [16.9-30.8] 2,013 25.0 [20.0-33.3] 237 20.0 [12.5-33.3] 15 25.0 [19.0-33.3] 252 
   Drug store 19.0 [11.1-28.9] 391 25.0 [15.4-30.0] 59 19.0 [11.1-29.0] 450 21.2 [13.3-31.6] 754 20.0 [14.0-32.4] 187 20.0 [13.6-31.6] 941 
   General retailer/itinerant 28.6 [18.2-40.0] 26 - 0 28.6 [18.2-40.0] 26 44.4 [16.7-45.5] 24 20.0 [20.0-127.3] 3 44.4 [16.7-45.5] 27 
   Total 19.0 [11.1-31.0] 2,400 25.0. [16.9-28.6] 89 20.0 [12.1-30.0] 2,489 23.1 [15.4-33.3] 1,015 20.0 [14.0-32.4] 205 22.2 [14.6-32.4] 1,220 
Community health worker - 0 0.0 [0.0-0.0] 2 0.0 [0.0-0.0] 2 - 0 - 0 - 0 
Tanzania - mainland – Total 38.5 [25.0-53.8] 789 33.3 [0.0-60.0] 51 36.8 [22.2-53.8] 840 47.1 [29.0-66.7] 1,046 45.9 [28.2-66.7] 62 47.1 [28.6-66.7] 1,108 
Public health facility  0.0 1 0.0 [0.0-0.0] 3 0.0 [0.0-0.0] 4 33.3 [33.3-33.3] 1 0.0 [0.0-0.0] 2 0.0 [0.0-0.0] 3 
Private not-for-profit health facility 57.5 [6.7-66.7] 5 0.0 1 6.7 [0.0-60.0] 6 - 0 - 0 - 0 
Private for-profit outlet             
   Health facility/pharmacy 37.9 [25.0-53.8] 736 33.3 [23.1-71.4] 30 37.5 [25.0-53.8] 766 38.5 [23.1-56.5] 872 75.0 [33.3-111.1] 38 41.0 [25.0-66.7] 910 
   Drug store 41.3 [25.0-53.8] 47 33.3 [29.6-71.4] 17 40.6 [25.0-56.3] 64 50.0 [33.3-76.5] 173 47.1 [32.2-66.7] 22 49.3 [33.3-69.2] 195 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 
   Total 38.5 [25.0-53.8] 783 33.3 [25.0-71.4] 47 38.5 [25.0-55.2] 830 47.1 [29.0-66.7] 1,045 47.1 [32.2-66.7] 60 47.1 [32.2-66.7] 1,105 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
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Table 2.3.16: Cont. 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
Median markup  
[IQR] 
No. of  
products 
Median markup  
[IQR] 
No. of  
products 
Median markup  
[IQR] 
No. of  
products 
Median markup 
[IQR] 
No. of  
products 
Median markup  
[IQR] 
No. of  
products 
Median markup  
[IQR] 
No. of  
products 
Uganda – Total 66.7 [42.9-100.0] 1,585 60.0 [33.3-100.0] 1,185 66.7 [33.3-100.0] 2,770 50.0 [27.3-87.5] 2,322 50.0 [29.9-87.5] 870 50.0 [28.2-87.5] 3,192 
Public health facility  0.0 [0.0-0.0] 27 0.0 [0.0-0.0] 52 0.0 [0.0-0.0] 79 0.0 [0.0-0.0] 63 0.0 [0.0-0.0] 15 0.0 [0.0-0.0] 78 
Private not-for-profit health facility 89.2 1 11.4 [0.0-100.0] 6 89.2 [0.0-89.2] 7 38.5 [-83.3-66.7] 12 33.3 [33.3-80.0] 14 33.3 [33.3-80.0] 26 
Private for-profit outlet             
   Health facility/pharmacy 66.7 [42.9-100.0] 1,490 71.4 [42.9-122.2] 648 66.7 [42.9-100.0] 2,138 50.0 [30.0-87.5] 1,987 53.8 [33.3-87.5] 555 50.0 [33.3-87.5] 2,542 
   Drug store 80.6 [42.9-117.4] 66 66.7 [37.1-100.0] 460 66.7 [39.1-100.0] 526 55.6 [30.4-100.0] 259 50.0 [25.0-100.0] 285 50.0 [27.3-100.0] 544 
   General retailer/itinerant - 0 33.3 [20.0-60.0] 3 33.3 [20.0-60.0] 3 122.2 [122.2-122.2] 1 - 0 122.2 [122.2-122.2] 1 
   Total 69.2 [42.9-100.0] 1,556 66.7 [37.9-100.0] 1,111 66.7 [40.0-100.0] 2,667 50.0 [30.0-92.3] 2,247 50.0 [30.0-89.7] 840 50.0 [30.0-90.5] 3,087 
Community health worker 42.9 1 0.0 [0.0-0.0] 16 0.0 [0.0-0.0] 17 - 0 51.5 [51.5-51.5] 1 51.5 [51.5-51.5] 1 
Zanzibar – Total 18.3 [0.0-32.5] 84 0.0 [0.0-0.0] 29 10.0 [0.0-30.8] 113 41.2 [25.0-66.7] 73 29.2 [3.3-46.4] 8 41.2 [25.0-60.0] 81 
Public health facility  0.0 [0.0-0.0] 30 0.0 [0.0-0.0] 21 0.0 [0.0-0.0] 51 25.0 [0.0-120.0] 3 0.0 [0.0-0.0] 2 0.0 [0.0-25.0] 5 
Private not-for-profit health facility 20.8 [16.7-25.0] 2 42.9 [42.9-42.9] 1 25.0 [16.7-42.9] 3 - 0 - 0 - 0 
Private for-profit outlet             
   Health facility/pharmacy 26.8 [14.3-33.3] 46 27.5 [10.0-100.0] 6 26.8 [14.3-34.5] 52 42.9 [25.0-66.7] 59 38.1 [25.0-50.0] 6 42.9 [25.0-66.7] 65 
   Drug store 26.5 [20.7-30.8] 6 0.0 1 23.1 [9.1-30.8] 7 41.2 [25.0-60.0] 11 - 0 41.2 [25.0-60.0] 11 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 
   Total 26.8 [17.1-33.3] 52 25.0 [0.0-100.0] 7 25.0 [14.3-33.3] 59 41.2 [25.0-66.7] 70 38.1 [25.0-50.0] 6 41.2 [25.0-63.3] 76 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Note: Nigeria baseline data collection was conducted in 2009. 
IQR = Interquartile range  
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.3.17: Gross markup between purchase price and retail selling price of quality-assured ACTs, at baseline (2010) and endline (2011) 
Indicator 2.5 Median percentage markup between purchase price and retail selling price of quality-assured ACTs, by urban-rural location and type of outlet, according to country 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
Median markup 
 [IQR] 
No. of  
Products 
Median markup  
[IQR] 
No. of  
products 
Median markup 
[IQR] 
No. of 
products 
Median markup  
[IQR] 
No. of  
products 
Median  
markup [IQR] 
No. of  
products 
Median markup 
 [IQR] 
No. of  
products 
Ghana – Total 37.5 [25.0-66.7] 224 33.3 [19.0-66.7] 161 33.3 [20.0-66.7] 385 50.0 [36.4-66.7] 627 50.0 [33.3-66.7] 257 50.0 [33.3-66.7] 884 
Public health facility  7.1 [0.0-400.0] 34 38.9 [3.9-150.0] 83 31.6 [0.0-150.0] 117 25.0 [0.0-42.9] 50 11.1 [0.0-50.0] 90 22.2 [0.0-50.0] 140 
Private not-for-profit health facility - 0 61.8 [43.3-66.7] 3 61.8 [43.3-66.7] 3 25.0 [19.0-50.0] 12 0.0 [0.0-87.5] 6 25.0 [0.0-50.0] 18 
Private for-profit outlet             
   Health facility/pharmacy 36.5 [28.2-47.8] 150 25.0 [18.7-36.3] 34 32.4 [25.0-40.1] 184 50.0 [36.4-66.7] 337 33.3 [7.1-66.7] 36 50.0 [33.3-66.7] 373 
   Drug store 46.7 [28.6-66.7] 40 33.3 [20.0-66.7] 41 33.3 [20.0-66.7] 81 50.0 [36.4-66.7] 226 50.0 [40.0-66.7] 123 50.0 [36.4-66.7] 349 
   General retailer/itinerant - 0 - 0 - 0 42.9 [36.4-42.9] 2 66.7 [50.0-66.7] 2 50.0 [42.9-66.7] 4 
   Total 37.5 [28.2-66.7] 190 33.3 [20.0-50.0] 75 33.3 [21.1-50.0] 265 50.0 [36.4-66.7] 565 50.0 [36.4-66.7] 161 50.0 [36.4-66.7] 726 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Kenya – Total 24.4 [0.0-50.0] 819 0.0 [0.0-0.0] 925 0.0 [0.0-24.7] 1,744 42.9 [33.3-72.4] 1,746 0.0 [0.0-42.9] 1,482 25.0 [0.0-60.0] 3.228 
Public health facility  0.0 [0.0-0.0] 320 0.0 [0.0-0.0] 792 0.0 [0.0-0.0] 1,112 0.0 [0.0-0.0] 375 0.0 [0.0-0.0] 1,066 0.0 [0.0-0.0] 1.441 
Private not-for-profit health facility 0.0 [0.0-0.0] 33 0.0 [0.0-0.0] 23 0.0 [0.0-0.0] 56 0.0 [0.0-14.3] 30 0.0 [0.0-25.0] 68 0.0 [0.0-18.4] 98 
Private for-profit outlet             
   Health facility/pharmacy 36.8 [18.5-71.4] 277 32.3 [0.0-100.0] 62 35.4 [14.6-80.0] 339 53.8 [33.3-100.0] 701 42.9 [33.3-100] 129 50.0 [33.3-100.0] 830 
   Drug store 42.9 [25.8-66.7] 187 42.9 [20.0-100.0] 36 42.9 [25.0-78.6] 223 48.1 [33.3-77.8] 607 60.0 [33.3-73.9] 162 53.8 [33.3-73.9] 769 
   General retailer/itinerant - 0 - 0 - 0 33.3 [14.3-53.8] 33 14.3 [14.3-33.3] 57 20.0 [14.3-33.3] 90 
   Total 40.5 [24.7-66.7] 464 40.0 [12.5-100.0] 98 40.0 [19.0-80.0] 562 50.0 [33.3-81.8] 1,341 42.9 [33.3-73.9] 348 48.1 [33.3-73.9] 1.689 
Community health worker 60.6 [50.0-71.1] 2 0.0 [0.0-0.0] 12 0.0 [0.0-0.0] 14 - 0 - 0 - 0 
Madagascar – Total 0.0 [0.0-15.7] 333 0.0 [0.0-25.0] 1,329 0.0 [0.0-25.0] 1,662 11.1 [0.0-42.9] 563 0.0 [0.0-42.1] 2,154 0.0 [0.0-42.9] 2.717 
Public health facility  0.0 [0.0-0.0] 145 0.0 [0.0-0.0] 1,187 0.0 [0.0-0.0] 1,332 0.0 [0.0-0.0] 198 0.0 [0.0-0.0] 1,756 0.0 [0.0-0.0] 1.954 
Private not-for-profit health facility 0.0 [0.0-0.0] 4 - 0 0.0 [0.0-0.0] 4 0.0 [0.0-0.0] 68 0.0 [0.0-0.0] 7 0.0 [0.0-0.0] 75 
Private for-profit outlet             
   Health facility/pharmacy 0.0 [0.0-38.1] 158 0.0 [0.0-66.7] 2 0.0 [0.0-38.6] 160 39.5 [28.9-61.3] 206 42.9 [42.9-100.0] 9 42.9 [35.1-66.7] 215 
   Drug store 38.9 [25-38.9] 20 38.9 [25.0-87.5] 103 38.9 [25.0-42.9] 123 50.0 [32.3-66.7] 72 50.0 [25-71.4] 324 50.0 [27.7-66.7] 396 
   General retailer/itinerant 100.0 [11.1-200.0] 6 50.0 [33.3-50.0] 8 50.0 [33.3-50.0] 14 50.0 [50.0-50.0] 2 50.0 [40.0-66.7] 6 50.0 [40.0-66.7] 8 
   Total 25.0 [0.0-38.9] 184 50.0 [25.0-66.7] 113 38.1 [12.9-50.0] 297 40.6 [29.9-66.7] 280 50.0 [33.3-66.7] 339 43.5 [33.3-66.7] 619 
Community health worker - 0 50.0 [0.0-100.0] 29 50.0 [0.0-100.0] 29 100.0 [0.0-100.0] 17 100.0 [0.0-100.0] 52 100.0 [0.0-100.0] 69 
Niger – Total 35.0 [14.3-35.1] 362 20.0 [0.0-50.0] 180 25.0 [0.0-42.9] 542 35.0 [16.7-50.0] 661 0.0 [0.0-33.3] 264 20.0 [0.0-40.0] 925 
Public health facility  0.0 [0.0-0.0] 82 0.0 [0.0-0.0] 132 0.0 [0.0-0.0] 214 0.0 [0.0-0.0] 183 0.0 [0.0-0.0] 205 0.0 [0.0-0.0] 388 
Private not-for-profit health facility - 0 - 0 - 0 -100.0 [-100.0- -100.0] 1 -100.0 [-100.0- -100.0] 5 -100.0 [-100.0- -100.0] 6 
Private for-profit outlet             
   Health facility/pharmacy 35.0 [35.0-35.0] 209 11.4 [11.4-11.4] 4 35.0 [35.0-35.0] 213 35.1 [35.0-35.1] 301 -30.0 [-30.0- -30.0] 7 35.1 [35-35.1] 308 
   Drug store 42.9 [35.0-51.5] 11 30.0 [20.0-40.0] 2 40.0 [27.3-42.9] 13 38.0 [25.0-40.0] 13 - 0 38.0 [25.0-40.0] 13 
   General retailer/itinerant 33.3 [25.0-50.0] 60 42.9 [25.0-50.0] 42 33.3 [25.0-50.0] 102 35.1 [20-66.7] 163 40.0 [25.0-66.7] 47 40.0 [23.1-66.7] 210 
   Total 35.0 [25.0-42.9] 280 42.9 [25.0-50.0] 48 35.0 [25.0-50.0] 328 35.1 [25.0-60.0] 477 40.0 [23.1-66.7] 54 35.1 [25.0-60.0] 531 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Nigeria – Total 33.3 [20.0-50.0] 673 25.0 [0.0-42.9] 103 30.8 [17.1-50.0] 776 50.0 [25.0-87.5] 1,284 42.9 [20.0-66.7] 554 50.0 [25.0-75.0] 1,838 
Public health facility  0.0 [0.0-0.0] 51 0.0 [0.0-0.0] 19 0.0 [0.0-0.0] 70 0.0 [0.0-0.0] 70 0.0 [0.0-0.0] 63 0.0 [0.0-0.0] 133 
Private not-for-profit health facility 900.0 [0.0-900.0] 2 500.0 [0.0-500.0] 3 500.0 [0.0-500.0] 5 500.0 [66.7-500.0] 9 100.0 [100.0-100.0] 2 500.0 [66.7-500.0] 11 
Private for-profit outlet             
   Health facility/pharmacy 25.0 [16.9-45.5] 341 66.7 [42.9-66.7] 4 37.5 [20.0-66.7] 345 50.0 [25.0-114.3] 125 66.7 [34.6-100.0] 11 50.0 [26.8-100.0] 136 
   Drug store 31.6 [20.0-50.0] 262 33.3 [25.0-50.0] 73 33.3 [20.0-50.0] 335 50.0 [25.0-76.5] 1,038 50.0 [25.0-75.0] 474 50.0 [25.0-75.0] 1,512 
   General retailer/itinerant 33.3 [13.6-50.0] 12 50.0 [50.0-50.0] 1 33.3 [13.6-50.0] 13 50.0 [38.9-66.7] 36 25.0 [10.0-50.0] 3 50.0 [36.4-66.7] 39 
   Total 30.8 [19.0-50.0] 615 33.3 [25.0-66.7] 78 33.3 [20.0-50.0] 693 50.0 [25.0-87.5] 1,199 50.0 [25.0-75.0] 488 50.0 [25.0-76.5] 1,687 
Community health worker 500.0 [66.7-500.0] 5 0.0 [0.0-0.0] 3 66.7 [0.0-500.0] 8 0.0 [0.0-0.0] 6 15.4 1 15.4 [15.4-15.4] 7 
Tanzania - mainland – Total 25.0 [0.0-41.2] 153 0.0 [0.0-0.0] 95 0.0 [0.0-0.0] 248 66.7 [42.9-100.0] 862 0.0 [0.0-53.8] 187 42.9 [0-77.8] 1049 
Public health facility  0.0 [0.0-0.0] 7 0.0 [0.0-0.0] 77 0.0 [0.0-0.0] 84 0.0 [0.0-0.0] 11 0.0 [0.0-0.0] 67 0.0 [0.0-0.0] 78 
Private not-for-profit health facility - 0 0.0 [0.0-0.0] 8 0.0 [0.0-0.0] 8 - 0 0.0 [0.0-0.0] 4 0.0 [0.0-0.0] 4 
Private for-profit outlet             
   Health facility/pharmacy 33.3 [20.0-50.0] 140 0.0 [0.0-0.0] 2 32.7 [15.4-47.1] 142 66.7 [42.9-100.0] 639 25.0 [0.0-100.0] 28 66.7 [42.9-100.0] 667 
   Drug store 36.4 [33.3-66.7] 6 66.7 [50.0-133.3] 7 50.0 [36.4-100.0] 13 66.7 [42.9-100.0] 209 66.7 [40.0-87.5] 83 66.7 [42.9-100.0] 292 
   General retailer/itinerant - 0 50.0 [50.0-50.0] 1 50.0 [50.0-50.0] 1 81.8 [81.8-87.5] 3 0.0 [0.0-0.0] 5 0.0 [0.0-25.0] 8 
   Total 34.6 [26.3-52.4] 146 50.0 [50.0-100.0] 10 50.0 [26.3-66.7] 156 66.7 [42.9-100.0] 851 53.8 [25.0-87.5] 116 66.7 [42.9-100.0] 967 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
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Table 2.3.17: Cont. 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
Median markup 
 [IQR] 
No. of 
products 
Median markup  
[IQR] 
No. of 
products 
Median markup 
[IQR] 
No. of 
products 
Median markup 
[IQR] 
No. of 
products 
Median markup 
[IQR] 
No. of  
products 
Median markup 
[IQR] 
No. of  
products 
Uganda – Total 0.0 [0.0-50.0] 423 0.0 [0.0-0.0] 2,271 0.0 [0.0-0.0] 2,694 100.0 [40.0-200.0] 1,944 33.3 [0.0-140.0] 2.589 56.3 [0.0-150.0] 4,533 
Public health facility  0.0 [0.0-0.0] 167 0.0 [0.0-0.0] 2,062 0.0 [0.0-0.0] 2,229 0.0 [0.0-0.0] 338 0.0 [0.0-0.0] 1.603 0.0 [0.0-0.0] 1,941 
Private not-for-profit health facility 0.0 [0.0-0.0] 4 0.0 [0.0-0.0] 19 0.0 [0.0-0.0] 23 0.0 [0.0-0.0] 19 0.0 [0.0-0.0] 43 0.0 [0.0-0.0] 62 
Private for-profit outlet             
   Health facility/pharmacy 50.0 [25.0-87.5] 245 66.7 [33.3-100.0] 99 57.9 [25.0-100.0] 344 140.0 [81.8-250.0] 1,213 140.0 [100.0-233.3] 417 140.0 [100.0-233.3] 1,630 
   Drug store 100.0 [50.0-118.2] 7 42.9 [25.0-71.4] 65 50.0 [33.3-81.8] 72 127.3 [66.7-200.0] 369 100.0 [50.0-200.0] 444 100.0 [60.0-200.0] 813 
   General retailer/itinerant - 0 100.0 [100.0-100.0] 1 100.0 1 6.4 [6.4-100.0] 2 66.7 [50.0-66.7] 4 66.7 [50.0-66.7] 6 
   Total 60.0 [33.3-100.0] 252 50.0. [25.0-87.5] 165 50.0 [33.3-100.0] 417 133.3 [71.4-233.3] 1,584 114.3 [66.7-212.5] 865 127.3 [66.7-220.0] 2,449 
Community health worker - 0 0.0 [0.0-0.0] 25 0.0 [0.0-0.0] 25 0.0 [0.0-42.9] 3 0.0 [0.0-0.0] 78 0.0 [0.0-0.0] 81 
Zanzibar – Total 0.0 [0.0-0.0] 126 0.0 [0.0-0.0] 213 0.0 [0.0-0.0] 339 73.2 [0.0-100.0] 362 0.0 [0.0-14.3] 282 0.0 [0.0-100.0] 644 
Public health facility  0.0 [0.0-0.0] 120 0.0 [0.0-0.0] 212 0.0 [0.0-0.0] 332 0.0 [0.0-0.0] 118 0.0 [0.0-0.0] 210 0.0 [0.0-0.0] 328 
Private not-for-profit health facility - 0 - 0 - 0 - 0 100.0 [100.0-117.4] 3 100.0 [100.0-117.4] 3 
Private for-profit outlet             
   Health facility/pharmacy 33.3 [16.9-33.3] 5 0.0 1 25.1 [14.3-33.3] 6 100.0 [77.8-100.0] 141 100.0 [66.7-100.0] 30 100.0 [66.7-100.0] 171 
   Drug store 0.0 1 - 0 0.0 1 100.0 [66.7-100.0] 101 100.0 [60.0-100.0] 37 100.0 [66.7-100.0] 138 
   General retailer/itinerant - 0 - 0 - 0 211.1 [122.2-300.0] 2 83.3 [66.7-100.0] 2 111.1 [83.3-211.1] 4 
   Total 25.1 [14.3-33.3] 6 0. 1 16.9 [0.0-33.3] 7 100.0 [66.7-100.0] 244 100.0 [60.0-100.0] 69 100.0 [66.7-100.0] 313 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Note: Nigeria baseline data collection was conducted in 2009. IQR = Interquartile range 
Source: AMFm Phase 1 Independent Evaluation Outlet Survey 
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Table 2.3.18: Gross markup between purchase price and retail selling price of quality-assured ACTs, by presence of the AMFm logo, at endline, 2011 
Median percentage markup between purchase price and retail selling price of quality-assured ACTs, by presence of the AMFm logo, urban-rural location and type of outlet, according to country 
Country/Type of outlet 
WITH LOGO WITHOUT LOGO 
Urban Rural Total Urban  Rural Total 
Median markup  
[IQR] 
No. of  
Products 
Median markup  
[IQR] 
No. of  
products 
Median markup  
[IQR] 
No. of  
products 
Median markup  
[IQR] 
No. of  
products 
Median markup  
[IQR] 
No. of  
products 
Median markup 
[IQR] 
No. of  
products 
Ghana - Total 50.0 [36.4-66.7] 555 50.0 [33.3-66.7] 242 50.0 [36.4-66.7] 797 33.3 [20.8-50.0] 72 33.3 [9.1-50.0] 13 33.3 [20.0-50.0] 85 
Public health facility  25.0 [0.0-50.0] 41 15.4 [0.0-50.0] 79 25.0 [0.0-50.0] 120 20.3 [0.0-22.2] 9 11.1 [0.0-33.3] 10 15.4 [0.0-33.3] 19 
Private not-for-profit health facility 25.0 [19.0-50.0] 12 0.0 [0.0-87.5] 6 25.0 [0.0-50.0] 18 - 0 - 0 - 0 
Private for-profit outlet             
   Health facility/pharmacy 50.0 [44.4-76.5] 278 33.3 [7.1-66.7] 36 50.0 [36.4-66.7] 314 33.3 [25.0-50.0] 59 - 0 33.3 [25.0-50.0] 59 
   Drug store 50.0 [36.4-66.7] 222 50.0 [40.0-66.7] 120 50.0 [36.4-66.7] 342 50.0 [33.3-66.7] 4 50.0 [9.1-50.0] 2 50.0 [20.0-50.0] 6 
   General retailer/itinerant 42.9 [36.4-42.9] 2 66.7 [66.7-66.7] 1 42.9 [36.4-66.7] 3 - 0 50.0 [50-50.0] 1 50.0 [50.0-50.0] 1 
   Total 50.0 [37.6-66.7] 502 50.0 [36.4-66.7] 157 50.0 [36.4-66.7] 659 33.3 [25.0-50.0] 63 50.0 [9.1-50.0] 3 36.4 [25.0-50.0] 66 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Kenya - Total 42.9 [33.3-78.6] 1,473 33.3 [0.0-60.0] 852 33.3 [0.0-66.7] 2,325 0.0 [0.0-33.3] 272 0.0 [0.0-0.0] 630 0.0 [0.0-0.0] 902 
Public health facility  0.0 [0.0-0.0] 164 0.0 [0.0-0.0] 501 0.0 [0.0-0.0] 665 0.0 [0.0-0.0] 210 0.0 [0.0-0.0] 565 0.0 [0.0-0.0] 775 
Private not-for-profit health facility 13.6 [-100.0-33.3] 17 0.0 [0.0-57.9] 23 0.0 [0.0-50.0] 40 0.0 [0.0-0.0] 13 0.0 [0.0-0.0] 45 0.0 [0.0-0.0] 58 
Private for-profit outlet             
   Health facility/pharmacy 53.8 [33.3-100.0] 674 59.1 [33.3-100.0] 120 53.8 [33.3-100.0] 794 32.6 [11.1-100.0] 27 39.5 [0.0-39.5] 9 39.5 [0.0-39.5] 36 
   Drug store 48.1 [33.3-78.6] 585 60.0 [33.3-73.9] 153 53.8 [33.3-73.9] 738 42.9 [33.3-71.4] 22 33.3 [33.3-66.7] 9 40.0 [33.3-66.7] 31 
   General retailer/itinerant 33.3 [14.3-53.8] 33 14.3 [14.3-33.3] 55 14.3 [14.3-33.3] 88 - 0 41.7 [33.3-50.0] 2 41.7 [33.3-50.0] 2 
   Total 50.0 [33.3-81.8] 1,292 48.1 [33.3-73.9] 328 50.0 [33.3-75.0] 1,620 40.0 [14.3-71.4] 49 39.5 [33.3-50.0] 20 39.5 [15.4-66.7] 69 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Madagascar - Total 30.0 [0.0-57.9] 344 0.0 [0.0-0.0] 1,190 0.0 [0.0-32.4] 1,534 0.0 [0.0-30.1] 219 0.0 [0.0-100.0] 964 0.0 [0.0-100.0] 1,183 
Public health facility  0.0 [0.0-0.0] 97 0.0 [0.0-0.0] 861 0.0 [0.0-0.0] 958 0.0 [0.0-0.0] 101 0.0 [0.0-0.0] 895 0.0 [0.0-0.0] 996 
Private not-for-profit health facility 0.0 [0.0-0.0] 42 0.0 [0.0-0.0] 4 0.0 [0.0-0.0] 46 0.0 [0.0-0.0] 26 0.0 [0.0-0.0] 3 0.0 [0.0-0.0] 29 
Private for-profit outlet             
   Health facility/pharmacy 42.9 [35.1-66.7] 140 42.9 [42.9-42.9] 7 42.9 [38.1-66.7] 147 37.0 [11.1-38.6] 66 100.0 [100.0-100.0] 2 38.2 [24.2-66.7] 68 
   Drug store 60.0 [40.0-100.0] 59 50.0 [25.0-66.7] 307 50.0 [32.4-71.4] 366 28.2 [27.1-32.3] 13 66.7 [25.0-100.0] 17 32.3 [27.1-57.9] 30 
   General retailer/itinerant 66.7 [66.7-66.7] 1 36.7 [33.3-40] 2 40.0 [33.3-40] 3 50.0 [50.0-50.0] 1 50.0 [50-66.7] 4 50.0 [50.0-66.7] 5 
   Total 50.0 [36.4-73.9] 200 42.9 [33.3-66.7] 316 42.9 [33.3-66.7] 516 33.3 [24.2-38.6] 80 66.7 [50.0-100.0] 23 44.2 [28.2-66.7] 103 
Community health worker 0.0 [0.0-100.0] 5 0.0 [0.0-0.0] 9 0.0 [0.0-0.0] 14 100.0 [25.0-100.0] 12 100.0 [100.0-100.0] 43 100.0 [100.0-100.0] 55 
Niger – Total 35.1 [22.2-60.0] 362 9.1 [0.0-50.0] 107 33.3 [0.0-50.0] 469 25.0 [0.0-35.0] 298 0.0 [0.0-0.0] 157 0.0 [0.0-33.3] 455 
Public health facility  0.0 [0.0-35.1] 96 0.0 [0.0-0.0] 64 0.0 [0.0-0.0] 160 0.0 [0.0-0.0] 86 0.0 [0.0-0.0] 141 0.0 [0.0-0.0] 227 
Private not-for-profit health facility - 0 -100.0 [-100.0- -100.0] 5 -100.0 [-100.0- -100.0] 5 -100.0 [-100.0- -100.0] 1 - 0 -100.0 1 
Private for-profit outlet             
   Health facility/pharmacy 35.1 [35.1-35.1] 138 -30.0 [-30.0- -30.0] 4 35.1 [35.1-35.1] 142 35.0 [35.0-35.0] 163 35.1 [35.1-56.0] 3 35.0 [35.0-35.0] 166 
   Drug store 35.1 [25.0-40.0] 11 - 0 35.1 [25.0-40.0] 11 40.0 [38.0-40.0] 2 - 0 40.0 [38.0-40.0] 2 
   General retailer/itinerant 42.9 [25.0-75.0] 117 40.0 [23.1-66.7] 34 40.0 [25.0-66.7] 151 25.0 [17.6-60] 46 33.3 [25.0-50.0] 13 33.3 [20.0-50.0] 59 
   Total 35.1 [27.3-66.7] 266 40.0 [20.0-66.7] 38 36.4 [25-66.7] 304 35.0 [20.0-35.1] 211 33.3 [25.0-50.0] 16 35.0 [25.0-50.0] 227 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Nigeria - Total 50.0 [25.0-87.5] 1,100 50.0 [25.0-75.0] 442 50.0 [25.0-87.5] 1,542 25.0 [12.5-50.0] 184 15.4 [0.0-50.0] 112 25.0 [5.9-50.0] 296 
Public health facility  0.0 [0.0-0.0] 45 0.0 [0.0-0.0] 21 0.0 [0.0-0.0] 66 0.0 [0.0-0.0] 25 0.0 [0.0-0.0] 42 0.0 [0.0-0.0] 67 
Private not-for-profit health facility 500.0 [66.7-500.0] 6 - 0 500.0 [66.7-500.0] 6 500.0 [500.0-500.0] 3 100.0 [100.0-100.0] 2 500.0 [100.0-500.0] 5 
Private for-profit outlet             
   Health facility/pharmacy 66.7 [33.3-114.3] 106 66.7 [62.2-100.0] 6 66.7 [33.3-114.3] 112 12.5 [9.5-25.0] 19 34.6 [26.8-80.0] 5 12.5 [9.5-33.3] 24 
   Drug store 50.0 [25.0-87.5] 906 50.0 [25.0-76.5] 412 50.0 [25.0-84.6] 1,318 25.0 [15.4-50.0] 132 42.9 [20.0-60.0] 62 26.3 [16.7-53.8] 194 
   General retailer/itinerant 50.0 [38.9-81.8] 31 25.0 [10.0-50.0] 3 50.0 [33.3-66.7] 34 50.0 [38.9-50.0] 5 - 0 50.0 [38.9-50.0] 5 
   Total 50.0 [26.3-87.5] 1,043 50.0 [25.0-76.5] 421 50.0 [25.0-87.5] 1,464 25.0 [14.3-50.0] 156 42.9 [20.0-60.0] 67 26.3 [15.4-50.0] 223 
Community health worker 0.0 [0.0-0.0] 6 - 0 0.0 [0.0-0.0] 6 - 0 15.4 1 15.4 1 
Tanzania - mainland - Total 66.7 [42.9-100.0] 772 30.0 [0.0-66.7] 139 51.5 [0.0-87.5] 911 53.1 [40-75] 90 0.0 [0.0-0.0] 48 0.0 [0.0-0.0] 138 
Public health facility  0.0 [0.0-0.0] 10 0.0 [0.0-0.0] 32 0.0 [0.0-0.0] 42 0.0 1 0.0 [0.0-0.0] 35 0.0 [0.0-0.0] 36 
Private not-for-profit health facility - 0 0.0 [0.0-0.0] 4 0.0 [0.0-0.0] 4 - 0 - 0 - 0 
Private for-profit outlet             
   Health facility/pharmacy 81.8 [42.9-100.0] 562 100.0 [66.7-100.0] 25 81.8 [49.3-100.0] 587 57.9 [36.4-66.7] 77 0.0 [0.0-0.0] 3 0.0 [0.0-50.0] 80 
   Drug store 66.7 [42.9-100.0] 197 53.8 [33.3-78.6] 78 66.7 [42.9-100.0] 275 53.1 [50.0-75.0] 12 100.0 [66.7-102.5] 5 66.7 [53.1-102.5] 17 
   General retailer/itinerant 81.8 [81.8-87.5] 3 - 0 81.8 [81.8-87.5] 3 - 0 0.0 [0.0-0.0] 5 0.0 [0.0-0.0] 5 
   Total 66.7 [42.9-100.0] 762 56.3 [33.3-87.5] 103 66.7 [42.9-100.0] 865 53.1 [50.0-75.0] 89 25.0 [0.0-100.0] 13 50.0 [0.0-75.0] 102 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
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Table 2.3.18: Cont. 
Country/Type of outlet 
WITH LOGO WITHOUT LOGO 
Urban Rural Total Urban  Rural Total 
Median markup  
[IQR] 
No. of  
Products 
Median markup  
[IQR] 
No. of  
products 
Median markup  
[IQR] 
No. of  
products 
Median markup  
[IQR] 
No. of  
products 
Median markup  
[IQR] 
No. of  
products 
Median markup 
[IQR] 
No. of  
products 
Uganda - Total 113.3 [60.0-233.3] 1,560 66.7 [0.0-150.0] 2,067 100.0 [0.0-180.0] 3,627 15.0 [0.0-100.0] 384 0.0 [0.0-0.0] 522 0.0 [0.0-14.3] 906 
Public health facility  0.0 [0.0-0.0] 208 0.0 [0.0-0.0] 1,261 0.0 [0.0-0.0] 1469 0.0 [0.0-0.0] 130 0.0 [0.0-0.0] 342 0.0 [0.0-0.0] 472 
Private not-for-profit health facility 100.0 [-100.0-150.0] 3 0.0 [0.0-108.3] 10 0.0 [0.0-108.3] 13 0.0 [0.0-0.0] 16 0.0 [0.0-0.0] 33 0.0 [0.0-0.0] 49 
Private for-profit outlet             
   Health facility/pharmacy 150.0 [100.0-284.6] 1,019 150.0 [100.0-233.3] 371 150.0 [100.0-233.3] 1,390 100.0 [15.4-150.0] 194 133.3 [37.1-200] 46 128.6 [37.1-185.7] 240 
   Drug store 133.3 [66.7-200.0] 328 100.0 [56.3-200.0] 414 100.0 [60.0-200.0] 742 80.0 [50.0-166.7] 41 66.7 [40-105.7] 30 71.4 [42.9-120.6] 71 
   General retailer/itinerant 6.4 [6.4-6.4] 1 66.7 [66.7-66.7] 3 66.7 [50-66.7] 4 100.0 [100.0-100.0] 1 0.0 1 0.0 [0.0-0.0] 2 
   Total 150.0 [81.8-233.3] 1,348 127.3 [66.7-220.0] 788 133.3 [66.7-233.3] 2,136 100.0 [40.0-150.0] 236 71.4 [37.1-150.0] 77 100.0 [40.0-150.0] 313 
Community health worker 42.9 [42.9-42.9] 1 0.0 [0.0-0.0] 8 0.0 [0.0-0.0] 9 0.0 [0.0-0.0] 2 0.0 [0.0-0.0] 70 0.0 [0.0-0.0] 72 
Zanzibar - Total 80.9 [0.0-100.0] 346 0.0 [0.0-14.3] 274 0.0 [0.0-100.0] 620 0.0 [0.0-30.4] 16 0.0 [0.0-22.7] 8 0.0 [0.0-30.4] 24 
Public health facility  - 108 0.0 [0.0-0.0] 204 0.0 [0.0-0.0] 312 0.0 [0.0-0.0] 10 0.0 [0.0-0.0] 6 0.0 [0.0-0.0] 16 
Private not-for-profit health facility - 0 100.0 [100.0-117.4] 3 100.0 [100.0-117.4] 3 - 0 - 0 - 0 
Private for-profit outlet             
   Health facility/pharmacy 100.0 [80.0-100.0] 135 100.0. [66.7-100.0] 29 100.0 [73.2-100.0] 164 56.7 [25.0-100.0] 6 45.5 [45.5-45.5] 1 45.5 [25.0-100.0] 7 
   Drug store 100.0 [66.7-100.0] 101 100.0 [60.0-100.0] 36 100.0 [66.7-100.0] 137 - 0 220.0 [220.0-220.0] 1 220.0 [220.0-220.0] 1 
   General retailer/itinerant 211.1 [122.2-300.0] 2 83.3 [66.7-100.0] 2 111.1 [83.3-211.1] 4 - 0 - 0 - 0 
   Total 100.0 [66.7-100.0] 238 100.0 [60.0-100.0] 67 100.0 [66.7-100.0] 305 56.7 [25.0-100.0] 6 132.7 [45.5-220.0] 2 61.6 [30.4-100.0] 8 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
IQR = Interquartile range  
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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2.3.3 Total gross markup from first line buyer purchase price to retail selling price 
Table 2.3.19 presents the median total gross markup on QAACTs. For this indicator, the markup 
is calculated by comparing the retail price per AETD for each QAACT bearing the AMFm logo 
with the average first line buyer purchase price for that product in that country (see Section 
1.6.2.4). It captures both the additional costs and profit margins that are added by first line 
buyers, any intermediate wholesalers and retailers. Interpretation focuses on the private for-profit 
sector because the key policy questions relate to transmission of the subsidy to customers in 
these outlets. The total gross markup was low in Kenya and Madagascar (USD 0.40 and USD 
0.45), followed by Tanzania mainland (USD 0.84) and Ghana (USD 0.87); and was over USD 
1.00 in the remaining countries, with the highest value in Uganda (USD 1.83). It was similar in 
rural and urban areas in Ghana, Niger, Nigeria and Uganda. It was higher in urban areas in 
Kenya, Tanzania mainland and Zanzibar; and higher in rural areas in Madagascar.  
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Table 2.3.19: Median total gross markup from first line buyer price to retail selling price for quality-assured ACTs bearing the AMFm logo, in 2010 US 
dollars, at endline, 2011 
Indicator 2.6: Median total absolute markup from first line buyer purchase price per adult equivalent treatment dose (AETD) to retail selling price per adult equivalent treatment 
dose for quality-assured ACTs with the AMFm logo by urban-rural location and type of outlet, according to country 
 Urban Rural Total 
Country/Type of outlet Median markup [IQR] No. of products Median markup [IQR] No. of products Median markup [IQR] No. of products 
Ghana – Total 0.87 [0.77-1.77] 1,298 0.84 [0.77-1.18] 501 0.86 [0.77-1.70] 1,799 
Public health facility  0.85 [0.77-1.07] 107 0.85 [0.77-0.87] 259 0.85 [0.77-0.87] 366 
Private not-for-profit health facility 0.87 [0.86-1.43] 12 -0.09 [-0.17-0.77] 11 0.86 [-0.09-0.90] 23 
Private for-profit outlet       
   Health facility/pharmacy 1.10 [0.77-1.81] 806 0.77 [0.76-1.08] 61 1.08 [0.77-1.80] 867 
   Drug store 0.86 [0.77-1.76] 371 0.83 [0.77-1.71] 169 0.86 [0.77-1.71] 540 
   General retailer/itinerant 1.08 [0.77-1.08] 2 9.85 [9.85-9.85] 1 1.08 [0.77-9.85] 3 
   Total 0.89 [0.77-1.77] 1,179 0.83 [0.77-1.71] 231 0.87 [0.77-1.77] 1,410 
Community health worker - 0 - 0 - 0 
Kenya – Total 0.50 [0.35-1.08] 1,684 0.30 [-0.03-0.46] 864 0.35 [0.30-0.73] 2,548 
Public health facility  -0.05 [-0.11- -0.04] 173 -0.05 [-0.11- -0.04] 448 -0.05 [-0.11- -0.04] 621 
Private not-for-profit health facility 0.39 [-0.11-0.99] 21 0.35 [-0.05-0.53] 25 0.35 [-0.05-0.62] 46 
Private for-profit outlet       
   Health facility/pharmacy 0.55 [0.39-1.12] 782 0.41 [0.35-0.99] 152 0.46 [0.35-1.04] 934 
   Drug store 0.52 [0.35-1.09] 667 0.35 [0.30-0.53] 172 0.41 [0.35-0.89] 839 
   General retailer/itinerant 0.35 [0.30-0.63] 41 0.30 [0.30-0.35] 67 0.30 [0.30-0.35] 108 
   Total 0.52 [0.35-1.09] 1,490 0.35 [0.30-0.66] 391 0.40 [0.30-0.89] 1,881 
Community health worker - 0 - 0 - 0 
Madagascar – Total 0.28 [0.14-0.65] 554 -0.04 [-0.07-0.28] 1,350 -0.04 [-0.07-0.36] 1,904 
Public health facility  -0.06 [-0.07- -0.04] 100 -0.07 [-0.07- -0.06] 873 -0.06 [-0.07- -0.04] 973 
Private not-for-profit health facility -0.06 [-0.07- -0.04] 46 -0.06 [-0.07- -0.05] 4 -0.06 [-0.07- -0.04] 50 
Private for-profit outlet       
   Health facility/pharmacy 0.36 [0.25-0.78] 325 0.82 [0.36-1.64] 7 0.38 [0.28-0.82] 332 
   Drug store 0.36 [0.28-0.82] 72 0.53 [0.29-0.99] 444 0.48 [0.28-0.99] 516 
   General retailer/itinerant 0.95 [0.95-2.53] 2 0.53 [0.28-0.84] 4 0.53 [0.28-0.84] 6 
   Total 0.36 [0.28-0.82] 399 0.53 [0.28-0.95] 455 0.45 [0.28-0.84] 854 
Community health worker 0.27 [0.03-0.61] 9 -0.04 [-0.04-0.13] 18 0.11 [-0.04-0.27] 27 
Niger – Total 0.92 [0.61-1.55] 282 -0.06 [-0.08- -0.02] 77 0.61 [-0.06-1.32] 359 
Public health facility  0.61 [-0.04-0.73] 102 -0.06 [-0.08- -0.02] 65 -0.06 [-0.07-0.61] 167 
Private not-for-profit health facility - 0 -0.07 [-0.08- -0.05] 4 -0.07 [-0.08- -0.05] 4 
Private for-profit outlet       
   Health facility/pharmacy 1.11 [0.63-1.92] 151 0.54 [0.54-1.53] 4 1.11 [0.63-1.90] 155 
   Drug store 0.89 [0.72-2.70] 12 1.13 [1.13-1.24] 2 1.13 [0.89-1.24] 14 
   General retailer/itinerant 1.53 [1.03-2.32] 17 1.37 [1.37-1.4] 2 1.37 [1.17-1.92] 19 
   Total 1.31 [0.73-2.32] 180 1.24 [1.13-1.37] 8 1.31 [0.84-1.84] 188 
Community health worker - 0 - 0 - 0 
Nigeria - Total 1.32 [0.73-2.26] 1,251 1.35 [0.75-2.23] 468 1.33 [0.74-2.25] 1,719 
Public health facility  -0.06 [-0.10- -0.06] 45 -0.10 [-0.15- -0.06] 23 -0.06 [-0.15- -0.06] 68 
Private not-for-profit health facility 2.26 [0.58-2.81] 7 1.33 1 1.33 [0.58-2.81] 8 
Private for-profit outlet       
   Health facility/pharmacy 0.74 [0.71-2.61] 138 2.19 [1.02-3.41] 8 1.02 [0.73-2.83] 146 
   Drug store 1.32 [0.74-2.26] 1,016 1.35 [0.84-2.26] 431 1.33 [0.74-2.26] 1,447 
   General retailer/itinerant 1.64 [1.30-2.25] 39 1.79 [1.64-5.03] 4 1.64 [1.33-2.25] 43 
   Total 1.32 [0.74-2.26] 1,193 1.37 [0.87-2.26] 443 1.33 [0.74-2.26] 1,636 
Community health worker -0.08 [-0.10- -0.06] 6 6.92 1 -0.06 [-0.10-6.92] 7 
Tanzania - mainland - Total 0.98 [0.56-1.53] 1390 0.62 [0.47-1.10] 245 0.78 [0.47-1.21] 1,635 
Public health facility  0.24 [-0.04-0.60] 16 -0.04 [-0.05-0.55] 55 -0.04 [-0.05-0.55] 71 
Private not-for-profit health facility 1.12 [0.78-1.84] 4 -0.05 [-0.06--0.03] 4 -0.02 [-0.05-0.78] 8 
Private for-profit outlet       
   Health facility/pharmacy 1.15 [0.56-1.65] 986 0.73 [0.49-1.21] 38 1.12 [0.56-1.46] 1,024 
   Drug store 1.10 [0.68-1.83] 378 0.78 [0.49-1.20] 148 0.80 [0.55-1.21] 526 
   General retailer/itinerant 0.58 [0.49-0.59] 6 - 0 0.58 [0.49-0.59] 6 
   Total 1.10 [0.58-1.71] 1,370 0.78 [0.49-1.20] 186 0.84 [0.55-1.21] 1556 
Community health worker - 0 - 0 - 0 
154 
 
 
Table 2.3.19: Cont  
 Urban Rural Total 
Country/Type of outlet Median markup [IQR] No. of products Median markup [IQR] No. of products Median markup [IQR] No. of products 
Uganda - Total 1.83 [1.05-3.00] 1,983 1.44 [-0.03-2.22] 2,348 1.44 [0.34-2.29] 4,331 
Public health facility  -0.11 [-0.12- -0.03] 211 -0.11 [-0.12- -0.03] 1,265 -0.11 [-0.12- -0.03] 1,476 
Private not-for-profit health facility 2.81 [1.05-4.57] 5 0.85 [-0.03-1.44] 13 0.85 [-0.03-1.44] 18 
Private for-profit outlet       
   Health facility/pharmacy 1.90 [1.44-3.79] 1,359 1.9 [1.44-3.06] 552 1.90 [1.44-3.10] 1,911 
   Drug store 1.83 [1.11-2.61] 406 1.75 [1.05-2.29] 500 1.75 [1.05-2.29] 906 
   General retailer/itinerant 1.83 [1.83-1.83] 1 1.05 [0.81-2.22] 10 1.05 [0.81-2.22] 11 
   Total 1.89 [1.12-3.06] 1,766 1.83 [1.11-2.67] 1,062 1.83 [1.11-2.69] 2,828 
Community health worker 1.83 [1.83-1.83] 1 -0.02 [-0.02- -0.02] 8 -0.02 [-0.02- -0.02] 9 
Zanzibar - Total 0.53 [0.41-1.80] 478 -0.06 [-0.06-0.53] 318 0.53 [-0.06-1.11] 796 
Public health facility  -0.06 [-0.06- -0.03] 123 -0.06 [-0.06- -0.03] 225 -0.06 [-0.06- -0.03] 348 
Private not-for-profit health facility - 0 0.29 [0.23-1.33] 3 0.29 [0.23-1.33] 3 
Private for-profit outlet       
   Health facility/pharmacy 1.11 [0.53-2.30] 188 1.11 [0.53-1.83] 43 1.11 [0.53-2.27] 231 
   Drug store 1.11 [0.53-2.27] 165 0.88 [0.53-2.05] 44 1.11 [0.53-2.27] 209 
   General retailer/itinerant 1.41 [0.53-2.30] 2 0.53 [0.53-0.53] 3 0.53 [0.53-0.53] 5 
   Total 1.11 [0.53-2.27] 355 0.88 [0.53-1.83] 90 1.11 [0.53-2.27] 445 
Community health worker - 0 - 0 - 0 
*Median total gross markup is the median of the difference between the retail selling price and the mean first line buyer price for each QAACT. 
**First Line Buyer (FLB) price data were provided by The Global Fund.  
*** An AETD is the number of milligrams (mg) of a given drug that is required to treat a 60 kg adult. AETDs were calculated for every audited antimalarial. 
IQR = Interquartile range 
Source: AMFm Phase 1 Independent Evaluation Outlet Survey  
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2.3.4 Availability and cost to patients of diagnostic tests (RDT/microscopy) 
Table 2.3.20 shows the availability of any diagnostic test for malaria in outlets stocking 
antimalarials at baseline and endline, indicating the percentage of outlets having either malaria 
microscopy or malaria RDTs. At endline, availability of any diagnostic test was highly variable 
across countries, varying from 3% of outlets in Nigeria to 56% in Zanzibar. Availability of 
diagnostics was significantly higher in the public sector than in private for-profit outlets in all 
countries. Kenya, Uganda and Zanzibar stand out as the only countries with substantial 
availability in the private for-profit sector, with 14%, 21% and 32% availability, respectively. 
There were significant differences between availability in all outlets in urban and rural areas in 
Kenya, Nigeria and Zanzibar, with higher availability in rural areas in Niger and Zanzibar, and 
higher availability in urban areas in Kenya. There was no change in availability of any diagnostic 
between baseline and endline, except in Madagascar where it increased from 9 to 19%, and 
Uganda where it increased from 18% to 32%. 
 
Table 2.3.21 shows the availability of malaria microscopy in outlets stocking antimalarials. At 
endline, availability of microscopy varied from 1% in Niger to 34% in Zanzibar. Microscopy 
was significantly more likely to be available in the public sector than in private for-profit outlets 
in all countries. Public sector availability varied from 5% in Madagascar to 42% in Kenya. There 
was no change in availability of microscopy between baseline and endline in any country. 
 
Table 2.3.21 shows the availability of RDTs in outlets stocking antimalarials. At endline, RDT 
availability varied from 2% in Nigeria to 35% in Zanzibar. As with microscopy, RDTs were 
significantly more likely to be available in the public sector than in private for-profit outlets in all 
countries. Public sector availability was high in some countries, at 94% in Madagascar, 64% in 
Niger and 85% in Zanzibar, but only 9% in Nigeria. Following the patterns seen for “any 
diagnostic” (Table 2.3.20), there was no increase in availability of RDTs between baseline and 
endline except in Madagascar and Uganda, indicating that the gains in availability seen in these 
two countries are due to increasing availability of RDTs rather than microscopy. 
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Table 2.3.20: Availability of any diagnostic test for malaria at baseline (2010) and endline (2011) 
Percentage of outlets where any test for malaria (RDTs or microscopy) was available (n) as a percentage of outlets with any antimalarials in stock at the time of 
the survey visit (N), by location and type of outlet, according to country 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N 
Ghana - Total 10.7 (7.2-15.5) 600 10.8 (8.8-13.2) 543 10.8 (9.0-12.9) 1,143 6.6 (4.8-9.1) 564 12.1 (8.4-17.0) 379 8.7 (6.8-11.1) 943 
Public health facility  48.1 (33-63.7) 68 75.6 (65.1-83.7) 135 71.8 (62.6-79.4) 203 42.5 (32.4-53.1) 93 40.3 (28.4-53.4) 203 40.9 (31.9-50.6) 296 
Private not-for-profit health facility 49.2 (17-82) 5 61.2 (35.5-81.9) 9 59.1 (37.0-78.0) 14 20.0 (3.7-62) 4 12.7 (2.0-50.3) 8 15.7 (4.7-41.5) 12 
Private for-profit outlet             
   Health facility/pharmacy 14.4 (8.4-23.4) 314 37.6 (24.9-52.4) 62 23.3 (17.2-30.8) 376 13.6 (8.7-20.6) 265 35.2 (18.1-57.3) 26 16.5 (11.4-23.3) 291 
   Drug store 1.7 (0.6-5) 211 0.0 331 0.2 (0.1-0.7) 542 0.6 (0.1-2.6) 199 1.3 (0.4-4.3) 139 0.9 (0.3-2.2) 338 
   General retailer/itinerant 0.0 2 0.0 3 0.0 5 0.0 3 0.0 3 0.0 6 
   Total 7.6 (4.4-12.9) 527 2.7 (1.7-4.2) 396 3.7 (2.6-5.2) 923 4.1 (2.2-7.2) 467 3.9 (2.1-7.1) 168 4.0 (2.6-6.2) 635 
Community health worker - 0 100.0 3 100.0 3 - 0 - 0 - 0 
Kenya - Total 23.8 (20.3-27.8) 1,026 15.6 (12.8-18.9) 869 17.6 (15.2-20.2) 1,895 27.5 (23.2-32.2) 1,042 18.8 (15.5-22.6) 799 21.2 (18.5-24.3) 1,841 
Public health facility  38.2 (29.1-48.3) 135 47.0 (38.7-55.4) 258 45.0 (38.2-52.0) 393 69.9 (58.9-79) 137 54.8 (45.8-63.5) 294 56.0 (47.6-64.0) 431 
Private not-for-profit health facility 83.3 (61.7-93.9) 23 92.8 (72.6-98.4) 15 90.1 (76.3-96.2) 38 91.5 (64.3-98.5) 19 79.3 (61.4-90.2) 27 81.7 (66.5-91.0) 46 
Private for-profit outlet             
    Health facility/pharmacy 49.4 (37.1-61.8) 358 42.5 (26.8-60.0) 103 45.6 (34.9-56.8) 461 58.3 (50.4-65.7) 406 32.9 (22.9-44.7) 112 42.6 (35.1-50.4) 518 
   Drug store 10.3 (6.1-16.8) 267 11.3 (8.2-15.4) 156 11.1 (8.4-14.6) 423 13.8 (10.1-18.5) 326 5.8 (2.6-12.2) 145 9.0 (6.0-13.3) 471 
   General retailer/itinerant 0.0 239 0.0 316 0.0 555 0.0 154 0.0 221 0.0 375 
   Total 20.2 (16-25.1) 864 10.2 (7.9-13.1) 575 12.7 (10.6-15.1) 1,439 24.3 (20.2-28.9) 886 9.2 (5.7-14.3) 478 13.9 (10.9-17.4) 1,364 
Community health worker 0.0 4 0.0 21 0.0 25 - 0 - 0 - 0 
Madagascar - Total 10.3 (6.4-16.2) 1,437 9.1 (6.1-13.4) 962 9.4 (6.7-12.9) 2,399 15.0 (12.6-17.8) 979 19.3 (14.5-25.1) 1,387 18.7 (14.6-23.6) 2,366 
Public health facility  75.1 (65.4-82.9) 67 94.1 (88.6-97) 444 88.8 (82.8-92.8) 511 98.5 (93.8-99.6) 65 93.9 (91.4-95.8) 553 94.4 (92.1-96.1) 618 
Private not-for-profit health facility 31.9 (10.9-64.3) 6 - 0 31.9 (10.9-64.3) 6 91.6 (67.4-98.3) 25 60.8 (18.9-91.2) 5 72.7 (41.7-90.9) 30 
Private for-profit outlet             
   Health facility/pharmacy 16.3 (7.9-30.8) 122 0.0 9 9.2 (4.9-16.6) 131 16.6 (12.2-22.1) 105 0.0 12 9.1 (4.9-16.1) 117 
   Drug store 0.8 (0.1-5.0) 28 0.0 227 0.3 (0.1-1.5) 255 0.0 28 1.7 (0.7-3.9) 347 1.5 (0.6-3.5) 375 
   General retailer/itinerant 0.0 1,212 0.0 244 0.0 1,456 0.0 741 0.0 404 0.0 1,145 
   Total 2.0 (1.3-2.9) 1,362 0.0 480 0.4 (0.3-0.7) 1,842 2.5 (1.5-4.1) 874 0.1 (0.1-0.3) 763 0.5 (0.3-0.9) 1,637 
Community health worker 0.0 2 16.0 (3.2-52.3) 38 15.9 (3.2-52.2) 40 88.5 (72.9-95.6) 15 64.6 (45-80.3) 66 65.2 (45.8-80.6) 81 
Niger - Total 4.5 (2.9-6.9) 833 5.4 (4.0-7.1) 1,198 5.2 (4.1-6.6) 2,031 5.6 (4.7-6.6) 923 7.3 (5.8-9.1) 737 6.8 (5.7-8.2) 1,660 
Public health facility  70.5 (57.4-80.9) 91 59.1 (52.2-65.5) 385 60.2 (53.9-66.1) 476 67.0 (62.5-71.2) 102 65.2 (57.1-72.5) 220 65.5 (58.5-71.8) 322 
Private not-for-profit health facility 68.0 (15.2-96.2) 4 - 0 68.0 (15.2-96.2) 4 49.2 (11.3-88.1) 2 100.0 1 83.3 (41.4-97.2) 3 
Private for-profit outlet             
   Health facility/pharmacy 31.1 (14.4-54.7) 106 0.0 12 26.5 (11.9-49.1) 118 43.2 (34.1-52.7) 95 0.0 4 40.7 (31.7-50.4) 99 
   Drug store 0.0 14 0.0 7 0.0 21 4.4 (1.1-15.8) 15 0.0 3 1.9 (0.4-8.0) 18 
   General retailer/itinerant 0.0 617 0.0 792 0.0 1,409 0.0 709 0.0 509 0.0 1,218 
   Total 1.5 (0.6-3.7) 737 0.0 811 0.3 (0.1-0.7) 1,548 2.4 (1.8-3.1) 819 0.0 516 0.7 (0.5-1.0) 1,335 
Community health worker 0.0 1 0.0 2 0.0 3 - 0 - 0 - 0 
Nigeria - Total 1.5 (0.8-3.0) 1,693 8.9 (4.3-17.3) 354 3.1 (1.7-5.7) 2,047 6.2 (3.3-11.1) 1,010 5.9 (3.4-10.1) 467 6.1 (4.0-9.2) 1,477 
Public health facility  33.2 (21.6-47.3) 181 28.3 (9.1-60.9) 45 28.6 (10-59.1) 226 58.5 (35.8-78.1) 42 15.4 (7.8-28.1) 51 29.2 (17.9-43.7) 93 
Private not-for-profit health facility 92.7 (61.1-99.0) 6 85.5 (29-98.8) 2 86.1 (33.9-98.7) 8 79.7 (39.3-96.0) 6 100.0  3 87.3 (51.3-97.8) 9 
Private for-profit outlet             
   Health facility/pharmacy 27.8 (22.6-33.8) 713 28.5 (21.4-36.8) 24 28.3 (22.8-34.6) 737 32.8 (22.5-45.0) 94 31.5 (11.9-61.0) 31 32.3 (21.4-45.5) 125 
   Drug store 1.3 (0.5-3.0) 704 0.0 261 1.1 (0.4-2.6) 965 0.7 (0.2-2.1) 794 1.1 (0.2-6.5) 359 0.8 (0.3-2.4) 1,153 
   General retailer/itinerant 0.0 83 0.0 16 0.0 99 0.0 71 0.0 19 0.0 90 
   Total 1.4.0 (0.7-2.9) 1,500 4.6 (1.7-11.7) 301 2.0 (1.0-3.9) 1,801 3.7 (1.9-7.0) 959 3.9 (1.5-9.9) 409 3.7 (2.1-6.5) 1,368 
Community health worker 0.0 6 0.0 6 0.0 12 0.0 3 0.0 4 0.0 7 
Tanzania - mainland - Total 9.6 (6.7-13.7) 315 12.7 (8.9-17.8) 302 12.0 (8.9-16) 617 11.9 (8.8-15.9) 583 16.0 (10-24.6) 191 14.5 (10.4-19.9) 774 
Public health facility  42.2 (6.8-87.9) 5 36.5 (22.7-52.9) 55 36.9 (23.5-52.7) 60 91.9 (55.4-99) 6 45.9 (27.6-65.4) 48 47.7 (29.7-66.3) 54 
Private not-for-profit health facility 55.6 (27.3-80.7) 6 80.7 (51.1-94.4) 16 76.0 (53.1-89.9) 22 100.0 4 47.8 (4.9-94.2) 2 75.6 (25.6-96.5) 6 
Private for-profit outlet             
   Health facility/pharmacy 24.9 (10.4-48.6) 219 37.2 (5.6-85.6) 12 27.2 (12.5-49.4) 231 49.3 (35.9-62.9) 313 19.6 (2.2-72.3) 16 41.5 (26.1-58.7) 329 
   Drug store 0.8 (0.1-4.5) 84 0.0 148 0.3 (0-1.7) 232 2.0 (1.2-3.3) 256 2.4 (0.7-7.8) 113 2.2 (1-4.7) 369 
   General retailer/itinerant 0.0 1 0.0 70 0.0 71 0.0 4 6.8 (0.5-49.5) 12 6.3 (0.5-45.5) 16 
   Total 5.2 (2.1-12.1) 304 0.5 (0.1-3.8) 230 1.7 (0.7-4.0) 534 8.7 (6.5-11.6) 573 3.5 (1.5-8.2) 141 5.8 (3.9-8.6) 714 
Community health worker - 0 0.0 1 0.0 1 - 0 - 0 - 0 
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Table 2.3.20: Cont. 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N 
Uganda - Total 31.4 (22.9-41.3) 540 15.0 (11.1-20.0) 1,873 18.4 (13.7-24.3) 2,413 38.0 (31.8-44.6) 1,400 30.2 (23-38.4) 1,715 31.8 (25.7-38.5) 3,115 
Public health facility  50.7 (38.1-63.3) 76 33.1 (26.8-40.1) 693 34.9 (28.9-41.3) 769 76.2 (64.9-84.7) 144 74.7 (68.1-80.3) 532 74.9 (69.1-79.9) 676 
Private not-for-profit health facility 100.0 4 47.0 (16.4-80.0) 26 55.0 (21.5-84.5) 30 92.2 (59.8-99) 12 96.0 (75.3-99.5) 26 95.6 (79.4-99.2) 38 
Private for-profit outlet             
   Health facility/pharmacy 44.2 (40.7-47.7) 385 47.8 (39.9-55.8) 355 46.0 (41.6-50.5) 740 54.2 (49.3-59) 805 54,0 (46,0-61.8) 386 54.1 (49.1-58.9) 1,191 
   Drug store 9.3 (3.3-23.8) 72 3.6 (2.2-5.8) 751 4.3 (2.6-7.2) 823 10.1 (7.8-12.9) 433 6.6 (4.3-10,0) 675 7.1 (5.0-10.0) 1,108 
   General retailer/itinerant 0.0 2 0.0 19 0.0 21 0.0 4 0.0 14 0.0 18 
   Total 29.1 (19.5-41) 459 11.4 (7.2-17.5) 1,125 15.5 (10.2-22.8) 1,584 34.9 (27.4-43.3) 1,242 16.8 (11.8-23.3) 1,075 21.1 (15.9-27.3) 2,317 
Community health worker 0.0 1 14.3 (0.8-77.5) 29 14.0 (0.8-76.4) 30 0.0 2 71.1 (39.7-90.2) 82 70.8 (39.5-90.0) 84 
Zanzibar - Total 56.1 189 71.8 124 62.3 313 46.8 222 72.5 120 55.8 342 
Public health facility  94.6 56 92.8 83 93.5 139 97.9 48 97.4 76 97.6 124 
Private not-for-profit health facility 100.0 2 100.0 1 100.0 3 100.0 1 100.0 1 100.0 2 
Private for-profit outlet             
   Health facility/pharmacy 69.9 73 90.9 11 72.6 84 63.4 82 75.0 16 65.3 98 
   Drug store 0.0 57 4.0 25 1.2 82 3.4 88 0.0 24 2.7 112 
   General retailer/itinerant 0.0 1 0.0 4 0.0 5 33.3 3 0.0 3 16.7 6 
   Total 38.9 131 27.5 40 36.3 171 32.4 173 27.9 43 31.5 216 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Note: Malaria testing is considered to be available if the respondent reported that the service was available in the outlet on the day of the survey visit. Nigeria baseline data collection was conducted in 
2009. 
CI = Confidence interval 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.3.21: Availability of malaria microscopy at baseline (2010) and endline (2011) 
Percentage of outlets where malaria microscopic tests were available (n) among outlets with any antimalarials in stock at the time of the survey visit (N), by urban-rural location and type of outlet, 
according to country 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N 
Ghana - Total 6.7 (3.5-12.3) 600 4.7 (3.4-6.3) 542 5.1 (3.8-6.7) 1,142 4.7 (3.1-7.1) 564 6.7 (3.6-11.9) 378 5.5 (3.8-7.8) 942 
Public health facility  18.1 (12.0-26.2) 68 22.5 (15.5-31.6) 134 21.9 (15.7-29.6) 202 25.9 (15.2-40.5) 93 24.1 (13.4-39.5) 203 24.6 (16-35.9) 296 
Private not-for-profit health facility 34.4 (8.7-74.3) 5 61.2 (35.5-81.9) 9 56.5 (34.9-75.9) 14 0.0 4 12.7 (2.0-50.3) 8 7.4 (1.2-33.8) 12 
Private for-profit outlet             
   Health facility/pharmacy 11.7 (5.8-22.1) 314 23.8 (13.3-39) 62 16.3 (10.6-24.3) 376 11.3 (6.9-18) 265 9.3 (1.6-39.1) 25 11.1 (6.9-17.4) 290 
   Drug store 0.0 211 0.0 331 0.0 542 0.6 (0.1-2.6) 199 0.7 (0.1-3.8) 139 0.6 (0.2-1.9) 338 
   General retailer/itinerant 0.0 2 0.0 3 0.0 5 0.0 3 0.0 3 0.0 6 
   Total 5.4 (2.4-11.6) 527 1.7 (0.9-3.2) 396 2.4 (1.5-4.1) 923 3.4 (1.9-6.2) 467 1.3 (0.4-4.2) 167 2.7 (1.6-4.7) 634 
Community health worker - 0 0.0 3 0.0 3 - 0 - 0 - 0 
Kenya - Total 21.2 (17.5-25.3) 1,026 13.7 (11.4-16.4) 871 15.5 (13.5-17.6) 1,897 24.7 (20.7-29.3) 1,042 15.1 (12.4-18.3) 799 17.8 (15.4-20.6) 1,841 
Public health facility  31.5 (23.5-40.7) 135 42.3 (33.6-51.4) 258 39.8 (32.6-47.5) 393 58.4 (46.3-69.5) 137 40.7 (32.3-49.7) 294 42.0 (34.1-50.4) 431 
Private not-for-profit health facility 83.3 (61.7-93.9) 23 92.8 (72.6-98.4) 15 90.1 (76.3-96.2) 38 80.0 (53-93.4) 19 79.3 (61.4-90.2) 27 79.4 (64.6-89.1) 46 
Private for-profit outlet             
   Health facility/pharmacy 45.3 (32.5-58.8) 358 34.7 (21.8-50.3) 103 39.5 (29.9-49.9) 461 55.3 (48.2-62.1) 406 25.4 (17-36.2) 112 36.8 (29.2-45.2) 518 
   Drug store 7.5 (4.1-13.4) 267 9.9 (6.4-15.1) 156 9.4 (6.3-13.8) 423 11.0 (8.6-14.0) 326 4.7 (2.0-10.6) 145 7.2 (4.8-10.8) 471 
   General retailer/itinerant 0.0 239 0.0 318 0.0 557 0.0 154 0.0 221 0.0 375 
   Total 17.9 (13.6-23.1) 864 8.5 (6.5-11.1) 577 10.8 (9.0-13.0) 1,441 22.1 (18.3-26.4) 886 7.2 (4.6-11) 478 11.8 (9.4-14.7) 1,364 
Community health worker 0.0 4 0.0 21 0.0 25 - 0 - 0 - 0 
Madagascar - Total 1.5 (0.9-2.4) 1,437 0.1 (0.1-0.3) 962 0.4 (0.3-0.7) 2,399 3.5 (2.7-4.5) 979 1.1 (0.3-3.9) 1,387 1.4 (0.6-3.3) 2,366 
Public health facility  8.4 (3.2-20.1) 67 1.9 (0.8-4.1) 444 3.7 (2.1-6.4) 511 22.1 (15.3-30.8) 65 3.1 (1.9-4.8) 553 5.2 (3.9-6.8) 618 
Private not-for-profit health facility 4.7 (0.9-21.5) 6 - 0 4.7 (0.9-21.5) 6 36.2 (23.3-51.5) 25 0.0 5 14.0 (6.5-27.5) 30 
Private for-profit outlet             
   Health facility/pharmacy 5.1 (2.3-11.2) 122 0.0 9 2.9 (1.4-6.0) 131 4.3 (2.3-8) 105 0.0 12 2.4 (1.2-4.8) 117 
   Drug store 0.0 28 0.0 227 0.0 255 0.0 28 0.0 347 0.0 375 
   General retailer/itinerant 0.0 1,212 0.0 244 0.0 1,456 0.0 741 0.0 404 0.0 1,145 
   Total 0.6 (0.4-0.9) 1,362 0.0 480 0.1 (0.1-0.3) 1,842 0.6 (0.3-1.2) 874 0.0 763 0.1 (0-0.2) 1,637 
Community health worker 0.0 2 0.0 38 0.0 40 0.0 15 5.7 (1.2-22.5) 66 5.6 (1.2-22.2) 81 
Niger - Total 3.2 (1.8-5.4) 833 0.2 (0.1-0.5) 1,198 0.8 (0.5-1.3) 2,031 3.2 (2.6-3.9) 923 0.4 (0.1-1) 737 1.1 (0.8-1.5) 1,660 
Public health facility  40.5 (33-48.5) 91 2.7 (1.5-5.1) 385 6.5 (4.6-9) 476 33.6 (26.9-41.1) 102 1.4 (0.4-5) 220 6 (4.1-8.7) 322 
Private not-for-profit health facility 68.0 (15.2-96.2) 4 - 0 68.0 (15.2-96.2) 4 0.0 2 100.0 1 67.1 (23.4-93.1) 3 
Private for-profit outlet             
   Health facility/pharmacy 27.8 (11.6-53.0) 106 0.0 12 23.8 (9.7-47.5) 118 31.1 (21.7-42.2) 95 0.0 4 29.3 (20.2-40.4) 99 
   Drug store 0.0 14 0.0 7 0.0 21 0.0 15 0.0 3 0.0 18 
   General retailer/itinerant 0.0 617 0.0 792 0.0 1,409 0.0 709 0.0 509 0.0 1,218 
   Total 1.3 (0.5-3.6) 737 0.0 811 0.3 (0.1-0.7) 1,548 1.7 (1.1-2.5) 819 0.0 516 0.5 (0.3-0.8) 1,335 
Community health worker 0.0 1 0.0 2 0.0 3 - 0 - 0 - 0 
Nigeria - Total 1.0 (0.5-2.0) 1,702 8.8 (4.3-17.2) 357 2.6 (1.3-5.2) 2,059 4.5 (2.1-9.3) 1,010 4.3 (2.3-8.1) 467 4.5 (2.7-7.4) 1,477 
Public health facility  33.2 (21.6-47.3) 181 28.3 (9.1-60.9) 45 28.6 (10.0-59.1) 226 36.4 (17.6-60.5) 42 10.4 (4.7-21.7) 51 18.7 (10.9-30.2) 93 
Private not-for-profit health facility 92.7 (61.1-99) 6 85.5 (29.0-98.8) 2 86.1 (33.9-98.7) 8 79.1 (39.5-95.6) 6 100.0 3 86.9 (51.7-97.6) 9 
Private for-profit outlet             
   Health facility/pharmacy 24.4 (20.0-29.4) 716 28.1 (21.2-36.1) 24 27.2 (22.2-32.9) 740 28.8 (18.7-41.7) 94 28.3 (9.6-59.5) 31 28.6 (17.9-42.4) 125 
   Drug store 0.7 (0.2-2.2) 710 0.0 264 0.6 (0.2-1.9) 974 0.0 (0.0-0.1) 794 0.0 359 0.0 (0.0-0.1) 1,153 
   General retailer/itinerant 0.0 83 0.0 16 0.0 99 0.0 71 0.0 19 0.0 90 
   Total 0.9 (0.4-1.9) 1,509 4.5 (1.6-11.6) 304 1.5 (0.7-3.3) 1,813 2.7 (1.2-5.9) 959 2.7 (0.9-8.0) 409 2.7 (1.4-5.1) 1,368 
Community health worker 0.0 6 0.0 6 0.0 12 0.0 3 0.0 4 0.0 7 
Tanzania - mainland - Total 8.0 (4.5-13.9) 315 6.9 (4.4-10.6) 302 7.1 (4.9-10.2) 617 11.2 (8-15.4) 583 6.8 (3.7-12.1) 191 8.4 (5.8-11.9) 774 
Public health facility  42.2 (6.8-87.9) 5 13.5 (6.8-25.1) 55 15.5 (8.0-27.9) 60 91.9 (55.4-99) 6 17.6 (9-31.6) 48 20.5 (11.5-33.8) 54 
Private not-for-profit health facility 55.6 (27.3-80.7) 6 62.5 (32.7-85.1) 16 61.2 (36.4-81.4) 22 100.0 4 47.8 (4.9-94.2) 2 75.6 (25.6-96.5) 6 
Private for-profit outlet             
   Health facility/pharmacy 18.5 (5.0-49.1) 219 37.2 (5.6-85.6) 12 21.9 (7.7-48.5) 231 48.1 (34.5-62.0) 313 19.6 (2.2-72.3) 16 40.6 (25.3-57.8) 329 
   Drug store 0.0 84 0.0 148 0.0 232 1.3 (0.6-2.6) 256 1.3 (0.3-5.5) 113 1.3 (0.5-3.1) 369 
   General retailer/itinerant 0.0 1 0.0 70 0.0 71 0.0 4 0.0 12 0.0 16 
   Total 3.4 (0.8-12.8) 304 0.5 (0.1-3.8) 230 1.3 (0.4-3.9) 534 8 (5.7-11) 573 1.9 (0.6-5.6) 141 4.6 (3-7) 714 
Community health worker - 0 0.0 1 0.0 1 - 0 - 0 - 0 
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Table 2.3.21: Cont. 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N 
Uganda - Total 25.6 (21.3-30.4) 540 12.4 (9.7-15.8) 1,873 15.2 (11.8-19.3) 2,413 27.8 (22.7-33.6) 1,400 14.0 (10.7-18.1) 1,715 16.8 (13.3-21.0) 3,115 
Public health facility  50.7 (38.1-63.3) 76 29.6 (24.4-35.4) 693 31.7 (26.6-37.2) 769 52.3 (42.4-62.1) 144 38.3 (33.4-43.4) 531 40.3 (35.8-44.9) 675 
Private not-for-profit health facility 100.0 4 45.2 (15.9-78.3) 26 53.5 (21.1-83.2) 30 92.2 (59.8-99) 12 75.3 (44.7-92) 26 77.1 (49.2-92.2) 38 
Private for-profit outlet             
   Health facility/pharmacy 35.3 (31.6-39.1) 385 43.1 (35-51.6) 355 39.3 (33.9-45) 740 42.5 (36.9-48.3) 805 41.7 (36.5-47.1) 386 42.0 (38.2-46) 1,191 
   Drug store 6.4 (2-18.8) 72 2.2 (1.2-4) 751 2.7 (1.5-5.1) 823 3.4 (1.7-6.7) 433 2.3 (1.2-4.7) 676 2.5 (1.4-4.4) 1,109 
   General retailer/itinerant 0.0 2 0.0 19 0.0 21 0.0 4 0.0 14 0.0 18 
   Total 22.8 (17.5-29.2) 459 9.5 (6.3-13.9) 1,125 12.5 (8.7-17.7) 1,584 25.4 (19.6-32.3) 1,242 10.9 (7.5-15.6) 1,076 14.3 (10.6-19.1) 2,318 
Community health worker 0.0 1 2.0 (0.1-22.8) 29 2.0 (0.1-21.9) 30 0.0 2 2.0 (0.4-8.6) 82 2.0 (0.4-8.6) 84 
Zanzibar - Total 40.7 189 24.2 124 34.2 313 34.2 222 32.5 120 33.6 342 
Public health facility  44.6 56 21.7 83 30.9 139 50 48 34.2 76 40.3 124 
Private not-for-profit health facility 100.0 2 100.0 1 100.0 3 100.0 1 100.0 1 100.0 2 
Private for-profit outlet             
   Health facility/pharmacy 68.5 73 90.9 11 71.4 84 59.8 82 75 16 62.2 98 
   Drug store 0.0 57 4.0 25 1.2 82 1.1 88 0 24 0.9 112 
   General retailer/itinerant 0.0 1 0.0 4 0.0 5 33.3 3 0 3 16.7 6 
   Total 38.2 131 27.5 40 35.7 171 29.5 173 27.9 43 29.2 216 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Note: Malaria microscopic testing is considered to be available if the respondent reported that the service was available in the outlet on the day of the survey visit. Nigeria baseline data collection was conducted in 2009. 
CI = Confidence interval  
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.3.22: Availability of RDTs at baseline (2010) and endline (2011) 
Percentage of outlets where rapid diagnostic tests for malaria were available (n) among outlets with any antimalarials in stock at the time of the survey visit (N), by urban-rural location and type of 
outlet, according to country 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N 
Ghana - Total 5.0 (3.4-7.3) 601 7.5 (5.7-9.8) 543 7.0 (5.5-8.9) 1,144 3.0 (2.0-4.5) 575 8.8 (5.9-13.0) 382 5.3 (3.9-7.1) 957 
Public health facility  36.1 (21.9-53.4) 68 62.4 (53.2-70.8) 135 58.7 (50.5-66.6) 203 32.3 (20.5-46.9) 94 32.2 (21.2-45.7) 204 32.3 (23.5-42.5) 298 
Private not-for-profit health facility 14.8 (3.1-48.4) 5 13.8 (2.5-50.3) 9 13.9 (3.4-43.1) 14 20.0 (3.7-62.0) 4 0.0 9 7.9 (1.6-31.0) 13 
Private for-profit outlet             
   Health facility/pharmacy 4.2 (2.4-7.3) 315 17.9 (8.7-33.5) 62 9.5 (5.5-15.8) 377 3.1 (2.0-4.8) 272 26.7 (11.7-50) 26 6.2 (3.6-10.4) 298 
   Drug store 1.7 (0.6-5.0) 211 0.0 331 0.2 (0.1-0.7) 542 0.0 202 0.6 (0.1-3.5) 140 0.2 (0.0-1.4) 342 
   General retailer/itinerant 0.0 2 0.0 3 0.0 5 0.0 3 0.0 3 0.0 6 
   Total 2.9 (1.8-4.7) 528 1.3 (0.7-2.5) 396 1.6 (1.0-2.6) 924 0.8 (0.5-1.5) 477 2.6 (1.2-5.7) 169 1.4 (0.9-2.4) 646 
Community health worker - 0 100.0 3 100.0 3 - 0 - 0 - 0 
Kenya - Total 4.9 (3.1-7.8) 1,027 2.4 (1.2-4.8) 870 3.0 (1.9-4.8) 1,897 6.1 (4.4-8.4) 1,047 4.7 (2.7-8.1) 801 5.1 (3.4-7.4) 1,848 
Public health facility  9.0 (3.6-20.4) 135 5.6 (2.1-13.8) 258 6.3 (3.1-12.6) 393 17.6 (8.8-32.1) 137 19.8 (9.3-37.3) 294 19.6 (9.7-35.7) 431 
Private not-for-profit health facility 17.8 (6.2-41.3) 23 18.1 (4.8-48.9) 15 18.0 (6.8-39.9) 38 32.1 (15.6-54.8) 19 3.9 (0.6-20.4) 27 9.4 (4.3-19.6) 46 
Private for-profit outlet             
   Health facility/pharmacy 7.6 (4.5-12.7) 358 8.6 (2.0-30.3) 103 8.1 (3.4-18.1) 461 7.7 (3.6-15.8) 407 7.4 (3.4-15.4) 112 7.5 (4.3-12.8) 519 
   Drug store 4.4 (2.0-9.5) 268 1.4 (0.2-10.5) 156 2.1 (0.6-6.9) 424 5.7 (2.6-12.2) 329 1.1 (0.1-7.8) 145 2.9 (1.3-6.7) 474 
   General retailer/itinerant 0.0 239 0.0 317 0.0 556 0.0 155 0.0 223 0.0 378 
   Total 4.0 (2.3-6.8) 865 1.7 (0.5-5.3) 576 2.3 (1.1-4.6) 1,441 5.0 (3.0-8.2) 891 2 (0.8-4.7) 480 2.9 (1.8-4.8) 1,371 
Community health worker 0.0 4 0.0 21 0.0 25 - 0 - 0 -- 0 
Madagascar - Total 10.0 (6.1-16.0) 1,437 9.1 (6.1-13.4) 962 9.3.0 (6.6-12.8) 2,399 14.5 (12.2-17.3) 979 19.2 (14.5-25.1) 1387 18.6 (14.5-23.5) 2,366 
Public health facility  74.2 (64.7-81.9) 67 93.3 (87.4-96.6) 444 88.0 (82.0-92.2) 511 96.1 (90.1-98.5) 65 93.7 (91.2-95.5) 553 94.0 (91.7-95.7) 618 
Private not-for-profit health facility 31.9 (10.9-64.3) 6 - 0 31.9 (10.9-64.3) 6 85.4 (67.6-94.3) 25 60.8 (18.9-91.2) 5 70.3 (40.1-89.4) 30 
Private for-profit outlet             
   Health facility/pharmacy 14.0 (6.5-27.6) 122 0.0 9 7.9 (4.1-14.9) 131 15.7 (11.5-21.1) 105 0.0 12 8.6 (4.7-15.3) 117 
   Drug store 0.8 (0.1-5.0) 28 0.0 227 0.3 (0.1-1.5) 255 0.0 28 1.7 (0.7-3.9) 347 1.5 (0.6-3.5) 375 
   General retailer/itinerant 0.0 1,212 0.0 244 0.0 1,456 0.0 741 0.0 404 0.0 1145 
   Total 1.7 (1.0-2.8) 1,362 0.0 480 0.4 (0.0.2-0.7) 1,842 2.3 (1.4-3.9) 874 0.1 (0.1-0.3) 763 0.5 (0.3-0.9) 1637 
Community health worker 0.0 2 16.0 (3.2-52.3) 38 15.9 (3.2-52.2) 40 88.5 (72.9-95.6) 15 64.6 (45.0-80.3) 66 65.2 (45.8-80.6) 81 
Niger - Total 2.7 (1.6-4.4) 833 5.3 (4-7.1) 1,198 4.8 (3.7-6.2) 2,031 4.3 (3.3-5.5) 923 7 (5.5-8.9) 737 6.3 (5.2-7.6) 1,660 
Public health facility  53.7 (36.3-70.2) 91 58.8 (51.9-65.4) 385 58.3 (51.8-64.5) 476 58.9 (51.7-65.8) 102 64.8 (56.7-72.2) 220 64.0 (57.0-70.5) 322 
Private not-for-profit health facility 0.0 4 - 0 0.0 4 49.2 (11.3-88.1) 2 0.0 1 16.2 (2.7-57.6) 3 
Private for-profit outlet             
   Health facility/pharmacy 12.4 (4.6-29.5) 106 0.0 12 10.6 (3.8-26.3) 118 25.7 (17.2-36.6) 95 0.0 4 24.3 (16.2-34.8) 99 
   Drug store 0.0 14 0.0 7 0.0 21 4.4 (1.1-15.8) 15 0.0 3 1.9 (0.4-8) 18 
   General retailer/itinerant 0.0 617 0.0 792 0.0 1,409 0.0 709 0.0 509 0.0 1218 
   Total 0.6 (0.2-1.9) 737 0.0 811 0.1 (0.0-0.4) 1,548 1.4 (1.0-2.1) 819 0.0 516 0.4 (0.3-0.6) 1335 
Community health worker 0.0 1 0.0 2 0.0 3 - 0 - 0 - 0 
Nigeria - Total 0.6 (0.2-2) 1,692 2.6 (0.8-8.2) 355 1.1 (0.5-2.5) 2,047 2.7 (1.7-4.4) 1,011 2.2 (0.7-6.8) 467 2.5 (1.5-4.2) 1,478 
Public health facility  10.2 (4.0-23.6) 179 9.1 (1.7-37.1) 45 9.1 (1.9-34.6) 224 34.7 (12.7-66.1) 42 7.6 (3.0-18.0) 51 16.3 (7.1-33.0) 93 
Private not-for-profit health facility 15.3 (2.2-59.5) 6 0.0 2 1.3 (0.1-12.9) 8 27.1 (3.5-79.4) 6 0.0 3 16.9 (2.4-62.3) 9 
Private for-profit outlet             
   Health facility/pharmacy 10.2 (6.9-14.9) 712 8.3 (1.3-38.4) 24 8.8 (2.2-28.9) 736 8.9 (3.4-21.2) 94 7.2 (1.3-31.0) 31 8.3 (3.6-17.9) 125 
   Drug store 0.6 (0.1-2.4) 706 0.0 262 0.5 (0.1-2.0) 968 0.7 (0.2-2.1) 795 1.1 (0.2-6.5) 359 0.8 (0.3-2.4) 1,154 
   General retailer/itinerant 0.0 83 0.0 16 0.0 99 0.0 71 0.0 19 0.0 90 
   Total 0.6 (0.2-2.1) 1,501 1.3 (0.4-4.4) 302 0.7 (0.3-1.8) 1,803 1.4 (0.7-3.0) 960 1.6 (0.3-8.9) 409 1.5 (0.6-3.5) 1,369 
Community health worker 0.0 6 0.0 6 0.0 12 0.0 3 0.0 4 0.0 7 
Tanzania - mainland - Total 1.6 (0.5-5.0) 315 6.8 (3.6-12.4) 302 5.6 (3.1-10.2) 617 1.7 (0.8-3.4) 583 13.0 (7.5-21.7) 191 8.9 (5.4-14.4) 774 
Public health facility  0.0 5 25.0 (12.6-43.6) 55 23.3 (11.7-41.0) 60 20.2 (2.7-70.1) 6 40.3 (23.2-60.1) 48 39.6 (23.1-58.8) 54 
Private not-for-profit health facility 0.0 6 27.2 (9.6-56.8) 16 22.1 (7.5-49.7) 22 0.0 4 47.8 (4.9-94.2) 2 22.4 (3.1-72.3) 6 
Private for-profit outlet             
   Health facility/pharmacy 6.4 (1.7-21.9) 219 0.0 12 5.2 (1.4-18.2) 231 5.4 (2.1-12.8) 313 0.0 16 4.0 (1.4-10.4) 329 
   Drug store 0.8 (0.1-4.5) 84 0.0 148 0.3 (0.0-1.7) 232 0.7 (0.2-2.0) 256 1.0 (0.1-7.7) 113 0.9 (0.2-3.6) 369 
   General retailer/itinerant 0.0 1 0.0 70 0.0 71 0.0 4 6.8 (0.5-49.5) 12 6.3 (0.5-45.5) 16 
   Total 1.8 (0.6-5.4) 304 0.0 230 0.5 (0.1-1.5) 534 1.3 (0.6-2.9) 573 1.6 (0.4-6.7) 141 1.5 (0.6-3.8) 714 
Community health worker - 0 0.0 1 0.0 1 - 0 - 0 - 0 
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Table 2.3.22: Cont 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N 
Uganda - Total 9.5 (4.7-17.9) 540 3.5 (1.6-7.3) 1,873 4.7 (2.6-8.4) 2,413 16.9 (14.5-19.6) 1,402 20.5 (13-30.8) 1,717 19.7 (13.6-27.8) 3,119 
Public health facility  0.6 (0.1-3.9) 76 4.1 (1.3-11.7) 693 3.7 (1.2-10.6) 769 35.6 (24.6-48.5) 144 55.7 (46.6-64.5) 533 52.9 (44.6-60.9) 677 
Private not-for-profit health facility 20.8 (3.9-63) 4 6.7 (1.5-25.7) 26 8.8 (2.7-25.4) 30 28.6 (20.1-39.0) 12 54.0 (31.1-75.4) 26 51.3 (30.7-71.5) 38 
Private for-profit outlet             
   Health facility/pharmacy 14.9 (11.1-19.9) 385 7.7 (4.0-14.4) 355 11.2 (7.5-16.4) 740 22.3 (20.0-24.7) 807 20.7 (13.4-30.5) 387 21.4 (17.0-26.6) 1,194 
   Drug store 2.9 (1.3-6.5) 72 1.7 (0.7-3.8) 751 1.9 (0.9-3.6) 823 6.9 (5.3-8.9) 433 4.4 (2.7-6.9) 675 4.8 (3.3-6.9) 1,108 
   General retailer/itinerant 0.0 2 0.0 19 0.0 21 0.0 4 0.0 14 0.0 18 
   Total 9.7 (5.2-17.6) 459 2.7 (1.2-5.9) 1,125 4.3 (2.3-8) 1,584 15.5 (12.3-19.5) 1,244 7.9 (5.2-11.7) 1,076 9.6 (7.1-12.9) 2,320 
Community health worker 0.0 1 14.3 (0.8-77.5) 29 14.0 (0.8-76.4) 30 0.0 2 71.1 (39.7-90.2) 82 70.8 (39.5-90.0) 84 
Zanzibar - Total 22.8 189 57.3 124 36.4 313 22.1 222 60 120 35.4 342 
Public health facility  66.1 56 85.5 83 77.7 139 72.9 48 92.1 76 84.7 124 
Private not-for-profit health facility 0.0 2 0.0 1 0.0 3 0.0 1 0.0 1 0.0 2 
Private for-profit outlet             
   Health facility/pharmacy 8.2 73 0.0 11 7.1 84 14.6 82 12.5 16 14.3 98 
   Drug store 0.0 57 0.0 25 0.0 82 2.3 88 0.0 24 1.8 112 
   General retailer/itinerant 0.0 1 0.0 4 0.0 5 0.0 3 0.0 3 0.0 6 
   Total 4.6 131 0.0 40 3.5 171 8.1 173 4.7 43 7.4 216 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Note: Nigeria baseline data collection was conducted in 2009. 
CI = Confidence Interval 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.3.23: Cost to adult patients of malaria microscopy, in 2010 US dollars, at baseline (2010) and endline (2011) 
Median cost to ADULT patients for one malaria diagnostic test with microscopy by urban-rural location and type of outlet, according to country 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
Median cost 
[IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Ghana - Total 2.05 [2.05-2.74] 19 1.37 [0.80-1.37] 37 1.37 [0.82-2.05] 56 3.13 [0.00-3.75] 37 0.00 [0.00-0.00] 43 0.00 [0.00-3.13] 80 
Public health facility  1.37 [1.03-2.05] 10 1.03 [0.68-1.37] 26 1.03 [0.68-1.37] 36 0.00 [0.00-0.31] 24 0.00 [0.00-0.00] 42 0.00 [0.00-0.00] 66 
Private not-for-profit health facility 2.74 [2.74-2.74] 1 1.37 [1.03-1.48] 5 1.37 [1.03-1.71] 6 - 0 - 0 - 0 
Private for-profit outlet             
   Health facility/pharmacy 2.05 [2.05-2.74] 8 1.37 [1.37-2.05] 6 2.05 [1.37-2.05] 14 3.13 [3.13-3.75] 13 0.00 1 3.13 [1.88-3.75] 14 
   Drug store - 0 - 0 - 0 - 0 - 0 - 0 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 
   Total 2.05 [2.05-2.74] 8 1.37 [1.37-2.05] 6 2.05 [1.37-2.05] 14 3.13 [3.13-3.75] 13 0.00 1 3.13 [1.88-3.75] 14 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Kenya - Total 0.66 [0.66-1.31] 237 0.66 [0.39-0.66] 188 0.66 [0.53-0.66] 425 0.92 [0.58-1.15] 267 0.58 [0.46-0.58] 193 0.58 [0.46-1.04] 460 
Public health facility  0.53 [0.39-0.66] 56 0.53 [0.26-0.66] 127 0.53 [0.26-0.66] 183 0.58 [0.35-0.58] 83 0.46 [0.35-0.58] 137 0.46 [0.35-0.58] 220 
Private not-for-profit health facility 0.66 [0.66-1.31] 19 0.39 [0.00-0.66] 14 0.66 [0.00-0.66] 33 0.58 [0.58-0.92] 14 0.58 [0.46-0.58] 22 0.58 [0.46-0.58] 36 
Private for-profit outlet             
   Health facility/pharmacy 0.66 [0.66-1.31] 144 0.66 [0.53-0.79] 31 0.66 [0.66-1.31] 175 1.15 [0.58-1.15] 147 0.58 [0.58-1.15] 28 0.69 [0.58-1.15] 175 
   Drug store 1.31 [1.31-1.31] 18 0.66 [0.66-0.66] 16 0.66 [0.66-1.31] 34 1.15 [0.58-1.15] 23 0.58 [0.58-0.58] 6 0.58 [0.58-1.15] 29 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 
   Total 0.92 [0.66-1.31] 162 0.66 [0.53-0.79] 47 0.66 [0.66-1.31] 209 1.15 [0.58-1.15] 170 0.58 [0.58-0.92] 34 0.69 [0.58-1.15] 204 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Madagascar - Total 0.28 [0.00-0.94] 23 0.00 [0.00-0.00] 4 0.00 [0.00-0.84] 27 0.43 [0.00-1.07] 24 0.00 [0.00-0.00] 14 0.00 [0.00-0.21] 38 
Public health facility  0.00 [0.00-0.47] 12 0.00 [0.00-0.00] 4 0.00 [0.00-0.47] 16 0.43 [0.00-1.07] 14 0.00 [0.00-0.13] 13 0.13 [0.00-0.43] 27 
Private not-for-profit health facility 4.68 [4.68-4.68] 1 - 0 4.68 [4.68-4.68] 1 0.00 [0.00-0.94] 5 - 0 0.00 [0.00-0.94] 5 
Private for-profit outlet             
   Health facility/pharmacy 0.94 [0.84-2.81] 10 - 0 0.94 [0.84-2.81] 10 1.50 [0.85-1.50] 5 - 0 1.50 [0.85-1.50] 5 
   Drug store - 0 - 0 - 0 - 0 - 0 - 0 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 
   Total 0.94 [0.84-2.81] 10 - 0 0.94 [0.84-2.81] 10 1.50 [0.85-1.50] 5 - 0 1.50 [0.85-1.50] 5 
Community health worker - 0 - 0 - 0 - 0 0.00 1 0.00 [0.00-0.00] 1 
Niger - Total 3.08 [1.03-4.11] 47 1.03 [0.82-1.44] 8 2.06 [1.03-4.11] 55 2.97 [1.39-3.96] 40 0.00 [0.00-0.79] 4 1.39 [0.79-2.97] 44 
Public health facility  1.23 [1.03-2.06] 34 1.03 [0.82-1.44] 8 1.03 [1.03-1.64] 42 1.39 [0.99-1.39] 29 0.79 [0.00-0.99] 3 0.99 [0.79-1.39] 32 
Private not-for-profit health facility 2.06 [2.06-3.08] 3 - 0 2.06 [2.06-3.08] 3 - 0 0.00 1 0.0 1 
Private for-profit outlet             
   Health facility/pharmacy 4.11 [3.08-5.14] 10 - 0 4.11 [3.08-5.14] 10 3.96 [2.97-4.95] 11 - 0 3.96 [2.97-4.95] 11 
   Drug store - 0 - 0 - 0 - 0 - 0 - 0 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 
   Total 4.11 [3.08-5.14] 10 - 0 4.11 [3.08-5.14] 10 3.96 [2.97-4.95] 11 - 0 3.96 [2.97-4.95] 11 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Nigeria - Total 0.74 [0.74-1.86] 195 1.86 [0.74-2.23] 14 1.86 [0.74-2.23] 209 1.77 [1.18-4.13] 55 1.18 [0.89-2.95] 17 1.77 [1.18-2.95] 72 
Public health facility  0.97 [0.74-1.49] 34 1.86 [0.37-2.23] 7 1.86 [0.37-2.23] 41 1.18 [1.18-7.09] 21 0.59 [0.30-1.48] 8 1.18 [0.59-1.77] 29 
Private not-for-profit health facility 2.23 [2.23-2.23] 3 0.74 [0.74-0.74] 1 0.74 [0.74-0.74] 4 1.77 [1.18-1.77] 4 1.18 [1.18-1.18] 2 1.18 [1.18-1.77] 6 
Private for-profit outlet             
   Health facility/pharmacy 2.23 [1.49-3.72] 157 2.23 [1.49-2.23] 6 2.23 [1.49-2.23] 163 1.77 [1.18-4.13] 29 1.77 [0.89-3.54] 7 1.77 [1.18-3.54] 36 
   Drug store 0.74 [0.74-0.74] 1 - 0 0.74 [0.74-0.74] 1 2.36  1 - 0 2.36  1 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 
   Total 0.74 [0.74-2.23] 158 2.23 [1.49-2.23] 6 2.23 [0.74-2.23] 164 1.77 [1.18-4.13] 30 1.77 [0.89-3.54] 7 1.77 [1.18-3.54] 37 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Tanzania - mainland - Total 0.35 [0.35-0.70] 9 0.35 [0.21-0.35] 21 0.35 [0.21-0.35] 30 0.31 [0.31-0.62] 32 0.19 [0.00-0.31] 12 0.31 [0.12-0.31] 44 
Public health facility  0.35 [0.35-0.35] 1 0.21 [0.00-0.21] 8 0.21 [0.14-0.35] 9 0.31 [0.31-0.31] 5 0.00 [0.00-0.31] 8 0.12 [0.00-0.31] 13 
Private not-for-profit health facility 0.35 [0.35-0.70] 3 0.35 [0.28-0.35] 11 0.35 [0.35-0.35] 14 0.31 [0.31-0.31] 4 0.31 [0.31-0.31] 1 0.31 [0.31-0.31] 5 
Private for-profit outlet             
   Health facility/pharmacy 0.35 [0.35-0.70] 5 0.35 [0.35-0.35] 2 0.35 [0.35-0.7] 7 0.62 [0.31-0.62] 21 0.31 [0.31-0.31] 1 0.62 [0.31-0.62] 22 
   Drug store - 0 - 0 - 0 0.31 [0.31-0.62] 2 0.31 [0.31-0.31] 2 0.31 [0.31-0.31] 4 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 
   Total 0.35 [0.35-0.70] 5 0.35 [0.35-0.35] 2 0.35 [0.35-0.70] 7 0.62 [0.31-0.62] 23 0.31 [0.31-0.31] 3 0.31 [0.31-0.62] 26 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
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Table 2.3.23: Cont. 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
Median cost 
[IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Uganda - Total 0.93 [0.70-1.16] 96 0.46 [0.00-0.93] 354 0.70 [0.46-0.93] 450 0.78 [0.78-1.17] 340 0.59 [0.00-0.78] 357 0.78 [0.39-0.98] 697 
Public health facility  0.00 [0.00-0.00] 41 0.00 [0.00-0.00] 206 0.00 [0.00-0.00] 247 0.00 [0.00-0.00] 75 0.00 [0.00-0.00] 193 0.00 [0.00-0.00] 268 
Private not-for-profit health facility 0.46 [0.23-0.93] 4 0.46 [0.46-0.70] 14 0.46 [0.23-0.70] 18 0.78 [0.2-1.17] 11 0.39 [0.2-0.78] 20 0.39 [0.2-0.78] 31 
Private for-profit outlet             
   Health facility/pharmacy 0.93 [0.93-1.39] 47 0.93 [0.46-0.93] 122 0.93 [0.70-0.93] 169 0.78 [0.78-1.17] 241 0.78 [0.59-1.17] 133 0.78 [0.78-1.17] 374 
   Drug store 0.70 [0.46-0.93] 4 0.70 [0.46-0.93] 12 0.70 [0.46-0.93] 16 0.78 [0.39-1.17] 13 0.59 [0.39-0.98] 11 0.59 [0.39-0.98] 24 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 
   Total 0.93 [0.93-1.39] 51 0.93 [0.46-0.93] 134 0.93 [0.70-0.93] 185 0.78 [0.78-1.17] 254 0.78 [0.59-0.98] 144 0.78 [0.78-1.17] 398 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Zanzibar - Total 0.35 [0.35-0.49] 77 0.00 [0.00-0.35] 30 0.35 [0.00-0.35] 107 0.29 [0.29-0.58] 76 0.00 [0.00-0.29] 39 0.29 [0.00-0.58] 115 
Public health facility  0.00 [0.00-0.35] 25 0.00 [0.00-0.00] 18 0.00 [0.00-0.14] 43 0.00 [0.00-0.29] 24 0.00 [0.00-0.00] 26 0.00 [0.00-0.00] 50 
Private not-for-profit health facility 0.18 [0.00-0.35] 2 0.35 [0.35-0.35] 1 0.35 [0.00-0.35] 3 1.17 [1.17-1.17] 1 0.29 [0.29-0.29] 1 0.73 [0.29-1.17] 2 
Private for-profit outlet             
   Health facility/pharmacy 0.35 [0.35-0.70] 50 0.35 [0.21-0.35] 10 0.35 [0.35-0.53] 60 0.58 [0.29-0.58] 49 0.29 [0.29-0.58] 12 0.58 [0.29-0.58] 61 
   Drug store - 0 0.21 [0.21-0.21] 1 0.21 [0.21-0.21] 1 0.29 [0.29-0.29] 1 - 0 0.29 [0.29-0.29] 1 
   General retailer/itinerant - 0 - 0 - 0 0.87 [0.87-0.87] 1 - 0 0.87 [0.87-0.87] 1 
   Total 0.35 [0.35-0.7] 50 0.35 [0.21-0.35] 11 0.35 [0.35-0.49] 61 0.58 [0.29-0.58] 51 0.29 [0.29-0.58] 12 0.58 [0.29-0.58] 63 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Note: Malaria microscopic testing is considered to be available if the respondent reported that the service was available in the outlet on the day of the survey visit. Nigeria baseline data collection was conducted in 2009. 
* For the Madagascar and Nigeria ACTwatch surveys, the questionnaire did not distinguish between the price of diagnosis for adults and children. Therefore, this table presents the general figures reported for these countries. 
na = Not applicable, IQR = Interquartile range 
Source: AMFm Phase 1 Independent Evaluation Outlet Surve 
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Table 2.3.24: Cost to child patients of malaria microscopy, in 2010 US dollars, at baseline (2010) and endline (2011) 
Median cost for CHILD patients for one malaria diagnostic test with microscopy by urban-rural location and type of outlet, according to country 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
Median cost 
[IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Median 
cost [IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Ghana – Total 2.05 [2.05-2.74] 19 1.37 [0.68-1.37] 36 1.37 [0.68-2.05] 55 3.13 [0.00-3.75] 37 0.00 [0.00-0.00] 43 0.00 [0.00-3.13] 80 
Public health facility  1.37 [0.68-2.05] 10 1.03 [0.68-1.37] 25 1.03 [0.68-1.37] 35 0.00 [0.00-0.31] 24 0.00 [0.00-0.00] 42 0.00 [0.00-0.00] 66 
Private not-for-profit health facility 2.74 [2.74-2.74] 1 1.37 [1.03-1.48] 5 1.37 [1.03-1.71] 6 - 0 - 0 - 0 
Private for-profit outlet             
   Health facility/pharmacy 2.05 [2.05-2.74] 8 1.37 [0-1.37] 6 1.37 [0.00-2.05] 14 3.13 [3.13-3.75] 13 0.00 1 3.13 [1.88-3.75] 14 
   Drug store - 0 - 0 - 0 - 0 - 0 - 0 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 
   Total 2.05 [2.05-2.74] 8 1.37 [0-1.37] 6 1.37 [0.00-2.05] 14 3.13 [3.13-3.75] 13 0.00 1 3.13 [1.88-3.75] 14 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Kenya – Total 0.66 [0.66-1.31] 237 0.66 [0.26-0.66] 188 0.66 [0.39-0.66] 425 0.58 [0.58-1.15] 266 0.58 [0.23-0.58] 192 0.58 [0.35-0.58] 458 
Public health facility  0.00 [0.00-0.39] 56 0.26 [0.00-0.66] 127 0.26 [0.00-0.66] 183 0.23 [0.00-0.58] 83 0.12 [0.00-0.58] 137 0.12 [0.00-0.58] 220 
Private not-for-profit health facility 0.66 [0.66-0.66] 19 0.00 [0.00-0.66] 14 0.66 [0.00-0.66] 33 0.58 [0.58-0.92] 14 0.58 [0.35-0.58] 22 0.58 [0.35-0.58] 36 
Private for-profit outlet             
   Health facility/pharmacy 0.66 [0.66-1.31] 144 0.66 [0.39-0.66] 31 0.66 [0.66-1.31] 175 0.81 [0.58-1.15] 146 0.58 [0.46-0.58] 27 0.58 [0.58-1.15] 173 
   Drug store 1.31 [0.66-1.31] 18 0.66 [0.66-0.66] 16 0.66 [0.66-1.31] 34 0.92 [0.58-1.15] 23 0.58 [0.58-0.58] 6 0.58 [0.58-1.15] 29 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 
   Total 0.79 [0.66-1.31] 162 0.66 [0.53-0.66] 47 0.66 [0.66-1.31] 209 0.92 [0.58-1.15] 169 0.58 [0.58-0.58] 33 0.58 [0.58-1.15] 202 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Madagascar – Total       0.43 [0.00-1.07] 24 0.00 [0.00-0.00] 14 0.00 [0.00-0.21] 38 
Public health facility  - - - - - - 0.43 [0.00-1.07] 14 0.00 [0.00-0.13] 13 0.13 [0.00-0.43] 27 
Private not-for-profit health facility - - - - - - 0.00 [0.00-0.94] 5 - 0 0.00 [0.00-0.94] 5 
Private for-profit outlet - - - - - -       
   Health facility/pharmacy - - - - - - 1.50 [0.85-1.50] 5 - 0 1.50 [0.85-1.50] 5 
   Drug store - - - - - - - 0 - 0 - 0 
   General retailer/itinerant - - - - - - - 0 - 0 - 0 
   Total - - - - - - 1.50 [0.85-1.50] 5 - 0 1.50 [0.85-1.50] 5 
Community health worker - - - - - - - 0 0.00 1 0.00 [0.00-0.00] 1 
Niger – Total 2.06 [0.00-4.11] 47 0.00 [0.00-0.00] 9 0.00 [0.00-3.08] 56 0.99 [0.00-3.96] 41 0.00 [0.00-0.00] 4 0.00 [0.00-2.97] 45 
Public health facility  0.00 [0.00-0.00] 34 0.00 [0.00-0.00] 9 0.00 [0.00-0.00] 43 0.00 [0.00-0.00] 30 0.00 [0.00-0.00] 3 0.00 [0.00-0.00] 33 
Private not-for-profit health facility 2.06 [2.06-3.08] 3 - 0 2.06 [2.06-3.08] 3 - 0 0.00 [0.00-0.00] 1 0.00 1 
Private for-profit outlet             
   Health facility/pharmacy 4.11 [3.08-5.14] 10 - 0 4.11 [3.08-5.14] 10 3.96 [2.97-4.95] 11 - 0 3.96 [2.97-4.95] 11 
   Drug store - 0 - 0 - 0 - 0 - 0 - 0 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 
   Total 4.11 [3.08-5.14] 10 - 0 4.11 [3.08-5.14] 10 3.96 [2.97-4.95] 11 - 0 3.96 [2.97-4.95] 11 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Nigeria – Total       1.77 [1.18-4.13] 55 1.18 [0.89-1.48] 17 1.18 [1.18-2.95] 72 
Public health facility  - - - - - - 1.18 [1.18-7.09] 21 0.00 [0.00-0.30] 8 1.18 [0.00-1.77] 29 
Private not-for-profit health facility - - - - - - 1.77 [1.18-1.77] 4 1.18 [1.18-1.18] 2 1.18 [1.18-1.77] 6 
Private for-profit outlet - - - - - -       
   Health facility/pharmacy - - - - - - 1.77 [1.18-4.13] 29 1.18 [0.89-3.54] 7 1.77 [1.18-3.54] 36 
   Drug store - - - - - - 2.36 1 - 0 2.36 1 
   General retailer/itinerant - - - - - - - 0 - 0 - 0 
   Total - - - - - - 1.77 [1.18-4.13] 30 1.18 [0.89-3.54] 7 1.77 [1.18-3.54] 37 
Community health worker - - - - - - - 0 - 0 - 0 
Tanzania - mainland – Total 0.35 [0.00-0.35] 9 0.35 [0.00-0.35] 21 0.35 [0.00-0.35] 30 0.31 [0.19-0.62] 31 0.00 [0.00-0.31] 12 0.19 [0.00-0.31] 43 
Public health facility  0.00 1 0.00 [0.00-0.00] 8 0.00 [0.00-0.00] 9 0.00 [0.00-0.00] 5 0.00 [0.00-0.00] 8 0.00 [0.00-0.00] 13 
Private not-for-profit health facility 0.35 [0.35-0.70] 3 0.35 [0.28-0.35] 11 0.35 [0.35-0.35] 14 0.31 [0.31-0.31] 4 0.31 [0.31-0.31] 1 0.31 [0.31-0.31] 5 
Private for-profit outlet             
   Health facility/pharmacy 0.35 [0.35-0.35] 5 0.35 [0.35-0.35] 2 0.35 [0.35-0.35] 7 0.62 [0.31-0.62] 20 0.31 [0.31-0.31] 1 0.31 [0.31-0.62] 21 
   Drug store - 0 - 0 - 0 0.31 [0.31-0.62] 2 0.31 [0.31-0.31] 2 0.31 [0.31-0.31] 4 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 
   Total 0.35 [0.35-0.35] 5 0.35 [0.35-0.35] 2 0.35 [0.35-0.35] 7 0.62 [0.31-0.62] 22 0.31 [0.31-0.31] 3 0.31 [0.31-0.62] 25 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
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Table 2.3.24: Cont. 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
Median cost 
[IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Median 
cost [IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Uganda – Total 0.93 [0.46-0.93] 96 0.46 [0.00-0.93] 354 0.70 [0.23-0.93] 450 0.78 [0.59-1.17] 340 0.39 [0.00-0.78] 357 0.78 [0.20-0.78] 697 
Public health facility  0.00 [0.00-0.00] 41 0.00 [0.00-0.00] 206 0.00 [0.00-0.00] 247 0.00 [0.00-0.00] 75 0.00 [0.00-0.00] 193 0.00 [0.00-0.00] 268 
Private not-for-profit health facility 0.46 [0.23-0.93] 4 0.46 [0.46-0.70] 14 0.46 [0.23-0.70] 18 0.78 [0.0-1.17] 11 0.39 [0.20-0.59] 20 0.39 [0.20-0.78] 31 
Private for-profit outlet             
   Health facility/pharmacy 0.93 [0.70-1.16] 47 0.93 [0.46-0.93] 122 0.93 [0.70-0.93] 169 0.78 [0.78-1.17] 241 0.78 [0.59-0.98] 133 0.78 [0.78-1.17] 374 
   Drug store 0.70 [0.46-0.93] 4 0.46 [0.46-0.93] 12 0.70 [0.46-0.93] 16 0.78 [0.39-1.17] 13 0.59 [0.39-0.78] 11 0.59 [0.39-0.78] 24 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 
   Total 0.93 [0.70-1.16] 51 0.93 [0.46-0.93] 134 0.93 [0.46-0.93] 185 0.78 [0.78-1.17] 254 0.78 [0.39-0.98] 144 0.78 [0.59-1.17] 398 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Zanzibar – Total 0.35 [0.18-0.46] 76 0.00 [0.00-0.35] 30 0.35 [0.00-0.35] 106 0.29 [0.23-0.58] 76 0.00 [0.00-0.29] 39 0.29 [0.00-0.58] 115 
Public health facility  0.00 [0.00-0.18] 24 0.00 [0.00-0.00] 18 0.00 [0.00-0.07] 42 0.00 [0.00-0.23] 24 0.00 [0.00-0.00] 26 0.00 [0.00-0.00] 50 
Private not-for-profit health facility 0.18 [0.00-0.35] 2 0.35 [0.35-0.35] 1 0.35 [0.00-0.35] 3 1.17 [1.17-1.17] 1 0.29 [0.29-0.29] 1 0.73 [0.29-1.17] 2 
Private for-profit outlet             
   Health facility/pharmacy 0.35 [0.35-0.56] 50 0.35 [0.21-0.35] 10 0.35 [0.35-0.49] 60 0.58 [0.29-0.58] 49 0.29 [0.09-0.29] 12 0.41 [0.29-0.58] 61 
   Drug store - 0 0.21 [0.21-0.21] 1 0.21 [0.21-0.21] 1 0.29 [0.29-0.29] 1 - 0 0.29 [0.29-0.29] 1 
   General retailer/itinerant - 0 - 0 - 0 0.87 [0.87-0.87] 1 - 0 0.87 [0.87-0.87] 1 
   Total 0.35 [0.35-0.56] 50 0.35 [0.21-0.35] 11 0.35 [0.35-0.49] 61 0.58 [0.29-0.58] 51 0.29 [0.09-0.29] 12 0.41 [0.29-0.58] 63 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Note: Malaria microscopic testing is considered to be available if the respondent reported that the service was available in the outlet on the day of the survey visit.  Nigeria baseline data collection was conducted in 2009. 
* For the Madagascar and Nigeria ACTwatch surveys, the questionnaire did not distinguish between the price of diagnosis for adults and children. Therefore, this table presents the general figures reported for these countries. 
na = Not applicable, IQR = Interquartile range 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.3.25: Cost to adult patients of rapid diagnostic tests for malaria (RDTs), in 2010 US dollars, at baseline (2010) and endline (2011) 
Median cost to ADULT patients for one rapid diagnostic test for malaria, by urban-rural location and type of outlet, according to country 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
Median cost 
[IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Ghana - Total 0.68 [0.00-2.74] 42 0.00 [0.00-0.34] 89 0.00 [0.00-0.68] 131 0.00 [0.00-1.88] 43 0.00 [0.00-0.00] 67 0.00 [0.00-0.00] 110 
Public health facility  0.00 [0.00-0.00] 29 0.00 [0.00-0.00] 80 0.00 [0.00-0.00] 109 0.00 [0.00-0.00] 30 0.00 [0.00-0.00] 62 0.00 [0.00-0.00] 92 
Private not-for-profit health facility - 0 0.00 1 0.00 1 1.88 [1.88-1.88] 1 - 0 1.88 [1.88-1.88] 1 
Private for-profit outlet             
   Health facility/pharmacy 2.74 [1.71-3.42] 10 0.68 [0-2.05] 5 1.71 [0.68-2.40] 15 1.88 [1.56-2.50] 12 0.00 [0.00-1.25] 4 1.25 [0.00-1.88] 16 
   Drug store 0.68 [0.68-1.37] 3 - 0 0.68 [0.68-1.37] 3 - 0 2.5 [2.5-2.5] 1 2.50 [2.50-2.50] 1 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 
   Total 2.74 [1.37-2.74] 13 0.68 [0.00-2.05] 5 1.37 [0.68-2.05] 18 1.88 [1.56-2.50] 12 0.00 [0.00-1.25] 5 1.25 [0.00-2.50] 17 
Community health worker - 0 0.00 [0.00-0.68] 3 0.00 [0.00-0.68] 3 - 0 - 0 - 0 
Kenya - Total 1.31 [0.00-1.31] 42 0.00 [0.00-0.66] 24 0.00 [0.00-1.31] 66 1.15 [0.58-1.38] 88 0.35 [0.00-0.58] 50 0.58 [0.00-1.15] 138 
Public health facility  0.00 [0.00-0.00] 5 0.00 [0.00-0.00] 13 0.00 [0.00-0.00] 18 0.00 [0.00-0.00] 25 0.00 [0.00-0.35] 43 0.00 [0.00-0.35] 68 
Private not-for-profit health facility 0.00 [0.00-0.66] 4 0.00 [0.00-0.00] 2 0.00 [0.00-0.00] 6 0.58 [0.58-1.15] 6 0.35 [0.35-0.35] 1 0.58 [0.35-0.58] 7 
Private for-profit outlet             
   Health facility/pharmacy 1.31 [0.92-1.31] 26 0.00 [0.00-0.00] 8 0.53 [0.00-1.31] 34 1.15 [1.15-1.73] 44 1.15 [0.35-1.15] 5 1.15 [0.58-1.15] 49 
   Drug store 1.31 [1.31-1.97] 7 1.31 [1.31-1.31] 1 1.31 [1.31-1.31] 8 1.15 [1.15-1.73] 13 0.58 [0.58-0.58] 1 1.15 [1.15-1.15] 14 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 
   Total 1.31 [0.92-1.97] 33 0.00 [0.00-1.31] 9 1.31 [0.00-1.31] 42 1.15 [1.15-1.73] 57 0.58 [0.35-1.15] 6 1.15 [0.58-1.15] 63 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Madagascar - Total 0.00 [0.00-0.00] 81 0.00 [0.00-0.00] 430 0.00 [0.00-0.00] 511 0.00 [0.00-0.00] 111 0.00 [0.00-0.00] 584 0.00 [0.00-0.00] 695 
Public health facility  0.00 [0.00-0.00] 51 0.00 [0.00-0.00] 424 0.00 [0.00-0.00] 475 0.00 [0.00-0.00] 61 0.00 [0.00-0.00] 530 0.00 [0.00-0.00] 591 
Private not-for-profit health facility 0.00 [0.00-0.00] 3 - 0 0.00 [0.00-0.00] 3 0.00 [0.00-0.00] 22 0.00 [0.00-0.00] 2 0.00 [0.00-0.00] 24 
Private for-profit outlet             
   Health facility/pharmacy 0.00 [0.00-0.00] 27 - 0 0.00 [0.00-0.00] 27 0.00 [0.00-3.12] 17 - 0 0.00 [0.00-3.12] 17 
   Drug store - 0 - 0 - 0 - 0 0.00 [0.00-0.17] 6 0.00 [0.00-0.17] 6 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 
   Total 0.00 [0.00-0.00] 27 - 0 0.00 [0.00-0.00] 27 0.00 [0.00-3.12] 17 0.00 [0.00-0.17] 6 0.00 [0.00-0.85] 23 
Community health worker - 0 0.00 [0.00-0.00] 6 0.00 [0.00-0.00] 6 0.00 [0.00-0.00] 11 0.00 [0.00-0.00] 46 0.00 [0.00-0.00] 57 
Niger - Total 0.00 [0.00-0.00] 40 0.00 [0.00-0.00] 238 0.00 [0.00-0.00] 278 0.00 [0.00-0.00] 79 0.00 [0.00-0.00] 160 0.00 [0.00-0.00] 239 
Public health facility  0.00 [0.00-0.00] 37 0.00 [0.00-0.00] 238 0.00 [0.00-0.00] 275 0.00 [0.00-0.00] 65 0.00 [0.00-0.00] 160 0.00 [0.00-0.00] 225 
Private not-for-profit health facility - 0 - 0 - 0 0.00 [0.00-0.00] 2 - 0 0.00 [0.00-0.00] 2 
Private for-profit outlet             
   Health facility/pharmacy 3.08 [0.00-4.11] 3 - 0 3.08 [0.00-4.11] 3 1.98 [0.00-1.98] 11 - 0 1.98 [0.00-1.98] 11 
   Drug store - 0 - 0 - 0 0.99 [0.99-0.99] 1 - 0 0.99 [0.99-0.99] 1 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 
   Total 3.08 [0.00-4.11] 3 - 0 3.08 [0.00-4.11] 3 1.98 [0-1.98] 12 - 0 1.98 [0.00-1.98] 12 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Nigeria - Total 1.49 [1.12-3.72] 510 2.23 [2.23-2.23] 17 2.23 [1.86-2.23] 527 1.18 [1.18-1.77] 28 0.30 [0.30-1.77] 12 1.18 [0.41-1.77] 40 
Public health facility  0.00 [0.00-0.00] 24 2.23 [2.23-2.23] 4 2.23 [2.23-2.23] 28 1.18 [1.18-1.77] 12 0.00 [0.00-1.77] 6 1.18 [0.59-1.77] 18 
Private not-for-profit health facility - 0 - 0 - 0 1.77 [1.77-1.77] 3 - 0 1.77 [1.77-1.77] 3 
Private for-profit outlet             
   Health facility/pharmacy 1.12 [0.74-1.86] 485 2.23 [1.49-2.23] 13 1.49 [1.12-2.23] 498 7.09 [7.09-28.34] 8 1.77 [1.77-2.36] 3 2.36 [1.77-7.09] 11 
   Drug store 3.72 [3.72-3.72] 1 - 0 3.72 [3.72-3.72] 1 0.59 [0.59-0.89] 5 0.30 [0.30-0.30] 3 0.30 [0.30-0.59] 8 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 
   Total 1.49 [1.12-3.72] 486 2.23 [1.49-2.23] 13 2.23 [1.12-2.6] 499 1.77 [0.59-7.09] 13 0.30 [0.30-1.77] 6 0.89 [0.30-2.36] 19 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Tanzania - mainland - Total 5.85 [1.41-5.85] 8 0.00 [0.00-0.00] 17 0.00 [0.00-0.00] 25 0.62 [0.12-0.62] 11 0.00 [0.00-0.31] 23 0.00 [0.00-0.31] 34 
Public health facility  - 0 0.00 [0.00-0.00] 14 0.00 [0.00-0.00] 14 0.12 [0.12-0.12] 1 0.00 [0.00-0.19] 20 0.00 [0.00-0.19] 21 
Private not-for-profit health facility - 0 0.00 [0.00-1.41] 3 0.00 [0.00-1.41] 3 - 0 0.00 1 0.00 1 
Private for-profit outlet             
   Health facility/pharmacy 5.85 [5.85-5.85] 7 - 0 5.85 [5.85-5.85] 7 0.62 [0.62-1.25] 8 - 0 0.62 [0.62-1.25] 8 
   Drug store 1.41 [1.41-1.41] 1 - 0 1.41 [1.41-1.41] 1 0.62 [0.62-0.62] 2 0.94 [0.94-0.94] 1 0.94 [0.62-0.94] 3 
   General retailer/itinerant - 0 - 0 - 0 - 0 0.00 1 0.00 1 
   Total 5.85 [1.41-5.85] 8 - 0 5.85 [1.41-5.85] 8 0.62 [0.62-0.62] 10 0.94 [0.00-0.94] 2 0.62 [0.00-0.94] 12 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
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Table 2.3.25: Cont. 
Median cost to ADULT patients for one rapid diagnostic test for malaria, by urban-rural location and type of outlet, according to country 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
Median cost 
[IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Uganda - Total 1.39 [0.93-1.86] 76 0.93 [0.00-1.39] 101 0.93 [0.46-1.39] 177 1.17 [0.78-1.17] 276 0.00 [0.00-0.59] 539 0.00 [0.00-0.98] 815 
Public health facility  0.00 1 0.00 [0.00-0.00] 26 0.00 [0.00-0.00] 27 0.00 [0.00-0.00] 46 0.00 [0.00-0.00] 357 0.00 [0.00-0.00] 403 
Private not-for-profit health facility - 0 0.46 [0.00-1.39] 3 0.46 [0.00-1.39] 3 1.17 [0.00-1.96] 3 0.00 [0.00-0.78] 14 0.00 [0.00-0.78] 17 
Private for-profit outlet             
   Health facility/pharmacy 1.39 [1.39-2.32] 73 1.39 [0.93-1.39] 49 1.39 [1.16-1.86] 122 1.17 [0.98-1.17] 198 1.17 [0.78-1.56] 90 1.17 [0.98-1.56] 288 
   Drug store 0.70 [0.70-0.93] 2 0.93 [0.46-1.07] 17 0.93 [0.70-0.93] 19 1.17 [0.78-1.17] 29 0.78 [0.39-0.98] 30 0.78 [0.39-1.17] 59 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 
   Total 1.39 [1.02-1.86] 75 0.93 [0.93-1.39] 66 1.39 [0.93-1.39] 141 1.17 [0.98-1.17] 227 0.98 [0.78-1.17] 120 1.17 [0.78-1.17] 347 
Community health worker - 0 0.00 [0.00-0.00] 6 0.00 [0.00-0.00] 6 - 0 0.00 [0.00-0.00] 48 0.00 [0.00-0.00] 48 
Zanzibar - Total 0.00 [0.00-0.00] 43 0.00 [0.00-0.00] 71 0.00 [0.00-0.00] 114 0.00 [0.00-0.00] 53 0.00 [0.00-0.00] 86 0.00 [0.00-0.00] 139 
Public health facility  0.00 [0.00-0.00] 37 0.00 [0.00-0.00] 71 0.00 [0.00-0.00] 108 0.00 [0.00-0.00] 39 0.00 [0.00-0.00] 84 0.00 [0.00-0.00] 123 
Private not-for-profit health facility - 0 - 0 - 0 - 0 - 0 - 0 
Private for-profit outlet             
   Health facility/pharmacy 1.76 [0.70-2.11] 6 - 0 1.76 [0.70-2.11] 6 0.58 [0.44-1.46] 12 0.29 [0.00-0.58] 2 0.58 [0.29-1.17] 14 
   Drug store - 0 - 0 - 0 0.15 [0.00-0.29] 2 - 0 0.15 [0.00-0.29] 2 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 
   Total 1.76 [0.70-2.11] 6 - 0 1.76 [0.70-2.11] 6 0.58 [0.29-1.17] 14 0.29 [0.00-0.58] 2 0.58 [0.29-0.87] 16 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Note: Nigeria baseline data collection was conducted in 2009. 
* At baseline for the Madagascar and Nigeria ACTwatch surveys, the questionnaire did not distinguish between the price of diagnosis for adults and children. This table, therefore, presents the general figures reported for 
these countries. 
na = Not applicable, IQR = Interquartile range 
Source: AMFm Phase 1 Independent Evaluation Outlet Survey 
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Table 2.3.26: Cost to child patients of rapid diagnostic tests for malaria (RDTs), in 2010 US dollars, at baseline (2010) and endline (2011) 
Median cost to CHILD patients for one rapid diagnostic test for malaria, by urban-rural location and type of outlet, according to country 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
Median cost 
 [IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Median cost [IQR] No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Ghana – Total 0.34 [0.00-2.74] 42 0.00 [0.00-0.00] 88 0.00 [0.00-0.34] 130 0.00 [0.00-0.00] 42 0.00 [0.00-0.00] 68 0.00 [0.00-0.00] 110 
Public health facility  0.00 [0.00-0.00] 29 0.00 [0.00-0.00] 80 0.00 [0.00-0.00] 109 0.00 [0.00-0.00] 30 0.00 [0.00-0.00] 63 0.00 [0.00-0.00] 93 
Private not-for-profit health facility - 0 0.00 1 0.00 1 0.00 1 - 0 0.00 1 
Private for-profit outlet             
   Health facility/pharmacy 2.74 [1.71-3.42] 11 0.68 [0.00-0.68] 4 0.68 [0.00-2.74] 15 1.88 [1.56-2.5] 11 0.00 [0.00-1.25] 4 1.25 [0.00-1.56] 15 
   Drug store 0.34 [0.34-0.34] 2 - 0 0.34 [0.34-0.34] 2 - 0 - 1 0.00 1 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 
   Total 2.74 [0.68-2.74] 13 0.68 [0.00-0.68] 4 0.68 [0.00-2.74] 17 1.88 [1.56-2.5] 11 0.00 [0.00-1.25] 5 1.25 [0.00-1.56] 16 
Community health worker - 0 0.00 [0.00-0.68] 3 0.00 [0.00-0.68] 3 - 0 - 0 - 0 
Kenya – Total 1.31 [0.00-1.97] 41 0.00 [0.00-0.66] 24 0.00 [0.00-1.31] 65 1.15 [0.58-1.15] 88 0.00 [0.00-0.58] 49 0.58 [0.00-1.15] 137 
Public health facility  0.00 [0.00-0.00] 5 0.00 [0.00-0.00] 13 0.00 [0.00-0.00] 18 0.00 [0.00-0.00] 25 0.00 [0.00-0.00] 42 0.00 [0.00-0.00] 67 
Private not-for-profit health facility 0.00 [0.00-0.66] 4 0.00 [0.00-0.00] 2 0.00 [0.00-0.00] 6 0.58 [0.58-1.15] 6 0.35 [0.35-0.35] 1 0.58 [0.35-0.58] 7 
Private for-profit outlet             
   Health facility/pharmacy 1.31 [0.92-1.97] 25 0.00 [0.00-0.00] 8 0.00 [0.00-1.31] 33 1.15 [0.92-1.73] 44 1.15 [0.23-1.15] 5 1.15 [0.58-1.15] 49 
   Drug store 1.31 [1.31-1.97] 7 1.31 [1.31-1.31] 1 1.31 [1.31-1.31] 8 1.15 [1.15-1.15] 13 0.58 [0.58-0.58] 1 1.15 [0.58-1.15] 14 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 
   Total 1.31 [1.31-1.97] 32 0.00 [0.00-1.31] 9 1.31 [0.00-1.31] 41 1.15 [1.15-1.38] 57 0.58 [0.23-1.15] 6 1.15 [0.58-1.15] 63 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Madagascar – Total - - - - - - 0.00 [0.00-0.00] 114 0.00 [0.00-0.00] 588 0.00 [0.00-0.00] 702 
Public health facility  - - - - - - 0.00 [0.00-0.00] 61 0.00 [0.00-0.00] 531 0.00 [0.00-0.00] 592 
Private not-for-profit health facility - - - - - - 0.00 [0.00-0.00] 22 0.00 [0.00-0.00] 2 0.00 [0.00-0.00] 24 
Private for-profit outlet - - - - - -       
   Health facility/pharmacy - - - - - - 0.00 [0.00-3.12] 17 - 0 0.00 [0.00-3.12] 17 
   Drug store - - - - - - - 0 0.00 [0.00-0.13] 6 0.00 [0.00-0.13] 6 
   General retailer/itinerant - - - - - - - 0 - 0 - 0 
   Total - - - - - - 0.00 [0.00-3.12] 17 0.00 [0.00-0.13] 6 0.00 [0.00-0.85] 23 
Community health worker - - - - - - 0.00 [0.00-0.00] 14 0.00 [0.00-0.00] 49 0.00 [0.00-0.00] 63 
Niger – Total 0.00 [0.00-0.00] 40 0.00 [0.00-0.00] 244 0.00 [0.00-0.00] 284 0.00 [0.00-0.00] 79 0.00 [0.00-0.00] 159 0.00 [0.00-0.00] 238 
Public health facility  0.00 [0.00-0.00] 37 0.00 [0.00-0.00] 244 0.00 [0.00-0.00] 281 0.00 [0.00-0.00] 65 0.00 [0.00-0.00] 159 0.00 [0.00-0.00] 224 
Private not-for-profit health facility - 0 - 0 - 0 0.00 [0.00-0.00] 2 - 0 0.00 [0.00-0.00] 2 
Private for-profit outlet             
   Health facility/pharmacy 3.08 [0.00-4.11] 3 - 0 3.08 [0.00-4.11] 3 1.98 [0.00-1.98] 11 - 0 1.98 [0.00-1.98] 11 
   Drug store - 0 - 0 - 0 0.99 [0.99-0.99] 1 - 0 0.99 [0.99-0.99] 1 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 
   Total 3.08 [0.00-4.11] 3 - 0 3.08 [0.00-4.11] 3 1.98 [0.00-1.98] 12 - 0 1.98 [0.00-1.98] 12 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Nigeria – Total - - - - - - 1.18 [1.18-1.77] 27 0.30 [0.00-1.77] 11 1.18 [0.30-1.77] 38 
Public health facility  - - - - - - 1.18 [1.18-1.77] 12 0.00 [0.00-0.00] 6 1.18 [0.00-1.18] 18 
Private not-for-profit health facility - - - - - - 1.77 [1.77-1.77] 3 - 0 1.77 [1.77-1.77] 3 
Private for-profit outlet - - - - - -       
   Health facility/pharmacy - - - - - - 7.09 [7.09-22.44] 8 1.77 [1.77-2.36] 3 2.36 [1.77-7.09] 11 
   Drug store - - - - - - 0.89 [0.89-0.89] 4 0.30 [0.30-0.30] 2 0.30 [0.30-0.89] 6 
   General retailer/itinerant - - - - - - - 0 - 0 - 0 
   Total - - - - - - 7.09 [0.89-22.44] 12 0.89 [0.30-1.77] 5 1.77 [0.41-7.09] 17 
Community health worker - - - - - - - 0 - 0 - 0 
Tanzania - mainland – Total 5.85 [1.41-5.85] 8 0.00 [0.00-0.00] 17 0.00 [0.00-0.00] 25 0.31 [0.00-0.62] 11 0.00 [0.00-0.00] 23 0.00 [0.00-0.00] 34 
Public health facility  - 0 0.00 [0.00-0.00] 14 0.00 [0.00-0.00] 14 0.00 1 0.00 [0.00-0.00] 20 0.00 [0.00-0.00] 21 
Private not-for-profit health facility - 0 0.00 [0.00-1.41] 3 0.00 [0.00-1.41] 3 - 0 0.00 1 - 1 
Private for-profit outlet             
   Health facility/pharmacy 5.85 [5.85-5.85] 7 - 0 5.85 [5.85-5.85] 7 0.62 [0.62-1.25] 8 - 0 0.62 [0.62-1.25] 8 
   Drug store 1.41 [1.41-1.41] 1 - 0 1.41 [1.41-1.41] 1 0.31 [0.31-0.62] 2 0.94 [0.94-0.94] 1 0.94 [0.62-0.94] 3 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 1 0.00 1 
   Total 5.85 [1.41-5.85] 8 - 0 5.85 [1.41-5.85] 8 0.62 [0.31-0.62] 10 0.94 [0.00-0.94] 2 0.62 [0.00-0.94] 12 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
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Table 2.3.26: Cont. 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban Rural Total 
Median cost 
 [IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Median cost  
[IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Median cost 
[IQR] 
No. of 
products 
Uganda – Total 1.39 [1.02-1.86] 76 0.93 [0.00-1.39] 102 0.93 [0.46-1.39] 178 1.17 [0.78-1.17] 271 0.00 [0.00-0.59] 541 0.00 [0.00-0.78] 812 
Public health facility  0.00  1 0.00 [0.00-0.00] 26 0.00 [0.00-0.00] 27 0.00 [0.00-0.00] 46 0.00 [0.00-0.00] 357 0.00 [0.00-0.00] 403 
Private not-for-profit health facility - 0 0.46 [0.00-1.39] 3 0.46 [0.00-1.39] 3 0.00 [0.00-1.96] 3 0.00 [0.00-0.78] 15 0.00 [0.00-0.78] 18 
Private for-profit outlet             
   Health facility/pharmacy 1.39 [1.39-2.32] 73 1.39 [0.93-1.39] 49 1.39 [1.16-1.86] 122 1.17 [0.78-1.17] 194 1.17 [0.78-1.56] 91 1.17 [0.78-1.37] 285 
   Drug store 0.70 [0.70-0.93] 2 0.93 [0.46-1.07] 17 0.93 [0.70-0.93] 19 1.17 [0.78-1.17] 28 0.78 [0.39-0.98] 30 0.78 [0.39-1.17] 58 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 
   Total 1.39 [1.16-1.86] 75 0.93 [0.93-1.39] 66 1.39 [0.93-1.39] 141 1.17 [0.78-1.17] 222 0.98 [0.78-1.17] 121 1.17 [0.78-1.17] 343 
Community health worker - 0 0.00 [0.00-0.00] 7 0.00 [0.00-0.00] 7 - 0 0.00 [0.00-0.00] 48 0.00 [0.00-0.00] 48 
Zanzibar – Total 0.00 [0.00-0.00] 43 0.00 [0.00-0.00] 71 0.00 [0.00-0.00] 114 0.00 [0.00-0.00] 54 0.00 [0.00-0.00] 86 0.00 [0.00-0.00] 140 
Public health facility  0.00 [0.00-0.00] 37 0.00 [0.00-0.00] 71 0.00 [0.00-0.00] 108 0.00 [0.00-0.00] 39 0.00 [0.00-0.00] 84 0.00 [0.00-0.00] 123 
Private not-for-profit health facility - 0 - 0 - 0 - 0 - 0 - 0 
Private for-profit outlet             
   Health facility/pharmacy 1.58 [0.70-2.11] 6 - 0 1.58 [0.7-2.11] 6 0.58 [0.58-1.75] 13 0.00 [0.00-0.00] 2 0.58 [0.29-1.75] 15 
   Drug store - 0 - 0 - 0 0.15 [0.00-0.29] 2 - 0 0.15 [0.00-0.29] 2 
   General retailer/itinerant - 0 - 0 - 0 - 0 - 0 - 0 
   Total 1.58 [0.70-2.11] 6 - 0 1.58 [0.7-2.11] 6 0.58 [0.29-1.75] 15 0.00 [0.00-0.00] 2 0.58 [0.29-1.75] 17 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Note: Nigeria baseline data collection was conducted in 2009. 
* At baseline for the Madagascar and Nigeria ACTwatch surveys, the questionnaire did not distinguish between the price of diagnosis for adults and children. This table, therefore, presents the general figures reported for 
these countries. 
na = Not applicable, IQR = Interquartile range; 
Source: AMFm Phase 1 Independent Evaluation Outlet Survey 
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2.4 Market share of quality-assured ACTs 
 
Question 4: Has the AMFm mechanism helped increase the market share of quality-assured 
ACTs relative to all antimalarial treatments in the public, private for-profit and not-for-profit 
sectors in rural/urban areas? 
 
Tables 2.4.1-2.4.4 shows the percent distribution of antimalarial sales volumes by 
antimalarial category for public health facilities, private not-for-profit facilities, private for-
profit outlets and all outlets (not shown for CHWs alone due to their low total sales volumes). 
For public health facilities (Table 2.4.1), the market share for QAACTs at endline was lowest 
in Madagascar (13%) and Niger (27%) and highest in Uganda (81%). Substantial and 
significant increases in QAACT market share between baseline and endline were seen in 
Nigeria (42 percentage points), Ghana (23 percentage points), Uganda (17 percentage points) 
and Zanzibar (15 percentage points). The increase was concentrated in rural areas in Uganda, 
and in urban areas in Ghana, Nigeria and Zanzibar. The increases in QAACT market share 
were mainly at the expense of non-QAACTs in Ghana and Zanzibar and at the expense of 
nATs in Uganda and Nigeria. It should be noted that there are legitimate uses of nATs, such 
as use of SP for intermittent preventive treatment for pregnant women and infants, and 
quinine for management of severe malaria. It is therefore not a policy objective to reduce 
availability or market share of these products to zero. 
 
Table 2.4.2 shows the percent distribution of antimalarial sales volumes by antimalarial 
category for private not-for-profit facilities. The small number of AETDs recorded in this 
sector makes it inappropriate to comment on market share in Madagascar, Niger, Nigeria, 
Tanzania mainland and Zanzibar. QAACT market share in this sector was 74% at endline in 
Ghana, 82% in Kenya and 51% in Uganda. Large increases were seen in Ghana (61 
percentage points) and Kenya (54 percentage points), but there was no change in Uganda. 
The increase in Ghana was mainly at the expense of non-quality-assured ACTs and the 
increase in Kenya was at the expense of nAT.  
 
Table 2.4.3 shows the percent distribution of antimalarial sales volumes by antimalarial 
category for private for-profit facilities. QAACT market share at endline was highest in 
Ghana (52%), Kenya (61%) and Zanzibar (61%). It was lowest in Niger (8%). Large and 
significant increases were seen in Ghana, Kenya, Nigeria, Madagascar, Tanzania mainland, 
Uganda and Zanzibar, ranging from 15 percentage points in Madagascar to 59 percentage 
points in Zanzibar. In Niger, the market share increased by 4 percentage points, from 4% to 
8%. In all countries except Niger, there was a large decrease in the market share of nAT. 
Zanzibar also saw a substantial decrease in the market share of oral AMT, from 20% to less 
than 1%, eliminating it from the market. In most countries the increase in QAACT market 
share was the same in rural and urban areas, apart from Niger where most of the increase 
occurred in rural areas. 
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Table 2.4.4 shows the percent distribution of antimalarial sales volumes by antimalarial 
category for all outlets combined. In most countries, the QAACT market share for all sectors 
combined was very similar to the QAACT market share for private for-profit outlets, 
reflecting the dominance of the private for-profit sector in antimalarial sales. The exceptions 
were Tanzania mainland and Uganda, where the QAACT market share overall was higher 
than in the private for-profit sector (42% vs. 32% in Tanzania mainland and 57% vs. 39% in 
Uganda). Large and significant changes were seen in Ghana, Kenya, Nigeria, Tanzania 
mainland, Uganda and Zanzibar, ranging from 16 percentage points in Tanzania mainland to 
48 percentage points in Zanzibar. Madagascar saw a significant increase in QAACT share in 
urban areas of 23 percentage points. There was a large decrease in the market share of nAT in 
all countries except Madagascar, where the decrease was small, and Niger which saw an 
increase in the share of nAT and a corresponding fall in QAACT share. Ghana also saw a 
decrease in the share of non-quality-assured ACTs, and Zanzibar saw a substantial decrease 
in the market share of oral AMT, from 12% to less than 1%. In Ghana, Kenya and Uganda, 
increases in QAACT market share were similar in rural and urban areas, while all of the 
increase in QAACT market share in Tanzania mainland occurred in rural areas. In Zanzibar, 
urban areas saw the greater increase.  
 
Table 2.4.5 shows the market share for QAACTs with and without the AMFm logo, by 
sector. The vast majority of QAACTs sold in the private for-profit sector bore the AMFm 
logo in all countries except Niger, where both product types had a very low market share 
(each less than 5%), and where QAACTs overall comprised less than 8% of the total sales 
volume in the private for-profit sector. In the public sector, the picture was more mixed. The 
majority of QAACTs carried the logo in Ghana, Kenya, Nigeria, Madagascar, Uganda and 
Zanzibar, but those without the logo predominated in Niger, and Tanzania mainland. 
 
Table 2.4.6 shows the market share of each sector in total volumes of antimalarials. A key 
feature was the predominance of the private for-profit sector which had the largest share of 
the market in all countries at endline - Ghana (71%), Kenya (62%), Madagascar (70%), Niger 
(49%), Nigeria (92%), Tanzania mainland (59%), Uganda (53%) and Zanzibar (87%). No 
change in the private sector share was seen in Ghana, Kenya, Niger or Nigeria between 
baseline and endline. However, increases in the private sector share were seen in Uganda 
(from 40% to 53%), Tanzania mainland (from 45% to 59%) and in Zanzibar (from 62% to 
87%). In Uganda, this shift mainly took place in rural areas, while it took place in both rural 
and urban areas in Zanzibar. Madagascar saw a fall in the private sector share, from 82% to 
70%. Community health workers were responsible for a neglible share of antimalarial 
distribution in all countries, however these providers are harder to identify than other outlets 
and it is possible that they were not fully captured in the initial census of providers.  
 
Table 2.4.7 shows the market share in total volumes of antimalarials for private for-profit 
outlets only. This provides an indication of which types of outlet within the private for-profit 
sector are the most important providers of antimalarials. At endline in Uganda and Zanzibar, 
the largest shares of antimalarials were sold in private for-profit health facilities/pharmacies 
(58% and 75% in Uganda and Zanzibar, respectively); in Kenya, Madagascar, Nigeria and 
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Tanzania mainland, the largest shares were sold in drug stores, ranging from 60% to 84%. In 
Ghana, private health facilities/pharmacies and drug stores sold roughly equal shares of 
antimalarials. General stores and itinerant vendors were responsible for the largest share of 
private for-profit sales volumes in Niger (65%) and this sector was also responsible for a 
large share in Madagascar (37%). Between baseline and endline, no substantial changes were 
seen in market share within the private for-profit sector in Kenya and Madagascar. Zanzibar 
showed an eight percentage point fall in the share of private health facilities/pharmacies and a 
corresponding increase in the share of drug stores between surveys. By contrast, in Ghana, 
Nigeria and Uganda, an increase in market share of between 10 and 20 percentage points was 
seen for private health facilities/pharmacies, with a fall in sales from drug stores. Niger also 
saw an increase in market share for private health facilities/pharmacies (28 percentage 
points), with a fall in the market share of general stores and itinerant vendors. 
 
Table 2.4.8 shows the market share of each sector in volumes of QAACTs sold. Private for-
profit outlets made up the majority of sales of QAACTs at endline in Ghana, Kenya, 
Madagascar, Nigeria and Zanzibar, ranging from 64% to 91%. However, in Niger, Tanzania 
mainland and Uganda at endline, the majority of QAACT sales came from public health 
facilities. Between baseline and endline surveys, the public sector market share of QAACTs 
fell by between 16 and 78 percentage points in Ghana, Kenya, Madagascar and Zanzibar, 
where this was accompanied by a commensurate increase in the private for-profit sector 
QAACT market share. Although sales of QAACTs from public health facilities made up the 
majority of the market share at endline in Niger, Tanzania mainland and Uganda, these 
countries also saw declines in the market share of QAACTs from public health facilities and 
increases of 27-40 percentage points in the market share of QAACTs from private for-profit 
outlets.It should be noted that without information about the total market size, one cannot 
infer from changes in market share whether there have been absolute increases or decreases 
in total sales volumes in each sector. 
Table 2.4.9 shows the breakdown of private for-profit QAACT sales by outlet type, 
indicating the relative importance of different types of private for-profit outlets in QAACT 
supply. Market share was roughly equal at endline for private health facilities/pharmacies and 
drug stores in Ghana, Madagascar and Uganda, while drug stores were responsible for the 
majority of QAACT sales in Kenya, Nigeria and Tanzania. In Zanzibar, private for-profit 
QAACT sales were dominated by private health facilities/ pharmacies. In Niger, almost two-
thirds (65%) of private for-profit QAACT sales at endline were from general retailers and 
itinerant vendors. In comparison with baseline, the drug store market share of QAACT sales 
fell in Madagascar, Nigeria, Tanzania mainland and Uganda, with an increase in the market 
share from private health facilities or pharmacies. By contrast, in Kenya and Zanzibar, there 
was a decline in the market share for private health facilities/pharmacies and an increase for 
drug stores. A 20 percentage point decline in the general store/itinerant vendors’ market share 
of QAACT sales was seen in Niger, with corresponding 10 percentage point increases in both 
private health facilities/pharmacies and drug stores. 
 
.
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Table 2.4.1: Percent distribution of antimalarial sales volumes for public health facilities, at baseline (2010) and endline (2011)  
Total number of AETDs of each type of antimalarial sold or distributed in the week preceding the survey visit (n), as a percentage of all antimalarial AETDs sold or distributed in the week preceding the 
survey visit for public health facilities with any antimalarials in stock at the time of the survey visit (N), by urban-rural location, according to country 
 
Country/Antimalarial 
BASELINE ENDLINE PERCENTAGE POINT CHANGE 
Urban Rural Total Urban Rural Total Urban Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N* % (95% CI) N % (95% CI) N % (95% CI) N* % (95% CI) % (95% CI) % (95% CI) 
Ghana - Total 100.0 5,552 100.0 11,544 100.0 17,096 100.0 1,935 100.0 3,425 100.0 5,360    
Quality-assured ACTs 27.5 (14.0-40.9)  47.9 (32.4-63.4)  45.6 (31.6-59.7)   71.9 (62.2-81.6)  67.5 (58-77.1)  69.0 (61.3-76.6)  44.5 (28.1-60.8) 19.6 (1.6-37.6) 23.3 (7.5-39.1) 
Non-quality-assured ACTs 57.7 (34.9-80.4)  35.9 (23.4-48.4)  38.3 (26.7-49.8)  26.3 (17.1-35.5)  21.7 (14.1-29.3)  23.2 (17.3-29.1)  -31.4 (-55.6- -7.1) -14.2 (-28.6-0.3) -15.1 (-27.8- -2.3) 
Oral artemisinin therapy 0.0  1.3 (-0.5-3.0)  1.1 (-0.5-2.7)  0.0  0.1 (-0.1-0.4)  0.1 (0.0-0.2)  0.0 -1.1 (-2.9-0.6) -1.0 (-2.6-0.5) 
Non-oral artemisinin monotherapy 1.0 (0.1-1.9)  2.4 (0.3-4.6)  2.3 (0.4-4.1)  0.1 (0.0-0.3)  2.5 (0.9-4.0)  1.7 (0.4-3.0)  -0.9 (-1.8-0.0) 0.0 (-2.6-2.6) -0.6 (-2.8-1.6) 
Non-artemisinin therapy 13.8 (-1.1-28.7)  12.5 (3.8-21.3)  12.7 (4.7-20.7)  1.6 (0.1-3.1)  8.2 (3.4-12.9)  6.1 (1.8-10.3)  -12.2 (-27-2.6) -4.4 (-14.2-5.5) -6.6 (-15.6-2.3) 
Kenya - Total 100.0 3,327 100.0 3,078 100.0 6,405 100.0 2,368 100.0 5,358 100.0 7,726    
Quality-assured ACTs 58.3 (39.9-76.6)  60.3 (34.3-86.3)  60.0 (38.2-81.8)  37.7 (18.8-56.5)  48.3 (10.8-85.7)  47.6 (13.1-82)  -20.6 (-46.7-5.4) -12.0 (-57.1-33) -12.4 (-52.8-27.9) 
Non-quality-assured ACTs 0.3 (-0.1-0.6)  0.4 (-0.2-1.1)  0.4 (-0.1-0.9)  0.6 (-0.2-1.5)  0.0 (0.0-0.1)  0.1 (0.0-0.1)  0.4 (-0.5-1.3) -0.4 (-1.0-0.2) -0.3 (-0.9-0.2) 
Oral artemisinin therapy 0.0  0.0  0.0  0.0  0.0  0.0  0.0 0.0 0.0 
Non-oral artemisinin monotherapy 0.7 (-0.5-2.0)  0.0  0.1 (-0.1-0.4)  0.0 (0.0-0.1)  0.4 (-0.4-1.2)  0.4 (-0.4-1.1)  -0.7 (-1.9-0.5) 0.4 (-0.4-1.2) 0.2 (-0.6-1.0) 
Non-artemisinin therapy 40.7 (21.9-59.5)  39.2 (13.1-65.3)  39.5 (17.5-61.4)  61.7 (42.3-81.1)  51.3 (13.6-89)  52.0 (17.3-86.8)  21.0 (-5.7-47.7) 12.1 (-33.3-57.5) 12.6 (-28.1-53.2) 
Madagascar - Total 100.0 782 100.0 216 100.0 997 100.0 1,094 100.0 774 100.0 1,868    
Quality-assured ACTs 20.7 (6.2-35.2)   28.6 (4.2-53.0)   27.4 (6.9-47.9)  10.2 (4.3-16.1)  13.0 (2.2-23.8)  12.7 (3.2-22.1)  -10.5 (-25.9-4.9) -15.6 (-42.0-10.7) -14.7 (-37.0-7.5) 
Non-quality-assured ACTs 2.0 (-1.0-4.9)  5.8 (-3.4-14.9)  5.2 (-2.7-13.1)  0.0  1.0 (-0.4-2.5)  0.9 (-0.4-2.2)  -2.0 (-4.9-0.9) -4.7 (-13.9-4.4) -4.3 (-12.1-3.6) 
Oral artemisinin therapy 0.0  0.0  0.0  0.0  0.0  0.0  0.0 0.0 0.0 
Non-oral artemisinin monotherapy 0.0  0.0  0.0  0.0  0.0  0.0  0.0 0.0 0.0 
Non-artemisinin therapy 77.3 (62-92.7)  65.6 (41.2-90.1)  67.4 (46.9-88.0)  89.8 (83.9-95.7)  86.0 (74.2-97.8)  86.4 (76.2-96.7)  12.5 (-3.7-28.7) 20.3 (-6.4-47.1) 19.0 (-3.7-41.7) 
Niger - Total 100.0 10,960 100.0 5,444 100.0 16,404 100.0 5,379 100.0 8,140 100.0 13,519    
Quality-assured ACTs 58.7 (40.6-76.9)  23.4 (9.2-37.6)  36.9 (20.2-53.7)  36.3 (33.8-38.8)   25.4 (22.5-28.3)  27.0 (24.2-29.7)  -22.4 (-40.6- -4.2) 2 (-12.3-16.4) -10.0 (-26.8-6.9) 
Non-quality-assured ACTs 20.4 (11.2-29.5)  14.0 (2.6-25.5)  16.5 (8.3-24.7)  19.5 (18.6-20.3)  12.5 (10.1-14.8)  13.4 (11.3-15.6)  -0.9 (-10.0-8.2) -1.6 (-13.1-10) -3 (-11.4-5.4) 
Oral artemisinin therapy 0.0  0.4 (-0.4-1.2)  0.2 (-0.2-0.7)  0.0 (0.0-0.1)  0.1 (0.0-0.2)  0.1 (0.0-0.1)  0.0 (0.0-0.1) -0.3 (-1.1-0.5) -0.2 (-0.6-0.3) 
Non-oral artemisinin monotherapy 0.0  0.0 (0.0-0.1)  0.0  0.5 (0.4-0.6)  0.3 (0.2-0.3)  0.3 (0.2-0.4)  0.5 (0.4-0.6) 0.2 (0.1-0.3) 0.3 (0.2-0.4) 
Non-artemisinin therapy 20.9 (4.6-37.2)  62.2 (42.7-81.7)  46.4 (26.3-66.4)  43.7 (41.1-46.3)  61.8 (56.7-66.9)  59.2 (54.5-63.9)  22.8 (6.5-39.2) -0.4 (-20.4-19.6) 12.9 (-7.6-33.3) 
Nigeria - Total 100.0 12,549 100.0 1,202 100.0 13,751 100.0 4,700 100.0 1,881 100.0 6,581    
Quality-assured ACTs 8.3 (-2.4-19.0)  6.0 (-0.5-12.5)  6.4 (0.7-12.2)  60.6 (40.8-80.4)  40.1 (22.1-58.0)  48.1 (34.0-62.1)  52.3 (29.9-74.7) 34.1 (15.0-53.1) 41.7 (26.5-56.8) 
Non-quality-assured ACTs 35.0 (21.0-49.0)  0.5 (-0.2-1.2)  7.2 (0.7-13.6)  8.1 (0.1-16.2)  7.2 (-0.5-14.9)  7.6 (1.9-13.2)  -26.9 (-42.9- -10.8) 6.7 (-1.0-14.3) 0.4 (-8.2-9.0) 
Oral artemisinin therapy 1.6 (0.4-2.9)  0.3 (-0.1-0.7)  0.6 (0.1-1.0)  1.5 (0.3-2.7)  0.3 (-0.1-0.7)  0.8 (0.1-1.4)  -0.1 (-1.8-1.6) 0.0 (-0.6-0.5) 0.2 (-0.6-1.0) 
Non-oral artemisinin monotherapy 0.9 (0.5-1.3)  1.2 (-0.3-2.8)  1.2 (-0.1-2.4)  2.0 (1.1-2.8)  7.4 (-3.4-18.3)  5.3 (-1.3-11.9)  1.0 (0.1-2.0) 6.2 (-4.7-17.1) 4.1 (-2.6-10.8) 
Non-artemisinin therapy 54.2 (40.7-67.8)  91.9 (84.6-99.3)  84.7 (73.9-95.4)  27.8 (13.4-42.2)  45.0 (28.6-61.5)  38.3 (25.9-50.7)  -26.4 (-46.1- -6.7) -46.9 (-64.9- -28.9) -46.4 (-62.7- -30.1) 
Tanzania - mainland - Total 100.0 1,273 100.0 3,144 100.0 4,417 100.0 1,885 100.0 8,146 100.0 10,031    
Quality-assured ACTs 89.8 (69.0-110.7)  37.9 (17.6-58.2)  58.3 (27.4-89.2)  75.8 (53.5-98.0)  55.4 (34.9-75.8)  56.6 (37.4-75.7)  -14.1 (-44.2-16) 17.5 (-11.0-45.9) -1.8 (-37.7-34.2) 
Non-quality-assured ACTs 7.0 (-10.1-24.1)  0.5 (-0.2-1.1)  3 (-2.6-8.7)  0.3 (-0.4-1.0)  0.2 (-0.1-0.6)  0.2 (-0.1-0.6)  -6.7 (-23.6-10.3) -0.2 (-1.0-0.5) -2.8 (-8.4-2.8) 
Oral artemisinin therapy 0.0  0.0  0.0  0.0  0.0  0.0  0.0 0.0 0.0 
Non-oral artemisinin monotherapy 1.8 (-2.5-6.0)  0.0  0.7 (-0.7-2.1)  0.1 (-0.1-0.4)  0.0  0.0  -1.6 (-5.9-2.6) 0.0 -0.7 (-2.1-0.7) 
Non-artemisinin therapy 1.4 (0.8-2.0)  61.6 (41.7-81.6)  38.0 (8.9-67.0)  23.8 (1.5-46.1)  44.4 (23.9-64.9)  43.2 (24.0-62.4)  22.4 (0.3-44.4) -17.2 (-45.5-11.0) 5.3 (-29.2-39.7) 
Uganda - Total 100.0 425 100.0 17,466 100.0 17,891 100.0 5,907 100.0 10,144 100.0 16,052    
Quality-assured ACTs 71.7 (62.9-80.5)  63.9 (52.2-75.6)  64.2 (52.9-75.4)  57.1 (41-73.2)  84.9 (79.6-90.3)  81.3 (74.5-88.0)  -14.6 (-32.8-3.5) 21.0 (8.4-33.6) 17.1 (4.2-30.0) 
Non-quality-assured ACTs 6.2 (-2.2-14.6)  0.4 (0.0-0.9)  0.7 (0.0-1.3)  3.4 (-0.3-7.2)  0.2 (-0.1-0.5)  0.6 (0.0-1.2)  -2.8 (-11.7-6.2) -0.3 (-0.8-0.3) -0.1 (-1.0-0.9) 
Oral artemisinin therapy 0.0  0.0  0.0  0.0  0.0  0.0  0.0 0.0 0.0 
Non-oral artemisinin monotherapy 0.0  0.0  0.0  0.0 (0.0-0.1)  0.0  0.0  0.0 (0.0-0.1) 0.0 0.0 
Non-artemisinin therapy 22.1 (4.9-39.3)  35.7 (23.8-47.5)  35.2 (23.7-46.6)  39.5 (22-56.9)  14.9 (9.6-20.2)  18.1 (11.6-24.7)  17.4 (-6.7-41.4) -20.8 (-33.5- -8.1) -17.0 (-29.9- -4.2) 
Zanzibar - Total 100.0 508 100.0 342 100.0.0 850 100.0 241 100.0 278 100.0 518    
Quality-assured ACTs 16.2   32.7   22.8   43.0   33.8   38.1   26.8 1.2 15.3  
Non-quality-assured ACTs 34.0  0.9  20.7  2.8   2.2  2.5   -31.2 1.4 -18.2 
Oral artemisinin therapy 0.2   0.0   0.1   0.0  0.0  0   -0.2 0.0 -0.1 
Non-oral artemisinin monotherapy 0.4   3.2   1.5  0.5  0.0  0.2   0.0 -3.2 -1.3 
Non-artemisinin therapy 49.1  63.3   54.8   53.8   63.9   59.2   4.7  0.7 4.4 
Note: The sum of urban and rural Ns may not exactly equal the total N due to rounding. Nigeria baseline data collection was conducted in 2009. Baseline market share estimates for Nigeria are calculated without excluding 
oversampled public health facilities, private health facilities and pharmacies in urban areas. Therefore, urban baseline market share estimates are weighted too heavily in total baseline estimates. 
CI = Confidence interval 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.4.2: Percent distribution of antimalarial sales volumes for private not-for-profit facilities, at baseline (2010) and endline (2011)  
Total number of AETDs of each type of antimalarial sold or distributed in the week preceding the survey visit (n), as a percentage of all antimalarial AETDs sold or distributed in the week preceding the survey 
visit for private not-for-profit facilities with any antimalarials in stock at the time of the survey visit (N), by urban-rural location, according to country 
 
Country/Antimalarial 
BASELINE ENDLINE PERCENTAGE POINT CHANGE 
Urban Rural Total Urban Rural Total Urban Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N* % (95% CI) N % (95% CI) N % (95% CI) N* % (95% CI) % (95% CI) % (95% CI) 
Ghana - Total  100.0 1,108  100.0 3,155  100.0 4,262  100.0 2,723  100.0 929  100.0 3,652    
Quality-assured ACTs 8.4 (4.6-12.1)  13.3 (1.7-24.8)  12.7 (2.4-23,0)  75.4 (59.4-91.3)  65.1 (60.8-69.4)  73.8 (59.7-87.8)  67.0 (50.8-83.2) 51.8 (39.6-64,0) 61.0 (43.8-78.2) 
Non-quality-assured ACTs 88.8 (84.7-92.9)  53.0 (36.8-69.2)  57.1 (41.7-72.5)  16.3 (0.4-32.2)  4.2 (-0.9-9.3)  14.4 (1.1-27.7)  -72.5 (-88.8- -56.3) -48.8 (-65.6- -32.1) -42.7 (-62.8- -22.6) 
Oral artemisinin therapy 0.0  0.0  0.0  0.0  0.5 (-0.5-1.5)  0.1 (-0.1-0.2)  0.0 0.5 (-0.5-1.5) 0.1 (-0.1-0.2) 
Non-oral artemisinin monotherapy 2.1 (1.5-2.7)  10.7 (0.6-20.8)  9.7 (0.6-18.8)  1.6 (1.1-2.1)  1.3 (0.7-2,0)  1.6 (1.1-2,0)  -0.5 (-1.3-0.3) -9.4 (-19.5-0.7) -8.2 (-17.2-0.8) 
Non-artemisinin therapy 0.7 (0.6-0.8)  23.0 (11.9-34.0)  20.5 (10.0-30.9)  6.8 (5.7-7.8)  28.9 (21.7-36.1)  10.2 (5-15.4)  6.1 (5.0-7.2) 5.9 (-7.1-18.9) -10.2 (-21.8-1.3) 
Kenya - Total  100.0 952  100.0 737  100.0 1,689  100.0 357  100.0 620  100.0 976    
Quality-assured ACTs 68.7 (40.6-96.9)  16.4 (-2.5-35.3)  27.7 (-1.7-57,0)  89.9 (85.5-94.3)  80.6 (73.9-87.3)  81.8 (75.8-87.8)  21.2 (-7,0-49.3) 64.2 (44.4-84,0) 54.1 (24.5-83.7) 
Non-quality-assured ACTs 10.2 (-1.4-21.8)  3.1 (-3.7-9.9)  4.6 (-2.1-11.3)  2.1 (-0.9-5.1)  0.0  0.3 (-0.1-0.7)  -8.1 (-19.9-3.8) -3.1 (-9.8-3.6) -4.3 (-11,0-2.3) 
Oral artemisinin therapy 0.0  0.0  0.0  0.0  0.0  0.0  0.0 0.0 0.0 
Non-oral artemisinin monotherapy 4.4 (-2.4-11.2)  0.4 (-0.5-1.2)  1.2 (-0.7-3.2)  1.1 (0.1-2.1)  0.4 (,00-0.9)  0.5 (0.1-0.9)  -3.3 (-10.1-3.4) 0.1 (-0.9-1,0) -0.7 (-2.7-1.3) 
Non-artemisinin therapy 16.6 (-5.1-38.4)  80.2 (56.4-104,0)  66.5 (31.5-101.4)  6.9 (3.5-10.2)  19.0 (12.2-25.8)  17.4 (11.2-23.6)  -9.8 (-31.5-12,0) -61.2 (-85.6- -36.7) -49.0 (-84.1- -14,0) 
Madagascar - Total  100.0 19 - 0  100.0 19  100.0 237  100.0 22  100.0 258    
Quality-assured ACTs 15.8 (-6.5-38,0)  -  15.8 (-6.5-38,0)  41.3 (21.1-61.5)  85.1 (55.8-114.3)  66.3 (38.3-94.3)  25.6 (-3.7-54.8) - 50.6 (15.5-85.6) 
Non-quality-assured ACTs 0.0  -  0.0  0.0  0.0  0.0  0.0 - 0.0 
Oral artemisinin therapy 0.0  -  0.0  0.0  0.0  0.0  0.0 - 0.0 
Non-oral artemisinin monotherapy 0.0  -  0.0  0.0  0.0  0.0  0.0 - 0.0 
Non-artemisinin therapy 84.2 (62,0-106.5)  -  84.2 (62,0-106.5)  58.7 (38.5-78.9)  14.9 (-14.3-44.2)  33.7 (5.7-61.7)  -25.6 (-54.8-3.7) - -50.6 (-85.6- -15.5) 
Niger - Total  100.0 26 - 0  100.0 26  100.0 7  100.0 913  100.0 920  -  
Quality-assured ACTs 0.0  -  0.0  40.1 (40.1-40.1)  32.5 (32.5-32.5)  34.8 (31.4-38.2)  40.1 (0.0-0.0) - 34.8 (31.4-38.2) 
Non-quality-assured ACTs 16.2 (-15.6-48,0)  -  16.2 (-15.6-48,0)  13.8 (13.8-13.8)  29.1 (29.1-29.1)  24.6 (17.6-31.5)  -2.4 (-33.3-28.5) - 8.4 (-23.3-40,0) 
Oral artemisinin therapy 0.0  -  0.0  0.9 (0.9-0.9)  0.0  0.3 (-0.1-0.7)  0.9 (0.9-0.9) - 0.3 (-0.1-0.7) 
Non-oral artemisinin monotherapy 0.0  -  0.0  0.0  0.3 (0.3-0.3)  0.2 (0.1-0.3)  0.0 - 0.2 (0.1-0.3) 
Non-artemisinin therapy 83.8 (52,0-115.6)  -  83.8 (52,0-115.6)  45.2 (45.2-45.2)  38.0 (38.0-38.0)  40.1 (36.9-43.4)  -38.7 (-69.6- -7.8) - -43.7 (-74.7- -12.6) 
Nigeria - Total  100.0 231  100.0 152  100.0 383  100.0 351  100.0 36  100.0 387    
Quality-assured ACTs 6.8 (-2.6-16.2)  34.8 (34.1-35.5)  33.8 (32.0-35.6)  39.2 (-5.2-83.5)  49.4 (35.4-63.4)  40.3 (0.2-80.4)  32.4 (-12.7-77.5) 14.7 (0.7-28.6) 6.5 (-33.5-46.5) 
Non-quality-assured ACTs 10.0 (-1.4-21.3)  28.2 (27.9-28.5)  27.5 (26.0-29.1)  0.8 (-1.2-2.8)  0.0  0.7 (-1.0-2.4)  -9.2 (-20.6-2.3) -28.2 (-28.5- -27.9) -26.8 (-29.1- -24.5) 
Oral artemisinin therapy 15.5 (-6.1-37.1)  0.0   0.5 (-0.7-1.7)  0.1 (-0.1-0.3)  14.0 (7.2-20.0)  1.6 (-1.8-5.0)  -15.4 (-36.8-6.1) 14.0 (7.3-20.7) 1.1 (-2.5-4.6) 
Non-oral artemisinin monotherapy 1.9 (-0.8-4.7)  0.3 (0.3-0.3)  0.4 (0.3-0.5)  35.7 (5.7-65.8)  0.7 (0.4-1.1)  32.0 (2.2-61.7)  33.8 (3.8-63.8) 0.4 (0.1-0.8) 31.6 (1.9-61.2) 
Non-artemisinin therapy 65.9 (34.5-97.2)  36.7 (36.4-37.1)  37.7 (35.3-40.1)  24.2 (8.4-40.0)  35.8 (19.1-52.6)  25.4 (11.3-39.5)  -41.7 (-76.6- -6.8) -0.9 (-17.6-15.7) -12.3 (-26.5-2.0) 
Tanzania - mainland - Total  100.0 783  100.0 2,158  100.0 2,941  100.0 308  100.0 22  100.0 329    
Quality-assured ACTs 27.4 (21.5-33.4)  13.6 (2.4-24.8)  17.3 (5.1-29.5)  37.2 (8.3-66.0)  92.6 (78.7-106.6)  43.2 (16.8-69.7)  9.7 (-19.4-38.8) 79.0 (61.4-96.7) 25.9 (-2.9-54.6) 
Non-quality-assured ACTs 15.2 (13.8-16.5)  6.5 (4.4-8.6)  8.8 (5.1-12.6)  25.2 (-11.6-62,0)  0.0  22.4 (-10.8-55.6)  10.0 (-26.4-46.3) -6.5 (-8.6- -4.4) 13.6 (-19.4-46.6) 
Oral artemisinin therapy 0.0  0.0  0.0  0.0  0.0  0.0  0.0 0.0 0.0 
Non-oral artemisinin monotherapy 0.5 (0.5-0.6)  0.1 (-0.1-0.2)  0.2 (-0.1-0.5)  2.5 (-1.2-6.2)  0.0  2.2 (-1.1-5.6)  2.0 (-1.7-5.6) -0.1 (-0.2-0.1) 2.0 (-1.3-5.3) 
Non-artemisinin therapy 56.9 (49.5-64.2)  79.8 (68.6-91.1)  73.7 (58.3-89,0)  35.2 (4.1-66.3)  7.4 (-6.6-21.3)  32.1 (4.6-59.7)  -21.7 (-53.2-9.9) -72.5 (-90.2- -54.8) -41.5 (-72.6- -10.4) 
Uganda - Total  100.0 356  100.0 738  100.0 1,093  100.0 518  100.0 1,878  100.0 2,395    
Quality-assured ACTs 
58.0 (38.6-77.3)  41.2 (17.7-64.6)  47.4 (27.5-67.3)   63.6 (49.4-77.7)  49.5 (21.8-77.3)  50.5 (24.3-76.7) 
 
 
5.6 (-17.9-29.1) 8.4 (-27.3-44.1) 3.1 (-29.3-35.5) 
Non-quality-assured ACTs 10.3 (-13.7-34.4)  7.3 (-3.5-18.1)  8.4 (-2.3-19.2)  11.0 (2.2-19.9)  3.6 (-1.7-8.9)  4.1 (-1.0-9.2)  0.7 (-24.3-25.7) -3.7 (-15.5-8.1) -4.3 (-16,0-7.3) 
Oral artemisinin therapy 0.0  0.8 (-0.9-2.6)  0.5 (-0.6-1.6)  0.0  0.0  0.0  0.0 -0.8 (-2.5-0.9) -0.5 (-1.6-0.6) 
Non-oral artemisinin monotherapy 0.5 (0.3-0.6)  0.5 (-0.3-1.3)   0.5 (0.0-1.0)  1.6 (-0.2-3.3)  0.5 (-0.2-1.2)  0.6 (-0.1-1.2)  1.1 (-0.6-2.8) 0 (-1,0-1,0) 0.1 (-0.7-0.9) 
Non-artemisinin therapy 31.2 (26.5-35.9)  50.2 (27.1-73.4)  43.2 (25.8-60.6)  23.8 (9.3-38.4)  46.4 (16.2-76.5)  44.8 (16-73.6)  -7.4 (-22.5-7.7) -3.9 (-41.3-33.6) 1.7 (-31.5-34.8) 
Zanzibar - Total  100.0 8  100.0 7  100.0 15 - 0  100.0 4  100.0 4 -   
Quality-assured ACTs 0.0   0.0  0.0   -  100.0   100.0   - 100.0  100.0 
Non-quality-assured ACTs 35.5   89.8   59.5   -  0.0  0.0   - -89.8 -59.5 
Oral artemisinin therapy 0.0  0.0  0.0   -  0.0  0.0   - 0  0.0  
Non-oral artemisinin monotherapy 0.0   0.0   0.0  -  0.0   0.0  - 0 0.0  
Non-artemisinin therapy 64.5   10.2   40.5  -  0.0   0.0  - -10.2  -40.5 
Note: The sum of urban and rural Ns may not exactly equal the total N due to rounding.  
Nigeria baseline data collection was conducted in 2009. Baseline market share estimates for Nigeria are calculated without excluding oversampled public health facilities, private health facilities and pharmacies in urban areas. 
Therefore urban baseline market share estimates are weighted too heavily in total baseline estimates. 
CI = Confidence interval 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.4.3: Percent distribution of antimalarial sales volumes for private for-profit facilities, at baseline (2010) and endline (2011) 
Total number of AETDs of each type of antimalarial sold or distributed in the week preceding the survey visit (n), as a percentage of all antimalarial AETDs sold or distributed in the week preceding the survey visit for private 
for-profit facilities with any antimalarials in stock at the time of the survey visit (N), by urban-rural location, according to country 
Country/Antimalarial 
BASELINE ENDLINE PERCENTAGE POINT CHANGE 
Urban Rural Total Urban Rural Total Urban Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N* % (95% CI) N % (95% CI) N % (95% CI) N* % (95% CI) % (95% CI) % (95% CI) 
Ghana - Total  100.0 24,920  100.0 27,186  100.0 52,107  100.0 16,881  100.0 5,695  100.0 22,576    
Quality-assured ACTs 5.8 (2.0-9.6)  6.6 (2.6-10.7)  6.5 (3.1-9.8)  52.5 (49.0-56.1)  49.2 (36.7-61.7)  51.8 (47.9-55.7)  46.7 (41.5-51.9) 42.6 (29.6-55.6) 45.3 (40.3-50.4) 
Non-quality-assured ACTs 47.3 (35.0-59.7)  26.1 (21.0-31.2)  30.2 (25-35.4)  21.7 (16.2-27.2)  12.3 (8.4-16.2)  19.7 (15.1-24.2)  -25.6 (-39.0- -12.3) -13.8 (-20.1- -7.4) -10.5 (-17.3- -3.7) 
Oral artemisinin therapy 4.7 (3.2-6.3)  5.1 (3.0-7.1)  5.0 (3.3-6.7)  3.3 (2.3-4.3)  4.4 (2.1-6.7)  3.5 (2.6-4.5)  -1.4 (-3.3-0.4) -0.7 (-3.7-2.4) -1.5 (-3.4-0.5) 
Non-oral artemisinin monotherapy 5.6 (-0.3-11.6)  3.1 (0.1-6.1)  3.6 (0.9-6.3)  1.4 (0.9-1.9)  2.8 (0.2-5.5)  1.7 (1.0-2.4)  -4.2 (-10.1-1.7) -0.3 (-4.2-3.6) -1.9 (-4.6-0.9) 
Non-artemisinin therapy 36.6 (24.7-48.4)  59.1 (52.7-65.5)  54.8 (48.5-61)  21.1 (15.3-26.9)  31.2 (19.0-43.4)  23.3 (18.0-28.6)  -15.5 (-28.5- -2.4) -27.9 (-41.5- -14.2) -31.5 (-39.6- -23.3) 
Kenya - Total  100.0 17,221  100.0 6,295  100.0 23,516  100.0 22,995  100.0 6,767  100.0 29,761    
Quality-assured ACTs 25.5 (16.4-34.5)  5.9 (3.8-7.9)  12.1 (6-18.2)  62.2 (54.7-69.6)  61.0 (49.3-72.6)  61.4 (53.6-69.2)  36.7 (25.1-48.3) 55.1 (43.3-66.8) 49.3 (39.5-59.1) 
Non-quality-assured ACTs 22.1 (13.0-31.1)  5.3 (1.3-9.3)  10.7 (4.1-17.3)  13.3 (8.7-17.9)  3.4 (1.2-5.7)  7.2 (4.5-9.9)  -8.8 (-18.9-1.2) -1.9 (-6.4-2.6) -3.5 (-10.6-3.6) 
Oral artemisinin therapy 0.6 (-0.5-1.7)  1.8 (0-3.6)  1.4 (-0.1-2.9)  0.2 (-0.2-0.6)  0.0  0.1 (-0.1-0.2)  -0.4 (-1.6-0.8) -1.8 (-3.5- -0.1) -1.3 (-2.8-0.2) 
Non-oral artemisinin monotherapy 1.7 (0.1-3.3)  0.5 (0.2-0.8)  0.9 (0.3-1.4)  1.2 (0.2-2.1)  0.1 (0.0-0.2)  0.5 (0.1-0.9)  -0.5 (-2.4-1.3) -0.4 (-0.6- -0.1) -0.4 (-1.0-0.3) 
Non-artemisinin therapy 50.2 (34.2-66.1)  86.5 (82.5-90.5)  74.9 (63.8-86.0)  23.2 (14.1-32.4)  35.5 (23.7-47.3)  30.8 (22.4-39.2)  -26.9 (-45.1- -8.7) -51.0 (-63.3- -38.7) -44.1 (-57.8- -30.3) 
Madagascar - Total  100.0 9,266  100.0 1,408  100.0 10,675  100.0 4,241  100.0 1,692  100.0 5,933    
Quality-assured ACTs 6.3 (3.8-8.8)  7.0 (2.9-11.1)  6.8 (3.6-10.1)  35.0 (23.2-46.8)  18.0 (7.1-29.0)  22.0 (12.9-31.0)  28.7 (16.8-40.7) 11.0 (-0.5-22.6) 15.1 (5.6-24.6) 
Non-quality-assured ACTs 1 (0.0-2.0)  0.0  0.2 (-0.1-0.5)  0.4 (0.1-0.7)  0.0  0.1 (0.0-0.2)  -0.6 (-1.6-0.4) 0.0 -0.1 (-0.4-0.2) 
Oral artemisinin therapy 0.0  0.0  0.0  0.0  0.0  0.0  0.0 0.0 0.0 
Non-oral artemisinin monotherapy 0.0  0.0  0.0  0.0  0.0  0.0  0.0 0.0 0.0 
Non-artemisinin therapy 92.7 (90.0-95.4)  93.0 (88.9-97.1)  92.9 (89.7-96.1)  64.6 (52.8-76.4)  82.0 (71.0-92.9)  77.9 (68.9-87)  -28.1 (-40.1- -16.1) -11.0 (-22.6-0.5) -15.0 (-24.5- -5.5) 
Niger - Total  100.0 9,712  100.0 8,020  100.0 17,733  100.0 21,454  100.0 4,125  100.0 25,579    
Quality-assured ACTs 8.8 (2.7-14.9)  1.5 (0.6-2.4)  3.7 (1.2-6.2)  9.7 (9.0-10.3)  6.7 (6.3-7.2)  7.6 (7.2-8.0)  0.9 (-5.2-7.0) 5.2 (4.2-6.2) 3.9 (1.4-6.4) 
Non-quality-assured ACTs 7.8 (3.5-12.2)  0.1 (-0.1-0.2)  2.4 (1.0-3.8)  3.2 (2.8-3.5)  1.4 (1.2-1.5)  1.9 (1.7-2.0)  -4.7 (-9.0- -0.4) 1.3 (1.1-1.5) -0.5 (-1.9-0.9) 
Oral artemisinin therapy 0.2 (0.0-0.4)  0.0  0.1 (0-0.2)  0.0  0.0  0.0  -0.2 (-0.4-0.0) 0.0 -0.1 (-0.1-0.0) 
Non-oral artemisinin monotherapy 0.1 (-0.1-0.3)  0.0  0.0 (0.0-0.1)  0.0  0.0  0.0  -0.1 (-0.3-0.1) 0.0 0.0 (-0.1-0.0) 
Non-artemisinin therapy 83.0 (75.3-90.7)  98.4 (97.5-99.4)  93.8 (90.5-97.2)  87.1 (86.2-88.0)  91.9 (91.4-92.5)  90.6 (90.0-91.1)  4.1 (-3.6-11.8) -6.5 (-7.6- -5.4) -3.3 (-6.7-0.1) 
Nigeria - Total  100.0 86,795  100.0 11,174  100.0 97,970  100.0 53,647  100.0 11,333  100.0 64,979    
Quality-assured ACTs 2.3 (1.2-3.4)  1.6 (0.3-2.9)  2.2 (1.2-3.2)  17.1 (13.1-21.1)  19.7 (15.1-24.3)  17.8 (14.4-21.1)  14.8 (10.7-19.0) 18.1 (13.4-22.8) 15.6 (12.1-19.1) 
Non-quality-assured ACTs 5.5 (1.3-9.8)  2.5 (0.6-4.3)  5.1 (1.5-8.8)  9.8 (6.2-13.4)  4.2 (2.2-6.3)  8.4 (5.4-11.3)  4.3 (-1.3-9.8) 1.8 (-1.0-4.5) 3.2 (-1.4-7.9) 
Oral artemisinin therapy 9.1 (4.8-13.3)  3.4 (1.7-5.0)  8.3 (4.4-12.2)  4.9 (3.6-6.1)  3.2 (2.1-4.3)  4.4 (3.5-5.3)  -4.2 (-8.6-0.2) -0.2 (-2.2-1.8) -3.9 (-7.9-0.1) 
Non-oral artemisinin monotherapy 0.4 (-0.1-1.0)  0.2 (0.0-0.4)  0.4 (-0.1-0.9)  0.6 (0.0-1.3)  0.3 (0.1-0.4)  0.5 (0.1-1.0)  0.2 (-0.6-1.1) 0.1 (-0.2-0.3) 0.1 (-0.5-0.8) 
Non-artemisinin therapy 82.7 (80.0-85.4)  92.4 (89.0-95.7)  84.0 (80.9-87.0)   67.6 (62.1-73.1)  72.6 (67.3-77.9)  68.9 (64.8-73.0)  -15.1 (-21.2- -9.0) -19.7 (-26.0- -13.5) -15.1 (-20.2- -10.0) 
Tanzania - mainland - Total  100.0 3,444  100.0 2,711  100.0 6,155  100.0 19,063  100.0 6,713  100.0 25,776    
Quality-assured ACTs 2.8 (1.9-3.7)   1.0 (0.1-1.9)   2.2 (1.1-3.3)  30.4 (25.3-35.6)  33.8 (19-48.6)  32.1 (24-40.3)  27.6 (22.4-32.7) 32.7 (18.1-47.4) 30.0 (21.9-38.1) 
Non-quality-assured ACTs 13.0 (6.3-19.7)   0.9 (-0.1-1.9)  8.6 (1.0-16.2)  10.2 (5.3-15.1)  2.3 (0.6-4.0)  6.1 (2.9-9.4)  -2.8 (-11.0-5.5) 1.4 (-0.5-3.4) -2.5 (-10.7-5.7) 
Oral artemisinin therapy 0.0  0.0  0.0  0.0  0.0  0.0  0.0 0.0 0.0 
Non-oral artemisinin monotherapy 0.2 (0.0-0.3)  0.0  0.1 (0.0-0.2)  0.0 (0.0-0.1)  0.0  0.0  -0.1 (-0.3- 0) 0.0 -0.1 (-0.2-0.0) 
Non-artemisinin therapy 84.1 (76.5-91.7)  98.1 (96.7-99.5)  89.1 (80.4-97.9)  59.4 (50.5-68.3)  63.9 (47.8-80.0)  61.7 (52.3-71.1)  -24.7 (-36.3- -13.1) -34.2 (-50.1- -18.2) -27.4 (-40.1- -14.7) 
Uganda - Total  100.0 2,646  100.0 12,129  100.0 14,775  100.0 22,832  100.0 14,444  100.0 37,276    
Quality-assured ACTs 
3.9 (2.6-5.3)  5.6 (2-9.2)  5.1 (2.5-7.7)  
 
36.8 (32.4-41.3)  39.3 (28.6-50.0)  38.5 (31.5-45.5)  
32.9 (28.4-37.5) 33.8 (22.6-44.9) 33.4 (26-40.8) 
Non-quality-assured ACTs 31.9 (23.3-40.4)  22.0 (15.2-28.8)  24.9 (18.7-31.0)  19.1 (15.2-23.0)  21.1 (4.4-37.8)  20.4 (9.2-31.6)  -12.8 (-21.9- -3.6) -0.9 (-18.7-16.9) -4.5 (-17.1-8.1) 
Oral artemisinin therapy 0.0  0.0  0.0  0.0  0.0  0.0  0.0 0.0 0.0 
Non-oral artemisinin monotherapy 1.3 (0.5-.02)  0.3 (0.1-0.5)  0.6 (0.1-1.0)  1.0 (0.4-1.5)  0.8 (-0.1-1.8)  0.9 (0.2-1.5)  -0.3 (-1.2-0.6) 0.6 (-0.4-1.5) 0.3 (-0.4-1.1) 
Non-artemisinin therapy 63.0 (52.6-73.3)  72.2 (65.2-79.2)  69.5 (62.9-76.1)  43.1 (36.6-49.7)  38.8 (30.4-47.1)  40.3 (33.8-46.7)  -19.8 (-31.9- -7.8) -33.4 (-44.1- -22.7) -29.2 (-38.3- -20.2) 
Zanzibar - Total  100.0 1,335  100.0 97  100.0 1,432  100.0 3075  100.0 299  100.0 3,374    
Quality-assured ACTs 2.1  0   2.0  60.1  66.9  60.7  58.0  66.9 58.7 
Non-quality-assured ACTs 26.4  14.0  25.6   22.1  2.5   20.3   -4.4  -11.5 -5.3 
Oral artemisinin therapy 20.6  4.5  19.5   0.2  0.6   0.2  -20.4 -3.9  -19.3 
Non-oral artemisinin monotherapy 0.8  0  0.8   0.3   0.4  0.3  -0.5 0.4 -0.5 
Non-artemisinin therapy 50  81.5   52.1   17.3  29.6  18.4   -32.6  -52.0  -33.7  
Note: The sum of urban and rural Ns may not exactly equal the total N due to rounding. 
Nigeria baseline data collection was conducted in 2009. Baseline market share estimates for Nigeria are calculated without excluding oversampled public health facilities, private health facilities and pharmacies in urban areas. 
Therefore urban baseline market share estimates are weighted too heavily in total baseline estimates. Baseline QAACT market share is also likely to be biased upwards, however, the magnitude of this bias is minimal because of 
the very low share of antimalarial sales accounted for by health facilities and pharmacies (2.3% at baseline in urban areas). 
CI = Confidence interval 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.4.4: Percent distribution of antimalarial sales volumes for all outlets (all sectors combined), at baseline (2010) and endline (2011)  
Indicator 4.1: Total number of AETDs of each type of antimalarial sold or distributed in the week preceding the survey visit (n), as a percentage of all antimalarial AETDs sold or distributed in the week preceding 
the survey visit for all outlets with any antimalarials in stock at the time of the survey visit (N), by urban-rural location, according to country 
 
Country/Antimalarial 
BASELINE ENDLINE PERCENTAGE POINT CHANGE 
Urban Rural Total Urban Rural Total Urban Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N* % (95% CI) N % (95% CI) N % (95% CI) N* % (95% CI) % (95% CI) % (95% CI) 
Ghana - Total  100.0 31,580  100.0 41,915  100.0 73,495  100.0 21,538  100.0 10,050  100.0 31,588    
Quality-assured ACTs 9.7 (6.1-13.3)  18.7 (12.1-25.4)  17.3 (11.6-22.9)  57.8 (52-63.6)  56.9 (49.1-64.7)  57.6 (52.8-62.3)  48.1 (41.4-54.8) 38.2 (28-48.3) 40.3 (33.0-47.6) 
Non-quality-assured ACTs 51.2 (41.1-61.2)  30.9 (25.5-36.3)  34.2 (29.1-39.3)  21.0 (15.8-26.3)  14.8 (10.9-18.8)  19.3 (15.4-23.3)  -30.1 (-41.4- -18.9) -16.0 (-22.6- -9.4) -14.9 (-21.2- -8.5) 
Oral artemisinin therapy 3.7 (2.6-4.7)  3.6 (2.2-5.0)  3.6 (2.4-4.8)   2.5 (1.8-3.2)  2.6 (1.0-4.2)  2.5 (1.9-3.2)  -1.2 (-2.4-0.1) -1 (-3.1-1.1) -1.1 (-2.5-0.3) 
Non-oral artemisinin monotherapy 4.6 (-0.1-9.3)  3.5 (1.3-5.7)  3.7 (1.7-5.7)  1.4 (0.9-1.8)   2.6 (1.1-4.1)  1.7 (1.1-2.3)  -3.3 (-7.9-1.4) -0.9 (-3.6-1.7) -2.0 (-4.0-0.0) 
Non-artemisinin therapy 30.8 (22.4-39.2)  43.3 (36.5-50.0)  41.2 (35.2-47.2)  17.3 (12.0-22.7)  23.1 (16.8-29.4)  18.9 (14.5-23.3)  -13.5 (-23.4- -3.7) -20.2 (-29.3- -11.1) -22.3 (-29.7- -15) 
Kenya - Total  100.0 21,528  100.0 10,216  100.0 31,743  100.0 25,719  100.0 12,745  100.0 38,464    
Quality-assured ACTs 32.9 (23.9-42)  23.2 (9.7-36.7)  25.8 (14.4-37.3)  60.3 (54.3-66.3)  56.0 (36.2-75.8)  57.1 (42.2-72)  27.4 (16.6-38.1) 32.9 (9.1-56.6) 31.3 (12.7-49.9) 
Non-quality-assured ACTs 18.0 (11.3-24.6)  3.7 (1.3-6.1)  7.6 (3.6-11.5)  11.9 (7.4-16.4)  1.8 (0.5-3.0)  4.5 (2.5-6.4)  -6.0 (-14.0-1.9) -1.9 (-4.6-0.8) -3.1 (-7.5-1.2) 
Oral artemisinin therapy 0.5 (-0.4-1.4)  1.1 (-0.3-2.5)  0.9 (-0.2-2.1)   0.2 (-0.2-0.6)  0.0  0.0 (0.0-0.1)   -0.3 (-1.2-0.7) -1.1 (-2.5-0.3) -0.9 (-2.0-0.2) 
Non-oral artemisinin monotherapy 1.7 (0.3-3)  0.3 (0.1-0.6)  0.7 (0.3-1.1)  1.1 (0.2-1.9)  0.2 (-0.1-0.6)  0.5 (0.1-0.8)  -0.6 (-2.2-0.1) -.0.1 (-0.5-0.3) -0.2 (-0.8-0.3) 
Non-artemisinin therapy 47.0 (33.7-60.2)  71.7 (58.8-84.5)  65.0 (51.6-78.4)  26.5 (18.1-34.9)  42.0 (21.5-62.4)  37.9 (21.9-53.9)  -20.4 (-35.9--4.9) -29.7 (-53.6--5.8) -27.1 (-47.8--6.4) 
Madagascar - Total  100.0 10,069  100.0 1,684  100.0 11,754  100.0 5,573  100.0 2,512  100.0 8,085    
Quality-assured ACTs 7.8 (4.7-11)  13.2 (7.4-19.0)  12.1 (7.4-16.7)  31.2 (21.2-41.2)  18.0 (8.8-27.3)  20.7 (12.6-28.8)  23.4 (13-33.7) 4.9 (-5.9-15.7) 8.6 (-0.6-17.9) 
Non-quality-assured ACTs 1.1 (0.0-2.2)  1.8 (-0.1-3.7)  1.7 (0.1-3.2)  0.3 (0.1-0.6)  0.4 (-0.1-1.0)  0.4 (0.0-0.8)  -0.8 (-1.9-0.3) -1.4 (-3.3-0.6) -1.2 (-2.8-0.3) 
Oral artemisinin therapy 0.0  0.0  0.0  0.0  0.0  0.0  0.0 0.0 0.0 
Non-oral artemisinin monotherapy 0.0  0.0  0.0  0.0  0.0  0.0  0.0 0.0 0.0 
Non-artemisinin therapy 91.0 (87.9-94.2)  85.0 (79.3-90.7)  86.3 (81.6-91)  68.5 (58.5-78.4)  81.5 (72.2-90.9)  78.9 (70.8-87.0)  -22.6 (-32.9- -12.2) -3.5 (-14.3-7.3) -7.4 (-16.7-1.9) 
Niger - Total  100.0 20,698  100.0 13,472  100.0 34,169  100.0 26,841  100.0 13,177  100.0 40,018    
Quality-assured ACTs 34.0 (14.6-53.4)  10.5 (5.1-15.9)  18.4 (9.1-27.6)  11.1 (10.2-12.1)  9.0 (8.4-9.6)  9.6 (9.0-10.1)  -22.8 (-42.1- -3.5) -1.5 (-6.9-3.9) -8.8 (-18.0-0.4) 
Non-quality-assured ACTs 14.2 (7.4-20.9)  5.8 (1.1-10.6)  8.6 (4.4-12.9)  4.1 (3.5-4.6)  2.7 (2.3-3.1)  3.1 (2.7-3.4)  -10.1 (-16.8- -3.4) -3.1 (-7.8-1.6) -5.5 (-9.8- -1.3) 
Oral artemisinin therapy 0.1 (0.0-0.2)  0.2 (-0.2-0.5)  0.1 (-0.1-0.4)  0.0  0.0  0.0  -0.1 (-0.2-0.0) -0.1 (-0.5-0.2) -0.1 (-0.3-0.1) 
Non-oral artemisinin monotherapy 0.1 (-0.1-0.2)  0.0  0.0 (0.0-0.1)  0.1 (0.0-0.1)  0.0  0.0  0.0 (-0.1-0.1) 0.0 0.0 (0.0-0.1) 
Non-artemisinin therapy 51.7 (28.4-75)  83.6 (75.9-91.2)  72.9 (61.1-84.7)  84.7 (83.3-86.2)  88.3 (87.3-89.2)  87.3 (86.5-88.2)  33.0 (9.9-56.2) 4.7 (-2.9-12.3) 14.5 (2.7-26.2) 
Nigeria - Total  100.0 99,613  100.0 12,545  100.0 112,159  100.0 58,701  100.0 13,283  100.0 71,985    
Quality-assured ACTs 2.4 (1.2-3.6)  2.8 (0.8-4.8)  2.4 (1.4-3.5)  19.0 (14.2-23.9)  22.9 (18.2-27.7)  20.1 (16.2-24.1)  16.7 (11.7-21.6) 20.2 (15.1-25.3) 17.7 (13.6-21.8) 
Non-quality-assured ACTs 5.7 (1.5-9.9)  2.6 (0.8-4.3)  5.2 (1.7-8.8)  9.6 (6.2-13.1)  4.7 (2.5-6.8)  8.2 (5.5-10.9)  3.9 (-1.5-9.3) 2.1 (-0.7-4.9) 3.0 (-1.5-7.5) 
Oral artemisinin therapy 9.0 (4.8-13.2)  2.9 (1.6-4.2)  8.1 (4.2-12.0)  4.7 (3.5-5.8)  2.8 (1.7-3.8)  4.1 (3.3-5.0)  -4.4 (-8.7-0.0) -0.1 (-1.8-1.5) -3.9 (-7.9-0.0) 
Non-oral artemisinin monotherapy 0.4 (-0.1-1.0)  0.4 (0.0-0.7)  0.4 (-0.1-0.9)  1.1 (0.5-1.7)  1.4 (-0.3-3.1)  1.2 (0.5-1.8)  0.7 (-0.2-1.5) 1.0 (-0.7-2.8) 0.7 (-0.1-1.6) 
Non-artemisinin therapy 82.5 (79.9-85.0)  91.5 (87.7-95.2)  83.9 (80.9-86.8)  65.6 (59.9-71.3)  68.3 (63.1-73.4)  66.3 (62.1-70.6)  -16.9 (-23.1- -10.6) -23.2 (-29.5- -16.9) -17.5 (-22.7- -12.4) 
Tanzania - mainland - Total  100.0 5,500  100.0 8,016  100.0 13,516  100.0 21,256  100.0 14,880  100.0 36,137    
Quality-assured ACTs 32.2 (17.6-46.8)  20.7 (9.6-31.8)  26.3 (13.9-38.6)  34.0 (28.6-39.4)  45.9 (31.9-59.9)  42.2 (32.0-52.3)  1.8 (-13.6-17.2) 25.2 (7.6-42.8) 15.9 (0.1-31.7) 
Non-quality-assured ACTs 11.3 (7.3-15.3)  2.0 (0.4-3.5)  6.5 (3.1-9.9)  9.7 (4.4-15.1)   1.1 (0.2-2.1)  3.8 (1.4-6.3)   -1.6 (-8.1-5) -0.8 (-2.6-1) -2.7 (-6.8-1.5) 
Oral artemisinin therapy 0.0  0.0  0.0  0.0  0.0  0.0  0.0 0.0 0.0 
Non-oral artemisinin monotherapy 0.7 (-0.5-1.9)  0.0  0.3 (-0.2-0.9)  0.1 (0.0-0.2)  0.0  0.0 (0.0-0.1)  -0.6 (-1.8-0.6) 0.0 -0.3 (-0.9-0.2) 
Non-artemisinin therapy 55.8 (41.8-69.8)  77.3 (67.2-87.5)  66.9 (52.1-81.7)  56.2 (48-64.4)  52.9 (39.0-66.9)  54.0 (44.0-64.0)  0.4 (-15.6-16.4) -24.4 (-41.5- -7.3) -12.9 (-30.6-4.7) 
Uganda - Total  100.0 3,430  100.0 30,392  100.0 33,821  100.0 29,263  100.0 26,551  100.0 55,814    
Quality-assured ACTs 18.9 (3.5-34.2)  43.7 (35.3-52.2)   40.0 (31.7-48.2)  41.7 (34.7-48.8)  61.5 (55.3-67.8)  56.7 (51.2-62.3)  22.9 (6.4-39.4) 17.8 (7.5-28.1) 16.8 (7.1-26.5) 
Non-quality-assured ACTs 26.1 (11.8-40.4)  8.1 (4.4-11.9)  10.8 (6-15.7)  15.5 (12.2-18.9)  10.0 (1.7-18.3)  11.4 (5.4-17.4)  -10.6 (-24.9-3.8) 1.9 (-7.1-10.9) 0.5 (-7.1-8.1) 
Oral artemisinin therapy 0.0  0.0 (0.0-0.1)  0.0 (0.0-0.1)  0.0  0.0  0.0  0.0 0 (-0.1-0) 0.0 (-0.1-0.0) 
Non-oral artemisinin monotherapy 1.0 (0.2-1.8)  0.1 (0.0-0.2)  0.2 (0.0-0.5)  0.8 (0.4-1.2)  0.4 (0.0-0.8)  0.5 (0.2-0.8)  -0.2 (-1.1-0.7) 0.3 (-0.1-0.7) 0.3 (-0.1-0.7) 
Non-artemisinin therapy 54.1 (48.6-59.5)  48.0 (40.9-55.2)  48.9 (42.9-55)  42.0 (36.6-47.4)  28.0 (21.3-34.8)   31.4 (24.9-37.9)  -12.1 (-19.6- -4.5) -20.0 (-29.7- -10.4) -17.5 (-26.3- -8.8) 
Zanzibar - Total  100.0 1,852  100.0 446  100.0 2,298  100.0 3,316  100.0 581  100.0 3,897    
Quality-assured ACTs 6.0  25.1   9.7   58.9   51.3   57.8   52.9  26.2  48.1 
Non-quality-assured ACTs 28.6  5.1.0  24.0   20.7  2.3   17.9  -7.9  -2.7 -6.1 
Oral artemisinin therapy 14.9  1.0  12.2   0.2   0.3  0.2   -14.8  -0.7  -12  
Non-oral artemisinin monotherapy 0.7   2.5   1.1   0.3  0.2   0.3  -0.4 -2.2  -0.8  
Non-artemisinin therapy 49.8   66.4   53  20  45.8  23.8  -29.8  -20.6  -29.2  
 Note: The sum of urban and rural Ns may not exactly equal the total N due to rounding. 
Nigeria baseline data collection was conducted in 2009. Baseline market share estimates for Nigeria are calculated without excluding oversampled public health facilities, private health facilities and pharmacies in urban areas. 
Therefore urban baseline market share estimates are weighted too heavily in total baseline estimates. Baseline QAACT market share is also likely to be biased upwards, however, the magnitude of this bias is minimal because 
of the very low share of antimalarial sales accounted for by health facilities and pharmacies (2.3% at baseline in urban areas). 
CI = Confidence interval 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.4.5: Market share of quality-assured ACTs, by presence of the AMFm logo at endline, 2011 
Total number of AETDs of quality-assured ACTs sold or distributed in the week preceding the survey visit (n), as a percentage of all antimalarial AETDs sold or distributed in the week preceding the 
survey visit for all outlets with any antimalarials in stock at the time of the survey visit (N), by presence of the AMFm logo, type of outlet, and urban-rural location, according to country 
Country/Type of outlet 
WITH LOGO WITHOUT LOGO 
Urban Rural Total Urban  Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N
*
 % (95% CI) N % (95% CI) N % (95% CI) N
*
 
Ghana – Total 56.2 (50.3-62.1) 21,538 55.3 (46.8-63.7) 10,050 56.0 (51.1-60.8) 31,588 1.6 (0.8-2.3) 21,538 1.6 (0.2-3.1) 10,050 1.6 (0.9-2.3) 31,588 
Public health facility 71.9 (62.2-81.6)  63.6 (54.3-72.9)  66.3 (58.5-74.1)  0.0  3.9 (-0.5-8.4)  2.7 (-0.2-5.5)  
Private not-for-profit health facility 75.4 (59.4-91.3)  65.1 (60.8-69.4)  73.8 (59.7-87.8)  0.0  0.0  0.0  
Private for-profit outlet 50.5 (46.7-54.3)  48.7 (36.0-61.3)  50.1 (46.0-54.1)  2.1 (1.1-3.0)  0.5 (0.1-0.9)  1.7 (0.9-2.5)  
Community health worker -  -  -  -  -  -  
Kenya - Total 56.1 (50.5-61.7) 25,719 48.5 (30.3-66.6) 12,745 50.5 (36.7-64.3) 38,464 4.2 (2.2-6.2) 25,719 7.5 (3.5-11.6) 12,745 6.7 (3.8-9.6) 38,464 
Public health facility 23.7 (9.1-38.4)  35.8 (6.1-65.4)  34.9 (7.7-62.1)  13.9 (3.1-24.7)  12.5 (0.4-24.7)  12.6 (1.2-24.0)  
Private not-for-profit health facility 61.5 (30.4-92.5)  41.8 (14.4-69.1)  44.4 (19.8-68.9)  28.4 (-3.2-60.1)  38.8 (10.4-67.2)  37.4 (12.3-62.6)  
Private for-profit outlet 59.4 (52.5-66.3)  59.9 (48.1-71.6)  59.7 (51.9-67.4)  2.8 (0.6-4.9)  1.1 (0.4-1.9)  1.7 (0.7-2.8)  
Community health worker -  -  -  -  -  -  
Madagascar - Total 27.5 (18.2-36.7) 5,573 15.4 (6.7-24.1) 2,512 17.8 (10.3-25.3) 8,085 3.7 (1.2-6.3) 5,573 2.7 (0.6-4.7) 2,512 2.9 (1.1-4.6) 8,085 
Public health facility 7.3 (3.4-11.1)  10.4 (0.5-20.3)  10.1 (1.4-18.7)  2.9 (0.0-5.9)  2.6 (0.6-4.5)  2.6 (0.8-4.4)  
Private not-for-profit health facility 20.0 (2.4-37.7)  30.2 (-24-84.3)  25.8 (-5.6-57.2)  21.3 (-0.8-43.4)  54.9 (-6.4-116.2)  40.5 (-1.3-82.3)  
Private for-profit outlet 31.9 (20.5-43.3)  17.7 (6.8-28.6)  21.0 (12.1-29.9)  3.1 (0.9-5.4)  0.3 (-0.1-0.7)  1.0 (0.3-1.7)  
Community health worker 71.7 (42.1-101.3)  0.8 (-0.9-2.4)  1.1 (-0.6-2.9)  28.3 (-1.3-57.9)  64.3 (40.1-88.5)  64.1 (40.0-88.2)  
Niger - Total 4.9 (4.5-5.4) 26,841 3.8 (3.5-4.1) 13,177 4.1 (3.9-4.4) 40,018 6.2 (5.7-6.7) 26,841 5.1 (4.8-5.4) 13,177 5.4 (5.1-5.7) 40,018 
Public health facility 17.1 (15.4-18.9)  11.8 (10.5-13.2)  12.6 (11.3-13.9)  19.1 (18.2-20.0)  13.3 (11.7-14.9)  14.1 (12.7-15.5)  
Private not-for-profit health facility 18.0 (18.0-18.0)  30.4 (30.4-30.4)  26.7 (21.1-32.3)  19.2 (19.2-19.2)  2.1 (2.1-2.1)  7.3 (-0.5-15.0)  
Private for-profit outlet 4.2 (3.9-4.5)  2.7 (2.5-3)  3.1 (2.9-3.4)  5.4 (5.1-5.8)  4.0 (3.8-4.2)  4.4 (4.2-4.6)  
Community health worker -  -  -  -  -  -  
Nigeria - Total 16.3 (12.3-20.4) 58,701 16.7 (12.1-21.3) 13,283 16.4 (13.2-19.6) 71,985 2.7 (0.2-5.2) 58,701 6.3 (1.5-11.1) 13,283 3.7 (1.4-6.0) 71,985 
Public health facility 24.6 (7.0-42.2)  8.2 (-2.1-18.4)  14.6 (5.6-23.6)  36.0 (1.3-70.7)  31.9 (11.2-52.6)  33.5 (14.9-52.1)  
Private not-for-profit health facility 32.2 (-0.3-64.8)  40.5 (26.5-54.4)  33.1 (3.6-62.6)  7.0 (-4.8-18.8)  9.0 (4.6-13.3)  7.2 (-3.5-17.8)  
Private for-profit outlet 15.8 (12.1-19.5)  18.1 (13.4-22.8)  16.4 (13.3-19.5)  1.3 (0.5-2.1)  1.6 (0.8-2.4)  1.4 (0.8-2.0)  
Community health worker 100.0 (100.0-100.0)  1.3 (-1.5-4.1)  2.0 (-1.6-5.6)  0.0  18.4 (4.8-32.0)  18.3 (4.7-31.9)  
Tanzania - mainland - Total 30.5 (25.1-36.0) 21,256 23.7 (11.3-36) 14,880 25.8 (17-34.6) 36,137 3.5 (0.4-6.5) 21,256 22.2 (6.2-38.3) 14,880 16.4 (4.5-28.3) 36,137 
Public health facility 59.1 (27.6-90.6)  18.3 (-0.6-37.1)  20.7 (2.3-39.1)  16.6 (-4.8-38.1)  37.1 (14.0-60.1)  35.9 (13.8-58)  
Private not-for-profit health facility 32.7 (-0.7-66.1)  70.6 (11.7-129.5)  36.8 (6.1-67.6)  4.5 (-0.8-9.7)  22.0 (-22.9-67.0)  6.4 (-0.6-13.4)  
Private for-profit outlet 28.1 (23.4-32.8)  30.4 (17.1-43.6)  29.3 (22-36.5)  2.3 (-0.3-5.0)  3.4 (0.5-6.3)  2.9 (0.8-4.9)  
Community health worker -  -  -  -  -  -  
Uganda - Total 35.4 (27.7-43.1) 29,263 45.9 (36.2-55.5) 26,551 43.3 (36-50.7) 55,814 6.3 (3.6-9.0) 29,263 15.7 (10.1-21.2) 26,551 13.4 (8.6-18.3) 55,814 
Public health facility 49.4 (28.4-70.4)  61.3 (48.5-74.1)  59.8 (48.4-71.1)  7.7 (1.4-14.0)  23.6 (10.8-36.3)  21.5 (9.8-33.3)  
Private not-for-profit health facility 11.0 (1.0-21.0)  18.4 (-2.5-39.3)  17.9 (-1.5-37.2)  52.5 (35.0-70.1)  31.2 (14.0-48.3)  32.6 (16.0-49.2)  
Private for-profit outlet 31.9 (27.7-36.1)  34.6 (25-44.2)  33.7 (27.4-39.9)  4.9 (3.7-6.2)  4.8 (1.9-7.6)  4.8 (2.9-6.8)  
Community health worker 77.5 (29.5-125.5)  13.6 (-5.4-32.7)  14.6 (-4.7-33.8)  22.5 (-25.5-70.5)  85.5 (66.5-104.5)  84.6 (65.4-103.8)  
Zanzibar - Total 55.9 3,316 51.1 581 55.2 3,897 3 3,316 0.2 581 2.6 3,897 
Public health facility 34.5  33.8  34.1  8.5  0.0  3.9  
Private not-for-profit health facility   0.0  0.0    0.0  0.0  
Private for-profit outlet 57.6  66.6  58.3  2.6  0.3  2.4  
Community health worker -  -  -  -  -  -  
Note: The sum of urban and rural Ns may not exactly equal the total N due to rounding. 
CI = Confidence interval 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.4.6: Percent distribution of antimalarial sales volumes of ALL antimalarials by outlet type at baseline (2010) and endline (2011) 
Total number of AETDs sold or distributed in the week preceding the survey visit by each outlet type (n), as a percentage of all antimalarial AETDs sold or distributed in the week 
preceding the survey visit by all outlets with any antimalarials in stock at the time of the survey visit (N), by urban-rural location and type of outlet, according to country 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban Rural Total 
%  N %  N %  N* % N % N % N* 
Ghana – Total 100.0 31,580 100.0 41,915 100.0 73,495 100.0 21,538 100.0 10,050 100.0 31,588 
Public health facility  17.4  28.0  26.2  6.2  34.4  13.9  
Private not-for-profit health facility 4.9  7.6  7.2  17.7  8.8  15.3  
Private for-profit outlet 77.6  64.3  66.5  76  56.7  70.8  
Community health worker 0.0  0.1  0.1  0.0  0.0  0.0  
Kenya – Total 100.0 21,528 100.0 10,216 100.0 31,743 100.0 25,719 100.0 12,745 100.0 38,464 
Public health facility  16.1  30.1  26.3  9.3  44.5  35.3  
Private not-for-profit health facility 5  6.7  6.2  1.5  3.6  3.0  
Private for-profit outlet 78.9  62.5  66.9  89.2  51.9  61.7  
Community health worker 0.1  0.7  0.5  0.0  0.0  0.0  
Madagascar – Total 100.0 10,069 100.0 1,684 100.0 11,754 100.0 5,573 100.0 2,512 100.0 8,085 
Public health facility  10.8  15.4  14.5  16.2  30.2  27.4  
Private not-for-profit health facility 0.0  0.0  0.0  3.5  1.2  1.6  
Private for-profit outlet 89.1  80.5  82.3  80.2  67.0  69.7  
Community health worker 0.0  4.0  3.2  0  1.6  1.3  
Niger – Total 100.0 20,698 100.0 13,472 100.0 34,169 100.0 26,841 100.0 13,177 100.0 40,018 
Public health facility  50.4  41.0  44.2  23.8  59.2  45.9  
Private not-for-profit health facility 0.1  0.0  0.0  0.0  8.1  5.1  
Private for-profit outlet 49.5  58.9  55.8  76.1  32.6  49.0  
Community health worker 0.0  0.1  0.0  0.0  0.0  0.0  
Nigeria – Total 100.0 99,613 100.0 12,545 100.0 112,159 100.0 58,701 100.0 13,283 100.0 71,985 
Public health facility  0.6  14.5  2.8  3.8  15.3  7.1  
Private not-for-profit health facility 0.0  1.5  0.2  1.1  0.4  0.9  
Private for-profit outlet 99.3  83.7  96.9  95.0  84.2  92.0  
Community health worker 0.0  0.3  0.1  0.0  0.2  0.0  
Tanzania - mainland – Total 100.0 5,500 100.0 8,016 100.0 13,516 100.0 21,256 100.0 14,880 100.0 36,137 
Public health facility  31.3  45.6  38.6  7.6  55.9  40.8  
Private not-for-profit health facility 8.8  22.6  15.9  1.8  0.1  0.6  
Private for-profit outlet 59.9  31.8  45.4  90.5  44.0  58.5  
Community health worker 0.0  0.0  0.0  0.0  0.0  0.0  
Uganda – Total 100.0 3,430 100.0 30,392 100.0 33,821 100.0 29,263 100.0 26,551 100.0 55,814 
Public health facility  14.1  63.6  56.0  21.9  46.7  40.7  
Private not-for-profit health facility 9.9  3.0  4.1  1.6  7.0  5.7  
Private for-profit outlet 75.9  33.0  39.5  76.5  46.0  53.4  
Community health worker 0.1  0.4  0.4  0.0  0.4  0.3  
Zanzibar – Total 100.0 1,852 100.0 446 100.0 2,297 100.0 3,316 100.0 581 100.0 3,897 
Public health facility  27.4  76.7  37.0  7.3  47.9  13.3  
Private not-for-profit health facility 0.5  1.5  0.7  0.0  0.7  0.1  
Private for-profit outlet 72.1  21.8  62.3  92.7  51.5  86.6  
Community health worker 0.0  0.0  0.0  0.0  0.0  0.0  
Note: The sum of urban and rural Ns may not exactly equal the total N due to rounding. Nigeria baseline data collection was conducted in 2009. Baseline market share estimates for Nigeria are 
calculated without excluding oversampled public health facilities, private health facilities and pharmacies in urban areas. Therefore urban baseline market share estimates are weighted too heavily in 
total baseline estimates. 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.4.7: Percent distribution of antimalarial sales volumes by private for-profit outlets by outlet type at baseline (2010) and endline (2011) 
Total number of AETDs sold or distributed in the week preceding the survey visit by each private for-profit outlet type (n), as a percentage of all antimalarial AETDs sold or distributed in 
the week preceding the survey visit by all private for-profit outlets with any antimalarials in stock at the time of the survey visit (N), by urban-rural location and country 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban Rural Total 
% N % N % N % N % N % N 
Ghana – Total private for –profit 100.0 24,920 100.0 27,186 100.0 52,107 100.0 16,881 100.0 5,695 100.0 22,576 
Health facility/pharmacy 58.8  27.2  33.3  54.0  26.3  47.9  
Drug store 41.0  72.5  66.4  45.8  73.0  51.8  
General retailer/itinerant 0.2  0.2  0.2  0.2  0.6  0.3  
Kenya – Total private for –profit 100.0 17,221 100.0 6,295 100.0 23,516 100.0 22,995 100.0 6,767 100.0 29,761 
Health facility/pharmacy 62.4  15.2  30.3  31.8  31.9  31.9  
Drug store 34.1  72.9  60.5  65.9  57.2  60.5  
General retailer/itinerant 3.5  11.8  9.2  2.3  10.8  7.6  
Madagascar – Total private for –profit 100.0 9,266 100.0 1,408 100.0 10,675 100.0 4,241 100.0 1,692 100.0 5,933 
Health facility/pharmacy 55.6  2.6  14.6  49.0  9.6  18.8  
Drug store 6.6  60.1  48.0  27.0  49.4  44.1  
General retailer/itinerant 37.8  37.3  37.4  24.0  41.0  37.1  
Niger – Total private for –profit 100.0 9,712 100.0 8,021 100.0 17,733 100.0 21,454 100.0 4,125 100.0 25,579 
Health facility/pharmacy 14.9  -  4.4  42.4  1.3  25.3  
Drug store 6.3  0.8  2.4  14.5  3.2  9.8  
General retailer/itinerant 78.8  99.2  93.1  43.1  95.6  65.0  
Nigeria – Total private for –profit 100.0 86,795 100.0 11,174 100.0 97,970 100.0 53,647 100.0 11,333 100.0 64,979 
Health facility/pharmacy 1.7  6.0  2.3  17.0  6.6  14.3  
Drug store 94.1  90.8  93.7  81.4  91.6  84.0  
General retailer/itinerant 4.2  3.2  4.0  1.6  1.8  1.7  
Tanzania - mainland – Total private for –profit 100.0 3,444 100.0 2,711 100.0 6,155 100.0 19,063 100.0 6,713 100.0 25,776 
Health facility/pharmacy 66.6  2.4  43.5  43.3  25.0  33.9  
Drug store 33.4  83.9  51.5  56.4  74.4  65.7  
General retailer/itinerant -  -  5.0  0.3  0.6  0.5  
Uganda – Total private for –profit 100.0 2,646 100.0 12,129 100.0 14,775 100.0 22,832 100.0 14,444 100.0 37,276 
Health facility/pharmacy 64.3  27.1  38.0  75.5  49.0  58.2  
Drug store 33.5  72.5  61.1  24.5  50.4  41.4  
General retailer/itinerant 2.2  0.4  0.9  -  0.6  0.4  
Zanzibar – Total private for -profit 100.0 1,335 100.0 97 100.0 1,432 100.0 3,075 100.0 299 100.0 3,374 
Health facility/pharmacy 86.1  46.7  83.4  77.7  47.4  75.0  
Drug store 13.9  53.3  16.6  21.7  51.9  24.4  
General retailer/itinerant -  -  -  0.6  0.7  0.6  
Note: The sum of urban and rural Ns may not exactly equal the total N due to rounding.  
Nigeria baseline data collection was conducted in 2009. Baseline market share estimates for Nigeria are calculated without excluding oversampled public health facilities, private health facilities and 
pharmacies in urban areas. Therefore, urban baseline market share estimates are weighted too heavily in total baseline estimates. Baseline market share for health facilities/pharmacies in this table is also 
likely to be biased upwards, however, the magnitude of this bias is minimal because of the very low share of antimalarial sales accounted for by public and private health facilities and pharmacies (2.3% 
at baseline in urban areas). 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.4.8: Percent distribution of sales volumes of quality-assured ACTs by outlet type at baseline (2010) and endline (2011) 
Total number of AETDs of quality-assured ACTs sold or distributed in the week preceding the survey visit by each outlet type (n), as a percentage of all AETDs of quality-assured ACTs 
sold or distributed in the week preceding the survey visit by all outlets with any antimalarials in stock at the time of the survey visit (N), by urban-rural location and type of outlet, according 
to country. 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban Rural Total 
%  N %  N %  N % N % N % N 
Ghana - Total 100.0 2,893 100.0 7,759 100.0 10,651 100.0 12,141 100.0 5,768 100.0 17,909 
Public health facility  49.3  71.4  69.4  7.8  40.9  16.7  
Private not-for-profit health facility 4.3  5.4  5.3  23.1  10.1  19.6  
Private for-profit outlet 46.4  22.7  24.9  69.1  49.0  63.7  
Community health worker -  0.4  0.4  -  -  -  
Kenya - Total 100.0 7,780 100.0 2,586 100.0 10,366 100.0 15,811 100.0 7,341 100.0 23,152 
Public health facility  28.4  78.5  61.2  5.8  38.4  29.4  
Private not-for-profit health facility 10.4  4.7  6.7  2.3  5.1  4.3  
Private for-profit outlet 61.0  15.9  31.5  91.9  56.5  66.3  
Community health worker 0.2  0.9  0.6  -  -  -  
Madagascar - Total 100.0 569 100.0 243 100.0 812 100.0 1,724 100.0 425 100.0 2,150 
Public health facility  28.4  33.6  32.9  5.3  21.8  16.8  
Private not-for-profit health facility 0.3  -  -  4.6  5.6  5.3  
Private for-profit outlet 71.3  42.8  46.7  90.0  66.9  73.9  
Community health worker -  23.6  20.4  0.1  5.7  4.0  
Niger - Total 100.0 7,742 100.0 1,410 100.0 9,152 100.0 6,928 100.0 2,462 100.0 9,390 
Public health facility  87.2  91.6  88.9  36.7  73.1  55.5  
Private not-for-profit health facility -  -  -  0.1  12.1  6.3  
Private for-profit outlet 12.8  8.4  11.1  63.2  14.7  38.2  
Community health worker -  -  -  -  -  -  
Nigeria - Total 100.0 4,286 100.0 557 100.0 4843 100.0 11,889 100.0 2,902 100.0 14,791 
Public health facility  2.2  31.5  7.4  12.2  26.7  16.9  
Private not-for-profit health facility -  19.4  3.4  2.3  0.8  1.8  
Private for-profit outlet 95.8  49.1  87.6  85.4  72.4  81.3  
Community health worker 2.0  -  1.6  -  0.1  -  
Tanzania - mainland - Total 100.0 1,315 100.0 1,310 100.0 2625 100.0 7,464 100.0 6,827 100.0 14,292 
Public health facility  87.3  83.5  85.8  17.0  67.4  54.7  
Private not-for-profit health facility 7.5  14.9  10.5  2.0  0.2  0.7  
Private for-profit outlet 5.2  1.6  3.8  81.0  32.4  44.6  
Community health worker -  -  -  -  -  -  
Uganda - Total 100.0 606 100.0 10,928 100.0 11,533 100.0 11,886 100.0 15,263 100.0 27,149 
Public health facility  53.6  92.8  90.0  30.0  64.4  58.3  
Private not-for-profit health facility 30.6  2.9  4.8  2.4  5.6  5.1  
Private for-profit outlet 15.8  4.2  5.0  67.5  29.4  36.2  
Community health worker -  0.1  0.1  -  -  -  
Zanzibar - Total 100.0 111 100.0 112 100.0 223 100.0 1,953 100.0 298 100.0 2,250 
Public health facility  74.2  100.0  87.1  5.3  31.6  8.8  
Private not-for-profit health facility -  -  0.0  -  1.3  0.2  
Private for-profit outlet 25.8  -  12.9  94.7  67.1  91.1  
Community health worker -  -  -  -  -  -  
Note: The sum of urban and rural Ns may not exactly equal the total N due to rounding.  
Nigeria baseline data collection was conducted in 2009. Baseline market share estimates for Nigeria are calculated without excluding oversampled public health facilities, private health facilities and 
pharmacies in urban areas. Therefore urban baseline market share estimates are weighted too heavily in total baseline estimates. 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.4.9: Percent distribution of sales volumes of quality-assured ACTs by private for-profit outlets by outlet type at baseline (2010) and endline 
(2011) 
Total number of AETDs of quality-assured ACTs sold or distributed in the week preceding the survey visit by each private for-profit outlet type (n), as a percentage of all AETDs of quality-
assured ACTs sold or distributed in the week preceding the survey visit by all private for-profit outlets with any antimalarials in stock at the time of the survey visit (N), by urban-rural 
location and type of outlet, according to country. 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban Rural Total 
%  N %  N %  N % N % N % N 
Ghana – Total private for –profit 100.0 1,098 100.0 1,759 100.0.0 2,857 100.0 8,798 100.0 2,867 100.0 11,665 
Health facility/pharmacy 87.4  46.9  53.9  57.4  37.2  53.2  
Drug store 12.6  53.1  46.1  42.4  62.4  46.5  
General retailer/itinerant -  -  -  0.3  0.4  0.3  
Kenya – Total private for –profit 100.0 4,983 100.0 430 100.0 5,413 100.0 14,564 100.0 4,316 100.0 18,880 
Health facility/pharmacy 74.3  25.5  58.2  26.0  26.0  26.0  
Drug store 25.7  74.5  41.8  72.8  65.0  68.0  
General retailer/itinerant -  -  -  1.2  9.1  6.1  
Madagascar – Total private for –profit 100.0 435 100.0 117 100.0 552 100.0 1,518 100.0 330 100.0 1,848 
Health facility/pharmacy 71.5  6.8  20.2  80.5  37.4  53.3  
Drug store 24.9  71.7  62.0  19.5  62.0  46.3  
General retailer/itinerant 3.5  21.5  17.8  -  0.6  0.4  
Niger – Total private for –profit 100.0 882 100.0 120 100.0 1,003 100.0 4,635 100.0 365 100.0 5,000 
Health facility/pharmacy 34.1  -  24.4  42.3  8.3  35.5  
Drug store 7.1  2.3  5.7  12.7  23.0  14.8  
General retailer/itinerant 58.9  97.7  69.9  45.0  68.7  49.7  
Nigeria – Total private for –profit 100.0 3,392 100.0 424 100.0 3,815 100.0 9,367 100.0 2,207 100.0 11,573 
Health facility/pharmacy 2.8  9.5  3.4  16.6  10.7  14.9  
Drug store 95.1  90.5  94.6  82.6  89.3  84.5  
General retailer/itinerant 2.1  -  1.9  0.8  0.1  0.6  
Tanzania - mainland – Total private for –profit 100.0 85 100.0 27 100.0 111 100.0 5,788 100.0 2,438 100.0 8,225 
Health facility/pharmacy 88.7  3.3  74.1  58.3  13.7  34.1  
Drug store 11.3  81.2  23.2  41.0  86.3  65.6  
General retailer/itinerant 3.2  -  2.6  0.7  -  0.3  
Uganda – Total private for –profit 100.0 95 100.0 523 100.0 618 100.0 8,371 100.0 5,610 100.0 13,981 
Health facility/pharmacy 77.5  19.0  32.2  73.2  43.6  53.5  
Drug store 22.5  81.0  67.8  26.7  55.6  46.0  
General retailer/itinerant -  -  -  0.1  0.8  0.5  
Zanzibar – Total private for –profit 100.0 29 - 0 100.0 29 100.0 1,849 100.0 200 100.0 2,049 
Health facility/pharmacy 96.5    96.5  77.6  48.9  74.8  
Drug store 3.5    3.5  21.9  50.1  24.7  
General retailer/itinerant -  -  -  0.5  1.0  0.5  
Note: The sum of urban and rural Ns may not exactly equal the total N due to rounding. Nigeria baseline data collection was conducted in 2009. Baseline market share estimates for Nigeria 
are calculated without excluding oversampled public health facilities, private health facilities and pharmacies in urban areas. Therefore, urban baseline market share estimates are weighted 
too heavily in total baseline estimates. Baseline market share for health facilities/pharmacies in this table is also likely to be biased upwards, however, the magnitude of this bias is minimal 
because of the very low share of antimalarial sales accounted for by public and private health facilities and pharmacies (2.3% at baseline in urban areas). 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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2.5 Provider Knowledge of first line antimalarial treatment and quality-assured 
ACT dosing regimen 
2.5.1  Provider Knowledge of first line antimalarial treatment 
 
Table 2.5.1 shows the percentage of providers who could correctly state their country’s first-line 
antimalarial. At endline, the percentage was relatively high in Ghana (85%), Kenya (71%), 
Tanzania mainland (96%), Uganda (79%) and Zanzibar (94%); somewhat lower in Nigeria 
(51%); and only 33% in Madagascar and Niger. In Ghana, Kenya, Madagascar, Niger, Nigeria 
and Uganda, knowledge of the first-line medicine was higher in public health facilities than in 
private for-profit outlets, but in Tanzania mainland and Zanzibar there was no difference. 
Significant increases in knowledge between baseline and endline were seen in Ghana, Kenya, 
Niger, Nigeria and Tanzania mainland, in all cases reflecting an increase in knowledge in the 
private for-profit sector. Nigeria also showed an increase in the public sector, where knowledge 
had been relatively low at baseline (39%).  
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Table 2.5.1: Provider knowledge of first line antimalarial treatment at baseline (2010) and endline (2011) 
Percentage of providers able to correctly identify the antimalarial for first line treatment (n) among outlets with antimalarials in stock at the time of the survey visit (N), by urban-
rural location and type of outlet, according to country 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N 
Ghana - Total 84.2 (80.2-87.5) 598 73.5 (68.3-78.2) 543 75.6 (71.2-79.5) 1,141 89.8 (82.8-94.2) 573 78.5 (69.7-85.3) 381 85.4 (80.1-89.5) 954 
Public health facility  97.8 (91.8-99.4) 67 97.0 (92.1-98.9) 135 97.1 (93.0-98.9) 202 99.6 (98.1-99.9) 94 96.2 (92.3-98.2) 204 97.2 (94.4-98.6) 298 
Private not-for-profit health facility 100.0 5 88.3 (60.5-97.4) 9 90.3 (65.3-97.9) 14 100.0 4 100.0 8 100.0 12 
Private for-profit outlet             
   Health facility/pharmacy 88.5 (82.1-92.8) 314 88.9 (75.2-95.5) 62 88.6 (82.7-92.7) 376 97.5 (93.5-99.1) 270 100.0 26 97.9 (94.4-99.2) 296 
   Drug store 78.6 (73.1-83.1) 210 69.7 (63.7-75.1) 331 70.8 (65.5-75.6) 541 86.2 (76.1-92.5) 202 70.8 (59.8-79.8) 140 80.2 (72.8-86.0) 342 
   General retailer/itinerant 44.3 (9.3-86.0) 2 32.1 (11.7-62.8) 3 33.6 (14.3-60.5) 5 64.5 (20.5-92.8) 3 32.7 (3.8-85.7) 3 48.5 (16.0-82.4) 6 
   Total 83.0 (78.7-86.6) 526 70.7 (65.0-75.8) 396 73.2 (68.5-77.4) 922 89.0 (81.2-93.9) 475 72.3 (61.4-81.1) 169 83.3 (76.9-88.2) 644 
Community health worker - 0 100.0 3 100.0 3 - 0 - 0 - 0 
Kenya - Total 67.2 (60.1-73.5) 1,035 48.1 (41.2-55.1) 877 52.7 (46.5-58.7) 1,912 76.6 (68.8-83.0) 1,048 68.2 (58.7-76.3) 799 70.6 (63.4-76.8) 1,847 
Public health facility  95.2 (88.1-98.1) 137 96.9 (94.0-98.5) 259 96.5 (94.0-98.0) 396 94.8 (86.8-98.1) 137 97.9 (94.8-99.1) 294 97.6 (95.0-98.9) 431 
Private not-for-profit health facility 96.0 (77.2-99.4) 23 96.7 (79.2-99.6) 15 96.5 (85.8-99.2) 38 97.7 (85.3-99.7) 19 87.8 (71.3-95.5) 27 89.8 (75.6-96.2) 46 
Private for-profit outlet             
   Health facility/pharmacy 88.3 (80.4-93.3) 363 80.7 (67.9-89.2) 103 84.2 (75.6-90.1) 466 91.8 (87.1-94.9) 408 83.7 (75.5-89.6) 113 86.8 (81.5-90.8) 521 
   Drug store 82.9 (77.9-87.0) 269 54.5 (40.1-68.1) 156 60.7 (45.4-74.2) 425 88.0 (85.2-90.4) 328 86.2 (79.9-90.7) 145 86.9 (83.2-90) 473 
   General retailer/itinerant 16.6 (11.1-24.1) 239 15.5 (9.6-24.1) 323 15.7 (10.6-22.7) 562 26.0 (14.2-42.9) 156 33.9 (21.0-49.7) 220 32.5 (21.6-45.7) 376 
   Total 62.8 (54.9-70.1) 871 39.0 (32.7-45.8) 582 44.9 (39.1-50.9) 1,453 75.5 (67.5-82.0) 892 61.8 (50.5-72.0) 478 66.1 (57.9-73.4) 1,370 
Community health worker 79.5 (26.1-97.7) 4 69.6 (28.5-93.0) 21 69.9 (29.5-92.8) 25 - 0 - 0 - 0 
Madagascar - Total 23.2 (14.6-34.8) 1,434 23.1 (14.5-34.7) 962 23.1 (15.9-32.4) 2,396 35.3 (30.7-40.3) 979 32.7 (26.6-39.3) 1,384 33.0 (27.7-38.8) 2,363 
Public health facility  70.3 (62.7-76.9) 67 86.3 (80.3-90.7) 444 81.8 (76.3-86.3) 511 90.9 (81.7-95.7) 65 85.6 (78.9-90.4) 553 86.2 (80.2-90.6) 618 
Private not-for-profit health facility 89.1 (59.1-97.9) 6 - 0 89.1 (59.1-97.9) 6 82.4 (67.8-91.3) 26 71.0 (26.0-94.5) 5 75.5 (45.7-91.8) 31 
Private for-profit outlet             
   Health facility/pharmacy 68.1 (62-73.7) 122 89.6 (51.2-98.6) 9 77.5 (64.7-86.6) 131 77.0 (69.8-82.9) 105 66.5 (27.6-91.2) 12 72.2 (52.9-85.8) 117 
   Drug store 58.1 (51-64.8) 28 37.6 (28.3-47.9) 227 45.4 (36.6-54.5) 255 84.4 (76.5-90.0) 28 51.0 (43.8-58.2) 346 54.5 (47.5-61.4) 374 
   General retailer/itinerant 3.3 (2.4-4.5) 1,209 7.7 (3.9-14.6) 244 6.8 (3.7-12.3) 1,453 13.1 (9.5-17.8) 740 13.7 (9.4-19.6) 403 13.7 (9.8-18.7) 1,143 
   Total 16.9 (10.5-26.1) 1,359 11.3 (7.0-17.6) 480 12.5 (8.7-17.7) 1,839 26.7 (22.6-31.2) 873 18.1 (13.9-23.1) 761 19.4 (15.7-23.6) 1,634 
Community health worker 70.1 (21.7-95.2) 2 60.9 (37-80.5) 38 60.9 (37-80.5) 40 100.0 15 70.5 (55.9-81.9) 65 71.3 (57-82.2) 80 
Niger - Total 22.1 (15.6-30.4) 833 15.9 (12.7-19.8) 1,198 17.2 (14.2-20.7) 2,031 40.5 (34.4-47) 924 30.3 (26.1-34.8) 738 33.1 (29.6-36.8) 1,662 
Public health facility  90.5 (81.5-95.4) 91 84.9 (79.5-89.1) 385 85.5 (80.6-89.3) 476 97.2 (94-98.7) 102 88.6 (84.1-92.0) 220 89.8 (85.9-92.7) 322 
Private not-for-profit health facility 37.5 (5.8-85.5) 4 - 0 37.5 (5.8-85.5) 4 100.0 2 100.0 1 100.0 3 
Private for-profit outlet             
   Health facility/pharmacy 76.5 (66.1-84.5) 106 96.4 (70.1-99.7) 12 79.4 (69.4-86.8) 118 82.2 (73.9-88.3) 95 100.0 4 83.2 (75.2-89.0) 99 
   Drug store 59.3 (17.4-90.9) 14 61.5 (22.0-90.0) 7 60.7 (29.4-85.1) 21 78.5 (58.4-90.5) 15 100.0 3 90.5 (77.6-96.3) 18 
   General retailer/itinerant 15.5 (8.5-26.4) 617 8.3 (5.7-11.9) 792 9.7 (7.0-13.3) 1,409 34.4 (27.7-41.9) 710 22.5 (17.7-28.1) 510 25.7 (21.7-30.2) 1,220 
   Total 19.2 (12.5-28.4) 737 8.9 (6.3-12.6) 811 11.1 (8.4-14.5) 1,548 37.6 (31.3-44.3) 820 23.0 (18.2-28.7) 517 27.2 (23.2-31.6) 1,337 
Community health worker 0.0 1 51.0 (5.7-94.7) 2 44.6 (5.7-91.4) 3 - 0 - 0 - 0 
Nigeria - Total 15.4 (11.3-20.7) 1,677 15.7 (12.2-20.0) 345 15.5 (12.1-19.6) 2,022 54.3 (44.0-64.2) 1,029 53.0 (43.3-62.5) 471 53.8 (46.5-60.9) 1,500 
Public health facility  52.5 (40.7-64.0) 179 38.1 (26.3-51.5) 43 39.0 (27.8-51.5) 222 99.0 (96.2-99.8) 43 80.8 (65.1-90.4) 52 86.7 (74.6-93.5) 95 
Private not-for-profit health facility 35.7 (8.0-78.0) 5 0.0 2 2.6 (0.3-17.6) 7 100.0 6 93.1 (54.1-99.4) 3 97.4 (81.1-99.7) 9 
Private for-profit outlet             
   Health facility/pharmacy 32.8 (26.4-40.0) 711 23.6 (18.4-29.8) 24 25.8 (20.9-31.4) 735 77.9 (70.2-84.2) 99 47.6 (32.3-63.3) 31 66.9 (57.9-74.8) 130 
   Drug store 15.0 (10.4-21.1) 693 9.4 (5.2-16.5) 254 14.1 (10.1-19.4) 947 51.4 (39.9-62.8) 804 50.7 (40.0-61.5) 362 51.2 (42.9-59.4) 1,166 
   General retailer/itinerant 13.7 (6.6-26.4) 83 0.0 16 10.9 (5.4-20.6) 99 25.9 (11.8-47.8) 74 23.6 (7.7-53.3) 19 25.3 (13.4-42.8) 93 
   Total 15.0 (11.0-20.3) 1,487 10.6 (7.2-15.5) 294 14.3 (10.8-18.6) 1,781 52.3 (42.0-62.3) 977 49.4 (39.5-59.3) 412 51.2 (43.9-58.4) 1,389 
Community health worker 58.3 (19.4-89.0) 6 21.2 (2.7-72.4) 6 37.5 (13.5-69.9) 12 100.0 3 19.1 (2.3-70.4) 4 22.3 (3.1-71.9) 7 
Tanzania - mainland - Total 94.5 (89.3-97.2) 320 86.6 (80.3-91.1) 304 88.4 (83.1-92.2) 624 95.6 (91.3-97.8) 596 96.1 (91.5-98.3) 191 95.9 (93.0-97.7) 787 
Public health facility  100.0 5 96.4 (86.1-99.2) 55 96.7 (87.0-99.2) 60 90.0 (50.4-98.8) 7 97.6 (90.5-99.4) 48 97.2 (90.9-99.2) 55 
Private not-for-profit health facility 100.0 6 100.0 17 100.0 23 79.1 (27.1-97.5) 4 100.0 2 88.9 (47.2-98.6) 6 
Private for-profit outlet             
   Health facility/pharmacy 96.5 (93.1-98.3) 220 100.0 12 97.2 (94.3-98.6) 232 97.3 (89.3-99.4) 321 99.5 (95.3-100) 16 97.9 (91.7-99.5) 337 
   Drug store 94.1 (86.5-97.5) 88 90.8 (85.2-94.4) 149 91.9 (87.7-94.8) 237 96.0 (92.5-97.9) 259 95.9 (87.0-98.8) 113 95.9 (91.6-98.1) 372 
   General retailer/itinerant 0.0 1 70.7 (58.5-80.4) 70 70.2 (58.2-80.0) 71 81.9 (30.9-97.9) 5 91.0 (82.9-95.4) 12 90.2 (82.9-94.5) 17 
   Total 93.9 (88.2-96.9) 309 82.7 (75.1-88.4) 231 85.6 (79.2-90.3) 540 96.0 (92.5-98.0) 585 95.5 (88.4-98.3) 141 95.7 (92.1-97.7) 726 
Community health worker - 0 100.0 1 100.0 1 - 0 - 0 - 0 
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Table 2.5.1: Cont. 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N 
Uganda - Total 76.2 (63.4-85.5) 544 77.8 (72.2-82.6) 1,869 77.5 (72.3-82.0) 2,413 81.3 (79.1-83.4) 1,412 77.9 (72.2-82.7) 1722 78.6 (74.1-82.5) 3,134 
Public health facility  92.2 (83.4-96.5) 76 95.9 (93.9-97.2) 693 95.5 (93.4-97) 769 93.6 (85.2-97.4) 144 95.8 (92.6-97.7) 534 95.5 (92.7-97.3) 678 
Private not-for-profit health facility 100.0 4 91.3 (78.3-96.9) 27 92.6 (80.1-97.5) 31 100.0 13 92.2 (73.9-98.0) 28 93.0 (76.7-98.2) 41 
Private for-profit outlet             
   Health facility/pharmacy 72.3 (67.0-77.1) 389 68.7 (61.1-75.4) 356 70.5 (65.4-75.1) 745 83.1 (81.0-85.0) 814 79.3 (72.5-84.8) 388 81.0 (77.0-84.5) 1,202 
   Drug store 78.5 (55.3-91.5) 72 75.6 (69.4-80.8) 745 76.0 (70-81.1) 817 76.9 (72.1-81.0) 435 73.0 (67.8-77.6) 676 73.5 (69.1-77.6) 1,111 
   General retailer/itinerant 59.8 (7.5-96.5) 2 55.3 (36.9-72.4) 19 55.9 (37.3-73) 21 51.5 (11.1-90.1) 4 27.1 (6.6-66.1) 14 28.5 (7.7-65.7) 18 
   Total 74.7 (61.1-84.8) 463 73.8 (68.2-78.8) 1,120 74.0 (68.8-78.6) 1,583 80.3 (78.0-82.3) 1,253 73.1 (67.4-78.1) 1078 74.8 (70.4-78.8) 2,331 
Community health worker 100.0 1 95.9 (93.2-97.6) 29 96.0 (93.2-97.7) 30 100.0 2 93.0 (87.6-96.1) 82 93.0 (87.6-96.1) 84 
Zanzibar - Total 81.5 189 90.3 124 85.0 313 93.2 222 94.2 120 93.6 342 
Public health facility  91.1 56 97.6 83 95.0 139 95.8 48 96.1 76 96.0 124 
Private not-for-profit health facility 50.0 2 100.0 1 66.7 3 100.0 1 100.0 1 100.0 2 
Private for-profit outlet             
   Health facility/pharmacy 82.2 73 81.8 11 82.1 84 97.6 82 100.0 16 98.0 98 
   Drug store 71.9 57 80.0 25 74.4 82 88.6 88 87.5 24 88.4 112 
   General retailer/itinerant 100.0 1 25.0 4 40.0 5 66.7 3 66.7 3 66.7 6 
   Total 77.9 131 75.0 40 77.2 171 92.5 173 90.7 43 92.1 216 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Note: Nigeria baseline data collection was conducted in 2009. 
CI = Confidence interval  
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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2.5.2 Provider knowledge of quality-assured ACT dosing regimen for an adult and a child 
Tables 2.5.2 and 2.5.3 show the percentage of providers with QAACTs in stock who could 
correctly state the dosing regimen for a QAACT of their choice for adults and children. At 
endline, over 90% of QAACT stockists could correctly state the adult dose in Ghana, Kenya and 
Tanzania mainland, and over 80% in Uganda and Zanzibar (Table 2.5.2). Only 49% of providers 
in Madagascar could correctly state the adult dose. Data were available at baseline and endline in 
Ghana, Kenya, Tanzania mainland, Uganda and Zanzibar. Of these countries, significant 
increases from baseline in knowledge were seen in Ghana, Tanzania mainland and Zanzibar in 
both the public and private for-profit sectors. 
 
The results for child doses at endline were similar to those for adult doses in Tanzania mainland 
and Uganda, but were lower for child doses in Ghana, Kenya, Nigeria and Zanzibar, and higher 
for child doses in Madagascar (Table 2.5.3). Knowledge of child dosing increased significantly 
from baseline in Ghana, Tanzania mainland and Zanzibar.  
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Table 2.5.2: Provider knowledge of dosing regimen for quality-assured ACTs (QAACTs) for an adult, at baseline (2010) and endline (2011) 
Percentage of providers able to describe correctly the dosing regimen for quality-assured ACTs for an adult (n) among outlets with QAACTs in stock at the time of the survey visit 
(N), by urban-rural location and type of outlet, according to country 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N 
Ghana – Total 70.8 (60.6-79.3) 357 55.8 (47.2-64.1) 210 60.5 (53.7-66.9) 567 91.4 (88.7-93.6) 475 88.1 (83.2-91.8) 302 90.2 (87.8-92.2) 777 
Public health facility  41.3 (32.6-50.7) 58 43.3 (33.6-53.5) 115 43.0 (34.5-52.0) 173 91.9 (82.2-96.6) 64 84.5 (77.0-89.9) 166 86.5 (80.8-90.8) 230 
Private not-for-profit health facility 30.0 (5.3-76.9) 2 50.3 (15.5-84.8) 4 46.9 (16.8-79.5) 6 100.0 3 100.0 8 100.0 11 
Private for-profit outlet             
   Health facility/pharmacy 88.8 (83.6-92.5) 237 81.8 (59.7-93.2) 31 87.0 (80.6-91.6) 268 92.2 (88.6-94.7) 240 100.0 23 93.3 (89.8-95.6) 263 
   Drug store 45.5 (30.8-61.0) 60 57.9 (44.7-70.1) 57 55.5 (44.4-66.1) 117 90.7 (86.6-93.7) 165 88.0 (80.5-92.9) 103 89.7 (86.1-92.4) 268 
   General retailer/itinerant - 0 - 0 - 0 100.0 3 49.2 (7.3-92.3) 2 79.7 (36.3-96.4) 5 
   Total 74.9 (64.1-83.3) 297 61.2 (49.5-71.8) 88 66.5 (58.0-74.0) 385 91.3 (88.3-93.5) 408 88.4 (81.8-92.9) 128 90.3 (87.6-92.5) 536 
Community health worker - 0 65.2 (37.3-85.6) 3 65.2 (37.3-85.6) 3 - 0 - 0 - 0 
Kenya – Total 95.2 (91.2-97.4) 515 95.6 (92.5-97.4) 311 95.4 (93.2-97) 826 90.5 (84.8-94.2) 819 91.6 (86.4-94.9) 584 91.3 (87.5-94.0) 1,403 
Public health facility  85.8 (71.8-93.5) 103 94.1 (88.3-97.1) 206 92.5 (87.1-95.7) 309 94.8 (90.8-97.1) 127 90.3 (85.3-93.8) 284 90.7 (86.0-93.9) 411 
Private not-for-profit health facility 97.6 (85.2-99.7) 15 100.0 14 99.5 (96.3-99.9) 29 100.0 16 93.9 (68.3-99.1) 27 95.1 (72.8-99.3) 43 
Private for-profit outlet             
   Health facility/pharmacy 97.0 (89.8-99.1) 244 93.0 (77.8-98.1) 51 95.3 (88.1-98.2) 295 87.9 (83.3-91.4) 344 97.1 (88.9-99.3) 87 93.4 (88.4-96.4) 431 
   Drug store 97.0 (92.6-98.8) 151 97.2 (86.3-99.5) 36 97.1 (91.9-99) 187 92.3 (82.3-96.8) 302 95.7 (89-98.4) 120 94.2 (89.1-97.0) 422 
   General retailer/itinerant - 0 - 0 - 0 74.2 (53.2-88.0) 30 75.4 (61.8-85.4) 66 75.3 (63.1-84.4) 96 
   Total 97.0 (93.4-98.6) 395 95.7 (87.6-98.6) 87 96.3 (92.5-98.2) 482 90.0 (83.7-94) 676 91.8 (85.0-95.7) 273 91.1 (86.6-94.2) 949 
Community health worker 100.0 2 100.0 4 100.0 6 - 0 - 0 - 0 
Madagascar –Total - - - - - - 71.6 (64.1-78.1) 201 45.2 (33.7-57.3) 726 49.2 (38.5-60.0) 927 
Public health facility  - - - - - - 85.7 (74.7-92.4) 53 84.5 (80.0-88.1) 488 84.6 (80.5-87.9) 541 
Private not-for-profit health facility - - - - - - 74.3 (56.0-86.7) 22 100.0 2 87.6 (69.2-95.7) 24 
Private for-profit outlet - - - - - -       
   Health facility/pharmacy - - - - - - 72.2 (65.8-77.9) 87 9.7 (0.6-64.4) 2 66.5 (52.7-77.9) 89 
   Drug store - - - - - - 73.9 (64.3-81.7) 25 64.4 (50.9-76) 174 66.1 (54.9-75.7) 199 
   General retailer/itinerant - - - - - - 0.0 2 33.7 (6.1-79.8) 4 32.7 (6.1.0-78.4) 6 
   Total - - - - - - 72.0 (66.9-76.6) 114 56.5 (38.4-72.9) 180 62.3 (50.0-73.2) 294 
Community health worker - - - - - - 0.0 12 0.0 56 0.0 68 
Niger – Total 88.5 (72.8-95.7) 149 76.7 (61.1-87.3) 163 80.4 (68.7-88.5) 312 -      
Public health facility  86.6 (52.0-97.5) 50 92.0 (84.0-96.2) 137 91.2 (83.4-95.5) 187 - - - - - - 
Private not-for-profit health facility - 0 - 0 - 0 - - - - - - 
Private for-profit outlet       - - - - - - 
   Health facility/pharmacy 83.9 (60.0-94.7) 55 100.0 3 87.2 (65.3-96.1) 58 - - - - - - 
   Drug store 75.4 (47.2-91.3) 8 100.0 1 83.1 (53.7-95.4) 9 - - - - - - 
   General retailer/itinerant 93.0 (74.8-98.3) 35 53.6 (24.4-80.6) 22 68.3 (44.1-85.4) 57 - - - - - - 
   Total 89.0 (74.1-95.8) 98 57.8 (29.2-81.9) 26 71.8 (51.9-85.7) 124 - - - - - - 
Community health worker - 0 - 0 - 0 - - - - - - 
Nigeria – Total - - - - - - 83.2 (78.0-87.3) 592 73.4 (62.1-82.3) 245 79.4 (73.6-84.2) 837 
Public health facility  - - - - - - 97.0 (90.2-99.1) 32 73.6 (46.5-89.9) 28 81.4 (60.4-92.6) 60 
Private not-for-profit health facility - - - - - - 67.9 (15.4-96.1) 4 93.1 (54.1-99.4) 3 78.8 (33.6-96.5) 7 
Private for-profit outlet - - - - - -       
   Health facility/pharmacy - - - - - - 95.5 (82.0-99.0) 65 90.9 (70.2-97.7) 13 94.7 (84.5-98.3) 78 
   Drug store - - - - - - 82.2 (76.2-87.0) 467 73.2 (60.3-83.0) 196 78.7 (72.2-84.0) 663 
   General retailer/itinerant - - - - - - 45.9 (20.7-73.4) 21 0.0 3 41.7 (18.6-69.1) 24 
   Total - - - - - - 82.9 (77.8-87.0) 553 73.7 (61.7-83.0) 212 79.5 (73.8-84.3) 765 
Community health worker - - - - - - 33.3 (33.3-33.3) 3 9.0 (0.6-62.4) 2 10.2 (0.9-59.5) 5 
Tanzania - mainland – Total 68.2 (47.4-83.6) 112 84.4 (72.4-91.8) 59 80.7 (70.9-87.7) 171 95.9 (90.5-98.3) 459 99.0 (96.1-99.7) 130 97.9 (95.7-98.9) 589 
Public health facility  56.9 (9.7-94.2) 3 88.8 (74.7-95.5) 35 86.3 (73.0-93.6) 38 88.3 (45.0-98.6) 6 100.0 38 99.4 (96.0-99.9) 44 
Private not-for-profit health facility 66.7 (66.7-66.7) 3 100.0 6 92.7 (67.6-98.7) 9 72.2 (18.2-96.8) 3 100.0 2 87.2 (42.2-98.4) 5 
Private for-profit outlet             
   Health facility/pharmacy 85.7 (74.9-92.3) 97 28.2 (3.0-83.2) 3 79.0 (59.3-90.7) 100 98.6 (97.0-99.3) 286 100.0 13 98.9 (97.6-99.5) 299 
   Drug store 59.2 (26.8-85.1) 9 68.1 (36.4-88.9) 13 64.6 (41.7-82.3) 22 96.1 (89.8-98.6) 161 98.3 (93.7-99.6) 75 97.4 (94.4-98.8) 236 
   General retailer/itinerant - 0 42.5 (4.0-92.9) 2 42.5 (4.0-92.9) 2 100.0 3 100.0 2 100.0 5 
   Total 71.4 (51.4-85.6) 106 62 .0 (37.8-81.4) 18 66.7 (50.4-79.7) 124 96.6 (91.5-98.7) 450 98.4 (94.1-99.6) 90 97.6 (94.9-98.9) 540 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
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Table 2.5.2: Cont. 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N 
Uganda – Total 91.2 (80.6-96.3) 265 83.9 (75.3-89.8) 768 85.3 (77.6-90.7) 1,033 95.3 (93.9-96.3) 1,123 87.2 (74.8-94) 1,282 89.1 (79.5-94.5) 2,405 
Public health facility  96.2 (85.2-99.1) 58 93.5 (89.8-95.9) 605 93.7 (90.2-96) 663 99.6 (97.2-99.9) 129 98.4 (95.9-99.4) 483 98.6 (96.5-99.4) 612 
Private not-for-profit health facility 100.0 2 78.1 (46.5-93.6) 10 82.7 (53.0-95.3) 12 100.0 10 100.0 24 100.0 34 
Private for-profit outlet             
   Health facility/pharmacy 97.0 (94.9-98.3) 199 84.3 (66.2-93.7) 74 92.6 (82.6-97) 273 94.5 (91.8-96.4) 682 96.1 (91.7-98.2) 304 95.4 (93.1-96.9) 986 
   Drug store 59.7 (25.5-86.5) 6 87.8 (74.7-94.6) 64 84.6 (70.9-92.6) 70 95.5 (93.2-97.1) 297 94.3 (91.1-96.4) 411 94.5 (91.9-96.3) 708 
   General retailer/itinerant - 0 0.0 1 0.0 1 100.0 3 66.0 (47.6-80.6) 9 68.3 (52.5-80.8) 12 
   Total 89.1 (72.4-96.3) 205 86.1 (75.3-92.6) 139 87.1 (78.3-92.6) 344 95.0 (93.5-96.1) 982 93.9 (91-95.9) 724 94.2 (92.1-95.7) 1,706 
Community health worker - 0 24.8 (13.5-41.2) 14 24.8 (13.5-41.2) 14 46.3 (5.2-93.1) 2 16.6 (4.1-47.9) 51 16.8 (4.2-47.9) 53 
Zanzibar – Total 34.5 55 40.8  76 38.2 131 85.3 170 82.7 104 84.3 274 
Public health facility  28.6 42 40.0 75 35.9 117 82.9 41 82.4 68 82.6 109 
Private not-for-profit health facility - 0 - 0 - 0 0.0 1 100.0 1 50.0 2 
Private for-profit outlet             
   Health facility/pharmacy 58.3 12 100.0 1 61.5 13 89.6 67 86.7 15 89.0 82 
   Drug store - 1 - 0 0.0 1 83.3 60 77.8 18 82.1 78 
   General retailer/itinerant - 0 - 0 - 0 100.0 1 100.0 2 100.0 3 
   Total 53.8 13 100.0 1 57.1 14 86.7 128 82.9 35 85.9 163 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Note: “describe  correctly” implies that the respondent correctly stated the number of tablets that should be taken at a time, the number of times the medicine should be taken per day and the duration of 
the dose in number of days for a 60kg adult for a specific product which they selected from the QAACTs that they stocked. These data are not available for Madagascar and Nigeria at baseline, as they 
were not collected in the ACTwatch questionnaire. Data are not available for Niger at endline at this time. Nigeria baseline data collection was conducted in 2009. 
CI = Confidence interval 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.5.3: Provider knowledge of dosing regimen for quality-assured ACTs (QAACTs) for a child, at baseline (2010) and endline (2011) 
Percentage of providers able to describe correctly the dosing regimen for quality-assured ACTs for a child (n) among outlets with QAACTs in stock at the time of the survey visit 
(N), by urban-rural location and type of outlet, according to country 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N 
Ghana – Total 34.4 (28.9-40.3) 361 33.3 (25.9-41.7) 207 33.7 (28.2-39.6) 568 51.1 (44.9-57.2) 460 46.6 (40.2-53.0) 280 49.4 (44.8-53.9) 740 
Public health facility  46.9 (38.9-55.0) 57 34.8 (26.2-44.5) 114 36.4 (28.7-44.9) 171 67.9 (55.8-77.9) 65 49.8 (42.6-56.9) 154 54.9 (48.3-61.4) 219 
Private not-for-profit health facility 0.0 2 100.0 4 83.4 (57.0-95.0) 6 100.0 3 56.4 (22.9-84.9) 7 74.1 (45.4-90.7) 10 
Private for-profit outlet             
   Health facility/pharmacy 45.6 (39.5-51.9) 241 47.1 (31.5-63.3) 29 46.0 (39.9-52.2) 270 70.3 (63.5-76.2) 238 63.9 (39.8-82.5) 21 69.4 (62.8-75.3) 259 
   Drug store 8.6 (4.9-14.9) 61 27.2 (18.4-38.2) 57 23.7 (16.3-33.1) 118 40.3 (34.4-46.4) 151 43.9 (35.9-52.2) 96 41.6 (36.9-46.6) 247 
   General retailer/itinerant - 0 - 0 - 0 35.5 (7.2-79.5) 3 0.0 2 21.3 (4.3-61.7) 5 
   Total 33.7 (27.9-40.1) 302 29.9 (21.7-39.5) 86 31.4 (25.8-37.6) 388 49.1 (42.7-55.5) 392 44.9 (37.9-52.2) 119 47.8 (42.8-52.7) 511 
Community health worker - 0 0.0 3 0.0 3 - 0 - 0 - 0 
Kenya – Total 77.3 (63.1-87.2) 490 72.8 (63.9-80.1) 301 74.4 (66.8-80.7) 791 67.7 (60.7-74.0) 823 66.2 (59.9-71.9) 587 66.6 (61.8-71.1) 1,410 
Public health facility  90.6 (82.2-95.3) 102 86.8 (78.8-92.1) 208 87.5 (80.9-92.1) 310 88.1 (80.7-92.9) 127 88.5 (81.4-93.1) 285 88.5 (81.9-92.8) 412 
Private not-for-profit health facility 81.4 (53.0-94.5) 17 66.9 (27.4-91.5) 12 70.6 (37.5-90.5) 29 94.6 (78.5-98.8) 16 81.1 (54.6-93.9) 27 83.6 (61.2-94.3) 43 
Private for-profit outlet             
   Health facility/pharmacy 80.2 (63.4-90.5) 229 68.2 (47.3-83.7) 43 75.2 (62.0-84.9) 272 61.6 (49.0-72.9) 345 65.0 (56.6-72.5) 88 63.7 (56.5-70.2) 433 
   Drug store 66.2 (48.7-80.2) 140 56.3 (43.7-68.1) 30 60.4 (50.3-69.7) 170 70.0 (62.2-76.7) 305 60.3 (49.1-70.5) 120 64.4 (56.7-71.3) 425 
   General retailer/itinerant - 0 - 0 - 0 40.4 (19.4-65.5) 30 41.7 (28.3-56.5) 67 41.6 (29.2-55.0) 97 
   Total 74.1 (57.2-85.9) 369 61.0 (51.8-69.4) 73 67.4 (57.9-75.7) 442 65.8 (57.9-72.9) 680 57.7 (51.1-64.0) 275 60.6 (55.4-65.7) 955 
Community health worker 100.0 2 73.9 (57.5-85.6) 8 74.8 (59.9-85.4) 10 - 0 - 0 - 0 
Madagascar – Total - - - - - - 59.2 (51.4-66.5) 195 59.2 (53.6-64.6) 717 59.2 (54.3-63.9) 912 
Public health facility  - - - - - - 73.6 (56.6-85.7) 51 65.0 (57.2-72.0) 483 65.9 (58.8-72.3) 534 
Private not-for-profit health facility - - - - - - 76.5 (56.6-89.0) 21 34.7 (3.1-90.0) 2 54.6 (18.3-86.6) 23 
Private for-profit outlet - - - - - -       
   Health facility/pharmacy - - - - - - 51.5 (40.7-62.2) 87 100.0 2 56.0 (42.8-68.3) 89 
   Drug store - - - - - - 39.7 (20.7-62.5) 23 42.9 (35.9-50.2) 173 42.4 (35.5-49.6) 196 
   General retailer/itinerant - - - - - - 0.0 2 0.0 4 0.0 6 
   Total - - - - - - 48.0 (38.4-57.8) 112 37.7 (30.4-45.6) 179 41.6 (35.6-47.7) 291 
Community health worker - - - - - - 75.5 (60.0-86.3) 11 63.7 (55.8-71.0) 53 64.0 (56.3-71.1) 64 
Niger – Total 62.2 (52.4-71.2) 184 74.9 (64.0-83.3) 179 70.6 (63.3-77.0) 363 53.7 (47.1-60.2) 302 60.2 (50.2-69.3) 204 57.7 (51.1-64.1) 506 
Public health facility  71.3 (53.1-84.5) 61 82.0 (75.7-87) 146 80.3 (74.4-85) 207 86.3 (78.1-91.8) 90 84.2 (77.1-89.4) 149 84.6 (78.6-89.1) 239 
Private not-for-profit health facility 100.0 1 - 0 100.0 1 0.0 1 100.0 1 80.6 (32.5-97.3) 2 
Private for-profit outlet             
   Health facility/pharmacy 47.7 (29.2-66.8) 65 94.6 (52.5-99.6) 3 56.3 (34.3-76.1) 68 54.1 (37.8-69.6) 65 91.6 (61.9-98.6) 4 57.9 (41.7-72.5) 69 
   Drug store 97.1 (78.4-99.7) 8 100.0 1 98.0 (84.5-99.8) 9 88.4 (69.8-96.2) 9 48.7 (8.5-90.7) 2 67.1 (29.7-90.8) 11 
   General retailer/itinerant 58.9 (43.5-72.6) 49 65.4 (46.3-80.6) 29 62.9 (50.3-74.0) 78 45.8 (37.4-54.4) 137 36.8 (23.1-52.9) 48 41.0 (32.3-50.3) 185 
   Total 59.9 (48.5-70.2) 122 67.6 (48.7-82.1) 33 64.1 (53.1-73.9) 155 48.3 (40.9-55.7) 211 38.0 (24.8-53.3) 54 43.1 (35.1-51.4) 265 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Nigeria – Total - - - - - - 51.0 (40.4-61.4) 594 61.6 (51.3-70.9) 247 55.1 (46.9-63.0) 841 
Public health facility  - - - - - - 73.6 (44.9-90.5) 32 54.8 (30.9-76.6) 29 60.9 (41.6-77.4) 61 
Private not-for-profit health facility - - - - - - 100.0 5 93.1 (54.1-99.4) 3 97.0 (78.9-99.7) 8 
Private for-profit outlet - - - - - -       
   Health facility/pharmacy - - - - - - 55.6 (31.5-77.2) 64 65.8 (36.2-86.7) 13 57.4 (37.0-75.6) 77 
   Drug store - - - - - - 48.3 (37.6-59.1) 470 61.0 (49.7-71.1) 197 53.3 (44.5-61.9) 667 
   General retailer/itinerant - - - - - - 49.7 (23.2-76.4) 20 100.0 3 54.4 (28.6-78.1) 23 
   Total - - - - - - 49.3 (38.7-60.0) 554 61.5 (50.7-71.2) 213 53.7 (45.1-62.1) 767 
Community health worker       66.7 (66.7-66.7) 3 100.0 2 98.4 (82.3-99.9) 5 
Tanzania - mainland – Total 68.9 (45.0-85.8) 110 80.1 (68.2-88.2) 62 77.6 (67.5-85.2) 172 87.0 (76.4-93.3) 443 93.8 (85.7-97.5) 119 91.3 (85.2-95.0) 562 
Public health facility  78.5 (21.4-98.0) 3 84.3 (72.0-91.8) 37 83.8 (71.9-91.3) 40 88.3 (45.0-98.6) 6 98.2 (87.3-99.8) 37 97.8 (89.2-99.6) 43 
Private not-for-profit health facility 100.0 3 93.3 (60.9-99.2) 7 94.7 (67.2-99.4) 10 60.4 (11.6-94.7) 3 100.0 2 81.8 (32.4-97.7) 5 
Private for-profit outlet             
   Health facility/pharmacy 81.2 (71.6-88.1) 95 8.3 (0.7-54.9) 3 72.7 (55-85.3) 98 88.0 (79.1-93.4) 278 96.1 (83.0-99.2) 12 89.9 (81.8-94.6) 290 
   Drug store 43.8 (14.7-77.9) 9 70.4 (34.8-91.4) 12 59.4 (36-79.2) 21 87.9 (75.6-94.4) 153 90.8 (77.8-96.6) 67 89.5 (81.2-94.4) 220 
   General retailer/itinerant - 0 35.7 (4.4-87.1) 3 35.7 (4.4-87.1) 3 63.1 (12.0-95.5) 3 100.0 1 81.6 (28.5-98.0) 4 
   Total 61.1 (43.7-76.1) 104 59.0 (30.6-82.4) 18 60.0 (42.6-75.2) 122 87.5 (76.6-93.8) 434 91.2 (78.5-96.7) 80 89.5 (81.7-94.2) 514 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
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Table 2.5.3: Cont.  
Percentage of providers able to describe correctly the dosing regimen for quality-assured ACTs for a child (n) among outlets with QAACTs in stock at the time of the survey visit 
(N), by urban-rural location and type of outlet, according to country 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N 
Uganda – Total 65.9 (44.4-82.4) 264 82.2 (77.1-86.4) 771 79.1 (72.3-84.5) 1,035 78.4 (74.8-81.6) 1,129 82.3 (78.5-85.5) 1,270 81.4 (78.2-84.1) 2,399 
Public health facility  93.8 (82.2-98.0) 59 90.4 (86.3-93.3) 606 90.7 (86.7-93.6) 665 92.2 (85.2-96) 131 95.3 (93.0-96.8) 480 94.8 (92.8-96.3) 611 
Private not-for-profit health facility 100.0 2 78.1 (46.5-93.6) 10 82.7 (53.0-95.3) 12 77.1 (63.5-86.7) 10 94.8 (78.9-98.9) 24 92.8 (80.8-97.5) 34 
Private for-profit outlet             
   Health facility/pharmacy 63.3 (41.5-80.7) 197 75.7 (58.7-87.2) 75 67.8 (52.9-79.7) 272 75.2 (70.5-79.5) 687 81.4 (72.1-88.2) 299 78.6 (72.7-83.5) 986 
   Drug store 23.8 (3.6-72.2) 6 67.4 (57.3-76.1) 65 62.5 (49.8-73.6) 71 81.3 (74.6-86.6) 296 79.7 (74.3-84.2) 407 80.0 (75.5-83.8) 703 
   General retailer/itinerant - 0 0.0 1 0.0 1 37.6 (5.0-87.3) 3 40.7 (26.4-56.8) 9 40.5 (26.5-56.3) 12 
   Total 54.9 (27.0-80.0) 203 68.4 (60.4-75.4) 141 64.1 (52.9-73.9) 344 77.4 (73.2-81.1) 986 78.9 (73.4-83.5) 715 78.5 (74.3-82.1) 1,701 
Community health worker - 0 100.0 14 100.0 14 46.3 (5.2-93.1) 2 86.1 (74.7-92.9) 51 85.8 (74.8-92.5) 53 
Zanzibar – Total 37.9 58 35.2 71 36.4 129 52.1 169 48.5 97 50.8 266 
Public health facility  43.5 46 35.7 70 38.8 116 56.8 44 51.5 66 53.6 110 
Private not-for-profit health facility - 0 - 0 - 0 100 1 0.0 1 50.0 2 
Private for-profit outlet             
   Health facility/pharmacy 20.0 10 0.0 1 18.2 11 53.7 67 50.0 12 53.2 79 
   Drug store 0.0 2 - 0 0.0 2 46.4 56 43.8 16 45.8 72 
   General retailer/itinerant - 0 - 0 - 0 0.0 1 0.0 2 0.0 3 
   Total 16.7 12 0.0 1 15.4 13 50 124 43.3 30 48.7 154 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Note: “ describe correctly” implies that the respondent correctly stated the number of tablets that should be taken at a time, the number of times the medicine should be taken per day and the duration of the dose in number of days for child under 2 
years (10kg) for a specific product which they selected from the QAACTs that they stocked. These data are not available for Madagascar and Nigeria at baseline, as they were not collected in the ACTwatch questionnaire. Nigeria baseline data 
collection was conducted in 2009. 
CI = Confidence interval 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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2.5.3 Reasons for not stocking quality-assured ACTs 
Table 2.5.4 shows the reasons given for not stocking QAACTs by private providers (results are 
not reported for public health facilities and Community Health Workers (CHWs) as it is assumed 
that they do not have control over the products they stock). At endline in Ghana, Kenya, 
Madagascar and Niger, the three most commonly reported reasons for not stocking QAACTs 
were “QAACTS are not available from my suppliers,” “I don’t know about these drugs” and “my 
customers do not ask for them.” By contrast in Nigeria, Tanzania mainland and Uganda the three 
most common reasons were “QAACTs are too expensive,” “my customers do not ask for them” 
and “I am temporarily out of stock.” In Zanzibar the three most common reasons were 
“QAACTs are not available from my suppliers,” “my customers do not ask for them” and “I am 
temporarily out of stock.” 
 
Some changes were evident between baseline and endline (no baseline data were available for 
Madagascar and Nigeria). The percentage of respondents in private for-profit outlets saying that 
QAACTs were too expensive fell in Ghana, Kenya, Niger and Zanzibar; the percentage saying 
they didn’t know about QAACTs fell in Ghana and Uganda; the percentage saying that they 
were not available from their suppliers fell in Niger and the percentage saying they were not 
allowed to sell QAACTs fell in Zanzibar. Increases were seen in those saying they were 
temporarily out of stock in Niger, Tanzania mainland, Uganda and Zanzibar; and in those saying 
that customers can get QAACTs free from public health facilities in Uganda.  
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Table 2.5.4: Reasons for not stocking quality-assured ACTs (QAACTs) for private providers, at baseline (2010) and endline (2011) 
Providers stating a specific reason why they were not stocking QAACTs (n) as a percentage of all outlets not stocking QAACTs at the time of the survey visit (N), by urban-rural location and type of 
reason specified, according to country 
Country/Type of reason specified 
BASELINE ENDLINE 
Urban Rural Total Urban Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N 
Ghana             
Too expensive 37.0 (31.3-43.1) 219 28.1 (21.9-35.3) 305 29.3 (23.8-35.5) 524 5.3 (1.5-16.8) 39 5.1 (1.9-12.7) 40 5.2 (2.3-11.1) 79 
They are not available/my suppliers do not have it in stock 29.8 (23.5-37) 219 37.8 (29.8-46.5) 305 36.7 (29.7-44.3) 524 54.2 (40.4-67.4) 39 43.5 (27.2-61.2) 40 49.0 (37.8-60.4) 79 
My customers do not ask for them 19.0 (13.9-25.5) 219 16.7 (11.9-22.9) 305 17.0 (12.7-22.4) 524 20.9 (10.6-37.2) 39 11.4 (5.9-21) 40 16.3 (10.2-25.1) 79 
I don’t know about these drugs 31.6 (24.4-39.9) 219 44.0 (36.2-52.2) 305 42.3 (35.5-49.4) 524 8.2 (3.0-20.4) 39 26.6 (16.2-40.3) 40 17.1 (10.4-26.8) 79 
Other 25.8 (19.1-34) 219 13.8 (9.7-19.4) 305 15.5 (11.7-20.2) 524 29.7 (20.3-41.2) 40 28.8 (15.5-47.1) 44 29.3 (20.7-39.6) 84 
Kenya             
Too expensive 32.5 (26.7-39) 467 27.0 (21.5-33.4) 490 28.1 (23.2-33.5) 957 12.4 (9.5-15.9) 299 10.6 (7.6-14.6) 316 10.9 (8.4-14.1) 615 
Not profitable 6.8 (3.1-14.4) 467 3.7 (2.2-6.1) 490 4.3 (2.8-6.6) 957 3.7 (2-6.8) 299 3.2 (1.9-5.5) 316 3.3 (2.2-5.1) 615 
The outlet is not allowed to sell them 11.5 (7.9-16.3) 467 7.2 (3.9-12.8) 490 8 (5.1-12.4) 957 9.3 (6.1-13.8) 299 11.4 (8.9-14.6) 316 11.0 (8.8-13.6) 615 
They have too many side effects 1.1 (0.5-2.4) 467 0.7 (0.2-3.2) 490 0.8 (0.3-2.4) 957 1.6 (0.4-5.9) 299 1.5 (0.4-5.5) 316 1.5 (0.5-4.4) 615 
They do not work well 2 (1.1-3.6) 467 1.4 (0.5-3.6) 490 1.5 (0.7-3.1) 957 4.5 (2.2-9) 299 5.6 (1.9-15) 316 5.3 (2.2-12.4) 615 
They are not available/my suppliers do not have it in stock 20.5 (16.2-25.6) 467 32.9 (26.7-39.8) 490 30.5 (25.1-36.4) 957 25.3 (20.2-31.1) 299 28.1 (19-39.4) 316 27.5 (20.1-36.5) 615 
My customers do not ask for them 30.8 (24.8-37.5) 467 24.1 (18.9-30.4) 490 25.4 (20.8-30.8) 957 18.8 (15.4-22.7) 299 15.1 (10.5-21.3) 316 15.9 (11.9-20.8) 615 
I don’t know about these drugs 28.1 (23.7-32.9) 467 30.8 (24.4-38) 490 30.3 (25.1-36) 957 22.4 (17.6-28) 299 27.3 (21.6-33.9) 316 26.3 (21.6-31.7) 615 
I am temporarily out of stock 9.5 (6.3-14.2) 467 7.9 (4.8-12.7) 490 8.2 (5.6-12) 957 18.0 (12.7-24.9) 299 12.0 (7.3-19.1) 316 13.2 (9-18.9) 615 
Other 11.2 (8.4-14.8) 467 7.2 (4.9-10.5) 490 8 (5.9-10.7) 957 11.6 (7.9-16.7) 299 9.6 (6.1-14.8) 316 10.0 (7-14.1) 615 
Madagascar             
Too expensive - - - - - - 3.3 (2.3-4.7) 1,029 4.1 (2-8.1) 697 4 (2.2-7.3) 1,726 
Not profitable - - - - - - 0.7 (0.3-1.5) 1,029 0.6 (0.2-1.3) 697 0.6 (0.3-1.2) 1,726 
This outlet is not allowed to sell them - - - - - - 14.3 (11.6-17.5) 1,029 6.6 (4.3-10.1) 697 7.7 (5.6-10.6) 1,726 
The have too many side effects - - - - - - 0.3 (0.1-0.7) 1,029 0.2 (0-1.5) 697 0.2 (0-1.1) 1,726 
They do not work well - - - - - - 0.2 (0.1-0.4) 1,029 0.2 (0-1.3) 697 0.2 (0-1.1) 1,726 
The are not available/my suppliers do not have it in stock - - - - - - 31.4 (27.1-36) 1,029 37.8 (30.5-45.7) 697 36.9 (30.5-43.7) 1,726 
My customers do not ask for them - - - - - - 25.5 (20.4-31.3) 1,029 18.1 (14.1-23.1) 697 19.2 (15.6-23.4) 1,726 
I don't know about these drugs - - - - - - 33.3 (28.9-38) 1,029 35.9 (29.3-43.1) 697 35.5 (29.7-41.8) 1,726 
I am temposrily out of stock - - - - - - 3.5 (1.5-8.1) 1,029 2.4 (1.3-4.1) 697 2.5 (1.5-4.1) 1,726 
Other - - - - - - 1.9 (0.9-3.7) 1,029 3.7 (1.9-6.9) 697 3.4 (1.9-6.1) 1,726 
Niger             
Too expensive 34.2 (26.4-43.0) 669 28.2 (22.2-35.1) 1,004 29.2 (24.1-35) 1,673 10.7 (8.8-13.0) 736 15.1 (12.8-17.6) 632 14.1 (12.2-16.1) 1,368 
Not profitable 9.3 (5.2-16.0) 669 5.7 (3.1-10.2) 1,004 6.3 (3.9-9.9) 1,673 4.6 (3.5-6.0) 736 3.2 (2.2-4.5) 632 3.5 (2.7-4.5) 1,368 
The outlet is not allowed to sell it 6.7 (3.8-11.6) 669 4.8 (2.7-8.3) 1,004 5.1 (3.3-8.0) 1,673 5.2 (4.1-6.8) 736 2.6 (1.8-3.8) 632 3.2 (2.5-4.2) 1,368 
They are not available/my suppliers do not have it in stock 28.3 (21.9-35.8) 669 42.9 (37.8-48.2) 1,004 40.4 (35.9-45.1) 1,673 23.6 (20.2-27.4) 736 27.8 (23.2-32.9) 632 26.8 (23.1-30.8) 1,368 
My customers do not ask for them 29.9 (23-37.9) 669 24.7 (18.6-32.2) 1,004 25.6 (20.3-31.8) 1,673 24.1 (20.6-27.9) 736 18.1 (13.8-23.4) 632 19.5 (16.1-23.5) 1,368 
I don’t know about these drugs 29.4 (22.5-37.6) 669 28.6 (22.1-36.2) 1,004 28.8 (23.1-35.2) 1,673 24.3 (19.8-29.5) 736 31.4 (25.7-37.8) 632 29.8 (25.3-34.7) 1,368 
I am temporarily out of stock 3.6 (1.9-6.7) 669 4.2 (3.1-5.7) 1,004 4.1 (3.1-5.4) 1,673 15.6 (10.8-22.2) 736 12.1 (9.2-15.7) 632 12.9 (10.3-16.0) 1,368 
Other 5.8 (3.6-9.1) 684 4.4 (3.0-6.4) 1,004 4.7 (3.4-6.3) 1,673 8.6 (6.4-11.4) 736 7.1 (4.3-11.4) 643 7.4 (5.1-10.6) 1,368 
Nigeria             
Too expensive - - - - - - 33.3 (27.2-40.1) 402 36.9 (27.6-47.2) 202 34.7 (29.5-40.3) 604 
Not profitable - - - - - - 4.8 (3.2-7.1) 402 2.4 (0.9-6.3) 202 3.9 (2.4-6.1) 604 
Not allowed to sell - - - - - - 6.2 (3.5-10.6) 402 3.0 (1.1-7.9) 201 4.9 (3.1-7.7) 603 
Not available - - - - - - 15.5 (8.6-26.5) 402 20.4 (14.4-28.2) 201 17.4 (11.8-24.9) 603 
My customers do not ask for them - - - - - - 46.4 (40.1-52.7) 401 29.0 (22.2-36.9) 202 39.7 (33.7-45.9) 603 
Do not know about QAACTs - - - - - - 17.0 (10.2-27) 402 15.0 (9.2-23.5) 202 16.2 (11.3-22.7) 604 
Temporarily out of stock - - - - - - 17.6 (9.8-29.5) 402 17.1 (11.0-25.8) 202 17.4 (11.7-25.1) 604 
Other - - - - - - 17.9 (11.7-26.5) 402 16.6 (11.6-23.2) 202 17.4 (13.0-22.9) 604 
Tanzania – mainland             
It is too expensive 44.8 (35.9-53.9) 134 26.0 (20.0-33.1) 238 29.8 (24.1-36.2) 372 20.5 (11.4-33.9) 93 25.6 (13.9-42.4) 55 23.9 (15.2-35.4) 148 
It is not profitable 5.1 (1.9-13.1) 134 3.1 (1.8-5.4) 238 3.5 (2.2-5.6) 372 8.5 (4.4-15.9) 93 7.6 (2.2-23.1) 55 7.9 (3.5-17) 148 
The outlet is not allowed to sell it 16.0 (10.0-24.5) 134 22.0 (12.7-35.4) 238 20.8 (12.9-31.7) 372 15.3 (6.6-31.5) 93 13.3 (7.2-23.2) 55 13.9 (8.6-21.8) 148 
It has too many side effects 0.0 (0.0-0.0) 134 1.4 (0.5-3.7) 238 1.1 (0.4-3.0) 372 0.0 93 0.0 55 0.0 148 
It does not work well 0.8 (0.1-4.9) 134 0.3 (0.0-2.4) 238 0.4 (0.1-1.8) 372 1.5 (0.2-10.1) 93 1.4 (0.2-9.7) 55 1.5 (0.3-6.1) 148 
It is not available/my suppliers do not have it in stock 21.9 (12.8-34.9) 134 31.7 (24.3-40.1) 238 29.7 (23.4-36.8) 372 5.4 (2.2-12.5) 93 21.5 (12.6-34.1) 55 16.0 (9.3-26.2) 148 
My customers do not ask for it 22.2 (12.1-37.1) 134 18.6 (9.8-32.5) 238 19.3 (11.6-30.5) 372 36.1 (20.8-54.9) 93 15.8 (6.4-34.1) 55 22.7 (12.8-36.9) 148 
I don’t know about these drugs 24.0 (17.5-31.8) 134 37.1 (27.8-47.5) 238 34.4 (26.9-42.8) 372 2.5 (0.5-10.8) 93 16.4 (6.5-35.5) 55 11.7 (4.5-27) 148 
I am temporarily out of stock 0.6 (0.3-1.2) 134 0.3 (0-2.1) 238 0.3 (0.1-1.3) 372 17.6 (8.4-33.2) 93 16.4 (5.9-38.2) 55 16.8 (8.3-31.1) 148 
Other  0.1 (0.0-0.7) 148 2.8 (1.2-6.5) 238 2.2 (0.9-5.3) 372 14.8 (6.5-30.3) 93 5.8 (1.7-18.4) 55 8.9 (4.3-17.3) 148 
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Table 2.5.4: Cont. 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N 
Uganda             
It is too expensive 54.2 (40.1-67.6) 249 56.4 (51.3-61.4) 1,064 56.0 (51.0-60.8) 1,313 35.9 (26.9-46.1) 225 45.8 (37.7-54.1) 369 44.4 (37.5-51.5) 594 
It is not profitable 5.3 (2.7-9.9) 249 6.6 (4.7-9) 1,064 6.3 (4.7-8.4) 1,313 4.2 (2.3-7.6) 225 5.4 (3.1-9.2) 369 5.2 (3.2-8.5) 594 
The outlet is not allowed to sell it / Government drug only 20.6 (15.7-26.4) 249 28.3 (22.7-34.6) 1,064 26.7 (21.8-32.2) 1,313 17.3 (14.6-20.5) 224 20.9 (15.3-27.9) 369 20.4 (15.5-26.4) 593 
It has too many side effects 0.9 (0.1-5.4) 249 0.5 (0.2-1.3) 1,064 0.6 (0.3-1.3) 1,313 1.6 (0.7-3.6) 225 0.7 (0.2-2.7) 369 0.8 (0.3-2.3) 594 
It does not work well 1.5 (0.5-4.7) 249 1.0 (0.4-2.3) 1,064 1.1 (0.5-2.1) 1,313 7.5 (3.9-14.2) 225 2.2 (1.1-4.2) 369 2.9 (1.7-5) 594 
It is not available/my suppliers do not have it in stock 13.6 (6.1-27.5) 249 15.7 (12-20.2) 1,064 15.3 (11.8-19.5) 1,313 6.9 (4.5-10.4) 224 9.9 (7.3-13.4) 369 9.5 (7.2-12.5) 593 
My customers do not ask for it 29.3 (22.3-37.5) 249 25.1 (18.8-32.6) 1,064 26.0 (20.7-32) 1,313 22.8 (16.3-31.0) 225 20.3 (14.9-27.2) 369 20.7 (15.8-26.6) 594 
I don’t know about these drugs 12.9 (7.6-21.2) 249 17.1 (13.1-22) 1,063 16.2 (12.6-20.7) 1,312 4.9 (3.2-7.5) 225 6.2 (3.5-10.9) 369 6.1 (3.6-10.0) 594 
I am temporarily out of stock 1.5 (0.6-3.7) 249 2.2 (1.4-3.4) 1,064 2.0 (1.4-3) 1,313 22.3 (16.7-29.0) 225 21.9 (17.7-26.8) 369 22.0 (18.2-26.2) 594 
I am not responsible for stocking 4.0 (1.1-13.2) 249 2.4 (1.4-4.1) 1,063 2.8 (1.6-4.7) 1,312 19.5 (15.7-23.9) 225 11.1 (6.7-18.0) 369 12.3 (8.2-18) 594 
New outlet  0.6 (0.1-3.9) 249 1 (0.5-1.9) 1,063 0.9 (0.5-1.7) 1,312 2.1 (1.2-3.9) 225 3.4 (1.4-7.8) 369 3.2 (1.5-6.9) 594 
Customers can get it for free in public facilities 0.9 (0.1-5.6) 249 1.2 (0.6-2.3) 1,063 1.1 (0.6-2.1) 1,312 5.7 (3.9-8.4) 225 9.1 (5.8-14.0) 369 8.6 (5.7-12.8) 594 
Other 2.6 (2-3.4) 249 0.3 (0.1-1) 1,063 0.8 (0.4-1.6) 1,312 0.4 (0.1-3.1) 225 1.3 (0.5-3.5) 369 1.2 (0.5-3.0) 594 
Zanzibar             
Too expensive 29.3 123 17.5 40 26.4 163 11.6 43 7.7 13 10.7 56 
Not profitable 5.7 123 12.5 40 7.4 163 9.3 43 0.0 13 7.1 56 
Not allowed to sell 32.5 123 42.5 40 35.0 163 9.3 43 23.1 13 12.5 56 
Too many side effects 1.6 123 2.5 40 1.8 163 4.7 43 0.0 13 3.6 56 
Does not work well 10.6 123 10.0 40 10.4 163 7.0 43 7.7 13 7.1 56 
Not available 16.3 123 12.5 40 15.3 163 23.3 43 7.7 13 19.6 56 
Customers do not ask 17.1 123 20.0 40 17.8 163 32.6 43 23.1 13 30.4 56 
Don’t know about QAACTs 0.8 123 0.0 40 0.6 163 9.3 43 15.4 13 10.7 56 
Temporarily out of stock 4.9 123 5.0 40 4.9 163 11.6 43 15.4 13 12.5 56 
Avilable for free in PHF 2.4 123 2.5 40 2.5 163 4.7 43 0.0 13 3.6 56 
Other 5.7 123 2.5 40 4.9 163 16.3 43 7.7 13 14.3 56 
Note: A provider could give more than one response to this question. Percentages may add to more than 100 because more than one reason can be given. This indicator excludes responses from public health facilities and CHWs. These data are not available 
for Madagascar and Nigeria at baseline, as they were not collected in the ACTwatch questionnaire. Nigeria baseline data collection was conducted in 2009. 
CI = Confidence interval 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys    
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2.6 AMFm logo, recommended retail price and provider training 
 
Table 2.6.1 shows the percentage of providers who recognized the AMFm green leaf logo when 
it was shown to them. This question was included at baseline, both to measure the effect of any 
early promotion activities in those countries where small numbers of copaid drugs arrived before 
the completion of baseline data collection, and also as a measure of "noise" arising from yea-
saying bias among respondents. As would be expected at baseline, recognition was low, at 2% in 
Niger, 7% in Ghana, 9% in Tanzania mainland and Zanzibar, and 12% in Uganda. However, in 
Kenya, recognition was somewhat higher, at 19%, reflecting the fact that the baseline survey 
took place after the initial launch activities and the arrival of the first copaid drugs in Kenya. The 
relatively high level of recognition in Uganda could have reflected the Consortium for ACT 
Private Sector Subsidy (CAPSS) project which had been implemented for several years in a 
limited number of districts. This project used a green leaf logo very similar to the AMFm logo. 
Baseline data for this indicator were not collected in Madagascar and Nigeria. 
 
At endline, logo recognition had increased substantially in all countries from baseline. 
Recognition was highest in Tanzania mainland (87%), Ghana and Zanzibar (both 93%), and 
lowest in Niger (30%) and Madagascar (31%). Recognition of the logo was higher in urban than 
rural areas in Ghana, Madagascar, Niger and Zanzibar.  
 
For those providers that recognized the logo, Table 2.6.2 shows their views on its meaning 
(multiple responses were allowed). The most common meaning in Ghana, Kenya, Madagascar, 
Niger and Zanzibar was “effective/quality antimalarial.” In Nigeria, Tanzania mainland and 
Uganda, the most common meaning was “ACT.” Other common meanings were “affordable 
antimalarial” and “antimalarial.” The percentage that did not know what it meant varied from 9% 
in Ghana to 31% in Niger.  
 
Table 2.6.3 shows the sources from which providers had seen or heard of the AMFm logo. The 
most common source was TV/radio in Ghana, Kenya, Madagascar and Zanzibar; and on malaria 
medicine packaging in Niger, Nigeria, Tanzania mainland and Uganda. TV/ radio was a more 
common source in urban than in rural areas in Ghana only.  
 
Table 2.6.4 shows the percentage of QAACTs audited bearing the AMFm logo. At baseline, in 
all countries other than Kenya, less than 1% of QAACTs had the logo, as expected as no or very 
few copaid ACTs had been released into the market at that time. It is possible that some of the 
logo observations seen were recorded in error. In Kenya, 11% of QAACTs carried the logo at 
baseline, rising to 28% in private for-profit outlets. This reflects the timing of the baseline 
survey, which followed the initial launch and arrival of the first copaid drugs (see Section **). At 
endline, the percentage of QAACTs bearing the logo was substantial in all countries, ranging 
194 
 
from 50% in Madagascar to 96% in Zanzibar. The percentage of QAACTs bearing the logo was 
higher in urban areas than rural areas in Kenya, Madagascar and Tanzania mainland. 
 
Table 2.6.5 shows the percentage of all antimalarials audited other than QAACTs that bore the 
AMFm logo. One would expect this to be extremely low as only QAACTs can be subsidized and 
thus officially be marked with the logo. In all countries, less than 2% of all antimalarials other 
than QAACTs bore the logo at baseline and endline. It is likely that some of these cases reflect 
interviewer error.  
 
Table 2.6.6 shows the percentage of respondents at endline that had heard of “the program that 
reduces the prices of antimalarial medicines known as ACTs.” In all countries, provider 
knowledge of the AMFm program was lower than recognition of the logo (Table 2.6.1), but 
followed a similar pattern, with knowledge being lowest in Niger (23%) and Madagascar (13%) 
and highest in Tanzania mainland (72%), Ghana (76%) and Zanzibar (69%). No differences were 
observed between urban and rural areas. 
 
Table 2.6.7 shows the sources from which providers had heard of the AMFm program. The most 
common source in all countries was TV/radio. Other sources commonly mentioned were in 
training, on malaria medicine packaging, in public health facilities and on posters/ billboards. 
TV/ radio was a more common source in rural than in urban areas in Uganda only. 
 
Recommended retail prices for copaid QAACTs were set in all countries except Madagascar. 
Table 2.6.8 shows that the percentage of respondents stating at that there was an RRP for 
QAACTs bearing the green leaf logo varied from 13% in Niger to 84% in Ghana. Knowledge of 
the RRP was higher in urban areas than in rural areas in Ghana, Niger and Zanzibar. Knowledge 
of the RRP was higher in public health facilities than in private for-profit outlets in Madagascar 
and Niger, but higher in private for-profit outlets in Nigeria. 
 
Of those respondents that knew there was an RRP for QAACTs bearing the green leaf logo, 
Table 2.6.9 shows that the percentage stating the correct RRP for an adult dose was over 90% in 
Ghana, Kenya and Zanzibar. It was also quite high in Tanzania mainland (82%) and Niger 
(61%), but much lower in Nigeria (11%) and Uganda (5%). The percentage stating the correct 
response was higher in urban areas in Ghana only. It was higher in public health facilities than in 
private for-profit outlets in Niger, but higher in private for-profit outlets in Nigeria.  
 
Table 2.6.10 shows the percentage of outlets with at least one staff member that had received 
training on antimalarials with the AMFm logo at endline. This ranged from 6% in Madagascar to 
52% in Ghana. Training coverage figures were similar across the public and private for-profit 
sectors except in Madagascar, where public sector training coverage was higher. There were no 
rural/urban differences except in Zanzibar, where coverage was lower in urban areas (33%) than 
in rural areas (46%). 
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Table 2.6.1: Provider recognition of AMFm logo, at baseline (2010) and endline (2011) 
Providers able to recognize AMFm logo (n) as a percentage of the number of outlets with antimalarials in stock at the time of the survey visit (N), by urban-rural location and type of outlet, according 
to country 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
% (95 % CI)  N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N 
Ghana - Total 7.5 (5.5-10.1) 599 7.4 (5.0-10.9) 542 7.4 (5.4-10.2) 1141 97.3 (95.0-98.6) 572 87.3 (80.3-92.1) 380 93.4 (90.2-95.6) 952 
Public health facility  9.8 (5.6-16.7) 67 10.6 (6.8-16.0) 135 10.5 (7.1-15.2) 202 98.9 (94.5-99.8) 94 96.4 (93.5-98) 202 97.1 (95.0-98.4) 296 
Private not-for-profit health facility 36.3 (9.4-75.7) 5 13.8 (2.5-50.3) 9 17.7 (5.2-45.6) 14 100.0 4 100.0 9 100.0 13 
Private for-profit outlet             
   Health facility/pharmacy 9.7 (6.9-13.6) 314 13.3 (7.2-23.1) 62 11.1 (7.9-15.3) 376 100.0 270 100.0 26 100.0 296 
   Drug store 4.3 (2.6-6.9) 211 6.6 (4.3-10.2) 330 6.3.0 (4.2-9.4) 541 96.6 (93.3-98.3) 201 83.0 (74.1-89.3) 140 91.3 (87.0-94.2) 341 
   General retailer/itinerant 0.0 2 0.0 3 0.0 5 64.5 (20.5-92.8) 3 66.3 (36.4-87.2) 3 65.4 (37.3-85.7) 6 
   Total 6.8 (5.0-9.1) 527 7.0 (4.7-10.4) 395 7.0 (5.1-9.6) 922 97.2 (94.7-98.5) 474 84.0 (75.2-90.1) 169 92.7 (89.0-95.2) 643 
Community health worker - 0 - 3 - 3 - 0 - 0 - 0 
Kenya - Total 29.5 (24-35.6) 1,032 16.0 (12.1-20.8) 875 19.2 (15.5-23.5) 1,907 84.2 (77.9-89) 1048 73.8 (65.0-81.0) 800 76.7 (70.2-82.2) 1,848 
Public health facility  19.2 (12.4-28.5) 136 16.9 (11.6-23.9) 257 17.4 (12.9-23.0) 393 84.4 (73-91.5) 137 79.8 (68.2-87.9) 293 80.1 (69.4-87.7) 430 
Private not-for-profit health facility 31.0 (15.1-53.3) 23 6.1 (1.3-24.8) 15 13.3 (5.8-27.5) 38 73.0 (37.7-92.4) 19 60.6 (42.7-76.1) 27 63.1 (47.1-76.6) 46 
Private for-profit outlet             
   Health facility/pharmacy 46.4 (34.5-58.7) 362 43.7 (29.2-59.4) 103 44.9 (35.1-55.1) 465 92.2 (88.9-94.6) 408 90.0 (83.0-94.4) 113 90.9 (86.6-93.9) 521 
   Drug store 34.5 (27.2-42.8) 271 16.1 (8.2-29.2) 156 20.2 (11.7-32.5) 427 97.9 (95.1-99.1) 329 95.6 (90.0-98.2) 145 96.5 (93.4-98.2) 474 
   General retailer/itinerant 10.3 (6.4-16.1) 236 9.2 (6.7-12.6) 323 9.4 (7.2-12.3) 559 45.3 (36.9-54) 155 50.0 (38.4-61.5) 222 49.1 (39.5-58.8) 377 
   Total 30.7 (24.1-38.1) 869 16.5 (11.9-22.4) 582 20.0 (15.6-25.3) 1,451 84.5 (78.0-89.4) 892 73.4 (62.8-81.9) 480 76.9 (69.4-83.0) 1,372 
Community health worker 16.1 (2.6-58.1) 4 9.8 (4-22.2) 21 10.0 (4.2-21.8) 25 - 0 - 0 - 0 
Madagascar - Total       49.8 (44.1-55.5) 982 34.4 (29.4-39.8) 1,388 36.5 (32.0-41.3) 2,370 
Public health facility  - - - - - - 89.5 (79.4-95.0) 65 76.1 (70.4-81.0) 553 77.6 (72.4-82.0) 618 
Private not-for-profit health facility - - - - - - 83.8 (46.7-96.8) 26 71.0 (26.0-94.5) 5 76.0 (44.2-92.7) 31 
Private for-profit outlet             
   Health facility/pharmacy - - - - - - 96.4 (93.5-98.1) 105 50.5 (24.3-76.4) 12 75.6 (54.9-88.8) 117 
   Drug store - - - - - - 96.8 (89.4-99.1) 28 70.5 (62.1-77.8) 347 73.3 (65.4-80.0) 375 
   General retailer/itinerant - - - - - - 30.1 (24.0-36.9) 743 23.6 (18.4-29.9) 405 24.5 (19.9-29.9) 1,148 
   Total - - - - - - 43.7 (38.4-49.1) 876 28.2 (23.4-33.6) 764 30.5 (26.2-35.2) 1,640 
Community health worker - - - - - - 92.4 (66.8-98.7) 15 33.2 (20.2-49.4) 66 34.6 (21.4-50.7) 81 
Niger - Total 2.6 (1.5-4.4) 833 1.3 (0.7-2.2) 1,198 1.5 (1-2.3) 2,031 39.6 (35.0-44.4) 924 26.8 (23.6-30.3) 738 30.3 (27.6-33.1) 1,662 
Public health facility  11.5 (5.5-22.8) 91 2.3 (1.3-4.1) 385 3.2 (2-5.1) 476 90.4 (80.8-95.5) 102 72.7 (66.5-78.1) 220 75.2 (69.9-79.8) 322 
Private not-for-profit health facility 0.0 4  0 0.0 4 100.0 2 100.0 1 100.0 3 
Private for-profit outlet             
   Health facility/pharmacy 7.2 (2.3-20.8) 106 3.6 (0.3-29.9) 12 6.7 (2.3-18.4) 118 86.8 (79.3-91.8) 95 100.0 4 87.5 (80.4-92.3) 99 
   Drug store 0.0 14 0.0 7 0.0 21 96.5 (87.3-99.1) 15 30.7 (5.6-77.0) 3 59.9 (30.0-83.9) 18 
   General retailer/itinerant 2.0 (1.0-3.9) 617 1.2 (0.6-2.2) 792 1.3. (0.8-2.2) 1,409 33.3 (27.9-39.1) 710 20.9 (17.3-25.0) 510 24.3 (21.3-27.6) 1,220 
   Total 2.2 (1.2-4.1) 737 1.2 (0.6-2.2) 811 1.4 (0.9-2.2) 1,548 36.9 (32.1-42.1) 820 21.1 (17.6-25.1) 517 25.6 (22.7-28.8) 1,337 
Community health worker 0.0 1 0.0 2 0.0 3 - 0 - 0 - 0 
Nigeria - Total       54.1 (42.8-64.9) 1,032 50.8 (43.0-58.5) 472 52.8 (45.4-60.0) 1,504 
Public health facility  - - - - - - 62.2 (32.0-85.2) 43 44.6 (26.9-63.8) 52 50.3 (34.7-65.7) 95 
Private not-for-profit health facility - - - - - - 100.0 6 53.2 (7.4-94.1) 3 82.4 (34.3-97.7) 9 
Private for-profit outlet             
   Health facility/pharmacy - - - - - - 77.7 (66.1-86.1) 99 59.6 (44.6-72.9) 32 71.1 (61.5-79.1) 131 
   Drug store - - - - - - 52.0 (38.7-65.0) 807 52.0 (43.0-60.9) 362 52.0 (43.0-60.9) 1,169 
   General retailer/itinerant - - - - - - 35.3 (17.8-58.0) 74 15.4 (5.4-36.6) 19 30.3 (16.6-48.8) 93 
   Total - - - - - - 53.3 (41.9-64.5) 980 51.3 (42.8-59.8) 413 52.6 (44.8-60.3) 1,393 
Community health worker - - - - - - 33.3 (33.3-33.3) 3 73.6 (21.7-96.5) 4 72.0 (21.7-96.0) 7 
Tanzania - mainland - Total 15.3 (10.9-21.0) 322 7.3 (4.8-11.1) 305 9.1 (6.7-12.2) 627 90.8 (86.5-93.8) 596 84.1 (75.3-90.2) 191 86.6 (80.9-90.8) 787 
Public health facility  0.0 5 6.1 (2.3-15.3) 56 5.7 (2.1-14.3) 61 100.0 7 84.7 (66.4-94.0) 48 85.4 (67.8-94.2) 55 
Private not-for-profit health facility 18.5 (5.9-45.4) 6 13.8 (3.1-44.6) 17 14.7 (4.5-38.8) 23 75.2 (22.9-96.9) 4 100.0 2 86.8 (42.3-98.3) 6 
Private for-profit outlet             
   Health facility/pharmacy 22.1 (11.2-39.0) 222 0.0 12 18.1 (9.1-32.6) 234 91.7 (75.9-97.5) 321 44.7 (12.1-82.7) 16 79.5 (55.5-92.4) 337 
   Drug store 14.9 (10.4-20.8) 88 12.3 (7.5-19.7) 149 13.2 (9.4-18.2) 237 90.5 (85.0-94.2) 259 87.3 (75.0-94.0) 113 88.7 (81.8-93.2) 372 
   General retailer/itinerant 0.0 1 0.0 70 0.0 71 100.0 5 70.0 (31.0-92.4) 12 72.7 (37.4-92.2) 17 
   Total 16.0 (11.5-21.9) 311 7.1 (4.1-12.1) 231 9.5 (6.7-13.3) 542 90.8 (86.5-93.9) 585 83.7 (73.0-90.7) 141 86.9 (80.7-91.3) 726 
Community health worker - 0 0.0 1 0.0 1 - 0 - 0 - 0 
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Table 2.6.1: Cont. 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
% (95 %I)  N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N 
 Uganda - Total 17.1 (9.6-28.6) 544 10.4 (6.7-15.9) 1,876 11.8 (8.1-16.8) 2,420 70.6 (61.4-78.3) 1411 64.6 (55.6-72.6) 1,713 65.8 (58.2-72.6) 3,124 
Public health facility  9.3 (5.0-16.6) 76 6.1 (4.3-8.5) 693 6.4 (4.7-8.7) 769 67.5 (51.0-80.6) 144 73.7 (65.5-80.5) 531 72.8 (65.5-79.0) 675 
Private not-for-profit health facility 20.8 (3.9-63.0) 4 13.2 (2.5-47.1) 27 14.3 (3.6-42.7) 31 81.7 (48.3-95.5) 13 44.9 (24.8-66.9) 28 49.0 (29.4-68.9) 41 
Private for-profit outlet             
   Health facility/pharmacy 24.2 (19.8-29.1) 389 20.9 (13-31.7) 356 22.5 (17.7-28.2) 745 74.4 (69.6-78.6) 814 76.2 (70.7-81) 385 75.4 (72..0-78.5) 1,199 
   Drug store 8.9 (4.4-17.0) 72 8.9 (5.8-13.5) 752 8.9 (6.1-12.9) 824 66.5 (52.8-78.0) 435 67.8 (57.8-76.4) 673 67.6 (58.9-75.2) 1,108 
   General retailer/itinerant 0.0 2 8.8 (1.7-35.3) 19 7.6 (1.4-32.3) 21 0.0 3 3.5 (0.4-25.4) 14 3.4 (0.4-24.3) 17 
   Total 17.5 (9.9-29) 463 11.1 (6.9-17.3) 1,127 12.5 (8.6-18) 1,590 70.7 (61.2-78.8) 1,252 67.9 (59.8-75) 1,072 68.6 (61.9-74.5) 2,324 
Community health worker 0.0 1 8.1 (3.3-18.7) 29 7.9 (3.3-17.9) 30 0.0 2 38.6 (19.2-62.4) 82 38.4 (19.2-62.2) 84 
Zanzibar - Total 10.6 189 6.5 124 8.9 313 96.4 222 85.8 120 92.7 342 
Public health facility  7.1 56 4.8 83 5.8 139 100.0 48 84.2 76 90.3 124 
Private not-for-profit health facility 50.0 2 100.0 1 66.7 3 100.0 1 100.0 1 100.0 2 
Private for-profit outlet             
   Health facility/pharmacy 9.6 73 18.2 11 10.7 84 98.8 82 93.8 16 98.0 98 
   Drug store 14.0 57 4.0 25 11.0 82 94.3 88 87.5 24 92.9 112 
   General retailer/itinerant 0.0 1 0.0 4 0.0 5 33.3 3 66.7 3 50.0 6 
   Total 11.5 131 7.5 40 10.5 171 95.4 173 88.4 43 94.0 216 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Note: All respondents were shown a visual aid depicting the AMFm logo and were asked whether they have seen the symbol before. Providers are “able to recognize the AMFm logo” if they answer that they have seen the 
symbol before. These data are not available for Madagascar and Nigeria at baseline, as they were not collected in the ACTwatch questionnaire. Nigeria baseline data collection was conducted in 2009. 
CI: Confidence interval 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.6.2: Provider knowledge of the meaning of the AMFm logo at endline, 2011 
Providers stating a specific meaning of the AMFm logo (n) as a percentage of outlets that recognized the AMFm logo (N), , by 
urban-rural location and type of outlet, according to country 
 Urban Rural Total 
Country/Meaning of AMFm logo % (95% CI) N % (95% CI) N % (95% CI) N 
Ghana       
Effective/quality antimalarial 64.2 (54.4-73.0) 559 58.8 (47.1-69.7) 345 62.2 (54.7-69.3) 904 
Affordable antimalarial 58.3 (50.7-65.6) 559 35.1 (26.2-45.2) 345 49.8 (43.5-56.2) 904 
An antimalarial in high demand 14.5 (10.1-20.4) 559 9.1 (4.7-17) 345 12.6 (9.1-17.1) 904 
Effective/quality medicine 4.7 (2.6-8.2) 559 8.5 (4.1-16.7) 345 6.1 (3.8-9.6) 904 
Affordable medicine 4.1 (2.0-8.3) 559 2.5 (0.5-11.9) 345 3.5 (1.8-6.9) 904 
I don’t know what it means 6.9 (4.5-10.3) 559 13.1 (7.9-20.9) 345 9.1 (6.6-12.5) 904 
Other 15.3 (10.7-21.5) 559 21.7 (15.0-30.5) 345 17.7 (13.6-22.6) 904 
Kenya       
Effective/quality antimalarial 28.2 (23.0-34.0) 921 28.7 (22.6-35.6) 618 28.5 (23.9-33.6) 1,539 
Affordable antimalarial 19.1 (13.7-26) 921 14.0 (7.7-24.0) 618 15.6 (10.7-22.1) 1,539 
An antimalarial in high demand 2.0 (1.1-3.6) 921 4.3 (2.4-7.5) 618 3.6 (2.2-5.9) 1,539 
Effective/quality medicine 4.9 (2.8-8.5) 921 6.8 (4.7-9.9) 618 6.2 (4.5-8.6) 1,539 
Affordable medicine 6.5 (4.8-8.7) 921 3.2 (1.2-8.3) 618 4.2 (2.5-6.9) 1,539 
Artemisinin Combined Therapy (ACT) 28.3 (24.8-32.1) 921 23.1 (19.2-27.6) 618 24.7 (21.7-28) 1,539 
Recommended treatment 8.8 (6.5-11.7) 921 5.0 (3.1-8.0) 618 6.2 (4.6-8.3) 1,539 
Subsidized medicine 7.1 (5.6-9.0) 921 3.5 (0.9-12.6) 618 4.7 (2.3-9.0) 1,539 
I don’t know what it means 20.9 (17-25.4) 921 27.0 (22.1-32.5) 618 25.1 (21.6-29.1) 1,539 
Other meaning: Herbal medicine/environment 3.6 (2.2-5.9) 921 7.7 (4.8-12.2) 618 6.4 (4.3-9.5) 1,539 
Other meaning: Antimalarial 4.7 (2.9-7.4) 921 6.6 (4.1-10.6) 618 6.0 (4.1-8.9) 1,539 
Other meaning: Other 6.6 (4.9-8.8) 921 7.8 (5.2-11.5) 618 7.4 (5.5-9.9) 1,539 
Madagascar       
Effective/quality antimalarial 36.9 (28.2-46.5) 418 33.0 (23.8-43.6) 785 33.7 (25.9-42.4) 1,203 
Affordable antimalarial 13.5 (9.6-18.8) 418 6.1 (3.6-10.0) 785 7.4 (5.1-10.8) 1,203 
Effective/quality medicine 4.9 (3.1-7.7) 418 7 (3.6-13.4) 785 6.7 (3.7-11.7) 1,203 
It means nothing 5.8 (3.3-10.2) 418 3.9 (1.9-7.9) 785 4.3 (2.4-7.3) 1,203 
I don't know what it means 18.5 (13.1-25.5) 418 21.6 (16.0-28.6) 785 21.0 (16.2-26.8) 1,203 
Other meaning: Antimalarial 7.5 (3.7-14.6) 418 11.0 (6.6-17.8) 785 10.4 (6.6-15.9) 1,203 
Other meaning: Medicine from a plant 4.8 (2.8-8) 418 6.7 (4.0-11.0) 785 6.3 (4.1-9.8) 1,203 
Other meaning: Antimalarials/ACT from a plant 5.6 (3.5-8.7) 418 5.1 (3.0-8.6) 785 5.2 (3.4-8.0) 1,203 
Other meaning: Malaria 1.5 (0.6-3.9) 418 3.3 (1.7-6.3) 785 3.0 (1.7-5.4) 1,203 
Other meaning: "Green"/ "Plant"/"Health"/"Environment" 4.1 (2.2-7.4) 418 3.4 (1.8-6.3) 785 3.5 (2.1-5.9) 1,203 
Other meaning: Other 12.3 (9.1-16.5) 418 6.5 (4.4-9.6) 785 7.6 (5.6-10.2) 1,203 
Niger        
Effective/quality antimalarial 40.3 (32.6-48.6) 414 44.3 (35.3-53.7) 262 42.9 (36.4-49.6) 676 
Affordable antimalarial 18.1 (13.9-23.2) 414 15.2 (10.8-21.0) 262 16.3 (12.9-20.3) 676 
An antimalarial in high demand 9.9 (7.9-12.3) 414 10.0 (6.3-15.6) 262 10.0 (7.3-13.5) 676 
Effective/quality medicine 7.6 (5.2-10.9) 414 4.8 (2.4-9.7) 262 5.8 (3.8-8.8) 676 
Affordable medicine 5.1 (3.5-7.3) 414 2.7 (1.4-5.2) 262 3.5 (2.4-5.1) 676 
I don’t know what it means 32.5 (28.3-37.1) 414 30.5 (25.0-36.5) 262 31.2 (27.3-35.4) 676 
Other 6.1 (5.1-7.3) 414 4.7 (3.4-6.4) 262 5.1 (4.1-6.3) 676 
Nigeria       
Effective/quality antimalarial 20.8 (15.3-27.5) 589 26.7 (19.4-35.5) 234 23.0 (18.3-28.6) 823 
Affordable antimalarial 5.5 (3.8-8.1) 589 3.4 (1.4-7.7) 233 4.7 (3.3-6.8) 822 
An antimalarial in high demand 3.1 (1.6-5.8) 589 2.8 (1.0-7.2) 234 3.0 (1.7-5.1) 823 
Effective/quality medicine 4.3 (2.6-7.1) 589 6.7 (4.0-10.8) 234 5.2 (3.6-7.5) 823 
It means nothing 3.1 (1.4-7.0) 589 2.4 (0.9-6.7) 234 2.9 (1.5-5.4) 823 
Artemisinin Combination Therapy 33.3 (25.5-42.2) 589 22.6 (15.4-31.8) 233 29.3 (23.3-36.0) 822 
An antimalarial 4.4 (1.4-12.9) 589 1.5 (0.7-3.3) 234 5.9 (2.6-13.1) 823 
Logo or trademark 2.3 (1.3-4.0) 589 0.8 (0.3-1.9) 234 3.1 (2.0-4.9) 823 
Other 15.6 (10.6-22.2) 589 6.8 (4.2-10.9) 234 22.4 (17.9-27.6) 823 
Tanzania – mainland       
 Effective/quality antimalarial 29.2 (21.6-38.2) 563 17.7 (12.0-25.3) 164 22.1 (16.8-28.6) 727 
 Affordable antimalarial 21.2 (15.5-28.3) 563 22.6 (15.6-31.6) 164 22.1 (17.1-28.1) 727 
An antimalarial in high demand 16.4 (10.1-25.5) 563 12.1 (6.9-20.5) 164 13.8 (9.3-19.9) 727 
Effective/quality medicine 12.2 (8.6-17.2) 563 12.0 (7.0-19.8) 164 12.1 (8.5-17) 727 
Affordable medicine 11.4 (7.4-17.3) 563 13.6 (9.6-18.8) 164 12.8 (9.7-16.6) 727 
A medicine in high demand 5.3 (3.2-8.7) 563 0.4 (0.1-2.7) 164 2.3 (1.2-4.3) 727 
Artemisinin combination therapy  50.2 (38.4-61.9) 563 56.4 (46.7-65.5) 164 54.0 (46.2-61.6) 727 
Medicinal plant 13.3 (9.9-17.7) 563 6.6 (4.1-10.4) 164 9.1 (6.7-12.4) 727 
I don’t know what it means 9.4 (5.7-15.1) 563 11.7 (6.6-19.8) 164 10.8 (7.1-16) 727 
Other 4.8 (2.8-7.9) 563 5.6 (2.7-11.1) 164 5.3 (3.2-8.6) 727 
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Table 2.6.2: Cont. 
 Urban Rural Total 
Country/Meaning of AMFm logo % (95% CI) N % (95% CI) N % (95% CI) N 
Uganda       
Effective/quality antimalarial 13.7 (11.1-16.7) 1,045 9.7 (6.5-14.2) 1,209 10.6 (7.8-14.2) 2,254 
Affordable antimalarial 5.5 (4.0-7.4) 1,046 2.1 (1.1-3.9) 1,211 2.8 (1.7-4.6) 2,257 
Effective/quality medicine 3.0 (2.1-4.5) 1,046 1.9 (1.0-3.8) 1,211 2.2 (1.3-3.7) 2,257 
A drug / medicine 8.6 (6.4-11.5) 1,044 5.9 (4.5-7.6) 1,211 6.5 (5.2-8.1) 2,255 
An antimalarial 33.7 (29.5-38.2) 1,044 33.1 (24.9-42.4) 1,210 33.2 (26.6-40.5) 2,254 
An ACT  91.3 (89.4-92.9) 1,047 88.8 (83.8-92.5) 1,214 89.4 (85.5-92.3) 2,261 
Herbal medicine 15.7 (12.7-19.4) 1,045 14.1 (11.1-17.9) 1,210 14.5 (11.9-17.5) 2,255 
Subsidized medicine 3.7 (2.7-5.1) 1,045 1.3 (0.7-2.4) 1,210 1.8 (1.1-2.9) 2,255 
I don’t know what it means 22.5 (20.4-24.8) 1,043 27.3 (23.8-31) 1,211 26.2 (23.3-29.4) 2,254 
Trademark/Logo/Symbol 2.4 (1.9-3.1) 1,047 3.1 (2.0-4.9) 1,214 2.9 (2.0-4.3) 2,261 
Others 12.0 (9.6-15.0) 1,047 9.6 (7.5-12.1) 1,214 10.1 (8.2-12.3) 2,261 
Zanzibar       
Effective/quality antimalarial 44.9 214 54.4 103 47.9 317 
Affordable antimalarial 18.2 214 15.5 103 17.4 317 
An antimalarial in high demand 23.4 214 23.3 103 23.3 317 
Effective/quality medicine 29.0 214 34.0 103 30.6 317 
Affordable medicine 11.7 214 7.8 103 10.4 317 
High demand medicine 10.3 214 10.7 103 10.4 317 
ACT 45.3 214 34.0 103 41.6 317 
Recommended treatment 10.7 214 10.7 103 10.7 317 
Subsidized medicine 12.1 214 9.7 103 11.4 317 
Environmental/herbal medicine product 5.6 214 3.9 103 5.0 317 
I don’t know what it means 14.5 214 9.7 103 12.9 317 
Other 5.6 214 4.9 103 5.4 317 
Note: Providers could give more than one response to this question. Percentages may add to more than 100. 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.6.3: Sources from which providers have seen or heard of the AMFm logo at endline, 2011 
Providers stating a specific source where they have seen or heard of the AMFm logo (n) as a percentage of providers that 
recognized the AMFm logo (N), by urban-rural location and type of source specified, according to country 
 Urban Rural Total 
Country/Source % (95% CI) N % (95% CI) N % (95% CI) N 
Ghana       
On malaria medicine packaging 58.9 (48.7-68.4) 563 65.8 (56.3-74.3) 349 61.4 (54.1-68.2) 912 
On medicine packaging 20.4 (15.3-26.5) 563 4.7 (2.1-9.9) 349 14.6 (11.0-19.2) 912 
On posters 9.4 (6.9-12.7) 563 11.0 (7.8-15.1) 349 10.0 (7.9-12.5) 912 
On TV/radio 83.7 (78-88.1) 563 69.0 (60.4-76.4) 349 78.3 (73.5-82.4) 912 
In newspapers/magazines 4.5 (3.1-6.4) 563 1.5 (0.7-3.6) 349 3.4 (2.4-4.8) 912 
In pharmacies/ drug shops 26.5 (22.0-31.6) 563 20.5 (15.6-26.6) 349 24.3 (20.9-28.1) 912 
In public health facilities 11.2 (8.5-14.5) 563 14.2 (10.1-19.7) 349 12.3 (10.0-15.1) 912 
In training 29.2 (22.3-37.2) 563 45.1 (36.8-53.6) 349 35.0 (29.4-41.1) 912 
From a supplier 12.4 (9.3-16.3) 563 7.4 (4.6-11.7) 349 10.6 (8.3-13.4) 912 
Other 9.2 (7.1-11.8) 563 9.4 (6.0-14.4) 349 9.2 (7.3-11.6) 912 
Kenya       
On malaria medicine packaging 56.7 (49.9-63.2) 921 51.0 (42.4-59.6) 618 52.8 (46.5-58.9) 1,539 
On medicine packaging 27.3 (19.7-36.4) 921 23.1 (18.8-28.0) 618 24.4 (20.6-28.6) 1,539 
On posters 13.7 (10.0-18.4) 921 14.6 (8.4-24.1) 618 14.3 (9.6-20.8) 1,539 
On TV/radio 70.8 (65.5-75.6) 921 65.6 (58.8-71.8) 618 67.2 (62.2-71.8) 1,539 
In newspapers/magazines 6.4 (4.8-8.6) 921 6.6 (4.2-10.3) 618 6.6 (4.8-9.0) 1,539 
In pharmacies/ drug shops 16.2 (12.8-20.2) 921 21.4 (15.3-29.1) 618 19.8 (15.2-25.4) 1,539 
In private clinics 3.7 (2.3-5.9) 921 6.9 (3.7-12.4) 618 5.9 (3.5-9.9) 1,539 
In public health facilities 11.2 (7.9-15.7) 921 16.7 (11.4-23.8) 618 15.0 (10.9-20.3) 1,539 
In training 6.2 (4.3-8.8) 921 5.5 (3.6-8.4) 618 5.7 (4.2-7.7) 1,539 
From a supplier 6.2 (3.9-9.8) 921 1.7 (0.9-3.2) 618 3.1 (2.0-4.8) 1,539 
From a public event 1.9 (1.0-3.6) 921 3.8 (1.7-8.1) 618 3.2 (1.6-6.2) 1,539 
Other 8.5 (6.3-11.5) 921 9.6 (7-12.9) 618 9.2 (7.3-11.6) 1,539 
Madagascar       
On malaria medicine packaging 31.2 (25.2-37.9) 418 20.3 (15.4-26.4) 785 22.3 (17.9-27.5) 1,203 
On medicine packaging 10.4 (5.3-19.6) 418 3.9 (2.1-7.4) 785 5.1 (3.1-8.4) 1,203 
On posters 17.6 (12.4-24.3) 418 15.8 (11.5-21.3) 785 16.1 (12.4-20.7) 1,203 
On billboards 6.1 (3.4-10.7) 418 4.6 (2.4-8.7) 785 4.9 (2.9-8.1) 1,203 
On TV/radio 55.2 (50.0-60.2) 418 45.5 (36.9-54.5) 785 47.3 (40.2-54.6) 1,203 
In newspapers/magazines 3.8 (2.2-6.3) 418 1.8 (1.1-3.2) 785 2.2 (1.5-3.3) 1,203 
In pharmacies/drug shops 9.5 (7.2-12.3) 418 10.7 (7.5-15.1) 785 10.5 (7.8-14) 1,203 
In public health facilities 6.9 (4.3-10.9) 418 12.5 (6.4-23.1) 785 11.5 (6.3-20.1) 1,203 
In training 12.7 (9.2-17.2) 418 15.0 (10.6-20.8) 785 14.6 (10.9-19.3) 1,203 
From a public event 3.9 (2.6-5.9) 418 3.4 (1.9-6.1) 785 3.5 (2.2-5.6) 1,203 
From a local leader 5.9 (4.1-8.5) 418 6 (3.4-10.5) 785 6.0 (3.7-9.5) 1,203 
On clothing 0.8 (0.3-2.1) 418 4.4 (2.6-7.4) 785 3.8 (2.3-6.1) 1,203 
Other source 8.7 (6.2-12.2) 418 9.6 (6.4-14.3) 785 9.5 (6.7-13.2) 1,203 
Niger       
On malaria medicine packaging 58.3 (52.7-63.7) 414 55.6 (49.2-61.9) 264 56.6 (52-61.1) 678 
On medicine packaging 13.2 (9.0-18.9) 415 10.9 (6.9-16.8) 264 11.7 (8.6-15.9) 679 
On posters 11.7 (8.8-15.2) 415 13.3 (9.5-18.3) 264 12.7 (10.0-16.0) 679 
On billboards 20.7 (15.6-26.9) 415 12.5 (8.0-19.0) 264 15.4 (11.8-19.9) 679 
On TV/radio 24.1 (18.4-30.9) 415 16.1 (11.1-22.7) 264 19.0 (14.9-23.7) 679 
In pharmacies/ drug shops 15.4 (11.7-20.0) 415 6.8 (4.9-9.4) 264 9.9 (8.0-12.1) 679 
In public health facilities 7.8 (6.0-10.2) 415 16.0 (11.0-22.7) 264 13.1 (9.7-17.5) 679 
In training 3.5 (2.4-5.0) 415 7.4 (5.0-10.7) 264 6.0 (4.4-8.1) 679 
From a supplier 4.2 (3.0-6.1) 415 2.9 (1.4-5.7) 264 3.3 (2.2-5) 679 
Don't know 3.3 (2.0-5.2) 415 2.8 (1.1-7.1) 264 3.0 (1.6-5.4) 679 
Other 14.1 (10.9-18.1) 415 3.1 (1.6-6.0) 264 7.0 (5.4-9.2) 679 
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Table 2.6.3: Cont. 
 Urban Rural Total 
Country/Type of outlet % (95% CI) N % (95% CI) N % (95% CI) N 
Nigeria       
On malaria medicine packaging 57.7 (48.1-66.8) 591 52.0 (45.6-58.3) 234 55.6 (49.3-61.7) 825 
On medicine packaging 22.0 (15.1-30.9) 591 23.1 (15.9-32.4) 234 22.4 (17.1-28.9) 825 
On posters 12.0 (9.6-14.7) 591 4.6 (2.1-9.8) 234 9.2 (7.0-12.1) 825 
On billboards 3.6 (1.8-7.4) 591 1.2 (0.5-2.8) 234 2.7 (1.5-5.0) 825 
On TV/radio 23.7 (16.7-32.5) 591 23.2 (15.8-32.8) 234 23.5 (18.2-29.9) 825 
On a prescription 4.7 (2.3-9.5) 591 2.5 (0.7-8.0) 234 3.9 (2.1-7.1) 825 
In newspapers/magazines 4.8 (2.8-8.2) 590 0.9 (0.2-3.1) 234 3.3 (2.0-5.6) 824 
In pharmacies/ drug shops 15.1 (10.0-22.3) 591 15.2 (10.1-22.3) 234 15.2 (11.3-20.1) 825 
In public health facilities 5.9 (4.1-8.5) 591 11.6 (6.4-20.1) 234 8.1 (5.6-11.5) 825 
In training 15.8 (12.5-19.9) 591 14.9 (9.7-22.3) 234 15.5 (12.4-19.1) 825 
Don’t know 3.1 (1.5-6.0) 591 1.2 (0.3-5.0) 234 2.4 (1.2-4.5) 825 
Other 10.1 (7.4-13.6) 591 15.1 (11.5-19.7) 234 12.0 (9.7-14.7) 825 
Tanzania-mainland       
On malaria medicine packaging 64.4 (58.6-69.9) 563 70.6 (61.2-78.5) 164 68.3 (62.2-73.8) 727 
On medicine packaging 31.6 (23.2-41.4) 563 17.3 (10.5-27.1) 164 22.8 (16.5-30.6) 727 
On posters 8.2 (6.0-11.3) 563 11.4 (6.3-19.8) 164 10.2 (6.7-15.2) 727 
On billboards 10.6 (7.0-15.6) 563 14.7 (10.3-20.6) 164 13.1 (9.9-17.2) 727 
On TV/radio 65.5 (58.4-72) 563 62.3 (49.3-73.7) 164 63.5 (55.1-71.2) 727 
On a prescription 7.9 (4.9-12.4) 563 9.8 (5.2-17.8) 164 9.1 (5.7-14.0) 727 
In newspapers/magazines 9.0 (6.2-12.8) 563 8.9 (4.4-17.1) 164 8.9 (5.7-13.7) 727 
In pharmacies/drug shops 12.2 (7.4-19.5) 563 11.3 (6.4-19.2) 164 11.7 (7.9-17.0) 727 
In private clinics 4.0 (2.0-8.1) 563 2.6 (0.7-8.5) 164 3.1 (1.5-6.4) 727 
In public health facilities 9.1 (5.5-14.7) 563 12.4 (7.4-19.9) 164 11.1 (7.6-15.9) 727 
In training 6.2 (3.7-10.1) 563 9.5 (4.3-19.7) 164 8.2 (4.6-14.3) 727 
Other 6.3 (4.0-9.8) 563 5.5 (3.2-9.4) 164 5.8 (4.0-8.4) 727 
Uganda       
On malaria medicine packaging 52.4 (47.7-57.1) 1,047 50.3 (44.7-56) 1,214 50.8 (46.3-55.3) 2,261 
On medicine packaging 21.2 (16.4-26.9) 1,046 13.0 (9.0-18.3) 1,213 14.8 (10.9-19.7) 2,259 
On posters 15.5 (13.0-18.4) 1,047 11.3 (7.5-16.6) 1,214 12.2 (9.0-16.4) 2,261 
On TV/radio 27.7 (24.5-31.1) 1,047 31.0 (22.4-41.2) 1,214 30.3 (23.5-38.1) 2,261 
In newspapers/magazines 4.8 (4.0-5.8) 1,047 2.6 (1.6-4.3) 1,213 3.1 (2.1-4.5) 2,260 
In pharmacies/drug shops 23.1 (20.1-26.4) 1,047 17.3 (13.4-22.1) 1,212 18.6 (15.2-22.5) 2,259 
In private clinics 7.7 (6.1-9.7) 1,047 9.2 (6.2-13.3) 1,212 8.9 (6.5-12.0) 2,259 
In public health facilities 13.9 (11.8-16.5) 1,046 23.0 (17.4-29.8) 1,214 21.0 (16.5-26.4) 2,260 
In training 6.4 (4.9-8.3) 1,047 7.8 (5.9-10.3) 1,213 7.5 (6.0-9.4) 2,260 
On a T-Shirt 3.9 (2.5-6.1) 1,046 3.7 (1.9-7.1) 1,213 3.8 (2.2-6.3) 2,259 
Don’t Know 3.7 (2.4-5.6) 1,047 1.8 (0.6-4.8) 1,213 2.2 (1.1-4.2) 2,260 
Other 10.0 (8.5-11.9) 1,047 10.2 (7.2-14.2) 1,214 10.2 (7.7-13.2) 2,261 
Zanzibar       
On malaria medicine packaging 68.7 214 52.4 103 63.4 317 
On medicine packaging 40.7 214 32.0 103 37.9 317 
On posters 33.2 214 24.3 103 30.3 317 
On billboards 26.6 214 24.3 103 25.9 317 
On TV/radio 81.3 214 75.7 103 79.5 317 
From a prescription 6.5 214 1.9 103 5.0 317 
In newspapers/magazines 15.4 214 16.5 103 15.8 317 
In pharmacies/drug shops 20.6 214 23.3 103 21.5 317 
In a private clinic 13.1 214 13.6 103 13.2 317 
In public health facilities 20.6 214 27.2 103 22.7 317 
In training 15.9 214 23.3 103 18.3 317 
From a supplier 5.1 214 1.0 103 3.8 317 
From a public event 2.8 214 5.8 103 3.8 317 
On a T-shirt/cap 1.9 214 4.9 103 2.8 317 
I don’t know 0.0 214 1 103 0.3 317 
Other 3.7 214 6.8 103 4.7 317 
Note: Providers could give more than one response to this question. Percentages may add to more than 100. 
CI = Confidence interval 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.6.4: Percentage of quality-assured ACTs bearing the AMFm logo, at baseline (2010) and endline (2011) 
Quality-assured ACTs bearing the AMFm logo (n) as a percentage of all quality-assured ACTs audited (N), by urban-rural location and type of outlet, according to country 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N 
Ghana - Total 0.2 (0.1-0.5) 756 0.6 (0.1-3.0) 376 0.4 (0.1-1.8) 1,132 90.8 (88.2-92.8) 1,563 94.3 (91.1-96.3) 568 91.8 (89.7-93.5) 2,131 
Public health facility  0.9 (0.2-3.6) 134 0.0 228 0.1 (0.0-0.6) 362 90.1 (83.0-94.4) 132 90.3 (81.8-95.0) 303 90.2 (84.3-94.0) 435 
Private not-for-profit health facility 0.0 7 0.0 6 0.0 13 100.0 12 91.6 (60.7-98.7) 12 96.6 (81.3-99.5) 24 
Private for-profit outlet             
   Health facility/pharmacy 0.1 (0.0-0.6) 539 0.0 55 0.1 (0.0-0.4) 594 81.6 (79.2-83.9) 1,024 92.3 (81.4-97) 69 82.7 (80.1-85.0) 1,093 
   Drug store 0.0 76 1.3 (0.3-6.2) 76 1 (0.2-5.1) 152 96.4 (94.5-97.7) 392 96.7 (92.4-98.6) 182 96.5 (94.8-97.7) 574 
   General retailer/itinerant - 0 - 0 - 0 100.0 3 50.8 (7.7-92.7) 2 80.3 (37.2-96.6) 5 
   Total 0.1 (0.0-0.4) 615 1.0 (0.2-5.2) 131 0.6 (0.1-2.8) 746 90.6 (87.9-92.7) 1,419 95.7 (91.8-97.7) 253 91.8 (89.5-93.6) 1,672 
Community health worker - 0 0.0 11 0.0 11 - 0 - 0 - 0 
Kenya - Total 23.9 (17.8-31.4) 1,029 6.1 (3.1-11.7) 1,020 11.2 (7.8-16.0) 2,049 89.4 (86.0-92.1) 2,048 69.8 (61.6-76.9) 1,619 75.7 (69.7-80.8) 3,667 
Public health facility  1.0 (0.3-4.0) 346 0.4 (0.1-0.9) 831 0.5 (0.2-1.0) 1,177 47.3 (36.6-58.2) 395 47.3 (32.9-62.2) 1,102 47.3 (33.7-61.4) 1,497 
Private not-for-profit health facility 4.7 (1.3-15.9) 49 0.0 41 1.1 (0.3-4.4) 90 45.8 (16.8-78.0) 41 36.9 (20.8-56.7) 81 38.4 (23.4-55.9) 122 
Private for-profit outlet             
   Health facility/pharmacy 32.0 (26.9-37.6) 403 25.5 (14.5-40.8) 85 29.4 (23.6-36.0) 488 94.2 (91.9-95.9) 852 91.5 (87.7-94.2) 177 92.6 (90.3-94.4) 1,029 
   Drug store 38.5 (28.7-49.3) 228 19.5 (5.2-51.5) 48 27.1 (12.9-48.4) 276 93.9 (90.9-95.9) 719 95.2 (89.2-97.9) 189 94.5 (91.6-96.5) 908 
   General retailer/itinerant - 0 - 0 - 0 100.0 41 97.5 (91.3-99.3) 70 97.8 (92.3-99.4) 111 
   Total 34.6 (28.4-41.4) 631 21.8 (9.1-43.6) 133 28.3 (18.9-39.9) 764 94.2 (92.3-95.6) 1,612 94.2 (91.4-96.2) 436 94.2 (92.5-95.5) 2,048 
Community health worker 40.5 (4.2-91.4) 3 0.0 15 0.8 (0.1-10.2) 18 - 0 - 0 - 0 
Madagascar - Total - - - - - - 64.0 (57.6-69.9) 874 46.5 (36.1-57.1) 2,403 50.3 (41.6-59.0) 3,277 
Public health facility  - - - - - - 55.3 (36.6-72.7) 201 52.8 (44.6-60.9) 1,789 53.1 (45.5-60.6) 1,990 
Private not-for-profit health facility - - - - - - 49.0 (34.5-63.6) 78 45.7 (8.3-88.7) 7 47.4 (22.6-73.4) 85 
Private for-profit outlet - - - - - -       
   Health facility/pharmacy - - - - - - 67.9 (64.1-71.5) 480 62.2 (11.1-95.6) 9 67.5 (61.3-73.1) 489 
   Drug store - - - - - - 78.8 (59.2-90.5) 86 92.7 (88.5-95.5) 486 89.8 (84.2-93.6) 572 
   General retailer/itinerant - - - - - - 47.9 (9.9-88.5) 3 51.5 (19.1-82.7) 11 51.4 (19.6-82.2) 14 
   Total - - - - - - 69.9 (65.0-74.4) 569 83.6 (74.6-89.9) 506 76.6 (71.1-81.4) 1,075 
Community health worker - - - - - - 34.6 (20.8-51.5) 26 10.4 (2-40) 101 11.1 (2.4-38.5) 127 
Niger - Total 1.4.0 (0.5-4.3) 432 0.2 (0.0-1.3) 289 0.6 (0.2-1.8) 721 65.1 (60.7-69.3) 757 54.0 (46.0-61.7) 295 59.0 (54.0-63.7) 1,052 
Public health facility  0.5 (0.1-3.6) 123 0.4 (0.0-2.5) 237 0.4 (0.1-1.8) 360 56.1 (49.2-62.8) 222 32.1 (23.2-42.6) 226 37.7 (30.4-45.6) 448 
Private not-for-profit health facility 0.0 1 - 0 0.0 1 0.0 1 100.0 5 95.4 (70.6-99.4) 6 
Private for-profit outlet             
   Health facility/pharmacy 0.4 (0.1-2.5) 223 0.0 5 0.4 (0.1-2.3) 228 53.7 (45.2-62.1) 328 87.4 (48.5-98.1) 8 55.6 (46.6-64.3) 336 
   Drug store 7.9 (1.3-35.7) 13 0.0 2 5.1 (0.7-28.8) 15 84.1 (68.7-92.7) 20 74.4 (38.6-93.0) 4 79.2 (58.6-91.1) 24 
   General retailer/itinerant 1.6 (0.2-10.1) 72 0.0 45 0.6 (0.1-4.0) 117 71.8 (65.8-77.1) 186 75.9 (65.2-84.0) 52 73.7 (68.0-78.7) 238 
   Total 1.7 (0.5-5.8) 308 0.0 52 0.8 (0.2-2.9) 360 67.5 (62.4-72.3) 534 76.0 (66.1-83.8) 64 70.9 (66.1-75.3) 598 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Nigeria - Total - - - - - - 70.7 (44.6-87.8) 73 32.2 (12.5-61.0) 65 43.8 (24.4-65.2) 138 
Public health facility  - - - - - - 60.9 (44.2-75.4) 10 39.0 (14.2-71.2) 6 52.2 (32.8-70.9) 16 
Private not-for-profit health facility - - - - - - 81.5 (73.0-87.8) 195 79.6 (47.5-94.4) 25 81.2 (72.8-87.5) 220 
Private for-profit outlet - - - - - - 86.5 (80.8-90.7) 1,185 87.7 (81.2-92.1) 501 87.0 (82.8-90.3) 1,686 
   Health facility/pharmacy - - - - - - 80.3 (38.7-96.3) 45 100.0 4 81.9 (43.6-96.4) 49 
   Drug store - - - - - - 85.7 (80.6-89.6) 1,425 87.3 (80.7-91.9) 530 86.3 (82.3-89.5) 1,955 
   General retailer/itinerant - - - - - - 100.0 6 16.6 (1.2-76.8) 3 23.7 (2.6-78.5) 9 
   Total - - - - - - 84.8 (79.8-88.8) 1,514 80.6 (71.5-87.3) 604 83.1 (78.8-86.7) 2,118 
Community health worker - - - - - - 70.7 (44.6-87.8) 73 32.2 (12.5-61.0) 65 43.8 (24.4-65.2) 138 
Tanzania - mainland - Total 0.4 (0.1-1.9) 275 0.4 (0-2.6) 141 0.4 (0.1-1.8) 416 89.9 (85.5-93.1) 1,689 68.6 (55.6-79.3) 356 76.9 (68.5-83.6) 2,045 
Public health facility  0.0 9 0.0 101 0.0 110 64.0 (38.8-83.3) 26 43.3 (30.5-57.0) 130 44.5 (32.2-57.5) 156 
Private not-for-profit health facility 0.0 7 0.0 13 0.0 20 70.8 (24.3-94.8) 6 55.0 (6.5-95.6) 7 60.3 (16.0-92.4) 13 
Private for-profit outlet             
   Health facility/pharmacy 1.2 (0.3-5.3) 245 0.0 5 1.1 (0.2-4.9) 250 88.0 (83.4-91.5) 1,226 56.2 (9.8-93.8) 48 81.9 (63.5-92.1) 1,274 
   Drug store 0.0 14 3.7 (0.6-21.3) 17 1.9 (0.3-12.8) 31 92.1 (89.1-94.4) 425 95.5 (88.9-98.2) 166 93.8 (90.9-95.9) 591 
   General retailer/itinerant - 0 0.0 5 0.0 5 100.0 6 0.0 5 28.0 (4.8-75.1) 11 
   Total 0.6 (0.1-2.9) 259 2.6 (0.4-16.3) 27 1.5 (0.3-7.1) 286 91.3 (88.3-93.6) 1,657 90.4 (81.2-95.4) 219 90.9 (86.8-93.8) 1,876 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
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Table 2.6.4: Cont. 
Country/Type of outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
% (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N 
Uganda - Total 1.3 (0.4-4.2) 550 0.8 (0.3-2.4) 2,342 0.9 (0.4-2.1) 2,892 85.3 (78.8-90) 2,536 77.1 (67.8-84.4) 2,958 79.1 (71.8-84.9) 5,494 
Public health facility  0.3 (0.0-2.6) 169 0.2 (0.1-0.5) 2,063 0.2 (0.1-0.5) 2,232 65.1 (45-80.9) 351 77.7 (67.6-85.3) 1615 76.0 (67.1-83.1) 1,966 
Private not-for-profit health facility 0.0 7 0.0 32 0.0 39 22.4 (6.7-53.7) 23 26.5 (12.9-46.7) 63 26.1 (13.4-44.6) 86 
Private for-profit outlet             
   Health facility/pharmacy 0.5 (0.2-1.4) 366 1.4 (0.5-3.7) 128 0.8 (0.3-1.9) 494 89.2 (85.4-92.1) 1,696 87.2 (78.3-92.8) 645 88.1 (83.4-91.7) 2,341 
   Drug store 9.6 (2.4-31.1) 8 2.5 (0.6-9.9) 93 3.1 (1.0-9.4) 101 89.9 (85.3-93.2) 461 91.2 (86.8-94.2) 546 90.9 (87.3-93.5) 1,007 
   General retailer/itinerant - 0 100.0 1 100.0 1 68.2 (12-97.1) 2 95.7 (69.8-99.5) 11 94.6 (71.7-99.2) 13 
   Total 2.2 (0.9-5.1) 374 3.0 (0.8-10.9) 222 2.8 (1-7.4) 596 89.4 (86.0-92.0) 2,159 89.9 (85.9-92.9) 1,202 89.8 (86.9-92.1) 3,361 
Community health worker - 0 0.0 25 0.0 25 30.1 (2.7-87.1) 3 15.7 (3.1-52.6) 78 15.8 (3.1-52.3) 81 
Zanzibar - Total 0.0 139 0.9 221 0.6 360 95.4 525 97.3 339 96.2 864 
Public health facility  0.0 124 0.9 220 0.6 344 91.9 135 97.0 234 95.1 369 
Private not-for-profit health facility - 0 - 0 - 0 100.0 1 100.0 3 100.0 4 
Private for-profit outlet             
   Health facility/pharmacy 0.0 13 0.0 1 0.0 14 94.4 213 98.0 50 95.1 263 
   Drug store 0.0 2 - 0 0.0 2 99.4 174 98.0 49 99.1 223 
   General retailer/itinerant - 0 - 0 - 0 100.0 2 100.0 3 100.0 5 
   Total 0 15 0.0 1 0.0 16 96.7 389 98.0 102 96.9 491 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Note: Nigeria baseline data collection was conducted in 2009. 
CI = Confidence interval 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.6.5: Percentage of all antimalarials other than quality-assured ACTs bearing the AMFm logo, at baseline (2010) and endline (2011) 
All antimalarials other than quality-assured ACTs bearing the AMFm logo (n) as a percentage of all antimalarials audited (N), by urban-rural location and type of outlet, according 
to country 
Country/Type of Outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
% (95% CI)  N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N 
Ghana - Total 0.9 (0.6-1.2) 7,174 0.6 (0.4-1.0) 3,370 0.7 (0.5-1.0) 10,544 0.4 (0.1-1.1) 4,048 0.3 (0.1-1.2) 1,182 0.4 (0.1-0.9) 5,230 
Public health facility  0.2 (0.0-0.8) 271 0.0 476 0.0 (0.0-0.1) 747 0.0 277 0.0 493 0.0 770 
Private not-for-profit health facility 0.0 31 0.0 65 0.0 96 0.0 18 0.0 36 0.0 54 
Private for-profit outlet             
   Health facility/pharmacy 0.9 (0.6-1.2) 5,206 0.4 (0.2-0.8) 809 0.7 (0.5-1.0) 6,015 0.1 (0.1-0.4) 2,755 1.4 (0.4-5.2) 142 0.2 (0.1-0.5) 2,897 
   Drug store 0.9 (0.5-1.6) 1,660 0.7 (0.5-1.2) 2,014 0.8 (0.5-1.1) 3,674 0.6 (0.2-2.0) 997 0.2 (0.0-1.2) 507 0.5 (0.2-1.4) 1,504 
   General retailer/itinerant 0.0 6 0.0 6 0.0 12 0.0 1 0.0 4 0.0 5 
   Total 0.9 (0.6-1.2) 6,872 0.7 (0.4-1.1) 2,829 0.7 (0.5-1.0) 9,701 0.4 (0.1-1.2) 3,753 0.3 (0.1-1.6) 653 0.4 (0.2-1) 4,406 
Community health worker - 0 - 0 - 0 - 0 - 0 - 0 
Kenya - Total 0.7 (0.4-1.1) 4199 0.7 (0.3-1.4) 2,102 0.7 (0.4-1.2) 6,301 1.9 (1.0-3.5) 3,933 1.3 (0.6-2.7) 1,927 1.5 (0.9-2.5) 5,860 
Public health facility  0.3 (0.0-1.7) 314 0.1 (0.0-0.5) 656 0.1 (0.0-0.5) 970 0.6 (0.2-2.2) 327 1.2 (0.5-2.6) 775 1.1 (0.5-2.5) 1,102 
Private not-for-profit health facility 0.0 83 0.0 37 0.0 120 0.0 60 0.0 80 0.0 140 
Private for-profit outlet             
   Health facility/pharmacy 0.7 (0.4-1.4) 2,265 2.6 (1.0-6.9) 451 1.4 (0.6-3.2) 2,716 2.6 (1.1-6.3) 2,066 2.5 (0.7-8.2) 463 2.6 (1.2-5.5) 2,529 
   Drug store 0.9 (0.4-1.9) 1,279 0.4 (0.3-0.8) 588 0.6 (0.4-0.9) 1,867 1.9 (1.2-2.8) 1,338 0.3 (0.0-1.6) 407 1.0 (0.6-1.6) 1,745 
   General retailer/itinerant 0.0 254 0.3 (0.0-2.2) 352 0.3 (0.0-1.8) 606 0.0 142 2.3 (0.9-5.8) 202 1.9 (0.7-4.8) 344 
   Total 0.7 (0.5-1.2) 3,798 0.8 (0.4-1.7) 1,391 0.8 (0.5-1.3) 5,189 2.0 (1.1-3.6) 3,546 1.5 (0.6-3.3) 1,072 1.7 (1.0-2.8) 4,618 
Community health worker 0.0 4 0.0 18 0.0 22 - 0 - 0 - 0 
Madagascar - Total - - - - - - 0.5 (0.3-0.9) 1602 0.3 (0.1-0.8) 2,284 0.3 (0.2-0.7) 3,886 
Public health facility  - - - - - - 0.8 (0.1-3.8) 97 0.8 (0.3-2.0) 799 0.8 (0.3-1.8) 896 
Private not-for-profit health facility - - - - - - 0.0 38 0.0 6 0.0 44 
Private for-profit outlet - - - - - -       
   Health facility/pharmacy - - - - - - 0.7 (0.3-1.3) 569 0.0 28 0.5 (0.2-1.2) 597 
   Drug store - - - - - - 1.3 (0.3-4.7) 142 0.1 (0.0-0.6) 1,018 0.3 (0.1-1.0) 1,160 
   General retailer/itinerant - - - - - - 0.0 756 0.0 424 0.0 1,180 
   Total - - - - - - 0.5 (0.2-1) 1,467 0.0 (0.0-0.1) 1,470 0.1 (0.1-0.3) 2,937 
Community health worker - - - - - - - 0 8.8 (1.1-46.9) 9 8.8 (1.1-46.9) 9 
Niger - Total 0.5 (0.3-0.9) 3,676 0.2 (0.1-0.7) 2,151 0.3 (0.2-0.6) 5,827 2.7 (2.2-3.4) 3,375 1.3 (0.8-2.1) 1,179 1.8 (1.4-2.3) 4,554 
Public health facility  0.5 (0.2-1.6) 382 0.2 (0.1-0.8) 1,084 0.2 (0.1-0.7) 1,466 5.9 (4.2-8.4) 405 3.1 (1.8-5.4) 563 3.7 (2.5-5.5) 968 
Private not-for-profit health facility 0.0 11 - 0 0.0 11 0.0 4 8.3 (8.3-8.3) 12 7.7 (6.6-8.9) 16 
Private for-profit outlet             
   Health facility/pharmacy 0.6 (0.3-1.1) 2,241 0.9 (0.1-5.4) 69 0.6 (0.3-1.1) 2,310 2.1 (1.6-2.9) 1,941 66.4 (19.5-94.1) 7 2.6 (1.7-3.7) 1,948 
   Drug store 1.7 (0.2-11.3) 61 0.0 22 0.8 (0.1-5.4) 83 3.4 (1.8-6.4) 109 0.0 8 2.3 (1.1-4.9) 117 
   General retailer/itinerant 0.4 (0.1-1.2) 980 0.2 (0.1-1.0) 974 0.3 (0.1-0.8) 1,954 2.5 (1.7-3.6) 916 0.6 (0.2-1.7) 589 1.2 (0.7-1.8) 1,505 
   Total 0.5 (0.3-0.9) 3,282 0.2 (0.1-0.9) 1,065 0.3 (0.2-0.7) 4,347 2.4 (1.8-3.2) 2,966 0.7 (0.3-1.7) 604 1.4 (1.0-1.9) 3,570 
Community health worker 0.0 1 0.0 2 0.0 3 - 0 - 0 - 0 
Nigeria - Total - - - - - - 0.1 (0.0-0.4) 8,270 0.2 (0.1-0.8) 2,999 0.2 (0.1-0.4) 11,269 
Public health facility  - - - - - - 0.0 133 0.0 138 0.0 271 
Private not-for-profit health facility - - - - - - 0.0 30 0.0 7 0.0 37 
Private for-profit outlet - - - - - -       
   Health facility/pharmacy - - - - - - 0.2 (0.0-1.0) 1,240 0.0 154 0.2 (0.0-0.9) 1,394 
   Drug store - - - - - - 0.1 (0.0-0.3) 6,602 0.3 (0.1-0.9) 2,627 0.2 (0.1-0.4) 9,229 
   General retailer/itinerant - - - - - - 1.1 (0.2-5.3) 265 0.0 64 0.8 (0.1-4.3) 329 
   Total - - - - - - 0.1 (0.0-0.4) 8,107 0.3 (0.1-0.9) 2,845 0.2 (0.1-0.4) 10,952 
Community health worker - - - - - - - 0 0.0 9 0.0 9 
Tanzania - mainland - Total 0.4 (0.2-0.9) 3,984 0.2 (0.1-0.9) 1,132 0.3 (0.1-0.7) 5,116 1.1 (0.6-2.0) 6,741 1.7 (0.9-3.0) 899 1.4 (0.9-2.1) 7,640 
Public health facility  0.0 10 0.0 111 0.0 121 0.0 20 2.3 (0.3-14.6) 68 2.1 (0.3-13.4) 88 
Private not-for-profit health facility 0.0 48 0.0 70 0.0 118 0.0 23 0.0 6 0.0 29 
Private for-profit outlet             
   Health facility/pharmacy 0.7 (0.3-1.6) 3329 0.0 130 0.6 (0.2-1.4) 3,459 1.0 (0.5-2.4) 4,726 0.1 (0.0-0.9) 200 0.9 (0.4-2.0) 4,926 
   Drug store 0.4 (0.1-1.3) 596 0.4 (0.1-1.3) 734 0.4 (0.1-0.9) 1,330 1.1 (0.5-2.5) 1,956 1.7 (0.9-3.3) 612 1.4 (0.8-2.3) 2,568 
   General retailer/itinerant 0.0 1 0.0 84 0.0 85 8.5 (3.8-18.0) 16 0.0 13 2.1 (0.3-13.6) 29 
   Total 0.4 (0.2-1) 3926 0.3 (0.1-1.2) 948 0.4 (0.2-0.8) 4,874 1.1 (0.6-2.1) 6,698 1.6 (0.8-3.1) 825 1.3 (0.9-2.1) 7,523 
Community health worker - 0 0.0 3 0.0 3 - 0 - 0 - 0 
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Table 2.6.5: Cont. 
All antimalarials other than quality-assured ACTs bearing the AMFm logo (n) as a percentage of all antimalarials audited (N), by urban-rural location and type of outlet, according 
to country 
Country/Type of Outlet 
BASELINE ENDLINE 
Urban Rural Total Urban  Rural Total 
% (95% CI)  N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N % (95% CI) N 
Uganda - Total 0.7 (0.4-1.2) 4,746 0.4 (0.2-0.6) 6,694 0.5 (0.3-0.7) 11,440 0.2 (0.2-0.3) 8,688 0.1 (0.0-0.5) 5,983 0.2 (0.1-0.4) 14,671 
Public health facility  0.8 (0.1-7.0) 208 0.7 (0.4-1.4) 1,444 0.7 (0.4-1.4) 1,652 0.3 (0-1.7) 389 0.3 (0.1-0.9) 1,147 0.3 (0.1-0.8) 1,536 
Private not-for-profit health facility 0.0 21 0.0 110 0.0 131 0.0 56 0.0 113 0.0 169 
Private for-profit outlet             
   Health facility/pharmacy 0.7 (0.3-1.5) 4,177 0.1 (0.0-0.2) 2,413 0.4 (0.2-0.9) 6,590 0.3 (0.2-0.4) 6,729 0.3 (0.0-2.3) 2,514 0.3 (0.1-0.9) 9,243 
   Drug store 0.8 (0.2-3.0) 330 0.4 (0.2-0.8) 2,685 0.5 (0.3-0.9) 3,015 0.1 (0.0-0.5) 1,511 0.1 (0.0-0.6) 2,143 0.1 (0.0-0.4) 3,654 
   General retailer/itinerant 0.0 8 3.5 (0.6-17.8) 24 2.4 (0.4-13.4) 32 0.0 2 0.0 8 0.0 10 
   Total 0.7 (0.4-1.3) 4,515 0.4 (0.2-0.7) 5,122 0.5 (0.3-0.7) 9,637 0.2 (0.1-0.3) 8,242 0.1 (0-0.6) 4,665 0.2 (0.1-0.4) 12,907 
Community health worker 0.0 2 0.0 18 0.0 20 0.0 1 0.0 58 0.0 59 
Zanzibar - Total 1.1 626 0.5 213 1.0 839 1.6 370 0.0 101 1.3 471 
Public health facility  3.0 100 0.0 115 1.4 215 0.0 35 0.0 33 0.0 68 
Private not-for-profit health facility 0.0 7 0.0 3 0.0 10 0.0 5 0.0 2 0.0 7 
Private for-profit outlet             
   Health facility/pharmacy 1.0 381 2.4 41 1.2 422 2.2 223 0.0 38 1.9 261 
   Drug store 0.0 137 0.0 50 0.0 187 1.0 102 0.0 26 0.8 128 
   General retailer/itinerant 0.0 1 0.0 4 0.0 5 0.0 5 0.0 2 0.0 7 
   Total 0.8 519 1.1 95 0.8 614 1.8 330 0.0 66 1.5 396 
Community health worker - 0 - 0 - 0 - 0 - 0  0 
Note: Nigeria baseline data collection was conducted in 2009. 
CI = Confidence interval  
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.6.6: Provider knowledge of the AMFm program at endline, 2011 
Providers who have heard of “a program that reduces the prices of antimalarial medicines known as ACTs” (n) as a percentage of 
outlets with antimalarials in stock at the time of the survey visit (N), by urban-rural location and type of outlet, according to 
country 
 Urban Rural Total 
Country/Type of outlet % (95% CI) N % (95% CI) N % (95% CI) N 
Ghana – Total 79.4 (73.9-84.0) 572 69.5 (58.9-78.3) 382 75.5 (70.1-80.2) 954 
Public health facility  90.8 (85.3-94.3) 94 85.0 (80.0-89.0) 204 86.8 (82.9-89.8) 298 
Private not-for-profit health facility 100.0 4 53.7 (24.1-80.9) 9 71.9 (43.4-89.5) 13 
Private for-profit outlet       
   Health facility/pharmacy 84.5 (78.7-89.0) 269 89.2 (69.3-96.8) 26 85.1 (79.8-89.2) 295 
   Drug store 75.7 (68.7-81.5) 202 64.7 (52.6-75.1) 140 71.4 (64.9-77.0) 342 
   General retailer/itinerant 100.0 3 32.7 (3.8-85.7) 3 66.2 (22.2-93.1) 6 
   Total 78.3 (72.5-83.1) 474 65.9 (53.7-76.3) 169 74.1 (68.2-79.2) 643 
Community health worker - 0 - 0 - 0 
Kenya – Total 64.2 (57.0-70.8) 1,045 56.1 (49.1-62.9) 801 58.4 (53.0-63.7) 1,846 
Public health facility  70.3 (60.4-78.5) 137 67.3 (55.8-77.0) 294 67.5 (56.9-76.6) 431 
Private not-for-profit health facility 75.6 (50.8-90.3) 19 47.5 (30.5-65.1) 27 53.0 (37.6-67.9) 46 
Private for-profit outlet       
   Health facility/pharmacy 72.3 (62.8-80.1) 406 65.9 (49.8-79.0) 112 68.4 (58.2-77.0) 518 
   Drug store 70.9 (65.2-76.0) 328 67.3 (57.0-76.2) 145 68.7 (62.1-74.7) 473 
   General retailer/itinerant 36.5 (24.7-50.3) 155 40.3 (30.7-50.7) 223 39.7 (31.4-48.6) 378 
   Total 63.7 (56.4-70.4) 889 54.6 (46.6-62.4) 480 57.4 (51.4-63.2) 1,369 
Community health worker - 0 - 0 - 0 
Madagascar – Total 15.0 (12.7-17.6) 980 12.3 (10.0-15.2) 1,387 12.7 (10.6-15.1) 2,367 
Public health facility  17.8 (12.1-25.3) 65 14.1 (10.2-19.2) 553 14.5 (10.9-19.1) 618 
Private not-for-profit health facility 25.8 (14.5-41.6) 25 31.3 (5.9-76.9) 5 29.2 (10.2-59.8) 30 
Private for-profit outlet       
   Health facility/pharmacy 38.3 (30.9-46.3) 105 25.8 (10.0-52.2) 12 32.7 (22.4-44.9) 117 
   Drug store 14.5 (7.6-25.7) 28 16.2 (12.0-21.4) 347 16.0 (12.2-20.7) 375 
   General retailer/itinerant 9.3 (7.4-11.7) 742 10.3 (7.1-14.7) 404 10.1 (7.3-13.9) 1,146 
   Total 13.9 (11.6-16.6) 875 11.1 (8.2-15.0) 763 11.5 (9.0-14.8) 1,638 
Community health worker 33.8 (17.5-55.1) 15 16.9 (10.1-26.9) 66 17.3 (10.6-27.0) 81 
Niger – Total 27.2 (24.4-30.3) 917 22.0 (19.3-25.0) 731 23.4 (21.3-25.7) 1,648 
Public health facility  78.0 (70.4-84.0) 102 48.9 (40.5-57.5) 220 53.0 (45.7-60.3) 322 
Private not-for-profit health facility 100.0 2 100.0 1 100.0 3 
Private for-profit outlet       
   Health facility/pharmacy 58.9 (49.2-67.9) 95 91.6 (61.9-98.6) 4 60.7 (51.0-69.7) 99 
   Drug store 66.1 (44.6-82.5) 15 0.0 3 29.3 (13.9-51.6) 18 
   General retailer/itinerant 21.9 (18.7-25.5) 703 18.5 (15.2-22.3) 503 19.5 (16.9-22.3) 1206 
   Total 24.5 (21.5-27.8) 813 18.5 (15.2-22.3) 510 20.2 (17.7-23.0) 1323 
Community health worker - 0 - 0 - 0 
Nigeria – Total 36.1 (27.0-46.2) 1,009 36.4 (26.2-48.0) 465 36.2 (29.2-43.8) 1,474 
Public health facility  40.5 (22.7-61.1) 42 52.6 (36.4-68.3) 50 48.4 (35.5-61.5) 92 
Private not-for-profit health facility 41.7 (6.2-88.7) 6 6.9 (0.6-45.9) 3 28.6 (5.0-75.2) 9 
Private for-profit outlet       
   Health facility/pharmacy 54.3 (41.6-66.4) 94 55.9 (32.2-77.3) 31 54.9 (42.7-66.5) 125 
   Drug store 35.1 (24.3-47.7) 793 33.6 (23.1-45.9) 358 34.5 (26.5-43.5) 1,151 
   General retailer/itinerant 19.7 (14.8-25.7) 71 19.1 (6.8-43.3) 19 19.5 (14.0-26.5) 90 
   Total 35.8 (26.4-46.5) 958 35.1 (24.5-47.4) 408 35.6 (28.3-43.6) 1,366 
Community health worker 33.3 (33.3-33.3) 3 0.0 4 1.3 (0.1-12.7) 7 
Tanzania - mainland – Total 74.5 (68.4-79.8) 583 71.1 (64.4-77.0) 191 72.3 (67.5-76.7) 774 
Public health facility  100.0 6 65.8 (50.0-78.8) 48 67.1 (51.7-79.6) 54 
Private not-for-profit health facility 75.2 (22.9-96.9) 4 100.0 2 86.8 (42.3-98.3) 6 
Private for-profit outlet       
   Health facility/pharmacy 83.8 (65.5-93.4) 313 84.8 (43.6-97.6) 16 84.1 (68.2-92.9) 329 
   Drug store 72.7 (64.6-79.5) 256 74.0 (66.0-80.7) 113 73.4 (67.9-78.4) 369 
   General retailer/itinerant 46.6 (10.9-86.2) 4 59.5 (48.7-69.4) 12 58.5 (47.3-68.9) 16 
   Total 74.0 (67.5-79.6) 573 72.9 (65.7-79.1) 141 73.4 (68.5-77.8) 714 
Community health worker - 0 - 0 - 0 
Uganda – Total 31.5 (27.4-35.8) 1,400 23.8 (20.5-27.5) 1,707 25.4 (22.4-28.6) 3,107 
Public health facility  29.5 (17.1-45.8) 144 27.5 (23.1-32.3) 527 27.7 (23.4-32.5) 671 
Private not-for-profit health facility 33.9 (23.7-45.9) 12 42.9 (27.8-59.5) 26 41.9 (28.2-56.9) 38 
Private for-profit outlet       
   Health facility/pharmacy 36.4 (34.7-38.1) 805 32.2 (27.1-37.7) 384 34.0 (30.9-37.3) 1,189 
   Drug store 25.6 (20.1-32.0) 433 22.5 (18.5-27.1) 674 23.0 (19.4-27.0) 1,107 
   General retailer/itinerant 0.0 4 3.5 (0.4-25.4) 14 3.3 (0.4-23.8) 18 
   Total 31.5 (27.5-35.8) 1,242 24.1 (20.0-28.8) 1072 25.8 (22.2-29.8) 2,314 
Community health worker 53.7 (6.9-94.8) 2 15.2 (14.1-16.3) 82 15.3 (14.2-16.5) 84 
Zanzibar – Total 68.9 222 68.3 120 68.7 342 
Public health facility  83.3 48 78.9 76 80.6 124 
Private not-for-profit health facility 100.0 1 0.0 1 50.0 2 
Private for-profit outlet       
   Health facility/pharmacy 73.2 82 56.3 16 70.4 98 
   Drug store 56.8 88 45.8 24 54.5 112 
   General retailer/itinerant 66.7 3 66.7 3 66.7 6 
   Total 64.7 173 51.2 43 62.0 216 
Community health worker - 0 - 0 - 0 
CI = Confidence interval 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.6.7: Sources from which providers heard of the AMFm program at endline, 2011 
Providers stating a specific source where they have seen or heard of  “a program that reduces the prices of antimalarial medicines 
known as ACTs” (n) as a percentage of providers that have heard of  “a program that reduces the prices of antimalarial medicines 
known as ACTs” (N), by urban-rural location and type of source specified, according to country 
 Urban Rural Total 
Country/Source % (95% CI) N % (95% CI) N % (95% CI) N 
Ghana       
On malaria medicine packaging 13.3 (8.8-19.7) 469 14.7 (8.2-24.8) 294 13.8 (9.9-19) 763 
On medicine packaging 3.0 (1.4-6.5) 469 3.1 (1.0-9.0) 294 3.0 (1.6-5.7) 763 
On TV/radio 90.0 (82.3-94.5) 469 86.1 (80.8-90.1) 294 88.6 (83.7-92.1) 763 
In newspapers/magazines 4.3 (2.5-7.4) 469 1.6 (0.7-3.7) 294 3.4 (2.1-5.3) 763 
In pharmacies/ drug shops 8.6 (5.5-13.4) 469 8.8 (5.0-15.0) 294 8.7 (6.1-12.3) 763 
In public health facilities 2.9 (1.2-6.6) 469 3.9 (2.3-6.6) 294 3.3 (1.9-5.5) 763 
In training 35.0 (25.6-45.6) 469 57.2 (50.1-64.0) 294 42.9 (35.9-50.3) 763 
From a supplier 4.4 (2.7-6.9) 469 3.5 (1.6-7.6) 294 4.1 (2.7-6.1) 763 
From a friend/family member 3.9 (2.4-6.1) 469 2.6 (1.1-6.1) 294 3.4 (2.2-5.2) 763 
Other 9.8 (7.1-13.3) 469 8.5 (5.1-14.1) 294 9.3 (7.1-12.2) 763 
Kenya       
On malaria medicine packaging 15.3 (11.0-21.1) 738 11.1 (5.6-20.8) 499 12.4 (8.1-18.6) 1,237 
On medicine packaging 8.9 (5.0-15.3) 738 7.4 (4.2-12.8) 499 7.9 (5.2-11.8) 1,237 
On posters 9.3 (6.7-12.8) 738 6.8 (3.6-12.4) 499 7.6 (5.1-11.1) 1,237 
On TV/radio 92.3 (89.5-94.4) 738 91.5 (87-94.5) 499 91.7 (88.6-94.0) 1,237 
In newspapers/magazines 14.4 (11.4-18.1) 738 11.2 (6.8-17.9) 499 12.2 (8.9-16.5) 1,237 
In pharmacies/ drug shops 5.6 (3.2-9.4) 738 7.3 (4.7-11.2) 499 6.8 (4.7-9.6) 1,237 
In private clinics 0.9 (0.4-2.1) 738 4.7 (2.0-10.8) 499 3.5 (1.5-8.0) 1,237 
In public health facilities 6.3 (3.7-10.7) 738 11.4 (6.9-18.3) 499 9.8 (6.3-14.9) 1,237 
In training 8.3 (5.5-12.2) 738 9.0 (6.4-12.5) 499 8.8 (6.7-11.4) 1,237 
From a supplier 8.1 (6.1-10.8) 738 1.4 (0.6-3.0) 499 3.4 (2.3-5.1) 1,237 
From a public event 2.6 (1.4-5.0) 738 3.6 (1.9-6.8) 499 3.3 (2.0-5.6) 1,237 
Other source: Other 7.9 (5.5-11.0) 738 6.7 (4.8-9.4) 499 7.1 (5.5-9.0) 1,237 
Madagascar       
On malaria medicine packaging 3.9 (1.5-9.7) 133 2.7 (1.0-7.2) 197 2.9 (1.3-6.5) 330 
On posters 1.6 (0.5-5.3) 133 3.8 (0.9-14.2) 197 3.5 (0.9-12) 330 
On TV/radio 63.3 (56.7-69.5) 133 68.6 (57.2-78.2) 197 67.8 (58.2-76.1) 330 
In public health facilities 5.4 (2.7-10.6) 133 15.8 (9.3-25.5) 197 14.1 (8.6-22.4) 330 
In training 19.3 (14.1-25.7) 133 23.3 (12.9-38.4) 197 22.6 (13.6-35.1) 330 
From a supplier 8.7 (5.8-13) 133 0.7 (0.2-2.0) 197 2.0 (1.2-3.4) 330 
From a public even 6.2 (3.4-11.0) 133 3.6 (1.5-8.6) 197 4.0 (2.0-7.9) 330 
From a friend/family member 1.2.0 (0.5-3.0) 133 3.1 (0.7-12.8) 197 2.8 (0.7-10.6) 330 
Don't know 0.0 133 0.1 (0.0-0.7) 197 0.1 (0.0-0.6) 330 
Other source 7.8 (4.9-12.4) 133 6.5 (3.5-12.0) 197 6.8 (4.0-11.2) 330 
Niger       
On malaria medicine packaging 13.2 (8.8-19.3) 299 2.4 (1.2-4.8) 199 5.8 (4-8.4) 498 
On posters 5.0 (3.0-8.1) 299 3.0 (1.1-7.6) 199 3.6 (2.0-6.4) 498 
On billboards 23.4 (18.3-29.4) 299 16.2 (11.0-23.3) 199 18.5 (14.3-23.6) 498 
On TV/radio 53.5 (49.1-57.9) 299 62.7 (53.2-71.3) 199 59.8 (53.3-66.0) 498 
On a prescription 8.0 (5.5-11.6) 298 7.8 (4.7-12.8) 199 7.9 (5.5-11.3) 497 
In private clinics 3.8 (2.5-5.7) 299 8.8 (5.2-14.6) 199 7.2 (4.6-11.1) 498 
In public health facilities 6.4 (4.5-9) 299 11.2 (7.5-16.3) 199 9.7 (7.0-13.2) 498 
In training 8.1 (5.9-11) 299 4.6 (2.5-8.3) 199 5.7 (4.0-8.2) 498 
From a local leader 4.8 (3.1-7.3) 299 3.0 (1.2-7.3) 199 3.6 (2.0-6.2) 498 
From a friend/family member 5.8 (3.6-9.2) 299 4.6 (1.7-12.1) 199 5.0 (2.6-9.4) 498 
Other 25.3 (20.5-30.7) 299 12.2 (7.6-19.2) 199 16.4 (12.7-20.8) 498 
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Table 2.6.7: Cont. 
 Urban Rural Total 
Country/Source % (95% CI) N % (95% CI) N % (95% CI) N 
Nigeria       
On malaria medicine packaging 14.0 (7.8-23.7) 397 21.3 (12.7-33.4) 167 16.9 (11.6-24.0) 564 
On medicine packaging 3.0 (1.1-7.8) 394 2.7 (1.1-6.5) 164 2.9 (1.4-5.7) 558 
On posters 5.1 (3.1-8.4) 394 4.1 (1.6-10.2) 164 4.7 (3.0-7.5) 558 
On TV/radio 48.9 (37.6-60.3) 394 67.8 (56.6-77.3) 164 56.4 (47.8-64.6) 558 
In newspapers/magazines 7.2 (4.8-10.8) 394 1.0 (0.2-4.3) 164 4.8 (2.9-7.7) 558 
In pharmacies/drug shops 6.4 (4.2-9.6) 394 4.3 (1.7-10.4) 164 5.5 (3.7-8.2) 558 
In private clinics 4.0 (1.5-10.3) 392 2.6 (0.6-9.6) 163 3.4 (1.5-7.5) 555 
In public health facilities 10.2 (5.4-18.3) 394 12.1 (7.4-19.1) 164 10.9 (7.2-16.2) 558 
In training 37.6 (30.4-45.3) 393 29.6 (21.8-38.7) 164 34.4 (28.8-40.5) 557 
From a supplier 4.8 (2.2-10.0) 394 5.5 (2.1-13.5) 164 5.1 (2.8-9.1) 558 
From a public event 6.4 (3.2-12.4) 393 4.1 (1.7-9.6) 163 5.5 (3.2-9.2) 556 
From a friend/family member 5.1 (3.2-8.1) 393 3.2 (1.2-8.3) 164 4.4 (2.8-6.8) 557 
Don’t know 2.0 (0.7-5.8) 394 0.0 164 1.2 (0.4-3.6) 558 
In a meeting 12.3 (4.9-27.6) 394 3.4 (1.1-9.9) 164 8.7 (3.9-18.6) 558 
Other 21.5 (13.1-33.2) 394 6.0 (2.9-12.2) 164 15.4 (9.8-23.3) 558 
Tanzania-mainland       
On malaria medicine packaging 12.7 (6.1-24.5) 463 3.6 (1.4-9.0) 138 7.0 (3.6-13.2) 601 
On medicine packaging 5.1 (1.7-14.6) 463 0.4 (0.1-3.2) 138 2.2 (0.7-6.7) 601 
On posters 9.8 (6.6-14.5) 463 15.7 (9.5-24.9) 138 13.5 (9.2-19.5) 601 
On billboards 8.8 (4.3-17.2) 463 12.9 (7.5-21.5) 138 11.4 (7.2-17.6) 601 
On TV/radio 91.3 (86.8-94.3) 463 91.8 (86.2-95.3) 138 91.6 (87.9-94.2) 601 
On a prescription 3.8 (1.6-8.7) 463 0.0 138 1.4 (0.5-3.8) 601 
In newspapers/magazines 9.1 (6.6-12.5) 463 6.9 (3.1-14.4) 138 7.7 (4.9-12.0) 601 
In pharmacies/ drug shops 4.1 (1.1-14.4) 463 1.3 (0.3-5.1) 138 2.4 (0.8-6.6) 601 
In public health facilities 5.1 (2.6-10) 463 4.1 (1.5-10.5) 138 4.5 (2.4-8.4) 601 
In training 6.3 (3.6-10.6) 463 4.8 (2.0-11.2) 138 5.4 (3.1-9.2) 601 
Other 7.2 (4.3-11.8) 463 5.5 (2.7-10.9) 138 6.1 (3.8-9.6) 601 
Uganda       
On malaria medicine packaging 10.6 (4.9-21.7) 500 3.7 (1.9-6.8) 453 5.4 (2.8-10.3) 953 
On medicine packaging 5.3 (3.1-9.1) 501 2.0 (0.7-5.4) 453 2.8 (1.4-5.7) 954 
On posters 5.2 (3.7-7.2) 501 0.9 (0.2-3.3) 453 2.0 (0.9-4.1) 954 
On TV/radio 65.8 (61.7-69.7) 501 76.7 (71.6-81.2) 453 73.9 (69.6-77.8) 954 
On a prescription 3 (1.9-4.9) 501 0.9 (0.2-3.9) 453 1.5 (0.7-3.2) 954 
In newspapers/magazines 14.4 (11.9-17.3) 501 5.3 (3.0-9.1) 453 7.6 (5.1-11.1) 954 
In pharmacies/ drug shops 8.8 (6.4-11.9) 501 8.3 (5.1-13.1) 453 8.4 (5.8-12.0) 954 
In private clinics 3.4 (1.6-6.9) 500 2.3 (1.1-4.8) 452 2.6 (1.4-4.6) 952 
In public health facilities 8.4 (6.5-10.9) 501 7.1 (4.0-12.4) 453 7.4 (4.8-11.3) 954 
In training 15.7 (11.1-21.7) 501 11.2 (7.9-15.7) 452 12.3 (9.3-16.2) 953 
From a supplier (including medical representative) 8.3 (6-11.4) 501 4.6 (2.4-8.7) 453 5.5 (3.5-8.6) 954 
From a friend/family member 10.4 (7.9-13.4) 501 8.4 (6-11.6) 453 8.9 (6.9-11.4) 954 
Don’t Know 0.0 500 0.2 (0.1-0.7) 453 0.2 (0.0-0.5) 953 
Other 11.7 (8.6-15.7) 501 8.9 (6.4-12.2) 453 9.6 (7.5-12.1) 954 
Zanzibar       
On malaria medicine packaging 19.0 153 12.2 82 16.6 235 
On medicine packaging 15.7 153 9.8 82 13.6 235 
On posters 23.5 153 15.9 82 20.9 235 
On billboards 20.9 153 11.0 82 17.4 235 
On TV/radio 94.8 153 91.5 82 93.6 235 
On a prescription  13.7 153 9.8 82 12.3 235 
In newspapers/magazines 15.7 153 11.0 82 14.0 235 
In pharmacies/drug shops 12.4 153 14.6 82 13.2 235 
In private clinics 16.3 153 9.8 82 14.0 235 
In public health facilities  19.6 153 19.5 82 19.6 235 
In training 15.7 153 22.0 82 17.9 235 
From a supplier 2.0 153 6.1 82 3.4 235 
From a public event 1.3 153 3.7 82 2.1 235 
From a friend/family member 0.7 153 3.7 82 1.7 235 
I don’t know 0.0 153 0.0 82 0.0 235 
Other 2.6 153 2.4 82 2.6 235 
Note: Providers could give more than one response to this question. Percentages may add to more than 100. 
CI = Confidence interval 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.6.8: Providers stating that there is a maximum/recommended retail price (RRP) for antimalarials 
with the AMFm logo at endline, 2011 
Providers stating that there is a RRP for antimalarials with the AMFm logo (n) as a percentage of outlets with antimalarials in 
stock at the time of the survey visit (N), by urban-rural location and type of outlet, according to country 
 Urban Rural Total 
Country/Type of outlet % (95% CI) N % (95% CI) N % (95% CI) N 
Ghana – Total 91.3 (86.8-94.4) 572 73.4 (61.7-82.6) 381 84.3 (78.5-88.8) 953 
Public health facility  90.2 (85.5-93.5) 94 90.2 (86.5-92.9) 203 90.2 (87.4-92.4) 297 
Private not-for-profit health facility 100.0 4 78.2 (54.9-91.3) 9 86.7 (67-95.5) 13 
Private for-profit outlet       
   Health facility/pharmacy 96.6 (95.3-97.6) 269 92.5 (69.3-98.5) 26 96.1 (93.8-97.6) 295 
   Drug store 89.6 (83.6-93.5) 202 67.1 (52.9-78.7) 140 80.8 (73.3-86.5) 342 
   General retailer/itinerant 64.5 (20.5-92.8) 3 32.7 (3.8-85.7) 3 48.5 (16.0-82.4) 6 
   Total 91.2 (86.4-94.4) 474 68.4 (54.2-79.8) 169 83.4 (76.9-88.4) 643 
Community health worker - 0 - 0 - 0 
Kenya – Total 79.3 (73.4-84.1) 1,047 68.6 (59.2-76.6) 801 71.6 (64.7-77.6) 1,848 
Public health facility  71.3 (59.5-80.8) 137 79.1 (68.0-87.2) 294 78.6 (68.4-86.1) 431 
Private not-for-profit health facility 87.7 (61.6-97.0) 19 59.9 (37.1-79.0) 27 65.3 (45.8-80.8) 46 
Private for-profit outlet       
   Health facility/pharmacy 84.0 (77.4-89.0) 407 80.5 (71.7-87.1) 112 81.9 (76.3-86.4) 519 
   Drug store 93.8 (91.0-95.8) 329 92.8 (83.8-97.0) 145 93.2 (88.4-96.1) 474 
   General retailer/itinerant 41.7 (31.5-52.7) 155 42.9 (31.0-55.7) 223 42.7 (32.7-53.4) 378 
   Total 79.3 (73.4-84.2) 891 67.2 (55.9-76.7) 480 70.9 (63.0-77.8) 1,371 
Community health worker - 0 - 0 - 0 
Madagascar – Total 21.0 (16.6-26.3) 979 14.5 (10.3-20.1) 1,387 15.4 (11.6-20.2) 2,366 
Public health facility  39.7 (30.3-49.9) 65 27.6 (23.0-32.8) 553 29.0 (24.6-33.7) 618 
Private not-for-profit health facility 28.2 (15.8-45.1) 25 82.4 (31.8-97.9) 5 61.5 (33.6-83.4) 30 
Private for-profit outlet       
   Health facility/pharmacy 39.6 (26.4-54.5) 105 16.0 (3.3-51.9) 12 28.9 (15.5-47.4) 117 
   Drug store 24.0 (12.3-41.4) 28 14.7 (10.3-20.7) 347 15.7 (11.3-21.4) 375 
   General retailer/itinerant 13.8 (9.9-19.0) 741 9.0 (5.0-15.7) 404 9.7 (6.0-15.3) 1,145 
   Total 18.2 (12.8-25.2) 874 9.7 (5.9-15.5) 763 11.0 (7.4-16.0) 1,637 
Community health worker 52.5 (26.2-77.5) 15 27.9 (16.4-43.4) 66 28.5 (17.0-43.6) 81 
Niger – Total 21.9 (19.4-24.7) 921 10.2 (8.4-12.4) 737 13.4 (11.8-15.3) 1,658 
Public health facility  83.7 (76.8-88.9) 101 45.6 (38.5-52.8) 220 50.9 (44.4-57.4) 321 
Private not-for-profit health facility 49.2 (11.3-88.1) 2 100.0 1 83.3 (41.4-97.2) 3 
Private for-profit outlet       
   Health facility/pharmacy 69.5 (58.5-78.7) 95 100.0 4 71.2 (60.6-80.0) 99 
   Drug store 79.7 (60.5-90.9) 15 30.7 (5.6-77.0) 3 52.4 (25.9-77.6) 18 
   General retailer/itinerant 15.1 (12.3-18.3) 708 5.5 (4.0-7.4) 509 8.1 (6.7-9.7) 1,217 
   Total 18.8 (16.5-21.4) 818 5.7 (4.3-7.7) 516 9.5 (8.1-11.0) 1,334 
Community health worker - 0 - 0 - 0 
Nigeria – Total 15.8 (12.3-19.9) 1,014 13.7 (10.5-17.8) 469 15.0 (12.5-17.8) 1,483 
Public health facility  7.3 (1.4-30.1) 42 3.6 (1.1-11.2) 52 4.7 (1.7-12.2) 94 
Private not-for-profit health facility 52.6 (18.0-84.9) 6 6.9 (0.6-45.9) 3 35.5 (11.1-70.8) 9 
Private for-profit outlet       
   Health facility/pharmacy 21.9 (12.7-35.1) 94 19.3 (8.4-38.3) 31 20.9 (13.4-31.2) 125 
   Drug store 16.1 (12.1-21.2) 797 15.0 (11.3-19.7) 360 15.7 (12.8-19.2) 1,157 
   General retailer/itinerant 1.2 (0.3-3.9) 72 8.3 (2.2-26.5) 19 3.0 (1.0-8.5) 91 
   Total 15.7 (12.4-19.6) 963 15.2 (11.5-19.7) 410 15.5 (13.0-18.4) 1,373 
Community health worker 33.3 (33.3-33.3) 3 0.0 4 1.3 (0.1-12.7) 7 
Tanzania - mainland – Total 63.4 (57.3-69.2) 583 58.8 (50-67.1) 191 60.5 (54.4-66.3) 774 
Public health facility  68.1 (25.7-93.0) 6 62.2 (44.2-77.4) 48 62.5 (45-77.2) 54 
Private not-for-profit health facility 29.7 (4.0-81.1) 4 47.8 (4.9-94.2) 2 38.2 (9.3-78.8) 6 
Private for-profit outlet       
   Health facility/pharmacy 79.1 (67.1-87.5) 313 42.1 (11.2-80.8) 16 69.4 (50.3-83.5) 329 
   Drug store 61.8 (54.3-68.7) 256 61.1 (53.9-68) 113 61.4 (56.2-66.4) 369 
   General retailer/itinerant 31.3 (3.7-84.2) 4 34.6 (26.2-44) 12 34.3 (25.7-44.2) 16 
   Total 63.9 (57.7-69.6) 573 57.6 (49.6-65.1) 141 60.3 (54.9-65.5) 714 
Community health worker - 0 - 0 - 0 
Uganda – Total 12.3 (10.4-14.5) 1,404 9.4 (6.9-12.7) 1,719 10.0 (7.8-12.6) 3,123 
Public health facility  7.6 (3.7-14.9) 144 12.4 (9.0-16.9) 533 11.7 (8.7-15.6) 677 
Private not-for-profit health facility 13.3 (3.4-39.7) 12 11.3 (4.5-25.5) 27 11.5 (5.1-24.0) 39 
Private for-profit outlet       
   Health facility/pharmacy 15.8 (13.0-19.2) 809 15.4 (10.5-22.0) 387 15.6 (12.4-19.4) 1,196 
   Drug store 8.5 (6.2-11.5) 433 8.9 (5.7-13.8) 676 8.9 (6-12.9) 1,109 
   General retailer/itinerant 0.0 4 0.0 14 0.0 18 
   Total 12.6 (10.7-14.7) 1,246 10.1 (7.2-14.0) 1,077 10.7 (8.3-13.7) 2,323 
Community health worker 0.0 2 1.7 (0.3-8.6) 82 1.6 (0.3-8.6) 84 
Zanzibar – Total 84.7 222 72.5 120 80.4 342 
Public health facility  85.4 48 73.7 76 78.2 124 
Private not-for-profit health facility 100.0 1 0.0 1 50.0 2 
Private for-profit outlet       
   Health facility/pharmacy 92.7 82 75.0 16 89.8 98 
   Drug store 77.3 88 70.8 24 75.9 112 
   General retailer/itinerant 66.7 3 66.7 3 66.7 6 
   Total 84.4 173 72.1 43 81.9 216 
Community health worker - 0 - 0 - 0 
Note: Recommended retail prices were set for copaid ACTs in all pilots except Madagascar.  
CI = Confidence interval 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.6.9: Providers stating the correct maximum/recommended retail price (RRP) for antimalarials with 
the AMFm logo at endline, 2011 
Providers stating the correct RRP for antimalarials with the AMFm logo (n) as a percentage of providers who responded that 
there was a RRP for antimalarials with the AMFm logo (N), ), by urban-rural location and type of outlet, according to country 
 Urban Rural Total 
Country/Type of outlet % (95% CI) N % (95% CI) N % (95% CI) N 
Ghana – Total 94.8 (92.4-96.5) 533 87.6 (82.8-91.3) 317 92.4 (89.9-94.3) 850 
Public health facility  92.5 (81.2-97.3) 85 95.9 (92.4-97.8) 186 94.9 (91.1-97.1) 271 
Private not-for-profit health facility 100.0 4 85.3 (45.9-97.5) 7 92.0 (64.3-98.6) 11 
Private for-profit outlet       
   Health facility/pharmacy 97.0 (93.1-98.7) 261 92.2 (64.5-98.7) 25 96.4 (92.3-98.4) 286 
   Drug store 94.0 (90.8-96.1) 181 84.8 (76.6-90.5) 98 91.0 (87.4-93.6) 279 
   General retailer/itinerant 100.0 2 0.0 1 66.2 (20.0-93.9) 3 
   Total 94.9 (92.6-96.5) 444 84.7 (77.5-90.0) 124 92.0 (89.2-94.2) 568 
Community health worker - 0 - 0 - 0 
Kenya – Total 92.4 (89.7-94.5) 887 95.5 (93.1-97.1) 581 94.5 (92.7-95.9) 1,468 
Public health facility  91.8 (84.2-95.9) 103 94.5 (86.9-97.8) 240 94.3 (87.5-97.5) 343 
Private not-for-profit health facility 79.4 (49.7-93.7) 16 76.4 (43.0-93.3) 16 77.2 (51.9-91.4) 32 
Private for-profit outlet       
   Health facility/pharmacy 88.1 (81.9-92.4) 378 95.1 (82.4-98.8) 90 92.3 (87.3-95.5) 468 
   Drug store 96.8 (91.3-98.8) 313 98.6 (95.5-99.5) 132 97.8 (95.2-99.0) 445 
   General retailer/itinerant 87.3 (75.8-93.8) 77 95.0 (87.8-98.0) 103 93.6 (87.9-96.7) 180 
   Total 92.9 (90.1-94.9) 768 96.6 (93.6-98.2) 325 95.3 (93.4-96.7) 1,093 
Community health worker - 0 - 0 - 0 
Madagascar – Total       
Public health facility  - - - - - - 
Private not-for-profit health facility - - - - - - 
Private for-profit outlet - - - - - - 
   Health facility/pharmacy - - - - - - 
   Drug store - - - - - - 
   General retailer/itinerant - - - - - - 
   Total - - - - - - 
Community health worker - - - - - - 
Niger – Total 66.3 (61.7-70.6) 268 56.4 (43.5-68.5) 132 60.8 (53.0-68.1) 400 
Public health facility  85.7 (77.9-91.1) 80 84.1 (75.5-90.0) 99 84.4 (77.9-89.4) 179 
Private not-for-profit health facility 100.0 1 0 1 19.4 (2.7-67.5) 2 
Private for-profit outlet       
   Health facility/pharmacy 71.9 (58.7-82.1) 77 100.0 4 74.1 (61.3-83.9) 81 
   Drug store 84.6 (60.6-95.1) 11 100.0 1 89.6 (70.0-97.0) 12 
   General retailer/itinerant 57.5 (50.4-64.4) 99 27.8 (14.3-46.9) 27 42.9 (33.3-53.2) 126 
   Total 61.8 (56.4-66.9) 187 31.8 (17.6-50.5) 32 48.8 (40.0-57.7) 219 
Community health worker - 0 - 0 - 0 
Nigeria – Total 10.8 (4.9-22.4) 198 11.6 (4.4-27.3) 73 11.1 (6.0-19.6) 271 
Public health facility  0.0 6 0.0 4 0.0 10 
Private not-for-profit health facility 0.0 2 0.0 1 0.0 3 
Private for-profit outlet       
   Health facility/pharmacy 18.6 (2.8-64.2) 23 17.0 (3.3-55.1) 7 18.0 (4.7-49.6) 30 
   Drug store 10.4 (4.9-20.5) 160 11.6 (3.7-31.3) 58 10.8 (5.8-19.5) 218 
   General retailer/itinerant 0.0 6 0.0 3 0.0 9 
   Total 11.4 (5.2-23.1) 189 12.0 (4.5-28.2) 68 11.6 (6.4-20.3) 257 
Community health worker 0.0 1 - 0 0.0 1 
Tanzania - mainland – Total 83.4 (74.4-89.7) 412 80.3 (68.5-88.5) 113 81.5 (73.7-87.4) 525 
Public health facility  61.2 (13-94.3) 4 63.9 (42.3-81.1) 29 63.8 (43.0-80.5) 33 
Private not-for-profit health facility 100.0 1 100.0 1 100.0 2 
Private for-profit outlet       
   Health facility/pharmacy 89.4 (80.4-94.5) 249 17.6 (5.8-42.4) 11 77.9 (58.2-89.9) 260 
   Drug store 82.4 (71.8-89.6) 157 88.7 (76.0-95.1) 68 85.9 (78.0-91.3) 225 
   General retailer/itinerant 100.0 1 100.0 4 100.0 5 
   Total 83.8 (74.4-90.2) 407 87.3 (76.5-93.6) 83 85.7 (78.8-90.6) 490 
Community health worker - 0 - 0 - 0 
Uganda – Total 4.2 (2.2-7.9) 231 4.7 (2.3-9.7) 194 4.6 (2.6-8.2) 425 
Public health facility  0.0 18 2.1 (0.3-14.5) 67 1.9 (0.2-13.2) 85 
Private not-for-profit health facility 0.0 2 0.0 3 0.0 5 
Private for-profit outlet       
   Health facility/pharmacy 5.5 (2.9-10.2) 169 8.1 (2.3-24.5) 61 7 (3.2-14.5) 230 
   Drug store 1.5 (0.2-9.1) 42 4.0 (1.5-10.4) 61 3.7 (1.4-9.2) 103 
   General retailer/itinerant - 0 - 0 - 0 
   Total 4.4 (2.3-8.3) 211 5.4 (2.5-11.4) 122 5.1 (2.8-9.2) 333 
Community health worker - 0 0.0 2 0.0 2 
Zanzibar – Total 98.4 188 95.4 87 97.5 275 
Public health facility  97.6 41 94.6 56 95.9 97 
Private not-for-profit health facility 100.0 1 - 0 100.0 1 
Private for-profit outlet       
   Health facility/pharmacy 98.7 76 100.0 12 98.9 88 
   Drug store 98.5 68 94.1 17 97.6 85 
   General retailer/itinerant 100.0 2 100.0 2 100.0 4 
   Total 98.6 146 96.8 31 98.3 177 
Community health worker - 0 - 0 - 0 
Note: No data are shown for Madagascar as an RRP was not set for copaid ACTs in this country.  
CI = Confidence interval 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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Table 2.6.10: Providers who have received training on antimalarials with the AMFm logo at endline, 2011 
Percentage of outlets with at least one staff member that received training on antimalarials with the AMFm logo (n) among 
outlets with any antimalarials in stock at the time of the survey visit (N), by urban-rural location and type of outlet, according to 
country 
 Urban Rural Total 
Country/Type of outlet % (95% CI) N % (95% CI) N % (95% CI) N 
Ghana – Total 52.0 (44.7-59.2) 571 50.9 (40.3-61.4) 381 51.5 (45.4-57.6) 952 
Public health facility  59.8 (47.9-70.6) 94 60.3 (49.4-70.3) 204 60.2 (51.8-68.0) 298 
Private not-for-profit health facility 80.0 (38.0-96.3) 4 38.7 (13.2-72.2) 8 55.9 (29.6-79.2) 12 
Private for-profit outlet       
   Health facility/pharmacy 40.3 (34.2-46.7) 268 72.2 (53.7-85.2) 26 44.5 (38.8-50.3) 294 
   Drug store 55.6 (46.2-64.6) 202 47.2 (36.1-58.4) 140 52.3 (45.0-59.4) 342 
   General retailer/itinerant 0.0 3 32.7 (3.8-85.7) 3 16.4 (2.6-58.6) 6 
   Total 50.9 (43.5-58.3) 473 48.8 (37.7-60.0) 169 50.2 (44.0-56.4) 642 
Community health worker - 0 - 0 - 0 
Kenya – Total 15.3 (11.7-19.8) 1,047 11.2 (8.4-14.8) 800 12.3 (10-15.1) 1,847 
Public health facility  20.0 (14.4-27.2) 137 11.6 (7.3-17.9) 294 12.2 (8.1-18.1) 431 
Private not-for-profit health facility 19.0 (6.5-44.2) 19 19.8 (9.2-37.6) 27 19.7 (10.3-34.3) 46 
Private for-profit outlet       
   Health facility/pharmacy 18.4 (12.6-26.1) 407 25.0 (15.1-38.5) 112 22.5 (15.3-31.8) 519 
   Drug store 19.9 (15.1-25.8) 329 11.6 (6.9-18.9) 144 15 (11.1-19.9) 473 
   General retailer/itinerant 0.0 155 3.1 (1.0-9.0) 223 2.5 (0.8-7.3) 378 
   Total 15.1 (11.3-19.8) 891 10.7 (7.1-15.6) 479 12 (9.2-15.5) 1,370 
Community health worker - 0 - 0 - 0 
Madagascar – Total 10.1 (7.1-14.3) 979 5.1 (3.6-7.1) 1,387 5.8 (4.3-7.6) 2,366 
Public health facility  21.8 (13.1-34.1) 65 14.8 (10.9-19.7) 553 15.6 (11.9-20.1) 618 
Private not-for-profit health facility 27.8 (15-45.7) 25 31.3 (5.9-76.9) 5 30 (10.7-60.5) 30 
Private for-profit outlet       
   Health facility/pharmacy 30.9 (22.5-40.7) 105 0.0 12 16.9 (8.6-30.3) 117 
   Drug store 41.4 (14.4-74.8) 28 8.3 (5.0-13.5) 347 11.8 (7.1-19.1) 375 
   General retailer/itinerant 0.2 (0.1-0.7) 741 0.7 (0.3-1.8) 404 0.7 (0.3-1.6) 1,145 
   Total 7.1 (4.5-11.0) 874 1.4 (0.8-2.2) 763 2.2 (1.5-3.3) 1,637 
Community health worker 66.1 (48.2-80.4) 15 17.0 (7.0-36.0) 66 18.2 (7.8-36.8) 81 
Niger – Total 14.7 (11.6-18.5) 1,014 11.4 (7.9-16.3) 468 13.3 (10.7-16.3) 1,482 
Public health facility  25.6 (12-46.4) 43 24.9 (12.4-43.8) 51 25 0.(12.9-42.7) 94 
Private not-for-profit health facility 41.0 (8.4-84.0) 6 6.9 (0.6-45.9) 3 8.5 (1.1-42.7) 9 
Private for-profit outlet       
   Health facility/pharmacy 16.7 (12.5-22.0) 94 13.6 (3.4-41.7) 31 14.1 (4.4-36.6) 125 
   Drug store 15.5 (11.9-20.0) 796 9.6 (6.3-14.2) 360 13.2 (10.3-16.8) 1,156 
   General retailer/itinerant 3.4 (0.7-14.1) 72 8.9 (2.2-29.4) 19 4.8 (1.7-13.0) 91 
   Total 14.6 (11.5-18.4) 962 9.9 (6.3-15.3) 410 12.8 (10.1-16.0) 1,372 
Community health worker 33.3 (33.3-33.3) 3 0.0 4 1.3 (0.1-12.7) 7 
Nigeria – Total 15.8 (12.2-20.1) 1,014 11.4 (7.9-16.3) 468 14.0 (11.2-17.4) 1,482 
Public health facility  11.2 (3.2-32.4) 43 24.9 (12.4-43.8) 51 20.3 (10.8-34.9) 94 
Private not-for-profit health facility 41.2 (6.0-88.6) 6 6.9 (0.6-45.9) 3 28.3 (4.9-75.2) 9 
Private for-profit outlet       
   Health facility/pharmacy 25.9 (11.6-48.3) 94 13.6 (3.4-41.7) 31 21.3 (11.0-37.2) 125 
   Drug store 15.5 (11.9-20.0) 796 9.6 (6.3-14.2) 360 13.2 (10.3-16.8) 1,156 
   General retailer/itinerant 3.4 (0.7-14.1) 72 8.9 (2.2-29.4) 19 4.8 (1.7-13.0) 91 
   Total 15.7 (12.4-19.7) 962 9.9 (6.3-15.3) 410 13.5 (10.7-16.9) 1,372 
Community health worker 33.3 (33.3-33.3) 3 0.0 4 1.3 (0.1-12.7) 7 
Tanzania - mainland – Total 16.4 (10.3-25) 583 18.8 (13.4-25.8) 191 17.9 (13.7-23.2) 774 
Public health facility  11.7 (1.4-55.0) 6 17.4 (8.6-32.1) 48 17.2 (8.6-31.3) 54 
Private not-for-profit health facility 29.7 (4.0-81.1) 4 0.0 2 15.8 (2.1-62.8) 6 
Private for-profit outlet       
   Health facility/pharmacy 17.0 (8.4-31.3) 313 76.1 (41.4-93.5) 16 32.6 (17.2-52.9) 329 
   Drug store 16.3 (9.3-26.9) 256 19.5 (12.9-28.4) 113 18.1 (13-24.6) 369 
   General retailer/itinerant 0.0 4 0.0 12 0.0 16 
   Total 16.2 (9.8-25.6) 573 19.6 (13.9-26.9) 141 18.1 (13.6-23.7) 714 
Community health worker - 0 - 0 - 0 
Uganda – Total 17.3 (15-19.8) 1,402 14.9 (12.2-18.0) 1,715 15.4 (13.2-17.8) 3,117 
Public health facility  10.7 (5.3-20.4) 144 12.7 (9.7-16.3) 532 12.4 (9.7-15.7) 676 
Private not-for-profit health facility 4.5 (0.5-28.5) 12 12.0 (3.1-36.2) 27 11.2 (3.1-32.8) 39 
Private for-profit outlet       
   Health facility/pharmacy 16.8 (13.7-20.4) 807 23.0 (15.3-33.1) 386 20.3 (15.3-26.3) 1,193 
   Drug store 19.5 (15.5-24.3) 433 14.8 (11.7-18.4) 675 15.5 (12.8-18.6) 1,108 
   General retailer/itinerant 0.0 4 0.0 14 0.0 18 
   Total 17.9 (15.4-20.7) 1,244 16.2 (12.9-20.1) 1,075 16.6 (14-19.5) 2,319 
Community health worker 0.0 2 8.5 (2.5-25.3) 81 8.5 (2.5-25.1) 83 
Zanzibar – Total 33.3 222 45.8 120 37.7 342 
Public health facility  35.4 48 39.5 76 37.9 124 
Private not-for-profit health facility 0.0 1 100.0 1 50.0 2 
Private for-profit outlet       
   Health facility/pharmacy 43.9 82 75.0 16 49.0 98 
   Drug store 23.9 88 50.0 24 29.5 112 
   General retailer/itinerant 0.0 3 0 3 0.0 6 
   Total 32.9 173 55.8 43 37.5 216 
Community health worker - 0 - 0 - 0 
CI = Confidence interval 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys 
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3 Results from Household Surveys 
Household survey data were use to assess the evaluation question on ACT use. 
 
Question 3: Has the AMFm mechanism helped increase use of quality-assured ACTs, including 
among vulnerable groups, such as poor people, rural residents and children? 
 
3.1 Fever prevalence 
Table 3.1.1 shows the percentage of children under five years with fever in the two weeks 
preceding the survey according to urban-rural residence and wealth. The prevalence of fever 
among young children varies widely among the countries, ranging from less than one child in 10 
(9%) in Madagascar to more than four children in 10 (45%) in Uganda. It is important to note 
that fever can have many causes and it is highly seasonal, so comparisons among countries have 
to be interpreted with caution. 
 
The prevalence of fever was slightly higher among children living in rural areas than in urban 
areas in Ghana, Kenya, Niger and Nigeria, but it is higher in urban areas in the remaining 
countries. The most pronounced urban-rural difference in fever prevalence among young 
children is observed in Tanzania mainland where 30% of children in urban areas and 21% of 
children in rural areas had fever in the two weeks preceding the survey. Fever prevalence is 
lowest among children in the highest wealth quintile in Ghana, Niger, Nigeria and Uganda, but 
contrary to expectations, it is highest in the highest wealth quintile in Kenya, Madagascar and 
Zanzibar. In Tanzania mainland, fever is more prevalent in the two highest wealth quintiles than 
in any of the three lowest wealth quintiles. 
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Table 3.1.1: Prevalence of fever among children under five years by selected background characteristics  
Percentage of children under five years with fever in the 2 weeks preceding the survey, by urban-rural residence and wealth 
quintile, according to country 
Country/background 
characteristics 
BASELINE ENDLINE 
PERCENTAGE POINT 
CHANGE 
Percentage N Source Percentage N Source Percentage N 
Ghana 19.9 2,731 GDHS 2008      
Residence         
Urban 19.0 1,039       
Rural  20.5 1,692       
Wealth quintiles         
Lowest 19.7 693       
Second 22.3 610       
Middle 22.0 507       
Fourth 19.6 528       
Highest 14.3 393       
Kenya – Total 27.3 2,814 KMIS 2010      
Residence         
Urban 26.4 397       
Rural  27.5 2,417       
Wealth quintiles         
Lowest 25.5 812       
Second 25.7 645       
Middle 25.2 520       
Fourth 31.1 471       
Highest 32.4 367       
Madagascar – Total 9.3 11,976 MDHS 2009      
Residence         
Urban 12.5 1,311       
Rural  8.9 10,665       
Wealth quintiles         
Lowest 9.1 3,065       
Second 9.3 2,664       
Middle 8.2 2,406       
Fourth 9.3 2,137       
Highest 11.3 1,705       
Niger – Total 26.8 8,727 NMICS 2006      
Residence         
Urban 23.4 1,383       
Rural  27.5 7,344       
Wealth quintiles         
Lowest 29.0 1,879       
Second 27.3 1,739       
Middle 27.7 1,658       
Fourth 27.3 1,797       
Highest 22.5 1,655       
Nigeria 15.9 24,975 NDHS 2008      
Residence         
Urban 12.8 7,690       
Rural  17.2 17,284       
Wealth quintiles         
Lowest 17.8 5,634       
Second 17.1 5,566       
Middle 16.0 4,787       
Fourth 14.9 4,533       
Highest 12.9 4,455       
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3.2 Antimalarial treatment among children with fever 
Table 3.2.1 shows the percentage of children with fever in the two weeks preceding the survey 
who received any antimalarial treatment by urban-rural residence and wealth quintile. Overall, 
Tanzania mainland and Uganda have the highest percentage of children who received any 
antimalarials, and the lowest percentages are reported in Zanzibar and Madagascar. By 
background characteristics, urban children are more likely to be treated with any antimalarial 
than rural children in Ghana, Kenya, Niger, Nigeria and Tanzania mainland. Regarding wealth 
quintiles, in Madagascar, Niger, Nigeria, Tanzania mainland and Uganda (in the ACTwatch 
survey), the percentage of children who received treatment with any antimalarial is highest 
among children in the highest wealth quintile. In Ghana, the percentage treated with any 
antimalarial increases steadily from the lowest to the fourth wealth quintile (from 28% to 64%) 
before decreasing to 42% in the highest wealth quintile. In Kenya, the percentage treated is 
lowest in the lowest wealth quintile, but there is no clear pattern of treatment of children with 
any antimalarial in the higher wealth quintiles. 
Table 3.1.1: Cont. 
Country/background 
characteristics 
BASELINE ENDLINE 
PERCENTAGE POINT 
CHANGE 
Percentage N Source Percentage N Source Percentage N 
Tanzania – mainland – Total 23.1 7,461 TDHS 2010      
Residence         
Urban 30.1 1,463       
Rural  21.3 5,998       
Wealth quintiles         
Lowest 23.1 1,608       
Second 19.4 1,793       
Middle 21.2 1,679       
Fourth 28.6 1,382       
Highest 25.1 998       
Uganda – Total 44.7 3,727 UMIS 2009      
Residence         
Urban 47.8 489       
Rural  44.3 3,238       
Wealth quintiles         
Lowest 55.1 836       
Second 45.2 799       
Middle 44.0 767       
Fourth 40.0 687       
Highest 35.9 638       
Zanzibar – Total 19.1 206 TDHS 2010      
Residence         
Urban 21.6 71       
Rural  17.7 135       
Wealth quintiles         
Lowest 14.8 10       
Second 20.5 26       
Middle 17.9 30       
Fourth 16.2 62       
Highest 21.8 78       
Note: Relevant endline data were not available for any of the countries at the time of submission of this report on August 31, 2012.  
N = Number of children under five years 
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Table 3.2.1: Any antimalarial treatment of fever among children under five years by selected background 
characteristics 
Indicator 3.3: Percentage of children with fever in the 2 weeks preceding the survey who received any antimalarial 
treatment, by urban-rural residence and wealth quintile, according to country 
Country/background 
characteristics 
BASELINE ENDLINE 
PERCENTAGE POINT 
CHANGE 
% N Source % N Source % N 
Ghana – Total 43.0 544 GDHS 2008      
Residence         
Urban 52.6 197       
Rural  37.5 347       
Wealth quintiles         
Lowest 27.9 136       
Second 38.9 136       
Middle 47.5 111       
Fourth 63.5 104       
Highest 42.4 56       
Kenya – Total 35.1 769 KMIS 2010      
Residence         
Urban 45.7 105       
Rural  33.4 664       
Wealth quintiles         
Lowest 20.3 207       
Second 41.1 166       
Middle 34.0 131       
Fourth 46.8 146       
Highest 39.0 119       
Madagascar- Source 1 - Total 19.7 1,116 MDHS 2009      
Residence         
Urban 14.9 164       
Rural  20.5 952       
Wealth quintiles         
Lowest 19.1 279       
Second 24.2 249       
Middle 22.9 198       
Fourth 14.7 198       
Highest 16.4 192       
Madagascar Source 1 - Total 47.2 2,120 ACTwatch 2009      
Residence         
Urban 44.0 1,061       
Rural  47.6 1,059       
Wealth quintiles         
Lowest 44.5 422       
Second 47.3 429       
Middle 49.2 426       
Fourth 49.6 427       
Highest 50.4 416       
Niger
1 –Total 33.0 2,343 NMICS 2006      
Residence         
Urban 45.1 324       
Rural  31.1 2,019       
Wealth quintiles         
Lowest 26.0 545       
Second 37.9 474       
Middle 30.2 460       
Fourth 32.4 491       
Highest 41.6 373       
Nigeria –Total 33.2 3,968 NDHS 2008      
Residence         
Urban 41.1 987       
Rural  30.5 2,981       
Wealth quintiles         
Lowest 21.9 1,001       
Second 26.4 953       
Middle 35.5 765       
Fourth 40.2 674       
Highest 52.7 575       
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Artemisinin-based combination therapy (ACT) is the recommended first-line antimalarial drug 
for all the pilot countries. Table 3.2.2 shows the percentage of children with fever in the 2 weeks 
preceding the survey who received ACT treatment by urban-rural residence and wealth quintile. 
The percentage of children who were given ACTs for their fever varies across countries, ranging 
from only 1% in Madagascar to 38% in Tanzania mainland. In all countries except Kenya and 
Tanzania mainland, the percentage of children with fever who were given ACTs is higher among 
children in urban areas than in rural areas, with the largest difference observed in Ghana (13 
percentage points). The percentage of children with fever who received ACTs generally 
increases with an increase in wealth quintiles except in Uganda and Tanzania mainland where 
sick children from the lowest wealth quintile have the highest percentage treated with ACTs. 
 
Table 3.2.1: Cont.  
Indicator 3.3: Percentage of children with fever in the 2 weeks preceding the survey who received any antimalarial 
treatment, by urban-rural residence and wealth quintile, according to country 
Country/background 
characteristics 
BASELINE ENDLINE 
PERCENTAGE POINT 
CHANGE 
Percentage N Source Percentage N Source Percentage N 
Tanzania – mainland - Total 60.1 1,715 TDHS 2010      
Residence         
Urban 68.3 441       
Rural  57.3 1,274       
Wealth quintiles         
Lowest 57.3 371       
Second 58.4 346       
Middle 57.5 355       
Fourth 59.8 394       
Highest 70.8 250       
Uganda - Source 1 - Total 59.6 1,667 UMIS 2009      
Residence         
Urban 52.7 234       
Rural  60.7 1,433       
Wealth quintiles         
Lowest 63.0 461       
Second 60.1 361       
Middle 54.5 338       
Fourth 57.2 277       
Highest 62.1 229       
Uganda - Source 2 - Total 51.2 1,752 ACTwatch 2009      
Residence         
Urban na na       
Rural  na na       
Wealth quintiles         
Lowest 53.4 356       
Second 47.1 357       
Middle 46.2 343       
Fourth 53.2 360       
Highest 58.3 334       
Zanzibar – Total 16..9 39 TDHS 2010      
Residence         
Urban *        
Rural  *        
Wealth quintiles         
Lowest *        
Second *        
Middle *        
Fourth *        
Highest *        
Note: Relevant endline data were not available for any country at the time of submission of this report on August 31, 2012. 
N= Number of children with fever in the 2 weeks preceding the survey, na = Not available, 1ACT data not available for Niger, * Percentages not 
shown because the number of cases is too small to produce reliable results. 
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Table 3.2.2: ACT treatment among children under five years with fever by selected background 
characteristics 
Indicator 3.1: Percentage of children under five years with fever in the 2 weeks preceding the survey who received ACT 
treatment, by urban-rural residence and wealth quintile, according to country 
Country/background 
characteristics 
BASELINE ENDLINE 
PERCENTAGE POINT 
CHANGE 
Percentage N Source Percentage N Source Percentage N 
Ghana – Total 21.5 544 GDHS 2008      
Residence         
Urban 29.9 197       
Rural  16.7 347       
Wealth quintiles         
Lowest 7.5 136       
Second 20.1 136       
Middle 26.6 111       
Fourth 33.6 104       
Highest 26.6 56       
Kenya- Total 18.0 769 KMIS 2010      
Residence         
Urban 15.8 105       
Rural  18.4 664       
Wealth quintiles         
Lowest 14.8 207       
Second 20.7 166       
Middle 14.4 131       
Fourth 27.4 146       
Highest 12.2 119       
Madagascar- Source 1- Total 1.0 1,116 MDHS 2009      
Residence         
Urban 1.8 164       
Rural  0.9 952       
Wealth quintiles         
Lowest 1.1 279       
Second 0.3 249       
Middle 1.6 198       
Fourth 0.3 198       
Highest 1.9 192       
Madagascar Source 1- Total 3.3 2,120 ACTwatch 2009      
Residence         
Urban 4.6 1061       
Rural  3.1 1059       
Wealth quintiles         
Lowest 0.9 422       
Second 3.2 429       
Middle 5.4 426       
Fourth 5.8 427       
Highest 4.4 416       
Total 3.3 2,120       
Niger
1
- Total na na NMICS 2006      
Residence         
Urban na na       
Rural  na na       
Wealth quintiles         
Lowest na na       
Second na na       
Middle na na       
Fourth na na       
Highest na na       
Nigeria- Total 2.4 3,968 NDHS 2008      
Residence         
Urban 4.3 987       
Rural  1.8 2981       
Wealth quintiles         
Lowest 1.3 1001       
Second 1.5 953       
Middle 1.9 765       
Fourth 2.4 674       
Highest 6.4 575       
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Table 3.2.2: cont. 
Country/background 
characteristics 
BASELINE ENDLINE PERCENTAGE POINT 
CHANGE 
Percentage N Source Percentage N Source Percentage N 
Tanzania – mainland- Total 37.9 1,715 TDHS 2010      
Residence         
Urban 33.7 441       
Rural  39.4 1,274       
Wealth quintiles         
Lowest 44.6 371       
Second 37.5 346       
Middle 36.6 355       
Fourth 33.0 394       
Highest 38.4 250       
Uganda - Source 1- Total 23.3 1,667 UMIS 2009      
Residence         
Urban 26.4 234       
Rural  22.8 1433       
Wealth quintiles         
Lowest 24.4 461       
Second 23.1 361       
Middle 20.9 338       
Fourth 22.0 277       
Highest 26.5 229       
Uganda - Source 2- Total 20.8 1,752 ACTwatch 2009      
Residence         
Urban na        
Rural  na        
Wealth quintiles         
Lowest 24.5 356       
Second 16.7 357       
Middle 15.8 343       
Fourth 20.8 360       
Highest 26.4 334       
Uganda – Zanzibar - Total 5.6 39 TDHS 2010      
Residence *        
Urban         
Rural  *        
Wealth quintiles *        
Lowest *        
Second *        
Middle *        
Fourth *        
Highest *        
Note: Relevant endline data not available for any of the countries at the time of submission of this report on August 31, 2012. 
N = Number of children under five years, na = Not available, 1ACT data not available for Niger, * Percentages not shown because the number of 
cases is too small to produce reliable results. 
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Prompt treatment of fever is important, especially among young children. Table 3.2.3 shows the 
percentage of children under age five with fever in the two weeks preceding the survey who 
received ACT treatment the same day or the next day after the onset of fever by urban-rural 
residence and wealth quintile. In half of pilot countries, only a small percentage of children with 
fever (less than 5%) received prompt treatment with ACTs. The percentage is highest in 
Tanzania mainland (27%), followed by Uganda (14% in the 2009 MIS and 18% in the 2009 
ACTwatch survey) and Ghana (12%). Prompt treatment with ACTs is higher in urban areas than 
in rural areas in every survey except for Tanzania mainland and Kenya, and it generally increases 
with an increase in wealth quintiles. For example, in Ghana, the percentage of young children 
with fever in the preceding two weeks who received ACT treatment increases from 3% among 
the poorest children to 20% among the wealthiest children. 
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Table 3.2.3: Prompt ACT treatment of fever among under five children by selected background 
characteristics 
Indicator 3.2: Percentage of children with fever in the 2 weeks preceding the survey who received ACT treatment 
the same day/next day after fever onset, by urban-rural residence and wealth quintile, according to country 
Country/background 
characteristics 
BASELINE ENDLINE PERCENTAGE POINT 
CHANGE 
Percentage N Source Percentage N Source Percentage N 
Ghana – Total 12.1 544 GDHS 2008      
Residence         
Urban 17.1 197       
Rural  9.3 347       
Wealth quintiles         
Lowest 2.9 136       
Second 12.2 136       
Middle 15.6 111       
Fourth 16.0 104       
Highest 19.9 56       
Kenya – Total 10.6 769 KMIS 2010      
Residence         
Urban 10.6 105       
Rural  10.6 664       
Wealth quintiles         
Lowest 7.3 207       
Second 13.6 166       
Middle 8.3 131       
Fourth 17.0 146       
Highest 7.0 119       
Madagascar- Source 1 - Total 0.4 1,116 MDHS 2009      
Residence         
Urban 1.8 164       
Rural  0.1 952       
Wealth quintiles         
Lowest 0.0 279       
Second 0.0 249       
Middle 0.0 198       
Fourth 0.3 198       
Highest 1.9 192       
Madagascar Source 1 - Total 3.1 2,120 ACTwatch 2009      
Residence         
Urban 3.8 1061       
Rural  3.0 1059       
Wealth quintiles         
Lowest 0.6 422       
Second 3.2 429       
Middle 5.3 426       
Fourth 5.5 427       
Highest 4.2 416       
Niger
1
- Total na na NMICS 2006      
Residence na na na      
Urban na na na      
Rural  na na na      
Wealth quintiles na na na      
Lowest na na na      
Second na na na      
Middle na na na      
Fourth na na na      
Highest na na na      
Nigeria – Total 1.1 3,968 NDHS 2008      
Residence         
Urban 1.8 987       
Rural  0.9 2981       
Wealth quintiles         
Lowest 0.9 1001       
Second 0.5 953       
Middle 0.7 765       
Fourth 1.3 674       
Highest 2.7 575       
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3.3 Diagnostic testing 
 
Data on diagnostic testing were not available for Ghana, Niger, Nigeria and Madagascar because 
the selected surveys did not include questions on this aspect. It should be noted that the question 
is used as a proxy for malaria diagnostic testing; however, the formulation of the question is not 
specific to malaria, “At any time during the illness, did (NAME) have blood taken from his/her 
finger or heel for testing?” Overall, for all countries with data, malaria diagnostic testing was 
very low, ranging between 6% in Madagascar and 20% in Zanzibar. Diagnostic testing was more 
common in urban areas than in rural areas, with the largest difference in Tanzania mainland 
where the percentage was 4 times higher in urban than rural areas. For all countries, the 
percentage of diagnostic testing is lower among children in the lower wealth quintiles than in the 
highest quintiles (Table 3.3.1) 
 
Table 3.2.3: Cont.  
Country/background 
characteristics 
BASELINE ENDLINE PERCENTAGE POINT 
CHANGE 
Percentage N Source Percentage N Source Percentage N 
Tanzania – mainland - Total 26.7 1,715 TDHS 2010      
Residence         
Urban 22.5 441       
Rural  28.1 1,274       
Wealth quintiles         
Lowest 30.5 371       
Second 27.5 346       
Middle 27.6 355       
Fourth 22.2 394       
Highest 25.8 250       
Uganda - Source 1 - Total 13.7 1,667 UMIS 2009      
Residence         
Urban 20.1 234       
Rural  12.6 1,433       
Wealth quintiles         
Lowest 12.0 461       
Second 12.5 361       
Middle 13.6 338       
Fourth 14.0 277       
Highest 18.6 229       
Uganda - Source 2 - Total 17.6 1,752 ACTwatch 2009      
Residence         
Urban na        
Rural  na        
Wealth quintiles         
Lowest 20.5 356       
Second 12.9 357       
Middle 13.9 343       
Fourth 18.1 360       
Highest 23.1 334       
Zanzibar – Total 4.0 39 TDHS 2010      
Residence         
Urban * *       
Rural  * *       
Wealth quintiles         
Lowest * *       
Second * *       
Middle * *       
Fourth * *       
Highest *        
Note: Relevant endline data not available for any country at the time of submission of this report on August 31, 2012 
N= Number of children with fever in the 2 weeks preceding the survey, na = Not available; 1ACT data not available for Niger, * Percentages not 
shown because the number of cases is too small to produce reliable results. 
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Table 3.3.1: Diagnostic testing among children under five years with fever by selected background characteristics 
Percentage of children under five years with fever in the two weeks before the survey who had blood taken from a finger or heel for 
testing 
Country/background 
characteristics 
BASELINE ENDLINE 
PERCENTAGE POINT 
CHANGE 
Percentage N Source Percentage N Source Percentage N 
Ghana – Total na na GDHS 2008      
Residence         
Urban na na       
Rural  na na       
Wealth quintiles na na       
Lowest na na       
Second na na       
Middle na na       
Fourth na na       
Highest na na       
Kenya – Total 11.8 769 KMIS 2010      
Residence         
Urban 18.8 105       
Rural  10.8 664       
Wealth quintiles         
Lowest 4.2 207       
Second 10.8 166       
Middle 11.2 131       
Fourth 15.7 146       
Highest 22.4 119       
Madagascar- Source 1 - Total na na MDHS 2009      
Residence         
Urban na na       
Rural  na na       
Wealth quintiles na na       
Lowest na na       
Second na na       
Middle na na       
Fourth na na       
Highest na na       
Madagascar Source 2 - Total 6.0 2,120 ACTwatch 2009      
Residence         
Urban 5.9 1,061       
Rural  6.0 1,059       
Wealth quintiles         
Lowest 3.7 422       
Second 6.7 429       
Middle 5.6 426       
Fourth 10.3 427       
Highest 10.8 416       
Niger
1
 – Total na na NMICS 2006      
Residence         
Urban na na       
Rural  na na       
Wealth quintiles         
Lowest na na       
Second na na       
Middle na na       
Fourth na na       
Highest na na       
Nigeria- Source 1 - Total na na NDHS2008      
Residence         
Urban na na       
Rural  na na       
Wealth quintiles         
Lowest na na       
Second na na       
Middle na na       
Fourth na na       
Highest na na       
Nigeria- Source 2 - Total 5.6 3,274 ACT watch 2009      
Residence         
Urban 6.5 1,160       
Rural  5.0 2,114       
Wealth quintiles         
Lowest 3.8 625       
Second 4.8 624       
Middle 4.4 650       
Fourth 5.3 617       
Highest 9.1 621       
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3.4 Antimalarial treatment among children with fever from the poorest 
households 
Table 3.3.1 shows the percentage of children with fever in the 2 weeks preceding the survey in 
the poorest households (lowest two wealth quintiles) who received treatment for malaria. The 
percentage of children with fever who received treatment with any antimalarial (Indicator 3.6) 
varies substantially across countries, from 22% in Madagascar to 62% in Uganda. Tanzania 
mainland has the second highest percentage (58%), followed by Ghana (33%), Niger (32%) and 
Kenya (30%). The percentage of children who received ACTs (Indicator 3.4) is 41% in Tanzania 
mainland, 24% in Uganda, 17% in Kenya, 14% in Ghana, and only 1% in Madagascar and 
Nigeria. These percentages decrease considerably when examining prompt treatment with ACTs 
(Indicator 3.5).  
Table 3.3.1: cont. 
Country/background 
characteristics 
BASELINE ENDLINE 
PERCENTAGE POINT 
CHANGE 
Percentage N Source Percentage N Source Percentage N 
Tanzania – mainland - Total 16.1 1,715 TDHS 2010      
Residence         
Urban 36.3 441       
Rural  9.2 1,274       
Wealth quintiles         
Lowest 9.6 371       
Second 7.1 346       
Middle 11.2 355       
Fourth 20.8 394       
Highest 37.9 250       
Uganda - Source 1 - Total 17.1 1,667 UMIS 2009      
Residence         
Urban 26.6 234       
Rural  15.6 1,433       
Wealth quintiles         
Lowest 15.3 461       
Second 13.1 361       
Middle 14.3 338       
Fourth 19.8 277       
Highest 28.2 229       
Uganda - Source 2 - Total 11.1 1,752 ACTwatch 2009      
Residence         
Urban na na       
Rural  na na       
Wealth quintiles         
Lowest 5.7 356       
Second 9.6 357       
Middle 10.0 343       
Fourth 10.7 360       
Highest 21.4 334       
Zanzibar – Total 20.2 39 TDHS 2010      
Residence         
Urban *        
Rural  *        
Wealth quintiles         
Lowest *        
Second *        
Middle *        
Fourth *        
Highest *        
Note: Relevant endline data not available for any of the countries at the time of submission of this report on August 31, 2012. 
N = Number of children under five years, na =Not available, * Percentages not shown because the number of cases is too small to produce 
reliable results if broken down into residence and wealth quintiles 
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Table 3.4.1: Treatment of fever among children under five years from the poorest households (lowest two 
wealth quintiles), by urban-rural residence 
Indicator 3.4: Percentage of children with fever in the 2 weeks preceding the survey in the poorest households (lowest two 
wealth quintiles) who received ACT treatment, according to country 
Indicator 3.5: Percentage of children with fever in the 2 weeks preceding the survey in the poorest households (lowest two 
wealth quintiles) who received ACT treatment the same/next day after the onset of fever, according to country 
Indicator 3.6: Percentage of children with fever in the 2 weeks preceding the survey in the poorest households (lowest two 
wealth quintiles) who received treatment with any antimalarials, according to country 
Country/background 
characteristics 
BASELINE ENDLINE PERCENTAGE POINT 
CHANGE 
Percentage N Source Percentage N Source Percentage N 
Ghana   GDHS 2008      
Any antimalarial treatment 33.4 272       
ACT treatment  13.9 272       
Prompt ACT treatment 7.4 272       
Kenya   KMIS 2010      
Any antimalarial treatment 29.6 473       
ACT treatment 17.4 473       
Prompt ACT treatment 10.1 473       
Madagascar   MDHS 2009      
Any antimalarial treatment 21.5 528       
ACT treatment 1.0 528       
Prompt ACT treatment 0.0 528       
Niger   NMICS 2006      
Any antimalarial treatment 31.5 1,019       
ACT treatment Na 1,019       
Prompt ACT treatment Na 1,019       
Nigeria   NDHS 2008      
Any antimalarial treatment 24.1 1,954       
ACT treatment 1.0 1,954       
Prompt ACT treatment 0.8 1,954       
Tanzania - mainland – Source   TDHS 2010      
Any antimalarial treatment 57.8 717       
ACT treatment 41.1 717       
Prompt ACT treatment 29.1 717       
Uganda   UMIS 2009      
Any antimalarial treatment 61.7 822       
ACT treatment 23.8 822       
Prompt ACT treatment 12.3 822       
Zanzibar   TDHS 2010      
Any antimalarial treatment * 7       
ACT treatment * 7       
Prompt ACT treatment * 7       
Note: Relevant endline data not available for any country at the time of submission of this report on August 31, 2012. 
N= Number of children with fever in the 2 weeks preceding the survey na = Not available, * Percentage not shown because the number of cases 
is too small to produce reliable results  
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4 Implementation process and context - Findings from the country 
case studies 
4.1 Ghana 
4.1.1 AMFm implementation process 
4.1.1.1 Governance structure for AMFm 
In 2010, an AMFm coordinating committee (AMFmCC) was established to plan, coordinate and 
oversee the implementation of activities in Ghana. The members are drawn from the Ministry of 
Health, Regulatory Agencies, multilateral and bilateral partners, the private sector, academic and 
research institutions, first line buyers (FLBs), professional associations, civil society 
organizations and the County Coordinating Mechanism (CCM) for Global Fund programs. The 
AMFmCC Secretariat is at the NMCP. 
4.1.1.2 AMFm copaid ACT supply mechanism 
Of the 32 FLBs registered with the Global Fund, 30 were from the private sector and one each 
from the public (MOH) and NGO sectors. All major players in the pharmaceutical sector who 
applied for registration with the Global Fund as FLBs were successfully registered, among them 
local manufacturers of ACTs. However, only 14 private sector FLBs and the MOH placed orders 
for copaid ACTs. The reasons given for private sector FLBs being unable to place orders with 
the pre-qualified manufacturers were that manufacturers preferred working with FLBs with 
whom they already had experience as local distribution agents and that they were not keen to 
change the memoranda of understanding they had with existing agents. As a result of the AMFm, 
FLBs scaled down significantly the import of non copaid ACTs while local manufacturers 
stopped or significantly scaled down production of ACTs, thus ensuring that copaid ACTs 
rapidly gained market share. 
 
The first order of copaid ACTs arrived in August 2010. Between June 2010 and December 2011, 
about 20 million doses of copaid ACTs were delivered to both private and public sector FLBs, 
constituting 56% of orders approved by the Global Fund in the same period. The public sector 
did not place its first order for copaid ACTs until mid-2011 because the Central Medical Stores 
(CMS) still held significant quantities of non-copaid ACTs ordered in 2010. However, in the 
intervening period, the CMS experienced stockouts of non-copaid ACTs and authorized the 
Regional Medical Stores (RMS) and health facilities to obtain copaid ACTs directly from the 
private sector. The first public sector orders of 1.4 million copaid treatments arrived in 
November 2011. As of December 2011, the public sector accounted for less than 10% of the 
delivered quantities.  
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All malaria medicines, including copaid and non-copaid ACTs with the exception of quinine 
formulations imported as finished pharmaceutical products, are liable to various taxes and levies. 
These taxes are charged on the prevailing market value of the medicine plus the cost of shipping 
and insurance or cost-insurance-freight (CIF). The AMFmCC, through the MoH, has negotiated 
with the Ministry of Trade to allow the calculation of taxes for copaid ACTs to be based on the 
co-payment cost rather than their actual value through a waiver system. The waiver, known as 
the “destination inspection waiver” allows for calculation of taxes based on declared value rather 
than the value determined through an independent customs inspection. Since this waiver must be 
obtained for each shipment of copaid ACTs, the committee has also been able to get the support 
of both the MoH and the Ministry of Trade to fast track the preparation of waiver documents so 
that the documents are ready when the copaid ACTs arrive in the country to minimize time spent 
at the port of entry. With the waiver of the destination inspection, all the taxes levied on the 
copaid ACTs add up to 15% of the CIF value of each shipment. However, given that the 
insurance and freight costs are higher than the co-payment cost and are paid by the Global Fund, 
the tax paid on the copaid ACTs by the FLBs represents a significant mark-up cost. The MoH 
has made a request to the Ministry of Finance to allow the taxes to be based on the free on board 
(FOB) rather than the CIF value of the medicines. As of December 2011, no decision had been 
made on this request. 
 
The AMFmCC also negotiated with the National Health Insurance Agency to reduce the 
reimbursement rate for malaria treatments from Gh₡ 4.00 (USD 2.57) to Gh₡ 1.50 (USD 0.96), 
thus encouraging private sector health care providers to stock copaid ACTs.  
 
At the time of endline outlet survey data collection, there were reports of challenges related to 
the approvals for orders for copaid ACTs placed by FLBs, with the approved quantities falling 
short of the quantities ordered, long delivery lead times for ordered ACTs and consequent 
stockouts along the private sector distribution chain. As a consequence, some first line buyers 
reported considering restocking non-copaid ACTs to meet demand.  
 
The transportation of medicines and other commodities to the northern, upper eastern and upper 
western regions is affected by poor road infrastructure, which increases transportation costs. 
FLBs transported copaid ACTs with other medical supplies to their regional depots countrywide 
ensuring that the medicines were available for purchase or further distribution within their retail 
networks in the regions. Medical supplies are transported in bulk at regular intervals, rather than 
in small quantities to the regional warehouses. Reports from monitoring activities carried out by 
the NMCP and the Pharmacy Council in the northern regions show that between April and July 
2011 the proportion of pharmacies and licensed chemical shops stocking copaid ACTs increased 
by more than 40 percentage points, supporting the fact that FLBs were able to distribute copaid 
ACTs even in regions with the poorest transport infrastructure. In the public sector, the central 
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and regional medical stores have an insufficient fleet of vehicles to transport medicines to health 
facilities and as a result, health facilities often use their own means to collect required supplies 
from regional medical stores while the regional stores do the same to collect their stocks from the 
CMS. The CMS sells public sector copaid ACTs to the RMSs at Gh₡ 0.07-0.30 (USD 0.04-
0.20), while the RMSs sell the copaid ACTs to public health facilities at Gh₡ 0.10-0.50 (USD 
0.06-0.32). Public health facilities sell the copaid ACTs at Gh₡ 0.20-0.70 (USD 0.13-0.45) and 
claim this cost from the NHIS for patients covered under the insurance scheme and directly from 
patients who are not members. Prior to the delivery of public sector copaid ACTs, the CMS, 
RMS and public health facilities procured copaid ACTs directly from FLBs or private 
wholesalers at prices ranging from Gh₡ 0.70-1.20 (USD 0.45-0.77) while patients paid Gh₡ 1.50 
(USD 0.96). 
4.1.2 Implementation of AMFm supporting interventions 
4.1.2.1 Communication 
AMFm was launched in Accra on February 17, 2011, by the Honourable Minister for Health and 
was attended by local leaders and dignitaries, including the WHO country representative, the 
Director of AMFm at the Global Fund and representatives from the private sector, civil society 
and other partners in malaria control. The launch was preceded by a publicity week using both 
print and electronic media and community mobilization all targeted at the general public. The 
launch also marked the beginning of a yearlong media campaign raising awareness about AMFm 
and was followed by launches in five of the 10 regions. All launch activities were supported by 
the Global Fund AMFm grant. 
 
An intensive awareness campaign using electronic and print media and supported by community-
based mobilization activities was successfully implemented from mid-February 2011. Over 
10,000 radio spots and 400 television commercials were aired in English and 7 local languages 
nationally. Three key messages were promoted: 1) ACTs are the only effective treatment for 
malaria, 2) the green leaf logo identifies subsidized ACTs and 3) ACTs with the green leaf are 
available, effective and affordable at Gh₡ 1.50 (USD 0.96).  
 
4.1.2.2 Recommended retail price 
The recommended retail price (RRP) of Gh₡ 1.50 (USD 0.94) for an adult dose was agreed on 
by all stakeholders and the AMFmCC. The price took into consideration taxes, logistics and 
overhead costs and supply chain mark-ups in the private sector. Although the price was not 
printed on the package, the RRP was widely publicized in media campaigns, and public 
awareness was generally high. In order to ensure adherence to the RRP, the Pharmaceutical 
Society of Ghana made appeals to all pharmacists to respect pricing and mark-ups for AMFm 
medicines in order to ensure that the pilot was successful.  
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It was reported that one downside of the communication campaign was that the advertised RRP 
became the minimum retail price for the ACTs, with those retailers who might have been selling 
them at a lower price raising the cost to match the RRP. 
4.1.2.3 Training 
Four thousand public health workers drawn from all regions were trained on malaria case 
management, including diagnosis, monitoring and reporting. All 1,400 targeted pharmacists and 
500 private medical practitioners successfully completed a one-day training course linked to 
Continuing Professional Development (CPD) points conducted by their respective professional 
associations. Over 7,400 of the targeted 8,500 licensed chemical sellers (LCS) received three 
days’ training on malaria case management and AMFm conducted by the Pharmacy Council. All 
training activities were scheduled for completion in the first quarter of 2012, but due to the long 
time it has taken to get training plans approved by the Global Fund, the activities will not be 
completed as scheduled. Regional regulatory officers from the Ghana Food and Drugs Board 
were also trained on malaria case management and on the conduct of routine monitoring of 
pharmaceutical services for dispensing practices and pricing. 
4.1.2.4 Other AMFm supporting interventions 
Two operational research projects were ongoing at the time of endline outlet survey data 
collection, but neither involved interventions likely to have influenced the Independent 
Evaluation indicators. 
4.1.2.5 Pharmacovigilance 
The Food and Drugs Board initiated cohort event monitoring of adverse events in four sentinel 
sites linked to regional and district health facilities in Ashanti and Western Regions of Ghana. 
The Board also conducted two rounds of post market surveillance of copaid and non-copaid 
ACTs at all levels of the supply chain from the port of entry to distribution to retail points in both 
the public and private sectors. Neither of these activities is likely to have influenced the AMFm 
outcomes. 
 
4.1.3 Implementation of non-AMFm interventions 
4.1.3.1 Home based care 
Home Based Care (HBC) is a community-based intervention aimed at increasing access to 
prompt treatment for malaria with ACTs in areas where malaria burden is high and access to 
health facilities is low. Access to prompt treatment is limited in rural areas due to lack of 
physical access as more health facilities are located in urban areas and due to socioeconomic 
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factors which also affect the urban poor. The main target of HBC is children less than five years 
old who are at a high risk of malaria morbidity and mortality. Children with suspected malaria 
receive presumptive treatment with copaid amodiaquine-artesunate at the community level. HBC 
was initiated through a rolling campaign targeting 26 districts from May 2011. This activity 
increased the number of districts implementing HBC through support by Global Fund Round 8, 
UNICEF and other partners to 149. 
4.1.3.2 Long-lasting insecticidal nets 
The AMFm pilot was implemented concurrently with a national door-to-door distribution and 
hang-up campaign of long-lasting insecticidal nets (LLINs), and at the time of endline outlet 
survey data collection, 5 million (40%) of the targeted 12 million LLINs aimed at achieving 
universal coverage had been distributed and hung up for use. Used consistently, LLINs are 
associated with a reduction in both malaria transmission and malaria-related morbidity and 
mortality. However, the limited availability and use of diagnostics during the AMFm 
implementation period makes it unlikely that this increased coverage of LLINs will have had a 
major impact on the use of copaid ACTs. 
4.1.4  Key events and context 
There was catastrophic flooding in the Eastern Region in July 2011 and in Greater Accra in 
October 2011 to which the NMCP and National Disaster Management Committee responded 
with the distribution of LLINs to those lacking nets, as well as free RDTs and ACTs to 
emergency treatment centers and health facilities for prompt diagnosis and treatment of malaria. 
Data from the health information system for the period do not show any significant changes in 
malaria cases in the affected regions. 
4.1.5  Conclusion 
Table 4.1.1 summarizes of key factors likely to have supported or hindered achievement of 
AMFm goals in Ghana and Figure 4.1.1 presents a timeline of all key events related to AMFm 
implementation and context. 
 
The AMFm pilot has been successfully implemented in Ghana with availability of copaid ACTs 
and adherence to the recommended retail price both reported to be widespread. The 
communications campaign successfully used electronic and print media, workshops and 
community mobilization activities to create awareness about copaid ACTs. Implementation of all 
supporting interventions planned was at an advanced stage, except for home based care and the 
operational research activities which had only been recently initiated. Over 12,000 health 
workers in both the public and private sectors, including licensed chemical sellers and some 
community health workers, had been trained with more scheduled for training in 2012. Sentinel 
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sites to strengthen pharmacovigilance and post-market surveillance were set up, and operational 
research aimed at improving the uptake of diagnosis-based treatment was initiated.  
 
The expansion of home based care for suspected malaria to 26 districts was initiated in May 
2011 and is expected to continue throughout the AMFm implementation period using the Global 
Fund Round 8 grant. 
 
One of the obstacles to achieving a reduction in copaid ACT prices was the delay in delivery of 
adequate quantities of the medicines. The capping of quantities ordered and long lead times for 
delivery of copaid ACTs have resulted in stockouts along the private sector supply chain. As a 
result, non quality-assured ACTs may regain some market share as FLBs place orders to meet 
the demand unmet by AMFm copaid ACTs. 
 
 
Table 4.1.1: Summary of key factors likely to have supported or hindered achievement of AMFm goals in 
Ghana 
Factors which are likely to have supported 
achievement of AMFm goals 
Factors which are likely to have hindered 
achievement of AMFm goals 
 Wide distribution network of public and especially 
private sector FLBs 
 Expansion of home based care 
 Declaration of a recommended retail price (RRP) 
 Monitoring visits by regulatory officers from the 
Pharmacy Council 
 Public awareness campaign 
 Cessation of manufacture of ACTs by 4 out of 5 
local manufacturers 
 A decline in the importance of non-copaid ACTs in 
favor of copaid ACTs 
 Training of frontline health workers in both the 
public and private sectors 
 Poor road infrastructure along distribution 
networks 
 Taxes and duties 
 Long lead times to delivery of ACTs 
 Capping of quantities ordered 
 Stockouts and re-introduction of non-quality 
assured ACTs 
 Preference for chloroquine and artemisinin 
monotherapies by some patients and clinicians  
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Figure 4.1.1:Timeline of key events related to AMFm implementation process and context in Ghana 
Activity 
2010 2011 
Jun Jul  Aug  Sep  Oct  Nov  Dec  Jan   Feb  May  Apr May Jun Jul Aug  Sep  Oct Nov Dec 
AMFm grants and orders                    
AMFm grant signed 
 
                                    
AMFmCC meetings 
                   First orders placed for copaid ACTs 
                   Delivery of private sector copaid ACTs                                       
Delivery of public sector copaid ACTs                                       
AMFm supporting interventions                    
Public awareness - talk shows                                       
National Launch                                       
Regional Launches                                       
Public awareness media campaign                                       
Training of public sector health workers                                       
Training of pharmacists                                       
Training of LCS and Medical Counter 
Assistants (MCA)                                       
Training of medical doctors                                       
Training of regulatory officers                                       
Training of community-based assistants                                       
Post market surveillance                                       
Private sector monitoring visits                                       
Expansion of home based care                                       
Pharmacovigilance                                       
Research activities                    
IE baseline outlet survey data collection                                       
IE endline outlet survey data collection                                        
IE Country case study                    
Operational research (OR) ethics approvals 
                   OR community mobilization 
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4.2 Kenya 
4.2.1 AMFm implementation process 
4.2.1.1 Governance structure for AMFm 
There are five main governance structures - some old and some new - which are pertinent to 
the governance of AMFm in Kenya. These are: 
1. the Kenya Country Mechanism (KCM) or National Oversight Committee (NOC), 
previously the Global Fund Country Coordinating Mechanism (CCM)  
2. the Malaria Interagency Coordinating Committee (MICC) 
3. the Global Fund Technical Working Group (TWG)  
4. the AMFm TWG or Task Force  
5. Stakeholder Forums  
 
The latter two were established as a direct result of the need for planning and coordination 
around AMFm; the first three have been in existence for far longer. The KCM/NOC focuses 
on all Global Fund coordination issues, for instance the selection of principal recipients (PRs) 
and management of the process for the selection of sub-recipients (SRs) in coordination with 
the PRs and the programs.  
 
The MICC is the highest decision making body for malaria in Kenya. It meets quarterly and 
receives updates on all areas of malaria control to facilitate key decisions for which the 
necessary technical discussions and deliberations have already taken place within the 
respective TWGs. The Global Fund TWG oversees and provides technical assistance in the 
implementation of Global Fund malaria-related activities. 
 
The AMFm TWG was formed out of the initial group of stakeholders who took part in the 
AMFm proposal writing for Kenya with ad hoc representation from other stakeholders on a 
need-to basis. The core members are the Division of Malaria Control (DOMC) Case 
Management TWG, M&E TWG and Advocacy, Communication and Social Mobilization 
TWG; Clinton Health Access Initiative (CHAI); Pharmacy & Poisons Board (PPB) and 
PSI/Kenya.  
 
The TWG spearheads the planning, coordination and monitoring of all AMFm-related 
activities and reports back to the Case Management TWG. The meetings are said to have 
been very useful in tracking progress, identifying constraints and responding flexibly to novel 
issues. 
 
The main challenge of the AMFm TWG has been the slow progress of key AMFm activities 
such as private sector training courses and IEC/BCC activities which led to some fatigue on 
“discussing the same issues of delays over and over”, leading to a slowing down of the 
dialogue. In the lead up to the grant signing, the TWG met weekly, then after grant signature 
monthly.  
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The Stakeholder Forums were seen as crucial for advocacy and sensitization for AMFm, 
especially with the private sector, and were included in the grant proposal as an avenue for 
engaging with stakeholders in much the same way as Global Fund grants have annual or 
semi-annual stakeholder workshops. There are three key phases to the Stakeholder Forums; 
the pre-grant phase, the early period of grant writing and post-grant signature. The pre-grant 
phase involved advocacy for AMFm both within and outside government. The grant-writing 
phase involved engaging with those who would be directly affected by AMFm professionally 
or economically, such as the Pharmaceutical Society of Kenya, large pharmaceutical 
distributors, local manufacturers and other health professionals. At least four stakeholder 
meetings were held in the run up to AMFm in 2009 and 2010. 
 
The pre-grant Stakeholder Forums are viewed as largely successful in fulfilling their stated 
objectives. By the time the copaid medicines came to the country, AMFm was said to be well 
understood. Indeed, many expressed the opinion that “we would have been lost without the 
[stakeholder] forums”. Some private sector stakeholders were very enthusiastic and even 
offered to help kick-start the IEC/BCC campaigns with their own funds given the delays in 
procuring IEC/BCC services.  
 
A perceived challenge has been poor attendance at the forums, and getting the various players 
“to put all their cards on the table”. There were initial misgivings about AMFm because of 
local manufacturers and importers fearing loss of business, and lack of understanding of the 
mechanism’s objectives and operation. The latter has been overcome by and large, although 
the issue of how local manufacturers take part in such procurement processes still remains 
salient (ALMA et al. 2011).  
 
4.2.1.2 AMFm copaid ACT supply mechanism 
Public sector 
The first line buyer (FLB) for the public sector was the Kenya Medical Supplies Agency 
(KEMSA). The initial determination of what quantities of AL to order was done by the 
DOMC and partners through a formal quantification workshop, but the quantities determined 
(31 million doses including a buffer stock of 13 million) had to be aligned with available 
resources (about USD 14 million), so only 16.6 million doses were tendered for. The tender 
process took from October 2010 to May 2011. Contracts were signed with Ajanta Limited for 
the two older age packs in April 2011 and with Novartis Pharma AG for Coartem Dispersible 
for the two pediatric age packs in May 2011. Both orders were split into two equal call-
downs, with an initial call-down of 50% requested immediately, although in practice they 
were received in more batches - “in dribs and drabs.” The first consignment arrived on June 
27, 2011, and by December 2011, 8.5 million doses for the public sector had been delivered 
in Kenya, but Ajanta Limited had not delivered their full order by December 2011. These 
delays were perceived to be partly due to a global shortage of the artemesia active 
pharmaceutical ingredient (API). An additional emergency procurement was made through 
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the President’s Malaria Initiative (PMI) for 4 million doses, of which 3 million arrived 
between July and December 2011. Public sector facility stockouts were not reported in 2011, 
except for a four-week period in July and August (DOMC et al. 2010, 2011a, 2011b). 
 
It is acknowledged that despite the strides made by KEMSA in building up efficient 
procurement and supply management systems, government procurement processes for ACTs 
were still very long. It took nine months between the tender closure and the first consignment 
of the copaid ACTs being delivered in Kenya, which is fairly typical of medicine 
procurement processes. What was unusual was that six months after the first consignment of 
copaid ACTs was delivered, Ajanta Limited had not been paid for their consignment. Indeed 
by December 2011 no manufacturer had received the government share of the price of copaid 
ACTs delivered to the public sector. This appeared to reflect administrative bottlenecks in 
terms of invoicing and invoice processing involving the DOMC, KEMSA and the PR 
(Ministry of Finance). Novartis Pharma AG had to make special representations to their risk 
management section not to bar further orders to KEMSA, and KEMSA had to make 
representations to Ajanta not to stop further deliveries. The delay in payment may have 
further compounded public sector delivery delays due to a shortage of API. 
 
Private sector 
Seven private sector FLBs were registered and established relationships with manufacturers, 
three with Novartis Pharma AG, and the others with four other manufacturers. Six were 
reported to be active in ordering copaid ACTs with one having dropped out much earlier in 
the process. There were no major issues reported in the registration of FLBs, the 
determination of order quantities or customs clearance, although at first there was some 
confusion as to whether customs levies should be charged on the full or subsidized price of 
copaid ACTs. The DOMC and CHAI, through the relevant Stakeholder Forums and the 
AMFm TWG, were instrumental in clarifying the process and providing assistance. 
 
The first private sector copaid ACTs were received in Kenya in August 2010. For the 18 
month period from July 2010 (soon after grant signing) to December 2011, a total of 12.8 
million treatment doses were received in Kenya by private sector FLBs. There was no 
discernible pattern in the total monthly receipts, except from April-August 2011 when the 
drug supply was on an upward trend, peaking in August 2011 and declining thereafter.  
 
In sharp contrast to the issues identified above for the public sector, the speed and efficiency 
of the private sector “surprised everybody.” The first consignment of copaid ACTs was in 
Kenya “before the ink dried on the AMFm grant signature.” In fact, the speed of the private 
sector practically dictated the pace of some activities which were scheduled for much later, 
such as the national launch in August 2010, so that members of the public could tie the new 
copaid ACTs with the government’s efforts at increasing access to quality-assured ACTs and 
to ensure that the recommended retail price (RRP) was adhered to. 
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Some FLBs that were new to the ACT market were very innovative and daring in their 
ordering and marketing, and quickly made substantial orders. However, orders from Novartis 
were slower to arrive, with the first consignment not being delivered until January 2011, for a 
number of reasons: 
 Novartis had to register a new packaging for the private sector Coartem  
 Novartis made a strategic decision to work with “very enthusiastic” FLBs rather than 
their traditional agents for premium Coartem, and the process of identifying and 
establishing these new partners took time 
 Some traditional FLBs for Coartem were initially skeptical about AMFm and 
therefore very conservative in their ordering 
 Novartis faced supply constraints due to the need to meet orders in other countries, 
meaning that delivery times were longer than expected  
 
Several FLBs reported that from August 2011, the demand-shaping levers applied by the 
Global Fund to align orders more with the burden of disease led to a restriction in the number 
of packs for the two older age groups which could be ordered, and a slowing down in the 
order process.  
 
Private sector FLBs reported that quantities imported soon disappeared off the shelves as 
there was a huge, unanticipated demand. Many ramped up their sales teams to increase sales 
in rural areas by hiring additional telemarketers and travelling regional representatives. 
 
4.2.2 Implementation of AMFm supporting interventions 
The first disbursement from the Global Fund to cover supporting interventions was for USD 
7.4 million, which was received in August 2010. Requests to the Global Fund for further 
disbursements were made in December 2010 and July 2011, but these were both declined. 
The December 2010 request was declined primarily because there were still substantial funds 
remaining from the first disbursement, and the July 2011 request was declined primarily due 
to accounting issues. It is possible that the decline of further disbursement requests led to 
some slowing down of SI implementation in the latter half of 2011, although there were also 
other causes of SI delays, as described below. 
 
4.2.2.1 Communication 
The most important supporting intervention for AMFm—in scale, scope and financial 
expenditure—was the IEC/BCC campaign, which was allocated a total of USD 5,681,487 up 
to December 2011. The campaign was tendered in stages by KEMSA, with various 
components won by Access Leo Burnett, ReelForge, 29 radio stations, and 4 TV stations.  
 
The main IEC/BCC activities that were planned were the following: 
 
1. National launch 
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2. Developing and airing five radio messages  
3. Developing and airing four TV messages 
4. Developing, printing and disseminating 400,000 posters 
5. Holding community meetings in 558 locations 
6. Facilitating 186 road shows. 
 
The messaging in the print, electronic and broadcast media was graduated, with earlier 
messages focusing on what AMFm is, including the price of the ACTm medicines and their 
superiority to other non-recommended medicines, and recognition of outlets where ACTm 
medicines were sold. Later messages focused on the need to get tested before treatment, the 
need to use ACTm when positive for malaria and the need to adhere to the full treatment dose 
even when symptoms of the illness subside. With time, prevention messages such as the use 
of long-lasting insecticide treated nets (LLINs) were also incorporated. The main target areas 
were Nyanza, Western and Coast provinces, although radio and TV spots had a national 
reach.  
 
Stakeholders agreed that this was the biggest malaria IEC/BCC campaign they had ever seen, 
and that it was very successful in its stated objectives of: 
o demand creation for AMFm copaid ACTs 
o creating awareness about the RRP of Ksh 40 (USD 0.46) 
o the need for diagnostics before dispensing ACTs 
 
On the other hand, the sheer scale of the IEC/BCC campaign—it accounted for more than 
80% of the entire SI budget—led to risk aversion in procuring the services, leading to further 
delays in a system which was already fraught with procurement challenges. This was 
compounded by the fact that it was the first time KEMSA had procured IEC/BCC services as 
opposed to commodities and as a result there was “…a lot of back and forth; a lot of learning 
for all concerned.”  
 
The national launch was held on August 26, 2010, at a hotel in Nairobi, officiated by the 
Minister of Public Health and Sanitation, and was widely reported in the media. A newspaper 
supplement was distributed through the local daily papers in September 2011.  
 
Other activities were substantially delayed by the procurement challenges. Due to the delays 
in IEC/BCC procurement, PSI/Kenya and CHAI co-funded a stop-gap measure between 
December 2010 and January 2011, involving “sold here” posters for retail outlets, and radio 
and TV spots. 
 
Over 70% of the IEC/BCC budget was for radio messaging, which began in February 2011, 
with a total of 17,560 radio spots estimated to have been aired between March and December 
2011. Posters were also printed, although there were some problems with their distribution. 
The road shows took place by December 2011, albeit with some logistic difficulties, but the 
community meetings had not yet begun. 
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4.2.2.2 Recommended retail price 
The RRP of copaid ACTs as communicated to members of the public through the IEC/BCC 
messages was Ksh 40 (USD 0.46) for all pack sizes. The price was arrived at through the 
Stakeholder Forums with the private sector. FLBs were of the opinion that the RRP should 
not be displayed on the packaging to allow for free competition and hopefully further price 
reductions. The Pharmacy and Poisons Board (PPB) has no legal mandate to enforce prices 
for pharmaceuticals. The only enforcement strategy therefore is customer awareness and 
empowerment through public messages. 
 
Between August and December 2010, initial media reports showed high prices of the copaid 
ACTs circulating in the market, reflecting limited supply at that time. However, once the full 
(Global Fund-funded) media campaign had kicked in, prices stabilized at or close to the RRP. 
It should be mentioned that the Pharmaceutical Society of Kenya (PSK) was very active in 
sensitizing members to keep the prices of copaid ACTs low in accordance with the RRP. In 
addition to emails sent to members in the last quarter of 2010, regional meetings were 
organized for further sensitization. Health Action International (HAI) price monitoring 
surveys (HAI/Africa 2011a, 2011b) indicated a median price of approximately Ksh 40 in 
private sector outlets. The DOMC’s own inspection visit in Nyanza province involving 240 
retail pharmacies in April 2011 showed a similar outcome. 
 
The issue of “price stigma”—that the copaid medicines are viewed as poor quality or suspect 
because they are very inexpensive—has come up in previous assessments (Appleford 2011) 
and is one that is still of concern to the DOMC and stakeholders. 
 
4.2.2.3 Training 
Training, as with other SIs, was outsourced via an open national tender, won by four 
agencies: Sema, Lisa, MEDS Consultancy and Maseno University. The target was to train 
5,890 private sector health workers, with 4,520 to be trained by mid-grant (July 31, 2011). 
However, training did not begin until October 2011, reflecting delays due to procurement 
challenges and the need to supply a revised training plan to the Global Fund. By December 
2011, only 733 private sector health workers had been trained in Western and Nyanza 
provinces. The DOMC reckoned that doctors and pharmacists had been underrepresented 
because these were three-day residential training courses and perhaps the strategy of using 
their professional associations to reach out to them was not effective.  
 
The private sector FLBs have also been instrumental in sensitizations/trainings. They have 
trained their own distributors and reached out to healthcare professionals through their 
regular meetings by sponsoring continuous education meetings or sponsoring the DOMC 
case management officers to give talks at annual professional gatherings such as those for 
clinical officers and pharmacists. It is estimated that approximately 1,000 healthcare 
professionals have been covered through such strategies between January and December 
2011. 
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4.2.2.4 Pharmacovigilance 
Pharmacovigilance (PV) and post-market surveillance activities under AMFm have benefited 
from ongoing work under other funding streams and technical assistance, notably from 
USAID through United States Pharmacopeia, Management Sciences for Health and WHO. 
For antimalarials and ACTs, quality has been the main focus of these PV and regulatory 
activities. Five sentinel sites (Nairobi, Mombasa, Kakamega, Eldoret and Kisumu) have been 
established and supplied with a mini-lab, which can perform qualitative and semi-quantitative 
tests (USP et al. 2007). To date, the DOMC has conducted two rounds of quality testing—the 
first in 2009 under USP funding and the second between January and February 2011 using 
AMFm SI funds. An inspection visit was also conducted in Nyanza province in April 2011 
involving 240 chemists. A routine inspection by the PPB in mid-November 2011 also 
resulted in a crackdown on unlicensed outlets in that province while AMFm IE endline outlet 
survey data collection was ongoing. Only one PV supervisory visit has been conducted using 
AMFm resources, reflecting the delayed disbursement of funds. 
 
ACTs are still prescription-only medicines (POM) in Kenya. However, in practical terms, the 
POM status of ACTs has not been an impediment to access to copaid ACTs because of the 
disconnect between de jure regulation and real-life medicine regulation in Kenya (Amin et al. 
2007). Many POM medicines are available over-the-counter (OTC) and regulatory 
infringement such as the presence of unregistered pharmacies and even unregistered products 
has been documented.  
 
4.2.2.5 Other AMFm supporting interventions 
Two other supporting interventions planned under AMFm were improving ACT access 
through community health workers (CHWs) to help reach poor and vulnerable populations, 
and operational research. 
 
The DOMC proposed to piggyback on Kenya’s overall Community Strategy for health by 
improving access to ACTs through existing community health units in Western and Nyanza 
provinces, where the burden of malaria is highest. The strategy was to procure and distribute 
ACTs to CHWs, train 80 community health extension workers and 2,000 CHWs on malaria 
case management in the same provinces and strengthen supervision. Some 1.18 million 
copaid AL treatment doses were procured and distributed in Western and Nyanza between 
June and December 2011. The training and supervision activities had not taken place by 
December 2011, due to delays in procurement for training, the design and production of 
training materials.  
 
No operational research planned under AMFm and funded by the Global Fund had taken 
place by December 2011.  
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4.2.3 Implementation of non-AMFm interventions 
In addition to AMFm, two other key malaria interventions were implemented during 2011: 
 
 Increased ACT and RDT availability in parts of North Eastern, Coast and Rift Valley 
Provinces following increased commodity supply to avert a predicted epidemic in the 
last quarter of 2011. In August 2011, the Kenya meteorological department issued a 
red alert of possible torrential rains in parts of Coast Province, North Eastern and Rift 
Valley for the period October-December 2011. In response, the DOMC anticipated a 
sharp increase in malaria cases and developed a response plan in collaboration with 
the UK Department for International Development, the US President’s Malaria 
Initiative, Mentor Initiative and UNICEF. Activities took place between August and 
December 2011. Approximately 400,000 RDTs were sent to public facilities in the 
epidemic-prone areas identified. Also, the usual distribution cycle of antimalarials 
from KEMSA was hastened so that the areas did not run out of stock during the 
anticipated epidemic and surveillance and monitoring activities were enhanced. In 
addition, some 20,000 ampoules of artesunate injections were sent for severe cases. 
An IEC/BCC strategy was also drawn up for the emergency campaign involving 
demand creation for proper diagnosis and effective treatment of malaria. 
Advertisements were placed on radio, especially on vernacular stations in the affected 
areas. A number of radio talk shows and call-in sessions were also done. Affected 
districts were assisted in overall planning and coordination and given money in case 
the epidemic did happen. As it turned out, the anticipated very heavy rains did not 
come to pass. However, the response is likely to have increased QAACT and RDT 
availability in the public sector, as well as QAACT market share. 
 
 Approximately 6 million LLINs were distributed. From March 2011, the DOMC 
undertook a rolling campaign aimed at distributing approximately 11 million LLINs 
in the whole of Western, Nyanza, and Coast Provinces and selected districts in Rift 
Valley and Central Provinces in line with the epidemiology of malaria in Kenya. The 
LLINs were procured by a combination of Global Fund, PMI, World Bank and World 
Vision funds, with the bulk of funding coming from the Global Fund Round 4 Phase 2 
malaria grant. The objective of the campaign was to enable Kenya to attain universal 
coverage of nets, i.e., one net for every two persons at risk of malaria. By December 
2011, approximately 6 million LLINs had been distributed to all targeted provinces 
except Coast. The impact on AMFm indicators is not clear, although it is likely to 
have reduced malaria incidence and therefore demand for ACTs. 
 
Although Kenya’s official policy is that all suspected cases of malaria should be subject to a 
blood test for confirmation, in practice, availability of diagnostic tests in the public and 
private sector has remained very limited. In addition to the RDTs distributed to the epidemic 
prone areas (see above), RDT have been rolled out to six districts participating in a pilot of 
SMS for life. 
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Finally, the international ban on artemisinin monotherapies in 2006 and subsequent reissuing 
of government circulars in 2006 and 2008 in Kenya which ban the sale, manufacturer and 
importation of artemisinin monotherapies have reduced the supply of monotherapies. The ban 
was reinforced by the AMFm FLB undertaking with the Global Fund not to sell these 
medicines, and this is likely to have provided a supportive environment for AMFm.  
 
4.2.4 Key events and context 
Two key contextual factors are the increase in domestic prices and the high levels of political 
support for AMFm. 
 
The AMFm price indicator is likely to have been affected by the loss of value of the Kenya 
shilling against the main international currencies, high inflation and fuel shortages, which all 
led to price increases for essential commodities. The Kenya shilling had been stable against 
the United States dollar until February 2011 at around between Ksh 70 and 80 to the USD, 
when it started fluctuating, hitting rock bottom in October 2011, at 101.4 to the dollar, 
subsequently regaining its value from mid-October 2011 onwards after the Central Bank of 
Kenya intervened. Understandably the cost of fuel and transportation went up as well. 
Monthly inflation was estimated at 3.21% in October 2010; by September 2011, it was at 
17.32%. Similarly, the cost of a liter of premium petrol went from Ksh 95.0 in October 2010 
to 118.03 in August 2011 (Parliamentary Service Commission 2011). One might expect these 
price shocks to have a knock-on effect on ACT prices because of increased import costs and 
increased cost of inland transportation. However, this was believed to be unlikely to have 
been significant for copaid ACTs because of the low cost paid by FLBs and the margin 
available with the Ksh 40 RRP being sufficient to absorb some increases in distribution costs, 
especially for pediatric doses.  
 
The fact that AMFm enjoyed high level political support from the Minister of Public Health 
and Sanitation has been instrumental in advocacy and pushing the process forward. The 
emphasis on the importance of reducing childhood mortality was therefore seen to override 
domestic concerns such as loss of market share by local manufacturers. 
 
4.2.5 Conclusion 
Table 4.2.1 summarizes of key factors likely to have supported or hindered achievement of 
AMFm goals in Kenya and Figure 4.2.1 presents a timeline of all key events related to 
AMFm implementation and context. 
The key findings of the case study can be summarized as follows: 
 There was enthusiastic uptake of the opportunity to order copaid ACTs by private 
sector FLBs, and no major issues in supply to the private sector were reported until 
the last quarter of 2011 when the application of demand shaping levers by the Global 
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Fund began to slow down and restrict some orders. However, given that downstream 
supply does not quickly dry up even with stockouts at the central level, this is unlikely 
to have substantially affected QAACT availability at the time of the endline outlet 
survey, though it may have affected availability during collection of the remote areas 
study data.  
 By contrast, the public sector drug supply has faced significant delays due to 
procurement and delivery challenges.  
 A large scale IEC/BCC campaign has been implemented that is perceived to have 
been successful in creating demand and raising awareness about the RRP. The 
campaign was delayed by several months, but stop-gap activities were put in place by 
other stakeholders in the mean time. 
 Training activities for private sector health workers were also heavily delayed, 
meaning that only 733 had been trained by December 2011.  
 A response to a predicted malaria epidemic in late 2011 may have served to increase 
QAACT availability and market share in some provinces.  
 AMFm has received high-level political support, and private sector stakeholders have 
also been very supportive. 
Table 4.2.1: Summary of key factors likely to have supported or hindered achievement of AMFm goals in 
Kenya 
Factors which are likely to have supported 
achievement of AMFm goals  
Factors which are likely to have hindered 
achievement of AMFm goals 
 Effective sensitization and mobilization of private 
sector FLBs 
 Fast pace of the private sector in terms of ordering, 
processing and distribution systems 
 Increased distribution of ACTs to epidemic areas as 
part of epidemic preparedness and response 
 RRP which was well publicized. Large-scale 
IEC/BCC campaign 
 Ban on monotherapies, and FLBs undertaking with 
the Global Fund not to sell artemisinin 
monotherapies 
 Lack of enforcement of POM status of ACTs 
 Delays in public sector procurement process for 
ACTs  
 Delays in delivery of some public and private 
orders 
 Inadequate supplies in the private sector at first 
which may have pushed up prices  
 Delays in procurement of IEC/BCC and training 
interventions 
 Rationing of orders through demand levers may 
have affected QAACT availability in 2012 
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Figure 4.2.1: Timeline of key events related to AMFm implementation process and context in Kenya 
 
Activity 
2009 2010 2011 
Jul Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 
AMFm grants and orders                     
Application to the Global Fund for AMFm   
           
       
AMFm Grant signature  
            
       
First disbursement request  
            
       
First disbursement under AMFm grant  
            
       
Arrival of first consignment of copaid ACTs – Harleys Limited  
            
       
AMFm supporting interventions                     
AMFm National Launch  
            
       
IEC/BCC activities  
            
       
Public sector tender award to Ajanta and first Ajanta calldown  
            
       
Inspection visit to 240 chemists in Nyanza  
            
       
Public sector tender award to Novartis and first Novartis calldown  
            
       
First consignment of public sector copaid ACTs delivered by Ajanta  
            
       
End Global Fund Round 4 Phase II (host grant for AMFm)  
            
       
New Global Fund order management system begins to affect Kenya orders  
            
       
Forecast of torrential rains in parts of Kenya  
            
       
Second calldown of public sector ACTs  
            
       
Lowest recorded value of the Kenya shilling to the dollar  
            
       
Signing of Round 10 malaria grant  
            
       
Training of 732 private health workers in Western and Nyanza Provinces  
            
       
Crackdown on unregistered pharmacies in Nyanza province  
            
       
Non AMFm interventions                     
LLIN campaign  
            
       
Receipt of PMI emergency procurement of ACTs for public sector  
            
       
Research activities                     
IE baseline outlet survey data collection  
            
       
IE endline outlet survey data collection   
            
       
IE country case study   
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4.3 Madagascar 
4.3.1 Description of the AMFm implementation process 
4.3.1.1 Governance structure for AMFm 
 
The Principal Recipient (PR) of the AMFm program is SALAMA, the public sector central 
medical stores in Madagascar. There are a number of sub-recipients (SRs), including 
Population Services International (PSI), which has been in charge of designing and 
disseminating advertising for the AMFm subsidized drugs, as well as SAF-FJKM, SALFA, 
and ASOS, three faith-based organizations in charge of training community health workers 
(CHWs) on AMFm and malaria case management. The Clinton Health Access Initiative 
(CHAI) has also been a key player in the establishment and development of the program, 
providing key technical and logistical support. Despite several attempts by the involved 
parties, a permanent AMFm steering committee in Madagascar has not been established. 
Madagascar’s AMFm grant runs from May 1, 2010 through June 30, 2012. 
 
4.3.1.2 AMFm copaid ACT supply mechanism 
Initially, 12 private sector importers were approached by the Global Fund through point 
persons at CHAI and at the National Malaria Control Program (Programme National de Lutte 
contre le Paludisme, or PNLP), who set up group information sessions as well as one-to-one 
meetings with importers. Eight importers signed contracts to become first line buyers (FLBs), 
and they have proceeded to place orders. There was general consensus among those 
interviewed for this project that all of the country’s main importers are involved in the 
project. The Unité de Gestion de Projet (UGP), the public sector procurement agency linked 
to the Ministry of Health, is also an FLB and has placed orders for copaid antimalarials. The 
first copaid medicines were delivered to private FLBs in October 2010 and to the public 
sector FLB, UGP, in February 2011. By December 2011, 1,688,178 doses of AMFm copaid 
artemisinin-based combination therapies (ACTs) had been delivered to Madagascar. Roughly 
76% of the doses were artesunate-amodiaquine (ASAQ), the country’s first-line treatment. 
The rest was artemether-lumefantrine (AL), the country’s second-line treatment. 
 
Issues related to clearing customs created initial tensions between first line buyers and the 
local authorities. There were month-long delays once the first set of shipments arrived in 
Madagascar. Officials at Ivato International Airport in Antananarivo were not familiar with 
the two invoice system used, which includes one invoice with the original unsubsidized price 
of the shipment and one with the actual amount paid by the FLB. Officials became suspicious 
upon seeing the discrepancy and consequently blocked the release of the shipments. 
SALAMA and the Ministry of Budget and Finance intervened to clear misunderstandings 
regarding the invoices, updated officials on the program, and streamlined the process of 
clearing customs.  
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Lead times between approval of an order by the Global Fund and delivery have varied since 
the start of the program, ranging from a couple of weeks to nearly six months. FLBs mostly 
agreed that lead times had been particularly long in the second half of 2011. These delays 
seemed to be a source of frustration and tension between the FLBs and the Global Fund.  
4.3.2 Implementation of AMFm supporting interventions 
4.3.2.1 Communication 
An official launch held in Antananarivo in January 2011, helped to initially spread the word 
about the program, which in Madagascar is known as ACTm. Communication activities for 
different target audiences were designed and disseminated starting in April 2011. The 
advertising campaign, designed by PSI, emphasized three points: that AMFm-funded ACTs 
were effective, inexpensive and safe.  
 
Approximately half of the country’s estimated 3,000 private medical practitioners were given 
promotional materials with the ACTm logo—1,450 prescription pads, 1,450 informational 
leaflets on ACTs and AMFm and 1,450 pens. Promotional materials were also provided for 
roughly half of the businesses making up Madagascar’s private supply chain, which is 
composed of 30 to 40 wholesalers, 200 pharmacies, and 2,000 drug stores. A total of 1,150 
targeted informational leaflets and 1150 pens were distributed, as well as 100 large posters 
for retail outlets and 250 standing posters.  
 
Community health workers (CHWs) were also targeted. Approximately 2,400 “flip books” of 
images, which are used as a teaching tool, were produced and distributed, along with 2,400 
badges, 2,400 pens, 2,400 baseball caps, 2,400 t-shirts and 2,400 bags, all of which had the 
ACTm logo. The proportion of CHWs nationwide who were given promotional material is 
unclear. One respondent mentioned that between May 2010 and December 2011, the number 
of CHWs in the country increased from 9,000 to 17,000.  
 
Communication activities for the general population were also designed and disseminated. A 
TV commercial, which included a song entitled ‘ACTm, je t’aime’ (meaning ‘ACTm, I love 
you’), was produced and broadcast once or twice a day on national television. Radio spots in 
eight different Malagasy dialects were also broadcast once or twice a day on national radio, 
and three to five times a day on regional radio, starting in April 2011. Emphasis was given to 
the radio campaign, given that access to television is relatively limited in Madagascar. 
However, the abovementioned TV and radio campaigns came to an end in May 2011. The 
Drug Agency of Madagascar (Direction d’Agence de Medicament de Madagascar, or 
DAMM), which is part of the Ministry of Health, banned the ACTm public campaign, citing 
a law that prohibits the advertising of prescription drugs to the general population, except in 
cases of national public health emergencies. Although representatives from CHAI and 
SALAMA tried to argue that malaria was a serious public health threat, the DAMM refused 
to reconsider its decision. Radio and television spots were cancelled and plans for a number 
of other promotion activities such as billboards were aborted.  
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As of December 2011, CHAI and SALAMA representatives planned to shift the campaign 
from marketing to education in order to meet the DAMM’s guidelines that all advertising had 
to be non-medication specific. The effect of the advertising ban on ACT sales is still 
uncertain; the ban was implemented at the beginning of the dry season, making it unclear 
whether decreased sales of ACTs should be attributed to a seasonal drop in malaria incidence 
or to the interruption in advertising. It is important to note, however, that the DAMM’s 
decision did affect the abovementioned promotional materials distributed to prescribers, 
private sector actors and CHWs. 
 
Additionally, the main supplier of copaid ASAQ carried out its own promotional campaign 
across the country, conducting information sessions nationwide, which were attended by 
approximately 1,100 health practitioners and private sector actors. Participants in information 
sessions were sometimes given informational posters about the product being advertised as 
well. 
4.3.2.2 Recommended retail price 
There is no maximum or recommended retail price for copaid ACTs in Madagascar. The 
agreement between FLBs and the Global Fund states that FLBs would add a ‘reasonable 
margin’ in absolute terms to the products. During discussions leading to the signing of the 
contract with the Global Fund, FLBs agreed that a margin of 150 ariary (or USD 0.07) per 
dose would be added on average across the different products. Although FLBs are 
contractually required to maintain this ‘reasonable margin’, they are not obligated to maintain 
the particular 150 ariary margin. However, as of December 2011, all FLBs were still 
following the agreed upon 150 ariary margin. 
 
At the retail level, pharmacies have an unofficial margin of 33% for all pharmaceutical 
products which, according to some respondents, is usually also respected. However, prices 
tend to be higher in drug stores in remote areas. As was frequently mentioned by respondents, 
transportation is an important cost at all levels of the supply chain. Given how remote and 
inaccessible some rural areas are, FLBs argued that having to pay for the cost of 
transportation, compounded by an already low profit margin, would result in a loss to the 
business. It was therefore agreed that the cost of transportation outside of Antananarivo 
would not be covered by the importers, which is not always the case with medications that 
have higher profit margins.  
 
Although there are no taxes on any medications in Madagascar, importers do have to pay 
some fees at customs to cover storage, unloading and transit costs. Some of the fees are 
calculated according to weight and value of the shipment, while others are standard fees 
across all shipments. This arrangement makes it less profitable to import smaller quantities of 
drugs. The fees apply to all pharmaceutical products, including copaid medications. 
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4.3.2.3 Training 
Training for medical practitioners on malaria case management, ACTs and 
pharmacovigilance has been carried out as planned by the National Malaria Control 
Programme (PNLP). About a third of the country’s 3,000 medical doctors and 250 
paramedics had been trained by December 2011. Some respondents considered the training of 
the rest of the country’s medical practitioners to be a key element in increasing use of ACTs.  
 
Training of community health workers on malaria case management and use of rapid 
diagnostic tests (RDTs) and ACTs was done in a cascade-style manner. A total of 88 trainers, 
4 for each of Madagascar’s 22 regions, were coached on how to train CHWs on malaria case 
management, diagnosis and treatment in June 2010. Consequently, between July 2010 and 
June 2011, 2,442 CHWs were trained nationwide by three FBOs, SAF-FJKM, SALFA, and 
ASOS. Although by and large the training seems to have been successful, there were reports 
that CHW activities had to be halted in the last few months of 2011 because funds destined 
for such activities, as well as for general population advertisement, had been frozen. 
 
Additionally, the DAMM trained 44 laboratory technicians between May and June 2011 on 
ACT drug quality issues. The training was done in conjunction with the purchase of 22 new 
microscopes, one for each region. Furthermore, two medical doctors were trained between 
November and December 2011 by the Agence Française de Sécurité Sanitaire des Produits de 
Santé (French Agency for Sanitary Security of Health Products), on issues related to 
pharmacovigilance. 
 
CHAI also conducted a pilot training program on medical promotion and its effect on sales of 
ACTs starting in the second half of 2011. Medical representatives informed medical 
professionals and retailers about the benefits of ACTs in 21 districts covering five regions 
(Boeny, Sava, Fenoarivo-Antsinana, Vatovavy-Fitovinany and Anosy) across the East and 
North-West of the country starting in September 2011. As of December 2011, medical 
representatives had held information sessions with 235 physicians and 234 retail outlets. An 
evaluation on the effect of the medical representative activities was scheduled to be carried 
out in March 2012 and August 2012.  
 
Additionally, the University of Antananarivo and the PNLP conducted a pilot study to look at 
the use of RDTs among private non-for-profit health providers following training on the 
importance of diagnostics and their management. The training, which was given to 10 health 
centers in the coastal town of Toamasina, took place at the end of May 2011. Preliminary 
findings suggest that health providers improved their use of malaria diagnostics after the 
intervention.  
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4.3.2.4 Other AMFm supporting interventions 
RDTs seem to be available in the public sector as well as via CHWs. However, they are very 
rarely found in the private sector, and they are mostly sold in a handful of pharmacies that 
target an expatriate and more affluent clientele.  
 
Malaria prevention activities, financed by a number of international organizations, were 
carried out in the months following the start of the AMFm program in Madagascar. Between 
2010 and 2011, the PNLP expanded its campaign of mosquito net distribution to include a 
further 20 districts, which represent roughly a sixth of the districts in the country. In 
November 2010, PSI, along with other several partners, such as the United States Agency for 
International Development (USAID) and the President’s Malaria Initiative (PMI), among 
others, began a large-scale campaign financed by the Global Fund to distribute nearly 5 
million long-lasting insecticide-treated mosquito nets. The campaign seems to have been 
carried out in 17-19 of the country’s 22 regions. Additionally, in November 2010, Roll Back 
Malaria, a partnership of different national and international actors, expanded its indoor 
residual spraying (IRS) campaign to include the east coast of the country. These initiatives 
may have had an effect on malaria incidence and, consequently, on the demand for treatment. 
 
Furthermore, the Global Fund, through its National Strategy Application (NSA), funded the 
training of 34,000 CHWs on integrated management of childhood illnesses (IMCI), including 
malaria, which is set to be complete by the end of 2012. Although it is unclear how many 
CHWs had already been trained by December 2011, the trainings that had already taken place 
by then could have had an effect on dissemination of information about malaria diagnosis and 
treatment by the time of the endline survey. 
 
Population Services International (PSI) has also been involved in the sale and distribution of 
subsidized ACTs since 2008. Their product, ACTIpal® (artesunate-amodiaquine), is branded 
for use of children under the age five years, and it is distributed through both CHWs, and the 
private sector supply chain. There are two different age packs (2-11 months and 1-5 years). 
The original recommended retail price for both ACTipal products was 100 ariary (about USD 
0.05), which was increased to 200 ariary for drug retailers in November 2010, while the RRP 
for CHWs remained at 100 ariary. PSI bought 300,000 doses of ACTIpal® in February 2010, 
100,000 doses in September 2010 and 305,000 doses in August 2011. The presence of copaid 
ACTs in the market may have increased interest in, and use of, the product. 
 
A ban on the importation and sale of chloroquine was set in motion around June 2011, which 
would have likely increased the market share of ACTs. However, the ban was recalled late in 
December 2011, after the legislation service of the Ministry of Health opposed it. A 
respondent mentioned that this was likely due to pressure from importers who still had large 
stocks of chloroquine to sell. 
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4.3.3 Key events and context 
According to most respondents, Madagascar continues to suffer from the consequences of the 
coup d’état that took place in March 2009, when Andry Rajoelina ousted Marc 
Ravalomanana from power. Although the coup took place before the AMFm program started, 
most respondents agreed that the political and economic situation of the country has been 
steadily deteriorating since 2009, which may have had multiple effects on the program.  
 
As a result of the coup, Madagascar was suspended from international trade organizations 
and key preferential trade agreements, such as the Southern Africa Development Community 
(SADC) and the Africa Growth Opportunity Act (AGOA). As key trading partners were lost, 
it seems that companies went out of business, unemployment rose and, consequently, the 
purchasing power of the population dropped.  
 
Furthermore, it seems that government spending has decreased since the coup. According to 
some respondents, this is particularly visible in the closure of public health facilities across 
the country, as well as in the lack of upkeep in transportation and telecommunications 
infrastructure. A deterioration of the roads may have made transportation of goods more 
difficult and costly.  
 
The political instability that followed the coup of 2009 may have also had some 
consequences on the program. A frequent turnover of Ministers of Health has meant that 
issues that require ministerial approval often take a long time to be approved, as the process 
has to be restarted every time a new minister takes office. Furthermore, some respondents 
mentioned that the uncertain political situation means that political actors often shy away 
from backing potentially controversial ideas, such as the ban on importation and sales of 
chloroquine. 
4.3.4  Conclusion 
Table 4.3.1 summarizes of key factors likely to have supported or hindered achievement of 
AMFm goals in Madagascar and Figure 4.3.1 presents a timeline of all key events related to 
AMFm implementation and context. 
 
In general terms, the implementation of the AMFm program in Madagascar was mostly 
successful. Eight private sector FLBs and one public sector FLB signed contracts with the 
Global Fund and placed orders between the end of 2010 and 2011. Initial issues related to 
delays at customs have generally been resolved. However, the long lead times between the 
order approval at the Global Fund and the arrival of the order seem to be creating frustration 
among FLBs, as are the low profit margins that private FLBs are earning from the sale of the 
AMFm products.  
 
The national communication campaign set off to a good start, with simple and regionally-
targeted messages on both radio and television. However, the subsequent ban of 
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advertisements by the DAMM has possibly hindered the effort to inform the general 
population about the program. The precise effect on demand for ACTm products has yet to be 
determined. Between a third and half of medical practitioners and private sector actors have 
been given training or information about AMFm, as have over 2,400 CHWs.  
 
The difficult political and economic situation that Madagascar is facing may have had an 
effect on the program, as it is likely that the population’s purchasing power has declined. 
Furthermore, a decrease in government spending, which seems to have led to the closure of 
health facilities and to the lack of upkeep of transportation and telecommunications 
infrastructure, may be making access to health more difficult and expensive. 
 
Table 4.3.1. Summary of key factors likely to have supported or hindered achievement of AMFm goals in 
Madagascar 
Factors which are likely to have supported 
achievement of AMFm goals  
Factors which are likely to have hindered 
achievement of AMFm goals 
 Increase in CHWs 
 Low markups agreed on by actors 
 Research project on medical representatives 
 Training of doctors and health practitioners in 
ACT use 
 Delays in delivery from manufacturer 
 Fluctuating costs of transportation and inadequate 
road upkeep 
 2/3 of doctors not trained, continuation of 
prescription of other drugs  
 Ban on TV and radio advertising 
 Political and economic crisis leading to fall in 
purchasing power 
 Frozen funds for CHW activities 
 Decrease in number of public health facilities 
249 | P a g e  
 
 
Figure 4.3.1: Timeline of key events related to AMFm implementation process and context in Madagascar 
 
Activity 
2010 2011 2012 
Early Apr May Jun Jul  Aug  Sep Oct  Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct  Nov Dec Jan Feb 
CHAI/PNLP: Hold meetings with 12 potential first-line buyers                         
PSI: Purchase of 300,000 doses of ACTIpal®                         
Start of AMFm Phase 1                         
Baseline outlet survey – ACTwatch                         
PNLP: Training of trainers of health agents on malaria case management, ACTs and 
pharmacovigilance  
 
                      
SALFA, SAF-FJKM, ASOS: Training of CHWs                         
PSI: Purchase of 100,000 doses of ACTIpal®                         
PNLP: Training of health agents on malaria case management, ACTs and 
pharmacovigilance  
 
                      
First line buyers (private sector): Approval by Global Fund of private sector orders of 
copaid ACTs  
 
                      
NSA: Training of 34,000 CHWs in IMCI                         
PSI, USAID, PMI, UNICEF, Canadian Red Cross: Campaign to distribute 5 million nets                         
Roll Back Malaria (multi-actor initiative): Expansion of indoor residual spraying (IRS) 
campaign to include Eastern region  
 
                      
UGP: Approval by Global Fund of public sector orders of copaid ACTs                         
First line buyers (private sector): Arrival of private sector orders of copaid ACTs                         
CHAI/SALAMA: National launch of AMFm program                         
UGP: Arrival of public sector order of copaid ACTs                         
SANOFI: Information sessions about ASAQ Winthrop                         
CHAI/SALAMA: Radio and television campaign                         
PSI/SALAMA: Distribution of IEC supports for health agents                         
PSI/SALAMA: Distribution of IEC supports for CHWs                         
PSI/SALAMA: Distribution of IEC supports for wholesalers, pharmacies and depots                         
DAMM: Training on laboratories and minilabs                         
DAMM: Ban on AMFm public advertising campaign                         
MOH: Introduction of chloroquine ban                         
PSI: Purchase of 305,000 doses of ACTIpal®                         
CHAI: MR training of health agents as part of pilot study                         
Endline outlet survey                         
MOH: Withdrawal of chloroquine ban                         
PNLP: Launch of indoor residual spraying (IRSA) campaign financed by Global Fund 
Round 7  
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4.4 Niger 
4.4.1  AMFm implementation process 
AMFm was launched in Niger in March 2011. Apart from the provision of ACTs, successful 
implementation of AMFm relies on a number of supporting interventions, including good 
governance; IEC/BCC; training of key actors; regulatory changes to facilitate purchase and 
distribution of ACTs; operational research to monitor the efficacy of ACTs; adverse drug events 
after introduction of copaid ACTs; activities to facilitate access to treatment among poor and 
vulnerable groups and increasing use of malaria diagnostic tests for the rational use of copaid 
ACTs. 
4.4.1.1 Governance structure for AMFm  
The Ministry of Health (MOH) created the AMFm steering committee (SC) in March 2010 to 
oversee AMFm implementation in Niger. The SC has 20 members, including representatives of 
MOH, technical and financial partners of MOH, the private sector and civil society. The SC 
played a major role in reaching an agreement on the pricing of copaid ACTs by leading the 
discussions and building a consensus among wholesalers and retailers from the public and 
private sectors. The SC successfully organized the launch of AMFm in March 2011, with the 
presence of the former Prime Minister. The SC established a communication group to oversee 
the AMFm communication strategy and carefully review communication and marketing material 
produced by the SR and Sub-Sub-Recipient (SSR) before public release. Problems experienced 
by the SC included difficulty in holding regular meetings and lack of financial resources to 
support SC activities. 
4.4.1.2 AMFm copaid ACT supply mechanism 
Registration as FLB 
A total of seven organizations registered as first line buyers in Niger, of which five were private 
for-profit organizations, one UN agency and one public agency (Office National des Produits 
Pharmaceutiques et Chimiques (ONPPC)). Three private for-profit buyers had placed orders for 
copaid QAACTs by end of 2011 (Laborex, Ubipharm and Saphar). The Clinton Health Access 
Initiative (CHAI) technical assistant to the National Malaria Control Program (NMCP) provided 
advice and necessary forms for registration as a First Line Buyer (FLB). No difficulty was 
experienced during registration. Some local wholesalers were interested in registering but failed 
to get approval from headquarters or the main partner. Other wholesalers were cautious because 
of limited resources.  
Ordering and delivery of AMFm copaid ACTS 
The process of ordering copaid ACTs was explained to all registered FLBs by the CHAI 
technical assistant to the NMCP, who provided initial ordering forms, names and contact details 
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of manufacturers of QAACTs, types of antimalarials available from each manufacturer and the 
name of the contact person for placing orders. The decision regarding the choice of 
manufacturers was based on pre-existing business relationships between the FLB and the 
manufacturer, although some manufacturers made the first move to try to establish collaboration 
with FLBs by offering to supply copaid ACTs. Copaid ACTs were supplied by Novartis 
Pharmaceuticals (Coartem), Sanofi Aventis (Arsucam), Guilin Pharmaceutical (Arsumoon) and 
Ajanta Pharma Ltd. (Artefan).  
FLBs from the private sector decided which of the first-line antimalarial drugs to buy and 
determined the number of treatment units and the types of package size (infant, child and adult 
packs) to order based on the company’s previous ordering history and anticipated demand. The 
standard procedure is that the FLB should make a request for a quotation to the manufacturer (or 
quotations from multiple manufacturers, if required) before placing a formal order after 
completing, signing and then sending the necessary forms to the manufacturer. The manufacturer 
then submits the order to the Global Fund for approval before starting the manufacturing process. 
Some manufacturers request an upfront payment of the 5% due from the FLB. Finally, the 
manufacturer notifies the FLB when the medicines are ready for shipping.  
In the public sector, the ONPPC is responsible for ordering copaid ACTs. ONPPC has some 
financial and administrative autonomy; however, as a publicly-funded pharmaceutical company 
they still have to comply with a number of administrative and financial regulations and to 
participate in the implementation of the country’s health development plan. For instance, the 
board of management has to approve the activity plan and has to authorize any transaction 
involving large amounts of money. Apart from that, the procedures for ordering and delivery of 
copaid ACTs are similar to those in the private sector. The number of treatment units is 
determined by public health service needs, and the budget is allocated by the government for 
purchasing these medicines. The NMCP provides advice on malaria-related matters. 
The United Nations Development Program (UNDP) ordered copaid ACTs through their 
procurement support office in Denmark, which prepared a proposal for bids and sent invitations 
to all pre-qualified manufacturers of QAACTs. Norvatis was the only manufacturer to respond 
and therefore was chosen to supply AL to the UNDP office in Niger. These copaid ACTs were 
donated to the NMCP and distributed through the ONPPC. The number of treatment units and 
the types of package size of purchased drugs were determined by the NMCP. 
Overall, ordering of copaid ACTs was straightforward. The main problem was the long delays in 
manufacturing. For instance, because of the high demand for Coartem, Novartis failed to supply 
Coartem to Saphar and Laborex. These FLBs turned to Ajanta Pharma Ltd. to supply Artefan 
after advice from the AMFm SC. The first order was placed on August 16, 2010; however, the 
first copaid ACTs arrived in the country six months later (on February 3, 2011). 
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Clearing of AMFm copaid ACTs through customs 
On average, assuming that the required documents are available, it takes 48 hours to clear copaid 
ACTs and other medicines through customs. One of the important documents required is a 
clearance authorization issued by the Director of Pharmacy, Laboratory and Traditional 
Medicine at MOH. Medicines, including copaid ACTs, are free from value added tax (VAT), but 
are subject to a 4% import tax. For the specific case of copaid ACTs, this tax applies to only the 
fraction of the medicine value paid by the FLB (5%) and not to the real value that includes the 
95% of the cost paid by the Global Fund. Medicines and other products imported by international 
organizations and NGOs are exempted from tax. The decision to apply tax to 5% of the market 
value of copaid ACTs was a key factor in keeping the cost of copaid ACTs as low as the cost of 
non-artemisinin therapies when they reach the end user. However, whether all customs personnel 
are aware that this new regulation for copaid ACTs applies only to the amount paid by the FLB 
is questionable. One FLB reported being requested to pay tax on the market value of the copaid 
ACTs by a newly appointed Chief Customs Officer. 
Distribution of AMFm copaid ACTs 
Distribution of copaid ACTs relies on two distribution systems: the public and the private 
system. In the public sector, ONPPC is the official supplier of medicines to public health 
facilities, and it has a special unit (Unité de Gestion Spécifique) for the management of 
purchased commodities. The public distribution system uses a well-established network of four 
regional warehouses and 44 phamarcies populaires across the country. Pharmacies populaires 
supply copaid ACTs to health districts, Centres de santé intégré and cases de santé. To ensure 
that copaid ACTs are accessible to the majority of the population, the public drug distribution 
network was extended to registered rural drug depots, and efforts were made to strengthen the 
distribution system by authorizing the private sector to supply public facilities with copaid ACTs 
when ONPPC cannot meet the demand for copaid ACTs.  
 
The FLBs from the private sector have their own distribution network for medicines (including 
copaid ACTs), which is largely focused on private pharmacies in Niamey and to some extent 
other main cities in the country. Laborex has established three regional distribution points and 
Saphar uses a private transport system to supply medicines to cities other than Niamey. 
Occasionally, the public and private FLBs of copaid ACTs supply NGOs. 
 
As noted above, difficulties in the distribution of copaid ACTs were observed at the very 
beginning of AMFm implementation because Novartis failed to supply FLBs from the private 
sector (Saphar and Laborex) with Coartem. Lack of an effective transportation system to deliver 
medicines (including copaid ACTs) to areas outside Niamey is considered a major constraint by 
FLBs from the private sector, who are inadequately equipped to distribute medicine across the 
country. 
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4.4.2 Implementation of AMFm supporting interventions 
4.4.2.1 Communication 
National launch of AMFm 
After some delay due to late arrival of copaid ACTs in the country, a national launch of AMFm 
was organized on March 23, 2011. The guest of honor at the ceremony was the former Prime 
Minister. The ceremony was widely broadcast on national radio and television. The speeches 
focused on explaining what the program involves and the cost, quality and accessibility of the 
medicines. A speech from the Director of the Global Fund was also read at the ceremony. 
Financial resources for the AMFm launch activities were provided by the country’s AMFm 
grant. Key informants were unanimous in the feeling that the launch was a great success not only 
because of the attendance by high ranking officials, but also because of widespread 
communications to the population about the launch. 
 
IEC/BCC activities 
Catholic Relief Services (CRS) was the sub-recipient for information, education and 
communication (IEC) and behavior change communication (BCC) activities and has 
longstanding experience in IEC/BCC, with a large network of communication specialists across 
the country. Planned IEC/BBC activities included interpersonal communication targeted at 
mothers and guardians of children to sensitize them about the accessibility of ACTs and the role 
of these medicines for malaria treatment, together with mass communication, social mobilization 
and advocacy using a variety of communication channels (radio, TV, mobile TV, and religious 
and community leaders). Organizations specializing in community sensitization and 
mobilization, such as Organisation National des Educateurs Novateurs (ONEN), Regi-PUB and 
Animas-Sutura, were subcontracted to develop AMFm communication materials, which were 
reviewed by the SC communication committee before submission to the SC for approval and 
release to the public. The types of communication materials developed include leaflets, large 
billboards for posting on main roads, and TV spots showing AMFm medicine and the distinctive 
AMFm logo on the packaging. IEC/BCC activities started in January 2011. Audio messages 
were also broadcast by national and private radio stations, which were considered more efficient 
for reaching the largest fraction of the population. It is estimated that only about 30% of 
activities were implemented as a result of several factors, including delays in receiving funds, 
delays in the selection of communication companies to develop communication materials and 
suspension of disbursement of the AMFm supporting intervention grant in the second half of 
2011. One major communication problem experienced during IEC/BCC activities was that the 
first TV spot on copaid ACTs was focused on Coartem with no mention of other brand names of 
copaid ACTs. This led the population to ask for Coartem only for treatment of malaria in the 
early stages of AMFm implementation, dismissing ASAQ and other brand names of AL, and it 
raised complaints from representatives of other manufacturers of copaid ACTs. This 
communication error was rapidly fixed after instructions were issued by the SC. 
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4.4.2.2 Recommended retail price 
The SC led discussions on the pricing of copaid AMFm drugs. Many meetings were held among 
the SC, FLBs, registered pharmacies, civil society, representatives of MOH and the Ministry of 
Finance (MOF), and technical and financial partners of the MOH before an agreement was 
reached on the pricing of copaid ACTs. The MOH issued a decree on October 28, 2010, fixing 
the retail price to the public at 200 FCFA (USD 0.40) for a child’s treatment course and 350 
FCFA (USD 0.69) for an adult dose throughout the country. This decree also fixed the margin 
between the retail price and the purchase price divided by the retail price at 35% for FLBs and 
65% for registered private retailers. FLBs are entitled to only 25% of the profit margin when 
they supply copaid ACTs to drug depots. Agreeing upon retail prices for copaid ACTs before the 
launch of AMFm was a major achievement, considering that retail prices of 800-1,000 CFA 
(USD 1.58-1.98) had been proposed in the application to the Global Fund, and the private sector 
was looking forward to implementing these prices. The role of CHAI in the process of 
negotiating the price for copaid ACTs in Niger was widely acknowledged. A senior pharmacist 
was hired, after a long delay, to support enforcement of agreed retail prices of copaid ACTs. The 
report of an inspection carried out by the pharmacist indicated that overall recommended prices 
were respected, except in a very few cases where retail prices of 1000 CFA (USD 1.98) or more 
were observed. Supervision visits in private pharmacies and public health facilities by the SC 
reported similar findings. The availability of rapid diagnosis tests (RDT) for malaria to promote 
rational use of copaid ACTs in the public sector was very limited. 
 
4.4.2.3 Training 
One of the training activities was a three-day training workshop organized by the PR for sub and 
sub-sub recipients of AMFm. The workshop focused on the Global Fund financial and 
programmatic procedures, and on management of the supply chain. A joint workshop by the 
principal recipient (PR) and the NMCP (sub-recipients-SR) in October, 2010, trained 25 trainers 
in the public sector to in turn train 750 health personnel from the public sector in seven of the 
eight regions in December 2010.The training was focused on explaining what AMFm was about, 
how to identify copaid ACTs, malaria diagnosis, malaria case management and the correct 
dosage of copaid ACTs. Two staff members of the Laboratoire National de Santé Publique et 
d’Expertise (LANSPEX), the national public health laboratory, were trained in drug quality 
control using high-performance liquid chromatography (HPLC) in 2011 in Morocco and Algeria. 
 
Other training activities could not be implemented as planned, mainly because of financial 
problems due to the suspension by the Global Fund of disbursement of funds from the AMFm 
supporting intervention grant. This includes the training of 316 and 105 health personnel from 
the private sector in 2010 and 2011, respectively, the training of 22 managers of Pharmacies 
Populaires and the training of 25 trainers and 750 and 75 health personnel in the public sector 
and the private sector, respectively. Similarly, training of community health workers on malaria 
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case management, training of pharmacists and drug vendors on dispensing medicines and 
counseling patients, training on business opportunities with AMFm, training of health personnel 
on interpersonal communication and training of FLBs to promote safe and effective use of ACTs 
did not take place as planned. 
4.4.2.4 Other AMFm supporting interventions 
Regulatory interventions 
The following regulatory changes were made to support AMFm implementation, some of which 
have already been described above:  
 A decree fixing the cost of copaid ACTs to the public was issued by MOH. The 
regulation, which was issued before the start of AMFm, fixed the wholesale and retail 
profit margin for medicines in general, including ACTs. 
 The 4% import tax on medicines was to be applied only to the 5% of the value of copaid 
ACTs incurred by the FLB. 
 The drug distribution network was expanded to include existing village drug depots 
which can now be supplied with copaid ACTs by ONPPC or the private sector. 
 Licenses to sell medicine were made available at the departmental or regional level rather 
than at the Directorate of Pharmacy, Laboratory and Traditional Medicine within MOH 
as per the previous regulation. 
 To minimize risk of stockouts, MOH instructed the ONPPC to supply the private sector 
with copaid ACTs and instructed FLBs from the private sector to supply public health 
facilities whenever necessary. 
 A regulation under AMFm allowed advertisements and messages on copaid ACTs in the 
media for IEC/BBC activities. 
 
Pharmacovigilance 
Strengthening the pharmacovigilance system was a key component of AMFm supporting 
interventions in Niger. However, at the end of December 2011, the focal point for 
pharmacovigilance had not been recruited and trained. Since the launch of AMFm, the only 
activities that were carried out were the revision and printing of the form for recording adverse 
events and the design of pharmacovigilance forms for use at the community level to collect and 
report cases of adverse drug effects. However, printed forms could not be distributed to health 
facilities and pharmacies in the public and private sector because of a lack of financial resources. 
Therefore, the pharmacovigilance data collection system had not been established and no data 
had been collected, analyzed or reported for monitoring adverse events related to copaid ACTs. 
Sensitization of personnel dispensing medicines on adverse events also had not taken place. 
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Reaching the poor and other vulnerable groups 
IEC/BCC activities were deployed using strategies aimed at reaching the whole population, 
including communities living in remote rural areas. More than 100 AMFm messages broadcast 
on community radios and community meetings were organized to convey keys messages on 
copaid ACTs. It is important to stress that malaria treatment was free at public health facilities 
for vulnerable groups such as children under five and pregnant women before AMFm. This 
policy was maintained and the drug distribution network was expanded to include existing drug 
depots in rural areas to reduce physical barriers to malaria treatment by bringing ACTs closer to 
home. 
 
Research 
In vivo efficacy studies of ACTs were planned in 2010 (baseline) and 2011 (at the end of AMFm 
phase 1) in three sentinel sites as part of the AMFm supporting interventions to be undertaken in 
collaboration with the Centre de Recherches Médicales et Sanitaires (CERMES - a medical 
research institution), the NMCP and Niamey Hospital. In vitro sensitivity tests of P. falciparum 
to artemisinin and its derivates and partner drugs, and determination of molecular markers of 
resistance to artemisinin or derivates and amodiaquine had also been planned for monitoring 
drug resistance. A trial of in vivo efficacy of AL and artesunate-amodiaquine (ASAQ) was 
conducted in 2010 in 79 children in Gaya. In vivo results are available but in vitro assays and 
studies of genetic mutations associated with resistance to AL and ASAQ were not completed due 
to the suspension of SI disbursement. No drug efficacy monitoring activity was carried out in 
2011 as a supporting intervention to AMFm.  
 
A study of the impact of using mobile phone technology and stock management tools at the 
Centre de Santé Intégré (CSI) on the quality of data and availability of copaid ACTs was started 
in 2011 as a joint collaboration between the NMCP, the Department of Statistics and Epidemic 
Surveillance, a telephone operator in Niger, CERMES and the Department of Nutrition. A 
computer program was developed, stock management tools and mobile phones connected to a 
fleet were distributed in intervention CSIs in Maradi and Tahoua, and a group of control CSIs 
was enrolled. Personnel were trained in completing data collection tools and in using a mobile 
phone to send data; however, data collection has not been completed and activities were stopped 
due to the suspension of SI disbursement. 
 
Regarding studies of traceability of copaid ACTs and assessment of drug vendors’ knowledge 
about copaid ACTs, only the activity of marking samples of copaid ACTs was undertaken, but 
field evaluation could not be undertaken because of financial problems. Research on expanded 
use of RDTs in the public sector and initiation of RDT use in the private sector also failed to 
materialize. 
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4.4.3  Key events and context 
AMFm implementation in Niger has received strong political support from local authorities. No 
changes other than those mentioned earlier were made to the drug regulatory system.  
 
In addition to 795,990 doses of AL (Coartem) acquired by UNDP during the Global Fund’s 
Round 7 activities, MOH received 319,000 doses of dihydroarteminsin piperaquine (DHA-PPQ, 
Duo-Cotexin®) and 181,000 doses of ASAQ from the Chinese in September-November, 2011. 
 
The proportion of the national budget allocated to MOH increased to 9.5% in 2011 from 7.8% in 
2010. The budget allocated to the NMCP was higher in 2011 than in previous years. The annual 
GDP growth in Niger was estimated at around 2.3% in 2011, and the inflation rate was estimated 
at 3.8%, suggesting that no major negative factors affected the economy in 2011. However, it 
should be noted that rainfall in 2011 was erratic and unevenly distributed, causing droughts and 
flooding, and it is forecast that 38% of the population will face food shortages by the first half of 
2012.  
 
One major event in 2011 was an investigation by the Global Fund’s Office of the Inspector 
General independent of the AMFm but which contributed to limited implementation of AMFm 
supporting interventions. Fewer LLINs were distributed or sold in Niger in 2011 than in 2009 
and 2010.  
4.4.4  Conclusion 
Table 4.4.1 summarizes of key factors likely to have supported or hindered achievement of 
AMFm goals in Niger and Figure 4.4.1 presents a timeline of all key events related to AMFm 
implementation and context. 
 
AMFm implementation in Niger benefited from strong political support as illustrated by the 
participation of high level officials at the launch ceremony. The launch of AMFm was widely 
communicated in the country as a result of well-planned media coverage and effective decision 
making. A steering committee comprising various partners of MOH was set up by national 
authorities to oversee the implementation of AMFm. The SC played a significant role in 
resolving bottlenecks faced at various stages of AMFm implementation in the context of a lack 
of financial resources.  
 
The public and private sectors have played a key role in the distribution of copaid ACTs across 
the country; however, logistical problems faced by the private sector need to be addressed to 
strengthen the distribution system. Long delays in the acquisition of copaid ACTs have been 
experienced by FLBs. In spite of these unexpectedly long delays in delivering copaid ACTs, the 
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distribution system worked quite well to sustain the provision of the medicines throughout the 
high malaria transmission season, when antimalarial treatment is most needed.  
 
Slight alterations were made to the existing regulatory framework for medicines to support 
AMFm implementation by authorizing advertisements on drugs to be broadcast in the media, to 
fix standard prices for copaid ACTs and to expand the drug distribution network to ensure that 
copaid ACTs are financially accessible and as close to the population as possible.  
 
The suspension of disbursement by the Global Fund in the second half of 2011 caused a 
slowdown in the implementation of AMFm supporting interventions such as IEC/BCC, training, 
pharmaco-vigilance and research activities.  
 
Based on available information, no social, political or economic factors were reported to have 
significantly interfered with the implementation of AMFm in 2011. However, the donation of 
ACTs outside of the AMFm context, the cumulative effect of ITNs acquired in the last three 
years and rainfall patterns in 2011 may need consideration when interpreting the impact of 
AMFm. 
 
Table 4.4.1: Summary of key factors likely to have supported or hindered achievement of AMFm goals in 
Niger 
Factors which are likely to have supported 
achievement of AMFm goals  
Factors which are likely to have hindered achievement 
of AMFm goals 
 Strong support from local authorities  
 Establishment of the AMFm steering committee 
 Effective technical assistance from CHAI 
 Smooth process for registration of FLBs and 
ordering 
 National launch and the presence of highranking 
officials 
 Effective public awareness campaign 
 Agreement to sell copaid ACTs at a cost as low 
as the cost of monotherapies 
 Allowing some profit margin on copaid ACTs 
 Use of the distinctive AMFm logo on copaid 
ACTs 
 Availability of a well-established drug 
distribution network in the public sector to boost 
coverage 
 Expansion of the public sector drug distribution 
network to rural depots 
 Delivery of licenses to sell medicines at the 
departmental and regional level 
 Agreement to impose tax on the fraction of the 
medicine value paid by the FLB only and not on 
the real value of the medicine  
 Non issuance of clearance authorization for 
monotherapies 
 Long delays in manufacturing and delivering copaid 
ACTs to FLBs 
 Limited number of manufacturers of QAACTs 
 Suspension of disbursement of SI grant 
 Lack of financial resources to implement important 
supporting interventions  
 Lack of financial resources to support AMFm SC 
 Lack of RDT tests to promote rational use of copaid 
ACTs 
 Delayed start of inspection activities 
 Marketing focused on Coartem during early stage of 
IEC activities  
 Partial implementation of training activities in the 
public sector and lack of training in the private sector; 
in particular, the planned strategy for extending ACTs 
to the community level was interrupted 
 Lack of data on acceptability and compliance with 
treatment 
 Inadequate estimation of the country needs for copaid 
ACTs 
 Very low levels of orders of copaid drugs by private 
sector buyers due to limited communication and 
training activities 
 Private sector inadequately equipped to supply copaid 
ACTs to remote areas  
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Figure 4.4.1: Timeline of key events related to AMFm implementation process and context in Niger 
 
Activity 
2010 2011 
Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec  
AMFm grants and orders                       
AMFm Grant signing                        
Establishment of the Steering Committee                       
Ordering of drugs (First order placed on August 16, 2010)                       
Delivery of copaid ACTs in the country (First copaid ACTs arrived in 
the country on February 3, 2011) 
         
  
 
          
AMFm supporting interventions                       
Pricing of copaid ACTs agreed                       
Training of public health personnel                       
IEC/BCC activities                       
Official launch of AMFm                       
Distribution of copaid ACTs                       
Expansion of drug distribution network                       
Appointment of an inspector                       
Inspection on pricing of copaid ACTs                       
Supervision visits in private pharmacies and public health facilities by 
the SC. 
         
  
 
          
Research activities                       
Baseline IE outlet survey data collection                       
Endline IE outlet survey data collection                       
Drug efficacy studies                       
IE Country case study                       
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4.5 Nigeria 
4.5.1 AMFm intervention process 
4.5.1.1 Governance structure for AMFm 
The main governance structure established for AMFm in Nigeria is the AMFm Task Force. 
The activities of the Task Force are operationalized through the administrative functions of 
the AMFm Secretariat. The AMFm Task Force was set up by the Country Coordinating 
Mechanism (CCM) and has 15 members from the public sector, the private sector, national 
and international non-governmental organizations, and the United Nations. The Task Force 
was originally chaired by the Clinton Health Access Initiative (CHAI) and was later chaired 
by the National Malaria Control Programme (NMCP). The AMFm Secretariat is the desk 
office for the hands-on administration of AMFm. Presently, the AMFm focal persons from 
the two Principal Recipients are jointly administering the Secretariat, which is domiciled 
within the NMCP, with technical assistance from CHAI. 
4.5.1.2 AMFm copaid ACT supply mechanism 
The increasing availability of ACTs in the national supply chain in the public and private 
sector in Nigeria was facilitated by the rapid expansion of the number of importers of quality-
assured ACTs. Timely advocacy surrounding the launching of AMFm has helped to secure 
buy-in and mobilization of the private sector for AMFm (especially among local 
manufacturers) and has helped to reduce resistance from importers and manufacturers. 
Following the development of criteria and structures for the engagement of AMFm First Line 
Buyers (FLBs), Nigeria registered 54 FLBs (one in the public sector, two in the private not-
for-profit sector, and 51 in the private-for-profit sector), of whom 28 had placed orders at the 
time the case study was being conducted. The participation of a large number of FLBs in 
Nigeria has resulted in a sizeable importation drive, such that Nigeria accounts for about 40% 
of global copaid ACTs delivered. Six pre-qualified international manufacturers have supplied 
copaid ACTs to Nigeria, since Nigeria does not have any domestic manufacturers that are 
pre-qualified. Despite the substantial participation of the private sector, the non-qualification 
of domestic manufacturers for AMFm, which was the fulcrum for concerted agitation against 
AMFm at its onset, makes it difficult to guarantee their sustained acquiescence. 
 
Ordering and delivery of AMFm copaid ACTs 
 
The National Malaria Control Programme places orders through the Voluntary Pooled 
Procurement (VPP) system, whereas the private sector Sub-Recipient (SFH) and FLBs place 
individual orders directly with the manufacturers. Through the end of December 2011, a total 
of 80 million treatments had been ordered in Nigeria, out of which about 59 million had been 
delivered.  
 
A key challenge for product ordering in the public sector was the late approval of 
Procurement Supply Management (PSM) plans, arising from unfulfilled Condition Precedent 
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(CP) requirements, as well as training delays in rolling out the Logistics Management 
Information System (LMIS). The termination of the Global Fund Round 8 malaria grant to 
the Yakubu Gowon Centre (YGC) and the subsequent delay of the release of funds 
contributed to a delay in the procurement of ACTs, which had an adverse effect on the supply 
of copaid ACTs to the public sector. The challenges in the private sector have mainly been 
linked to delays in the approval of orders. The long lead times and uncertain processes for 
final approval of copaid ACT orders have led to a sluggish national ACT supply chain and 
back orders, creating difficulties for achieving increases in the availability and market share 
of copaid ACTs. This problem was sometimes aggravated by the skewed distribution of the 
limited available stock to the major urban hubs, contributing to sub-optimal access to ACTs 
in rural areas. 
 
Clearing customs of AMFm Phase 1 copaid ACTs 
Clearing of goods through customs for all players (the NMCP, private not-for-profit (SFH), 
and private FLBs) was facilitated through waivers from the Federal Ministry of Finance and 
the National Agency for Food and Drug Administration and Control (NAFDAC). While the 
clearing of copaid ACTs for public-sector consignees has always been expedited, the private-
for-profit sector FLBs have sometimes experienced bottlenecks in the custom clearing 
process at the ports. Some FLBs have had to pay demurrage costs, with a few opting to pay 
tax on the subsidized import price to avoid the eventuality of demurrage. Demurrage 
payments and unexpected/unofficial clearing costs have resulted in some affected importers 
increasing the price of copaid ACTs to cut their losses, which makes it more difficult to 
achieve the goal of affordability.  
 
Distribution of AMFm Phase 1 copaid ACTs 
The distribution mechanism for copaid ACTs varies by the type of outlet. In the public sector, 
the manufacturer delivers copaid ACTs directly to the State Stores (through the 3
rd
 Party 
Logistics Providers) for further distribution to the health facilities by the Sub-Recipients 
(SRs) to the NMCP. Proprietary Patent Medicine Vendors (PPMVs) are the cornerstone of 
the private sector distribution system through the private sector SR (SFH). From SFH 
warehouses, copaid ACTs are distributed to wholesalers or SRs, who deliver the drugs to the 
facilities. In the private for-profit sector, distribution of copaid ACTs by private sector first 
line buyers is based on existing distribution networks and mechanisms since this was a 
condition of registration as an importer (First Line Buyer). Copaid ACTs are distributed 
through wholesalers/distributors who sell to pharmacists, PPMVs and finally consumers, as 
well as through medical representatives, who sell copaid ACTs directly, along with their 
normal consignments sold to hospitals, pharmacists and PPMVs. However, the tardy and 
inadequate supply of copaid ACT orders has led to complications down the supply chain, 
whereby distribution and availability become inadequate and retail costs are sometimes 
subject to increase by the retailers, with possible decreased affordability.  
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4.5.2 Implementation of AMFm supporting intervention 
4.5.2.1 Communication 
The AMFm Task Force has spearheaded the buy-in and mobilization of the private sector for 
participation in AMFm, as well as clarifying implementation modalities. The strong support 
of the AMFm Task Force and the AMFm Secretariat has sustained public and private sector 
interest, while strong advocacy and interventions in the public and private sectors have 
created an enabling environment for the FLBs and have been an asset to build on for 
sustained imports of ACTs into the country. The AMFm Secretariat has organized 
stakeholders’ meetings with the public and private sectors, and has maintained a functional 
interface with AMFm stakeholders, particularly with First Line Buyers. The Clinton Health 
Access Initiative has supported AMFm with technical expertise, starting even before the 
grant signing.  
 
There was a successful national launch of AMFm on March 31, 2011, which sensitized the 
public and private sectors alike to AMFm. However, the country has not yet carried out any 
subnational launches, although sectoral launches have been organized for the public sector, 
professional associations and faith-based organizations. 
 
The official rollout of major IEC (information, education and communication) and BCC 
(behavior change communication) activities was delayed until June 2011. However, some 
key IEC/BCC activities were started in both the public and private sectors. These activities 
included advocacy visits to policymakers at the State and Local Government Area (LGA) 
levels, community dramas, roadshows, television advertisements, radio jingles, the erection 
of billboards and other activities. The roadshows, especially by the key AMFm implementers 
(the PRs, along with their SRs), have likely contributed to increased use of copaid ACTs 
through key messages that emphasize the use of quality ACTs for malaria treatment. The 
mobilization of the community has promoted the community uptake of copaid ACTs, as well 
as their proper use and price, thus creating a demand for ACTs and likely increasing their 
market share. Contributions by development partners working in the field of malaria have 
helped to promote a unitary message against monotherapy use, which could have led to an 
increase in the use of copaid ACTs and their market share. However, delays in rolling out the 
BCC supporting intervention may have limited the demand for copaid ACTs and might also 
have contributed to sustained high prices, particularly in the private sector. 
4.5.2.2 Recommended Retail Price 
Pricing of AMFm ACTs has been regulated by a participatory process to set the 
recommended maximum national retail prices and to create a good environment for lowering 
the price of ACTs. The setting up of a national pricing structure for the recommended 
maximum retail prices was seen as key to achieving a steep decrease in the price of ACTs 
across all sectors and levels of care (even for ACTs that are not copaid), as well as increased 
use of ACTs. The participatory and methodical setting of prices for each level of the 
distribution chain has contributed to the increased affordability of ACTs. The recommended 
retail price was initially 75 nairas (USD 0.44) and then raised to 100 nairas (USD 0.59) and 
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was not shown on the drug packaging at the time of the case study. Price enforcement plans 
are in motion, and consultations are ongoing with regulatory bodies in Nigeria such as the 
Consumer Protection Council (CPC) and the Pharmacists Council of Nigeria (PCN). 
However, there have been some pockets of resistance to the approved price, leading to some 
measure of non-compliance. In addition, the frequent stockouts of some weight bands of 
ACTs sometimes results in the sale of multiple packs of a smaller weight band in lieu of the 
unavailable drugs for the correct weight band. 
 
Furthermore, the decreasing motivation of PPMVs and other retailers to stock and sell copaid 
ACTs because of the low price margin coupled with the low volume of stock available for 
sale may have presented a challenge to achieving increases in the market share, affordability 
and use. The preference for operators of high-end facilities not to stock copaid ACTs because 
of the low approved price in relation to the high overheads may have led to limited 
availability of copaid ACTs in those facilities and a concomitant higher market share of non-
subsidized ACTs and monotherapies. 
4.5.2.3 Training 
Diverse training activities have been held in both the public and private sectors across various 
cadres and levels of health staff to improve the knowledge of providers and to ensure the 
correct use of the medicines and commodities distributed. The rollout of the LMIS system 
has commenced, but the Health Facility (HF) training did not start as planned, except in the 
seven World Bank supported states. The training plan for health facilities was designed as On 
the Job Training (OJT), but it was discovered that OJT would take considerably more time 
and expense than originally planned. John Snow, Inc. (JSI) and the Support to Nigeria 
Malaria Programme (SuNMaP) subsequently trained in 7 states each. Without the training in 
all states, the LMIS system cannot be fully rolled out.  
4.5.2.4 Other AMFm supporting interventions 
Regulatory interventions 
NAFDAC has demonstrated its regulatory readiness for AMFm by granting over-the-counter 
(OTC) status to ACTs, which enabled increased availability of ACTs, and by providing 
multiple waivers for AMFm, including the liberalization of the 1:1 import franchise policy 
and reductions in the cost of analysis of AMFm products. The 1:1 policy had stipulated that 
only the company that registers a medicine has the permission to import it to the country (that 
is, One Procuct – One Company). The liberalization of the policy permitted other FLBs to 
import the medicine. These regulatory actions may have helped promote availability, market 
share and affordability of copaid ACTs through the combined import volume of about 28 
importing FLBs and a reduction in clearing costs. However, the impact of the OTC status of 
copaid ACTs has been limited by gaps in the supply of orders. Prior to AMFm, NAFDAC 
had reclassified chloroquine as a treatment for conditions other than malaria. The 
reclassification of chloroquine could have provided the supply sector with the leeway to 
continuously manufacture and import chloroquine, thus contributing to maintaining a high 
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level of stock of chloroquine in circulation and possibly leading to a limited market share for 
copaid ACTs. 
Malaria diagnosis 
In 2011, the malaria treatment guidelines were revised to stipulate that malaria should be 
diagnosed with a laboratory test or with a rapid diagnostic test (RDT) before providing 
antimalarial treatment for persons of all ages, including children. A pilot program to 
introduce RDTs has commenced in 12 states—six in the north (implemented by the NMCP) 
and six in the south (implemented by SFH). Activities to train primary health workers and 
private health providers on the use of RDTs and to increase the supply of RDTs (although 
limited in scope and quantity) should lead to greater rational use of ACTs. 
 
Pharmacovigilance 
Pharmacovigilance training and sensitization has commenced, with an explicit structure set 
for national cross-sectoral interventions, as the feedback system is being strengthened for 
reporting and processing Adverse Drug Reactions (ADRs). Capacity building for 
pharmacovigilance and the development of Cohort Event Monitoring (CEM) aimed to give 
health care providers the necessary tools to advance the use of ACTs, thus potentially 
increasing confidence in their rational use and minimizing the possibility of widespread 
disenchantment with ACTs in the event of suspected adverse reactions. However, the system 
for collecting pharmacovigilance feedback (through ADR forms) is still developing, so the 
maximum benefits have yet to be realized.  
 
Research 
The AMFm program, within the context of malaria control programming, and in consonance 
with other RBM stakeholders, is keeping pace with relevant research of a wide scope as well 
as focused Operational Research (OR). However, there is a need for research projects to be 
more widely disseminated and archived, especially as research activities related to the 
objectives of AMFm are ongoing in the public and private sector and across different line 
agencies and development partners. 
 
Interventions focused on poor and vulnerable populations 
There is a renewed drive to train Role Model Care Givers (RMCG) on the management of 
malaria (including using RDTs for malaria diagnosis and dispensing ACTs) for poor and 
vulnerable populations (children under five years and pregnant women). This strategy is 
aimed at increasing access to ACTs, the use of ACTs, and ACT affordability in settings 
where RMCGs are operating. However, the supply gap of ACTs has prevented the full 
potential of this program from having the expected impact. Interventions from partners such 
as the World Bank, community directed distribution by PPMVs, and community directed 
information by organizations such as NIFAA are jumpstarting ACT access for poor and 
vulnerable populations. 
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Monitoring and evaluation 
The monitoring of public and private sector implementation by the AMFm PRs and SRs is 
ongoing and covering key areas. However, information obtained on implementation has not 
yet been optimally coordinated between the public and private sectors into one national 
system.  
 
4.5.2.5 Implementation of non-AMFm supporting interventions 
Various malaria control interventions have been carried out in Nigeria from October 2010 to 
December 2011. The Nigerian government, through allocations to the health sector from the 
Millennium Development Goals Fund provided nets for five states at a cost of $46.7 million 
and RDTs worth $1.9 million. Interventions carried out with funds from the Global Fund and 
other malaria control partners include the procurement and distribution of ACTs on the Rd 8 
GF grant in both the public and private sector, as well as by the World Bank, USAID, 
UNICEF, SuNMaP, and other partners. These interventions include the procurement and 
distribution of RDTs, long lasting insecticidal nets (LLINs), indoor residual spraying, and 
larviciding in two states (Lagos and Rivers), as well as ongoing BCC activities in both the 
public and private sectors.  
 
Others interventions include training and implementation of Home Management of Malaria 
(HMM), general health system strengthening (including that of the laboratory services for 
diagnosis) and the training of lower health care cadres in the use of rapid diagnostic test kits.  
 
ACTs have been included in the Essential Medicine List (5
th
 Revision, 2010), while 
chloroquine tablets, syrups and injections have been expunged, providing a basis for 
providers to use and claim ACTs for primary care and mopping up chloroquine formulations 
from health facilities.  
4.5.3 Key events and context 
There are promising developments in the health care delivery system, such as the Midwives 
Service Scheme, the National Strategic Development Health Plan, and the Community 
Insurance thrust of the National Health Insurance. However, the impact of these programs on 
health care, and how they have influenced ACT availability, access and use, are yet to be 
evaluated. 
 
The termination of the Yakubu Gowon Centre (YGC) grant in October 2011, preceded by 
months of non-disbursement, is a major contextual influence in the availability, access, and 
use of ACTs in the public sector. There have been specific strikes in the health sector, which 
could decrease the use of ACTs because of the likely resort to self medication with any 
medicine, including monotherapies. The increased threat to national security caused by 
activities of Boko Haram could have indirect effects on the transporting and availability of 
copaid ACTs to those areas affected, particularly rural areas, resulting in general hitches in 
program implementation. 
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4.5.4 Conclusion 
Table 4.5.1 summarizes of key factors likely to have supported or hindered achievement of 
AMFm goals in Nigeria and Figure 4.5.1 presents a timeline of all key events related to 
AMFm implementation and context. 
 
The signing of the AMFm grant agreement with the Global Fund and the commencement of 
its implementation has heralded new hope for Nigeria’s populace, whose national malaria 
burden contributes a large proportion of the global burden of malaria. The commitment to the 
AMFm project has been demonstrated by the achievements made ahead of the signing of the 
grant agreement, such as major regulatory changes and advocacy aimed at critical public and 
private sector stakeholders. The implementation timeline (from inception in October 2010 to 
the present) demonstrates notable achievements as well as substantial program and contextual 
challenges. 
 
The reactions to AMFm have evolved from initial skepticism, through cautious embrace, to 
vigorous involvement by the private sector in particular. There has been participation from a 
diverse group of stakeholders in the public and private sectors, as well as development 
partners, civil society and faith-based organizations. Communities have also felt the impact of 
BCC activities to support the greater use of ACTs, albeit to a limited extent. Despite the less 
than adequate delivery and distribution of ACTs as per orders made, key informants observe 
that AMFm has triggered a substantial decrease in prices, with attendant gains in 
affordability, market share, and use, as the supply of copaid ACTs has increased.  
 
An added benefit of the AMFm program is that the National Malaria Control Programme and 
development partners in Nigeria have expanded the original scope of their malaria 
interventions through savings made on ACT purchases through AMFm, and they have been 
able to add opportunities across all tiers of health care through the supporting interventions, 
which include capacity development, BCC, malaria diagnosis and pharmacovigilance. 
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Table 4.5.1: Summary of key factors likely to have supported or hindered achievement of AMFm goals in 
Nigeria 
Factors likely to have supported achievement of AMFm 
goals  
Factors likely to have hindered achievement of AMFm 
goals 
 Procurement of ACTs with Global Fund Round 8, 
AMFm, World Bank, and DFID/SuNMaP Funds 
 Liberalization of 1:1 Marketing Franchise Policy: 
there are now 54 FLBs on AMFm 
 National AMFm pricing structure  
 Reduction of costs of NAFDAC analysis 
 Waiver of ports’ duties 
 Facilitation of clearing customs by AMFm 
 AMFm Launch - national and sectoral  
 Effects of NAFDAC regulation of ACTs as OTC  
 PPMVs well sensitized 
 Procurement of ACTs by funding streams 
 IEC/BCC on the ACT policy and AMFm 
 “WHO Bans Monotherapies” media parley 
 Wide distribution networks for ACTs  
 Inclusion of ACTs in 2010 EDL (Health Facilities 
and National Health Insurance Scheme)  
 Buy-in of health professionals into AMFm 
 Training of health care providers across cadres and 
sectors 
 Sensitization/training of CSOs and FBOs 
 BCC activities by PRs, public and private sectors 
 BCC activities by CSOs, FBOs 
 Media report on ban on monotherapies and on 
inclusion of ACTs in 2010 EDL 5
th
 version 
 Home Management of Malaria activities  
 Implementation of the National Strategic Health 
Development Plan (NSHDP) 
 Introduction of Social Health Insurance Programs 
(SHIP) 
 Termination of Global Fund Round 8 grant to 
YGC 
 Delayed approval of ACT orders to FLBs 
 Inadequate supply of ACTs 
 Unstable supply of ACTs 
 Demurrages with customs clearing 
 High transport costs to rural areas 
 High overheads in urban/ secondary care 
settings 
 MOU on price ONLY with FLBs 
 Inadequate ACT supply pipelines  
 Inadequate distribution of ACTs to rural areas 
 Re-indication of chloroquine 
 Interrupted ACT supplies nationally 
 Availability of chloroquine in market 
 Late/inadequate rollout of BCC 
 Occasional strikes by health workers 
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 Figure 4.5.1: Timeline of key events related to the AMFm implementation process and context in Nigeria 
 2009 2010 2011 2012 
 Activity 
Aug Sep Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan 
Baseline outlet survey – ACTwatch                          
CHAI: Radio hypes on AMFm                          
NAFDAC: Approval to bring in Coartem under AMFm for 2 Principal 
Recipients: SFH/YGC 
  
                       
NMCP: No Objection Letter obtained for AMFm FLBs                          
AMFm Grant signed                           
GF funds accessed                          
FMoH: Inclusion of ACTs on the EDL                           
FMoH: Exclusion of chloroquine from EDL                          
Acquisition of an all duty/taxes waiver from FMoF                          
Media launch of AMFm                          
Development and airing of PV jingles targeting public                          
CHAI: Soft launch/media parley/mass media campaign/National Tease 
Campaign 
  
                       
SFH: Malaria case mgt training for PPMVs/senior HCP-private for 
profit/CSOs-private for profit/quant/forecasting training for PPMVs/TOT 
workshop on PV for doctors/pharm/record keeping (M&E) for PPMVs 
  
                       
Ongoing Task Force meetings with FLBs                          
SFH: Review of training manual and raining content / training of senior 
HCP on PV ADRs/reporting 
  
                       
AMFm national launch                          
NMCP: Advocacy to policymakers at state/LGAS, community 
opinion//traditional/religious leaders 
  
                       
NMCP: TV Advertisements/radio jingles/spots/community 
drama/roadshows - North and South Nigeria 
  
                       
National sensitization meeting with women groups                           
AMFm Secretariat: advocacy to FMoF/agencies on custom clearance                          
Meeting with FLBs on PSM reporting tool                          
NMCP: Training on malaria management for senior HCP                          
NMCP: Malaria quant/forecasting for states                          
SFH: Development and printing of training manual, training on PV for 
Community Health Extension Workers and Community Health Officers, 
training on PV for doctors, pharmacists, nurses, lab techs 
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 2009 2010 2011 2012 
 Activity 
Aug Sep Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan 
NMCP: RDTs store assessment in 6 states/repairs                          
SFH: BCC rolled out                          
NMCP: Training of PHC H/HWs on RDTs refresher training for HW on 
RDTs 
  
                       
AMFm public sector sensitization                           
NAFDAC: Capacity building on research                           
AMFm Presentations at ACPN conference                          
NMCP: Distribution of RDTs to HFs -Kaduna/Nasarawa                          
Pharmacovigilance: Development and printing of posters, 
fliers/handbills on ADRs 
  
                       
Pharmacovigilance: Distribution of posters, fliers/ handbills on ADRs                          
NMCP: Malaria case management. Training for senior HCP                          
NMCP: Lab diagnosis/RDTs-CNOs, lab techs CHEWS                          
NMCP: Supervision/retrieval of RDT data from HFs                          
NAFDAC: PV: Development, printing of CEM materials/refresher 
training for 13 institutions 
  
                        
AMFm Presentations at NMA conference                          
NMCP: Erection of billboards                          
NAFDAC: Training of NAFDAC - minilab test kits                          
PV: Development of PV pins and distribution                          
NMCP: Training of CSOs on case management                          
Endline IE outlet survey data collection                          
SFH: TOT on PV for HCs - public and private                          
AMFm Secretariat: Pricing consultations with CPC and PCN                           
SFH: Review/finalization of PPMV manual with PCN                          
NMCP: National refresher TOT for RMCGs                           
Pharmacovigilance: Development/printing of Cohort Event (CEM) 
program materials for 18 institutions 
  
                       
PV-Development and airing of PV jingles - general public                          
Advocacy to the Hon. Minister of Health and DG NAFDAC to 
postpone/waive the policy on Text Message Authentification System 
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4.6 Tanzania - Mainland 
4.6.1 AMFm implementation process  
4.6.1.1 Governance structures for AMFm 
There are a number of key bodies involved in governance of AMFm-related grants. The 
Principal Recipient (PR) is the Ministry of Finance and Economic Affairs (MOFEA), and the 
Local Fund Agent is PricewaterhouseCoopers (PwC). The lead sub-recipient is the National 
Malaria Control Programme (NMCP), which channels money to the other sub-recipients (SR) 
who are responsible for the AMFm supporting interventions: Health Focus 
(communications), Tanscott (private sector monitoring and evaluation), Tanzania Food and 
Drug Authority (TFDA) (private sector training), Medical Stores Department (MSD) (public 
sector procurement), and Tanzania National Malaria Movement (TANAM) (community 
mobilization).  
 
AMFm is mainly managed through the ACT Technical Working Group (TWG) based in the 
NMCP’s Case Management Cell. Membership comprises NMCP, TFDA, MSD, Johns 
Hopkins University (JHU), Population Services International (PSI), the US President’s 
Malaria Initiative (PMI) and the Clinton Health Access Initiative (CHAI). Some aspects of 
AMFm are also covered by other TWGs under the NMCP: the Behaviour Change 
Communication (BCC) TWG which meets monthly, and the monitoring and evaluation 
(M&E) TWG which meets quarterly. 
 
Tanzania’s AMFm grant was approved in November 2009, and in August 2010, the PR 
signed an amendment to the Round 7 host grant to include implementation of AMFm Phase 
1. 
4.6.1.2 AMFm copaid drug supply mechanism 
Private sector  
As of December 2011, there were 10 private sector first line buyers (FLBs) registered in 
Tanzania mainland, and five had formed relationships with manufacturers and placed orders.  
 
The copaid drug supply system to the private sector has functioned relatively smoothly in 
Tanzania mainland. The five FLB that have established relationships with manufacturers did 
so without any major challenges with registration or ordering, with facilitation provided by 
both CHAI and the NMCP. A total of 8,122,020 copaid ACT doses had been received by the 
end of 2011 (around one dose for every 5-6 people). Copaid drug orders were dominated by 
AL, the first line drug in mainland Tanzania, with ASAQ accounting for only 7% of 
deliveries by the end of December 2011.  
 
No orders were reported to have been cancelled or cut. However, orders were slow to start 
(with only 1,250,050 doses received by the end of March 2011), as initially FLBs were 
unfamiliar with the order process and found it difficult to predict demand. There were some 
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delays in deliveries (with a mean of 88 days from approval, although the time from ordering 
to delivery may be substantially longer). Initially this was partly felt to reflect the Global 
Fund’s quality control process which required samples from all orders to be tested in a lab in 
Vietnam, leading to delays in shipment of orders of up to 4 weeks, and some stockouts for 
FLBs in Tanzania mainland. From July 2011, it was agreed that drugs could be shipped 
before quality approval was obtained, leading to a significant improvement in order times. 
Other reasons for order delays were reported to be lack of stock at the manufacturer level, 
and possibly use of the Global Fund’s “demand shaping levers” in the last quarter of 2011, as 
the relevant Global Fund body meets only once a month.  
 
No major problems or delays were reported with clearing customs for private sector drugs, 
which took a matter of days. Private sector FLBs reported high demand for the copaid drugs 
which tended to sell quickly. FLBs were actively promoting copaid drugs through their own 
marketing and distribution activities, for example through printing their own promotional 
materials and contacting potential customers. Despite not expecting large profits from copaid 
drugs, FLBs were said to be willing to participate due to the benefits of establishing new 
markets and business relationships, and a desire to work in a socially responsible way. 
 
It appears that the relatively smooth ordering and distribution process in the private sector 
will have made an important contribution in increasing availability and therefore market 
share and use of ACTs. In March 2011, only 12% of private outlets were stocking copaid 
drugs (Tanscott Associates (T) Ltd., 2011a), but by August/September 2011 several studies 
indicated that availability in private retail outlets was clearly over 50% and likely over 70% 
(Tanscott Associates (T) Ltd., 2011b; Health Action International, 2011; Cohen et al., 2011). 
However, had FLBs submitted larger orders, it seems likely that they would have been able to 
increase their sales even further, as there was clearly some unmet demand, indicated by one 
FLB rationing supplies by restricting them to more malaria prone areas of the country, and 
others reporting stockouts. In addition, the limited number of FLB-manufacturer relationships 
established for AMFm may have restricted total orders which might have increased if 
manufacturers had formed more multi-FLB relationships. Some FLBs were clearly 
disappointed that they had not been able to form relationships with manufacturers. Some 
FLBs indicated that there was still a market for premium ACTs which were not copaid, even 
when they were up to 20 times the price of copaid ACT, because the former is perceived to 
be of superior quality (Clinton Health Access Initiative, 2011). 
 
Public sector 
For the public sector, the Medical Stores Department (MSD) was registered as an FLB (no 
not-for-profit FLBs were registered in Tanzania mainland). 
 
The supply mechanism in the public sector was much more problematic than in the private 
sector. By the end of December 2011, only 4.9 million doses of public sector copaid drugs 
had arrived in Tanzania mainland, with deliveries in July and September 2011 (one dose for 
every 9-10 people). This is estimated to be equivalent to only 2-4 months’ worth of supplies 
for the public sector. This was supplemented by an additional 6.5 million doses procured by 
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PMI, delivered in three tranches in March, July and November 2011. However, this still 
comprised only around 5-8 months’ worth of supplies in total which, given the low stocks in 
the system at the start of AMFm, has been highly inadequate.  
 
There were several reasons for the delayed public sector procurement of copaid drugs: 
 Initial misunderstandings about the AMFm ordering system (e.g., the order was originally 
tendered on the basis of manufacturer rather than copaid prices) 
 concerns about how the Tanzania Food and Drug Authority (TFDA) service fees for drug 
clearance, storage and distribution would be covered  
 delays in delivery due to limited manufacturer capacity (e.g., PMI orders were said to 
have been delayed by 2-3 months because of lack of capacity at Novartis) 
 the time taken for reorganization of Global Fund grants – the first disbursement from the 
grant hosting AMFm was in December 2010, but it was then decided that all malaria 
grants from the Global Fund should be consolidated into one funding stream termed 
“Single Stream Funding” (SSF). This process took some time, requiring merging of 
budgets, work plans and indicators, with the SSF grant finally signed in May 2011 and 
the first disbursement in June 2011.  
 irregularities in accounting for previous procurements which delayed the approval process 
of new orders once SSF had been signed.  
 
As a result, no public sector orders were approved between May 2011 and February 2012. 
The consequences have been severe, combined with some in-county distribution challenges, 
leading to very high stockout levels in public health facilities, described as “very, very bad.” 
However, the stockouts do not appear to be that dissimilar from stockout levels seen in 
previous years when similar procurement challenges have been experienced. In May and 
August 2011, over one-fifth and over one-quarter of public facilities, respectively, had no AL 
packs at all, and stockout levels for individual pack sizes ranged from 29% to 63% (USAID | 
DELIVER PROJECT, 2011a and b). The average duration of individual AL pack stockouts 
was between 17 and 22 days in May 2011 and between 24 and 30 days in August 2011. This 
is likely to have substantially boosted demand for private sector copaid ACTs and therefore, 
probably private sector QAACT availability and market share, while decreasing availability 
and market share of QAACTs in the public sector. The overall effect on QAACT use is likely 
to have been negative. 
4.6.2 Implementation of AMFm supporting interventions 
The main AMFm supporting interventions implemented in mainland Tanzania have been 
related to communications, the recommended retail price (RRP) and training of staff from 
Accredited Drug Dispensing Outlets (ADDO). 
 
4.6.2.1 Communication 
Communications activities have been implemented by Health Focus, involving a soft launch 
with a press conference on January 25, 2011, a national launch on April 29, 2011, TV and 
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radio spots, marketing materials and community-based activities. Implementation of the mass 
media and marketing components began after the national launch, which was well timed with 
the increase in availability of copaid products in country. It was reported that before the 
launch, one private sector FLB was receiving orders for about 2,000 ACT doses per month, 
but that after the launch 200,000 doses were ordered in two days. By December 2011, about 
105,000 marketing materials had been produced, including flipcharts for training, stickers, 
leaflets, posters for shops, large posters, t-shirts, calendars, caps, kangas (printed cloth used 
for clothing) and bags. By the same date, 12,700 radio and TV spots had been aired on 
national and local stations, and 48 advertisements had been placed in newspapers. 
 
Community-level communications activities were delayed by about three months due to the 
delay in the second disbursement of AMFm funds until August 2011, which was related to 
the reorganization of Global Fund grants under SSF. They involve mobile video units 
(MVUs), road shows, clinic shows and school activities, implemented through community 
change agents (CCAs) and local community-based organizations (CBOs). CCAs are a type of 
community health worker with basic education, who undertake health promotion for a range 
of health problems through activities such as school campaigns, cultural shows, group 
discussions, clinic shows and house visits, and receive an allowance of TSh 10,000 (USD 
6.00) per month. Due to budget limitations, community-level activities were restricted to two 
districts in each of 12 selected regions, with only 12 CCAs per district. 
 
Although some stakeholders felt that the campaign could have been improved, the national 
launch and TV and radio spots were generally perceived to have been important in raising 
awareness about the copaid products, the green leaf logo and the RRP, and in stimulating 
demand for the drugs. The green leaf logo was reported to be well understood and to be an 
effective way of promoting the copaid drugs, and the logo was valued by the FLBs as a way 
to signal the quality of the products. These activities are likely to have had a substantial 
positive impact on QAACT availability and affordability, and probably on market share and 
use.  
 
However, the impact of the community activities was likely to have been more mixed. While 
some community activities such as MVUs were felt to have been very well attended, the 
overall impact was likely to have been limited at the time of the endline OS data collection, 
given that the activities only began in September 2011, and that they were only taking place 
in 24 out of 121 districts, with only 12 CCAs per district. Health Focus estimated that they 
had reached 441,080 people at the community level, which would represent only around 1% 
of the total population. Some stakeholders argued that opportunities had been missed to 
“piggy back” on existing malaria promotion through CCAs under the COMMIT/RCC 
programs (see below).  
 
A national survey conducted for monitoring and evaluation of the communications activities 
in December 2011 found that 88% of respondents had heard of “price subsidized ACTs that 
are available in the private sector,”, with radio being the key source of awareness (74%), 
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followed by TV (27%) and health facility staff (24%). Only 1% had heard of the program 
through community dialogue (Synovate Ltd., 2012). 
 
A separate award to TANAM to conduct awareness activities was delayed due to Global 
Fund disbursement delays, so these activities had not begun by the end of the outlet survey 
endline data collection.  
4.6.2.2 Recommended retail price 
An RRP was set at TSh 1,000 (USD 0.62) for an adult dose of copaid ACT. The RRP was 
promoted widely on the TV and radio spots. It was not printed on drug packaging and to start 
with was not on the marketing materials. This appeared to have reflected concerns from some 
stakeholders that printing the RRP would make it difficult to change later on, and might 
prevent retailers from selling at a price below the RRP. However, from July-August 2011, the 
RRP was added to marketing materials, partly due to pressure from the Minister of Health. 
 
This adult RRP was generally perceived to be appropriate and well promoted. Several 
research studies indicated that by mid to late 2011 median prices were not far above the RRP 
(between TSh 1,000 and 1,500). However, there was a lack of clarity on whether there was an 
RRP for smaller packs, and these were much less promoted, with concerns that as a result 
prices charged for these packs were not far below those for adults. It is therefore likely that 
the RRP had a positive impact on affordability, market share and use for adults, but that this 
effect may have been diminished to some degree for younger age groups.  
4.6.2.3 Training 
The main supporting intervention for training under AMFm was the rollout of the ADDO 
program to additional regions. ADDOs are Accredited Drug Dispensing Outlets, which are 
created by providing additional training and support to drug stores, previously known as 
Duka la Dawa Baridi (DLDB). ADDO dispensers undergo a 35-day training program and are 
allowed to sell a limited range of prescriptions only medicines (POM), including ACTs. In 
contrast, DLDBs were officially allowed to stock Over-the-Counter (OTC) medicines only, 
although many do stock POM products. Once a region has undergone ADDO conversion, no 
DLDB should continue to operate there. 
 
Prior to AMFm, the ADDO program had been rolled out in eight regions. With AMFm 
funding, the rollout in six additional regions was completed January-March 2011, and an 
additional region had begun a rollout with USAID funding to CHAI in December 2011. 
Some regions which already had ADDOs had also organized some “local” ADDO trainings, 
funded by the trainees. However, the completion of the remaining regions had not taken place 
by the end of 2011 because of delays in disbursement of Global Fund funds. This partly 
reflected the process of harmonization of funding under SSF. In addition, the SSF included a 
condition withholding all training funds until a revised training plan was approved and this 
was not achieved until early 2012.  
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A one-day re-training program covering malaria (and IMCI and family planning) was 
implemented in Lindi and Mtwara regions in August-September 2011 with USAID funding. 
This involved development of new ADDO training materials which will also be used in 
future 35-day training courses. The re-training program is likely to have raised awareness of 
AMFm, but plans to cover a further six regions were delayed beyond the end of 2011 due to 
contractual issues.  
 
One might expect that as DLDBs were not allowed to stock the POM ACTs, distribution of 
copaid drugs would be restricted in regions without ADDO rollout. However, it is well 
known that DLDBs frequently stock a wide range of POM antimalarials, and respondents 
generally agreed that no authorities were actively preventing DLDBs from stocking copaid 
drugs, because it was accepted that there was a need for ACT coverage to increase. 
Therefore, the impact of the delays in ADDO rollout on AMFm indicators is unclear. There 
may also have been erosion of the quality differences between ADDOs and DLDBs due to 
poor ADDO regulation and supervision, turnover of ADDO staff and increasing use of people 
with lower level qualifications as ADDO dispensers. However, one might expect untrained 
DLDBs to be less aware of the importance of stocking ACTs, and all ADDO and DLDB staff 
that had not received the re-training may be less aware of the RRP and meaning of the logo. 
In sum, the ADDO training may have had a small positive impact on QAACT availability 
and affordability, but the impact on market share and use is likely to have been limited due to 
the delays in training and the context within which DLDBs without ADDO training were 
stocking POM medicines.  
 
Separate AMFm training/sensitization was planned for private health facility staff, but this 
has not taken place due to a misallocation of the funds.  
4.6.2.4 Other AMFm supporting interventions 
Other AMFm supporting interventions concerned pharmacovigilance (PV) and M&E. Some 
small scale PV activities had taken place, but these seem unlikely to have affected the key 
AMFm outcomes. M&E activities were contracted to Tanscott Associates. Delays in 
finalizing their methodology and in disbursement of funds meant that very limited data were 
available by the time of the endline outlet survey, so they are unlikely to have fed into 
implementation plans. However, it is possible that both a national census of private outlets in 
early 2011 and subsequent data collection in private outlets in 43 districts in August-
November 2011 may have served to raise awareness about AMFm and the RRP in the outlets 
visited, and therefore to have increased QAACT availability and affordability. A similar 
impact may have occurred due to other research studies, such as the Tanzania Remote 
Distribution Incentive Program (TZ-RDIP) project, in Lindi, Mtwara and Rukwa, which 
involved repeated retail audits in ADDOs, and possibly the baseline IE Outlet Survey itself.  
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4.6.2.5 Implementation of non-AMFm interventions 
The USD 1.3 million so far disbursed for AMFm communications was vastly over-shadowed 
by the USD 25 million awarded for malaria communications activities over the previous five 
years under the Community and Malaria Initiative in Tanzania (COMMIT) project funded by 
USAID/PMI and the Rolling Continuation Channel (RCC) funded by the Global Fund. Johns 
Hopkins University is the prime recipient for COMMIT, with a sub-contract to PSI, and PSI 
receives the RCC funds through the NMCP. COMMIT/RCC communications cover malaria 
treatment and prevention using mass media and community activities. The programs use a 
common platform at the community level, and both use the same umbrella slogan “malaria 
haikubaliki” (malaria is unacceptable). They work in a total of 18 regions, covering over 
2,000 CCAs (compared with less than 300 CCAs involved in Health Focus AMFm 
activities). One must therefore be cautious in attributing general improvements in malaria-
related knowledge to the Health Focus campaign, which was conducted against the 
background of these much broader promotion activities. However, the COMMIT/RCC 
communications deliberately did not promote the green leaf logo (reflecting USAID 
requirements), so any awareness of the logo, where copaid drugs were available, and the RRP 
can broadly be attributed to the AMFm-specific communications. A wide range of other 
partners are also involved in malaria-related communication activities although on a smaller 
scale.  
 
Other important malaria control interventions rolled out during this period were rapid 
diagnostic tests (RDTs), distribution of long-lasting insecticidal nets (LLINs) and indoor 
residual spraying (IRS) in limited areas.  
 
In the interval between the baseline and endline outlet surveys, RDTs were rolled out in 
public health facilities in six additional regions, making a total of 11. One might expect this 
to decrease ACT use in these regions and potentially increase use of health facilities, but in 
practice the impact is likely to have been muted due to high levels of RDT stockouts and 
frequent dispensing of ACTs to RDT negative patients. The RDT rollout in the remaining 10 
regions was expected to be completed by the end of 2011, using Global Fund money, but 
funding had been delayed due to the process around the SSF, and the withholding of all 
training funds after the SSF was approved, as the RDT rollout involves health worker 
training. 
 
Tanzania has had a long-standing voucher program to increase access to treated nets, with the 
distribution of LLINs beginning in 2009. It became accepted that this alone would be 
insufficient to achieve the target levels of ITN coverage, leading to the development of two 
mass campaigns—the Catch Up Mass Campaign aimed at children under five years in 2009 
and the Universal Coverage Campaign (UCC). The UCC was rolled out nationwide between 
October 2010 and October 2011, with distribution of over 18 milllion nets leading to a huge 
increase in LLIN coverage between the baseline and endline IE outlet surveys. In addition, by 
2010/11 over 6 million people in 18 rural districts of the Lake Zone were covered by IRS for 
mosquitoes. While data are not available on impact, it is likely that these interventions have 
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led to a decrease in malaria prevalence, although the impact on AMFm indicators is unclear. 
It is possible that fevers on average will present as less severe as fewer will be due to malaria, 
which might lead to less use of antimalarials in general, but it is not clear that this would 
reduce the market share of ACTs. Other malaria control interventions include larviciding and 
prevention of malaria in pregnancy, but large-scale changes in their implementation did not 
take place during AMFm Phase 1.  
 
A ban on artemisinin monotherapies (AMTs) has been in place since 2008 in Tanzania 
mainland and is likely to have provided a supporting environment for AMFm. Moreover, a 
move to restrict availability of non-artemisinin therapies (nATs) by refusing any new product 
registrations, and beginning the process of banning imports may have had a positive influence 
on the QAACT market share, although this is likely to have been limited by continued high 
nAT availability on the market.  
 
Finally, a number of innovations have been introduced to improve monitoring and 
distribution of antimalarial stocks for public health facilities, including SMS for Life, the 
Integrated Logistics System (ILS) gateway, direct drug delivery to health facilities and 
upgrades of MSD zonal stores. However, it does not appear that these would have had a 
major impact on public sector drug supplies by the time of the endline data collection.  
4.6.3  Key event and context 
The only key contextual factor raised by stakeholders was the rapid depreciation of the 
Tanzanian Shilling during the past two years, from TSh 1,319 to the USD in January 2011 to 
TSh 1,749 in November 2011, before recovering to TSh 1,572 by the end of December 2011. 
The depreciation will have increased the price of imports and may to some small degree have 
offset the impact of the ACT subsidy. However, given the magnitude of the subsidy and the 
relatively good performance described above on RRP adherence, it is likely that the impact of 
the depreciation on AMFm indicators was quite small. 
4.6.4  Conclusion 
Table 4.6.1 summarizes key factors likely to have facilitated or hindered achievement of 
AMFm goals and Figure 4.6.1 presents a timeline of all key events related to AMFm 
implementation and context.  
 
In sum, implementation of AMFm in the private for profit sector in Tanzania mainland 
proceeded relatively well. The process of registering FLBs and placing and receiving orders 
went smoothly, and demand and sales were reported to be high, with FLBs undertaking their 
own promotional activities. The national communication campaign was reported to be 
effective in raising awareness on AMFm, in the context of other larger on-going malaria 
treatment communication campaigns. The green leaf logo was reported to be an effective 
communications tool, and the RRP was well publicized, at least for adults, with reasonable 
adherence. However, the RRP for smaller pack sizes suffered from a lack of clarity which 
may have led to higher prices for these packs. While ADDO rollout was delayed, this was 
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unlikely to have substantially constrained availability of copaid drugs, as no authorities 
prevented other drug shops from stocking them.  
 
However, the picture in the public sector was much more problematic due to major delays in 
public sector procurement of copaid drugs, which contributed to severe stockouts of ACTs in 
public health facilities. 
 
Table 4.6.1: Summary of key factors likely to have supported or hindered achievement of AMFm goals in 
Tanzania mainland 
Factors which are likely to have supported 
achievement of AMFm goals  
Factors which are likely to have hindered 
achievement of AMFm goals 
 Smooth process for registration of FLBs and 
ordering copaid drugs in the private sector 
 Promotional activities by FLBs 
 National launch and AMFm mass media 
communication campaign 
 Setting of RRP allowing adequate profit margin 
for providers 
 Inclusion of RRP on marketing materials 
 Use of green leaf logo  
 ADDO re-training (only 2 regions) 
 M&E data collection may have raised awareness 
in interviewed outlets 
 COMMIT/RCC communication activities 
promoting ACTs 
 Tolerance by regulatory authorities of DLDBs 
stocking copaid drugs 
 Ban on AMTs and moves to reduce availability of 
nATs 
 Underestimation of demand by private sector 
FLBs and delays in orders of copaid drugs 
 Major public sector procurement problems 
leading to public sector stockouts of QAACTs 
 Delays in and small scale of community-level 
AMFm communication campaign 
 Delays in second funding disbursement for 
training activities, especially ADDO re-training 
focusing on malaria 
 Limited number of FLB-manufacturer 
relationships established 
 Lack of RRP on drug packaging 
 Lack of clear RRP for non-adult pack sizes 
 Delay in including RRP on marketing materials 
 Lack of promotion of green leaf logo during 
COMMIT/RCC communication activities 
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Figure 4.6.1: Timeline of key events related to AMFm implementation process and context in Tanzania mainland 
Activity 
2010 2011 
Aug Sep  Oct Nov  Dec  Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 
AMFm grants and orders 
                 AMFm grant amendment signed                  
Private sector orders of copaid ACTs approved by Global Fund 
                 Private sector copaid ACTs delivered to Tanzania – mainland 
                 Public sector orders of copaid ACTs approved by Global Fund 
                 Public sector copaid ACTs delivered to Tanzania – mainland 
                 AMFm supporting interventions  
                 Soft launch of AMFm                  
National launch of AMFm             
 
  
 
                
AMFm mass media campaign and distribution of marketing materials                 
        RRP added to AMFm marketing materials 
                 AMFm community-level communication activities in 24 districts1 
                 ADDO training in 7 new regions      
   
     
    ADDO re-training on malaria in Lindi and Mtwara regions                       
  
   
Sensitization of health professionals on pharmacovigilance in selected 
areas of 6 regions               
   
              
Introduction of adverse drug reaction (ADR) reporting cards for patients                          
 
    
Tanscott national census of private outlets           
   
                 
Tanscott M&E data collection in 43 districts                      
     Non-AMFm interventions 
                 COMMIT/RCC malaria communications activities in 18 regions 
                 JHU-Voices malaria communications at CECAFA cup 
                 Rollout of RDTs to public facilities in additional 6 regions         
   
                    
Universal Coverage ITN campaign (UCC)     
             
    
Research activities 
                 Baseline IE outlet survey data collection  
   
             
Endline IE outlet survey data collection   
   
                    
   HAI price tracking surveys 
                 RDIP household and outlet data collection in 3 regions             
        
      
CHAI mystery shopper survey in DSM                     
  
  
1 Some limited community level activities began from May 2011, but most did not begin until September 2011. 
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4.7 Uganda 
4.7.1  AMFm implementation process 
4.7.1.1 Amending the AMFm host grant  
Uganda’s application to participate in AMFm was approved by the Global Fund Board in 
November 2009. However, Uganda was the last of the participating countries to sign the 
grant amendment necessary to commence AMFm. An amendment to the Round 4, Phase II 
malaria grant was finally signed on the February 10, 2011, the Global Fund’s final deadline 
for AMFm grant amendments, after protracted negotiations between the Government of 
Uganda (GoU) and the Global Fund. 
 
The primary impasse during the negotiations leading up to the grant amendment was the 
GoU’s concern over the potential impact that AMFm-subsidized antimalarials could have on 
the domestic pharmaceutical industry (Nanyunja et al. 2011). In particular, there were fears 
that inexpensive ACTs imported through AMFm would harm the financial sustainability of 
the Kampala-based manufacturer Quality Chemicals Industries Limited (QCIL), if the latter 
was not eligible to supply ACTs under AMFm. QCIL was established in 2005 to create 
domestic capacity to produce high-quality antiretroviral drugs and ACTs. It is a partnership 
between a Ugandan pharmaceutical importer and distributor (Quality Chemicals Limited), an 
Indian pharmaceutical manufacturer (Cipla Limited) and the Government of Uganda. QCIL is 
regarded by the GoU as a strategic investment. 
 
At the time the Global Fund Board approved Uganda’s application to AMFm, QCIL was not 
eligible to supply ACTs under AMFm. In order to receive a copayment under AMFm, a 
manufacturer must meet the requirements of the Global Fund’s Quality Assurance Policy, 
among other obligations. QCIL’s manufacturing plant received Good Manufacturing 
Practices certification in 2008, and eventually became WHO pre-qualified to manufacture 
artemether-lumefantrine (AL) under license from Cipla Limited in December 2010.  
 
Once QCIL became pre-qualified to produce AL, negotiations between the GoU and the 
Global Fund advanced. This permitted Uganda to participate in AMFm. QCIL requested to 
sign an AMFm Master Supply Agreement in May, 2011, which was signed in late 2011, but 
no AMFm orders were made for QCIL-manufactured products before the end of 2011. 
4.7.1.2 Governance structures 
The Principal Recipient for all Global Fund grants in Uganda, including the AMFm host 
grant, is the Ministry of Finance, Planning and Economic Development. The Sub-Recipient 
for malaria grants is the National Malaria Control Programme (NMCP).  
 
Other key bodies involved in the governance of the AMFm host grant include: 
 The Global Fund Focal Coordinating Office (FCO) 
 The Country Coordinating Mechanism (CCM) 
 The Local Fund Agent (LFA) 
 The AMFm Task Force 
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The FCO is situated in the MoH Planning Department. It coordinates the implementation of 
Global Fund grants in all three disease areas. It is responsible for coordinating grant 
applications, selecting suppliers (known as sub-sub recipients (SSRs)) and submitting 
program updates and progress reports. The FCO also acts as the Secretariat for the CCM.  
  
PricewaterhouseCoopers is the LFA in Uganda. The LFA’s role is to provide oversight and 
advisory services to the Global Fund secretariat. In the context of AMFm, the LFA is 
responsible for assessing the capacity of the PR to undertake the AMFm supporting 
interventions,; reviewing grant amendment documentation, such as progress updates and 
disbursement requests; and conducting spot-checks of FLBs to ensure that they are 
complying with the conditions of participation set out in the first line buyer undertaking 
agreements (The Global Fund, 2011b). 
 
The AMFm Task Force was established to provide oversight and advice to the NMCP on 
AMFm implementation. It is a multi-sectoral body comprised of representatives of 
government agencies (MoH and National Drug Authority (NDA)), implementing partners, 
civil society organizations, public, private for-profit and private not-for-profit antimalarial 
procurers, the LFA, UN agencies and organizations providing advisory and technical 
assistance (e.g., PMI and CHAI). The specific roles of the Task Force are to share 
information on AMFm activities and implementation challenges, advise the NMCP on 
programmatic decisions and provide oversight on establishing a Recommended Retail Price 
(RRP) for AMFm copaid ACTs, and to support quantification and forecasting (NMCP 
2011b). The Task Force also has a Manufacturer and First-Line Buyer Working Group and an 
Advocacy and Social Marketing Working Group.  
 
Between February and October 2011, the Task Force met 13 times and the Manufacturer and 
First-Line Buyer Working Group met 9 times (NMCP 2011a). Key informants indicated that 
they generally found the meetings to be a useful forum for sharing information. Several 
respondents mentioned that they appreciated the opportunity to interact with the private 
sector first line buyers. Some respondents indicated that, while they had initially found the 
Task Force and Working Group meetings to be useful, the meetings had “lost momentum” as 
a result of delays in receiving orders and in implementing supporting interventions. Indeed, 
the Chair of the Manufacturer and First-Line Buyer Working Group noted in the minutes for 
a meeting in mid-2011 that attendance was dwindling.  
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4.7.1.3 AMFm copaid drug supply mechanism 
 
Public sector 
Prior to AMFm, ACTs were procured for the public sector using GoU funds and funding 
from the Global Fund. During 2009 and 2010, the GoU purchased approximately 8 million 
treatment courses from QCIL. By mid-2010 the stocks available in the National Medical 
Stores (NMS) were well below the recommended minimum stock levels, as a result of 
bottlenecks in procurement through the Global Fund grants (PMI 2010; SURE 2010). The 
situation improved in the latter half of the year. Ajanta Pharma signed a contract in April 
2010 to supply ACTs with funds from the Round 4, Phase II malaria grant. The first tranche 
of ACTs, totaling 9.4 million treatment courses, was delivered by Ajanta to the NMS and 
Joint Medical Stores over May-October 2010. In addition, QCIL delivered a consignment of 
ACTs to the NMS in December 2010 and January 2011. Nevertheless, the December 2010 
stock status report shows that the NMS was out of stock of the infant age-band of AL, in spite 
of the deliveries received from Ajanta in October 2010 (SURE 2010).  
 
There was a gap in placing orders for ACTs in the public sector in early 2011. Following the 
pre-qualification of QCIL in December 2010, it was expected that Uganda would soon join 
AMFm. Orders for the public sector were put on hold to take advantage of the cost savings 
that would arise from the AMFm co-payment. The contract from the Round 4, Phase II 
malaria grant with Ajanta Pharma for a second tranche of ACTs was eventually cancelled.  
 
Although the amendment to the AMFm host grant was signed on February 10, 2011, the first 
order was not approved until June 14, 2011. Two explanations for the delay were offered by 
key informants. First, key informants indicated that there were minor delays as a result of 
discussions between the NMS, the NMCP and Securing Ugandans’ Rights to Essential 
Medicines (SURE) regarding the appropriate composition of the order. In January 2011, the 
NMS indicated to the Health Policy Advisory Committee of the MoH that, rather than 
distribute all four age-bands of AL, it intended to distribute the 24-tablet packages only. They 
proposed that health workers could cut or divide the 24-tablet packages to the appropriate 
size, given a patient’s weight. This would save space in the NMS warehouses, and simplify 
logistics. In contrast, the national quantification prepared by SURE calculated treatment 
needs in terms of the four age-bands, and the NMCP asserted that it was necessary to have all 
age-bands available in health facilities to ensure appropriate case management. An agreement 
was reached that the NMS would continue to distribute all age-bands of AL.  
 
Second, key informants indicated that there was a further delay in the approval of the first 
order resulting from confusion over who would supply ACTs to the public sector. The 
Ministry of Health initially intended to order nearly 20 million doses of AL from Cipla 
Limited using QCIL as the first line buyer. It was envisioned that this order would cover the 
public sector’s needs for a period of two years. In the meantime, DFID initiated an 
emergency procurement of ACTs through AMFm with Crown Agents Uganda as the first line 
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buyer in response to looming stockouts at the NMS that were expected in May-June 2011. 
This created concern over the financial implications for QCIL and possible excess stocks in 
the public sector. An agreement was reached that DFID would make a one-off emergency 
procurement of pediatric formulations of AL to prevent a gap in stock, and QCIL would 
supply the remaining stock either as a first line buyer receiving orders from Cipla or a 
manufacturer.  
 
Key informants reported no further difficulties related to the approval or placing orders of 
AMFm copaid ACTs for the public sector. 
 
In total, 20.7 million treatment courses of AMFm copaid ACTs were approved and delivered 
for Uganda’s public sector in 2011. The first order of copaid ACTs for the public sector was 
delivered in July 2011. Eighty percent of the total treatment courses delivered in 2011 had 
arrived in Uganda by September 1, 2011. The October 1, 2011 Stock Status Report indicated 
that, based on average monthly consumption, the stock levels of the three pediatric package 
sizes would last more than 8 months, and stocks of the adult-sized package would last more 
than three months (SURE 2011). The high volume of ACTs that arrived at the NMS in July 
and August 2011 for the public sector took up significant space in the NMS warehouses. 
Receipt of other drug orders had to be rescheduled to accommodate the AMFm ACTs. 
 
Once received by the NMS, copaid ACTs were warehoused and distributed according to 
standard procedures. Hospitals and Health Center Level IVs place orders according to their 
needs, while Health Center Level IIs and Health Center Level IIIs receive a standard kit of 
medicines and other health commodities, including ACTs, approximately every two months. 
No challenges specific to the public sector distribution of AMFm copaid ACTs were cited by 
key informants. However, several respondents mentioned the inherent difficulties of 
determining the appropriate kit contents and quantities in push distribution systems. 
 
Private not-for-profit sector 
The Joint Medical Stores (JMS) is the primary procurement body for the private not-for-
profit sector, particularly faith-based health facilities. Prior to AMFm, the JMS received 
stocks from two main sources: donors (such as PMI and the Global Fund) and stocks 
purchased with JMS funds directly from manufacturers. Stocks received from funders are 
provided free of charge to private not-for-profit health facilities, whereas stocks purchased 
with JMS funds are sold at an 18% markup. While donated stocks are reserved for private 
not-for-profit providers, all registered outlets may purchase the medicines bought with JMS 
resources. All stocks are stored centrally in warehouses in Kampala. Clients must arrange 
pick-up or delivery, as the JMS does not distribute products.  
 
Similar to the public sector, stocks of AL were very low at the JMS in the first half of 2010. 
By the end of June, 2010, the JMS was completely out of stock of three of the four age-bands 
of AL, and only had 17 packages of the18-tablet package size in stock (SURE 2011). The 
JMS received part of the Global Fund Round 4, Phase II order that was delivered by Ajanta in 
the third quarter of 2011, which improved the level of stock. In April and May 2011, 2.1 
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million treatments of AL procured by PMI were delivered to the JMS, and 1.5 million 
treatments of AL procured by DFID were delivered in August and September 2011.  
 
As of January 2012, there were three registered first line buyers from Uganda’s not-for-profit 
sector. By the end of 2011, two of the private not-for-profit first line buyers had placed a total 
of four orders for AMFm copaid ACTs. The first orders for the private not-for-profit outlets 
arrived in Uganda in July 2011. A total of 1.1 million treatments were ordered and 0.6 
million treatments were delivered by the end of 2011. 
 
The JMS sold AMFm copaid ACTs with a markup of 18%. The JMS selling price for a 24- 
tablet package of copaid AL was reportedly USD 0.24.
15
 The JMS manages their stock based 
on the principal of First In, First Out. They lowered the price of their existing stocks of AL to 
the same prices as the AMFm copaid ACTs to ensure that they could exhaust their stocks of 
antimalarials that were previously purchased at a higher price. Antimalarials donated to the 
JMS at no cost were still provided to private not-for-profit facilities free of charge.  
 
The process of placing and receiving orders for the private not-for-profit sector was described 
as straightforward. Both first line buyers had a pre-existing relationship with Cipla, which 
facilitated orders. The second order placed by the JMS was delayed by 134 days from the 
date that the order was approved by the Global Fund to the date of delivery to the first port of 
entry. However, the JMS was notified by the manufacturer in advance that the order would 
likely be delayed. In spite of the delay receiving the second order, the JMS was reported to 
have good stock levels in the last quarter of 2011 due to stocks remaining from orders 
recieved in mid-2011 from PMI and DFID (SURE 2012). 
 
Private for-profit sector 
By January 2012, nine private for-profit first line buyers had registered to participate in 
AMFm, with four first line buyers placing orders from four manufacturers by the end of 
2011. In total, 15 orders for a total of 7.9 million treatment courses were approved in 2011, 
and 6.9 million treatment courses were delivered by the end of the year.  
 
No major issues related to registering as first line buyers or placing orders were reported. The 
first line buyers that had placed orders had pre-existing relationships with the manufacturer 
from which they ordered copaid ACTs. As of December 2011, there was a 1:1 relationship 
between first line buyers and manufacturers. In some cases, the first line buyer was the Local 
Technical Representative (LTR) for the manufacturer’s AMFm ACTs. This likely facilitated 
orders, because according to national regulations the LTR is required to approve all orders. 
Nevertheless, in the cases where the first line buyer was not the LTR for the AMFm copaid 
product that they ordered, interviewed first line buyers explained that the LTR always 
approved the order quickly. Some first line buyers expressed dissatisfaction that, as a result of 
the 1:1 relationship, they were unable to purchase stocks of copaid ACTs from the 
                                                 
15
 The exchange rate used was the average interbank exchange rate for 2011 Ugandan Shilling 2,337 to the 
USD. 
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manufacturer of their choice. They suggested that this reduced competition among first line 
buyers, and might also reduce availability.  
 
Ordered copaid ACTs cleared Ugandan customs smoothly. The National Drug Authority 
(NDA) was briefed on AMFm in advance. There was some initial confusion on whether the 
2% clearance fee would be charged on the full value or the subsidized value of drugs 
imported through AMFm. This appears to have been resolved prior to any AMFm copaid 
ACTs arriving in Uganda. AMFm copaid ACTs cleared customs in 1-2 days.  
 
Challenges related to receiving orders were noted. Some first line buyers reported that their 
orders were delayed or cut. Many first line buyers thought that Uganda was at a disadvantage 
compared with other countries, as a result of joining AMFm late. They felt that the 
participating manufacturers were already overloaded with orders by the time Ugandan first 
line buyers were permitted to place orders. As a result of delays in receiving orders, some 
first line buyers indicated that they experienced stockouts of all or some age-bands in 
between orders  
 
With regards to distribution, AMFm copaid ACTs were distributed through the first line 
buyers’ normal distribution chain. Some first line buyers noted that initially the uptake of 
copaid ACTs was very slow, due to existing stocks of ACTs in the supply chain. This 
backlog took 1-3 months to clear, after which demand for the copaid ACTs increased. The 
first line buyers were unanimous that sales volumes had the potential to increase 
dramatically. In particular, all respondents thought that a national-scale communications 
campaign would likely lower prices and increase demand for AMFm copaid products. Other 
first line buyers thought that there was scope to increase orders through direct distribution 
(sometime referred to as van-selling). The First-Line Buyers Working Group sought 
permission from the NDA to permit direct-distribution of AMFm copaid ACTs. At the time 
of the interviews, the NDA had not yet decided whether they would permit this.  
 
4.7.2  Implementation of AMFm Supporting Interventions 
The amendment to the AMFm host grant included a budget of USD 28.6 million for 
supporting interventions. Major planned activities included USD 16.8 million for the 
procurement and scale-up of RDTs in the public sector in 22 districts; USD 4.3 million for 
provider training, supervision and monitoring; and USD 3.1 million for public awareness and 
communications activities. However, implementation of the AMFm supporting interventions 
had not yet started by the end of data collection for the endline Outlet Survey. Although 
interim supporting interventions were initiated, key informants were unanimous that these 
stop-gap activities were inadequate.  
 
The AMFm supporting interventions were stalled as a result of delays disbursing the first 
tranche of funds for supporting intervention activities. The Round 4, Phase II grant, which 
hosts AMFm, has had performance problems in the past. In 2009, the performance of the 
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grant was rated as a C, the lowest possible rating. The performance rating has since 
improved. Nevertheless, special conditions were specified in the grant amendment letter, as a 
result of these performance issues. The PR was required to fulfill reporting requirements 
before funds were disbursed. The Progress Update and Disbursement Request was submitted 
to the Global Fund on June 27, 2011, and the first disbursement for USD 5.6 million was 
disbursed to the Ministry of Finance, Planning and Economic Development in November 
2011. Prior to the arrival of the disbursement, considerable effort was made to initiate the 
process to select the SSRs that would deliver services, like information, education and 
communication (IEC) and training activities, but no funds had been spent by the end of 2011.  
 
4.7.2.1 National Launch 
A national launch was held on April 29, 2011 in Buliisa District, as part of World Malaria 
Day celebrations. The vice president officiated at the ceremonies. The event was well-
attended and garnered some coverage in national and regional newspapers and television 
programs.  
 
Key informants had mixed views on the impact of the national launch. Some respondents 
expressed concern that the national launch was held too early, as only small quantities of 
copaid ACTs had arrived in Uganda. Others remarked that Buliisa District was too remote for 
the launch, and that the launch would have received better coverage if it were held in 
Kampala or another large town. Many suggested that the media coverage of the launch was 
overshadowed by violent demonstrations that took place in Kampala on that same day.  
 
4.7.2.2 Communications activities 
All respondents were unanimous in their concern that the absence of scaled AMFm 
communication activities was hindering the project’s implementation. At the time of the case 
study interviews, all respondents felt that public awareness about AMFm was very low. Most 
key informants speculated that the prices of AMFm copaid ACTs were likely to be higher 
than target levels in most private-for-profit outlets. In the absence of marketing, low prices 
were likely to be perceived as a signal of low quality. Key informants thought that 
shopkeepers would keep the price of AMFm copaid ACTs at similar levels as other ACTs to 
avoid perceptions that they are selling low-quality products.  
  
A small-scale marketing campaign, referred to as AMFm pre-disbursement marketing was 
instigated as a stop-gap measure while waiting for Global Fund monies designated for 
IEC/BCC purposes. Support was raised from multiple partners. MMV donated USD 80,000 
to fund radio spots, CHAI contributed USD 15,000 for the design and translation of 
marketing materials, while PACE produced the ratio spots, the Malaria Consortium 
contributed to the graphic design and World Vision played a role in dissemination. Another 
USD 6,800 was contributed by CHAI, Surgipharm, QCL and Philips Pharma to print point-
of-sale materials, although no materials were printed by the end of 2011. Over a three month 
period, 9,000 radio spots advertised that the AMFm copaid antimalarials were rolled out.  
287 | P a g e  
 
 
Uganda’s experience with the Consortium for ACT Private Sector Subsidy (CAPSS) project, 
which distributed subsidized ACTs bearing a green-leaf logo in drug shops, facilitated the 
pre-disbursement marketing activities. Materials produced for CAPSS were updated with 
ease. 
 
Uganda’s experience with the Consortium for ACT Private Sector Subsidy (CAPSS) project, 
which distributed subsidized ACTs bearing a green-leaf logo in drug shops, facilitated the 
pre-disbursement marketing activities. Materials produced for CAPSS were updated with 
ease. 
 
In addition, some implementing partners used existing platforms to publicize AMFm. For 
example, Malaria and Childhood Illness NGO Secretariat (MACIS) used their bi-annual 
newsletter to disseminate information about AMFm.  
 
The participating first line buyers were also actively promoting copaid ACTs. Some 
interviewed first line buyers either printed their own point-of-sale materials, or used posters 
or other promotional items provided by the manufacturer.  
 
Nevertheless, most respondents felt that the scale of the pre-disbursement marketing activities 
was too small to have a significant impact on awareness of AMFm.  
 
Recommended retail prices 
RRPs were set by the AMFm Task Force, in consultation with the Manufacturers and First-
Line Buyers Working Group. RRPs were established for each age-band of AL and artesunate-
amodiaquine (Table 4.7.1). The price was set to factor in costs and “reasonable” markups for 
importers, wholesalers and retailers. The RRPs in nearby countries, namely Kenya and 
Tanzania, were taken into consideration when setting the RRP for Uganda.  
 
Table 4.7.1 Recommended retail prices for AMFm copaid ACTs in 2010 US dollars 
Artemether + Lumefantrine Artesunate + Amodiaquine 
Pack size RRP (Ush) RRP (USD) Pack size RRP (Ush) RRP (USD) 
6x1 300 0.12 25/67.5mg 
3x1 
200 0.08 
6x2 600 0.23 50/135mg 
3x1 
400 0.16 
6x3 900 0.35 100/270mg 
3x1 
600 0.23 
6x4 1200 0.47 100/270mg 
3x2 
800 0.31 
 
While the RRPs were generally perceived to be appropriate, most respondents thought 
awareness of the recommendations was poor. Prices were printed on some point-of-sale and 
other promotional materials, but not on medicine packaging. Adherence to the recommended 
prices was thought to be low among retailers and wholesalers. Many first line buyers 
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expressed frustration over the lack of adherence to recommended prices, as they believe that 
high prices were limiting uptake of copaid ACTs.  
 
Other supporting interventions 
No other AMFm supporting interventions took place prior to the end of endline data Outlet 
Survey data collection.  
 
4.7.2.3 Implementation of other interventions with potential implications for AMFm 
outcomes 
The kit-based drug supply system 
The introduction of the kit-based supply system in mid-2011 is widely believed to have 
improved the availability of essential medicines in Level II and Level III Health Centers. 
Under the kit-based system, each Level II and Level III Health Center receives a standard kit 
of drugs and commodities. Facilities are supposed to receive the kits bimonthly, the 
composition of which is determined by the facility type. Previously Hospitals and Health 
Centers at all levels ordered essential medicines from a budget line at the NMS. An 
assessment of the kit-based system conducted six months after national implementation found 
that the number of days out of stock of five tracer medicines decreased by 30% in Health 
Center IIs and 74% in Health Center IIIs (MOH, 2011a).  
 
Recent refinements to the kit-based system might have further improved availability in public 
health facilities. The standard kit is revised every six months. Health facilities are now also 
able to adjust the quantities of drugs they receive by writing to the District Health Officer, 
copying the NMS. This allows the kit to be customized to the needs of the health facility, and 
could help prevent stockouts of ACTs in health facilities with large catchment populations or 
high burden of malaria. In April 2011, the NMS introduced last-mile delivery to Level II 
Health Centers and Level III Health Centers. Many stakeholders believe that this will 
improve delivery schedules and prevent bottlenecks in the distribution system.  
 
Integrated Community Case Management (ICCM) 
Since 2010, ICCM has used voluntary Village Health Teams (VHTs) to provide care for 
children under five years for malaria, diarrhea, pneumonia and neonatal care. VHTs receive 
training and are supplied with ACTs and other health commodities. VHTs have been trained 
and are currently receiving supplies in 24 of 112 districts. VHTs receive standard supply kits 
through a push system supported by the district health officer.  
 
Implementation of RDTs in the public and private not-for-profit sector 
Workers in public health facilities in 21 districts were trained on the effective use of RDTs in 
malaria case management in December 2010 and January 2011. Stocks of RDTs for these 21 
districts were planned to be procured as part of the AMFm supporting interventions. As this 
procurement had not taken place by the end of 2011, the RDT training was unlikely to have 
decreased ACT use in the participating districts.  
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PMI has supported the procurement of RDTs for private not-for profit health facilities. These 
are distributed through the Joint Medical Stores. 
 
Consortium for ACT Private Sector Subsidy (CAPSS) 
In 2008-2010, the CAPSS project, led by the Ministry of Health Uganda and Medicines for 
Malaria Venture (MMV), piloted the distribution of subsidized ACTs through the private 
sector in four districts (Budaka, Pallisa, Kaliro and Kamuli). The pilot distributed 1.1 million 
doses of subsidized ACTs, which continued to be supplied until 2011 as a bridge until the 
AMFm copaid drugs arrived in Uganda. The ACT distributed through CAPSS was Coartem 
(AL) repackaged with a green leaf logo that was the prototype for the AMFm logo. The 
CAPSS project used RRPs, which ranged from 200-800 Ush. The RRPs were communicated 
in the mass-marketing campaign that accompanied the project, and they were printed on the 
packages. It is likely that stock of the CAPSS-subsidized ACTs remained in the market at the 
time of the baseline and possibly the endline outlet surveys in Uganda. Uganda’s 
participation in CAPSS was thought to have contributed to the country’s preparedness for 
AMFm.  
 
In late 2011, MMV launched CAPSS Plus, which introduced RDTs and respiratory timers 
into private drug shops in the four intervention districts. Both CAPSS and CAPSS Plus 
included a strong training component.  
 
Other important interventions 
Other important malaria control interventions that rolled out during this period were the mass 
distribution of 7.3 million Long Lasting Insecticidal Nets (LLINs) targeted to pregnant 
women and children under five years in March-June 2010 and the long-standing PMI-
supported Indoor Residual Spraying program in 10 districts. 
 
In addition, ACTs were granted over-the-counter (OTC) status by the Committee of National 
Formularies. This permits registered drug shops and VHTs to sell and distribute ACTs. At the 
time of the key informant interviews, a statutory instrument granting ACTs OTC status was 
still required. In the interim, the NDA provided a formal letter to the MOH granting 
permission for the ACTs to be distributed as OTC products. The budget for the AMFm 
supporting interventions included provisions to support the implementation of this regulatory 
change, but no funds had been spent by the end of 2011. 
 
4.7.3  Key events and context 
The main contextual factor raised by key informants was the rapid depreciation of the 
Ugandan Shilling against the US dollar. On January 1, 2009, 1 US dollar was worth 1,944 
Ugandan Shillings, but by October 2011, this had depreciated to 2,830 Ush per USD. The 
exchange rate recovered slightly by the end of the year. Respondents thought that the 
currency fluctuations were contributing to inflation, which affected the purchasing power of 
Ugandan households. Stakeholders thought that this could reduce the demand for all 
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antimalarials in the private sector. 
4.7.4  Conclusion 
Table 4.7.2 summarizes key factors likely to have facilitated or hindered achievement of 
AMFm goals and Figure 4.7.1 presents a timeline of all key events related to AMFm 
implementation and context.  
 
In spite of Uganda’s late start in participating in AMFm, significant quantities of copaid 
ACTs had arrived in Uganda by the end of 2011. A total of 28,226,700 treatment courses 
were delivered over 8 months in 2011. The vast majority of copaid ACTs delivered were 
destined for the public sector (73.4%), while 24.5% were for the private-for-profit sector and 
2.1% were for the private-not-for profit sector. Implementation of AMFm was hindered by 
the delayed start of the supporting interventions. Public awareness of AMFm was thought to 
be low, as was adherence to the RRP. Implementation of the supporting interventions, 
particularly national-scale communications activities, would have likely increased demand 
for AMFm copaid ACTs.  
 
Table 4.7.2: Summary of key factors likely to have supported or hindered achievement of AMFm goals 
in Uganda) 
Factors which are likely to have supported 
achievement of AMFm goals  
Factors which are likely to have hindered 
achievement of AMFm goals 
 Smooth process for registration of FLBs and 
ordering copaid ACTs in the private sector 
 Promotional activities by FLBs 
 Inclusion of RRP on marketing materials 
 Use of green leaf logo 
 Improvement of logistics in the public sector 
pharmaceutical distribution chain 
 Preparedness for a private sector ACT subsidy as 
a result of the CAPSS pilot 
 FLB commitment to honoring recommended 
prices 
 Late start  
 No supporting interventions implemented by end 
of 2011 
 Lack of RRP on drug packaging 
 Limited number of FLB-manufacturer 
relationships established 
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Figure 4.7.1: Timeline of key events related to AMFm implementation process and context Uganda 
 
2010 2011 
Activity Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 
AMFm grants and orders   
                 AMFm grant amendment signed                     
Private for-profit sector orders of copaid ACTs approved by 
Global Fund 
  
                 Private for-profit sector copaid ACTs delivered to Uganda   
                 Public sector orders of copaid ACTs approved by Global 
Fund 
  
                 Public sector copaid ACTs delivered to Uganda   
                 Private not-for-profit sector orders approved by Global Fund    
                 Private not-for-profit copaid ACTs delivered to Uganda   
                 Other ACT procurements for the public sector    
                 
 
9.4 million treatments of AL delivered from Ajanta Pharma                    
3.3 million treatments of AL delivered from QCIL               
 
  
 
                
Other ACT procurement for the private not-for-profit 
sector 
  
                  
        PMI funded delivery to JMS   
                 DFID funded delivery to JMS   
                 AMFm supporting interventions   
                 PUDR for supporting interventions submitted        
   
     
    Disbursement received by Ministry of Finance                        
  
   
National Launch                 
   
            
Pre-disbursement marketing activities: radio spots                            
 
    
Pre-disbursement marketing activities: point-of-sale 
materials  
  
          
   
                  
Non-AMFm interventions    
                 Introduction of the kit-based supply system   
                 Introduction of last-mile delivery    
                 Training of public sector health workers on RDTs in 21 
districts 
  
        
   
                    
Delivery of RDTs purchased by PMI for PNFP facilities        
             
    
Mass distribution of LLINs   
                 CAPSS16   
                 CAPSS Plus   
                 Research Activities   
                 Baseline IE outlet survey data collection    
   
             
Endline IE outlet survey data collection     
   
                    
   HAI price tracking surveys   
                 
                                                 
16
 Although CAPSS officially ended in June 2010, MMV continued to supply subsidised ACTs to the intervention districts until the arrival of AMFm drugs. 
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4.8 Zanzibar 
4.8.1  AMFm implementation process 
Zanzibar’s AMFm application was approved in November 2009. In November 2010, the 
Government of Zanzibar signed a two-year grant with the Global Fund to implement AMFm 
Phase 1. In 2010, the Principal Recipient (PR), the Ministry of Health and Social Welfare 
(MoHSW), signed an amendment to the host Global Fund Round 8 grant of Euro 426,968 to 
implement Phase 1 of AMFm. The country officially launched AMFm on June 23, 2011, with a 
national-level marketing campaign for copaid ACTs. 
4.8.1.1 Governance structure for AMFm in Zanzibar 
The AMFm governance structure in Zanzibar was established to advise the Zanzibar National 
Malaria Control Program (ZMCP) during AMFm implementation. The AMFm governance 
structure is made up of an AMFm Coordination Body and Task Force Team that include 
representatives from government, the private sector, implementation partners, civil society and 
donors. The Coordination Body meets quarterly while the Task Force Team can meet at any 
time, if required. The most recent meeting before the beginning of the country case study was 
held on September 29, 2011. In addition, a Marketing Working Group that includes 
implementation partners and the ZMCP was established to support behavior change 
communication and social marketing activities under AMFm. One of its first major tasks was the 
marketing campaign that started in June 2011 with the official launch event. The governance 
structure has been very active and instrumental in the smooth implementation of the AMFm 
program in Zanzibar. 
 
Selection and registration of first line buyers 
In the public sector, the Ministry of Health (through the ZMCP) is the FLB responsible for 
forecasting, quantification and procurement of all drugs, including copaid ACTs. The Central 
Medical Store (CMS) is responsible for storage and distribution of all drugs, including the copaid 
ACTs.  
 
In the private sector, the selection process was very transparent. The Pharmaceutical Association 
in the private sector was informed about the project and asked to select only one first line buyer 
(FLB) given the small size of the population and the low level of malaria prevalence (<1%). 
Given the perceived small profit margin, not many wholesalers were interested. They 
unanimously decided to nominate Izmir Pharmacy, because the owner was the only business 
owner with background training in pharmacy. The decision of the association was then 
communicated to the AMFm Coordination Body and Task Force, which communicated the name 
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to the Global Fund for approval. After approval, the Global Fund sent the terms of the agreement 
to the FLB for signature in April 2010. 
 
According to key informants, the registration process of the FLB was smooth. It involved filling 
out a number of forms and getting approval from the Global Fund. The private sector was 
engaged from the beginning when the proposal for AMFm was being prepared. 
 
Ordering and delivery of AMFm copaid ACTs 
 Public sector 
The public sector procurement process in Zanzibar is based on Voluntary Pool Procurement, 
which requires the Global Fund to facilitate the whole process of the procurement. Medicines are 
procured by the Global Fund after receiving and approving a request, and the medicines are then 
sent to the country. Sanofi-Aventis and Novartis (manufacturers) are the main suppliers for 
Zanzibar. The public sector placed an order for 91,075 treatment doses (2,450 of 25/67.5 mg for 
infants, 43,350 of 50/135 mg for children and 45,275 of 100/270 mg for adults), which were 
delivered on September 29, 2011. The interval between the request date and the delivery date 
was 60 days. 
 
The quantification of ACTs in the public sector is done using the Zanzibar Integrated Logistics 
System (ZILS), which is a form that collects stock and sales information from health facilities 
across Zanzibar. This tool helps in understanding the trends in distribution and provides better 
quantification of supply needs. Other factors such as climate, seasons and locations are all taken 
into account in the quantification. 
 
 Private sector 
The private sector uses a different procurement system. The FLB places the order with required 
quantities directly with the suppliers, who request approval from the Global Fund. When the 
order is approved by the Global Fund, the FLB is asked to pay its share of the co-payment. The 
shipment process only starts after the FLB has paid its share. 
 
Izmir Pharmacy received the first consignment of copaid ACTs on April 21, 2011, totaling 
110,000 ASAQ FDC treatment doses from Sanofi-Aventis. On April 29, 2011, an additional 
order for 40,000 ASAQ doses was received. At the time of the country case study (November 
2011), a total of 200,000 doses of copaid ACTs had been ordered and of these, 150,000 had been 
delivered (15,000 of 25 mg/67.5 mg, 15,000 of 50 mg/135 mg and 120,000 of 100 mg/270 mg). 
Izmir signed an agreement with Novartis to begin procuring AL (the second alternative for first-
line treatment for uncomplicated malaria in Zanzibar) with the plan to purchase 150,000 doses 
per year. Under this agreement, an order for 50,000 AL doses was placed in June 2011, but the 
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order was rejected by the Global Fund with the justification that this quantity was not needed due 
to the low incidence of malaria in Zanzibar. 
 
In the private sector, there is no clear framework for quantifying need for copaid ACTs. The FLB 
determines order quantities based on previous experience with sales of antimalarials and the 
projected demand for these commodities along their distribution networks.  
Customs clearance of AMFm copaid ACTs 
When consignments arrive at the customs office, the ZFDB performs drug quality tests on a 
sample of the copaid ACTs to ensure that the quality of the drug is in compliance with the 
requirements of Zanzibar. The test process is simple and takes two days on average to obtain the 
full results. No quality issues were reported; hence, both the private and public sectors were able 
to clear the copaid ACTs in 2-3 days after arrival of the drugs. 
 
There are no taxes imposed on all medicines, including AMFm products, in Zanzibar. However, 
there are charges for storage, documentation and clearance. These charges depend on the size of 
the cargo. Storage charges of USD 20 start after seven days if the goods have not yet cleared. 
The average cost for documentation, releasing, handing and destuffing (unloading containers) is 
about USD 150. Other costs, such as costs for transportation and porters, are negotiable 
depending on the size of the cargo.  
 
Distribution of AMFm copaid ACTs 
The distribution process is different for the public and private sectors. In the private sector, the 
distribution is more demand oriented. Once the FLB has received and cleared the orders, the 
drugs are immediately sent to distribution points/stores for other wholesalers or retailers to 
purchase the drugs. The FLB has a list of 300 wholesalers and 450 retailers who are immediately 
(the same or next day) informed about the arrival of the copaid ACTs and the price.  
 
In the public sector, there is a progressive shift from a push to pull system which is being tested 
in 19 health facilities. At the time of the study, the distribution was based on the push system. 
The CMS is responsible for the distribution. Quarterly, CMS delivers all allocated commodities 
(including copaid ACTs) to each district and then directly to the facilities. It takes a maximum of 
one week for drugs to reach the various health facilities. The longest time is in some districts 
where the health facilities are scattered. To ensure proper distribution of the malaria 
commodities, the ZMCP contributes to the CMS 6% of the total cost of the stored commodities 
for storage, distribution and monitoring costs. 
 
In the public sector, stockouts of ACTs were experienced in a few facilities (no exact number 
was provided) for two months (August-September 2011). This was due to non-availability of 
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ACTs at the CMS because of a delay in procurement. Although the CMS distributes 
commodities quarterly, CMS can immediately make a special delivery if a stockout is reported. 
Because of the small size of Zanzibar, requests are delivered without delay. 
 
The proper distribution of drugs in Zanzibar has been affected by challenges in record keeping. 
In the public sector, there are gaps in data reported on the prescription and dispensing of 
medicine, and this problem is worse in the private sector. This situation makes it difficult to have 
proper quantification of copaid ACTs needed. 
 
There are some remote areas that are difficult to reach, especially during the rainy season. Out of 
the 149 health facilities, 24 are considered to be in hard-to-reach areas. However, using 
alternative means of transport such as small boats and motorbikes, these areas are supplied with 
commodities, including copaid ACTs. 
 
4.8.2 Implementation of AMFm supporting interventions 
4.8.2.1 Communication 
AMFm launch 
The official launch of AMFm took place on June 23, 2011. The launch activities included a guest 
of honor speech by the Minister of Health, a meeting with pharmaceutical wholesalers and 
retailer and distribution partners, and activities that involved district and community members. 
 
IEC/BCC activities 
A public awareness campaign using electronic and print media and supported by community-
based mobilization activities has been successfully implemented. The campaign’s key messages 
were on the availability and affordability of ACTs as the most effective treatment for malaria. A 
key supporting intervention in Zanzibar was the national IEC/BCC and social marketing 
campaign.  
 
After the launch, marketing campaigns to create awareness on the availability and price of 
copaid ACTs among the community and health workers through media (i.e., live programs and 
radio and TV advertisements) commenced in the second week of July 2011. These activities 
were ongoing at the time of the country case study in November 2011. Community meetings at 
the shehia level (the lowest level of the government administrative structure) were conducted in 
all 10 districts of Zanzibar from August-September 2011 to create further awareness. A second 
phase of the post-launch marketing campaign was planned to start in December 2011 with a 
focus on diagnostics and the rational use of medicines, price monitoring (among private sector 
pharmaceutical dealers) and increasing accessibility to remote areas. 
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A budget was put in place for IEC/BCC activities in three phases. The first phase was for all 
marketing materials to make the public more aware of the program. The second phase had just 
started at the time of the country case study in November 2011. The second phase focused on 
affordability, high quality and correcting the belief that cheap drugs are associated with low/poor 
quality (price stigma). The third phase, which was in the planning stage at the time of the country 
case study, will focus on the need for diagnosis before treatment with ACTs. 
4.8.2.2 Recommended retail price 
In the public sector, copaid ACTs are provided for free to patients, while in the private sector the 
recommended prices for a treatment are 1,000 TSH for an adult dose and 800 TSH for a child’s 
dose. An assessment performed using mystery shoppers in August 2011 revealed that the 
recommended prices are being followed. Out of the 39 outlets with copaid ACTs in stock at the 
time of the survey, only one shop/outlet exceeded the recommended price. In two districts, the 
price of copaids ACT was the same for all the dosages. 
 
The prices were considered reasonable and affordable for most, and no issue was observed in the 
application of the recommended prices. However, some retailers from the private sector would 
have preferred a higher resale price for higher profit margins. 
4.8.2.3 Training 
At the time of this country case study in November 2011, key informants reported some training 
activities planned for the near future; one of them was the training of health care workers on 
product distribution and storage, supported by the Global Fund. 
 
In the private sector, it was reported that about 75 health providers were trained on drugs and 
adverse effects. The training was divided into three groups of 25 participants each in October and 
November 2011.  
 
In addition, training for pharmacists on monitoring and evaluation was ongoing at the time of 
this study. Out of the 20 pharmacies in Zanzibar, 13 were reported to be represented. The 
training focuses on the tracking tools that will be used and monthly reporting. The ZMCP also 
plans to start training pharmacists and other health care workers on diagnosis and selling based 
on the prescriptions. One of the challenges reported was the lack of funding to do more extensive 
training, especially because it was not included in the initial budget. 
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4.8.2.4 Other AMFm supporting interventions 
Regulatory interventions 
Despite the official ban on oral artemisinin monotherapies, the drugs still exists in Zanzibar. Key 
informants blame their presence on suppliers from mainland Tanzania. To enforce the ban, the 
ZFDB has performed regular inspections of private drug outlets. Illegal (banned) drugs found in 
stock are confiscated and the owner of the outlet is given a warning. The outlet can be closed if 
the offense is repeated. However, no important violations regarding antimalarials were reported 
during the period of the evaluation.  
 
Some regulatory activities were implemented within the framework of AMFm. The AMFm 
Coordination Body and Task Force worked with the ZFDB to impose new by-laws banning the 
importation of artemisinin monotherapies. All the pharmaceutical importers, distributors and 
retailers were notified by ZFDB about the new by-laws in June 2011. Two months later, in 
August, a mystery shopper exercise was conducted and results indicated that a few outlets were 
still stocking artemisinin monotherapies. The ZFDB is working to ensure that stock available on 
the shelves is phased out gradually since no further importation will be allowed. ZFDB and 
ZMCP are working together to monitor the price and accessibility of copaid ACTs in the private 
sector with regular inspections. 
 
Each quarter, ZMCP and ZFDB team up to sample around 10 formal outlets per district, 
consisting of a mix of pharmacies, Over-The-Counter (OTCs) shops and private clinics on 
Unguja and Pemba Islands to assess the availability of ACTm (copaid ACTs), the availability of 
non-ACT antimalarials and prices of copaid ACTs. According to the August 2011 report, overall 
availability of any antimalarials was 75% and availability of ACTm drugs was 61%. Out of the 
100 outlets sampled, 39 outlets had subsidized ACTs with the ACTm logo. The availability of 
copaid ACTs varied across districts, from 9% in Micheweni to 87% in Zanzibar urban district. 
 
Malaria diagnosis 
The malaria diagnosis policy recommends parasitological confirmation of malaria before 
treatment. To ensure that the recommendation is followed by health workers, the ZMCP 
performs Rapid Diagnosis Test (RDT) supervision at the district level monthly. The main aim of 
the district visit is to reinforce good and timely collection of data, and best practices in laboratory 
activities and performance and in storage and record keeping. A team of laboratory supervisors 
from 10 districts in Zanzibar supervise the health facilities within their respective districts. 
During supervision, monthly data on RDT diagnosis are collected. Some of the challenges 
encountered are due to delayed distribution of RDTs by CMS and the lack of trained laboratory 
staff on RDT quality control, which contributes to low testing rates in most of the public health 
facilities. 
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One of the challenges reported is that it is hard to get clear and accurate statistics on testing from 
all health facilities. There are instances reported of patients with a negative malaria test still 
being given ACTs and getting better. This situation could promote misuse of ACTs. 
 
Pharmacovigilance 
Awareness is being created through training of medical and paramedical officers on how to 
report adverse drug reactions (ADR) to the relevant authority. Yellow health cards were 
distributed throughout public and private health facilities in urban, city urban, peri-urban and 
critical areas for recording and reporting ADRs. In the private sector, 75 health providers were 
trained on where to report and what to report in three groups of 25 participants in October and 
November 2011.  
 
The ZFDB and ZMCP also provided pharmacovigilance training for public health workers in 
Unguja and Pemba in February 2011. This knowledge helped the workers in different health 
facilities to recognize and report ADR. 
 
The Pharmacovigilance Unit (PV-Unit) conducts supervision and monitoring after training. A 
team of supervisors visits public health facilities and collects all ADR forms in order to review 
the accuracy of reported cases. Supervisors conduct on the job training for health workers on 
how to identify ADRs and correctly complete the forms. Health care workers are reminded to 
report all suspected cases in a timely manner. 
 
There are challenges in enforcing the established regulations. Assessments need to be set up to 
monitor these procedures. It is planned that once the funds are available, such studies and 
assessments will be done. Inspections are currently underway. 
 
Research 
No major research was conducted independently during the evaluation period. However, the 
ZMCP and the ZFDB performed ongoing activities to monitor availability, stockouts, prices and 
the quality of ACTs. These monitoring activities provided valuable information for the AMFm 
program. For example, the mystery shopper exercise conducted during the same period 
demonstrated that all the outlets were in compliance with the recommended price for copaid 
ACTs.  
 
Other operational research studies on the introduction of RDTs and Knowledge, Aptitude and 
Practice were in the planning phase at the time of the country case study. 
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4.8.3  Key events and context 
There were no key events that are likely to have affected AMFm implementation reported at the 
time of this evaluation. The presidential election took place in October 2011, but it did not affect 
the implementation of AMFm according to key informants. No abnormal rainfall was reported 
during the evaluation period. 
 
Regarding other malaria control interventions, the Global Fund and USAID are supporting the 
scaling up of malaria diagnosis through the procurement and distribution of RDTs and 
strengthening the quality of microscopy services. Since 2009, 8 million RDTs and 110 
microscopes have been procured and distributed, supported by relevant training of health 
workers. However, the quantities of RDTs procured over the period were insufficient to ensure 
full coverage of public sector health facilities. 
4.8.4 Conclusion 
Table 4.8.1 summarizes key factors likely to have facilitated or hindered achievement of AMFm 
goals in Zanzibar and Figure 4.8.1 presents a timeline of all key events related to AMFm 
implementation and context.  
 
Overall, the implementation of AMFm in Zanzibar has gone well, with smooth registration and 
drug ordering and distribution processes. The AMFm Coordination Body and the Task Force 
Team put in place are functional and very active in pushing AMFm-related activities and 
resolving bottlenecks. The supporting interventions were also fairly well implemented, with 
island-wide public awareness activities starting with the official launch of AMFm, which 
involved all the key stakeholders, followed by continuous sensitization on ACTs through various 
media. Regulatory enforcement activities have been implemented and the ZFDB, in 
collaboration with the ZMCP, is monitoring them. Some training activities were implemented, 
but some were delayed and scheduled to take place in December 2011. There were no key events 
that may have affected the AMFm implementation reported at the time of this evaluation. No 
abnormal rainfall was reported during the evaluation period. 
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Table 4.8.1: Summary of key factors likely to have supported or hindered achievement of AMFm goals in 
Zanzibar 
Factors which are likely to have supported 
achievement of AMFm goals  
Factors which are likely to have hindered achievement 
of AMFm goals 
 Only one first line buyer 
 Creation of the AMFm Coordination Body and 
Task Force Team, which were functional and 
included all sectors 
 Private sector engagement activities 
 Smooth registration process for FLBs 
 Public awareness campaign starting with the 
official AMFm launch, involving all key 
stakeholders 
 Smooth customs clearance of copaid ACTs with 
the cost waived 
 Continuous public awareness about copaids 
ACTs 
 Continuous monitoring of availability, price and 
quality of copaid ACT by ZMCP and ZFDB 
 Ban on AMTs and enforcement of the ban bylaw 
 Enforcement and support for diagnostic tests 
 Good distribution mechanism in the private and 
public sectors 
 Small size of Zanzibar and its population 
 No proper quantification of ACTs in the public and 
private sectors 
 Push system for the distribution of copaid ACTs in the 
public sector 
 Delays in most of the training planned by the ZFDB 
due to a lack of funding 
 No interaction between FLBs in Zanzibar and 
Tanzania mainland 
 Low prevalence of malaria in Zanzibar so that the 
private sector may not have a business incentive for 
stocking copaid ACTs because of low demand  
 Concern about the profit margin from the private 
sector 
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Figure 4.8.1: Timeline of key events related to AMFm implementation process and context in Zanzibar 
Activity 2009 2010 2011 
Nov Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 
AMFm grants and orders                       
AMFm application approved                       
AMFm grant signed                        
FLB agreement signed with Global Fund                       
Private sector placed order for copaid 
ACTs 
                      
Delivery of private sector copaid ACTs*                        
Public sector placed order for copaid 
ACTs 
                      
Delivery of public sector copaid ACTs                       
Distribution of copaid ACTs – private                       
Distribution of copaid ACTs – public                       
AMFm supporting interventions                       
AMFm coordinating committee meetings                        
Ban notification on monotherapies                       
National launch                       
Monitoring of RDT use                       
Regional district meetings                       
Public awareness media campaign                       
Training public sector health workers                       
Training pharmacists                       
Non-AMFm interventions                       
Free distribution campaign for LLINs (to 
start in December 2011) 
                      
Research Activities                       
Baseline IE outlet survey data collection                       
Endline IE outlet survey data collection                       
IE country case study                       
Mystery Shopper Exercise                       
* The first drugs arrived in Zanzibar on April 21, 2011 
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5 Results from the remote area study 
It should be noted that, although the estimates for remote areas are presented in the tables side by 
side with the ones for non-remote areas, the main purpose is not to compare the two types of 
location, especially since there are no benchmarks for comparing these areas. Ideally, as implied 
in the TERG recommendation, we would have preferred to have baseline data to allow the 
estimation of changes in remote areas over time. However, the remote area studies were added to 
the Independent Evaluation several months after the baseline outlet surveys had been completed 
and the AMFm intervention had started. Using the definition of remote areas, we did not find a 
sufficient number of remote area clusters in the baseline data to calculate reliable baseline 
estimates. This situation limits our ability to assess changes between baseline and endline in the 
remote areas. Therefore, the description of the results is focused on the remote areas, but with 
reference to baseline data from rural areas when applicable. This is not to say that rural areas are 
equivalent to remote areas; however, we can safely assume that the estimates of availability in 
remote areas at baseline are likely to have been no higher than (and probably lower than) the 
estimates for all rural areas combined. 
5.1 Description of the sample 
Table 5.1.1 presents the breakdown of the sample by outlets enumerated and outlets with 
antimalarials in stock at the time of the survey in remote areas, and Table 5.1.2 presents the 
distribution of the outlets by the outcome of the interview. In Ghana, interviews were conducted 
in all 164 outlets that met the screening criteria, and 91% of those outlets were reported to have 
antimalarials in stock. An additional 9% had antimalarials in stock at some time in the past three 
months even though they were not in stock at the time of the survey. In Kenya, a much larger 
number of outlets was enumerated overall (4,244) because in contrast to the case of Ghana, a 
broader grouping of outlets was classified as having the potential to sell antimalarials and thus 
was included in the census. For example, general retailers were systematically enumerated in 
Kenya but not Ghana. Of the 3,241 outlets screened in Kenya, only 14% (468) met the screening 
criteria and had interviews conducted. Eighty-five percent of the outlets in which interviews 
were conducted reported that they had antimalarials in stock at the time of the survey. 
 
Table 5.1.3 presents the distribution of the outlets enumerated by type of outlet. In both Ghana 
and Kenya, the majority of the outlets enumerated were from the private for-profit sector—67% 
(148 out of 221) in Ghana and 90% (3,836 out of 4,244) in Kenya. Community health workers 
were the second most common type of outlet in both countries, although there were almost as 
many public health facilities as community health workers in Ghana. Private not-for-profit 
outlets were nearly nonexistent in remote areas in Ghana (4), and there were very few in Kenya 
(19). 
Table 5.1.4 presents the distribution of outlets with antimalarials in stock at the time of the 
survey. Of the 149 outlets with antimalarials in Ghana, almost two-thirds (97) were private for-
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profit outlets and about one-sixth (26) were public health facilities. A similar pattern was 
observed in Kenya, where private for-profit sector outlets represented 83% (328) of all outlets 
with antimalarials, followed by public health facilities. In contrast to Ghana, where 22 
community health workers (CHW) had antimalarials in stock, in Kenya only 1 CHW reported 
having antimalarials in stock. 
 
Table 5.1.1: Number of remote area outlets enumerated and number stocking antimalarials at the time of the 
survey, according to country, 2011-2012 
Country/Period of data collection 
# of outlets 
enumerated* 
# of 
outlets 
screened 
# of outlets 
which met 
screening 
criteria 
# of outlets 
in which 
interviews 
were 
conducted 
# of outlets 
stocking 
antimalarials 
at the time of 
the survey 
visit 
# of outlets 
without 
antimalarials in 
stock at the time 
of the survey visit 
but that had 
antimalarials in 
stock sometime in 
the 3 months 
preceding the 
survey 
Ghana – Total  221 194 164 164 149 15 
Remote areas in endline survey* 60 47 35 35 32 3 
Remote areas in additional survey** 161 147 129 129 117 12 
Kenya- Total 4,244 3,241 468 468 396 72 
Remote areas in endline survey* 1,196 888 150 150 125 25 
Remote areas in additional survey** 3,048 2,353 318 318 271 47 
* Data collection period: Ghana: November 7-28, 2011, Kenya: October 7 - December 10, 2011 
** Data collection period: Ghana: March 4-13, 2012, Kenya: February 27 - March 16, 2012 
Source: AMFm Phase 1 Independent Evaluation Endline Outlet Surveys and Remote Area Surveys 
 
Table 5.1.2 Number of outlets in remote areas at endline by final interview status, according to country, 2011-
2012 
 Number of outlets 
Country/Final interview status 
Remote areas in 
endline survey* 
Remote areas in 
additional 
survey** Total 
Ghana    
Number of outlets:    
Outlets not screened 13 14 27 
Outlets did not meet screening criteria 12 18 30 
Outlets met screening criteria, but not interviewed 0 0 0 
Completed interviews 35 129 164 
Partially completed interviews 0 0 0 
Response rate (%)    
Percentage of outlets enumerated that were screened 78.3 91.3 87.8 
Percentage of outlets meeting screening criteria that were interviewed* 100.0 100.0 100.0 
Kenya    
Number of outlets:    
Outlet not screened 308 695 1,003 
Outlet did not meet screening criteria 738 2,035 2,773 
Outlet met screening criteria, but not interviewed 0 0 0 
Completed interview 148 316 464 
Partially completed interview 2 2 4 
Response rate (%)    
Percentage of outlets enumerated that were screened** 74.2 77.2 76.4 
Percentage of outlets meeting screening criteria that were interviewed* 100.0 100.0 100.0 
* Data collection period: Ghana: November 7-28, 2011, Kenya: October 7 - December 10, 2011 
** Data collection period: Ghana: March 4-13, 2012, Kenya: February 27 - March 16, 2012 
Source: AMFm Phase 1 Independent Evaluation Endline Outlet Surveys and Remote Area Surveys 
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Table 5.1.3: Number of outlets enumerated by type of outlet in remote areas at endline, according to country, 
2011-2012 
Country/Type of outlet 
 Number of outlets 
Remote areas in 
endline survey* 
Remote areas in 
additional survey** Total 
Ghana    
Public health facility 8 25 33 
Private not-for-profit health facility 3 1 4 
Private for-profit outlet 49 99 148 
Community health worker 0 36 36 
Total 60 161 221 
Kenya    
Public health facility 21 40 61 
Private not-for-profit health facility 4 15 19 
Private for-profit outlet 1,145 2,691 3,836 
Community health worker 26 302 328 
Total 1,196 3,048 4,244 
 * Data collection period: Ghana: November 7-28, 2011, Kenya: October 7 - December 10, 2011 
** Data collection period: Ghana: March 4-13, 2012, Kenya: February 27 - March 16, 2012 
Source: AMFm Phase 1 Independent Evaluation Endline Outlet Surveys and Remote Area Surveys 
 
 
Table 5.1.4: Number of outlets with antimalarials in stock by type of outlet in the remote areas at endline, 
according to country, 2011-2012 
Country/Type of outlet 
Number of outlets 
Remote areas in 
endline survey* 
Remote areas in additional 
survey** Total 
Ghana – Total 32 117 149 
Public health facility 5 21 26 
Private not-for-profit health facility 3 1 4 
Private for-profit outlet 24 73 97 
Community health worker 0 22 22 
Kenya – Total 125 271 396 
Public health facility 17 35 52 
Private not-for-profit health facility 3 12 15 
Private for-profit outlet 105 223 328 
Community health worker 0 1 1 
* Data collection period: Ghana: November 7-28, 2011, Kenya: October 7 - December 10, 2011 
** Data collection period: Ghana: March 4-13, 2012, Kenya: February 27 - March 16, 2012 
Source: AMFm Phase 1 Independent Evaluation Endline Outlet Surveys and Remote Area Surveys 
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5.2 Availability of quality-assured ACTs in remote areas 
 
Table 5.2.1 presents the availability of antimalarials in remote areas and non-remote areas. The 
availability of antimalarials (all outlets combined) in remote areas was very high at endline in 
Ghana (97%) and low in Kenya (11%) reflecting different enumeration processes. In Kenya, all 
general stores with the potential to stock antimalarials were enumerated, whereas in Ghana, only 
those outlets believed to stock antimalarials were enumerated. In both countries, public health 
facilities and private not-for-profit outlets had high availability of antimalarials. In Ghana, 100% 
of the public health facilities and private not-for-profit outlets stocked antimalarials, while in 
Kenya the availability was 91% and 100%, respectively. Only a few of the private for-profit 
outlets (10%) and CHW (less than 1%) stocked antimalarials in Kenya. In contrast, the 
availability of antimalarials in the limited number of these types of outlets enumerated in Ghana 
was more than 60%. 
 
Table 5.2.2 presents the availability of quality-assured ACTs (QAACTs) among all outlets with 
antimalarials in remote areas and non-remote areas. In both countries, most outlets in remote 
areas had QAACTs, but the availability of QAACTs in all types of outlets combined was much 
higher in Ghana (78%) than in Kenya (56%). Public health facilities in remote areas in both 
countries had very high levels of availability of QAACTs (96% in Ghana and 95% in Kenya). In 
contrast, private for-profit outlets had availability of 68% in Ghana and less than 50% in Kenya 
(46%). In reference to baseline data for rural areas (Table 2.2.6 in Section 2), there has 
apparently been a substantial increase in availability of QAACTs in remote areas in both 
countries for all outlets combined and for private for-profit outlets. Indeed, the availability of 
QAACTs for all outlets in remote areas was three times as high as the availability in rural areas 
at baseline (26%) in Ghana and twice as high as the availability in rural areas (27%) in Kenya. 
 
Table 5.2.3 presents the availability of QAACTs with the AMFm logo in remote areas and non-
remote areas. The availability of QAACTs with the AMFm logo in all types of outlets combined 
in remote areas was 60% in Ghana and 49% in Kenya. In both countries, the availability of 
QAACTs with the AMFm logo was even higher in public health facilities (85% in Ghana and 
61% in Kenya). Two-thirds of private for-profit outlets in remote areas in Ghana had QAACTs 
with the AMFm logo. However, in Kenya availability was less than half (45%) in private for-
profit outlets. Since the quantity of QAACTs with the AMFm logo available in-county was 
extremely limited at baseline, the substantial levels of availability observed in remote areas of 
Ghana and Kenya at endline are attributable to the reach of the AMFm program. 
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Table 5.2.1: Outlets in remote areas and non-remote areas with antimalarials in stock at endline, 2011-2012 
Indicator 1.1 Percentage of outlets in remote areas and non-remote areas that had any antimalarials in stock at the time of the survey visit (n) among all outlets where 
screening questions were completed (N), by type of outlet, according to country, 2011-2012 
Country/Type of outlet 
Remote areas 
Non-remote areas In endline survey* In additional survey** Total 
Percentage (95% CI) N Percentage (95% CI) N Percentage (95% CI) N Percentage (95% CI) N 
Ghana – Total  68.1 (44.6-85.0) 47 79.6 (64.9-89.2) 147 76.8 (64.2-86.0) 194 97.2 (94.7-98.6) 506 
Public health facility 100.0 5 100.0 21 100.0 26 96.5 (87.0-99.1) 57 
Private not-for-profit health facility 100.0 3 100.0 1 100.0 4 100.0 10 
Private for-profit outlet 61.5 (37.6-80.9) 39 80.2 (59.3-91.9) 91 74.6 (56.4-87.0) 130 97.5 (94.9-98.8) 438 
Community health worker - 0 64.7 (54.3-73.9) 34 64.7 (54.3-73.9) 34 0.0 1 
Kenya – Total 12.0 (7.9-17.7) 888 10.3 (8.0-13.1) 2,353 11.0 (9.0-13.5) 3,241 12.2 (11.1-13.5) 9,980 
Public health facility 90.7 (63.7-98.2) 19 90.7 (73.8-97.1) 39 90.7 (79.0-96.2) 58 96.0 (90.4-98.4) 112 
Private not-for-profit health facility 100.0 3 100.0 12 100.0 15 92.8 (80.8-97.5) 47 
Private for-profit outlet 10.2 (6.5-15.5) 840 9.0 (6.7-12.0) 2,001 9.6 (7.6-12.0) 2,841 11.0 (9.8-12.4) 9,498 
Community health worker 0.0 26 0.3 (0.1-0.8) 301 0.2 (0.1-0.8) 327 0.0 323 
Note: Data from non-remote areas come from the main endline outlet surveys. CI = Confidence interval 
* Data collection period: Ghana: November 7-28, 2011, Kenya: October 7 - December 10, 2011 
** Data collection period: Ghana: March 4-13, 2012, Kenya: February 27 - March 16, 2012 
Source: AMFm Phase 1 Independent Evaluation Endline Outlet Surveys and Remote Area Surveys 
 
Table 5.2.2:Outlets in remote areas and non-remote areas with quality-assured ACTs in stock at endline, 2011-2012 
Indicator 1.5 Percentage of outlets in remote areas and non-remote areas that had quality-assured ACTs in stock at the time of the survey visit (n) among all outlets with any 
antimalarial in stock at the time of the survey visit (N), by type of outlet, according to country, 2011-2012 
Country/Type of outlet 
Remote areas 
Non-remote areas In endline survey* In additional survey** Total 
Percentage (95% CI) N Percentage (95% CI) N Percentage (95% CI) N Percentage (95% CI) N 
Ghana – Total 71.9 (59.0-81.9) 32 79.5 (66.1-88.5) 117 77.9 (67.0-85.9) 149 83.8 (78.8-87.8) 487 
Public health facility 80.0 (26.6-97.8) 5 100.0 21 96.2 (74.5-99.5) 26 80.0 (63.6-90.1) 55 
Private not-for-profit health facility 100.0 3 100.0 1 100.0 4 90.0 (57.5-98.4) 10 
Private for-profit outlet 66.7 (55.3-76.4) 24 68.5 (41.6-86.9) 73 68.0 (47.6-83.3) 97 84.1 (78.5-88.5) 422 
Community health worker - 0 95.5 (80.0-99.1) 22 95.5 (80.0-99.1) 22 - 0 
Kenya – Total 55.7 (33.9-75.5) 123 56.7 (39.7-72.3) 269 56.2 (43.4-68.2) 392 70.8 (63.8-76.8) 1,223 
Public health facility  98.3 (78.7-99.9) 17 92.7 (69.4-98.6) 34 95.4 (82.2-98.9) 51 96.4 (89.9-98.8) 105 
Private not-for-profit health facility 100.0 3 100.0 12 100.0 15 98.6 (93.1-99.7) 43 
Private for-profit outlet 45.7 (20.5-73.3) 103 46.1 (25.6-67.9) 222 45.9 (30.0-62.6) 325 65.5 (57.2-72.9) 1,075 
Community health worker - 0 100.0 1 100.0 1 - 0 
Note: Data from non-remote areas come from the main endline outlet surveys. CI = Confidence interval 
* Data collection period: Ghana: November 7-28, 2011, Kenya: October 7 - December 10, 2011 
** Data collection period: Ghana: March 4-13, 2012, Kenya: February 27 - March 16, 2012 
Source: AMFm Phase 1 Independent Evaluation Endline Outlet Surveys and Remote Area Surveys 
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Table 5.2.3: Outlets in remote areas and non-remote areas with quality-assured ACTs with the AMFm logo in stock at endline, 2011-2012 
Percentage of outlets in remote areas and non-remote areas that had quality-assured ACTs with the AMFm logo in stock at the time of the survey visit (n) among all outlets 
with any antimalarial in stock at the time of the survey visit (N), by type of outlet, according to country, 2011-2012 
Country/Type of outlet 
Remote areas 
Non-remote areas In endline survey* In additional survey** Total 
Percentage 
(95% CI) 
 
N 
Percentage 
(95% CI) 
 
N 
Percentage  
(95% CI) 
 
N Percentage (95% CI) N 
Ghana – Total 68.8 (57.4-78.2) 32 58.1 (30.7-81.3) 117 60.4 (37.7-79.3) 149 81.5 (76.7-85.6) 487 
Public health facility 60.0 (26.1-86.5) 5 90.5 (69.7-97.5) 21 84.6 (65.6-94.1) 26 76.4 (59.4-87.7) 55 
Private not-for-profit health facility 100.0 3 100.0 1 100.0 4 80.0 (49.4-94.2) 10 
Private for-profit outlet 66.7 (55.3-76.4) 24 65.8 (39.2-85.1) 73 66.0 (45.9-81.6) 97 82.2 (76.9-86.5) 422 
Community health worker - 0 0.0 22 0.0 22  0 
Kenya –Total 46.7 (25.1-69.6) 123 50.4 (35.5-65.1) 269 48.5 (36.2-61.0) 392 64.0 (56.3-71.0) 1,223 
Public health facility 51.6 (28.1-74.4) 17 68.8 (44.3-85.9) 34 60.5 (44.6-74.4) 51 68.9 (54.0-80.8) 105 
Private not-for-profit health facility 58.7 (33.0-80.3) 3 80.2 (41.2-95.9) 12 73.3 (44.0-90.6) 15 58.8 (37.0-77.6) 43 
Private for-profit outlet 45.4 (20.1-73.2) 103 44.5 (24.7-66.2) 222 44.9 (29.2-61.8) 325 63.5 (55.6-70.8) 1,075 
Community health worker - 0 100.0 1 100.0 1 - 0 
Note: Data from non-remote areas come from the main endline outlet surveys; CI = Confidence interval 
* Data collection period: Ghana: November 7 - 28, 2011, Kenya: October 7, 2011 - December 10, 2011 
** Data collection period: Ghana: March 4 - 13, 2012, Kenya: February 27 - March 16, 2012. 
Source: AMFm Phase 1 Independent Evaluation Endline Outlet Surveys and Remote Area Surveys 
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5.2.1 Stockouts of quality-assured ACTs in remote areas 
Table 5.2.4 presents data on stockouts of QAACTs in outlets in remote areas and non-remote 
areas. As indicated in Section 2.2.1, stockouts refer to an outlet being out of stock of all 
QAACTs for at least one day in the last seven days, as reported by the respondent. Stockouts in 
remote areas were almost nonexistent in Ghana, where only 1% of all the outlets reported them. 
In Kenya, 8% of all outlets in remote areas reported stockouts, and stockouts were slightly more 
common in private for-profit outlets (11%).  
 
Table 5.2.4: Outlets in remote areas and non-remote areas with stockouts of quality-assured ACTs at endline, 
2011-2012 
Indicator 1.6. Percentage of outlets in remote areas and non-remote areas that were out of stock of all quality-assured ACTs for at 
least 1 day in the last 7 days (n) among outlets with any quality-assured ACTs in stock at the time of the survey visit or in the 4 
weeks preceding the survey visit (N), by type of outlet, according to country, 2011-2012 
Country/Type of outlet 
Remote areas 
Non-remote areas In endline survey* In additional survey** Total 
Percentage 
 (95% CI) 
 
N 
Percentage 
 (95% CI) 
 
N 
Percentage 
 (95% CI) 
 
N 
Percentage 
 (95% CI) N 
Ghana – Total 4.2 (0.5-26.7) 24 0.0 97 0.8 (0.1-6.5) 121 1.5 (0.7-3.3) 406 
Public health facility 0.0 4 0.0 21 0.0 25 0.0 46 
Private not-for-profit health facility 0.0 3 0.0 1 0.0 4 0.0 10 
Private for-profit outlet 5.9 (0.7-36.6) 17 0.0 54 1.4 (0.2-11.2) 71 1.7 (0.7-3.9) 350 
Community health worker - 0 0.0 21 0.0 21 - 0 
Kenya – Total 8.3 (4.1-15.9) 64 8.5 (5.4-13.2) 141 8.4 (5.8-12.0) 205 4.4 (3.0-6.5) 968 
Public health facility 7.8 (1.1-39.6) 19 0.0 35 3.8 (0.6-21.8) 54 0.7 (0.1-4.9) 101 
Private not-for-profit health facility 0.0 2 0.0 12 0.0 14 5.1 (0.8-26.5) 40 
Private for-profit outlet 8.8 (4.7-15.9) 43 13.8 (10.1-18.6) 92 11.3 (8.0-15.8) 135 5.1 (3.3-7.8) 826 
Community health worker - 0 0.0 2 0.0 2 0.0 1 
Note: Data from non-remote areas come from the main endline outlet surveys. CI = Confidence interval 
* Data collection period: Ghana: November 7-28, 2011, Kenya: October 7 - December 10, 2011 
** Data collection period: Ghana: March 4-13, 2012, Kenya: February 27 - March 16, 2012 
Source: AMFm Phase 1 Independent Evaluation Endline Outlet Surveys and Remote Area Surveys 
5.2.2 Population coverage of outlets with quality-assured ACTs in remote areas 
Table 5.2.5 presents the percentage of population living in a subdistrict with at least one outlet 
with QAACTs in stock in remote areas and non-remote areas. As indicated in Section 2.2.10, this 
indicator should be interpreted with caution as the coverage could be affected by population 
density; therefore, having one outlet with QAACTs is not necessarily a good measure of access 
to QAACTs, especially in remote areas which are generally sparsely populated. In both 
countries, 100% of the population in remote areas lived in subdistricts where at least one outlet 
had QAACTs in stock. This pattern is similar for QAACTs with the AMFm logo. At baseline in 
rural areas, the coverage for QAACTs was also very high (100% in Ghana and 94% in Kenya) as 
reported in Table 2.2.10 in Section 2. Note that at baseline, the indicator on QAACTs with the 
AMFm logo was not measured. 
 
309 | P a g e  
 
 
Table 5.2.5: Percentage of the population living in “subdistricts” in remote areas and non-remote areas with outlets with quality-assured ACTs in stock at endline, 2011-2012 
Indicator 1.7 Population living in a censused “subdistrict” where there was at least one of a given type of outlet with a quality-assured ACT in stock at the time of the survey visit (n) as a percentage of the 
total population living in all the censused “subdistricts” (N), by type of outlet, according to country 
Country/Type of outlet 
Remote areas 
Non-remote areas In endline survey* In additional survey** Total 
Percentage 
 (95% CI) 
 
N 
Percentage 
 (95% CI) 
 
N 
Percentage  
(95% CI) 
 
N 
Percentage  
(95% CI) N 
Ghana         
At least one public health facility stocking 
quality-assured ACTs 55.1 (6.7 - 95.4) 75,063 90.2 (42.7 - 99.1) 175,620 79.7 (48.3 - 94.3) 250,683 56.6 (39.8 - 72.0) 726,307 
At least one private not-for-profit health 
facility stocking quality-assured ACTs 44.9 (4.6 - 93.3) 75,063 9.8 (0.9 - 57.3) 175,620 20.3 (5.7 - 51.7) 250,683 17.7 (8.8 - 32.3) 726,307 
At least one private for-profit outlet stocking 
quality-assured ACTs 82.0 (12.4 - 99.3) 75,063 100.0 175,620 94.6 (63.8 - 99.4) 250,683 96.2 (85.4 - 99.1) 726,307 
At least one community health worker stocking 
quality-assured ACTs 0.0 75,063 19.1 (3.4 - 60.9) 175,620 13.4 (2.8 - 45.5) 250,683 0.0 726,307 
At least one outlet of any type stocking 
quality-assured ACTs 100.0 75,063 100.0 175,620 100.0 250,683 100.0 726,307 
At least one outlet of any type stocking 
quality-assured ACTs with AMFm logo 100.0 75,063 100.0 175,620 100.0 250,683 100.0 726,307 
Kenya         
At least one public health facility stocking 
quality-assured ACTs 
86.5 (31.9-98.9) 108,185 88.2 (51.9-98.1) 195,329 87.4 (59.7-97.0) 303,514 90.2 (78.6-95.8) 1,054,659 
At least one private not-for-profit health 
facility stocking quality-assured ACTs 
24.8 (4.2-71.0) 108,185 27.5 (9.0-59.2) 195,329 26.1 (10.4-51.7) 303,514 52.9 (37.0-68.3) 1,054,659 
At least one private for-profit outlet stocking 
quality-assured ACTs 
86.5 (31.9-98.9) 108,185 72.5 (40.8-91.0) 195,329 79.8 (55.0-92.7) 303,514 90.5 (74.9-96.8) 1,054,659 
At least one community health worker stocking 
quality-assured ACTs 
0.0 108,185 2.0 (0.2-16.2) 195,329 1.0 (0.1-7.5) 303,514 0.0 1,054,659 
At least one outlet of any type stocking 
quality-assured ACTs 
100.0 108,185 100.0 195,329 100.0 303,514 100.0 1,054,659 
At least one outlet of any type stocking 
quality-assured ACTs with AMFm logo 
100.0 108,185 100.0 195,329 100.0 303,514 99.4 (95.7-99.9) 1,054,659 
Note: Data from non-remote areas come from the main endline outlet surveys. CI = Confidence interval 
* Data collection period: Ghana: November 7-28, 2011, Kenya: October 7 December 10, 2011 
** Data collection period: Ghana: March 4-13, 2012, Kenya: February 27 - March 16, 2012 
Source: AMFm Phase 1 Independent Evaluation Outlet Surveys and Remote Area Surveys 
310 | P a g e  
 
 
5.3 Pricing of quality-assured ACTs in remote areas 
 
Table 5.3.1 presents the median cost of QAACTs (all formulations) in outlets in remote areas 
and non-remote areas. In Ghana, the median cost per AETD in remote areas was USD 0.95 in 
public health facilities and USD 1.25 in private for-profit outlets. In Kenya, the median cost was 
USD 0.00 in public health facilities and USD 0.81 in private for-profit outlets. 
 
Table 5.3.2 presents the median cost to patients of QAACTs for pediatric formulations only in 
remote areas and non-remote areas. In Ghana, the median cost of pediatric formulations of 
QAACTs per treatment was USD 0.28 in the public health facilities, and more than twice that 
price in the private for-profit outlets (USD 0.63) in remote areas. In Kenya the median price was 
USD 0.00 in the public sector and USD 0.46 in the private for-profit outlets. 
 
Table 5.3.3 presents the median cost to patients of non-quality assured ACTs (all formulations) 
in remote areas and non-remote areas. In remote areas in both countries, the price of non-quality 
assured ACTs in the private for-profit was very high, especially in Kenya (USD 8.06) where it 
was more than twice the price of non-quality assured ACTs in similar outlets in Ghana (USD 
3.13). 
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Table 5.3.1: Cost to patients of quality-assured ACTs (including formulations for adults and children) in remote areas and non-remote areas at endline, 
in US dollars, 2011-2012 
Indicator 2.1: Median cost to patients of one adult equivalent treatment dose (AETD) of quality-assured ACTs in remote areas and non-remote areas by type of 
outlet, according to country 
Country/Type of outlet 
Remote areas 
Non-remote areas In endline survey* In additional survey** Total 
Median cost 
[IQR] 
Number 
of 
products 
Median cost 
[IQR] 
Number 
of 
products 
Median cost 
[IQR] 
Number 
of 
products 
Median cost 
[IQR] 
Number 
of 
products 
All quality-assured ACTs 
Ghana – Total 0.94 [0.94-1.25] 36 1.25 [0.94-1.88] 151 1.25 [0.94-1.88] 187 0.95 [0.94-1.88] 923 
Public health facility  0.94 [0.94-0.94] 5 0.95 [0.94-1.88] 41 0.95 [0.94-1.88] 46 0.94 [0.94-0.94] 66 
Private not-for-profit health facility 0.4 7 [0.00-0.94] 4 0.94 1 0.94 [0.00-0.94] 5 0.94 [0.00-0.94] 20 
Private for-profit outlet 1.00 [0.94-1.25] 27 1.25 [0.94-1.88] 87 1.25 [0.94-1.88] 114 1.25 [0.94-1.88] 837 
Community health worker - 0 1.25 [1.25-1.50] 22 1.25 [1.25-1.50] 22 - 0 
Kenya – Total 0.00 [0.00-0.58] 132 0.00 [0.00-0.77] 280 0.00 [0.00-0.69] 412 0.46 [0.00-0.61] 1,864 
Public health facility  0.00 [0.00-0.00] 63 0.00 [0.00-0.00] 119 0.00 [0.00-0.00] 182 0.00 [0.00-0.00] 342 
Private not-for-profit health facility 0.00 [0.00-0.00] 6 0.00 [0.00-0.31] 40 0.00 [0.00-0.31] 46 0.00 [0.00-1.04] 116 
Private for-profit outlet 0.69 [0.46-1.84] 63 0.81 [0.58-1.38] 117 0.81 [0.46-1.38] 180 0.46 [0.46-0.92] 1,406 
Community health worker - 0 1.73 [1.15-3.45] 4 1.73 [1.15-3.45] 4 - 0 
Quality-assured ACTs with AMFm logo 
Ghana –Total 0.94 [0.94-1.25] 35 1.25 [0.94-1.88] 121 1.00 [0.94-1.88] 156 0.94 [0.94-1.88] 845 
Public health facility  0.94 [0.72-0.94] 4 0.94 [0.94-1.88] 35 0.94[0.94-1.25] 39 0.94 [0.94-0.94] 62 
Private not-for-profit health facility 0.47 [0.00-0.94] 4 0.94 1 0.94[0.00-0.94] 5 0.94 [0.00-0.95] 19 
Private for-profit outlet 1.00 [0.94-1.25] 27 1.25 [0.94-1.88] 85 1.25[0.94-1.88] 112 1.00 [0.94-1.88] 764 
Community health worker - 0 - 0 - 0 - 0 
Kenya – Total 0.46 [0.00-1.15] 81 0.46 [0.00-1.15] 211 0.46 [0.00-1.15] 292 0.46 [0.46-0.69] 1,539 
Public health facility  0.00 [0.00-0.00] 18 0.00 [0.00-0.00] 72 0.00 [0.00-0.00] 90 0.00 [0.00-0.00] 156 
Private not-for-profit health facility 0.00 [0.00-0.00] 3 0.00 [0.00-0.31] 23 0.00 [0.00-0.31] 26 0.46 [0.00-0.69] 45 
Private for-profit outlet 0.69 [0.46-1.84] 60 0.81 [0.58-1.38] 112 0.69 [0.46-1.38] 172 0.46 [0.46-0.92] 1,338 
Community health worker - 0 1.73 [1.15-3.45] 4 1.73 [1.15-3.45] 4 - 0 
Quality-assured ACTs without AMFm logo 
Ghana –Total 3.75 1 1.25 [1.25-1.88] 30 1.25 [1.25-2.00] 31 6.88 [1.25-8.76] 77 
Public health facility  3.75 1 1.56 [1.25-2.00] 6 1.88 [1.25-3.75] 7 1.41 [0.94-2.19] 4 
Private not-for-profit health facility - 0 - 0 - 0 0.94 1 
Private for-profit outlet - 0 2.00 [1.50-2.50] 2 2.00 [1.50-2.50] 2 7.51 [1.50-8.76] 72 
Community health worker - 0 1.25[1.25-1.50] 22 1.25 [1.25-1.50] 22 - 0 
Kenya – Total 0.00 [0.00-0.00] 51 0.00 [0.00-0.00] 69 0.00 [0.00-0.00] 120 0.00 [0.00-0.46] 325 
Public health facility  0.00 [0.00-0.00] 45 0.00 [0.00-0.00] 47 0.00 [0.00-0.00] 92 0.00 [0.00-0.00] 186 
Private not-for-profit health facility 0.00 [0.00-0.00] 3 0.00 [0.00-0.31] 17 0.00 [0.00-0.31] 20 0.00 [0.00-1.15] 71 
Private for-profit outlet 3.45 [0.00-3.45] 3 1.15 [1.15-1.73] 5 1.73 [0.92-3.45] 8 0.92 [0.52-2.30] 68 
Community health worker - 0 - 0 - 0 - 0 
Note: Data from non-remote areas come from the main endline outlet surveys. IQR = Interquartile range 
* Data collection period: Ghana: November 7-28, 2011, Kenya: October 7 -December 10, 2011 
** Data collection period: Ghana: March 4-13, 2012, Kenya: February 27 - March 16, 2012  
Source: AMFm Phase 1 Independent Evaluation Endline Outlet Surveys and Remote Area Surveys 
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Table 5.3.2: Cost to patients of quality-assured ACTs (pediatric formulations only) in remote areas and non-remote areas at endline, in US dollars, 
2011-2012 
Indicator 2.1: Median cost to patients of one PEDIATRIC FORMULATION of quality-assured ACTs for a two-year old child (10kg) in remote areas and non-remote areas 
by type of outlet, according to country 
Country/Type of outlet 
Remote areas 
Non-remote areas In endline survey* In additional survey** Total 
Median cost 
[IQR] 
Number 
of 
products 
Median cost 
[IQR] 
Number 
of 
products 
Median cost 
[IQR] 
Number 
of 
products 
Median cost 
[IQR] 
Number 
of 
products 
All quality-assured ACTs 
Ghana – Total 0.69 [0.38-0.84] 4 0.3 80 [0.31-0.63] 46 0.38 [0.31-0.63] 50 0.63 [0.63-0.94] 156 
Public health facility  0.53 [0.13-0.94] 2 0.28 [0.24-0.47] 10 0.28 [0.24-0.47] 12 0.24 [0.24-0.47] 5 
Private not-for-profit health facility - 0 - 0 - 0 0.59 [0.24-0.94] 2 
Private for-profit outlet 0.69 [0.63-0.75] 2 0.63 [0.63-0.94] 17 0.63 [0.63-0.94] 19 0.63 [0.63-0.94] 149 
Community health worker - 0 0.31 [0.31-0.38] 19 0.31 [0.31-0.38] 19 - 0 
Kenya – Total 0.00 [0.00-0.46] 13 0.00 [0.00-0.40] 52 0.00 [0.00-0.46] 65 0.35 [0.00-0.46] 254 
Public health facility  0.00 [0.00-0.00] 7 0.00 [0.00-0.00] 20 0.00 [0.00-0.00] 27 0.00 [0.00-0.00] 41 
Private not-for-profit health facility 0.00 1 0.00 [0.00-0.23] 9 0.00 [0.00-0.23] 10 0.00 [0.00-0.46] 14 
Private for-profit outlet 0.46 [0.46-0.69] 5 0.40 [0.35-0.58] 22 0.46 [0.35-0.58] 27 0.46 [0.35-0.46] 199 
Community health worker - 0 0.58 1 0.58 1 - 0 
All quality-assured ACTs with AMFm logo 
Ghana – Total 0.63 [0.13-0.75] 3 0.63 [0.47 -0.94] 21 0.63 [0.42-0.84] 24 0.63 [0.63-0.94] 147 
Public health facility  0.12 1 0.24 [0.24-0.47] 6 0.24 [0.24-0.47] 7 0.24 [0.24-0.43] 4 
Private not-for-profit health facility - 0 - 0 - 0 0.59 [0.24-0.94] 2 
Private for-profit outlet 0.69 [0.63-0.75] 2 0.63 [0.63-0.94] 15 0.63 [0.63-0.94] 17 0.63 [0.63-0.94] 141 
Community health worker - 0 - 0 - 0 - 0 
Kenya – Total 0.32 [0.00-0.46] 10 0.00 [0.00-0.46] 42 0.00 [0.00-0.46] 52 0.35 [0.23-0.46] 212 
Public health facility  0.00 [0.00-0.00] 5 0.00 [0.00-0.00] 16 0.00 [0.00-0.00] 21 0.00 [0.00-0.00] 19 
Private not-for-profit health facility - 0 0.00 [0.00-0.00] 4 0.00 [0.00-0.00] 4 0.00 [0.00-0.58] 6 
Private for-profit outlet 0.46 [0.46-0.69] 5 0.40 [0.35-0.58] 21 0.46 [0.35-0.58] 26 0.46 [0.35-0.46] 187 
Community health worker - 0 0.58 1 0.58 1 - 0 
Quality-assured ACTs without AMFm logo 
Ghana – Total 0.94 1 0.31 [0.31-0.38] 25 0.31 [0.31-0.38] 26 0.94 [0.47-1.25] 9 
Public health facility  0.94 1 0.39 [0.28-0.70] 4 0.47 [0.31-0.94] 5 0.47 1 
Private not-for-profit health facility - 0 - 0 - 0 - 0 
Private for-profit outlet - 0 0.50 [0.38-0.63] 2 0.50 [0.38-0.63] 2 0.94 [0.50-3.13] 8 
Community health worker - 0 0.31 [0.31-0.38] 19 0.31 [0.31-0.38] 19 - 0 
Kenya – Total 0.00 [0.00-0.00] 3 0.00 [0.00, 0.23] 10 0.00 [0.00, 0.00] 13 0.00 [0.00-0.17] 42 
Public health facility  0.00 [0.00-0.00] 2 0.00 [0.00-0.00] 4 0.00 [0.00-0.00] 6 0.00 [0.00-0.00] 22 
Private not-for-profit health facility 0.00 1 0.00 [0.00-0.23] 5 0.00 [0.00-0.23] 6 0.00 [0.00-0.46] 8 
Private for-profit outlet - 0 1.44 1 1.44 1 0.58 [0.46-0.58] 12 
Community health worker - 0 - 0 - 0 - 0 
Note: Data from non-remote areas come from the main endline outlet surveys. IQR = Interquartile range 
* Data collection period: Ghana: November 7-28, 2011, Kenya: October 7 - December 10, 2011 
** Data collection period: Ghana: March 4-13, 2012, Kenya: February 27 - March 16, 2012 
Source: AMFm Phase 1 Independent Evaluation Endline Outlet Surveys and Remote Area Surveys 
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Table 5.3.3: Cost to patients of non-quality-assured ACTs (including formulations for adults and children) in remote areas and non-remote areas at 
endline, in US dollars, 2011-2012 
Indicator 2.2: Median cost to patients of one adult equivalent treatment dose (AETD) of non-quality-assured ACTs (including formulations for adults and 
children) in remote areas and non-remote areas by type of outlet, according to country 
Country/Type of outlet 
Remote areas 
Non-remote areas In endline survey* In additional survey** Total 
Median cost 
 [IQR] 
Number  
of 
products 
Median cost 
 [IQR] 
Number 
 of 
products 
Median cost  
[IQR] 
Number 
 of  
products 
Median cost  
[IQR] 
Number 
of 
products 
Ghana – Total 2.50 [0.94-3.75] 29 3.13 [1.25-4.55] 89 2.74 [1.25-4.38] 118 3.44 [2.82-5.63] 1,092 
Public health facility  0.75 [0.63-1.25] 3 1.03 [0.94-4.55] 14 0.94 [0.94-4.55] 17 1.88 [0.94-4.55] 65 
Private not-for-profit health facility 1.25 [0.00-3.75] 4 - 0 1.25 [0.00-3.75] 4 1.88 [1.03-5.19] 12 
Private for-profit outlet 2.74 [1.25-4.38] 22 3.13 [1.88-4.69] 72 3.13 [1.88-4.38] 94 3.52 [2.82-5.84] 1,015 
Community health worker - 0 1.50 [0.75-2.50] 3 1.50 [0.75-2.5] 3 - 0 
Kenya – Total 8.06 [3.45-15.35] 32 5.87 [3.80-18.13] 67 5.87 [3.45-15.35] 99 6.45 [4.03-11.05] 1,248 
Public health facility  0.00 [0.00-0.00] 2 0.00 [0.00- 0.00] 2 0.00 [0.00-0.00] 4 0.00 [0.00-5.18] 12 
Private not-for-profit health facility - 0 0.97 1 0.97 1 5.76 [0.00-7.67] 14 
Private for-profit outlet 8.29 [3.45-15.35] 30 6.33 [4.03-18.13] 64 8.06 [4.03-15.54] 94 6.68 [4.03-11.05] 1,222 
Community health worker - 0 - 0 - 0 - 0 
Note: Data from non-remote areas come from the main endline outlet surveys. IQR = Interquartile range 
* Data collection period: Ghana: November 7-28, 2011, Kenya: October 7 -December 10, 2011 
** Data collection period: Ghana: March 4-13, 2012, Kenya: February 27 - March 16, 2012  
Source: AMFm Phase 1 Independent Evaluation Endline Outlet Surveys and Remote Area Surveys 
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5.4 Gross markup between purchase price and retail selling price of quality-
assured ACTs in remote areas 
Table 5.4.1 presents the median percentage markup between the purchase price and the retail 
selling price of QAACTs in remote areas and non-remote areas. It should be noted that the gross 
markups do not take into account the cost of doing business. The median percentage markup in 
private for-profit outlets in remote areas was 50% in Ghana for all QAACTs and for QAACTs 
with the AMFm logo. In Kenya, the markup for all QAACTs was 0% in public health facilities 
and 43% in private for-profit outlets. Regarding QAACTs with the AMFm logo in Kenya, the 
markup was 0% in public health facilities, 43% in private for-profit outlets. 
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Table 5.4.1: Gross markup between purchase price and retail selling price of quality-assured ACTs in remote areas and non-remote areas at endline, in 
US dollars, 2011-2012 
Median percentage markup between purchase price and retail selling price of quality-assured ACTs in remote areas and non-remote areas by type of outlet, 
according to country 
Country/Type of outlet 
Remote areas 
Non-remote areas In endline survey* In additional survey** Total 
Median 
percentage 
markup  
[IQR] 
Number 
of 
products 
Median percentage 
markup [IQR] 
Number  
of 
 products 
Median 
percentage 
markup [IQR] 
Number 
 of  
products 
Median 
percentage 
markup 
 [IQR] 
Number 
 of 
 products 
All quality-assured ACTs 
Ghana – Total 60.0 [36.0-82.0] 21 50.0 [43.0-67.0] 70 50.0 [36.0-67.0] 91 50.0 [33.0-67.0] 489 
Public health facility  114.0 [00.0-114.0] 3 83.0 [25.0-196.0] 12 100.0 [19.0-192.0] 15 25.0 [0.0-50.0] 23 
Private not-for-profit health facility 62.0 [36.0-87.0] 2 - 0 62.0 [36.0-0.87] 2 25.0 [0.0-0.63] 16 
Private for-profit outlet 55.0 [31.0-74.0] 16 50.0 [43.0-67.0] 58 50.0 [40.0-67.0] 74 50.0 [36.0-67.0] 450 
Community health worker - 0 - 0 - 0 - 0 
Kenya – Total 0.0 [0.0-39.5] 121 0.0 [0.0-42.9] 251 0.0 [0.0-40.0] 372 25.0 [0.0-60.0] 1,618 
Public health facility  0.0 [0.0-0.0] 63 0.0 [0.0-0.0] 116 0.0 [0.0-0.0] 179 0.0 [0.0-0.0] 326 
Private not-for-profit health facility 0.0 [0.0-0.0] 6 0.0 [0.0-0.0] 28 0.0 [0.0-0.0] 34 0.0 [0.0-25.0] 92 
Private for-profit outlet 42.9 [33.3-100.0] 52 42.9 [20.0-66.7] 103 42.9 [33.3-81.8] 155 42.9 [33.3-66.7] 1,200 
Community health worker - 0 42.9 [42.9-62.3] 4 42.9 [42.9-62.3] 4 - 0 
Quality-assured ACTs with AMFm logo 
Ghana – Total 60.0 [36.0-82.0] 21 50.0 [43.0-67.0] 63 50.0 [40.0-67.0] 84 50.0 [33.0-67.0] 467 
Public health facility  114.0 [0.0-114.0] 3 138.0 [53.0-200.0] 7 114.0 [53.0-192.0] 10 25.0 [0.0-50.0] 21 
Private not-for-profit health facility 62.0 [36.0-0.87] 2 - 0 62.0 [36.0-87.0] 2 25.0 [0.0-63.0] 16 
Private for-profit outlet 55.0 [31.0-74.0] 16 50.0 [43.0-67.0] 56 50.0 [40.0-67.0] 72 50.0 [36.0-67.0] 430 
Community health worker - 0 - 0 - 0 - 0 
Kenya – Total 33.3 [0.0-77.8] 71 5.3 [0.0-50.0] 189 33.3 [0.0-60.0] 260 33.3 [0.0-60.0] 1,332 
Public health facility  0.0 [0.0-0.0] 18 0.0 [0.0-0.0] 69 0.0 [0.0-0.0] 87 0.00 [0.0-0.00] 143 
Private not-for-profit health facility 0.0 [0.0-0.0] 3 0.0 [0.0-0.0] 16 0.0 [0.0-0.0] 19 0.00 [0.0-57.9] 37 
Private for-profit outlet 53.8 [33.3-100.0] 50 42.9 [25.0-66.7] 100 42.9 [33.3-81.8] 150 48.1 [33.3-66.7] 1,152 
Community health worker - 0 42.9 [42.9-62.3] 4 42.9 [42.9-62.3] 4 - 0 
Quality-assured ACTs without AMFm logo 
Ghana – Total - 0 42.9 [19.0-100.0] 7 42.9 [19.0-100.0] 7 36.4 [20.0-50.0] 21 
Public health facility  - 0 31.6 [19.0-100.0] 5 31.6 [19.0-100.0] 5 111.5 [15.4-207.7] 2 
Private not-for-profit health facility - 0 - 0 - 0 - 0 
Private for-profit outlet - 0 57.1 [42.9-71.4] 2 57.1 [42.9-71.4] 2 36.4 [20.0-50.0] 19 
Community health worker - 0 - 0 - 0  0 
Kenya – Total 0.0 [0.0-0.0] 50 0.0 [0.0-0.0] 62 0.0 [0.0-0.0] 112 0.0 [0.0-0.0] 286 
Public health facility  0.0 [0.0-0.0] 45 0.0 [0.0-0.0] 47 0.0 [0.0-0.0] 92 0.0 [0.0-0.0] 183 
Private not-for-profit health facility 0.0 [0.0-0.0] 3 0.0 [0.0-0.0] 12 0.0 [0.0-0.0] 15 0.0 [0.0-0.0] 55 
Private for-profit outlet 39.5 [0.0-39.5] 2 25.0 [19.0-316.7] 3 39.5 [19.0-39.5] 5 33.3 [28.6-66.7] 48 
Community health worker - 0 - 0 - 0 - 0 
Note: Data from non-remote areas come from the main endline outlet surveys. IQR = Interquartile range 
* Data collection period: Ghana: November 7-28, 2011, Kenya: October 7 -December 10, 2011 
** Data collection period: Ghana: March 4-13, 2012, Kenya: February 27 - March 16, 2012 
Source: AMFm Phase 1 Independent Evaluation Endline Outlet Surveys and Remote Area Surveys 
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5.5 Availability and cost to patients of malaria diagnostic tests in remote areas 
 
Table 5.5.1 presents the percentage of outlets with malaria diagnostic tests (malaria microscopy 
or rapid diagnostic tests (RDTs)) in remote areas and non-remote areas. The availability of 
diagnostic tests was generally low in remote areas in both countries. For all types of outlets 
combined, the percentage of outlets in which malaria microscopy was available was only 15% in 
Ghana and 14% in Kenya. However, more than 50% of public health facilities in Ghana and one-
third of public health facilities in remote areas of Kenya provided malaria microscopy tests. Less 
than 10% of private for-profit outlets in remote areas in both countries had malaria microscopy 
tests available. A similar level and pattern were observed for the availability of RDTs. It should 
be noted that the low level of availability of malaria diagnostic tests is a reflection of the low 
availability of RDTs at the national level, especially in the private for-profit sector. 
 
Table 5.5.2 presents the median cost to patients for one malaria diagnostic test in remote areas 
and non-remote areas for Kenya only (results are not shown for Ghana because of the small 
number of outlets with malaria diagnostic tests in that country). In remote areas in Kenya, in the 
public health facilities the cost of malaria microscopy was USD 0.58 for adult and USD 0.00 for 
child patients. In the private for-profit outlets, the price for adult patients (USD 1.15) was about 
twice the price for child patients (USD 0.58). Rapid diagnostic tests for malaria were free for 
adult and child patients in remote areas in public health facilities and USD 1.15 in private for-
profit outlets. 
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Table 5.5.1: Availability of malaria diagnostic tests in remote areas and non-remote areas at endline, 2011-2012 
Percentage of outlets where malaria diagnostic tests were available (n) as a percentage of outlets with any antimalarials in stock at the time of the survey visit (N) in remote areas 
and non-remote areas by type of outlet, according to country 
Country/Type of outlet 
Remote areas 
Non-remote areas In endline survey* In additional survey** Total 
Percentage 
(95% CI) N 
Percentage 
(95% CI) N 
Percentage 
(95% CI) N 
Percentage 
(95% CI) N 
Malaria microscopy 
Ghana – Total 3.2 (0.5-17.0) 31 18.1 (9.6-31.6) 116 15.0 (8.2-25.8) 147 8.2 (5.7-11.5) 478 
Public health facility  0.0 5 71.4 (36.4-91.6) 21 57.7 (29.9-81.4) 26 36.4 (23.9-50.9) 55 
Private not-for-profit health facility 0.0 2 100.0 1 33.3 (3.9-86.0) 3 20.0 (4.6-56.4) 10 
Private for-profit outlet 4.2 (0.7-20.9) 24 6.9 (2.9-15.9) 72 6.3 (2.7-13.8) 96 4.1 (2.2-7.6) 413 
Community health worker - 0 0.0 22 0.0 22 - 0 
Kenya – Total 13.8 (7.6-23.9) 124 14.6 (9.9-21.2) 269 14.2 (10.3-19.3) 393 20.4 (17.3-23.9) 1,214 
Public health facility  29.3 (9.5-62.2) 17 34.9 (20.7-52.4) 35 32.3 (19.7-48.0) 52 50.0 (39.1-60.8) 105 
Private not-for-profit health facility 58.7 (33.0-80.3) 3 47.7 (18.6-78.4) 12 51.2 (28.9-72.9) 15 82.2 (66.7-91.5) 43 
Private for-profit outlet 9.6 (3.5-23.8) 104 8.1 (2.6-22.6) 221 8.9 (4.4-16.9) 325 12.7 (9.3-17.0) 1,066 
Community health worker - 0 0.0 1 0.0 1 - 0 
Rapid diagnostic test for malaria 
Ghana – Total 3.1 (0.6-15.7) 32 14.5 (7.1-27.4) 117 12.1 (6.3-22.0) 149 4.5 (3.0-6.8) 487 
Public health facility  0.0 5 61.9 (30.1-86.0) 21 50.0 (24.3-75.7) 26 25.5 (15.4-39.0) 55 
Private not-for-profit health facility 0.0 3 0.0 1 0.0 4 10.0 (1.3-48.7) 10 
Private for-profit outlet 4.2 (0.7-20.9) 24 5.5 (2.5-11.7) 73 5.2 (2.4-10.5) 97 1.7 (0.8-3.4) 422 
Community health worker - 0 0.0 22 0.0 22 - 0 
Kenya – Total 9.2 (4.2-19.0) 124 12.8 (5.2-28.3) 270 11.0 (6.2-18.9) 394 4.0 (2.6-6.1) 1,221 
Public health facility  38.8 (11.3-76.0) 17 51.3 (20.0-81.6) 35 45.4 (23.5-69.2) 52 7.3 (3.1-16.4) 105 
Private not-for-profit health facility 0.0 3 44.2 (20.9-70.3) 12 30.1 (9.1-64.9) 15 10.7 (4.7-22.7) 43 
Private for-profit outlet 3.1 (0.9-10.4) 104 1.9 (0.5-6.3) 222 2.5 (1.1-5.9) 326 3.1 (1.8-5.4) 1,073 
Community health worker - 0 0.0 1 0.0 1 - 0 
Note: Data from non-remote areas come from the main endline outlet surveys. CI = Confidence interval 
* Data collection period: Ghana: November 7-28, 2011, Kenya: October 7 -December 10, 2011 
** Data collection period: Ghana: March 4-13, 2012, Kenya: February 27 - March 16, 2012 
Source: AMFm Phase 1 Independent Evaluation Endline Outlet Surveys and Remote Area Surveys 
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Table 5.5.2: Cost to patients of malaria diagnostic tests in remote areas and non-remote areas at endline, in US dollars, Kenya, 2011-2012 
Median cost to patients for one malaria diagnostic test in remote areas and non-remote areas by type of test and type of outlet, Kenya 
Country/Type of outlet 
Remote areas 
Non-remote areas In endline survey* In additional survey** Total 
Median cost 
[IQR] 
Number of 
products 
Median cost 
[IQR] 
Number of 
products 
Median cost 
[IQR] 
Number of 
products 
Median cost 
[IQR] 
Number of 
products 
Malaria microscopy - Cost for adult patient 
Kenya – Total 0.58 [0.58-1.15] 17 0.69 [0.58-1.15] 32 0.58 [0.58-1.15] 49 0.58 [0.46-0.92] 266 
Public health facility  0.58 [0.58-1.15] 6 0.58 [0.35-1.15] 15 0.58 [0.46-1.15] 21 0.46 [0.35-0.58] 60 
Private not-for-profit health facility 0.58 [0.35-0.58] 2 0.58 [0.58-0.58] 5 0.58 [0.58-0.58] 7 0.58 [0.46-0.58] 34 
Private for-profit outlet 0.69 [0.58-1.15] 9 1.15 [1.15-1.15] 12 1.15 [0.58-1.15] 21 0.92 [0.58-1.15] 172 
Community health worker - 0 - 0 - 0 - 0 
Malaria microscopy - Cost for child patient 
Kenya – Total 0.58 [0.35-0.58] 17 0.58 [0.00-1.15] 32 0.58 [0.00-0.69] 49 0.58 [0.35- 0.69] 272 
Public health facility  0.00 [0.00-1.15] 6 0.00 [0.00-0.58] 15 0.00 [0.00-0.58] 21 0.35 [0.00-0.58] 61 
Private not-for-profit health facility 0.58 [0.35-0.58] 2 0.58 [0.58-0.58] 5 0.58 [0.58-0.58] 7 0.58 [0.35-0.58] 34 
Private for-profit outlet 0.58 [0.58-0.58] 9 1.15 [0.58-1.15] 12 0.58 [0.58-0.86] 21 0.58 [0.58-1.15] 177 
Community health worker - 0 - 0 - 0 - 0 
Rapid diagnostic test for malaria - Cost for adult patient 
Kenya – Total 0.58 [0.00-1.15] 11 0.00 [0.00-0.35] 21 0.00 [0.00-0.58] 32 0.58 [0.35-1.15] 61 
Public health facility  0.58 [0.00-1.15] 9 0.00 [0.00-0.35] 13 0.00 [0.00-0.58] 22 0.10 [0.00-0.23] 11 
Private not-for-profit health facility - 0 0.00 [0.00-0.00] 5 0.00 [0.00-0.00] 5 0.58 [0.35-0.58] 7 
Private for-profit outlet 1.15 [0.35-1.15] 2 0.46 [0.46-1.73] 3 1.15 [0.35-1.15] 5 1.15 [0.58-1.15] 43 
Community health worker - 0 - 0 - 0 - 0 
Rapid diagnostic test for malaria - Cost for child patient 
Kenya – Total 0.58 [0.00-1.15] 11 0.00 [0.00-0.00] 21 0.00 [0.00-0.58] 32 0.58 [0.35-1.15] 60 
Public health facility  0.58 [0.00-1.15] 9 0.00 [0.00-0.00] 13 0.00 [0.00-0.58] 22 0.00 [0.00-0.00] 10 
Private not-for-profit health facility - 0 0.00 [0.00-0.00] 5 0.00 [0.00-0.00] 5 0.58 [0.35-0.58] 7 
Private for-profit outlet 1.15 [0.23-15] 2 0.46 [0.46-1.73] 3 1.15 [0.23-1.15] 5 1.15 [0.58-1.15] 43 
Community health worker - 0 - 0 - 0 - 0 
Note: Data from non-remote areas come from the main endline outlet surveys. IQR = Interquartile range 
* Data collection period: Kenya: October 7 -December 10, 2011 
** Data collection period: Kenya: February 27 - March 16, 2012 
Source: AMFm Phase 1 Independent Evaluation Endline Outlet Surveys and Remote Area Surveys 
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5.6 Market share for quality-assured ACTs in remote areas 
 
Table 5.6.1 presents the percent distribution of antimalarial sales volumes in remote areas and 
non-remote areas. CHWs are not shown separately due to low total sales volumes. In Ghana, for 
all sectors combined, the market share of all QAACTs in remote areas (59%) was mostly 
dominated by QAACTs with the AMFm logo. Non-artemisinin therapies had the second highest 
market share (25%). In Kenya, the market share was similar for QAACTs (48%) and non-
artemisinin therapies (50%). While very few ACTs that were not quality assured were sold or 
distributed in Kenya, in remote areas of Ghana the market share was more than 10%. Referring 
to the baseline data for rural areas (Table 2.4.4 in Section 2), the market share of QAACTs seems 
to have increased substantially in both countries; however, the market share of non-artemisinin 
therapies also increased. It should be mentioned again that non-artemisinin therapies, such as SP, 
are still needed for IPTp. 
 
In public health facilities, in both countries, QAACTs had the highest market share in remote 
areas (60% in Ghana and 77% in Kenya). More than 90% of the QAACTs sold or distributed in 
public health facilities in Ghana had the AMFm logo, whereas only half of the QAACTs in 
Kenya had the AMFm logo in remote areas. ACTs that were not quality assured had the second 
highest market share in Ghana (25%). In contrast, in Kenya, no QAACTs that were not quality-
assured were sold or distributed, and the second highest market share was for non-artemisinin 
therapy (23%). Compared with the baseline data for rural areas (Table 2.4.1 in Section 2), there 
seems to have been a gain in market share for QAACTs in both countries. 
 
In private not-for-profit outlets in Ghana, QAACTs and non-artemisinin therapies had an equal 
market share in remote areas (around 50%), while in Kenya, non-artemisinin therapies had the 
dominant market share (71%). There seems to have been a substantial increase in market share of 
QAACTs in remote areas based on the level of the market share at baseline in rural areas, which 
was 13% for Ghana and 16% for Kenya (Table 2.4.2 in Section 2). 
 
In private for-profit outlets, QAACTs had the dominant market share (76%) in remote areas in 
Ghana, while in Kenya, the most commonly sold antimalarials in remote areas were non-
artemisinin therapies (57%). However QAACTs still had an important market share in Kenya 
(40%). Compared with the market share of QAACTs at baseline in rural areas, which was 7% in 
Ghana and 6% in Kenya (Table 2.4.3 in Section 2), there was a substantial increase in the market 
share of QAACTs in the remote areas 
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Table 5.6.1: Percent distribution of antimalarial sales volumes in remote areas and non-remote areas at 
endline, 2011-2012 
Total number of AETDs of each type of antimalarial sold or distributed in the week preceding the survey visit (n), as a percentage of all 
antimalarial AETDs sold or distributed in the week preceding the survey visit for outlets with any antimalarials in stock at the time of the survey 
visit (N) in remote areas and non-remote areas, according to type of antimalarial and country 
Country/Type of antimalarial 
Remote areas 
Non-remote areas In endline survey* 
In additional 
survey** Total 
Percentage  N Percentage  N Percentage  N Percentage  N 
All sectors combined 
Ghana –Total 100.0 2,088 100.0 3,902 100.0 5,990 100.0 29,500 
All quality-assured ACTs 71.1  52.2  58.8  55.7  
Quality-assured ACTs with AMFm logo 71.1  49.1  56.8  54.1  
Quality-assured ACTs without AMFm logo 0.0  3.2  2.1  1.6  
Non-quality-assured ACTs 9.4  16.1  13.8  19.9  
Artemisinin monotherapy 5.1  1.0  2.4  4.2  
Non-artemisinin therapy 14.4  30.7  25.0  20.2  
Kenya –Total 100.0 1,661 100.0 5,707 100.0 7,368 100.0 36,803 
All quality-assured ACTs 50.2  46.1  48.0  58.4  
Quality-assured ACTs with AMFm logo 36.0  39.0  37.6  53.2  
Quality-assured ACTs without AMFm logo 14.2  7.2  10.4  5.2  
Non-quality-assured ACTs 1.6  2.0  1.8  5.0  
Artemisinin monotherapy 0.1  0.1  0.1  0.6  
Non-artemisinin therapy 48.1  51.8  50.1  36.0  
Public health facilities 
Ghana –Total 100.0 128 100.0 1,160 100.0 1,287 100.0 5,232 
All quality-assured ACTs 45.0  61.8  60.1  70.4  
Quality-assured ACTs with AMFm logo 45.0  56.1  55.0  68.0  
Quality-assured ACTs without AMFm logo 0.0  5.7  5.1  2.4  
Non-quality-assured ACTs 45.4  22.9  25.1  21.7  
Artemisinin monotherapy 2.9  0.5  0.7  1.7  
Non-artemisinin therapy 6.7  14.9  14.1  6.1  
Kenya –Total 100.0 250 100.0 1,522 100.0 1,772 100.0 7,477 
All quality-assured ACTs 92.6  68.7  77.4  43.3  
Quality-assured ACTs with AMFm logo 22.8  47.9  38.7  36.1  
Quality-assured ACTs without AMFm logo 69.8  20.7  38.7  7.2  
Non-quality-assured ACTs 0.0  0.0  0.0  0.1  
Artemisinin monotherapy 0.0  0.0  0.0  0.4  
Non-artemisinin therapy 7.4  31.3  22.6  56.3  
Private not-for-profit facilities 
Ghana –Total 100.0 673 100.0 491 100.0 1,163 100.0 2,979 
All quality-assured ACTs 66.9  22.4  48.1  68.8  
Quality-assured ACTs with AMFm logo 66.9  22.4  48.1  68.8  
Quality-assured ACTs without AMFm logo 0.0  0.0  0.0  0.0  
Non-quality-assured ACTs 1.2  0.0  0.7  20.7  
Artemisinin monotherapy 1.5  0.5  1.1  1.9  
Non-artemisinin therapy 30.4  77.1  50.1  8.6  
Kenya –Total 100.0 162 100.0 1,654 100.0 1,816 100.0 814 
All quality-assured ACTs 73.5  21.0  28.8  83.6  
Quality-assured ACTs with AMFm logo 72.1  14.8  23.3  38.5  
Quality-assured ACTs without AMFm logo 1.4  6.2  5.5  45.0  
Non-quality-assured ACTs 0.0  0.0  0.0  0.3  
Artemisinin monotherapy 0.5  0.1  0.1  0.5  
Non-artemisinin therapy 26.0  78.9  71.1  15.6  
Private for-profit facilities 
Ghana –Total 100.0 1,068 100.0 595 100.0 1,663 100.0 2,713 
All quality-assured ACTs 81.5  64.9  75.6  51.5  
Quality-assured ACTs with AMFm logo 81.5  64.9  75.6  51.4  
Quality-assured ACTs without AMFm logo 0.0  0.0  0.0  0.1  
Non-quality-assured ACTs 10.1  16.5  12.4  23.3  
Artemisinin monotherapy 8.4  0.1  5.4  8.7  
Non-artemisinin therapy 0.0  18.5  6.6  16.5  
Kenya –Total 100.0 1,249 100.0 2,511 100.0 3,760 100.0 28,513 
All quality-assured ACTs 38.6  41.6  40.0  67.0  
Quality-assured ACTs with AMFm logo 37.8  41.3  39.4  65.1  
Quality-assured ACTs without AMFm logo 0.8  0.4  0.6  2.0  
Non-quality-assured ACTs 2.1  3.7  2.8  8.4  
Artemisinin monotherapy 0.1  0.1  0.1  0.7  
Non-artemisinin therapy 59.2  54.5  57.1  23.8  
Note: Data from non-remote areas come from the main endline outlet surveys. CI = Confidence interval 
* Data collection period: Ghana: November 7-28, 2011, Kenya: October 7 - December 10, 2011 
** Data collection period: Ghana: March 4-13, 2012, Kenya: February 27 - March 16, 2012 
Source: AMFm Phase 1 Independent Evaluation Endline Outlet Surveys and Remote Area Surveys 
321 | P a g e  
 
 
5.7 AMFm logo in remote areas 
Table 5.7.1 presents the percentage of providers able to recognize the AMFm logo in remote and 
non-remote areas. In remote areas of both countries, more than two-thirds of providers (69%) 
were able to recognize the AMFm logo for all outlets combined. This percentage was more than 
60% for private for-profit outlets in both countries (76% in Ghana and 68% in Kenya) in remote 
areas. 
 
Table 5.7.2 presents the percentage of QAACTs bearing the AMFm logo in remote areas and 
non-remote areas. In Ghana, for all outlets combined, 83% of QAACTs in remote areas had the 
AMFm logo. The percentage of QAACTs bearing the AMFm logo was lower in Kenya (66%). 
In the private for-profit sector, more than 90% of QAACTs bore the AMFm logo in both Ghana 
and Kenya. 
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Table 5.7.1: Provider recognition of the AMFm logo in remote areas and non-remote areas at endline, 2011-2012 
Percentage of providers able to recognize the AMFm logo (n) as a percentage of the number of outlets with antimalarials in stock at the time of the survey visit (N) in remote areas 
and non-remote areas by type of outlet, according to country 
Country/Type of outlet 
Remote areas 
Non-remote areas In endline survey* In additional survey** Total 
Percentage (95% CI) N Percentage (95% CI) N Percentage (95% CI) N Percentage (95% CI) N 
Ghana – Total 78.1 (60.9-89.1) 32 66.7 (40.0-85.7) 117 69.1 (47.3-84.8) 149 94.4 (90.5-96.8) 485 
Public health facility  100.0 5 95.2 (75.7-99.2) 21 96.2 (79.1-99.4) 26 100.0 55 
Private not-for-profit health facility 100.0 3 100.0 1 100.0 4 100.0 10 
Private for-profit outlet 70.8 (53.2-83.8) 24 78.1 (55.8-91.0) 73 76.3 (58.9-87.8) 97 93.6 (88.8-96.4) 420 
Community health worker - 0 0.0 22 0.0 22 - 0 
Kenya – Total 66.0 (42.3-83.7) 124 71.0 (56.7-82.0) 267 68.5 (56.4-78.5) 391 79.7 (73.1-85.0) 1,219 
Public health facility  63.9 (36.4-84.6) 17 85.6 (68.1-94.3) 35 75.4 (58.6-87.0) 52 78.9 (64.4-88.6) 104 
Private not-for-profit health facility 58.7 (33.0-80.3) 3 73.5 (27.0-95.4) 12 68.8 (35.9-89.7) 15 63.7 (45.5-78.6) 43 
Private for-profit outlet 66.6 (37.1-87.0) 104 67.1 (49.7-80.8) 219 66.8 (51.4-79.3) 323 80.6 (73.2-86.4) 1,072 
Community health worker - 0 100.0 1 100.0 1 - 0 
Note: Data from non-remote areas come from the main endline outlet surveys. CI = Confidence interval 
* Data collection period: Ghana: November 7-28, 2011, Kenya: October 7 - December 10, 2011 
** Data collection period: Ghana: March 4-13, 2012, Kenya: February 27 - March 16, 2012 
Source: AMFm Phase 1 Independent Evaluation Endline Outlet Surveys and Remote Area Surveys 
 
Table 5.7.2: Percentage of quality-assured ACTs bearing the AMFm logo in remote areas and non-remote areas at endline, 2011-2012 
Quality-assured ACTs bearing the AMFm logo (n) as a percentage of all antimalarials audited (N) in remote areas and non-remote areas by type of outlet, according to country 
Country/Type of outlet 
Remote areas 
Non-remote areas In endline survey* In additional survey** Total 
Percentage (95% CI) N Percentage (95% CI) N Percentage (95% CI) N Percentage (95% CI) N 
Ghana – Total 97.2 (78.3-99.7) 36 80.1 (49.2-94.4) 161 83.2 (56.6-95.0) 197 91.2 (87.1-94.1) 955 
Public health facility 80.0 (37.1-96.5) 5 84.1 (53.6-96) 44 83.7 (56.8-95.2) 49 93.2 (80.0-97.9) 73 
Private not-for-profit health facility 100.0 4 100.0 1 100.0 5 95.0 (68.8-99.4) 20 
Private for-profit outlet 100.0 27 97.8 (92.1-99.4) 93 98.3 (94.0-99.6) 120 91.0 (86.7-93.9) 862 
Community health worker - 0 0.0 23 0.0 23 - 0 
Kenya – Total 60.6 (46.8-72.8) 140 72.3 (64.0-79.4) 290 66.1 (59.8-71.8) 430 78.1 (70.2-84.3) 1,912 
Public health facility 26.8 (12.4-48.6) 63 56.9 (30.4-80.1) 119 40.3 (25.6, 57.0) 182 56.6 (38.5-73.1) 342 
Private not-for-profit health facility 44.6 (30.3-60.0) 6 52.6 (39.3-65.5) 41 50.9 (40.3-61.3) 47 37.7 (21.5-57.3) 116 
Private for-profit outlet 95.9 (93.2-97.5) 71 92.9 (88.1-95.9) 126 94.6 (91.6-96.6) 197 94.1 (91.9-95.8) 1,454 
Community health worker - 0 100.0 4 100.0 4 - 0 
Note: Data from non-remote areas come from the main endline outlet surveys. CI = Confidence interval 
* Data collection period: Ghana: November 7-28, 2011, Kenya: October 7 -December 10, 2011 
** Data collection period: Ghana: March 4-13, 2012, Kenya: February 27 - March 16, 2012 
Source: AMFm Phase 1 Independent Evaluation Endline Outlet Surveys and Remote Area Surveys 
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5.8 Summary of results 
The remote area studies were conducted only at the endline so no baseline data were 
available to assess changes over time in availability, price and market share of QAACTs in 
these areas. However, using the baseline data from rural areas, we attempted to estimate 
changes in availability, assuming that the baseline estimates for remote areas were likely to 
have been the same or lower than estimates from rural areas. This is a conservative approach, 
but does not imply that baseline estimates from rural areas are statistically comparable with 
those from remote areas at endline. 
 
The results show that QAACTs were widely available in remote areas in both Ghana and 
Kenya at endline. The availability of QAACTs is particularly high in public health facilities 
(96% in each country), but still substantial in private for-profit outlets (66% in Ghana and 
45% in Kenya). Although the availability of QAACTs is lower in remote areas than in non-
remote areas, there has been a substantial increase in availability if we use the level of 
availability in rural areas at baseline as a reference (26% in Ghana and 27% in Kenya). In 
remote areas in both countries, QAACTs had a substantial market share (59% in Ghana and 
48% in Kenya), and this was dominated by QAACTs with the AMFm logo. Overall, the 
findings suggest that the AMFm program has been instrumental in making QAACTs more 
available in remote areas in these two countries. 
 
The median price of QAACTs with the AMFm logo at endline was similar in remote and 
non-remote areas (about USD 1.00 in both areas in Ghana and USD 0.46 in both areas in 
Kenya). These median prices are very much in line with the recommended retail prices of 
USD 0.94 in Ghana and USD 0.46 in Kenya. The median prices of all QAACTs in private 
for-profit facilities in remote areas at endline (USD 1.25 in Ghana and USD 0.81 in Kenya) 
are much lower than the median prices of all QAACTs in rural areas at baseline (USD 2.74 in 
Ghana and USD 2.36 in Kenya). 
 
The availability of diagnostic tests for malaria was very low in both remote and non-remote 
areas in both countries, especially in the private for-profit sector. When the tests were 
available, they were fairly inexpensive; however, due to the small number of cases, the price 
data should be interpreted with caution. 
 
In both countries the majority of providers in the remote areas were able to recognize the 
AMFm logo, suggesting that IEC/BCC efforts were able to reach these areas. The majority of 
QAACTs in remote areas had the AMFm logo. 
 
Despite the challenges in geographical access posed by remote areas, the results suggest that 
the AMFm intervention has been able to reach these areas in Ghana and Kenya. This 
contributed to making QAACTs more available and more affordable in these disadvantaged 
areas. 
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6 Results from the logo study (exit interviews and focus group 
discussions) 
6.1 Exit interviews 
6.1.1 Description of the sample 
Table 6.1.1 shows the number of potential respondents contacted and the number of 
respondents who were interviewed in urban and rural clusters of Ghana, Kenya, Madagascar 
and Nigeria. The response rates indicate the percentage of individuals who participated in the 
study out of those contacted. The number of refusals is remarkably consistent from one 
country to the next (59-95 refusals per country or an average of five refusals per cluster). In a 
few rural clusters, no one who was approached refused to participate. In one rural cluster in 
Madagascar, interviewers were unable to contact more than 40 potential respondents. 
 
Table 6.1.1: Number of individuals contacted by the interviewer and the number who were interviewed by 
urban/rural clusters, according to country, 2012 
Country 
Residence 
Total  Urban Rural 
Contacted Interviewed 
Response 
rate Contacted Interviewed 
Response 
rate Contacted Interviewed 
Response 
rate 
Ghana 332 290 87.3 302 285 94.4 634 575 90.7 
Kenya 323 286 88.5 333 289 86.8 659 575 87.3 
Madagascar 328 292 89.0 262 236 90.1 590 528 89.5 
Nigeria 373 314 84.2 334 298 89.2 707 612 86.6 
Source: AMFm phase 1 Independent Evaluation - Additional Studies - Exit Interviews 
 
Table 6.1.2 shows the distribution of respondents by sex and age group in urban and rural 
clusters. The percentage of respondents who were female was 41% in Nigeria, 48% in Ghana, 
59% in Madagascar and 61% in Kenya. In Kenya and Nigeria, the largest group of 
respondents was age 25-34 years, while in Ghana and Madagascar, the largest group was 
respondents age 35 years and older. The overall number of respondents in the sample was 
lower in Madagascar than elsewhere (n=528) because few people came to the outlets in one 
specific rural cluster. 
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Table 6.1.2: Number of respondents by sex, age and urban/rural cluster, according to country, 2012 
Country, sex and age 
Residence 
Total Urban Rural 
Ghana (Total) 290 285 575 
Sex    
 Male 149 151 300 
 Female 140 134 274 
 Missing  1 0 1 
Age in years    
 <25 62 57 119 
 25-34 102 110 212 
 35+ 117 112 229 
 Missing 9 6 15 
Kenya (Total) 286 289 575 
Sex    
 Male 110 112 222 
 Female 176 177 353 
Age in years    
 <25 41 57 98 
 25-34 149 119 268 
 35+ 94 111 205 
 Missing 2 2 4 
Madagascar (Total) 236 292 528 
Sex    
 Male 100 119 219 
 Female 136 173 309 
Age in years    
 <25 38 50 88 
 25-34 106 103 209 
 35+ 92 139 231 
 Missing 0 0 0 
Nigeria (Total) 314 298 612 
Sex    
 Male 183 178 361 
 Female 131 120 251 
Age in years    
 <25 76 95 171 
 25-34 146 125 271 
 35+ 83 74 157 
 Missing 9 4 13 
Source: AMFm phase 1 Independent Evaluation - Additional Studies - Exit Interviews 
6.1.2 Reasons for choosing a malaria treatment 
Respondents were asked to give a reason for having accepted or purchased the antimalarial 
they had received on their visit to the outlet. Multiple answers were accepted. Table 6.1.3 
shows that in all countries except Nigeria, the most common response was “Doctor/health 
care personnel recommended it” (52% in Madagascar, 49% in Ghana and 43% in Kenya). In 
Nigeria, the most common response was “It is effective” (52%). That answer was also 
common in Kenya (32%) and Madagascar (27%). The response “It is cheap” was mentioned 
by 2% in Ghana, 8% in Madagascar, 16% in Kenya and 26% in Nigeria. Other common 
responses were “I’ve used it before” (Kenya and Nigeria) and “Pharmacist recommended it” 
(Ghana, Kenya and Nigeria). It should be noted that by “Pharmacist” respondents may not 
necessarily mean a trained pharmacist, but it could be a staff member in a drug shop. 
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Table 6.1.3: Reasons for choosing a malaria treatment 
Percentage of respondents stating a specific reason for choosing a particular malaria treatment (n) as a percentage of all 
respondents who received an antimalarial (N), by urban-rural cluster, according to country, 2012 
Country/reason 
Residence 
Total  Urban Rural 
Ghana (Number of respondents) 169 138 307 
 It is free 4.1 4.3 4.2 
 It is cheap 3.0 1.4 2.3 
 It is strong 3.0 1.4 2.3 
 It is effective 21.3 15.2 18.6 
 Pharmacist recommended it 32.5 33.3 32.9 
 Doctor/health personnel recommended it 47.9 50.0 48.9 
 I’ve used it before 1.2 5.1 2.9 
 Friend/relative recommended it 1.8 5.1 3.3 
 Radio/TV 0.0 0.0 0.0 
 Other 2.4 0.7 1.6 
Kenya (Number of respondents) 163 154 317 
 It is free 4.3 5.2 4.7 
 It is cheap 16.0 15.6 15.8 
 It is strong 16.0 9.7 12.9 
 It is effective 28.8 35.7 32.2 
 Pharmacist recommended it 16.6 17.5 17.0 
 Doctor/health personnel recommended it 40.5 46.1 43.2 
 I’ve used it before 28.8 16.9 23.0 
 Friend/relative recommended it 4.3 5.2 4.7 
 Radio/TV 3.1 4.5 3.8 
 Other 3.1 3.9 3.5 
Madagascar (Number of respondents) 147 158 305 
 It is free 1.4 .6 1.0 
 It is cheap 4.8 10.1 7.5 
 It is strong 2.0 1.9 2.0 
 It is effective 27.9 25.3 26.6 
 Pharmacist recommended it 8.8 5.7 7.2 
 Doctor/health personnel recommended it 40.8 62.7 52.1 
 I’ve used it before 3.4 3.2 3.3 
 Friend/relative recommended it 0.7 1.3 1.0 
 Radio/TV 0.0 0.0 0.0 
 Other 19.7 0.6 9.8 
Nigeria (Number of respondents) 143 65 208 
 It is free 2.8 13.8 6.3 
 It is cheap 25.9 26.2 26.0 
 It is strong 11.9 12.3 12.0 
 It is effective 53.1 49.2 51.9 
 Pharmacist recommended it 13.3 12.3 13.0 
 Doctor/health personnel recommended it 10.5 23.1 14.4 
 I’ve used it before 18.2 29.2 21.6 
 Friend/relative recommended it 5.6 13.8 8.2 
 Radio/TV 0.0 0.0 0.0 
 Other 0.0 0.0 0.0 
Source: AMFm phase 1 Independent Evaluation - Additional Studies - Exit Interviews 
6.1.3 Source of information about ACTs 
Respondents were asked to name the medicines they knew about that were used to treat 
malaria in their area. If they did not spontaneously mention any ACT, they were asked if they 
had ever heard of a medicine for malaria called ACTs; those who knew about ACTs were 
asked to cite the source from which they had heard about ACTs most recently. Table 6.1.4 
shows the media sources and locations from which respondents had heard of ACTs most 
recently. The percentage of those who had heard of ACTs ranged from 34% in Nigeria to 
51% in Ghana. Radio was by far the dominant source of information in every country except 
Ghana, with 81% of respondents in Kenya naming radio as their source, and 41% and 40% in 
Nigeria and Madagascar, respectively, naming radio as their source. In Ghana, television was 
more important than radio; 60% of respondents in Ghana named television as their most 
recent source of information about ACTs. Television was cited by 26% of respondents in 
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Madagascar. Only 5-13% of respondents reported finding out about ACTs at a health center 
or clinic. 
 
Table 6.1.4: Source from which respondents had most recently heard of ACTs 
Percentage who mentioned hearing about ACTs from a specific source most recently (n) among respondents who have ever 
heard of ACTs (N), by urban/rural clusters, according to country, 2012 
Country/Source 
Residence 
Total Urban Rural 
Ghana (Number of respondents) 169 123 292 
 Billboard 0.0 0.0 0.0 
 Family/friends 3.6 5.7 4.5 
 Health center/clinic 4.1 4.9 4.5 
 Internet 0.0 0.0 0.0 
 Newspaper/magazine 0.0 0.0 0.0 
 Pharmacy 1.8 4.1 2.7 
 Poster 0.0 .0.8 0.3 
 Public event 1.2 0.0 0.7 
 Radio 23.7 28.5 25.7 
 Television 64.5 54.5 60.3 
 Other 0.0 0.8 0.3 
 Don’t remember 1.2 0.8 1.0 
Kenya (Number of respondents) 128 121 249 
 Billboard 0.0 0.8 0.4 
 Family/friends 0.8 2.5 1.6 
 Health center/clinic 6.3 6.6 6.4 
 Internet 0.0 0.0 0.0 
 Newspaper/magazine 0.8 0.8 0.8 
 Pharmacy 2.3 2.5 2.4 
 Poster 0.0 0.0 0.0 
 Public event 0.8 0.0 0.4 
 Radio 80.5 81.8 81.1 
 Television 7.8 5.0 6.4 
 Other 0.0 0.0 0.0 
 Don’t remember 0.0 0.0 0.0 
Madagascar (Number of respondents) 88 127 215 
 Billboard 0.0 0.0 0.0 
 Family/friends 13.6 3.1 7.4 
 Health center/clinic 20.5 7.1 12.6 
 Internet 0.0 0.0 0.0 
 Newspaper/magazine 0.0 0.0 0.0 
 Pharmacy 1.1 4.7 3.3 
 Poster 0.0 0.0 0.0 
 Public event 9.1 7.9 8.4 
 Radio 47.7 34.6 40.0 
 Television 2.3 41.7 25.6 
 Other 5.7 0.0 2.3 
 Don’t remember 0.0 0.0 0.0 
Nigeria (Number of respondents) 102 106 208 
 Billboard 8.8 4.7 6.7 
 Family/friends 11.8 5.7 8.7 
 Health center/clinic 11.8 10.4 11.1 
 Internet 1.0 0.9 1.0 
 Newspaper/magazine 1.0 0.0 0.5 
 Pharmacy 16.7 11.3 13.9 
 Poster 3.9 1.9 2.9 
 Public event 0.0 0.9 0.5 
 Radio 25.5 55.7 40.9 
 Television 18.6 8.5 13.5 
 Other 1.0 0.0 0.5 
Note: Missing information for Madagascar: Rural: 0.8%; Total: 0.5% 
Source: AMFm phase 1 Independent Evaluation - Additional Studies - Exit Interviews 
 
6.1.4  Knowledge of AMFm logo 
Respondents were asked if they had ever seen the AMFm logo and, if so, whether they had 
ever seen the logo in the outlet they had just visited. Overall, the percentage of respondents 
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who reported they had seen the logo was highest in Ghana (61%), intermediate in Kenya and 
Nigeria (32% each) and lowest in Madagascar (only 9%). 
 
Among respondents who had ever seen the AMFm logo, Table 6.1.5 shows that the majority 
in most of the countries said they had never seen the logo in the outlet or they were not sure 
whether or not they had ever seen the logo in the outlet. The largest percentage of respondent 
who had seen the logo in the outlet they visited was in Nigeria (46%) and Kenya (43%). The 
percentages were much lower in Ghana (27%). Except in Ghana, the logo was much more 
likely to be seen in outlets in urban areas than in rural areas. 
 
Table 6.1.5: Respondents who saw the AMFm logo in the outlet they visited 
Percentage who have ever seen the AMFm logo in the outlet where they were interviewed (n) among 
respondents who have ever seen the AMFm logo (N), by urban/rural clusters, according to country, 2012 
Country 
Residence 
Total Urban Rural 
Ghana (Number of respondents) 193 159 352 
 Seen AMFm logo 20.7 34.0 26.7 
 No/not sure 79.3 66.0 73.3 
Kenya (Number of respondents) 100 82 182 
 Seen AMFm logo 47.0 37.8 42.9 
 No/not sure 53.0 62.2 57.1 
Madagascar (Number of respondents) 3 42 45 
 Seen AMFm logo - - - 
 No/not sure - - - 
Nigeria (Number of respondents) 111 83 194 
 Seen AMFm logo 56.8 32.5 46.4 
 No/not sure 43.2 67.5 53.6 
Note: Percentages for Madagascar are not shown because the number of cases is fewer than 50.  
Source: AMFm phase 1 Independent Evaluation - Additional Studies - Exit Interviews 
 
Table 6.1.6 shows that respondents who came to an outlet to get malaria treatment were 
hardly more likely than all respondents who had seen the AMFm logo to have seen it in the 
outlet. The difference was largest in Kenya (53% of those who came to obtain malaria 
treatment, compared with 43% of all respondents who came to the outlet for any reason). 
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Table 6.1.6: Respondents who saw the AMFm logo in the outlet they visited (among those who visited the outlet to 
obtain an antimalarial) 
Percentage who have ever seen the AMFm logo in the outlet where they were interviewed (n) among 
respondents who have ever seen the AMFm logo and visited the outlet to get malaria treatment (N) by 
urban/rural clusters, according to country, 2012 
Country 
Residence 
Total  Urban Rural 
Ghana (Number of respondents) 108 85 193 
 Seen AMFm logo 27.8 40.0 33.2 
 Not seen/not sure 72.2 60.0 66.8 
Kenya (Number of respondents) 47 43 90 
 Seen AMFm logo 59.6 46.5 53.3 
 Not seen/not sure 40.4 53.5 46.7 
Madagascar (Number of respondents) 3 27 30 
 Seen AMFm logo - - - 
 Not seen/not sure - - - 
Nigeria (Number of respondents) 89 54 143 
 Seen AMFm logo 56.2 38.9 49.7 
 Not seen/not sure 43.8 61.1 50.3 
Note: Percentages for Madagascar are not shown because the number of cases is fewer than 50.  
Source: AMFm phase 1 Independent Evaluation - Additional Studies - Exit Interviews 
 
Table 6.1.7 shows dramatic contrasts by country in the places identified by respondents 
where they had seen the AMFm logo. In Ghana, where 61% of respondents had seen the 
AMFm logo, 60% of those who saw the logo saw it on television. In Kenya, where 32% of 
respondents had seen the logo, the logo was seen mainly on antimalarial drug packages 
(59%), at health centers or clinics (43%) and in pharmacies (33%). Relatively few 
respondents had seen the logo in media other than television. In Nigeria, on the other hand, 
the largest percentage of respondents saw the logo on a billboard (35%).  
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Table 6.1.7: Source from which respondents have ever seen the AMFm logo 
Percentage who saw the logo from specific sources among respondents who have ever seen the AMFm logo, by urban/rural 
clusters, according to country, 2012 
Country 
Residence 
Total Urban Rural 
Ghana (Number of respondents) 193 159 352 
Billboard 2.1 2.5 2.3 
Health center/clinic 11.4 16.4 13.6 
Internet 0.0 0.0 0.0 
Newspaper/magazine 0.5 0.0 0.3 
On antimalarial drug packages 13.0 22.6 17.3 
Pharmacy 20.2 20.8 20.5 
Poster 1.0 4.4 2.6 
Public event 1.0 0.0 0.6 
Television 69.4 48.4 59.9 
Other 2.1 3.1 2.6 
Kenya (Number of respondents) 100 82 182 
Billboard 0.0 1.2 0.5 
Health center/clinic 44.0 41.5 42.9 
Internet 0.0 0.0 0.0 
Newspaper/magazine 4.0 1.2 2.7 
On antimalarial drug packages 60.0 58.5 59.3 
Pharmacy 44.0 19.5 33.0 
Poster 6.0 4.9 5.5 
Public event 0.0 0.0 0.0 
Television 16.0 15.9 15.9 
Other 2.0 4.9 3.3 
Madagascar (Number of respondents) 3 42 45 
Billboard - - - 
Health center/clinic - - - 
Internet - - - 
Newspaper/magazine - - - 
On antimalarial drug packages - - - 
Pharmacy - - - 
Poster - - - 
Public event - - - 
Television - - - 
Other - - - 
Nigeria (Number of respondents) 111 83 194 
Billboard 28.8 42.2 34.5 
Health center/clinic 12.6 6.0 9.8 
Internet 1.8 0.0 1.0 
Newspaper/magazine 0.0 1.2 0.5 
On antimalarial drug packages 0.0 0.0 0.0 
Pharmacy 27.0 18.1 23.2 
Poster 7.2 6.0 6.7 
Public event 0.0 1.2 0.5 
Television 15.3 15.7 15.5 
Other 0.0 7.2 3.1 
Note: Percentages for Madagascar are not shown because the number of cases is fewer than 50.  
Source: AMFm phase 1 Independent Evaluation - Additional Studies - Exit Interviews 
 
6.1.5 Meaning of the AMFm logo 
Respondents were asked about the meaning of the AMFm logo. The associations that 
respondents made with the logo are significant since the promotion of ACTs seeks to create 
an association of the logo with effective and inexpensive antimalarial drugs. Table 6.1.8 
shows the responses of those who reported that they have ever seen the AMFm logo. The 
most common response in Kenya and Nigeria and the second most common response in 
Ghana was that the logo meant "herbal medicine": 46% in Kenya, 41% in Nigeria and 36% in 
Ghana. About one-third of respondents said the logo meant “malaria medicine” (38% in 
Ghana, 31% in Kenya and 35% in Nigeria). In addition, in Nigeria, 28% mentioned “good 
quality malaria medicine” and 21% mentioned ACTs. These results should be interpreted in 
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the context of the timing and reach of the supporting interventions on the logo that varied 
across countries. 
 
Table 6.1.8: Meaning of the AMFm logo: Respondents who have seen the AMFm logo before 
Percentage of respondents stating a specific meaning of the AMFm logo (n) as a percentage of all respondents who reported having seen the 
AMFm logo before (N), by urban-rural cluster, according to country, 2012 
Country/Meaning 
Residence 
Total 
Urban Rural 
Ghana (Number of respondents) 193 159 352 
Malaria medicine 40.9 34.6 38.1 
Good quality malaria medicine 10.4 5.7 8.2 
ACTs 9.3 3.8 6.8 
Good quality ACTs 5.2 2.5 4.0 
Reasonably priced malaria medicine 0.0 0.6 0.3 
Strong medicine 1.6 1.3 1.4 
Herbal medicine 34.2 39.0 36.4 
Don’t know 11.9 14.5 13.1 
Other 6.2 11.3 8.5 
Kenya (Number of respondents) 100 82 182 
Malaria medicine 35.0 26.8 31.3 
Good quality malaria medicine 20.0 11.0 15.9 
ACTs 9.0 12.2 10.4 
Good quality ACTs 3.0 11.0 6.6 
Reasonably priced malaria medicine 13.0 2.4 8.2 
Strong medicine 20.0 20.7 20.3 
Herbal medicine 37.0 56.1 45.6 
Don’t know 3.0 11.0 6.6 
Other 9.0 9.8 9.3 
Madagascar (Number of respondents) 3 42 45 
Malaria medicine - - - 
Good quality malaria medicine - - - 
ACTs - - - 
Good quality ACTs - - - 
Reasonably priced malaria medicine - - - 
Strong medicine - - - 
Herbal medicine - - - 
Don’t know - - - 
Other - - - 
Nigeria (Number of respondents) 111 83 194 
Malaria medicine 34.2 34.9 34.5 
Good quality malaria medicine 30.6 24.1 27.8 
ACTs 16.2 8.4 12.9 
Good quality ACTs 23.4 18.1 21.1 
Reasonably priced malaria medicine 0.0 0.0 0.0 
Strong medicine 19.8 19.3 19.6 
Herbal medicine 52.3 26.5 41.2 
Don’t know 2.7 14.5 7.7 
Other 7.2 4.8 6.2 
Note: Percentages for Madagascar are not shown because the number of cases is fewer than 50.  
Source: AMFm phase 1 Independent Evaluation - Additional Studies - Exit Interviews 
6.1.6 Summary of results from exit interviews 
These findings indicate that the promotion of ACTs as the main treatment for malaria is well 
underway in Kenya, and to a lesser degree in Ghana, but that the situation is much different 
in Nigeria and Madagascar. In Madagascar in particular, few people had heard of ACTs or 
seen the logo. More than half of those who had seen the logo in Madagascar did not know 
what it means, which is not surprising since the supporting interventions on the logo had not 
started in Madagascar by the time of the logo survey. The reliance on the recommendations 
of health care personnel and pharmacists (respondents may have been referring to drug store 
staff) suggests that the promotion of ACTs through those channels will be crucial in 
encouraging the use of ACTs in the future. It should be noted that while this study provides 
interesting insights about the population-level awareness of the AMFm program, the results 
should be interpreted with caution because of the small number and the non-random selection 
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process of participants. The results cannot be generalized to groups other than the 
participants. However, some of the keys issues raised can be the subject of further assessment 
to better understand the implications for the implementation of the AMFm program in these 
countries. 
6.2 Focus group discussions 
It should be noted that the FDGs are only meant to understand and report on perceptions of 
participants about malaria medicines and the AMFm logo, not to measure coverage or 
effectiveness of the awareness compaigns. The following findings should be interpreted 
within this context. 
6.2.1 Description of the sample 
Focus group discussions for the AMFm Phase 1 logo study were conducted in four countries: 
Ghana, Kenya, Nigeria and Madagascar.  
 
Two focus group discussions (FGD) were held in each of the eight clusters in each country. 
The FGD participants were classified by gender, and the clusters were identified as urban or 
rural, since such a classification would increase homogeneity within the groups and because 
the research team thought there might be systematic differences by gender and by residence 
in the way participants discussed these issues. 
6.2.2 Knowledge of treatment of malaria 
The discussion of antimalarial treatments was normally preceded by a brief discussion of 
common symptoms of malaria. The description of symptoms did not vary much within 
groups, between men and women, or from country to country; participants seemed to know 
all too well what malaria felt like. In the discussions of how to treat malaria, participants 
mentioned treatments for fever and treatments for the malaria itself. It was not always 
possible to determine if participants were referring to treatments that were seeking to treat the 
symptoms, the underlying illness, or both. Participants in all groups mentioned treatments 
that could reduce high fever. 
 
Treatments for malaria fall into three categories based on the origin of the medication. First, 
there are herbal medicines, most often leaves boiled so the sick person can drink the water or 
inhale the steam under a cover. Second, there are monotherapies that have been available for 
decades: chloroquine, Nivaquine, quinine, Fansidar, Halfan and related drugs (respondents 
referred to a mix of generic and brand names, and we have reported these directly as 
mentioned by respondents). Recent monotherapies include amodiaquine or artesunate. Third, 
there are ACTs that were known in some clusters but not in others. 
 
The discussions of treatments for malaria, with expectations that individuals may recall the 
names of specific medications, are complicated by three phenomena often mentioned in these 
FGDs. One, we often heard individuals say that they do not know what they were given, 
since they went to the health care provider who gave them the necessary drugs to treat them. 
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Two, participants often referred to specific drugs by their color or by the number of tablets 
included in a full dose. A person will say: “I use the yellow one” or “I use the three by three 
drug” or “I use the 442.” And three, in many group discussions, several persons stated that 
individuals are different; the medicine that works for you may not work for me, which 
complicates any generalization about what people think about the effectiveness of a specific 
drug. 
 
Herbal medicines were often cited as treatments for malaria in Ghana and Nigeria, but were 
rarely cited in Kenya and Madagascar. The consensus position in Madagascar was that when 
one feels malaria symptoms, one needs to consult a community health worker or a nurse or 
doctor at a health center right away. The consensus in most of the FGDs in Ghana was that 
drugs such as chloroquine, Nivaquine and Fansidar are no longer readily available in outlets. 
6.2.3 Knowledge and perceived availability of ACTs 
Participants in focus group discussions were asked about their knowledge and use of ACTs 
and any specific ACTs available in their region. The moderators found that asking about 
different types of ACTs made little sense to people, for the participants in the majority of 
groups did not have a clear concept of what an ACT might be, and thus could not describe 
any types. In one group, they established a contrast between ACTs for infants and ACTs for 
children less than five years of age. Participants often noted that they may have used an ACT 
given or prescribed by a health care provider, but they were not sure whether or not they used 
an ACT since they did not know what they had been given. 
 
In Kenya, some participants in FGDs reported that Coartem and AL were available, while 
other participants mentioned that ACTs were not available. The urban men’s group in Kenya 
reported that they had never heard of ACTs. Participants had heard of ACTs on the radio and 
on television, but they had not yet seen the medicines in shops. Both women’s and men’s 
groups stated that some people take Coartem or AL, and in general, they like them because 
they are effective and have no side effects. People in several groups complained that the 
Coartem pills were too many (24) and they were too large to swallow easily. 
 
Knowledge of ACTs in Nigeria varied greatly from one cluster to another. Six of the 16 
groups reported they knew nothing about ACTs, while in another four, at least one person 
said they knew about using ACTs to treat malaria. The other groups knew about ACTs and 
spoke about using Coartem, a medicine they found was expensive. Participants in several 
groups noted that while they do not know about ACTs, it is possible that doctors had given 
them an ACT without explaining what medicine they had been given. Several groups noted 
that the effectiveness of medicines varied widely with individuals. 
 
In Ghana, only two groups reported that they did not know about ACTs. In one of these 
groups (rural men), participants had a long discussion about whether local medicine or white 
man's medicine was more effective. In half of the clusters, participants were familiar with at 
least one ACT and found the medicine very effective, either artesunate-amodiaquine or 
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artemether-lumefantrine. The former was far more frequently mentioned than the latter. In the 
other groups, participants had seen advertisements on television over the past year or so, but 
were uncertain if the health care provider in health centers had given them an ACT or another 
drug for malaria. Several groups talked about the uncertainty of the price of ACTs, saying 
that they had to pay more than the price advertised, which might be an indication of the 
effects of the demand-shaping levers, given that the data collection for the FGDs occurred in 
February 2012. 
 
The discussions of ACTs in Madagascar showed that five of the 16 groups knew about ACTs 
and used them to treat malaria. The main ACT available was Actipal, although Coartem was 
mentioned in one group. Several groups mentioned that community health workers sold or 
gave out ACTs for malaria. Several other groups reported that Actipal was free at the local 
government health center (Centre de Santé de Base). In half of the groups, most of the 
participants had never used an ACT themselves, but they had seen advertisements for ACTs 
on television several times. One group of rural women and one group of rural men had not 
heard of ACTs. 
6.2.4 Knowledge and perception of the AMFm logo 
After a discussion of the symptoms and treatments of malaria familiar to the participants, and 
sometimes following a discussion of ACTs, the focus group moderator showed the AMFm 
logo to the group and asked if they had seen this image. They were then asked what the logo 
meant or what image the logo brought to mind. 
 
In Kenya, seven of the 16 FGDs said they had never seen the logo, although they had heard 
about it on the radio and/or television. In the other clusters, several individuals had seen the 
logo on medicine displayed in a chemist shop or similar outlet. The most common images 
that the logo suggested were a leaf, a tea leaf and herbal medicine. In one urban cluster, the 
women said the logo might mean cheap medicine for malaria, or government medicine, 
preferred medicine, or good quality medicine. Several groups suggested that the image of a 
mosquito be added to the logo for better comprehension. 
 
The discussion groups in Ghana, with both men and women, all had some participants who 
had seen the logo on television, on billboards, or in chemist shops. In one rural cluster, the 
women said that the logo stands for ACTs; one person in that group stated that she buys the 
medicine when she sees the logo. In an urban cluster, several women noted that while the 
logo suggests herbal medicine to them, they have learned that it refers to malaria treatment. 
People in nearly all the clusters now associate the logo with treatment for malaria. 
 
In Nigeria, in four of the eight female groups and one male group, no one had seen the logo 
before that day. In the 11 other groups, always at least one person, and sometimes several, 
had seen the logo on television and/or had heard of the logo on the radio. In one urban 
cluster, most of the men had seen the logo on television, and one person reported seeing it on 
a box of medicine. The men in that group said the logo suggested herbs or a leaf. Those same 
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men did not understand what was meant by ACTs. FGD participants said the logo suggested 
a leaf or a flower or local herbs to them. It should be noted that some of the participants may 
not have been exposed to any BCC campaigns about the AMFm logo and may not have seen 
the logo previously. Therefore, the perception is not necessarily a reflection of the 
effectiveness of the awareness campaign. 
 
The FGD participants in Madagascar had not often seen the AMFm logo. In five of the eight 
clusters for women, no one had seen the logo to date. Among the clusters with males, three of 
the eight had never seen the logo. For the most part, those who had seen the logo had seen it 
advertised on television. In one urban cluster, more than half the women had seen the logo on 
TV or said they had seen it on drug packaging. In one rural cluster, most of the men had seen 
the logo on television, and they knew about ACTs. One man said the logo goes with the 
ACTs. While many had seen the logo as part of an advertisement on television, or heard 
about it as part of a radio show, very few had yet to try the medication. Most participants 
interpreted/perceived the logo as a leaf, a plant, herbal medicine or nature. In five different 
groups, it was suggested that the image of a mosquito should be on the logo. It should be 
noted that given the low exposure to the AMFm logo and any awareness campaigns, these 
responses should not be seen as a reflection of the effectiveness of these campaigns. 
The reading of the FGD texts in each country was done in sequence to facilitate the 
comparison of male and female groups and urban versus rural groups. No consistent patterns 
were found of difference between men and women or by residence in relation to the 
treatments mentioned, the knowledge of ACTs or the knowledge of the AMFm logo. Overall, 
the discussions of symptoms of malaria and of treatment options were livelier and more 
spontaneous than were discussions of the types of ACTs or knowledge of the logo. 
 
FGD participants in Kenya, Nigeria and Madagascar did not have sufficient familiarity with 
the AMFm logo to form associations between the logo and effective malaria treatment. Only 
in Ghana had nearly all participants seen the logo in advertisements and on billboards and on 
antimalarial drugs. Many had also used the medicine themselves. In several groups, women 
said that while they did not know the name of the medicine, they recognized the logo and that 
was the medicine they had used. 
6.2.5 Summary of the results of the focus group discussions 
It should be noted that the findings of the focus group discussions (FGD) do not necessarily 
address the coverage or effectiveness of the awareness campaigns, but highlight some of the 
social perceptions about malaria medicine and the AMFm logo. The FGD revealed the 
following: 
 
 FGD participants in Madagascar spoke more about the importance of consulting a 
health care professional for malaria treatment than did those from other countries. 
 In all countries, individuals with experience of using ACTs find they are very 
effective in treating malaria. 
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 FGDs revealed a great deal of variation in whether or not participants knew about 
ACTs or had used them themselves. 
 Most participants in these FGDs associate the AMFm logo with leaves or herbal 
medicine, although many of the participants had not seen the logo before, or had not 
been exposed to accompanying communications. In part, this could be the result of 
the late introduction and limited reach of the supporting interventions on the AMFm 
logo, especially in Madagascar and Nigeria. 
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7 Summary of key findings from relevant operational research 
During the Phase 1 timeframe, a number of operational research (OR) studies have been 
conducted alongside AMFm implementation in the pilot countries. These studies offer 
potential insights into the effects of additional or complementary interventions aimed at 
improving malaria case management. They include projects proposed by countries in their 
AMFm applications funded by Global Fund grants, a program of operations research 
commissioned and managed by the Clinton Health Access Initiative (CHAI), research 
conducted by the ACT Consortium that is led by the London School of Hygiene and Tropical 
Medicine and funded by the Bill and Melinda Gates Foundation, and an additional study 
commissioned directly by the Global Fund in response to specific requests and priorities of 
the AMFm Ad Hoc Committee. 
 
The criteria we have applied for including a summary of the results of these studies in this 
report are the following: 
 
1. Studies that report the effectiveness of interventions related to enhancing malaria case 
management in the public or private sectors in the context of AMFm implementation 
in the Phase 1 pilot countries 
 
2. Studies for which endline results were made available to the IE team by May 11, 
2012. 
Only studies from the CHAI OR portfolio were made available by the deadline above. They 
include studies of a number of different interventions aimed at enhancing malaria case 
management. The interventions and key results are summarized in the table below. With the 
exception of the Cambodia subsidy program, these were all implemented at a sufficiently 
small scale that the interventions themselves are unlikely to have influenced the AMFm 
indicators. Note that the Cambodia study has been included in this summary even though 
Cambodia is not an operational AMFm pilot and is not included in the broader Independent 
Evaluation; this is because it has been the site of a national-scale intervention providing 
subsidized ACTs and RDTs through private outlets since 2003 and it offers important 
insights for AMFm implementation. Baseline findings from the Tanzania Remote 
Distribution Incentive Project are included even though no intervention was eventually 
implemented, because the baseline results and consequent decision not to implement the 
intervention provide important data regarding the availability of ACTs in remote areas. 
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Summary of operations research studies 
Country and timeframe Intervention Scale of implementation Research design/methods Key findings 
Tanzania 
February 2011 – January 2012 
(Yadav, Cohen, Alphs et al. 
2012) 
 3 regions initially selected 
(Lindi, Mtwara and Rukwa); 
Lindi dropped from later 
survey rounds due to budget 
constraints. 
Retail audits conducted in all 
Accredited Drug Dispensing Outlets 
(ADDOs) in the selected regions.  
 
Five audit rounds conducted between 
Feb 2011 and Jan 2012. Audits 
recorded availability and price of 
ACTm (QAACTs with AMFm logo). 
 
Principal components analysis was 
used to estimate a remoteness index 
for each ADDO, comprising distance 
to supplier, distance to region‐specific 
major towns, subjective road quality 
classifications assigned by the survey 
teams, altitude of ADDO and 
population in the area surrounding the 
ADDO. The measure was divided into 
quintiles, with the first three quintiles 
taken to be “remote” areas while the 
top two were assumed to be 
“non‐remote” areas. 
Summary: Availability of QAACTs with the AMFm logo increased in both regions over the period of 
study. Availability in remote outlets was slightly lower than in non-remote outlets by round 5, but 
availability in remote outlets was high enough that the plan to introduce an incentive scheme to encourage 
uptake in remote areas was abandoned. 
 
Stocking of ACTm increased over time in both Rukwa and Mtwara. By the fourth survey round, ACTm 
stocking in Mtwara reached over 85% of all ADDOs. Availability in Rukwa continued to rise up until the 
final survey round, reaching over 60% 
 
In Mtwara, ACTm stocking was spatially widespread by the second and third survey rounds. Spatial 
patterns of ACTm stocking in Rukwa were initially concentrated in areas adjacent to Lake Rukwa, 
spreading to the more urbanized areas of Sumbawanga and Mbeya, and by the final round nearly every 
area of the region had at least one ADDO which stocked ACTm.  
 
In all rounds more ADDOs were stocking adult packs of ACTm than child packs; in round 5, fewer than 
30% of ADDOs stocked child packs.  
 
The gap in availability between remote and non-remote outlets decreased substantially over the 5 survey 
rounds, so that by round 5, ACTm was stocked by 61% of remote outlets and 65% of non-remote outlets 
in Rukwa, and by 86% of remote outlets and 95% of non-remote outlets in Mtwara.  
 
There were no significant differences in the price of adult artemether-lumefantrine between between 
remote and non‐remote ADDOs in any audit round.  
Uganda 
March 2011 – April 2012 
(Cohen, Fink et al. n.d.) 
Introduction of 
RDTs in drug 
shops: 
Training, initial 
supply of RDTs 
provided free of 
charge, link to 
wholesaler who 
would re-stock. 
108 shops in 67 villages in 7 
districts in Eastern Uganda 
invited to participate 
Longitudinal study of outlets receiving 
the intervention, with monthly 
monitoring of shops, administrative 
data on RDT sales from wholesaler, 
and monthly household surveys (n=30 
households x 67 villages); follow up 
was over 6 months. 
Summary: Results indicate that drug shop staff can successfully administer RDTs, that there is interest 
among shopkeepers in stocking them, and that use of RDTs provided in drug shops can reduce 
inappropriate antimalarial use. 
 Of 108 shops invited to the training, 92 (85%) attended and successfully completed training. Of 67 
targeted villages, RDTs were available in at least one shop in 59 villages (88%). 
Of 92 shops with trained staff, 56 (61%) restocked RDTs at least once in 6 months. 
Over 6 months, 13,420 RDTs were sold (=2200/month). There was a high variance in RDT sales, with 6 
shops accounting for 40% of volume. 
Median RDT price was USH 1,000 (USD 0.40), a 100% markup on purchase price.  
Compliance with protocols for treatment, storage and waste management was high. 
Intervention has potential to improve targeting: 30% of patients with a positive RDT received an ACT; 
10.5% of those with negative RDT received an ACT. 
Uganda 
November 2010 - August 
2011 
(Cohen, Yavuz and Ward. 
n.d.) 
Effect of RDTs on 
adherence to ACT 
treatment. 
Effect of medicine 
packaging on 
adherence to ACT 
treatment (results 
not yet available) 
Catchment areas of 9 drug 
shops located in and around 
3 small trading centers in the 
east of Luwero district 
Randomized controlled trial. Random 
assignment of treatment (standard 
ACT packaging or specialized 
packaging); random assignment of 
RDTs to purchasers of ACTs; follow-
up surveys of 85% of ACT purchasers 
at their home to determine adherence. 
Summary: The data on effectiveness of packaging on adherence are not yet available.  
Adherence to subsidized ACTs in standard packaging is only modest (65%). Being offered a malaria 
diagnosis via RDT does not appear to affect adherence. 
Among patients who purchased subsidized ACTs in standard AMFm approved packaging, 65% were 
probably adherent (completed entire treatment course, assessed through inspection of blister pack + self-
report during a follow-up visit after 3 days). 
RDT positive patients were adherent in 66% of cases, similar to those not offered a RDT.  
RDT negative patients who nonetheless bought an ACT adhered in 55% of cases, although the difference 
from those not offered an RDT is not significant. 
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Summary of operations research studies, cont. 
Country and timeframe Intervention Scale of implementation Research design/methods Key findings 
Kenya 
May – December 2009 (pre-
AMFm) 
(Cohen et al. 2012; Abdul 
Latif Jameel Poverty Action 
Lab 2012) 
Varying levels of 
subsidy for ACTs 
(92%, 88%, 80%); 
some received 
subsidy for ACTs 
and RDTs (provided 
free, or at 85% 
subsidy) 
Households living near 4 
rural drug shops in Busia, 
Mumias and Samia districts, 
Kenya.   
Randomized controlled trial. 
Households within 4 km of the drug 
shops (n=2,928) were sampled and 
randomly assigned to treatment groups 
(no subsidy, ACT subsidy, RDT 
subsidy and ACT subsidy). A subset 
received a surprise RDT after drug 
shop visit to assess targeting of ACTs 
to patients with malaria parasites. 
Summary: ACT subsidy in drug shops led to increased treatment seeking for malaria, especially for 
children; a shift towards drug shops for treatment; a high rate of overtreatment for adults. A slightly lower 
subsidy did not compromise access for children although it reduced ACT use for adults; targeting of ACTs 
to those with malaria improved when the subsidy level was slightly lower. The RDT subsidy nearly 
doubled the share of illness episodes tested for malaria. 
Households not seeking treatment for fever decreased by 42% (p<0.01). Among literate households, there 
was a shift away from public facilities (from 38% to 24%, p<0.05) and toward drug shops (from 44% to 
65%, p<0.01). Among illiterate households, most were already using the private sector, and the increase, 
from 59% to 66%, was not statistically significant.  
The subsidy increased ACT use more by the poorest households (from 11% to 38%, p<0.01), with a 
smaller and non-significant increase (8 percentage points) for literate-headed households. Among children 
under 18 years, the subsidy increased the share of ill children treated with ACTs from 34% to 47%; and 
among the poorest households, the subsidy increased ACT treatment of ill children from 15% to 44% 
(significance not reported). Overtreatment was uncommon among children (82% of children for whom a 
subsidized ACT was purchased tested positive for malaria). The ACT subsidy led to significant 
overtreatment by adults (only 25% of those who purchased a subsidized ACT tested positive for malaria). 
A slightly lower subsidy reduced ACT treatment by adults, but not for children; a lower subsidy also led to 
improved targeting of ACTs (75% of those purchasing an ACT at 80% and 88% subsidy had malaria, 
compared with only 56% at 92% subsidy, statistical significance not provided).  
The RDT subsidy doubled the share of illness episodes tested for malaria, from 22% to 43%. However, 
non-compliance with the test result was high (49% of those over age 5 who tested negative for malaria 
nonetheless purchased an ACT).   
Cambodia 
2003 onwards (scale-up of 
social marketing) 
October 2010 – February 
2011 (fieldwork for this 
study) 
(Yeung et al. 2011) 
Subsidized ACTs 
and RDTs in the 
private sector 
operating through a 
social marketing 
program, introduced 
in 2000 and scaled 
up to national level 
in 2003 
The subsidy program 
operates at the national level 
(from 2003) 
Mixed methods cross-sectional study 
in 12 health center catchment areas. 
 Individual methods were:  
Census survey of 217 retail drug 
providers; RDT use assessed among 
57 providers in retail drug shops and 
11 village malaria workers; mystery 
shoppers in 211 retail drug shops; 8 
focus group discussions; quality 
testing of RDTs retrieved from 12 
drug shops in 12 different districts; 
temperature and humidity logged 
during RDT transit to 5 provinces and 
under routine storage conditions in 5 
shops 
Summary: The Cambodian experience of widespread availability of subsidized ACTs and RDTs in the 
private sector demonstrates the importance of locating these products within the context of the diversity of 
providers and their health care practices, and the management of fever more generally. 
Uptake of RDTs varied by type of provider (56% of mystery clients presenting with fever were advised to 
receive a blood test among cabinets (small private clinics); only 15% in grocery shops; differences related 
to self-perceived provider roles – “selling” vs. “treating”; Although the quality of RDTs can be 
compromised at multiple points in the distribution chain, temperature and humidity levels were acceptable 
during transit from central to provincial level; excessive temperatures were only observed during the final 
journey to retail shops. Only 55% of retail shops sold RDTs, 83% of these performed RDTs; some 
problems with RDT use were identified (e.g., blood collection, interpretation, and sharps disposal). 
81% of retail shops surveyed sold the social marketing product (AS-MQ), and there were few problems of 
stockouts; some AMT was present, although regulation of AMT was reported to have reduced stocking 
behavior. Registration status was valued by providers, increasing their adherence to the MOH ban on 
AMT, despite limited understanding of the purpose of the ban.  
Treatment practices were influenced by a complex set of contextual and immediate factors. Providers 
tailored medicines to illness, severity, patient condition, preferences and side effects.  
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Summary of operations research studies, cont. 
Country and timeframe Intervention Scale of implementation Research design/methods Key findings 
Ghana 
May – October 2011 
(Goldberg and Fink n.d.) 
Text message 
reminders to 
improve adherence 
to ACT treatment 
Patients recruited from 69 
randomly selected health 
providers (ranging from 
small drug shops to large 
public health facilities) in 
Tamale city (the capital of 
Northern Region). 
Randomized controlled trial. All patients 
who purchased antimalarials from 
selected facilities, living within 30 
minutes drive of the shop, with access to 
personal or shared mobile phone. 
Participants randomized to control or 
treatment group; treatment group divided 
into those receiving “short” and “long” 
reminder messages. Follow-up 
interviews conducted 72 hours after 
enrollment to collect self-reports of 
adherence and pill-count from those who 
retained blister packs.  
Summary: Overall adherence to ACTs is low (58% among the control group). Overall, the intervention 
had no significant effect (adherence was 58% among the control group and 61% among the intervention 
group). The shorter message had a larger effect than the longer message (65.1% adherence vs. 58%), but 
this was still not significant. The effect on children was larger and statistically significant (56% in control 
group vs. 68% in intervention group, p<0.05); and the shorter message was more effective than the longer 
message (74% vs. 62%, p<0.01).  
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These studies cover a range of different types of interventions that have the potential to improve 
malaria case management and targeting of antimalarials, particularly in private sector outlets. 
The interventions include studies which modify the core AMFm intervention by varying the 
subsidy level to examine the impact on both ACT use and targeting; and measures which could 
complement the AMFm subsidy on ACTs, such as providing subsidized RDTs to improve 
targeting of ACTs to those with malaria and increasing treatment adherence through text 
messaging. All of the studies show that such interventions are feasible to implement at a small 
scale (with the exception of the Cambodia study which took place against the backdrop of a 
national level program). However, the evidence on their effectiveness is mixed, and more 
evidence of the effectiveness and cost-effectiveness of such measures in large-scale programs is 
needed. 
 
The studies also provide important background information on the context in which the ACT 
subsidy is being introduced, such as the low level of adherence to ACT treatment (56% among 
children in Ghana (Goldberg and Fink n.d.) and 65% in Uganda (Cohen, Yavuz and Ward n.d.), 
and on the generally high use of ACTs for treatment of non-malarial fevers. These findings on 
background adherence to and targeting of ACTs need to be interpreted in light of the broader 
evidence base which shows relatively poor adherence to and targeting of antimalarials in general. 
A recent review identified 23 studies of adherence to ACTs (Bruxvoort, 2012), most of which 
were undertaken in health facilities or specialized malaria clinics. Many of these were 
undertaken in the context of trials of interventions to improve adherence, or reported adherence 
outcomes along with clinical outcomes. A variety of different definitions of adherence and 
reporting methods were used. The studies which attempted to measure adherence under “real 
life” conditions reported adherence of 64-88% among patients at public health facilities, 
comparable with the levels of adherence observed in the AMFm OR studies. 
 
Similarly, evidence of poor targeting of ACTs to those with malaria parasites found in these 
studies is consistent with existing evidence of the effects of introducing RDTs into health 
facilities. A variety of studies have shown that health care providers continue to prescribe 
antimalarials even in face of a negative RDT in as many as half or more cases (Whitty et al, 
2008); and that a complex set of factors affect providers’ prescribing behaviours, including initial 
training, influence of peers, pressure to conform with patient expettions, and quality of 
diagnostic support for febrile illness (Chandler et al, 2008). Successful deployment of RDTs to 
improve targeting of ACTs will require a comprehensive package of training and support, 
together with a clear understanding of the social and contextual influences on provider behavior 
(Chandler et al, 2010). 
 
The evidence summarized here should also be seen in the context of the broader literature on 
improving malaria case management, which is summarized in review papers such as Goodman et 
al. (2007), Smith et al. (2009) and Wafula and Goodman (2010). These reviews have found that 
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medicine sellers are willing to participate in such interventions and that a range of interventions 
can be effective in improving provider knowledge and treatment practices. These include various 
forms of training; quality assurance programs such as accreditation, franchising and supervision; 
demand generation and consumer information; and adapting medicine packaging. Characteristics 
of successful programs include starting with a careful assessment of the context (including the 
legal and market environment), involving a wide range of stakeholders in the design of the 
interventions, including medicine sellers and central and local governments, and using a mix of 
approaches. The literature also suggests that achieving sustained changes in provider behavior 
requires compatibility between the financial incentives of providers and the desired behavior 
changes.
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8 Success metrics and interpretation 
8.1  Ghana 
The success metrics scorecard for Ghana is shown in Figure 8.1.1. Achievement of the AMFm 
objectives, the supply of AMFm copaid drugs, implementation of supporting interventions, and 
contextual factors that could affect the achievement of the AMFm benchmarks are discussed 
below. 
8.1.1  Achievement of AMFm objectives  
Availability: QAACT availability across all outlets increased by 52 percentage points, from 
31% at baseline to 83% at endline (Benchmark 1). Ghana has therefore easily met the benchmark 
of a 20 percentage point increase in QAACT availability (p<0.0001). There has been no increase 
in availability in the public sector. The largest rise was in private for-profit outlets, which saw an 
increase in QAACT availability of 58 percentage points. QAACT availability increased more in 
rural than in urban areas, resulting in elimination of the urban-rural gap in QAACT availability 
that was observed at baseline among all outlets and in private for-profit outlets. Even in remote 
areas, 78% of all outlets had QAACTs in stock at the time of the remote areas study (96% of 
public health facilities and 68% of private for-profit facilities). Availability of QAACTs with the 
AMFm logo was much higher than that of QAACTs without the logo (80% vs. 13%), although 
there was still relatively high availability of QAACTs without the logo in private for-profit 
health facilities/pharmacies at endline (43% of outlets). Availability of nAT in private for-profit 
outlets decreased by 12 percentage points, from 94% at baseline to 82% at endline. At endline, 
47% of private for-profit outlets still stocked oral AMT. Non-quality-assured ACTs were also 
still prevalent at endline in both public health facilities (63%) and private for-profit outlets 
(67%). Non-quality assured ACTs were more commonly found in urban than in rural outlets. 
 
Price: Dramatic decreases in median QAACT prices were observed between baseline and 
endline. Across all outlets, the median price per AETD fell from USD 3.42 to USD 0.94. In 
public health facilities, the QAACT price fell from USD 2.74 to USD 0.94, while in the private 
for-profit sector, the median price of QAACTs fell from USD 3.42 to USD 1.13, which is 
slightly higher than the RRP of USD 0.94. At endline, QAACTs were slightly more expensive in 
urban than rural areas (USD 1.25 vs. USD 0.94), but no difference in price was observed 
between private for-profit outlets in remote and non-remote areas. Between baseline and endline, 
the price of non-artemisinin therapy increased, from USD 1.03 to USD 1.50 overall, and from 
USD 0.91 to USD 1.31 in private for-profit outlets.  
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Figure 8.1.1: AMFm success metrics scorecard – Ghana 
Availability
Benchmark 1: 20 percentage point increase from baseline in availability of all QAACTS
Percentage point change, 95% CI for change and p-value for test that QAACT availability is at least 
20 percentage points higher, by type of outlet
Type of outlet
Baseline 
(%)
Endline
(%)
Change
(95% CI) p
Public health facility
Private for-profit outlet
86.2
24.8
80.7
82.6
-5.5 (-14.5-3.5)
57.8 (51.7-63.8)
np
<0.0001
Total* 30.7 82.7 51.9 (46.2-57.7) <0.0001
Price
Benchmark 2: Median price of QAACTs with the AMFm logo is less than 3 times the median 
price of the most popular  antimalarial that is not a QAACT, in tablet form**
Ratio of medians, 95% CI for ratio, p-value for test that ratio is < 3, in private for-profit outlets only 
Median price of 
QAACTs with 
logo
Median price 
of most 
popular non-
QAACT
Ratio 
(95% CI) p
Private for-profit outlet USD 0.94 USD 0.31 3.0 (2.9-3.2) 0.8127
Benchmark 3: Median price of QAACTs with the AMFm logo is less the median price of AMT 
tablets
Difference in prices in USD (QAACT – AMT), 95% CI for difference, p-value for test that difference is 
negative, in private for-profit outlets only 
Median price of 
QAACTs with logo
Median price 
of AMT
Difference 
(95% CI) p
Private for-profit outlet USD 0.94 USD 1.88 -0.94 
(-0.95 - -0.93)
<0.0001
Use
Benchmark 4: 5-10 percentage point increase from baseline in percentage of children under 
age 5 years with fever in the last 2 weeks who received ACT treatment
Percentage point change and p-value for t-test that use is at least 5 percentage points higher 
Baseline 
(%)
Endline
(%)
Change
(95% CI) p
Children under 5 years 21.5 na na na
Market share
Benchmark 5: 10-15 percentage point increase from baseline in the market share of all 
QAACTs
Percentage point change, 95% CI and p-value for test that market share of QAACTs is at least 10 
percentage points higher, by type of outlet
Baseline 
(%)
Endline
(%)
Change
(95% CI) p
Public health facility
Private for-profit outlet
45.6
6.5
69.0
51.8
23.3 (7.5-39.1)
45.3 (40.3-50.4)
0.0490
<0.0001
Total* 17.3 57.6 40.3 (33.0 -47.6) <0.0001
Benchmark 6: Decrease in market share of oral AMTs 
Percentage point change in market share, 95% CI for change and p-value for test that change is
negative, by type of outlet
Type of outlet
Baseline 
(%)
Endline
(%)
Change
(95% CI) p
Public health facility
Private for-profit outlet
1.1
5.0
0.1
3.5
-1.0 (-2.6-0.5)
-1.5 (-3.4-0.5)
0.0979
0.0676
Total* 3.6 2.5 -1.1 (-2.5-0.3) 0.0593
Notes: Green shading = benchmark was achieved, with strong statistical evidence (generally p<0.01); Amber shading = either benchmark was nearly, but not fully, met, or the evidence that the change seen was
unlikely to be due to chance is weak (p≥0.05); Red shading = benchmark was not met ; Grey shading for Benchmarks 3 and 6 = metrics are not relevant because the number of AMT products was very low at
baseline. ACT = Artemisinin-based combination therapy; AMT = Artemisinin monotherapy; CI = Confidence interval; RRP = Recommended Retail Price; na = not available; np = not presented because
availability exceeded 80 percent at baseline; QAACT = Quality-assured artemisinin-based combination therapy; SI = Supporting intervention; * Total includes CHWs and private not-for-profit facilities that are
not shown separately; ** The most popular antimalarial in tablet form that was not a QAACT in the private for-profit sector in Ghana was SP.
Further results
QAACT price in private for-profit outlets fell from USD 3.42  at baseline to  USD 1.13  at endline
(USD 1.25 in urban areas, USD 0.94 in rural areas).  The median price of QAACTs with the AMFm
logo was the same as the RRP of USD 0.94 (2010 prices) for an adult dose. 
QAACT availability in all outlets increased  by 36 percentage points in urban areas and 53 percentage 
points in rural areas, effectively closing the urban/rural gap in availability at endline.
QAACT market share was very similar in urban and rural outlets at endline.
Private for-profit outlets were responsible for 71% of all antimalarial sales at endline.
Process and context data
The AMFm agreement was signed on July 14 , 2010, and the first copaid drugs arrived in August 
2010 (15.5 months before endline). 
SIs including mass communication started in February 2011 giving 9 months of effective 
implementation before baseline.  Global Fund demand levers meant that only 27% of orders were 
approved in second half of 2011. Contextual factors include LLIN distribution concurrent with 
AMFm implementation (5 million nets distributed by the end of 2011).
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The median price in private for-profit outlets for a QAACT carrying the AMFm logo was USD 
0.94 per AETD. This is 3.0 times the median price of the most popular antimalarial which is not 
a QAACT in tablet form (SP), and therefore Ghana appears to have just missed Benchmark 2, 
which states that the ratio should be less than 3. The price of copaid QAACTs in the private for-
profit sector was lower than that of AMT tablets (USD 1.88), meaning that Benchmark 3was 
comfortably met. In fact, the median price for copaid QAACTs in the private for-profit sector 
was only half as high as the median price for tablets. The median price of QAACTs without the 
AMFm logo was still very high at endline – USD 6.88 across all sectors and USD 7.51 in private 
for-profit outlets. There was very little change in the price of non-quality assured QAACTs 
between baseline and endline, when they were USD 3.44 across all outlets and USD 3.50 in 
private for-profit outlets. The gross percentage markup on QAACTs, measured among private 
for-profit outlets, increased from 33% to 50% between baseline and endline. However, with the 
large decrease in the median price of QAACTs, this amounts to a much smaller absolute markup 
at endline. The average markup was the same in remote and non-remote areas. The gross 
percentage markup in private for-profit outlets at endline was higher on copaid than on non-
copaid QAACTS (50% vs. 36%), but again, because of the very large differences in the price of 
these products, the absolute markup on copaid QAACTs was much lower. As a comparator, the 
median gross percentage markup on nAT in the private for-profit sector was the same as for 
QAACTs (50%). The median total markup from the first line buyer price to the retail price in 
private for-profit outlets was USD 0.87. 
 
Market share: The market share of QAACTs has more than tripled overall, from 17% to 58% of 
all antimalarials sold/distributed in the week preceding the survey. There was no difference in 
the market share between urban and rural areas, and QAACT market share reached the same 
level in remote and non-remote areas. Benchmark 5 of a 10 percentage point increase in market 
share from baseline to endline has easily been achieved overall, with a 40 percentage point 
increase (p<0.0001); it has also been met in each sector individually (with percentage point 
increases ranging from 23 to 61). The market share of oral AMTs was very low at baseline (4% 
in all types of outlets combined) and has remained very low at endline (3%). The decrease 
between baseline and endline (Benchmark 6) is of borderline statistical significance (p=0.06 for a 
test that the change was negative), but the relevance of this benchmark to Ghana is questionable 
given the low share for oral AMTs at baseline. 
 
In the public and private non-profit sectors, the gain in QAACT market share was primarily due 
to a shift from non-quality assured ACT to QAACTs; while in private for-profit facilities, the 
main shift was from nAT to QAACTs, with a 45 percentage point increase in the QAACT 
market share and a 32 percentage point decrease in the nAT market share. This is consistent with 
QAACTs displacing nAT in the private sector. QAACTs with the AMFm logo accounted for 
97% of all QAACTs sold or distributed, across all outlets and private for-profit outlets. 
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The private for-profit sector was responsible for at least two-thirds of all antimalarials sold or 
distributed at baseline and endline, with a higher market share at endline in urban areas than rural 
areas (76% vs. 57%). 
8.1.2  Supply of AMFm copaid drugs  
A total of 32 private for-profit FLBs were registered with the Global Fund as of January 31, 
2012, and orders were placed by 14 of these private for-profit FLBs by December 2011. The 
Ministry of Health also registered as a public sector FLB, as did the Church Health Association 
of Ghana (CHAG), a private not-for-profit organization. The first orders for copaid QAACTs 
were placed in July 2010 by a private for-profit FLB and were delivered in August 2010. 
Distribution of these drugs did not begin until after the end of baseline data collection. Early 
problems with import procedures were resolved quickly, and a waiver was granted by the 
Ministry of Finance allowing taxes to be calculated on the FLB price rather than the market 
value of the drugs. 
 
The first public sector FLB orders were placed only in July 2011 and were delivered in October 
2011. The country case study indicates that this was because the Central Medical Stores (CMS) 
still held significant quantities of non-copaid ACTs ordered in 2010. Delays occurred in the 
procurement and delivery of public sector QAACT orders, and both the public sector and private 
not-for-profit providers were reported to have purchased QAACTs from private for-profit FLBs. 
Eighty-four percent of all public health facilities (including those without antimalarials in stock 
on the day of the interview) had QAACTS in stock at baseline, falling to 78% at endline (the 
change is borderline statistically significant). The private not-for-profit FLB had not placed an 
order by the end of 2011. 
 
Stockouts of QAACTs along the private sector distribution chain were reported at the time of 
endline data collection as a consequence of the exercise of the Global Fund “demand levers,” and 
some FLBs reported that they were considering restocking non-copaid ACTs to meet demand. 
As indicated in Table 1.2.2 only 27% of QAACTs requested by private sector FLBs were 
approved by the Global Fund in Q3 and Q4 of 2011. Delivery times were reported to have 
increased from eight weeks at the start of AMFm to as long as seven months. 
 
A total of 24,673,726 copaid QAACT treatments were delivered between July 2010 and 
December 2011, amounting to 1.01 treatments per capita (the whole population of Ghana is 
considered at risk of malaria), of which 95% (0.95 treatments per capita) were delivered to 
private for-profit FLBs. A total of 15.5 months elapsed between the date the first drugs arrived in 
Ghana (August 2010) and the midpoint of endline outlet survey fieldwork. Supporting 
interventions started in February 2011, giving only 9 months of effective SI implementation. 
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8.1.3  Implementation of supporting interventions  
A total of USD 22,042,722 was available through the Global Fund for SIs at the time of grant 
signing (this does not take into account interventions funded through other programs). As of 
November 2011, USD 10,312,120 had been disbursed, giving a per capita disbursement on SIs of 
USD 0.42. The commencement of SIs trailed the arrival of drugs in Ghana by approximately six 
months. Supporting interventions included communications, training of 12,000 health workers 
from the public and private sectors and some pharmacovigilance activities. Two operational 
research studies took place, but these were on a limited scale and therefore unlikely to have 
influenced AMFm outcomes.  
 
The RRP of USD 0.94 for an adult dose did not appear on the packaging of copaid QAACTS, 
but was widely promoted in media campaigns and by the Pharmaceutical Society of Ghana to its 
members. It seems likely that the RRP was a significant factor in “anchoring” the price of 
QAACTs in Ghana. Provider awareness of the RRP was high (84%), with higher awareness in 
urban than in rural areas (91% vs. 73%). Of those who were aware of the RRP, 92% stated its 
correct level (95% in urban areas and 87% in rural areas). 
 
Provider knowledge of the AMFm program was high, at 76% overall. Knowledge exceeded 85% 
in the public sector and in private for-profit health facilities/pharmacies. Over 50% of 
respondents stated that they had received some training on antimalarials with the AMFm logo, 
including 45% of private for-profit health facility/pharmacies and 60% of public health facilities. 
There was an increase in provider knowledge of the first line drug, with increases among private 
for-profit health facilities/pharmacies (8 percentage points, from 89% to 97%), and drug stores (9 
percentage points, from 71% to 80%. The latter increase was only marginally significant). 
 
Between baseline and endline there was a significant decrease in the responses “too expensive” 
(29% to 5%) and “my customers do not ask for them” (42% to 17%) as reasons for not stocking 
QAACTs among private for-profit providers.  
 
There was a very high level of provider recognition of the AMFm logo at endline (93% overall 
and uniformly high across all sectors), although recognition was lower in rural than in urban 
areas (87% vs. 97%). Even in remote areas, 69% of providers reported that they had seen the 
logo. Of those recognizing the logo, 62% said it meant an effective/quality antimalarial, and 50% 
said it was an affordable antimalarial. Nine percent of respondents did not know what it meant. 
Logo recognition among the general population was lower, with 61% of exit survey respondents 
reporting that they had seen the logo. Television was the most common source cited. Of those 
who had seen the logo, 38% associated it with malaria medicine and 36% associated it with 
herbal medicine.  
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8.1.4  Context  
A variety of taxes and duties are levied on imported antimalarials (other than quinine products 
which are exempt from all taxes). These are levied on the value of the commodity (the FLB price 
in the case of copaid QAACTs) plus shipping and insurance costs. In contrast, active 
pharmaceutical ingredient imported for use in locally manufactured nATs is tax exempt.  
 
The period of pilot implementation was one of economic and political stability. Other programs 
supporting AMFm outcomes, such as home-based care, did not operate through the private 
sector, and they are unlikely to have affected availability and market share in these outlets. There 
was no increase in the availability of diagnostics between baseline and endline; and the 
availability of RDTs in public health facilities decreased from 59% to 32% (p<0.05). Mass 
distribution of LLINs took place during the AMFm pilot period, with 5 million nets distributed 
by the end of 2011. The National Health Insurance Scheme covers approximately 65% of 
outpatient service users in the public and private not-for-profit sectors, and the reimbursement 
rate for malaria treatment was reduced to encourage people to obtain copaid ACTs. ACTs had 
over-the-counter status. 
8.1.5  Summary 
Copaid QAACTs were available in Ghana for 15.5 months before the endline outlet survey, 
although supporting interventions were only implemented for 9 months before the survey. There 
is strong evidence that Ghana has met Success Benchmarks 1 (QAACT availability) and 5 
(QAACT market share). The results for Benchmark 2 (QAACT price relative to the most popular 
antimalarial which is not a QAACT in tablet form suggest Ghana just missed the threshold; and 
the decrease in oral AMT market share (Benchmark 6) is of borderline statistical significance. 
However, the oral AMT market share was at a very low level (2.5%), despite relatively high 
availability in private for-profit outlets. The evidence about impressive changes in the 
availability and price of QAACTs, together with strong evidence of increased knowledge and 
awareness, the flow of copaid drug orders and the evidence on SI implementation, provide 
plausible evidence that AMFm is responsible for the substantial increase observed in QAACT 
market share. The high levels of availability and market share in remote areas underline the 
success of AMFm in reaching more vulnerable populations. These changes occurred despite the 
implementation of the Global Fund’s demand levers, which substantially reduced the share of 
orders requested that were approved in the last 2 quarters of 2011. These changes are unlikely to 
be due to other contextual factors. The decrease in the market share of nAT in private for-profit 
outlets is consistent with AMFm crowding out nATs and not simply shifting demand from other 
ACTs. Although there was a large decrease in the price of QAACTs, the price benchmark 
appears just to have been missed. This may be because the relatively high RRP is acting as a 
floor for the QAACT price, and stopping it from falling below this level. This could also be due 
to the very low price of the most popular antimalarial which is not a QAACT (USD 0.31 for 
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tablets and all dosage forms), making this quite a difficult benchmark to reach. Differential tax 
treatment of imported medicines compared with locally produced drugs may have further 
contributed to the large difference between the price of QAACTs and SP. 
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8.2 Kenya  
The success metrics scorecard for Kenya is shown in Figure 8.2.1. Achievement of the AMFm 
objectives, the supply of AMFm copaid drugs, implementation of supporting interventions, and 
contextual factors that could affect the achievement of the AMFm benchmarks are discussed 
below. 
8.2.1  Achievement of AMFm objectives  
Availability: QAACT availability across all outlets increased by 34 percentage points, from 
32% at baseline to 66% at endline (Benchmark 1). Kenya has therefore easily met the benchmark 
of a 20 percentage point increase in QAACT availability (p=0.0007). Substantial increases were 
seen in both urban and rural areas (28 and 36 percentage points, respectively). Even in remote 
areas, QAACTs were available in 56% of outlets at the time of the remote areas study. The 
largest increase was in private for-profit outlets, which saw an increase in QAACT availability of 
39 percentage points. At endline, in the public and private not-for-profit sectors, availability of 
QAACTs with and without the AMFm logo was very similar, but in the private for-profit sector, 
availability of QAACTs with the logo was 59% compared with only 5% for QAACTs without 
the logo. QAACTs with the logo had also substantially penetrated remote areas, with 45% of 
private for-profit outlets stocking them. Availability of nATs fell significantly, from 91% to 81% 
overall and from 93% to 77% in private for-profit outlets. 
 
Price: The median price of QAACTs in the private for-profit sector fell dramatically between 
baseline and endline, from USD 2.63 per AETD to USD 0.58, although the endline median price 
was still somewhat higher than the RRP of USD 0.46. There were significant falls in both urban 
and rural areas, although prices remained slightly higher in urban areas at endline (USD 0.61 
versus USD 0.46 in rural areas). In the public and private not-for-profit sectors, the median price 
remained USD 0.00 at baseline and endline, reflecting the policy of free ACT provision. Due to 
an increase in sales in the private for-profit sector, the overall median price rose from USD 0.00 
to USD 0.46.  
 
The median price at endline for a QAACT with the AMFm logo was USD 0.46 per AETD 
overall (exactly equal to the RRP) and USD 0.52 in the private for-profit sector. Prices were 
slightly higher in remote than non-remote areas (USD 0.69 vs. USD 0.46), although the remote 
areas study took place four months after the endline outlet survey when the Global Fund’s 
demand levers may have placed upward pressure on QAACT prices. The median among private 
for-profit outlets is exactly equal to the median price of the most popular antimalarial which is 
not a QAACT (SP) in private for-profit outlets, whether this is measured in tablet form or among 
all dosage types, therefore Kenya comfortably met pricing Benchmark 2. It was not possible to 
compute Benchmark 3 for Kenya, as the number of AMT products audited at endline was fewer 
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than 50. By contrast, there was no significant change in the price of non-quality assured ACTs in 
the private for-profit sector between baseline (USD 7.00) and endline (USD 6.91). Of providers 
not stocking QAACTs, the percentage who said this was due to their high price fell substantially, 
from 28% at baseline to 11% at endline. 
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Figure 8.2.1: AMFm success metrics scorecard – Kenya 
Availability
Benchmark 1: 20 percentage point increase from baseline in availability of all QAACTS
Percentage point change, 95% CI for change and p-value for test that QAACT availability is at least 
20 percentage points higher, by type of outlet
Type of outlet
Baseline 
(%)
Endline
(%)
Change
(95% CI) p
Public health facility
Private for-profit outlet
87.5
21.2
97.0
60.2
9.5 (0.7-18.3)
38.9 (29.7-48.2)
np
<0.0001
Total* 31.2 65.8 34.6 (25.8-43.4) 0.0007
Price
Benchmark 2: Median price of QAACTs with the AMFm logo is less than 3 times the median 
price of the most popular  antimalarial that is not a QAACT , in tablet form**
Ratio of medians, 95% CI for ratio, p-value for test that ratio is < 3, in private for-profit outlets only 
Median price of 
QAACTs with 
logo
Median price 
of most 
popular non-
QAACT
Ratio 
(95% CI) p
Private for-profit outlet USD 0.52 USD 0.52 1.0 (0.6-1.5) <0.0001
Benchmark 3: Median price of QAACTs with the AMFm logo is less the median price of AMT 
tablets
Difference in prices in USD (QAACT – AMT), 95% CI for difference, p-value for test that difference is 
negative, in private for-profit outlets only 
Median price of 
QAACTs with 
logo
Median price 
of AMT
Difference 
(95% CI) p
Private for-profit outlet USD 0.52 ns ns ns
Use
Benchmark 4: 5-10 percentage point increase from baseline in percentage of children under 
age 5 years with fever in the last 2 weeks who received ACT treatment
Percentage point change and p-value for t-test that use is at least 5 percentage points higher 
Baseline 
(%)
Endline
(%)
Change
(95% CI) p
Children under 5 years 18.0 na na na
Market share
Benchmark 5: 10-15 percentage point increase from baseline in the market share of all 
QAACTs
Percentage point change, 95% CI and p-value for test that market share of QAACTs is at least 10
percentage points higher, by type of outlet
Baseline 
(%)
Endline
(%)
Change
(95% CI) p
Public health facility
Private for-profit outlet
60.0
12.1
47.6
61.4
-12.4 (-52.8-27.9)
49.3 (39.5-59.1)
0.8636
<0.0001
Total* 25.8 57.1 31.3 (12.7-49.9) 0.0125
Benchmark 6: Decrease in market share of oral AMTs 
Percentage point change in market share, 95% CI for change and p-value for test that change is
negative, by type of outlet
Type of outlet
Baseline 
(%)
Endline
(%)
Change
(95% CI) p
Public health facility
Private for-profit outlet
0.0
1.4
0.0
0.1
0.0
-1.3 (-2.8-0.2)
0.9790
0.0407
Total* 0.9 0.0 -0.9 (-2.0-0.2) 0.0603
Notes: Green shading = benchmark was achieved, with strong statistical evidence (generally p<0.01); Amber shading = either benchmark was nearly, but not fully, met, or the evidence that the change seen was
unlikely to be due to chance is weak (p≥0.05); Red shading = benchmark was not met ; Grey shading for Benchmarks 3 and 6 = metrics are not relevant because the number of AMT products was very low at
baseline. ACT = Artemisinin-based combination therapy; AMT = Artemisinin monotherapy; CI = Confidence interval; RRP = Recommended Retail Price; na = not available; np = not presented because
availability exceeded 80 percent at baseline; ns = not shown because the number of observations for either baseline or endline is fewer than 50 outlets/products (availability/price) or fewer than 500 AETDs
(market share); QAACT = Quality-assured artemisinin-based combination therapy; SI = Supporting intervention; * Total includes CHWs and private not-for-profit facilities that are not shown separately;
** The most popular antimalarial in tablet form that was not a QAACT in the private for-profit sector in Kenya was SP.
Further results
QAACT price in private for-profit outlets fell from USD 3.42 at baseline to USD 1.13 at endline
(USD 1.25 in urban areas, USD 0.94 in rural areas). The median price of QAACTs with the AMFm
logo is the same as the RRP of USD 0.94 (2010 prices) for an adult dose.
QAACT availability in all outlets increased by 36 percentage points in urban areas and 53 percentage
points in rural areas, effectively closing the urban/rural gap in availability at endline.
QAACT market share was very similar in urban and rural outlets at endline.
Private for-profit outlets were responsible for 71% of all antimalarial sales at endline.
Process and context data
The AMFm agreement was signed on July 14 , 2010 and the first copaid drugs arrived in August
2010 (15.5 months before endline). During Q3 and Q4, only 56% of treatments requested by
private for-profit buyers were approved, due to Global Fund demand management.
SIs including mass communication started in February 2011 giving 9 months of effective
implementation before baseline. Contextual factors included an emergency response to a predicted
malaria epidemic which did not arise; mass distribution of LLINs, depreciation of Kenya shilling;
high level political support for AMFm.
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The gross percentage markup on QAACTs, measured among private for-profit outlets, increased 
slightly from 40% to 48% between baseline and endline, although with the large decrease in the 
median price of QAACTs, this amounts to a much smaller absolute markup at endline. The gross 
percentage markup in private for-profit outlets at endline was higher on QAACTs with the logo 
than on QAACTs without the logo (50% vs. 40%), but again, because of the large differences in 
the price of these products, the absolute markup on copaid QAACTs was much lower. Markups 
on QAACTs were the same in remote and non-remote areas. As a comparator, the gross 
percentage markup on non-artemisinin therapy (nAT) in the private for-profit sector was very 
similar across the two periods, at 48% and 50% respectively, and very similar to that of 
QAACTS at endline. The median total markup from first line buyer price to retail price in private 
for-profit outlets was low, at only USD 0.40. 
 
Market share: Market share of QAACTs has increased overall from 26% to 57% of all 
antimalarials sold/distributed in the week preceding the survey, with similar increases in urban 
and rural areas. Benchmark 5 of a 10 percentage point increase in market share from baseline to 
endline was achieved overall (p=0.01) and within the private for-profit (p<0.0001) and private 
not-for-profit sectors (p=0.002). Surprisingly, there is some evidence that QAACT market share 
fell in the public sector, although the decrease was not significant. Even in remote areas, 
QAACT market share was 48% among all outlets (77% in public health facilities and 40% in 
private for-profit outlets). Overall market share of oral AMTs was negligible at baseline (0.9%) 
and almost zero at endline (0.05%) (p=0.06 for Benchmark 6 that the change was negative, 
although this benchmark is not relevant in the context of such low oral AMT sales at baseline). 
 
In the private for-profit and private not-for-profit sectors, the gain in QAACT market share was 
accompanied by a decrease in the market share of nAT (falls in nAT market share of 44 and 49 
percentage points, respectively); there was also some indication of a reduction in the market 
share of non-quality-assured ACTs in urban areas.  
 
At endline, QAACTs with the AMFm logo accounted for 88% of all QAACTS dispensed overall 
and 97% of all QAACTs dispensed in the private for-profit sector. 
 
The private for-profit sector was responsible for 67% of all antimalarials sold or distributed at 
baseline, accounting for 79% and 63% in urban and rural areas, respectively. At endline, the 
share in urban areas had further risen to 89%, but in rural areas the share had fallen to 52%, 
giving an overall endline share of 62%. 
 
8.2.2  Supply of AMFm copaid drugs 
Seven private sector FLBs registered and established relationships with manufacturers, and the 
FLB for the public sector was the Kenya Medical Supplies Agency (KEMSA). Orders were 
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placed with six of these private for-profit FLBs by December 2011. The first orders for copaid 
QAACTs were placed in July 2010 by a private for-profit FLB and delivered in August 2010. 
The first public sector orders were placed in April 2011 and delivered from June 2011, in several 
batches. Public sector facility stockouts were not reported except for a four-week period in July 
and August 2011. This was corroborated by the finding that at endline 94% of all public facilities 
had QAACTs in stock, compared with only 80% of public facilities at baseline. Some delays 
were reported in deliveries from manufacturers to FLB, and the Global Fund “demand levers” 
were said to have slowed down approval of orders from August 2011. During Q3 and Q4 of 
2011, only 56% of treatments requested by private for-profit and private not-for-profit FLBs 
were approved by the Global Fund, as a result of the exercise of the demand management 
process (see Table 1.2.2). Between August 2010 and the end of December 2011, a total of 14.1 
million treatment doses had been received by private sector FLBs, and between June 2010 and 
the end of 2011, 14.3 million were received by the public sector, amounting to a total of 0.9 
treatments per person at risk of malaria (76% of the Kenyan population are considered at risk).  
 
There were no major issues reported in the registration of FLBs, the determination of order 
quantities or customs clearance, although at first there was some confusion as to whether 
customs levies should be charged on the full or subsidized price of copaid ACTs.  
 
The first copaid drugs arrived in Kenya in August 2010, with a national launch in the same 
month (see below), but baseline outlet survey data collection was conducted from September to 
November 2010. By the end of baseline data collection, 1,613,600 copaid treatments had arrived 
in Kenya. This implies that some of the indicators may capture limited AMFm implementation at 
baseline, meaning that the achievements in terms of QAACT availability, price and market share 
may have been somewhat under-estimated. A total of 15 months elapsed between the date the 
first drugs arrived in Kenya and the midpoint of endline outlet survey fieldwork. 
8.2.3  Implementation of supporting interventions 
A total of USD 16,571,492 was available through the Global Fund for SIs at the time of grant 
signing (this does not take into account interventions funded through other programs). As at 
November 2011, USD 7,426,298 had been disbursed, giving a per capita disbursement on SIs of 
USD 0.18. Although a national launch was conducted in August 2010, the start of most SIs 
trailed the arrival of drugs in Kenya by approximately six months starting in February 2011, 
giving only 9 months of effective SI implementation. The main supporting intervention was an 
IEC/BCC campaign. Training was also planned, although by December 2011 only 733 private 
sector health workers had been trained. During the endline outlet survey, 12% of respondents in 
private for-profit outlets said they had received some training on antimalarials with the AMFm 
logo. Pharmacovigilance activities were also conducted, but no operational research had taken 
place by December 2011. The RRP of USD 0.46 for all pack sizes did not appear on the 
packaging of copaid QAACTS, but was widely promoted in media campaigns, and appears to 
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have had an important influence on retail prices. Provider awareness of the RRP was high during 
the endline outlet survey (72% of providers), especially in private for-profit health facilities and 
pharmacies (82%) and drug stores (93%). Of those who were aware of the RRP, 95% stated its 
correct level.  
 
There was a significant increase in provider knowledge of the first-line antimalarial; this was 
already almost universal at baseline among public and private not-for-profit providers, but 
among private for-profit providers it increased from 45% to 66%.  
 
Provider recognition of the AMFm logo rose from 19% at baseline to 77% at endline. Even in 
remote areas, 69% of providers had seen the logo. Of those recognizing the logo, 29% said it 
meant an effective/quality antimalarial, 25% an ACT and 16% an affordable antimalarial. One-
quarter of respondents did not know what it meant. Provider knowledge of the AMFm program 
was 58%, with no significant differences across sectors. Logo recognition was lower among 
people exiting outlets, as only 32% reported that they had seen the logo, although 81% 
respondents in Kenya heard about ACTs on the radio. The most common sources for seeing the 
logo were drug packaging, a health center/clinic and a pharmacy. 
8.2.4  Context 
Two other initiatives may have contributed to QAACT availability in the public sector: ACT 
provision through the President’s Malaria Initiative (PMI) and emergency provision of 
antimalarials to parts of Kenya in preparation for a predicted epidemic in late 2011 (although the 
epidemic did not materialize). The ban on artemisinin monotherapies since 2006 is also thought 
to have provided an environment conducive to expansion of QAACT market share. Mass 
distribution of long-lasting insecticidal nets (LLINs) may have reduced antimalarial demand to 
some degree. There were no significant changes in the availability of diagnostics between 
baseline and endline. There was a substantial depreciation of the Kenya shilling between baseline 
and endline outlet surveys, but this was not thought to have had a major impact on QAACT 
prices. Political support for AMFm is reported to have been high. ACTs did not have over-the-
counter status. 
8.2.5  Summary 
There is strong evidence that Kenya has met Success Benchmark 1 on QAACT availability, 2 on 
price, and 5 on market share. Data are not available to assess Benchmark 4 on use, and 
Benchmark 6 on decrease in AMT market share is not relevant given the negligible AMT share 
at baseline. The evidence about changes in the availability and price of QAACTs, together with 
strong evidence of increased knowledge and awareness, the flow of copaid drug orders and the 
evidence on implementation of the IEC/BCC campaign, provide plausible evidence that AMFm 
is responsible for the substantial increase in QAACT market share observed. These changes 
occurred despite the implementation of the Global Fund’s demand levers, which had a significant 
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effect on the share of orders approved in the last two quarters of 2011. Substantial levels of 
QAACT availability and market share were also observed in remote areas. QAACT prices in 
private for-profit outlets were slightly higher in remote areas, although the demand levers may 
have placed upward pressure on prices by the time the remote areas survey was undertaken. 
Contextual factors that could also have contributed to increased QAACT availability (PMI 
procurement and epidemic preparedness) operated mainly in the public sector where QAACT 
market share appeared actually to have fallen, and not in the private for-profit and private not-
for-profit sectors, which saw substantial and significant increases. The decrease in the market 
share of nAT in private for-profit outlets is consistent with a view that AMFm is crowding out 
less effective antimalarials.  
8.3 Madagascar 
The success metrics scorecard for Madagascar is shown in Figure 8.3.1. Achievement of the 
AMFm objectives, the supply of AMFm copaid drugs, implementation of supporting 
interventions, and contextual factors that could affect the achievement of the AMFm benchmarks 
are discussed below. 
8.3.1  Achievement of the objectives 
Availability: There was no significant difference in overall QAACT availability between 
baseline (23%) and endline (28%), meaning that Madagascar did not meet Benchmark 1. There 
was no change in QAACT availability in the private for-profit sector, which remained low (8% 
at baseline and 9% at endline). However, there was considerable variation within the private for-
profit sector. QAACT availability at baseline and endline was much higher in private for-profit 
health facilities/ pharmacies (47% at baseline and 63% at endline) and drug stores (56% at 
baseline and endline), than in general retailers (3% at baseline and 2% at endline). These latter 
outlets are not licensed to stock or sell ACTs. A very high number of general stores were 
screened for the outlet surveys, of which antimalarials were stocked by 32% baseline and 21% at 
endline (principally cholorquine), meaning that general stores represented a high proportion of 
private for-profit antimalarial outlets, thereby pulling down average QAACT availability in the 
private for-profit sector as a whole. For private for-profit health facilities/pharmacies and drug 
stores, QAACT availability at endline was substantially higher in urban areas (90% and 88%, 
respectively) than in rural areas (30% and 53%, respectively), and this urban-rural disparity 
appeared to have widened since baseline. This was reflected in the significantly higher QAACT 
availability in the urban private for-profit sector as a whole at endline (19% versus 8% in rural 
areas). 
 
In public facilities, QAACT availability was already high at baseline (83%) and increased further 
to 94% at endline. This represents a significant increase from baseline. The increase in public 
facility availability was particularly marked in urban areas (from 66% to 91%). QAACT 
availability was high among community health workers (CHWs) at both baseline (99.8%) and 
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endline (92%). At endline, in public facilities and private for-profit health facilities/pharmacies, 
availability of QAACTs with and without the AMFm logo was very similar, but in drug stores, 
availability of QAACTs with the logo was 51% compared with only 12% for QAACTs without 
the logo. 
 
Price: In the public and private not-for-profit sectors, the median QAACT price remained USD 
0.00 at baseline and endline, reflecting the policy of free ACT provision. Pooling all sectors, the 
median price also remained at zero. However, the median price of QAACTs in the private for-
profit sector increased significantly between baseline and endline, from USD 0.14 to USD 0.60 
per AETD. This mainly reflected significant increases in prices in drug stores and general
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Figure 8.3.1: AMFm success metrics scorecard – Madagascar 
 
Availability
Benchmark 1: 20 percentage point increase from baseline in availability of all QAACTS
Percentage point change, 95% CI for change and p-value for test that QAACT availability is at least 
20 percentage points higher, by type of outlet
Type of outlet
Baseline 
(%)
Endline
(%)
Change
(95% CI) p
Public health facility
Private for-profit outlet
83.2
8.1
93.7
9.2
10.5 (4.7-16.4)
1.0 (-3.3 – 5.4)
np
0.9999
Total* 23.4 28.1 4.6 (-7.2 - 16.5) 0.9943
Price
Benchmark 2: Median price of QAACTs with the AMFm logo is less than 3 times the median price 
of the most popular  antimalarial that is not a QAACT , in tablet form**
Ratio of medians, 95% CI for ratio, p-value for test that ratio is < 3, in private for-profit outlets only 
Median price of 
QAACTs with logo
Median price 
of most popular 
non-QAACT
Ratio 
(95% CI) p
Private for-profit outlet USD 0.51 USD 0.32 1.6 (1.6-1.6) <0.0001
Benchmark 3: Median price of QAACTs with the AMFm logo is less the median price of AMT 
tablets
Difference in prices in USD (QAACT – AMT), 95% CI for difference, p-value for test that difference is 
negative, in private for-profit outlets only 
Median price of 
QAACTs with logo
Median price 
of AMT
Difference 
(95% CI) p
Private for-profit outlet USD 0.51 ns ns ns
Use
Benchmark 4: 5-10 percentage point increase from baseline in percentage of children under 
age 5 years with fever in the last 2 weeks who received ACT treatment
Percentage point change and p-value for t-test that use is at least 5 percentage points higher 
Baseline 
(%)
Endline
(%)
Change
(95% CI) p
Children under 5 years 1.0 -3.3*** na na na
Market share
Benchmark 5: 10-15 percentage point increase from baseline in the market share of all QAACTs
Percentage point change, 95% CI and p-value for test that market share of QAACTs is at least 10 
percentage points higher, by type of outlet
Baseline 
(%)
Endline
(%)
Change
(95% CI) p
Public health facility
Private for-profit outlet
27.4
6.8
12.7
22.0
-14.7 (-37-7.5)
15.1 (5.6-24.6)
0.9851
0.1428
Total* 12.1 20.7 8.6 (-0.6-17.9) **** 0.6150
Benchmark 6: Decrease in market share of oral AMTs 
Percentage point change in market share, 95% CI for change and p-value for test that change is negative, 
by type of outlet
Type of outlet
Baseline 
(%)
Endline
(%)
Change
(95% CI) p
Public health facility
Private for-profit outlet
0.0
0.0
0.0
0.0
0.0
0.0
-
-
Total* 0.0 0.0 0.0 -
Notes: Green shading = benchmark was achieved, with strong statistical evidence (generally p<0.01); Amber shading = either benchmark was nearly, but not fully, met, or the uncertainty around the point estimate
for benchmark indicates that it was met but with weak statistical evidence (p≥0.05); Red shading = benchmark was not met; Grey shading for Benchmarks 3 and 6 = metrics are not relevant because the number of
AMT products was very low at baseline. ACT = Artemisinin-based combination therapy; AMT = Artemisinin monotherapy; CI = Confidence interval; na = not available; np = not presented because availability
exceeded 80 percent at baseline; ns = not shown because the number of observations for either baseline or endline is fewer than 50 outlets/products (availability/price) or fewer than 500 AETDs (market share);
QAACT =Quality-assured artemisinin-based combination therapy; SI = Supporting intervention; * Total includes CHWs and private not-for-profit facilities that are not shown separately; ** The most popular
antimalarial in tablet form that was not a QAACT in the private for-profit sector in Madagascar was chloroquine; *** Based on two different baseline surveys (DHS and ACTwatch); **** The power to detect a 10
percentage point increase in market share was only 70% in Madagascar, compared with the usual minimum standard of 80%; therefore, p-values should be interpreted with caution.
Further results
Sample contains large number of general stores stocking antimalarials, but these are less likely to stock
QAACTs; QAACT availability in all outlets was same in urban and rural areas (28%); QAACT
availability was higher in private health facilities/pharmacies than drug stores or general stores, some
evidence that availability increased in these outlets (from 47% to 63%); in these outlets, availability
much higher in urban than rural areas, and the disparity increased from baseline.
QAACT price in private for-profit sector increased from USD 0.14 to USD 0.60 (low baseline price in 
private outlets in rural areas, and in drug stores and general stores in urban areas, may reflect ACTipal). 
Private for-profit share of all antimalarials was 49 percent at endline. 
Process and context data
The AMFm agreement was signed on May 11, 2010, and the first copaid drugs arrived in October
2010 (14 months before endline).
Some SIs took place in July 2010. National launch took place January 2011. Communications
activities started in April 2011, but were halted after one month. Other SIs included training of
doctors, paramedics, lab technicians and CHWs, and an intervention involving medical
representatives. There was no RRP. Contextual factors included national scale social marketing of
pediatric ACTs to CHWs and private retailers from 2008; IRS and mass distribution of LLINs;
continued effects from the 2009 coup d’état, leading to political and economic deterioration.
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retailers, especially in rural areas. It is clear that QAACT prices at baseline were well below their 
unsubsidized levels in all rural private for-profit outlet types, and in drugstores and general stores 
in urban areas. This is likely to have reflected the pediatric ACT subsidy program for Actipal 
(artesunate-amodiaquine) that PSI had been operating in Madagascar since 2008 with 
distribution through CHWs and retailers. Retail sector Actipal had an RRP of 100 ariary (about 
USD 0.05), which was increased to ariary 200 (USD 0.10) in November 2010, implying a 
recommended price per AETD of USD 0.10-0.20 at baseline and USD 0.20-0.40 at endline. 
Distribution of Actipal continued during AMFm phase 1, with procurement of 705,000 
treatments between February 2010 and August 2011. As a result, at endline in rural drug stores 
and general stores, the median price of QAACTs without the logo was similar to the median 
price of QAACTs with the logo. However, in urban areas, QAACTs without the logo were much 
more costly than those with the logo in the private for-profit sector (median of USD 0.51 with 
the logo and USD 9.10 without the logo), indicating that unsubsidized QAACTs were still 
common in urban areas. Moreover, the median price of non-quality-assured ACTs in the private 
for-profit sector was much higher than for QAACTs, and it had significantly increased between 
baseline (USD 5.61) and endline (USD 9.14). 
 
The median price at endline for a QAACT with the logo in private for-profit outlets (USD 0.51) 
was 1.6 times the median price of the most popular antimalarial which is not a QAACT in tablet 
form (chloroquine) in private for-profit outlets. Madagascar therefore comfortably met price 
Benchmark 2. Benchmark 3 was not relevant in Madagascar as there were no price observations 
for oral AMT, reflecting its absence from the market. 
 
The gross percentage markup on QAACTs, measured among private for-profit outlets, increased 
slightly between baseline (38%) and endline (44%), and was almost the same at endline for 
QAACTs with the logo (43%) and QAACTs without the logo (44%). As a comparator, the gross 
percentage markup on non-artemisinin therapy (nAT) in the private for-profit sector was 67% at 
both baseline and endline. The median total markup from first line buyer price to retail price in 
private for-profit outlets was low, at only USD 0.45 suggesting that the low mark up informally 
agreed by FLBs was adhered to. 
 
Market share: Overall market share of QAACTs was 12% at baseline and 21% at endline, but 
this change did not meet Benchmark 5 of a 10 percentage point increase; however the power to 
detect a 10 percentage point increase in market share is below the usual minimum standard of 
80%, so the p-value should be interpreted with caution. In the private for-profit sector, market 
share increased from 7% to 22%. This 15 percentage point change is significantly different from 
zero, but the p-value (0.14) provides only weak evidence that the 10 percentage point threshold 
was met. The gain in QAACT market share in this sector was accompanied by a reduction in the 
market share of nAT. Surprisingly, there is some evidence that QAACT market share fell in the 
public sector, although this decrease was not significant. The public sector QAACT market share 
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also seems surprisingly low at endline (13%), given that QAACT availability was 91% in all 
public health facilities (including those without antimalarials in stock on the day of the 
interview), with nATs accounting for 79% of market share. Overall market share of oral AMTs 
was zero at baseline and endline, meaning that Benchmark 6 was not relevant in Madagascar. At 
endline, QAACTs with the AMFm logo accounted for 86% of all QAACTS dispensed overall 
and 95% of all QAACTs dispensed in the private for-profit sector.  
 
The private for-profit sector was responsible for 82% of all antimalarials sold or distributed at 
baseline, and 70% at endline, with the private sector share being slightly higher in urban areas at 
both time points. 
 
8.3.2  Supply of AMFm copaid drugs 
Eight private sector FLBs registered and placed orders with manufacturers, and the FLB for the 
public sector was the public sector procurement agency, the Unité de Gestion de Projet (UGP). 
Orders were placed with all eight of these private for-profit FLBs by December 2011. The first 
orders for copaid QAACTs were placed in September 2010 by a private for-profit FLB, with 
small quantities being delivered in October and December 2010 and larger quantities in February 
2011. The first public sector orders were placed in December 2010, with first deliveries in 
February 2011.  
 
Lead times between approval and delivery have ranged from a couple of weeks to nearly six 
months, and were reported to have been particularly long in the second half of 2011. There were 
also initially some problems with customs clearance leading to month-long delays, but these 
were resolved. The Global Fund had not applied “demand levers” to constrain order approval for 
Madagascar (see table 1.2.2). Public sector availability was quite high at endline, with 91% of all 
public health facilities having QAACTs in stock.  
 
By the end of December 2011, a total of 1.2 million treatment doses had been received by private 
sector FLBs, and 489,000 by the public sector, amounting to only 0.08 treatments per capita or 
one treatment for every 12 people (the whole population of Madagascar is considered at risk of 
malaria). A total of 14 months elapsed between the date the first drugs arrived in Madagascar 
and the midpoint of endline outlet survey fieldwork. Some supporting interventions began in July 
2010, before the first copaid drugs arrived. 
 
8.3.3  Implementation of supporting interventions  
A total of USD 2,052,437 was available through the Global Fund for SIs at the time of grant 
signing (this does not take into account interventions funded through other programs). As of 
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November 2011, USD 1,334,422 had been disbursed, giving quite a low per capita disbursement 
on SIs of USD 0.06 (and all disbursed funds may not have been spent by December 2011).  
A national launch was conducted in January 2011, with communication activities beginning in 
April 2011. Promotional materials were provided to private medicine practitioners, businesses in 
the private sector supply chain, and CHWs. A radio and TV campaign was begun in April 2011, 
but terminated in May 2011 because it was deemed to contravene the law prohibiting advertising 
of prescription drugs to the general population. There was no maximum or recommended retail 
price for copaid ACTs in Madagascar, although at endline 15% of respondents stated that there 
was one, perhaps referring to the RRP for Actipal. 
 
About one-third of the country’s 3,000 medical doctors and 250 paramedics had been trained by 
December 2011. Training was also conducted for CHWs, with 2,442 trained between July 2010 
and June 2011, and laboratory technicians were trained on drug quality issues. During the 
endline outlet survey, 16% of public facility respondents and 30% of private not-for-profit 
respondents said they had received some training on antimalarials with the AMFm logo. Training 
coverage was quite high in urban private for-profit facilities/pharmacies and drug stores (31% 
and 41%, respectively), but was low in rural areas and in both rural and urban general stores. 
Provider knowledge of the first-line antimalarial remained quite low at endline (at 33% of all 
providers). 
 
CHAI conducted a pilot intervention starting in September 2011 for training medical detailers, 
covering around one-fifth of Madagascar’s districts. As of December 2011, medical 
representatives had held information sessions with 235 physicians and 234 retail outlets. 
 
At endline, provider recognition of the AMFm logo was 37% overall. Recognition was over 73% 
in public facilities, private not-for-profit facilities, private for-profit facilities/pharmacies and 
drug stores, but only 35% among CHWs and 25% among general retailers. Recognition was over 
96% among urban private for-profit facilities/pharmacies and drug stores. Of those recognizing 
the logo, 34% said it meant an effective/quality antimalarial, and 10% an antimalarial. One-
quarter of respondents did not know what it meant. Only 13% of respondents overall had heard 
of the AMFm program although knowledge of the program was higher in private for-profit 
health facilities/pharmacies (33%). Recognition of the AMFm logo was also very low among 
exit survey respondents, with only 9% reporting that they had seen the logo; 60% of these said 
they did not know its meaning. The most common source of exposure to the logo was television 
(40%), followed by antimalarial drug packaging and a health center/clinic (20% each). 
8.3.4  Context 
ACTs do not have over-the-counter status, and their sale is not permitted in general stores. In 
addition to the distribution of subsidized Actipal (see above), other malaria control interventions 
of relevance to the Malagasy context were expansion of indoor residual spraying and mass 
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distribution of long-lasting insecticidal nets (LLINs), which may have affected antimalarial 
demand to some degree. While microscopy coverage remained very low, there was a significant 
increase in availability of RDTs from 9% at baseline to 19% at endline, which may also have 
reduced demand for antimalarials. At endline, RDT availability was 94% in public facilities, 
70% in private not-for-profit facilities and 65% among CHWs, but remained very low in the 
private for-profit sector.  
 
Madagascar continues to suffer from the consequences of the coup d’état in March 2009, which 
is said to have led to a steadily deteriorating economic and political situation. For example, it 
was reported that after the coup many companies went out of business, unemployment rose and 
the purchasing power of the population fell. Government spending is also reported to have fallen 
leading to a deterioration in public health facilities and in infrastructure more generally. Political 
instability has led to frequent turnover in Ministers of Health, and therefore delays in program 
implementation.  
8.3.5  Summary 
Madagascar has not met success Benchmarks 1 on QAACT availability or 5 on QAACT market 
share. However, Benchmark 2 on the relative price of copaid QAACTs compared with the most 
popular antimalarial which is not a QAACT was met, despite the lack of an RRP. Benchmarks 3 
and 6 were not relevant because there was an almost complete absence of oral AMT in the 
market at baseline and endline. Data are not available to assess Benchmark 4 on use.  
 
Although a significant increase in QAACT market share was observed from baseline to endline 
in the private for-profit sector, the increase was not sufficient to meet the market share 
benchmark, especially given the lack of improvement in the public sector. This limited 
improvement in market share was associated with the low level of copaid drugs delivered to 
Madagascar, at only one treatment for every 12 people, or 0.08 treatments per capita. This partly 
reflects long delivery times, but more importantly low copaid drug orders, which amounted to 
only one treatment for every 11 people, or 0.09 treatments per capita. Reasons for these low 
orders are likely to reflect low confidence by FLBs, reluctance to order due to a lack of data on 
the unmet need for ACTs within the private sector and a fear of overstocking. The low level of 
provider and exit survey respondent awareness and understanding of the logo are no doubt due to 
the curtailment of the mass media campaign, which is likely to have had a substantial impact on 
consumer demand for QAACTs. However, the Madagascar experience should be seen in the 
light of the recent political instability and economic challenges, which provided a highly 
problematic context for both the public and private sectors during the period of AMFm Phase 1. 
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8.4 Niger 
The success metrics scorecard for Niger is shown in Figure 8.4.1. Achievement of the AMFm 
objectives, the supply of AMFm copaid drugs, implementation of supporting interventions, and 
contextual factors that could affect the achievement of the AMFm benchmarks are discussed 
below. 
8.4.1 Achievement of the objectives 
Availability: QAACT availability among all outlets increased by 10 percentage points between 
baseline and endline, from 9% to 19% (Benchmark 1). This was a statistically significant 
increase, but did not meet the AMFm benchmark of a 20 percentage point increase. There was a 
significant increase in public sector outlets (from 45% to 73%) and a smaller, but also 
significant, increase in private for-profit outlets from 6% at baseline to 14% at endline. A very 
high number of general stores and itinerant vendors were screened for the outlet surveys, and it 
was common for them to have antimalarials in stock (42% of general stores and 63% of itinerant 
vendors enumerated at baseline stocked antimalarials), meaning that they represented a high 
proportion of private for-profit antimalarial outlets. They had lower stocking rates of QAACTs at 
endline (13% compared with 62% in private health facilities/pharmacies and 65% in drug stores), 
which therefore pulls down average QAACT availability in the private for-profit sector as a 
whole. Endline availability was higher in urban areas than rural areas, for all outlets combined 
and for private for-profit outlets. Availability of QAACTs with the AMFm logo was slightly 
higher than of those without the logo (13% vs. 9%), although availability of QAACTs without 
the logo was higher (58%) than those with the logo (30%) in public health facilities. Availability 
of nATs in the private for-profit sector declined only marginally (from 99% at baseline to 95% at 
endline). Oral AMT was rarely available in Niger, other than in private for-profit health 
facilities/ pharmacies, where it was still 9% at endline. The availability of non-quality-assured 
ACTs increased slightly between baseline and endline among all outlets, from 4% to 8%, and 
was higher in urban than rural areas at endline (13% vs.7%). 
 
Price: The median price per adult equivalent treatment dose (AETD) of QAACTs fell 
considerably between baseline and endline, from USD 2.06 to USD 0.79 among all outlets. The 
median price remained zero in public health facilities, and in private for-profit outlets the median 
price fell from USD 2.47 to USD 1.19, somewhat higher than the RRP of USD 0.69 for an adult 
treatment. QAACT prices fell much more in private health facilities/pharmacies (from USD 9.38 
to USD 1.98), where they had been considerably more expensive than among general 
retailer/itinerant vendors at baseline. Non-quality-assured QAACTs remained very expensive at 
endline, at USD 7.58 in private for-profit outlets. 
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Figure 8.4.1: AMFm success metrics scorecard – Niger 
Availability
Benchmark 1: 20 percentage point increase from baseline in availability of all QAACTS
Percentage point change, 95% CI for change and p-value for test that QAACT availability is at 
least 20 percentage points higher, by type of outlet
Type of outlet
Baseline 
(%)
Endline
(%)
Change
(95% CI) p
Public health facility
Private for-profit outlet
44.8
6.3
72.9
13.8
28.1 (16.9-39.3)
7.6 (4.6-10.6)
0.0781
0.9999
Total* 9.4 19.4 10.0 (7.0-13.1) 0.9999
Price
Benchmark 2: Median price of QAACTs with the AMFm logo is less than 3 times the median 
price of the most popular  antimalarial that is not a QAACT , in tablet form **
Ratio of medians, 95% CI for ratio, p-value for test that ratio is < 3, in private for-profit outlets only
Median price of 
QAACTs with 
logo
Median price 
of most 
popular non-
QAACT
Ratio 
(95% CI) p
Private for-profit outlet USD 1.19 USD 0.48 2.5 (2.2 -2.8) <0.0001
Benchmark 3: Median price of QAACTs with the AMFm logo is less the median price of AMT 
tablets
Difference in prices in USD (QAACT – AMT), 95% CI for difference, p-value for test that difference is 
negative, in private for-profit outlets only 
Median price of 
QAACTs with 
logo
Median price 
of AMT
Difference 
(95% CI) p
Private for-profit outlet USD 1.19 ns ns ns
Use
Benchmark 4: 5-10 percentage point increase from baseline in percentage of children under 
age 5 years with fever in the last 2 weeks who received ACT treatment
Percentage point change and p-value for t-test that use is at least 5 percentage points higher 
Baseline 
(%)
Endline
(%)
Change
(95% CI) p
Children under 5 years 2.4 na na na
Market share
Benchmark 5: 10-15 percentage point increase from baseline in the market share of all 
QAACTs
Percentage point change, 95% CI and p-value for test that  market share of QAACTs is at least 10-
percentage points higher, by type of outlet
Baseline
(%)
Endline
(%)
Change
(95% CI) p
Public health facility
Private for-profit outlet
36.9
3.7
27.0
7.6
-10.0 (-26.8 -6.9)
3.9 (1.4 -6.4)
0.9898
0.9999
Total* 18.4 9.6 -8.8 (-18.0 -3.8) 0.9999
Benchmark 6: Decrease in market share of oral AMTs 
Percentage point change in market share, 95% CI for change and p-value for test that change is
negative, by type of outlet
Type of outlet
Baseline 
(%)
Endline
(%)
Change
(95% CI) p
Public health facility
Private for-profit outlet
0.2
0.1
0.1
0.0
-0.2 (-0.6-0.3)
-0.1 (-0.14-0.02)
0.2655
0.0823
Total* 0.1 0.0 -0.1 (-0.3-0.1) 0.1266
Notes: Green shading = benchmark was achieved, with strong statistical evidence (generally p<0.01); Amber shading = either benchmark was nearly, but not fully, met, or the evidence that the change seen
was unlikely to be due to chance is weak (p≥0.05); Red shading = benchmark was not met ; Grey shading for Benchmarks 3 and 6 = metrics are not relevant because the number of AMT products was very
low at baseline; ACT = Artemisinin-based combination therapy; AMT = Artemisinin monotherapy; CI = Confidence interval; RRP = Recommended retail price; na = not available; ns = not shown because
the number of observations for either baseline or endline is fewer than 50 outlets/products (availability/price) or fewer than 500 AETDs (market share); QAACT = Quality-assured artemisinin-based
combination therapy; SI = Supporting intervention; * Total includes CHWs and private not-for-profit facilities that are not shown separately; ** The most popular antimalarial in tablet form that was not a
QAACT in the private for-profit sector Niger was chloroquine.
Further results
QAACT price in private for-profit outlets fell from USD 2.47 at baseline to  USD 1.19  at endline; 
it was  USD 1.39 in urban areas and USD 1.19 in rural areas.  The price of QAACTs  with the 
AMFm logo at endline was also USD 1.19, higher than the RRP of USD 0.69 (2010 prices).
QAACT availability was higher in urban (27%) than rural (16%) areas at endline.
QAACT market share was similar in urban and rural areas  at endline.
The private for-profit share of all antimalarials was 49% at endline.
Process and context data
The AMFm agreement was signed on May 31, 2010 and the first copaid drugs arrived in February 
2011 (9.5 months before endline). 
SIs started in January 2011 but implementation was impeded by delays in receiving funds, delays in 
the selection of communications firm to implement the activities and suspension of  disbursement 
on the AMFm SI grant in  the second half of 2011. SI implementation therefore took  place for 6 
months, but no SIs took place after June 2011. Other important contextual factors include adverse 
weather, difficult transport outside the main cities and problems of insecurity.
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The median price in private for-profit outlets for a QAACT carrying the AMFm logo was USD 
1.19 per AETD. This is d 2.5 times higher than the price of chloroquine tablets, the most popular 
antimalarial which is not a QAACT, suggesting that Niger achieved AMFm Benchmark 2, which 
states that the ratio should be less than 3. It was not possible to compute Benchmark 3 for Niger, 
as the number of AMT products audited at endline was fewer than 50. The median price of 
QAACTs without the AMFm logo in private for-profit outlets was somewhat higher than those 
with the logo (USD 1.98). 
 
The gross percentage markup on QAACTs in private for-profit outlets was 35% at baseline and 
endline, so with the reduction in QAACT prices, this meant a substantial reduction in absolute 
markup on QAACTs. The percentage markup was very similar on copaid and non-copaid 
QAACTs, leaving much higher absolute markups for retail sales of QAACTs without the AMFm 
logo. As a comparator, the median gross percentage markup on nAT in the private for-profit 
sector was quite a bit higher (85% at endline). 
 
Market share: QAACT market share measured across all outlets fell from 18% at baseline to 
10% at endline, although the change is not significantly different from zero; and there was a 
significant increase in the share of nAT, from 73% at baseline to 87% at endline. This means that 
Benchmark 5 of a 10 percentage point increase in QAACT market share from baseline to endline 
has not been achieved in Niger. The public sector saw no significant shifts in market share 
among the different antimalarial product categories. In the private for-profit sector, the QAACT 
share doubled, but from a very low starting level of 4% at baseline to 8% at endline. QAACTs 
without the AMFm logo had a slightly higher market share than QAACTs with the logo overall 
(5% vs. 4%), suggesting very low penetration of copaid QAACTs into the supply chain. At 
endline, public health facilities were responsible for 46% of total sales of antimalarials, while the 
private not-for-profit sector and private for-profit sector accounted for 5% and 49%, respectively. 
These patterns were little changed from baseline. 
8.4.2 Supply of AMFm copaid drugs  
Seven first line buyers had registered with the Global Fund as of January 31, 2012. This was 
made up of five private for-profit firms, one UN agency and one public sector agency. Three of 
the five private for-profit FLBs placed orders by the end of 2011. The first order to be placed by 
a private for-profit first line buyer (FLB) was in August 2010, and the medicines arrived in Niger 
in January 2011. It was reported that the manufacturer with whom the order was originally 
placed did not supply the medicines, and the order was then placed with another manufacturer. 
This delay in drug delivery meant that the effective implementation period before the endline 
outlet survey was 9.5 months. The first public sector order was placed in January 2011, approved 
in that same month, and medicines were delivered to the public sector in February 2011. By the 
end of 2011, a total of 2,225,120 treatments had been delivered to Niger, or 0.14 treatments per 
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capita (the whole population of Niger is considered to be at risk of malaria). Eighty percent of 
drugs delivered were ordered by the public sector FLB, and only 0.03 treatments per capita were 
delivered to private sector FLBs. 
 
New regulatory measures were taken to ensure QAACT supply to the public health system, 
including allowing the public sector distribution system to supply private rural drug depots and 
authorizing the private sector to supply public facilities with copaid ACTs when the public 
pharmaceutical stores cannot meet the demand for copaid ACTs. 
8.4.3  Implementation of supporting interventions 
A total of USD 1,731,526 was available through the Global Fund for SIs at the time of grant 
signing (this does not take into account interventions funded through other programs). As of 
November 2011, disbursements amounted to USD 977,676, giving a per capita disbursement on 
SIs of USD 0.06. Given delays in implementation (see below), this may overestimate the actual 
expenditure on SIs. The formal AMFm launch took place in March 2011, but IEC/BCC activities 
started in January 2011, at about the time of the arrival of the first copaid drugs in Niger. A 
broad range of activities were planned, including interpersonal communication, promotion 
through the mass media, social mobilization and advocacy activities. However, only about 30% 
of planned activities took place due to delays in receiving funds, delays in the selection of 
communications firms to undertake the activities and the suspension of disbursement of the 
Global Fund AMFm supporting intervention grant in the second half of 2011, following an 
investigation by the Global Fund’s Office of the Inspector General. An RRP was set at USD 0.40 
for a child dose and USD 0.69 for an adult dose. Training activities started in December 2010, 
and a total of 25 trainers and 750 public sector health workers were trained on AMFm. In 
addition, two people received training on drug quality testing. Other planned training did not take 
place.  
 
The effects of the limited implementation of SIs can be seen in the mixed performance on 
indicators of provider knowledge and awareness of AMFm. There was a significant increase in 
the level of provider knowledge of the first-line antimalarial, which nearly doubled between 
endline and baseline, from 17% to 33%. This was already high at baseline among public sector 
providers (86%) and private health facilities/pharmacies (79%), but among general retailers/ 
itinerant vendors, the level of knowledge increased from 10% at baseline to 26% at endline. 
There was a large reduction between baseline and endline in the proportion of those who gave 
“too expensive” (from 29% to 14%) and “my suppliers do not have it in stock” (40% to 27%) as 
reasons for not supplying QAACTs, although no change in the frequency of “my customers do 
not ask for them” (20% at endline) as a response. At endline, 30% of all respondents recognized 
the AMFm logo, with higher levels of recognition in public health facilities (75%) than private 
for-profit providers (26%). Thirty-one percent of those who recognized the logo, however, did 
not know its meaning, and only 23% of providers had heard of the AMFm program. Only 13% 
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of all respondents knew of the RRP for copaid QAACTs (8% among general retailers/itinerant 
vendors), and of those aware of the RRP, 61% knew the correct value. Only 2% of all 
respondents said that someone in their outlet had participated in training related to AMFm.  
 
A number of supporting regulatory interventions were implemented during AMFm Phase 1. 
These included measures to increase QAACT availability in rural areas, such as allowing rural 
drug depots to be supplied by either the Central Medical Stores or the private sector; allowing 
public health facilities to procure drugs from private FLBs and changes in regulation to allow 
mass media advertising on copaid ACTs. Some limited pharmacovigilance activities were 
planned, but they had not been implemented by the end of 2011.  
8.4.4  Context 
In addition to the suspension of disbursement on the AMFm supporting intervention grant, which 
was an important constraint on implementation, a number of contextual features may have 
affected AMFm. The security situation in Niger continued to be challenging. Rainfall in 2011 
was erratic and uneven leading to both drought and flooding. Fewer LLINs were distributed in 
2011 than in previous years. The Chinese government supplied an additional 500,000 doses of 
ACT (DHA-PP and ASAQ), equivalent to about 20% of AMFm copaid ACT deliveries, which 
may have increased the availability of non-quality-assured ACTs in public facilities. ACTs did 
not have over-the-counter status. 
8.4.5  Summary 
Niger appears to have met Success Benchmark 2 relating to the price of copaid QAACTs, which 
specifies that the median price should be less than three times the price of the most popular 
antimalarial which is not a QAACT. It has not, however, achieved Benchmark 1 on availability 
or Benchmark 5 on market share of QAACTs. The market share of oral AMT (Benchmark 6) 
was already so low that it is not relevant to assessing the impact of AMFm in Niger. The amount 
of time elapsed between the arrival of copaid drugs and the endline outlet survey was only 
around 9.5 months, so the short time for implementation could be responsible for the slow 
progress of the program. However, it also seems that the quantity of copaid QAACTs ordered, 
particularly by private for-profit FLBs, was too low to have made much of an impact on 
availability and market share. The implementation of supporting interventions, which might have 
helped to increase demand for copaid QAACTs, and thereby might have stimulated private for-
profit orders, was also derailed by delays and the suspension of the Global Fund SI grant. 
Finally, the implementation context in Niger is challenging, with problems of adverse weather 
interrupting supply chains, difficult transport outside the main cities and problems of insecurity. 
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8.5  Nigeria  
The success metrics scorecard for Nigeria is shown in Figure 8.5.1. Achievement of the AMFm 
objectives, the supply of AMFm copaid drugs, implementation of supporting interventions and 
contextual factors that could affect the achievement of the AMFm benchmarks are discussed 
below. 
8.5.1 Achievement of the objectives 
Availability: QAACT availability in all outlets increased from 28% to 54%, an increase of 26 
percentage points from baseline to endline (Benchmark 1). There is therefore some evidence that 
Nigeria has met the benchmark of a 20 percentage point increase in QAACT availability 
(p=0.14), although the large p-value means we do not have strong evidence for this. There was 
no difference in availability between urban and rural areas at endline. In public health facilities, 
availability was 46% at baseline and 57% at endline, but this increase was not statistically 
significant. The major contributor to the overall increase in availability was the private for-profit 
sector, in which availability increased significantly from 27% to 53%. Forty-seven percent of all 
outlets stocked QAACTs with the AMFm logo at endline, but a relatively high proportion of 
outlets stocked QAACTs without the logo (38% of public health facilities and 14% of private 
for-profit health facilities). Availability of nAT remained very high at endline (97% in all 
outlets). There was no reduction in the availability of oral AMT, which was still available in 35% 
of private for-profit outlets and 15% of public health facilities at endline; and no change in 
availability of non-quality-assured ACTs (27% of all outlets at endline). The use of AMTs 
became widespread when chloroquine and SP were found to be less effective but ACTs were not 
yet widely available, a situation that has complicated attempts to eliminate AMTs from the 
market even after they were banned. It should be noted that Nigeria has several nationally-
approved ACTs that are included in the non-quality-assured category. 
 
Price: There was a substantial fall in the price of QAACTs between baseline and endline. 
Among all outlets, the median price per AETD fell from USD 3.72 at baseline to USD 1.48 at 
endline (p<0.0001). In public health facilities the median price of QAACTs was USD 0.00 at 
baseline and at endline, while the median price of nAT was USD 0.71 at endline, indicating the 
policy of free ACTs in those facilities. In private for-profit outlets, the decline in median price of 
QAACTs is even larger, from USD 4.47 to USD 1.48 (p<0.0001). There was little change over 
this period in the prices of nAT, oral AMT or non-quality-assured ACTs. 
 
Despite this large decline in the price of QAACTs in private for-profit outlets, the ratio of the 
median price of QAACTs with the AMFm logo to that of the most popular antimalarial which is 
not a QAACT was 3.1, and therefore Nigeria missed Benchmark 2, which states that the ratio 
should be less than 3. The price of QAACTs with the AMFm logo was less than that of tablet 
AMT (USD 2.66), meaning that Benchmark 3 has been met.The median price for QAACTs with 
the logo is just over half of that for AMTs of either form. The median price of QAACTs without 
the AMFm logo was USD 2.36 at endline. 
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Figure 8.5.1: AMFm success metrics scorecard – Nigeria 
Availability
Benchmark 1: 20 percentage point increase from baseline in availability of all QAACTS
Percentage point change, 95% CI for change and p-value for test that QAACT availability is at least 
20 percentage points higher, by type of outlet
Type of outlet
Baseline 
(%)
Endline
(%)
Change
(95% CI) p
Public health facility
Private for-profit outlet
46.3
26.6
56.7
52.9
10.4 (-14.4-35.2)
26.3 (15.1-37.5)
0.7765
0.1342
Total* 27.7 53.5 25.8 (15.1-36.5) 0.1438
Price
Benchmark 2: Median price of QAACTs with the AMFm logo is less than 3 times the median price 
of the most popular  antimalarial that is not a QAACT, in tablet form **
Ratio of medians, 95% CI for ratio, p-value for test that ratio is < 3, in private for-profit outlets only
Median price of 
QAACTs with logo
Median price 
of most 
popular non-
QAACT
Ratio 
(95% CI) p
Private for-profit outlet USD 1.48 USD 0.47 3.1 (3.1-3.2) 0.9998
Benchmark 3: Median price of QAACTs with the AMFm logo is less the median price of AMT 
tablets
Difference in prices in USD (QAACT – AMT), 95% CI for difference, p-value for test that difference is 
negative, in private for-profit outlets only 
Median price of 
QAACTs with logo
Median price 
of AMT
Difference 
(95% CI) p
Private for-profit outlet USD 1.48 USD 2.65 -1.17            
(-1.24- -1.10)
<0.0001
Use
Benchmark 4: 5-10 percentage point increase from baseline in percentage of children under age 
5 years with fever in the last 2 weeks who received ACT treatment
Percentage point change and p-value for t-test that use is at least 5 percentage points higher 
Baseline 
(%)
Endline
(%)
Change
(95% CI) p
Children under 5 years 2.4 na na na
Market share
Benchmark 5: 10-15 percentage point increase from baseline in the market share of all 
QAACTs
Percentage point change, 95% CI and p-value for test that market share of QAACTs is at least 10-
percentage points higher, by type of outlet
Baseline 
(%)
Endline
(%)
Change
(95% CI) p
Public health facility
Private for-profit outlet
6.4
2.2
48.1
17.8
41.7 (26.5-56.8)
15.6 (12.1-19.1)
<0.0001
0.0009
Total* 2.4 20.1 17.7 (13.6-21.8) 0.0002
Benchmark 6: Decrease in market share of oral AMTs
Percentage point change in market share, 95% CI for change and p-value for test that change is
negative, by type of outlet
Type of outlet
Baseline 
(%)
Endline
(%)
Change
(95% CI) p
Public health facility
Private for-profit outlet
0.6
8.3
0.8
4.4
0.2 (-0.6-1.0)
-3.9 (-7.9-0.1)
0.7038
0.0288
Total* 8.1 4.1 -3.9 (-7.9-0.0) 0.0258
Notes: Green shading = benchmark was achieved, with strong statistical evidence (generally p<0.01); Amber shading = either benchmark was nearly, but not fully, met, or the evidence that the change
seen was unlikely to be due to chance is weak (p≥0.05); Red shading = benchmark was not met ; Grey shading for Benchmarks 3 and 6 = metrics are not relevant because the number of AMT products
was very low at baseline; ACT = Artemisinin-based combination therapy; AMT = Artemisinin monotherapy; CI = Confidence interval; RRP = Recommended retail price; na = not available; ns = not shown
because the number of observations for either baseline or endline is fewer than 50 outlets/products (availability/price) or fewer than 500 AETDs (market share); QAACT = Quality-assured artemisinin-
based combination therapy; SI = Supporting intervention; * Total includes CHWs and private not-for-profit facilities that are not shown separately; ** The most popular antimalarial in tablet form that
was not a QAACT in the private for-profit sector in Nigeria was SP.
Further results
QAACT price in private for-profit sector  fell from USD 4.47 to USD 1.48 at endline, and was similar 
in rural and urban areas.  
The price of QAACTs  with the AMFm logo at endline was also USD 1.48, higher than the RRP of 
USD 0.60 (2010 prices).
No difference in QAACT availability between urban and rural areas in availability at endline.
QAACT market share was very similar in urban (19%) and rural (23%) areas at endline.
At endline, private for-profit outlets were responsible for 92% of all antimalarials distributed. 
Process and context data
The AMFm agreement was signed on October 5, 2010 and the first copaid drugs arrived in January 
2011 (9.5 months before endline). SIs started in  April 2011 (giving 6 months of implementation 
before endline) but this was constrained by the suspension of the Global Fund grant to one of the 
recipient organizations, and mass communication activities only started in August/September 
2011.  Global Fund demand levers reduced order approval to 24% in the second half of 2011. 
Contextual factors include LLINs and IRS (in some states), a large domestic pharmaceutical 
manufacturing sector and federal elections in 2011. 
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QAACTs with the AMFm logo were being sold on average for 2.4 times more than the 
recommended retail price for an adult dose of USD 0.59.  
 
The gross percentage markup on QAACTs, measured among private for-profit outlets, was 50% 
at endline compared with 33% at baseline; it was also 50% on copaid QAACTs. However, with 
the large decrease in the median price of QAACTs, this amounts to a much smaller absolute 
markup at endline. The level of the markup on copaid QAACTs is similar to the median markup 
of 41% charged on nATs. The median total markup from the first line buyer price to the retail 
price in private for-profit outlets was USD 1.33. 
 
Market share: Overall, measured across all outlets, the market share of QAACTs increased 
from 2% at baseline to 20% at endline (18 percentage points). The QAACT share of all 
antimalarials sold increased even more dramatically in the public sector, from 6% at baseline to 
48% at endline, while in private for-profit outlets it increased from 2% to 18%. 
 
The increase in QAACT share in both the public sector and the private for-profit sector was 
accompanied by a large reduction in the share of nATs, which fell in the public sector from 85% 
to 38%, and in the private for-profit sector from 84% to 69%. The share of non-quality-assured 
QAACTs remained fairly constant, and was 8% in all outlets at endline. The private sector 
accounted for over 90% of all antimalarials distributed at baseline and at endline.  
8.5.2 Supply of AMFm copaid drugs  
A total of 54 FLBs were registered with the Global Fund as of January 31, 2012 (51 private for-
profit, 2 private not-for-profit and 1 public sector). Orders were placed with 28 of these private 
for-profit FLBs by December 2011. The country case study noted the absence of two major 
importing firms who declined to participate in AMFm because they were reluctant to undermine 
the market for their existing products. It seemed that these firms were involved in supply of both 
non-quality-assured ACTs and AMTs, which may help to explain the continued substantial 
presence of these products in the market.  
 
The first public sector order was placed in March 2011 and delivered in May 2011. The private 
sector ordering process proceeded smoothly at the beginning, with the first orders placed in 
October 2010 and arriving in Nigeria in January 2011. In total, 28 FLBs had placed orders by the 
end of 2011. Approximately 9.5 months elapsed between the arrival of the first copaid drugs and 
the midpoint of endline outlet survey fieldwork. However, at the time of the endline outlet 
survey data collection, serious delays and shortfalls in supply were being reported by the private 
sector, linked to the exercise of the Global Fund demand levers. Concerns seemed to be 
developing among private sector suppliers regarding the low volumes of medicines being 
supplied and the pressure that this was placing on prices and availability. Evidence from the 
Global Fund orders database suggests a substantial buildup of unfilled orders by the end of 2011, 
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with orders for 47 million doses pending by December 2011. Table 1.2.2 indicates that only 24% 
of treatments requested by private FLB in the second half of 2011 had been approved by the end 
of December. However, it is not entirely clear that this pressure would have fed through to the 
retail level by the time of endline data collection.  
 
A range of challenges with the customs clearing process were reported in the processing of 
shipments, particularly for private for-profit FLBs. These led to delays and in some cases to 
increased costs, either due to taxes being applied inappropriately or to demurrage charges 
incurred. Shortages of supply in the private sector were also reported to have affected the 
willingness of private sector outlets to stock them and to have limited distribution outside of 
major urban centers, although there is no evidence from the endline outlet survey that QAACT 
availability in private for-profit outlets in rural areas was lower than in urban areas.  
 
By the end of 2011, a total of 58,902,076 copaid ACT doses had been delivered in Nigeria. This 
amounted to 0.37 doses per capita (the whole population of Nigeria is considered at risk of 
malaria), of which 76% went to private for-profit FLBs, 15% to public sector FLBs and 9% to 
private not-for-profit FLBs.  
8.5.3 Implementation of supporting interventions 
Global Fund resources available at the time of grant signing for implementation of supporting 
interventions (SIs) in Nigeria were originally allocated in grants to three separate organizations: 
the Yakubu Gowon Center for National Unity and International Cooperation (USD 7,214,102); 
the National Malaria Control Programme (USD 15,658,997); and the Society for Family Health 
(USD 23,231,858), giving a total of USD 46,104,957. The Yakubu Gowon grant was suspended 
because of use of the parallel foreign currency market to exchange USD for Nigerian naira and 
misappropriation of the proceeds of these transactions. None of the funds from this grant were 
disbursed, and the suspension of this grant was reported to have had a substantial effect on the 
implementation of SIs. From the remaining two grants, USD 15,304,587 had been disbursed by 
November 2011, amounting to USD 0.10 per capita for SIs. 
 
Implementation of supporting interventions trailed the arrival of the first copaid drugs by 
approximately three months, giving about six months from the start of implementation of SIs 
before the midpoint of the endline outlet survey. The National Launch was held on March 31, 
2011. Some delays in initiating communications activities were caused by problems of 
coordination among the Principal Recipients (PRs). In the interim, a number of activities were 
undertaken by other stakeholders such as professional associations and pharmaceutical firms. 
The Society for Family Health (SFH) only started to implement its behavior change 
communication (BCC) activities in August 2011, and some mass media activities did not start 
until September 2011. The range of activities implemented from April 2011 onwards included 
advocacy, mass media communications, community dramas and road shows. The costs of these 
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activities were increased because of the need to translate materials into multiple languages and to 
take account of cultural differences. Training was undertaken by the NMCP, focused on public 
sector health workers including lab technologists, civil society organizations and different types 
of community health extension workers. SFH training programs emphasized the private for-
profit sector, targeting Patent Proprietary Medicine Vendors (PPMVs), private sector health 
workers and pharmacists. 
 
Regulatory changes introduced alongside AMFm included relaxing the requirement that only one 
importer is permitted to import a particular product, waiving the “franchise levy” on copaid 
QAACTs and reducing analysis fees for copaid QAACTs levied by the National Agency for 
Food and Drug Administration and Control (NAFDAC). Other supporting regulatory changes 
included the inclusion of ACTs in the Nigerian Essential Drugs List, 5
th
 edition (2010) and the 
removal of chloroquine from the list, although this was subsequently reclassified for treatment of 
non-malaria illness, allowing it to continue to be manufactured and imported. ACTs were 
reclassified as over-the-counter drugs in 2006, allowing them to be sold/ distributed in a wide 
variety of outlets. Oral artemisinin monotherapies were banned in 2006, with their importation 
and local manufacturing prohibited by law. However, their continued presence on the market 
suggests that this regulation is not fully enforced. 
 
The RRP was originally set at N 75 (USD 0.44) for an adult dose and increased to N 100 (USD 
0.59) in November 2011, with lower prices for children’s doses. These RRPs involved a 
reduction in the RRP of N 120 (USD 0.70) that had been applied by SFH for an earlier 
subsidized product that was no longer available when AMFm started. The new RRP was not 
printed on the packaging of copaid drugs, but was widely promoted in radio jingles. A set of 
price enforcement plans was developed, but at the time of endline data collection these had not 
yet been implemented. 
 
There was a large increase between baseline and endline in knowledge of the first-line drug, 
from 16% to 54% among all outlets. A particularly large increase was recorded among public 
health facilities (from 39% to 87%). Overall, 53% of respondents recognized the AMFm logo 
and 36% of respondents said they knew of the AMFm program. Only 15% knew of the existence 
of the RRP and only 11% of these correctly stated it. Fourteen percent of all outlet survey 
respondents said they received some kind of training on AMFm. The exit survey found that 32% 
of respondents had seen the AMFm logo before, and that the most common sources were 
billboards (35%) and pharmacies (23%).  
 
Rapid Diagnostic Tests (RDTs) were being gradually introduced through activities by the NMCP 
in six states in the north and in the private sector by SFH in six states in the south. However, 
availability of diagnostics was very low overall at endline, with only 6% of outlets reporting 
availability of any diagnostic testing. This was higher in the public sector (29%) than in private 
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for-profit sector (4%). Within the private for-profit sector, availability of diagnostic testing was 
higher in health facilities/pharmacies (32%) and negligible in drug shops (1%).  
8.5.4 Context 
There is a large pharmaceutical manufacturing sector in Nigeria, which means that the 
introduction of AMFm was met with strong initial resistance because the locally produced ACTs 
were not eligible for the subsidy. A number of other development partners have provided support 
for malaria control during this period, including support for the distribution of long-lasting 
insecticidal nets (LLINs), the use of indoor residual spraying (IRS) in two states and scale-up of 
RDTs. General elections for Nigeria were held in April 2011. These elections brought some 
temporary restrictions on movement, which were, however, prolonged in some northern states 
due to the ensuing post-election crises between April and May 2011. Nigeria is experiencing 
ongoing terrorist attacks from the Boko Haram group, which have escalated in frequency and 
impact since September 2011, a situation which led to the President’s declaration of a state of 
emergency in 15 Local Government Areas in three States (Borno, Yobe and Plateau) on 
December 29, 2011. As stated above, ACTs had over-the-counter status. 
8.5.5 Summary 
Nigeria fully met Success Benchmarks 3 (QAACT price relative to AMT), 5 (QAACT market 
share) and 6 (AMT market share). There is some evidence that Nigeria also met Benchmark 1 
(availability). Nigeria just missed the threshold for Benchmark 2 (QAACT prices relative to the 
most popular antimalarial which is not a QAACT in tablet form). The price of SP tablets was 
quite low (USD 0.47), making this target difficult to meet, but there was also poor adherence to 
the RRP. This could reflect the relatively low awareness of the RRP or perhaps market pressures 
linked to the exercise of the Global Fund demand levers. Benchmark 4 could not be calculated. 
These results were achieved despite the context of instability caused by the post-election crisis 
and terrorist attacks, which may have affected supply in some areas. There have been impressive 
increases in knowledge of the first-line drug, particularly in public health facilities, but 
achievements in recognition of the AMFm logo and knowledge of the AMFm program are more 
modest, consistent with the relatively short period of implementation of SIs before the endline 
outlet survey was conducted. 
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8.6  Tanzania mainland 
8.6.1  Achievement of AMFm objectives  
Availability: QAACT availability across all outlets increased by 44 percentage points, from 
26% at baseline to 70% at endline (Benchmark 1). Tanzania has therefore easily met the 
benchmark of a 20 percentage point increase in QAACT availability (p<0.0001). There has been 
no increase in availability in the public sector, which was already 80% at baseline. Rather, the 
increase was concentrated in private for-profit outlets, which saw an increase in QAACT 
availability of 56 percentage points, with QAACTs available at endline in 79% of private for-
profit health facilities/ pharmacies and 69% of drug stores. Similar increases in availability were 
observed in urban and rural areas. At endline, availability of QAACTs with the AMFm logo was 
much higher than that of QAACTs without the logo, overall (62% vs. 21%), and in private for-
profit outlets (63% vs. 10%), although in public health facilities QAACTs without the logo were 
still common (55% vs. 64%). Oral AMT was almost entirely absent from the market at both 
baseline and endline. Availability of non-quality-assured ACTs increased by 11 percentage 
points overall and by 15 percentage points in private for-profit outlets, being more common in 
urban than in rural outlets. 
 
Price: In public and private non-profit health facilities, the median QAACT price remained at 
USD 0.00 at baseline and endline reflecting the policy of free provision. Dramatic decreases in 
median QAACT prices were observed in the private for-profit sector between baseline and 
endline, from USD 5.28 to USD 0.94 per AETD, although this was still somewhat higher than 
the RRP of USD 0.62. The price decrease was much greater in private for-profit outlets in urban 
areas than in rural areas, reflecting the relatively low median price at baseline in rural areas 
(USD 1.41) for which the reasons are unclear. It is possible that this reflects the presence of 
products subsidized by other programs in the market at baseline. However, at endline, QAACTs 
were still slightly more expensive in urban private for-profit outlets than in rural outlets (USD 
1.25 vs. USD 0.87). Between baseline and endline, the price of non-artemisinin therapy in the 
private for-profit sector remained unchanged at USD 1.41.  
 
The median price in private for-profit outlets for a QAACT carrying the AMFm logo was USD 
0.94 per AETD. This is exactly the same as the median price of the most popular antimalarial 
which is not a QAACT (SP) in tablet form, and therefore Tanzania has comfortably met 
Benchmark 2, which states that the ratio should be less than 3. As the number of oral AMT 
products in the market was negligible, Benchmark 3 was not relevant to Tanzania. There was 
very little change in the price of non-quality-assured QAACTs, which remained at over USD 
9.00 in the private for-profit sector at baseline and endline.  
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Figure 8.6.1: AMFm success metrics scorecard – Tanzania mainland  
Availability
Benchmark 1: 20 percentage point increase from baseline in availability of all QAACTS
Percentage point change, 95% CI for change and p-value for test that QAACT availability is at 
least 20 percentage points higher, by type of outlet
Type of outlet
Baseline 
(%)
Endline
(%)
Change
(95% CI) p
Public health facility
Private for-profit outlet
80.1
10.8
81.4
66.4
1.3 (-15.8-18.4)
55.6 (46.4-64.8)
np
<0.0001
Total* 25.5 69.5 44.0 (35.8-52.1) <0.0001
Price
Benchmark 2: Median price of QAACTs with the AMFm logo is less than 3 times the median price 
of the most popular  antimalarial that is not a QAACT, in tablet form **
Ratio of medians, 95% CI for ratio, p-value for test that ratio is < 3, in private for-profit outlets only
Median price of 
QAACTs with logo
Median price 
of most 
popular non-
QAACT
Ratio 
(95% CI) p
Private for-profit outlet USD 0.94 USD 0.94 1.0 (1.0-1.0) <0.0001
Benchmark 3: Median price of QAACTs with the AMFm logo is less the median price of AMT 
tablets
Difference in prices in USD (QAACT – AMT), 95% CI for difference, p-value for test that difference is 
negative, in private for-profit outlets only 
Median price of 
QAACTs with logo
Median price 
of AMT
Difference 
(95% CI) p
Private for-profit outlet USD 0.94 ns ns ns
Use
Benchmark 4: 5-10 percentage point increase from baseline in percentage of children under 
age 5 years with fever in the last 2 weeks who received ACT treatment
Percentage point change and p-value for t-test that use is at least 5 percentage points higher 
Baseline 
(%)
Endline
(%)
Change
(95% CI) p
Children under 5 years 37.9 na na na
Market share
Benchmark 5: 10-15 percentage point increase from baseline in the market share of all 
QAACTs
Percentage point change, 95% CI and p-value for test that  market share of QAACTs is at least 10-
percentage points higher, by type of outlet
Baseline 
(%)
Endline
(%)
Change
(95% CI) p
Public health facility
Private for-profit outlet
58.3
2.2
56.6
32.1
-1.8 (-37.7-34.2)
30.0 (21.9 -38.1)
0.7414
<0.0001
Total* 26.3 42.2 15.9 (0.1-31.7)*** 0.2302
Benchmark 6: Decrease in market share of oral AMTs
Percentage point change in market share, 95% CI for change and p-value for test that change is
negative, by type of outlet
Type of outlet
Baseline 
(%)
Endline
(%)
Change
(95% CI) p
Public health facility
Private for-profit outlet
0.0
0.0
0.0
0.0
0.0
0.0
-
-
Total* 0.0 0.0 0.0 -
Notes: Green shading = benchmark was achieved, with strong statistical evidence (generally p<0.01); Amber shading = either benchmark was nearly, but not fully, met, or the evidence that the change seen
was unlikely to be due to chance is weak (p≥0.05); Red shading = benchmark was not met ; Grey shading for Benchmarks 3 and 6 = metrics are not relevant because the number of AMT products was very
low at baseline; ACT = Artemisinin-based combination therapy; AMT = Artemisinin monotherapy; CI = Confidence interval; RRP = Recommended retail price; na = not available; np = not presented
because availability exceeded 80 percent at baseline; ns = not shown because the number of observations for either baseline or endline is fewer than 50 outlets/products (availability/price) or fewer than 500
AETDs (market share); QAACT = Quality-assured artemisinin-based combination therapy; SI = Supporting intervention; * Total includes CHWs and private not-for-profit facilities that are not shown
separately; ** The most popular antimalarial in tablet form that was not a QAACT in the private for-profit sector in Tanzania mainland was SP; *** The power to detect a 10 percentage point increase in
market share was only 35% in Tanzania mainland, compared with the usual minimum standard of 80%; therefore, p-values should be interpreted with caution
Further results
QAACT price in private for-profit outlets fell from USD 5.28 to USD 0.94 with a greater decrease
in urban areas (endline pirce in urban areas was USD 1.25 and rural areas USD 0.87).  The price of 
QAACTs with the AMFm logo  (USD 0.94) was higher than the RRP of USD 0.62. 
QAACT availability increased by similar amounts in urban and rural areas, and availabilty in urban 
and rural areas was similar in all outlets and private for-profit outlets. QAACT market share at 
endline was 34% in urban areas and 46% in rural areas.  Private for-profit outlets were responsible 
for 59% of all antimalarials at endline. 
Process and context data
The AMFm agreement was signed on August 6th, 2010 and the first copaid drugs arrived in October 
2010 (13.5 months before endline). SIs started in  January 2011 and mass communications began in 
April 2011 giving 7 months implementation before endline.  Demand levers only had a modest 
impact in Tanzania, with 90% of orders in Q3 and Q4 of 2011 approved. Contextual factors include 
a large scale malaria control communications campaign funded by PMI and the Global Fund, 
distribution of RDTs to public facilities, IRS and mass distribution of LLINs, and depreciation of 
the Tanzanian shilling. 
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The gross percentage markup on QAACTs, measured among private for-profit outlets, increased 
from 50% to 67% between baseline and endline. However, with the large decrease in the median 
price of QAACTs, this amounts to a much smaller absolute markup at endline. The gross 
percentage markup in private for-profit outlets at endline was higher on copaid than on non-
copaid QAACTS (67% vs. 50%). As a comparator, the median gross percentage markup on nAT 
in the private for-profit sector was 67% at baseline and 77% at endline. The median total markup 
from the first line buyer price to the retail price in private for-profit outlets was USD 0.84, 
slightly higher in urban areas (USD 1.10) than in rural areas (USD 0.78). 
 
Market share: The market share of QAACTs overall increased by 16 percentage points from 
26% at baseline to 42% at endline. The increase took place mainly in the private for-profit sector, 
which saw a 30 percentage point increase from 2% to 32%. By contrast, the market share was 
unchanged in public health facilities, where a fall in QAACT market share in urban areas was 
not sufficiently offset by an increase in rural areas. The evidence that Benchmark 5 (10 
percentage point increase in market share from baseline to endline) has been met for all sectors 
combined is not strong (p=0.23); however, the power to detect a 10 percentage point increase in 
market share is below the usual minimum standard of 80%, therefore p values should be 
interpreted with caution. However, in the private for-profit sector alone, the increase was 
significantly greater than 10 (p<0.0001). Benchmark 6 was not relevant to Tanzania given the 
negligible market share of oral AMTs at both baseline and endline. 
 
In the private for-profit sector, the gain in QAACT market share was primarily due to a shift 
from nATs to QAACTs, with a 30 percentage point increase in the QAACT market share and a 
27 percentage point decrease in the nAT market share. This is consistent with argument that 
QAACTs are displacing nAT in the private sector. QAACTs with the AMFm logo accounted for 
61% of all QAACT volumes across all outlets and 91% among private for-profit outlets. 
 
The private for-profit sector was responsible for 59% all antimalarials sold or distributed at 
endline, with a much higher private for-profit market share at endline in urban areas than rural 
areas (91% vs. 44%). The private for-profit share had increased from 45% at baseline, mainly 
reflecting a fall in the private not-for-profit sector share in urban and rural areas and a fall in the 
public sector market share in urban areas.  
8.6.2  Supply of AMFm copaid drugs 
A total of 10 private for-profit FLBs were registered with the Global Fund, and five formed 
relationships with manufacturers and placed orders by the end of 2011. For the public sector, the 
Medical Stores Department (MSD) was registered as an FLB. The first orders for copaid 
QAACTs were placed in August 2010 by a private for-profit FLB and were delivered in October 
2010. It is possible that some copaid drugs were on the retail market before the end of baseline 
outlet survey data collection, which finished in November 2010, but the baseline results 
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indicated that this was very limited as very few products bearing the AMFm logo were audited. 
The copaid drug supply system to the private sector was reported to have functioned relatively 
smoothly, although orders were slow initially and some delivery times were long. 
 
The first public sector FLB order was placed in April 2011, with delivery starting from July 
2011. There were a number of problems with public sector delivery, including delays in the 
initial procurement process, delays in delivery and delays in approval of the second round of 
orders. As a result, only 4,917,000 public sector treatments had arrived in Tanzania between July 
and the end of December 2011, which fell far short of requirements. Emergency procurement by 
PMI went some way to addressing this gap, although supplies were still insufficient, leading to 
high stockout levels in public facilities, with over one-fifth and over one-quarter of public 
facilities having no stock of the first-line antimalarial in May and August 2011, respectively. The 
IE outlet survey confirmed this, showing that only 76% of all public health facilities (including 
those without antimalarials in stock on the day of the interview) had QAACTs in stock at 
endline, which was unchanged from the 75% observed at baseline. 
 
A total of 13,039,620 copaid QAACT treatments were delivered between October 2010 and 
December 2011, amounting to 0.31 treatments per capita (the whole population of Tanzania is 
considered at risk of malaria), of which 62% were delivered to private for-profit FLBs. The 
Global Fund’s demand levers are likely to have had only a small effect in Tanzania, with 90% of 
orders requested by private sector FLBs in the second half of 2011 receiving Global Fund 
approval. A total of 13.5 months elapsed between the date the first drugs arrived in Tanzania 
(October 2010) and the midpoint of endline outlet survey fieldwork. Supporting interventions 
started in January 2011, giving only 10 months of effective SI implementation, and only 7 
months from the start of the communications campaign (see below). 
8.6.3  Implementation of supporting interventions 
A total of USD 3,284,890 was available through the Global Fund for SIs at the time of grant 
signing (this does not take into account interventions funded through other programs). As of 
November 2011, USD 1,303,223 had been disbursed, giving a per capita disbursement on SIs of 
only USD 0.03. However, actual AMFm related expenditure is considerably higher than this as 
funding for upgrading of drug stores to accredited drug dispensing outlets (ADDOs) was mainly 
covered by other Global Fund grants. A national launch was held in April 2011, followed by a 
mass media campaign, and distribution of promotional materials. Additional community-level 
communication activities began in August 2011 in 24 out of 121 districts. The main training 
activity involved upgrading drug stores to ADDOs in an additional six regions in January to 
March 2011, involving a 35-day training program. A one-day supplementary training covering 
AMFm was also implemented in August to September 2011 in two regions that had undergone 
ADDO conversion before AMFm. Other supporting interventions covered pharmacovigilance 
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activities, and monitoring and evaluation, but these were not expected to have influenced AMFm 
outcomes. 
 
The RRP of USD 0.64 for an adult dose did not appear on the packaging of copaid QAACTS, 
but was widely promoted in media campaigns. It seems likely that the RRP was a significant 
factor in “anchoring” the price of QAACTs in Tanzania. Provider awareness of the RRP was 
quite high (61%), with similar awareness in urban and rural areas. Of those who were aware of 
the RRP, 82% stated its correct level. 
 
There was a very high level of provider recognition of the AMFm logo at endline (87% overall 
and uniformly high across all sectors), with recognition similar in urban and rural areas. Of those 
recognizing the logo, 54% said it meant an ACT, 22% an effective/quality antimalarial and 22% 
an affordable antimalarial. Eleven percent of respondents did not know what it meant. Provider 
knowledge of the AMFm program was also high, at 72% overall.  
 
Overall 17% of respondents stated that they had received some training on antimalarials with the 
AMFm logo, with similar figures across sectors and in urban and rural areas. Provider 
knowledge of the first-line drug was already high at baseline at 88% and increased significantly 
to 96% at endline.  
8.6.4 Context  
The USD 1.3 million disbursed for AMFm communications was complementary to a USD 25 
million malaria communications program over the previous five years funded by PMI and the 
Global Fund, covering malaria prevention and treatment in 18 regions. One must therefore be 
cautious in attributing general improvements in malaria-related knowledge to the AMFm 
campaign, which was conducted against the background of these broader promotional activities. 
Other important malaria control interventions rolled out during this period were RDTs in public 
health facilities in six regions, distribution of 18 million LLINs between October 2010 and 
October 2011, and indoor residual spraying in limited areas, all of which may have reduced 
demand for antimalarials. There was no increase in the availability of diagnostics between 
baseline and endline, with endline availability at 48% in public facilities and 6% in private for-
profit outlets, although there was some indication of increasing RDT availability in public health 
facilities. A ban on AMTs, which had been in place since 2008, is likely to have provided a 
supporting environment for AMFm. ACTs did not have over-the-counter status. The Tanzanian 
Shilling experienced rapid depreciation during 2011 which may have put upward pressure on the 
price of imported drugs, but the impact is not expected to have been large on copaid drug prices.  
379 | P a g e  
 
8.6.5 Summary 
There is strong evidence that Tanzania has met Success Benchmark 1 (QAACT availability), and 
there is evidence to suggest that Tanzania has likely also met Benchmark 2 (QAACT price 
relative to the most popular antimalarial which is not a QAACT). It is possible that Benchmark 5 
(QAACT market share) was also met across all sectors, but the evidence is not strong, However, 
we can be confident that the required 10 percentage point increase in market share was easily 
achieved in the private for-profit sector. Benchmarks 3 and 6 are not relevant to Tanzania given 
the negligible presence of oral AMT in the market at baseline and endline. Data were not 
available to assess Benchmark 4 on use. The evidence about impressive changes in the 
availability and price of QAACTs, together with strong evidence of awareness of AMFm, as well 
as the flow of copaid drug orders and the evidence on SI implementation, provide plausible 
evidence that AMFm is responsible for the increases observed in QAACT market share. These 
changes may have also been supported by the complementary malaria communications campaign 
funded by other sources. The decrease in the market share of nAT in private for-profit outlets 
suggests that AMFm may be crowding out nATs and not simply shifting demand from other 
ACTs.  
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8.7 Uganda 
8.7.1  Achievement of AMFm objectives  
Availability: QAACT availability across all outlets increased by 46 percentage points, from 
21% at baseline
17
 to 67% at endline (Benchmark 1). There is strong evidence that Uganda has 
therefore met the benchmark of a 20 percentage point increase in QAACT availability 
(p<0.0001). The increase was slightly higher in urban areas (57 percentage points) than in rural 
areas (43 percentage points). In the public sector, QAACT availability remained high, at 87% at 
baseline and 92% at endline, meaning that most of the overall increase arose in the private for-
profit sector, which saw an increase in QAACT availability of 54 percentage points. There is 
strong evidence that the increase in availability in private for-profit outlets was greater than the 
20 percentage point threshold (p<0.0001). Availability of QAACTs with the AMFm logo was 
much higher than that of QAACTs without the logo overall (58% vs. 16%), in the public sector 
(83% vs. 42%) and in the private for-profit sector (61% vs. 8%). Availability of QAACTs with 
the logo was higher in urban than in rural areas (70% vs. 55%). Availability of non-quality-
assured ACTs fell significantly, from 48% at baseline to 28% at endline. Non-quality assured 
ACTs were more commonly found in urban than in rural outlets at baseline and endline. 
Availability of oral AMT was negligible at baseline and endline. 
 
Price: In the public and private not-for-profit sectors and for Community Health Workers 
(CHWs), the median price remained USD 0.00 at baseline and endline, reflecting the policy of 
free ACT provision. In the private for-profit sector, the median QAACT price at endline was 
USD 1.96 in urban and rural areas. In urban areas this represented a fall of over 50% from the 
baseline median of USD 4.64 (p=0.001), but in rural areas the decrease from USD 2.32 at 
baseline was not significant. The median price for QAACTs at endline was much higher than the 
RRP, which was USD 0.47. Due to an increase in QAACT sales in the private for-profit sector, 
the overall median price rose from USD 0.00 to USD 1.37 (p=0.0004). There were no significant 
changes in the cost of non-artemisinin therapy or non-quality assured ACT in the private for-
profit sector between baseline and endline. 
 
The median price in private for-profit outlets for a QAACT carrying the AMFm logo was USD 
1.96 per AETD. This is 3.3 times the median price of the dominant antimalarial which is not a 
QAACT (SP) in tablet form, and therefore Uganda did not meet Benchmark 2, which states that 
the ratio should be less than 3. Benchmark 3 was not relevant in Uganda as there was only one 
price observation for oral AMT, reflecting its absence from the market. 
                                                 
17
 At baseline there were 35 observations of Artemether + Lumefantrine (AL) that were manufactured at Quality 
Chemicals International Limited’s (QCIL) factory in Kampala. These were not classified as QAACTs at baseline, 
because QCIL’s AL product did not comply with the Global Fund’s Quality Assurance policy until after the baseline 
survey (refer to Appendix I for further details). This has not affected the comparability of availability at baseline and 
endline, as most outlets stocking QCIL’s ACT at baseline had other QAACTs in stock. Indeed, only one outlet (a 
public health facility) that stocked the ACT manufactured by QCIL at baseline had no other QAACT in stock.  
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Figure 8.7.1: AMFm success metrics scorecard – Uganda 
Availability
Benchmark 1: 20 percentage point increase from baseline in availability of all QAACTS
Percentage point change, 95% CI for change and p-value for test that QAACT availability is at 
least 20 percentage points higher, by type of outlet
Type of outlet
Baseline 
(%)
Endline
(%)
Change
(95% CI) p
Public health facility
Private for-profit outlet
87.3
11.3
91.7
65.5
4.3 (-1.2-9.8)
54.2 (47.3-61.0)
np
<0.0001
Total* 21.0 67.1 46.2 (39.5 -52.9) <0.0001
Price
Benchmark 2: Median price of QAACTs with the AMFm logo is less than 3 times the median 
price of the most popular  antimalarial that is not a QAACT, in tablet form **
Ratio of medians, 95% CI for ratio, p-value for test that ratio is < 3, in private for-profit outlets only
Median price of 
QAACTs with 
logo
Median price 
of most 
popular non-
QAACT
Ratio 
(95% CI) p
Private for-profit outlet USD 1.96 USD 0.59 3.3 (3.3-3.3) 0.9999
Benchmark 3: Median price of QAACTs with the AMFm logo is less the median price of AMT tablets
Difference in prices in USD (QAACT – AMT), 95% CI for difference, p-value for test that difference is 
negative, in private for-profit outlets only 
Median price of 
QAACTs with 
logo
Median price 
of AMT
Difference 
(95% CI) p
Private for-profit outlet USD 1.96 ns ns ns
Use
Benchmark 4: 5-10 percentage point increase from baseline in percentage of children under 
age 5 years with fever in the last 2 weeks who received ACT treatment
Percentage point change and p-value for t-test that use is at least 5 percentage points higher 
Baseline 
(%)
Endline
(%)
Change
(95% CI) p
Children under 5 years 23.3*** na na na
Market share
Benchmark 5: 10-15 percentage point increase from baseline in the market share of all QAACTs
Percentage point change, 95% CI and p-value for test that  market share of QAACTs is at least 10-
percentage points higher, by type of outlet
Baseline 
(%)
Endline
(%)
Change
(95% CI) p
Public health facility
Private for-profit outlet
64.2
5.1
81.3
38.5
17.1 (4.2-30.0)
33.4 (26.0-40.8)
0.1380
<0.0001
Total* 40.0 56.7 16.8 (7.1-26.5)**** 0.0846
Benchmark 6: Decrease in market share of oral AMTs
Percentage point change in market share, 95% CI for change and p-value for test that change is
negative, by type of outlet
Type of outlet
Baseline 
(%)
Endline
(%)
Change
(95% CI) p
Public health facility
Private for-profit outlet
0.0
0.0
0.0
0.0
0.0
0.0
-
-
Total* 0.0 0.0 0.0 (-0.06-0.02) 0.1560
Notes: Green shading = benchmark was achieved, with strong statistical evidence (generally p<0.01); Amber shading = either benchmark was nearly, but not fully, met, or the evidence that the change seen was
unlikely to be due to chance is weak (p≥0.05); Red shading = benchmark was not met ; Grey shading for Benchmarks 3 and 6 = metrics are not relevant because the number of AMT products was very low at
baseline; ACT = Artemisinin-based combination therapy; AMT = Artemisinin monotherapy; CI = Confidence interval; RRP = Recommended retail price; na = not available; np = not presented because
availability exceeded 80 percent at baseline; ns = not shown because the number of observations for either baseline or endline is fewer than 50 outlets/products (availability/price) or fewer than 500 AETDs
(market share); QAACT = Quality-assured artemisinin-based combination therapy; SI = Supporting intervention; * Total includes CHWs and private not-for-profit facilities that are not shown separately;
** The most popular antimalarial in tablet form that was not a QAACT in the private for-profit sector in Uganda was SP; *** Source of baseline information for Benchmark 4 is the 2009-10 Malaria Indicator
Survey; ****The power to detect a 10 percentage point increase in market share was only 66% in Uganda, compared with the usual minimum standard of 80%; therefore, p-values should be interpreted with
caution.
Further results
QAACT price in urban areas fell from USD 4.64 to USD 1.96, with the rural decrease smaller and
not significant; the median price of QAACTs with the AMFm logo was about 4 times higher than
the RRP of USD 0.47 (2010 prices).
Retail markup on QAACTs increased from 50% to 127% (compared with 67% on nAT at endline).
There was a larger increase in QAACT availability in urban than rural areas (57 vs. 43 percentage
points) and endline availability was higher in urban areas (77% vs. 65%). Endline market QAACT
market share was higher in rural than urban areas (62% vs. 42%).
Process and context data
The AMFm agreement was signed on February 11, 2011, and the first copaid drugs arrived in April
2011 (7 months before endline).
By December 2011 no SIs had begun other than a small-scale communications campaign. Exercise
of Global Fund demand levers meant that only 57% of orders in Q3 and Q4 of 2011 were approved.
Other contextual factors were delays in placement of the first public sector order, and there was
significant depreciation of the Ugandan shilling against the dollar.
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Surprisingly, there was no difference in the private for-profit sector between the median price of 
QAACTs with and without the AMFm logo overall, although in urban areas the price of 
QAACTs without the AMFm logo was USD 2.74. 
 
The gross percentage markup on QAACTs, measured among private for-profit outlets, increased 
from 50% to 127% between baseline and endline, with similar increases in urban and rural areas. 
The gross percentage markup in private for-profit outlets at endline was higher for QAACTs 
with the logo than on those without the logo (133% vs. 100%). In rural areas, the difference in 
markup between QAACTs with and without the logo is even greater (127% v. 71%). Since the 
median price of QAACTs with the AMFm logo is the same as the median price of QAACTs 
without the logo, the higher markups on QAACTs with the logo could indicate that retailers in 
rural areas are taking advantage of the subsidy to obtain higher markups on the copaid products. 
As a comparator, the median gross percentage markup on nAT in the private for-profit sector 
remained at 67% at baseline and endline. The median total markup from the first line buyer price 
to the retail price in private for-profit outlets was USD 1.83. 
 
Market share: The market share of QAACTs overall increased significantly from 40% to 57%, 
an increase of 17 percentage points (95% CI 7.1-26.5). This represents a significant increase 
from baseline, and provides some evidence that Benchmark 5 of a 10 percentage point increase 
had been met, although the evidence is not strong (p=0.08). However, the power to detect a 10 
percentage point increase in market share is below the usual minimum standard of 80%; 
therefore, p values should be interpreted with caution. Similar results were obtained for the 
public sector alone, where QAACT market share also increased significantly, by 17 percentage 
points (95% CI 4.2-30.0). There was almost no change in QAACT market share in private not-
for-profit outlets (47% to 51%). However, in the private for-profit sector, the QAACT market 
share increased substantially, from 5% to 39%. There is strong evidence that the increase 
exceeded the 10 percentage point threshold (p<0.0001), with similar increases in urban and rural 
areas. The overall market share of oral AMTs was close to zero at baseline and endline, meaning 
that Benchmark 6 was not relevant for Uganda. 
 
In the public and private for-profit sectors, the gain in QAACT market share was primarily due 
to a shift from nAT to QAACTs. In the public sector, there was a 17 percentage point increase in 
QAACT market share and a 17 percentage point fall in nAT market share, and in private for-
profit facilities there was a 33 percentage point increase in the QAACT market share and a 29 
percentage point decrease in nAT market share. This is consistent with the argument that 
QAACTs are displacing nAT in the public and private sectors. 
 
QAACTs with the AMFm logo accounted for 76% of all QAACTs sold or distributed across all 
outlets, and 88% of QAACT volumes in private for-profit outlets. At baseline, the private for-
profit sector was responsible for 76% of all antimalarials sold or distributed in urban areas and 
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33% in rural areas. At endline, there was no change in the share in urban areas (77%), but in 
rural areas the private for-profit share increased to 46%, at the expense of the public sector, for 
which the rural share fell from 64% to 47%. 
8.7.2  Supply of AMFm copaid drugs  
A total of 9 private for-profit and 3 private not-for profit FLBs were registered with the Global 
Fund as of January 31, 2012. QCIL also registered as a first line buyer for the public sector, as 
did Crown Agents. Orders were placed with 4 of these private for-profit FLBs by December 
2011. 
 
The first orders for copaid QAACTs were placed in March 2011 by private for-profit and private 
not-for-profit FLBs, with first deliveries arriving in April 2011 for private for-profit FLB and in 
June 11 for the private not-for-profit FLB. Delays in receiving orders were reported in both the 
private for-profit and private not-for-profit sector. The second order of the Joint Medical Stores 
(JMS), a private not-for-profit FLB, was delayed by 134 days from the date that the order was 
approved to the date of delivery to the first port of entry. This is unlikely to have affected 
availability of QAACTs in private not-for-profit facilities in the endline survey because the JMS 
had good stock levels through the second half of 2011. The private-for profit FLBs reported that 
some orders were delayed or cut, and indicated that they experienced stockouts of all or some 
age-bands in between orders. This is supported by evidence from Table 1.2.2 that only 57% of 
treatments requested by private sector FLBs in Q3 and Q4 of 2011 were approved. This might 
have affected availability and market share in private for-profit outlets. Nevertheless, the 
thresholds for the availability and market share success metrics were clearly met in private for-
profit outlets in Uganda. 
 
The first public sector FLB orders were placed only in June 2011 with deliveries beginning from 
July 2011, but no stockouts of the adult package size of AL at the National Medical Stores 
(NMS) were reported. However, stock levels of the adolescent and pediatric package sizes of AL 
were low by December 2010, and by March 2011 the NMS was out of stock of these pack sizes. 
By September 2011, the NMS had received substantial quantities of copaid ACTs. QAACT 
stocking levels in all public health facilities were similar at baseline (84%) and endline (91%). 
This is consistent with the case study findings that stock levels of ACTs at the NMS were high in 
the months preceding both the baseline and endline surveys. 
 
A total of 28,226,700 copaid QAACT treatments were delivered between April 2011 and 
December 2011, amounting to 0.84 treatments per capita (the whole population of Uganda is 
considered at risk of malaria). Of these, 73% were delivered to the public sector, 25% to the 
private for-profit sector, and 2% to the private not-for-profit FLB.  
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Only 7 months elapsed between the date the first drugs arrived in Uganda (April 2011) and the 
midpoint of endline outlet survey fieldwork, so the implementation period was quite short.  
8.7.3  Implementation of supporting interventions  
A total of USD 28,575,151 was available through the Global Fund for SIs at the time of grant 
signing (this does not take into account interventions funded through other programs). The first 
disbursement of USD 5,554,024 was made by November 2011, but none of these funds were 
spent by the end of 2011. The only AMFm supporting interventions that occurred prior to the 
end of endline data collection were the National Launch that was held as part of World Malaria 
Day celebrations, and the small-scale AMFm pre-disbursement marketing campaign. In addition, 
some first line buyers either printed their own point-of-sale materials, or used posters or other 
promotional items provided by the manufacturer. These activities likely had limited influence on 
AMFm outcomes, due to their small scale. 
 
An RRP of USD 0.47 for an adult dose was set, but did not appear on the packaging of copaid 
QAACTs. Key informant interviews revealed that awareness and adherence to the RRP was 
thought to be low. This was confirmed by the endline outlet survey results. Only 10% of 
providers were aware that there was an RRP on copaid QAACTs, with awareness similar across 
urban/rural locations and outlet types. Of those who were aware of the RRP, only 5% stated its 
correct level. Poor awareness of the RRP might have contributed to the relatively high median 
prices for QAACTs bearing the AMFm logo that were observed in the endline outlet survey.  
 
Provider knowledge of the AMFm program was somewhat higher than awareness of the RRP, at 
25% overall. Attendance of training on antimalarials with the AMFm logo was reported by only 
15% of respondents, with similar levels across the public (12%), private not-for-profit (11%) and 
private for-profit (17%) sectors. Provider knowledge of the first-line drug was high at baseline 
(78%) and endline (79%), with particularly high levels of over 95% in public health facilities at 
both time points. Between baseline and endline there was a significant decrease in the response 
“I don’t know about these drugs” (16% to 6%) as a reason for not stocking QAACTs among 
private for-profit providers. 
 
There was a high level of provider recognition of the AMFm logo at endline (66% overall), with 
similar results in urban and rural areas. Of those recognizing the logo, 89% said it meant an ACT 
and 33% said it meant an antimalarial (multiple responses were allowed). Twenty-six percent of 
all respondents did not know what it meant. Given that the implementation of AMFm supporting 
interventions was limited at the time of the survey, providers might have recognized the logo 
from the CAPSS (Consortium for ACT Private Sector Subsidy) program. CAPSS distributed 
subsidized ACTs to the private sector from 2008-2010 in four districts and used a logo very 
similar to the AMFm logo on its packaging and marketing materials.  
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8.7.4  Context  
ACTs were recently granted over-the-counter status. This regulatory change was seen as 
legalizing the longstanding practice of drug shops selling ACTs. Further implementation of this 
regulatory change was expected as part of the AMFm supporting interventions, but like other 
AMFm supporting interventions these activities had not started by the end of 2011. There was no 
significant increase in the availability of microscopy between baseline and endline, but 
availability of RDTs increased significantly in public health facilities (from 4% to 53%) and in 
private non-profit outlets (from 9% to 51%), leading to significant increases in availability of any 
diagnostic, especially in rural areas. RDT availability in the private for-profit sector remained 
low, at 10% at endline. There was a substantial depreciation of the Ugandan shilling between the 
baseline and endline outlet surveys. 
8.7.5  Summary 
There is strong evidence that Uganda has met Success Benchmark 1 (QAACT availability), and 
some evidence that it has met Benchmark 5 (market share). The threshold of a 10 percentage 
point increase in QAACT market share was clearly met in the private for-profit sector. 
Benchmark 2 (QAACT price relative to the most popular antimalarial which is not a QAACT) 
was not met, with a ratio of 3.3 which is above the threshold set of 3. Benchmarks 3 and 6 were 
not relevant to Uganda as oral AMT was so rare at both baseline and endline. Data were not 
available to calculate Benchmark 4. The improvements in QAACT availability and market share 
were achieved despite the relatively short time between first arrival of copaid drugs and the 
endline outlet survey (7 months), and the lack of AMFm supporting interventions. Large 
improvements in availability and market share in the private for-profit sector were also achieved 
even though only a quarter of copaid drugs delivered went to private for-profit FLB, and in spite 
of the exercise of the Global Fund’s demand management levers. It is likely that these 
improvements were due to AMFm, given the high share of QAACTs with a logo among all 
QAACTs in the private for-profit sector at endline (88%). The share of antimalarials distributed 
by the private for-profit sector rose in rural areas between baseline and endline, which may partly 
be explained by an expansion of RDT availability in the public and private not-for-profit sectors, 
which should have reduced ACT use in these facilities. The decrease in the market share of nAT 
suggests that AMFm is crowding out nATs and not simply shifting demand from other ACTs. 
The failure to meet Benchmark 2 is indicative of a particularly high retail price for copaid 
QAACTs, reflecting very high gross percentage retail markups, and a high total markup from 
FLB price to retail selling price. This may have been influenced by lack of awareness of the 
RRP, with only 10% of respondents being aware that there was an RRP and only 5% of these 
knowing its level. 
386 | P a g e  
 
 
8.8 Zanzibar 
The success metrics scorecard for Zanzibar is shown in Figure 8.8.1. Achievement of the AMFm 
objectives, the supply of AMFm copaid drugs, implementation of supporting interventions, and 
contextual factors that could affect the achievement of the AMFm benchmarks are discussed 
below. 
8.8.1 Achievement of AMFm objectives  
Availability: QAACT availability across all outlets increased by 39 percentage points, from 
46% at baseline to 85% at endline (Benchmark 1), easily meeting the benchmark of a 20 
percentage point increase in QAACT availability. Availability was slightly higher in rural than in 
urban areas at endline (90% vs. 82%). Virtually all of the increase in QAACT availability 
occurred in private for-profit outlets, as availability in public sector health facilities was already 
92% at baseline and increased only marginally to 94% at endline. Within the private for-profit 
sector, QAACT availability increased by 71 percentage points from 9% at baseline to 80% at 
endline. Availability at endline was slightly higher in private health facilities/pharmacies (89%) 
than in drug stores (74%). At endline, QAACTS with the AMFm logo made up a large majority 
of QAACTS, with 83% of all outlets stocking QAACTs with the logo, compared with 6% 
stocking QAACTs without it. Availability of QAACTs with the logo was lower in urban areas 
(79%) than in rural areas (89%). 
 
There was a large reduction in availability of nATs in all sectors, falling from 88% to 47% across 
all outlets and from 98% to 57% in private for-profit outlets. Availability of oral AMT in the 
private for-profit sector also fell substantially, from 30% of all outlets at baseline to only 1% at 
endline. Finally, the availability of non-quality assured ACTs also fell in all outlets, from 35% to 
19%, but with a particularly large reduction in availability in the public sector, from 32% to 8%.  
 
Price: Because nearly all the QAACTs at baseline were in public health facilities (and therefore 
free), the increased availability in the for-profit sector led to an increase in the overall median 
price from USD 0.00 at baseline to USD 0.58. However, there was a very substantial decrease in 
the median price of QAACTs in private for-profit outlets, from USD 5.99 at baseline to USD 
1.17 at endline. The endline median price is 83% higher than the recommended retail price 
(RRP) of USD 0.58 for an adult dose. The median price per AETD of QAACTs in private for-
profit outlets was similar in urban and rural areas. There was little change in the price of nATs in 
private for-profit outlets between baseline and endline (USD 2.54 vs. USD 2.62).  
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Figure 8.8.1: AMFm success metrics scorecard – Zanzibar 
Availability
Benchmark 1: 20 percentage point increase from baseline in availability of all QAACTS
Percentage point change, 95% CI for change and p-value for test that QAACT availability is at 
least 20 percentage points higher, by type of outlet
Type of outlet
Baseline 
(%)
Endline
(%)
Change
(95% CI) p
Public health facility
Private for-profit outlet
92.1
8.8
93.5
80.1
1.5
71.3
Total* 45.8 85.1 39.3
Price
Benchmark 2: Median price of QAACTs with the AMFm logo is less than 3 times the median 
price of the most popular  antimalarial that is not a QAACT , in tablet form **
Ratio of medians, 95% CI for ratio, p-value for test that ratio is < 3, in private for-profit outlets only
Median price of 
QAACTs with 
logo
Median price 
of most 
popular non-
QAACT
Ratio 
(95% CI) p
Private for-profit outlet USD 1.17 USD 0.79 1.5
Benchmark 3: Median price of QAACTs with the AMFm logo is less the median price of AMT 
tablets
Difference in prices in USD (QAACT – AMT), 95% CI for difference, p-value for test that difference is 
negative, in private for-profit outlets only 
Median price of 
QAACTs with 
logo
Median price 
of AMT
Difference 
(95% CI) p
Private for-profit outlet USD 1.17 USD 7.46 -6.30
Use
Benchmark 4: 5-10 percentage point increase from baseline in percentage of children under 
age 5 years with fever in the last 2 weeks who received ACT treatment
Percentage point change and p-value for t-test that use is at least 5 percentage points higher 
Baseline 
(%)
Endline
(%)
Change
(95% CI) p
Children under 5 years na na na na
Market share
Benchmark 5: 10-15 percentage point increase from baseline in the market share of all QAACTs
Percentage point change, 95% CI and p-value for test that  market share of QAACTs is at least 10-
percentage points higher, by type of outlet
Baseline 
(%)
Endline
(%)
Change
(95% CI) p
Public health facility
Private for-profit outlet
22.8
2.0
38.1
60.7
15.3
58.7
Total* 9.7 57.8 48.1
Benchmark 6: Decrease in market share of oral AMTs
Percentage point change in market share, 95% CI for change and p-value for test that change is
negative, by type of outlet
Type of outlet
Baseline 
(%)
Endline
(%)
Change
(95% CI) p
Public health facility
Private for-profit outlet
0.1
19.5
0.0
0.2
-0.1
-19.3
Total* 12.2 0.2 -12.0
Notes: Confidence intervals and p-values are not shown for Zanzibar because a complete census of antimalarial selling outlets was undertaken; consequently, green shading = benchmark was achieved;
Amber shading = benchmark was nearly, but not fully, met; Red shading = benchmark was not met ; Grey shading for Benchmarks 3 and 6 = metrics are not relevant because the number of AMT products
was very low at baseline; ACT = Artemisinin-based combination therapy; AMT = Artemisinin monotherapy; CI = Confidence interval; RRP = Recommended retail price; na = not available; QAACT
=Quality-assured artemisinin-based combination therapy; SI = Supporting intervention; * Total includes CHWs and private not-for-profit facilities that are not shown separately; ** The most popular
antimalarial in tablet form that was not a QAACT in the private for-profit sector in Zanzibar was amodiaquine.
Further results
QAACT price in the private for-profit sector fell from USD 5.99 to USD 1.17 (USD 1.17 urban, USD 
0.93 rural).  The price of QAACTs with the AMFm logo (USD 1.17) was higher than the RRP of 
USD 0.58 (2010 prices).  
QAACT availability was slightly lower in urban than rural outlets at endline (82%. vs. 90%); QAACT 
market share was slightly  higher in urban outlets (58.9%) vs. rural outlets (51.3%).  The private 
sector share of all antimalarials distributed increased from 62% at baseline to 87% at endline. 
Process and context data
The AMFm agreement was signed on November 10, 2010 and the first copaid drugs arrived in 
April 2011 (6.5 months before endline). 
Supporting interventions started in May 2011. The national launch took place in June 2011 and 
mass media communications commenced in  July 2011 (3 months before endline). Important 
contextual factors included early adoption of ACTs as first-line drug (in 2003), enforcement of 
AMT ban, allowing ACTs to be sold in drug stores, scale up of diagnostics, IRS and distribution of 
LLINS, and a dramatic reduction in the number of malaria cases. 
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The median price of QAACTs with the AMFm logo in private for-profit outlets at endline was 
USD 1.17 per AETD. This is 1.48 times the price of the most popular antimalarial which is not a 
QAACT in tablet form which in Zanzibar was amodiaquine (with a price of USD 0.79 per 
AETD). Zanzibar has therefore clearly met Benchmark 2, which states that the ratio of median 
prices should be less than 3. The median price of QAACTs with the logo was also much lower 
than the price of AMT tablets (USD 7.46) so Benchmark 3 was also met. 
 
At endline, the gross percentage markup on QAACTs in private for-profit outlets was 100%. 
This is higher than the median markup on nAT in private for-profit outlets, which was 50% at 
endline. However, as the median price of QAACTs (USD 1.17) is much lower than that of nATs 
(USD 2.62) this amounts to a smaller absolute markup on QAACTs. The total gross markup 
from the first line buyer price to retail price in private for-profit outlets was $1.11. 
 
Market share: Zanzibar has seen a nearly six-fold increase in the market share of QAACTs 
from baseline to endline, from 10% of all antimalarial AETDs sold/dispensed at baseline to 58% 
at endline. Benchmark 5 of a 10% increase in QAACT market share has therefore been easily 
achieved. In public sector outlets, the QAACT share has increased by 15 percentage points, from 
23% to 38%, with the main shift being away from non-quality-assured ACTs, from 21% at 
baseline to only 3% at endline. In private for-profit sector outlets, the increase in QAACT market 
share is even more dramatic, with a 59 percentage point increase, from 2% at baseline to 61% at 
endline. In the private for-profit sector, the increase in QAACT market share has been 
accompanied by a decrease in the market share of nATs, from 52% at baseline to 18% at endline. 
QAACTs with the logo make up 96% of total QAACT volume in all outlets combined and 
among private for-profit outlets. QAACTs with the AMFm logo are now over half of 
antimalarial sales, while QAACTs without the logo make up only 3%. 
 
Benchmark 6 has also been achieved, with the market share of AMTs measured in all outlets 
falling by 12 percentage points from 12% to nearly 0 at endline. The largest decrease was seen 
among private for-profit outlets, where the oral AMT share decreased from 20% at baseline to a 
negligible 0.2% at endline. These results suggest that improved availability of QAACTs is 
achieving both the AMFm objectives of increasing use of effective antimalarial medicines and 
decreasing use of AMT. 
 
Between baseline and endline there has been quite a substantial reduction in the relative 
importance of the public sector as a source of antimalarials, as evidenced by its share of all 
antimalarials sold, from 37% at baseline to 13% at endline. This was accompanied by an increase 
in the share sold by for-profit outlets (from 62% at baseline to 87% at endline). Although the 
public sector is more important in rural areas, its share there has also fallen substantially, from 
77% at baseline to 48% at endline. 
389 | P a g e  
 
8.8.2  Supply of AMFm copaid drugs 
Because Zanzibar is a small country and the prevalence of malaria is low, it was agreed at the 
start of AMFm that only one private for-profit FLB should be registered. In the public sector, the 
Ministry of Health (through the ZMCP) is responsible for forecasting, quantification, and 
procurement of all drugs, including copaid ACTs. Ordering of copaid ACTs is done through the 
Global Fund’s Voluntary Pooled Procurement (VPP) system. The process of selecting the private 
sector FLB was reported to have been smooth. 
 
The first order of copaid QAACTs was placed by the private for-profit FLB in February 2011 
and these drugs were delivered in April 2011. A public sector order was placed in July 2011 and 
delivered in September 2011. By the end of 2011, a total of 241,075 treatments had been 
delivered, amounting to 0.19 treatments per capita (the whole population of Zanzibar is 
considered at risk of malaria). A request from the private sector FLB in August 2011 (after the 
introduction by the Global Fund of its demand management procedures) to purchase 47,000 units 
of the alternative first line treatment artemether-lumefantrine was not approved by the Global 
Fund on the grounds that it was not warranted by the level of malaria incidence in Zanzibar. 
Artemether-lumefantrine is recommended for patients who cannot tolerate artesunate-
amodiaquine.  
 
The outlet survey recorded a decrease in availability of QAACTs among all public health 
facilities (including those without antimalarials in stock on the day of the interview) between 
baseline and endline, from 84% to 73%. This may have captured residual problems of stockouts 
in public health facilities that were reported to have occurred in August/ September 2011, due to 
delays in procurement by the Central Medical Store. Endline country fieldwork took place during 
October and November 2011. 
 
Only 6.5 months elapsed between the arrival of the first copaid drugs in Zanzibar (April 2011) 
and the midpoint of endline outlet survey fieldwork (October 2011).  
8.8.3  Implementation of supporting interventions 
Approximately USD 585,000 was available through the Global Fund for supporting interventions 
at the time of grant signing, and as of November 2011, USD 150,000 had been disbursed, giving 
a per capita disbursement on Global Fund-supported SIs of USD 0.11. Some sensitization of key 
stakeholders including pharmacy owners and the Ministry of Health took place before the 
official launch in June 2011. The main supporting interventions began about one month after the 
arrival of the first copaid drugs in Zanzibar, in May 2011, giving only 5.5 months of SI 
implementation before the midpoint of the endline outlet survey. Communications activities 
included a national launch (in June 2011), a media campaign focusing on availability and price 
of copaid ACTs (starting in July 2011) and community meetings. Relatively little training took 
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place before the endline outlet survey. It was reported that 75 health providers received training 
on drugs and adverse effects, and 13 pharmacists were being trained on monitoring and 
evaluation. Training activities were said to be limited because they had not been included in the 
original budget for SIs. Public and private providers also received some training in 
pharmacovigilance and reporting of adverse drug reactions.  
 
The RRP of USD 0.58 for an adult dose and USD 0.47 for a child’s dose did not appear on the 
packaging of copaid ACTs, but the RRP was promoted through banners, billboards, stickers and 
radio/TV messages.  
 
Provider knowledge of the first-line drug was already high at baseline (85% overall), but 
knowledge increased to 94% at endline. There was a larger increase in provider knowledge 
among private for-profit providers, from 77% at baseline to 92% at endline. Knowledge of the 
AMFm logo was very high at endline (93%), was high in all sectors, and most respondents 
associated the logo with effective, quality or subsidized antimalarials, or that the logo meant an 
ACT. Only 13% of respondents did not know what the logo meant. Knowledge of the AMFm 
program was quite a bit lower (69%). Eighty percent of providers were aware of the RRP (85% 
in urban areas, 73% in rural areas) and among those familiar with the RRP, there was nearly 
universal knowledge of the correct RRP for adults (98%). Given the limited provider training, it 
seems likely that the high level of knowledge was the result of the mass media campaign and 
other communications activities. 
 
Although there has been a ban on use of AMT and SP for malaria treatment since 2008, there 
seems to have been an intensification of its enforcement as a consequence of AMFm. The 
AMFm Coordination Body and Task Force worked with the Zanzibar Food and Drugs Board 
(ZFDB) to impose new by-laws banning the importation of artemisinin monotherapies, and all 
pharmaceutical importers, distributors and retailers were notified by ZFDB about the new by-
laws in June 2011. 
8.8.4  Context  
Zanzibar has seen a dramatic decrease in malaria incidence since around 2003 (Aregawi et al. 
2011). This is a consequence of intensified control efforts including an early shift to ACTs as the 
first-line drug for case management (in 2003); expanded coverage of vector control 
interventions, including free mass distribution of LLINs and use of indoor residual spraying; and 
scaling up of malaria diagnosis through the procurement and distribution of RDTs and 
strengthening the quality of microscopy services. Since 2009, 8 million RDTs and 110 
microscopes have been procured and distributed, supported by relevant training of health 
workers. At endline, 98% of public health facilities with antimalarials in stock had some 
diagnostic capacity, and 85% had RDTs. Availability of diagnostics in the private for-profit 
sector is more variable, with 65% of private health facilities/pharmacies having any test 
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available, and only 3% of drug stores having any test available. At the time of the country case 
study the introduction of RDTs in the private sector was being piloted. Over-the-counter 
medicine sellers are allowed to stock and sell ACTs, a factor which has likely had an important 
influence on increased availability of QAACTs in the private for-profit sector. 
8.8.5 Summary 
Zanzibar has met with all of the Success Benchmarks that could be assessed. These very 
substantial improvements in QAACT availability and market share, reductions in QAACT 
prices, and the reductions in availability and market share of nATs, AMTs and non-quality-
assured ACTs have occurred despite less than 7 months of effective implementation of AMFm, 
and with a relatively limited flow of copaid antimalarials into the country (0.19 treatments per 
capita delivered as of the end of 2011). It seems appropriate to conclude, therefore, that in 
Zanzibar AMFm has met with a highly supportive and conducive environment. Key regulatory 
steps to support OTC sales of QAACTs and to intensify enforcement of the ban on AMT are 
likely to have played an important role in the achievement of the benchmarks, in addition to core 
AMFm interventions of the supply of copaid QAACTs and the strong communication campaign. 
Although information on appropriate use of ACTs is not collected as part of the IE, the relatively 
high availability of diagnostic testing in the public sector should contribute to rational use of 
QAACTs, providing another supporting contextual factor. In this light, the shift in market share 
toward the private for-profit sector, where diagnostic testing is not universally available, should 
be seen with some concern, and efforts to improve availability of RDTs especially in drug stores 
are needed. 
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9 Conclusion 
9.1 Conclusion 
A number of key findings can be distilled on the process and impact of AMFm: 
 
1. Achievement of success benchmarks – Figure 9.1.1 provides an overview of the 
performance of each pilot against the AMFm success benchmarks. Of the 8 pilots, success 
benchmarks were clearly met in 5 pilots for availability, 5 pilots for QAACT price relative to 
the most popular antimalarial that is not a QAACT, and 4 pilots for QAACT market share 
(all shaded green). It is also possible that benchmarks were met in a one additional pilot for 
availability and price, and in 3 additional pilots for market share, although the evidence is not 
as strong (shaded amber). The success benchmarks related to AMT price and market share 
were met in all pilots with sufficient AMTs in the market to make these benchmarks relevant.  
 
2. AMFm and the private for-profit sector – AMFm has been a “game changer” in the 
private for-profit sector for all pilots except Niger and Madagascar, with a dramatic impact 
on the antimalarial market, through large increases in QAACT availability, decreases in 
QAACT prices, and increases in QAACT market share. These changes were substantial and 
achieved in only a few months, demonstrating the power of tapping into the distributional 
capacity of the private sector. The changes are very likely to be largely attributable to 
AMFm. The private for-profit sector response was similar in rural and urban areas, in some 
cases reducing or closing a rural-urban gap in availability and market share. There was 
considerable penetration of copaid QAACTs even in remote areas in Ghana and Kenya, 
where this was evaluated. 
 
3. AMFm and the public sector – AMFm led to fewer fundamental changes to public sector 
antimalarial supply, where QAACT supply continued to be hindered by problems with 
procurement and grant requirements, leading to substantial delays in ordering. Increases in 
QAACT market share were seen in the public sector in four pilots (Ghana, Nigeria, Uganda 
and Zanzibar), although in Nigeria most QAACTs distributed through the public sector were 
not copaid. QAACTs were available in less than 80% of all public facilities at endline in five 
pilots, and there was generally no change in public sector QAACT prices as most countries 
already provided QAACTs for free at baseline (except Ghana where public sector QAACT 
prices fell). 
 
4. Limited impact in Madagascar and Niger – The impact of AMFm on the private for-profit 
sector was limited in Madagascar and Niger, where orders of copaid ACTs were very low. 
Explanations may include (i) the lack of full-scale mass media campaigns; (ii) the structure 
of the private for-profit antimalarial sector, which had a much higher proportion of general 
stores, and in Niger itinerant vendors, who are not allowed to stock QAACTs; and (iii) an 
unfavourable context of political and/or economic instability and severe weather conditions. 
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5. Effect of duration of implementation – Longer duration of implementation appears to be 
positively correlated with performance, if the combined presence of copaid ACTs and the 
operation of a large-scale sustained IEC/BCC campaign is considered a proxy for full AMFm 
implementation. With the exception of Zanzibar, pilots with earlier start dates achieved more 
success benchmarks. No large-scale sustained IEC/BCC campaign was in place by the end of 
2011 in Madagascar, Niger or Uganda, and these pilots achieved fewer benchmarks. 
However, it is possible that delayed start dates reflect weaker implementation capacity in 
general, and therefore one should be cautious in attributing performance to duration of 
implementation alone. 
 
6. Prices and markups in the private for-profit sector – The price of copaid QAACTs in the 
private for-profit sector at endline was very variable across pilots, ranging from USD 0.51 in 
Madagascar to USD 1.96 in Uganda. Reasons for this variability are unclear but may include 
(i) variations in the RRP and its promotion through national IEC/BCC campaigns; (ii) 
guidelines on markups (in Madagascar); (iii) differences in cost structure including tax 
components; and (iv) time since copaid ACTs first arrived in each country. The median retail 
gross markup on copaid QAACTs was less than 70% in all pilots (which can be considered 
reasonable for the retail sector), except Uganda (133%) and Zanzibar (100%). 
 
7. Crowding out oral artemisinin monotherapy – Even at baseline, the market share for oral 
AMT was less than 4% in Ghana and less than 1% in Kenya, Madagascar, Niger, Tanzania 
Mainland and Uganda. In Nigeria and Zanzibar, where oral AMT market share was 
somewhat higher at baseline, large and significant falls were observed, likely reflecting a 
combination of the AMFm subsidy and complementary regulatory measures with particularly 
strong enforcement of the latter in Zanzibar. 
 
8. Availability of non-artemisinin therapies – nAT availability fell in some countries, but 
remained very high in most countries. However, most of the increase in QAACT market 
share was at the expense of nAT market share. 
 
9. Market structure – The private sector was a major player in the antimalarial market in all 
pilots, accounting for between 40% and 97% of antimalarial sales volumes at baseline, and 
between 49% and 92% at endline. There was no clear pattern across pilots in the change in 
private for-profit market share between baseline and endline. 
 
10. Availability of malaria diagnosis – Diagnostic availability (RDT or microscopy) varied 
substantially in the public sector, from 29% in Nigeria to 98% in Zanzibar at endline. 
However, in private for-profit outlets, only three pilots had substantial availability at endline 
(Kenya - 14%, Uganda – 21%, Zanzibar - 32%). In this sector, health facilities/pharmacies 
have higher availability of diagnostics than drug and general stores. 
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11. Results of operational research – Results from studies of interventions to enhance the 
implementation of antimalarial subsidies by improving targeting and/or drug use show that 
implementation of such interventions is feasible on a small scale, but more evidence on 
effectiveness and cost-effectiveness of large-scale programs is needed to inform policy. 
 
12. Issues not covered by the Independent Evaluation – A number of important issues related 
to AMFm policy decisions were beyond the scope of the Independent Evaluation, including 
the impact on targeting copaid ACTs to persons with parasitemia; advice provided to 
patients; adherence to dosing regimens; global artemisinin supply and prevalence of 
counterfeit products. 
 
13. Possible hindering factors for AMFm in some countries include: 
 Delays in the public sector procurement process for copaid ACTs  
 Issues with Global Fund grants and delays in procurement of supporting interventions, 
meaning that implementation of most SIs lagged behind the arrival of copaid ACTs by 
several months 
 Suspension of Global Fund disbursements or grants interrupting implementation of 
supporting interventions 
 Application of Global Fund demand levers to ration orders 
 Political and/or economic instability 
 An antimalarial provider market dominated by highly informal outlets operating outside 
of regulated distribution channels (in Madagascar and Niger) 
 
14. Possible facilitating factors for AMFm in some countries include: 
 Strong AMFm governance structures (including steering committees), involvement of the 
private sector and technical assistance from the Clinton Health Access Initiative  
 Generally smooth operation of the registration process for first-line buyers and ordering 
through the copayment mechanism  
 Strong, large-scale mass media campaigns, including promotion of the AMFm logo 
 Longer duration of implementation 
 Establishment and promotion of an RRP set at an appropriate level 
 Complementary regulatory changes, such as giving ACTs over-the-counter status, and 
implementation of the AMT ban 
o AMFm training in some countries (although only Ghana and Zanzibar had over 
20% training coverage)  
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Figure 9.1.1: Overview of the achievement of the AMFm Success Benchmarks by county, indicating benchmarks achieved (in green), nearly or possibly 
achieved (in amber) and not achieved (in red), (point estimate, and p-value for statistical test of whether the level stated in the benchmark was achieved) 
Benchmark  Ghana Kenya Madagascar Niger Nigeria 
Tanzania 
mainland Uganda Zanzibar* 
1. 20 percentage point increase in 
QAACT availability  
52 
(p<0.01) 
35 
(p<0.01) 
4.6  
(p=0.99) 
10 
(p=0.99) 
26 
(p=0.14) 
44  
(p<0.01) 
46 
(p<0.01) 
39 
2.  Median price of QAACTs with 
AMFm logo is <3 times the median 
price of the most popular 
antimalarial in tablet form that is 
not a QAACT (ratio)  
3.0 
(p=0.81) 
1.0 
(p<0.01) 
1.6 
(p<0.01) 
2.5 
(p<0.01) 
3.1 
(p=0.99) 
1.0 
(p<0.01) 
3.3 
(p=0.99) 
1.5 
3. Median price of QAACTs with 
AMFm logo is less than the median 
price of AMT tablets (difference, 
QAACT – AMT)  
-0.94 
(p<0.01)    
-1.17 
(p<0.01)   
-6.3 
4. 5 percentage point increase in 
percentage of children with fever 
who received ACT treatment  
 na  na  na  na  na  na  na  na 
5. 10 percentage point increase in 
market share of QAACTs  
40 
(p<0.01) 
31 
(p=0.01) 
8.6 
(p=0.61) 
-8.8 
(p=0.99) 
18 
(p<0.01) 
16 
(p=0.23) 
17 
(p=0.08) 
48 
6. Decrease in market share of oral 
AMTs (percentage point change)      
-3.9 
(p=0.03)   
-12 
Notes: Green shading = the benchmark was achieved, with strong statistical evidence (generally p<0.01); Amber shading = either the benchmark was nearly, but not fully, met, or the evidence that the 
change seen was unlikely to be due to chance is weak (p≥0.05). However, the power to detect a 10 percentage point increase in market share was only 35% in Tanzania, 66% in Uganda and 70% in 
Madagascar, compared with the usual minimum standard of 80%; therefore, p-values should be interpreted with caution. Red shading = the benchmark was not met; Grey shading for Benchmarks 3 and 
6 = not relevant because the number of AMT products was very low at baseline. * p-values not shown for Zanzibar because a complete census of antimalarial stocking outlets was undertaken; na = not 
available; ACT= artemisinin-based combination therapy; AMT= artemisinin montherapy; QAACT= quality-assured artemisinin-based combination therapy 
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